<SEC-DOCUMENT>0000950170-22-003998.txt : 20220317
<SEC-HEADER>0000950170-22-003998.hdr.sgml : 20220317
<ACCEPTANCE-DATETIME>20220317063128
ACCESSION NUMBER:		0000950170-22-003998
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220317
DATE AS OF CHANGE:		20220317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikena Oncology, Inc.
		CENTRAL INDEX KEY:			0001835579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40287
		FILM NUMBER:		22746669

	BUSINESS ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-343-8292

	MAIL ADDRESS:	
		STREET 1:		50 NORTHERN AVE.
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ikna-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-16T15:36:02.5961+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ikna="http://www.ikenaoncology.com/20211231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_bec7d1a7-68ee-411c-8334-470e5b31718b" name="us-gaap:PreferredStockValue" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_70301994-e88a-4217-9c45-d103d1876a85" name="us-gaap:PreferredStockValue" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d76f71c9-2042-4b06-8c63-f4b8806de07f" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220">http://www.ikenaoncology.com/20211231#ResearchAndDevelopmentMember</ix:nonNumeric><ix:nonFraction id="F_7fdb186e-815c-4baa-b15f-3f79588d331f" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_88f610e1-84c9-450b-8088-d8260b8a860e" unitRef="U_pure" decimals="4" scale="0" format="ixt:numdotdecimal">0.1397</ix:nonFraction><ix:nonNumeric id="F_06ffd91e-b7c3-4c7f-8398-70d37a92ab69" name="dei:AmendmentFlag" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonFraction id="F_2ce08d35-be16-47c1-8be1-42857608cb48" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6242453e-6005-48f3-94c4-c7e1e8f8f635" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric id="F_fc0a9acd-1f51-4c1f-ba72-2d676951d1d7" name="dei:EntityCentralIndexKey" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de">0001835579</ix:nonNumeric><ix:nonFraction id="F_474b6704-871e-4bad-bd66-06110622c38a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_d31c53a8-537c-4399-a1e0-f3fda99cb66b" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de">http://www.ikenaoncology.com/20211231#ResearchAndDevelopmentMember</ix:nonNumeric><ix:nonNumeric id="F_7402aa32-4d60-4e85-9dcb-3a14cb833246" name="dei:DocumentFiscalPeriodFocus" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de">FY</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ikna-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_a4cf98b3-916a-4266-a09d-ad4151809aea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aaa01b2e-dd1f-4221-87af-21a855fd6176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_252420a7-5245-4f24-a1b3-549a5657e10c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e48cebc-3625-4ce6-9967-9afa2709e2dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12fe0903-8181-40c3-af42-92ad1bc22546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb6c9d92-b86d-45de-b6ed-45a7a20b5125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2e15ff7-280d-4489-8017-9492ffa9ab32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:NotSubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_967cd9a5-9ca9-47d7-aeb3-bede932bd3d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04f5fcbc-3f2a-4fe4-b203-67a710042614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef57b772-1e45-4cbb-82ff-1cd3052d6512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc07950d-ff60-4171-bee4-68de5e8006fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_85fb6b92-dfdb-4f1c-b04e-5cb23fd29f2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f814b099-b5e9-4532-849e-ed0d7f1514b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b400e939-9adf-46fa-ab34-47a059eaa533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:VertexPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2da448fd-bf19-4ae7-a240-59e52b66aea8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53dec454-cb02-4c8b-823d-02e9a70817b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f1aee2b-76d8-4d4e-b29d-300c4f6ff2c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74803d30-fb65-4987-a08f-21d2e606fe63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b875a6d3-58ee-468a-91f5-65132ce52f74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb2b28a5-0c8c-41e7-a631-b5a284180f8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80c83882-abbc-4f18-9ffe-8a6f1fe9f705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c24f3ba8-ff6c-4e9e-a73d-2853c35d6b11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c95a6922-ca79-4e5a-9bb5-f9b65cbb34cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4162d822-49e3-40a4-b0e7-b0f69534abbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:VertexPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e00cf6c-4267-4556-8c5c-74e987e32883"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7884ad66-cfc9-4e7d-b37b-a43da1f827a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2df7bdbe-e8b1-4c47-ba9d-7aa5fe65b63d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73a95a4f-2717-441c-8d33-6cca61d172fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66a7df3f-5f7f-4365-885c-11ae27335bd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-21</xbrli:startDate><xbrli:endDate>2020-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9449ae95-9c4e-423a-a742-487a9fa3d5c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77bf16f4-0053-4b65-a6e3-44bc05446deb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9ea63bc-0e26-4e82-ae9c-c05ca061173e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_932834ea-9c54-4858-96f9-52377c047cc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38798bf1-ddbf-4fcd-90e3-e5ba57c070a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_064ada85-12cf-4684-b1a0-b4034e155188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e968a25-daad-4006-af2c-b4b4e11eefe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ea44336-4474-480c-bcd2-a098f4164455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_305a280c-d1de-4413-b7dc-476f60a09329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3dd7a94f-ebbb-475e-ab24-17fd8d19e2fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95669789-5d67-45fb-83c2-2a62765d4576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c92572d4-da38-4f18-8896-9db108cd3d8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8f918b3-befa-4a88-93fc-46d5041b9f1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d2ca6ed-69e8-4b73-9331-739f008d6068"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d387d5e-0476-4899-8453-c870bec1b749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7dc9500-a312-4bbb-8606-fbcf3215bf2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ccefeed-c353-4dec-a464-be4c75fc07a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9265d692-1067-4446-93b5-77437f4ec759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_640f8a26-ca73-4101-8b04-267f50272b4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ead8d980-42b0-4dc9-aa5e-8601926b283e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84ac8be9-5cfc-47f7-b50e-f6ab75a07026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93401a31-e235-4435-b893-a060400d5a04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de1f00a8-10d4-4a23-8b9b-2bef95a2e119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e5351be-0edc-42b6-8e62-f402a7a84729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f3abad8-6574-4e7c-b859-64ad14c715ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eae5cf94-03a9-47a6-b996-4d2859e9ca20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c5c2a21-5b8b-4673-9f3c-9fd33b740459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cab5b9e5-69a0-4f7b-8c1a-81cbd3afcba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-31</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d59e96ca-e70a-4673-a757-3997f4bdb74c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3d09b30-c88f-47ac-8386-fd1150b5ef28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_035aefe6-e027-41ce-80d2-5bcb01214d81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99ed35bd-4774-4330-bc6b-2c695190c3de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb63a3a7-a4a7-4296-b5a8-5e3cd9e88878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-20</xbrli:startDate><xbrli:endDate>2021-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a363f018-7c61-490f-9200-7d87e22a642d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cf264ba-3822-4bc8-8611-e5f6c96c4ced"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c47f385d-2c66-422c-92c6-8542e19860cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3d192b9-f1b8-48f5-80bc-54ccb8098dcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b136456-ad76-446f-a0d8-ef8a597b5f71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2ad82ad-ba0d-444e-bbea-c7c079ec8603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3af77da4-b3d1-4363-bc9c-05213b03b1ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e239a4a-5d8e-4aa5-91c9-b646ab6d2361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dd562f4-b1c2-450b-8d06-e06ff831105e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1751049c-5a01-4bb3-88da-acd002119349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb21e98b-d1d5-4830-95ae-a8521474d69b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ca75a5f-a6d6-4a47-bdba-3f6e337cfabb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53a98858-94fb-4019-b8a9-8e6c8638bbb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_554ecddb-159f-4002-a088-c37b9e72c32d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:VertexPharmaceuticalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c6adf68-b45d-444a-96ff-b973670159ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1b60113-9aac-46bb-90fa-37d525cc890a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7dcb7f3-11ce-4fd1-9003-09bb1c7904e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88f610e1-84c9-450b-8088-d8260b8a860e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97c448a4-24df-47b4-8856-f4896b80ad75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7eb39d52-adcf-40e5-ae5d-09ebf80bd382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-31</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc3f0817-4c02-46a4-a64c-d9eba5dae732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b652551b-9695-4fe5-8980-18380f280c59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5cf5caa-b798-49d2-bb71-6baf51e18554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6feba73-11f7-4c3f-bf74-b2fc74138690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bc3c318-3f9b-4004-b2d0-fd1298f6297d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_249d1b32-5370-4599-8e89-ab6c0f09b80f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8900e3a-21a4-40ca-8258-8f61c746cc01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c083b51c-b8f6-4949-af7d-87bfd8ace549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesAOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f861265f-3133-42fb-a89c-dac532459910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_890c650a-b769-4a05-90cd-2d91b6fcb220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c03768c-e908-427c-98a3-dac6ad6d0a7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad57f0bc-0185-4d7c-aeac-29addd35778c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f40c434-b11e-4ddd-b726-08e4052dba90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8ca6c84-2e8a-4657-be34-b7027d2c0a54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d0023fe-0f0c-46e9-b39d-3d9294d1fdf8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58e59c96-9c20-4175-a767-95e0b0fd9b9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de68a06b-52a5-428b-8fda-644108120c2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a718982-72b2-4b6f-8b37-4cb567dba4b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33e372af-72dd-4109-9ecf-cd6de6a18366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6838680a-d30e-45b3-9c96-ca296d3f4897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ce46fba-908a-4541-9693-823709dea22f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-30</xbrli:startDate><xbrli:endDate>2021-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df1f510f-8f9a-4d97-92ef-ba74f342490f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eba92ba2-7e7b-497e-aa6d-b51e12ffe499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aea069f1-935a-4fb9-93fe-05cda26d80fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45284bec-8438-4ce2-8397-a8f69b9c192b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f03341b9-2f76-48f3-8446-954e602ed32f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_905f0da9-40cb-4e6b-881a-7396023d88fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b98e2af-28de-4a15-9b16-1d31248fde7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6bda0fb6-7d7a-41ad-a5b7-dd54a0540cc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c485b7cf-0678-46d2-94de-86fa847eed87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesA1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:StockPurchaseAgreementWithBMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b95089c-ecad-4ea3-b482-0bde43865eb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de81f154-ee2b-4f17-b724-5dba00646bdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835579</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>ikna:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_FinancialInstitution"><xbrli:measure>ikna:FinancialInstitution</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec10c90d-19aa-4472-a625-bdff4b7533e2" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd60d503-206d-4997-8a7a-dad7cecade5a" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a48aaf5-ae7a-4272-acdf-7e2d4f2850d6" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73fb70dd-2b27-4f03-8fc1-3bab59badcd0" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bea4cf2e-21d0-4f17-b327-2ca19864b0f7" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75d1659a-b7ff-494f-add6-cbea096fcce3" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0860bb77-ddbb-4cfb-a1ac-c375bc0224dc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-40287</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:21.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7972686-82d3-4a51-bff3-606775c3779f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityRegistrantName"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:21.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65a7454b-41ab-43ac-9788-265b778e301c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98a506ab-9ddf-4cf4-8642-9fa520edef03" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">81-1697316</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_055c112c-9863-4f23-8fab-aad2a3394472" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">645 Summer Street</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8075a6fc-cc68-491a-bfc3-146355af89a7" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 101</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1bb89fe-f414-4544-b578-1c5acab49efc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a7cfdfd-72f9-4326-a934-b923e5dcd31e" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">MA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d66197ca-1ed7-4e88-bd86-ad3e6c4e1e8a" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">02210</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6d5389e-0162-4f4c-ae5e-2fb78a07f441" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">857</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1889869-796d-4074-b719-3d9c57ec97cb" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">273-8343</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58f735ce-bfca-414f-8e32-45fc25d661af" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fea3eb77-d852-47a1-be1b-d6c3af3c8ea8" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IKNA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb868f23-5203-4a20-9895-25d97178f314" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5580c5b2-72ac-47fd-ade0-81f0023ec428" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38636d8b-9bbc-45de-ba5e-f5a5c1ae6cd6" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6460eef5-bd3a-4f94-9b51-edd7ffda9ed5" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b901a2bc-3f8a-4de2-9c16-bdaa1e7b7337" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.295%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:55.362%;"></td>
    <td style="width:1.178%;"></td>
    <td style="width:20.492%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:2.226%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23c1477b-4b53-4880-a3c8-7204af62e1df" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d2d1de9-1971-4fd5-81ad-b73e5af80683" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16d8b808-e52b-43b8-aaa5-598cd4adfedb" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f24138c-23d7-4da4-ac6c-93228535ee08" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e68ec91e-86f3-4064-ab61-54e8bfe47fc6" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9744;     </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_787594eb-fde1-4740-bb5e-feedbdaf29ff" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on June 30, 2021 was $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba7f31df-e007-4b82-bab3-8ee5eea1cfe0" contextRef="C_eae5cf94-03a9-47a6-b996-4d2859e9ca20" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">296.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> 10, 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">was </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9a3559d-e102-4b59-a6a8-42cb67730773" contextRef="C_de81f154-ee2b-4f17-b724-5dba00646bdc" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,108,995</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_e04406e5-2128-47a5-9b11-c3f6122eead0" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant&#x2019;s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.004%;"></td>
    <td style="width:81.998%;"></td>
    <td style="width:6.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Reserved</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:bottom;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:6.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of the Material and Other Risks Associated with Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to numerous material and other risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a targeted oncology company with a limited operating history. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no products approved for commercial sale and have not generated any revenue from product sales. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require additional capital to finance our operations, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never successfully completed any clinical trials for our oncology programs, and we may be unable to do so for any product candidates we develop. Certain of our oncology programs are still in preclinical development and may never advance to clinical development. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third parties to conduct our company sponsored Phase 1 clinical trials of IK-930, IK-175, and IK-007 and expect to rely on third parties to conduct clinical trials for our other programs that enter clinical trials. In addition, our product candidates may be evaluated in investigator-sponsored clinical trials. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The material and other risks summarized above should be read together with the text of the full risk factors below and with the other information set forth in this Annual Report, including our consolidated financial statements and the related notes, as well as with other documents that we file with the SEC. If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above, or described in full below, are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">express or implied </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). These statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forward-looking statements in this prospectus include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to efficiently discover and develop product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability and the potential to successfully manufacture our drug substances and product candidates for preclinical use, for clinical trials, and on a larger scale, for commercial use, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to commercialize our products, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the implementation of our business model, and strategic plans for our business and product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimates of our future expenses, revenue, capital requirements, and our needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future agreements with third parties in connection with the commercialization of product candidates and any other approved product;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our financial performance; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the rate and degree of market acceptance of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments in the United States and relevant foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract and retain key scientific or management personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of laws and regulations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our use of proceeds from our initial public offering; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments relating to our competitors and our industry; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effect of the ongoing COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other risks and uncertainties, including those under the caption &#x201c;Risk Factors.&#x201d; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#x201c;Risk Factors&#x201d; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or into which we may enter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 1. BUSINESS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment (TME), with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. Our focus on patient-driven development is platform and process agnostic, allowing us to research both known and novel targets, with a shared guiding principle of aiming to address the unmet need of a biomarker-defined patient population. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust pipeline of discovery-stage targeted oncology programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. In our ongoing first-in-human clinical trial, we are focusing on indications that provide the potential for rapid clinical development to achieve proof-of-concept, such as NF2 deficient mesothelioma and solid tumors with YAP1 or TAZ gene fusions, including epithelioid hemangioendothelioma, or EHE, in which 100% of patients have Hippo pathway alterations. We also plan to assess IK-930 in combination with other targeted therapies across several indications, including EGFR mutated non-small cell lung cancer (NSCLC) and KRAS mutated cancers. In October 2021, our Investigational New Drug Application, or IND, for IK-930 was accepted by the U.S. Food and Drug Administration, or FDA, and we subsequently initiated a first in human Phase 1 clinical trial of IK-930 in patients with advanced solid tumors with a high frequency of Hippo pathway alternations. The first patient was dosed in January 2022, and we are currently recruiting patients in this ongoing Phase 1 clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our discovery efforts are focused on additional targeted oncology programs, following our philosophy of designing treatments for patients&#x2019; populations identified through the genetic make-up of their tumors. Our pre-clinical pipeline is growing to include additional Hippo pathway and RAS pathway-targeting programs, including our program against the novel target extracellular signal related kinase 5 (ERK5). We are generating mechanistic and translational data to accompany our approaches and identify underserved RAS-mutated cancer patient populations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment (TME). These programs are all built on the same foundation of biomarker-driven clinical trial design and patient enrichment, aiming to develop therapies that can precisely be used for specific cancer patients. IK-175 is an oral inhibitor of aryl hydrocarbon receptor, or AHR, which we are evaluating in a Phase 1a/1b clinical trial in solid tumors and in urothelial carcinomas as monotherapy and in combination with nivolumab. We expect to report initial clinical data from this trial in the second half of 2022. Additionally, we plan to initiate a second Phase 1b trial with IK-175 in head and neck squamous cell carcinoma (HNSCC) in the second half of 2022. The IK-175 program is partnered with Bristol-Myers Squibb Company. The partnership also includes our IK-412 program, which experienced manufacturing delays previously disclosed in 2021. Considering these delays and the timeline of the partnership, we made the strategic decision to pause IK-412 development activities for the remainder of the Bristol Myers Squibb collaboration agreement term once the ongoing committed Chemistry, Manufacturing, and Controls (CMC) work has been completed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also within TME immune signaling, IK-007, which inhibits the prostaglandin E receptor 4, or EP4, in the COX2 pathway, is being evaluated in a Phase 1b clinical trial in combination with pembrolizumab for the treatment of patients with MSS CRC. We recently completed enrollment in this trial and expect to report data at a medical conference in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current pipeline is shown below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /><br /></span><img src="img39825204_0.jpg" alt="img39825204_0.jpg" style="width:624px;height:336px;" /><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are dedicated to bringing next generation targeted oncology therapies to cancer patients. We plan to achieve this goal with diverse approaches to targeted oncology and immune signaling and through our deep understanding of complex biologic pathways, biomarker-driven discovery, our experience and skills in drugging novel and previously intractable targets, and robust translational research informing clinical development. The key components of our current strategy are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Advance IK-930 through clinical development. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing IK-930, an oral small molecule inhibitor of TEAD, to evaluate its potential to bring single agent therapeutic benefit to patients with tumors harboring genetic mutations in the Hippo signaling pathway. IK-930 as monotherapy is currently being evaluated in a Phase 1 clinical trial in cancer patients. Our clinical development strategy is designed to achieve clinical proof-of-concept in genetically defined subset of solid tumors where significant unmet medical need exists, to leverage the potential for fast-to-market opportunities in orphan indications, and to evaluate combination of IK-930 with other targeted therapies to address therapeutic resistance, such as with an epidermal growth factor receptor, or EGFR, inhibitor in broader indications. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Progress our research in both the Hippo pathway and RAS pathway towards identification of potential development candidates and advancement through clinical development. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a robust discovery effort to continue to identify potential opportunities for targeted oncology pipeline growth, including additional programs within the Hippo and RAS pathways. Our continued efforts in the Hippo pathway have the potential to result in additional candidates that could complement IK-930 and further our leadership in the space. Our discovery efforts in RAS are aiming to develop therapies for RAS-driven cancers, including KRAS mutated cancers, where there is significant unmet need. This work includes targeting multiple nodes in the pathway. For example, we are studying small molecules targeting ERK5 in the RAS signaling pathway that we believe may have the potential to bring therapeutic benefit to patients with KRAS mutant cancers that are not currently addressed by existing KRAS inhibitors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Continue advancing IK-175, a BMS-partnered program, through Phase 1b clinical trials aiming to achieve key near-term financial milestone. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bristol Myers Squibb, our strategic partner, has the exclusive right to exclusively license each of IK-175 and IK-412 worldwide through completion of Phase 1b clinical trials. The IK-412 program experienced manufacturing delays previously disclosed in 2021. Considering these delays and the timeline of the partnership, we made the strategic decision to pause IK-412 development for the remainder of the BMS contract term once the ongoing committed CMC work has been completed. IK-175 is being evaluated in a Phase 1 clinical trial in bladder cancer enriched for nuclear AHR positive patients using our proprietary AHR biomarker assay. We are currently recruiting patients in the expansion cohorts of both the combination and monotherapy arms of the trial. If Bristol Myers Squibb exercises their option to exclusively license IK-175, we would receive $50 million in opt-in fees, which would provide a meaningful source of non-dilutive capital. We would be eligible to receive clinical, regulatory, and commercial milestone payments and royalties on worldwide net sales.    </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Maximize the value of our pipeline through continued discovery efforts and growth; generating a pipeline of programs supported by robust translational research and designed for biomarker-defined patient populations. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we seek to expand our targeted oncology pipeline and advance it through proof-of-concept clinical trials, we plan to build a fully integrated biotechnology company. As we grow, we plan to advance programs that fit with our philosophy of patient-driven development and identify biomarker-defined populations in need that can benefit from targeted therapeutics. We hold worldwide development and commercial rights to our targeted oncology programs, and we intend to continue to develop our capabilities in late-stage clinical development and commercialization to maximize the potential value of these programs. In addition to internally identified targets, we are open to opportunistically in-license or acquire discovery and clinical programs for which we can leverage our expertise in drug discovery and structural biology-guided chemistry, with a focus on mechanisms of actions targeting cancer drivers that complement our existing targeted oncology programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Targeted Oncology Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-930, a TEAD inhibitor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-930 is an internally discovered oral small molecule inhibitor of the TEAD family of transcription factors in the Hippo signaling pathway. TEAD functions as the ultimate step in the Hippo signal transduction pathway by driving expression of genes involved in cell proliferation and survival. The Hippo pathway is widely accepted as a key and prevalent driver of cancer pathogenesis and is genetically altered in approximately 10% of all cancers, and such genetic alterations are often associated with poor clinical outcomes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-930 is a novel inhibitor of TEAD that exploits a recently discovered and promising binding pocket on TEAD to enable the inhibitory effect upon the Hippo pathway. TEAD activity is dependent on binding of the fatty acid palmitate to a central lipid pocket. IK-930 blocks palmitate from binding TEAD, thereby disrupting TEAD-dependent gene transcription. The mechanism of action of IK-930 is differentiated from historically unsuccessful attempts that targeted protein-to-protein interactions, or PPIs, using either small molecules or cyclic peptides. Using structural biology-guided chemistry, we were able to generate novel TEAD inhibitor compounds across several chemical series directed to this binding pocket in TEAD and profile them using various in vitro and in vivo assays assessing potency, selectivity, tolerability and activity. By selecting IK-930 based upon these characteristics, we believe IK-930 has the potential to bring therapeutic benefit to patients with tumors harboring genetic mutations in the Hippo signaling pathway. Moreover, activation of the Hippo pathway confers resistance to certain targeted therapies, such as EGFR inhibitors and MEK inhibitors, which supports the potential for IK-930 to be combined with these therapies to overcome therapeutic resistance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently evaluating IK-930 in a first-in-human Phase 1 clinical trial as a monotherapy in Hippo-mutated cancers. The study aims to evaluate the safety and preliminary antitumor activity of IK-930 in Hippo-mutated cancers in orphan indications such as NF2-deficient malignant pleural mesothelioma and EHE, a rare type of vascular sarcoma. The FDA granted IK-930 orphan designation for the treatment mesothelioma in the first quarter of 2022. In addition, we plan to evaluate IK-930 in combination with other targeted agents in the Phase 1 clinical trial, with the aim of potentially addressing therapeutic resistance in more prevalent tumor indications characterized by genetic alterations, including EGFR mutant NSCLC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Role of the Hippo pathway and TEAD in oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Hippo pathway is a highly conserved developmental signaling pathway that modulates the regulation of multiple biological processes including cell proliferation, survival, differentiation, organ size, and tissue homeostasis. Dysregulation of the Hippo pathway is associated with the induction of hyperproliferation, cellular invasion, metastasis, cancer cell maintenance and therapeutic resistance and has been linked to other pro-tumorigenic activities such as activation of regulatory T cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Hippo signaling cascade begins with NF2, a gene that encodes the scaffold protein merlin, which links multiple extracellular cues to an intracellular signaling cascade. Merlin activates the kinases MST1 and MST2, or MST1/2, which subsequently phosphorylate and activate the kinases LATS1 and LATS2, or LATS1/2. LATS1/2 phosphorylates two key transcriptional coactivators of TEAD: YAP1 and TAZ. When phosphorylated, YAP1 and TAZ are sequestered to the cytoplasm where they are targeted for proteasome-mediated degradation. When the upstream portion of the signaling cascade is inactivated through normal regulation or through inactivating mutations, YAP1 and TAZ are not phosphorylated and can shuttle into the nucleus. Once inside the nucleus, YAP1 and TAZ bind TEAD to enable the transcription of TEAD target genes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Hippo Pathway Diagram</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><img src="img39825204_1.jpg" alt="img39825204_1.jpg" style="width:573px;height:625px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nuclear YAP1 was observed to lead to increased TEAD activity as measured by higher levels of TEAD gene transcription. These data suggest that the addition of a TEAD inhibitor to an EGFR inhibitor regimen in patients with EGFR resistant tumors may be able to overcome therapeutic resistance to EGFR inhibition. In addition to resistance to EGFR targeting, there are emerging data indicating the Hippo pathway is involved in resistance to other targeted therapies as well, including MEK inhibition inhibitors in BRAF and RAS mutated cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Two Clinical Strategies to Inhibit the Hippo Pathway with IK-930 to Address Multiple Cancer Patient Populations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_2.jpg" alt="img39825204_2.jpg" style="width:624px;height:286px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Epidemiology of Hippo pathway driven cancers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Published literature suggests that approximately 10% of all solid tumors present with dysregulated Hippo pathway and subsequent activation of TEAD. Dysregulation can occur at multiple nodes within the pathway. For example, the tumor suppressor gene NF2 can undergo inactivating mutations or YAP1 and TAZ can undergo gene fusion or amplification. These genetic alterations lead to tumor formation in mouse models and therefore are believed to be genetic drivers of cancer. Moreover, there is cross-talk between the Hippo pathway and multiple other signal transduction pathways, such as EGFR, which can lead to aberrant TEAD activation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on available epidemiological data, we estimate that approximately 125,000 newly diagnosed cancer patients annually within the United States have tumors which harbor genetic alterations in the Hippo pathway, based on the incidence of cancers with YAP1 and TAZ gene amplification or fusion as well as NF2 loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The figure below illustrates the incidence of individuals with newly diagnosed cancers that harbor Hippo pathway genetic alterations in the United States on an annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Incidence of Hippo Pathway Genetic Alterations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_3.jpg" alt="img39825204_3.jpg" style="width:624px;height:340px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Genetic alterations in the Hippo pathway are present in diverse cancer types but there are certain cancers, including more prevalent indications such as lung squamous cell carcinoma, and rarer indications such as mesothelioma and sarcoma, which are reported to have a particularly high incidence of genetic alterations in the Hippo pathway and where alterations are considered to drive tumor formation and growth and are associated with a poor patient prognosis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss of function mutations in NF2 are found in approximately 40% of cases of malignant mesothelioma and are associated with poor prognosis, including a significantly shorter progression free survival and overall survival. IK-930 has orphan designation for the treatment of mesothelioma. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Multiple soft tissue sarcomas have YAP1 and TAZ gene fusions. For example, approximately 90% of epithelioid hemangioendothelioma, or EHE, have TAZ-CAMTA1 fusions and the remaining 10% have YAP1-TFE3 fusions, which are directly linked to the etiology of these cancers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In squamous lung cancer, YAP1 and TAZ amplifications are found in approximately 6% and 29%, respectively, based on internal analysis of The Cancer Genome Atlas (TCGA) using the Genome Data Commons and cBioportal tools. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our translational strategy, we have conducted bioinformatics analyses of the genomic and transcription profiles of cancer patients, broadening our understanding of the pathway's role in certain cancers, and supporting our indication selection and clinical development plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Genetic Analysis of Indications with Hippo Alterations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_4.jpg" alt="img39825204_4.jpg" style="width:415px;height:160px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted genetic (top image) and transcriptional analysis (bottom image) of Hippo pathway dependency that identified a common subset of cancers. The data show the results from the genetic analysis of Hippo pathway alterations and the transcription analysis of YAP/TAZ activation. The overlapping cancer types present as indications with high potential for impact through Hippo pathway inhibition. For example, mesothelioma, head &amp; neck squamous cell carcinoma, cholangiocarcinoma, and non-small cell lung cancers demonstrate high frequencies of Hippo pathway alterations as well as high YAP/TAZ activity scores.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Transcriptional Analysis of YAP/TAZ Activity Scores</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_5.jpg" alt="img39825204_5.jpg" style="width:456px;height:177px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beyond the role of certain Hippo pathway alterations in driving cancer, several pathway components are known to drive resistance to targeted therapies such as EGFR inhibitors. Approximately 30% of patients with non-small-cell lung carcinoma, or NSCLC, will have EGFR mutations. Tagrisso (osimertinib) is an EGFR inhibitor approved for the first-line treatment of patients with NSCLC whose tumors have certain EGFR mutations. Despite the robust clinical activity exerted by osimertinib, patients often develop resistance to this treatment, which poses a significant challenge due to the scarcity of post-osimertinib pharmacological options available to date. Early use of osimertinib raises the question of the optimal management of osimertinib resistance and the role of targeted agent combinations in this patient population. We believe this population also represents a substantial opportunity for TEAD inhibitors. Published data from patient tumor samples shows that, upon acquired resistance to EGFR inhibitors through specific mutations in EGFR, there is an increase in nuclear YAP1 in tumors as compared to baseline. In EGFR mutant lung cancer cell lines in vitro, the increase in nuclear YAP1 was observed to lead to increased TEAD activity as measured by higher levels of TEAD gene transcription. These data suggest that the addition of a TEAD inhibitor to an EGFR inhibitor regimen in patients with EGFR resistant tumors may be able to overcome therapeutic resistance to EGFR inhibition. In addition to EGFR resistance, additional information is emerging from newly marketed and later stage clinical development targeted oncology programs, including suggested resistance to MEK inhibitors. We have generated preclinical data supporting our belief of the clinical opportunity to treat patients with multiple types of genetically-defined tumors and tumors with resistance to other targeted therapies with IK-930.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Disease Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The epidemiology findings in mesothelioma, EHE, soft tissue sarcomas as well as other solid tumors including meningioma point to the critical role of the Hippo pathway in tumor formation. In addition to the strong biological rationale for pursuing development of IK-930 in these cancers, we believe that these are areas of high unmet medical need in which IK-930 has the potential to provide meaningful clinical benefit to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malignant mesothelioma is a rare cancer in the tissue lining the lungs and is a very aggressive cancer with a poor prognosis. After initial diagnosis, patients are reported to have a median life expectancy of 15 months. Approximately 3,000 people in the United States are diagnosed with mesothelioma each year. On average, about 2,500 mesothelioma-related deaths occur in the United States each year. There are few effective treatment options for advanced unresectable malignant mesothelioma and to date only two treatments have been approved by the FDA for the treatment of this condition. The combination of cisplatin and pemetrexed was the first systemic treatment approved by the FDA in 2004, followed only by the May 2020 FDA approval of Nivolumab in combination with ipilimumab. Even with this newly approved treatment, the median overall survival of these patients is 18 months, with most of the patients eventually progressing and dying from their disease. IK-930 has orphan designation for the treatment of mesothelioma. Approximately 40% of malignant mesothelioma patients are associated to NF2 deficiency and this genetic alteration has been described to contribute to asbestos-induced mesotheliomagenesis in animal models, showing that NF2 drives the malignant behavior of this subset of mesothelioma cases. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to mesothelioma, meningioma also has high frequency of NF2 deficiency. Meningioma is the most common central nervous system, or CNS, tumor, accounting for approximately one-third of primary CNS tumors. Surgery and/or radiation therapy, or RT, constitute the initial therapeutic approach for meningiomas. Furthermore, surgery and/or RT can control disease in some patients with recurrence. Unfortunately, despite the appropriate use of surgery and RT for initial disease management and management of recurrent disease, there is a subset of patients in whom disease cannot be controlled with local approaches. Experience with systemic treatments is limited and although several agents have been studied, none have an established role in prolonging progression-free survival or overall survival. The outcome of this subset of patients with persistent or recurrent meningiomas continue to be poor, underscoring the substantial need for new therapies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Soft Tissue Sarcomas, or STS, represent a rare and heterogeneous group of solid tumors derived from mesenchymal progenitor cells and characterized by a variety of genetic alterations. Recent molecular and genetic studies in large cohorts of STS cases have demonstrated an essential role of YAP1/TAZ in sarcomagenesis, implying that a YAP1/TAZ directed therapeutic approach could represent a rational strategy in a selected subgroup of these tumors. STS account for 1% of all adult malignancies. While the clinical outcome of these diseases has improved in the last decade with the use of anthracycline-based chemotherapy and the introduction of novel therapies targeting different cell pathways and the use of immune checkpoints, the prognosis for a significant subgroup of patients with STS is still poor and there is an unmet medical need for these patients. For these reasons, the identification of novel molecular targets is important in these rare malignancies. Recent studies in a large cohort of STS tumors showed that myxoid liposarcomas, synovial sarcomas and angiosarcomas, in addition to EHE, expressed the highest levels of YAP1/TAZ gene expression, potentially driving tumorigenesis in these subsets of STS.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EHE is a rare STS that grows from the cells that make up the lining of blood vessels with an incidence of one case per million people in which 100% of the cases harbor genetic alterations of Hippo pathway  with approximately 90% of the cases harboring a genetic fusion between TAZ and CAMTA1(TAZ-CAMTA1) and the other 10% of cases harboring a genetic fusion between YAP1 and TFE3 (YAP1-TFE3). This cancer can occur anywhere in the body with the most common sites being the liver, lungs, and bone. It usually occurs in people between 30 and 50 years of age but can occur in young children and older people. Surgery and radiotherapy have been used as treatment for localized disease and several interventions have been used with palliative intent in the recurrent or metastatic cases, including steroids, interferon, and others, but there is currently no specific targeted therapy approved for the treatment of advanced EHE. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite the successful expansion of personalized oncology using targeted therapies to selectively treat patients with specific mutations in key oncogenic drivers, intrinsic and acquired resistance to targeted agents is a growing clinical problem. Activation of YAP1/TAZ has been associated with the development of resistance to various targeted agents, including in EGFR mutant NSCLC, and in KRAS mutant tumors such as pancreatic carcinoma, CRC, and NSCLC. In EGFR mutant NSCLC, the successful early use of 3rd generation anti-EGFR inhibitors has improved the clinical outcome for these patients in not only in first line metastatic disease but also early disease and has become a new therapeutic paradigm for this patient population. However, the most efficient approach to managing emerging resistance to early use of 3rd generation EGFR inhibitors remains to be determined. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our Solution, IK-930</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-930 is an oral small molecule inhibitor of TEAD that binds to a recently discovered lipid binding pocket on TEAD itself. TEAD activity is dependent on binding of the fatty acid palmitate to a central lipid pocket. IK-930 blocks palmitate from binding TEAD, thereby disrupting TEAD-dependent gene transcription. The mechanism of action of IK-930 is differentiated from historically unsuccessful attempts that targeted PPIs using either small molecules or cyclic peptides. It is often difficult to discover compounds that disrupt PPIs with sufficient potency due to the typically undruggable shallow PPI pockets and large surface areas that make up tight PPIs. We believe that targeting the lipid binding pocket of TEAD has the potential to yield more potent and selective molecules as compared to these historical attempts. Using structural biology-guided chemistry, we were able to generate novel TEAD inhibitor compounds, including IK-930, across several chemical series directed to this binding pocket in TEAD and profile them using various in vitro and in vivo assays assessing potency, selectivity, tolerability, and activity. We are currently conducting a Phase 1 clinical trial of IK-930 in multiple tumor types, including cancers with high frequencies of Hippo pathway alterations. In addition to primary cancers linked to the Pathway we plan to evaluate IK-930 in patients with the potential for acquired resistance to other targeted therapies. We have generated preclinical data supporting our belief of the clinical opportunity to treat EGFR and MEK resistant patients with IK-930.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our ongoing translational work coupled with our clinical development strategy positions us to select patients most likely to benefit from TEAD inhibition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our preclinical studies, we believe IK-930 is a potent, well tolerated and selective TEAD inhibitor with favorable pharmacologic properties. In a TEAD reporter cell line, IK-930 inhibited TEAD-dependent transcription with an EC50 of 25 nM, and inhibited proliferation of H226 cells, an NF2 mutant mesothelioma cell line, with an EC50 of 21 nM, demonstrating that IK-930 has high potency in inhibiting activated Hippo signaling in cultured cancer cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The figure below illustrates the inhibition of TEAD by IK-930.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Inhibition of TEAD by IK-930 blocks TEAD-Dependent Transcription and Proliferation in H226 Cells Containing an NF2 Mutation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_6.jpg" alt="img39825204_6.jpg" style="width:407px;height:335px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of IK-930 to selectively inhibit proliferation in Hippo pathway mutated cells was demonstrated in the H28 mesothelioma cell line which does not have any Hippo pathway mutations. This cell line is insensitive to IK-930. However, knockdown of NF2 using CAS9-CRISPR converts H28 into an IK-930 sensitive tumor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The figure below illustrates IK-930 blocking the proliferation of cells with NF2 loss but not in cells with normal NF2.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-930 Blocks Proliferation in Cells with NF2 Loss but Not in Cells with Normal NF2</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_7.jpg" alt="img39825204_7.jpg" style="width:389px;height:319px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also observed that IK-930 was significantly selective for TEAD as assessed in these cell-based assays relative to a safety panel of 45 receptors, enzymes and ion channels, a human ether-a-go-go related gene, or hERG, assay and a panel of Cytochrome P450, or CYP, inhibition assays.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We observed favorable PK/PD of IK-930 in preclinical studies. We observed that IK-930 exhibited antitumor activity in preclinical tumor models with Hippo pathway mutations. IK-930 dosed in a H226 NF2 mutant mouse xenograft model led to antitumor activity throughout the treatment period. We observed similar activity in a xenograft model using a LATS1 fusion/LATS2 deleted tumor model. IK-930 dosed in NF2 mutant and LATS1 fusion/LAT2 deleted mouse xenograft models led to tumor growth inhibition compared to vehicle.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The figures below illustrate the antitumor activity of IK-930 in Hippo mutant xenograft models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Antitumor Activity of IK-930 in Hippo Mutant Xenograft Models</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_8.jpg" alt="img39825204_8.jpg" style="width:617px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to potential for single agent activity in tumors with genetic alterations in the Hippo pathway, we believe there is an opportunity for IK-930 to be beneficial in combination with other targeted therapies in the therapeutic resistance setting. Alterations in the Hippo pathway have been connected to post-targeted treatment tumor growth or recurrence. For example, YAP1 activation (nuclear localization) has been shown to drive resistance to EGFR targeted therapies. NSCLC patients who develop resistance to EGFR inhibitors have higher levels of nuclear YAP expression in their tumors compared to baseline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have generated robust preclinical data supporting our confidence in the clinical opportunity to treat EGFR resistant patients with IK-930. We observed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> that inhibitors of EGFR (osimertinib) promote YAP1 nuclear localization in EGFR mutant NSCLC cells. Moreover, we observed that IK-930 is able to kill EGFR resistant lung cancer cells </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in combination with osimertinib. We observed increased apoptosis </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and activity </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of IK-930 combined with EGFR inhibition. In the H1975 EGFR mutant lung cancer xenograft mouse model, we observed meaningful tumor growth inhibition in the group treated with IK-930 in combination with osimertinib, as well as complete regressions in the group treated with IK-930 in combination with osimertinib and trametinib, a MEK inhibitor, supporting that shutting down the mitogen-activated protein kinase, or MAPK, survival pathway further leads to antitumor activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The figure below illustrates </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (top) and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (bottom) models of IK-930 in EGFR mutant lung cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-930 in EGFR Mutant Lung Cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_9.jpg" alt="img39825204_9.jpg" style="width:471px;height:351px;" />&#160;</p>
  <p style="margin-left:63.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Tra: Trametinib</span></p>
  <p style="margin-left:63.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Osi: Osimertinib</span></p>
  <p style="margin-left:63.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">OT: Osi + Tra Combo</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_10.jpg" alt="img39825204_10.jpg" style="width:481px;height:311px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also conducted studies in several tumor models of KRAS-mutant cancers assessing the combination of IK-930 with trametinib. In two models of KRAS G13D, HCT116 and LoVo IK-930 combined with trametinib demonstrated robust anti-tumor activity than either single agent alone.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-930 Combination with Trametinib in two KRAS G13D CRC Models</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><img src="img39825204_11.jpg" alt="img39825204_11.jpg" style="width:624px;height:215px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a mouse model of KRAS G12S model A549 combination of IK-930 with trametinib showed significant impact on tumor inhibition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-930 Combination with Trametinib in KRAS G12S NSCLC Model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_12.jpg" alt="img39825204_12.jpg" style="width:624px;height:387px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Importantly, in all three of these models, IK-930 added activity only when treatment with trametinib was present, suggesting the resistance of the tumor is linked to the Hippo pathway and could benefit from TEAD inhibition. These data support studying IK-930 in combination with targeted therapies in multiple tumor types, including EGFR and KRAS mutant tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-930 clinical development strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the broad role of the Hippo signaling pathway on tumor biology and cancer progression, we plan to focus development of IK-930 on biomarker selected patient populations based on NF2 loss, and/or YAP1 and TAZ gene fusion or gene amplification in patients with solid tumors. We plan to utilize a comprehensive clinical development strategy focused on genetically defined patient populations targeting indications of high unmet medical need, which includes the following components:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assessing potential in rapid proof-of-concept and fast-to-market opportunities of IK-930 monotherapy for patients with solid tumors harboring genetic alterations in the Hippo pathway in rare and orphan disease indications; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expanding our clinical development plan into combinations with other targeted therapies as well as broader indications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ongoing Phase 1 clinical trial of IK-930 is exploring IK-930 as a monotherapy and is planned to also assess IK-930 in combinations with other targeted therapies. The monotherapy arm of the trial is evaluating the safety and activity of IK-930 in rare and orphan tumors associated with specific genetic alterations such as NF2 loss. The clinical trial, is designed to determine the maximum tolerated dose and the recommended Phase 2 dose, as illustrated in the figure below. The first patient in this trial was dosed with IK-930 in January 2022. Currently, we are enrolling  the monotherapy dose escalation cohort with patients with tumors known to have high incidence of Hippo pathway alterations. In the monotherapy dose expansion we plan to include multiple cohorts and select patients prospectively based on specific Hippo genetic alterations such as NF2 loss and/or YAP1 and TAZ gene fusion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Phase 1 Clinical Trial of IK-930</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_13.jpg" alt="img39825204_13.jpg" style="width:624px;height:388px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the combination arm of the Phase 1 clinical trial, we plan to include three different cohorts and explore indications based on emerging efficacy data from the monotherapy arm, as well as biomarker defined tumors with known mechanisms of tumor escape where IK-930 may be able to overcome resistance to targeted therapies, such as EGFR resistant NSCLC, and potentially improve effectiveness of targeted therapies. We expect to provide a clinical data update from this trial in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Early-Stage Research to Expand Targeted Oncology Portfolio</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Across our early-stage pipeline, we are conducting work in both the Hippo and RAS pathway in the effort to develop therapies for cancers that target key nodes and feedback connections between mutations and alterations. The image below is a depiction of select areas of the RAS pathway and Hippo pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"><br /><br /></span><img src="img39825204_14.jpg" alt="img39825204_14.jpg" style="width:624px;height:354px;" /><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Efforts in the RAS Pathway</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This work is across multiple nodes in the pathway, both known and novel. We believe that positive clinical data from the recently approved KRAS G12C inhibitors provide support for modulating targets in the KRAS pathway, including potentially G12D, G12V, and others that are not being addressed by current product candidates or approved therapies. In addition, clinical therapeutic resistance to G12C inhibitors has developed and emerging data suggests cancer cells continue to rely on MAPK signaling pointing toward a need for vertical combinations within the pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing small molecule inhibitors of ERK5 for the potential to treat patients with KRAS mutant cancers. We believe that ERK5 provides an opportunity to address unmet medical need in the RAS pathway by modulating a key target that is downstream of RAS and therefore applicable to cancers with oncogenic KRAS mutations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ERK5 Rationale</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ERK5 is a member of the MAPK family. It is composed of an N-terminal kinase domain and a C-terminal tail responsible for sub-cellular localization and transcriptional activation. ERK5 can be activated in response to a range of mitogenic stimuli such as growth factors, G protein-coupled receptor agonists, cytokines and cellular stresses (e.g., hypoxia, shear stress). Through the MAPK signaling cascade, mitogen-activated protein kinase 5, or MEK5 activates ERK5 by phosphorylating the N-terminal domain, thereby enabling ERK5 kinase activity. ERK5 is an important mediator of tumorigenesis and metastatic progression, and a fundamental component of drug resistance in cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As illustrated in the figure below, we observed single agent antitumor activity in both a pancreatic and lung patient derived xenografts in mice using a small-molecule ERK5 inhibitor. This inhibitor is a potent and selective tool compound with an IC50 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of 35 nM with high selectivity for ERK5 but has a short half-life and short PD effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ERK5 inhibition reduces tumor growth in patient-derived mouse xenograft models of pancreatic and lung cancer</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_15.jpg" alt="img39825204_15.jpg" style="width:620px;height:160px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, we observed increased antitumor activity with dual ERK5 and MEK inhibition in KRAS mutant cancers in preclinical studies. In a three dimensional cell culture system, we observed that combined ERK5 and MEK inhibition led to synergistic antitumor activity (synergy score &gt; 1.5) in two mutant KRAS lung cancer cell lines, NCI-H2122 (G12C KRAS mutation) and A-549 (G12S KRAS mutation), but not in the wildtype KRAS lung cancer cell line NCI-H520.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Synergy of ERK5 and MEK inhibition in KRAS mutant but not wild type cells in 3D cell culture system</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_16.jpg" alt="img39825204_16.jpg" style="width:302px;height:237px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In preclinical studies in KRAS primary human tumor models of lung and pancreatic cancer, we observed synergistic effects on tumor inhibition by combining this inhibitor tool compound of ERK5 and trametinib. These models contained mutations in the RAS pathway. These data, as illustrated in the figure below, suggest that, in addition to single agent potential in KRAS-mutated cancers, there is potentially a clinical opportunity for ERK5 inhibitors to be used in combination with MEK inhibitors and other targeted therapies to address therapeutic resistance in these patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Synergistic combination of MEK inhibitor and ERK5 inhibitor in KRAS mutant pancreatic (right) and lung (left) primary human tumor xenografts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_17.jpg" alt="img39825204_17.jpg" style="width:587px;height:117px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">RAS Signaling Opportunity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite continuous industry efforts in the past several decades to develop therapies for KRAS mutant cancers, therapies directly targeting KRAS G12C are only now beginning to show clinical promise. In the United States, about 13% of patients with NSCLC harbor the KRAS G12C mutation. Although there has been recent progress with these compounds that directly inhibit mutant KRAS, the majority of the KRAS space remains open. At this time, 85% of KRAS mutations (G12D, G12V, G13, others) are not being addressed by clinical stage product candidates or approved therapies. KRAS mutations are estimated to occur in about 26% of all cancers, including 25% of lung cancers, 90% of pancreatic cancers and between 27% and 56% of colorectal cancers. We believe that new approaches to key nodes and novel targets, like ERK5, represent differentiated opportunities to address these high unmet medical need segments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we continue to narrow in on potential targets and product candidates, we are looking extensively at the patient populations that have the potential to benefit from new therapies. There are three indications we believe represent unmet needs despite the recent advancement in the space: NSCLC, pancreatic cancer and CRC.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">NSCLC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: There are an estimated 228,000 new cases of lung cancer diagnosed and approximately 135,000 deaths in the United States annually. NSCLC is estimated to account for approximately 80% to 85% of lung cancer cases and KRAS mutations are estimated to occur in about 25%. Previously, patients were treated primarily with radiation therapy or combinations of cytotoxic drugs. In the past 15 years, a number of targeted agents have been developed based on alterations in the genes for EGFR and anaplastic lymphoma kinase gene, or ALK, significantly improving the outcome of patients with NSCLC harboring these genetic alterations. Furthermore, in the last five years, the introduction of immunotherapy for the treatment of NSCLC patients has also improved the outcome of the treatment in patients, especially those with high PD-L1 expression. However, a significant proportion of NSCLC patients are ineligible for these novel therapies or develop resistance to existing treatments, representing an important unmet medical need. Approximately two-thirds of NSCLC patients are ineligible for treatment with EGFR or ALK targeted therapies, representing an important unmet medical need. Despite the availability of these new therapies, the prognosis in NSCLC remains poor, with an overall five-year survival for all patients diagnosed with NSCLC estimated to be approximately 19% and until recently there were no specific therapeutic options for this subset of patients. Even with the emergence of KRAS inhibitors targeting G12C mutations, most NSCLC patients with KRAS mutations will eventually progress and die due to their disease. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pancreatic cancer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The American Cancer Society estimates that about 57,600 patients will be diagnosed with pancreatic cancer in 2020. The tendency of pancreatic cancer to spread silently before diagnosis makes it one of the deadliest cancer diagnoses. In metastatic pancreatic cancer, surgery and radiation are </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">used only for symptom control. Chemotherapy, such as gemcitabine and 5-FU/leucovorin/oxaliplatin/irinotecan, can help improve pancreatic cancer symptoms and survival. The drug olaparib (Lynparza) has been approved for metastatic patients with the BRCA gene mutation whose cancer has responded well to chemotherapy. Unfortunately, in spite of the development of new treatments for pancreatic cancer, deaths due to this tumor are on the rise. The National Cancer Institute has identified targeting oncogenic RAS as one of the four major priorities for pancreatic cancer research.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">CRC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CRC is the second leading cause of cancer deaths in the United States. Despite the reduction of incidence and improvement of early detection in the United States, approximately 86% of patients are diagnosed after the onset of symptoms when their disease is relatively advanced. Patients with advanced CRC are treated with radiation and chemotherapy drugs such as 5-fluorouracil, oxaliplatin and capecitabine, as well as recently approved antibodies, that inhibit angiogenesis, such as bevacizumab. In a subset of CRC patients, treatment with antibodies targeting epidermal growth factor receptor, or EGFR, (for example, the agent cetuximab) has been shown to be effective both as monotherapy and in combination with chemotherapy. However, approximately 40% of patients have a mutation in the KRAS gene that renders cetuximab ineffective.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Immune Signaling Programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to our programs targeting the RAS and Hippo pathways, we are also advancing programs that target immune-signaling pathways that contribute to the TME. These programs, like our targeted oncology pipeline, are supported by robust biomarker research that allow us to prospectively select patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Two of our immune signaling programs, IK-175 and IK-412, are partnered with BMS. Through our strategic partnership, Bristol Myers Squibb has the exclusive right to license each of IK-175 and IK-412 through completion of Phase 1b clinical trials. IK-175 is an inhibitor of AHR and both unselected patients and those with activated AHR are currently being enrolled in the dose expansion cohort of a Phase 1 clinical trial of patients with locally advanced or metastatic solid tumors, including bladder cancer. IK-412 is an enzyme therapy designed to lower levels of immunosuppressive kynurenine in the TME. The IK-412 program experienced manufacturing delays previously disclosed in 2021. Considering these delays and the timeline of the partnership we have made the strategic decision to pause IK-412 development for the remainder of the Bristol Myers Squibb collaboration agreement term once the ongoing CMC work has been completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-175, an AHR antagonist</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-175 is a potent, selective oral antagonist of AHR. We observed evidence of antitumor activity of IK-175 as a monotherapy and in combination with an anti-PD-1 antibody in preclinical models. We are currently enrolling patients with bladder cancer in a Phase 1 clinical trial of IK-175, evaluating it as both a monotherapy and in combination with nivolumab in both unselected population and enriched with patients whose tumors have activated AHR . Pursuant to our master collaboration agreement with Celgene Corporation (now Bristol Myers Squibb), or the Bristol Myers Squibb Collaboration Agreement, we are responsible for development of IK-175 through the completion of a Phase 1b clinical trial, through the completion of which Bristol Myers Squibb has an exclusive right to exclusively license IK-175 worldwide. See &#x201c;&#x2014;License and Collaboration Agreements&#x2014;Master Collaboration Agreement with Bristol-Myers Squibb&#x201d; for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dual role of AHR in cancer progression</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR is a ligand-dependent transcription factor that drives tumor progression through direct cancer cell and immunosuppressive effect in the TME. In some tumors, such as bladder cancer, high levels of AHR lead to constitutive, always-on activation and direct stimulation of tumor cell growth. AHR is also a critical component of a dominant immunosuppressive pathway in cancer, a pathway that modulates the function of cells in both the innate and adaptive components of the immune system. AHR is, in its inactive form, found in the cytosol, outside the nucleus. Upon binding of a signaling molecule or ligand, AHR migrates to the nucleus and functions as a transcription factor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR is overexpressed and constitutively activated in a number of tumors, including, but not limited to, bladder cancer and advanced breast cancer. Constitutive activation of AHR also has been reported in head and neck squamous cell carcinoma as well as castration-resistant prostate cancer. In melanoma, constitutive activation of AHR is believed to represent a significant mechanism of resistance to approved inhibitors of BRAF kinase. Inhibition of constitutively active AHR in patient-derived acute myeloid leukemia cells has been shown to sensitize these cells to killing by natural killer cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bladder cancer overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We prioritized patients with bladder cancer as a lead indication for the development of IK-175 based on the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Poor prognosis of patients with bladder cancer is associated with a high AHR transcript profiling score; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">High levels of AHR mRNA and protein as measured by immunohistochemistry and RNAscope are found in bladder cancers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR amplifications have been described in approximately 5% to 22% of bladder cancer patients; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nuclear localization of AHR is high in bladder cancers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bladder cancer is the most common malignancy involving the urinary system and there were an estimated 81,400 new cases of bladder cancer and 17,980 deaths in the United States in 2020. The five-year survival for patients with early-stage disease is 88%; however, for patients with metastatic disease or cancer that has spread to other parts of the body, the five-year survival drops to 5%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The most common treatment for patients diagnosed with advanced or metastatic bladder cancer is chemotherapy with platinum-based drugs such as carboplatin or cisplatin in combination with gemcitabine. Patients with metastatic disease that progresses during or after platinum-based chemotherapy are increasingly being treated with checkpoint immunotherapy. A number of PD-1 and PD-L1 checkpoint inhibitors have been approved by the FDA for the treatment of patients with refractory bladder cancer. Objective response rates in clinical trials with checkpoint inhibitors have generally been between 13% and 29%. The median overall survival of patients with advanced or metastatic bladder cancer from the start of initial therapy is 12.7 months. Other drugs have been recently approved for use in patients with metastatic bladder cancer after failure to platinum based regimens and checkpoint inhibitors including Enfortumab vedotin and Sacituzumab govitecan (antibody directed conjugates or ADCs).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:5.695pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our solution, IK-175</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-175 is an internally discovered small molecule AHR antagonist that we are developing for the treatment of advanced or metastatic solid tumors, including bladder cancer where AHR-activation is known to lead to poor prognoses. We observed that IK-175 is potent and selective for AHR in multiple </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assays and species.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an ongoing, open-label Phase 1 clinical trial evaluating IK-175 as a monotherapy and in combination with nivolumab. The dose-escalation cohorts enrolled locally advanced or metastatic solid tumor patients. Currently we are enrolling in our expansion cohorts for patients with bladder cancer, including selection for patients who are AHR biomarker positive. Clinical pharmacokinetic and pharmacodynamic data supports once-daily clinical dosing in patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-175 indication and patient selection strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our IK-175 clinical development strategy is focused on enrolling patients who are most likely to respond to an AHR antagonist. As part of our robust translational strategy, we have explored three tumor profiling technologies centered on AHR to help guide indication selection and/or candidate patients:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR gene amplification: Increases in the number of copies of the AHR gene as assessed by Fluorescent In Situ Hybridization, or FISH, are observed in over 5% of multiple cancers such as esophageal, bladder and lung cancers. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nuclear AHR positivity: Constitutive activation of AHR leads to its localization to the nucleus, which can be directly measured by a proprietary immunohisto chemical staining assay that we developed. In the monotherapy expansion cohort, we are prospectively enriching for patients with tumors that exhibit activated AHR using this assay. With the proprietary assay we developed, we assessed multiple tumor samples and found bladder cancer has the highest percentage of nuclear AHR positivity of those sample test. Head and neck cancer, melanoma, and ovarian cancer also resulted in higher-than-average scores, as displayed in the image below. The assay also is being used in our ongoing clinical trial to select patients with high nuclear-AHR positivity. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Immunohistochemistry Tumor Microarray Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_18.jpg" alt="img39825204_18.jpg" style="width:465px;height:295px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR-dependent gene transcription: Activation of AHR leads to changes in transcription of many genes which can be quantified by standard mRNA transcription profiling technologies. We discovered this gene transcription expression signature. We generated a profile of the transcriptional changes induced by AHR activation across a panel of cell lines. We then used this profile to score tumors based on available transcript profiling data in public databases. We found that bladder cancer patients with transcriptional profiles that scored highest using our activated AHR profile had poorer prognoses compared to those with low scores, as illustrated in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AHR-activated Gene Transcription Signature is Associated with Poor Overall Survival in Bladder Cancer Patients (c)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_19.jpg" alt="img39825204_19.jpg" style="width:310px;height:295px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ongoing Phase 1 clinical trial and clinical development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently enrolling patients with locally advanced or metastatic solid tumors in an open-label Phase 1 clinical trial evaluating IK-175 as a monotherapy and in combination with nivolumab, including dose expansion cohorts for patients with bladder cancer in both all comers and AHR positive tumors. The primary endpoint of this trial is safety and tolerability. As of February 1, 2022, we have completed the dose escalation of both treatment we are currently enrolling patients in both the monotherapy and combination dose expansion cohorts. To date, we have not observed any dose limiting toxicities, or DLTs, to date and have not reached the maximum tolerated dose in both treatment arms. In the first four dose cohorts, we observed dose responsive target gene inhibition in whole blood assay from patient samples, as set forth in the graph below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-175 Target Modulation in Patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_20.jpg" alt="img39825204_20.jpg" style="width:452px;height:294px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to present initial clinical data from this program in the second half of 2022. Additionally, we plan to initiate a clinical trial in HNSCC as second indication to explore for IK175 in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-007, an EP4 antagonist <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-007 is an oral selective antagonist of the EP4 receptor. IK-007 has been well tolerated in over 900 subjects to date in non-oncology clinical trials. We are conducting a Phase 1b clinical trial of IK-007 in combination with pembrolizumab for the treatment of patients with MSS CRC, which represents approximately 85% of patients with CRC. In this Phase 1b clinical trial, we observed encouraging preliminary evidence of tolerability and antitumor activity and did not observe any DLTs in the initial dose escalation cohort. In addition, we have identified higher baseline levels of urinary PGEM, a metabolite in the EP4 pathway, as a potential biomarker that we believe is associated with clinical benefit. The trial completed enrollment in the fourth quarter of 2021. We anticipate presenting clinical data from this program in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Role of EP4 Pathway in cancer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prostaglandin-endoperoxide synthase 2, or COX2, is an enzyme that is responsible for the production of prostaglandins during inflammation, including Prostoglandin E2 or PGE2. PGE2 sends its signals through four distinct receptors, known as EP1 through EP4, and these receptors in immune cells can have either stimulatory or suppressive activities. We believe that blocking immunosuppressive activity by inhibiting EP4, the higher affinity immunosuppressive receptor of PGE2, could be valuable in treating cancer. We also believe that selectively blocking PGE2 signaling through EP4 could lower the likelihood of toxicities that may result from fully blocking this fundamental pathway. The figure below illustrates the mechanism of action of IK-007.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IK-007 selectively blocks EP4, the high affinity immunosuppressive receptor in the COX2/PGE2 pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_21.jpg" alt="img39825204_21.jpg" style="width:393px;height:377px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A large body of literature demonstrates that activation of the PGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:5.695pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> pathway in cancer augments tumor initiation, progression and therapeutic resistance. Increased expression of pathway components, including EP4, is associated with decreased survival, therapeutic and preventive precedent in a number of cancer types, including CRC. When activated, EP4 affects the activity of a broad range of cells within the innate and adaptive immune system culminating in an immunosuppressive TME. Preclinical studies suggest that a selective antagonist of EP4 has the potential to bring therapeutic benefit to tumors such as CRC by changing the immunosuppressive TME so that tumors can become more accessible to the penetration of immune cells and more susceptible to the activity of checkpoint inhibitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MSS CRC Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CRC is the second leading cause of cancer deaths in the United States. The National Cancer Institute estimates that there were 147,950 new cases of CRC and 53,200 CRC related deaths in the United States in 2020. Approximately 35% of patients newly diagnosed with CRC will die within five years. PD-1 checkpoint inhibitors have been approved in a subset of CRC known as microsatellite instability-high, or MSI-H, tumors. MSI-H tumors are found in about 15% of CRC patients, with microsatellite stability, or MSS, tumors representing the remaining 85% of patients. The prognosis of MSS CRC patients is significantly poorer than that of MSI-H patients. MSS CRC represents a large unmet clinical need. Interim data of single agent treatment with pembrolizumab showed an overall response rate in MSS CRC of 0% (0/18).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our solution, IK-007</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-007 is a selective EP4 antagonist originally discovered by Pfizer that we licensed to explore as a potential cancer therapy. IK-007 has been dosed in over 900 adults in previous non-oncology clinical trials, including in two Phase 2 clinical trials on the treatment of osteoarthritic knee pain. In normal healthy volunteers studies, IK-007 was found to be well tolerated when administered as a single dose up to 1000 mg and as multiple doses up to 300 mg twice a day for 14 days. Based on the biological rationale for PGE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:bottom;font-size:5.695pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/EP4 in CRC and the high unmet medical need in MSS CRC, in particular given that single agent pembrolizumab is inactive in these patients, we are currently conducting a Phase 1b clinical trial of IK-007 in combination with pembrolizumab for the treatment of patients with MSS CRC. Encouraging preliminary evidence of antitumor activity and higher baseline levels of a potential predictive PGE2 metabolite biomarker, called PGEM, are emerging from the ongoing trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the end of 2021, the trial completed enrollment and patients continue in follow-up. We anticipate presenting clinical data from this program in the second half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Ongoing Phase 1b trial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are conducting a single arm Phase 1b clinical trial of IK-007 in combination with pembrolizumab in patients with MSS CRC patients who have received at least two lines of prior systemic therapy and progressed, and therefore unlikely to respond to pembrolizumab monotherapy. The primary endpoint of this trial is safety and tolerability of IK-007 alone and in combination with pembrolizumab.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While early in development, we are encouraged by the observed antitumor activity of IK-007 in combination with pembrolizumab. As of the last data cut in 2021, we observed evidence of clinical benefit (complete response, or CR, partial response, or PR, and stable disease, or SD, for 16 weeks) in four out of 20 evaluable patients treated at 300 mg bid p.o. as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One patient had a CR and remained on study for 22 months; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One patient experienced 29% tumor shrinkage that was close to meeting the criteria for a PR; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One patient had durable stable disease for over six months (prolonged SD); and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One patient had a mixed response with shrinkage of some but not all tumors and stable disease for 17 weeks (prolonged SD). </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patient who reached a CR had received five prior lines of therapy. This highly refractory patient&#x2019;s tumor also exhibited low tumor mutational burden, or TMB, reducing the likelihood that the antitumoral response could be due to pembrolizumab treatment alone as high TMB is often associated with response to anti-PD-1 therapies. Tumor response was observed soon after commencement of dosing with IK-007. A significant shrinkage of 48% of the tumor size was observed by CT scan after approximately two months of combined therapy. With additional cycles of treatment, evidence of tumor in this patient disappeared and the patient was classified as a complete responder, as illustrated in the figure below. This patient was on treatment for 22 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Complete response in an MSS CRC patient treated with 300 mg IK-007 and 200 mg pembrolizumab, and association with high urinary PGEM levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_22.jpg" alt="img39825204_22.jpg" style="width:620px;height:316px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img39825204_23.jpg" alt="img39825204_23.jpg" style="width:389px;height:269px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, we have identified a biomarker in the EP4 pathway, higher baseline levels of urinary PGEM, that we believe can help us select for patients who may benefit the most from IK-007. An ad hoc analysis of the first 33 patients enrolled in the study showed that there was a significant correlation between higher baseline levels of urinary PGEM and clinical benefit observed and with prolonged time on treatment (defined as over 16 weeks on study drug). High urine levels of PGEM (&gt; 50 ng/mg creatinine) were present in approximately 20% (21.2% with 95% CI 9.0-38.9) of the first 33 CRC patients tested for PGEM in the study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The most common related adverse events were Grade 1 or Grade 2 fatigue, pruritus and Grade 3 or Grade 4 increased gamma-glutamyl transferase, a liver enzyme.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the early positive tolerability profile of IK-007 in the first two cohorts (300 mg BID) in combination with pembrolizumab as well as encouraging signs of activity at this dose, we amended the protocol to explore three more</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">dose escalation levels of IK-007: 450 mg, 600 mg and 900 mg BID in combination with pembrolizumab. No DLTs in the three additional dose escalation cohorts were observed up to 900 mg BID. Most adverse events observed included myalgia, anemia, decrease appetite, insomnia and diarrhea, mostly Grade 1 or Grade 2. We also observed transient elevations of liver function tests, or LFTs, that in a few cases required IK-007 dose modifications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on these data, we selected the dose of 900 mg BID of IK-007 in combination with pembrolizumab (200 mg) every three weeks for the dose expansion cohort. The trial is fully enrolled and patients are currently undergoing follow-up.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In selecting patients to receive IK-007, our objective is to focus treatment on patients who are most likely to respond. We generated a validated urine PGEM biomarker assay. We used it to measure baseline PGEM urinary levels to select patients who are more likely to respond in our MSS CRC dose expansion cohort.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also conducted a second open-label single arm Phase 1b clinical trial of IK-007 in combination with pembrolizumab in patients with advanced or metastatic post anti-PD-1/L1 treatment in NSCLC. Based on the combined data generated in the interim period for efficacy and safety, we decided not to further explore this combination in NSCLC and terminated this clinical trial in December 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that IK-007 may have the potential to bring therapeutic benefit beyond MSS CRC and we may expand into certain additional indications in which there is high unmet medical need and biological rationale for the key role of EP4 pathway in cancer progression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-007 in Inflammatory Breast Cancer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inflammatory breast cancer, or IBC is a rare, aggressive form of breast cancer with high unmet medical need. While it represents less than 5% of all breast cancers, it progresses quickly and is most often diagnosed when it has already reached stage 3 or 4. There is a higher incidence of IBC in younger women as it can go undetected in early stages without the regularity of mammograms seen in older patients. Additionally, IBC has a higher incidence in African American women. Increased COX-2 is expressed in the EP4 pathway is in 40-50% of IBC patients and has been associated with poor prognosis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2021, an investigator-initiated trial (IIT) of IK-007 in combination with the chemotherapy agent eribulin was launched in metastatic IBC led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center and it is currently enrolling patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biotechnology and pharmaceutical industries are characterized by rapid innovation of new technologies, fierce competition and strong defense of intellectual property. While we believe that our pipeline and our knowledge, experience and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We compete in the segments of the pharmaceutical, biotechnology, and there are other companies focusing on structural biology-guided chemistry-based drug design to develop therapies in the fields of cancer and other diseases. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets that pursue targeted oncology therapeutics. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe principal competitive factors to our business include, among other things, our ability to identify promising biomarkers, our ability to successfully transition research programs into clinical development, our ability to raise capital, and the scalability of our pipeline and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our competitors may obtain regulatory approval of their products more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a significant premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-930</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other companies that have publicly disclosed that they are developing TEAD inhibitors are: Vivace Therapeutics, Inc., Novartis International AG (Novartis), Inventiva S.A., Kyowa Hakko Kirin Co., Ltd., SpringWorks Therapeutics, Inc., Cedilla Therapeutics, Inc., BridGene Biosceiences, Sanofi, and Roche/Genentech. Vivace Therapeutics, Inc. and Novartis are both in Phase 1 clinical trials with their programs. All other programs are preclinical.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-175</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of one other AHR antagonist in clinical development under development by Bayer AG, or Bayer. Bayer is currently enrolling patients with advanced solid tumors in a Phase 1 trial for BAY-2416964 in advanced solid tumors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-007</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-007 is one of the EP4 antagonists currently in clinical development. The other programs in clinical development are from Ono Pharmaceutical (ONO-4578), Adlai Nortye/Eisai (AN-0025 / E-7046), and Ionova (INV-1120) which are in Phase 1 clinical trials. Tempest Therapeutics&#x2019;TPST-1495, a dual antagonist that selectively blocks EP2 and EP4, is in Phase 1 clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">     </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">License and Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Master Collaboration Agreement with Bristol-Myers Squibb</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, we entered into the BMS Collaboration Agreement with Celgene Corporation (which was acquired by BMS in November 2019) under which BMS may elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that modulate the activity of two collaboration targets, kynurenine and AHR, excluding AHR agonists except for inverse agonists, or the Collaboration Candidates, which we are developing as IK-175 and IK-412. The BMS Collaboration Agreement triggered an upfront payment of $95.0 million, which consisted of approximately $80.5 million in cash and an equity investment of approximately $14.5 million for which we issued 14,545,450 shares of our Series A-1 Preferred Stock pursuant to a separate stock purchase agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On a program-by-program basis, through the completion of a Phase 1b clinical trial for each of IK-175 and IK-412, BMS has the exclusive right with respect to such Collaboration Candidate to a worldwide exclusive license with us to develop, commercialize and manufacture the compound (and products and diagnostic products containing such compounds) underlying such Collaboration Candidate. Additionally, if we do not complete a Phase 1b clinical trial by the end of the research term (as defined below), we may elect to provide a data package to BMS upon which BMS may exercise the foregoing option for an additional $0.25 million fee.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As previously disclosed in 2021, the IK-412 program experienced manufacturing delays as a key component required in the manufacturing of IK-412 is similarly essential to the manufacturing of COVID-19 vaccines and therapies. Considering these delays and the timeline of the BMS partnership, we have made the strategic decision to pause IK-412 development activities for the remainder of the BMS contract term once the ongoing committed CMC work has been completed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If and when BMS exercises its rights for a Collaboration Candidate, and as a result of the timing of our submission of INDs with respect to each Collaboration Candidate, BMS is required to pay us $50.0 million, in the case of an exercise of its option with respect to IK-175, and $40.0 million, in the case of an exercise of its option with respect to IK-412. The option exercise fees are payable within fifteen (15) days after the execution of each license agreement. Upon the execution of each license agreement, we will become eligible to receive up to $265.0 million under such license agreement in regulatory milestones and $185.0 million in commercial milestones as well as a tiered royalties at rates ranging from the high single to low teen percentages based on worldwide annual net sales by BMS, subject to specified reductions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BMS will continue to pay royalties on a Collaboration Candidate-by-Collaboration Candidate and country-by-country basis, until the latest of (i) there being no valid claim under the licensed patents covering the Collaboration Candidate, (ii) expiration of all regulatory exclusivity for the Collaboration Candidate in such country, and (iii) twelve (12) years after the first commercial sale of the Collaboration Candidate in the applicable country (the Royalty Term), after which the applicable license granted to BMS in such country will become non-exclusive, fully paid-up, perpetual, irrevocable and royalty-free.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research term under the BMS Collaboration Agreement continues for a period of five (5) years from its effective date. The term of any license agreement described above would continue on a Collaboration Candidate-by-Collaboration Candidate and country-by-country basis until the expiration of all Royalty Terms under such agreement, unless earlier terminated as described below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The BMS Collaboration Agreement may be terminated (i) by either party on a program-by-program basis if the other party remains in material breach of the BMS Collaboration Agreement following a cure period to remedy the material breach, (ii) by BMS at will on a program-by-program basis or in its entirety, (iii) by either party, in its entirety, upon bankruptcy or insolvency of the other party, or (iv) automatically, on a program-by-program basis if BMS fails to timely deliver an opt-in notice to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each license agreement may be terminated (i) by either party if the other party remains in material breach of the license agreement following a cure period to remedy the material breach, (ii) by BMS at will, (iii) by either party, in its entirety, upon bankruptcy or insolvency of the other party, or (iv) by us, in its entirety, if BMS challenges a patent licensed by us to BMS under the license agreement or any jointly-owned collaboration patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon our termination of a license agreement for BMS&#x2019; breach, bankruptcy or insolvency or patent challenge, we would receive (i) upon our timely request, a nonexclusive worldwide license under BMS&#x2019; know-how and patents covering the applicable licensed compound to the extent that such compound (or product or diagnostic product containing such compound) has been or is in active development or commercialization as of termination; and (ii) subject to determination of an applicable license payment in accordance with the license agreement, an exclusive license for the foregoing. If BMS terminates a license agreement for our breach or bankruptcy or insolvency, BMS&#x2019; license will survive for six (6) months. Additionally, in the event of our material breach, BMS may elect to have the license agreement continue, with all future payments under that license agreement reduced by 50%. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent License Agreement with the University of Texas at Austin</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2015, we entered into an exclusive patent license agreement, or the License Agreement, with the University of Texas at Austin, or the University, pursuant to which the University granted us a worldwide license to certain technology and IP rights relating to a kynurenine-degrading enzyme, which we are developing as IK-412.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the License Agreement, and we pay a license fee of approximately $40,000 per year. We will also be obligated to make milestone payments to the University of up to an aggregate of $0.7 million upon meeting certain development milestones and up to an aggregate of $4.0 million upon meeting certain regulatory milestones, as well as low single digit royalties based on worldwide annual net sales on any licensed product, subject to specified reductions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will be obligated to continue to pay royalties on a licensed product-by-licensed product and country-by-country basis, as long as there is an existing valid claim under the licensed patents in such country. Please see &#x201c;Business&#x2014;Intellectual Property&#x2014;IK-412,&#x201d; for additional information concerning the intellectual property related to the License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the Licensed Agreement expires on licensed product-by-licensed product and country-by-country basis until the expiration of all royalty terms, unless earlier terminated as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The License Agreement may be terminated (i) by either party if the other party remains in breach of the license agreement following a cure period to remedy the breach, (ii) by us at will, (iii) by the University, in its entirety, upon our bankruptcy or insolvency, or (iv) by the University, in its entirety, if we challenge a patent licensed by the University to us under the license agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with AskAt</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection of our acquisition of Arrys Therapeutics, Inc., or Arrys, in December 2018, we acquired in-process research and development assets related to AskAt Inc.&#x2019;s, or AskAt, selective EP4 antagonists, namely IK-007 which we are currently developing in a Phase 1b clinical trial in MSS CRC and IK-008 which is a backup molecule, based on the intellectual property associated with a License Agreement, or the AskAt Agreement, between Arrys and AskAt, dated December 14, 2017. Pursuant to the AskAt Agreement, AskAt granted Arrys an exclusive license worldwide, other than China and Taiwan, to the research and development of the licensed compounds in human diseases. AskAt controls the prosecution and maintenance of all intellectual property rights pertaining the licensed technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the AskAt Agreement, we are obligated to make milestone payments to AskAt, including up to $4.0 million upon the achievement of certain clinical development milestones, as well as milestone payments of up to an aggregate of $600 million upon the achievement of certain worldwide annual net sales milestones. We are also obligated to pay low single-digit royalties on annual worldwide net sales on a licensed-product-by-licensed product and country-by-country basis, for the period beginning upon the first commercial sale in such country and ending upon the later of (i) 10 years from the first commercial sale in such country, or (ii) the expiration of valid claims in such country. Please see &#x201c;Business&#x2014;Intellectual Property&#x2014;EP4 Antagonist Patent Families,&#x201d; for additional information concerning the intellectual property related to the AskAt Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the AskAt Agreement expires on licensed product-by-licensed product and country-by-country basis upon the expiration of the royalty term for such licensed product, unless earlier terminated as described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The License Agreement may be terminated (i) by either party if the other party remains in material breach of the license agreement following a cure period to remedy the breach, (ii) by us for convenience upon 180 days&#x2019; notice or (iii) by either party, in its entirety, upon bankruptcy or insolvency of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We seek to protect the intellectual property and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and future products, and methods of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">using the same, as well as any other relevant inventions and improvements that we believe to be commercially important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. Our commercial success depends, in part, on our ability to obtain, maintain, enforce and protect our intellectual property and other proprietary rights for the technology, inventions and improvements we consider important to our business, and to defend any patents we may own or in-license in the future, prevent others from infringing any patents we may own or in-license in the future, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Protection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates, future products, and proprietary technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents and any issued patents we may obtain do not guarantee us the right to practice our technology or commercialize our product candidates. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or in-license in the future. Any issued patents that we may own or in-license in the future may be challenged, invalidated, circumvented, or have the scope of their claims narrowed. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#x2019;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier expiring patent. The term of a patent claiming a new drug product may also be eligible for a limited patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The term extension period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. The term extension period cannot be longer than five years, and the term extension period may not extend the patent term beyond 14 years from the date of FDA approval. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension in consultation with the FDA. In the future, if our product candidates receive approval by the FDA, we expect to apply for patent term extensions on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors. There can be no assurance that our pending patent applications, and any patent applications that we may in the future file or license from third parties, will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any patents we may own or in-license in the future. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, our overall patent portfolio includes forty-nine (49) patent families comprising issued patents, pending U.S. and PCT International patent applications, and pending patent applications in foreign jurisdictions. The patents and patent applications have claims relating to our current product candidates, methods of use and manufacturing processes, as well as claims directed to potential future products and developments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">TEAD Inhibitor Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we solely own ten patent families related to TEAD inhibitors and degraders, compositions thereof, and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2040 to 2042, not including any patent term adjustment, patent term extension, or supplementary protection certificate (SPC). The non-provisional patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one TEAD patent family directed to a first collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2022, this TEAD patent family contains two pending U.S. applications, and pending applications in foreign jurisdictions, such as Europe, Japan, Australia, Canada, India, South Korea, Mexico, Argentina, and Taiwan. For one of our pending U.S. patent applications, the United States Patent &amp; Trademark Office has mailed an Issue Notification stating that a U.S. patent is set to issue on March 15, 2022 based on this patent application. This application includes composition of matter claims encompassing IK-930. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one TEAD patent family directed to a second collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2022, this TEAD patent family contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, Australia, Canada, India, South Korea, Mexico, Argentina, and Taiwan. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one TEAD patent family directed to a third collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2022, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one TEAD patent family directed to a fourth collection of TEAD inhibitors, compositions thereof, and methods of their use. As of March 1, 2022, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one TEAD patent family directed to a collection of TEAD degrader compounds, compositions thereof, and methods of their use. As of March 1, 2022, this patent family contains one pending PCT application. Any U.S. or foreign patents that issue from this TEAD patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current lead TEAD inhibitor, IK-930, compositions thereof, and methods of the use, are covered by our solely owned pending U.S. and foreign patent applications that, if granted and all appropriate maintenance fees paid, are expected to expire from 2040 to 2042, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ERK5 and RAS Signaling Pathway Program Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we exclusively own fifteen patent families related to inhibitors targeting the ERK5 and RAS signaling pathway, compositions thereof, and methods of their use. For the ERK5 program, we exclusively own four pending PCT applications and over two pending U.S. provisional patent applications. For the RAS signaling pathway program, we exclusively own over nine pending U.S. provisional patent applications. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2041 to 2042, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">EP4 Antagonists Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we have an exclusive license to six patent families directed to EP4 antagonists, crystal forms thereof, compositions thereof, and methods of their use. The U.S. and foreign patents that have issued in these patent families and any further U.S. or foreign patents that may issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2024 to 2037, not including any patent term adjustment, patent term extension, or SPC. These patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one EP4 in-licensed patent family directed to crystal forms of EP4 antagonists, compositions thereof, and methods of their use. As of March 1, 2022, this EP4 in-licensed patent family contains a U.S. patent and patents in foreign jurisdictions, such as Europe, Japan, Canada, India, South Korea, and Mexico. The U.S. and foreign patents in this EP4 in-licensed patent family, if all appropriate maintenance fees paid, are expected to expire in 2026, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one EP4 in-licensed patent family directed to EP4 antagonists, compositions thereof, and methods of their use. As of March 1, 2022, this EP4 in-licensed patent family contains a U.S. patent and patents in foreign jurisdictions, such as Europe, Japan, Canada, South Korea, Mexico, and Brazil. These U.S. and foreign patents in this EP4 in-licensed patent family, if all appropriate maintenance fees paid, are expected to expire in 2024, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one EP4 in-licensed patent family directed to use of certain EP4 antagonists for treating cancer. As of March 1, 2022, this EP4 in-licensed patent family contains U.S. patents, patents in foreign jurisdictions, such as Europe, Japan, Canada, South Korea, and Mexico, and pending applications in the U.S. and Europe. These U.S. and foreign patents and any further U.S. or foreign patents that may issue from this EP4 in-licensed patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2030, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have one EP4 in-licensed patent family directed to use of certain EP4 antagonists for treating NASH-associated liver cancer. As of March 1, 2022, this EP4 in-licensed patent family contains U.S. patents, patents in foreign jurisdictions such as Europe, Japan, Canada, and Mexico, and pending applications in foreign jurisdictions, such as India. These U.S. patents, if all appropriate maintenance fees are paid, are expected to expire in 2036, not including any patent term extension, or patent term extension. These foreign patents and any further foreign patents that may issue from this EP4 in-licensed patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2037, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have two additional EP4 in-licensed patent families directed to use of EP4 antagonists for (i) treating immune disease or allergy and (ii) treating cartilage disease. As of March 1, 2022, these EP4 in-licensed patent families contained three U.S. patents, patents in foreign jurisdictions such as Europe, Japan, Canada, South Korea, and Mexico, and pending applications in foreign jurisdictions such as Japan, Europe, India, and South Korea. These U.S. and foreign patents and any further foreign patents that may issue from these EP4 in-licensed patent families, if granted and all appropriate maintenance fees paid, are expected to expire in 2031 and 2034, respectively, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, 2022, we and AskAt Inc. jointly own three patent families directed to EP4 antagonist compositions, methods of making certain EP4 antagonists and their formulations, and methods of their use. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. These patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EP4 jointly-owned patent family one is directed to use of EP4 antagonists in combination with an immuno-oncology agent for treating cancer. As of March 1, 2022, EP4 jointly-owned patent family one contains one U.S. patent, and pending applications in the U.S. and foreign jurisdictions, such as Europe, Japan, China, Australia, and Canada. The U.S. parent and any further any U.S. or foreign patents that may issue from EP4 jointly-owned patent family one, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EP4 jointly-owned patent family two is directed to methods of making certain EP4 antagonists and the compositions thereof. As of March 1, 2022, EP4 jointly-owned patent family two contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, China, Canada, and India. Any U.S. or foreign patents that issue from EP4 jointly-owned patent family two, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EP4 jointly-owned patent family three is directed to certain EP4 antagonist formulations, and the methods of use thereof. As of March 1, 2022, EP4 jointly-owned patent family three contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, China, and Canada. Any U.S. or foreign patents that issue from EP4 jointly-owned patent family three, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we solely own two patent families directed to EP4 antagonist salts and crystal forms, and methods of using EP4 antagonists. Any U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2039 to 2041, not including any patent term adjustment, patent term extension, or SPC. These patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EP4 solely-owned patent family one is directed to crystal forms of certain EP4 antagonists. As of March 1, 2022, this EP4 solely-owned patent family contains pending U.S. and European applications. Any U.S. or foreign patents that issue from this EP4 solely-owned patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EP4 solely-owned patent family two is directed to methods for selecting patients for EP4 antagonist treatment. As of March 1, 2022, this EP4 solely-owned patent family contains a pending PCT application. Any U.S. or foreign patents that issue from this EP4 solely-owned patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, our current lead EP4 antagonist IK-007 salt and crystal forms thereof, compositions thereof, and uses of IK-007 or a salt or crystal form thereof are covered by select patents and/or patent applications described above. These select patents and patent applications include over seven (7) issued U.S. patents, multiple pending U.S. patent applications, a PCT international patent application, and issued patents and pending patent applications in foreign jurisdictions that, if granted and all appropriate maintenance fees paid, are expected to expire from 2024 to 2041, not including any patent term adjustment, patent term extension, or SPC, as described in more detail above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">AHR Antagonists Patent Families</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we solely own seven patent families related to AHR antagonists, compositions thereof, and methods of their use. U.S. patents that have issued in these patent families and any further U.S. or foreign patents that issue from these patent families, if granted and all appropriate maintenance fees paid, are expected to expire from 2038 to 2041, not including any patent term adjustment, patent term extension, or SPC. The non-provisional patent families are described in more detail below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family one is directed to AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2022, this AHR antagonists patent family contains two U.S. patents, patents in foreign jurisdictions such as Singapore, and pending applications in the U.S. and foreign jurisdictions, such as Europe, Japan, China, Australia, Canada, India, South Korea, and Mexico. These U.S. and foreign patents and any further U.S. or foreign patents that may issue from AHR antagonists patent family one, if granted and all appropriate maintenance fees paid, are expected to expire in 2038, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family two is directed to AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2022, this AHR antagonists patent family contains one U.S. patent, and pending applications in the U.S. and foreign jurisdictions, such as Europe, Japan, China, Australia, Canada, India, South Korea, and Mexico. This U.S. patent and any further U.S. or foreign patents that </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may issue from AHR antagonists patent family two, if granted and all appropriate maintenance fees paid, are expected to expire in 2038, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family three is directed to AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2022, this AHR antagonists patent family contains a pending U.S. application, and pending applications in foreign jurisdictions, such as Europe, Japan, China, and Canada. Any U.S. or foreign patents that issue from AHR antagonists patent family three, if granted and all appropriate maintenance fees paid, are expected to expire in 2039, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family four is directed to crystal forms of certain AHR antagonists, compositions thereof, and methods of their use. As of March 1, 2022, AHR antagonists patent family four contains a pending U.S. application and a pending PCT application. Any U.S. or foreign patents that issue from AHR antagonists patent family four, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family five is directed to certain AHR antagonist formulations, and methods of their use. As of March 1, 2022, this AHR antagonists patent family contains a pending PCT application. Any U.S. or foreign patents that issue from AHR antagonists patent family five, if granted and all appropriate maintenance fees paid, are expected to expire in 2040, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family six is directed to methods of selecting patients for AHR antagonist treatment. As of March 1, 2022, this AHR antagonists patent family contains a pending PCT application. Any U.S. or foreign patents that issue from AHR antagonists patent family six, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AHR antagonists patent family seven is directed to methods of using AHR antagonists. As of March 1, 2022, this AHR antagonists patent family contains a pending PCT application. Any U.S. or foreign patents that issue from AHR antagonists patent family seven, if granted and all appropriate maintenance fees paid, are expected to expire in 2041, not including any patent term adjustment, patent term extension, or SPC.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, we and Oregon Health &amp; Science University (OHSU) jointly own one patent family related to methods of using AHR antagonists, which contains a pending U.S. provisional application. Any U.S. or foreign patents that issue from this patent family, if granted and all appropriate maintenance fees paid, are expected to expire in 2042, not including any patent term adjustment, patent term extension, or SPC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 1, 2022, our solely owned patents and patent applications covering current lead AHR antagonist IK-175, salts and crystal forms thereof, compositions thereof, and methods of the use include two issued U.S. patents, multiple pending U.S. and PCT international patent applications, patents in foreign jurisdictions such as Singapore, and pending patent applications in Europe, Japan, Australia, Canada, China, and other foreign jurisdictions, all of which are described above where, if granted and all appropriate maintenance fees paid, are expected to expire from 2038 to 2041, not including any patent term adjustment, patent term extension, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">IK-412</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We own and exclusively license patents and patent applications related to our IK-412 program. Our in-licensed patent portfolio related to this program includes three patent families that include patents and patent applications covering our IK-412 biologic drug product as a composition of matter and methods of using the same, alone or in combination with other therapeutic agents. The three exclusively licensed patent families are licensed from the University of Texas at Austin.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 8, 2022, the first in-licensed patent family includes two issued patents in the U.S., which are projected to expire in 2034 and 2035, respectively, excluding any patent term extensions, if applicable. The first in-licensed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patent family also includes issued patents in Europe, Hong Kong, Australia, China, Israel, India, Japan, Korea, New Zealand, and South Africa, and such patents are expected to expire in 2034, excluding any patent term extensions, if applicable. Within this first in-licensed patent family, patent applications are pending in the U.S., Brazil, Canada, China, Europe, Japan, Korea, and South Africa.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 8, 2022, the second in-licensed patent family includes two issued patents in the U.S., which are projected to expire in 2035, excluding any patent term extensions, if applicable. Within this second in-licensed patent family, patent applications are pending in the U.S., Canada, Europe, Israel, and Japan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 8, 2022, the third in-licensed patent family includes patent applications in the U.S., Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Eurasian Patent Organization, Hong Kong, Europe, Israel, India, Japan, Korea, Mexico, New Zealand, Singapore, Thailand, Taiwan, and South Africa. Patents that issue from these applications are projected to expire in 2039, excluding any patent term adjustments or extensions, if applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 8, 2022, we also solely own patent applications related to our IK-412 program. The company-owned patent portfolio related to this program consists of one patent family that currently includes one U.S. patent application and one PCT international patent application covering our IK-412 biologic drug product as a composition of matter and methods of using the same, alone or in combination with other therapeutic agents. Patents issuing from the company-owned patent family are projected to expire in 2040, excluding any patent term adjustments or extensions, if applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Trade Secret Protection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to patents, we rely on unpatented trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. In particular, we anticipate that with respect to the building of our compound library, our trade secrets and know-how will over time be disseminated within the industry through independent development and public presentations describing the methodology. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. These agreements may also be breached, and we may not have an adequate remedy for any such breach. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Trademark Protection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have filed for and obtained Notices of Allowance for trademark protection with the U.S. Patent and Trademark Office for the IKENA and IKENA ONCOLOGY word marks for goods and services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to receiving marketing approvals, we expect to commence commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe that such an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates that obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for clinical testing and commercial manufacture if our product candidates receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of our drug candidates are small molecules and are manufactured in synthetic processes from available starting materials. The chemistry appears amenable to scale-up and does not currently require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If necessary, we expect to rely on third parties for the manufacture of companion diagnostics for our products, which are assays or tests to identify an appropriate patient population. Depending on the technology solutions we choose, we may rely on multiple third parties to manufacture and sell a single test.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Governmental Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and biologics. We, along with our vendors, contract research organizations, or CROs, clinical investigators and contract manufacturing organizations, or CMOs will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and biologics and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, where we are initially focusing our drug development, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and biologics under the FD&amp;C Act and the Public Health Service Act, or PHSA, as amended, their implementing regulations. Both drugs and biologics are also subject to other federal, state and local statutes and regulations. If we fail to comply with applicable FDA or other requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality control, safety, marketing, advertising, promotion, packaging, labeling, export, import, distribution, or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#x2019;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates must be approved for therapeutic indications by the FDA before they may be marketed in the United States. For drug product candidates regulated under the FD&amp;C Act, FDA must approve a New Drug Application, or NDA. For biologic product candidates regulated under the FD&amp;C Act and PHSA, FDA must approve a Biologics License Application, or BLA. The process is similar and generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must be updated annually and when certain changes are made; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation and submission to the FDA of an NDA or BLA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of one or more FDA pre-approval or pre-license inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biological product&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payment of user fees for FDA review of the NDA or BLA; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the NDA or BLA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical studies and clinical trials for drugs and biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before testing any drug or biologic in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product chemistry, formulation and stability, as well as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before clinical trials may begin. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes the results of animal and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold. FDA must notify the sponsor of the grounds for the hold and any identified deficiencies must be resolved before the clinical trial can begin. Submission of an IND may result in the FDA not allowing clinical trials to commence or not allowing clinical trials to commence on the terms originally specified in the IND. A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until the deficiencies articulated by FDA are corrected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trial sponsor&#x2019;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on www.ClinicalTrials.gov, a clinical trials database maintained by the National Institutes of Health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA will nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Phase 1 clinical trials involve initial introduction of the investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#x2019;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and well-controlled Phase 3 trials are required by the FDA for approval of an NDA or BLA. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FDA released a draft guidance entitled &#x201c;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#x201d; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of NDA or BLA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators fifteen days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#x2019;s initial receipt of the information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. marketing approval for drugs and biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA or BLA package requesting approval to market the product for one or more indications. An NDA is a request for approval to market a new drug for one or more specified indications and must contain proof of the drug&#x2019;s safety and efficacy for the requested indications. A BLA is a request for approval to market a new biologic for one or more specified indications and must contain proof of the biologic&#x2019;s safety, purity and potency for the requested indications. The marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug, or the safety, purity and potency of the investigational biologic, to the satisfaction of the FDA. FDA must approve an NDA or BLA before a drug or biologic may be marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA reviews all submitted NDAs and BLAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA or BLA. The FDA reviews an NDA or BLA to determine, among other things, whether the product is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards designed, including cGMP requirements, designed to assure and preserve the product&#x2019;s continued identity, strength, quality and purity. Under the goals and polices agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA or BLA and respond to the applicant, and six months from the filing date of a new molecular entity NDA or BLA for priority review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, under PDUFA, as amended, each NDA or BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, special monitoring or other risk-minimization tools.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may refer an application for a novel drug or biologic to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA or BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if the FDA approves a product, depending on the specific risk(s) to be addressed it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan drug designation and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States when there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, though companies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developing orphan products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances, such as a subsequent product&#x2019;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product. Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. Further, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited development and review programs for drugs and biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs and biologics to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include fast track designation, breakthrough therapy designation, priority review and accelerated approval, and the purpose of these programs is to either expedite the development or review of important new drugs and biologics to get them to patients more quickly than standard FDA review timelines typically permit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A new drug or biologic is eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, a new drug or biologic may be eligible for breakthrough therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient product development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product submitted to the FDA for approval, including a product with fast track or breakthrough therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including priority review designation and accelerated approval. A product is eligible for priority review, once an NDA or BLA is submitted, if the product that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#x2019;s goal date to take action on the marketing application is six months compared to ten months for a standard review. Products are eligible for accelerated approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accelerated approval is usually contingent on a sponsor&#x2019;s agreement to conduct, in a diligent manner, adequate and well-controlled additional post-approval confirmatory studies to verify and describe the product&#x2019;s clinical benefit. The FDA may withdraw approval of a drug or an indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the Agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric information and pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and BLAs and certain NDA and BLA supplements must contain data that can be used to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires that a sponsor who is planning to submit a marketing application for a product candidate that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. Unless otherwise required by regulation, PREA does not apply to a drug or biologic for an indication for which orphan designation has been granted, except that PREA will apply to an original NDA or BLA for a new active ingredient that is orphan-designated if the drug or biologic is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A drug can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. post-approval requirements for drugs and biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Drugs and biologics manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as &#x201c;off-label use&#x201d;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe approved products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, including not only by company employees but also by agents of the company or those speaking on the company&#x2019;s behalf, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Failure to comply with these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties, including liabilities under the False Claims Act where products are obtain reimbursement under federal health care programs. Promotional materials for approved drugs and biologics must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or BLA or NDA or BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA or BLA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization. In addition, manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs and biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third party manufacturers that a sponsor may use. Manufacturers and manufacturers&#x2019; facilities are also required to comply with applicable product tracking and tracing requirements. Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual program user fee for any marketed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulation of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Companion diagnostics identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FD&amp;C Act, and its implementing regulations, and other federal and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a premarket approval application, or PMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a pre-amendment device that was in commercial distribution before May 28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device and assesses whether the subject device is comparable to the predicate device with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#x2019;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#x2019;s review of an initial PMA is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#x201c;In Vitro Companion Diagnostic Devices.&#x201d; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#x2019;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles for co-development of an in vitro companion diagnostic device with a therapeutic product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#x2019;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#x2019;s facilities for compliance with its authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other regulatory matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Following product approval, where applicable, the manufacturing, sales, promotion and other activities around product candidates and/or commercialization are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA. Regulatory agencies with authority over product candidates may include, and are not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other healthcare laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, physicians, and third-party payors, both governmental and commercial, will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including, but not limited to, those described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus treble damages, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act, or FCA. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil and criminal false claims laws, including the FCA, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity, and potentially individuals associated with the entity, from participation in Medicare, Medicaid and other federal healthcare programs. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating to the privacy and security of individually identifiable health information including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, for certain payments and &#x201c;transfers of value&#x201d; provided to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations extend to include transfers of value made in the previous year to certain non-physician providers such as physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Analogous state and foreign laws and regulations, including, but not limited to, state anti-kickback and false claims laws, may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These myriad data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies continue to scrutinize interactions between healthcare companies and healthcare providers and increase investigations, prosecutions, convictions and significant settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to similar actions, penalties and sanctions. Ensuring business arrangements comply with applicable healthcare laws, as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#x2019;s attention from its business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Insurance Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the U.S. and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the U.S. such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the U.S., the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. No uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Factors payors consider in determining reimbursement are based on whether the product is, among other considerations:<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#x2019;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Current and future healthcare reform legislation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and certain foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. The ACA includes provisions of importance to our potential product candidates that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded manufacturers&#x2019; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#x201c;average manufacturer price,&#x201d; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the types of entities eligible for the 340B drug discount program; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide point-of-sale-discounts off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#x2019; outpatient drugs to be covered under Medicare Part D; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#x2019;s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Then, a one percent (1%) payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the two percent (2%) payment reduction will resume on July 1, 2022. . In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three (3) to five (5) years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, including bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At a federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#x2019;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#x2019;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#x201c;best price&#x201d; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. However, on December 29, 2021, CMS rescinded the Most Favored Nations rule. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug sponsor to make its drug products available to eligible patients as a result of the Right to Try Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Compliance with other federal and state laws or requirements; changing legal requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any products that we may develop are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, labeling, packaging, distribution, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws, among other requirements to which we may be subject.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The failure to comply with any of these laws or regulatory requirements may subject firms to legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, relabeling or repackaging, or refusal to allow a firm to enter into supply contracts, including government contracts. Any claim or action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Prohibitions or restrictions on marketing, sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling or packaging; (iii) the recall or discontinuation of our products; or (iv) additional recordkeeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other U.S. environmental, health and safety laws and regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain workers&#x2019; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government regulation of drugs and biologics outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, manufacturing, commercial sales and distribution of our products. For instance, in the United Kingdom and the EU, medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Centralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EU, and in the additional Member States of the European Economic Area (Iceland, Lichtenstein and Norway. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue engineered products) and products with a new active substance indicated for the treatment of certain diseases, which includes products for the treatment of cancer. For medicines that do not fall within one of the mandatory categories, an applicant still has the option of submitting an application for a centralized marketing authorization to the European Medicines Agency, or EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EU, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EU. If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, the EMA&#x2019;s Committee for Medicinal Products for Human Use, or CHMP, is responsible for conducting an initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit/risk ratio. Under the centralized procedure the maximum timeframe for the evaluation of a marketing authorization application, or MAA, by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#x2019;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National authorization procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure: </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Decentralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU Member State for a medicinal product that has not yet been authorized in any EU Member State and that does not fall within the mandatory scope of the centralized procedure. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mutual recognition procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EEA Member States in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization. </span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In both cases, as with the centralized procedure, the competent authorities of the EEA Member States assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required. The MHRA also has the power to have regard to marketing authorizations approved in EU Member States through decentralized or mutual recognition procedures with a view to more quickly granting a marketing authorization in the UK or Great Britain.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EU, new products for therapeutic indications that are authorized for marketing (i.e., innovator products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from referencing the preclinical and clinical trial data contained in the dossier of the innovator product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the innovator product was first authorized in the EU. The additional two-year period of market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be considered by the EMA to be a new chemical entity, and products may not qualify for data exclusivity. Even if a product is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company could nevertheless also market another version of the product if such company obtained marketing authorization based on a MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the EEA are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, in the EEA a medicinal product may be designated as orphan if it meets the following criteria (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; and (2) either (a) such condition affects no more than five in 10,000 persons in the EEA when the application is made, or (b) it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EEA to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar medicinal product for the same indication, although similar, is safer, more effective or otherwise clinically superior than the authorized product; (ii) the marketing authorization holder of the authorized product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder of the authorized product cannot supply enough orphan medicinal product. An orphan product can also obtain an additional two years of market exclusivity in the EU for pediatric studies. The ten-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to obtaining a marketing authorization in the EU, applicants must demonstrate compliance with all measures included in an EMA-approved pediatric investigation plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulation (EC) No 1901/2006, the so-called Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP. If an applicant obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate or SPC, provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to 2 years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2017, the EU adopted the Regulation (EU) 2017/746 on in vitro diagnostic medical devices, or IVDR, which will become applicable on 26 May 2022 and will repeal Directive 98/79/EC on in vitro diagnostic medical devices. Devices that comply with the requirements of the IVDR will be entitled to bear the CE conformity marking, indicating that the device conforms to the general safety and performance requirements of the IVDR, and, accordingly, can be commercially distributed throughout the EU (in-vitro diagnostic medical devices cannot be marketed in the EU without a CE Mark). The method of assessing conformity varies depending on the class of the product, but normally involves a third-party assessment by a &#x201c;Notified Body&#x201d;. This third-party assessment may consist of an audit of the manufacturer&#x2019;s quality system and specific testing of the manufacturer&#x2019;s product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted which replaced the Clinical Trials Directive 2001/20/EC. The Clinical Trials Regulation was entered in to application on January 31, 2022 and is directly applicable in all the EU Member States (meaning no national implementing legislation in each Member State is required). The transitory provisions of the new Clinical Trials Regulation offer sponsors the possibility to choose between the requirements of the previous Clinical Trials Directive and the Clinical Trials Regulation if the request for authorization of a clinical trial is submitted in the year after the new Clinical Trials Regulation became applicable. If the sponsor chooses to submit under the Clinical Trials Directive, the clinical trial continues to be governed by the Directive until three years after the new Clinical Trials Regulation became applicable. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point, through the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the EU Member States, plus Norway, Liechtenstein and Iceland.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government regulation of data collection outside of the United States</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Internationally, numerous jurisdictions have their own data security and privacy legal framework with which we will be required to comply if we conduct clinical trials in those jurisdictions or otherwise conduct jurisdictions in those jurisdictions. In the event we conduct clinical trials in the European Union or otherwise collect personal data from data subjects in the European Union, we will be subject to additional privacy restrictions. The collection and use of personal health data in the EEA is governed by the General Data Protection Regulation, or the GDPR, which became effective on May 25, 2018. The GDPR applies to the processing of personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, enhanced requirements for securing personal data, requirements to conduct privacy impact assessments for &#x201c;high risk&#x201d; processing, limitations on retention of personal data, mandatory data breach notification and &#x201c;privacy by design&#x201d; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and Liechtenstein, which may deviate slightly from the GDPR, may result in fines of up to 4% of a company&#x2019;s global revenue for the preceding financial year, or &#x20ac;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the right to claim material and non-material damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time, resources and expense, and we may be required to put in place additional controls and processes ensuring compliance with the new data protection rules. There continues to be a level of uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, further to the UK&#x2019;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the UK&#x2019;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#x2019;s data protection regime, which is independent from but aligned to the EU&#x2019;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#x2019;s GDPR, the European Commission (&#x201c;EC&#x201d;) has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC&#x2019;s new standard contractual clauses but has published a draft version of a UK-specific transfer mechanism, which, once finalized, will enable transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Data protection authority activity differs across the EU, with certain authorities applying their own agenda which shows there is uncertainty in the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the EU, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, many jurisdictions outside of Europe are also considering and/or have enacted comprehensive data protection legislation. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. In addition, should we utilize third party distributors outside of the United States, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.0589583333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 23, 2016, the electorate in the UK voted in favor of leaving the EU, commonly referred to as Brexit, and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore broadly aligns with current EU regulations, however it is likely that these regimes will diverge in future now that Great Britain&#x2019;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Human Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 28, 2022, we had 67 full-time employees, of which 34 have M.D. or Ph.D. degrees. Within our workforce, 46 employees are engaged in research and development and 21 are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our website address is https://www.ikenaoncology.com/. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our code of conduct, corporate governance guidelines and the charters of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are available through the &#x201c;Corporate Governance&#x201d; portion of our website.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 1A. R</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our common stock involves a high degree of risk. In evaluating the Company and our business, careful consideration should be given the risks described below, as well as the other information in this Annual Report on Form 10-K and in other documents that we file with the SEC. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a targeted oncology company with a limited operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We commenced operations in 2016 and are a targeted oncology company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Since our inception, we have devoted substantially all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. We have no products approved for commercial sale and therefore, have never generated any revenue from product sales, and we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and there is no assurance that we will obtain approvals in the future. Our targeted oncology programs are still in preclinical development. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our net losses were $34.1 million and $44.3 million for the years ended December 31, 2021 and 2020, respectively. We had an accumulated deficit of $145.5 million as of December 31, 2021. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development expenses to increase significantly in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain regulatory approval for our product candidates, we will incur significant sales, marketing and manufacturing expenses. As a public company, we will continue to incur additional costs that we did not incur as a private company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract, hire and retain qualified personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully open clinical trial sites and recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of manufacturing our product candidates and products, should they receive regulatory approval, which may vary depending on the quantity of production and the terms of our agreements with manufacturers; expenditures that we will or may incur to develop additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of demand for our products should they receive regulatory approval, which may vary significantly; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have no products approved for commercial sale and have not generated any revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have generated minimal collaborative revenue from our product candidates and have not generated revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant revenue unless and until we obtain regulatory approval of, and begin to sell, one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successfully complete our ongoing and planned preclinical studies for our targeted oncology and TME programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely file and the acceptance of our investigational new drug applications, or IND, for our programs in order to commence our planned clinical trials or future clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successfully enroll subjects in, and complete, our ongoing and planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate and successfully complete all safety and efficacy studies required to obtain U.S. and foreign regulatory approval for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical supply and commercial manufacturing; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain and maintain acceptance of the products, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">position our products to effectively compete with other therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain and maintain healthcare coverage and adequate reimbursement; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enforce and defend intellectual property rights and claims; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">implement measures to help minimize the risk of the COVID-19 pandemic to our employees as well as patients and subjects enrolled in our clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintain a continued acceptable safety profile of our products following approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will require additional capital to finance our operations, which may not be available on acceptable terms, or at all. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development of pharmaceutical products is capital-intensive. We are currently advancing multiple targeted oncology programs through preclinical development toward identification of potential therapeutic candidates and subsequent planned IND filings. Additionally, we are conducting Phase 1 clinical trials of three of our candidates, IK-930, IK-007 and IK-175. Consequently, we expect our expenses to significantly increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate and complete clinical trials of, and seek regulatory approval for, our product candidates. In addition, depending on the status of regulatory approval or, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our current or future product candidates or otherwise expand more rapidly than we presently anticipate. We have begun to and expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 30, 2021, we completed our initial public offering of our common stock, or IPO, and expect that the net proceeds from the IPO, together with our existing cash and cash equivalents will be sufficient to fund our operations through mid-2024. However, our future capital requirements will depend on and could increase significantly as a result of many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of product discovery, preclinical and clinical development, laboratory testing and clinical trials for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential additional expenses attributable to adjusting our development plans (including any supply related matters) to the COVID-19 pandemic; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, prioritization and number of our research and development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcomes of regulatory reviews of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the achievement of milestones or occurrence of other developments that trigger payments under our existing collaboration agreements or any additional collaboration agreements we may establish; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of securing manufacturing arrangements for clinical and commercial production; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to the development of any companion diagnostics we may use in the future; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets in general and more recently due to the COVID-19 pandemic may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product that has received regulatory approval or be unable to expand our operations or otherwise capitalize on our business opportunities as desired, which could materially affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that risk may materially adversely affect your rights as a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, acquiring, selling or licensing intellectual property rights, and making capital expenditures, declaring dividends or other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to meet certain milestones in connection with debt financing and the failure to achieve such milestones by certain dates may force us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us which could have a material adverse effect on our business, operating results and prospects</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also could be required to seek funds through arrangements with additional collaborators or otherwise at an earlier stage than otherwise would be desirable. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves, any of which may have a material adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. Since late 2019, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes COVID-19 has spread to most countries across the world, including all 50 states within the U.S., including Boston, Massachusetts, where our primary office and laboratory space is located. The coronavirus pandemic continues to evolve, with new variants of the SARS-CoV-2 virus identified, and has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, mask and vaccine mandates and other public health safety measures. The extent to which COVID-19 impacts our operations or those of our third party partners, including our preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the variants of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The continued spread of COVID-19 globally and the continued identification of new variants of the SARS-CoV-2 virus could adversely impact our preclinical or clinical trial operations in the U.S., including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, similar to other biopharmaceutical companies, we may experience delays in initiating IND-enabling studies, protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials as well as in activating new trial sites. COVID-19 may also affect employees of third-party CROs located in affected geographies that we rely upon to carry out our clinical trials. In addition, as a result of medical complications associated with microsatellite stable colorectal cancer, or MSS CRC, the patient populations that our most advanced and other product candidates target may be particularly susceptible to COVID-19, which may make it more difficult for us to identify patients able to enroll in our current and future clinical trials and may impact the ability of enrolled patients to complete any such trials. Any negative impact COVID-19 has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As previously disclosed in 2021, the IK-412 program experienced manufacturing delays as a key component required in the manufacturing of IK-412 is similarly essential to the manufacturing of COVID-19 vaccines and therapies. Considering these delays and the timeline of the BMS partnership, we have made the strategic decision to pause IK-412 development activities for the remainder of the BMS contract term once the ongoing committed CMC work has been completed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will continue to monitor the impact of COVID-19 related supply chain issues relating to the rest of our business. Additionally, timely enrollment in planned clinical trials is dependent upon clinical trial sites the rest of which could be adversely affected by global health matters, such as pandemics. We are currently and plan to conduct clinical trials for our product candidates in geographies which are currently being affected by the ongoing COVID-19 pandemic. Some factors from the COVID-19 pandemic that have delayed and may continue to delay, or have otherwise adversely affected enrollment in the clinical trials of our product candidates, as well as our business generally, include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential negative affect on the operations of our third-party manufacturers; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operations, staffing shortages, travel limitations or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of components required in our manufacturing process for certain of our programs due to COVID-19 related vaccination and treatment efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in federal, state and local regulations as part of a response to the ongoing COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have taken precautionary measures intended to help minimize the risk of the virus to our employees, including requiring certain of our employees to work remotely, suspending all non-essential travel worldwide for our employees and discouraging employee attendance at industry events and in-person work-related meetings, as indicated and necessary, and which could negatively affect our business. We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the Securities and Exchange Commission, or the SEC, or FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other factors arising from COVID-19 and any variants could worsen in countries that are already afflicted with COVID-19 or could continue to spread to additional countries. Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operation and financial condition. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have never successfully completed any clinical trials for our oncology programs, and we may be unable to do so for any product candidates we develop. Certain of our oncology programs are still in preclinical development and may never advance to clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not yet demonstrated our ability to successfully complete clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. IK-930 is in clinical development, however, our other targeted oncology programs are still in preclinical development and may never advance to clinical development.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently advancing multiple targeted oncology programs through preclinical development toward potential therapeutic candidates and subsequent IND, including targeting ERK5 as part of our RAS pathway research.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to file such IND or INDs for any of our other product candidates on the timelines we expect, if at all. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Commencing each of these clinical trials is subject to finalizing the trial design based on discussions with the FDA and other regulatory authorities. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their positions, including, but not limited to, regarding the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or result in the composition of stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a new drug application, or NDA, or a biologics license application, or BLA, to the FDA, a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, or other marketing applications to regulatory authorities in other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">jurisdictions, for each product candidate and, consequently, the regulatory approval of each product candidate. We currently have two product candidates from our TME program in clinical development. We are conducting a Phase 1 trial with IK-175 in patients with bladder cancer with activated aryl hydrocarbon receptor, or AHR, and a Phase 1b trial with IK-007 in combination with pembrolizumab for the treatment of patients with advanced or progressive microsatellite stable colorectal cancer, or MSS CRC. We initiated a Phase 1 clinical trial of IK-930 in the first quarter of 2022. However, we do not know whether these or any of our future clinical trials will begin on time or be completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are required to conduct additional preclinical studies or clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive, or are only modestly positive, or, if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not obtain regulatory approval at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in obtaining regulatory approval for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue to be subject to post-marketing testing requirements; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience having the product removed from the market after obtaining regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discovery and development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work, that the genetic alterations targeted by our programs drive the formation and spread of cancer, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we are successful in identifying patients with specific target alterations, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type, commercialize our product candidates and achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical studies and future and ongoing clinical trials may not be successful. Currently, we have three programs in early clinical development and our other targeted oncology programs are in preclinical development. It is impossible to predict when, or if, any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and outcomes are uncertain. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. Our preclinical studies and future and ongoing clinical trials may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or otherwise obtain access to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our products that receive regulatory approval. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain regulatory approval, and we may not realize the full commercial potential of any of these therapeutic products that obtain regulatory approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, top-line, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received all of the necessary data or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary top-line data we previously published. As a result, preliminary, interim and top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the price of our common stock to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, regulatory agencies and others may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could adversely impact the potential of the particular program, the likelihood of obtaining regulatory approval of the particular product candidate, commercialization of any approved product and the business prospects of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is derived from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">information that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the preliminary, interim or top-line data that we report differ from actual results, or if regulatory authorities or others, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be significantly impaired, which could materially harm our business, operating results, prospects or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience delays in initiating or completing our preclinical studies or clinical trials, including as a result of delays in obtaining, or failure to obtain, the FDA&#x2019;s clearance to initiate clinical trials under future INDs. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will not be delayed, require redesign, will enroll an adequate number of subjects on time, or will be completed on schedule, if at all. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may receive feedback from regulatory authorities that require us to modify the design or implementation of our preclinical studies or clinical trials or to delay or terminate a clinical trial; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulators or institutional review boards, or IRBs, or ethics committees may delay or may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective clinical research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical studies or clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product research or development programs; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical studies or clinical trials of our product candidates may not produce differentiated or clinically significant results across tumor types or indications; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our third party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, be unable to provide us with sufficient product supply to conduct or complete preclinical studies or clinical trials, fail to meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trials of our product candidates may be delayed due to complications associated with the COVID-19 and related variants; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could encounter delays if a clinical trial is suspended or terminated by us, including upon the recommendation of the Safety Monitoring Committee, or SMC, for such trial, by the IRBs of the institutions at which such trials are being conducted, or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors, including, but not limited to, failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, adverse findings upon an inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with, among other considerations, our clinical trial design or our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, principal investigators for our current and future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. Such an outcome could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused by the COVID-19 pandemic and related variance, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may significantly harm our business, operating results, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. In particular, because we are focused on patients with specific genetic mutations for the development of our targeted oncology programs, and on patients with specific biomarkers for the development of our TME programs, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience difficulties with identifying specific patient populations for any biomarker-defined trial cohorts. The patient eligibility criteria defined in our trial protocols, including biomarker-driven identification may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria. We will also rely on the willingness and ability of clinicians to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#x2019; product candidates. Furthermore, our ability to enroll patients may be significantly delayed by the ongoing COVID-19 and variant pandemic, and we cannot accurately predict the extent and scope of such delays at this point.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the competitive trial environment, the eligibility criteria of our ongoing and planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit or enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, limiting our ability to identify patients with the targeted genetic mutations for our clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA&#x2019;s expedited review and development programs, including breakthrough therapy designation and fast track designation, or otherwise seek to accelerate clinical development and regulatory timelines. Patient enrollment may be affected by other factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the severity of the disease under investigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efforts to obtain and maintain patient consents and facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reporting of the preliminary results of any of our clinical trials; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">factors we may not be able to control, including the impacts of the COVID-19 pandemic, that may limit patients, principal investigators or staff or clinical site availability. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We anticipate that certain of our current product candidates and future product candidates will be used in combination with third-party drugs or biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our current product candidates and any future product candidates have the potential to be administered in combination with checkpoint inhibitor immunotherapies or other standards of care like chemotherapies, targeted therapies or radiotherapy. For example, we plan to explore IK-930 in combination with epidermal growth factor receptor, or EGFR inhibition, and in combination with a </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mitogen-activated protein kinase, or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MEK inhibitor, in certain indications and we are currently evaluating IK-175 in combination with nivolumab, which is marketed by Bristol-Myers Squibb Company, or BMS. We are also currently conducting a Phase 1b clinical trial of IK-007 in combination with pembrolizumab, which is marketed by Merck. Our ability to develop and ultimately commercialize our current programs and product candidates and any future programs or product candidates used in combination with EGFR inhibitors, nivolumab, pembrolizumab, or other checkpoint inhibitor immunotherapies or other targeted therapies will depend on our ability to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with our commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs or biologics on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint inhibitor immunotherapies or other comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, operating results, stock price and prospects may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. The FDA, other U.S. regulatory agencies and/or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the combination therapy and not our current product candidates and any future product candidates. Moreover, following product approval, the FDA, other U.S. regulatory agencies and/or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive regulatory approval. Such developments may include changes to the other product&#x2019;s safety or efficacy profile, changes to the availability of the other product, quality, manufacturing and supply issues with respect to the other product, and changes to the standard of care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event that BMS, Merck or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing checkpoint inhibitor immunotherapies. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially reasonable terms, our business, financial condition, operating results, stock price and prospects may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Results from early preclinical studies and clinical trials of our programs and product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies and clinical trials of our programs and product candidates in our later preclinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any results from our early preclinical studies and clinical trials of our targeted oncology and TME programs or our product candidates may not necessarily be predictive of the results from later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies and clinical trials of our product candidates according to our current development timeline, the results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to file INDs for our programs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to nominate multiple development candidates stemming from our RAS-pathway and additional Hippo pathway research programs. We plan to progress candidates to IND, however, we may not be able to file such INDs or INDs for future product candidates for our targeted oncology or other programs on the timelines we expect. For example, due to supply chain issues in manufacturing of IK-412 due to the ongoing COVID-19 pandemic, we previously delayed the IND submission to the FDA and have now paused development. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that it will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory approvals for our planned clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. Because our targeted oncology programs and our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. For example, we conducted a second open-label single arm Phase 1b clinical trial of IK-007 in combination with pembrolizumab in patients with advanced or metastatic post anti-PD- 1/L1 treatment in non-small-cell lung carcinoma, or NSCLC, but based on the combined data generated in the interim period for efficacy and safety, we decided not to further explore this combination in NSCLC and terminated this clinical trial in December 2020. If the results of our ongoing or future preclinical studies and clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented from, or delayed in, obtaining regulatory approval for such product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. While we have initiated a clinical trial of IK-930, our lead targeted oncology program, in the first quarter of 2022, and are in early stages of clinical trials for IK-175 and IK-007, our TME programs, it is likely, as is the case with many oncology therapies, that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If on-target toxicity is observed, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, our product candidates could cause undesirable side effects that we have not yet observed. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. Most product candidates that commence clinical trials are never approved as products, and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development or regulatory approval of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to develop certain of our product candidates, in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates, in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. As is the case with many treatments for cancer and rare diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, operating results, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our product candidates modulate pathway for which there are currently no approved or effective therapies, which may result in uncertainty. We select programs for cancer driver targets based on compelling biological rationale. We explore new programs based on extensive preclinical data analysis which sometimes cannot predict efficacy or safety in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our product candidates utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. We utilize structural biology in tight integration with our medicinal chemistry and biology capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects in our ability to expand our pipeline of product candidates, and we cannot predict whether we will continue to have access to these capabilities in the future to support our pipeline development. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development of product candidates will not arise in the future, which may cause significant delays or we raise problems we may not be able to resolve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#x2019; lack of experience with them. The novelty of the mechanism of action of any of our product candidates may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. If our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more well-known product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business prospects, operating results and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may in the future choose to conduct additional clinical trials outside the United States, including in Europe, Australia or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practices, (ii) the trials were performed by clinical investigators of recognized competence and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving regulatory approval or clearance for commercialization in the applicable jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Although we intend to explore other therapeutic opportunities in addition to the programs and product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product candidates, our business could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products; or </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. Before we can commercialize any of our product candidates, we must obtain regulatory approval. Currently, all of our product candidates are in discovery, preclinical or clinical development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical studies or clinical trials, approval may be delayed, if obtained at all. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidate involved. Changes in regulatory approval policies during the development period, changes in or enactment of additional statutes or regulations, or changes in regulatory review policies for each submitted NDA, BLA, premarket approval application, or PMA, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to enroll a sufficient number of patients in our clinical studies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we were to obtain regulatory approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we experience delays in obtaining, or if we fail to obtain, approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the pharmaceutical, biotechnology, and other related markets that address structural biology-guided chemistry-based drug design to develop therapies in the fields of cancer and genetic diseases. There are other companies focusing on targeted oncology to develop therapies in the fields of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cancer and other diseases. We also compete more broadly across the market for cost-effective and reimbursable cancer treatments. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, our ability to identify biomarkers, ability to successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the companies that we compete against or which we may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. If these or other barriers to entry do not remain in place, other companies may be able to more directly or effectively compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The incidence and prevalence for target patient populations of our programs and product candidates have not been established with precision. Our lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of all cancers and these genetic alterations are generally associated with poor clinical outcomes. We are developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. KRAS mutations in the RAS signaling pathway occur in approximately 26% of all cancers. Additionally, we are currently evaluating the safety and tolerability of IK-175 in a Phase 1 dose expansion clinical trial in patients with solid tumors and intend to pursue development in patients with bladder cancer with activated AHR. AHR amplifications have been described in approximately 5% to 22% of bladder cancer patients. We are also developing IK-007 in a Phase 1b clinical trial in patients with MSS CRC. Patients with MSS CRC represent approximately 80% of all colorectal cancer patients, and these patients generally do not respond to approved checkpoint inhibitors. Our projections of both the number of people who have these diseases, as well as the subset of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">people with these diseases who have the potential to benefit from treatment with our programs and product candidates, are based on our estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label, the indications for which our product candidates are approved for sale, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with the cancers and solid tumors for which our product candidates may be approved as treatment may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be the wrong choice and may adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our current product candidates or any future product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never commercialized a product candidate for any indication. Even if our current product candidates and any future product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we may not generate significant revenue and may not become profitable or may be significantly delayed in achieving profitability. Market acceptance of our current product candidates and any future product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch, from existing therapies even when new and potentially more effective or safer treatments enter the market. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our or our competitors&#x2019; products, our products may not be accepted by the general public or the medical community. Future adverse events in targeted oncology, immune-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Efforts to educate the medical community and third-party payors on the benefits of our current product candidates and any future product candidates may require significant resources and may not be successful. If our current product candidates or any future product candidates are approved but do not achieve an adequate level of market acceptance, we could be prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our current product candidates and any future product candidates will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy of our current product candidates and any future product candidates as single agents and in combination with marketed checkpoint inhibitor immunotherapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the commercial success of the checkpoint blockade drugs with which our products may be co-administered; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of adverse events associated with our current product candidates and any future product candidates or those products with which they may be co-administered; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the clinical indications for which our product candidates are approved and the approved claims that we may make for the products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the product&#x2019;s FDA-approved labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for our current product candidates and any future product candidates that may be more restrictive than other competitive products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the standard of care for the targeted indications for our current product candidates and any future product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the relative convenience and ease of administration of our current product candidates and any future product candidates and any products with which they are co-administered; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of adequate coverage or reimbursement by third party payors, including government healthcare programs such as Medicare and Medicaid and other healthcare payors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the price concessions required by third-party payors to obtain coverage; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to pay out-of-pocket in the absence of adequate coverage and reimbursement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent and strength of our marketing and distribution of our current product candidates and any future product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our current product candidates and any future product candidates or to which we agree as part of a risk evaluation and mitigation strategy, or REMS, or voluntary risk management plan; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction of our current product candidates and any future product candidates, as well as competitive products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer our current product candidates and any future product candidates for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent and strength of our third-party manufacturer and supplier support; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the actions of companies that market any products with which our current product candidates and any future product candidates may be co-administered; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval of other new products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse publicity about our current product candidates and any future product candidates or any products with which they are co-administered, or favorable publicity about competitive products; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product liability claims. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement by government authorities for new products are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, since CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. However, one payer&#x2019;s determination to provide coverage for a product does not assure that other payers will also provide coverage for the drug product. Further, a payer&#x2019;s decision to provide coverage for a drug product does not imply that the payor will provide adequate reimbursement. Reimbursement agencies in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">European Union may be more conservative than CMS. Factors payors consider in determining reimbursement are based on whether the product is:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties to conduct our Phase 1 clinical trials of IK-930 and IK-175 and Phase 1b clinical trial of IK-007 and expect to rely on third parties to conduct clinical trials for our other targeted oncology and other TME programs, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates, including our Phase 1 clinical trials of IK-930 and IK-175 and Phase 1b clinical trial of IK-007, as well as any other current product candidates or future product candidates that may emerge from our targeted oncology and TME programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely and expect to continue to rely heavily on these parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, our principal investigators and our CROs are required to comply with regulations, including Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, significantly increase our expenditures and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we designed our Phase 1 clinical trials of IK-930 and IK-175 and Phase 1b clinical trial of IK-007 and intend to design the future clinical trials for our product candidates, these trials are conducted by CROs and we expect CROs will conduct all of our future clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have staffing difficulties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fail to comply with contractual obligations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience regulatory compliance issues; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development program may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our relationships with these third-party principal investigators or CROs terminate, we may not be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. For example, in September 2021, an investigator-initiated trial (IIT) of IK-007 in combination with the chemotherapy agent eribulin was launched in metastatic IBC led by Naoto Ueno, M.D., of the University of Texas MD Anderson Cancer Center.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Such arrangements will likely provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research, development, commercialization and/or strategic collaborations, including the existing collaboration that we have with Celgene Corporation (now part of BMS), are subject to numerous risks, which include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may have significant control or discretion in determining the efforts and resources that they will apply to a collaboration, and might not commit sufficient efforts and resources or might misapply those efforts and resources; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may have limited influence or control over the approaches to research, development and/or commercialization of product candidates in the territories in which our collaboration partners lead research, development and/or commercialization; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might not pursue research, development and/or commercialization of collaboration product candidates or might elect not to continue or renew research, development and/or commercialization programs based on nonclinical and/or clinical trial results, changes in their strategic focus, availability of funding or other factors, such as a business combination that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might delay, provide insufficient resources to, or modify or stop research or clinical development for collaboration product candidates or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators with sales, marketing and distribution rights to one or more product candidates might not commit sufficient resources to sales, marketing and distribution or might otherwise fail to successfully commercialize those product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might not properly maintain or defend our intellectual property rights or might use our intellectual property improperly or in a way that jeopardizes our intellectual property or exposes us to potential liability; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaboration activities might result in the collaborator having intellectual property covering our activities or product candidates, which could limit our rights or ability to research, develop and/or commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might not be in compliance with laws applicable to their activities under the collaboration, which could impact the collaboration and us; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes might arise between a collaborator and us that could cause a delay or termination of the collaboration or result in costly litigation that diverts management attention and resources; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations might be terminated, which could result in a need for additional capital to pursue further research, development and/or commercialization of our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, funding provided by a collaborator might not be sufficient to advance product candidates under the collaboration. For example, although BMS provided us with an $80.5 million upfront payment and a $14.5 million equity investment upon entering into that certain master collaboration agreement with Celgene Corporation (now BMS), we might need additional funding to advance product candidates prior to the completion of a Phase 1b clinical trial, the clinical milestone when BMS must decide whether to exercise its exclusive license rights to IK-175 or IK-412. On November 20, 2019, BMS acquired Celgene Corporation and BMS may take a different approach to our collaboration or determine not to continue the collaboration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a collaborator terminates a collaboration or a program under a collaboration, including by failing to exercise a license or other option under the collaboration, whether because we fail to meet a milestone or otherwise, any potential revenue from the collaboration would be significantly reduced or eliminated. In addition, we will likely need to either secure other funding to advance research, development and/or commercialization of the relevant product candidate or abandon that program, the development of the relevant product candidate could be significantly delayed, and our cash expenditures could increase significantly if we are to continue research, development and/or commercialization of the relevant product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any one or more of these risks, if realized, could reduce or eliminate revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations and/or growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We contract with third parties for the manufacture of our product candidates for preclinical development and clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products if any of our product candidates receive regulatory approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any contract manufacturing organization, or CMO, with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our failure, or the failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to establish any additional agreements with third-party manufacturers or do so on acceptable terms. Reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reliance on the third party for regulatory compliance and quality assurance; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The third parties upon whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The active pharmaceutical ingredients, or API, used in all of our product candidates are supplied to us from single-source suppliers. Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also unable to predict how changing global economic conditions or potential global health concerns such as the COVID-19 pandemic will further affect our third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For all of our product candidates, we intend to identify and qualify additional manufacturers to provide such API prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Establishing additional or replacement suppliers for the API used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The manufacture of biologics is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of product candidates for clinical trials or products for patients, if approved, could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies to handle living cells. Each lot of an approved biologic must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with good manufacturing practices, lot consistency and timely availability of raw materials. Even if we obtain regulatory approval for any of our current product candidates or any future product candidates, there is no assurance that our manufacturers will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s own evaluation of a potential collaboration. Such factors a potential collaborator will use to evaluate a collaboration may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the U.S. and other countries for our current or future product candidates, as well as for their respective compositions, formulations, methods used to manufacture them, and methods of treatment, in addition to successfully defending these patents against third-party challenges. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the U.S. and abroad related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully commercialize our current or future product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our patents have, or that any of our pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect our current or future product candidates. In addition, if the breadth or strength of protection provided by our patent applications or any patents we may own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, in jurisdictions outside the U.S., a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported co-owner of our patent rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such co-ownership. Furthermore, patents have a limited lifespan. In the U.S., and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a jurisdiction-by-jurisdiction basis; however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or in-license may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates, including generic versions of such drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same compounds, methods, formulations or other subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until at least 18 months after the earliest priority date of patent filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in patents we may own or in-license patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to certain pending patent applications covering our current or future product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office(s) may be significantly narrowed by the time they issue, if they ever do. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we acquire patent protection that we expect should enable us to establish and/or maintain a competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may become involved in post-grant proceedings such as opposition, derivation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others from whom we may in the future obtain licenses to such rights, in the U.S. Patent and Trademark Office (USPTO), the European Patent Office (EPO), or in other countries. In addition, we may be subject to a third-party submission to the USPTO, the EPO, or elsewhere, that may reduce the scope or preclude the granting of claims from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our pending patent applications. Competitors may allege that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing their patents and that we therefore cannot practice our technology as claimed under our patents or patent applications. Competitors may also contest our patents by claiming to an administrative patent authority or judge that the invention was not patent-eligible, was not original, was not novel, was obvious, and/or lacked inventive step, and/or that the patent application filing failed to meet relevant requirements relating to description, basis, enablement, and/or support; in litigation, a competitor could claim that our patents, if issued, are not valid or are unenforceable for a number of reasons. If a court or administrative patent authority agrees, we would lose our protection of those challenged patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, without payment to us, or could limit the duration of the patent protection covering our technology and current or future product candidates. Such challenges may also result in our inability to manufacture or commercialize our current or future product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent patents we may own or in-license by developing similar or alternative technologies or drugs in a non-infringing manner. For example, a third-party may develop a competitive drug that provides benefits similar to one or more of our current or future product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, even if we are able to issue patents with claims of valuable scope in one or more jurisdictions, we may not be able to secure such claims in all relevant jurisdictions, or in a sufficient number to meaningfully reduce competition. Our competitors may be able to develop and commercialize their products, including products identical to ours, in any jurisdiction in which we are unable to obtain, maintain, or enforce such patent claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. We may miss a filing deadline for patent protection on these inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be paid periodically. While an inadvertent lapse can, in some cases, be cured by payment of a late fee, or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names for our products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different trademarks or tradenames in different countries, or face other potentially adverse consequences to building our product brand recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our trademarks or trade names may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. If we are unable to obtain a registered trademark or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the protection afforded by patents we may own or in-license, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that may not be patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that may not be covered by patents. Although we require all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe any patents we may own or in-license. In addition, any patents we may own or in-license also may become involved in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that one or more of any patents we may own or in-license is not valid or is unenforceable or that the other party&#x2019;s use of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that any patents we may own or in-license do not cover the technology in question or that such third-party&#x2019;s activities do not infringe our patent applications or any patents we may own or in-license. An adverse result in any litigation or defense proceedings could put one or more of any patents we may own or in-license at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-grant proceedings provoked by third-parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may own or in-license. These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO post-grant proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices or courts where our patents may be challenged. The costs of these proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant proceedings within patent offices may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to detect infringement against any patents we may own or in-license. Even if we detect infringement by a third-party of any patents we may own or in-license, we may choose not to pursue litigation against or settlement with the third-party. If we later sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or in-license against such third-party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our current or future product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to damages or settlement costs resulting from claims that we or our employees have violated the intellectual property rights of third parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging wrongful disclosure of third-party confidential information by us or by another party, including current or former employees, contractors or consultants. In addition to diverting attention and resources to such disputes, such disputes could adversely impact our business reputation and/or protection of our proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intellectual property landscape relevant to our product candidates and programs is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our current or future licensors or strategic partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our current or future product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. For example, many of our employees were previously employed at other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s former employer. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those related to one or more of our current or future product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While certain activities related to development and clinical testing of our current or future product candidates may be subject to safe harbor of patent infringement under 35 U.S.C. &#167;271(e)(1), upon receiving FDA approval for such candidates we or any of our future licensors or strategic partners may immediately become party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that such product candidates infringe, misappropriate or otherwise violate their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our current or future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our current or future product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of issues, including, but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#x2019;s attention from our core business and may impact our reputation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#x2019;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#x2019;s attorneys&#x2019; fees; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a court prohibiting us from developing, manufacturing, marketing or selling our current product candidates, including IK-930, IK-007, IK-175, and IK-412, or future product candidates, such as against our RAS signaling target, ERK5, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">redesigning our current or future product candidates or processes so they do not infringe, misappropriate or violate third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may choose to challenge the patentability of claims in a third-party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#x2019;s patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our current or future product candidates or proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the U.S. by law enjoy a presumption of validity that can be rebutted in U.S. courts only with evidence that is &#x201c;clear and convincing,&#x201d; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current or future product candidates. Patent applications can take many years to issue. In addition, because some patent applications in the U.S. may be maintained in secrecy until the patents are issued, patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after their earliest priority filing date, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our current or future product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis. There may be currently pending third-party patent applications which may later result in issued patents that our current or future product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our current or future product candidates or other technologies, could be found to be infringed by our current or future product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our current or future product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our current or future product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current or future product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our current or future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our current or future product candidates, which could harm our business significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to obtain patent or other intellectual property protection for our current or future product candidates or our future products, if any, in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to pursue patent coverage of our current or future product candidates in all countries. Filing, prosecuting and defending patents on current or future product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our current or future product candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from competing. Much of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of any patents we may own or in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have in our patent applications or any patents we may own or in-license in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we may own or in-license at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license that are relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may from time to time be party to license and collaboration agreements with third parties to advance our research or allow commercialization of current or future product candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our current or future product candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our current or future product candidates, and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the priority of invention of any patented technology; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any granted patents we may own or in-license covering our current or future product candidates or other valuable technology could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad, including the USPTO and the EPO. A patent asserted in a judicial court could be found invalid or unenforceable during the enforcement proceeding. Administrative or judicial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">proceedings challenging the validity of our patents or individual patent claims could take months or years to resolve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or our licensors or strategic partners initiate legal proceedings against a third-party to enforce a patent covering one of our current or future product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, in the process of obtaining the patent during patent prosecution. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patent applications or any patents we may own or in-license in such a way that they no longer cover our current or future product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we may own or in-license, allow third parties to commercialize our current or future product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our future licensors&#x2019; priority of invention or other features of patentability with respect to our patent applications and any patents we may own or in-license. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our current or future product candidates and other technologies. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our future licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the current or future product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent patent reform legislation in the U.S. and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law on September 16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#x201c;first inventor to file&#x201d; system. The first-inventor-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the U.S. and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot guarantee that any of our or our licensors&#x2019; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the U.S. and abroad that is relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. As mentioned above, patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our current or future product candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current or future product candidates or the use of our current or future product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our current or future product candidates. We may incorrectly determine that our current or future product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the U.S. or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our current or future product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently prohibited from commercializing any of our current or future product candidates that are held to be infringing. We might, if possible, also be forced to redesign current or future product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third-party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patent applications that we own or may in-license may not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patents, should they issue, that we may own or in-license, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or in-license, should any patents issue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or may in-license; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or our future licensors or collaborators, might not have been the first to file patent applications covering a particular invention; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in the U.S. and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third-party may subsequently file a patent covering such trade secrets or know-how; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop or in-license additional proprietary technologies that are patentable; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable regulatory approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review designation for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our business strategy, we may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of more than 200,000 in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the United States, orphan drug</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, in EU, the European Commission, upon the recommendation of the EMA&#x2019;s Committee for Orphan Medicinal Products, grants orphan designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the EU and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized for marketing in the EU (or the product would be a significant benefit to those affected by the condition). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the product in the EU would generate sufficient return to justify the necessary investment in developing the product. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received orphan drug designation from the FDA for IK-930 for mesothelioma. Generally, if a product with an orphan designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in EU. The EU market exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain orphan drug exclusivity for any product candidates in addition to IK-930, that exclusivity may not effectively protect IK-930 or our other product candidate from competition because different products can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or approval process. While we may seek orphan drug designation for our product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek fast track designation for some of our product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek accelerated approval of our current or future product candidates using the FDA&#x2019;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA requires that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving Accelerated Approval, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#x2019;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If competitors are able to obtain regulatory approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA, the EMA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#x2019; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, in response to the COVID-19 pandemic, since March 2020, when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. On July 16, 2020, the FDA noted that it was continuing to expedite oncology product development with its staff</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">teleworking full-time. As of May 26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluate to be adequate, the FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#x2019;s inability to complete required inspections for their applications. Additionally, regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since enactment of the ACA, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts by third parties, if any, to challenge repeal or replace the ACA, will impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 2, 2011, the U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the temporary suspension, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022. In January 2013, the American Taxpayer Relief Act of 2012 became law, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 2, 2013, the U.S. American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On&#x202f;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax.  It is impossible to determine whether similar taxes could be instated in the future.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. In particular any policy changes through CMS as well as local state Medicaid programs could have a significant impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for our products. Any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our products. It is not clear how other future potential changes to the ACA will change the reimbursement model and market outlook for our current and future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our revenue prospects could be affected by changes in healthcare spending and policy in the U.S. and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain regulatory approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, arrangement, or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment of up to ten years, and exclusion from government healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA, or federal civil money penalties. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal civil and criminal false claims and civil monetary penalties laws, including the FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act. The FCA also permits a private individual acting as a &#x201c;whistleblower&#x201d; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) , and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services information related to certain payments and other transfers of value to physicians, nurse practitioners, certified nurse anesthetists, physician assistants, clinical nurse specialists, and certified nurse midwives as well as teaching hospitals. Manufacturers are also required to disclose ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the creation, maintenance, receipt, use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal price reporting laws, which would require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal AKS and FCA, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#x2019;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the European Union General Data Protection Regulation, or GDPR, which became effective May 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and individual imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, monitoring, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk minimization tools. </span><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, manufacturers and manufacturers&#x2019; facilities are required to comply with extensive FDA, and comparable foreign </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposition of a REMS which may include distribution or use restrictions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to conduct additional post-market clinical trials to assess the safety of the product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trial holds; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or other regulatory enforcement action; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to additional privacy restrictions. Most notably, in the European Union and the UK, the collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data, is subject to the GDPR and the UK GDPR, respectively, as well as applicable national data protection requirements. The GDPR and UK GDPR are wide-ranging in scope and impose numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. Compliance with the GDPR and UK GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European and UK-based activities. Similar comprehensive data protection requirements exist in many other jurisdictions around the world and will have any impact on any plans for expansion outside of the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Relating to Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on many of our key employees and members of our executive management team as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment letter agreements with certain of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, we have experienced a very competitive hiring environment in Boston, Massachusetts, where we are headquartered. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we may collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#x2019; personal data could result in significant liability under state (e.g., state breach notification laws), federal (e.g., HIPAA, as amended by HITECH), and international law (e.g., the GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in the losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenue or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020, creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. In March 2020, the California State Attorney General has proposed varying versions of companion draft regulations which are not yet finalized. Despite the delay in adopting regulations, the California State Attorney General became empowered to commence enforcement actions against violators beginning July 1, 2020. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, a new California privacy law, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022). Additionally, some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, on March 2, 2021, Virginia enacted the Consumer Data Protection Act (the &#x201c;CDPA&#x201d;) and, on July 8, 2021, Colorado&#x2019;s governor signed the Colorado Privacy Act (&#x201c;CPA&#x201d;), into law. The CDPA and the CPA will both become effective January 1, 2023. While the CDPA and CPA incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with U.S. and foreign and/or privacy data protection laws and regulations, it could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to successfully integrate acquisitions, which may adversely impact our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have in the past and in the future may continue to acquire complementary businesses or technologies. Acquired technologies, products or businesses may not perform as we expect, and we may fail to realize anticipated synergies or results. In addition, our acquisition strategy may divert management&#x2019;s attention away from our existing business, and expose us to unanticipated problems or legal liabilities, including responsibility as a successor for undisclosed or contingent liabilities of acquired businesses or assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have successfully integrated our past acquisitions of Arrys Therapeutics or Amplify Medicines, however, if we are unsuccessful in integrating any future acquisitions, it could impede us from realizing all of the benefits of those acquisitions and could weaken our business operations or future prospectus. The integration process may disrupt our business and, if new technologies, products or businesses are not implemented effectively, may preclude the realization of the full benefits expected by us and could harm our results of operations. In addition, the overall integration of new technologies, products or businesses may result in unanticipated problems, expenses, liabilities and competitive responses. The difficulties of integrating an acquisition include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issues in integrating the target company&#x2019;s technologies, product candidates or capabilities with ours; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintaining employee morale and retaining key employees; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">integrating the culture of the target company with ours; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preserving important strategic relationships and collaborations; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consolidating corporate and administrative infrastructures and eliminating duplicative operations. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, even if the operations of an acquisition are integrated successfully, we may not realize the full benefits of the acquisition, including the synergies, pipeline expansion or growth opportunities that we expect. These benefits may not be achieved within the anticipated time frame, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of February 28, 2022, we had 67 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if any of our product candidates receives regulatory approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The dual class structure of our common stock may also limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation entities affiliated with or managed by certain of our stockholders will hold an aggregate of 5,586,311 shares of our non-voting common stock. Upon written notice, these entities could convert a portion of these shares of non-voting common stock into up to an aggregate of 9.99% of our shares of common stock. Upon 61 days&#x2019; prior written notice, these entities could convert all of their respective shares of non-voting common stock into shares of common stock. Consequently, the holders of our non-voting common stock who have exercised their option to make this conversion, will have the effect of increasing the relative voting power of those prior holders of our non-voting common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise a company insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain stockholders over a three-year period), the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future or subsequent shifts in our stock ownership, some of which are outside our control. As of December 31, 2021, we had federal and state net operating loss carryforwards of approximately $18.2 million and $5.3 million respectively, and our ability to utilize those net operating loss carryforwards could be limited by an &#x201c;ownership change&#x201d; as described above, which could result in increased tax liability to us. Furthermore, our ability to utilize our net operating losses or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As a result, the amount of the net operating loss and tax credit carryforwards presented in our consolidated financial statements could be limited and may expire unutilized. Under the current law, federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our annual taxable income in taxable years beginning after December 31, 2020. State net operating loss carryforwards and other tax attributes may be similarly limited. Any such limitations may result in increased tax liabilities that could adversely affect our business, results of operations, financial position and cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in tax legislation could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#x2019; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our fifth amended and restated certificate of incorporation and amended and restated bylaws, contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice requirements for stockholder proposals and nominations for election to our board of directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds (2/3) of all outstanding shares of our voting stock then entitled to vote in the election of directors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement of approval of not less than a majority of all outstanding shares of our voting stock to amend any bylaws by stockholder action and not less than two-thirds (2/3) of all outstanding shares of our voting stock to amend specific provisions of our certificate of incorporation; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our fourth amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to our bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, or our amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv) any action asserting a claim that is governed by the internal affairs doctrine (the Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws will further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (the Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses in our amended and restated bylaws may limit our stockholders&#x2019; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#x201c;facially valid&#x201d; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risks</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international markets. See &#x201c;Risks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.&#x201d; In addition, the current military conflict between Russia and Ukraine could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions that may be initiated by nations including the U.S., the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs, CMOs and other third parties with which we conduct business. A severe or prolonged economic downturn or political unrest could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act and a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock less attractive to investors and adversely affect the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) December 31, 2026; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; disclosure; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Exchange Act and instead provide a reduced level of disclosure regarding executive compensation; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of executive officers.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the available exemptions available to us so long as we qualify as an &#x201c;emerging growth company.&#x201d; We have taken advantage of reduced reporting burdens in this Annual Report on Form 10-K. In particular, we have provided only two years of audited financial statements and have not included all of the executive compensation information that would be required if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to avail ourselves of this exemption and, therefore, we are not subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#x201c;emerging growth company,&#x201d; which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an &#x201c;emerging growth company,&#x201d; we may elect not to provide you with certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile and may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#x201c;smaller reporting company,&#x201d; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, and particularly after we are no longer an &#x201c;emerging growth company&#x201d; or a &#x201c;smaller reporting company,&#x201d; we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company or a smaller reporting company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In additional, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, or the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to securities litigation, which is expensive and could divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns, which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 1B. UNRESOLVED STAFF COMMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 2. PROPERTIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters is located in Boston, Massachusetts. We previously leased approximately 13,170 square feet of office and laboratory space, or the Boston Lease. The term of our Boston Lease expired on February 28, 2021. We entered into a lease to move our corporate headquarters and occupy approximately 20,752 square feet of office, laboratory and animal care space, or the New Lease. The New Lease commenced on February 19, 2021, and the term is expected to expire on May 31, 2026.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our existing facilities are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 3. LEGAL PROCEEDINGS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 4. MINE SAFETY DISCLOSURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock trades under the symbol &#x201c;IKNA&#x201d; on The Nasdaq Global Market and has been publicly traded since March 26, 2021. Prior to this time, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 10, 2022, there were approximately 20 holders of record of shares of our common stock. This number does not include stockholders for whom shares are held in &#x201c;nominee&#x201d; or &#x201c;street&#x201d; name.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividends</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings, if any, to support our business strategy and do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the sole discretion of our board of directors after taking into account various factors, including our financial condition, operating results, capital requirements and any plans for expansion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance under Equity Compensation Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds from Initial Public Offering</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 30, 2021, we closed our initial public offering, or IPO, in which we issued and sold 8,984,375 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,171,875</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of common stock, at a public offering price of $16.00 per share. All of the shares of common stock issued and sold in our initial public offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No. 333-253919), which was declared effective by the SEC on March 25, 2021. The offering terminated upon the closing of the IPO. Jefferies LLC, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cowen and Company, LLC, Credit Suisse Securities (USA) LLC and William Blair &amp; Company, L.L.C.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> acted as joint book-running managers for the offering. The aggregate gross proceeds to us from our initial public offering, inclusive of the over-allotment exercise, were $143.8 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate net proceeds to us from the IPO, inclusive of the over-allotment exercise, was approximately $131.3 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There has been no material change in the planned use of IPO proceeds from that described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on March 26, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 6. RESERVED</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 7. MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by these forward-looking statements. For convenience of presentation some of the numbers have been rounded in the text below. Please also see the section entitled &#x201c;Special Note Regarding Forward-Looking Statements.&#x201d; We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment (TME), with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. Our focus on patient-driven development is platform and process agnostic, allowing us to research both known and novel targets, with a shared guiding principle of aiming to address the unmet need of a biomarker-defined patient population. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust pipeline of discovery-stage targeted oncology programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. In our ongoing first-in-human clinical trial, we are focusing on indications that provide the potential for rapid clinical development to achieve proof-of-concept, such as NF2 deficient mesothelioma and solid tumors with YAP1 or TAZ gene fusions, including epithelioid hemangioendothelioma, or EHE, in which 100% of patients have Hippo pathway alterations. We also plan to assess IK-930 in combination with other targeted therapies across several indications, including EGFR mutated non-small cell lung cancer (NSCLC) and KRAS mutated cancers. In October 2021, our Investigational New Drug Application, or IND, for IK-930 was accepted by the U.S. Food and Drug Administration, or FDA, and we subsequently initiated a first in human Phase 1 clinical trial of IK-930 in patients with advanced solid tumors with a high frequency of Hippo pathway alternations. The first patient was dosed in January 2022, and we are currently recruiting patients in this ongoing Phase 1 clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our discovery efforts are focused on additional targeted oncology programs, following our philosophy of designing treatments for patients&#x2019; populations identified through the genetic make-up of their tumors. Our pre-clinical pipeline is growing to include additional Hippo pathway and RAS pathway-targeting programs, including our program against the novel target extracellular signal related kinase 5 (ERK5). We are generating mechanistic and translational data to accompany our approaches and identify underserved RAS-mutated cancer patient populations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment (TME). These programs are all built on the same foundation of biomarker-driven clinical trial design and patient enrichment, aiming to develop therapies that can precisely be used for specific cancer patients. IK-175 is an oral inhibitor of aryl hydrocarbon receptor, or AHR, which we are evaluating in a Phase 1a/1b clinical trial in solid tumors and in urothelial carcinomas as monotherapy and in combination with nivolumab. We expect to report initial clinical data from this trial in the second half of 2022. Additionally, we plan to initiate a second Phase 1b trial with IK-175 in head and neck squamous cell carcinoma (HNSCC) in the second half of 2022. The IK-175</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">program is partnered with Bristol-Myers Squibb Company. The partnership also includes our IK-412 program, which experienced manufacturing delays previously disclosed in 2021. Considering these delays and the timeline of the partnership, we made the strategic decision to pause IK-412 development activities for the remainder of the Bristol Myers Squibb collaboration agreement term once the ongoing committed Chemistry, Manufacturing, and Controls (CMC) work has been completed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also within TME immune signaling, IK-007, which inhibits the prostaglandin E receptor 4, or EP4, in the COX2 pathway, is being evaluated in a Phase 1b clinical trial in combination with pembrolizumab for the treatment of patients with MSS CRC. We recently completed enrollment in this trial and expect to report data at a medical conference in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated as a Delaware corporation on March 2, 2016, and our headquarters is located in Boston, Massachusetts. Since our inception, we devoted all of our efforts to organizing and staffing our company, acquiring intellectual property, business planning, raising capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. On March 30, 2021, we completed an IPO, in which we issued and sold 8,984,375 shares of our common stock at a public offering price of $16.00 per share, including 1,171,875 shares of common stock sold pursuant to the underwriters&#x2019; exercise of their option to purchase additional shares of common stock, for aggregate gross proceeds of $143.8 million. We raised approximately $131.3 million after deducting underwriting discounts and commissions and offering expenses payable by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have not had any products approved for sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant net losses in every year since our inception and expect to continue to incur significant expenses and increasing net losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year and could be substantial. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net losses were $34.1 million and $44.3 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $145.5 million. We anticipate that our expenses will increase significantly as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance the development of our product candidate pipeline; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate and continue research and preclinical and clinical development of potential new product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquire or in-license additional product candidates and technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expand our infrastructure and facilities to accommodate our growing employee base and ongoing development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish agreements with contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, in connection with our preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">require the manufacture of larger quantities of our product candidates for clinical development and potential commercialization; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seek marketing approvals for our product candidates that successfully complete clinical trials, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">add operational, financial and management information systems and personnel, including personnel to support our research and development programs, any future commercialization efforts and our transition to operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity instruments, debt financings, or other capital sources, which may include</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain marketing approval for our product candidates. The lengthy process of securing marketing approvals for new drugs requires the expenditure of substantial resources. Any delay or failure to obtain regulatory approvals would materially adversely affect the development efforts of our product candidates and our business overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings, when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash and cash equivalents of $232.2 million. We believe the existing cash and cash equivalents on hand as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements through mid 2024. To date, we have primarily financed our operations through proceeds from private placements of preferred stock, payments from a collaboration agreement, related party revenue and completion of the IPO. We expect to incur substantial operating losses and negative cash flows from operations for the foreseeable future as we continue to invest significantly in research and development of our programs. Our belief with respect to our ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from our estimates, we may need to seek additional funding sooner that would otherwise be expected. There can be no assurance that we will be able to obtain additional funding on acceptable terms, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Impact of COVID-19 Pandemic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We continue to monitor the impacts of the COVID-19 pandemic and its potential impact on our business including </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in our clinical trials, manufacturing capabilities, and ability to access necessary resources. We</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> have taken important steps to ensure the safety of our employees and their families and to reduce the spread of COVID-19. We have established a work-from-home policy for all employees while ensuring essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories. For employees working in our facilities, we have implemented stringent safety measures designed to comply with applicable federal, state and local guidelines instituted in response to the COVID-19 pandemic. We have also maintained efficient communication with our partners and clinical sites as the COVID-19 situation has evolved. We have taken these precautionary steps while maintaining business continuity so that we can continue to progress our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the first half of 2021, we were notified that a key component required in the manufacturing of IK-412, our novel kynurenine-degrading enzyme, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component has been delayed as resources have been allocated towards vaccine production in the near-term. With this information and manufacturing lead times, the IND submission for IK-412 was delayed. Considering these delays and the timeline of the BMS collaboration partnership we have made the strategic decision to pause IK-412 development for the remainder of the BMS contract term once the ongoing committed CMC work has been completed. We will continue to monitor the impact of COVID-19 related supply chain issues relating to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See &#x201c;Risk Factors&#x201d; for a discussion of the potential adverse impact of the COVID-19 pandemic on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of our Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval and successful commercialization efforts, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of our revenue has been derived from research and development revenue under our BMS Collaboration Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreement and Stock Purchase Agreement with BMS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, we entered into the BMS Collaboration Agreement with Celgene Corporation (which was acquired by BMS in November 2019), pursuant to which BMS may elect in its sole discretion to exclusively license rights to develop and commercialize compounds (and products and diagnostic products containing such compounds) that modulate the activity of two collaboration targets, kynurenine and aryl hydrocarbon receptor, or AHR, excluding AHR agonists for inverse agonists, which we are developing as IK-412 and IK-175, respectively. On a program-by-program basis, through the completion of a Phase 1b clinical trial for each of IK-175 and IK-412, BMS has the exclusive option to exclusively license to develop, commercialize and manufacture the relevant product candidate worldwide. Concurrent with execution of the BMS Collaboration Agreement, we entered into a stock purchase agreement with Celgene Corporation (now BMS) in November 2019, or the Stock Purchase Agreement, pursuant to which we issued Celgene Corporation 14,545,450 shares of Series A-1 preferred stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BMS paid a total of $95.0 million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement. We are eligible to receive $50.0 million, in case of an exercise of its option with respect to IK-175, and $40.0 million, in case of an exercise of its option with respect to IK-412. If we do not complete a Phase 1b clinical trial by the end of the research term, we may elect to provide a data package to BMS upon which BMS may exercise the foregoing option for an additional $0.25 million fee. Upon the delivery of each license, we become eligible to receive up to $265.0 million in regulatory milestones and $185.0 million in commercial milestones as well as a tiered royalties at rates ranging from the high single to low teen digits percentages based on worldwide annual net sales by BMS, subject to specified gross sale reductions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the first half of 2021, we were notified that a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component has been delayed as resources have been allocated towards vaccine production in the near-term. With this information and manufacturing lead times, the IND submission for IK-412 was delayed. Considering these delays and the timeline of the BMS collaboration partnership we have made the strategic decision to pause IK-412 development for the remainder of the BMS contract term once the ongoing committed CMC work has been completed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred for our research and development activities. These efforts and costs include external research costs, personnel costs, consultants, supplies, license fees and facility-related expenses. We expense research and development costs as incurred. These expenses include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employee-related expenses, including salaries, related benefits and stock-based compensation expense, for employees engaged in research and development functions; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred under agreements with CROs which are primarily engaged to support our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred under agreements with CMOs, which are primarily engaged to provide drug substance and product for our preclinical research and development programs, nonclinical and clinical studies and other scientific development services; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of acquiring and manufacturing preclinical study materials, including manufacturing registration and validation batches; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquisition of in-process research and development assets that have no alternative future use; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to compliance with quality and regulatory requirements; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payments made under third-party licensing agreements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our planned clinical development activities in the near term and in the future. At this time, we cannot accurately estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of, or obtain regulatory approval for, any of our current or future product candidates. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to add and retain key research and development personnel; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our successful enrollment in and completion of clinical trials, including our ability to generate positive data from any such trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size and cost of any future clinical trials for existing or future product candidates in our pipeline; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs associated with the development of any additional programs we identify in-house or acquire through collaborations and other arrangements and the success of such collaborations; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the terms and timing of any additional collaborations, license or other arrangement, including the timing of any payments thereunder; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain agreements and operate with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to manufacturing of our product candidates or to account for any future changes in our manufacturing plans; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain patents, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates, both in the United States and internationally; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain third-party insurance coverage and adequate reimbursement for our product candidates, if and when approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the acceptance of our product candidates, if approved, by patients, the medical community and third-party payors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">effectively competing with other products if our product candidates are approved; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of any business interruptions to our operations, including the timing and enrollment of patients in our planned clinical trials, or to those of our manufacturers, suppliers, or other vendors resulting from the ongoing COVID-19 pandemic or similar public health crisis; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain a continued acceptable safety profile for our therapies following approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A change in the outcome of any of these variables with respect to the development of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, patent, consulting, investor and public relations, accounting, auditing, tax services and insurance costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our general and administrative expenses will increase as our organization and headcount needed in the future to support continued research and development activities and potential commercialization of our product candidates. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, attorneys and accountants, among other expenses. Additionally, we expect to incur increased expenses associated with being a public company, including costs of additional personnel, accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48.673%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.302%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.302%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.259%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:8.05%;"></td>
    <td style="width:3.211%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(In thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Dollar Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Percent Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development revenue under<br />&#160;&#160;&#160;collaboration agreement</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,985</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,194</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,791</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">237</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,108</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,847</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,261</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,015</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,866</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,149</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65,123</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,713</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,410</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(34,138</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(44,519</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,381</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">263</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(240</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(91</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(34,115</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(44,256</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,141</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research and development revenue under collaboration agreement of $31.0 million and $9.2 million for the years ended December 31, 2021 and 2020, respectively, is related to an increase of revenue from the BMS Collaboration Agreement for the IK-175 and IK-412 programs which was executed in January 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The revenue increase on IK-412 is due to a decrease in our estimate of the total services to be performed on the IK-412 program during the remainder of the BMS Collaboration Agreement term. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays previously disclosed in 2021. Considering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">these delays and the timeline of the BMS partnership, the Company made the strategic decision to pause IK-412 development activities for the remainder of the BMS research term once the ongoing committed CMC work has been completed. As a result of the decision to pause, the Company recorded a change in estimate during the three months ended December 31, 2021 and recognized $16.5 million of research and development revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The revenue also increased on IK-175 is due to continued progression of the program </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">during the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48.747%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.454%;"></td>
    <td style="width:0.685%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.454%;"></td>
    <td style="width:0.685%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:9.315%;"></td>
    <td style="width:0.91%;"></td>
    <td style="width:1.167%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:8.062%;"></td>
    <td style="width:3.212%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(In thousands, except percentages)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Dollar Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Percent Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct research and development expenses by program:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-930</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,351</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,911</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,440</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-175</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,844</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,161</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,317</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(18</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-412</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,984</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,699</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(715</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IK-007</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,632</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,943</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,311</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(47</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other discovery stage programs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,708</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,556</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">229</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquisition of in-process research and development assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,140</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(11,140</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(100</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development personnel and overhead expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,589</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,437</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,108</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,847</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,261</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expens</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e was $47.1 million for the year ended December 31, 2021, compared to $44.8 million for the year ended December 31, 2020. Included within research and development personnel and overhead expenses is stock-based compensati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on expense of $2.4 million and $0.8 million for the years ended December 31, 2021 and 2020, respectively. The increase in research and development expense of $2.3 million was primarily attributable to </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the IND-enabling studies, manufacturing development costs and clinical trial start-up costs for IK-930, and research activities for other discovery stage programs. In addition, research and development expenses related to personnel and overhead expenses increased due to an increase in headcount. This increase in research and development expenses was partially offset by the write-off for the acquisition of in process research and development assets of $11.1 million as a result of the acquisition of Amplify in October 2020, and a net decrease in development activities for IK-175, IK-412, and IK-007.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense was $18.0 million for the year ended December 31, 2021, as compared to $8.9 million for the year ended December 31, 2020. General and administrative expense includes $2.7 million and $1.0 million of stock-based compensation expense for the years ended December 31, 2021 and 2020, respectively. The increase was primarily attributable to an increase in compensation expense due to an increase in headcount, as well as general increases in legal and consulting expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for several years, if ever. To date, we have financed our operations primarily through private placements of preferred stock, from upfront payments from the BMS Collaboration Agreement, from cash obtained from acquisitions, and most recently, from common stock in our IPO. In March 2021, we completed our IPO in which we received net proceeds, inclusive of the exercise by the underwriters of their option of purchase additional</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">shares, of approximately $131.3 million, after deducting underwriting discounts and commissions and estimated offering expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash and cash equivalents of $232.2 million. Based upon our current operating plans, we expect that our existing cash and cash equivalents balances will enable us to meet our planned operating expenses and capital expenditure requirements into mid-2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our sources and uses of cash for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:65.992%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.203%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.031%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(In thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided (used in) by operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(60,252</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(37,826</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,760</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,922</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,738</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,184</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,726</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,280</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we used $60.3 million of cash in operating activities. The net cash used in operating activities primarily consisted of our net loss of $34.1 million which includes non-cash charges of $5.2 million of stock-based compensation expense, and the realization of $31.0 million of previously deferred revenue recognized as a result of the BMS Collaboration Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, we used $37.8 million of cash in operating activities. We utilized cash to fund our net loss of $44.3 million, which includes non-cash expense recognized related to the acquisition of in process research and development assets of $11.1 million as a result of the acquisition of Amplify in October 2020 and the realization of $9.2 million of previously deferred revenue recognized as a result of the BMS Collaboration Agreement. There was $3.1 million of other non-cash expenses and a net use of $1.4 million to fund changes in prepaid expenses and other current assets, accounts payable, accrued expenses and other current liabilities and lease liability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net cash used in investing activities for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was primarily attributable to an increase in property and equipment purchased in connection with the commencement of our new lease. The net cash provided by investing activities for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was related to the $3.7 million of cash received in our acquisition of Amplify. These proceeds were offset by the use of $0.8 million of cash to acquire plant and equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the net cash provided by financing activities primarily reflects cash proceeds received in connection with the IPO. During the year ended December 31, 2020, the net cash provided by financing activities is related to net proceeds from the issuance of preferred stock of $116.2 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development for, initiate clinical trials for, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our existing cash and cash equivalents as of December 31, 2021, will enable us to fund our operating expenses and capital expenditure requirements through mid-2024. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the in-licensing or acquisition of assets in line with our strategy; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our headcount growth and associated costs as we expand our business operations and our research and development activities; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Any debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a non-cancelable operating lease agreement for our office, lab and animal care facility space in our Boston, Massachusetts corporate headquarters. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect lease payments under this commitment to total $1.8 million in 2022 and increase annually through the lease expiration in 2026. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our total future minimum lease payments for each of the next five years and in total are included in Note 14.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice of 30 days. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may incur potential contingent payments upon our achievement of clinical, regulatory and commercial milestones, as applicable, or that we may be required to make royalty payments under license agreements we have entered into with various entities pursuant to which we have in-licensed certain intellectual property such as our patent license agreement with the University of Texas at Austin and our license agreement with AskAt, Inc. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and have not been included in the table above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management&#x2019;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are more fully described in the Notes to our consolidated financial statements included elsewhere in this annual report on Form 10-K, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine revenue recognition we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and determine those that are performance obligations, then assess whether each promised good or service is distinct. When we offer options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, we evaluate whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, we then recognize as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, we recognize revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At each reporting date, we calculate the measure of progress for the performance obligations transferred over time. The calculation generally uses an input measure based on costs incurred to-date relative to estimated total costs to complete the transfer of the performance obligation. The measurement of progress is then used to calculate the total revenue earned, including any cumulative catch-up adjustment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays previously disclosed in 2021. Considering these delays and the timeline of the BMS partnership, the Company made the strategic decision to pause IK-412 development activities for the remainder of the BMS research term once the ongoing committed CMC work has been completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">vendors, including research laboratories, in connection with preclinical development activities; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CROs and investigative sites in connection with preclinical studies; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CMOs in connection with drug substance and drug product formulation of preclinical studies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We base the expense recorded related to external research and development on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs and CROs that supply, conduct and manage nonclinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We account for stock-based compensation awards in accordance with ASC 718, Compensation&#x2014;Stock Compensation (ASC 718). ASC 718 requires all stock-based payments, including grants of employee stock options, to be recognized in the consolidated statement of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of each stock option grant using the Black-Scholes option-pricing model. Calculating the fair value of stock-based awards requires that we make subjective assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to ASC 718, we measure stock-based awards at fair value on the date of grant and recognize the corresponding stock-based compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. We have historically granted stock options with exercise prices equivalent to the fair value of our common stock as of the date of grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Black-Scholes option-pricing model uses the following inputs: the fair value of our common stock, the expected volatility of our common stock, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. Due to the lack of a public market for our common stock and a lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us, including stage of product development, life science industry focus, length of trading history and similar vesting provisions. The historical volatility data is calculated based on a period of time commensurate with the expected term assumption. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available or until circumstances change, such that the identified entities are no longer representative companies. In the latter case, more suitable, similar entities whose share prices are publicly available would be utilized in the calculation. We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Payment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, to calculate the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. Under this approach, the weighted-average expected option term is presumed to be the average of the contractual term (ten years) and the vesting term (generally four years) of our stock options. We utilize this method due to lack of historical exercise data and the &#x201c;plain-vanilla&#x201d; nature of our stock-based awards. The expected term is applied to the stock option grant group as a whole, as we do not expect substantially different exercise or post-vesting termination behavior among our employee population. For options granted to non-employees, we utilize the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as we have never paid cash dividends and have no current plans to pay any cash dividends on our common stock. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Determination of Fair Value of Common Stock contractual obligation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Historically, the fair value of the shares of common stock underlying the stock options was determined by the Company&#x2019;s board of directors. Because there was no public market for the Company&#x2019;s common stock prior to the Company&#x2019;s IPO, the board of directors determined fair value of common stock at the time of grant of the option by considering a number of objective and subjective factors including independent third-party valuations of the Company&#x2019;s common stock, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock and the general and industry specific economic outlook, among other factors. Following the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock has been determined based on the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an &#x201c;emerging growth company,&#x201d; or an EGC, can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (2) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700.0 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting and non-voting common stock held by non-affiliates is more than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenues are more than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is more than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risk related to changes in interest rates. As of December 31, 2021 and 2020, our cash equivalents consisted of interest-bearing checking accounts and money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term nature and the low risk profile of our interest-bearing accounts, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents or on our financial position or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inflation generally affects us by increasing our costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our consolidated financial statements, together with the reports of our independent registered public accounting firms, appear beginning on page F-1 of this Annual Report for the year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TEM 9A. CONTROLS AND PROCEDURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Evaluation of Our Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer (both roles assumed by our Chief Executive Officer), has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K does not include a report of management's assessment regarding internal control over financial reporting or an attestation report of the company's registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EM 9B. OTHER INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principal Financial Officer</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As previously disclosed, Douglas Carlson resigned from his position as our Chief Operating Officer and Executive Vice President of Finance and principal financial and accounting officer in February 2022. Additionally, as previously disclosed, in February 2022, our board of directors appointed Francisco Olivera, our Vice President of Finance and Administration, as our principal accounting officer. On March 15, 2022, our board of directors appointed Mark Manfredi, Ph.D., our current President and Chief Executive Officer and principal executive officer, as our principal financial officer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2022 Annual Meeting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the date of this Annual Report on Form 10-K, we intend to hold our 2022 Annual Meeting of Stockholders (the &#x201c;2022 Annual Meeting&#x201d;) on or about June 9, 2022 at 8:30 a.m. local time virtually. We are providing the following disclosure in accordance with our Amended and Restated Bylaws (the &#x201c;Bylaws&#x201d;) and Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bylaws Advance Notice Deadline for Submission of Stockholder Proposals and Director Nominations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to our Bylaws, since the 2022 Annual Meeting is the first Annual Meeting following our initial public offering, for notice of stockholder proposals submitted outside of Rule 14a-8 of the Exchange Act and director nominations to be timely, they must be so received not later than the later of (A) the close of business on the 90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day before the 2022 Annual Meeting; or (B) the close of business on the 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> day following the day on which public announcement of the date of the 2022 Annual Meeting is first made by us. As this is our first public disclosure of the date of the 2022 Annual Meeting, to be considered timely, stockholder proposals submitted outside of Rule 14a-8 of the Exchange Act and director nominations, in each case intended to be brought before the 2022 Annual Meeting, must be received no later than the close of business on Monday, March 28, 2022. Any such stockholder proposals and director nominations must be directed to our Corporate Secretary at our corporate offices at Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, MA 02210. Such stockholder proposals and director nominations must also comply with the advance notice provisions contained in Sections 2 of our Bylaws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rule 14a-8 Deadline for the Submission of Stockholder Proposals</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we did not hold an annual meeting in 2021, pursuant to Rule 14a-8(e)(2) under the Exchange Act, the deadline for the receipt of any stockholder proposals submitted pursuant to Rule 14a-8 of the Exchange Act for inclusion in the Company&#x2019;s proxy materials for the 2022 Annual Meeting would be a reasonable time before the company begins to print and send its proxy materials. We have determined that Monday, March 28, 2022 is a reasonable time before we expect to begin to print and distribute its proxy materials for the 2022 Annual Meeting, and that any stockholder proposals must be received on or before the close of business on that day. Such proposals must be directed to our Corporate Secretary at our corporate offices at Ikena Oncology, Inc., 645 Summer Street, Suite 101, Boston, MA 02210. Such proposals must also comply with Rule 14a-8 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 11. EXECUTIVE COMPENSATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our independent public accounting firm is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0f32461-9dcd-4a7d-afb7-34dd3ee7899c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:AuditorName"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db6039bd-6be1-4fc0-890a-a16660f69ca7" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:AuditorLocation"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, PCAOB Auditor ID: 42.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required under this item is incorporated herein by reference to the Company&#x2019;s definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the Securities and Exchange Commission not later than 120 days after the close of the Company&#x2019;s fiscal year ended December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statements</span></div></div>
  <p style="margin-left:4.44%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See the Index to Consolidated Financial Statements in the Financial Statements Section beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:4.44%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statement schedules have been omitted as they are not required, not applicable, or the required information is included in the financial statements or notes to the financial statements.</span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.122%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:86.859%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex21.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Agreement and Plan of Merger by and among the Registrant, Arrys Merger Sub, Inc., Arrys Therapeutics, Inc. and OrbiMed Private Investments VI, LP, as stockholder representative, dated December 18, 2018 (Incorporated by reference to Exhibit 2.1 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Agreement and Plan of Merger by and among the Registrant, AMI Merger Sub, Inc., Amplify Medicines, Inc. and Atlas Venture Fund XI, L.P. as stockholder representative, dated October 1, 2020 (Incorporated by reference to Exhibit 2.2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex33.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Fifth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 30, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex35.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-40287) filed with the Securities and Exchange Commission on March 30, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Fourth Amended and Restated Investors&#x2019; Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of the Registrant&#x2019;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2016 Stock Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2021 Stock Option and Incentive Plan, and form of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 10.4 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.122%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:86.859%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Incorporated by reference to Exhibit 10.5 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835579/000119312521088609/d197729dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Amended and Restated Employment Agreement (Incorporated by reference to Exhibit 10.6 to the Registrant&#x2019;s Registration Statement on Form S-1/A (File No. 333-253919) filed with the Securities and Exchange Commission on March 22, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">License Agreement by and between the Registrant and AskAt, Inc., dated December 14, 2017, as amended on December 18, 2018 (Incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Master Collaboration Agreement by and between the Registrant and Celgene Corporation (now Bristol-Myers Squibb), dated January 14, 2019 (Incorporated by reference to Exhibit 10.8 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Patent License Agreement by and between the Registrant and The University of Texas at Austin, on behalf of the Board of Regents of the University of Texas System, dated March 29, 2015, as amended on May 18, 2016, December 15, 2016, October 24, 2017, April 25, 2018 and January 9, 2019 (Incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement between the Registrant and OPG MP Parcel Owner (DE) LLC, dated July 31, 2020 (Incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001835579/000119312521071313/d197729dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Subsidiaries of the Registrant (Incorporated by reference to Exhibit 21.1 to the Registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-253919) filed with the Securities and Exchange Commission on March 5, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1*+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="ikna-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ T</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 16. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.765%;"></td>
    <td style="width:2.174%;"></td>
    <td style="width:5.236%;"></td>
    <td style="width:46.825%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 17, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Manfredi</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mark Manfredi, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.678%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:43.874%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:21.419%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Manfredi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 17, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Mark Manfredi, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principal Executive Officer and Principal Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Francisco Oliveira</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Vice President of Finance and Administration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 17, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Francisco Oliveira</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principal Accounting Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ron Renaud</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 17, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Ron Renaud</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ David Bonita</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 17, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">David Bonita, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Iain D. Dukes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 17, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Iain D. Dukes, D.Phil.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jean-Fran&#xe7;ois Formela</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 17, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Jean-Fran&#xe7;ois Formela, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maria Koehler</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 17, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maria Koehler, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Otello Stampacchia</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 17, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Otello Stampacchia, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Richard Wooster</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Richard Wooster, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 17, 2022</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br /><br />INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.618%;"></td>
    <td style="width:7.382%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(PCAOB ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0511b34-8f48-45fa-b867-1848dabb6592" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_independent_registered"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Shareholders and the Board of Ikena Oncology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Ikena Oncology, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 17, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED BALANCE SHEETS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.62%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.081%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.081%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_157da8d0-c119-4428-b5d1-7501a7117667" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79c693ea-0fcc-44f1-a031-776cfa9c9a11" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b3cdae0-6255-40b6-a780-e63a382066c9" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96bb49ea-e9f9-42ab-bed6-b6c1df531fa3" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fe08dc2-b240-4ee4-af50-05c4186dcc90" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b33cac60-3fff-424a-8f31-85ee3faf1032" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">165,969</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da9a2a30-72d2-4a22-b4f0-8d06b2d7c639" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c91bca9c-36cc-4a6c-ade9-481b9bedc88b" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,393</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f07c6470-f3f0-44be-9b32-6d5b93c84fd3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7791982f-085c-4bc9-81b4-db9311871f5d" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd0958d4-30a3-4163-b40d-3a064c8c15c7" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="ikna:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,386</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ff21ceb-85df-4a40-ac4d-9105c8da713e" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="ikna:DepositsAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e83d31fd-6930-4cd3-b8f9-4a80ffe56d03" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_835257ff-ceaf-4a66-842c-d17455e7b7c0" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity<br />&#160;&#160;&#160;(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4555c935-8fcc-4cf3-b16e-b8b7e7fc0267" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b84e193-4d69-4fb1-916b-6b9f58799f91" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f23607d3-e0ad-40a6-ab12-174c705b7dfc" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,854</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_805c9528-e1b4-48b1-9f1e-9968f1105ed2" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23b70e5a-92f2-4677-8c9e-da068754140e" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f35d240-ce1b-412f-af32-5b30f8f09e27" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8e0db88-89e7-48ba-a1be-178315ededde" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_168605e1-1d22-470c-b1a6-05381873c940" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6af6b698-b9d5-4cfc-ab11-4f4b7acf50e3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30d32e0b-49a3-4e65-bbb7-808dcf354190" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term portion of lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4adeb3e-1233-4012-9c74-5cfb85b07985" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,135</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0473efe4-6bd9-48fa-9eca-edfddf4024e3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b73d23ba-b42f-4157-8f68-a2fb6ce61787" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,141</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4fc5822-71be-4504-b474-4a0394250fc1" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af968b44-4f04-46b7-9052-0c9a15771366" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,473</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2ce08d35-be16-47c1-8be1-42857608cb48;"><span style="-sec-ix-hidden:F_474b6704-871e-4bad-bd66-06110622c38a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencies (Note 15)</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable convertible preferred stock (Series A, A-1, A-2, and B), $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_090f4f11-0322-450a-ae95-323b4c1601f9" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_0d6a4e05-dd96-4d58-8ef5-a50a56644a65" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value.<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21ef3ec9-ce70-4978-880e-256ca1019977" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f4514dd8-553b-46de-977d-d781bf2e845e" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1fd6a053-6f5e-4be1-99b0-e9dbd89c663d" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized, issued and outstanding as of December 31, 2021; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2cb10a5-425f-4dcb-a028-9659078c1fbe" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_eb69895b-1614-48f8-acde-bc626763030a" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7d2d4029-f4d5-4b4a-93b8-efaa97073158" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />&#160;&#160;&#160;shares, authorized, issued and outstanding as of December 31, 2020 (liquidation<br />&#160;&#160;&#160;preference $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa3028d2-a061-40fe-9885-dd19ae27da55" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;as of December 31, 2021 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21493f00-1e10-4a22-81a4-874463281f22" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">202.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million as of December 31, 2020)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7467ec34-05b8-463d-90d1-2f74b18fc230" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f02e4c3f-6114-469f-a0e2-647f032839ff" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders&#x2019; deficit:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred Stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23f3422e-d897-4752-9fa9-bedecb7f19d6" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_0480a3d1-0fa5-4a7c-a187-d5a2787feec2" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c508ef2f-b198-40c9-adfd-fbea35631fb7" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31,<br />&#160;&#160;&#160;2021 and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_adc422c1-cadc-4ce8-8605-5ec3b7f58580" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31, 2020; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ad13fcd-1825-4095-bdc3-d7aa75ad253b" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0982c15a-29f2-48d3-99cd-65902ebec87a" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e9616bff-d96d-4bfb-9dfd-7d4a6f8388dd" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_291ccfac-e31d-4618-aab4-db7f1d43e86d" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares issued and<br />&#160;&#160;&#160;outstanding as of December 31, 2021 or December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_70301994-e88a-4217-9c45-d103d1876a85;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bec7d1a7-68ee-411c-8334-470e5b31718b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d58bcc8a-2c4a-4bea-803f-2d8eac834723" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_50c144b5-2fdb-42d8-9f27-3adc6df2ecda" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7434956e-b862-4573-a813-652073a5d373" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c69c06d-6f2f-481a-a314-b40f3487c6c8" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f20d0013-7ba0-4fa6-9d1e-3377350602c2" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,975,034</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />&#160;&#160;&#160;issued and outstanding as of December 31, 2021; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9f3958f-42f2-44e2-bbaa-03fda99779c1" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">230,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;shares authorized,<br />&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4dc1e385-a0ea-471f-a8ca-d39249238ddf" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_f0ed077a-a335-4005-9413-eaf965134cb6" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,096,903</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;issued and outstanding as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0571eed2-e3ca-46ea-b4a3-712cac26f2fe" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3deff738-46eb-42b2-b59c-4a8318ccc1ca" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac126601-9b74-4039-9930-6ea8bdee96d8" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d19cbd6-63ef-4c77-bfe1-c5f6e297d6e2" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated other comprehensive (loss) income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38232c8e-41e5-497d-b7bf-80bab96d013c" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">145,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b84d1ac0-f2a7-4ffc-b9fe-0500ccf990c3" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">111,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3823ca0-dbbe-4fd3-b370-9eabb2f444b3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5ef5e9c-58f5-4707-8646-beb8c21f3cbb" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">101,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities, redeemable convertible preferred stock and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c01fbb75-f01b-4c4c-b149-7a1c9bc611b8" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_138fd023-cf31-4787-8695-a2268a64569c" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.099%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.074%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:13.053%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development revenue under collaboration </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d76f71c9-2042-4b06-8c63-f4b8806de07f;"><span style="-sec-ix-hidden:F_d31c53a8-537c-4399-a1e0-f3fda99cb66b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">agreement</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8eebfe4a-3032-4645-9442-f65b8e40aef8" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0db272f2-6068-4280-baf4-9e7f15793b97" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9c7fdc3-0f21-42f0-b956-b461ba15bb11" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,108</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_643ad46b-4e67-453c-93af-a24f18ee6f39" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0dbd1eea-26da-4260-9c85-a941c25cbbff" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,015</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81631ecb-a751-4fa3-9336-353336c5573f" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7cfd760-6e6d-4d86-9e30-27e980484640" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a63bb337-22d1-4eb3-9352-2696ebc21211" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,713</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0734c2cf-bb21-456d-848c-a6cb7520a5c2" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,138</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dff6a63e-9c7b-457a-ad53-f5e8bac3c2ab" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bdeee6b-8494-4b08-afa1-0d053cbbadb5" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a096cbbc-edcb-4611-b980-71ff9e2bc556" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_293f1952-bd2a-4ef9-848d-46b565e7e9db" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60773824-17ba-4cd7-a2c4-3eece7bd15f7" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72af52a7-2f6a-48bc-8fd4-03b2a2812cf0" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5be22f80-7e06-42ed-8a30-ad6ab57f82ce" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">16.00</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares of common stock outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d424209e-7590-4b6c-9823-66de032f5f69" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,983,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e0f8c11-6a4d-4796-b2f3-c79dd9f28d75" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,765,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#x2019; EQUITY (D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">E</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FICIT)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:29.187%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:0.534%;"></td>
    <td style="width:7.938%;"></td>
    <td style="width:0.702%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:1.068%;"></td>
    <td style="width:7.341%;"></td>
    <td style="width:0.702%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:0.534%;"></td>
    <td style="width:8.085%;"></td>
    <td style="width:0.534%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:1.068%;"></td>
    <td style="width:7.474%;"></td>
    <td style="width:0.534%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:1.068%;"></td>
    <td style="width:7.509%;"></td>
    <td style="width:0.534%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:1.068%;"></td>
    <td style="width:7.355%;"></td>
    <td style="width:0.702%;"></td>
    <td style="width:0.99%;"></td>
    <td style="width:1.068%;"></td>
    <td style="width:7.362%;"></td>
    <td style="width:0.702%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Redeemable<br />Convertible<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additional<br />Paid-in<br />Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;<br />Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1d3fdd4-0352-4016-8e97-78e533dc6d9d" contextRef="C_9b136456-ad76-446f-a0d8-ef8a597b5f71" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">75,727,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4cc0b675-2904-4e83-963a-16900875918e" contextRef="C_9b136456-ad76-446f-a0d8-ef8a597b5f71" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dab9b40-e3a3-4e9b-a706-86cc8a2f9b30" contextRef="C_df1f510f-8f9a-4d97-92ef-ba74f342490f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,651,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b98e4823-43c4-4f30-af5f-483bdc9454a7" contextRef="C_df1f510f-8f9a-4d97-92ef-ba74f342490f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f677be8-5881-4e74-b178-0b04a1a9bfe8" contextRef="C_7dd562f4-b1c2-450b-8d06-e06ff831105e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4beb4286-99db-405c-8782-3d90e630a990" contextRef="C_4e968a25-daad-4006-af2c-b4b4e11eefe5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">67,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_982de6db-1f5c-4a29-9a6a-9a759ac96edc" contextRef="C_b875a6d3-58ee-468a-91f5-65132ce52f74" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,463</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of preferred stock and common stock in<br />&#160;&#160;&#160;connection with the acquisition of Amplify <br />&#160;&#160;&#160;Medicines, Inc.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e08d461d-8ea3-4022-90ef-a59f549684d7" contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883" name="ikna:TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,863,094</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17a56939-d975-4407-abdd-334e8f285362" contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883" name="ikna:TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,924</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e881cd5-4025-46ff-b3af-e3cc09058835" contextRef="C_c47f385d-2c66-422c-92c6-8542e19860cd" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">426,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_814965dd-9ca9-4419-b192-0b931a55948d" contextRef="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3295a477-7602-4b8a-b238-52989641e759" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of preferred stock in connection with<br />&#160;&#160;&#160;private placement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fab8831d-1583-4649-b8e9-ac5547d92ff4" contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883" name="ikna:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">85,806,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa2488d8-489d-4844-bc29-e59490b43cc9" contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a95d869-ee29-430c-86d9-ad031175dd8a" contextRef="C_c47f385d-2c66-422c-92c6-8542e19860cd" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_620b1c1e-8003-47d1-a6e0-9850898896ff" contextRef="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e225b86a-e541-4109-b6a8-93eccb2ae522" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31e89162-88c6-49cb-8520-be2880927be3" contextRef="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0759279-d5e9-45ab-b928-c33dd6a298f9" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b534e1d4-b2e1-4679-9483-cc14dfe78435" contextRef="C_ead8d980-42b0-4dc9-aa5e-8601926b283e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_528decc9-c7a9-48ea-ba5b-3daaf9afb36b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79b3c370-7673-433a-9453-fbeac5857aea" contextRef="C_73a95a4f-2717-441c-8d33-6cca61d172fc" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf7d1c3a-9000-48c9-b543-d094f8998fa4" contextRef="C_73a95a4f-2717-441c-8d33-6cca61d172fc" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa1a4a91-1ba8-4df3-8aa7-747cae2690b9" contextRef="C_4ca75a5f-a6d6-4a47-bdba-3f6e337cfabb" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,096,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e97f848f-d3fe-43e3-b021-3ab590dacd63" contextRef="C_4ca75a5f-a6d6-4a47-bdba-3f6e337cfabb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d3e916d-383e-49a0-a3f2-447cd7d4dc58" contextRef="C_aaa01b2e-dd1f-4221-87af-21a855fd6176" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b4b6383-3e1a-447b-8c5d-a28f8347aa37" contextRef="C_4f1aee2b-76d8-4d4e-b29d-300c4f6ff2c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">111,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79d51210-2320-4823-bef5-a3632f99d366" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">101,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial public offering, net of issuance costs <br />&#160;&#160;&#160;of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0aef5f52-e048-44b5-a502-8a28cebe2021" contextRef="C_2df7bdbe-e8b1-4c47-ba9d-7aa5fe65b63d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dee328c6-e8d0-4e83-a39c-ea779b43e492" contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,984,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2c27d7e-795a-4610-8d86-60c3791eddc9" contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a331a7d-65af-4d63-b11d-66f1912803a6" contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,293</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a1c24aa-db07-4c77-9c1e-9ca3513a6503" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of convertible preferred<br />&#160;&#160;&#160;stock into common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_975a1fc3-ebb0-4070-9ef5-cdbeb92edba4" contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9316c2c2-c114-467b-acef-618d2a37b398" contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c72c57bc-b0ae-4923-96e3-31468de2520a" contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,678,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c09146a-7c69-4162-ad7b-cf0ef3669e0d" contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc6c96b9-2893-4803-9f48-9df1bd55eefc" contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3438d432-6307-4973-92ef-1092f868c519" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df5a1d52-e188-4234-bc37-87cad2a84da1" contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">215,188</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_513af5b2-d171-448f-a086-303867f3b7e1" contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_780271b3-7db1-4ba3-b00f-b7e762362bfb" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc3de1df-49ab-486e-b6bc-723e9cf61d81" contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84b085f8-0cd3-4bc0-9be7-e137d199e16d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70905a4a-035e-41e8-9972-79b27c0e4a9e" contextRef="C_305a280c-d1de-4413-b7dc-476f60a09329" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67a97f3c-1179-41d2-8745-ca77af244edd" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance as of December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_215c9295-e93c-4b3f-a591-bf397a53b90c" contextRef="C_93401a31-e235-4435-b893-a060400d5a04" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">35,975,034</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_948b0432-e865-4b37-bc7a-26ff181c859e" contextRef="C_93401a31-e235-4435-b893-a060400d5a04" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6207541-d20f-4279-b371-bfa5f6980a2e" contextRef="C_04f5fcbc-3f2a-4fe4-b203-67a710042614" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23529365-09ba-4d4a-a9cd-e67e98fb39c9" contextRef="C_4f40c434-b11e-4ddd-b726-08e4052dba90" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">145,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bdc52a3-3168-49bf-a44d-d6e53614d20f" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">C</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">O</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NSOLIDATED STATEMENT OF CASH FLOWS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.167%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.03%;"></td>
    <td style="width:0.921%;"></td>
    <td style="width:1.595%;"></td>
    <td style="width:1.37%;"></td>
    <td style="width:13.03%;"></td>
    <td style="width:0.921%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ddc5755-6bbf-40a0-a7bc-ce09e08815c4" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce082770-6e12-4589-a15e-fd11b0a45dde" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash (used in) provided by<br />&#160;&#160;&#160;operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1db1333e-bb1f-4e89-8887-c60f4c057345" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7969399-3315-4660-8747-1c2f8fdd748b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd0bb34a-e5c6-4d0d-b7cc-19c919c0fd0c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_278a729b-a55b-411e-b68b-46e46a7d22a8" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash research and development expense for in-process research<br />&#160;&#160;&#160;and development acquired in acquisition</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1754de4-39bf-4580-be04-bc0c4ccedefb" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ResearchAndDevelopmentInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef6bde2d-de7a-4a4b-8517-b2625dd08dc9" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77bf18e3-38e0-4ac4-ae76-4f33314ca5c3" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66e901d2-39d3-47cd-9b43-d3879a5c1043" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07a6c48b-0f6c-4179-8fb5-dc90feaf86b3" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05b93051-bbb8-44cf-aee5-8a52a9353574" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29e0e612-9455-41fd-b1c2-41269d2a60e8" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b72fb660-7eb0-4a8e-87ca-642be688531d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58f94b97-bd68-41f2-9b76-5fc34618d4be" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_539936ed-6259-4f51-9251-29866ebb4101" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncreaseDecreaseInLeasingReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb1fe4a8-6ba9-4e1e-a2f8-7437791582dc" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:IncreaseDecreaseInLeasingReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc0421d2-0890-4632-9a4f-3b0004aee622" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ea35441-e58e-419c-9fdf-301b3e0d070b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deposits and other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc8be0fe-32f8-4117-9b23-053bf7599a1f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,514</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash flows used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1741f21f-e90c-43da-bd7a-f7e8b91373d0" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,252</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea542c5c-98ac-40a2-9348-e6d07b1a7310" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash obtained in asset acquisition</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6febdcea-f497-4121-858f-405519fdc77f" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments to acquire property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21381e29-ec79-4ec3-b17c-104aeea1f5e1" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a47d553c-a793-4fdd-bcc2-ff8046d41080" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash flows (used in) provided by investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_351756cc-bbbf-4ad0-9514-92150e23129b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36265e63-fd62-41b5-8970-4acb8316868b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of preferred stock, net of offering costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5251b3e6-1a99-4d02-affa-ec68cc97a63f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ab392a8-83c0-4740-8b82-7a49a2256b60" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from initial public offering, net of offering costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a25f07a-a9bf-464a-87b3-7cd8a04293e9" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:ProceedsFromPaymentForIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,302</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c3ab120-678c-400c-b861-4d92152ab835" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="ikna:ProceedsFromPaymentForIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3cc37e8f-d9a3-4bbf-8847-7ac3e7912302" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7393107-72ba-4693-9f53-99b90532990c" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:40.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash flows provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d10dc34-3b5d-44d2-aa2f-4dd696704bd7" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,738</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbb7c5c4-9ac5-4820-9b9c-64ab9ca8b971" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d8bc51b-075e-4a96-b147-b04ecde774e2" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,726</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c2999fe-516c-4b38-80f4-be5fc72c3985" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ffa9e63-f33a-4b4a-b3b4-d37d80041334" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08a9d709-45de-40c7-b7df-d359dc27d8b6" contextRef="C_b875a6d3-58ee-468a-91f5-65132ce52f74" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d48b3a03-e704-4002-9078-097e57024fec" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a20a8b7b-748f-4418-a8cd-fd7dc7089254" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_206cbc76-4f77-4d65-8eec-b47650353d63" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a00bf27-da44-412f-b161-45ec51d46fa9" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash included in other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d89ab509-a649-45e2-b26c-78c8581c22cc" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04aae3e3-557c-4be4-87fa-16e6fd363784" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f539f489-1394-4775-9b75-b48bd737eac1" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e61fa811-c313-4588-9bb8-595bd4f296bb" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">163,363</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosure of non-cash activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets obtained in asset acquisition</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e05b5aba-9aa2-4f82-b522-118a8a272312" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liabilities assumed in asset acquisition</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61802129-1691-4e9f-9759-4f4763ceaee9" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">970</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of equity instruments issued in connection with asset<br />&#160;&#160;&#160;acquisition</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_284ec3b8-3039-48dd-929b-b3ccc233d882" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,892</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of property and equipment in accounts payable and accrued<br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96288169-1320-4996-95f8-3a4e2ff17274" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77a3a714-8add-443c-b666-6047c767d3a2" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred transaction costs in accounts payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b536ce1-6274-42eb-8aa1-b6c14cb8efdc" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="ikna:Deferredtransactioncostsinaccountspayableandaccruedexpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets recognized upon adoption of ASC 842</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3333fcb-4319-4bf5-ae48-980a9f430262" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="ikna:RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets and lease liabilities recognized upon lease inception</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94d45c4b-6230-47c4-a2e1-cc1d61c09104" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,541</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IKENA ONCOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_598d58cf-ea7b-4118-87d2-ca54ff03986b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF BUSINESS AND ORGANIZATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment (TME), with approaches to targeting both cancer-driving targets and mechanisms of resistance to targeted therapies. Our focus on patient-driven development is platform and process agnostic, allowing us to research both known and novel targets , with a shared guiding principle of aiming to address the unmet need of a biomarker-defined patient population. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust pipeline of discovery-stage targeted oncology programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 22, 2021, ahead of the initial public offering, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29f0b849-6181-43b8-becd-febb4314616e" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7fdb186e-815c-4baa-b15f-3f79588d331f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.154</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Company&#x2019;s common stock. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of the Company&#x2019;s convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 25, 2021, the Company&#x2019;s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). In the IPO, which closed on March 30, 2021, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15739e67-eff2-4af0-9c1a-977b33f29e75" contextRef="C_c95a6922-ca79-4e5a-9bb5-f9b65cbb34cb" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,984,375</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, including full exercise of the underwriters&#x2019; over-allotment option to purchase an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4e34638-fbdb-4d09-8772-cdd8d2101f65" contextRef="C_3f3abad8-6574-4e7c-b859-64ad14c715ec" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,171,875</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03ec6e98-dd1f-486c-a2d2-495b9a996e4c" contextRef="C_53dec454-cb02-4c8b-823d-02e9a70817b1" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b77e4dcd-87bf-4511-9ff9-bc3a2ba928cb" contextRef="C_2da448fd-bf19-4ae7-a240-59e52b66aea8" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">131.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca6fdc7d-109d-4826-bf7a-801f66849adc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00d987d1-10da-4607-9dee-62fe38ebaf9b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation and Principles of Consolidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#x201c;Amplify&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb66cb15-01d2-4cdd-854a-c3023784e6a5" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and development revenue under a collaboration agreement, and intangible assets acquired in an asset acquisition and, for periods prior to the completion of the IPO, stock based compensation expense.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a322403-2c71-4c0a-9879-8df1ad5dca4d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:LiquidityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December 31, 2021, will be sufficient to enable us to advance our long-term strategic goals for at least the next 12 months from the filing of this annual report on Form 10-K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing, or terminating planned activities related to its product candidates.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2144c307-11dd-4ed5-a3c5-c23f91fc76e1" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segments: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc61491c-d5ed-400f-877f-8200b25e653f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf32a972-d405-4ede-8296-38d81a4f9776" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and of Significant Suppliers: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, substantially all of the Company&#x2019;s cash and cash equivalents were deposited at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08663525-f2c9-456e-a350-906fbe75c2ac" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:ConcentrationOfCreditRiskNumberOfFinancialInstitutions" unitRef="U_FinancialInstitution" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> highly rated financial institutions. The Company maintains balances in operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers and clinical research organizations to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_220f2da8-a1d7-4006-a7a7-ae7a7ddb372c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value of Financial Instruments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amounts reported for cash equivalents, accounts payable and accrued expenses approximate fair value because of their short maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cdebe0e-6ecf-4ed1-a03a-d4cea6fa43e1" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cash equivalents are generally composed of commercial paper, corporate notes, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6f46a72-ed6f-40f8-8b53-1bd0fe57986a" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Cash: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company maintained restricted cash totaling approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0682bc5-190c-428c-bcd3-c4ff7c6b4133" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_875f2e3b-44ee-41ab-a521-e92f6269e855" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, held in the form of a money market account as collateral for the Company&#x2019;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d678866-604d-44b8-9eeb-9094cd42b980" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3c65899-3a9b-48d6-8c44-c0eae8154976" contextRef="C_a4cf98b3-916a-4266-a09d-ad4151809aea" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Electronic equipment and software are depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d96bfaa0-d1ca-4268-9dee-1a58e96cf14c" contextRef="C_905f0da9-40cb-4e6b-881a-7396023d88fb" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31f99d28-7334-4136-a688-c3a7ea6a1266" contextRef="C_eb6c9d92-b86d-45de-b6ed-45a7a20b5125" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the shorter of their useful life or lease term.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a4e95d6-9100-4278-bdde-d084548d8b69" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Long-lived Assets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets consist of property and equipment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de344f6c-edf8-4bef-9755-666624c4f42f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd3a92c8-1d94-4ec0-ab9a-1a1d36503e65" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue Recognition: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to revenue recognition are recorded as deferred revenue. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbff147c-5877-4b4d-84a5-c4c3dd5de3a7" contextRef="C_9d2ca6ed-69e8-4b73-9331-739f008d6068" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts expected to be recognized as revenue within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4dc57546-d749-4e70-96f2-2c910b07bf39" contextRef="C_a363f018-7c61-490f-9200-7d87e22a642d" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had one collaborative agreement with Bristol-Myers Squibb (&#x201c;BMS&#x201d;), which the Company entered into in January 2019 (the &#x201c;BMS Collaboration Agreement&#x201d;). For a complete discussion of the accounting related to BMS Collaboration Agreement, see Note 7, Collaboration Agreement and Stock Purchase Agreement with BMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8868192-8973-4e71-ba2d-335e4f68d970" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Expense: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials. Research and development expense for the year ended December 31, 2020, also includes the write-off of acquired in-process research and development (&#x201c;IPR&amp;D&#x201d;) assets with no alternative future use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27dea584-cef0-4726-8439-536fbf7abb3e" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Asset Acquisitions:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db394961-2363-4be0-82f5-0a4eb3a15f36" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#x2019;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac609f84-eabe-4a82-989c-41a7e6a59ec4" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividend yield was assumed as the Company does not intend to pay dividends on its common stock.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef1c76e2-77c1-4594-a72c-9a0285dc03f9" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:LeasesPolicyPolicyTextBlock" escape="true" continuedAt="F_ef1c76e2-77c1-4594-a72c-9a0285dc03f9_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6242453e-6005-48f3-94c4-c7e1e8f8f635;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting Standards Codification</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC) 842 Leases, which was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d3acf18-1ecc-4467-b703-5b9e84013cbf" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8695050c-4d05-4b9a-a6de-41c58710ea4c" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company's operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_ef1c76e2-77c1-4594-a72c-9a0285dc03f9_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b6a2896-8ec3-45a0-96a3-eb9564f14b00" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Comprehensive Loss: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f2b75df-a72b-4b43-89cd-a225e224c186" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Issuance Costs: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred issuance costs consist of legal, accounting and other third-party fees that are directly associated with in-process equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the proceeds generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 30, 2021, the Company completed its IPO. Accordingly, the Company recognized offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50b2dccf-526b-424f-a7fa-1a918c3c8cdb" contextRef="C_c95a6922-ca79-4e5a-9bb5-f9b65cbb34cb" name="ikna:OfferingCostsRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from the gross proceeds associated with the closing of the IPO through additional paid-in capital in the accompanying consolidated balance sheet. The Company incurred deferred offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1acd174-e8b9-4fc6-96f0-b48be42848df" contextRef="C_c9ea63bc-0e26-4e82-ae9c-c05ca061173e" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2020 which were included in prepaid expenses and other current assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4fceffa6-ada1-4d98-a6b1-3255cbe29e2b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company Status: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e8d9a60-8a89-47cc-af4e-93b604008f38" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7cf6c95-ae78-426f-8fca-f6f728db1607" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99777e26-9e38-4049-94aa-12cb904a1b57" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.878%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.441%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.441%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.452%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.527%;"></td>
        <td style="width:0.685%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices in Active Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d76479d-b1ef-467d-a278-8acf7f8e6f52" contextRef="C_6b95089c-ecad-4ea3-b482-0bde43865eb7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c4c75c7-01ee-463c-993c-a8376fe13c50" contextRef="C_c1b60113-9aac-46bb-90fa-37d525cc890a" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Cash Equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b33886c4-8224-48bf-8f9a-077e91633d20" contextRef="C_f6feba73-11f7-4c3f-bf74-b2fc74138690" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5094eddc-4cb9-46e7-8851-30723aad6ac5" contextRef="C_53a98858-94fb-4019-b8a9-8e6c8638bbb5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.878%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.441%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.441%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.452%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.51%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:12.527%;"></td>
        <td style="width:0.685%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices in Active Markets<br />(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Observable Inputs<br />(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Unobservable Inputs<br />(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3c671f7-9c1c-4da6-a8c1-9b3aea342735" contextRef="C_6838680a-d30e-45b3-9c96-ca296d3f4897" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59475548-4c79-450f-bd1f-47b4218601b0" contextRef="C_6bda0fb6-7d7a-41ad-a5b7-dd54a0540cc5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Cash Equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7415ad57-595a-4d3c-ab63-469185856574" contextRef="C_1e48cebc-3625-4ce6-9967-9afa2709e2dd" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea359384-99f9-4d85-ab08-e915ab86089a" contextRef="C_a3d192b9-f1b8-48f5-80bc-54ccb8098dcf" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ca8791f-a5af-423a-b271-65cecd0dee26" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2ca67394-75b3-4062-ae27-418ce6291240" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_347e86ca-8c5c-40d7-bf41-13360c5f8134" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_83003673-fdf0-465f-864b-83f0f62169e3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between Level 1 and Level 2 financial assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aee58fc6-6bf3-4783-bf15-5db407f14409" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a7f1e88-2ff8-40c0-9f6f-504450b92c2d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.247%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:13.605%;"></td>
        <td style="width:0.817%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:13.605%;"></td>
        <td style="width:0.817%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical, manufacturing and scientific development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3eb3d5e-571f-45d3-8289-9312ac73a536" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="ikna:ClinicalManufacturingAndScientificDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ed160e5-5d14-4803-aa6e-643218e39c85" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="ikna:ClinicalManufacturingAndScientificDevelopmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89721938-8a2d-4d24-ae0a-e5f4fd989624" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28633099-1cf8-48aa-a1ba-343ad1baf308" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a30c3545-5cbe-4d1e-b237-bc070d425987" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0da0e44d-7698-4ad2-a7f9-40d161977af7" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_879d2abc-014f-4860-9c7d-58b62fcce897" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3a3f346-cf9c-49e7-b14c-362c7af3f7da" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,478</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e0490c8-132e-4851-981b-29cbe3ba64ae" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. PROPERTY AND EQUITPMENT, NET</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0878cc41-0b9c-4588-bc21-52aaaf5d79e4" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.832%;"></td>
        <td style="width:1.473%;"></td>
        <td style="width:1.928%;"></td>
        <td style="width:13.538%;"></td>
        <td style="width:1.285%;"></td>
        <td style="width:1.473%;"></td>
        <td style="width:1.928%;"></td>
        <td style="width:13.257%;"></td>
        <td style="width:1.285%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe2b62aa-b5ed-438a-8033-569c7f910521" contextRef="C_33e372af-72dd-4109-9ecf-cd6de6a18366" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,776</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54808c68-0826-42d8-94ba-7135996b1a0e" contextRef="C_7884ad66-cfc9-4e7d-b37b-a43da1f827a0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88d02de6-94c4-4124-b233-dbf3f6353ac0" contextRef="C_f861265f-3133-42fb-a89c-dac532459910" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19538da6-1dc0-4cad-b793-d42edc78f33c" contextRef="C_12fe0903-8181-40c3-af42-92ad1bc22546" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Electronic equipment and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20d7f299-8906-4725-83d7-51e3dc603ff4" contextRef="C_4d387d5e-0476-4899-8453-c870bec1b749" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ee0dbd3-a96c-40d9-af8b-dc4c54f25eb2" contextRef="C_1ea44336-4474-480c-bcd2-a098f4164455" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f20f3c38-48dd-403b-9b3f-9f7135c173a4" contextRef="C_f5cf5caa-b798-49d2-bb71-6baf51e18554" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c370917-41a3-4ff0-a844-947d1c955e3c" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,513</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d72f2cc-7e80-49d5-ae70-6e9a908d0d5d" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,081</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd77f8c8-ae37-4870-8032-ef55fba98070" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c69f3181-1eb3-4598-a613-23de71fc9c2f" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1568da09-8d09-4bbb-b94d-23f4f91aacce" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18c6ecb2-257c-4f23-b073-d6e5f2897be3" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense for the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d31b3c1-f4f4-4770-8eca-da5ed689f22f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eae23c5a-27d3-4185-b549-0cef7a03996d" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_afab7e61-5833-43dc-9928-e2e23b8c53f2" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_09d98a7f-ac86-4b68-95b6-04676a37928f" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ace347e5-606a-4362-822d-11a85b7fda97" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b24084e-91d3-4f2f-bb09-5be671672c26" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.194%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:13.631%;"></td>
        <td style="width:0.817%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:13.631%;"></td>
        <td style="width:0.817%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16694904-9fdf-42af-aa13-9a42b081f3fb" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,809</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5594f51-a6f2-4574-a744-f131cb9684d9" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,816</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c46711a-f4b9-4d6e-8764-a2c037f1f205" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="ikna:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,489</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ac774ea-cab5-4cf2-bdae-fb05cc7326f6" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="ikna:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbf418a6-20ef-4f20-915f-e3a02c157a3c" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">530</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_952c2414-3228-407b-b00b-0eafdab064ff" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f83f02a-5e8f-4823-81f9-a33eaae5721c" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8346905-cd5d-4ade-9842-ef1c1803d684" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">380</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44493149-97d9-4e71-929b-0392370cc561" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,854</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d93abb4-a569-4503-a046-6a16aa11107e" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae9cf183-6f10-4d7c-a0cd-b7f27378395e" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true" continuedAt="F_ae9cf183-6f10-4d7c-a0cd-b7f27378395e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. COLLABORATION AGREEMENT AND STOCK PURCHASE AGREEMENT WITH BMS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company entered into the BMS Collaboration Agreement with Celgene Corporation, which was acquired by BMS in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the BMS Collaboration Agreement, the Company entered into a stock purchase agreement with BMS, which resulted in the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79763eba-d343-475b-b8dd-de98ec5047e5" contextRef="C_c485b7cf-0678-46d2-94de-86fa847eed87" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,545,450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A-1 Preferred Stock (the &#x201c;Stock Purchase Agreement&#x201d;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Company&#x2019;s IPO, the series A-1 preferred stock converted into common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Structure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BMS Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the aryl hydrocarbon receptor (&#x201c;AHR&#x201d;), which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program (&#34;the research term&#34;). BMS has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, BMS is responsible for the worldwide development, manufacturing and commercialization of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BMS paid the Company a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_962370de-4321-4ffb-b2c3-131b662e4aef" contextRef="C_cab5b9e5-69a0-4f7b-8c1a-81cbd3afcba2" name="ikna:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">95.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f06a812-a6c2-4cad-885b-f239c07a60e3" contextRef="C_249d1b32-5370-4599-8e89-ab6c0f09b80f" name="ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in case of an exercise of its option with respect to IK-175, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dce8f3b4-c08a-4926-9cd0-bffc8f02dee4" contextRef="C_5e239a4a-5d8e-4aa5-91c9-b646ab6d2361" name="ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to BMS to support the decision to exercise the option for an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fde315c2-644b-4a64-adaa-1761191a6ab3" contextRef="C_cab5b9e5-69a0-4f7b-8c1a-81cbd3afcba2" name="ikna:OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" unitRef="U_USD" scale="6" decimals="-4" format="ixt:numdotdecimal">0.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fe2706a-b251-412a-b830-f6a9153f337d" contextRef="C_84ac8be9-5cfc-47f7-b50e-f6ab75a07026" name="ikna:MilestonePaymentsEligibleToReceive" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Considerations of the Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The BMS Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38b1fa04-82f7-4fe9-8441-15a8c48b64c2" contextRef="C_7eb39d52-adcf-40e5-ae5d-09ebf80bd382" name="ikna:UpfrontAmountAllocatedToEquityArrangements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the upfront from the BMS Collaboration Agreement was allocated to the equity arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the BMS Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71c65691-5206-4366-8436-56d79bbd80dd" contextRef="C_9449ae95-9c4e-423a-a742-487a9fa3d5c8" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">78.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the distinct performance obligations identified above, the Company allocated the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33db7bf2-d4e3-4696-8e4f-ffabb90ef4ac" contextRef="C_9449ae95-9c4e-423a-a742-487a9fa3d5c8" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">78.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e351b11-4ef2-4683-b56d-9c6870a41cf5" contextRef="C_fc3f0817-4c02-46a4-a64c-d9eba5dae732" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">41.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for research and development services for IK-175; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aca1cbde-fa98-4db6-90c8-0cd56a49d609" contextRef="C_3af77da4-b3d1-4363-bc9c-05213b03b1ac" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for research and development services for IK-412. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the BMS partnership, the Company made the strategic decision to pause IK-412 developm</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ent activities for the remainder of the BMS research term once the ongoing CMC work has been completed. As a result of the decision to pause, the Company recorded a change in estimate during the three months ended December 31, 2021 and recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84f15625-a7ff-4413-9049-6b1815e9fc5e" contextRef="C_c92572d4-da38-4f18-8896-9db108cd3d8f" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of research and development revenue.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_ae9cf183-6f10-4d7c-a0cd-b7f27378395e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recognized revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e13ae0e-6243-4e72-86b1-2ff68ce0d456" contextRef="C_035aefe6-e027-41ce-80d2-5bcb01214d81" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5">31.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdc3938c-2e8d-48f9-bfdf-f13c2cf05ffc" contextRef="C_c24f3ba8-ff6c-4e9e-a73d-2853c35d6b11" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, from the BMS Collaboration Agreement. The consolidated balance sheet as of December 31, 2021 includes deferred revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_622ced6e-ef5a-46d1-9b8a-41e12b2db556" contextRef="C_640f8a26-ca73-4101-8b04-267f50272b4b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5">24.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related this agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69886587-03eb-4c84-b03e-415af776183f" contextRef="C_640f8a26-ca73-4101-8b04-267f50272b4b" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01b8e3cf-691d-4e11-bd75-236aba151c54" contextRef="C_640f8a26-ca73-4101-8b04-267f50272b4b" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were classified as current and non-current, respectively. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for IK-175 and IK-412.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3a01ec3-57a2-4c11-a0d2-1c77be232fc9" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:RedeemableConvertiblePreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. REDEEMABLE CONVERTIBLE PREFERRED STOCK</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the Company&#x2019;s IPO on March 30, 2021, all issued and outstanding Redeemable Convertible Preferred Stock of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b41e8abd-dc26-4f91-9587-773eab474934" contextRef="C_1751049c-5a01-4bb3-88da-acd002119349" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c5f3b15-29b0-43ac-9ad1-b1e746885068" contextRef="C_3cf264ba-3822-4bc8-8611-e5f6c96c4ced" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,678,568</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock and are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35987cf8-d1be-4e29-8f69-99671cdcad0d" contextRef="C_80c83882-abbc-4f18-9ffe-8a6f1fe9f705" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> longer issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, the authorized capital stock of the Company included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f390d491-4df3-4f47-b604-06c2bfeb669a" contextRef="C_73a95a4f-2717-441c-8d33-6cca61d172fc" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock.</span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_049510f1-d807-4ae1-ae18-db4b1d8feb9b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:TemporaryEquityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, redeemable convertible preferred stock consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:29.828%;"></td>
        <td style="width:1.649%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:14.491%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.649%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:14.491%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.649%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.859%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.649%;"></td>
        <td style="width:1.371%;"></td>
        <td style="width:13.88%;"></td>
        <td style="width:0.685%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares<br />Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares Issued<br />and Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Liquidation<br />Preference</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86424d1a-0d33-4aaf-b93a-bd0c1382fd93" contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,000,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f61ce486-793d-4f3d-9807-d309c1be90f1" contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_fb2501b6-2413-41c0-a714-04e42066a4a3" contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,000,000</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26884425-f4a3-4c86-a4ea-1bd7cebbf138" contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9bd08948-9720-4f56-bab6-abaf22c01865" contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_443def15-881f-4cc0-a6f9-70065b1854ee" contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,727,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c95e15e-4431-49b9-adde-83e5407f31f0" contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_827fe749-2587-4630-b795-abf27b1f1f2d" contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">47,727,268</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_228ee6dc-1b86-4e56-96bf-f1d666e825b6" contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,035</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86173832-c758-4a6f-a610-83decc33fc2a" contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,727</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A-2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dce5ff83-8e00-4912-a541-1eab658d2eda" contextRef="C_b652551b-9695-4fe5-8980-18380f280c59" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,863,094</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6db6bcb1-66ab-4f17-9b0d-4a7e97654f8c" contextRef="C_b652551b-9695-4fe5-8980-18380f280c59" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_dac9f731-8cd3-46a7-ae59-cf5ebb7167a9" contextRef="C_b652551b-9695-4fe5-8980-18380f280c59" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,863,094</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7cae3d1-c074-4903-92da-22a5824eda93" contextRef="C_b652551b-9695-4fe5-8980-18380f280c59" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f612f2ba-e887-40ba-8ec5-816e2a731fda" contextRef="C_b652551b-9695-4fe5-8980-18380f280c59" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52a23cf1-b4ef-4960-85df-9b31b5acc61f" contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">85,806,214</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4961d228-1091-41d5-810a-27f86ade20ca" contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_2bb8acde-fd47-49e5-baf5-02fd8c7fe573" contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">85,806,214</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81d3599b-e25a-49f4-a2e0-446a115635e9" contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,188</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_702f39fa-0175-4304-bbb8-d7d809d832d0" contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e667f5a4-a979-4bec-80ea-416068ec6332" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_209aec18-2edb-4285-b759-c4fb2e00311a" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4fc9278f-7abf-4d20-ab4e-5677427e6309" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50e72a7a-e82f-4589-a3bf-c4118f6ba1bb" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,979</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be754fc8-2169-4bdb-af92-4e5aaf60555e" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:TemporaryEquityLiquidationPreference" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">202,227</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Preferred Stock had the following characteristics as of December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	Voting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Company&#x2019;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and have other special voting rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cfe45c4-2855-4583-b9aa-e43d6e825add" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:PreferredStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of outstanding shares of Preferred Stock shall be entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Dividends</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of Preferred Stock are entitled to an </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d29e7ab7-2b75-4c03-89f2-33edc397d807" contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc" name="ikna:TemporaryEquityNonCumulativeDividend" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% non-cumulative dividend. Dividends are payable only when, as and if declared by the Board. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59739d17-7c8a-4ce3-bdaa-95ad71810f4c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:DividendsCommonStock" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Through December 31, 2020 and the completion of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35d81a36-b2c5-48e5-b3a7-e2494144fb55" contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883" name="ikna:TemporaryEquityDividendDeclaredOrPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_408e55b1-6ecd-4380-be4c-9b7279c4ba83" contextRef="C_3dd7a94f-ebbb-475e-ab24-17fd8d19e2fa" name="ikna:TemporaryEquityDividendDeclaredOrPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared or paid by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)     Liquidation Preference</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed liquidation events, holders of shares of Preferred Stock then outstanding shall be entitled to receive the greater of (i) an amount per share equal to the Preferred Stock original issue price, plus any dividends declared but unpaid thereon or (ii) the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	Conversion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3feb9f2-294e-4694-ae5c-0f171d752449" contextRef="C_58e59c96-9c20-4175-a767-95e0b0fd9b9e" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for one and are automatically converted upon a qualified initial public offering or upon written consent of at least </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12085029-8dc1-4aa2-8646-a79791a79c62" contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc" name="ikna:PercentageOfHoldersOfOutstandingSharesOfPreferredStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain dividends and distributions, and mergers and reorganizations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The conversion ratio was changed to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ac07fee-b54e-447e-b06a-acca55e5fe0d" contextRef="C_252420a7-5245-4f24-a1b3-549a5657e10c" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" scale="0" decimals="3" format="ixt:numdotdecimal">7.154</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for one upon the Company&#x2019;s filing of its amendment to its Amended and Restated Certificate of Incorporation on March 22, 2021.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3868ee1b-e4db-4dfc-85bf-fb46b96dd9a7" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. COMMON STOCK</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5246cf27-46e8-497d-af2e-8104728b23e5" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1a2a11e-1bbc-4595-9e26-8568beffecff" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">230,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock authorized, respectively, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e884684-168a-4dc4-acc0-b3d73cf6e3e3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_e4fd1854-8a70-453a-9a6a-95bc38d4f20b" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">35,975,034</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49f7eb85-2a91-47d4-b468-b621979703f0" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8f94e9bd-b579-4030-817a-363493b1235f" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,096,903</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Voting: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dc5173b9-fb27-4f95-8959-c42ea4cb0a2a" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividends: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are distributed to the holders of common stock.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10</span><span><ix:nonNumeric id="F_b74c3860-4afb-4b6b-ba09-5fe77263c003" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_b74c3860-4afb-4b6b-ba09-5fe77263c003_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. STOCK BASED COMPENSATION</span></ix:nonNumeric></span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_b74c3860-4afb-4b6b-ba09-5fe77263c003_1" continuedAt="F_b74c3860-4afb-4b6b-ba09-5fe77263c003_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2016, the Company&#x2019;s board of directors and stockholders adopted the 2016 Stock Incentive Plan which was amended and restated in December 2020, (as so amended and restated, the &#x201c;2016 Plan&#x201d;) which permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code, and (2) options that do not so qualify.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">       </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021, the Company&#x2019;s board of directors approved, and on March 20, 2021, the Company&#x2019;s stockholders approved the 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_171e9dbc-d2a3-4a5c-a2a0-4a9e8c7bfc53" contextRef="C_cb63a3a7-a4a7-4296-b5a8-5e3cd9e88878" name="ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 30, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The 2021 Plan replaced the 2016 Plan as the board of directors had determined it would not to make additional awards under the 2016 Plan following the closing of the initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to officers, employees, directors and consultants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the effective date of the 2021 Plan, no further awards will be made under the 2016 Plan. Any options or awards outstanding under the 2016 Plan remain outstanding and effective and are governed by their existing terms. The shares of the Company&#x2019;s common stock subject to outstanding awards under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2021 Plan. No more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f216f317-14a9-4aee-a848-4f1accd46fe1" contextRef="C_de1f00a8-10d4-4a23-8b9b-2bef95a2e119" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,263,664</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock may be granted subject to incentive stock options under the 2021 Plan. In addition, the 2021 Plan contains an &#x201c;evergreen&#x201d; provision, which allows for an annual increase in the number of shares of common stock available for issuance under the 2021 Plan on the first day of each fiscal year during the period beginning in fiscal year 2022. The annual increase in the number of shares shall be equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5948fd60-af34-4646-96db-f88407d1df40" contextRef="C_9ce46fba-908a-4541-9693-823709dea22f" name="ikna:AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26c3db5d-78d9-4338-856f-c7824f3e7f6e" contextRef="C_2a718982-72b2-4b6f-8b37-4cb567dba4b5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,479</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remain available for future issuance under the 2021 Plan. The vesting periods for equity awards, which generally is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7ee8022-c7de-4ef4-8762-0cb737fb6147" contextRef="C_ef57b772-1e45-4cbb-82ff-1cd3052d6512" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, are determined by the Board of Directors. The contractual term for stock option awards is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2fcc612-2b1a-45cf-9359-b336f8b56a16" contextRef="C_ef57b772-1e45-4cbb-82ff-1cd3052d6512" name="ikna:StockOptionContractualTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:continuation></div>
  <div><ix:continuation id="F_b74c3860-4afb-4b6b-ba09-5fe77263c003_2"><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_825b8156-76c5-48d6-8304-a8a2cdf081c2" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.301%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:13.591%;"></td>
        <td style="width:0.817%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1.942%;"></td>
        <td style="width:13.591%;"></td>
        <td style="width:0.817%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5d3b3a3-6033-46fc-8f7c-cef6c539fe37" contextRef="C_bc07950d-ff60-4171-bee4-68de5e8006fc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a0b99df-3927-4e7d-80d3-ad6920045643" contextRef="C_3ccefeed-c353-4dec-a464-be4c75fc07a4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e12ba9d-db91-46b1-8052-40cbb0bd15c9" contextRef="C_de68a06b-52a5-428b-8fda-644108120c2e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17c20a45-5e2f-4a25-8ffc-01304fff5bb3" contextRef="C_bb21e98b-d1d5-4830-95ae-a8521474d69b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8d69f5c-69f8-4b3d-9b56-47afe4acc693" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c737cb56-33ee-4ff9-a0a8-3898efc2312b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average fair value of the stock options granted during the year ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a504273b-8eb4-4d62-9fbb-300b2cedd99a" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">6.13</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6528a562-fb63-45fd-ad4b-7e374647a9a1" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.53</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation balance for unvested options was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92a1eb94-4e0e-43c3-9f1e-e028b6f49d27" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> which is expected to be recognized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a78a0a4-9641-4e92-b3b4-e1a2b392f3a4" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.97</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c54a77e6-35ea-4a97-80ca-dd883c0382d9" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_c54a77e6-35ea-4a97-80ca-dd883c0382d9_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes stock option activity under the Plan for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_c54a77e6-35ea-4a97-80ca-dd883c0382d9_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.128%;"></td>
        <td style="width:1.188%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:9.935%;"></td>
        <td style="width:0.91%;"></td>
        <td style="width:1.188%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:9.496%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.188%;"></td>
        <td style="width:0.707%;"></td>
        <td style="width:10.074%;"></td>
        <td style="width:0.685%;"></td>
        <td style="width:1.188%;"></td>
        <td style="width:1.37%;"></td>
        <td style="width:9.517%;"></td>
        <td style="width:0.685%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bca76deb-2c57-457a-a278-ac53e9bcc18c" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,650,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b44ba32b-f8e8-4a21-8378-169fc65d6119" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.45</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fed4ceee-9fa0-4174-998d-68eeb1e8aa9b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.01</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b792740-dc66-482a-81ad-98af4b080401" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,463</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79755176-24a1-47d1-beaf-a838a14fa03c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,435,687</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b42e4447-f0e6-4eef-90d8-6f192a8ce49d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45ae54f9-d894-4a97-8ee5-d96a73e9e8ae" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">215,188</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddbe7bdb-0f83-4489-81c9-7e29e10cad4f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_009e05d9-6570-42d5-a99e-aade31af5b0c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98e1c7c1-9261-468c-a8b6-ac5ce127a6dc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79fa59fd-be60-4184-a2df-add665d7dcb3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cacc511-2066-404b-a105-cc57fe970c07" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0843db0-bc9a-4de7-9a32-aa857e94c48d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.27</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bc7a596-0b10-4140-8a23-a5c07a883d38" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested or expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2999e95-007d-4272-be70-4d2dfe12c682" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c17891c-8371-48f3-b4f9-b49093add791" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93485350-0362-4e01-a928-578bf6a01123" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.27</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba23f09d-8901-4603-ae5a-721c823cce69" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a42b71e-75cb-4f36-b7bd-856a80e75875" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,841,894</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c423af1-bef7-46b6-abce-a4541605fa7b" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b116ea04-3a39-4ef5-9678-5de98475315a" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.71</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae1c8fbf-8f3f-40aa-8ea6-4598fb3f828b" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intrinsic value of options exercised for the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4734b56c-cda0-476e-836d-11e6dffed957" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_980963b9-31d6-44f6-b9d9-326e954f5319" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98e64089-1384-48a6-bcbe-f86606861f48" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each option award granted during the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is estimated on the date of grant using the Black-Scholes option pricing model and the weighted average assumptions noted in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.059%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:10.8%;"></td>
        <td style="width:9.583%;"></td>
        <td style="width:2.897%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:0.744%;"></td>
        <td style="width:17.272%;"></td>
        <td style="width:2.525%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ba6f1b0-1662-4536-941d-549a5fa49822" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.68</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53428fa0-adfd-4a1a-bf0e-1b9008f53fb1" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">1.33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6837400d-b0d3-4184-9d57-3ea82ae15ec9" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.27</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc01c010-e076-43da-94ad-baffea811644" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.47</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e215cda-cd04-447f-b80b-d370e4b90c72" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7c574d9-96ea-4c6f-ae86-2a0ef1481666" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b59ff96-46bf-448c-9e38-469a28249ed2" contextRef="C_85fb6b92-dfdb-4f1c-b04e-5cb23fd29f2e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.00</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7dde1cfb-2967-4d32-a45d-5833ce2ff9f2" contextRef="C_97c448a4-24df-47b4-8856-f4896b80ad75" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_311ec8fd-f6a8-44db-886e-b9a1e6da83d3" contextRef="C_74803d30-fb65-4987-a08f-21d2e606fe63" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa7340c9-fc68-49f4-bee9-7931c3bdf603" contextRef="C_b7dc9500-a312-4bbb-8606-fbcf3215bf2f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility range</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9cefa88-c836-4501-9e7d-17556bc3ffbf" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">68.58</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c14c1e20-485a-4412-b1b1-1a42b5a7c3fc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">73.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fff1bc81-98d6-4860-8b0b-da55370828a5" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">73.15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4254c7c1-4982-4cf3-8241-7a0b87847d94" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">74.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 20, 2021, the Company&#x2019;s stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c8fdfa6-9041-4e2b-8d15-190efea725ee" contextRef="C_967cd9a5-9ca9-47d7-aeb3-bede932bd3d4" name="ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 30, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e6ab1f3-efde-44be-b930-250b6b75835f" contextRef="C_8e5351be-0edc-42b6-8e62-f402a7a84729" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">346,613</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc5ab3ae-c262-4790-aba8-84dd56349d3c" contextRef="C_d8f918b3-befa-4a88-93fc-46d5041b9f1a" name="ikna:IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00662e61-48b2-472f-a192-58eb9ace1277" contextRef="C_6b98e2af-28de-4a15-9b16-1d31248fde7e" name="ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been purchased by employees under the ESPP.</span></p></ix:continuation></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_146e1515-2303-42ca-b300-7c5554ccd85f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. EMPLOYEE BENEFIT PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a defined-contribution savings plan covering all eligible U.S. employees under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). During the years ended December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d673b94f-ae52-4479-8a14-cb7062784fa4" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_854932d5-1084-4f75-8188-3f2fac2c7f93" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t make any employer contributions to the plan. Employees can designate the investment of their 401(k) accounts into several mutual funds. Administrative costs of the plan for each of the years ended December 31, 2021 and 2020, were immaterial.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2945daaa-a919-4726-8003-949ad2a1d9cc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_2945daaa-a919-4726-8003-949ad2a1d9cc_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. INCOME TAXES</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91c18f39-52b9-4d76-82a2-b94462e5329d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.517%;"></td>
        <td style="width:1.473%;"></td>
        <td style="width:0.803%;"></td>
        <td style="width:12.008%;"></td>
        <td style="width:4.458%;"></td>
        <td style="width:1.473%;"></td>
        <td style="width:0.803%;"></td>
        <td style="width:12.008%;"></td>
        <td style="width:4.458%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax effected at statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d73da998-420f-4ffa-89af-74e62c64a85b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba98942c-d9c2-49e0-a4dd-c2713c19b4e6" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf4699b1-1d29-416d-bddd-1273da8607c1" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8461d96a-5656-49d9-973b-080b7efde5c6" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca55485d-d0a9-479a-859b-a967ba029dda" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_591e0207-49af-4fea-996d-4ea7f17519d0" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac0c2edc-59ca-47b5-9a1f-c8fe4ff82bc0" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired in-process R&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea229e43-b13e-47d1-a8a0-8856cd029cbe" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_775761cb-99db-4abe-8481-97c50ab78797" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_997f33a5-fba9-44c6-b14e-c83ac0545a0b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d57cd8d-1d76-4b4a-8412-5dd5b366988c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">32.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea9f0b04-edf4-4397-8ce4-2b03032f4cd3" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">23.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ab025b0-5644-476a-acd8-3b4149876b95" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s total deferred tax assets are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.779%;"></td>
        <td style="width:1.473%;"></td>
        <td style="width:1.928%;"></td>
        <td style="width:13.924%;"></td>
        <td style="width:1.285%;"></td>
        <td style="width:1.473%;"></td>
        <td style="width:1.928%;"></td>
        <td style="width:13.924%;"></td>
        <td style="width:1.285%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cca2863f-118b-4a8a-96be-bfbdefc67f22" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_977dce96-4477-45e0-9c52-89739eda72f2" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36d16f30-45a7-4cac-b493-b49f72c54e64" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,269</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb8f69e5-efe2-435f-b70f-23fefe40f4e9" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,593</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f54bd8a4-cc3d-4f8c-adb0-b010f3145092" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe0a7a8e-905d-446b-bd69-623160135aa6" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,023</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized start-up costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_736d3e86-3cac-4d1e-b206-60fcbf75c628" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6127611b-8768-496c-acbf-d9633bb66fa7" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40e80ef1-c6f6-4f5f-8997-3796ee8d4979" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06e0fadd-a349-47d0-9999-59b30c227617" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7439aa1-ac33-48f7-875b-6c02d963eeb4" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cf70fd2-6955-42d4-8448-e5c4eca8f5f8" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,234</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0818337a-ae92-42cf-b935-a1a2c43cd384" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,026</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_493f825f-54eb-4bf2-a445-9c898feb7d5a" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71a31753-fe9b-44b0-a288-aef9bcf5246e" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="ikna:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,908</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3231fdb-02d1-40f1-ab82-cae368289368" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8ccf511-de5e-4171-a634-e4b4ace84a05" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50ed4121-84fe-4050-9235-75b6ffe70b66" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8615f6a-cf6e-41ec-952d-e0a8d97ffb83" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b369e550-b743-4eae-9b0a-ab0d019b8464" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e36396f0-33c8-451c-8605-c0f4488c0b1a" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef980860-de33-4fc6-83af-52e68dde8011" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation Allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2efc523b-537d-4f3a-bf53-acb2ac2e091e" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,027</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd74fa89-1605-4db6-a359-b5d84a74de43" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,034</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets and liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0e6b850-ab06-44b0-873a-684a4551e25b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2021, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e97a4c0f-6d60-480f-aadf-acf61512b0cb" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million primarily due to the increase in the Company's book loss reported in the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf460918-1c35-477e-8cd1-4d4ec443a007" contextRef="C_c2e15ff7-280d-4489-8017-9492ffa9ab32" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">86.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21e15466-3c45-4060-8ae2-4f352e145000" contextRef="C_9c6adf68-b45d-444a-96ff-b973670159ef" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">83.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of Federal and State operating loss carryforwards respectively. The Federal net operating losses are not subject to expiration and the state net operating losses begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a8b031d-df86-41d0-95d9-43d15cae492f" contextRef="C_0d0023fe-0f0c-46e9-b39d-3d9294d1fdf8" name="ikna:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_937aa46a-3906-4efc-ab45-e58bdf10fb33" contextRef="C_0c5c2a21-5b8b-4673-9f3c-9fd33b740459" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f4eca15-697f-46d7-863f-2778a1d95cc9" contextRef="C_d59e96ca-e70a-4673-a757-3997f4bdb74c" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million respectively, to offset future income taxes, which will begin to expire beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_215e7ccc-be76-48c2-a161-0f847af28d63" contextRef="C_9265d692-1067-4446-93b5-77437f4ec759" name="ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear" format="ixt:datemonthyearen"><ix:nonNumeric id="F_37d12481-17aa-4f4d-9963-a3143e51f9d2" contextRef="C_f7dcb7f3-11ce-4fd1-9003-09bb1c7904e9" name="ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 2031</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company's ultimate parent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company follows the provisions of ASC 740-10, Accounting for Uncertainty in Income Taxes, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2021, and 2020, the Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e23e7d2a-1d94-47cb-bfb3-0497e62159f3" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_007b2d68-e52a-4773-ac1c-4857087c5408" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recorded tax reserves associated with any unrecognized tax benefits. The Company&#x2019;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December 31, 2021, and 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e610fbd0-2b16-4d04-a7da-fd563cf00e83" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a3680e2c-77f0-4a26-b89f-d862a48dd2d7" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reserves for uncertain tax positions. For the years ended December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f37b006-708c-49eb-8cf4-8d02e6b23a4c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a63f910f-e376-476a-a53e-8825dc1a8a73" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> estimated interest or penalties were recognized on uncertain tax positions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_2945daaa-a919-4726-8003-949ad2a1d9cc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's Federal and Massachusetts income tax returns for the years ended December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3eb15bc-d7ec-41c2-a814-9f6ff3a487f9" contextRef="C_fb2b28a5-0c8c-41e7-a631-b5a284180f8d" name="us-gaap:OpenTaxYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2d2d5e9-8bf5-4537-8511-a78dd838a9fc" contextRef="C_0bc3c318-3f9b-4004-b2d0-fd1298f6297d" name="us-gaap:OpenTaxYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> remain open and are subject to examination by the Internal Revenue Service and state taxing authorities.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cbd350c-66a9-45f8-b91c-fac5af0f4eb5" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. RESEARCH LICENSE AGREEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2015, the Company entered into an exclusive patent license agreement (the &#x201c;UT Austin License&#x201d;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#x201c;University&#x201d;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd8b5ec1-cf3b-45e2-b2cb-ad33d5b77a03" contextRef="C_5c03768c-e908-427c-98a3-dac6ad6d0a7d" name="ikna:LicenseMaintenanceFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_789c472e-2920-40f3-a27f-9449fdb53c17" contextRef="C_38798bf1-ddbf-4fcd-90e3-e5ba57c070a3" name="ikna:PotentialDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon meeting certain development milestones during the term of the UT Austin License. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b567880b-1fc6-4359-b8ab-7699787af5f8" contextRef="C_064ada85-12cf-4684-b1a0-b4034e155188" name="ikna:RoyaltiesTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2018, the Company acquired IPR&amp;D on an Arrys&#x2019; immune-oncology candidate based on the intellectual property associated with Arrys&#x2019; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d182c70b-39a7-402f-b098-9d164388e715" contextRef="C_aea069f1-935a-4fb9-93fe-05cda26d80fe" name="us-gaap:ResearchAndDevelopmentInProcess" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e2a2d71-5e68-40ec-aed9-3441ee474146" contextRef="C_f814b099-b5e9-4532-849e-ed0d7f1514b0" name="ikna:PotentialDevelopmentMilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, as well as certain sales event milestones ranging from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30a6f1f4-ff74-4ec7-9ab6-b27d69b6822c" contextRef="C_ad57f0bc-0185-4d7c-aeac-29addd35778c" name="ikna:PotentialSalesEventMilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca0070c0-090c-401f-a624-4384ad7d86df" contextRef="C_45284bec-8438-4ce2-8397-a8f69b9c192b" name="ikna:PotentialSalesEventMilestonePayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">250</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million contingent on sales in a calendar year, during the term of the AskAt License.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adbaf799-c874-4088-9d72-e2bfe4a09390" contextRef="C_eba92ba2-7e7b-497e-aa6d-b51e12ffe499" name="ikna:RoyaltiesTerms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10551298-8e0b-463a-bca5-d1ea74064d0f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. LEASE OBLIGATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2018, the Company entered into an operating lease with Vertex Pharmaceuticals Inc. (&#x201c;Vertex&#x201d;) to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5ac2030-19d9-402a-8490-b3c38b3b3647" contextRef="C_554ecddb-159f-4002-a088-c37b9e72c32d" name="ikna:AreaOfLeasedProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">13,170</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office, laboratory and vivarium space at 50 Northern Ave, Boston, Massachusetts, expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2999d8cc-467b-4098-b443-6ac77c544dc9" contextRef="C_b400e939-9adf-46fa-ab34-47a059eaa533" name="ikna:LesseeOperatingLeaseMaturityMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 2020</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In July 2020, the Company extended the term of the lease through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1f88253-c652-4527-a520-1fbf25e03747" contextRef="C_4162d822-49e3-40a4-b0e7-b0f69534abbf" name="ikna:OperatingLeaseTermExtendedExpirationPeriod" format="ixt:datemonthyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 2021</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 21, 2020, the Company entered into an operating lease agreement for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e50286d-4aea-4a8c-9407-86a79b950845" contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576" name="ikna:AreaOfLeasedProperty" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">20,752</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company&#x2019;s corporate headquarters. The commencement date of the lease was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9426996-8ce9-44df-aecd-d46dc66bcd48" contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2" name="ikna:LeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 19, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the lease term is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca014a1d-859f-41ff-abba-c4b6fb2bda8b" contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63 months</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The lease provides a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ffaa1d7-2a18-4190-92c8-ba7d7694e24e" contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2" name="ikna:LeaseRentFreePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-month</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> free rent period, which commenced on the lease commencement date. The base rent at commencement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f3ae466-554c-4d74-b3b7-2156769e17a2" contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2" name="ikna:OperatingLeaseMonthlyBaseRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand per month and escalates by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_588b99cf-50b8-4ada-8623-691a1d5c7969" contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2" name="ikna:PercentageEscalationInAnnualBaseRent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% annually for total lease payments during the term of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b9f4772-45ba-4158-b83a-31659d81fe6e" contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb4885fa-9179-4e01-9b39-b5fad4bc56a1" contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576" name="ikna:LetterOfCreditToSecureLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36aec6f6-3806-4759-9d3e-a76a989a8224" contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and an operating lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d7ee38a-de37-4607-bec0-2e8c599c5f8a" contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the commencement of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f4f96f4-e906-4380-9a56-021dd52b21f1" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.231%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.201%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.201%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d66e17d4-05c3-4ed9-937f-7bc1869a6e4b" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dbc7fdf-088e-4151-a5cc-3f9af7bb7723" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,011</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab2d8eb5-b4ad-47f0-b66f-ccf49f0d3927" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f5c73b9-058c-4f0b-b944-07b953a05f0b" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">706</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad6794fe-d7d4-4322-a741-c41d7e0938dc" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9356536-648c-4d41-9d7c-7e2289b4b230" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,717</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with our operating leases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a756527a-ea8a-40f6-bbf6-10f4d1f0dc46" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information relating to the Company&#x2019;s leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.235%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:1.606%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:13.2%;"></td>
        <td style="width:0.696%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of<br />&#160;&#160;&#160;lease liabilities (operating cash flows)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f4274f8-d946-421b-a66f-163ad294001f" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,259</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffdb23e1-d2d5-4209-9760-8794f038e581" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93513f03-5cc1-4e5b-aaa7-92e6c84deb7d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining lease terms and discount rates related to our leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.966%;"></td>
        <td style="width:1.627%;"></td>
        <td style="width:14.89%;"></td>
        <td style="width:1.627%;"></td>
        <td style="width:14.89%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Remaining lease term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94630ae6-0a1b-4fb2-974c-4063f1d62450" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac740cc9-a617-4953-b07d-b8acf028184b" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount Rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8345306-bad0-4a6a-ac4a-f5aea8dd2ab2" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a70fbf9-961a-48f6-baf2-91648088df17" contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12c8ea3f-5635-4c82-9213-7c12ad3ac94c" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future minimum lease payments for the Company&#x2019;s operating lease as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, were as follows (in </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thousands</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.788%;"></td>
        <td style="width:1.938%;"></td>
        <td style="width:1.381%;"></td>
        <td style="width:16.187%;"></td>
        <td style="width:0.707%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fiscal Year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Operating<br />Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17d8773b-260e-4219-9b53-c41a3b9a1c51" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,774</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_356d9c65-9f49-42ea-836f-4d34ea87f545" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,827</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_461b332e-f6c7-49d7-bd0c-27875f690525" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,882</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1fd7876-5a10-4628-9359-ae4b407ec826" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6b470ec-dc7c-496c-904a-bf4ab6c340c7" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3306b995-2cac-4867-b6fd-8c6fbbfcba0f" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less amounts representing interest or imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb7865c2-35b8-41be-adde-63b87e75c357" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3216d94-de1d-4c52-80dc-dd45bb71a2a5" contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fb4319e7-f4dd-430a-aac5-9408332a6faa" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_fb4319e7-f4dd-430a-aac5-9408332a6faa_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. COMMITMENTS AND CONTINGENCIES</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_fb4319e7-f4dd-430a-aac5-9408332a6faa_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December 31, 2021 or royalties on future sales of specified products that have not yet occurred as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_127702ce-2ae9-473b-80fa-6d1675c58292" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company entered into several agreements with a director and an entity affiliated with a director:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in Note 11 abov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e, the Company has entered into a license agreement with the University, which was affiliated with a director of the Company at the time of the license agreement. During the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Company recorded expenses in connection with University license fees and certain patent-related costs incurred on its behalf of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2633638b-d465-4033-baf7-828b77493d2c" contextRef="C_f2ad82ad-ba0d-444e-bbea-c7c079ec8603" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">233</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7dda7d0-dbaf-455d-acc8-49a4ae571c88" contextRef="C_b8ca6c84-2e8a-4657-be34-b7027d2c0a54" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">182</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand, respectively. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Certain entities affiliated with directors purchased shares in the IPO.</span></div></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3952032-902f-4b79-ad6c-b50b62b6d7c5" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, restricted common stock, restricted stock units and stock options are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share were the same for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e30f1564-76a9-4220-95c4-8f1d93133f4d" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.636%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:0.951%;"></td>
        <td style="width:16.472%;"></td>
        <td style="width:0.951%;"></td>
        <td style="width:1.165%;"></td>
        <td style="width:0.951%;"></td>
        <td style="width:17.892%;"></td>
        <td style="width:0.817%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_047643b9-29dd-4ceb-94ab-637898d406f9" contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">169,396,576</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to Purchase Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8452cce-696e-46ef-b3c4-fc50ba4e0daf" contextRef="C_a3d09b30-c88f-47ac-8386-fd1150b5ef28" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd76e819-94ff-4ae4-bc6a-71324bec69fa" contextRef="C_932834ea-9c54-4858-96f9-52377c047cc1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,650,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5aabbc8c-c6c6-4077-8c7a-94cda49bcdd0" contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,822,373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1985ef32-b52e-41f2-a288-89806cf9e9f8" contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">172,046,972</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>ikna-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of the Registrant&#x2019;s Securities Registered Pursuant to</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 12 of the Securities Exchange Act of 1934, as amended</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The following summary of the general terms and provisions of the registered capital stock Ikena Oncology, Inc. (&#x201c;Ikena&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d;) does not purport to be complete and is subject to, and qualified in its entirety by, reference to our Fifth Amended and Restated Certificate of Incorporation, or certificate of incorporation, our Amended and Restated Bylaws, or bylaws, each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part, and applicable provisions of the Delaware General Corporation Law, or the DGCL. Our common stock, par value $0.001 per share is registered pursuant to Section 12(b) of the Securities and Exchange Act of 1934 and trades on The Nasdaq Global Market under the symbol IKNA.  The summaries below do not purport to be complete statements of the relevant provisions of the certificate of incorporation, the bylaws or the DGCL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our authorized capital stock consists of </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,000,000 shares of common stock, par value $0.001 per share, or the common stock, including 8,000,000 shares of non-voting common stock, par value $0.001 per share, or the non-voting common stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and 10,000,000 shares of undesignated preferred stock, par value $0.001 per share, or the preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Common stock and non-voting common stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">holders of our common stock and non-voting common stock have identical rights subject to two exceptions. First, except as otherwise expressly provided in our certificate of incorporation or as required by applicable law, on any matter that is submitted to a vote by our stockholders, holders of our common stock are entitled to one vote per share of common stock, and holders of our non-voting common stock are not entitled to any votes per share of non-voting common stock, including for the election of directors. Second, holders of our common stock have no conversion rights, while holders of our non-voting common stock shall have the right to convert each share of our non-voting common stock into one share of common stock at such holder&#x2019;s election, provided that as a result of such conversion, such holder, together with its affiliates and any members of a Schedule 13(d) group with such holder, would not beneficially own in excess of 9.99% of our common stock immediately prior to and following such conversion, unless otherwise expressly provided for in our certificate of incorporation. However, this ownership limitation may be increased or decreased to any other percentage designated by such holder of non-voting common stock upon 61 days&#x2019; notice to us</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of our common stock and non-voting common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock and non-voting common stock have no preemptive rights or other subscription rights or redemption or sinking fund provisions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of our liquidation, dissolution or winding up, holders of our common stock and non-voting common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is listed on The Nasdaq Global Market under the trading symbol &#x201c;IKNA.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#x2019;s address is 250 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) 962-4284</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Preferred stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/107841642.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors has the authority, from time to time, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend  payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registration rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain holders of our shares of our common stock are entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of a fourth investors&#x2019; rights agreement, or the investors&#x2019; rights agreement, between us and certain holders of our common stock and holders preferred stock. The investors&#x2019; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us. All selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Demand registration rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of certain of our shares of common stock are entitled to demand registration rights. </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the investors&#x2019; rights agreement, we will be required, upon the written request of a majority of holders of the registrable securities then outstanding that would result in an aggregate offering price of at least $10.0 million, to file a registration statement and to use commercially reasonable efforts to effect the registration of all or a portion of these shares for public resale</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Short-form registration rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of certain of our shares of common stock are entitled to short-form registration rights. </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the investors&#x2019; rights agreement, if we are eligible to file a registration statement on Form S-3, upon the written request of at least 20% in interest of these holders to sell registrable securities at an aggregate price of at least $3.0 million, we will be required to use commercially reasonable efforts to effect a registration of such shares. We are required to effect only two registrations in any twelve-month period pursuant to this provision of the investor rights agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Piggyback registration rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the investors&#x2019; rights agreement, if we register any of our securities either for our own account or for the account of other security holders, certain holders of our common stock are entitled to include their shares in the registration. Subject to certain exceptions contained in the investors&#x2019; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our investors&#x2019; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expiration of registration rights</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The demand registration rights and short form registration rights granted under the investors&#x2019; rights agreement will terminate fifth anniversary of our IPO.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/107841642.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-takeover effects of our certificate of incorporation and bylaws and Delaware law</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Board composition and filling vacancies</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">No written consent of stockholders</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of directors by our stockholders without holding a meeting of stockholders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Meetings of stockholders</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advance notice requirements</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify the requirements as to form and content of all stockholders&#x2019; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amendment to certificate of incorporation and bylaws</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/107841642.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Undesignated preferred stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation provides </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exclusive forum</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for: (1) any derivative action or proceeding brought on our behalf; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers and employees to us or our stockholders; (3) any action asserting a claim arising pursuant to the Delaware General Corporation Law or our certificate of incorporation or by-laws (including the interpretation, validity or enforceability thereof) or (4) any action asserting a claim that is governed by the internal affairs doctrine; provided, however, that this provision shall not apply to any causes of action arising under the Securities Act or Exchange Act. In addition, our amended and restated bylaws will provide that, unless we consent in writing to an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action under the Securities Act (the Federal Forum Provision). Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit our stockholders&#x2019; ability to bring a claim in a forum they find favorable, and the designated courts may reach different judgments or results than other courts. In addition, there is uncertainty as to whether our Federal Forum Provision will be enforced, which may impose additional costs on us and our stockholders</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Section 203 of the Delaware General Corporation Law</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to the provisions of Section 203 of the Delaware General Corporation Law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; or</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/107841642.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 203 defines a business combination to include:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any merger or consolidation involving the corporation and the interested stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/107841642.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ikna-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-254858) pertaining to the 2016 Stock Incentive Plan, 2021 Stock Option and Incentive Plan, and 2021 Employee Stock Purchase Plan of Ikena Oncology, Inc. of our report dated March 17, 2022, with respect to the consolidated financial statements of Ikena Oncology, Inc., appearing in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.024in;word-break:break-word;padding-left:0.024in;vertical-align:bottom;padding-bottom:0.024in;padding-right:0.024in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.024in;word-break:break-word;padding-left:0.024in;vertical-align:bottom;padding-bottom:0.024in;padding-right:0.024in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Ernst &amp; Young LLP</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.024in;word-break:break-word;padding-left:0.024in;vertical-align:bottom;padding-bottom:0.024in;padding-right:0.024in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.024in;word-break:break-word;padding-left:0.024in;vertical-align:bottom;padding-bottom:0.024in;padding-right:0.024in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 17, 2022</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115337866.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ikna-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Mark Manfredi, certify that:</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.	I have reviewed this Annual Report on Form 10-K of Ikena Oncology, Inc.;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.39%;"></td>
    <td style="width:4.957%;"></td>
    <td style="width:3.237%;"></td>
    <td style="width:46.416%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 17, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Manfredi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mark Manfredi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal Executive Officer and Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ikna-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Francisco Oliveira, certify that:</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.	I have reviewed this Annual Report on Form 10-K of Ikena Oncology, Inc.;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.39%;"></td>
    <td style="width:4.957%;"></td>
    <td style="width:3.237%;"></td>
    <td style="width:46.416%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 17, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Francisco Oliveira</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Francisco Oliveira</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vice President of Finance and Administration</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ikna-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:18.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with this Annual Report on Form 10-K for the period ending December 31, 2021 of Ikena Oncology, Inc. (the &#x201c;Company&#x201d;) as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.4%;"></td>
    <td style="width:4.958%;"></td>
    <td style="width:3.238%;"></td>
    <td style="width:46.405%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 17, 2022</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mark Manfredi</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Mark Manfredi, Ph.D.</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal Executive Officer and Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Francisco Oliveira</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Francisco Oliveira</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vice President of Finance and Administration</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Principal Accounting Officer)</font></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img39825204_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA=&AE=R!/
M)T1O;FYE;&P    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M,P  DI(  @    ,S,P  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MCR<YZXQ2PZ_XGDU*PAGMDBCN(XY2'B(#*[,67(!PR+M].>M;6GW,_<['0_\
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M_P#/(?\ ?5)IW*A.*BB>BH/M#_\ /(?]]4?:'_YYC_OJE9E>TCW)Z*@^T/\
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M 4444 %%%% !1110 445S]GXJ@O/'%_X?0#-K CAQ_$_\2_@"OZT =!1110
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MO??^!\W_ ,533X-TD_Q7_P#X,)O_ (J@#>P?2C!]*P/^$,TG^]?_ /@PF_\
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M4?G0 M%)N'J/SHW#U'YT +12;AZC\Z-P]1^= "UPFC>&_LOQ$OO,CS:V^+F
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MAP.AP@&.IR#6Y'X<T>&!(8M.@2-)/-4!>C[=N[/KMX^E3-H^G.H5K*%E#1N
M5Z&/[A_X#CBJO'L28 \>0R6(N+?3II&\GSF1I538%0/("QXRF5!]2<5I:=XD
M34=1%DMI)'.-S2JS ^4H5&#'Z[P!]#4\OAS1I[6.VFTRV>")G9(RG +'+?F>
M34]GI=M8WEY=Q+FXO'#S2MC)"C"K] .!0W'H@+E%%%0(S2H;Q0<@'_01U'_3
M0UH>6G]U?RJA_P S0?\ KQ'_ *,-:- D-\M/[B_E1L3^ZOY4ZB@8WRT_N+^5
M'EI_<7\J=10 W8G]U?RH\M/[B_E3J* ,S7T4:'.0H!S'T'^VM:1C3<?D7KZ5
MG>(/^0%/_O1_^C%K3/WC]:.@NHSRT_NK^5&Q?[J_E3J*!C?+3^XOY4>6G]Q?
MRIU% #?+3^XOY4;$_NK^5.HH ;Y:?W5_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^
M5.HH ;L3^ZOY4;$_NK^5.HH ;Y:?W%_*CRT_NK^5.HH ;Y:?W%_*C8G]U?RI
MU% #?+3^XOY4>6G]Q?RIU% &=KJ)_P (]J/RK_Q[2=O]DU<A1/(C^5?NCM[5
M5UW_ )%W4?\ KVD_]!-7(?\ 41_[@_E1T%U%\M/[B_E1Y:?W%_*G44#&^6G]
MU?RHV)_=7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5&Q/[J_E3J* &[$_NK
M^58/CI%'P_U["@?Z!-V_V3705@>.O^2?:]_UX3?^@FFMR9_"RUX:1/\ A$])
M^5?^/*'M_L"M/RT_NK^59WAK_D4])_Z\H?\ T 5ITAK8;Y:?W5_*CRT_N+^5
M.HH&-\M/[B_E1Y:?W%_*G44 -\M/[J_E1L3^ZOY4ZB@!OEI_<7\J/+3^XOY4
MN1G&>?2EH ;L3^ZOY4;$_NK^5.HH ;Y:?W5_*CRT_N+^5.HH ;Y:?W%_*C8G
M]U?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4;$_NK^5.HH ;Y:?W%_*CRT_
MN+^5.HH ;Y:?W5_*CRT_N+^5.HH ;Y:?W5_*CRT_N+^5.HH ;Y:?W%_*C8G]
MU?RIU% #?+3^XOY4>6G]Q?RIU% #?+3^XOY4>6G]Q?RIU% #=B?W5_*CRT_N
M+^5.HH ;Y:?W%_*CRT_N+^5.HH ;L3^ZOY4>6G]U?RIU% #?+3^XOY4>6G]U
M?RIU% #?+3^XOY4;$_NK^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W5_*CRT_N+
M^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*K8^Z/I5:K0Z"ID;TNH4445!N%%
M%% &=K^HKI.A7-VT)GVJ$6(,%WLQ"@9/ &2.37,^"K74='U5]+U@W:2?9-]O
M$;\7,(C5@N!\BE6&0/3!XZ5TVOD?V'=!]-.J(R;7M 5'F*>OWB!TYKE/ %UH
M_P!N>+2_#\FEO=6BW*RS72SM+&&P!D.Q &>G YK6/P,A_$CI3_R-5S_UYQ?^
MAO5VJ1_Y&JY_Z\XO_0WJ[2Z'-+XF%%%%,D**** "BBB@#._YF@_]>(_]&&I+
MC6-.M#="YO(HC9HDEP&;_5*Q(4GZX-1_\S0?^O$?^C#7/^(O"NI:EJ6J&R>V
M^S:O;V\$SRL0UOY3DDA0#OR&Z9&#512;U!'8XS5&TUBQO[I[>TF,DD9<-A&P
M"C;6&<8R#QBN)N_ .JR274MK<0(]RUR909G G5KA)(XVXZ;%93Z;CUJ+_A7V
MJ"SN(A]F1)%F*6\-RRJC/<"51DJ0R@#!!&#TJN6/<#T&^O[;3;;[1?2B&+>D
M>X@GYF8*HX]20*L8K@&\%:O)YXNOL$\\TUK*MX'96C6,Q%H53! 7*,1SWZ54
M;X?:RUE=(TUNTK1JN1<MB[E$K.)Y0RD9P0"A!R,\\"CECW&>E8JO;7UM>2W,
M=M*)'M9?)F !^1\ X_(BN"G\!:[<7VHSR:FBS7,#K%<12E NZ)4\LIMW; 02
M/FXSG&:Z/P=H$^@6NH)<0VUN+J[\^."V<ND:E%7;D@=U-)QBEN!H>(/^0%/_
M +T?_HQ:OSW$5N5,\BQB201IN/WF)X'U-4/$'_("G_WH_P#T8M&O:7)JUM!!
M'*T7EW<4S.CE&"JV3@CO4H74M0WUM<3&*"99'#.I"@G!4@,,^H)%6*X;4/"V
MHV^EW26[&ZW/-M1I6+OYEQ$XW'K]U&R>U02^$]3>\2!;.U1&CE>,B9O+L"TR
MLHC./F8 $]!UXXJN6/<9Z!45S<PV</FW+A$WJF2/XF8*H_$D"N:TSPUJ%KJD
ML[7"6K;95>Z@;?)=EI RLZL, J 1WZG&!5=O"^JRZY=74C6BQ2NA'EL1Y@6=
M) 6&WKM4C))Y/&!1RJ^X'7Q317$8D@D61"2 R'()!P?U%/KAD\%7:2VB;(4M
MK>64[+>?ROO2[Q+]P_-CY2!SQUP:DN/!5P]G8QJ4;9),]TB3F,NSME9 Q5N5
M QT!&>#1RQ[@=>UU"E[':,^)Y$:1$QU52 3^H_.H;75;"^N)8+.ZCFEASO5#
MG&#@\]#SQQ6%HWAJ[L/$C7UPMOM\N>-KE)&,MQYDBLI8$8&T#;U/3TJ)M"UH
M>&8M%$&G216NV-9&<DSH">=I4A6Z$YW<YHY5W Z[%%<5;^#=0CCCE>YC6_18
MHQ="1BRJMN8VQ]6(/OCVI)?"%W/!IZ&V@MHK=666WM;LJ-Y*_O@Q0_-\I[ \
M]>M'*NX';45R+>%;F*.T>U2V-VE])<2RRN64AG)!*D'<0O Y!4]#775+26P!
M1112$%%%% !1110!0UW_ )%W4?\ KVD_]!-7(?\ 41_[@_E5/7?^1=U'_KVD
M_P#035R'_41_[@_E1T%U'T444#"H#>6XE\LS)GUSQ],^OM536;HP6^W=L!7>
M6SC&&7_&JD]\);E7M;;'F.ZH_D&1@%QDE!CG)XSV^M*4:C2<+?,S=6$6TS=H
MK'CU#4+CS#&D,(AA$CK(A)<Y;CK\HPON1FE;4KN2W^V0>2+<2K'Y3J=Q!(!.
M[/7G@8J^5B]M&US7HH/6BI-0K \=?\D^U[_KPF_]!-;]8'CK_DGVO?\ 7A-_
MZ"::W)G\++GAK_D4])_Z\H?_ $ 5IUS.@2:X/#>F"WM=/:'['%L:2X<,1L'4
M!#BKQF\2?PV6E_C=2?\ Q%(:V-BBL1IO%/\ #8Z3_P"!4G_Q%1/<>+Q]S3]'
M/_;U)_\ $T#.@HKF7NO&X^YIFC'_ +>G_P *K27GQ!'W-*T;\)V/]: N=?1T
MZ\"N!NK_ .)80^7IFFK[Q_,?U:N5UK_A-[]##K][<VUL_#QQ1^6I'IQU^F::
MBV1*HH[F]H/BYM1^*NH2++G3)4%G"^?E)0Y!!]R3^8KTJO-=0M/#&A?#BW\F
MX=0)#Y,BJ#)),1R"/P'T %4](O\ QI+;))H\\\T)'RK<1;U'XG_&GRW(]I9Z
M]3U:BN/L+WQZ<"\TO2W7N6E,9_0FNKMVG:W0W:)',1\ZQL64'V) S^52;)W)
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *M#H*JU:'05,C>EU"BBBH-PH
MHHH 9*Q2%V4J"%)!<\#Z^U<#\/+?4+;5+K[?IUM9^?&TS3)' AN22N"GE\E!
MEN3_ 'E[YKN-1LX;_3+FTNH1/#-&R/$6P'!'3/:N!^&=NMIJ%S"OA]=-9(BC
MS?9I(NA7;&K.3O ^;)''R@]Q6L?@9#^)'8'_ )&JY_Z\XO\ T-ZNU2/_ "-5
MS_UYQ?\ H;U=I=#FE\3"BBBF2%%%% !1110!G?\ ,T'_ *\1_P"C#6C6=_S-
M!_Z\1_Z,-:- D%%%% PHHHH **** ,WQ!_R I_\ >C_]&+6F?O'ZUF>(/^0%
M/_O1_P#HQ:TS]X_6CH'42BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** *&N_\B[J/_7M)_Z":N0_ZB/_ '!_*J>N_P#(NZC_ ->TG_H)JY#_
M *B/_<'\J.@NH^BBB@9%+;PSD>=&'P,#/U!_H*J:C:A\/%9B>1VRQ#E""!@'
M(_*M"BFFT3**DC)B^T0IA-*5%90CJK@_*.WOU-,2S:6X0S:6B@,IR9.!@X!Q
MGJ !^5;-%/F(]DNOZ?Y!1114FH5@>.O^2?:]_P!>$W_H)K?K \=?\D^U[_KP
MF_\ 0336Y,_A9<\-?\BGI/\ UY0_^@"M.LSPU_R*>D_]>4/_ * *TZ0UL%%%
M% PHHHH *:Z+)&4D4.C#!5AD&G44 >;V7AA+CQ]/IU[&9+&Q;[5$C<J0V-OZ
MC'_ :]'  4   #@ =J:(HQ,TH11(RA2^.2!G _4_G3Z;=R8Q4=@HHHI%!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5H=!56K0Z"ID;TNH4445!N%%%%
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M&HVQ%E4R$A Q[9*G'TK9I6:$,Q+ZI^1HQ+ZI^1I]% &5X@$G]AS\I]Z/L?\
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M)-1114B"BBB@#._YF@_]>(_]&&L:_P#"MW<^*K[5(9K?RKVS6V(=I T6%<9
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M8?4'D5)HFGL2T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[#:$2#[)!B7_ %G[I?G^O'/XT-96C&4M:P$S#$F8Q\X]^.?QJ>B@",V\)MS
M88S"1@Q[!M(^G2F"QM R,+6 ,B[%(B7*KZ#C@>U3T4 0R6EM*FV6VA=<@X:,
M$9'3\NU'V2V\UI?L\7F/C<_EC+8Z9/?%344 ,2"*.1Y(XD1Y#EV50"WU/>GT
M44""BBB@ HHHH **** *&N_\B[J/_7M)_P"@FKD/^HC_ -P?RJGKO_(NZC_U
M[2?^@FKD/^HC_P!P?RHZ"ZCZ***!C'BCDQYB*V.FX9_ST%5-1M6G0>5:V\S,
M?G\T>@X-7J*$[$RBI*S,R-+^-0!96J@J%=$/&T= /S-,2RG>Z22>PLQM(&_&
M2 #_ # Z5K457,R?9KJPHHHJ30*P/'7_ "3[7O\ KPF_]!-;]8'CK_DGVO?]
M>$W_ *"::W)G\++GAK_D4])_Z\H?_0!6GFLSPU_R*>D_]>4/_H K3I#6P9HR
M:**!AD^M&3ZT44#$(### $>XS5"]T+3;^-EGM(PQ'WT4*P_$5H44$M)[GE!T
M2ZUW6U\*WL\@M+"Y::3'&Y<#!_'M]37I-AHNFZ9 L5E9Q1JHP#MR?S/-/CTV
MVBU>;4D7%Q/$L3GU"DD?S_05;IMW)C!1 <=./I1112+"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "K0Z"JM6AT%3(WI=0HHHJ#<*0D*I)X &32T4 ,\Z/
M^^*/.C_OBGT4 8V]6\47!!R/L<7_ *&]7=Z^OZ57B_Y&RY_Z\XO_ $-ZU*J]
MC#V?-J4]Z^OZ4;U]?TJY11S#]DNY3WKZ_I1O7U_2KE%','LEW*>]?7]*-Z^O
MZ5<HHY@]DNYA;U_X2D\_\N(_]&&M'>OK^E0#_D;#_P!>0_\ 0S6G3YB5213W
MKZ_I1O7U_2KE%+F*]DNY3WKZ_I1O7U_2KE%','LEW*>]?7]*-ZCJ?TJY11S!
M[)=S"\0.O]A3\_Q1]O\ IHM:1==QY[^E5O$G_(!G_P!Z/_T-:U*?-H3[)<UB
MGO7U_2C>OK^E7**7,5[)=RGO7U_2C>OK^E7**.8/9+N5-R^OZ4F]?7]*N44<
MP>R7<I[U'?\ 2C>OK^E7**.8/9+N4]Z^OZ4;U]?TJY11S![)=RGO7U_2C>OK
M^E7**.8/9+N4]Z^OZ4;U]?TJY11S![)=RGO7U_2C>OK^E7**.8/9+N5-R^OZ
M4F]?7]*N44<P>R7<Q=<=3X>U'!_Y=I.W^R:N0NOD1\_P#M[4W7_^1<U'_KVD
M_P#035V#_CWC_P!T?RI\VA/LES;E;>OK^E&]?7]*N44N8KV2[E/>OK^E&]?7
M]*N44<P>R7<I[U]?THWKZ_I5RBCF#V2[E/>OK^E&]?7]*N44<P>R7<I[U]?T
MK!\=.I^'^O#/_+A+V_V3755S_CW_ ))[KW_7A-_Z":<9:HBI22@_0=X;8#PI
MI()Y^QPCI_L"M+>OK^E5_#'_ "*6D_\ 7G%_Z *U*'+4<:2<4RGO7U_2EW#U
M_2K=%+F*]DNY3WJ>_P"E&]?7]*N44<P>R7<I[U]?THWKZ_I5RBCF#V2[E/>O
MK^E&]?7]*N44<P>R7<I[U'?]*-ZCO^E7**.8/9+N4]Z^OZ4;U/?]*N44<P>R
M7<I[U]?THWKZ_I5RBCF#V2[E/>OK^E&]?7]*N44<P>R7<I[U]?THWKZ_I5RB
MCF#V2[E/>OK^E&]?7]*N44<P>R7<I[UQG/Z4;U]?TJY11S![)=RGO7U_2C>O
MK^E7**.8/9+N4]Z^OZ4;U]?TJY11S![)=RGO7U_2C>OK^E7**.8/9+N4]Z^O
MZ4;U]?TJY11S![)=RGO7U_2C>OK^E7**.8/9+N4]Z^OZ4;U]?TJY11S![)=R
MGO7U_2C>OK^E7**.8/9+N5-R^OZ4F]?7]*N44<P>R7<I[U]?THWKZ_I5RBCF
M#V2[E/>OK^E&]?7]*N44<P>R7<I[U]?THWJ._P"E7**.8/9+N4]Z^OZ4;U]?
MTJY11S![)=RGO7'7]*N#H***3=RXPY0HHHI%A1110 4444 9<7_(V7/_ %YQ
M?^AO6I67%_R-ES_UYQ?^AO6I39,0HHHI%!1110 4444 9@_Y&P_]>0_]#-:=
M9@_Y&P_]>0_]#-:=-DQZA1112*"BBB@ HHHH R_$G_(!G_WH_P#T-:U*R_$G
M_(!G_P!Z/_T-:H^-UE;0HA$KL/M</F!1(1LW<Y$?S8]<525[(C:3_KN=%17G
M=E<ZO8:6)FCU#SS900B7RBQR)9OF.X$@$;>H+ %<\\TDVI>(;^;37GAN5GB:
M&=;5;1EC<^0Q9F?''[P[=N1VXYS5^S?<.8]%HKS6+4?$$<EQ<VTMRWVF2%9;
MJXLG3R\1,2 @0\;\+G;[9[UTEK)X@N-)UF62;-VJO'9Q+#Y:AA&"&!/)RQ/6
MDX6ZC4KG345Y_=:G-I7A]'\-P:L;IUS+YT$C@RA<[6W@G)/7;P3W%6[O4_$U
MNUU-#YDJ,TZ1PBTSY*H5VN,<L<%C@]<#%'LV',=K17%R:IKO]JVD5G</)9F%
M76:XM'5KD[FW @)\I  QG;USR*U='U6==!=M0DFNM0M[5+FXC$&TJ63<(PH'
M7@C'6DX-!S&_17G=@/$\#6]I-!.ES)>17@>X=I(QO1Q(A*GA0P&%[;A56\LM
M?F2"9UN-]M]IEF:(R@J/M?6(9Y;9G ;.5JO9Z[BYO(].HKDM81F\=V4DK2"!
M;0&,>3*ZM)O/0H0JGIRP/%5;6]\42?8X9IY0;HV[RS?8P#"&#[U QCC:O)R1
MGWI<FEQ\QV]%<9;W>IB\-K<?:;:!A.8UCM"PN'\V089L'9A0I'3.[KVJA'>>
M)M-T:TM$ED9?*MRUS):G, :)LKA58G#*HS@D9YZY![-]PYCT*BN(MKG6;SQ9
MIJZBTW^CSMOBCM&6$(;<XDWD=V)&">/08KMZF4>4:=PHHHJ1F?K_ /R+FH_]
M>TG_ *":NP?\>\?^Z/Y52U__ )%S4?\ KVD_]!-78/\ CWC_ -T?RI]"?M#Z
M***104444 %%%% !1110 5S_ (]_Y)[KW_7A-_Z":Z"N?\>_\D]U[_KPF_\
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MDD#)')4KV]F-4K=2/M/^NYE'Q?IR7EY#)YHCM<#SE0N)#@EMH&3A0O)Z5/\
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M(.>E;5947AK2X8]JP,V1M+/*S,PRIP23_L*/H,5JTG;H-7ZF?K__ "+FH_\
M7M)_Z":NP?\ 'O'_ +H_E5+7_P#D7-1_Z]I/_035V#_CWC_W1_*ET%]H?111
M2*"BBB@ HHHH **** "N?\>_\D]U[_KPF_\ 03705S_CW_DGNO?]>$W_ *":
MJ.Z,ZGP2]"GH-]KL?AS34M=&@FA6TB"2->A2PV#G&WBM#^T?$?\ T ;?_P &
M _\ B*L>&/\ D4M)_P"O.+_T 5J4/<()\JU,+^T?$?\ T +;_P & _\ B*/[
M1\2?] "W_P#!@/\ XBMVBD59]S!_M+Q)_P!"_;_^# ?_ !-']I>)?^A?M_\
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M?M6Y S%<DY/(VAAC'7G'>I;KPU?W,B-&RQ*;&.TF!;.],'>HQWR%Y]S4DG7
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M#^0H ?13-C_\]#^0HV/_ ,]#^0H ?13-C_\ /0_D*-C_ //4_D* 'T4S8_\
MST/Y"C8__/0_D* 'T4S8_P#ST/Y"C8__ #T/Y"@!]%,V/_ST/Y"C8_\ ST/Y
M"@!]%,V/_P ]#^0HV/\ \]#^0H ?13-C_P#/0_D*-C_\]#^0H ?13-C_ //0
M_D*-C_\ /0_D* 'T4S8__/0_D*-C_P#/0_D* 'U0N=&M;K6K/4Y5/VBT5U3T
M(;U^G;ZU<V/_ ,]#^0HV/_ST/Y"F)I/<?13-C_\ /4_D*-C_ //0_D*0Q]%,
MV/\ \]#^0HV/_P ]#^0H ?13-C_\]#^0HV/_ ,]#^0H ?13-C_\ /0_D*-C_
M //0_D* 'T4S8_\ ST/Y"C8__/0_D* 'T4S8_P#ST/Y"C8__ #T/Y"@!]%,V
M/_ST/Y"C8_\ ST/Y"@!]%,V/_P ]3^0I] !1110 4444 1W !MI0R;QL.5SC
M=QTKSWX<M'<ZU<70^SQO]D5!;1)<@P ;1@^8 I.%4$CKM!KO-1F$-D^8YGWD
M1_N$W,-QQG'H,YKS3P?I&NR^)K8S7EY]ET[G%W'.A"D8(&YB&+<'!Z?PUM!>
MZR);H]!B_P"1LN?^O.+_ -#>LW5_"USJ^J2W$EW!!$T1AQ#"0\L9QE)#NPP'
M..!R?STHO^1LN?\ KSB_]#>M2L[M/0(JZ.#M_!UY?:A>+J CCLB75"T8\R82
M3K(^X@G.54+SC@]*N7'@:2:8E;NW6*5F,R-;9X,_FD)SA<C"DX/W178457M)
M#Y4<LG@S=-&]U<1S 2)(ZF+A\2O*1U[LR?@@K.C\(7T&MV42".2RC:"2XF>)
M>3&SOM3G(!=@2,=NM=U12]I(.5!1114%&8/^1L/_ %Y#_P!#-9^I>%I=2U5M
M1?494G26$VZ*/W:)&X?:1U))!R<CMZ5H#_D;#_UY#_T,UIU5VMB$KW.._P"%
M?P);A(9E25K26WFDVDF1I64N^,X&0&&/]JMW0M$BT*WN+>V(\F2X:6-<<H"!
M\I)Y.,'GTX[5J44.<FK,KE2"BBBI&%%%% &7XD_Y ,_^]'_Z&M:E9?B3_D S
M_P"]'_Z&M/UK6(=$M8;BYVB*2XCA9V;:$W'&XGVJK75D1]I_UW-&BN:3QYHP
MM_.NKA8HWGEBC93O#+&P4OQT&2/SJY+XITV&>:"1IUGA9%\KR&WR%B0NT8^;
M)!Z>E'++L5=&S17+W'C'R/ \7B!X8XQ*X4B1B%C&\KN/&> ,X S5R3Q#)#X0
MEU=[,-<PQ;I+-91D2<?)N['D?G1R,.9&Y17-+XYTQ87FNMT,0$83/+,S*Q9=
MO8KL;/TJ2Z\86"6,UU9%IXH3%OG9&6$!V0'YR,9"N#BCDEV#F1T-%9%WKP2T
ML7T^W:XGU"39;1R$Q _*6+,2,A0JD]">G'--F\2VMBPBU9)+2?R7E8;2Z?(I
M9@K@88A03_\ 7XHY6%T;-%8L7BO39O+6(732R2&,0BV?S!@*Q8KC(7#*<^XJ
M+_A-M#,LT<=R\LD3A-D43.7);9\H Y^88HY9=@NC?HK/UG53I6CO>1V[7$QV
MK#;AMK2R,0%7)Z9)_"L6[\>Z?:0/(X0$V<5U"C2!3+O)&T<=010HM[!=(ZJB
MN=T[Q7]O\47&D"V3]TTBEHYMSILV\NN!M!W<')Z4RV\81.U])=Q+%!:W)M@(
MB\DK/YFQ?E"8Y/H31R2#F1TM%8$WC#3_ +,SVQD=U@\\AX7547<5^<[3M.Y6
M&.N127WBVVMU5[6">X07B6KNL+X8DD'8<?.01C HY9=@NCH**P?^$UT(36\;
M7H4SQB12RD;002-WH?E/!]*ET3Q#'K=]?100R1Q6PB*-*C(SAUW9VD# HY96
MO8+HLZ__ ,BYJ/\ U[2?^@FKL'_'O'_NC^54M?\ ^1<U'_KVD_\ 035V#_CW
MC_W1_*ET%]H?1112*"BBB@ HHHH **** "N?\>_\D]U[_KPF_P#03705S_CW
M_DGNO?\ 7A-_Z":J.Z,ZGP2]"YX8_P"12TG_ *\XO_0!6I67X8_Y%+2?^O.+
M_P! %:E)[CA\*"BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117.^/-=;P]X-O;V%REPRB* CJ';@'\.3^%"U$VDKLZ*BL[
MP_J7]K^'K&^_BFA5G'HV,,/SS6C0"::N@HHHH&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=:TTZOI$]DEPUL\F"
MDRKNV,"&!P>HR.1WK!\*>'(M+U2[NQ)-)= O#=W$L84WLC,)#+P>@R5 [#(K
MJ9L?9Y-S,HVG++U''4>]>=?#*QN(+^XF9;H6;PEK9Y(%B616*DLV)&)<[0>@
MZMZXK6-^1ZD/=':1?\C9<_\ 7G%_Z&]:E9<7_(V7/_7G%_Z&]:E9L<0HHHI%
M!1110 4444 9@_Y&P_\ 7D/_ $,UIUF#_D;#_P!>0_\ 0S6G39,>H4444B@H
MHHH **** ,OQ)_R 9_\ >C_]#6K=[8P7RPBXSB&9)DP<?,IR*J>)/^0#/_O1
M_P#H:TWQ'I<VLZ:EE"YC5YE:1PVTJ%RP(_X$%JET(^T_Z[D1\,:=]L6>)YHI
MUDDD)1QE@[!F4@@_+D#Z563P1I4$TLT4ES'-(ZNLHEPT;!BPP<>K$<YX.*HP
M:/XE6".3S88;N0CSBLF0N\R&1AQDXW)@=]HIK:-XDFC8S3;F0[U$D^X&15?:
MZ\?*,LG'^SDUIK_,&G8VW\+V)T:UTY'N(X[23S(95DRZMSDY.<YW,.1WHM/"
MVG6.@3:/"9A92DL5:3)7."<'ZC/XUFG2_$=VZ//>R6HW@^7#/T7>,Y..3L4?
MBY] :J7.C^*)[=H7N&;_ $5H\_:L*Y,>W:1CDABQW'T7WI:]P^1KR^#]*:[N
M;R,RP37%P+II(Y/NOL*$@$$#()R.Y.>M2OX5L)%N8Y7N'M[IE>6W:3,;,"IW
M8QWVC/;KZUF/HFIM9:?#=Q?;[:.:5I;26XZ*>(PS8^?:,\>I&.E,72?$C&16
MNGBC+8*QW&,@;RNSCY%QL7'7J?>C7N'R-J7P]:/IMK9>=<)]D??;3++^]B(!
M PQZC:2N#GBJ3^"]*N+Q[J66ZFD>-XG9IMQ.Y#&QSC.<$\=,]JSI=!\0--:Y
MNI93"[,L[7(#(Q2-2QXY&1(=H]14QTGQ(BO-!=^7,0Q$8D CR58DXQR=S 9/
M]T>]&J^T'R-:;PY9&^^W)/<6]P'WF2.7&1L52I_V2$7\J2W\+V-KQ"\PB6<7
M$<6X;8V#%N.,XR3P36,FA:W+(CSO)NVNB^9=F01JTJ\,,?-^['YYI$TCQ3-N
M:6^D@^7.U;C.9<@$].$Y8A?]D>M'S#Y&])X?M[RQL[?5G>_^RR>;F;I(^#RP
M]MQP.W%5X?!^DP6=S:PQR)#<1^44#\(F]G"KZ %CCVQ6[14<S*LC-AT&R@OT
MO(A()DEED#;NOF8W ^W ./45#%X:MHG?_2;IXFN1=+"T@VI)YGF9'&?O=LUL
M44N9A9&./"^G"WNH<2[+I-DG[SMYC2<?\"=J(O#5G#)E9;DQK<BZCA,F4C?)
M)VCT)8G%;%%/F861A0^$=-@DS$9@C1>5+&7!65?F^]QG^(CC%6M'T*VT8S-;
MRW$SS! [SR;SA!M4?@*TZ*.9L+(S]?\ ^1<U'_KVD_\ 035V#_CWC_W1_*J6
MO_\ (N:C_P!>TG_H)J[!_P >\?\ NC^5+H+[0^BBBD4%%%% !1110 4444 %
M<_X]_P"2>Z]_UX3?^@FN@KG_ ![_ ,D]U[_KPF_]!-5'=&=3X)>A5\.^*M!@
M\,:9%-K%FDB6D2LIF&0=@XK1_P"$P\.C_F-67_?Y:=X9AC/A/2B8T)^QQ<[1
M_<%:GD1?\\D_[Y%#M<(<W*C)_P"$P\._]!JR_P"_PI/^$P\._P#0:LO^_P *
MUOL\/_/)/^^11]G@_P">,?\ WR*6A7O&3_PF/AS_ *#5E_W]%)_PF7AS_H-6
M?_?T5K?9H/\ GA'_ -\"C[+;_P#/"+_O@4:![QD_\)GX<_Z#5G_W\%)_PFGA
MO_H-6G_?RM;[);?\^\7_ 'P*/L=M_P ^\/\ WP*-!>\9'_";>&O^@U:?]_*3
M_A-_#/\ T&K3_ONM?[%:_P#/M#_W[%'V"T_Y]8/^_8HT#WS(_P"$X\,_]!JT
M_P"^Z3_A.O# _P"8U:_]]5K_ -GV?_/I!_WZ'^%)_9UE_P ^=O\ ]^E_PHT#
MWS'/CWPL/^8W:_\ ?1_PI/\ A/\ PM_T&[;\S_A6S_9MC_SY6_\ WZ7_  I/
M[+T\];&V_P"_*_X4:![_ )&-_P + \*_]!JW_P#'O\*/^%@^%?\ H-0?DW^%
M;']DZ=_SX6O_ 'Y7_"D_L?3?^@=:?]^%_P *>@O?\C'/Q#\*C_F,P_\ ?+?X
M4G_"Q/"G_09B_P"^'_PK8.BZ6>NFV?\ WX7_  IO]AZ2?^899_\ ?A?\*/=#
M]YY&.?B-X3'_ #&(_P#OT_\ \333\2?"8_YBRGZ0R?\ Q-;/]@Z0?^879_\
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M>"?]#BZ#/\;UI>:/[K_]\FLV$1]%,\T?W7_[Y-'FC^Z__?)I%CZ*9YH_NO\
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M .^30 ^BF>:/[K_]\FCS1_=?_ODT /KG_'O_ "3W7O\ KPF_]!-;OFC^Z_\
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MK@4^@ HHHH **** ,_7_ /D7-1_Z]I/_ $$U=@_X]X_]T?RJEK__ "+FH_\
M7M)_Z":NP?\ 'O'_ +H_E3Z$_:'T444B@HHJL=1M5F\LS)GUSP#Z9]?:IE.,
M?B=@+-%'6BJ **** "N?\>_\D]U[_KPF_P#03705S_CW_DGNO?\ 7A-_Z":J
M.Z,ZGP2]"YX8_P"12TG_ *\XO_0!6I67X8_Y%+2?^O.+_P! %:E)[CA\*"BB
MBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4456?4+6/4HK!YE%U+&TJ1=V52 3^HH LT444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7%_P C9<_]
M><7_ *&]8]]HNJS:WK-S!%@W5KY-M,+QE5?W9 W1@8/S,QSS6Q%_R-ES_P!>
M<7_H;UEZYX@O-*UB5)66&T%LSVX$.\W,@!+*&W *PXX(Y&>:TC>^AFK6U*&J
M^ ;A])\C3-2+2M&L<OVN,,) H"+]W &Q=Q QU.3SS7:QIY<2)Q\J@<#%<K)X
MW%NTBMI\TZ1QR&.5'4&=D=8R F<C+M@9I9?&YBA8_P!E2M-$[+/'YR 1XE\H
M8;^(ELX ]#3:G):C3BCJZ*Y%/%EREU(&@>XS,R0PQA1N#3>5&-Q/'W)&)]!4
MD7C83?91%ILA,K1)+^^0>4TCE5 _O?=+<=N:GDD/F1U5%%%049@_Y&P_]>0_
M]#-<OXK\$ZAX@U>\D@G6""Y:R'F)(5D18GD+D<=<.,?TKJ!_R-A_Z\A_Z&:S
M]1UB_7Q0;.T.RRM;99[J7R0X!)8[22PV_*G4 ]:TBVG=&>C6IF3^%M;NO!D&
MFR7-K%+:I$JVL2 0RF*56#;L;EW!1D<@$]ZQKGX?:W<R:A)FT4ZRLJ3IYI(L
MPTXEROR_.<#GISBK@\>:C9:'+>ZDL49N(!)9O<6[0*K[2S@@G+*HV\\;B<#U
MKNM-FDN-*M)IV1I9(4=VC'REBH)(]JMRG +1D9>D:1=1>)-6UC4BADN"EO:*
MC;O+MT&1GW9BS$?2MVBBL6[EK0****0S+\2?\@&?_>C_ /0UJMXNT=]=TF&R
M1"RM=1.[ @% #G</<'!_"K/B3_D S_[T?_H:TNO:H^DV"2PQB2::9(8U*LW+
M'DX4$G !/'I5QOI8CJ[_ -;G&MX>U6^N)-3US3YC<W%J$D6U>-VC:.5#& &.
MUA\I<@\'<15W3-,UN#6+>YCT^*VN980MW)+'&8$PF$,>UMZGH"H^7J?<Z4'C
M(-'MN-+NEG39'(J %5F8J/+#''(W?H?2H9/',9MXI8+";EMSHY7/E>6SEA\V
M,\#KZCUK2\]K"]TAN=)O?M6LK<Z2+ZXOD+6]ZA3;&/)V[?F.Y<-G &<[NO6L
M^S\-:CIHB^TV']H00W:7$L2"-/.4P;!B/(7<C#G.,\'K70-XRME=A]CN=BN1
MN.T94.(RX&<D;CC'4X-10>+MR;Y;<R N%"Q8!"_,V_)/(";2?3/?(HO.VP>Z
M70[WN@:A96^FR6AC@:&.)MH4L8\[5P<<9QZ9S7.IX2NM-M;*<PB^YW7-K#$B
MA&\D(CK&QVL5(YR><Y[8K9F\9VL8'E6=S.>"PCV_+PA[GKF51CUS39/&MHBK
MFVF!PPDRRXC8!S@\\\1L<C/&/6DN9;(>C,G3=*U6+6+*YU*PE#_8A$3;PP>6
MC!W(W#JO!4_)WS5&T\)ZQ%8Z=I[V@%EI\MM>0KY@XF+H9%QGHF)#[[QCI720
M^*)[G3K81VBQZA//]G,<S[8T<1>8Q)&> O;KGCUIW_"7Q1MY,EK))-DQJ8""
MLCAU1@N2" &;J0,@'TI\T^PK1*VHZ?>?\)A=7D-K<N);)(X)8TB*"0"3[S-\
MZX++C;45CH^M)=6<%S=Z@;021RS.UWEB?);<"<YV^9MX''X5+)XY0P0RP:?/
M@MND1RH;RO+9]PYQG@=?4>M32>-;6W:0SP3-"K',B( $&YE ()R22C=.U+W[
M;#T,M-+UQ[2:WOH+R0R:>\< BG40HY$FX2+N&2<K@X(Z=,&F76C^)((8[2TN
M=0%FKCYDE#R@F%1D$NORA]W&<=."*U7\8,SE8K%D"K()&=U;8ZNJ*,*?F!9L
M=>QI7\<6BL56RNI#Y?G*4"X,7]_KQVX//(IWGV%H5=-TO5_^$RAN]12ZD$/V
MA6GDF4Q%6V^7L0'Y3@'/ Y]:[&@'(S164I7+2L%%%%2,**** ,_7_P#D7-1_
MZ]I/_035V#_CWC_W1_*J6O\ _(N:C_U[2?\ H)J[!_Q[Q_[H_E3Z$_:'T444
MBC)UVZ,$&S)"E-Y([89?\:J2ZA)-=JT%OL9W=%/E;I%"@9RI(P23GZ?6MV2"
M*8@RQJY P-PS[_T%4]3LO/7]S9P3LY^<R<=!P<U:Y&DFCDJ0J7<HOL4XK[4K
MD2E6AA\B .RE,EVRWOP,+]1FAM3NY+4WL4D,<0F2+R77D@D G.>O/'X5-$E]
M$@5=/MD4J$=$/&T= #^)IB6$TETDD^G6@*E1OZX /IZ@=/I5^Z9VJ623=_F;
M-%%%8G>%<_X]_P"2>Z]_UX3?^@FN@KG_ ![_ ,D]U[_KPF_]!-5'=&=3X)>A
M<\,?\BEI/_7G%_Z *U*Y+P]+XE'AG3!!9Z6T7V2+87N9 2-HQD;*T?.\4_\
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M!#TTWGCWMI>C?^!#T6#G79_<=;17(_;/'_\ T"]&_P"_[TTWOQ [:5HW_?\
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MZ3I\7E^590)Y7";8P-O(;C\0#]:(])T^%66*RMT#$DA8P,Y()_4#\A5NBB[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC)1&4%E!()J[H?BZ#Q#X;GUG3=.O3'&A:.)Q&#<83</+<.8VSD#.[ .02""
M =!17EVC_$N^>ZL=2U>QU!;+4-$M+Y[2*.%DM#)(RM-OW ^6?D(4L7P>$R&
MZC2/B)H6M^+[KPY8S;KRW\WYA+$P<Q.$D&U7+H0QQ\ZKNP2NX#- '4T5QUUX
MZC>:_MUTK6K:.PU*'3Y[V-;;8)'DB"XW2$E6$J$D+D*QZ,,53\0>/G:UU2QT
MFPU:TGCM;]K?50EOY(>U!$A"NY; ?"\Q\YR/E^8 '>T5P"_$B=H=+AMM!U&>
MZN+NWMIQ*(8FVR1&02A3("-P4X#;2,'*@X!U=<\:'0?%L6G7>G3G31I=QJ%Q
M?H481"-D'W=V\_>Q@*22Z8!^; !U5%8^B^(H]7FO+::QN],O;'89[2]\O>JN
M"4<-&[H5.&&0QY4@XQ7+V_QE\/7MI=76GV]Y>P6C0M/);26[B*"5F59WQ+\B
M K\P;#H""R*.: /0**Y:+QRLT%D\?A[6VDN46:2!88C):PL^Q99%$GW3R0%W
M-A22HQ5'3O&,VGM=6FIQ7^IS?:M0,$L:0+E(&SY?5!NVD $C!QRU ';T5R,7
MQ"L+TRQV&GZE/(EDEXWDI$2BO"95!R_RDC !;"EC@,=K;9++QFLD,D46DZO=
M26]M93+(XMU:Z6X.U&7$@ .0V[(4#:V,\9 .JHKSJ_\ B;IVM6FKV?AG4'@O
M].\N594>WE$R"8(^%#.5&>"'5&PP(]1TMCXL6_OI;--'U"*>'4&L94E, *8C
M$GFD"0_NRK+@C+?,/EH Z"BN,U7Q!=:5XHUV&XN;V6QBL]-EB2VC@W6SS3W$
M3L"X&5/EH2&+$<[?2K=UX\L+)M0ENK&_BTZQ28G5&C3[-(\3A'C#;\JP<E1O
M"@E6P2!F@#J**X"'XP:-=6D4]AI>IWQDCN6V6AMY@AM]ID4NLQCX1U<'=M((
M .\A:TYOB-HMO=:C'*ER(=.MUN+BZ"H8D5HQ(H)W90D,N-P4,2=I.UMH!UE%
M<UH?BJR\;^%KV]T*ZEM6C>2W>2-X)7@E50>&4R1-PRL,%ASSSD5Y_'XPUO3M
M-\)W6I>(M2G.N:$L\KM;VR6\%Q+Y866600?NHU,V 3D9" ALMD ]EHJCHMG>
MZ?H]M;:KJDFK7D:?OKR6%(C*W<A$ 51Z#D@8R2>3@:#<:UK!\5V%YK!BFM-8
M^SVMS:VR*8(3;V\H55<."?WC#<V[DYQC"@ ZVBN$N9O$L7@TSV.H7U^([R5Y
M;M?LT=Y]E1BO[M3#Y3L=NX JN5XSG!KHM6\0P:'X;CU1HKK48-BMOA\M25V[
MC([.R1HH4$EF*@=.I H V:*XF'XI:5<3P+#IFJM#-#8W NA%'Y217;;(W8^9
MD8?Y2,;NI4,H+"6V\4S:G\0+"TL1>QZ9);WBEI8H_)NGADC3>C#+C:Q=>=H8
M8(###4 =C17FGB;4==LK_P 626WB;4K>'3H+2:WAAM;:3R_-9@X ,+,W"\ D
MGD]>*W? ]]?:^L^O2ZS=2V$X$,&E7$4*O:.GROYI1 PER.4R0I+#GC !UU%<
MSXGUN]L]1TNUTME16O[=+R1D#?NY'VB,9[GDY[!?]H&FV%WK-UXM\3Z;+J,0
MC@AMGL2ML!]G$@DSG)^<Y4')('L.<@'445SWAF;4H5U>WUB_?4(;&\,=O?RQ
MHCRQ^4C,&$:JA*NSKE0/NX(R#6-%X_>PTW3KW4=/U'4'URU?4;2&QABVP0JJ
MMY9+.N&",&+,=I;< 1E5H [JBN6F\?:?'<1B&ROKFT9X89+Z)8_)@FF56BB?
M+A@S>9$,A2H,JY8<X;HOC4W?P]D\4ZQILU@D4<LK0,\9+(I.,-O*C/3+%1D$
MG:.: .KHKSNY^(3V.OI?S6VK'29=*>Y>S-M$#;^7/L:8L2/EV\_?8,,% <UO
M7/C>U@U)K1-,U&X0RR6T-S$L?E3W**S&!27!#_*P!8*F1C=0!TU%<E9?$*UO
M_+6VT?4FEFL;>^@A+6X>6.9U08'F\%6;YMV,8.,\9CTWQI_PEL1M-$M[_2+V
M2W>YMI=0@C,<GE2!'4JKDE0Q"DC&0V5;N #L:*YV+QC:R>'=!UC[)<M!K3V\
M:"/8?(:8#;ORPX!.T[<GVQ6--\5].@M3/)H>M;5M;NZDVQPMY26LS13[B)<
MJ5W=<," I+';0!W=%<3JWC!E\8:+;6+W<6GC4)[:]N3'&;:<+9S2LH8Y<,C1
MH<C:#\PRV"!6L?C!H>JH/[(L;_49&NH[98K22VE8M(C-$Q(FPH;RW&&(*E3O
M"CF@#OZ*YWQ9XSL_!VE)J&JV5X]ML+S/%Y86W48SO9W52<L $4LS'.U6P:F\
M0^*(_#UWIML^EZAJ$NI/)% MDB-^\5"^T[G7&0K8/W1@[BO6@#<HKD;#XBV&
MIV%Q=V>EZK(L=I;WD"&% UU#.Q5'0%_E7*G)DV  ;B=OS4VQ^)6E:FNF_P!F
MV5]=OJ,;21QP>2Y4++Y1SB3#*&!RZED  )8!ER =A17G,'QBTNTT73+KQ+:2
M:9/J#,1"\]N/+B\S8)<&7+KS@A S_*QV8Q75>'O$Z>(?MK1Z7?645G/);O+=
M^4%:2-V1U7:[$X*]<8Y&#D$  W**Y6#QY;W%KYZ:)JZB;RC8!XHU_M$2;RAB
M8OM'RH6*R%&48+ 9%95_XJN]3NH9='O;S3XI=)U(RVTD,7F6US;O$N3E6^92
M[CJR$8(SP2 =_17%_P#"<1"32]#NUOK>_P!5L_W%^%A5&E\@R,45CN;:.2PC
M9 2%)SQ5/PI\1OM7A'27UFRU%]6GTVTG0&&-#J4DJA2T6&"CY\YW;  0>%(-
M 'H%%<C!\0[6YU6STZ#1-7>ZN?/#Q^7%_H[0R(DRO^\_A\Q&RNX,"-I8D"L^
M3XH"X\F+2M U"6Z&I0V5S;RO;B2$2*6!($V Q"D;6(93]X#@$ [ZBN0C\=01
M6)>/3M8U"Y,UXSVBI!YT$=O+Y<C'#JA56("@%G8$8#8;!:_$?3+W6$L;:PU%
MXGFAB%]Y<8@/G1B2%@V_)#@] "P_B"@@D Z^BN?U[QC9>'=8T^PO[2[(OYHK
M>.Y41B)9)7V(GS.&=B>2(PQ4?,P YK'O_BC9V"WLKZ!K,EM:6]S=&X06X66*
MWD$<K*K3!^&/1E!]J .XHKC9_B=HMEX@T_1=3BGL+Z]=$\FXEMU>$NQ6+<@E
M+'?@8V!MNX;]O.*-I\9?#NH*QTVWO;[;/!$!:&"8E9F98Y,+*2 67!1@)%R-
MR*#F@#T"BN.MOB7I$J2RWEGJ&G00V=U=M-=QH%Q;.J3H-KDED9P.!M/.UFP:
MIV?Q=T?48HCINF:E?2232P>7:-;3;9(XUD*ETF*<HP(8,5X()##% '>T5RWA
MSQE)XC\27EG;Z7<1:=%8VMW!>NT>)1,"P! <L,C&/E_A;)&5SU- !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5'<1M-;2Q1S26[NA59HPI:,D?>&X$9'7D$>H-25'<6
M\-W;2V]U$DT$R%)(I%#*ZD8*D'@@CC% '(Z?\.8+%M-\WQ#K-['I*.-/BN#;
MA;9V0H) $A7>P5F W[AR>*G/P_M&MHEDU;4FN8K!K#[83")&CR=I*B/8617D
M13MX61^I.:\]\,Z9>^$_"MGXPL-(TK3H+?2O),6GRY?47D= DEPI6-%V<MRQ
M^\?G4<UM7?C?QO9A8;FQTJUNH[#4+J>.YBRP^S>2ZG;%/(%WI,J["Y*_?RPP
MA .D'P\@^QQV;:_K#VIBBANH6>#;>1QX"H^(OEX^4F/8Q!Y)P,:FO>&1KM]8
M7?\ :M]826 E\K[*(2"TB%"Q\R-N0"<=N>0:X;6M3UC6/LT%]%I?]I6.N6#V
M<JPOY< F3=@Y;<Y7+ L-F\=DSQ;LO&WB6:^E$PTM[>QLKNYN?(MI"URUO.\1
M$1\S"A]H()#;""OSYR "]8?"FQTV2Q:SU[6(_L2VZK_Q[9<01F.,,WD[L"-F
M7 ('S$_>):N@\/\ ABW\/PWJ+>75])?3>;/-=^7O8A%0 ^6B@\*/F(+'NQXQ
MQ6L:MJ&J6EM;:R--O@E]H>IV5Y8Q,JQK-?QH%PS/SA6PX(W!F^48.;\VM^(U
ML94T Z)%J4FJW5LL3:?(PN65P%8A9EV *"SR$MT&%)(6@"4?"FT7318KXDUP
M0+IT6FJ/]%RL$3[D&?(ZCID]1UR>:Z#1_#"Z+J$T]OJVHRVTCR2K82M'Y,<D
MC;G<;4#<L6."Q4%C@#C'+-XSU];UK07.D2-_;C:9',MI)MDC;3UNHY /.Y(8
MX/.&7IMZUGZ?\0/%D^EV-_>1:*D4NGZ9J4RQ0REO+NI3&8ER_#<%PYR%SMVO
M]^@#JKKP%%<VNJ0#7=5B&I:G'J4C1BWS%(A0JJ9B(VCRX_O GY!SRV>=L_!M
M_?>(-9%S;:KI:ZJ;F*^O-NG,DT+E@JQ2A&N">4P)>%4$<845E^-O$]_K&E^*
MM%O;:SN=+.F:A-:RK;,H66TGBCV[W8^8P9P21&JJPPK.02.\TC5M8N?[?L;^
M33VOM-<+%<6T+^5EX5D4.A?.Y2W(##<I4_+NP "G'\.8$NA<G7]7>=9+:1)&
M^S91H$9%( A Y5F!R#UXQQC3UWPC9>(-0CNKRXNHP+.>QFAA90MQ#-MW*Q*E
M@044AD*D$=3TKAH?B!XM;PYIU^XT1YM1M-,NXUCMY=L(N9TA='_>9S^\#*W^
MPZD'&ZMP^*/$*ZBT2RZ7-';ZC%I-Q$EK()?->-6^T >:<)N<'RB"=@+>9VH
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M 7E@2I!!7GY0"Y)\*+"2QGM%U[6(HKBTEM)1$MJH999C+(0!!A26)'R@#'0
M\ULV?@RVL]7%Z=1OYXEN#=BRF:,PBY*;6F "!@3ECMW;-S%@H.".0/CSQJ+"
MVM?[#@.KW\V;$A;<K+#Y+29\H7F.J. ?-&0I8+P14\7C3Q?=:B4B@T6&%KFT
MMPCAY'0W%N).71RK>6QSE>)!P/+^^0#I+'P%I>GZA:WMM/=B:TFN9(B74_+.
M03&?EY12J%0>FQ>N*HV?@"XT-[>YT37KZ:[M;66TA_M!8&B5)91([LL<2LS
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M'[1;-$PFA,1E\Q,'<NP ELC(VX.>F*GIDTJP6\DSARL:EF$:%V( SPJ@DGV
M)- '*^&M8\&ZE:1Z#X>LHX+.[M9ITLCI,EK#-"'"2D*\:J1N< CJ=W3%:!\#
M>$S%'$?"^B^7$C1QI_9\6$1B2R@;> 222.^37E=K-J,;^%_+TC74M[?3+RWU
M+R].O()D1[F!]L;*@(<B,G@Y*A@/F*YO:BNOR:SJ<L5]XBBM%M'6RM8=/U!F
MFMS:@QDS>;A9!)R<IY^X$$E30!Z5%X.\,P6US;0>'-)C@NT2.XB2QB"S*OW5
M<!<,!V!Z5%>6_AGPU<6&H3:;:6D[-#I5K<P6.6C#L$CAW(I*)D@#.%!('&17
MFPN]733KBR/_  ELT4PL'DNIH-0#1NT3F9_W:"0J&$>8H2GS$ E1O-;6I2:E
MJ/P:\-K?1:P=2:[TP731V,S7,3Q7$;2R%"A8;1&[;F!!P.NX9 .S_P"$-\,?
M8&LO^$<TC[(\_P!H:W^PQ>6TN,>85VX+8XW=:BF\!>#[C/VCPIHDN9&E._3H
M6R[8W-RO4X&3WP*\PU&_U\:/!%8Q^*D:RO+XVTKP:B[.BW"M$K*%WR$Q,-K2
ML4P"-KMD+VOA&?4)?&FKBY.L26KF62-KV&>"*+,N%0)("K?( 5:-@-O#1H^X
MN ;]WX,\+ZA<>??^&](NIBJKYDUA$[84849*YP  !Z5"? /@YEVMX3T,@H(R
M#IL/W0<A?N],@''M7+^$KS5O^%E:@MXFM)9SK=IY=Y#=O$LB3CRV$CJ(5#1Y
MVB( 8 !:1N:AUBUUW2O$=Y+IT6MWL%GJ$6HHHN[EUG@F"126ZC=M;:P>0+T0
M!< ;J .W3PEX<BU*348] TM+Z7<9+E;*,2/N!#9;&3D$@^H)J*1=)T"VM?#^
MDPVVDOJ FCL(H+$^0) A=LA %' +8+*6P<'K7&7-EJ]CKHL%G\0O>6UQ:?8)
MTDNI;2:RV(+D2MDH9,BY(,A\SF+8<[15/24U"WT?P?<"'Q!=:G)>W,DK:C!=
MRF)A;3Q1[_,&(ES)&,G;NY8DX9J .B\+^$/"NFZ.G@V[TW2]1O-.MK>6\9M(
M$27/#)%,0P97?","P9B#NZ9Q74W&E:3#J+:[+IELVH0PE?MB6@>XV '*JP!<
M]_E'7TKRBTMM0N&U.]M8?%@O;?2;&\/VE;J)Y[F"65Y[=7. P8/M\M24._Y!
MA01HW=GK::#XH25?$ :UMI[G2GM[J\:1S<1(8HQABSO'(K@CD("IP,F@#N-7
MM?#/EQV>LZ7:31ZU=*#%-I_F)<3A,J9/E(#;4 !?'W0,]!5K_A%] _M4:G_8
M>F_V@I5A=_9(_-!5=JG?C/"\#G@<5YY?7&H7GBRPN9K7Q TRZE;R6H-G<FT%
MHUO@,ZA=J,)F.[<!*O?"#C6^%J:ZL=X_B"_U*XFDBA,]O>Z?<0+;W W>9L>:
M5P^3C/E8B&T%0,XH ZA?!WAE-,ETU?#FDK8S2"66U%C%Y3N.C%-N"W'4C-6A
MH6D#1FT@:59#36R&LOLZ>2<MN.4QMY8DGCJ<UY*EKXEN=/U6/4]3\2#4KEEB
M6&SLK^".VN_.*H_G>:RM!@DMY*A/+7) ;8#=L+B\NM+L8]83QI:JJW(G>U6\
M,@OQ(F"I*Y,)4L8]P\H#(<!J .QL?#/@35WO4M?#.CR-97<D%PLFDHA68JI?
M[R#.Y64[AD,".36Q)X9T&:"QAFT33I(M.(:RC:TC*VI&,&,8^3H.F.@KS^>6
MZA\675\+;7X[*/Q)*+M;6TO%\ZW?3?*#!$7]ZHGB4!U!VG# @')I>&[G6GF\
M/2ZQ_P )4R?V:(;^%X+R,H4AFWLS $2-N(Q]R4ML*/(,+0!Z#<>&- UO?JJZ
M1:1ZC=('34)=/1;J-@FU'_>)N#J,8W<C&*R-!^&FDV".-8TKPW=@[-D=EH26
ML9*]'=2\F]QDX;(QEL#DUBZ!8ZK=:7X?:_?Q$7UC1(+.^,MS=Q/9W,(0R.02
M#&S@2?O.,E%P3YGS7/!L?B >/-2DUB_U%EW7*/9RV%PMN$$P\ATG>4Q']V
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img39825204_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Q CT# 2(  A$! Q$!_\0
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M)8"?N.5'X'%=!7)>&V,MS++SAF+?F:ZV@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH #69/'LDQZ]/?VK3J&X@6="IH S**AN(KVV/R!94'9AS^=47U.\0X_L]3_
M ,#- &I163_:UY_T#E_[[-']K7G_ $#E_P"^S0!K45D_VM>?] Y?^^S1_:UY
M_P! Y?\ OLT :U%9/]K7G_0.7_OLT?VM>?\ 0.7_ +[- &M163_:UY_T#E_[
M[-']K7F.-.7_ +[- &L!DX%8FM:B&4V%L=\C\2,.P]*;+)J]\#&H$,9ZA!@_
MGUK1TGP\L!$DHRU %O0+'[+:@D<FMJFH@10!TIU !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME%26S$%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2<VVJPG/$J\_4<?X5T2'<@-<AJ4F[6+2('E$R1]3_P#6KK8/]2OTH DHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGE@PR;=R^_&*KGC?0R>'JN-V];):/JGO\T96IWLX\.VU]8ZF[IN0>8$ ,F6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0>]%9*RLO0_TJPEX5'S<@=3Z4 7J*:DBR+D&G4 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1S@$@'D ^U3U!NG?8****!A1110 4444 %%%% !1110 4444 %%%% !1110
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MEV[>GN*AU4C>."J/?0XKS"3@*Q/< <^U2Q6MY/M\JVD?(." <-ZD&N_AL[:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)R*TX)Q*O/#>E9-6.J$^8FHHHI&@4444 %%%% !1110 4444 %%%% !1110
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MBT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4'I10>E $#TQ(?,.6^[_ #J79O//2I0,# IW)L   P!@4444B@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BD)"C).!7GGBGXNZ)H,LEI9AM0O
M$X*Q'Y%/H6Z?EFIYM>5*[[+^OS!M+5GHE)D>HKYNU/XQ^*[XD6\EO9)V$4>X
MC\6S_*L%_'GBMV+'7;S)]& '\JV6&Q#ULEZO_)/\S-UHGUA17R[8?%#Q=8.I
M&J>>H_@N(U8'\1@_K7=>'_CDK.(M>L3$#QY]OEE_%3R/PS4RHUX:RC?T=_\
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M6_7_ -O*^T;U8&B_\AW5_P#?'_H35OU@:+_R'=7_ -\?^A-7H8O_ 'BAZO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX]*U**.>7<'0I/>*[;%&XT>PNIYYIK<-)/%Y,AW$;D].#^O6G1:7907:74<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img39825204_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +%!@P# 2(  A$! Q$!_\0
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MUC/_ "Z7'_?-'MZ?<+FK165_:_\ TZW'_?-!U;TM9_RI^VAW"YJT5E?VL?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*QZT4'J:,U1F%%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T
M %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&
M:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T
M%%&:,T %9%_H%O=2_:;=C:W8Y$L?<^X[UKYHS6=2E"JN6:N-.VQ3TZ.\2VVW
MYB>4' :,?>'J?>K>U?[H_*ES1FJA#EBHBN)M7^Z/RHVKZ#\J7-&:JP"8'H/R
MHP/0?E2YHS0 F!Z#\J,#T'Y4N:,T &!Z"C ]!1FC- !@>@HP/049HS0 ?A11
MFC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC-
M!11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11F
MC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC- %
MA>E+34^[3JDM!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH K'J:*#U-)5F8M%)10 M%)10 M%)10
MM%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10
MM%)3&E1#@GGVH DHJ#[2OH:/M*_W32N%F3T5!]I7^Z:/M*_W31<+,GHJ#[2O
M]TT?:5_NFBX69/14'VE?[IH^TK_=-%PLR>BH/M*_W30+A3UR*+A9D]%,5U;H
M:=3 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6B
MDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH L)]VG4U/
MN"G5#+6P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44 -HIU% #:*=10 VBG44
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M^\+GK]#WKJ00>E?,4<CQ2+)&Q1U.593@@UZSX#\;MJ>=,U%Q]LC&4<\>:O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *QZFB@]3259 M%)10
MM%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10
MM%)10 M%)10!5NH&;YXSAQ^M9[:@D3;+A&C/KC(K:J&:UBG&'4&E8+V,O^T[
M$=;N$?5J/[4L/^?R'_OL4^30;5SG8/RIG_"/6O\ =_2E8.8/[4L/^?R'_OL4
M?VI8?\_D/_?8H_X1ZU_N_I1_PCUK_=_2BP<P?VI8?\_D/_?8H_M2P_Y_(?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *IZFC\*4GDTF:LSN'X4?A1FC- 7#\*/PHS1
MF@+A^%'X49HS0%P_"C\*,T9H"X?A1^%&:,T!</PH_"C-&: N'X4?A1FC- 7#
M\*/PHS1F@+A^%'X49HS0%P_"C\*,T9H"X?A1^%&:,T!</PH_"C-&: N'X4?A
M1FC- 7#\*/PHS1F@+A^%'X49HS0%P_"C\*,T9H"XA.*7\*AN)-BH?5P*FS23
M5[!</PH_"C-&:87#\*/PHS1F@+A^%'X49HS0%P_"C\*,T9H"X?A1^%&:,T!<
M/PH_"C-&: N'X4?A1FC- 7#\*/PHS1F@+A^%'X49HS0%P_"C\*,T9H"X?A1^
M%&:,T!</PH_"C-&: N'X4?A1FC- 7#\*/PHS1F@+A^%'X49HS0%P_"C\*,T9
MH"X?A5>_B,^G74(ZR0NH_$&K&:,T">J/EV(%0T3?>C8HWU!Q3ZZ#XAZ(?#WB
MR6>.,K97O[U,= W\0_.N?!!&1TKT(2YE<^4Q%)TZC3-GPMK$.A>(;?4;B.22
M.+.5CQDY'O6A-XHMK_0)]-U&WEEDCG,MC,N,Q@G)5O:N6HIN";N3&O.,>5;?
MYG;'QO;_ /"7#4Q;3&QDM%M;B!L;G 7![XJO+XS-AHMIIOA_S;5(W=Y6E1&+
MDGCKGH*Y&BE[.)?UJKKKO^IU^I>)-&U]K&;6+6\>ZC@\J>6 JNY@>& __55'
M7_$%OJ&F6.E6$,R6-GEE:X;=(['UQP![5SU%-02)EB)R3OUW"J%X^Z4*/X15
MJ>81)G^(]!5>PLY-1OX[=.2[?,?0=S2F[(K#TW)W/6/AM \.FVP(^]E_S->I
MCH*X_P ):?Y,28&%4 #Z5V(.!7 W=W/J(+EBH]@_"C\*,T9I%W#\*/PHS1F@
M+A^%'X49HS0%P_"C\*,T9H"X?A1^%&:,T!</PH_"C-&: N'X4?A1FC- 7#\*
M/PHS1F@+A^%'X49HS0%P_"C\*,T9H"X?A1^%&:,T!</PH_"C-&: N'X4?A1F
MC- 7#\*/PHS1F@+A^%'X49HS0%P_"@=>:,T \T!<X+4-4^(B:C<)8Z+9O:K(
M1$S,,E>Q^]7,^,=1\<S^&;B/6M)M8+ LGF21L"0<\?Q&NCU/X@:[8:A=6\7@
M^YFAA=E$V]@& _B^[6#J'CN_\5Z(]J_@VZN+&8C+P3-R0>QV5JD^QP5)1::Y
MW_7R/5=._P"059\?\N\?_H(JS^%06>!86P$;1@1)\C=5^4<'Z5/FLSN3T)XO
MN4^F1<I3ZAFBV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZN3O<?W1V7\!7!1Q$IUY0MJK7\M_SZ>1;C97-"BBBN\@**** "BBB@ HHHH
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M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H')Q10!D@4
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MBC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
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M8@Q1BC</449'K0 8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
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M,B^[^-/J&:K8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2P>[@W;8\[U;J,#-11Z_;2:(^JB.00J<;<#=UQ7,0Y\/7R'.++4+?GT5MO\
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M/R$X^YZ"@#T/3_$;WOC76= -NJII\$$JRAN7\P$XQVQBN@KRA_#\NO\ Q?\
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M*/QH_&@ HH_&C\: "HY[>&ZB,4\:R1GJK#(J3\:Q/%=Q)!H;^5(4:1U0L#C
M)YK&O-4Z4IR5TD5'5V*UUX1LIPYL+B2V+##*C;E/L14^A0ZA8W$EA=7,$\$4
M8,>PC<O/0CK7.S6BZ5<VT&F:L%%VNR9MPPI]?:NCT#2]/L)))+>\^U7+K^\?
M=GC/I7DX;EE73A#E:WM+3T2Z_<C67PZLW**/QH_&O<, HH_&C\: "BC\:/QH
M ,9I-H]*7\:/QH 3:/2C:/2E_&C\: $VCTHVCTI?QH_&@!-H]*-H]*7\:/QH
M 3:/2C:/2E_&C\: #%%'XT?C0 44?C1^- !11^-'XT %%'XT?C0 44?C1^-
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MW^K3/NU/%L6W)"8^%XKI**PK4(5H\D]O6Q:=C%72M0_L::SDU)GF8C9*%QM
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M(RJ, MSS]: -?XCZW?>'_!L^H:=(L=RLT2!BN[AG /'TJOK'B2\T_P =^';
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M<MN\N13@@'N/2CQ#?^)K>ZAM_#^CVMTK(7EN+JX\M$.>% ')-9'PXTZ\T_\
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M^5<K&<EA&A/\6X_D*ENK/79?@]KGA:XTJX:_TT);0-%'\MW&)%*NGK\HY^E
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MY%"E!T0L!DBN]HH CAACMH(X(4"11J$1%Z* , "I*** "BBB@ HHHH ****
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M[!+/RT!WQX4@G/XUS$_PW\5WWA>V\-W7B'3QIMD8OLXBM2&D5&&!(<^@[=Z
M+GB=]8U+XIZ/HMEK5SIUE<::\UP(,;F ;^'/0GIGM5OPI)>Z-\0-8\+R:C=7
MUBMI%>6S7;[Y(LDJR[NXSS6S/X8FE\?V'B,7*"*UL7M3#M.YB3G.:DM_#<L/
MQ O/$AN$,4]BEJ(<'<"K$YSZ4 6/%VLOX>\):IJT2!Y;6W:1%;H6QQGVS7.>
M%_"VH36&DZ[<^)M6DU&9([BX5I 8)%8;C'Y>, 8.,CFNPU;2[;6M(N],O%+6
M]U$T4@!P<$8XKD-!\,>--*>RT^?Q-:2:-9L FRUQ<21KT1F)QTX)% &#XRO-
M)@NM5=O%6O2ZK$&:*+3MS1VAQE595&/KDU!J_B;7K[X4^$=1M=1:UU.^O((I
M+A1USN!)'?H#BML>!/$=C=ZU;:1KMI;Z1J]P]Q-YEN6GC9QA@K9QCCC/2I3\
M.[K_ (0CPYH'V^'S=)NXKAY=AQ($). .W6@"K=6VH^#?&7AGR]=U'4(=5F>U
MO8KR0,K-LR'48^7!'04:=:WOCW7O$%Q<ZUJ-E8:=>-8VEO92^5AD W.QQR<G
M@=*ZCQ'X;EUO6?#]]'<)$NEWAN'5@29!M(P/3K6)=>#O$FF^(-1O_"FM6=G;
M:FXEN;>[@,@27&"Z8/4^] &1XT\0W6C:MH'A>ZU/5&@>W>:]N[& M<3A>%4!
M0=N>Y%.\':[>/XFU+3K)]:GT(V)FBEU2!D>"8'!4,P!((YK?UCP;JETND:E8
M:T(_$6FHT?VR>'*3JWWE=1V],=*OZ+I_BK==GQ!JMA.DD1CBAL[<HJD_Q$DY
M/TH Y'X>Z;KVK>$;/Q/>Z_>76I/;R?9+<R;8 /F5=ZX^8Y&<TWP!?6UQJ=M%
MJNL:U;>*$5OM=A?2%8YVYR44C!4=MM=AX;\.7GA_P%:Z!'?HMY;P-&ETD>0K
M$DAMIZXSTK&@\'^(M2\1:3JGB?5=/G326:6!;*W*-(Y&,L3T'L* .^KC/BCJ
M-YI?@B6ZL+F2WG%U;J)(S@X,J@C\0:E\&WNM:KJ.NZC>RO\ V5)=F/38G7!"
M)PS?0G.*N^-O#DOBKPV^EPW"0.T\,N]P2,(X;''KB@#G?&3ZS>?$'PWHNFZQ
M-IT%Y;7+7+1 $LJ[3QGHW4 ]LU7T:[O?"_Q UC0&U&[O]-32QJ$(O)/,>-@2
M" W7!Q757_AR6\\;Z-KZW"+%I]O/"T1!RYD P0?;%0-X3>3X@7'B*2X1K:;3
M18FWVG=]XDG/I@T <MX/T?5/&/ANU\4W?B75+;4+QVEA6WD AA0.0$\O&&&!
MSGUK0TS(^-?B/GD:1;\_\"-1:7X)\7:!%_8^C^)K6'05E+1"2UW7$2$Y**<X
MQUKHK+PS+:^/-2\0O<H\5W916PBVG<"A)))]\T <_P" =6U"_P#AIJ5[=WDL
MUTDMX%E<Y8!2VW\JPD\0:S?^#/ 6D0ZG-!=Z[A;J^!S*$4$MM)[GIFM>W^'O
MB/3UU+2-.\1PV_A^]FEF*"WS<1^9]Y5;H!GO5J?X=W!\&^']/M=12WUG0BKV
MEV$RFX<$,O=2* ,.\T&XT+XN>$HO[7O;ZS=+@Q1WC[WB.WGY^I!]^E7=-UG4
MI=-^(KR7T[-974JVQ+<P@1Y 7TYK0M/!7B*Y\6:1XBUW7+:YGL?,7[/;P%(E
M5EQ\O?.>I-6[/P3<6UGXN@-Y$QUV9Y8R%/[H,FW!]: .*>VU^#X56_C63Q1J
M,FK6]NET(PX$!C!&8RF.<CJ?6MKQ1K@NO%VAZ9JNKRZ3H]UIS73-!-Y1EER,
M*7[  ].];]QX-N)OA8?"(NXQ.;(6OV@J=N1WQUQ7%^(;>,?$NWLIM8BT7[-I
M$<9NKF%)8[KG[JJ_RC&,GO0!T'PN2>=M;O#JFHZA8K>-!8SW4I99(A@[@".Q
MR,]ZE^)&NQ;K'PFFHQV$VJDFXN7<((;9?OD$]V^Z/J:/A_KNJ7NLZQI,U[;Z
MKIEB$^SZE;P")68]8\#@D>U=A?Z'I6JR+)J&FVETZC"M/"KD#TY% 'G7@N^T
M:#XG^([73KRT\@VEK%:)'("'VH>%]<5I_!U5?P1/*P!EFU&Z:4GNWF$<_ABM
M#1/ -CHWC35-=BMK%8KE(EMH8X I@*@AB..,^U97_"#^*-%N=1@\+:_:6FEW
M\S3M%<VY=[=W^\8R#CWYH P/!GAZ]U?PI9W>FRPQW>C:]=RVJ3Y\MTW%2AQR
M!R<$56O!Y4VK6E_,)K-+\7FM?9%.VXG<@16<>>O;=7I=GX<G\/\ @K^Q- G1
M+N.(K'<W SF1C\TC8ZG))JC<^ H&\#IH-I<^7<QR+<K=NNXO<!MV]QWR<YH
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MND^8]\UT-O;1VZ!54"J4;$2E<DC01H%':GT44R HHHH **** "BBB@ HHHH
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MPUKU\;+3-7M[BY +"-206 ZE<]1]*34?'/AK2=5&F7NKP17F0#&<G:3TW$#
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M'U&8F61(UPL0/(0>N!QFKFIZK8:+827VI7<5K:Q_>EE; % %RBL'1O&?AWQ
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M/FA8]?<>HK"=)QU/5P^-A6T>C.JHI 01D4N:R.P**,T9H **,T9H **,T9H
M**,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T9H **,T#DT ><Z
MWXC\9>%=7198K;4;*\G*6J*</ZA>*9J_C'1O%&C3:'K+7>AW$C+N,\>0"#GK
M5#Q1J^N>)==MK;1=#GSI5V76:0?*S#CGMBKC^ -?\3R)<^*]94#.1;VZ@[/8
M'I6EEU.-RFVU"[7GL>C6B)'96Z1OO18E"N/X@ ,&IJC@B6WMHH$SLB147/7
M&!4F:S.PE@ZM4]00?>/TJ>LY;FT-@HHHI%A1110 4444 %>:/86E[\?)&NK>
M.8PZ.KQ^8N0K;\9QZUZ75$:/IZZRVL"TC&H-$(3<?Q%,YV_3- ' ^#="TH?$
MGQK+_9]N62>()N0$*&3+8'09-<0WG1?![5[:W9([5/$;1R!\^6D/G#(8#^'I
MGVKW>UTFPLKZ\O;:V2.YO&5KB1>LA P"?PJO;>'-'M-/NK"'3H%M+MVDGAVY
M61F^\2#ZT <--X4\1:KJ&@W=U>^'+>"PNDG@DL8G5V7&"BD\8(JOK5M?> ;K
M6_$MHEAJV@WES]IO[>7 FA;A3L;HW;Y378:=X \,:5>Q7=GI:QS0G=#F5V6,
M_P"RI.!1+X \+SZDU_+I,;S/)YK NVQGSG<4SM)_"@#F4DM[_P"-2'4XT,/]
MC))I:3 8^9OG(!_B_7%%G;V9^-FJ1:9%$;=M(7^T$C4;#+N^3(Z9VUVFM^&-
M%\11Q)JNGQ7'DG,3'*M&?]EA@BI-%\/:3X>MW@TJQBM4D;<Y7)9SZDGD_C0!
MP?PI2V_X59(Z)#YZFZ5F"C=]YN#WK-\*:'I<GP O9'L(&DFLKJ:1R@+,XWD'
M/M@?E7HECX-\/Z;J5SJ%EIL<%Q=!A,49@K;OO?+G'/TJY;:%I=GHC:-;V4<>
MG-&T1MUSM*MG</QR: /(]1?5+NX^&JQS601[ O&VH M"T_EKUQ_%CI76:/X7
MUR#QW_;^J7VD*WV%K=[;3T9#*,Y#-GKCUKJ[SPQHFH:+#H]WIL$NGP!1% P.
M$"\#!ZC%0Z-X0T+0)WN-.L1'/(FQI6D9V*^F6)XH \G?_DVT?]?)_P#2DUU>
MLBUF^,?AN'51&UH-+E>T67[AN=P!Z\9V9KL3X5T,Z#_89TV'^R]V[[-SMSNW
M9Z_WN:DUGPYI'B"UCMM5L(KF.,YCW9!0^JD<C\* ..EBMHOCA8#2EB5SI4O]
MHB$ #;N'E[L?Q9Z9[5S_ (+T73'^"&K7#V,#37"7;2R,@+,5+ <^V!7I^B>&
M-&\.)*NE6$=L9B#*X)9W/NQ))J2TT#2K#1GTBUL8HM/<.&@7.TAL[OSR: /)
M=4TJP@_9PL[J*TB2X$-I<>:%^?S&E3+9ZYY-=9JNN7-QXPM]!T;3--DU1=/6
MXGO=0Z)'G 5<#<>23^-=9-X<TBXT!="EL(GTM41%MCG:%4@J/P('Y57U?P?H
M.NSP3ZCIR2S0+LCD#,C!?[N5()'M0!Q_PB,@G\71RO:NRZN^[[&,0[BHSL'I
MFNO\:_\ (BZ__P!@Z?\ ]%M5S2=!TK04F32K&&T69@\@B& Q P#^0%1>*+.?
M4/">L65JF^XN+*:*-<XRS(0!^9H \P>#PS_PSL\D*66#IX)==N[[1[GKNW5L
MQ:SJ)G\.:!9Z;83:X^D)<S76H\"*/A<# W%B>H%:'AKX;>'XM&TB?4]#M_[3
MAMXO.#$E?-51R5SM)]\5T>M^$]#\12P2ZI8)/+!D12!F1E!ZC*D''M0!Y[\.
MXY7U7X@6UU]BF?[0I=;1?W)?8V=H/^<BK/P_6U/P-22)8?--A.KLH&XXW<$]
M:[[2/#>C: ;@Z5I\-H;C;YOEC[^T8&:JZ?X+\/:7/>366F10&\1DG5&;:P;[
MPVYP,^U 'DVIFY/P@\ 1QO"MO)>P"<W()A^\=OF8_AS79P^%_$=UXNT/5]1O
M=!A%BSX%C$ZR3(RX*<]1T-=C_P ([HYT%=#.GP-I:IY8M67*!>N.:HZ3X'\.
MZ'?+>V&GB.X0%8W:5WV \$+N)Q0!R/PVTC3KB7QC=S64$MQ)K-U$TDB!B4!X
M7GMR:Y%XU;]G:[#(K+;7[I'N&?+43C@>@KV_3]'T_2A<BQM8X!=3-/-L_CD;
M[S'W-5XO#.BPZ)-HT>G0#39BQDM\95BQRWYF@#%\2>'+?Q!X9L;>PN[6RN8Y
MHKJU<HIC>51D!E_B!]*9X+\07E_JVKZ+J^FVEKJVG>7YTMH<QS*P^4^H/L:O
MKX!\,KHXTH:8OV-9?.5#(^4?&,JV<CCC@UH:+X=TGP]#+%I=DEN)6W2L"69S
MZLQ))H P_'6O)I+:/:1:9;7VHW]WY-F+K CB?'+$]N/3FN8\/+J$/QON(]1D
MTPW+:-^\73U8*,2<;L_Q?TQ7HNM:!I?B*S%IJMG'<PJV]0V05;U!'(/TJOI7
MA'0=$NQ=Z=IL4%R(S&9@279202"2<GD#K0!Q/P[T73)M"\57<MC!)<3ZK>QR
M2.@8LH8X'/;DUQULR2?"[P%#?-G2SK*QW0<_+Y8=MH;VSBO=+#2-/TRWGM[*
MU2&*>5YI57.'=_O$_6J@\*Z$/#YT'^R[?^RSG_12N5Y.?YT <3XP@T6'XE>"
M/LL=JFI&Z??Y0 <Q;#C..V<8KTZN>T_P-X:TN2"6TTF%)H)/-CE8EG5L8SN)
M)Z'ITKH: /.O',L?_"P_ I\Q/EO)<_,./DIGCIUM/B-X'U*9PMGY\L!D)^56
M9?ER?PK=N?AKX/O+I[FXT.&2=V+EVD?.3R3][BM:X\-:-=:&FBW&GPS:<BA5
M@DRP '3!//XYH X[QF1J'Q.\$V5LPDGMYY;N55.=D87&3Z<T[X67EO::+KEA
M<3)%<6.K737"R'!16?<&/L1WKJ=#\):%X<DFETNP2&:;B24L7=@.@W,2<>U5
M]6\!^&-;OVOM0TF*2Y< 22*S(9 .S;2-P^M '(^ ="T[Q%X'U-]2B+V5WJ]S
M>6[[BA5=_P LBL.0>"<UA7'E6VEW7B32K<?V1I\XBTOS\OY]R[!'NY">6QT7
M/I7L$^CV,^C/I'DB*Q:+R?*B^0!.F!CI1)H^G2Z/_9#V<)T_RQ%]GV_)L';%
M ',^&=5U6'QEJGAK4+W^T$M[2*[CNC&$8;R04('';(]JS?'FR3X@>"X-2"'2
M&GE8B3[C3A?D#9X]<9KL]'\/:5H*2KIMHL)E(,C;BS-CIDDD\5)J^BZ;KUBU
MEJMG%=VS$'RY!D9'0CT- '">*8;.+XK>#1IL<2WY,PNA" ";?;_%CMGUI_P\
MM;<>,?'+""(&/50$(097Y!T]*ZS1?".A>'II)M,TZ.&>0;7F)+N1Z;F).*O6
M6D:?IMU>7-G:I#->R>;<.N<R/C&30!SGQ4_Y)?X@_P"O4_S%4?!O@O3=.@TG
M5(M9U:6;[,C>3-?EXLE!QL]*[74-/M-5L)K&^@2>UG79)$_1AZ&L"S^'7A.P
MNH;FUT:**:%@T;"1_E(Z<;L4 <./#-MXE^,OBB.YO=0M1#:V[ V5R82V1WQU
MJ?2?#MOX;^-UG;6]Y?72R:/(Y:\G,K [\8!/05Z7!HVG6NK76J06D:7UTJI/
M,,[G"] ?I2MH^GOK*:PUK&=0CA,"W'\0C)R5^F: /*]+\*V/B+Q]XUEN]3U&
MS,5]&JBSO#"&!C!R0.M>L:=:QV6G6]K#-)-'"@19)7WLP'<MW-8>H?#_ ,*Z
MIJ$]_>:-#)=3G=++O=2YZ9."*V=+TJQT6P2QTZ 06R$E8PQ.,G)ZDF@#SKQJ
MFF2?&+P@NJB P&WFV"?&TR9^7KQ3[QK.Q^-UO/8*BI'HLTFHB <8#93<!W]*
MT?%7A)_$/Q#T.YN]/CN](BM)H[CS.@8XV\=?Q%=+H?A71/#B3+I6GQVYGQYK
MY+-)CIDDDF@#R#Q?J>HZ[\)[W5X+'0=-T28;K>(Y-P0'X((X5^^*Z;QBD#>(
M?AS-<)$0]T5D>11\V8A@$GWKIS\-O![--NT.W99B2T;%B@)ZD+G /N*U=7\-
M:/KVG16&IV$=Q;1$&-6R"A P"I'(- ')^*EC3XF>!%B550/= !1@#]W6!I$&
MO7?Q \9&PET078O%0KJ,;M+Y&P;-N/X.OXUZ7%X:T>%M-9+%-^FAA9LQ),6X
M8."3W'K5;6/!GA_7KQ;S4-.22Z5=HG1FC?;Z$J02* /+_$_AB?0/A7-I]]<V
MERMQKD<OEV@(BB5WY1<\@=?SKIO'6G66F7'@J:QM8;:2'5X84:) I",I!7CL
M<5UP\(Z -&32/[,A-@DHF6$Y(W@Y#9SDG-7;_2;#4_LOVVU2?[+,L\&[^"0=
M&'OS0!P]E!9)\;M8CEAMP7TN"1%9%Y(8Y(]ZJ^([/4/".HZ[XLTO^S]4TRXV
MR:E97)'F(4&T['Z=/X37::MX1T+7-0M[_4=/CFNX,".;<RL #G&01D9[&JMY
MX \+W^H27MSI,;S2OOE&]@LC>K*#@G\* -K2[V+4=)M+V!#'#<0K(B$8*@C(
M%6Z:B+&BHBA548"@8 %.H **** "BBB@"HWWV^M)2M]\_6DK4YF%%%% @HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "LO7UL7TW;J!D$!=1F/KG
MM6I6-XGMKBZTC9;1-+()%;:O7 -<^+;5"=E?38J'Q(HMX:T:.XBMFN+A995S
M&GF=15S2;'3M.U2XMK:2=KA8P7$AR ">U8LL^NS:G:WQT=@UNA4+S@YK3T1=
M0GUN[OKVR-MYD2J!V.#7ET)4O;+V=*SOORM:6_S-97MJSHJ***]PP"BBB@ H
MHHH **** "BBB@".5MH7W8"I*J7[^7'$?6915NI3O)H?0****H04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 V21(HVDD8*B LS'H
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M** "BBB@"HWWV^M)2M]\_6DK4YGN%%%% @HHHH **** "BBB@ HHHH ****
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MT445Z!F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<_+^9KT6BA3:'*A"6Z&HI2-5)R0 ,UPVJ>#-;?QI<^(M(U:WM9)HEBVR1%B
M%4'_ -!KNZ*2DUL5.G&:LSFD\/:AJ?AN]TKQ'J$=VUP<++!'LV#C'U((S7-+
MX$\5C23H7_"2Q?V3]W_5'S-F?N_E[UZ5134VB)4(2W_,S]$TBWT'1[;3;7)B
M@7:"W5CW)^IK%\)^$Y_#NIZU=RW4<RZA-YBJBD%!EC@_]]5U5%*[+]G&Z?;8
MY73/"<UCXYU37WN8WAO$"+"%.5Z=3^%8Q^'^KZ/K-U>^%M:2RAN26>WF3<H)
M/;Z9XKT.BGSLAT(-?B9'AW3-0TO3FCU/4GU"Z=R[RL, >P'I6;K'A6?4O&ND
M:ZEU&D5BI#1%22W7H?QKJ:*7,[W+=.+BHOH<C=>#YCX_M_$UC=1P#9LN8BIS
M*,8_EC\JS/\ A"?$5CXCU35='UJUMQ?R;V62$L0,Y _6O0:*?.R'0@_ON<E=
MZ)XJFTVR,7B"*/4K=W,CK%B*93T!7VJOH?@S4$\3_P#"1^(-12\OTCV1)$FU
M(Q@C^I_.NUHHYF/V,;IOIYG%:3X)O=,F\2RIJ8CDU:0O#)$I#0DLQ_'[PJA=
M^"/$NOBVM/$&O03:? X<K#%AY,>IKT2BCG>XOJ\+6Z>I@>*_#S^(/"\NCVTR
M0%M@5W!( 4@]OI61J'@6?4V\.07-Y$]AI4:": H?W[* ,_3C]37;44*314J4
M).[.0\3> -,UG19+2QMK6RN2RLDZQ8Q@\]/:D_X1"^EUSP]J4]]"[:9!Y4H"
M',IQC(]*["BCF8G1@W>W](X#QE\-AXDUN#5+.ZCM9@ )PRDA\'@\=^WY5J^,
M/!:>)TM9X+IK/4+0Y@G49_ _E7544<[T\@]A3UTWW..TKP]XI74(IM9\1+<6
M\*,HAACVB0D$9;UZYK)T;P1XL\/VTEKIOB"SC@>0R$-;DG)KT>BGSL7L(>?W
MLP[RQU^5M%-OJD$?V>56U',7_'PN.0O]WFMRBBH-C.UW1;/Q%HEWI-^A:VN8
MRC8X(]"/<5QUIX:^(.GV<>E6WBG3VL(U\N.YEM"URB=!WVE@.YKT*B@#BM9\
M'ZJ=8T_7M"U6.+5[:V^R3M>1EH[N/_;V\@YYR*=H_@_45U74-<U[48;O5KJV
M-I&((RL-O'Z*#R23U-=G10!Q6F^";JQ^%LOA)KV%[A[:2$7 0[ 6)P<=>]/U
M_P %W.L> ]/\/1WD4<UJ;8M,R$JWE$$X'OBNRHH X/6O!>NS^-E\3:+K%M:3
MQV2VRPS0EUDYR=_/3Z<YJ?1?!NHQ3ZWJNMZA!=:UJEO]FWP1E8H8@"%50>3R
M<DUVM% '"3> KJ7X?Z#X<%]")M,GMY7FV':XC;) ';-:WB7PS-KFN>'-0BN8
MXDTF[:X=&4DR KC ]*Z6B@#AIO"GB#1_$.I:GX6U&Q2#4W$US:7T3,HEQC<C
M+R,CJ*ZK1HM4ATU%UBY@N+W)+O;QE$QG@ 'GBK]% '->)?#$VNZYX<U"*YCB
M32;PW#HRDF0%<8'I45IX0:+QOKFMW,L,UIJ=I';?9BAR N<Y[$'-=510!R_@
MWPQ>^$X[S31?)<:/YF^PC8'S(%/)0GH5':MC6H]6ETYET6XM8+T,"K7*%D([
M@@<UH44 <58>$]:O_$=GK?BK4[:XDL-QL[.RC*11LPP78MRS8XJSJECXX75)
MY-'U?2C8RX*17ENVZ$XYP5/S#ZUUE% '$Z=\.K:+PEJ^CZE>/=W.LNTU]<A=
MN9&QRH[ 8&*SO^$(\5ZG8V>AZ]KMC/H=LR&3R(&6>Y5#E4<DX X&<=:]'HH
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M-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%% !FC-%%
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ME],L3Q7044 4M)TFRT/3(=.T^$0VL(Q'&#G'.:N,H92K $$8(/>EHH YO2_
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MD<KW#!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:**
M#!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP
M:** #!HP:** $;C'UI<&HY6VJO\ O 5)2Z@&#1@T44P#!HP:** #!HP:** #
M!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:
M** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #
M!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:
M** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #
M!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:** #!HP:
M*5%:0X'3UI-I#2;V'1$AS@9.*G5,'+<M2H@08%.K)ZN[-XJRL%%%%!04444
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MK(UA!%,9BW#[\\8[8Q7#^"?%_P#PC/ARP\*7^B:L=:LC]F\F*U9DD^8X</\
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MZV;34I5N+2[T]Y=GW0&1Q'T(/3/:O0/A]8:'::)/+H-E?VUM<3F1C?!A)*V
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MM_%%G(<2H\9Q]<GN,5+@T;1KTWU-RBJL&HV=R#Y5Q&V "><5:J35-/8****
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MD ]_K5*HC.6#ET.8R#U';-*51OJ>:V)O"LZ@^3<*X]&X)'UJA/I&HVY;="7
M^7<HR#]*I33,I8>I'H5##R-IQS^&*M0ZC?VV/+N'.>Q.<XJJ6>-F#HR$#&/3
MUS3O,!S@@C@#WHLF2I3CL;MOXI.0+F#&3]Y3@ ?UK:MM2M+K BF&XG 5N"?P
MKBL+SVQQ1Y94[D)4C&".N:ATUT.B&+DOB/0**XVTU>]LV"E_,B'\+=.??K6]
M9Z]:7.%<F)\9.[@9]C6;BT=<*T)FI10,$ @Y!Z&C%2;!11BC% !11BC% !11
MBC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC%
M!11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11B
MC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !
M11BC% !11BC% !11BC% !36?!"@98]!2%F=_+B&6[GL*MP6ZPC/WG/5C6<I]
M(EPA?5C8;?:=\G+>GI5BBBH2-TK!1113&%%%% !1110 4444 %%%% !1110
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MLG%H[85(SV+%%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112.ZHI9C@"@!20!DU
M&H>Z8K%P@ZO_ (410O=D,^4A[#NU:*JJ*%4  =A6+FY;;&L*?5C(H4A3:@Q[
M^M2444)6-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D"*
MI)"@%N20.M+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5)/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"CBD9E12S' '4FJJ"74F*Q$QVPZR=V^E1.HH^I48N6PYII+B0PV@R?XI.RU?
MM;..U3C+.?O.>IJ2"".WC$<:@*/UJ2LDFWS2W.B,5$****HH**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"G)_K&Y[TW\:63_6-]:;6RV.1[B_C1^-)13$+^-'XTE%
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M244 +^-'XTE% "_C1^-)10 OXT?C244 +^-'XTE% "_C1^-)10 OXT?C244
M+^-'XTE% "_C1^-)10 OXT?C244 +^-'XTE% "_C1^-)10 OXT?C24$@#)(
M'>@!?QJC<WS>=]EM%\VX/IT3W-0M<SZE.;;3^(QQ).>@^E;%CI\%A%LB&2?O
M.>K&N255U'RT]N_^7^9K"GU9#I^F+:DS3-YMRWWG/;V%:%%%5&*BK(W"BBBJ
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M***HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!I49R*4=*6B@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDUS#%;*[.T5Y9R"012C:VWHP'KQZ55FF4VI+0ZJBFJP=%<=& (I:LQ%HI**
M%HI** %HI** %HI** %HI** %HI** %H')P*%4L< <U:CB"#/4^M)NQ<8.0V
M*';\S=?3TJ:BBLF[G2HI*R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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MM6E4*, <5,I6-(4[ZL1$"# _.G445D="5@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *<O^M;ZTS%/E_U
MK?6F5LMCD>X8HQ113$&*,444 &*,444 &*,444 &*,444 &*,444 &*,444
M&*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,4
M44 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &
M*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,444 &*,44
M4 &*,444 &*,444 &*,444 &*,444 &*,444 &*,45+%"7Y/"TF[#2;=D-CC
M+GV]:MJH08 H  & .*6LW*YT1@HA1114EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img39825204_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (3 \\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFE/'RXZXXQFNJHJ?:LT^I1VOI9+IT5M^AYU=02W=KH=M;Z#=P36<\?GR&WP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J][96^HVCVMW'YD$F-
MRY(S@Y'3W%6*Y'XG,5^'FJE200(^0<?\M%IK?04DFFFKHN_\(/X=_P"@</\
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M5/\ D?\ X%_P _L[#?R1^Y';?\(/X=_Z!P_[^O\ _%4?\(/X=_Z!P_[^O_\
M%5Q/FR?WC1YLG]XT?ZU3_D?_ (%_P _L[#?R1^Y';?\ "#^'?^@</^_K_P#Q
M5'_"#^'?^@</^_K_ /Q5<3YLG]XT>;)_>-'^M4_Y'_X%_P  /[.PW\D?N1VW
M_"#^'?\ H'#_ +^O_P#%4?\ "#^'?^@</^_K_P#Q5<3YLG]XT>;)_>-'^M4_
MY'_X%_P _L[#?R1^Y';?\(/X=_Z!P_[^O_\ %4?\(/X=_P"@</\ OZ__ ,57
M$^;)_>-'FR?WC1_K5/\ D?\ X%_P _L[#?R1^Y';?\(/X=_Z!P_[^O\ _%4?
M\(/X=_Z!P_[^O_\ %5Q/FR?WC1YLG]XT?ZU3_D?_ (%_P _L[#?R1^Y';?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KD?B?_P D[U7Z1_\ HQ:ZZJ>JZ79ZUILVGW\7FVTV-Z;BN<$$
M<CGJ!0@9XIX/_P"19M_]]_\ T(UNUW=EX+T'3[5;:VLV2)22%\YSU.3U-6/^
M$8TG_GV/_?QO\:^2Q618FM7G4BU9MO=]7Z&L9I)(\\HKT/\ X1C2?^?8_P#?
MQO\ &C_A&-)_Y]C_ -_&_P :P_U=Q7\T?O?^0_:(\\HKT/\ X1C2?^?8_P#?
MQO\ &C_A&-)_Y]C_ -_&_P :/]7<5_-'[W_D'M$>>45Z'_PC&D_\^Q_[^-_C
M1_PC&D_\^Q_[^-_C1_J[BOYH_>_\@]HCSRBO0_\ A&-)_P"?8_\ ?QO\:/\
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M#48#/;N8_E90N\@^A [>] &W16-IOB*+58K>:VL+\V]P R3-$ N#WZYQ6S0
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MH&Y(X@GEG\\D?X5/?Z5'=:-)IT.V%=H$9 R$(((X],@50>UU2%KK4Y! ]_\
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MMJ-.Z]7_ )G%B<THX:I[.H]?0Z"^^'UM>J@:]D39GHF<_K5/_A5UI_T$9?\
MOV/\:R_^%GZE_P ^5I^3?_%4?\+/U+_GRM/R;_XJO>PV$JX:FJ5%6BNAY-;%
MY77FZE17;]34_P"%76G_ $$9?^_8_P :/^%76G_01E_[]C_&LO\ X6?J7_/E
M:?DW_P 51_PL_4O^?*T_)O\ XJM^7$]_R,O:Y1_+^9J?\*NM/^@C+_W['^-'
M_"KK3_H(R_\ ?L?XUE_\+/U+_GRM/R;_ .*H_P"%GZE_SY6GY-_\51RXGO\
MD'M<H_E_,U/^%76G_01E_P"_8_QH_P"%76G_ $$9?^_8_P :R_\ A9^I?\^5
MI^3?_%4?\+/U+_GRM/R;_P"*HY<3W_(/:Y1_+^9NI\.K9$5?MTAP,?ZO_P"O
M3O\ A7EM_P _TG_?O_Z]8'_"S]2_Y\K3\F_^*J]_PL*__P"?6V_)O\:Y*E*<
M/BZGM83&4,0FJ/V;&C_PKRV_Y_I/^_?_ ->C_A7EM_S_ $G_ '[_ /KUG?\
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M444I2<G=ETZ:IQY8A1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>*K-JWB(Z)K>NIK(":9>SI':&W0K)&C8VLW7IT(Z>]%@N>CU'#/#<(7@E21
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M_9^9]'P__P O/E^H4445PGT85ZAX&_Y%T?\ 75OY"O+Z]0\#?\BZ/^NK?R%
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M1=,O4N[:U8219\D/,[I#GKL4DA?P%5KCP'X=NI)VEL6*SL7>(3R+'N/5@@.
M?<"NDHHN*R,2_P#"6BZG>?:[FU8S%!&Y29T$BCH'"D;A]:OV&E66FZ6FFVL
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M37N^WI]SRO[.Q7_/MG&T5V7_  K36_\ GK9_]_&_^)H_X5IK?_/6S_[^-_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTME!IMJWG30N<^?*,*.20=JY;ZD5M6GA:WM[FQFFOKV[6P!%K'<.I6/(QG@
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M5UW_ *!=U_W[->L?\)CX?_Z"4?\ WRW^%'_"8^'_ /H)1_\ ?+?X5U_6*O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45#=W<%C:2W5U*L4$2EGD<X"@5AVW
MC33+BZMX9(;ZT6Y;;;375LT<<Q/0*Q[GMG&: .BHJ%[RUCN4MGN85G<96)G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2%SNV<XY^E7&A?J<]3,E!M<NU^NNBOM;[CU:BN$N[+3K/Q''IVIS/%I*6Q>
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M%% !1110 4444 %%%% !1110 444A=0P4L QZ#/)H 6BD9U4@,P&3@9/6EH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X+QP]U%XBTF:SYFAC>4#U"_,1^0-=[56;3;2XOH+V6$-<0
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M3_SQN_\ OA?_ (JK>F^+M/U2^CLX([@2/G!=1C@$]C[5Y56_X,_Y&BU^C_\
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M)A,5;=._. 0!]U<?BU%@N=51112&%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR%6/#^CG1=-,$DWVBYEE>>XGV[?,D8Y)QSCL/PK5HH"P4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D9E12S,%4=23BEK*\2?\@&Y_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-
M\,^*Y;NYU.WU*5<V^Z6-]H7Y%/S?EQ4>@^,))[+6-1U%O]'MW0Q(J@$!B<+[
M]J?+X$\ZS6(WNV07+R,Z*1NC<#*=?:KI\(120ZO;R3 0WS(8PBX\K;G'?GM7
M4W1U\SQ:<<>N5/I?KO=.U_1Z$EEXI\_4(+.[LOL[W"%X"LZR!L#.#C[IJK%X
MUD:R34)-)ECT\R^4T_F@E3G&=N,D58TOPW-:7<<UP]AB*/:HM[-4+'&-S'KG
MZ5%_PB<O_")'1?M:;S+YGF[#C[V>F:G]U?\ X<U_VUQ^3[;Z63_'L5IO$HTO
M5M5.R[NBD\40B:8;%+ GY!CCI6C'XI6&XN[?4[*2SFMX/M&W>)-Z9QP1WR<8
MJI=^#Y;F_N[D7B*)[B*8*4/&P$8Z]\U8UGP^EUJ-WJ4\KF!K V[11)E^N[</
M4^U-^R=OZ["7UR/,UWT6EMW\^Q$?%MS$+)[G1I88;V14AD,RG@G@D8XXYQ5?
M3?$@A1K:".\OKV>[D2.*64' 7&3NQPO_ ->L26:?4IM"LX=3AOA#<(1%'"4=
M%7&6DYX(''^-;\'A"XLY4N[6^1+V.XDE1FC)0J^,J1GZ\^]4XTXJS_4PIUL5
M5E>#;2_P];7M;3O8?/XT6VB=)-.E%['.L$EMY@R"P)!![@XJ0>)[\W[Z:-"E
M^WJGF>7YZ[-GKN_3&*@E\'37$OVNXO4>]DNDGE<1X7:N<*HSQ]:V%TAE\3OJ
M_G#:UL(/+V\]<YS4/V26GZG3!8R3]YM*Z_EVUU]=C/'C"&:SLVM;.6:\NW:-
M+;<%(*_>R>F*B?QG]F-^EYIDT,MFJET$@;)8@#!Z8YZTV+PA/:Q6TMM?(E];
M3O)'(8\J5?&5(S3D\,:D;K4;N;58_M-XBKN2#Y5QCC!)R,#%.U'^K]_\B.;'
M65]_^W;;?GS?(UM(U6?4?,$]BUN4 *NL@DC<'^ZPX-)XD_Y %S_P'_T(56T'
M09=*N[JYEFAS/@>3;1F.-<=\9/)JSXD_Y %S_P !_P#0A7GYCR_5ZO+MRO\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&Q]_8,<_6@#1HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I" PP0"/0T44   48  'H*6BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img39825204_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #X H(# 2(  A$! Q$!_\0
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MCG%A:BUEC;;/ 8@CH>VX#^=%OZL%_P"KFO1110 4444 %%%% !1110 4444
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M-0_\%Z?XT?V7XC_Z&H?^"]/\: -VBL+^R_$?_0U#_P %Z?XT?V7XC_Z&H?\
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MU^\WX?SJ/='_ ,\O_'JFMV4L=J8Z=_>@"W1110 4444 %%%% !1110 4444
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MFLZ^'K1IMRJ-KMK_ )G3@<SPU7$0IPH*+?733\#V"G/]\UGG7-'_ .@O8?\
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M"C@'&0>O-%I=P7ULES;2"2%\[7'0X./Z5-3U3)]V<>Z9GRZ)833V4[PDRV8
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M\H:[*&=4*,.13C]Z/&QW#SQE;VLN9?(XG^U-/_Y_8?\ OJL%[RV/C9+@3IY
MBP9/X<X]:]4_X36V_P"A1F_*&H/^%E:4M_\ V:?"TWVLKN$>V+IC.<]*TEG-
M*K:THZ:[]C*APXL/S:R]Y..W<Y#^U-/_ .?V'_OJC^U-/_Y_8?\ OJNV_P"$
MUMO^A1F_*&C_ (36V_Z%&;\H:K_6"C_-'[S#_5)?S2^XXG^U-/\ ^?V'_OJC
M^U-/_P"?V'_OJNV_X36V_P"A1F_*&C_A-;;_ *%&;\H:/]8*/\T?O#_5)?S2
M^XXG^U-/_P"?V'_OJKFA26.I>,=$@!AND\V1GC(WC&P\D5U7_":VW_0HS?E#
M5S2?&%G=ZS:V!T&:PENBRQRD1X) S@[>>E3+.:5=>RC*-WV9OAN'%A:L:]Y>
M[W1O?V'H_P#T"+#_ ,!U_P *<^AZ/O/_ !*+#_P'3_"KM.?[YK ]DSO[#T?_
M *!%A_X#K_A1_8>C_P#0(L/_  '7_"K]% %#^P]'_P"@18?^ Z_X4?V'H_\
MT"+#_P !U_PJ_10!0_L/1_\ H$6'_@.O^%']AZ/_ - BP_\  =?\*OT4 5H-
M"T<AS_9%AG&/^/=?\*B.AZ/D_P#$HL/_  '7_"M6#[DG^?6H3U/UH S_ .P]
M'_Z!%A_X#K_A3XM)TRWE66'3;.*5#E72!0RGV(%7** '^:_K1YK^M,HH ?YK
M^M'FOZTRB@"0R-L7GUI/-?UI#]Q?QIM #_-?UH\U_6F44 /\U_6CS7]:910
M_P U_6@2OD<]Z92C[P^M $DDC"5@#WIOFOZT2_ZU_K3* '^:_K1YK^M,HH ?
MYK^M'FOZTRB@!_FOZU-;NS,V3Z?SJM4]K]YOP_G0!=HHHH **** "BBB@ JG
MJRW#Z/>K:Y^T&!Q'CKNP<8JY133L[DRCS1:.%BNM%_X0M[: 0B_2R<.FS$BN
M%._/&1SGFF)<:CI<'EV=U<3M)HPN%21MVQP0,J.V 3Q[5W?EIDG8N3UXZTH5
M000HR!CIVK7VJ['#]2EI[UFE;16_4\ZO;MI-.U*&TU&XO[$Z>))7F??LEW#
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MG^%;M% &%_:GB/\ Z%9?_!@G^%*NJ>)-PQX67_P8)_A6Y3D^^* ,#^U/$?\
MT*R_^#!/\*Y#Q+<7]SXKLFU#318NMBX11.)=PW]<BO3*X_Q9X?UC5-<LK_3(
M[65(;5H'6>7802V<CBN3'4I5<-.$%=M&V'FH58REL<S15_\ X1;Q5_SXZ;_X
M%G_"C_A%O%7_ #XZ;_X%G_"ODO['QO\ )^*_S/8^NT/YOP90HJ__ ,(MXJ_Y
M\=-_\"S_ (4?\(MXJ_Y\=-_\"S_A1_8^-_D_%?YA]=H?S?@RA7+/_P E'C_Z
MX?\ LM=Q_P (MXJ_Y\=-_P# L_X5F'X=^*V\0C6?)T[Y4V>5]H/IC.<5V8/+
M,53]IS1WBTM5N_F8UL52ERV>S3)**O\ _"+>*O\ GQTW_P "S_A1_P (MXJ_
MY\=-_P# L_X5Q_V/C?Y/Q7^9M]=H?S?@RA15_P#X1?Q5_P ^6F_^!9_PI/\
MA%_%7_/EIO\ X%G_  H_L?&_R?BO\P^NT/YOP91IMO+<P^)M"DM+474XGDVP
MF0)N^0_Q'I6A_P (OXJ_Y\M-_P# L_X5;T?PMKT?B/3;Z_BLH;>S=Y#Y4Y=F
M)4@ #'O79@,LQ5+$PJ3C9+S7^9CB,52G2<8O4Z#^U/$?_0K+_P"#!/\ "E;5
M/$98_P#%++_X,$_PK<IS_?-?6'CF!_:GB/\ Z%9?_!@G^%']J>(_^A67_P &
M"?X5NT4 87]J>(_^A67_ ,&"?X5/97^MS7D4=WX?6V@8X>87BOL'T YK6HH
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M[ @01E7"L#G<2<C(P.326VBWMIH&AJ+,-)8W7GSVRE<MG>,CG!8%@W7M0!T
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M62-#"ZG]N_M'4"2^[R#/^ZY[;<=* 'X/I1@^E3?:%_YY_K_]:C[0O_//]?\
MZU #'!*1\'[OI3-K?W3^59VJZ''J5RMRVI:I;$H!Y=M<[$&.^,=:H_\ "*1?
M]!O7?_ T_P"% &_M;^Z?RHVM_=/Y5@?\(I%_T&]=_P# T_X4?\(I%_T&]=_\
M#3_A0!O[6_NG\J-K?W3^58'_  BD7_0;UW_P-/\ A1_PBD7_ $&]=_\  T_X
M4 ;^UO[I_*G(K;Q\I_*N>_X12+_H-Z[_ .!I_P *5?"<18#^W-=_\#3_ (4
M;VUO[I_*N'\:7VJ0>(["SL]2N;*%[-Y7$./F8/CG(]*V?^$4B_Z#>N_^!I_P
MKDO$6FKIGBVRC6\O;K?8NV;J7S"OSCH:#JP4(SQ$(R5TV1?:=<_Z&34OS7_"
MC[3KG_0R:E^:_P"%+10?4_V?A?Y$)]IUS_H9-2_-?\*/M.N?]#)J7YK_ (4M
M% ?V?A?Y$)]IUS_H9-2_-?\ "L-O$GB5?%JZ0/$5]]G:+?N^7=G&?2MVN2D_
MY*5'_P!</_9:#DQ>#H04.6*UDD=9]IUS_H9-2_-?\*/M.N?]#)J7YK_A2T4'
M7_9^%_D1:T+4M93Q;I5K/K%U=V]T9%DBGVD8"Y!&!P<UZ-M;^Z?RKRJWM!?>
M*]#MVGG@#R2_O('VN,(>AKMO^$4B_P"@WKO_ (&G_"@^:S&G"GB'&"LM#?VG
M^Z?RHVG^Z?RK _X12+_H-Z[_ .!I_P */^$4B_Z#>N_^!I_PH.$W]K?W3^5.
M=6WGY3^5<]_PBD7_ $&]=_\  T_X4K>%(@Q']MZ[_P"!I_PH WMK?W3^5&UO
M[I_*L#_A%(O^@WKO_@:?\*/^$4B_Z#>N_P#@:?\ "@#?VM_=/Y4;6_NG\JP/
M^$4B_P"@WKO_ (&G_"C_ (12+_H-Z[_X&G_"@#?VM_=/Y4;6_NG\JP/^$4B_
MZ#>N_P#@:?\ "C_A%(O^@WKO_@:?\* .F@!"29!Z?XU 0<GCO67IOAR.TNUN
MAJVKS&(Y\N:Z+(WU&.:VC.N?]7^O_P!:@"'!]*,'TJ;[0O\ SS_7_P"M1]H7
M_GG^O_UJ (<'THP?2IOM"_\ //\ 7_ZU'VA?^>?Z_P#UJ (<'THP?2IOM"_\
M\_U_^M1]H7_GG^O_ -:@"(@[%X]:3!]*G,XVK\GKW_\ K4GVA?\ GG^O_P!:
M@"'!]*,'TJ;[0O\ SS_7_P"M1]H7_GG^O_UJ (<'THP?2IOM"_\ //\ 7_ZU
M'VA?^>?Z_P#UJ (<'TH .X<=ZF^T+_SS_7_ZU G7(_=]_7_ZU $<H/FOQWIN
M#Z58><"1ALS@^O\ ]:F_:%_YY_K_ /6H AP?2C!]*F^T+_SS_7_ZU'VA?^>?
MZ_\ UJ (<'THP?2IOM"_\\_U_P#K4?:%_P">?Z__ %J (<'TJ>V'S-^'\Z3[
M0O\ SS_7_P"M4D,H<D!<=._O0!9HHHH **** "BBB@ HHHH **** "BBB@ H
MKFH]8GG\3WVGMJ=M;+;RQI%"8P7E#(&/)/J2.!5N/Q-:/:7EXT4J6EL64R\'
M<RMM*[0=P.>@(&: -JBL&X\40V,-TU]97-O+;PK.8CM9GC+;<K@D$@\$=?SJ
MKK7B2:#3+X0PSVE];B&54D56+1O(%R "1ZC'4&@#J**RX-9\][N$6-P+JV*[
MH#MRP8?*0<XQP>_&#4"^)(GB"K9W!NS=-:?9?EW>8J[CSG;C;SG- &W17.Q^
M+H);2VE6SF$UP)&6W>2-6"H=K$DMCKQC-6)O$D":3'JL-K<3V#1"9YDVC8A[
MX)R<<Y ]* -JBLG3KV:YUS5K=Y T$!A\H8' 9,GGOS4%A>ZCK$EQ<VTT,%K#
M<O B-$7,FP[6).1C)!QCTH W:*YN;Q!<1^)TM@L?]FB5;.1\?-Y[(7'.>F,#
MZM724 %(W3\12UE?\)%ICZE_9RSL;H/LV>6W4=LXQ0 M%3?9F]?TH^S-Z_I0
M Q_N1_[M,K.U7Q'I.DW*6E[<R1S*@8A8';@^X!%4?^$U\/?\_LO_ ("R?_$T
M ;]%8'_":^'O^?V7_P !9/\ XFC_ (37P]_S^R_^ LG_ ,30!OT5@?\ ":^'
MO^?V7_P%D_\ B:/^$U\/?\_LO_@+)_\ $T ;].3[XKGO^$U\/?\ /[+_ . L
MG_Q-.7QMX># _;9?_ 63_P")H W:Y+Q=9^')M2M)]9UN73;I862(1R;=Z9R>
MQ[U>_P"$U\/_ //[+_X"R?\ Q-<?XHU6PUCQ58RV4AE6.Q=6+Q%<'?Z,*PQ-
M;V%&56U[%1;3NG9DOV/P1_T.EY_W_P#_ +&C['X(_P"ATO/^_P#_ /8UF[5_
MN+_WR*-J_P!Q?^^17A?ZP?\ 3O\ '_@&WMJW\[^]FE]C\$?]#I>?]_\ _P"Q
MH^Q^"/\ H=+S_O\ _P#V-9NU?[B_]\BC:O\ <7_OD4?ZP?\ 3O\ '_@![:M_
M._O9I?8_!'_0Z7G_ '__ /L:@_L3X>&\^VGQ=<?:P-HD^T?,!Z=*J;5_N+_W
MR*YAU7_A8<?RK_J/3_9K?#YU[;F]RW*F]^WR)E5JO>3^]G<_8_!'_0Z7G_?_
M /\ L:/L?@C_ *'2\_[_ /\ ]C6;M7^XO_?(HVK_ '%_[Y%8?ZP?]._Q_P"
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MY/!5M+I<\#W<_P!MEG-T;D.P FW;@WE[MO& /H*Z=<A1N.3CDBEHH *:P'7
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M.FT4 .\Q_P"^WYT!WW#YVZ^M-I1]X?6@!\CN)7P[=?6F^8_]]OSI9?\ 6O\
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MX;M'$45N_P#"!^)_^>^D_F]'_"!^)_\ GOI/YO7J?7*/<^._L''?RK[T>?\
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MQ_N+^5'G'^XOY4 (8WV+\C=^U-\M_P"XWY5(9OE7Y%[]J3SC_<7\J &>6_\
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M0$ES("4C:-EW8ZXR*VZ\?TV]CL/%FBW4RRO'')+D11EVY3L!7H/_  F&F_\
M/IJW_@ ]>9B:*HU'!.Y]!E^+>+H*LU:]S?HK _X3'3?^?75O_ !Z/^$QTW_G
MUU;_ , 'KG.TWZ<_WS7/?\)CIO\ SZZM_P" #TK>,=-+$_9=6_\  !Z -ZBL
MO3=?LM5O!:P0W\;E2V9[1HUX]SQ6QY+>J_\ ?5 $=%2>4WJO_?5'E-ZK_P!]
M4 1T5)Y3>J_]]4>4WJO_ 'U0 ^#[DG^?6H3U/UJQ#&0K@D<^A^M1&)LGE?\
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M7E4JS:D[?EZ&!]I_Z=;[_P !7_PH^T_].M]_X"O_ (5O?\+!\4_W=+_[X?\
MQH_X6#XI_NZ7_P!\/_C3_P!9Z7\R^YG)_8^7?\_)?U\C!^T_].M]_P" K_X4
M?:?^G6^_\!7_ ,*WO^%@^*?[NE_]\/\ XT?\+!\4_P!W2_\ OA_\:/\ 6>E_
M,ON8?V/EW_/R7]?(X;RKG_A+_MWV"^^S>7MW_9GZX],5M_:?^G6^_P# 5_\
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M:2OI3US"^Q>*O^@]IW_@ ?\ &C[%XJ_Z#VG?^ !_QK=HH POL7BK_H/:=_X
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MYDOJ?RH\R7U/Y4 1TH^\/K3_ #)?4_E2B27<.3U]* &R_P"N?ZTRII))?-8
MG /'%-\R7U/Y4 1T5)YDOJ?RH\R7U/Y4 1T5)YDOJ?RH\R7U/Y4 1U/:_>;\
M/YTSS)?4_E4UN[L3N)[=O>@"U1110 4444 %%%% !1110 4UXTDV[T5MK!EW
M#.#ZCWHHH 1X8Y&#/&C, 0"5!(!ZC\:B2QLXX_+2U@5",;5C &,YQCZ\T44
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M^Z*** #RU)SM%'EI_=%%% !Y:?W11Y:?W1110 >6G]T4>6G]T444 'EI_=%
,11T%%% #J*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img39825204_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ J\# 2(  A$! Q$!_\0
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M;(JQ4-H\4EG"\ VPL@*#&,#''%353W)6P4444AA1110 4444 %%%% !1110
M4444 %%%% '/:GJ>K66J)(L5N--5TB*,?WLI;J5^GIWKH:X_Q)>P7-]'8/:7
M(U2&57L9(U)!SC+9Z# R#FNO&<#/7O0M@ZBT444 %%%% !1110 4444 %%%%
M !1110 4444 %8M[KC0^(K'2X8MZREO/D[)\N57ZGK6U7$RZ/K=IXDL)?[0@
MEMI+V29AY/S!2O0GZ<4=0Z';4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1137;
M8N30 ZBJ_P!J3U/Y4?:D]3^5 %BBJ_VI/4_E1]J3U/Y4 6**K_:D]3^5+]I3
M!.3Q[4 3T57^U)ZG\J/M2>I_*@"Q15?[4GJ?RH^U)ZG\J +%%5_M2>I_*C[4
MGJ?RH L457^U)ZG\J47*$@9/Y4 3TTHK'+*#]1437"J<'.?I2?:D]3^5 %@#
M P.E%5_M2>I_*C[4GJ?RH L457^U)ZG\J/M2>I_*@"Q15?[4GJ?RH^U)ZG\J
M +%%0?:4QG)Z^E)]J3U/Y4 6**K_ &I/4_E1]J3U/Y4 6**K_:D]3^5'VI/4
M_E0!8HJO]J3U/Y4?:D]3^5 %BBHDG5R0N>!GD4TW2 X)/Y4 38&<X&1WI:K_
M &I/4_E1]J3U/Y4 6**K_:D]3^5'VI/4_E0!8HJO]J3U/Y4?:D]3^5 %BBJ_
MVI/4_E2_:4P#D\^U $]%5_M2>I_*C[4GJ?RH L457^U)ZG\J1KZ"/'F2HF>F
M\@9_.@"S153^TK3_ )^H?^^U_P :/[2M/^?J'_OM?\: +=%5/[2M/^?J'_OM
M?\:5=0M6Z7,/_?P?XT 6J,54.HV@./M,/_?:_P"-']HVG_/S#_WVO^- %NBJ
MG]I6G_/U#_WVO^-']I6G_/U#_P!]K_C0!;HJI_:5I_S]0_\ ?:_XTHU"V8X6
M>-F/0*P)_G0!:HJO]J3U/Y4?:D]3^5 %BBH#<H,<GGVI/M2>I_*@"Q15?[4G
MJ?RJ:-PZAAT- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "J&K:F-+@
MA?[.\[S3I B(0,LW3D\8J_6)XFLKB^M]/CMA*&6_A=GBQN103EN>./I0!-::
M];3+=BZ!LI;-PDZ3L,+D94[@<$$&K1U73Q;1W)OK802$A)/-7:Q&<@'//0_E
M6/>V,^C6AETV&2ZN;BZ5[JXE7S90,8WA1@' P !C K%L=(U%_L37-G(VW79+
MIM\:KB,H</MR0.3^= '9C4K$V7VT7<'V7_GMY@V=<=>G7BF-K&F)#'*VH6HC
MD!*,95PV#@XYYY(%<Q+IM]#>277V*22"'6C=&)0"70Q!=ZCOACGUX-:7V9KW
MQ/I>H"PDC@C@N/FE0*4=BN"1V) /O0!LC4;(WILQ=P&Z'_+'S!OZ9Z=>E-75
M=/>>2!;VW::)2SH) 64#J2/05RNF:-,EV+;4!J;21:B]VC1A/(;+%E8MC/0X
M()SVZ4EM'K5YXBTB>ZLG@2VEG$J)"%2(%6 P^<N#@'@8H V;+Q-;:II\%W8&
M%]]P(726=4* L5SWR3C('>M3^T;+[;]B^UP?:O\ GCY@W],]/I7*6MA>KH>G
M6+V4XFM-5623*_*4\UFW ]Q@@UHZ"DU@\]A=:?,TS7LTPN @,;!F+!]WK@A<
M=>/2@#HZCFYC8#DX-25A6/A?3-'OI-0M4F$[!L[I68<\G@T 6]C_ -T_E1L?
M^Z?RJ;[5_L?K1]J_V/UH AV/_=/Y5S'B+QWHGA;4H+#49)?/E0NPC7/E+V+?
M7M76_:O]C]:\H^('PXU/Q)XI75=+DA$=Q&%N!*V/**C (]0: .X\,^)=/\6:
M8U]II?:CE)(I!AXS[CWK:"-M;Y3T]*XKX9>$[OP?IEVVHE3>W<@+1(V5C5>!
MSW)S7=BYR"=O3WH @V/_ '3^5&Q_[I_*IOM7^Q^M'VK_ &/UH AV/_=/Y4;'
M_NG\JF^U?['ZT?:O]C]: (=C_P!T_E1L?^Z?RJ;[5_L?K1]J_P!C]: (=C_W
M3^5*B/O'RGKZ5+]J_P!C]:5;G+ ;?UH CE1B^0I/X4S8_P#=/Y58>XV-C;G\
M:;]J_P!C]: (=C_W3^5&Q_[I_*IOM7^Q^M'VK_8_6@"'RW_NM^5<+JWQ7\.Z
M1JMQI[I=7$D#;'D@4%-W< ^U>@?:O]C]:\&UOX1^(6UN\DTQ8)[*24R1.\H5
ML,<X(]B: /0Y_B3X>M_#$&O&25X9Y/*6W4#S0PZ@CVZUU%C=0ZE807MFXFMI
MT#QNO0@UY!<?"+5?^$/M4AEB;64N&EE@+XC"L ,!O48!KU3PII8\,^&+'2 _
MG-;QX=^F6)R<>V30!H3R):VDEQ<,(H8@7=VX"J!R36%X7\7Z5XOBN7TQI UN
M^UXY1AL=F ]#6OKMFFN:!>Z7(QB6ZB:+>.=N1UKB/ACX(O\ PC<7][JC1_:)
M@(8XXVR-@.=Q/J?2@#L-<U>T\/:1/J>HL4MX1T ^9SV5?4FL/PY\0M#\4:F=
M/L3/'<>7YBK,N-_J![BK/Q \/R^+O"\EA;,([J.19H=Q^5V'\)],YKB? ?PT
MU?0_%4&JZL84BM4+1K$^XNY&,'T S0!ZSL?^Z?RHV/\ W3^53?:O]C]:/M7^
MQ^M $.QNZD?6DVGV_.F:E!!JNG36-RC^3,-K['*MCV(Z5S'_  KSP]_<O_\
MP-?_ !H ["W!#MG'3UJ-E.X]/SKF(/AUX>,F=M]P,\WCG^M1M\._#H/W;_\
M\#7_ ,: .IVGV_.C:?;\ZY7_ (5YX>_N7_\ X&O_ (T?\*\\/?W+_P#\#7_Q
MH ZK:?;\Z-I]OSKE?^%>>'O[E_\ ^!K_ .-'_"O/#W]R_P#_  -?_&@#JMI]
MOSHVGV_.N5_X5YX>_N7_ /X&O_C1_P *\\/?W+__ ,#7_P : .JVGV_.GE#L
M7IW[UR7_  KSP]_<O_\ P-?_ !IQ^'GAW8OR7_?_ )?7_P : .HVGV_.C:?;
M\ZY7_A7GA[^Y?_\ @:_^-'_"O/#W]R__ / U_P#&@#JMI]OSKRWQ1I]MJ/C3
M5!>QF80B%8P7.$!3)QCWKJ/^%>>'O[E__P"!K_XURDNEVVD>)-7LK,2^0AA(
M\R0NV2F3R:\_-)RAAI.+L]/S._+8QEB4I*ZU_(S_ /A'-(_Y\Q_WVW^-'_".
M:1_SYC_OMO\ &M7:?0T;3Z&OE?K-;^=_>SZ;ZO1_D7W(RO\ A'-(_P"?,?\
M?;?XTH\.Z0/^7,?]]M_C6IM/H:-I]#1]9K?SO[V'U>C_ "+[D97_  CFD?\
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M1:G'X;\/7FJW*%TMUW!%ZL3P!^>*XGPA\5+'6(KA-?>VTRYC(:,@G9(I_J*
M/0Z*P?\ A-_"W_0>L_\ OH_X4?\ ";^%O^@]9_\ ?1_PH WJ*P?^$W\+?]!Z
MS_[Z/^%'_";^%O\ H/6?_?1_PH WJ*P?^$W\+?\ 0>L_^^C_ (4?\)OX6_Z#
MUG_WT?\ "@#I;;[[?[M0M]XUBV_CCPL),?V[9DD8 W'_  J-O''A4MQKUG_W
MT?\ "@#=HK!_X3?PM_T'K/\ [Z/^%'_";^%O^@]9_P#?1_PH WJ*P?\ A-_"
MW_0>L_\ OH_X4?\ ";^%O^@]9_\ ?1_PH WJ*P?^$W\+?]!ZS_[Z/^%'_";^
M%O\ H/6?_?1_PH WJ<?N+^-<_P#\)OX6_P"@]9_]]'_"G-XW\*^6O_$^L^_\
M1_PH O7FLZ5ITJQ7VI6MM(PW!)9 "1ZXJO\ \)3X=_Z#EA_W^%>8:W-INM>+
M-7O;<P7D#/&$EQN'"#(&?>JO]GV7_/G;_P#?L5R5,6H2<;&,JRB[6/6?^$I\
M._\ 0<L/^_PKF=6T[P3K.JS:C/XF\F>8*'$%X%4[1@<5QG]GV7_/G;_]^Q1_
M9]E_SYV__?L5F\9%JSB)8FSNCIO^$<\"_P#0VW'_ ('T?\(YX%_Z&VX_\#ZY
MG^S[+_GSM_\ OV*/[/LO^?.W_P"_8J/K%+^1?@5]=GW?WG3?\(YX%_Z&VX_\
M#Z>GAKP)N(/BRX/'3[>*Y"\L+,6-P1:0 B)B"(QQQ6?X:L[630H7DMH78LV6
M9 3UJU6I<G-R+\"OK<[7N_O.]/ASP+GCQ=<?^!XJ)?"GP^6X:X7Q1*)F&&D%
M\-Q'N:YW^S[+_GSM_P#OV*/[/LO^?.W_ ._8J5B::VA^1+QDGO?[SIO^$<\"
M_P#0VW'_ ('U8L_!WA#49_(L?$E[<S8W>7%>[CCUQ7(_V?9?\^=O_P!^Q6AX
M:NM*T+QA:75U);V4!M9D,A&T$G;@5=.K2G)1Y%^!4,7.3M=_>=9_PK/1_P#H
M(ZO_ .!-6M-\ :3I>J6VH17>HRS6S%XUGGW+D@CI]#5O_A-_"W_0>L_^^C_A
M1_PF_A;_ *#UG_WT?\*ZU3@G=)?<;.I-JS;-ZBL'_A-_"W_0>L_^^C_A1_PF
M_A;_ *#UG_WT?\*L@Z!NB_2FUFV/B70M5NXK/3]5MKFY=25C0G) ZFM?[/)_
M=H BJ_;?ZA?\]ZJ_9Y/[M6X%*1!3UH DHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#'O=':\\16=\ZPO;PPNC(XR23TP,8K-_X1BZ5;I8V
MMU634TNT ) "*1QTZ\5U5%6JDD<TL)3DVWUU_"QS?_"/7,/B?^T;::);;;(R
MQMG*R. "<>A(!Z^M0IX:N[W4I+K4%LK</ \+BSW9FW#&6R!T_&NJHI^UD)X.
MD_2]_F<]8:9K,5FNE74ED]@L9A,J;O-9,8 QT!]\GI3M(L=;TU(+!Y+%[&#Y
M5E&[S&3L-O0'WS6_12=1L<<+&+33>GGT[!50V=K;EI8;6&.0@Y=8P#^8JW4<
M_P#JF^AJ#I*7F-[4>8WM3** '^8WM1YC>U,HH ?YC>U*)&VMTZ5'3A]UOI0
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M?\*LT4 5O[.T_P#Z!]G_ -^%_P */[.T_P#Z!]G_ -^%_P *LT4 5O[.T_\
MZ!]G_P!^%_PIQT[3]B_\2ZSSS_RP7_"IZP-8\9Z=H]\;!K6_NYXP#*+6'<(\
M\@$^I'-)M)78TF]$>?\ B26RLO&NM0[[>W7?$1'D(/\ 5CH*SO[0L?\ G]M_
M^_@KLKGQ3X8O;AKB[\)7\\S8W226(+'\:A_M_P '_P#0E7?_ (+Q7%4HTIR<
MN?\ (REA92=[/[CD_P"T+'_G]M_^_@H_M"Q_Y_;?_OX*ZS^W_!__ $)5W_X+
MQ1_;_@__ *$J[_\ !>*CZM2_G_(7U27G]QR?]H6/_/[;_P#?P4?VA8_\_MO_
M -_!76?V_P"#_P#H2KO_ ,%XH_M_P?\ ]"5=_P#@O%'U:E_/^0?5)>?W'&WE
M_9-8W %Y 28F  <<\50\-7EK%H4*27,*,&;*LX!ZUW?_  E7@;[9]D'A*?[4
M%W>3]A&['KBK*>(/!^XY\%W8XZ_V>*OV%-1Y7+?7H-89VLK_ ''(?VA8_P#/
M[;_]_!1_:%C_ ,_MO_W\%=8=?\'Y_P"1*N__  7BC^W_  ?_ -"5=_\ @O%1
M]6I?S_D+ZI+S^XY/^T+'_G]M_P#OX*V/!SV5]XWM8\V]RHM)R5.' ^[SBM3^
MWO!__0E7?_@O%='X7DT'48)=0TC1UL9(Y&MWWP".0$ $CZ<BM:-"$9\T97L-
M8=P?,S8_L[3_ /H'V?\ WX7_  H_L[3_ /H'V?\ WX7_  JS178:%;^SM/\
M^@?9_P#?A?\ "C^SM/\ ^@?9_P#?A?\ "K-% $:6EI Z20V=M$X'WDB"G\Q4
M_F-[4C=%^E-H ?YC>U7+<YA!JA5^V_U"_P">] $M%%% !1110 4444 %%%%
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M'_34O_ %_P#"NKWMZ_I1O;U_2@#E/^%A^'_34O\ P!?_  H_X6'X?]-2_P#
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M'DM(8&3*$[@(_85Q9A%RP[45=Z?F=6#DHUDVS7W'U-&X^IK#_P"$OT'_ *"
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M 'U0$AP<;<=^: *E%6_+@]4_[ZH\N#U3_OJ@"I15ORX/5/\ OJCRX/5/^^J
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MW+7.0^P>)?\ H5;W_OXO^-'V#Q+_ -"K>_\ ?Q?\:V?[5\:_]!O3_P#P$/\
MC1_:OC7_ *#>G_\ @(?\:Y?88;^KB_LK^[^)C?8/$O\ T*M[_P!_%_QH^P>)
M?^A5O?\ OXO^-;/]J^-?^@WI_P#X"'_&C^U?&O\ T&]/_P# 0_XT>PPW]7#^
MRO[OXF%<:9XFGM9H1X7O 9$*@F1>,CZU5T3P]XITW2X[-_#5T[(6)82*!SSZ
MUI:_XR\9Z#:P3OJ=A.)91$%%MC&>_6M==7\:K_S&M/Y'_/H?\:OV5!1MT8UE
MV\%'\3$^P>)?^A5O?^_B_P"-'V#Q+_T*M[_W\7_&MK^UO&I_YC>G_P#@(?\
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M:4!4Y'TQ6=5^V_U"_P">] $M%%% !1110 4444 %%%% !1110 4444 %%%%
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M0_E1M;T/Y5-YZ?\ /+]://3_ )Y?K0!#M;T/Y5EWOB+2-.U>TTF\O4BOKO\
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M^59>BZ*^BSR2R:QJ.HB1 H2[<$)SU&.];7GI_P \OUH AVMZ'\JO6XQ"N?\
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MHV-Z4J(V\<=Z %F^_4>:EF4E^!7,ZWXUT7P_K=EI-_*PN+K'*C*P@G +^@-
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M]&_Y\5_[[;_&I_M2/G_7S-?[*K?S+\3H?^$"E_Z'63_OB.C_ (0*7_H=9/\
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M;HOTIM/9&PO';M2;&]* &U?MO]0O^>]4MC>E7;<$0KG_ #S0!+1110 4444
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M=R[RYVGU'RU)Y/P\_P"ADUK_ +[?_P")K66!DX1CS;7_ !,H9G"-24^5ZV_
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M%N&^]@]_2@#M?LS_ -Y:/LS_ -Y:9YTG][]*/.D_O?I0!)]F?9C*]:3[,_\
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M_OHT?\)OX5_Z#]G_ -]&M7^SM/\ ^@?9_P#?A?\ "C^SM/\ ^@?9_P#?A?\
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MKTI/LS_WEI&F?"_-V]*;YTG][]* '_9G_O+5J%2D84]1Z52\Z3^]^E7(&+1
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MJ77_ )\7_P *;_PL3P_Z:E_X O0!U-%<M_PL3P_Z:E_X O1_PL3P_P"FI?\
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M^WYTVB@!WF/_ 'V_.G"1]K?,WYU'3A]UOI0 >8_]]OSH\Q_[[?G3:4*6Z#-
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M("0.Y (P.YK6MM,NI=:&K:@T(EBA,$$,)+*@8@LQ8@9)P.PP!WH V*PM/O\
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M"_Y[T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img39825204_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA=&AE=R!/
M)T1O;FYE;&P    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M,@  DI(  @    ,T,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \P;PWJS?#0Z>;&0W)U9IC%CG89F;/
MTP<UO:;I%[X;\336%G;O-X>U,,X"$C[%*1D@8Z*W/3H<5V-%.XK'/IX>T[0+
M.]N=/L;F\=XR'MY+J2;S1_= =B*YBS\.1:QXCTV:R\,#1+&PF-Q+--$$DE8
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M;N\W^6]S#$L8V(SG)60GHI[=: /4J*** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH *\2\4?\ )Y/@S_L"R?\ H%Y7MM>)>*/^3R?!G_8%D_\ 0+R@#VVBBB@
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M!U[ 5V<S^K6L>0\$_P"TOK'-IV^5NVQWG]IZW_T+_P#Y.I_A1_:>M_\ 0O\
M_DZG^%;-%<-UV/=L^YC?VGK?_0O_ /DZG^%?/6J>"/$[:Y*&T6Y5[J:1HEX.
M[G)P<\\&OIZL*Y\-W%S?QW;>(M422%G,05+;$>[@@9AY&..<UM2J\C=C*I3Y
MS,\*R:]IGA/3;*7P^V^"!4.Z[13^7:M?^T];_P"A?_\ )U/\*U8(VAMXXY)G
MG95 ,L@4,Y]3M &?H *DK)R3=[&BC96N8W]IZW_T+_\ Y.I_A61XFMK_ ,0Z
M*]AJ/A>:XA9U?9!J$:-D'@Y.!7844*5G=('&ZM<\Q\'> K32M<AO;CPYJEI<
M1SL\,KW<#Q1+MX#;9-Q/7HOI7IU%%$YN;NPC%15D%%%%04%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444$9!!Z&@#F]6T
M[7+3Q$=:\-I8W;36R6]S9WLSP!@C,R,DBH^#\[ @J0>.1CF3P[IFK)J5_K'B
M(VD=[>)'"MM9.SQP11[BHWL%+L2[$G:!T '&3RFH3_"G^V&T75K_ $NWFTJW
M2(?:-5$:H-S_ +O_ %@)92"2",C</6MSP5)X0^W:C;^"3#<11I$UQ=6MU]HA
M9COP@?<PW #)'HPH Z^BBB@#*U+Q/HFCWB6NJ:I:VL[*&\N60 JI. S?W03Q
MDX&:;JGBO0]%O!:ZIJ,5O-L61PP)$2,2H=R!A%)! 9L#@\\5Y[?QZBMU\3;Y
M;JP"V[JTUI?6OF+<6ZV4;!';<,1',@X'!+GGD5<T>XMKNU\?W%Y!]GCFM;=S
M#<?\L[<Z=&0ISV#>:/KNH ]-Z]*\2\4?\GD^#/\ L"R?^@7E;FI>!O$WC3P'
MX/\ L/C34?"]W::9']L^R"3-P[Q1?>VR)]TJW7/WCT[^=:/X4U7P?^U5X3L-
M<\3WGB6XDT^:9;N\#;T4Q7*B,;G<X!4GK_$>* /I:BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L:3_B<ZX8#S8Z:Z
MM(.TMQPRK[A 0W^\5_NFKFL7YTW2Y9XD$DYQ'!$3_K)6.U%_%B,GL,FJ#VKZ
M;H]KH]I*S75R2KSCAN3NFF]CR3Z;F45<49SERJY9L#_:&H2ZBPS#&3!:Y] <
M._XD8'LN1]XUITR&&.W@CA@0)'&H1%'10!@"GU+=V.$>6.N_4X3XC^ /^$O6
M&\_M+[']AA?Y/(\S?WZ[ACI[U!\-/A__ ,(L?[6_M+[5]OM$_=>1L\O.&Z[C
MGTZ"NNU_5+33].ECNY2C30N(P$9MQQ[#W%0>%]4L[W1;.WMI2\L%K$)%*,-I
MV@=QZUKSS]GR]">6//?J;=%%%8FH4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!9/_ $"\H ]MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:W<\$TUU=7T*7$SS-F7<V&) . 3[8]JZ:,XQE>1C.FVM'KU+GPCU.^U;P/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[MA+):SVI)(\N<*&'O\ *2/UJQ4E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !117F>JV\NM+X]U2:\NX;K19
M#!ICP7#H+4Q6D<X<*"%)+R'.0=P 4Y H ],KQ+Q1_P GD^#/^P+)_P"@7E=W
MJGBGQ3#H.B7_ (7\'_\ "1-?VPFN5_M**S^S$JA4?.#NSN;ITV^]>+:]XB\8
MR_M+^&=2N? OV?6X=,=+?1_[7A;[0FVYR_G ;5QN?@C/R>XH ^FZS?$B-)X5
MU9(U+.UE,%4#))*'BN(_X3;XG?\ 1(__ "Y;;_XFE7QM\32P#_"0A<\D>)+8
MD#Z8IIV=Q2U31XZ=.A,(B"G(.0<\YKZ/B\):+Y*;K'!VC.97_P :\]@L]9M]
M>;5(OA-=YP&CA_M>TVI("26QYF.<CC&!BM3_ (3;XG?]$C_\N6V_^)KLQ-93
MMRGB93AJU%3]M*]WIOY]UU.P_P"$0\/_ /0(M3]8ZYCXBZ)I.C> =1O]/TJQ
MCN8?*\MWMDDVYE13PP(Z$C\:K?\ ";?$[_HD?_ERVW_Q-9VOZW\1/$>AW&E:
MA\))!;W&W>8O$]J&&U@PP=I[@5S1FU)-L]F44XM(\\\(:[>-XPTNWV6@ANM0
MA65!91 $,RH0/EX!'ICN>IKZ7AL[6VQ]GMH8L=-D87'Y5\_Z9X0\6:1JUMJ,
M/POO9Y8)DN(HV\3V@$14C"L=GS\KNR,<,!VR>]_X3;XG?]$C_P#+EMO_ (FM
M:]2,VN4SHPE%>\>DT5YM_P )M\3O^B1_^7+;?_$UB>%/C/XQ\;Z5)J7ACX8_
M;K2*8P/)_;\,>'"JQ&'0'HR\XQS7,;G<:KXDT9/%.E;M2MQ]G:=9?G'R';C!
M_&NHM[B*ZMTGMI%EBD7<CJ<AAZUYU_PFWQ._Z)'_ .7+;?\ Q-'_  FWQ._Z
M)'_Y<MM_\35-IH23/2:*\V_X3;XG?]$C_P#+EMO_ (FC_A-OB=_T2/\ \N6V
M_P#B:D9Z!?M?K"O]F1V\DN[YA<2,BX^H4\]*R_#MGK.FVT=IJ$=CY"EV\R"9
MV;+,6Z% ._K7)_\ ";?$[_HD?_ERVW_Q-'_";?$[_HD?_ERVW_Q-.^EA6UN>
MDT5YM_PFWQ._Z)'_ .7+;?\ Q-'_  FWQ._Z)'_Y<MM_\32&>DT5Y)XA^*_C
MOPKH-QK.O?"S[)I]MM\V;_A(8'V[F"#Y50D_,P' [UI?\)M\3O\ HD?_ )<M
MM_\ $T >DT5YM_PFWQ._Z)'_ .7+;?\ Q-'_  FWQ._Z)'_Y<MM_\30!Z317
MFW_";?$[_HD?_ERVW_Q-'_";?$[_ *)'_P"7+;?_ !- 'I-%>;?\)M\3O^B1
M_P#ERVW_ ,31_P )M\3O^B1_^7+;?_$T >DT5YM_PFWQ._Z)'_Y<MM_\31_P
MFWQ._P"B1_\ ERVW_P 30!Z317C=U\9_&-EXRLO"ES\,=FMWT)GM[7^WX3O0
M!R3O";1_JWX)!X]Q6W_PFWQ._P"B1_\ ERVW_P 30!Z317FW_";?$[_HD?\
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M2"&%Y65F"*6*HI9C@= !R3[5SNG>.M-OHM?FF@N["'0<&[>\B\LA?*$NX+U
MVD=0#[4 5_ 'A2^\*_\ "3?VA+;R?VMX@NM3@\AF.V*7;M#9 PWRG(&1[FNM
MKG-'\6MJ&J6UAJ.D7>DS7MJ;NS%PR-YJ*5WJ=A.UUWH2I_O<$X.*O@WQ#JNL
MI:7&J&U:WU73H]3M!!$8V@1SGRGRS;B%9/F&,G=QTP =;1110 4444 %%%%
M!7)?%+PI?>-_AKJGA[2I;>&[O/)\M[EF6,;)D<Y*@GHI[=:W]7U6/1K$W4MM
M=W(W;1':0-*^<$]!T''4X'3FL6/QQ;W?A[0=1T^PN;F?7U5K*SRJO@QF0EV)
MVJ%4$DY/8#)(H T?">E3Z#X+T32+QHWN-/T^"UE:(DHS)&JDJ2 <9'&0*UZQ
M-,UZ77='NY-,MEM]1M)VM9[2\?'DS+@E6*9R-K!@1U#+TSQ)X1U6?7?!.AZM
M>!%N+_3[>YE$8(4.\:L< DX&30!KT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '$FWDF^-&J@*0LGAFWC#D?+G[1<<9_$5S.
MBWL&I^&O 'ABVDVZUH]S:_VE9(1YEF+:%ED,H_A!8  G[V\8R#FO7** ,74O
M!WA[5=/NK.[T:Q*70?S&%LF[<XPS@X^][]:U+2UAL;.&UM(UB@A0)&B* %4#
M   J:B@ HHHH **** "BBB@#R+1T>Q^&7@;4KF,I;:5K+7%XSJ1Y,3?:8MYX
MX :523T R3@"NC\-Q6'B?Q9XKU6/R=3T2\6SM8F9!)!.T*NSLA.5=09%&X<9
M0\\5W5% &,WABS.JQWGGW8BC=)%LA-BW5T4*K!.V !\H(7/.,\ULT44 %%%%
M !1110 5QWQ/C>3PK:"-&<_VSIQPHSP+N(DUV-% '"W.N:?X1^(.O7?B":.R
MM]0LK1[.:0X^TM'YJO$G]YQE2%&2=_ J?P1X46V^&OAZRU>V$6J6NEI#Y^Q?
M/M69/F".0=I&<<>E=G10!E:!H*>'K 6<%]=74"*JQ)<>7B(#LNQ%_7-:M%%
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MH"#R0>]=!10!AW^C):/;:EI5M)-=Z9926MG:)(J1L'V<$MTQY:\YZ9X/%6]
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M\':5KB+-I5Q:73"VF&8;FX5QM1U/#X0R,%((XSU48/$%G:V6B^+=*T51;Z1
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M_7M2T_38IE7]Y/=HL18C.%=L!O8]^N*DFU[2+:SBN[C5;**VFC,L<TEPBHZ
M E@Q." "#GIS0 RY\-Z'>ZM'JEYHVGW&H18\N[EM4:5,=,.1D?G6E5>PU&RU
M6QCO-+O+>]M9,[)[>59$?!QPRD@\U8H **** "BBB@ HHHH **** ([B4P6[
MRK%),47(CCQN;V&2!G\:RO[?N/\ H7]6_P"^(O\ XY6S1330CYAUCQOXG77+
MX1ZWJ4""X?;%]H8;!N/& <#'M7L_@GQ+?W'@O39;O3-5OYFB.ZY C82?,><E
MP3^(J6Y^%/A*[NI;B:PD,DSEW(N'ZDY/>NGTK2[71=+@T_3XS';0+MC4L6P,
MYZGZUTU:M.44HHPITYQE=L+"^DOD=I+&ZL]IP!<A06^FUC5NBBN4Z"*2U@EN
M(9Y8(WF@),4C("T>1@[3VR..*26SM9[J"YGMH9)[<L897C!:+<,-M)Y&1P<=
M:BOM5T_2U#:E?VUFI5G!N)EC&U>6/)Z#(R>V:CMM>TB\TO\ M.TU6RGL,[?M
M<5PC19SC&\''4@=>M %F"TMK6U%M;6\4, SB*- J\DD\#CDDG\:Q[7P)X1L;
MR.[LO"NB6]S$P>.:+3H4=&'0A@N0?>IY?%WAN#3C?S^(-*CLQ*8#<O>QB,2#
MJFXG&X>G6H=9U\VD6B3:8]O<P:E?Q6YE!WJT;JQW*0<?PC!Y% &Q/:P7)B-S
M!'*89!)'YB!MCCHPST/)Y]Z%M;=+B6X6")9IE599 @W.!G )ZD#)QGU-<IXC
M\<PZ'HDT]S>Z-87+ZA]AMFN+Y7C^^JF1Q\IRH)9D!XQRPSD;!\0Z;IFA6=[K
MVO:5''.B[;WS5@@G)&<IN=N#U W-]30!-=>'-$O;.VM+W1]/N+:T(-M#+:HZ
M0D="BD87'M3[K0=(OM/-C?:597-F9#*;>:W1XRY)8MM(QG))SUR:2\\0:-IP
M0ZAJUC:AU5E\^Y1-P8X4C)Y!/ ]:0^(=%76AI#:O8#4V&19&Y3SB.OW,[OTH
M +KP]HM[?+>WFD6%Q=K&8EN);9&D"$8*AB,X()&.G-6X;*UMI)'M[:&)Y0HD
M9(PI?:,+DCK@<#T%<W'\0M#U!=1BT+4M,O+S3Y1&\,NHQQJPR@+[AN(4%\9Q
MRPVULZKXAT70FB76]7L-.,YQ$+NY2+S#_L[B,_A0 ZZT/2;[3$TZ^TNRN;&,
MJ4M9K='B7'3"$8&.W%6IK6WN/*\^"*7R7$D6] ?+8<!AGH1D\CUJ&]U?3=-C
M$FHZA:VB,C.&GF5 57!9LD]!D9/;-/L-1LM5L8[S2[RWO;63.R>WE61'P<<,
MI(/- #UM;=+B6X6")9IE599 @W.!G )ZD#)QGU-4;WPSH6I:?!8:CHFG7=G;
MX\FWGM$>.+ Q\JD8''I6G10!ES>%] N+NUNKC0]-EN+,!;:9[2-G@ Y 1B,K
MCVJ;5=$TK7;=;?6],L]1A5MRQWENDJ@^H# C-7J* *%UH6DWVF)IM[I=E<V,
M>W9:S6Z/$NW[N$(P,=N.*M1VEO#-++#;Q1R38\UU0!I,# W'O@<#-2T4 9E]
MX;T+5+"&QU/1=/O+2W_U-O<6J21Q\8^52"!QZ5;33[*-K<QVD"&U4I;E8E'D
MJ1@A>/E! '3TJQ10!1GT/2;K2O[,N=+LIM/_ .?22W1HNN?N$8Z^U+#HNEVV
MEKIEOIMG%8+C;:) JQ#!R,(!CKSTZU=HH B-K ;M;HP1FX5#&LQ0;PI()4-U
MP2 <>PJE-X;T.XF@EN-&T^62WE::%WM48Q2,=S.I(X8GDD<DUI44 1V]O#:6
MZ06L,<$,8PD<:A54>@ X%2444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Y7JL\UEXO\2V^J^(?#^C)J;1I NM:>TK74
M'E*H6-_/C# ,7^0 D$DG[PKU2B@#RCR(K35;20SM?:+ID=I;:]=N"JW$Z*/*
MD*')&S*%\GH5R3L-3:9J_ABRL?&%CK#VZW-_JMY&;65?WE\#P%B4\R]<87.#
MZ5ZC67H>C?V,E^OG^=]LOIKO[FW9YASMZG./7]* .4\-:;+;>-]*355,FH6?
MA>"-W<[F5_,(?GUXQFN;\NXFBUKP_JGBK0=(O;[4IY#:W>FNU])F0F*6-OM"
M^80H3:RH0-H'\)KV.B@#S[1]5M-*\3'1-)U>RUFUNKJXDNK:(@WFG2,'=WD*
MDDINRHW*K#<HW-P*S;/5K>'PUJWAW1]4L->TNVT6Y,-W9D&2S"I@13E25+-D
MD'Y2=ARO!->IT4 >>:?J.FZ#K]EJ7B:YM[&VDT*VBL;V\D6.)""3+&'; 5CF
M,XSE@O?:<4-(M;>Y\=:/<Q6Z_P!FS7^H76G!DPNTQ19D4'H"_F,#@9SD=0:]
M2HH YWPVBQ>(O%"1J$4ZA&Y &/F:WB)/XUT5%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Q'C.YTVR\=>$KK62B6T/VQ_.E'[N$B-<.QZ*!_>/ .*
MY_Q"++6-)\7ZGI3)<:/?FPB\Z$_NKF590)'1@<-\IC4L.#MQDXKT.]T;[9XB
MTO5?/V?V>LZ^5LSYGF*HZYXQM]#G-:E '%WM[I7ASX@27WB&>VTZS;3(H-/N
M[IUCACP[>;&'; 5CF(XS\P48^[QBHJF/3[FSC\O3;KQ:D]B-NT-&8FW.H[*S
MAV'3.<]\UZ=10!YO%_R!;_\ [' ?^E24OBB[N=(^(SW]UKFC:):2:;'#:W6M
M6;2Q%M[F6-'\Z)48_NR022P Q]TUZ/10!YMX,T>&P\;6JM=PZDT.B,T%S% 8
MD"R74C81"S84 A1R>!UQ6;XDUPZI9W$=QK/V:^M]9A T2TBC$B(ETBK++N4R
M8( ;>NP<J 3W];HH \O\0W]HFF^,=,>YA6_.IV]P+5G E,1-L!(%ZE<\;NF>
M*V(M7T7P[XL\1-XJN[6PGO98C;2WKJ@N;<1*%CC+?>P_F909.6SCYAGN** /
M,]&T_9JG@>*\M3&L7]HRVL,R8:&,D&(;3T(0KQVZ<8KJO#:+%XB\4)&H13J$
M;D 8^9K>(D_C7144 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
H% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img39825204_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA=&AE=R!/
M)T1O;FYE;&P    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M-0  DI(  @    ,R-0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;[Q%HFHQR(L>FR3/(K9RV^(H,?B: *?CC6K[0] BN-+XN);VWM]WV5[G:CR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "O-OV?/^2$^'O\ MY_]*9:])KS;]GS_ )(3X>_[>?\
MTIEH ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R[7_D:M1_Z]
M;;_T*:M&;S#"_DD"3:=A/3..*\.\.0>('\?QM&+@WB7&+MSDX7=AMQZ8X(_E
M711I<\9.]K'EX[&/#U*4>1N[Z>EOU/=****YSU HHHH **** "BBB@ HHHH
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M=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIN(]F\$9!'/-7ZH:#_R+>F_]>D7_ * *OT/<%L%%%%(85EZ+_K-3_P"OY_\
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M496)=IRQY' Z]1]:X/0/$6M_;K&WU'Q!>&UFE5(KJ_\ #$ENEUD\*)-^$+=
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M14J;D9NO:6Q]*T5R::/XELVSI5W;P*.D%Q=27$7_ (\F\?0,![5)/K?B/3V
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M^E6]G?6,ELT$2KO:1&#'VVDUKU4_B9EA_P"%'T04445)L%9=A_R,.K?]L?\
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MV*Y;1/$\FIZY!9V_Q!T6^9I.((M,V&X Y81N9<,< \KNQUH ]!HHHH ****
M"O-OV?/^2$^'O^WG_P!*9:])KS;]GS_DA/A[_MY_]*9: /2:*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JKJ%@E_ %+M%-&=\,Z?>B?^\/Y$=""
M0>#5JBC8"AIU_),[V=^JQ7T(RZK]V1>@D3_9/IU!X/8FKX>_UVL?]A*3_P!
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M%(99HK.TK7;+6DWZ?]I:/:&$DMG+"K _W6=0&_#-:--IK<+WV"BBBD 4444
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M[>?_ $IEH ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD@74/.#!65],N4"9Z;BT8"CW.*$F]@ND;%%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5YM^SY_R0GP]_V\_^E,M>DUYM^SY_R0GP]_V\_P#I3+0!
MZ31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9+@20[TB9PH0'>&7=@<8SD@D@'85YM^SY_R0GP]_V\_^E,M'_";?$[_HD?\
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M,@SC(Y&1Z&@#UNBO-O\ A-OB=_T2/_RY;;_XFC_A-OB=_P!$C_\ +EMO_B:
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MQ*-3U358[V.W2:.SC6S$4D:2LK%9) QW@;5 PJ<#+;CR-ZBB@ HHHH ****
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MU$2:?'/<W-K:" JT<MPY>0O)N.\;F?:-JX#'KQCI*** "BBB@ HHHH ****
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M5R(;<2,LK_=;]UM.TH2"%'WL'..0#TVBN6TZ35+GQ9JL5QK4RV&E20JL*Q1
MS9@5F\QMF<9.[Y=ISGG'%9-GK6JR^)-+^SWVKSZ7K!E1;BYM[6.%/W3.C0@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*S_["TW_ )]O^7S[;_K&_P!=_>Z_IT]JT** *=OI-E:ZI=:C;0^7<W@47#*[
M!9-HP&*YV[L<;L9( &< 4S5=%M=9CC2\DO$6,D@6M]-;9SV;RG7</8Y%7Z*
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M[U'H&J3:K!>O<+&IM[^>V78",K&Y4$Y)YP.: -6BBB@ HHHH **** "BB@G
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MVWLS8"CUX4>E:'AR+[9KWB/58;6XMOMS0"":YM9('91 H^ZZAAAL\8ZUU=%
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img39825204_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_8.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MCL:2.4>:%+LK*5'$%.,KD35$H\E$!&0I4;&YR)\:FLD02=EEG+"S#QE)PFG
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M6[Y4*](L$#BY)4;-I+ D%0]M!:X(L&O<$6O/MKF;QE#8"BL%5JMC7+DTZ.K
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MDS?!VQL2M1R]Y7!C,E:I*Y+VA.N962.Z='UZ<F]J8'Y6V=%-S;L\T-2Y( T
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M-@+DG<FP W/( <A(?;N:G&)[FR*O$5E!5.;S,%5;M#\;#)^15LAL!,K4MBF
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MW9V*&I>ZVT D:B;[;BP!L2; "Y%XFK3!(U;BH*5K,3K(#:0 +GLD,2+@"Y)
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MKHX*C=A*3(6]"G/5JU!@@EDD$F&#WH(=[SH!)  ))(  YDG8 >TF<) !)(
M))/( ;DGV 2KZGG'QM)K^!6:FELL>HM9<=E\QBA<:J&X9/*C(=7R],USV7OD
M#8(&XSB)1B&.*U WR1\E4=9F]L7N+8@./]<YMZ=3;U%34R64%2 ;N@6["Z@,
M6TL6&X"DDBYY RKSBEI5[L0X+* CEM*^DQ4*6 6XO<"UP.<V%QY?<?&R8L4*
M,G"M<ND"FNT*:0L<-G,AKIM<[=TD%5;/);38HVX5O$WFQ-.+1N'M,EE+4X/?
MQZ->E3B^E$<^*QZJII+6%AJ-BRAB$](A2=1"V-R 0+'P-NFM3! U'?2 0K%
M7MH!< JI:XL"1>X\1>RV5RV:7./Z@R?WRA_^($.6T?2?]E5_W;2NIR7]I3_M
MB;IE4LC$1B)7*45;<3O(79S9;R7L;2M6&GM[.!@+&!L2CWKRD03"EQ03@IP_
ML]'[+"8=H/FFZV:,>]_Q=QYT"^4IQ'QCQ#GG"_E69KPIP]F>95\7D_#5+@[#
M5:>1X"H1U&64Z]'-L.N)3"(!27%/1IUL2%%?$ UWJ,WZ3E7%?!F#R[!X7'<!
MX?'XRA06GB,:V8NK8JJM]5<JV'<H:A[10,5IDZ$["J) 5K\=[T?RV80YJ*S@
MIC5 /2K3DS")IV?Y/5444O7^C4@-"#83S '!5EZ++ 62< >]E_R#Y0GD9^5=
MQA0X9J5.E)^G5<#B,92& S.M@>$7X=.+\V#8_#X?-,V.78ZEB%I:,76I8A,Q
MHBA1ITL-B:=1C1_0N$>D?@/+FQH7(QPL:J4VZV@E7,!C-&NU)WH8?KJ3(6O3
M5D-%M3%G1@-4G-%)WNC:FU)N_%J#:9 D(VA):C5Y*+RB  ](4M/7$G*RD_;Y
M):@PHH9H !'LL&]]NOW?ASR7?*RRWA_),N/E=YGE)P.4Y?A#E6&X<JYOA\L\
MWPE*E]GX?-,7FV&Q.84,'H\WHXROAZ%7$4Z:U7HTBVA?EL9QQP#6Q>*K#H^H
M8@5<16J=>^,7#O7UU&;KGH4\.Z46J7UM35W"%BH9K7,8<I*GMQ7Q<FT5,?Y!
M<<F=+0XY.K2V-,<--<T;9'>0U5ODA/)2HAK5JI*A9FU<].9HM:3MK:UJEH_+
M) J-U_5O01T?])_1[@,\PO2?TOXOI9Q68XRE7RK%8S(L/DWV)AZ6#K4L1ATJ
M)B\97Q?GU5Z3LM:HM+#G#KU":\179OS[B[-LDSAL,^1<.T\A2B@6O3I8I\3Y
MRYKTW5RIITTI]4BL+JI9]9UFR):M4 J:V*FYM7)R><ZWF<\KV6<GI15FHZ*-
M.;D\UK&[(J7C@@:^2]2-)*79KU&G>4QQ16=X.;<0XN"6),C:^-:Q$T0.<MCW
M^\,Z/02D&566DKWN &*M4O2<]S '53!-M1((NRD?((CI7J52K,K5BH%KE0R4
MAUJ>*EET5.9T@$6"L#86_8+8;6GK2S[9MV4*+'K"R'USJ&6<5>'EFS4UE;Y=
M!)!%)+%K'K!))N2B^1,S\SK3 %3 L,$1LCZD91^N1:.-(7U4RIUJBKI90&%:
MLB\F!!5R*0!!'H]HD=QEM17 5G<ZD8E&HT&8@%2I#H#5)!!Y@* 0.4J>LK:;
MQ;A0NIRT7GFK$IC=[_RNM5:BHNDT5C/$A#?%MV%.6.KKA.K2KIFSUT].K),6
MLR8I8\[TY'$CL[2AL;+!:TJ#2M!=K#5PZBBP04D!J/H ZM%!9-3*6W4Z2P=O
M1NIO:4Z&6@4;KU-1JSVIIJ)%1V8(^E6"DJ1JL4 8FS"8R4QJ[(O6_+:MIMQV
MFJVS^8W"NCH#7S#4D DDPJ1@M4SCW(*8FM3/DY9$SW%JJB=<39PT_ >K&?V6
M.GPU\/7,+T_.:->CUU2A>DRU%"4:[LQ=@'T=8'5PI(+EAM9 2"-P!8GC"H$K
M(:3%ZU!%4(I*!^K*,K,+A K;W8@$'8D@SKG3,^C\B!,JU9U#NZNW'YVBU2S6
M0JF\1+(\2\JM(3,EGT>=/.-+> H&V6M25]%K1)S5(-.+.J*"H1&;%C=2-+&P
M%0%U'>%U,HN.Z^DD>(L>^;$8'4@N33THS$;%M*L;'OL"+VY';F#*PI(*YV?;
M7+N[K=A$Z)@\7KB1\6:;B29@=03)_K-*S E-[3R$L>B/B*]=<DZ4-<0B9K<
M8I(RTY#W=HT8G?"##[=6E*5-&746%5S<6#7M35CRLBW8WY%R#N-J@I:I6J.K
M:54TJ:V-RH&JHRBU_P!(Q"BW,4P1SF%X7)IRSV7.XO#%_(MRXCQFIZP9Z_\
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MN*V<X/<@=$+,T("=?,Y:Y.)Z9$E*U]IAYQ8-?QSH!8V ))Y  D_@)PD*+D@
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MTA8F9I:$OE-[<C3DQ9F8W9BQWW8DG<DGGXDDGQ))D@JKLJA1ML !R  Y>
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MC+6#RP]H.QO94:)('L#]4'0G7:'VUTUF9F9C=F+'Q8DG\YJ554650H\%  _
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M*#^!-Y,F0DXQ$8B,1&(C$2MG*>[*GHRH9//;9OY1QYB\;"@6N<Z9"HB[R=.
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ML)>S?I2K:9>G*.'T"4,B$+C-[WT$2'>NF]"Y=6M>HU.B/Z;@G_9N/]J93F=
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M['W4W_O D9;_ $BKC3(^I52<6.;]LJ!_U8V.U%&--BK>_8'E*4E@NSET'O\
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M6!7_ )MY'F)I7.WG7&V&&W=?K,+A+>TFWN$?Q/Z/$]/I$1N?H98YY>ZI4_\
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M_=])F-IWY!^'L4H%_'_%J)M[2=O&4/L7P@N<=DZ/#..<O->5D']W<AD=B+I
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MSCB>@?0.K>#U>^5TT1]"Z96,FR>G[OD>G8C= [=_NZ^S^&\_71_"1^2B;?\
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M0/\ X(E_)>/Y.?X1#_M =$G_ (5P/_II'VQT0?\ 5/B#_OU7_P [CZ(<MO\
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M$:"WMUG+8\04Y@BS8S2+3V1+LOJH@1S=&-BP?K@]0$NH6G8-8KU>HWTWYM<
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M18W) N"1(O5*.BE05=E4$,-5VON$M<J+;FXMN;$"6ORJ71B(Q$8B,1/J,78
M8]!$/8 B%V UK8Q]NM[[0:WL.MB%TZ!UO>M;WO77>M>^(E2*WY%63;D.N-RA
M]#[8["J:X#:K'6UDV:RQXYP 5$:]G GAWE4+8+)96->!AL!-YK$V!E28#BW'
M(@R P!^E)-STE1D#/=737J12>]EL Q0G=>9ML>4I2JSJY%.S(^C2S ?JJUR5
M# &S<AJW'/OFX\9KMD-]P-_F4A@*" F,UEV%72$EGFFYZP28%<2!1#WJ3QZ1
M&1:''JV4Z7-,D8T1AK$0!7IB&Z(3UC8X(5)D:B!&"ABUU5MQI(U"X!%VWL03
MOM>QW$E2J&HI8KILS*-[@Z3I+ V4VU @;;VOR(EB,KED8B,1&(C$2KW(2^IQ
M1!K'(PU&FE]3[?:UCLQF1-AH624M3I9]D-=:-"*&U\9&W,4V6M3H^L;B[I5\
MGAHE*%T(2Q@<D>BU#45;3IK4N-=GLQ"Z200JECJ:_9V!M8-N-[#>55*C4['1
M=+HI.H W=@H"J1VB"02"5VY7.TT1AYAK'FR8NTF5:8CIF>7U:'&6%6T&:IE3
MTX6[49-BD2<+S7 8Z5IE@:^35)8<,C<J3S5X=G"0L[>)QB+,S/B%VSIHV4G5
MVUIK59-.VA]-K-?=K.K$%0 #LQ(M("O=@-'8:H])7U DNFO5=;;+J1E!U$D@
M7 !O+N93-$8B,1&(C$379:Y2!HC;PXQ2-AE\D2HQC98T8])(Z0[N A +(3*G
MU:2J3M*/0A^<M7>C7GITA1PTC<XJ]$(E'5 ) 8Z1WFU[#W=_NN/>)QB0"5&H
M]PN!?XGD/'G[ 3M*<!YI'--.6[-YA5A[=9]3VRY40&J8M-$DM06#:VF*,R-@
M:8!/#X_'!.,><&B6MZ^22)VB#,= T3).ETD924<+=#A7=3=T57NCIUFLJ1I2
MY!++<V(TFP#'5=0#=@)1U]D=BAUH_5Z%.K4]@0%:PN+-N2!ILUQV3+24_81%
MN5)5UK)6LUD36=74)L).RGJ@+3V@B:1ELDA36<M+)3%JS4!;D%(8J G( H&4
M(T))01Z &IUT.Z$WT,RW\=)(O\;2Y&UHC@6UJK6\-0!M\+R1<C)1B(Q$8B,1
M*O32^YQ +OK*O)'428NM[>GRBKH59+?8B%?)U$P357+K6,6.-7@C@!(H4%M@
MLF93'\J:JWU*Z(B5:Z()8^I"\EVBFK4V8/VD4,RE2!8N$L'ONUV!MI M>S7%
MI4U1EJ(I3LNQ56U"^H(S[I;T;*1?43?FMMY&_%_FF'DE,E$9)KU#'4*JOU=C
M-JQGL!/-7R)(T<T,A(X)>\9)C# *F[=.<"5YR>!;=9D >HW-49CZ4OBB],.5
M6CU8OJ)[6DW72&-KZJ9N=:6MVK+S7:QD:5?K3;2!V2VS!BMFTZ:@ &A[W[-V
M]%@2"+2].42^,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E#BN'TL#8Y@C+/CXZ&
MWR9%RR*@ 8"O!86K($1\7U&C+"W-A,(H*79NQ62'0*_!(A&^7%1.FF\ W(Z_
MK1I]$]9U?5:M79T\KZ=-]6CL^E;]:U]I1U)U>D.KZWKM.DZM7,C5JMIU=K9;
M[Z>7.^.42^,1&(C$1B(Q$A2XZ'B-VF055)7J=L#E6\A<95#W6"3)XB"]L?W.
M-O$14N(C6LT %1^H[('QK3F'EC-2I7=R*3&%!6J=&32H4U6"D, "&4," 0UM
M_: ?@)!Z:U-))8%22I4D$$@B^WL)'QF,XKT<+C3QRI6@QRUSG1E25O$H(=+'
M72DHY[/CC,D;3E:- J7.9K*S"-3B Q1_3BO*C[.%$SD+%)2(!P^U7ZVI4J6"
MZW9K#NN;^RY\3;<W/?.4:?54J=/46T(JZCWZ0!<"YL-MA?8;2?LKED8B,1&(
MC$1B)!U9T\=";&O*U'^0ERF77)*(\80J V";"8A6D$CI+% *V0!,7N!BM$RN
M*R:3-<X"&FTOEEA2A62A0HS4J0BQGU+30#2$![[ZF8W9CL-R-*V[@HW,K1-+
M5')NSD6VMI1195^!+-[V,G'*Y9&(C$1B(Q$8B<^[ X?63:T\Y5.,VM>"$U]R
M;H=@H,;+%ZPD+?-H0QP-?=[G7TG12IUM%Y8G:3-BZ[7!6_\ J(<E:7DV.-04
M#>QE*%H#-"UE1:(56U4JAJ7+#2Q;1J%@H(!T #M7%SSF9J+.U8LZZ:M,4[!3
MJ4+UFD@EB">WOM8VVM)KI>F)_%+$L6Y;AGD3G=G6##:PK81D#@[I (@R0>IU
MMA/C(G2,SY-9\ZJ'MZE%IS9]>W$U]+2@2JF)B1H- 81NCM!W4JJ(I5%9F[3:
MF+/I!N0 + *H MXG]:PLITV#M4J,K.RHG94J J%B-BS$DL[$F_@!RN;,Y5+8
MQ$8B,1&(E9>5U-6+?58@KB SF%0(*R4PJ1/CK,((^3H1X(%.(O/V9&U)66?0
M/2 :EXBZ9(YGJSG/1K:J/ E)2*@EJ=6TG6F^IE9K!@ K!?24J;W5NXFW+?QE
M59'J+I5E6Y4DLI;T6#"P#+WC?>1W:W&6RKEFM9OLNF-(H4,%E5.S@V5QFCWQ
MNNYO=JPD+-,7V-02SG"V78$6AEA2!N<VEV2&QYS6HJ[E4JA:LU^4O)DD*DE5
M:8<*KDL'6S."EF! +)H[3*-QN!J ;:UI!Z3U&0LU,!61KA"*@*$$A7+FRL;W
MV)"DKO>\N]E$T1B(Q$8B,1/@7=VB[-ZT+IOMV+6Q!T+I[;$'0@[%K6^F]ZT(
M.]Z]M"U\\1*15KQ]Y#P=BY4%*[LK$$OY!R*13Z)RJ)T_)V4-96(]UK$*W2/
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M/0=:LUNT6! !6_/D3()D7AZS1'%ZA9XS9<0L=1'YC?5C7DS7A&9,;7-W6QR
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MOY%1#D7$5YD<D09G'7M-:546-+HS(A!>#&-Q:M:KMP;HXN;4R58:)Z2&N91
M6TW2ZP5TO28JVI*34CN-)&AT4C:]^T";GN-N8 @:#VJKJ72]5:H-CJ!UHQ4[
MV([-@1X[C;?V<DN#0[7Y #Y ,,9X[V$X/]21JH93"^2%>NTR9&Y+"Y1,I-&9
MA"G1D<2%C8Y"^G\B:95'5*+:"3(B(\<4[LBEH.$XJ5?13ZLFHH#EP:;!3<@
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MWMD9V3POD$ZLJTIVFG#,@36#R'X.76E;SVI:<>VMW$N61&1/K$H/+4!+/6S
MF-GIFE66 !#::I*&L+/  ?62UPJ(NDG13Q"$WYFLK*#R_5O<^/LD7H%F<Z@-
M57#U.7(461B/>VFP\+WWY18/"^03.P;:FB><,R$BQ^4G"GD$D0GM2TTYL:N*
MKC5JU[CBDXM0$![A+05^K U+2@ 3-PG%-ZLH[1)N]\6L%"C23II5J?/F:H<
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I1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img39825204_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" CM"_D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDY^EZ ,2Y\8^%[*YDMKKQ)H\%Q$Q62*6^B5D([$%L@U%_P )WX/_ .AKT/\
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MC#_\50!T%%8]CXL\-ZG>1V=AX@TJ[NI,[(8+V.1VP"3A0<G !/X5L4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*#Z4 ?1-KH$I^$<?A]E/GMHGV1AWWF':?U-?/?P#OH[/XH6\3D W=K- N?7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKVA?]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?,'[1W_ "4/3_\ L%1_^C9:^GZ^
M8/VCO^2AZ?\ ]@J/_P!&RT <_P#!+_DKVA?]O'_I/)7U_7R!\$O^2O:%_P!O
M'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?,'[1W_)0]/_ .P5'_Z-EKZ?KY@_:._Y*'I__8*C_P#1LM '/_!+_DKV
MA?\ ;Q_Z3R5]?U\@?!+_ )*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_ /L%1_\ HV6OI^OF
M#]H[_DH>G_\ 8*C_ /1LM '/_!+_ )*]H7_;Q_Z3R5]?U\@?!+_DKVA?]O'_
M *3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7S!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\ DH>G_P#8*C_]&RT <_\ !+_D
MKVA?]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?,'[1W_ "4/3_\ L%1_^C9:^GZ^
M8/VCO^2AZ?\ ]@J/_P!&RT <_P#!+_DKVA?]O'_I/)7U_7R!\$O^2O:%_P!O
M'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?,'[1W_)0]/_ .P5'_Z-EKZ?KY@_:._Y*'I__8*C_P#1LM '/_!+_DKV
MA?\ ;Q_Z3R5]?U\@?!+_ )*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_ /L%1_\ HV6OI^OF
M#]H[_DH>G_\ 8*C_ /1LM '/_!+_ )*]H7_;Q_Z3R5]?U\@?!+_DKVA?]O'_
M *3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7S!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\ DH>G_P#8*C_]&RT <_\ !+_D
MKVA?]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?,'[1W_ "4/3_\ L%1_^C9:^GZ^
M8/VCO^2AZ?\ ]@J/_P!&RT <_P#!+_DKVA?]O'_I/)7U_7R!\$O^2O:%_P!O
M'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?,'[1W_)0]/_ .P5'_Z-EKZ?KY@_:._Y*'I__8*C_P#1LM '/_!+_DKV
MA?\ ;Q_Z3R5]?U\@?!+_ )*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_ /L%1_\ HV6OI^OF
M#]H[_DH>G_\ 8*C_ /1LM '/_!+_ )*]H7_;Q_Z3R5]?U\@?!+_DKVA?]O'_
M *3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7S!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\ DH>G_P#8*C_]&RT <_\ !+_D
MKVA?]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?,'[1W_ "4/3_\ L%1_^C9:^GZ^
M8/VCO^2AZ?\ ]@J/_P!&RT <_P#!+_DKVA?]O'_I/)7U_7R!\$O^2O:%_P!O
M'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?,'[1W_)0]/_ .P5'_Z-EKZ?KY@_:._Y*'I__8*C_P#1LM '/_!+_DKV
MA?\ ;Q_Z3R5]?U\@?!+_ )*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_ /L%1_\ HV6OI^OF
M#]H[_DH>G_\ 8*C_ /1LM '/_!+_ )*]H7_;Q_Z3R5]?U\@?!+_DKVA?]O'_
M *3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<MXH\:6V@-]E@
M07%\1DIGY8_3=_A7G]QXZ\0W$A87WE*3PL:* /TS713PTYJYYF)S;#X>7([M
M^1[317D.G?$36K24?:FCO(NZNH4_@0/YYKTS1=<L]>LA<V;G@X>-OO(?0U-2
MA.GJS3"9C0Q3M!V?9FE1116)WA1110 4444 %%<UK7CC2-&F:W+O<W"\,D(!
M"GT)/'\ZP5^*<1DP^D.$]1."?RV_UK6-"I)72.*IF6%I2Y93U^_\CT.BL31/
M%>EZ\=EM*R3@9\F4;6_#L?PK;K.47%V9TTZL*L>:#N@HHHI&@4444 %%%% !
M1110 4444 %%%% !1110 45F3>(M&MYGAFU.U21&*LK2 $$=0:9_PD^A?]!:
MS_[^BJY)=C)UZ2T<E]Z-:BLG_A)]"_Z"UG_W]%'_  D^A?\ 06L_^_HHY)=A
M?6*/\Z^]&M163_PD^A?]!:S_ ._HKBO'/C!;A1IFE7*M RYGFC;.[/\ "#Z>
MOY5<*,IRM8PQ./HT*;G=/R3.FU+QWH>FRF(SO<R*<$6ZAL?B2!^M4K?XE:++
M($EBNX0?XV0%1^1S^E>2T5W+"4[:GSDL\Q+E=62[6/H2ROK74;9;BSG2:(_Q
M(<_@?0^U6*\)T#7KK0-16X@8F(D"6(GAU_Q]#7KT?BK0I(U<:K:J& .&D (^
MH[5R5L/*#TU1[F!S.GB8>_:,E_6AL45D_P#"3Z%_T%K/_OZ*/^$GT+_H+6?_
M ']%8\DNQW?6*/\ .OO1K45D_P#"3Z%_T%K/_OZ*/^$GT+_H+6?_ ']%')+L
M'UBC_.OO1K45%;7,%Y;I/;2I+"_W70Y!YQ4M2:IIJZ"BBB@84444 %%%% !7
MFGQ+^+UAX&<:990)J&M.A)A+X2V!7Y6DQR23@[!@D<Y7*YW/B9XN_P"$+\#W
MNI1-B]D_T>SXS^^8'!Z$?* SX/!VX[UYI\#OA_#J4?\ PG>O;[N\EN':R$[!
MP6#?-.QR2S[]P&<8*EN25( ([?3/C;XYM)+BXU4:!:F7S8H9";1^K#:/+4RA
M1Z.><J?FZUIZC\)?B#%;JVF?$_4KF?> R74\\"A<'G<KN2<XXQW//'/M=% '
MSR_C[XF_#&[6W\76']KZ6,11W#8 < .%VSJ/O-MW$2 N0.@R37MWAGQ-I?B[
M0X=7TB?S;>3AE;AXG'5''9AG]01D$$W-4TNQUO3+C3=2MDN;.X39+$XX8?S!
M!P01R" 1R*^<O#4\WP=^-,^C7DLBZ+>L(?,E8A3"YS%*2=JDJ?E9L8'[P"@#
MW;QK9^*K[1HHO"&IVNGZB+A6DEN5#*8MK97E'YR5/3L>:X/_ (1WXY?]#GH?
M_?E?_D>O7Z* /G#7_$OQ;\.>,M+\+W?BJQ>]U+RO)DAM8C&OF2&-=Q,((Y!S
M@'BNP_X1WXY?]#GH?_?E?_D>L#XI?\G"^"O^W+_TJ>O?J .$\%:5\1['6)I/
M&&OZ=J.GFW*QQ6L85EEW+ACB).,!AU[CBN[HHH ***X7P7\5]"\=:S/I>EVF
MHPSPP&X9KF-%4J&5<#:['.6';UH [JBBB@#,\1:_8^%] O-:U)G6TM4#/Y:[
MF8DA54#U)('.!SR0.:\0TCQ%\2_B]>W0TB]C\/:#&ZI)-"""OS[L+)C>T@4C
M(4HI &=N[FY^TM>W":=X=T]9,6T\T\TB;1RZ! ISUX$C_G["O8_#FBP^'?#>
MG:/!L*6=ND1=(Q&)& ^9]HZ%CECR>2>30!Y)J?P[^*/A_P K4/#OCR^UFXCS
MNMKN5ESG"\+*[QMP6/S8Q@8R<5O_  N^*/\ PE&[P_X@3['XFM-R/'(GE_:=
MOWB%_AD&#N3V)'&0OI]?,WQ7,/@;XW:=KVFQNKR+#J$\4;B(.V]D=05' =4.
M[.<EVSG.* /HK7+J\L?#^I7>GP?:+V"UEEMX=A?S)%0E5VCDY( P.37CEGX9
M^+_C9X;[6?$C^'+-G=TM[8F.5%90P^2/!(SA<2/N7!SSU]RHH \-UKP#\3O"
M]O\ VOH'CO4=:EMD9WM9RY9AC'R1NSK(<%C@X/ VY.*Z3X1_%'_A.+-]+U-=
MFNV<6^1E7"7$8(7S!CA6R0"O3G(XR%].KYJ^'1N+_P#:.U:[TR;S;+[5?33R
M0RC9) 68*>#\ZEVC(QGL>V0 ?2M>(^.?BWKMSXM/@[P%:^9J"RFWEN6B#/YR
MM\RQJWRA5VL&9@1U(P &/I?CW7V\,>!-8U>-G6:"W*PNBJQ65R$1L-P0&92<
M]@>#TKS3]G+P]]FT+4_$,\6);R86\#/#@B-.6*N>JLS8('&8N^. "2'X2_$%
MM,,D_P 3M234-C$01SSM%NYVCS"X.#QD[.,G@XYS_#WQ+\5^"/&$'A#Q^(Y[
M=G6*/4&(5E4X5)/,. \?!RS#<,L2<J5KWJO%?VC/#\-SX9L-?BMW:[M+@022
M1H"!"X)RYQG <*!DX!D/=J /:J*Y3X::U-XA^'&AZC<;_/:W\J1I)#(SM&QC
M+ECR2Q3=^/4]:ZN@ KG/%7COP[X,MC)K.HQQS%-T=K'\\TG#8P@Y )4C<<+G
M@D5T=><>'_@AX+T&\:[>UGU27^ :DRRHG!!P@4*<Y_B!Q@$8- 'B7C;XM^+/
M$6I6EU:S7V@Z>T>;:"UN'3S1G:SEQM\SYE8=,#:0.=Q/UI7S%^T9_P E"TW_
M +!D?_HV6OIV@ HHHH **Y#7_B-H_AWQEI?A>\MKY[[4O*\F2%$,:^9(8UW$
ML".0<X!XKKZ "BBN0T#XC:/XB\9:IX7M+:^2^TWS?.DF1!&WER"-MI#$GEAC
M('% '7U\I?#/XGZQI?CNT&O:W?7>F71-K-]LNWD2'<1MD&]]JX8#+'HI:OJV
MOAS0_#UQX@AUMK5OWFFV+7Y3 ^=$= XR2,85F;OG;@#)H ^XZ*\X^#7CI_&7
MA(P7K9U/2]D$[%F8RIM^25BW\3;6!Y/*D\;@*]'H *YSQWXJA\&>#[_69"AF
MC39;1OC]Y,W"#&02,\D YVJQ'2NCKYY^*FHW'Q$^*&E> M*N,6MM+MN'1@5\
MTC,C$;\-Y: C'#!O,7O0!'\ _$NO:SXXO[?5-:U&^A737=8[JZ>50WF1C(#$
MC.">?>OHJOF/]G/_ )*'J7_8+D_]&Q5].4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?,'[1W_)0]/_ .P5'_Z-EKZ?KY@_
M:._Y*'I__8*C_P#1LM '/_!+_DKVA?\ ;Q_Z3R5]?U\@?!+_ )*]H7_;Q_Z3
MR5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 53U:]_L[2;N\P"88F=0>A('
M'ZU:=TC1G=E5%&2S'  K@O%OC?39=/N=,L@;IY5*-*IPB_0_Q?R]ZTI4W.22
M1RXO$PH4G*4K.VGJ>;3S27$\D\SEY)&+,QZDGJ:CHHKV3X%N^K"MGPUK\OA[
M5!=*ADB92LD0;&X=OR.#6-5W2]*O-8O!:V,7F2[2Q&0  .Y)Z5,U%Q:EL:49
M5(U$Z7Q=#OU^*5L3\^ER@>TH/]*E7XHZ>3\^GW('LRFN1_X0/Q+_ - W_P C
MQ_\ Q51_\(5XB_Z!DG_?:_XUS>RP_?\ $]CZ[FBWB_\ P'_@';)\3]))^>SO
M0/94/_LU2)\3-$8\P7R_6-?Z-7 ?\(CX@_Z!5Q^0J/\ X1C7?^@3>?\ ?HT>
MPH=_Q#^TLQ6\?_)3TA/B/H+9S]J7ZQ?X&LGQ)\0;:?2S;Z-)*L\IVM(R;=B]
M\>YKB#X?UH#)TB__ / 9_P#"JEQ9W5IM^TVTT.[[OF(5S],TXX>DG=&=7-<:
MX.,E:_6S1#11174>,/AFDMYDFA=DD0AE93@@CO7MOA36SKVA1W,F/M"$QS8[
ML._X@@UX?7J/POBD72;V4_ZMI@%^H'/\Q7+BXIPOV/:R.K..(Y%LT=W1117F
M'UX4444 %%%% !1110 4444 %%%% !1110!X/XD_Y&?5/^OJ3_T(UEU]"-8V
MCL6:U@9B<DF,$DTG]GV7_/G;_P#?I?\ "NZ.,25K'S=3(93FY<^_E_P3Y\HK
MZ#_L^R_Y\[?_ +]+_A1_9]E_SYV__?I?\*KZZNQ'^K\O^?GX?\$^?**^@_[/
MLO\ GSM_^_2_X5Q'COPBTX&J:9 -Z+B:&->H'1@!^M53Q<92LU8PQ.25*--S
MC+FMTL>9T445UGB!16YX:\-W/B"_5%5DM4/[Z;' 'H/>O98]+L(HDC2RMPB*
M%4>6#P*YZV(C3=MSU<#E53%1<[\J_,^?J*^@_P"S[+_GSM_^_2_X4?V?9?\
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M57S=\?9[K7/B+HGAVQE2X=($2.W5E!2>:0C#'L2HBX8X P>,Y(!](T444 >
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M>X\W?]ONIKG;MQY>"(L=>?\ 59SQUQVR?3J "BBB@#YB_:,_Y*%IO_8,C_\
M1LM?3M?,7[1G_)0M-_[!D?\ Z-EKZ=H **** / ?BE_R<+X*_P"W+_TJ>O?J
M\!^*7_)PO@K_ +<O_2IZ]^H *\!^%O\ R<+XU^E[_P"E25[]7@/PM_Y.%\:_
M2]_]*DH ]^KYB_9S_P"2AZE_V"Y/_1L5?3M?,7[.?_)0]2_[!<G_ *-BH /^
M2,?'+^YHEW^.+25O^!M^[=?]YO+[!J^G:\Q^.7A'_A)/ SZA N;[1]URG/WH
ML#S5Y( X ;/)^3 ^]1\#?%__  D?@9-.N&S?:/MMGX^]%@^4W  ' *XY/R9/
M6@#J_'?BJ'P9X/O]9D*&:--EM&^/WDS<(,9!(SR0#G:K$=*\X_9_\,3+I]_X
MSU%WEO=4=HH9)'+,T8;,CD[CDM(/XAD>7G.&K#^*FHW'Q$^*&E> M*N,6MK+
MMN'1@5\TC,C$;\-Y: C'#!O,7O7OUC96^FZ?;6%I'Y=M;1+#"F2=J* %&3R<
M #K0!\U?LY_\E#U+_L%R?^C8J^G:^8OV<_\ DH>I?]@N3_T;%7T[0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\P?M'?\E#
MT_\ [!4?_HV6OI^OF#]H[_DH>G_]@J/_ -&RT <_\$O^2O:%_P!O'_I/)7U_
M7R!\$O\ DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445SNN>--*T3=$9
M/M-T/^6,1S@_[1Z#^?M51C*3M%&=6M3HQYJCLCHB<#)KD]<\?:9I>Z&U/VVY
M'&(V^13[M_AG\*\^USQAJNN;HY)?(MC_ ,L(C@$>YZG^58EO;S74ZPV\3RRL
M<*B*23^%=M/"):U#YW%9Y*3Y,,OF_P!$:>L^)=4UUS]KN"(<Y$$?RH/P[_CF
MJ%E87>HW M[.WDGE/\*#./<^@KM]#^&TTVV?6)?)3KY$1RQ^IZ#\,_A7H=AI
MMEI=N(+*WCAC[A1R?<GJ3]:N>)A37+!&-#*<1B9>TQ#M?OO_ ,#^M#S(_#35
M1IOG"> W77[.#V_WNF?T]ZYRX\/ZO:R%)M-NE(.,^42#]".#7O5%81QDUOJ>
MC5R+#R2Y&U^)X?IWA#7-2E"QV,L29YDG4HH_/K^&:]4\->&;;PY9LB-YMS)S
M+,1C/L/05N45G5Q$JBMT.G!Y71PLN=:R[L****P/2"BBB@ K$\4>'H_$6EF#
M*I<1G?#(1T/H?8_X>E;=%.,G%W1G5I1JP<)JZ9\^7^GW>F736UY \,J]58=?
M<'N/>JU?0EW86E_$([RVBG0<@2(&Q],]*RE\&>'DD\P:7%NSGEF(_+.*[XXU
M6]Y'S=7(*G-^[FK>9Y%HNA7VNW@@M(B1D;Y#]U!ZDU[;I&EP:-ID-C;\I&.6
M/5CW)JS!;P6L(AMX8X8EZ)&H4#\!4E<U:NZFG0];+\MAA$W>\GU"BBBL#T@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%U'PEHFJ2-+<6
M*"5NLD9*$^YQP3]:I0> /#T#[C:O+Z"25B/TQ73T5:JS2LF<\L'AY2YI05_1
M$<%O#:PK#!$D42\*B* !^ J2BBH-TDE9!1110,**** "BBB@ HHHH **** "
MBBB@# \9^%+/QIX7NM%O&\KS<-%.$#-#(#E6 /X@XP2I89&<UXA\*/'-Q\/]
M<NO!7C!I[.W\T+"T[#99R')()[1OD'<#M'WNC%A]'5S'C'P!X?\ '%GY.K6F
M)UV^7>0!5GC ).T.0?EY;Y3D<YQG! !T<$\-U;Q7%O*DT$J!XY(V#*ZD9!!'
M!!'>I*\-/P8\9>&KA/\ A"O&TD-I]H:?[-<R21*I!&W<$W)*<##94 X'&#@3
MZCX+^->J6ZP7'C?3D17W@VLC6[9P1]Z.%21STSCIZ"@#T#QQ\0-%\"Z7)/?3
MI+?% ;>P20"68G(!QU5,J<L1@8/4X!\H^$7A>_\ &?C"\^(OB*-]@N#)9HZ;
MHY93D97>2=D7 7T(&&^0BNGT#X!Z+8ZHNJ:_JEWKMZ+@SL)E"12D\_O%)9G.
M[).6P> 01G/J\$$-K;QV]O$D,$2!(XXU"JB@8  '  ':@"2BBB@#P'XI?\G"
M^"O^W+_TJ>O?JX#Q3\,_^$E^(6B>*_[7^S?V9Y'^B_9M_F^7*TGW]XQG=CH<
M8KOZ "BBB@ KYC_9T_Y*'J7_ &#)/_1L5?3E% !1110 45@>-?#7_"8>$;[0
M?MGV/[5Y?[_R_,V;9%?[N1G[N.O>O--.\%_&O2K=H+?QOILB,^\FZD>X;. .
M&DA8@<=,XZ^IH ]:UG7-+\/:<]_J]]!9VJY^>9\;B 3M4=6; .%&2<<"O"OA
M9IUQ\1/BAJGCW5;?%K;2[K='4%?-(Q&H.S#>6@!SPP;RV[UKQ?!'Q!XDO%N_
M'GC">\V2R,+>U9G4!@#E&<!8_FQE0F,* /;V+2]+L=$TNWTW3;:.VL[=-D42
M#A1_,DG))/)))/)H DNKZTL?)^UW4%OY\JP0^;($\R1ONHN>K'!P!R:L5S'C
MSP39^/?#PTF\NI[;RY?/AEAP=L@5E7<".5^8D@$$XZBO/++X=_%?PV\EKX?\
M=6LNGA42+[=N8JJK@!4=)!&!DC"GD ?0 'M5?..J7K_$+]HW3#HTD%S8Z3+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOH89>XM>[W"BBBLCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#Q'XD:#K%_\=/".HV>E7UQ8V_V/SKF*W=XX]MR[-N8# P""<]!7MU%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?,'[1W_)0]/_[!4?\ Z-EKZ?KY@_:._P"2
MAZ?_ -@J/_T;+0!S_P $O^2O:%_V\?\ I/)7U_7R!\$O^2O:%_V\?^D\E?7]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF7P0\93>*?!AM+V4RZAI;""1V;+21D?(Q]^"OOMSWKTV@ HKC_'7Q'T?X?\
MV#^UK:^F^W>9Y?V1$;&S;G.YE_OCIGO7'_\ #1W@_P#Z!NN?]^(?_CM 'L%%
M>/\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..T >P5\P?M'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JJ=,T\S><;&V,I;?O\
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M6&&.WA2&%%CC0!551@ 4^N&M6=1W>Q]'@<##"0LM6]W_ %T"BBBL3N"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;2!1*?4J1\I^A(]ATKBO&?COQ!\6]7L]*T_3'2W23-O8P$R,SGC>[8'0'KP
M"?<T =-^S;I3R^(]8U<J?+M[5;<$C@L[!N/<"/\ 7WKZ1KD/AKX*3P-X0@TU
MBKWLK>?>2*<@RD 8'L  !],]ZZ^@ HHHH **** "OF#]H[_DH>G_ /8*C_\
M1LM?3]?,'[1W_)0]/_[!4?\ Z-EH Y_X)?\ )7M"_P"WC_TGDKZ_KY ^"7_)
M7M"_[>/_ $GDKZ_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M &\?^D\E?7] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7S!^T=_R4/3_P#L%1_^C9:^GZ^8/VCO^2AZ?_V"H_\
MT;+0!S_P2_Y*]H7_ &\?^D\E?7]?('P2_P"2O:%_V\?^D\E?7] !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4C,%4LQ 4#))/ %0WE[;:?:O<W<RQ0H
M,LS'_.37DOBKQI<:XS6MKN@L ?N_Q2^[>WM6M*C*H]-CAQN/I82-Y:OHC4\:
M>-8;Z"72=."R0-@2SD9#8.<+^(Z_EZUP%6+&QN=2NTM;2%I9G/"K_,^@]Z]4
MT+P!IUC9,-2C2\N95PY.=J#T7O\ CU^E>@Y4\/&Q\S&CB<SJN;V[]%Y'D=*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^8/VCO\ DH>G_P#8*C_]&RU]/U\P?M'?\E#T_P#[!4?_ *-E
MH Y_X)?\E>T+_MX_])Y*^OZ^0/@E_P E>T+_ +>/_2>2OK^@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K,UO7K'0;,SW<GS'_5Q+]YS[#^M9OB?QA:>'XS#
M'MGOV'RQ \)[MZ?3J?UKR+4-1N]5O'NKR9I96[GH!Z =A750PSGK+8\?,<UA
MA[TZ>L_P7]=B]K_B.^\0W7F7#;(5/[N!3\J?XGWIFA>'[[7[SR;5,(N/,F;[
MJ#W]_:M+POX-NM>D6XFW06 /,F.7]E_QZ?6O7+"PM=,LTM;.%8H4Z*._N?4^
M]=%6O&DN2&YY6"RZKC)>VQ#=G][_ .!_2*6@^'K'P_:>5:INE8?O)F'S.?Z#
MVK6HHKSG)R=V?54Z<:<5""LD%%%%(L**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^8/VCO^2AZ?\ ]@J/_P!&RU]/U\P?
MM'?\E#T__L%1_P#HV6@#G_@E_P E>T+_ +>/_2>2OK^OD#X)?\E>T+_MX_\
M2>2OK^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]_XO_C5>D>%_#EGX3\.6FAV$D\EM:[]C3L"YW.7.2 !U8]J ->BBB@ HHHH
M***^?OB!XH\3>/\ QY-X"\)2/%9VS-#=RQ.R"0@;93*V 1&I)7;R&/\ >)4
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MO?F0DK@@1?<VYR0&#$9ZG JYXH^$7A#Q'I;V\6DVFF701A!=6,"Q&-CCEE7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX5\=6MUI]Q8HL,-PULP*1!,JLJ8W @;0" <@C.,%C[5IFNZ1K7F_V5JMC?\
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MD9.!M!P016)\>O!VJ7,EAXST;SVFTV+9<^2^'A16+I*@ S\I9MQSQ\IQ@,0
M>W45QGP^^(ND>.M+A$%S&NL1VZO>V>PH4;HQ4'.Y-W0@G 9<X)Q5?XA_$[2/
M!.EW4<5W:W&NA,06!8L=QV\R;<[0 P;#%=P& >X /+;5+?Q5^U//*MI/+;6=
MRQDR"/+>WBV!R5/"^:BXR><J#UQ7T;7C/P%\(WEI9W_B_64G_M#5?E@:<G>T
M)(=I"2>=[8/(S\F02&KV:@ KQ7]I'38I?">D:F6?SK>]-NJ@C:5D0LQ/&<YB
M7'/<_A[56!XV\.?\);X,U30Q)Y<EU%^Z8M@"12'3<<'Y=RKG SC..: *?PSU
M*'5?AIX=N8%=46R2W(< '=$/+8\$\;D./;'3I75U\^_"/QPO@6XU#P3XSE?3
M7AN ;4W 8K&S$!D+9(5#E74@!>78MR,^YZQK>E^']/>_U>^@L[9<_/,^-Q )
MVJ.K-@'"C)..!0!Y)^TEJ4,7A31],97\^YO3<(P VA8T*L#SG.95QQV/X^C^
M =*71?A_H-@ML]LZ64;RPR;@RRN-\F0W(.]FX[=.*\1DDN?C?\7856&1O"^E
M/M9E+[#"&)W')4J\I '&& QP=A-?1-]>V^FZ?<W]W)Y=M;1--,^TG:B@EC@<
MG@'I0!8HKS3P1\:-$\::^VBK8W=E=R-(;7S,.LR*,C)'W'(#';R!M^\20*Z#
MQ_XWA\ Z-9ZI<64EW!->I;2+&X5D5E9BPR,,0%^[D9SU% '5T5QFB_%?P1KE
MOYL/B"TM75%9XKYQ;LA8?=^? 8C!!VD@>O(S7U_XQ>"- C;=K$=_/L#K#IV)
MRP+8^\#L!')(+ X'N,@'F'CK3H= _:/\.7.F,]N^HW%I<3B,A!N>8Q.!M X9
M5.[.<EFSUKZ*KY]\ ^'=2^)/Q(D^(^K6*66EQSB2VARV9I(U"Q[3D$A"JEFZ
M%EP!]X+]!4 %%%% '@/Q2_Y.%\%?]N7_ *5/7OU?,O[0T\UK\2]*N+:62*>+
M38I(Y(V*LC":4@@CD$'O7K?A#XN>%O$.AV\][K-CI^HK$GVNWNI!;A9#D'87
M.&7()&"2 1G!.* ._KP'X6_\G"^-?^WW_P!*DKK/&OQFT73K>;2?#4[ZOKUP
MAAM?L"B6..5@ AW8(<_-D*H;)7:<5YW\ ;&YTSXJ:U87D?EW5MI\T,R9!VNL
MT089'!P0>E 'TM7S%^SG_P E#U+_ +!<G_HV*OIVOF+]G/\ Y*'J7_8+D_\
M1L5 'MWQ,\(_\)IX'O=-C7=>Q_Z19\_\ME!P.H'S LN3P-V>U<!^SQXN^V:/
M=^%+IOWUAFXM>.L+-\XX'\+MG)))\SCA:]NKYJ^,GAV\\">-(?%WAZ2>UCU/
MSA),C$F&X=6$F&(^7>KDKSD$.1C P 6-3D_X7%\<8M-CD\WP]I.=VU\H\2,/
M,88?GS'(0,O.TH<?*:^C:\Q^!OA'_A'/ R:C<+B^UC;<OS]V+!\I>"0>"6SP
M?GP>E>G4 ?,7[.?_ "4/4O\ L%R?^C8J^G:^8OV<_P#DH>I?]@N3_P!&Q5].
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,'[1W_)0]/\ ^P5'
M_P"C9:^GZ^8/VCO^2AZ?_P!@J/\ ]&RT <_\$O\ DKVA?]O'_I/)7U_7R!\$
MO^2O:%_V\?\ I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBCX;^%/%[O/JNE1F\9&7[7 3%*"5 #$K]\@ 8WA@,=,9KJZ* /(/^&<O!_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\P?M'?\E#T_\ [!4?_HV6OI^OF#]H[_DH>G_]
M@J/_ -&RT <_\$O^2O:%_P!O'_I/)7U_7R!\$O\ DKVA?]O'_I/)7U_0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %,EEC@B>65U2-%+,S'  '4T^O+_'WBK[7*VCV,G[B,_OW4_?8?P_0?S^E:
M4J;J2LCDQF+AA:3G+?HN[,7Q=XED\0ZC^[++90DB%#W]6/N?TJ#PQX>F\0ZF
M(1E+:/#3R#^$>@]S6=ING7&JW\5E:INEE.!Z =R?85[AH>C6^A:9'9VXR1S(
M^.7;N37?6J*C#ECN?-8'"SQ]=UJWP]?/R_KH7;:VAM+:.WMXQ'%&H5%'0"I:
M**\P^O225D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J.>9+>WDFD^Y&I8_0"H;S4K.P7-S<1Q_[)/)_#K7
M+ZSXL@NK26TM87(D&TR.<?D* .<U&_FU*\>YF8DL?E7LH[ 55HHJ@"KUKK%_
M96[06URT<;')  /Y>E4:LZ?:&^U""V&?WC@$CJ!W/Y4 1SW,]RVZ>:25O5V)
MIB(\C!44LQZ!1DUZ%;>%-*M\%HFF8=Y6S^@P*UH;:"V7;!#'$OHB@?RI7 \Z
MMO#FJW6"MHR+ZR_+^AYK8MO!$AP;J[5?]F)<_J?\*[*BBX&+;>%=*M\%H6F8
M=Y6S^@P*TQ96JP- MO$L3##(J@ BIZ*0'%ZEX-F61I-/=70\B-SAA[ ]#66/
M#&L%MOV,Y]W7'\Z](HIW Y/2?!XAE6?4'5]O(B7D?B?Z5UE%%( HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KY@_:._Y*'I__ &"H_P#T;+7T_7S!
M^T=_R4/3_P#L%1_^C9: .?\ @E_R5[0O^WC_ -)Y*^OZ^0/@E_R5[0O^WC_T
MGDKZ_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***Q?$WB&'P]I;3MAKB3*P1G^)O4^P[TXQ<G9$5:D:4'.;LD8_CKQ
M5_9-J=.LY/\ 39E^9@?]4A[_ %/;\_2O)T1I'5$4L['  &233[JYFO+J2YN)
M#)-*Q9V/<UZ)\/\ PKY:IK5]'\[#-M&PZ#^^?Z?GZ5Z:4</3\SX^4JN:8JRT
M7Y(W?!OAA= L/-G4&_G ,AZ[!_=']??Z5TU%%>;.3F^9GUU&C"C35."T0444
M5)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9VLZO#I
M%IYCC=*W$:9ZG_"O/[_5[W47+7$[%3TC!PH_"@#U ,&S@@XZX-+7D2NZ,&1F
M5AT(."*Z'2?%MQ:#R[W=<18X;/SC\>].P'>5'-<0VT9DGE2-!_$[ "N'O?&-
M]/E;9$MT]?O-^9X_2L&>XFN9#)/*\CGN[9HL!W%[XQL;?*VR/<OZCY5_,\_I
M7.7OBC4[S*K*($/\,7!_/K6;:V-U>OLMH))3WVC@?4]JZ&R\%W$F&O)UA7^X
MGS-^?0?K0!R[,SL68DL>I)ZU>LM%U#4,&"V<H?XV^5?S/7\*[RR\/Z;8X,=N
M'<?QR_,?\!^%:E%P/.-2\-WVFPK*P66/'SM'D[#[_P"-8]>OU2FT?3IVW264
M!)Y)" 9_*BX'EZ(\CA$4LQ.  ,DUW/AG0'L,WEVH%PPPB?W![^YK<M[&TM.;
M>VBB/3*J ?SJQ1< HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7S!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\ DH>G
M_P#8*C_]&RT <_\ !+_DKVA?]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U_0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !165J_B
M+2]$4?;;D+(1E8E&YS^ Z?C7/'XG:1NXM+S;Z[5S^6ZM(TIR5TCEJXW#TI<L
MYI,ZS4=0M]+L);RZ?9%$N3ZGT ]S7B&NZU<:]JDEY.< _+''GA%["M+Q=XJ?
MQ%=(D >.QBY1&X+-W8X_(?\ UZH>'M"G\0:HEK%E8Q\TTG9%_P ?2NZA25*/
M//<^;S+&RQE54*.L?S?]?YFMX)\+'6[S[7=H?L$#<@_\M6_N_3UKU\    8
MZ 5!964&G645I;1A(8EVJH_SUJQ7%6JNI*_0^@P&"CA*7*MWNPHHHK([@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJI?ZE:Z;!YMS*
M%'\*CEF^@H X?Q;.\NO21L?EB554?AG^9K#J[JU^-3U*6[6/RP^!C.>@Q_2J
M54 444J(TCJB*69C@ #))H V-)\-W6JQ"<2)%!G&YN2?H*ZFR\)Z;:X:56N'
M'>3I^7^.:OZ/9'3]*@MF^^HR_P!3R:O5-P&I&D2!(T5%'15& *=110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7S!^T=_P E#T__ +!4?_HV6OI^OF#]H[_DH>G_ /8*
MC_\ 1LM '/\ P2_Y*]H7_;Q_Z3R5]?U\@?!+_DKVA?\ ;Q_Z3R5]?T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH50  , #M2T7 X"/P=JCMAC @]2^?Y"NDT?PW;:6PF=O.N.S$8"_0?UK;HI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7S!^T=_P E#T__ +!4?_HV6OI^
MOF#]H[_DH>G_ /8*C_\ 1LM '/\ P2_Y*]H7_;Q_Z3R5]?U\@?!+_DKVA?\
M;Q_Z3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5\P?M'?\E#T_\ [!4?_HV6OI^OF#]H[_DH
M>G_]@J/_ -&RT <_\$O^2O:%_P!O'_I/)7U_7R!\$O\ DKVA?]O'_I/)7U_0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C^)=>B\/Z2]R
MV&G;Y88S_$W^ ZFG&+D[(BI4C3@YS=DCG/B#XF^R6YT>T?\ ?RK^_8'[B'^'
MZG^7UKS*""6ZN(X($+RR,%11U)-+<7$MW<R7$[EY9&+.QZDFO2OA[X9^RP#6
M;M/WTJ_Z.I'W5/\ %]3_ "^M>I[N'I^9\?\ O,TQ?9?DOZ_$Z3PSH$7A_24M
MQAKA_FGD'\3>GT'0?_7K9HHKRY2<G=GV%.G&E!0@K)!1112+"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"CK%_\ V;I<UR,%U&$!_O'@?XUYA)(\LC22
M,6=CEF)Y)KO?&&TZ)@R*K>8I"D\M]/SK@*: ****8%W2M.;5+];595CR"2S>
M@]!W->AZ;I%II46VWC^<CYI&Y9O\^E<9X1A:37HW7[L2,S?B,?UKT*DP"BBB
MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!)Y*^OZ^0/@E_R5[0O^WC_ -)Y*^OZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4U#5K:>SFU"5%2UGBV.J1[OG()R,EV&"!]W/(84?\-'>#_\ H':Y_P!^(O\
MX[78>!OB-H_Q %^=)M[Z'[%Y?F?:D1<[]V,;6;^X?3M0!U]%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?,'[1W_)0]/\ ^P5'_P"C9:^GZ^8/VCO^2AZ?_P!@J/\ ]&RT <_\
M$O\ DKVA?]O'_I/)7U_7R!\$O^2O:%_V\?\ I/)7U_0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<=""W/&#C? 'P?JGAS0M4U#5K:>SFU"5%2UGBV.J1[OG()R,EV&"!]W/(84
M>OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\P?M'?\E#T_\ [!4?_HV6OI^OF#]H[_DH>G_]
M@J/_ -&RT <_\$O^2O:%_P!O'_I/)7U_7R!\$O\ DKVA?]O'_I/)7U_0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 52O-8TW3VVW=];POC.UY &_+K7'^./&,MA(
MVE::^R?'[Z8=4S_"/?W[5YD[M(Y=V+,3DDG))KKI85S7-)V/#QV<QH3=.FKM
M;]CV35_&VE6>DRW%G=PW-Q]V*-3DECW(]!7CMQ/+=7$D\[EY9&+.QZDFHZT_
M#T=C+KUFFI'%J9 ']#Z ^V<9]J[*=*-%-H\+%8VKCIQC*R6WEZG>_#[PS]D@
M&L7:?OY5_<*1]Q#_ !?4_P OK7>4    # '045Y=2;G+F9]CA<-##TE3AT_$
M****@Z HHHH **** "BBB@ HHHH **** "O/_%>F_8]3-PN/*N<L!Z-W_P ?
MQKO9IH[>%YI6"QH"S$]A7F6KZG)JNH/<-D(/EC7^ZM- 4**V-$T"76?,;S/)
MB3C?MW9;TZBMJ'P/&'!GO69>ZHF#^9)_E0!S.F:=+J=ZEO$.#R[=E7N:]0BC
M6&%(D&$10JCT J"QT^UTZ#RK:((O<]2WU-6J0!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%9VIZ_H^B[?[3U2SLRW*K/,J%OH"<FL^R\=^%-1E$5KXATY
MY&.U5,ZJ6/H <9JU3FU=)V%<Z&BCK14#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBL#Q9XTT/P5IRWFM7?E>9N$$**6DF8#)"J/P&3A02,D9% &_17A,OQ
MU\1Z]]H3P;X)N+KR)1NFD62X_=G=MW)&!L8XS]XC@CGK5O4?&GQKTNW6>X\$
M::Z,X0"UC:X;."?NQS,0..N,=/44 >UT5XSX?_:"TZ2\.G>+-*GT:ZB_=RS*
M&D02*#OW)C>GS  ##GGDC&:]B@GANK>*XMY4F@E0/')&P974C(((X(([T 24
M5SGC7Q'J7AC1HKW2_#UUKL[W"Q&VMBVY5*L=_P J,< J!T_B'-<'_P +>\8?
M]$FUS_OJ7_XQ0!Z_17B%U\?-8L=1@TZ\^'=];WUQM\FVFNG223<=J[5,.3D@
M@8ZFM#_A;WC#_HDVN?\ ?4O_ ,8H ]?HKA/!7CK7O%&L366J>"-1T*&.W,JW
M-T7*NP91L&Z-1DAB>O\ ">*[N@ HHHH **** "BJ>J:I8Z)I=QJ6I7,=M9VZ
M;Y97/"C^9).  .22 .37D(^-'B+Q7?O8^ /"$EV8W4M<WS?*%*DX<*0L9)!P
M3)SMZ9.  >U45X;J/Q:^(?@VX5_&'@NU%I(@$;VKLB[R3@&4-(N<*WR\'H>G
M7UKPSXFTOQ=H<.KZ1/YMO)PRMP\3CJCCLPS^H(R""0#8HK(\4>([/PEX<N]<
MOXYY+6UV;U@4%SN<(, D#JP[UY19?%/XD>+)4F\*>!H%LFB+"6\+,CD-M)64
MM&AYP-HR>#^ ![=17ANH_%KXA>#;A7\8>"[46DB@1O:NR+O). 90TBYPK?+P
M>AZ=?6_#/B;2_%VAPZOI$_FV\G#*W#Q..J..S#/Z@C(() ->BBO+?''QHL?#
MVJ2:!H-C)K.N;Q#LCYBCE.0$XRSN&V@HH'4C<""* /4J*\5F\:?&N#3!J+^"
M--,!17V)&SRX;&/W0F+YYY&W(YSC!KI_A_\ %[1?'=Q_9_D2:=JP0N+65PRR
M $Y\M^-Q  )! /)QD F@#T.BBB@ HHKG/&7CC1? NEI?:Q*^97V0V\(#2RGC
M.T$@8 .220!QW(! .CHKQ'3/B7\4?%OFWWACP78_V9QY;7;'YNH.)&>-7^96
M^Z.. ?>33?CAJ.B:R=(^(7AZ32YR_P MQ;1MM"[@N2C$EDR'.]&;.  IZT >
MU45'!/#=6\=Q;RI-!*@>.2-@RNI&001P01WJ2@ HHK$\3^+=%\'Z6]_K%['"
MH1FBA##S9R,?+&N<L<D>PSDD#F@#;HKYRA^-GB'Q'\3])M-+E^P:%<7\%N+9
MH8V>6,R %G8@D,P)X4X' &2-Q^C: "BBB@ HHHH **** "BBO#?AU\<=1\2>
M,H-%U^WTZV@NE9+>2W1D_?<%0Q>0C! 8  9+%1WH ]RHHHH ***H:YK%GX?T
M.]U>_?9:VD32OR 6QT5<D L3@ 9Y) H OT5X[\)OBQKOCSQ1=Z9J=IIT,$-D
MUPK6T;JQ8.BX.YV&,,>U>Q4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<9XR^*/AGP0Z0ZA</<WC-M:TL]LDL8V
M@[G!8!1@KC)R<\ @'%CXD>*&\(>!-2U6%T6\""&U#.H)E<[05!!#%02^W'(0
M]LFO /A3\-9OB'JEQKVNSR2:5#<'SR929;N;ABI.<@?,"S=3G Y)*@&_J7[2
MVHRVZKI?ANUMIM^6>ZN6G4K@\;5"$'..<]CQSQ7T[]I/7(KAFU30M.N8-F%2
MU=X&#9')9BX(QGC'<<\<^\:5X.\-:(]O)IF@Z=;36Z;(IX[9?- V[?\ 68W$
MD9!).3DYZU<U/0M(UKRO[5TJQO\ RL^7]JMTEV9QG&X'&<#\A0!Q?@OXR>&?
M&-PMEODTS4"B8@O&55E=C@I$^?G()  (!.<@=<>AU\\_%7X*:=HVAW'B'PN)
MXDML/<V)+2@1\ M&>6&.6;<2,$G(VX/=_!/QM-XM\'-;:A<//JFF.(9Y)"2T
ML;9,;DX S@,O4D[,D_-0!Z71110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_^P5'_
M .C9:^GZ^8/VCO\ DH>G_P#8*C_]&RT <_\ !+_DKVA?]O'_ *3R5]?U\@?!
M+_DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC9Z;:1VEA:P6MM'G9#!&$1<G)PHX'))_&K%%% '*>./A_HOCK2Y(+Z".*^"
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MBB@ HHHH **** "BBB@ KY@_:._Y*'I__8*C_P#1LM?3]?,'[1W_ "4/3_\
ML%1_^C9: .?^"7_)7M"_[>/_ $GDKZ_KY ^"7_)7M"_[>/\ TGDKZ_H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^B:+8^'M'M]*TV-H[2W!$:,Q8C+%CR>>I-:%%%8-MN[&%%%%( HHHH ****
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MU_\ :U>_5\U?">;_ (03XS:IX9U&XG2.X\RSC,@\I)9%8-$[*3_$H;;U/[P
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MXP?EKWZ@#YB_9S_Y*'J7_8+D_P#1L5?3M?,7[.?_ "4/4O\ L%R?^C8J^G:
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M (3GPC_T-.B?^#"+_P"*H YO0?A?X%^'\;ZM,L;O"P87^K3(1!\R[<9"HI#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5U= !1110 4444 %%%% !117!_%GQKJ7@3PK;:II<-K+/+>I;LMTC,H4H[9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<_[?\OK7KE+,,PY[TJ3TZL(1ZL****\8T"BBB@ HHHH **** "BBB@ HHHH
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M\:^"M2\!ZS#I>J3VDT\MNMPK6KLRA2S+@[E4YRA[>E?;=?,'[1W_ "4/3_\
ML%1_^C9: .?^"7_)7M"_[>/_ $GDKZ_KY ^"7_)7M"_[>/\ TGDKZ_H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *;(Z11M)(P5%!9F)P !WIU>??$7Q'Y47]BVK_.X#7!!Z+V7\>I]L
M>M73INI+E1S8O$QPU)U)?\.SD?%>OOX@UAYE)%K%E(%/]WU^I_P]*L>"_#IU
MW5@\R9LK<AI<]'/9?Q[^U8%I:37UY%:VZ%YI6"JON:]TT+1X=#TF&RAP2HS(
M^/ON>I_SVQ7H5ZBI0Y8GS&78:6-Q#K5=4M7YOM_70T@ !@# %%%%>8?8!111
M0 4444 %%%% !1110 4444 %%%% #)IH[>%YI6"QH"S$]A7F.KZE)JNH/</D
M)TC7^ZO:MSQ=K'FR_P!G0-\B',I'=O3\/Y_2N=L;.74+R.VA&7<XSV [DTT!
ML>%M'^WWGVJ9<V\)Z'^)NP_K7?U7LK.*PLX[:$81!CZGN35BD 4444 %%%%
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M]3VZ#O7K-+,,PY[TJ3TZON$(=6%%%%>,:!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]7]3VZ#N3ZM6&89ASWI4GIU??_@#C#JPHHHKQS0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C
MGGAM;>2XN)4AAB0O))(P544#)))X  [U\\^,_CSJVIZHFE>!HGA47&R.Z\D2
MRW><!0D;*=H+$XX+'Y?N\@^@?';6YM'^&5Q%!O#ZC/'9F1)"A13EVZ=050J1
MQPQ^AYO]GSP79P:"WBR[M-U_<2R16<KL&"0CY690/NL6WJ2><+Q@$[@#AT^&
MOQ:\616L&KSWPLI,3*VJ:D62,[3@M'N9U;!Q]W(S@XYJ0_!GXF>&+A+C0[I)
M)Y49'DTS4#"RKD'#%]F03C@9^[SCBOJ*B@#YE\,_&OQ7X1U0Z9XRM;J]@18X
MVCN(Q#<VXX^;E07)4YP_+<'<.<_1VEZI8ZWI=OJ6FW,=S9W";XI4/##^8(.0
M0>000>17(?%SPO8^)/A_J<MQ&@N].MY+NUN"F6C*#<RCD<,%VGMT."5%</\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^8/VCO\ DH>G_P#8*C_]&RU]/U\P?M'?\E#T_P#[!4?_ *-E
MH Y_X)?\E>T+_MX_])Y*^OZ^0/@E_P E>T+_ +>/_2>2OK^@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?QUKLFBZ*
M$MW*75TQ1&!Y51]XC]!^->-DDG)ZFO2/BG#(8],F )C4R*3V!.TC\\'\J\WK
MU,)%*G==3XW.JDY8IQ>RM;[@HHHKI/(/8/ &MMJFB&VF.9[/$>?5,?+_ "(_
M"NLKSCX6PONU*;!$>$4'L3R?\_6O1Z\C$14:C2/NLLJ2J82$I[_Y,****Q.\
M**** "BBB@ HHHH **** "BBB@!KNL<;2.P5%!+$] *\TUO5&U74&FY$2_+$
MI[+_ (FM_P 7ZOM7^S8&Y.#,1Z=E_K^5<I:VTMY<QV\*[I)&P!30&OX8TC^T
M;[SI5S;0$%L_Q-V'^/\ ]>O0JJZ=8Q:;8QVT711RW]X]S5JD 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 44C,J(SNP55&22< "O,/%_QO\/:!OMM*QJ]\,C]RV(4/N_?_@.?
MJ*UI4:E5\L%<3:6YZ=)+'#$TLKK'&@RSL< #U)KROQ?\=-"T3S+71%&K7@XW
MHV($/^]_%_P'CW%>&^*OB#XC\82L-3OF%KG*VD/R1+Z?+W^IR:Q-+TC4=;O5
ML]+LI[NX;I'"A8@>I]![GBO:H95""YJ[^70S<^QK>*/'/B'QA/OU:_=X0<I;
M1_)$GT4=?J<GWK,T?0]4\07RV>DV,]W.?X8ESM'J3T4>YP*]F\(?L_L?+N_%
M=U@=?L-JW/T>3^B_G7M>D:+IF@V*V6E64-I;K_!$N,GU)ZD^YYJZV94:*Y**
MO^0*#>Y\[7'P!\3PZ"+R.YM)M0SEK%&QA?9S@%O;I[FO.M0\.:WI3E+_ $B^
MMB/^>L#+_,5]NT5QT\WJQ^-)_@4Z:/C;0_AYXJ\0W"166C72HQP9YXS'&OKE
MFP./0<^U?2?PZ^'5EX#TQOG6YU2X ^T7.,#']Q/11^IY/8#MJ*PQ685*ZY=D
M.,$@HHHK@*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8'C;PS_PF
M/A"^T'[7]D^U>7^_\OS-NV17^[D9SMQU[UX__P ,RC_H;O\ RF__ &VO?Z*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF#]H[_ )*'I_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%17-S%9
MVLMS.X2*)2[L>P% FTE=G(_$/7O[/TH:= ^+B[&&P>5C[_GT_.O*889+B>.&
M)"\DC!54=23T%7=;U676M6GOI<CS&^1?[JCH/RKKOAOH/GW3ZQ.G[N$E( >[
M]S^ _G[5ZD4J%*[W/C:LI9EC.6.W3R7<[KP]H\>AZ-!9)@N!NE8?Q.>I_I]
M*U***\QMMW9]A3A&G%0CL@HHHI%A1110 4444 %%%% !1110 53NM6L+)BMQ
M=Q(PZKG)'X#FN?\ $_B"2"1K"S?:P'[V0=1["N,)).2<FG8#N=:\3VHTYDT^
M?S)Y/ER 1L'<\UPX!8@ $D\ #O25I:#/;6^LV\ETN4!P"3PK=B?I0!V_A_21
MI6G@.!]HE^:0^GH/PK6HHI %%%% !1110 4444 %%%% !1110 4444 %?,/Q
MK\;7&N>*)M#MYB--TU_+**>))APS'Z'*CZ'U-?3U?%GC6VFM/'&N0W 82+?3
M$EARV7)!_$<_C7K913C*JY/=(BH]#"HHHKZ,Q"O0_!7P?\0>+%AO)U_LW2Y
M&%Q,OS2*>Z)U/U.![FO/.M?:?@NWEM/ ^A03J5E2PA#*>JG8./PZ5YV8XJ>'
M@N3=EPC=E+PE\//#W@R$?V=9A[O&'O)\-*WT/\(]ABNJHHKYF<Y3?-)W9M:P
M4445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'B?X2^#O
M%4LUQ=Z9]FO9>6N[)O*<G=N+$?<9B2<LRDG/7@8C^'7PTA^'D^L&VU.2\@OW
MC,:20A6B5"^ 6!PQP_7"].G/'=T4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,'[1W_)0]
M/_[!4?\ Z-EKZ?KY@_:._P"2AZ?_ -@J/_T;+0!S_P $O^2O:%_V\?\ I/)7
MU_7R!\$O^2O:%_V\?^D\E?7] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOK^OD#X)?\E>T+_MX_\ 2>2OK^@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>/\ TGDKZ_KY ^"7_)7M"_[>/_2>2OK^@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "HKBY@M(&GN)4BB3EG=L 5+TKQ7Q;XEFU[4G5'(L8F(A0=#_ +1]
MS^E;4:+JRL<./QT<)3YFKM[([JZ^)&B02E(4N;@#^-$ 4_F0?TKA/%OB4^([
M^-HT>.UA7$:-UR>I/Z?E7/45Z-/#P@[K<^4Q.9XC$0<)O3R.A\':%_;FN(LB
MYM8,23>A'9?Q/Z9KVOI7D7@'7SI>K"PE ^SWCA2<<J_13].U>NUQ8MRY]=CW
M\CC36';CO?7] HHHKE/:"BBB@ HHHH **** "BBB@ HHK!\3:U_9UK]G@;_2
MI1P1_ OK_A0!C>+-;^T2G3[=_P!TA_>L/XF]/H/Y_2N?L;.;4+R.VA&7<]>P
M'<FH "S8 ))/YUZ'X<T4:79^9*O^E2C+_P"R/[O^-,#1T^QATVRCMH1\JCD]
MV/<FK5%%( HHHH **** "BBB@ HHHH **** "BBB@ JMJ.H6FDZ=<7]],L%K
M;H9))&Z*!_GI5DD $DX [U\Q_&'XD'Q/J)T72IC_ &/:O\[J>+F0?Q?[H[>O
M7TQU83"RQ%3E6W4F3LCF/B%XYN_'/B%KM]T=C#E+2W)^XGJ?]H]3^ [5;^&?
M@"?QSKP$H>/2;4AKN8<9]$4_WC^@Y],X/A;PS?\ B[7[?2=/3]Y(<O(1\L2#
MJ[>P_4X'>OK_ ,,^'+#PIH-OI&G1[88A\SG[TCGJ[>Y_^MT%>WC<3'"4E2I;
M_EYF<5S.[-&UM8+&TAM;6)(;>% D<:# 50, "IJ**^:W-@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPGX@? '[?>7.K>$98
M+=Y/G;3)!L3=@D^4W1<G;A" HR?F P![M7F'C3XX>'_">H76EV]O/JFI6^ Z
MPLJPJ^?F1I.2& ZX4\\'!S@ \HM+OXU^$(CH]K;:V88-H55LA>HHVC"I)M<;
M0 !M4X'/ .:DG\6?'"YMY('M=?5)%*,8]%", 1CAA$"I]P014]Q^TAXI:XD:
MVTG1XX"Y,:2)*[*N> 6#@$X[X&?05[I\//$=YXM\"Z;KE_'!'<W7F[T@4A!M
ME=!@$D]%'>@#PCP[\%?&/BS5X]2\6S3VEM+Y;SS74_F74R;>  =Q5@ J_/C;
MD<'!%?1VAZ-9^'M#LM(L$V6MI$L2< %L=6;  +$Y)..22:YSQQ\2M*\ 3V<>
MK6&HRI=JS12VJ1LI*D;E.YP01E3TQ\PP>N.@\.Z_8^*- L]:TUG:TND+)YB[
M64@E64CU!!'&1QP2.: -.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF#]H[_ )*'I_\ V"H_
M_1LM?3]?,'[1W_)0]/\ ^P5'_P"C9: .?^"7_)7M"_[>/_2>2OK^OD#X)?\
M)7M"_P"WC_TGDKZ_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ:R-I5
MXL6?,,#A,>NTXKY]/7FOHRO#_%UC::?XDNH+*0-%G<5 _P!6QY*_A7=@I:N)
M\[G])N,*G;0PZ***[SY@FM%D>]@6+/F&10N/7/%?0U>8^ _"DTMW%K%[&4@C
M^:!&&"[=F^@ZUZ=7FXN:E))=#ZW(\/.E2E.>G-M\@HHHKD/<"BBB@ HHHH *
M*** "BBFNZQQM([!4498GH!0!5U/48M,LGN9><<*O=F["O,KNZEO;J2XF;=(
MYR?;VJ_KVL-JUZ67(MX^(E_J?<T:#H[:M>A6R+>/F5OZ#W-,#7\)Z)YCC4KA
M?E4_N5/<_P![_"NSIJ(L<:HBA448 '0"G4@"BBB@ HHHH **** "BBB@ HHH
MH **** "BBO/OBI\1(O!6C?9[-U;6;M2+=.OE+T,C#V[>I]@:TI4I59J$-V)
MNQR?QK^)/V**7PIH\W^D2+B^F0_ZM3_RS!]2.OH..YQX'9V=SJ%[#9V<+S7,
M[B..-!DLQX %1S327$TDTTC22R,7=W.2S$Y))[FOI'X-?#;_ (1^R3Q#J\.-
M4N4_<1..;>,_R=AU]!QW-?2-T\OH:;_FS+63.H^&_@*V\#: (FV2:G< /=SC
MN>R+_LC]>3].THHKYJI4E4DYR>K-4K!1114#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"BI:Z#X)_\DAT+Z3_^CY* +OQ6T2'7?AIK<,NQ7M[=KR*1HPY1HAO^7T)
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M#X)?\E>T+_MX_P#2>2OK^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9);1<XY9N[-W-9OAG1?[.M?M$Z_Z5*.<_P "^G^-;U# ****0!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKZ_KY ^"7_)7M"_[>/\ TGDKZ_H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=0/J>I_#TKKZC$UN>7*MD=&48'V%/VDU[TOP04445RGL!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ3XHTMM-UJRCN[0L'V,2I5AT*L""IZC((X)'0FO-/^&CO!__ $#M<_[\1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,'[1W_ "4/3_\
ML%1_^C9:^GZ^8/VCO^2AZ?\ ]@J/_P!&RT <_P#!+_DKVA?]O'_I/)7U_7R!
M\$O^2O:%_P!O'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8/VCO\
MDH>G_P#8*C_]&RU]/U\P?M'?\E#T_P#[!4?_ *-EH Y_X)?\E>T+_MX_])Y*
M^OZ^0/@E_P E>T+_ +>/_2>2OK^@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK)\0Z];^']--U,-[L=L48
MZNW^'J::3D[(BI4C3BYS=DC5)"J2Q  Y)/:J<VL:=!%+*]];[8E+/B0$@8ST
MKQ/5]?U'6YS)>7#,N<K$IPB?0?UZUF5VQP6GO,^>J\0:VIPT\V:OB'6Y=>U>
M6\DRL?W8D/\  @Z#Z]S]:VO ?AS^UM1^W7*9L[9@<$<2/U ^@ZG\/6N17!8!
MC@9Y(&<5[WH=M96FBVD6GD-;>6"C]WSSN/N:UQ$_90Y8G'E>'^MXEU:KO;7U
M?^1H4445YA]@%%%% !1110 4444 %%%% !39)$BC:21@J*"68] *=7%^+=:\
MQSIMNWR*?WS#N?[OX4 8^N:L^K7YDY$*?+$I[#U^IJ7P]HYU6]S(#]FBYD/K
MZ+6=9VDM]=QVT"Y=S@>WN:].TZPBTVRCMH1PO5N['N33 LJH50J@  8 ':EH
MHI %%%% !1110 4444 %%%% !137=(XV=V"HH)9F.  .YKS_ %OXT^#-&F:%
M;R;4)%.&%C'O _X$2%/X$UI3I5*CM!7$VD>A5@^+_%NF^#-"DU/47S_## I^
M>9^RC^I["N+M_C[X.GCE9X]3MV1"RK+;KER.BC:QY/O@5X'XT\9:CXVUU]1O
MFV1KE;>W4Y6%/0>I]3W/X =^%RVI4G^]5DB9326A6\4>)]2\7:Y-JNIR[I7^
M5(U^Y$G95'8#_$]Z['X5?#*7QC?#4M21X]#MW^8]#<L/X%/IZG\!STH_#3X<
M77CC5?-G#PZ/;L/M$X&"Y_YYI[GN>P_ 'ZLL;&UTRQ@LK*!(+:! D<:# 4"N
M_'8V-"/L:6_Y$QC?5DD$$5K;QV\$:10Q*$2-!A54#  '85)117SIJ%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >0_M&_\D[L?^PI'_P"BI:M_ '3=.M?AM'>VC(]Y
M>7$C7C J61E8JJ' R %PP!_OD]&KJ/B1X7;Q?X$U+2H$1KPH)K4LBDB5#N !
M) 4L 4W9X#GMD5XQ^S[XUBTK4[KPOJ$Z16]\XELV<@#[1PI3..2X QDXR@ &
M6H Z#]I739I=$T'4U9/)M[B6W=23N+2*&4CC&,1-GGN/P[OX07UQJ'PIT">Y
MD\R187A!P!A(Y&1!QZ*JCWQSS4GQ2\)S>,O =YIMG"DNH1LMQ:!Y"@\Q3R,]
M,E"ZC/&6&<=1XQ\%OBCI/@ZQO-$UYI(+6:X^T0W,<)<(Q3#A\$G'R(!M4\DY
MXZ 'L'Q<\+V/B3X?ZG)<1QK=:=;R7=M<%,M&4&YE'(X8+M/;H<$J*XO]G3Q/
M<7VC:CX=NIX"FG[9;./@2;'9S)_O*&P<XX+X)P0 ?$CXV^'9_"=WI?AR?^TK
MK4(I+:1VADC2"-EVLQW!2S$$@ <=ST :O^SCX9D@LM3\37,&W[3BTM';<"4!
MS(0/NE2P0 \\HPXYR >[4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5\P?M'?\E#T__L%1_P#H
MV6OI^OF#]H[_ )*'I_\ V"H__1LM '/_  2_Y*]H7_;Q_P"D\E?7]?('P2_Y
M*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>4?$RYDDU^" D^7% "!VR2<G^7Y5ZO7G/Q/
MTOFTU564?\L'4GD]2"/U_2NC"M*HKGEYS&4L)+EZ6/.:***]4^*"O6_AM<R3
M>&7B<Y$,[*GLI ./S)_.O)55G8*H+,3@ =Z]N\(:.^B>'H;>48GD)EE'HQQQ
M^  %<N,:Y+'MY%";Q#DMDM3=HHHKS#ZX**** "BBB@ HHHH ***KWMY%86DE
MS,V$09]R>P% &=XBUD:79;(F'VF480?W1W:O.B2S$DDDGDGO5G4+Z74;V2YF
M/S,>!V4=@*W/"FB_:IQ?W"_N8S^[!_B;U^@_G3 V_#.B_P!G6GVB9?\ 29AS
MG^!?3_&MZBBD 4444 %%%% !1110 4444 %%%% 'SC\:OB)=:AK%QX8TV=H]
M/M&V710X,THZJ3_=4\8]03SQCQVM'7Q./$>IBZS]H%W*),_WMQS6=7V6&HQI
M4U&)SMW85:TV.TEU.UCOY9(K-ID$\D:[F5,C<0.YQFJM%;/5"/N+1M*L-$TB
MVT_2X4ALX4 C5.<CUSW)ZD]ZO5C>$!*/!6@B?/G#3K?S-W7=Y:YS^-;-?$SO
MS.[N=*"BBBI **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'DO[1,\T/PXMTBE=$FU*))55B
MZ[)&PWJ,JIP>X![4GP!\+V.G>!X_$ CCDU#4WD!F*?-'$CE!&#D\90L<8SD
MYVBN\\9^$[/QKX7NM%O'\KS<-%.$#-#(#E6 /X@XP2I89&<UX)X!\7ZM\'M?
MD\,>+K"2VTVZ<3L0H9H&8 >:I7(D0A0& )QMXY!5@#Z:HKF+'XC^"]0LX[J'
MQ1I2QOG GN5A<8..4<AAT[CWZ58_X3KPA_T-6A_^#"+_ .*H WZ*P/\ A.O"
M'_0U:'_X,(O_ (JK^F:[I&M>;_96JV-_Y6/,^RW"2[,YQG:3C.#^1H T****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^8/VCO^2AZ?_P!@J/\ ]&RU]/U\P?M'?\E#T_\ [!4?
M_HV6@#G_ ()?\E>T+_MX_P#2>2OK^OD#X)?\E>T+_MX_])Y*^OZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M./W(/9?7\?Y?6L#P[IT6I:HL<S 1H-[*>KX[5Z2    , =J& 4444@"BBB@
MHHHH **** "BBB@ HHK+\0Z_8>&-#N=6U*79;P+G ^\[=E4=R33C%R=EN!B?
M$3QU:^!O#[73;)-0GREG;D_?;^\?]D=3^ [U\CZA?W6JZA/?WT[3W5PYDDD<
M\L36IXN\57_C'Q!/JU^V"WRPP@Y6&,=%']3W))KL?A%\.#XLU0:KJ<1_L:T?
ME6'_ !\2#G9_NCO^7?CZ;#T88&BYU-^O^2,6W)Z'7_!/X;>2L7BS68/WC#=I
M\#C[H_YZD>O]W\_2O<Z15"J%4 *!@ =!2U\_B,1*O4<Y&J5D%%%%8#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMD-E[!=2&^4ODL[?=<#)PI0*O09*-[D@'+_\,RC_ *&[_P IO_VVC_AF4?\
M0W?^4W_[;7O]% '@'_#,H_Z&[_RF_P#VVO0/AG\,_P#A70U0?VO_ &A]N\K_
M )=O*V;-_P#M-G._VZ5W]% !1110 4444 %%%% !117"_%?PWK_BCPM;6/AV
MX\B\2]65V\\Q9C".",CW9>* -SQ/XRT+PAI[W>L7\<)"Y2 ',LI]%3J?KT'<
MBOG#P7XPU?Q+\:M.O;F\N4BO+YG^RB9C&B[3A<=" ,#IVK;TO]G/7[N[\S7-
M:LK>(D%C!OFD;UZA0/KD_2N*^&4(M_B_HT*DE8[UD!/4X#"@#['HHK#\8ZPW
MA_P;K&JQD"6VM7>(GIOQA?\ QXB@#QSXJ?&G4+76)_#OA258C WE7%ZJAG:3
MH4C!X&.A/7/3&,GF[;X=_%W5[4:E+>7\<CC<J76ILLI[C@M\OT.*K_ ;08]<
M^(;7]VGFQZ="UR"_.920JD^_+-]5%?5= 'RSH7Q1\;?#S7QI?B@7=W;1L!/:
MWIW2JI_BCD/)]N2I'IU'T[I]_;:IIUM?V4HEMKF-98G'\2D9%>0_M%>'H;OP
MG9ZZD8^U6,XB=^YB?/!]<-MQZ9/K4_[.^N/J'@J[TJ63<^FW/R#/*QR#</\
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M4E3N8Y,G'U4X!Z@]*^K:\X^-_AZ'6_AM>W/EAKK32+J%^X (#CZ;2>/4#TH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"NBKS<=C'B)V7PK;_,N,;!1117"4%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?D5_.O=OAQ<"Y^&WAR0-N T^%,_[JA<?I0!U%?+_ .T:H'Q$L2  3I49/O\
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH;2UM[&TAM+6%(;>%!''&@PJ*!@ #TJ:@ HHHH **** "OF#]H[_ )*'I_\
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MS/<GN:]#'XM8>'L:6_Y(F,;N[+0 4    < #M2T45\Z:A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5[VQL]2LY+2_M8+JVDQOA
MGC#HV"",J>#R ?PK(_X07PA_T*NA_P#@OB_^)K0UO6+/P_H=[J]^^RUM(FE?
MD MCHJY(!8G  SR2!7RQJ?B'QC\:O%$>D6J[;3S3+#9J<0VJ8"F21@,M@?Q'
M/+$*!N"T >V:EJ7P:TJW6:Y3PBZL^P"VM(;ALX)Y6-6(''7&.GJ*KZ=K_P %
M=5N&@MX?#".J;R;G34MUQD#AI$4$\],YZ^AKEM*_9I@5[>35_$<CKLS/!:6X
M0[MO19&)X![E.0.@SQ<U/]FO1Y?*_LKQ!?VN,^9]JB2?=TQC;LQW]<Y'3'(!
MZ9!X,\%75O%<6_AK0)H)4#QR1V,+*ZD9!!"X(([UIZ9H6D:+YO\ 96E6-AYN
M/,^RVZ1;\9QG:!G&3^9KY=FTWQ_\#]4%[&Z+9W+K&TL1\VVN=N&V," 5/W@"
M0K??VG&37TGX+\66?C7PO:ZU9KY7FY26 N&:&13AE)'X$9P2I4X&<4 ;]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?,'[1W_ "4/3_\ L%1_^C9:^GZ^8/VCO^2AZ?\ ]@J/
M_P!&RT <_P#!+_DKVA?]O'_I/)7U_7R!\$O^2O:%_P!O'_I/)7U_0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M =:L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?,'[1W_)0]/_ .P5'_Z-EKZ?KY@_:._Y
M*'I__8*C_P#1LM '/_!+_DKVA?\ ;Q_Z3R5]?U\@?!+_ )*]H7_;Q_Z3R5]?
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F7Q-U;S;NWTJ-OE
MA'FR@?WC]T?@,G_@5>D75Q'9VDUS,VV*)"['V R:\"U&^DU+4KB]E^_-(7(]
M/0?@.*Z\)"\N9]#P\\Q/LZ*I+>7Y(M>'=*.LZ[:V6#L9]TA'9!R?TX_&O=U4
M*H50  , #M7!?#/2?*L[C59%^:8^5$3_ '1U/XGC_@-=]2Q4^:=NQIDN&]EA
M^=[RU^70****Y3V HHHH **** "BBB@ HHHH *0D $D@ =2:6N9\7:M]FM18
MPM^]F'SD?PI_]>@#G/$&JG5-19D)\B/Y8Q[=S^/^%/\ #>D_VGJ :1<V\.&?
MW]%K)BB>>9(HU+.Y"J!W)KT[2-.32]/CMUP6^](W]YN],"]1112 **** "BB
MB@ HHHH **** $)"@DD #DDU\O?%_P"(I\6:M_96FS9T:S<X93Q<2#@O]!R!
M^)[\=O\ &WXC?8;>3PII$W^DS+B^E0_ZM"/]6/<CK[<=^/ K&RN=2OH+*SA:
M:YG<1QQH.68]!7O99@^5>WJ?+_,RG+HC7\&^$[[QGXB@TJS&U3\\\Q&1#&.K
M'^0'<D5]@Z'HMCX>T:VTK3H1%:VZ;5'<^I)[DGDFL#X=>!K;P/X=2U&V34)\
M27DX_B?^Z/\ 97H/Q/>NOKAS#&>WGRQ^%?U<J,;!1117GEA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(!1110 4444 %%%% !1110 4444 %%1SSPVMO)<7$J0P1(7DDD8*J*!DDD\
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M^K3Z8'.H1V4SVPCCWL90A*87!W'..,'-?.G_  F7QS_Y]=<_\$2__&J^GJ*
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MCFRI/]FV[M@$J,;Y 0<@EOE7C(!W$9!]V@@AM;>*WMXDA@B0)''&H544#
MX  [4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5\P?M'?\ )0]/_P"P5'_Z-EKZ?KY@_:._
MY*'I_P#V"H__ $;+0!S_ ,$O^2O:%_V\?^D\E?7]?('P2_Y*]H7_ &\?^D\E
M?7] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYC@<8SG (!T]>,^.OC]IVC2FQ\+1P:K=#(DNI"WD1L&Q@ 8,F0&Y!"\J06Y
M\O\ $'C?QK\6]5&E:=:SBU/"Z=8EMA4N,-,V<-@[!N;"C&0%R:]3\#? /2-&
M2.\\3E-4U%7+"!&/V9,,"O! +GCG=\OS$;3C) /-/#7@#QC\6]1&MZQ?SQV$
MGF#^T;KY\X).R*/(^7<QZ808;'(VU]#^#O 'A_P/9^3I-IF=MWF7DX5IY 2#
MM+@#Y>%^48'&<9R3T]% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\P?M'?\E#T_\
M[!4?_HV6OI^OF#]H[_DH>G_]@J/_ -&RT <_\$O^2O:%_P!O'_I/)7U_7R!\
M$O\ DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>
M,M6_LCPY<2(V)YOW,7KD]3^ R:WZ\E^(VK?;=<6QC;,5FN#CNYY/Y# _.ML/
M#GFD>?F>)]AAI-;O1?,XVO<O">D_V-X=MK=EQ,X\V7_>;M^ P/PKRWP9I/\
M:_B2W1US!!^^E],#H/Q./UKVRNC&5-H(\O(<-I*N_1?J%%%%<)](%%%% !11
M10 4444 %%%<OXOU5[:%+&%BKRKND(Z[>F/QY_*@"SJ'BRQLW:.$-<R#KL.%
M'X_X5D7'C6:6WDCBM1$[*0K^9G;[]*Y:BG8!>2?4FO1?#FD_V9IP,BXN)L-)
M[>@_"O.T=HY%=#AE((([&O3=$U'^T]+BN#CS/NR ?WA_G/XT,#0HHHI %%%%
M !1110 4444 %,FFCMX))II%CBC4N[L<!5 R23V%/KP#XW?$;[1))X2TB;]T
MAQ?S(?O,/^60/H/XO?CL:Z,-AY5ZBA$3=D<7\4OB!)XVU[R[9V71[1BMLAX\
MP]Y"/4]O0?4UG?#[P1=>./$262;H[*'#W<X'^K3T'^T>@_$]C6#HVCWNOZO;
M:7IT)ENKAPB*.GN3Z #DGL!7V!X*\(67@OP[#IEH \OW[B?&#-(>I^G8#L*]
M[%UX8.BJ=/?I_F917,[LV=/L+72]/M["RA6&VMT$<<:]%459HHKYIMMW9L%%
M%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *1F5!EF 'N:XOQ'XME2=[+37VA"
M5DF'4GT7_'\JXZ262:0R2R.[GJS,23773PDI*[=B'.Q[-U&117D%GJ-YI\@>
MUN'B/H#P?J.AKK8O'D8LE,MH[70X(4@(??/4?E2GA)Q^'4:FCLJAN;RVLTWW
M,\<2^KL!FO.[[QAJMWE8Y%MD/:(<_F>?RQ6')+)-(9)9&=SU9CDFJA@Y/XF)
MS['?WOC?3X,K:QR7+>OW%_,\_I7.7OB_5;O*QR+;(>T0Y_,\_EBLJSTV]OVQ
M:VTDO;*KP/J>@KHK'P+=28:]N$A7^XGS-_@/UK;DH4MR;R9RLDLDSEY79W/5
MF.2:GMM/O+Q2UO:RRJHR2B$C\Z]'LO"VDV6"+?SG'\4QW?IT_2M@*%4*H  Z
M 5$L8EI%#4.YXO17I^I^%M.U.0RLK0S'DO%QN^HZ5CKX!C#Y;4'*^@B /YYK
M2.*IM:Z"Y&<5'&\TBQQH7=CA549)->I^']+_ +)TI('_ -:QWR8_O'M^ P*7
M2] L-(^:WC+2XP99#EO_ *WX5IUS5\1[3W8[%QC8****Y2@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K'U_08M:MAR([F/\ U<G]#[5L
M4549.+N@W/)KW1-1T]V$]K(%'\:C<I_$56ALKJX?9#;2R-Z(A->Q45UK&.VJ
M(Y#C?#OA)X)TO-1 #(<I#G//8G_"NRHHKEJ5)5'>125@HHHJ!A1110 4444
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M'XIELI[72+K=:Z7YP4%HXL;CQU^9R2>0"Q4$[: /J?P/_P D_P##?_8+M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^8/VCO^2AZ?_V"H_\ T;+7T_7S!^T=_P E#T__
M +!4?_HV6@#G_@E_R5[0O^WC_P!)Y*^OZ^0/@E_R5[0O^WC_ -)Y*^OZ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *>K:A'I6E7-])]V%"P'J>P_$X%>
M!SS27$\D\K%I)&+LQ[DG)KT7XG:MMCMM)C;EOWTN/3HH_F?P%<'I&GR:KJUM
M8QYS,X4D=AU)_ 9->EA8<D'-]3Y+.:[K8A48=-/FST[X=:3]AT)KV1<2WC;A
MD=$' _J?Q%=C3(88[>".&)0L<:A%4=@!@"GUP5)N<G)GTV&H*A2C370****@
MW"BBB@ HHHH **** "N#\9HRZQ&YSM:(8/XFN\K"\5VMM-H[33-LDB.8VQR2
M?X?Q_I0@//:***H KO/!D;)H\C," \Q*^_ &?\^E<II6C76JSA8U*P@_/*1P
MH_J?:O2+6VBL[6.WA&(XUP*3 FHHHI %%%% !1110 44UW6-"[L%4=2QP!6!
MXR\76'@[PW-JUVP<XVV\(/,TA'"CV[D]@#50A*<E&*U8'+_%OXB#P?H_]GZ?
M*/[9O4/ED=8$Z&0^_4#WY[5\M$O+)D[G=S]22:O:WK-[XAUFZU7493+=7#[G
M/8>@'H , #T%>O?!'X<_:YH_%FKP_N(FS81./OL/^6A'H.WOSV&?I:<*> H<
MTM_S?8Q=Y,[;X1?#H>$=(_M/48A_;-X@W CFWC/(3Z]S^ [<^F445\Y6JRJS
M<Y;LU2L%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGGF2&-=TCL%4>I/ IE;WA/37OM9CF*GR;8B1F]Q]T?G_ "J9R48N3!*Y>LO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "FR2)%&TDC!40%F8] !3JY+X@ZM_9_AXVT;8FO
M#Y8P>0G\1_D/QJH1<Y**,<165"E*H^AYAKFIOK&LW5\V<2O\@/91PH_+%=I\
M,=)R]SJTB\#]S%GUZL?Y#\Z\]CC>65(XU+.Y"JH[D]*][T334TC1K6Q3'[I
M&([L>6/YDUZ&*DH4^1=3YC)Z+KXEUI]-?FR_1117FGUH4444 %%%% !1110
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MI-=3H/@YH9DNM2VEE.5@!R,_[1_I3G6A!7;!)L=I/@VSET^":]\[SY%W,@;
M&>G;/3%:\7A;18NEDK'U=V;^9K8HKS)5IR>YKRHJ1:7I\/\ JK&V0^HB7/\
M*K0 48  'H*6BLVV]QA1112 R-:\/6FLJ&?,5PHPLJC]".XKDYO ^IQL?*>"
M5<\$,0?U%>AT5M"O."LF2XIG"6?@2Y>0&\N8XX^XC^9C_0?K796-C;Z=:K;V
ML82,<^Y/J?>K-%*I6G4^)C22"BBBLAA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\P?M'?\E#T__L%1_P#HV6OI^OF#
M]H[_ )*'I_\ V"H__1LM '/_  2_Y*]H7_;Q_P"D\E?7]?('P2_Y*]H7_;Q_
MZ3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSC-7B[A1115%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***:[I&C/(RJBC)9C@ 4 .KC/'Q4I9 2+O4OE,\X..<?A2ZUXT5-T&EX9NAG
M8<#_ '1W^IKBY99)Y6EE=GD8Y9F.2:[L/0DI*<M")26PRBK,EA>0VR7$EM*L
M+_=<J<&JU=R:>QF%=?X"A8W=Y/\ P*@3\2<_TKGM-TB\U68);1$KGYI#PJ_4
MUZ;I.F0Z38):P\XY=R.6;N:Y<552CR]65%:W+U%%%>::A1110 4444 %%%%
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M1T.0P/((/<5M3JQJ*Z.BE6C55XCZ***T-0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH H:UJ]MH.CW&J7@D-O;@,XC&6Y(' _&N)_X75X5_YYZC_WX7_X
MJM[XAVMQ>^ M5MK2"6XG>-0D42%V;YU/ ')KYU_X1#Q-_P!"[JW_ (!2?_$U
MRUZLX2M$XL36J0DE!'MG_"ZO"O\ SSU'_OPO_P 51_PNKPK_ ,\]1_[\+_\
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M_"__ !5'_"ZO"O\ SSU'_OPO_P 57B?_  B'B;_H7=6_\ I/_B:/^$0\3?\
M0NZM_P" 4G_Q-'UBKV#ZU7[?@>Z:?\7?#>I:E:V$$=^)KF9(8]T*@;F( S\W
M3)KO:^9/"WA;Q#;^+M%GGT'5(HH[^!WD>SD5542*222. !7TW730G*:?,=F&
MJ3J)N84445N=(4444 %%%% !7SK\:-1U'QE\1],\!Z6L@%NZ!E(;:TTBAM[;
M2<HD9!SMRN9.U?15?,7@WG]J"Z_["FH_^@S4 ?0WAGPSI?A+0X=(TB#RK>/E
MF;EY7/5W/=CC] !@  :]%% !7&?$WP5#XV\'W5JENCZG;H9;"0@;ED&"4!)
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MP!G&5SD+][C.":[^OG7QA9-X7_:5T.\TZ1(CJD]M*ZI"JA1*QAE'<$L [%L
MY<]QFOHJ@#Y7^(^G0ZQ^T0^EW#.L%Y>65O(T9 8*\<2DC((S@^E;WP?U^^\#
M>/+[X?ZVR1P37#B(E=H%R  K!FVDI(JC'!R2F ,G.9XR_P"3H;7_ +"FG?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBH;NZAL;2:ZN'VQ1(78^PH$VDKLY#XB:]]@TP:9
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M.5R!A> !P. ,\Y)U-1\1:3I.J:;INH7L=O=ZD[):(X($K+C(W8P#\R@ D9)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4445XAH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF#]H[_ )*'I_\ V"H_
M_1LM?3]?,'[1W_)0]/\ ^P5'_P"C9: .?^"7_)7M"_[>/_2>2OK^OD#X)?\
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MX1D#EF[L>YJW2 **** "BBB@ HKR#XD?&>/P[=RZ-X>2*YU"/Y9[E_FCA/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ!':NXKY;_9YU5[/X@S6!D(BO[1UV=BZ$,#^ #_G7U)0 45\_P#[37_,K?\
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M#&@7'^E$%+VZC;_5#O&I_O>I[=.O32^+GQ27PY!)H.B3 ZO*N)ID/_'JI_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5F^(6E3PSJK6\3S3"SF,<<:%V=MA
MP HY))XP*TJ* /D#PE\,_'NIZA-!9V%]HZ21>7/<7B26RF,D97D9;.!P ?>N
M['[,\_D9;Q5&)L?<%@2N?KYG]*^A** /D#6- \9_!S78;J*[:!93^ZNK9BT,
MX'\+J1SU^ZP^F>M?2'PX\<P>/?#"Z@(UAO(6\F[@4Y"/C.1_LD<C\1VK-^-E
MI;77PHU=K@+FW,4L3$?=?S% Q[D,5_X%7F_[-$D@U3Q#&,^6T,+-]0SX_F:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[U1E^>X9>$]0@[#WZG]*[2BBN^,5%61ZD(1@K1"BBBJ*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>+^[!:+$WYEF_E7KGAGPIHWA#3!I^BV:V\1.YV)W/(WJS'DG^7;% &U7R?\
M%KP[>^"/B7_;=DI2WN[@7]I*!PLH8,R_4-SCT(KZPK-UWP_I?B72Y--U>SCN
MK5^=K<%3V92.0?<4 <GX4^+OA3Q%H\-S=:K9Z7>;<3VMY.L>QN^UFP&'H1VZ
MX/%<1\8OBUI%QX=G\.^';U+VXO,)<W$/,<<?4J&Z,6Z<9 &>]/U+]FO39K@O
MIGB*YM8B<^7/;+,1[ AEK4\._L]^&])NHKG5;NXU9XR"(G410DCU49)^A;'K
MF@#/_9Y\'S:=I5YXFO(2DE^HAM=PPWD@Y9OHS 8_W,]Q7MU-CC2&)(HD5(T
M5548"@= !V%.H **** "BBB@ KY@_:._Y*'I_P#V"H__ $;+7T_7S!^T=_R4
M/3_^P5'_ .C9: .?^"7_ "5[0O\ MX_])Y*^OZ^0/@E_R5[0O^WC_P!)Y*^O
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y[Q;XEC\/:;E
M"&O9@1"A[?[1]A^M5&+D[(SK5848.I-V2,3Q]XJ^R1-H]E)^_D'[]U/W%/\
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M^7J?1JVHX;[4SHH83[53[B.""&U@C@MXDBAC4*B(H"J!V %2445VGH!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MS!^T=_R4/3_^P5'_ .C9:^GZ^8/VCO\ DH>G_P#8*C_]&RT <_\ !+_DKVA?
M]O'_ *3R5]?U\@?!+_DKVA?]O'_I/)7U_0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%,EE2&)Y97"1HI9F8X  ZF@-BKJVJ6VC:;+>W381!PHZNW
M91[FO#M7U6YUK4I;VZ;+N?E4=$7LH]JU/%WB5_$&I?NRRV4)(A0]_5C[G]!4
M'ACP]-XAU181E;:/#3R#^%?0>Y[?_6KTZ%)4H\\MSY#,,7/&UE1HZQZ>;[FS
MX$\*_P!J7(U*]CS9PM\BL.)7']!_];UKUBHK:VAM+:.WMXQ'%&H5%'0"I:X:
MM5U)79]'@<''"TN1;]6%%%4-2UBSTJ,&XD^<_=C7EC61V%^BN0D\<?,?+L?E
M[%I.3^E5-2\72WMB8((#;L_#MOSQZ#BBP$GB?Q!]H+6%F_[D<2R _?/H/;^=
M<W;6TMW<)! A>1S@ 4R.-YI%CC4L['"J!R37HF@:&FDV^^0!KJ0?.W]T?W13
M GT;1XM(M-BX:9N9)/4^@]JTJ**0!1110 44$@ DG '>O.=?^-GA'1+EK:*:
M?4IE.&-FH9%/^^2 ?PS6E.C4JNT%<3:6YZ-6/XF\2Z=X3T.;5=3EV0Q\*@^]
M*_9%'<G_ .OT%>;6G[0_AZ1\76DZE O8IL?^HKQOQ[XZO_'.N&[GS%91$K:V
MV>(U]3ZL>Y_H*[\/EE6=2U161+FK:%3QCXOU'QIKLFI:@^U?NP0*?EA3LH_J
M>YKH/AC\-KCQOJ?VBZ#PZ+;M^_E'!E;_ )YJ?7U/8>Y%4?AYX O?'6M")=\.
MFP$&ZN<?=']U?5C^G7Z_66E:79:)IEOIVG6Z06ENFR.->P]?<GJ3W->ACL9'
M#0]C2W_+_@DQC?5DUI:6]A9PVEI"D-O"@2.-!A54= !4U%%?.-W-0HHHH **
M** "BBB@ HHHH **** "N9\7ZW)I]LEI;/MGF!+,.JI[>Y_H:Z:O//'"L-<C
M+=#"NW\S6^&BI5%<F3LCF:***]4R"I[2RN;Z80VL+ROZ*.GU/:H*]"\"HRZ+
M,Q& TYQQU^45G6J>SCS(:5V5=*\#HFV74Y-YZ^3&<#\3_A76P6\-K"(H(DCC
M7HJ# J2BO+G5E-^\S5)(****S&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 45A:YXQT#PZ"-2U.&.4?\L5.^3_ +Y&2/QKS37?CE(VZ+0=-"#H
M)[LY/X(I_J?I6<ZT(;LQJ5Z</B9[,[I&C.[*J*,EF. !7%Z[\5?#&B[HX[LZ
MA<#_ )9V@W#/N_W?R)^E>!ZUXIUSQ"Y;5-2GN%SD1D[8Q]%&!^E9MK:7-]<+
M;VEO+<3-]V.)"S'\!7+/%MZ01QSQS>D$%W<-=WL]RV=TLC.<G/4YJ&NMN/AI
MXJM=%?5)M-98TP6A#!I0O][:.P[]_:N2KDE&2W1PRC*/Q(***]!^''P]N?$6
MH0ZE?PM'I$+[CO&/M!!^Z/49ZG\.M.$'-V0X0<Y<L3W7PS%+#X4T>*<$2I8P
MJX/4,$&?UK4HHKUTK*Q[R5E8****8PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KY@_:._P"2AZ?_ -@J/_T;+7T_
M7S!^T=_R4/3_ /L%1_\ HV6@#G_@E_R5[0O^WC_TGDKZ_KY ^"7_ "5[0O\
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M,\I!ZJF,*?J6!_X#7A%<6(K23Y8GG8O$2C+DCH=*?B!XL,_G?V]>;O3?\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\P?M'?\ )0]/_P"P5'_Z-EKZ?KY@_:._Y*'I
M_P#V"H__ $;+0!S_ ,$O^2O:%_V\?^D\E?7]?('P2_Y*]H7_ &\?^D\E?7]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)!I$'&'N&'SR8_0>@I@0Z%H$6DQB23$ETP^9^R^P_P :VJ**0!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OF#]H[_DH>G_\ 8*C_ /1LM?3]
M?,'[1W_)0]/_ .P5'_Z-EH Y_P""7_)7M"_[>/\ TGDKZ_KY ^"7_)7M"_[>
M/_2>2OK^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,'[
M1W_)0]/_ .P5'_Z-EKZ?KY@_:._Y*'I__8*C_P#1LM '/_!+_DKVA?\ ;Q_Z
M3R5]?U\@?!+_ )*]H7_;Q_Z3R5]?T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!.!DT5YGXW\9_
M:#)I.F2?NONSS*?O_P"R#Z>I[_3KI2INI*R.7%XNGA:?//Y+N0^-O&7V]GTO
M39/]%!Q-*O\ RU/H/]G^?TZ\9965QJ%Y':VL3232'"J/\]*2UM9[VYCMK:)I
M)I#M5%')->R>%/"T'AZSW/MDOI!^]E]/]E?;^=>A.4,/"RW/EZ-&MF==SF].
MOEY(D\,>&;?P[9;1B2[D'[Z;'7_9'M6M>WL&GVS7%P^Q!^9/H/>K%>>>*K][
MO5WAW?NK?Y%'OW/Y_P J\V4G)W9]=2I0I04(*R1;O/&EW(Y%I#'$G8N-S?X5
M6A\7ZK&V7:*4>C)C^6*P:*1H7M4U6YU:Y\V<X4<)&.BC_/>I=&T6?5Y\+E(%
M/SRD<#V'J:S*]2T@P-I%JUO&L<;1@[5['O\ K0!+964%A;+;VZ!$7\R?4^]6
M***0!1110 4444 %%%0W=W;V-I-=W4R0V\*%Y)'.%51U)-&X%?6=8L= TFXU
M/4IUAM;==SN?T '<D\ 5\C^/?'%]XYUUKR?=%9Q96UML\1)ZGU8]S_0"M3XG
M_$:X\;ZMY-LSQ:-;,?L\1X,AZ>8P]3V'8?4UB>"O!NH>-M>CTZS!2%<-<W!&
M5A3U/N>P[G\37T>"PD<-#VU7?\C&4KNR-+X;_#Z[\=:UM;?#I5N0;JX _P#'
M%_VC^@Y] ?K+3["TTK3X+"Q@2"U@0)'&@X4"JOA_0=/\,Z+;Z5ID(CMH1C_:
M<]V8]R:TZ\G&XR6(G_=6QI&-@HHHKB*"BBB@ HHHH **** "BBL37?$=OH\9
MC7$MV1\L>>%]VJHQ<G9 W8NZIJUKI%MYUP_)^Y&/O.?:O-=7UJZUBX\R=ML:
MGY(E/"_XGWJM>WMQJ%RUQ<R%Y&[GH!Z#T%:N@^&I]7<2R9BM >7QRWLO^->C
M3I0HQYI;F3;EHC/T[2;W59&6TA+[1EF)P![9]:?+H>J0N4?3[G([K&6'YCBO
M4K2T@L;9;>VC$<:] /YGU-3UB\8[Z+0KD/,+'PKJMZXW6[6\?=YAMQ^'6N_T
MC2+?1[3R8/F9N9)".7/^'M6A16%6O*IH]AJ*04445B4%%%% !116;KVNV'AS
M29=2U&7RX8^ !]YV[*H[D_YXI-I*[$VDKLTJ*^;_ !)\5?$6MW#K:7+Z;9Y^
M2*V;#X]WZD_3 ]JYJ/Q-KT4OFQZUJ"/G.X7+@_SKE>+BGHCBECH)Z*Y]:T5X
M+X;^-&J:="\.M0?VDH7]W(I"2 ]@QQ@CWQGZUA>)/B?XB\1;X1<?8;-N/(M2
M5R/]INI_0>U4\5"UT6\;34;H]K\2?$7P[X:WQ3W?VF[7C[-;8=@?]H]%_$Y]
MJ\@\2?%SQ!K>^&R8:7:'C; V9"/=^OY8K@HXWED6.-&=V.%51DD^PKT'PW\(
M->UC9/J.-+M3S^]7,K#V3M^)'TKG=6K5=HG)*O6K.T#SUF:1RS$L['))Y)-=
MMX;^%GB+Q!LFEA_LZS//G7((8C_93J?QP/>O:_#?P_\ #WAC;):68FNU_P"7
MJXP[Y]NR_@!745I3PG6;-J>!ZU&<9X;^&'AWP[LF-O\ ;KQ>?/N@&P?]E>@_
M4^]=DRJZE64,K#!!&012T5UQBHJR1W1A&"M%')7WPS\(7\QFDT>..0]3 [1C
M_OD''Z5-I?P\\*Z1,L]MH\+3*<AYBTI![$!B0/P%=/12]G"][$^RA>]D%%%%
M6:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?,'[1W_)0]/_[!4?\ Z-EKZ?KY@_:._P"2AZ?_ -@J/_T;+0!S_P $
MO^2O:%_V\?\ I/)7U_7R!\$O^2O:%_V\?^D\E?7] !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\P?M'?\E#T_\ [!4?_HV6OI^O
MF#]H[_DH>G_]@J/_ -&RT <_\$O^2O:%_P!O'_I/)7U_7R!\$O\ DKVA?]O'
M_I/)7U_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5P_Q/5SH=HP^X+CYOKM./ZUV=Q<0VEN\]Q*L42#+.QP *\G\8>,
MSKF;&S398JV2S#YI".A]A^O\JZ,-"3FFNAY>;5Z<,/*$GJ]CD**?'%),VV-"
MQ]A5H:5=D9V >VX5Z<IQCNSY"GAJU57A%OT12KM?AD&'B"Z?H@M6W'L/F6N2
M-C<B01F%MQZ>GYUT6G"33[&2VC?'G$&8K_%CH/H,G_.,88BK'DLGN>EE6#K/
M$J<HM*.]_P CM=<\6!=UMIK MT:?L/\ =_QKCF9G<LQ+,QR2>234EO;37<ZP
MP1M)(W117=Z'X9AT[;/<[9;KJ/[J?3W]Z\S8^Q,K0_"C2[;G45*Q]5AZ%O\
M>]/I79(BQHJ(H55& H& !3J*0!1110 4444 %%%% !4-W=VUA:2W=W/'!;Q+
MNDED8*JCU)-8'C#QSHO@JP\_4Y\SN,PVL>#+*?8=A[GC\>*^8_&_Q%UKQQ=_
MZ7)]GL$;,-E$QV+[M_>;W/X 5W83 5,0[[1[_P"1,I)'>?$+XXSWWFZ7X3=[
M>VY62_(Q))_US'\(]^OIBO%P)+B8 !Y)9&P ,EF8_P S6KX;\+ZOXLU-;#2+
M1IY>"[]$B7^\S=A_/MFOICP!\*=(\%HEW-MOM8(^:Y=?EC]1&.WUZGVSBO9G
M5P^ ARQ6OX_,S2<CS[X>_ V2Y\K5/%J-%#PT>G X=_\ KH1]T?[(Y]<=*]\M
MK:"SMH[:VACA@B4+''&H55 Z  =*EHKP,1B:E>5YOY&J204445SC"BBB@ HH
MHH ***@N[RWL;=I[F58XQW;O[#UH2OH@/.?%EX]UK\ZELI#B-1Z8Z_KFL.KV
MLW<-_J]Q=0*RQR-D!NO2J->U35H)&+W"BBE56=@J@EB< #O5"/4_#4B2^';-
MDC5!LP0HQD@D$_CC-:M4-&LCI^CVMJWWT3YO8DY/ZFK]>+-IR;1LM@HHHJ1A
M45U<PV5I-=7#A(84:21ST50,D_D*HZKXBT;1%)U/4[:V.,['D&\_1>I_ 5Y;
MX\^*VCZKX>O='TA;J62X4)]H*[$ W G&?F.0".@ZUG.K&"U9E4K0@G=ZG!>-
M/&M_XOU1Y)'>.P1O]'M@?E4>I]6/<_TKEZ**\J4G)W9XDI.3NQ02#D'!]15S
M4-7U+5FC;4+^XNC&NU/.D+;1[9JE6]X+L(=4\9:59W$ G@EG DC;."O4YQ1&
M[=EU"*;?*NI6T/PUK'B.X\G2K&6X(.&<#")_O,>!7KGAKX*65MLN/$%S]KE'
M/V: E8Q[%NK?ABO5+:UM[*W2WM8(X($&%CB4*JCV J6O0IX:,=7J>K2P<(ZR
MU97L;"TTVU2UL;:*V@3[L<2!0/P%6***Z3KV"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD/'
M/Q&TCX?BP.JVU]-]M\SR_LD:-C9MSG<R_P!\>O>@#KZ*\@_X:-\(?] W7?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBN)\<:_J>CWMI'87/DK)&68>6K9.?<&@Y\5B88
M:DZL]EV.VHKQ_P#X3?Q%_P!!#_R#'_\ $T?\)OXB_P"@A_Y!C_\ B:5SRO\
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M;F+'&>,X% 'UI1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KY@_:._Y*'I__8*C_P#1LM?3]?,'[1W_ "4/3_\
ML%1_^C9: .?^"7_)7M"_[>/_ $GDKZ_KY ^"7_)7M"_[>/\ TGDKZ_H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVY$%J&Z>8V<$_0 GWQBKA!SDH1W8/0/%OQ$\.^# $U.Z9[LC<MI;KOE(]<9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OF#]H[_DH>G_\ 8*C_ /1LM?3]?,'[1W_)
M0]/_ .P5'_Z-EH Y_P""7_)7M"_[>/\ TGDKZ_KY ^"7_)7M"_[>/_2>2OK^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME<=J7BK7M8R+_5[R=#UC,I"?]\CC]*\26+@ME<N6.@OA5SZ:U+Q;X>T?(O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSOB:]^WWB\?9[+#D'_:;[H_//M7C'B?XY>)];WPZ:4TBU/&(#NE(]Y#T_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:J+/9R)2^M^[M9W_KU.LHHHJC[0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBJ>JZG;:/ID^H79800@%RHR>2!T_&A*X%RBN(_P"%K>&/^>MU_P!^
M#1_PM;PQ_P ];K_OP:T]E/L1[2/<[>BN(_X6MX8_YZW7_?@T?\+6\,?\];K_
M +\&CV4^P>TCW.WK$\1>*M*\,VXDOYCYC?ZN",9=_H/3W/%8,OQ8\-I"[1M=
M.X4E4\K&X]AGM7BVK:K=ZUJ4U_>REYI6S[*.P'H!6E*@Y/WM$14K)+W3T2Z^
M,UTS_P"B:1"B?]-I2Q/Y 5H:3\8K2:98M5T]K93QYT+[P/JN,X^F?I7CU%=+
MH4[6L8>VGW/JFTN[>^M8[FUF2:"091T.014U>"_#_P :CPS=RVU\\C:;,"Q"
MC<8W[$#WZ'\/2O0_^%K>&/\ GK=?]^#7).A*+LE<Z(U8M79V]%<1_P +6\,?
M\];K_OP:/^%K>&/^>MU_WX-3[*?8KVD>YV]%<1_PM;PQ_P ];K_OP:L6/Q*\
M.ZC?V]E;R7!FGD6- T) W$X%+V4^P<\>YU]%%%06%%%% !1110 4444 >0_%
MOXHZCX>U"V\+^%T\S7+C8SRHBRM%N/RQJG.9&XX(^ZPP"6!7/TGX$W&NV<5_
MX\\1ZM=:F\2@11W <VXRQV&1P^[J.F #NQNSFL?X?VO]K_M)>)+R\GG>;3Y;
MV2$E\YQ)Y(4YS\H1R !C&!V&*^AJ /G77_!?B[X/1MX@\,^()+K0K:X$LMG,
MY4#>VS]Y'G;(,;%+##9.0%QD>S^!_&5CXZ\-1:Q8QO"=QBN('Y,4H )7/1A@
M@@CJ".AR!MWUE;ZEI]S87<?F6US$T,R;B-R,"&&1R.">E?.W[-VHS0^*M:TI
M53R)[,7#,0=P:-PJ@<XQB5L\=A^(!ZG\3-*\<ZT-+T_P??\ V"WE\W[?<^:(
MMF-C1_, 9!DAA\GKSQ7+VO[.ND3>=/KGB+5K^]EE:1IXMD6[/)W!@Y+9R2<\
MYZ=S[-10!\V^)?"WB[X+W$&L^&]9N[S0%N#)) Y/EQL3M"S1@[6#+M7S !S_
M '3MS[OX0\2P^+_"EAKL%N]NEVC$Q.02C*Q5AD=1N4X/&1C@=*Y3XYWUO:?"
MC4H9Y-LEW)## ,$[W$BOCCI\J,>?3UQ5/]G_ $V:Q^&2W$K(5OKR6XB"DY"C
M;'AN.N8VZ9X(^E '9^,_%EGX*\+W6M7B^;Y6%B@#A6FD)PJ@G\2<9(4,<'&*
M\1\/^'/&/QLD.K>)M7GLO#R2YAAA3:DI#'(B3I\H9E\UMQZ#YL'%O]H.]OM6
M\4>'/"5E&[/*HF1!-A9I97,: @X *[3AB?XSTYS[MI6G0Z/H]CIENSM!9V\=
MO&TA!8JBA03@ 9P/2@#QG6O@$^D6_P#:7@C7M2@U:V1F1)YE5I21C:DB!-AQ
MN'.0<@$J,FMCX+_$V^\91WFD:[(DFJVB^=',J;3/$6P<A0%!4E1QC(8<<$GU
MJOF[6[:;PA^T[87-K:I'%J-Y%)&'8N'6X'E2OUR#O:4@'H0.,8% 'TC1110!
M3U'5M.T>W6XU34+6Q@9P@DNIEB4M@G&6(&< \>QKR7Q!\9KO7+P:'\-=.GU2
M_?A[Q[<^7&I  95.,89AEI %&.0P.1Z=XC\+Z-XMTZ.PURS^UVL<HF5/-=,.
M 0#E2#T8_G5C1M#TOP]IZ6&D6$%G:KC]W"F-QP!N8]6; &6.2<<F@#YV_9ZG
MGNOB5JUQ<S/-/+ITKR2R,69V,T1))/))/>OIFOF+]G/_ )*'J7_8+D_]&Q5]
M.T %%%% !17 ?#/XF?\ "Q?[4_XE']G_ & Q?\O/F[]^_P#V%QC9[]:[^@ H
MK \;>)O^$.\(7^O?9/M?V3R_W'F>7NW2*GWL'&-V>G:D\$^)O^$Q\(6.O?8_
MLGVKS/W'F>9MVR,GWL#.=N>G>@#@?VC?^2=V/_84C_\ 14M9W[._B[[;H]UX
M4N6_?6.;FUXZPLWSC@?PNV<DDGS,#A:T?VC?^2=V/_84C_\ 14M>,VMIJG@;
M3/"/C_2#N^TB97,B;T659)$*-P %>/ISNX<C&!@ ^Q**H:)K%GX@T.RU>P??
M;7<2RID@E<]5;!(# Y!&>""*OT %?./[1/B[[9JUIX4MF_=66+F[XZRLOR+R
M/X4;.02#YF#RM>[^*?$%OX5\,:AKET-T=I$7"9(\QSPB9 .-S%1G'&<GBOD;
M4-"OKWP1>>.]4=S/J&KB"(E=HEW+(\LF-H&-P4 J<9#C' H ^DO@I_R2+0OI
M/_Z/DKOJX'X*?\DBT+Z3_P#H^2N^H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M8/VCO^2AZ?\ ]@J/_P!&RU]/U\T_M!Z=>W_Q"L3:6LTX72XPQC0D ^;*<$T$
MRE&*O)V.6^"7_)7M"_[>/_2>2OK^ODSX/:1J.G_%K1);NRGAC!G!=T(4$P2
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M&/Q3^[7_ ('XG/+&4H[.Y]*:S\0/"F@%EU#7+1)5ZQ1OYL@^JKDC\:\^U?\
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M<DF=516%IWC#1M1D$2W!AE)P$G783^/3]:W::=RZ5:G55Z;3"BBB@T"BBB@
MHHHH **I7^KZ?IB@WMW'"2,A2<L?H!R:SE\9:$6P;QE'9FA< _IQ^-)R2W9C
M+$4H.TI)/U-ZBHK:ZM[R$36TT<T9Z,C BI:9JFFKH****!A1110 445RGBCQ
M@=)N!INF0+=ZHRAF5C^[@!Z%S[]AU_3*E)13E)V2$V=717CT\GB74'\R[\27
M43'^"T_=*OM\N,T^UO/%&EOYEIKTEV <F&^'F!O;<>1^&*\]9Q@'+E]K^#M]
M]BN6>_*>O45SWACQ5#KZ/!-";34H!F:V8YR/[RGNO\OY]#7HIIJZ)3N%%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Q/C/Q;)8.VF:>Y6X(_>S#J@/8>_O
MV^O3S=W>1V>1BSL<EF.235C4YGN-5NYI,[WF=CGUR:JU#9^?X_%U,36<I/3H
MNP5VOA'QA/;7,>GZC*9+=R%CD<Y,9[9/I_*N*HH,L-B:F&J*I3?_  3Z HJA
MHMV+W1;*?S5D=H$,A4Y^;:,@^^:OU9^APFIQ4EU"BBB@H**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME8X4_#!/\J3P%:+LH\WY!.52<K0=EZ7^[I^9U&G^#-1N,/?216B?W$/F/^?
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M''(#8&:K#PH!_P L\_62NQAM+FX4M!;S2@'!*(6Q^52_V7J'_/C<_P#?EO\
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M'_"5:G_?B_[XJ^?!AQQ?@GWA_P#LJ;_PALG_ #^K_P!^_P#Z]>Z\/G2ZR_\
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M2LX"0%@V0?+')P  0S,IR<CGCU:@#QG]H/PA<ZOH5GX@L+;S9M-WK=".(%S
M>=Y.<E4(/&#C>QX -=?\,O'MGXT\+V;27L#:U%%MO+;>!)N4A3)MP/E;*MD#
M:"VW.17;UY)K?P)L)M?_ +9\,:Y=^'+EG=V6V3<J%AC]UM9"@^]D9(^; P!B
M@#TCQ!X@T[PSH\^J:I<1PP1(Q"LZJTK!2VQ-Q 9R%.!GFO$/A+:WWCOXIZM\
M0+Y)(H+=F$"]B[IL6/.T!@D7!/!R4)ZFN@@^ J7VL17WBOQ;J6O)$H58Y R,
M0&SM+L[G9RW P?FR"*]6TO2['1-+M]-TVVCMK.W39%$@X4?S))R23R223R:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >/^,]-73?$4P1U*7'[\*#RN2<@CZY_"N?
MJ77+Z34-=O+MF)+RMM]E!P!^6*IB<]QFNF>#FDG'4_.L4XRK2E!:-LGHJ$S^
MBU'YC;PV>12A@ZDOBT,%$TK._N]/F\VTN)(7[E&QGZ^M=AI?Q&N8L1ZG;K.O
M_/2+Y6_+H?TJDZ>$-7MXWCO6TR]9 70HQCW8Y]NOH163=:#<PY>VEM[Z$<^9
M:2"3CW Y'Y5SRISANCTZ;Q>$]ZA.Z\G=?-=/N/5],\0Z7JX M+M#(?\ ED_R
MO^1Z_A6I7@ )4Y&01^E=#I?C36--VHTWVJ$?P3_,0/9NM3<]7#<01>E>-O-?
MY'KU%<KI?CW2K[:ER6LY3VDY3_OK_'%=1'(DL:R1NKHW(93D'\:H]VAB:5=7
MI23'45!=7MM8P^;=3QPQ]-TC 5C'QMX>#;?[0_'R7Q_Z#0.IB*--VJ32]6D=
M!156RU&SU&(R6=S%.HZ[&R1]1VJU0:QDI*\7=!1110,**** "BBB@ HHHH *
M*** "BBB@ HHHH ***XSQ-X^@TF9[.PC6YNDX=F/R1GTXZFKA"4W:)AB,13P
M\.>H[([.BO&)?'OB.20L+X1C.0JPI@?F/YUJZ3\2KZ"14U2)+F+H9(U"N/?'
M0_3BMWA*B5SSH9YA92Y7=>;7_!/4J*KV5[;ZC9QW5K*)(9!E6%6*Y6K'KIJ2
MNM@HHHH&%%%% !6=J.NZ7I/%]>Q0MC.PG+8_W1S6%XW\5/H=NEG9D?;9USN_
MYYKTS]3SCZ5YDFFWMZ[32D[G.2TA)9B>];*%.$/:5I*,?,\O%8^I&I['#0YI
M+?LCUJ+QQX<FD"+J2@DX&^-U'YD8'XUO0S17$2RP2I+&PRKHP(/T(KPQM!G"
MY612?<8JUHFMZCX6OU/S&V8_O(2?E<>H]#[T4WAL0G]7J*37FF8+,,70:^MT
MK1[KI^9[915*WU?3[FWCGCO(-DBAAF0 X/J.U.?5-/C&7OK9<^LRC^M9<K['
ML>TA:]T6Z*I?VQI?_02L_P#O^O\ C4?_  D&B_\ 07L/_ E/\:?++L)U::^T
MOO-&BLM_$FB)C.KV//I.I_D:8WBC0U0D:G;.0,A4D!)]@/6CDEV%[>EMS+[R
M]>ZA:Z=#YMU*(UZ#N2?8=ZYV;QO$'Q!8R.OJ\@4_D :YJ]O)M3O'NK@Y+?=7
M/"+V J+%?.XSB"E1FZ=*/-;K>R_X)TQHMJ[T.QL_&5E.X2YBDMB?XOO*/Q'/
MZ5T2.DB*\;*R,,JRG((KRLJ",$5HZ5K]SHR/$JB:%N51CC:?;_"M\OSJEBY^
MSDN673LPE2<==ST6BO/;OQO?*N6DMK9?7'_Q1KG[SX@0#/VCQ'"OJJ7"@_DM
M>Y&G*6RN9W/8'=(UW.ZJOJQQ5&;7-+@SOOH>.RMN_EFO#KKX@>'E8F34VF?_
M &8W;]<8K-F^)VB1\1PWDI]HU _5JVC@Z\MH/[A<R/<YO&.EQYV>=+_NIC^>
M*X;QWXVMHK!;V:)DBA!6.+=\TCGM^GZ&O-I?BB#_ ,>^BRO[O+C] IK.^U:E
MX^UBU@DM5MH[<$@<D#)&6.>N,"E4I+#0=;$:1CJ]5<SE526FK,?5-5UCQ'*9
M+RX,4!.4@3(4?AW^IYJHV@3+'O(F4?WC&<5[;I.@6&CQ*((5:7'S3.,L?Q[?
MA6I@>E?+5N,\2I6H+EBMEI_DQK!U9:RG9^AXGHGB75O#<R+)*UWI^<-$QSM'
MJN>G\J]0C\0Z1):17)U*U2*1=R^9*JG\B>M,UWPI8ZO [)&D%UCB11C<?1AW
MKQZ\T![2^F@F8QO&Q!3'3\:]G+L[PF8Q;Q#Y)KLM_N_,SG*>'TJ;=&>J7'CG
MP[;9SJ*R'TC5F_D*R;GXG:5'D003R>AVX_F17GHTJ$=7<_3%2#3;8=58_5J]
M/ZWED/YI?U\CEGBD_M/Y6_4Z>Y^)\K9\FT8#W<+_ $-9-QX^U&8G;#$/^NA9
MOZBJ(L;9>D0_'FI!;PKTB0?\!%5_;."A\%)_A_P3EG["?QIR]6_\R"?Q3J]V
MK0^<J+("I5(QR#QU/-2VUNMO$%'WC]X^IJ4*%Z #Z5V/ACP>+^);[40RV[<Q
MQ X+CU)[#_/U\C-\\A.DER\D>W=_@52I>U?LZ$4OZZG'T5[7;:98VBA;>T@C
M _NH ?SJO>Z#I>H1LL]E%D_QJNUA^(YKY19U#FUB[':\JG;26IXK-9PSN'=3
MD>AQFG);01_<B4>^,FNNO?!=S#K]E80NSV][.L,4VW)0L<88>W7WQ7JFF_!'
M0+;#7]Y>7KCJ 1$A_ 9/ZU]%A\36Q-)*G-N'KH<JP]=MP['@5:FF^&M;UC']
MGZ5=W"G^-(CL_P"^NGZU]-:9X-\-Z1@V6C6<;CI(T>]Q_P ";)_6MRM8X/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YZ^(DR>$M<N89$
M,DD[&6VC7JRL3@_0'(^HKSJ?5-<O6W-=?9E/(2+C']?UK7\6ZK+K_C'4]4G<
MONF:. 'HD2G" ?@,GW)J.R\/ZMJ"![:QE9",AFPH/T)QFGBLY^K^Y"RMNWW\
MKZ'ST<+2A4E[*/,[]K_<9,5YK=JVZ+47E_V93NS^>:ZGP[K4FMW2Z>ULRZB?
MNQ("?,_W1_2J%QX7UNUCWRZ?(5_V"'_12:RHY)[2[@O+9S%=VT@EAD'56!R*
MG"9[[5\M5IKNNGW=!5\+"I[M6/*^]K/_ ()Z%<6ES:OMN+>6%O21"I_6H>E>
MU:#XQT#Q+IUL\.I6#SS1*TEH9E+HQ )4J3G@\?A5RZ\+Z'>9\[2[;)ZE$V$_
MBN*]+ZVXNTXV,IY!+>G._JO^'/#3/(6RSLQ_VCFGK,#]X8KU2Z^&VB39,#W-
MN>P5PP_4$_K6)=?"VY7)M-2B?T$L93]1FIE+#U=]&<-7)L7'[-_1G% @C(.:
MO:?K&H:4^ZRNI(N<E0<J?J#P:NW/@/Q%:G*VBS =X9 ?T.#^E94UE?63!+VU
MF@8_=\V,KN^F>M<M2@HKFC*Z."=#$8=\S3C;KJB;4=3N]5NC<WDS22'@9Z*/
M0#L*J445SG/*4IMRD[MD]G>W.GW*7-K,T4J'AE/Z'U'M7L'AG7DU_2Q.0$N(
MSLF0=CZCV/\ CZ5XQ4L%U<6I8V\\L);J8W*Y_*A.QZ&79C/!S[Q?0][HKPY=
M;U9!A=4O5'H+AQ_6I5\2ZVI&-4NN/60FGS'MKB*EU@_P/;**\97Q;KR=-2F_
M$ _S%2KXU\0J,#43^,2'_P!EI\Q:XAP_6,OP_P SV&LG7O$%KH%IYLWSROQ'
M$IY8_P!![UYTOCS7U()N8V]C"O\ A61J&HWNN7_VBY;S)F 4!1@ #L!2E-)7
M9G7SZ$H<N'3YGM=&E?\ C/6[YR1=FW3/"0?+C\>OZU7MO%6N6K[DU*=_:5O,
M'_CV:BBT=V7,D@4^@&:>^C<'9-SZ,*\MYS@E+EY_P?\ D<7]GYM/][K?_%K]
MUST#PQXQBUIA:7:K#>?PX^[)]/0^U=57@[)<:?<I("4D1@R.OJ.A%;\WC_79
M?N201?[D0/\ /->G2J0J14HNZ?4Z\-G+HQ=/%I\R\M?F>LT5XM-XJU^?[^JS
MC_<"I_("L^:_U"XSY^HW<N?[\S'^9K9*'61<N(:*^&#?X?YGNDMQ! ,S31QC
M_;8#^=4)O$FB0?ZS5;//HLP8_D*\/,())+$D]Z3R%]35I4>LG]QSRXBD_A@O
MO_X8]2U_QWI::1<QZ9>^;>NNV/;&PVYZG) ' S^->6)$6Y;.3VI\=OND55R2
M3@"NCL[&.V0$@-)W;T^E<&99O1R^G:&K?W_\!&5*GB<YJW=HQCUZ?\.82V4I
M&1;N1_NU%+;%3AD9&]",5UM,DB25"LBA@?6OG:7%-93O*.GDST:G#$>7]W4U
M\UH9&A>*=2\-I-%:K#)'*0Q28$@'U&"*TW^).NMG"6:9_NQ'C\S6->Z5(LP$
M:NR'D%5R1[&EBT-7'S2W"_\ ;%?_ (NOKZ6:9?5IJK.<5?N>5"GF5-^P@I:=
MC1?XA>(6/%Q$OL(5_K5=_'/B1Q@ZFWX11C^2U$/#Z[A_I#%>X* '^9J5= MQ
MUDD/XC_"LYYWE5/>:?HK_H=4<!F\]VU_V]_P2!_%WB!\YU6X&?[I _E4#^(]
M;<Y.KWWX7##^1K431K->J%OJQJ=-/M4Z0)^5<<^*<MA\*;^7^9O'(\?+XZOX
MMF=ID,M](;V\EDF8?*AD8L>/K6U2*JHNU0 !V%+7Q6;9G/,*[F](K9=E_F?1
MX'!QPE%4UJ^K[L*BN+>.YA,<@R#W]*EHKSZ-:I1FJE-V:.J<(SBXR5TSGQH,
MN3F4 ?2I5T ?Q2L?H *VB0 22 !W-027]G%_K+N!/]Z0#^M?2OBO,):12^Y_
MYGDK(\##5Q_%E%="@'4N?JW_ -:IET>U7_EF#]2339/$.CQ_>U.U/^[(&_E5
M63QAH4?6_#'T6-S_ $K*6>YO4^&_R1HL%E]/[,?P-%=.MEZ11_\ ?(J9;:-?
MNC'T&*YZ3QWHJ?=:X?\ W8_\2*K/\0M/SB.SNF_WMH_J:QEB\WJJSD_P1K&>
M#I_#9>AU]%06=W#?VD5U;L&CD7(/]#[U/7A--.S.Y--705#<VL-Y;M!<1AXF
MZJ:FK/U'4&MGAMK?8UU,?E# D*HZL<=NWU(K7#4ZM6M&%'XF]+=Q3DHQO+8I
MMX.\.LQ9M)MR3W(/^- \'>'1_P PBU_[YJRES?#[\EN?I"P_]FJ9;N4?>"'Z
M C^M?3_V3GSWG+_P/_@F'M:3Z?@4AX1\/KTTFU'T2GCPOH8Z:; /H*M_:W_N
MK1]K?^ZM1+(LYE\4K_\ ;W_!$Y4'NOP*O_",:+_T#H?R-6K+2K'3F<V=K'"7
MP&*CK1]L8?PK3HKQ6E$;E06^[7)BLDS.C1E4JZQ6_O7_  !5,/%K9%JBBBO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR^_["LG_ **BKU^OE[X<_$]/!7@1](T[3I-2UZ^U*0P6X#;5#1QJC' RY+C
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MZVO_ +6KWZ@ HKQ'5/C)KGBC73H7PUTG[7)Y4N^[NHP",<"1 6"JHX(,G4L
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M )OOL:+#9;':FON;_0W(K&VA<.D>&'0Y)JQ6)YWC!(GNI_"LT5I$"\S,V&5
M,L0#@GC/:M:WN(KJW2>!P\3C<K#N*\[&X?%TFI8J]WWU._#>P2<:,>5=K6):
M***X3I"F22QQ#,DBH/5CBJ@T6;QIJ$VC6=\]G%:H);JY1-^&)PL>-PY/S'VV
M^]6%^!5F6)FUZY<GT@ _F37MX/)*N(I*JW9/^NYR5,3-2M"-_.Y5EUS2H?\
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ME%:_>>'Q^$U_Y:W9/LJ8_K5N/PS8)]XRR?[S8_E7LO\ PK;3?^?V[_\ '?\
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M2HJ*> 0>]=%;:G- H5L2(.@)Y'XUK>)OA3#IVAR7>D37=S<PG<\<A4[D[[0
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M_?Q__BJE'@7PN!C^Q;;\C_C1[:E_*:++Z?\ *ON/GDWUT?\ EN_YTGVVZ/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&G1/_!A%_P#%5P'_  SEX/\ ^@AK?_?^+_XW1_PSEX/_ .@AK?\ W_B_^-T
M<!\6=:L]*^*NE^+?"^H6-S(8HY)9;6\$H>5"5*N$?*J8]BD<!AGJ=U>_>.O^
M2?>)?^P5=?\ HIJX#_AG+P?_ -!#6_\ O_%_\;KO_'7_ "3[Q+_V"KK_ -%-
M0!Y)^SEX7L9+#4/%$\:2WB7!M+<LG, "!G93G&6#@=,@*><,17O5>0?LY?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)!'<VSN7$.[A65CSC. 023DC\/I>N=\?6*ZC\/O$%JRABUA,R@_WE0LOZ@4
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MGI4/Q4L'BW/;*&QP!,/Z@5EZC\4H[B18(R]K;L<22VZ":15[E<E1^OXUQ/\
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M498_=DAB&/\ @0D.?Q'XUQO_  @GC#_H5-<_\%TW_P 31_P@GC#_ *%37/\
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MZKX+^+/@?PI:L[V&M3ZA*N)9A;Q8 _NK^]Z?SKJO^&CO!_\ T#=<_P"_$/\
M\=KP#_A!/&'_ $*FN?\ @NF_^)H_X03QA_T*FN?^"Z;_ .)KGE)R=V=*22LC
MW_\ X:.\'_\ 0-US_OQ#_P#':/\ AH[P?_T#=<_[\0__ !VO /\ A!/&'_0J
M:Y_X+IO_ (FC_A!/&'_0J:Y_X+IO_B:0SW__ (:.\'_] W7/^_$/_P =H_X:
M.\'_ /0-US_OQ#_\=KP#_A!/&'_0J:Y_X+IO_B:/^$$\8?\ 0J:Y_P""Z;_X
MF@#W_P#X:.\'_P#0-US_ +\0_P#QVN)\1?$'X;ZY.]U;V&OV%TYRS16T)1CZ
ME?-'/T(KS;_A!/&'_0J:Y_X+IO\ XFC_ (03QA_T*FN?^"Z;_P")JHR<7="E
M%2T9T0\3^&/-P;C5Q'_>%C$3^7G?UKK_  U\2_AOX=E6Y_LS7[R\7[LTUO#A
M#ZJOFX'UY->7?\()XP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !-7*M.2
MLV0J44[I'O\ _P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.UX!_P@
MGC#_ *%37/\ P73?_$T?\()XP_Z%37/_  73?_$UD:'O_P#PT=X/_P"@;KG_
M 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM> ?\()XP_Z%37/_!=-_P#$T?\ "">,
M/^A4US_P73?_ !- 'O\ _P -'>#_ /H&ZY_WXA_^.T?\-'>#_P#H&ZY_WXA_
M^.UX!_P@GC#_ *%37/\ P73?_$T?\()XP_Z%37/_  73?_$T >_/^T9X-D1D
M?2];9&&&4V\)!'I_K:Y#4OB#\*=1E,HT3Q#:.QRWV9(5!_X"9"!^ %>8?\()
MXP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !-5&3CLQ.*>YZ9I_C[X4V$H
MD?1O$=VRD$?:%B(!'LL@!_&NQB_:)\%P1)%#I6M1QH,*B6\("CT $M>!?\()
MXP_Z%37/_!=-_P#$T?\ "">,/^A4US_P73?_ !-$I2ENP44MCW__ (:.\'_]
M W7/^_$/_P =H_X:.\'_ /0-US_OQ#_\=KP#_A!/&'_0J:Y_X+IO_B:/^$$\
M8?\ 0J:Y_P""Z;_XFI&>_P#_  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?
MB'_X[7@'_"">,/\ H5-<_P#!=-_\31_P@GC#_H5-<_\ !=-_\30![_\ \-'>
M#_\ H&ZY_P!^(?\ X[1_PT=X/_Z!NN?]^(?_ ([7@'_"">,/^A4US_P73?\
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M_P %TW_Q- 'O_P#PT=X/_P"@;KG_ 'XA_P#CM'_#1W@__H&ZY_WXA_\ CM>
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M_P".T?\ #1W@_P#Z!NN?]^(?_CM> ?\ "">,/^A4US_P73?_ !-'_"">,/\
MH5-<_P#!=-_\30![_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\
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M7@'_  @GC#_H5-<_\%TW_P 31_P@GC#_ *%37/\ P73?_$T >_\ _#1W@_\
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M  T=X/\ ^@;KG_?B'_X[7@'_  @GC#_H5-<_\%TW_P 31_P@GC#_ *%37/\
MP73?_$T >_\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..UX!_P
M@GC#_H5-<_\ !=-_\31_P@GC#_H5-<_\%TW_ ,30![__ ,-'>#_^@;KG_?B'
M_P".T?\ #1W@_P#Z!NN?]^(?_CM> ?\ "">,/^A4US_P73?_ !-'_"">,/\
MH5-<_P#!=-_\30![_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\ H&ZY_P!^(?\
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MG_?B'_X[7@'_  @GC#_H5-<_\%TW_P 31_P@GC#_ *%37/\ P73?_$T >_\
M_#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..UX!_P@GC#_H5-<_\
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M_P!^(?\ X[7@'_"">,/^A4US_P %TW_Q-'_"">,/^A4US_P73?\ Q- 'O_\
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M%TW_ ,30![__ ,-'>#_^@;KG_?B'_P".T?\ #1W@_P#Z!NN?]^(?_CM> ?\
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MG_?B'_X[7@'_  @GC#_H5-<_\%TW_P 31_P@GC#_ *%37/\ P73?_$T >_\
M_#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\ ?B'_ ..UX!_P@GC#_H5-<_\
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MU<KG_ G_ "3SPU_V"K7_ -%+704 %%%% !1110 4444 %%%% !1110 4444
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M^1ON0:=(MP[8(!Z':O7/S$9P<9(Q75Z3J4.L:-8ZI;JZP7EO'<1K( &"NH8
MX)&<'U-<QIOPF\":5<-/;>&[1W9=A%R7N%QD'A9"P!XZXSU]379T > _LS=/
M%/UM?_:U>K^/_!]OXX\)7.DS?+.,S6DA<J(YPI"%L Y7D@\'@G'."-?3-"T?
M1?-_LK2K&P\['F?9;=(M^,XSM SC)Z^IK0H ^=?AK\2IOA[<3>"O&L#V5O9N
M_E3>46:W8DL58*"71B<JPS][NI!7V/\ X6/X+_L_[=_PE&E>3Y7G;?M2^9MQ
MG'EYW[O]G&[/&,\5H>(/"VA^*K,6NN:9!>QK]PN,/'R"=KC#+G:,X(SC!XKE
M_P#A2?P\_P"A>'_@9<?_ !R@#(?XW:=JOBW2_#_A:PGU)KNZCBENW1D1(RRE
MV5,;FPGF9)VA=N?F%>K5F:+X<T7PY;^1HVEVEBA14<P1!6D"C"[VZL1D\L2>
M3ZUIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% &!XY4M\/O$BJ"6.E70 '4_NFKYW_9Y95^)4@8
M\MI\H7Z[D/\ (&OI[4+1;_3;JS?[MQ"\1^C C^M?)GP?O6T#XN:=!>?N3(\E
ME*KG&'8$!?KO"B@#Z\K)\4?\BEK7_7A/_P"BVK6KE/B9J::3\-O$%R[["UF\
M"'.#ND&Q<>^6% 'SQ\!4=OBG:%>BVTQ;GMMQ_,BOK*OF7]G'3'N/&>I:D5S%
M:67EY]'D88_1'KZ:H **** "BBB@ KY@_:._Y*'I_P#V"H__ $;+7T_7S!^T
M=_R4/3_^P5'_ .C9: .?^"7_ "5[0O\ MX_])Y*^OZ^0/@E_R5[0O^WC_P!)
MY*^OZ "BBB@ HHHH **** &2PQ7$3131I)&PPR.H(/U!K+_X17P_G_D#6(']
MT0*%_+&*UZ*EQC+=":3W(K:UM[.!8+6"*")?NQQ(%4?0"I:**H84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?\ QM_Y)#KO
M_;O_ .E$=?(%?7_QM_Y)#KO_ &[_ /I1'7R!0!]O^!/^2>>&O^P5:_\ HI:Z
M"N?\"?\ )//#7_8*M?\ T4M=!0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\0>._^2A^
M)?\ L*W7_HUJ]_\ V<?^2>:A_P!A63_T5%7@'CO_ )*'XE_["MU_Z-:O?_V<
M?^2>:A_V%9/_ $5%0![!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S!^T=_R4/3_ /L%
M1_\ HV6OI^OF#]H[_DH>G_\ 8*C_ /1LM '/_!+_ )*]H7_;Q_Z3R5]?U\@?
M!+_DKVA?]O'_ *3R5]?T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?_ !M_Y)#KO_;O
M_P"E$=?(%?7_ ,;?^20Z[_V[_P#I1'7R!0!]O^!/^2>>&O\ L%6O_HI:Z"N?
M\"?\D\\-?]@JU_\ 12UT% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'G_P ;?^20Z[_V[_\ I1'7R!7U_P#&W_DD.N_]N_\ Z41U
M\@4 ?;_@3_DGGAK_ +!5K_Z*6N@KG_ G_)//#7_8*M?_ $4M=!0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\0>._P#DH?B7_L*W7_HUJ]__ &<?^2>:A_V%9/\ T5%7
M@'CO_DH?B7_L*W7_ *-:O?\ ]G'_ ))YJ'_85D_]%14 >P4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5\P?M'?\E#T_\ [!4?_HV6OI^OF#]H[_DH>G_]@J/_ -&RT <_
M\$O^2O:%_P!O'_I/)7U_7R!\$O\ DKVA?]O'_I/)7U_0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!Y_\;?\ DD.N_P#;O_Z41U\@5]?_ !M_Y)#KO_;O_P"E$=?(% 'V
M_P"!/^2>>&O^P5:_^BEKH*Y_P)_R3SPU_P!@JU_]%+704 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<'XU^$V@^/-9AU35+O4H9XK=;=5M9$52H
M9FR=R,<Y<]_2N\HH \W\+?!3PWX1\1VFN6%[JLEU:[]B3RQE#N1D.0(P>C'O
M7I%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &/XI\-V?B[PY=Z'?R3QVMULWO P#C:
MZN,$@CJH[5YO_P ,X^#_ /H):Y_W_A_^-5[!10!3TG38=&T:QTNW:1H+*WCM
MXVD(+%44*"< #.!Z"KE%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E>K? +PKK.LWV
MJ7&H:RL][<27$BQS1!0SL6(&8R<9/J:[#P5X*TWP'HTVEZ7/=S02W#7#-=.K
M,&*JN!M51C"#MZUTE% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!^-?A-H/CS68=4U
M2[U*&>*W6W5;61%4J&9LG<C'.7/?TKO** /-_"WP4\-^$?$=IKEA>ZK)=6N_
M8D\L90[D9#D",'HQ[UZ1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^*?#=GXN\.7
M>AW\D\=K=;-[P, XVNKC!((ZJ.U>;_\ #./@_P#Z"6N?]_X?_C5>P44 4])T
MV'1M&L=+MVD:"RMX[>-I""Q5%"@G  S@>@JY110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTW5O@Y\2$&GWC,T06>WE(P)H6)&UQW&0RGZ9&.* /L&BJ>D:E#K.C66IV_\
MJ;N!)TSV#*"!^M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N/\8_$SPYX'N[>TU::=KF=#((K>,.RKG +
M<C )SCZ&M#QGXML?!?AJXU>]8$J-L$.[!FD/W4'\R>P!-?&OB'4]4US5I-:U
M8LUQ?YF5R,*R[BOR_P"R"I4?[M 'V[I&J6^MZ/9ZI:;_ +/=PK-'O&&VL,C(
M]:NUS/PZ_P"2;^&_^P=#_P"@"ND=UCC9V.%4$GZ4 9VN>(M'\-67VS6=1@LH
M"<*TK8+'KA1U8^P!K@9_C_X&BEV)-?S+_?CM2!_X\0?TKPFXNM6^+WQ,AA>X
M,;WTQC@5^5MH!EL >R@GW.?6O=[+X!^![:T6*XMKN[E PTTERRDGUPN /RH
MZ3PU\2O"?BR<6^EZM&UT>EO,IBD;_=#8W?AFNLKY2^+/PQC^'UQ9:GH]U.VG
MW$I5?,8>9!*/F ##&01G!ZC;S7N/PA\67/B_P#;W=\_F7MK*UI/)C'F,H!#'
MW*LN??- '>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QWXV?\ X23XV:C!
M)N GU9;(Y/.%81?R6OL-$6-%1%"JHP .@%?'-MM'QUBWX"CQ*-V>F/M-?8]
M 0",$9!KX[\-M_PB_P ;[6"$;4M=::SQGHAD,1_0FOL2OC750Y^-UZ(\[SXC
MDVXZY^TG% 'V51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5C^)/#&E>+=*_LW6;=I[7S!+L61D^89P<J
M0>YK8HH Y#2/A=X)T.836/AZU\U3N#SEIRI]1YA./PKYK\+<?'*R_P"PV?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M& ;;\P&[&,G&<UOT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\=B"!OWM]::;:27=_=06MM'C?-/($1<G RQX') _&@#RG]HW_DG=C_V%(_\
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M9 <[\XST5L$XKZ:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"IJNG0ZQH][IEPSK#>6\EO(T9 8*ZE21D$9P?2N/\%?"?0O F
ML3:GI=WJ4T\UN;=ENI$90I96R-J*<Y4=Z[NB@ HHHH *X3QM\)]"\>:O#J>J
M7>HPS10"W5;61%4J&9LG<C'.6/?TKNZ* *FE:=#H^CV6F6[.T%G;QV\;2$%B
MJ*%!. !G ]*MT44 <IXR^'7AWQU&AU>V=;J)-D5Y;OLE1=P.,\AAUX8'&XXP
M3FO,)_V:(3<2FV\5RQ0%R8TDL0[*N> 6$@!..^!GT%>]44 >$V7[--FEY&VH
M>)[BXMAG?'!:")SP<88NP'./X3^'6O5_"?@O0_!6G-9Z+:>5YFTSS.Q:29@,
M LQ_$X&%!)P!DUOT4 %4]4TNQUO2[C3=2MH[FSN$V2Q..&'\P0<$$<@@$<BK
ME% 'B&L_LWZ7=:B\^CZ[<:=;-D_9Y8//V$DG"MN4[0,  Y/').:@LOV:K1+N
M-M0\47%Q:C.^."T$3GCC#%V YQ_"?PZU[M10!PE_\)/#-[X*M/"B"ZM+"VN!
M<^9;NHEEE"E2SLRD$D-SP.@ P !71^%_#EGX2\.6FAV$D\EK:[]CSL"YW.SG
M)  ZL>U;%% %/5M.AUC1K[2[AG6"\MY+>1HR P5U*DC((S@^AKG/ OPYT?X?
MB_&DW-]-]M\OS/M3HV-F[&-JK_?/KVKKZ* "LOQ%H%CXHT"\T74E=K2Z0*_E
MMM92"&5@?4$ \Y''((XK4HH \)O?V:;-[R1]/\3W%O;'&R.>T$KCCG+!U!YS
M_"/QZT67[--FEW&VH>*+BXMAG?'!:")SQQAB[ <X_A/X=:]VHH Q_#/AG2_"
M.APZ1I$'E6\?+,W+RN>KN>[''Z #   V*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img39825204_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )M \$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N?\=_\D\\2_P#8*NO_ $4U=!7/^._^2>>)
M?^P5=?\ HIJ #P)_R3SPU_V"K7_T4M=!7/\ @3_DGGAK_L%6O_HI:Z"@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "N?\ '?\ R3SQ+_V"KK_T4U=!7/\ CO\ Y)YXE_[!5U_Z*:@
M\"?\D\\-?]@JU_\ 12UT%<_X$_Y)YX:_[!5K_P"BEKH* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY)&"T5K!)*20!N*H@9MH)Z^XYJC=^(K=+O2YH[K_ $*X$V\",EF90,+MQNW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&O\ L%6O_HI:Z"N?\"?\D\\-?]@JU_\ 12UT% !1110 4444 %%%% !1110
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M\?&VG6$][<ZQH2001M)(WV23@ 9/\5>*2V]QXQ&K^(=1UK3(+M>4MYYUC>7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMST\YW5@F>^!G]>*\PDD>61I)&+.QRS,<DFO>719$9'4,C##*1D$>E>?:KX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!5K_ .BEKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JM?:A9Z9:-=7US%;6Z
MD!I)6VJ,G YJS4<T$5Q&8YHDEC/574,#^!IJU]1JU]3#_P"$Y\*_]#!IW_?]
M:WP00"#D'I7&Z'IE@_C?Q5&UC;%$:TVJ8EPN8N<#'%=GTJZBBG:)I5C&+2C_
M %=!6#XE\1)HUNL,"//?S';##&NYB3TP/7_]9X%,U#Q('U$Z1HX%S? XE<<I
M!]3W;V[=3V!NZ9HL-C*UU*?/OI!AYWY('HOH/Y_@,<=23G/V4=.[[>2\W^"U
M["45'6?W'/Z#X.GENH]6\2LMQ>*WF068.Z*V)[G^_)ZL?PZ"NTHHKH222C%6
M2V0IS<W=A5'5-5@TN%6D#232';# @R\C>@']:AU36!9.EK;1&YU"4?NH%/\
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MP5=?^BFKH*Y_QW_R3SQ+_P!@JZ_]%-0 >!/^2>>&O^P5:_\ HI:Z"N?\"?\
M)//#7_8*M?\ T4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV.*,8"BIHHHX(DBBC6.-%"HB# 4#H .PI]%2IS+ECHE_7W@D%%%%9#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "F2Q1SQ/%*BR1NI5T<9# ]01W%/HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%6O_ **6N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-XCBE;2;Y+D0D!QM9&7TX8 X]^E:U !1110 4444 %%%% !7/^._^2>>)?\
ML%77_HIJZ"N?\=_\D\\2_P#8*NO_ $4U !X$_P"2>>&O^P5:_P#HI:Z"N?\
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M@O\ X5__ &S+_P (M_Q_>0=_^O\ ]7N7/^LXZ[?>N\H **** "BBB@ HHHH
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MVC=C=CG'2EHJZE5U-6D)*P4445F,**** "BBB@ HHHH **** "BBB@ HHHH
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MV1\NU1GIDY]JWJY+PQ9Z1;ZG(]AXQO=9E,1!MY]32X51D?-M'0]!GW]ZZV@
MHHHH **** "BBB@ KG_'?_)//$O_ &"KK_T4U=!7/^._^2>>)?\ L%77_HIJ
M #P)_P D\\-?]@JU_P#12UT%<_X$_P"2>>&O^P5:_P#HI:Z"@ HHHH ****
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M%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI&944LQ  ZDGI0 M%0_:[;_GXB_P"^Q4JLKJ&4AE/0@YS0 M%%% !1110
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M #P)_P D\\-?]@JU_P#12UT%<_X$_P"2>>&O^P5:_P#HI:Z"@ HHHH ****
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MX.MZA&0A'K#$>7]B<"M30O!&FZ->'4KAYM4UEQ\^HWK;Y/HG9![+73    #
M'044I5=.6"LOZW?](+!1116(PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBLO4/$FB:5D7VK6<##^!YEW?]\YS32OL)M+<U*R_$6H2:5X>O;Z
M%@CPQ[@QB,@7GJ5') K'_P"%@:;<\:38:KJN>C6EFVS_ +Z;:,>]-EU'Q=JL
M+P0>&K*SAD4J6U*[WAE/!!2,$_K5*+3U,W4BU:)Y^/BUJINVC.J:>(0@(E_L
M^3D^F-V?QKV/2KIKW2+.Z<Y::!)"=A3)(!^Z>1]*\%T3X>W7_"RET/4!&\-L
M!<SM'G8\?! &><$D+^?I7T*  ,#I5UE%6Y3'"NH[N84445B=9SM_X@UBTOI8
M+?PM>W<2'"SQSQJK^X!.:S=0UK5]3T^XL;KP1J#P7$;1N/M,/0C'KUKM**I2
M2Z&;@W]K\CY1;0-67Q#_ &)]CN/M^_:(.-_3/KCISUQ7O&F:QJ^DZ9;6%KX)
MU!8+>,1H/M$/0#J>>M=(=!T\^(EUTP_Z>(/(#]MN<YQZ]L^G%:5:3J\UM#"C
MAO9MM,YW3]?U>[OXH+CPM>VD+DAIY)XV5..X!S71445DW<ZHIK=W"L+6LWVK
M:?HQEEB@G22XG\MBID2/: FX'(!+@G'4#'>MVLS5M,EO);6\LYEAOK1F,3."
M4=6&&1P/X3Q]" >V"AF9JGAK2].TZYU#1[&UT[4+:)I8I[:$1EBH)"OMQO0]
M"IR.<]<&G66LZAJNIF"":SLQ&D4AM[B%GEF1E5BRX==JY)7.&Y!^E/N+77M9
MMWL=0@T^QM)1MF:VNGG>1.Z#=&@7(XSSU/'>EU?3=2U&9+5+33TM8G1X+SSW
M\^$C&=J;,9XQG>,@\CL0"WH;1NNH%+>&$_;I0WE+C>0<;F]6/<UJU0TNREL5
MNQ*R'SKJ29=I/"L<C/O5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)?)N-5WQR;8V.UUV\J<8([B@#N/ G_)//#7_ &"K7_T4M=!7/^!/^2>>&O\
ML%6O_HI:Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN'49S@.,,!GT--T31'T030IJ=[=VK8,45VXD,/7(5L9VXV@ YQCWH UJ***
M"BBB@ KG/%6@ZMJDEC?:'K+:=J-BS%%D!>"=6&"LB C/3@]1SCK71T4 <;X>
M\*:PGB1O$GB?58+W45MS;6T-I$8X+="06(!Y+$@<G_#&(WP\\36>GWGAS1_$
M=K:^&+N20^6UL3<6T4C$O%&V=N#EN3R,UZ;10!QVO>!S<Z=H0T"\73M1T# T
M^>2/S%";-C1N.ZLH )'/%+X:\*ZM;>(;KQ)XDU*"]U:6W%I$EK$4AMX0=Q50
M>22W))KL** "N?\ '?\ R3SQ+_V"KK_T4U=!7/\ CO\ Y)YXE_[!5U_Z*:@
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M"3A;J>2,[H_M=[-<B-O51([!3[CFM"YLK>\:!IX]YMY1-%R1M< @'CKP3UH
MGHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N?\ '?\ R3SQ+_V"KK_T4U=!7/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7/^._^2>>)?\ L%77_HIJZ"N?\=_\D\\2_P#8*NO_ $4U !X$
M_P"2>>&O^P5:_P#HI:Z"N?\  G_)//#7_8*M?_12UT% !1110 4444 %%%%
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M(/6NDHHI1A&/PJPHPC#X58****HH**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_QW_R3SQ+_ -@JZ_\
M135T%<SXWO+-_"FLZ4UY E[>6$T,,)<;V9T95^7KC)ZXH#K8F\"?\D\\-?\
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MPY%^8O;4.B;/1YO'2*?W.ESD?WI9%0?CC-<C///J%Y-J%W-'<3C(54;Y$ Z
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MVW)_F:UZ*Y?;/HE]QO[-=W]YD?V?K!ZZYC_=M$'\R:#I-\V?,UN[.?[B(O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^H B[LK>?WDC!(_'K7E?CW2K32M7MX;&(QQ-!O*;BP!W'IDG'2N@_P"%I_\
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M-,$B-@D'#!\'!!'X58_X6G_U(7CG_P $_P#]G1S1_E_,/8U/^?C^Y?Y'1?\
M"2N&VG0-:'J?LZD?HU \4Q=6TC644=6:Q;%<[_PM/_J0O'/_ ()__LZ/^%I_
M]2%XY_\ !/\ _9T<T>P>SJ_S_@=%_P );IX!,EOJ$8]7LY.?TH_X3'15 ,D\
M\>>@>UE_^)KG?^%I_P#4A>.?_!/_ /9T?\+3_P"I"\<_^"?_ .SHO#M^/_ #
MDK_SK[O^"=$?&?A\8W:BJD\X:-P?U%<YXO\ &K0K9_V!J<9)+^=L16]-OW@?
M>E_X6G_U(7CG_P $_P#]G7*^,?%-SXC^Q_8_!'B^ PERYFTAANSMQ]TGT-:4
MG3YU=??_ ,,<N.ABG0ER2UTV33W[W98LO'6OM?6ZW&I#R3(HDS#&!MSSSMKU
M >(=%(!_M>PY_P"GE/\ &O!+2?5+>\@FD\(>*'2.1691I,F2 >1S7H3^/]/D
MQO\ AIXO;'3.A*?_ &:M,0Z3:Y?P.;+(XU1E[7_R:[_4[H>(-&) &KV!)[?:
M4_QJ3^V-+_Z"5G_W_7_&O/\ _A.]+_Z)CXM_\$*__%4QO&NC,Q9OA9XJ)/<^
M'T_^*KG]SS/3_P!H\OQ/1%U;37.%U"U8^@F4_P!:?_:%E_S^6_\ W]7_ !KR
M^U^(/AF_\_[)\-O$5QY$K03>3H<;^7(OWD;#<,,C(/(I_P#PEFA?]$L\6_\
M@B'_ ,51[GF%\1V7WO\ R/4$O+63.RYA;'7#@T[[1!_SVC_[Z%>6-XJT%Q@_
M"WQ=^&B ?R>F?\)+X?\ ^B7>,?\ P3'_ .+HM#N_Z^87Q'9?>_\ (]95E==R
MD$'N#2UY$_B'P\YR?A=XS_#26'\I*3^WO#O_ $2_QK_X*F_^.46AW?W?\$.;
M$?RK_P "?_R)Z]7/^*_$C>&[6WF6V$YF<K@OMQ@9]*X$^(-!)S_PK;QY^%A*
M/_:M4M0DAUQ$BT;P9XITZ2,[I'U"SD"N/1<LW/Y5I2C3<TF_Z^\YL95Q4*$I
M1BD_)W?W<IT:?%&5Y%7^RTY('^N/^%>D5X*-!UE"&;1]1(')"VSY/TXK<_X2
M/2O^A#^(G_@%)_\ '*UQ%.E&W+_F<>68G&55+VBO:V^G?R/7J*\A_P"$CTK_
M *$/XB?^ 4G_ ,<H_P"$CTK_ *$/XB?^ 4G_ ,<KFM#O^'_!/5YZ_P#(O_ O
M^ >O45X['XKT2:29(O!'Q!=X7V2JMHY*-M#8;]YP=K*<'L0>]2?\)'I7_0A_
M$3_P"D_^.46AW_#_ ((<]?\ D7_@7_ /7J*\A_X2/2O^A#^(G_@%)_\ '*/^
M$CTK_H0_B)_X!2?_ !RBT._X?\$.>O\ R+_P+_@'KU%>0_\ "1Z5_P!"'\1/
M_ *3_P".4?\ "1Z5_P!"'\1/_ *3_P".46AW_#_@ASU_Y%_X%_P#UZBO(?\
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M0_\ "3V?_0H?$S_P$?\ ^+H_X2>S_P"A0^)G_@(__P 71:'?\ YZ_P#(OO\
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MF@G$T\L\32.TDC#,K/C<S8 '8=  /2M2@ HHHH **** "BBB@ HHHH ****
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M7^(M?^V>;_;/V;]QY6WR?)C*?>R=V<YZ#'O704 %%%% !1110 4444 %%%%
M!1110!S]I_R4/6/^P58_^C;NN@K/ATSRO$-YJWG9^TVD%MY6W[OEO*V[.><^
M;C&.-O?/&A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH *X/Q[9ZA9:]X=\7:?I\^HKI#S)=6ENH:5XI4"ED'<J1G
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M%T^UMIHM0N+NU%M]LW!1&@7.3M(SG';'I7J5% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<OH?\
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M!*_O6A )=<!@,!MN<XYS6\-)\,:AX,EAL++3[K2&1YHHA&LD*L >54Y"D'/
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M1VUT;BYA64Z8D4KM(^T;@\*#+*I/.X;02,]JLQCQFL0M6&B,0-O]H&27<?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img39825204_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %G!!,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;&3S+:==R,00?0@@]"#D$>HKS&POCHNK0^+[ZTOETB]NKTH?LSL\*R>7Y;%
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M5B8XD3[5<':H&=W_ -:K:C"@9)QW-=<)2?Q*PADUQ#;^7YTBIYCB--QQN8]
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M'B*S963N2922#VVC@8Z4 =51110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'BO_D3];_Z\)_\
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M:W%T9CES&AX#'U+;0?H:BO-,U7_A(-2N5@:2WE?%KCCR9O*"B8^HSQG^'K]
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M*** "BBB@ HHHH **** "BBB@ HHJM?WL6GVC7$N2!@*BC+.QZ*!W)--*^B
M@U._>V$=M:J)+ZXRL*'HOJ[?[(_7@=ZFT^PCT^U$2LTCL2\LK?>D<]6/^?:H
M-,LI8C)>WNUKZX WX.1&HZ1K[#]3DU?=UC0NYPHY)IR:2L!4U9YDTR<V[8FQ
MA<=>O;WQ6)X46^6282!Q;<Y#@_>SVS^.:Z"-&E<3RC&/N(?X1ZGWI+'_ %#?
M]='_ /0C7EU,,ZN*A7YFK)Z=_P"KEIVBT6:***](@**** "BBB@ HHHH ***
M* "BBB@ HHHH Y'Q;9)<:A:S'3-9NI(XV59=.N!$$!/(/S#DX%6/!LD+6]]%
M';ZI \4P21-1G\QP=H/')P,$5E:QKL>HW"-$_BNQ$8*E;73VVMSU.5-;'A%;
M;[+=2Q?VH\\DH,TVI1&.20@ # ( P  .!0!T=%%-$L;'"NI/H#0 ZBBH+R]M
M=.M)+N]N8K:VC&7EF<(JCIR3P* )Z*YQO'&C'PS'X@@:YN;&6;R(OL\#.\K;
MR@VJ.3D@TP^.=,CT,ZI<6NJ6R&X^S1V\]C(D\LA ("1D;FX[CT/I0!TU%<Q/
MX^T*'1K34U>ZG6[=HH;>"V=YRZ_?7RP-P*X.<]*W-,U*TUC3;?4+"836LZ;X
MW QD?0]#VQ0!0US_ )"WAW_L(-_Z3S5M5BZW_P A7P[_ -A!O_2>:MJ@ HJ&
MY:X6$FVCCDESPLCE1^8!K#UO7-2T31[C4+FSLPD2Y'^D,22> /N^M-1;V$W8
MZ*BO.OA]XKU76M/GM'2&XNK=MS/-,59E8D]E/0\?E7=6DE^\C"[MX(DQP8Y2
MY)_%153@XNS%&2DKHMU0N-<TFTG,%SJEE#,#@QR7"*WKT)J_6)JZ(=?T(E%)
M\Z7J/^F;5!1LHZR(KHP9&&0RG((IU8=G=7;3:G=75ZL5I;2O'&@C& H .YCU
MR"3P*AT74;R76)+.=[N6(V_FJ]S;K$<AL?+MZ@Y[C(H V+G4;&SE2.ZO((9)
M/N+)(%+<XXS[U:K'\1+=OIDR6UK!-&\;+,7;#JN.2HQ@GKP2*?>736WA>2ZL
M7RR6N^%I!G/R_*30!JT5SBKK+:G'9-JQ"2VWGM(($WHP(&U>,;><\Y/ YIFG
M7FIZV"([[[)]GB0.4B5C)(<Y)ST7CH/4\T =([K&C.[!449+,< "F07$-RA>
M&0.H8J2/4'!KGX[F?5]%TBUN&1YKT![AD&%*+RV!V!.!^-,T2^EENKVWB811
M6=Q,\RE?FERQ(V^BCU]>* .EFB6>%XGW!6&#M8@_@152STFVLYGG!EFG< &6
M=R[8'0 GH.>U8PN=66VTS4&U!"EY/$'MS$NQ4?LIZY''))[UT] !5*]TR*_8
M&2:XC&-K"*9D##T.*NT4 1P016T$<$*!(HU"JHZ "I*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XB&VU%_$6Y=Y<2
M9,G;;GGGTKL+AV)6",XDD[C^%>YJ.-%CU#8@PJP  ?B:\S'858J<$VUROH7&
M7+<MT445Z9 4444 %%%% !1110 4444 %%%% !7FFOZA%HOB8BUU[38"DSW#
MQ7%M+(\;R*%893@\<@'D?2O2ZX>&76TU?6%T>YT>TMQ>$O%?;GD+[5R_RD8!
MXP#F@#IO#\=K%X?L4LIS/;"(;)67:7'KCMGTK2JO8FX-C";MX9+@J/,: $(3
M_LYR<58H ***Y4P^1\3(2LTY6;3)79'E8H")$QA2<"@#JJ*\VMQ>>%X(GN+2
MRFN[R*[:WN[>9W;S CRC<#P05&..A JEJ4\^@Z+9W.F3SB:_T.2:Z?S2Q+@P
M_ON3PW[Q^??VH ]6K(\5_P#(GZW_ ->$_P#Z+:LG2[;^R_%U]I.FN8[1],BN
M%#L9%CF+NF[!.>0 2,C.VF^)K3Q OA76#+K%@\8LIBZKIS*2-AR ?-./K@T
M=9#_ *B/_='\J?3(?]3'_NC^5/H **J32WZRD0VT+Q]F:4@_EBN-\1>+=1T[
M6[6W2 *L!WW"QL6#@CH3CTY_*M(4Y3=D<N(Q=.A'FG?ML=[16='=:C+$LD=I
M;LC@,I\\\@_\!K00L44N &QR <X-0U8Z(S4MA2 1@C(J-8(5\O;$@\L83"CY
M1Z#TK/\ $,\MMI)D@D:-_.B&Y>N#(H/Z&L72M1N]2\1WFGRW4L$=G=22*I.&
MN5!P I_N+T(ZYQVZHHZ6/3[**Y>YCL[=+ASN:58@&8],DXR:?<VEM>Q"*ZMX
MIXPP8)*@89'0X/>L;7-1EDLY(;%;T-',@N6BMW#B+/SF,D?,<?W<GTK-L;B6
M]TC48,ZU-!:W02%HV,=S(A56P2Q5N"QZX.,9H ZJ6RM;C?YUM#)O3RVWQ@[E
MZ[3GJ/:G6UK;V< AM8(H(EZ)$@51^ KB[:>]U6R9)-5NHI;*P\X/$VPF7<X_
M><?-MV $$8)S[5U^GW+W&DVMU*N'D@21P!T)4$\4 3?9X?\ GC'R_F?='WO[
MWU]ZS-7T>2_2-;9[&(!R["XLA.-Q_B'(PP]>:--\06^I:C=VD<5PI@8!6DMI
M$##:&Y+* .O2J_C"W=]!N+F*\O+:6W0LC6T[1Y)(ZXZ_C0!>L-%M=/2T";W>
MUA,*.[9X)!8XZ9)'6K<EK!)N+0QEBP?<4!.X=&^H[5D07-S8ZJ-(MU\VV@@6
M>:YN[EF?#%A@9!R?E[G&*S#XPNU6]464$\D:1R6YB=UCD5Y GWF0 ]0<KD4
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M7@V^9R-YC$A8 D9P:]?HH \CT_4[?1M9@\7:BMQ%H=Y=WQAG:W?]T)/+V.5
MR _EM@D=QZUU?A'1XM0\%0QZC:RI%/<SW<<+EHF17E=DR 01\K9Q[UV-% ')
M7?A_3-*UWP_/9V[1RF^=2QF=^/L\W9B1VKK:Q=<_Y"WAW_L(-_Z3S5M4 %-D
MC25-DB*ZGLPR*=4-U=V]E 9[J9(8@0"[G &:$)M)78Z.WAA),4,:$]2J@5)5
M.SU;3]0D:.SO(9W4998W!(%7*;36XHRC)7B[H*@FLX;BYM[B129+=BT9!Q@D
M8/UX-3UG76M6EI]N\WS/]"1'EPN>&SC'KT-(HF;3;5K:ZMVC)BNF9I06/);K
M]*ALM&MK&Z-T)+B:X,?E>;/*7;9G..?>K$=]#-?S6<>YI(5!D8#Y5)Z*3ZXY
MQZ4R_P!1CL/*4QRS33,5CAA4%FP,GJ0, =R: ([S2(KZ<R2W-VJ%=CPQSE4<
M>X'KWJS-:0SV;6CI^X9-A53CCTJC_;B/9K<06%[/\S+)'&B[XF7J&!8<_3-.
MEURV6*U>WBGNFN4\R..! 6V#&6.2,#D#F@"X+2$72W.T^:L?E Y_ASG^E8-_
MI26SJME8W[-Y6P&VN?+63DD+(2<X&3S[FMZSO(;^SBNK=BT4J[E)&#]"/6IZ
M ,C1=%_LQ(C(ZL\=M';HJCA .3CZG^0JPNCV:313+&RRQ.[JP<Y^<Y8'U!/;
MI3M4U(:7:-<M:7-PB@LX@525 &23DBC3-0_M*U%P+2YME8 J)U4%@1G(P30!
M@)HS2ZA9QQ6=Y!;VUP)B)[@-%'C.!&H)SG/X"NLHJ*YF-O TJPRS$?\ +.(
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M *W/4Y[^AX]*EO(+O;:WL]U9P7MNSA<D^4ZL.0<\YX!S[5L%$+ARHW@8#8Y
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KWMY#86CW,Y(1>P&2Q/
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MZ/Y4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ_[H_E3Z9#_J(_\ ='\J?0 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-.%JSSSR>?>RC][,1C_@*CLH]/SR:O445Q-MZLH****0!1110 4444 %%%%
M!1110 4444 %%%% !7GNMZII$.JWD4GC?5+.X5R#;QIE(V]!^[.1^-=?XBGE
MM?#FHSP.R31V[LC+U! XQ66GB36=B_\ %(ZB>.OGP\_^/4 :GAU[F3PYI[WG
MF_:6@4R&;[Y..I]ZKZ]J7AZ&2"PUJ:T#S\Q).@;VSR"!UZFM6TFDN+2*::W>
MWD=<M"Y!9#Z$CBL+7X+"R-[J%\\KQ7MLMBUO%%YCR$EL!!W/S'C'OVH C\)W
M6@HO]GZ3;O#)'$,226WE-<(.-X.!O'O[^]=/7):->6^I:[9F.QU>V6SLVAC%
MW8M$AR5R2Q[X4<?6NMH **** "LCQ7_R)^M_]>$__HMJUZR/%?\ R)^M_P#7
MA/\ ^BVH U(?]1'_ +H_E3Z9#_J(_P#='\J?0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%5;S4K'3U+7EY! !_P ]) O\ZSSX
MCBFXT^QOK[/1HX2B?]]/@$>XS5*$GJD!M45BA_$5W]V&QT]#WD9IW'X#:/UH
M.@/<<ZCJU]=#O&KB%#[80#/XDT^5+=@8?Q/\3Q^&_";W*6ME?SF9$%K<_,"#
MWVCGC%<1\'=>/B/4I[>[TRTM(M.@$RF%"OF.6.&<GKM!./2O0?$7AOP_'HAB
METQ?+,BDF&0Q2$C_ &Q\Q_.J/@O2--@O[B:WMYTD:,"1GN6=7YX&T],<=.M1
M+,\/2?U-+WY:K^MNX<C?O=#LHP;AQ*X(C',:GO\ [1_I5BBBIC'E ****H H
MHHH **** "BBF22QPH7E=40=68X% "7'G^0WV<1F7^$2$A?QQ5#2;O4+Q7DN
MH[9(P[H/*9B<JQ7N.G%5-6U!=2TNYM=*ENGN)$(CGM5.$;L=YP,9ZX-<[\,[
M76C!>7NJWEPR>:T4<+MD;@WSM^?'YUHH^ZVR'+WDCT"BBBLRPHHHH **** "
MBBB@ HHHH **** "BBB@#B/&X6YOH;5M+CO$CM7GD;[8;:14##(##[P./NGT
M%)HVH2:==QI8VD*Z-+=);L\CNUTTKH&#L2<$<@8Z_A4_C::!RD+Z#:ZJUO"U
MT_VF38(TSMX.#DD]O:F>%]!T_P"W33SZ8+34+.8$QK>23KEERKG/!.#@'L.*
M .KU!I%TRZ:$D2B%RA"[CNP<<=_I7G>BII*FP$ECXM2Z!CW;TG6,/D9R =H7
M/X8KO=1L]0G>.73]2^RNGWHWA$D<@]"."/J#63'!XVD?9-?:'%&V09(K:5G7
MW +8)^M '3456L;>:UM%BN+N2[FZO,ZA=Q]@. /:K- !1110 4444 8NN?\
M(6\._P#80;_TGFK:K%US_D+>'?\ L(-_Z3S5M4 %%%% !1110 4444 %%%%
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MKHPR&'I3P   . *6N2/B6[_X29K:2:PM[!9)8"LA/FAD3=O)R %.>!CIWYH
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M,D&99) S.K [G) X/H:UZ*+Z6"VH4444AA1110 4444 %%%% !1110 4444
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MKJEA!?6,Z3VLZ!XY$Z,#0!FZY_R%O#O_ &$&_P#2>:MJL77/^0MX=_["#?\
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MQGOUQ7>'5-2ON-,TUDC/_+S?9C7ZA/O'\=M?-D_PVUV;Q=)$TVF,[SF8XO$
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M0O\ \(5%HW[LC[2LL+$\CY<(<\_TKK:YR+PU?R';J7B74;N'(/EQA( ?4$H
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M#\T5S?R,;YUQ<7LLR_\ 'O-_"S$9]ZZNL77/^0MX=_["#?\ I/-6U0 4444
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M ^8'E1QC)ZU[_P"$-.?2?!^D6$AB,D%JB.82"A..2".OUKT,13HPHPE'5O\
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MHXX(8G=XXD1I#ERJ@%C[^M244 %%%% !1110 4444 %%%% &+KG_ "%O#O\
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M&:J7/B/43<-:6&F13W8X,8N-WE_[Y VK^>?:N%^"EM>:SX#87FIW)LX[R1!
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M%%% !1110 4444 %%%% !1110 4444 >::[B7Q3J)-Y<.\3H%C%PP$'[L<J
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MO\W/T_&KIJ&MV<^(GB%R^SBGKK_6AV=%4/[-?_H(WO\ WVO^%']F,>NHWO\
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M-Y9SI/;3H'CE0Y5E/0BN3\3ZA9:+XUT#4]6F2WL!;W,*SR'"1RML(R>@)56
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M2'Q<1>K9GP_K/VAHS*$\J/E00"<^9CJ1^=;=A9QZ=IUK8PEC%;1)"A<Y)50
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M,T^'2M,M[" N8K=!&A<Y) ]:);"*74[:_8OYMO')$@!X(<J3G_O@?K0!F?\
M"1S_ /0N:U_W[B_^.5%:^+&O;2&ZM_#^M/!,@DC?RHQN4C(/,GI71$9!%5M.
ML8M,TVUL("QBMHEB0N<DA1@9]^* ,5O%I6\2T/A_61/)&TBIY4?*J5!/^LQP
M67\ZF_X2.X_Z%S6O^_<7_P <K6:S@:_CO2G^D1Q-$K9/"L5)&/JB_E4] '-V
MGB[[=;+<6V@:S)$Q(#"*,9()!ZR>H-$OB[R;J"VDT#65FGW>4OE1_-M&3_RT
M]*V=,TZ'2K!+. N8T+$%SD_,Q8_J31<:=#<ZA9WKEQ+:;_+ /!W#!S0!F_\
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MK]8OAZWF@;5_.B>/S-1ED3<,;E(7!'M0!M4444 %%%% !1110 4444 %%%%
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MU[<7$+P&]OY[I(I!AD1V^7<.Q(&<>]=!0 4444 %%%% !1110 4444 %%%%
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MYK2O&%M>Z1%>W=M=6KRSM D;6[@NP+8"C')(7\^*M1>*]+FEBC5K@;Y!$S-
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MZ(6@O);N+9&1*#(C*03G'!;(..U #X/%$TFN'2I;.U6XDCD:%8[Y9&RF/ED
M7Y,@]>:RM(\3W"V-IJ&NP-'(MG<3^9!<EE=%8 Y3"C=R .OZU>T?PK>6&H:;
M<7%Q8[+".2)5MK8HTP90-SL2?FXR>W)J.#P9.]K]CO[V%[:.WGM8C#$5?9(P
M8,221N!';B@"Q<^*KW3(//U713;I)!)+#Y=P)"612^QOE&UB <8R."/K:TWQ
M!=7.HVUI?:6;,7=N;BV83"0D#&588&UL,#U(Z\\53NO#FKZO;^3JVHVCK%#(
MD)@@92TC*4\Q\L>@)X&.2?:M=M*8ZCIEUYPQ90R1%=OW]P49]ON_K0!IT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-MJ+7<<@<DNC,[<C;\K MCJ>G:NEHH XVY\'L^L7LAMXKJSO9Q/)YE_/$4.
M"#&OR./E&.GOFFCPKJ3ZO:7,ZV+M;7YN3>.[M-)'\V$ (PF 0, D'':NTHH
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img39825204_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &L K(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *Q_%E]<:9X-UR_LY/+NK73[B:%]H.UUC8J<'@X('6
MMBN?\=_\D\\2_P#8*NO_ $4U '04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>;0/!NCZ5<$&>UM(XY=IR-^/FP>XSFHO'?\ R3SQ+_V"KK_T4U=!7/\ CO\
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M/&F))6E.?O, /Y5!J/\ QZ#_ *ZQ?^AK5NL(QM6EJ]EU?F/H%%%%;B"BBB@
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MFW-M!W#K]WC!]"480 ^E4!H.CC5/[4&DV U#.?M8MD\W/3[^,_K6A0 4444
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MB&)P?F/&3CID]3RFIWCV>D6/B62VFGEO-46[6&-<OY0BD$:@=?N $]\D\=J
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M%% !1110 4444 %%%% !115>_NFL;&:Y6UN+HQ+N\FW ,C#_ &02,GVS].:
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M(K0U+3X=4L6M)V=8V=')0@'*L&'4'NHJW10!4&GPKJ[ZD&?SG@6W*Y&W:&+
M],YRQ[USNI:5I^C6>E*DNM0R6:-%#>:?;&XD"G!9'58W!#8'5.W4&NMHH X[
M1M!N+O0-5AE>ZMDU.\,I-T,S/"0BMN'&TN%;CC:&' Q@=3/8VUS]F\V(-]FD
M$L."1M8 @'CV)JQ10!S&KZ'96T47V70;V\7SWG'V"]\B6!VQDH6E3:K<Y56
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)++87[ $6>H1F"7DX  ;AB<?PDUOUE:9>P>(;%+F?2;NV$<V4BU&W".K+T<
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M@.XP3QG(_ U;C)13(4ES6-:BBBH+"BBB@ HHHH **** "BBB@ HHHH ****
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M_+QST]% %73-.MM(TJTTVS0I;6D*0Q*3DA5  R>YXZUD^._^2>>)?^P5=?\
MHIJZ"N?\=_\ )//$O_8*NO\ T4U '04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJU_<)XFM_P!WJ9B70YXU:652RJ-K$[AD'(P,?K5I;F]&I-KJ:U=.?[:_LYK
MR@P>5YGEX"8X?'SYZX_.@#T*O,_%(\*+XNNQXSG,L;11M8H)9"(EQAP5C.02
MW.2,$=#P:],KBKMO$>D^+=4O-,\+KJ-M=I%^^-['$VY5P<9YV^V.N3WH E\#
M?\(9F^_X1+K\GVG_ %W^UM_UG_ NE=A6/H6HZU?F?^U]!_LK9M\O_3$G\S.<
M_='&,#\ZV* "BBB@ HHHH **** "N?\ '?\ R3SQ+_V"KK_T4U=!7/\ CO\
MY)YXE_[!5U_Z*:@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7^I6]K$C6T<++R% )+, JJ".23Z8R2 >GMM'EN+F.^UF5+FY0[H8$SY%N?\
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M4445B:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'454^V-+Q;0/+_MM\B?F>3^ -'V>XF_U]P57^Y!\O_CW7\L5G[5/X%?\OO\
M\KCL2S74%N0)) &/11RQ^@')K@+G4=0;4VF:65)U8A5&1MYZ8_I7H$-M#;@B
M*-4SU(')^I[U1DM+E[]+O[/9ED5E!+')R1@YV]L'\Z\O,\)6Q,8VE:SZ)O\
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M3<2R-<7C##3R=<?W5'15]A^.3S5VBBDW<84444 %%%% !1110 4444 %%%%
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MQ1:CHB6ESX@,$MZR7FW6KU@(OL\S#<?-^4>8L?/'.!WP0#M**Y__ (0W2_\
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M?$!@EO62[VZU>L!%]GF8;CYORCS%CYXYP.^#J?\ "&Z7_P _6N?^#V]_^/4
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M+ARH+#H<<B@"*Q@:VL+:W=MS11*A;U( &:GHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KS7Q!XBM/%FL7WA9-5L]/T:UD\G5;J6Y1)+@_Q
M6\0)R!V9OJ!7I50FUMV8LUO$23DDH.: .+M]3TSPSXUU^34;J"SM;RTM;BTD
MD8*DJ1JR,J'^(KA>!SAU]:UO %G<V/@32(;N)H9S#YCQ-UCWDMM/N-V/PKHC
M&C!0R*0IRN1T/M3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .8\2:MH4KW.A:SJ4VE9M_.$YN?LPD0Y#;),C)7N.V1QS7)>&KJ33;WP
MIJVM!+&T?2;G3TEE00(,31M#N' 0O&FX#CG(QVKU)D1\;U5L'(R,X-*R*ZE7
M4,IZ@C(H Y3P(//@UO4XR3:ZEJLUQ;-V>(*D88>H8QE@>X(-=91THH ****
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MS'C)P>.:PM4UK5M>\+Q/#<6MO<6NM06TS26$R"4B6,HPC=U9!\P)4DYZ ]Z
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img39825204_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )V _4# 2(  A$! Q$!_\0
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MZ***P.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JGJ'_ "Z_]?"?UJY5/4/^77_KX3^M..Y%7X&6****8@K*\1ZW%X<T&YU6
M:%YD@VYC0@%LD#O]:U:X_P"*/_)/-3_[9_\ H:U2U9%1N,&T:7ACQ1:>)M'D
MU"*-[;RG:.:*4@M&1SSCVYK/\*^/;7Q9JEU96UC/ ((_-661@1(N[:"!VKA=
M=N+OPYJ5]IMA&V/$ME (-IP%E.$8_D3^8K3L[*31O%OB.QTP'SK70(TAV#G<
M%'(]\\U7*CG5:=TNVYZ4-0L3=_9!>VQN1_RQ$J[_ /OG.:66^LX'D2:[MXVC
M7>ZO*JE5]3D\#WKQ&:+PK_PK6SFLWB/B=G0J4<FY,V_G/?%=1)I%KK7Q:2VU
MFW6X"Z1&\D3GY6<>H[\DT<I2K-[+M^)Z5%/#<0B:&6.2)AD2(P92/J*BM]0L
MKMG6VO+:=D^^(I58K]<'BO&CY]E\._$]I9M*EI!K1B98R24AR,@>W2M2X@\-
M1>*O"H\'FW-TTW^D"T;.8,#/F>^,]>:.47M[VT_J_0[S3?%VD:MJ=[IUK<J;
MBT?8=S*!*<$_N^?F'%4O"'BP:YHB7>IRV=M</<20QQA]F\*<# 8Y)KF/"-EH
M5E\0_$EO)!:0W4-P!I\; !E!5MWECZ>E<Y9Z!I<WPDUC6)+57U"*=_+G).Y,
M., >@Y-/E1'M9Z/U_ ]NN;JWLXO-NIXH(\XWRN%&?J:8UY:K;+<M=0"W;&V4
MR#8<].<XKR3Q4]Q=^(O#T=Y-IRVS:6CQMJH8V[2$?,3C^+IUJK?67V'X9Z[&
MFIZ?>0MJ$+*NGLQBA8D949_#IFA1&Z^KTV/87U/3XT=WO[54C;8[-,H"MZ$Y
MX/M3C?6@M!=F[@^S'_EMY@V>GWLXKS'Q18:/HLFA:5::3I,;74;2F[U,MY*G
M:,EN?F8^IK!M&_XM?XLC22%XDOTV>1GROO+R@/(7TIJ-Q2K--JQ[6E[:27+V
M\=U \Z#+1+("RCW&<T)>6LMNUQ'=0/ F=TJR JN.N3T&*\E=/#Z:WX-?PN\3
M:B\JFY,+%G*X&[S/?[W6HM:>YT.]U[P;:1L!K-U%)9[1PJ2'YQ^F/P-'*)UK
M:V/7+B^AATR:_1A-#'"TP,; AP 3P>G:N-@^)0:PBU*Z\.:I;Z7)_P O@VN@
MYQGCMFNDOK.+3O!UU90@"*WT]XU ]!&17!:5XET6Q^$*6=Q>V\ET]K)$+17#
M2%F) &T<CJ#0D.<FG:]M#TI;^T:Q2^^TQ"T= ZS,X52IZ')I\%Q!=1":WGBF
MB/\ '&X9?S%>2M9Q6;>"=.\3_N]+6UD:1)B5C\TDE0_T!7K5BQ@TIM9\6P:3
M>K9^'GL522XA),,4IP,K^O3UIV)]J^W]6/3H+VTNV=;:[@G9.&$4BL5^N#Q2
M+?6;W36J7=NUPO6)95+C_@.<UY=X<GCTZ?4M+L;33)]1CTN1H=1TIR1( .CC
M^]G]:P-'T]+K3M,N(]7\.V=RLZ.')<7A?=T;KDD^V*=B?:^1[-KNKQZ#HEUJ
MDL32I;J&*(0"V2!U/UK*TCQ3>:I-%Y_AR^L+.2,R?;)Y%\M5QD$_6CXB?\B%
MJ^?^>:_^AK67X.^PQPVXD\7MJ/F68#:?-,A6,;03P.?E (^E'0;D^>QV'V^R
M\F*;[9;^5*VV-_-7:Y]%.>3]*:^I6$2LTE]:HJOY;%IE&&_NGGK[5Y'X8-NG
MB[3$F\W_ (1YKRX;2?,QL\W( /\ A[U);1^&'U+QB->: 7"SRFW$S$$=>4']
M[./>G8S]K<]<GNK>VB\VXN(88S_'(X5?S-,^VVGV7[5]J@^S?\]O,&S_ +ZS
MBO(_M;?\(EX3L;^TL))9Q*8;G5"WDPH#QD9YR,8S5>R8#X>>,8DD@>)+J,I]
MGR(OO#E >0*+![4]D2\M9+AK>.Z@>=1DQ+("P'TSFD:]M$N5MGNH%N&Z1&10
MY_#.:\YN=&T_1M6\#W6GVXAN+B8":0,=TN5!.X]^IK/O#IFC^)I;TMI>MQW.
MH XWD7MN^[H/4 BF#FUN>C:=?:C<:[JEK<QV:VD!46YBE#2'/7>N?E_$"K\5
M_9SSM!#>6\DR_>C252P^H!S7FEX]U%??$5[(L)PL?*?> _BQ^&:I7L/AN/2/
M#C>&VA_MQIX<&W;,IX^??^/K_*@7/8]7DU"RA\SS;RWC\H@2;Y5&PGIG)XS4
MR.LB!T961AD,IR"/8UYW;:)INM?$CQ0FHVJ7"1QQE4<G )4#./7T/:M;X9,Q
M\%0J6)$<\J+DYP W H&I79U]%%%!0=ZUH?\ 4I]!63WK6A_U*?05E5V1TX7X
MF/HHHK [0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ'_+K
M_P!?"?UJY5/4/^77_KX3^M..Y%7X&6****8@J"[M+:^MFMKNWBN('QNCE4,I
MQSR#4]!IB*LNG64\MO+-9P226QS [1@F+_=/;\*<ME:QWLEZEM$MU(H1YP@#
MLHZ GJ14]!H"R*$>B:3%?&^CTRS2[)R9U@4/GZXJ<65H+XWPMH1=E/+,^P;R
MOINZXJ>B@5D5H=/LK9)U@M((EG8O,J1@"1CU+>I-166CZ9IKN]AIUI:N_P!Y
MH850GZD"KU)3%9%1M,L&OQ?M8VYO -HN#$/, Z?>ZTU=)TU+![!;"V6SD)+V
MXB&QB>3E>E7324!9%2ZTRPO+5+6ZL;>>W3 2*6(,JXZ8!Z5&=&TO[!]@_LVT
M^QD@F#R5V9'?&,5?---,EI%6\TVPU&%8;VRM[F)#E4FC#!?H#6-XD\*P:KX:
MOM+TZ.UL9+ID9G6+"DJ0<D+UX&*Z.@T[BE%/<S;#1K#3RDT5E:I=^6J27$<0
M5GP .3U[5EW?AF2^\=66OSSPFVLH"D,(0[]YS\Q/3'-=)102XJUADB)(C1R*
M&1@596&00>H-9UMX>T2SG6>VTBPAE7H\=NH(_'%:9I*8FDRO=V=K?P&"\MH;
MB(G)29 PS]#3(=.L;:S-G!9V\5JP(,*1@(<^HZ5:I*8K(J66F6&F!EL+&WM0
MYRWDQ!,_7%1#1-)6]^V#2[,76<^<(%W9]<XJ^:2F39$5Q;P7=N\%S#'-"XP\
M<BAE8>X-4(O#FAV[EX='L8V*E2R0*"01@CIT(K4I#3$TBD=)TUH+>!M/M3#;
M-N@C,0VQ'U4=C6'I7@ZWMKS5YM2CM+Y+V\-S$KP[O+Z^O?GM744E!+BF5KO3
MK&_@6"\L[>XA7E8Y8PRCZ ]*B_L?3!!/ -.M1#.098Q$NV3'3([U>I*8K(KR
M6-I*UNTEK"YMCF L@/E'U7T_"HETC3$OC>KIUJMV3DSB%=^?7.,U=-)3"R((
MK.UAN)KB*VB2:?'FR*@#28Z;CWJ&WT?3+.Y:YM=.M()V^])'"JL?Q J[10*Q
M7CLK6*YFN8[:))Y@!+*J ,^.F3WI;6SMK&#R;2WB@BR6V1*%&3U.!4U% "44
M44"#O6M#_J4^@K)[UK0_ZE/H*RJ[(Z<+\3'T445@=H4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 53U#_EU_Z^$_K5RJ>H?\NO_7PG]:<=R*OP
M,L4444Q!0:*#3 2@USVN^,=/T/48-+^SWFH:I.ADCL;"+S)=@ZN<D!1[DBM/
M3-4CU/3DO/L]S9@DJT5Y'Y4B$'!!!_F"0:06+M%87B+Q-%X>GT:)[5[C^U+Y
M+-"C@;"P)W'U'%;@(895@P]0<TQ,6DI Z,I974J.I!R!6;KOB'3/#>ER:EJE
MR(K5&5695+G+$ <#GO0(TS24B.LB*Z,&5N00<YKF;3Q[HM_XO_X1JU^U2WFV
M0F7R2L.4^\ QQD@\< C/>F!TYIII<@D@$9'49Z5A#Q9II\8OX7;SDU 0"969
M0(Y 1G:K9^]CG&.@- C<H-<Y=^--/M-.O[P6M[,+/4!IK11(I>28E0-H+ $9
M8<DBI!XFD_LY[J7P]K<4@D$:6QMU:60D9R K$ <=213N*S-VBLG0?$-IXAMK
MB2VBN();:8P7-M<Q[)(9 ,[6&2.A!R"16C<SK:VTLS<[$9PN<%L#.!3):)#2
M5GZ+J\6L^'[#5PGV>.[A68)(PRNX9P3TJIX@\1#1)M/M(;-KV^OY&2" 3+$,
M*I9F+-P!@?B:+BL]C:I*JV=Y)=/=))9SVWD2; TNW$GR@[EP3QSCG'2DO;TV
ML$4L-M+=^9,D6VW*G:&."QR0,#J>],DM&DH9E#!2RACT!/)^E(64=64<XY(Z
MTR1:0U3EU:RAU>+2I)PMY+"TR(1U12 >>F<D<5<--"8E)2TE,EA24M)3$!I*
M4TE,04444"$HHHH 2BBB@0=ZUH?]2GT%9/>M:'_4I]!6579'3A?B8^BBBL#M
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>H?\NO_7PG]:N5
M3U#_ )=?^OA/ZTX[D5?@98HHHIB"@T4&F!Y?-?VOA;XUZGJ6O2K:66IZ=%'9
MWDW$0*8W1ENBGC//]:I^*=8T'7/'/AZ;5[R&X\'O;3A9)6(M7NE./F/0X'0G
MCTKUB6**=-DT:2)G.UU!'Y&D>"%XA$\,;1#HC("H_"E8=SY\BMC>>'O#UK/Y
MS:-+XO9-.WLP)M"#MVGKMZXJUJZ7&C6GQ#TG1?.M],MM0LB\%L3^YA<9EV@<
M@'OCM7O)BB8(&C0A#E 5'R_3TI1%&K.PC0,_WR%&6^OK18+GB)71H]?\1#P8
MT1\/?\(S,;W[*Q,'GX.SVW[<9[]<UGZMX/TFV^ -OK,-DT^H7$=I<W%S*[2,
M/F )&3\H"DCCM7OB6\,431QPQI&W5%0 'ZBE\N,1>4(T\O&W9M&,>F*+"YC-
M\.KI"Z!:#01:_P!F[3Y/V4@Q]><8]\_C7GNK>)M"'QPT68ZS8^5;Z?/;S/YZ
MXCE+$;"<\-GM7JB(D2!(T5$'15& /PJ$V-F7+FTMRQ.2QB7.?7I3L*YSFC_V
M!_PL#Q)]A>Y.M>7;_;UDSY8&WY-G;IUKG]7T6;6O%WB@V+"/5;&*PN["3^[,
MJR8!]F&5/L:]("(K,X10S8W,!R?J:38H<L%4,W5@.33L*YXQ!?-KG@75+V(R
MV,MWXLB(W*"\#EX@1@\$@YZ^E=]JFL_\('X>FO=<UB75)9)A';><D<)=VX5,
MJ  ."2QZ#-=/Y,6"/*CP6W$;1RWK]?>DEABG7;-$DB]<.H8?K1839RW@1;(V
M%]<QZM8ZEJ=Y<FZU"2RF$D:2,,!!CHJJ !GKC-<QXB'A^7Q9XE7Q4T?VA;2+
M^R5E9@VPQG=Y '._?UV\]*].BMX+<$0PQ1 ]1&@7/Y4K11NZ.\:,R?=9E!*_
M0]J=M!7UN>+1IY]EX-@U*[TVVTO^P@8CJL!EMWGR P(W* ^W&,GIG%:<6@::
MVH>!8+F>TUJ,SWB+<^5\K1A6947))*J>!R>E>J/!#)$(GAC:(=$9 5'X4OEI
M\GR)\GW?E'R_3THY1.9Y5J[E+'Q5YC2K8'Q+ NH&+.1;;(M^<<A>F?;-7M57
MPO'H-D/"QLOLG]NV/F?8FS%O\P=,<9QUQ^->C!$&["*-_P![@?-]?6F+!"D8
MC6&-44Y"A  #ZX]:?*3S'D&KV::EXB\2QZOKFDZ9>BZVVKWUNS7$4.U?+>!M
MZX'7[HZYS6I>>']-U?5_&\VIPB[FM+6 PN[$;'^S$^8HSPV0#GJ*]+>&&219
M)(HW=/NLR E?H>U+L3+'8N7^]P/F^OK1RB<SR^%='D\3>#]3UQ+,R7>BC;<7
M0'[VX!CV_,>K\G'>O4#[TUH8F55:*,A#E05!"GV]*<:I*Q$G<2DI:2J(84E+
M24Q :2E-)3$%%%% A**** $HHHH$'>M:'_4I]!63WK6A_P!2GT%95=D=.%^)
MCZ***P.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M01+E54;V7G(QD'Y@.#FEL/'>GWU[91_8KV&SOY3%97TJKY4[8)  #%ES@X+
M9Q2WOAVZO-4\/2L4%O96=Q;W)#_,#)$J#;QSR#6+X5\&3Z'-I]M<>&M ;["0
M!JR/^]D 'RL$V9#^OS>M :#_  [KEU-I7A@WFHWC3WNH7<1VHC"8(92%<GD
M!1C;SP*T)_B!I\,LLO\ 9^I/I4,_V>754B4VZ.&VG^+<5#<%@,>]5-*\)ZG9
MV_A9)?(W:9?W5Q<;9,_))YNW;QR?G7/XU2?PIXD_X1^Y\'JNGG19Y7_XF)F;
MSE@>0N5\K;@OR1G=COBGJ+0U]4^(%EIE[J=L=+U2Y72RIO9[>)3'"C*&WDEA
MD 'H,G@\59TOQE9ZIJJ6'V#4+4SP-<VDMS"%6ZC7&YDY)&,@X8 X-4KOPQJ$
MMGXWAC\G.LQ[+/,G_3N(_FXXY'OQ5B?0=1?5] NH9(HQ8:=/;2.6R5D=$"D#
M'(!4T]2=":S\617.LVVFW.DZEI[WBNUI)=QJJS[!E@ &)4XYPP%=#7G&A^#]
M>@\2Z'J6HPP&2Q$HN[MM1EGDNF9"H<(P"H,]A_2O1Z:)E;H(:2E-)5$"4E+2
M4R1#24II*8@I#2TAH$)24M)3)84E+24Q :2E-)3$%%%% A**** $HHHH$'>M
M:'_4I]!63WK6A_U*?05E5V1TX7XF/HHHK [0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV]3^9J2)B2<FJCB%)I6%8FHHHKH$%%%% &?I'_($L/\ KVC_ /015RJ>D?\
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M*#10:0Q****D HHHI,!****EC"DI:2I&%%%%0P"DI:2I8T%)2TE2QA1114L
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ML5Z#'X6T"'6&UB/1[)-18EC<B$;\GJ<^OOUI+WPOH.HZB-0O-(LY[L8_?21
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MLX(XKJ0QX?/S,Q0$8(Z &IM)\4S//K-GKUK;Z?<Z0B2W$D,QEA,;@L&#$ C
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M.\/ZAKN@6,VE0"YO-,U"*^2WW ><$SE03WP:S/%]_J/CSP-JVD:3H6M6EW)
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MR]KK&M2^ ;Z\UY+:\B74_)C$5Q*DF?M07!88^5>P'4#!KK'\+75UXGL]6O\
M5EN([&5Y;6-;18Y1N!&UY <LH!/&!GC.<53/@:Y.F:CI7]M9TZYO%N[>,VHW
MP-YPE8%MWS D8' QGO1J%T69M?UR]\07]CH>FV4UKILB174UW<-&TCL Q6,!
M2.%(Y/<UL:S=7=GIS364=JTH(!:[G\J*,=V9L'@>@K)G\,:A#K][J.CZZUA#
MJ#I)>6[6JS9=0%W(Q(V$J #P>E6O$_A[_A(K*UA6Y6"2UN4N8S)")8V9<C#H
M2-PY]>N#35R':YSH^(%S_P ([J-ZME9W=[8:A#9,MI<[X9_,*89'^C]^A%3S
M^+]8TI]6M=9TRRCO+;37U*U%M.SI*BG!1B0"&!QTX.:SM9\%WUGX8U."WNI+
MN[U'4[2X9K2U6$P[7C!*J,C"A<_ASFKFK^%-1_LGQ#J%[J,FL:K/I<ME;+%;
M"(+&03M"@G+,V,GV' HU#W2U8^*-9&K:5!K&E6EK:ZO&QM&@N#(\;JF_;("
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ME2,****A@%)2TE2QH*2EI*EC"BBBI8!1114@)11128PHHHI#$HHHI %%%%(
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M#_EU_P"OA/ZU<JGJ'_+K_P!?"?UKGCN=E7X&6****8@HHHI %)2TE !1112
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MTY[B> 7<8EMX%N9E;*[(FSAB3T'RG\JBLO$&F:C):)9W)E^V0-<P,(F"O&"
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M[XUP2I()!/?D#\JU:SD[L HHHJ!A4L'WC452P?>-:4OC0GL3T445Z9 4444
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MC_OEO\*OY/K1D^M&@K3[K[O^"4/[8T__ )^1_P!\M_A2?VQI_P#S\C_OEO\
M"M#)]:;D^IIZ U/NON_X)0.KZ?\ \_*_]\M_A56*YAN_$$;P/O5;1P2%( .]
M?45L%CZFFDD]3331G*,GN_P_X(VD-+2&@IC32&E-(:HAB4&B@TR1*2EI*!!0
M:*#3$)24M)0 4&B@TQ#310:*8@H-%!H$-HHHIB"@T4&@0VM"R_U1K/K0LO\
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M-1****0!1112 ****0!WJVOW1]*J=ZMK]T?2NK"_$R9"T445W$E%?^0S<_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 53U#_ )=?^OA/ZU<JGJ'_ "Z_]?"?UIQW(J_ RQ1113$%%%%( I*6DH *
M***0!0**!2&%)2TE(84444F 4E+25+ *"0!DD >]%9NO@'0[H$9!"@C_ ($*
M25VD*<N2#EV1H;E_O#\Z-R_WA^=5CI>GY/\ H%K_ -^5_P */[+T_P#Y\;7_
M +\K_A4OE"\^R^__ (!9W+_>'YT%A_>'YU5_LO3_ /GQM?\ ORO^%']F:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY=?^OA/ZTX[D5?@98HHHIB"BBBD 4E+24 %%%%( H%% I#"J.K?\@Y_]^/\
M]#6KU4=6_P"0<_\ OQ_^AK3C\2(J_P .7HR\>II*4]325FS0*2EI*3 ****E
MC0E%%%2QA2&EI#4,!324II*EC$HHHJ6,****E@)1112&%%%%2,2BBBD 4444
M@"BBBD =ZMK]T?2JG>K:_='TKJPOQ,F0M%%%=Q(4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 53U#_ )=?^OA/ZU<JGJ'_ "Z_]?"?UIQW(J_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>H?\NO\ U\)_6KE4
M]0_Y=?\ KX3^M..Y%7X&6****8@HHHI %)2TE !1112 *!10*0PI*6DI#"BB
MBDP"DI:2I8!1114L:$HHHJ6,*0TM(:A@*:2E-)4L8E%%%2QA1114L!****0P
MHHHJ1B4444@"BBBD 4444@#O5M?NCZ54[U;7[H^E=6%^)DR%HHHKN)"BBB@
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=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img39825204_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (O ]H# 2(  A$! Q$!_\0
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M]KC]_P Q_C1]KC]_S'^- $]%0K<QMW(J4$'H: %HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***P/%?BNT\+:?YTN)+F3(@@!Y8^I] /6FDV
M[(B<XTXN4G9(V+R]M=/MFN+RXC@A7J\C8%<)JOQ:TJU9H].MI;QA_&Q\M/\
M']*\MUSQ%J7B&[-Q?W!?'W(QPB#T K*KLAADOB/"KYM.3M25E^)Z!<_%S7)&
M_<6UG"O;Y&8_J:A3XL>(E<%ELW'H8C_C7"T5K[*'8XGC<0W?G9ZII_QA.X+J
M.EC'=[=__93_ (UW>B^*]&U]<6-VIEQDPO\ *X_ ]?PKYPI\4TD$JRQ2-'(I
MRK*<$&HEAXO;0Z:.:5H/W_>1]345Y7X.^);/)'I^N.,L0L=T>.>P?_'\Z]21
MPZY!KCG!P=F>]0Q$*\.: ZBBBH-@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH 9)((T+&LV25I&))JS?,>%[?Y_PJE0 4444 %%%84GB(Q2:FCVH'
MV17:([^)=N-P]CR*J,7+8SJ5H4K.;L;M%9$>KW$VJM9QPVJHBQL[2S%6.\9^
M48YQ3XM3N?[;73KBT1/,B:5&CEW$ ''S#'&:?(R%B*;V[VV>YJ4445!N%2+.
M\8)4YQR1Z_\ UZCI0<$$=J -.WG6>(.I!J6L+2I]FH7-MGA'./YUNT %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME'<S63S->7D=N44[@0O\()[#I6']LTO1='U>&VU%=0O-3 B'E1NJ11[LDDL
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MQ.,JZ-D$?6L90E'=';2KTZRO!W):***DV"BBB@ HHHH **** "BBB@ HHHH
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MN@%FBFHXDC5U.58 @^U.JP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-13^%( HHHJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\JL5%$/WLS>K ?H*EJ8JR ****H HHHH **** "BBB@ HHHH **** "BBB@
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M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX8:8ZH;EEYF?C_='_P!?-<+H>BSZU?!0&$*G,DG]![U[_P"%-&6SMT8($55
M5?05Q5YWT/>RW#N/OLZF,;8U'M3J**YCV HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 44458!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ JIJ7_(/E_#^8JW534O^0?+^'\Q45?@EZ BW1115@%%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/]*Y<3#3F/7RJNU)TWLSVRBD4Y4&EKC/?"BBB@ HHHH **** "BBB@ HHHH
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MN0'U% QU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5XQ\7KEW\2VEJ?N1V@<?5F
M8'_T$5[/7C_QFL6AU'2]4"_NY(VMW;T(.X?S/Y5M0=IHX<QBY8=V(/!^GZ;>
M^$I+>\M8&FOKUK2.X= 7C8Q;DP>H^8?K3]-T:UT_PA?VU[8Q-J<MA/>,TD8+
MPJK!$ )Z?Q&N.MM>N[328]/A6-4CO%O%DP=P<# [XQ5Z\\9ZE>ZAJ5[-'!OO
M[7[(Z@':B?[//7ZYZUU.$KGBPKTE%76J5OZ_KJ;GBB(66C62VG]BPQ2:9$TD
M3Q1_:79ARRG;G\<]C6CKVE6.CZ=<:W#86UQ+]E@@2$1@I;EDYE=>Y/;WKC;_
M ,3'4[.*&[TJQ>6&V6VCN/W@=548!^]C/X5-_P )GJ!OI;AH;9TFM%LYH&4F
M.1%& 2,YS[TN217MZ5WY[>6YJ>'S;W/A75KC5M.LDTZ"W\JWF6$+(UQVP_4G
MN>U4=)/]D>"=4U,_+<:@PL+<]]OWI#^6!4$OBPW&DVNFSZ/I\L%JA6+/F#!/
M5L!P"W?.*BU_5;6ZL])T^P9FM;&W )9=N^5CESCZX%5RNYFZD%&Z>J5OF_\
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M\:RJTW-61V8+$PH3O(^F!THKQS3OB[J<)5;^RM[A.[1YC;^H_2N^T#QUHOB
MK%#,8+D_\L)OE8_0]#7'*C..Z/>HXZA5=HO7S.EHHSFBLSK"BBB@ HHHH **
M** "BBB@ HHHH \[^,6\>&K!@#L%Z-Q],HV*\:KZ&\=:*^O>$+ZSB&9PHEA
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M@SL,?[H_^OFL*\O=/0RVFW43/;K8Y@0GTJ6F1+MB4>@I]<)]&%%%% !1110
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M@7+66WYF[X5TP6UNK[-HP H]!745'#$L,811@"I*XSW@HHHH **** "BBB@
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M]B/[RSF')_A/;K6]XLCV=6/1DL6JZG !LNG( Z'GK]?YU>A\47\9Q+%'+T'
MQ_G-8N\K@%6!QQQUI1(IZ$'.,>])PBQQKU8]3JH/%EJY GADBR>H^8>U:EOJ
MEE=#]U<(3@$@G!%<'\K<8Z\4GEJ<$<?2H=%=#>&.FOB1Z317 VVI7]F08KAB
MHY*OR#6S:^*L86\@((&-Z=S]/I6;IR1UPQ=.6^ATM%5[:^MKM<P3*_.,=#^5
M6*S.E-/5!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHK'\3Z['X=T&XU!P&=1MB0_P 3GH/Z
M_0&FDV[(F<U"+E+9&=XN\;67A>(18%Q?N,I #C:/5CV'\Z\5UOQ)JGB"Y,U_
M<LXS\L2\(GT%4+V\N-0O);NZD:2:5BSLW<U!7H4Z2@O,^6Q>-J8AVVCV"BBB
MM3C"C.*** .P\,?$'4]!=8;AVO++H8Y&^9!_LGM].E>SZ-KECKMBEW93"2,\
M$="I]".QKYHK9\,>)9O#&M0W <_9)2([A,\%>S?45SUJ*:YEN>K@,=.$E3F[
MQ_(^D**KV=TEU;K(C!@1D$=ZL5PGT04444 %%%% !1110 4444 %%%% !111
M0!@>,?$2^&M ENUP;ESY<"GNY[_0#)KYYN+B6ZN))YY&DED8L[L<DD]Z]!^+
MNHF;7;2P!.RWAWD?[3'_   K&TOPA#J?A";54NI!? R^5;A1M<1@%O?.":[J
M*4(7?4^=Q\IXBNZ<=HG)T5U5KX3@E\&7&M3W4B72Q-/% JC:8PP7)/7DY_*F
M>(-#TC1,6PDU*6[:".57*((<L <$]:UYU>QPO#S4>9[;G,45V6K^#+317U"X
MN[R=+&!$6V.T>9<3,H;:!TVC/)K.FT"Q7P;_ &U!?O/<+.D,D0CVHA89QD\D
MCUZ4*:82PU2+:?3]#GJ*WM-TRT_X1?4]7OD+;72VM<$C]X>6;CKA>U6)?#^F
M7'A:[UG3;R[)LY5BD2YC51)NQRN"<=>AI\Z$J$FKKM?Y''WL2OY;$[><%O2N
MGM/AY<W42R)>*489!5"<BN;N_P#CW/U%>T?"Z]%WX>MDE +1YC_ 'C],5A7;
MCJCT<MA"K>,T<M8?#&,,#-YTQ]/NBNWTCP5%:H%6)(D[A1C/UKMQ&B]%%/KD
M<Y2W9[=.A3I_"BI9Z?#:(%115NBBI-0HHHH **** "BBB@ HHHH **** "L7
MQ)XFL?#.GFYNFW2-D10J?FD/]!ZFM6ZN8K.TFNIV"10H7=CV &37SEXDUZX\
M1:S-?3DA2=L4?9$'0?Y[UM1I<[UV.#'XOZO"T?B9/XC\7:IXEGW74NRW!^2W
MC.$7_$^YK!HHKO225D?,SG*<N:3NPHHHIDA6GHVOZEH-V+BPN6C/\2'E7'H1
MWK,HH:3T8XR<7S1=F>]^$O'5EXDC$#@07ZKEH2>&'JI[_3M77=:^68KJ>QFC
MN[60QSP,)$8=B*^A/"'B*/Q#HEO>+@.ZX=1_"PZBN"M2Y'=;'TN7XQUX\L_B
M1T5%%%8'HA1110 4444 %%%% !1110 455N]0M[-?WC9;^XO)KG;S5+J\^7/
ME19^ZO\ CUJHQ;,JE:,-S9O=;M;0%5/FR=E0Y /N:Y^\U>]O,@.8H^2%0X]N
MM5M@&/7WZTQW"@GIU-;1@D>?4Q,YZ(9Y8!Z?GWII*J/P[U:MK"\OCF"$[,YW
MMP./>MJT\+PH0UW*93D?*O"GZ_C]*IS42(8>I4.9WEVVQJSD'H!5ZWT#4KG&
M8A"O0E^H_#O796]I;VJA8(D0 8X'/YU-63JOH=4,%%?$SFX/"4?#7-R[-CH@
MZ'ZGK^5:4&@Z;;D%;96(((+DG%:5%0YMG3&C3CLB.."&$ 1Q(@' VJ!4E%%2
M:A5>^MC>64L"R-&S#Y74X*L.0?SJQ12E%233 XZWO+G4-5N[(*\-U.L4=RP&
M/+5-V\@^^0!_O5V"J$4*.@&!4:6T,=S+<)&HEE #N.K8Z5+7/AJ$J2?.[O7[
MKM_KJ-NX4445TB(Y((9@1)$C@C!W*#FJ,^@Z;<$EK95).24)&:TJ*:;1+C&6
MZ.;G\)1XS;7+JV.CCJ?J.@K,N- U*WSB,3+T!3J?P[5V]%4JDD82PM*72QYP
M6*-B160D]Q3@00#QZUW\]I;W2E9HE<$8R1SCZUBW?A:!R6M93"2<[3RH^GXU
MJJJZG+/ R7PNYSBJ8W#1L58=P<&M:S\07=MM6X'G1C ST8 ?S_&J-SI][8G,
M\)V==Z\CGU-0JX8?A5-1D8QE4I,[:SU.UO@/*D^?DE&^\*MUP(3G*G'/:MBQ
MUV>$A+H&5/[W\0K*5-K8[:6+4M)'345#;W4-U&'A<,,#(SR/K4U9'8G<****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,O)=6T.$O:N2TMN@R8SW('=?;M7G\=TC</\ (WOTKT85%)'RN(PLZ,K-$]%
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M]!_,5G5^"7H-$R6L*'*Q@?A4H '04M%:""BBB@ HHHH **** "BBB@ HHHH
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M3^66C"[GDN9.,] #R?\ /K5]T62-D<!E88(/<52TW3VLO-:68S.[G:Q'1<Y
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MV6/M-S'&3T4MR?H.M303Q7,"30N'C<95AT(J2B2BBB@ HHHH **** "BBB@
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M\D%PQYSV5O7V-<M6ARJ\3V<'F7M&J=7?N>L44U&#J".E.KF/7"BBB@ HHHH
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MZ$46X#<L,?+E3VR>,U7.1[!IV;Z7.8H\Z6W*SP.T<T3!T=>H(YKKM0T[2IO
MR:U'I_\ 9URUUY,*B9G$Z8Y.&].>1Z5Q\AQ$_P#NFA-23)E!TY+7S/H3P5XD
M7Q#H5O<G E(VR =G'7_'\:Z>O$/A#?O$]U;$_('5A^((_I7MRG*@UYLU:31]
M9AYNI34F+1114FP4444 %%%% !1110 4444 %%%% !7E7Q)\;2)+)H6F2E0H
MVW4JGDG^X/Z_EZUZ%XAU0:-X?O=0XW0Q$IGNQX7]2*^;)9'FE>61BSN2S,>I
M)[UTX>FI/F9Y.:8ETXJE'=[^@RBBBNT^>"BMN/P?X@EA6:/2YFB8 APRX(/3
MO4-KX9UN]MOM-MIEQ)"<X95^]CKCN?PI<T>YI[&I_*S*HK2L/#^K:I'))96$
MLR1OL<C VMZ')ZU2N;6>RN9+>YA>&:,X>-Q@@T76Q+A)*[6AL>&O%E[X8O%E
MB9I+0D>? 3PP[D>A%?0&F:E;ZI8Q75M('BE4.K#N#7S"1D$>HKTCX0ZZ_P!G
MGTR5R1"P:,'LK=1^?\ZYL3!?$CV,JQ#O[)[=#V*BD!R,TM<9[H4444 %%%%
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MD>K0PL*.N[&V\"V\011@"I:**S.H**** "BBB@ HHHH **** "BBB@ HHHH
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M=?R3_4[K[7;>4DOVB+RW.$?>,,?0'OT-11ZKITTBQQ7]J[L<*JS*23[#-</
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% #'BCD9&>-6*'<I89VGU'I4,NGV4TWG
M2V=O)+D'>T2EOSQ5@C((YY]*Y"TLA'XCU:$75\8[2&.2%6NY& )4DYR>>G>K
M@KWUV.>O/D<5RWN_TO\ H=6+: 0& 0QB$YS'M&TYZ\5&=.LFF$QL[<RKC#F)
M<C'3G%<5X7N[F:_TI4GO59X'DNOM<I9)AT4H"3T/IBIM*UMI?$L5T=0$MOJ$
MLL*VWF@^4%P(SM[9P?SK1TI)O4Y88ZE.,6X[NWY?YI';21I+&T<B*Z,,%6&0
M?PJ."TMK52MO;Q0JW41H%!_*N!_M&^M=*U9Y;R9DN?M'D.7.8I(W/R@]LKR/
M]TUJ74MQ9ZPEUJ37OV"3R1;SP3$)$<#(=>^3W.>M'LFM+E+&PE[W+V^5[_U\
MSIDTS3XRQCL;92RE6*Q*,@]0>.E3M#$\/DO&C1$8V%01CTQ7.:/%+K5Q>WUS
M>72/#>/#%%%,42-4(X('!)[YK"T^\NI-4MUCN+Y;F34I%,DLK>0T2DY0 G&<
M= !2]FW?78'BXP46H:2V_+]3NH]/LH5VQ6=O&-P;"Q*.1T/3J*D:V@=W=H(V
M9UV.2@)9?0^HK@Y;Z4P1BXN[SR3K4T;^5(^_8 <*-O./84^]BOD\)M>7%Q?Q
M3)<!+<M.Z/Y)< ;QGDX)Z\T_9/2[(^NQL^6&RN=O;V=K:;OLUM##NZ^6@7/Y
M4Q--L(Y&D2RME=@06$2@D'J,XKF=0N)M$UB=+6>=XX-)DF5)I6D&_?U.2<X_
ME23I/IFEZ7JL6H74MS-+")1),624/U 7H/;%+V;[[FCQ,%=.'P[^7H=8;> ^
M7F&,^5_J_E'R?3TIRQ1K*\JQH)'P&8#EL=,FN$?4+VU379)+N9H)WNH827/[
MF1 2H![9&?Q6NUTYF?3+1F8LQA0DDY).T5,X.*W-:&(C5DTE9K^OR+-%%%9G
M4%%%% !4<\"7,#PR;MCC!VL5/YCD5)10)I-69Y^D)BT'Q'=1S77G6US+!"QN
M'.U!MP,$^YYZUMW\\JZUX<197 >.8NH8X;$8Z^M;,.E6<$5U$D(,=W(TDRL2
M0S-UZU#9:#I]A+YD,3EPFQ3)*S[%]%R3@?2MW43W_K0\^.$J1LE;I?Y2O^*T
M.)TG6+VPT:2W>XEEN-0@1[-I&+$2,WEL ?;AJMV<UU]FL=*>[N!%/J,\,LPD
M.\JG1=W49KJH] TV(6(6W_X\23;Y8G;GK]?QI7T'3I+1[9X,QM,9_OG<LA.2
MP.<@_2J=6#Z&,,#722<ME;=^3?WZKTL<SJKS:3<:OI]I<SFV_LTW #RLYB?=
MCAB<C(]ZL^%Y)'UF9(C=0VZ6B&2"ZD+,TAYWKDG"X]ZW(_#^G1VMS!Y+,+E=
MLSO(S.X]"Q.:L)IEI'>17:1D3Q0^0K!C]ST/K4NI%Q:-882HJJG=673[]/Q_
M0YRY:;4M2U8S+<7"6+I'':0W!AX*Y+D@C)]*S;V_BGDTV7R]2FM#I\DOE13M
MY@(;AF((SC\?I77WVAV%_/Y\T<BS%=C212M&67T)4C(^M.AT:PMYH)8H K01
M&&,;C@(3DC'>FJL5_7D*>#JR;U6K_6_;HM+7MZ'-6CW=_)HFF7M[(T4EHUQ*
M\,I4S'/RJ6'/ ZU7OI;JR76;>WN9WATN6WN8MTC%@#RR$]2,9X-=.?#FF?8X
M+40NJ6[%H665@\>3DX8'(J>#1[&VLIK2.']U.#YNYBS29&"2QY)H]K'^O47U
M.JU9O7O=W^&UOOU_X)Q\FOSVVL:CJ!G)L9X9HK8;N-\:K@CMR<U8N-)%O_PC
M\<TUT9;A@ER?M,@W?+D_Q<<^E;[>&=)>QMK)K7,%M)YD:[SPW?G//6KUS8V]
MW-;S3(6>W??&<D8.,4.K%;?UV!8*HT_:-/9K[TY?\ Y47\VGZOK]M'!?7$21
M1+'Y3;Q%^[ZDLV1Z_A6]X:D>7PUI\DCL[M""68Y)-6ETRT2>\G6,^9> +,=Q
M^8 8'TX]*EM+6&QM(K6W7;%$NU 3G J)S35EY?D=%"A.$^9O37\7=?@34445
MD=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img39825204_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_15.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M*ZH$VV-E0G* Y(-G#N+<#FJ4T?6Q70G.S_B/]9&<V\_WB7XFNNS?JJ\UFI\
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MX)"Y-G*,Q\6X[0%H$<GU,C4,KY%96+G+CQICM:!;'OX<#W=HW$M9NP/(2?\
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M9/-%*38Z3)4A'7Z6',FA#(!9\Q%1'9%M*ARFEQ96"J&3O<*9D+$D8_&4=6-
M%6KP,0"30OFY5]5EQ*7;:PQ9GPNH&WO!L#HRV205!\8LBK/E.ZGFB1T6=Y_X
M^5ZY>:_TGI1V@5VR7*ZU*$*@5(V:LD!L\^JJ,A&VAK]8@((MBZ\281]0N'@P
MBTM3DR;(<5PY-HR.$4JH8A5-E@ :YOSXL^AXG=CW=VA<AF*@L0  219JO(=!
MZCF3CE)>,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E'_3O;^A<R]$^">=U$E#A5;O/:^C4O
MI,22+@SI!6OUSAE]NPJ+"F2F7)(EUFQ QDQR4/6Q(>;C[B.N*BO/-.;8D5L>
M=B.<>-67GH3D13?KP3,<KLN3 H/&3(RMQU QNPKTY FG$/B$UH?8SM=5S4XX
MZ#^(!1/ ZY23\!+<BQ7FDUBZ,=&2WN!M384>S940'@.U*G/NQ%OHGMI>TVW/
M<-0;<.<#9^AZ*Q4K\S5WTE?T@;BNT\9UP7?FRAMW3H+JO/UE6*I\:$*1H;?4
M+OY;Z71*'9_-G4/1?*2WYYH=FG="'<;M-?IM] /B1<AE^E,0C5CA2AUBLCK4
M>77&)QV<.%(83$=V.C.[:N1689$QN-K#;O!92+]ZP#P.;H><R&L&W<V)E4XW
MR(=RG<$(5A5^'D@@M0KDU)IKGO>Y=C\;>Y>]TRB5^@F?-=/[F-I%J"=(K/;:
M!=+US/C\F^ZL53L0,.,!V>I"2LX) <EMMR8)$G'-!GOH2Q!&*W0X%3-@0L6&
M0H6!4HRAGVTP))!(!/RH]")H,Y?#FR* #C#A2&#JS*FZU(%$ T+];'!!$YJ5
MWX@ON<]S&//K?4V[75+K9_!=5"^DC7FC7/$5'I7HZ^,5CL7**_7[-!'U#K$2
MC!Y@XQ"MH44U''O36!\XA*40@R6^@X, ?E:*C4$XAEW6N)248D>)"Q!!!)Z>
M72<PU&8J:;<I.G R'$5 ;*VUU /#;0000.":-R?>O^U?87G5KUG5;5TCGW3C
MGAFX>3NN%[5 H 6DS/07 ^]D#82S<2-5Y1$T*IO8X<R&IZ@'J?+B;MDIH%!_
M H[A.3&D43#AR=R0K(,XRH!N+=WDQ@$.#0)3D;@U[>>>+EWS9L?? LK' <+D
MA:[S'D)!0BS3@@[2I )H5Y3I+\/GL71?1?F2K^A>C6$"5>[=8;ET.E5VN1A2
M8/,N:$;%-'4;F$TF+;;4>L]4#"VV[N3)_:)LW278 SNT1A,5IOGU"+CRG&H/
M@"JQ)/C8 %FYZ D\ <51\YTZ=VR8AD8@[RS* *VJ2=JGU90*8^MR[&83:,1&
M(C$1B(Q$8B,1&(C$1B(Q$K#T_P!45+D9>RA[C3+Q$57H]1GQR?W[ET$"=%7&
MQ.U:&88.'>EAQE5&0##$EJ;)Z7(HFYC,.?(KZ#C0^?N-JF(N 0R\DBO&2" #
M5!222"*VAOC4R?,J$AE857/@ (8U=E@ +X\6TGRN8Z?Z^H<2RLU*'3^A'#!F
M>7#T1(9BC/0NDG:L>I=9O :HD)=[A0V7Z07O0E@X0MKU6 S681N95R]BABWG
MU.Z:K)4#C=>[PA@Q4D!2?$%- 6>18%QWPW;0K$FP"-M,05# 6P]TL ;H<&B0
M)*,?O/(T\ZH74[#?*O0J=TD !L54G]#L 2E*FQ;&$CV"!"7HZ1B,I+MC9"7)
M@YI]Y^,IM]*OFEI2\IL;<R@%BI(.T%NAH]/*_.6[Q-JN6558 @L0MV+ Y/6O
M*2I GP2D&&3&3(A$:1B1YX\A D,S(,^#,91(B3(<N.MQB5$E,.-OQY##BV7V
M5H=:6I"DJW7IUEP018-@\@CH1ZSU8B,1&(D2VGB//+EUWDW<3PR9)Z)Q,/TD
M#SXHT5GQH8P=UF'6H%U;EBF'D0"CD^+4@J(KL]EY8_;#RX>VER'5*N'8(Z ^
M%RI85U*7MY\O>/SE"BET<CQ(&"F^@>MW'G[H^4@6_> ?.?2>SS.ZV0;?4W(I
M>N-=0-C W3[T#HUAZ1P&0+5RNZV"C##<>MF3=9'!X(-K4^ \.D"F]:D0'""6
MB#=UU&1$"#;05U!**6"Y 0P#$6 ;)Z]3*-@QNV\AK+(Y 9@I;'6TD T2  /2
MOCS/8/\ !/F. U18NZ-+(0.=V[T/=:\,+6,Z2&N&/4XVVA^TLF(<F:MDR*LP
MN[V*"P+()>B"6):-#D,*8;5H<^4[O%6\8U- #C%6RCU!!4&QR:Y@8,8VBB0K
M9& )L7EW;[]0=QX/2^)AN<?#U\[<P:Y:P&WU@\QQ.]B;[R>/?NU=.Z!%H$FN
MTFS\\K-8J\6VV4K&$T>N52X'1XJK1&FAZ5R&)4S4R1#B.,RVHR.7)V Y%*OM
M15W6P8D[0+8D#D^E=)"Z?&FVMYV,&7<[-1"E0!N)X 8@#IS\!,U \*<&%W;H
MUM&KZF/"]:)=%/=%Y) [-TV#P^UV7K5?)UKH]E*\IAV5BIR"]L'F2,LAM4+[
M@S87FK5 @P[-"@EXU>^<A0=MH%"ML7> AM0&J^*^=<77$MW*6Q&X!BQ9 [!&
M+@AB4!HDV2>.OB][F1D.^%MY-@42_P#/I [JAT1T>@\FYH:(V7L_2#MC%U+@
M]H<N'&X%0.S[ [-IVN='/N4BO:KJA["=#(GWYB:ZZ2>GW.JREE;P JSL*10+
MR"GL53;AUNY3]%Q;67QD,J*;=B:QFTHW8VGI5?&S-KL_PZ?-5O@6ALW#Z4]9
MK5=..]+D]*C]=Z%$ZJ+Z5PGF@WD?/.A@NAL'D68;<HE&';'&SJ9[LJS2B1@F
M>W/GDI#ZH&HRBJ*T%=-NQ=I7(Q=E*UM*EC8%<4*JA).GQ&[#$DHV[>V\,B!%
M8,#8.T43?BLW=R9+IY?Y-T/B /SW=(MJLO.P,WGQ./\ CEYMIBVD"G,[<"O5
M9*';P5+3;6>);L]='$B\XL5ER3"OO+4YQUJ0XG*+E=<AR*0&(8&E4"F!4@*
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M7RU-*=SK_6#%>=W=;ZBCBY-< >A.W:H3S'-H=<2=B31]2:EVY%@AA-E10AM
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M&^8H8'_E?[BRFCUO34/\DU$G0:=]V;_#OLL_E:CF2]0K_P!/2?PBM$YX6#]
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MT2D(T_!E-MOM2 >CZFGOD1F/Q]P4M6S;E<$]:!!&\CX$'(68_P Z])7"%*$
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MG]A.UZRE:J,=&/&:I0P?,:_)CIGRWAS(RBUIQ8  U &O1!SC(A$6#,D1'B3
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M2>L]       <  4 /0 =)!GKW]DWU!_P[]K_ ,-;-E\/UN+^(GXA*9OJLO\
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M))-D^_YF=P1<>3"B*%5<>4!5% <X_P#V?7SEO\QF\8B5W]>_LF^H/^'?M?\
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M-&^IW3C*(<T82I4VGO0+[S>M6B\1)[CJ3S>Q0R'!'%8'W])@FAN/&'D=,90
MEB58%=I"A^H8-X6*K73DFP:J99 YI5 ((.ZV9.A4KXD!8>?2K\SY&1.0U-ZD
M<] UN55J[3)D-TY+G@*K;;#? [) S82QL@2U<[8!K-ELI0_-(OV"P%S@:.2E
MV H3<E2"3F]DYE7.YB;+=.2H4\ "MH)  J@ >@'3I+H-J@$!3S8!+"R22=S
M$W=FQU)Z]9)65EI#_<>?2>ET5RO0!D$D4CF0YP.J=>+CSO0HR&E??!9V+9Z+
M%FGV)@6<ED@R/3&7 ,Z86))*9AS'7V[HVTW="B#X0U@^1#<$'_KJ.DID7<M
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MM5T**'1_DU#A,?.)!B1HL9K3<:#$;3I*$(9CL_ZB,PP:;4ZS,N'38<VISY&
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MB7*V,_/6IXD=L1PY,)FCQHI+<D$2I4N0F3RA::1+SY$DF2GRY)G9R"QN@ .
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M![S'B(Z':1<]!/I9^FWVJ1?_  +]#&3LO29%5L':?MEKFTN%\#@%-0NCSMV
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M#L7&^JR/L6\V=WU?A%ZD@L#UAHWPX?%]!^BX/X=73\MK[.US+S,-7C[PM/\
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MJ.]&=5%E28,E+;[:FEJCS83T>9#?TE>]LRHC[$F.YI+K#S;J$+2_]^O]X_\
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M)L! *'_E8^M"_P!GUN57$ *9LA-MSWV7IN.W]OTJ;Y^B_P R_K[OO[V'J?\
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M5"$H\JW=/9  :JY##D,%*D D-1#+1(') //$IWR4"25Z^\IX*DA@2 5L;6L
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M.>1<'-C )W70)H!B> QJJZTK<'GPGC@R>*U8(%KKX6S"FR30P^+A%X#9@04
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MY36"OE3D!@Q1;!+$27#//;1TFU 2$O\ "S#JI77.C1>K7V#);L HO&;BF+M
M'DXTT8P-L 1B'H<!-C($TI'GR,K@,+X8*#U'N+L7H1T4UZ'J094XD)4URI8@
M\'WVW-U!ZMSQ1'D0)J(#Q!PZL"I @*Q:X;,PY--3I2+#O4\CHCS@KR>:.)RM
M0M*)QYM'*NCB1.>F39S!*.S931\C9GB!B;8YG)LU8 '3T;>*'04PX X'0"JD
M# @%#=[V[KZKL(/'(*\&[)ZDW9FQVWR+Q.[H-HL0(A.T==;ERM.%7GF6B,45
MQ46,),PY*)$!U\5^C[R^?$CSXLT:[/#2U$8$^(7(Q)$#,ZU1 KIQY6YK[^\;
MXU5'B2V%&NP3?Q^"#_KNT/I8-@@D3U-^4>.:APH4@--DLPV4M+;;ELAHTO7\
MGG3>7R%.#:W$""(>IE4Z[>&7V X\9$1.(1IT6/&=@1=-P<KGF_AZGWE8<FSP
M57^5=([I*JC_ #K]ED\J'NL?[R=:R":K%="5QB>2*, A<$2R1,OLR2LUF!';
MC-2"$B-&AL/2W&VTJ><9BQVUK^>TM(UO[.J$V2: LW0Z311M %DT*LFR?F9G
-,B3&(C$1B(Q$8B?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img39825204_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_16.jpg
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M 0$               (#! 4&" D!!__$ %41  $# @(%!0<,$ 8!!0$   $
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MWGYL@CYU_-M%FMS&P&8NL!T#,2ZPZ22I/>\'.&7F8^<<;N?E&8G*&W)MK):
MTWVC5L7ZUTDTO8RL'.--/Z@VEZTRC8^O2",!&D<0K2&CPB(=.,.#< 9FBHD
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M<#&!Y:YX:T/<+@.> ,Q MJ!-R!T#4OKME?\ PC_6N?\ 9SQ1:]PZSP3;*_\
MA'^M<_[.$U[AUG@HJ=*)G O7E'C[(MJA!0MD@M3*5-7+2ZJKW>1C8&S1< $O
M69FN):;:D"E$V]&.3(2RM&D5+04G#L$63T[65DBIU]$7@2%G,O<QT,C8YGB-
MKG,<[*\/YZ&YC)^T)+7!Q)%VM5OKPPF)KS.QLC)XG201F4M8]K,S',YF:S9
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..A1;%R<(F$3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img39825204_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_17.jpg
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M "%)^T2"6&?A4%3@G.[V'.)^MCX@4P461F!<#A IPN1\3'<,C Q[G@'[+>J
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M%&"1R<*V2.[\;T=JS3D^PZ^VE?8UAJ4!)BSU9ZGS0-/<&!@KCA'95_V/O0J
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MS\W,IQG,^G5%H+ERVF9&U*R62F.+)F<9:1L95?0#TSZ@?B<_"*T85EU)EFG
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ME<DC'=ALA8N8J'"\PB-B0OE>GQ4N%1F*@ _$0JD@@$GY]O[*-(BAR6!V*68
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MN9EDN=BH<!DC;!"_L]B"?0DLQQV[ 5^I;K_ULT7U9H$'6.@-9UC65-A?&X[
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MKL-+*SJWFA'FN<XX8J=X'.1Z^8H)QGC?SZ%C@'!PPAC7;NY0, AQC!YV^4Q
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MC:UN97B\JXQ<0[?*N )T<5R>M0P6&J7=II]S'?64-_<6MM>>EQ!')((IU*?
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MEADM\N?*W.T3326^IO0.(+RT]7N@58F24>/B2V[MZQV#&,8_5F4$_'U1%/\
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M<Z:_Z.,K'&YYC8BW\^5L#=++OD; W,<"I(_1-JS]6-;4/&/\V*B Q_X>P_\
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M261G=BJ%(H_5F\:>KI'#10Z1 H15,:VDS@L!\3[I+IG!8\A0VU1@8)!8\_\
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M'VEJM$+43FZU-V%%'$[6@/08@>L%1(ZVW,^F^W2"Q70.8>O[H&G*GC [#O\
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MNA4J1J:A5N;+M1"K7ZZ5*TI-$"$;$VSW>-5++&$7 6\54--39 ^TEP)!LXQ
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D..-YSE"U8RI7+Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img39825204_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 7_"6\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEC[K%,\9_,[OY4 ?1]%<CX'^(VA^/+5VTZ1X;R(9FLY\"1!ZC'#+[C\<5UU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\?M)V*1^(M$OP,//:O"Q]=C9'_HPUZC\%=0?4/A5I!D.7@\R GV5V"_^.XH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,\2)?R>%M732
MRXU%K*86IC;:WF[#LP3T.['-?+?B3PS\6KJQ8Z[;:Y>6HY,?GF=1CN41C^>*
M^MZ* /E+X0>-/"WA+5@-:T@I>2$H-5+[_(!XQLQ\H]6&3^'3ZKCD2:))8G5X
MW 964Y# ]"#Z5\\?M%>%+.RN-/\ $EI"D4EV[07048#N!E6^N P)]A7:? '7
MI]6^'S6=RY=]-N&MXR3D^60&4?AEA] * /%?C<2?B]K@)/'V?'M^XCKZI\+_
M /(HZ+_UXP?^BUKY?^.UH;?XK:A*<XN88)1GVC"?^R5]->"[@7?@7P_<  >9
MIUNQ /0^6N10!N5X5^TM_P @GP__ -=YO_05KW6O _VF+@"W\-VP )9KB0\]
M,",#^9_*@#=_9Q)/P\OP2>-5DQ[?NHJ\9^,A)^+.O9.?WD?_ **2O;OV>K0V
M_P -7E.<7-_+*,^RHG_LE>+_ !LMGM_BSK)8$++Y,B$]P8DS^H(_"@#ZQT;_
M ) >G_\ 7M'_ .@BKU9?AJX6\\*Z1<IC;-90R#'H4!K4H \ _::Z>%_^WO\
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M%;7_ -&K0!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !4<<$,3;HXHT.,950*DHH
M**** "BBB@"-((HF+1Q(A/4JH%2444 %%%% !4<<$41)CB1">NU0*DHH ***
M* "BBB@ HHHH **** / /VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_:
M:Z>%_P#M[_\ :->/^!/^2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M/VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_::Z>%_P#M[_\ :->/^!/^
M2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** / /VFNGA?_ +>__:->/^!/
M^2A>&O\ L*VO_HU:]@_::Z>%_P#M[_\ :->/^!/^2A>&O^PK:_\ HU: /M^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** / /VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_:
M:Z>%_P#M[_\ :->/^!/^2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HJ.:X@MUW3S1Q+ZNP4?K1%/#<+NAECD7U1@1^E%A<RO8DHHH
MH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"__ &]_^T:\?\"?
M\E"\-?\ 85M?_1JU[!^TUT\+_P#;W_[1KQ_P)_R4+PU_V%;7_P!&K0!]OT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5P/C+QN]C,^FZ4X\]>)9QSL/]T>_OVKK]:O
M3IVB7EVIP\43%3_M8X_7%>".[2.SNQ9F.22>2:Z\+24WS2Z'AYSCIT(JE3=F
M^OD.GGFN96EGE>61CDL[$D_B:6WN9[699;>:2*1>C(Q!%145Z5NA\GS.][ZG
MJ?@WQLVIRKINID?:B/W4W02>Q]_Y_P ^YKYVBE>"9)HF*R(P96'4$=#7O^FW
M?V[2[6[Q@S1+(1Z9&:\W%4E!\T>I];DV-G7@Z=1W<>OD6J***Y#VPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** / /VFNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU
M:]@_::Z>%_\ M[_]HUX_X$_Y*%X:_P"PK:_^C5H ^WZ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *KWM]:Z=:/=7DR0P)C=(YX&3@?J15BO(?B[XA\VZ@T&!_EAQ-<8_O$?*OX
M Y_$>E73ASRL1.7*KGKU%<=\-_$/]N>&8XI7W7=EB&3)Y*_PM^(X^H-=C2E%
MQ=F5%W5T%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH RO$UJU[X:U"!1EC"6 '<CG^E>$=*^C*\E\:>$)M,NI-0LHB]C(=S!1
M_J2>W^[Z'\/KVX2HE>#/GL\PDYI5H*]M&<;1117H'RX=3BO?=$MGL]#L;>08
MDC@16'O@9_6O.O!'A"6\NHM4OXBEK&0\2-P9#V./3^=>J5YV+J*345T/JLCP
MDZ<76FK7V] HHHKC/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ _::Z>%_\
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M_$/]N>&8XI7W7=EB&3)Y*_PM^(X^H-1B8?:15"?V3L:***XSI"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "CJ,&BB@#"O/!N@7LAD
MDTZ-7/>)BGZ XI;+P?H-C*)8M.C:0=&D)?\ 0G%;E%7[2=K7.?ZK0YN;D5_1
M!1114'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"__;W_ .T:
M\?\  G_)0O#7_85M?_1JU[!^TUT\+_\ ;W_[1KQ_P)_R4+PU_P!A6U_]&K0!
M]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* / /VFNGA?_ +>__:->/^!/^2A>&O\ L*VO_HU:]@_::Z>%_P#M[_\ :->/
M^!/^2A>&O^PK:_\ HU: /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 > ?M-=/"__;W_ .T:\?\  G_)0O#7_85M?_1JU[!^TUT\
M+_\ ;W_[1KQ_P)_R4+PU_P!A6U_]&K0!]OT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11574M0@TK3
M;B_N6VPP1EV]\=A[GI1N!YG\7?$6%@T&W?DXFN<'_OE3_/\ *O)JN:KJ4^KZ
MK<ZA<MF6>0N?;T ]@.*IUZE.')&QP3ES2N%%%*JL[!5!9B<  9)-60>M?"+Q
M#NBGT&=^4S-;9/;^)?SY_$UZI7SGI.D^)]'U:VU"VT/5!+ X<#[))R.X/'0C
M(_&OHBWF^T6T4WEO'YB!MDBX9<C.".QK@Q$4I774[*,FXV9)1117.;!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"_\ V]_^T:\?\"?\E"\-
M?]A6U_\ 1JU[!^TUT\+_ /;W_P"T:\?\"?\ )0O#7_85M?\ T:M 'V_1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5-2TRSU>R>SOX?.MW(+(6(S@Y'0BK=%%[ <O\ \*Z\)_\ 0'3_
M +^R?_%4?\*Z\)_] =/^_LG_ ,57445?M)]R>2/8Y?\ X5UX3_Z Z?\ ?V3_
M .*H_P"%=^$_^@.G_?V3_P"*KJ**/:3[AR1["*H50HZ 8%+114%!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% '@'[373PO_P!O?_M&O'_ G_)0
MO#7_ &%;7_T:M>P?M-=/"_\ V]_^T:\?\"?\E"\-?]A6U_\ 1JT ?;]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 > ?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JU[!^TUT\+
M_P#;W_[1KQ_P)_R4+PU_V%;7_P!&K0!]OT444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F1G&>?
M2H[FXBM+:6YG<)#$A=V/90,DUXWX8\=2R?$2>[NG*VFIN(2I/$8'$?Y=/Q)K
M2%-R3:Z$2FHM)GM-%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X!^TUT\+_ /;W_P"T:\?\"?\ )0O#7_85M?\ T:M>P?M-=/"_
M_;W_ .T:\?\  G_)0O#7_85M?_1JT ?;]%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%<W$5I;2W,
M[A(8D+NQ[*!DF@#SSXM>(?L>EQ:+ ^)KOYYL=HP>!^)'_CI]:\8Z'-:GB+69
M=?UZZU*7(\U_D4_PH.%'Y8K+KTZ4.2-C@J2YI7/HGP)XA_X2'PS!-(^ZZ@_<
MSYZEAT;\1@_7-=-7@7PV\0_V)XF2"9\6E[B&3/0-_"WY\?0FO?:X:T.21UTI
M\T0HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4U71Q,BWL:^:CRE@&&<CZ@Y&:RQ-N74TH7YCKJ***X3K"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "H+R]MM/MGN;N9(84ZLQ_P Y
MJ5W6*-I'8*B@LQ/0 5XEXH\13:_J;/N9;6,E88\\ >I]S6U&BZK\CS\PQ\<)
M3O:\GLCM+WXGV$,A6SL9K@#C<[B,'Z<&G6/Q.T^:0)>6<UL"0-ZL) /KP#^A
MKRRBN_ZK2M:Q\W_;6+YKW7I9?\/^)]#6MW;WMLEQ:S)+"XRKH<@U-7BOA+Q+
M-H.I(KN38RL!,AZ+_M#W'ZU[2"& (.0>AK@K473E;H?2X#'1Q=/FV:W0M%%%
M8G>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>+)7A\*ZDZ9
MW>25X]#P?T->&5]!ZA9K?Z=<VC' FC9,^F1UKP.\M)K&[EM;A"DL3%6!]17H
M8)JS1\OQ!"7/"?2UB"BBBNT^>"O>O#TC2^'--=R2QMDR3W^4<UX=I]C-J5_#
M9VZ[I96"CV]S[5[[:6R6=G!;1_<AC6-?H!BN'&M62/H^'X2YISZ;$U%%%<!]
M,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?+)964AC2-!WDDXS]6.,XP.@H ^KZ*^6;WX4?$[P_9MJ=K>2S21KO9;"^<S
M=3@<$GV7)KIOA3\:+^ZU>#P]XJF$WVAO+MKY@%=9#P$?'4'H#USUSG( /H"B
MBLCQ/XCL?"?AZ[UG46(@MUSM7[TC'A57W)XH UZ*^3[CQA\0_BKK[66D2W,4
M1.Y;6SD,44*>KOD9^K'D]!T%6;_X5_$[PU9MJ5K>32M&-S#3KYS*H'H."?\
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MG/?C\JZBF12I/"DL3AXW4,K*<@@]#3Z\N4G)W9WI)*R"BBBD,**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *BENK>!@LL\4;'H'< FI:^?=2MO^$N_:=CL[SY[730A"8XQ&F\
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M;6VMZ)JL4:K/>0RQ2D?Q>64VD^^'QGV'I7HOP*U&6_\ A=9),Q8VDTMNI/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_;O_ .B(Z^J?"_\ R*.B_P#7C!_Z+6OFO]H*Q:U^)7V@J0MW9Q2!NQ(RA_\
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M-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]4\9>&]$O39ZIK=
MC9W(4,8II@K8/0X-;E>?>,/@]X?\:Z\VL:E>:G%<&-8MMM+&J87IPR$YY]:
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M .*^#O\ P@NC2'7_ !-J]LNI1R$6EK(CL(0/^6APN"V>GIUZ]/;?^%N^ O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@#P#]IKIX7_P"WO_VC7C_@3_DH7AK_ +"MK_Z-6O8/VFNGA?\
M[>__ &C7C_@3_DH7AK_L*VO_ *-6@#[?HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:#;3 K)]E$C ]1O);'_CU=;2 !5"J  !@ =J6@ HHHH **** "BBB@ HHHH
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MO,::=F=Z=U=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"MK_ .C5H ^WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHF5&69;AH2%!^8;EYH ZJBOD"*X^(]]XCDT+2/%&KZO=Q\.UCJ<SQ+ZY<D#
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M!P0A!+8^H&/QKTNO)_VA-+DOOAY'=Q(S?8KM)7QV4@J3^9% '2_"[PI:>%?
M^GQ10JMW=0I<74N/F=V&<'V . *[.N2^&OB.V\3^ ]+NX)%,L4*V]P@.2DB
M @_7&1[$5UM !7CWQQ\/FTT^T\;Z2?LNKZ9,F^>/@NA.!GUP2/P)%>PUY7\?
M->M=-^'LFF.P-UJ4B)$F>=JL&9OH, ?B* .^\,:TGB+POINKH !=VZR$#LV/
MF'X'(KQWX^^$H;%++QIIB?9[V.X2.Y:/C<>J2?[P(QGW'I7I'PKLIM/^&.@P
M3J5D-MYA![!B6'Z$5C?':2)/A5?K)U>:%4]VW@_R!H [/POJ_P#;WA;2]5XS
M=VR2MCLQ'/ZYK6KCOA4CQ_"[P\)"2?LH//H22/T(KL: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / /VFNGA?_M[
M_P#:->/^!/\ DH7AK_L*VO\ Z-6O8/VFNGA?_M[_ /:->/\ @3_DH7AK_L*V
MO_HU: /M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH @N[.VO[5[:[@CG@?&Z.1<@X.1Q]17*>*-(\,:
M%X=N]0ET6Q)C7$:^4!N<\*/SZ^V:[*O'OB[XA\^]@T*!_P!W!B6?'=R/E'X
MY_'VK6BG*22,ZC2C<\R)R2?7TI***](X0H!P<T44 ?2GA'6XO$'ANTO4VB3;
MY<R+_"Z\$8[>H]B*VZ\0^%7B+^S==;2YWQ;7V F3PLHZ?GT^N*]OKS:L.25C
MNIRYHW"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\B^(GP[\
M;^)?%3:CH'B&&QL3"B"%KV:([AG)VHI% 'KM%?.W_"F_BE_T.%O_ .#.Y_\
MB*/^%-_%+_H<+?\ \&=S_P#$4 >_ZAJ5EI-E)>:A=PVMM&,O+,X51^)KYYM-
M9_X69^T)I]]IT;MINGD%)"I'[N/)WGTW.>/J.]2P?L\>)=2NO-U[Q-:^\D?F
M7#G_ +[V_P Z]C\%> M$\":>]MI43--+@SW4IS)*1TR>P'8#C\>: .HHHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X!^TUT\+_]O?\
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M/AF":1]UU!^YGSU+#HWXC!^N:C$P^TBJ$_LG34445R'2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\=1_\%MO_P#$4?V]\>_^>.H_^"VW_P#B* /I.BOFS^WOCW_SQU'_ ,%MO_\
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M?^ <W_Q- 'HE%5["^M]2T^WOK1_,M[B-98GP1N5AD'!Y'%6* "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ _::Z>%_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXE>.F\ >'8=2CLEO));A81&TA0<@DG.#Z4 =G169X<U*XUCPYI^IW4"6\UW
MDQB1BP3<,@9/7@UIT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 > ?M-=/"__ &]_^T:\?\"?
M\E"\-?\ 85M?_1JU[!^TUT\+_P#;W_[1KQ_P)_R4+PU_V%;7_P!&K0!]OT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7CWQ=\0^?>P:% _[N#$L^.[D?*/P!S^/M7J.N:K#H>BW>I3\
MI FX#^\W11^)(%?,]Y=S7][/=W#[YIG,CMZDG-=.&A=\SZ&%>=ERD%%%%=QR
M'LGPL\4POH5QIE_<)&;!3*CR-@>23SR?[I_0BO2@0P!!!!Z$5\IK(Z!@K%0P
MVM@]1Z'\A7N_PR\0_P!L^&UM)GS=6.(FSU*?PG\AC\/>N*O2M[Z.JC4O[K.V
MHHHKE.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** / /VFNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU:]@_::Z>%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***\V\9^-IA<2:9I4IC6,[9IUX8GN%/8>_^3I3I
MRJ.R.;%XNGA:?//_ (<[RZU?3;)]EU?VT+_W7E ;\NM+:ZMIU\VRUOK:9_[J
M2@G\NM> ,Q8DL22>I-"LR,&1BK Y!!Y%=GU)6W/!_P!8)\WP*WJ?1=%>=^"O
M&LL\\>EZI+O9OEAG8\D_W6/?V->B5QU*<J<K,]["XJGB:?/#_A@HHHK,Z0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,;VX>VN9"8HU;#SX..O\*#& !Z<8[^RV/PR\$:?"L4/AC375>AGA$S?F^2:
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MVUMN*B9AU9B.=H/&.Y!SP.?8-8^$?@G5].>T_L.VLW*X2>S41R(?7(X/XY%
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M%4J.I*[/H<)A*>%I\D/^'"BBBLSI"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS6X/N9/WA_\ 0J^</C>[/\7=:5F)""!5'H/(C/\ ,FOJ;PHJIX/T1$4*JV$
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MQP'P,DGI0!\<45]?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.4
M?(%%?7__  I+X>?]"]_Y.W'_ ,<H_P"%)?#S_H7O_)VX_P#CE 'R!70>!/\
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M_+K]0*^DHY$EC62-@R. RL#D$'O6?_PCVB?] ?3_ /P&3_"M!$2*-8XU5$4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%KN/!E_::GX+T:[L64V[6<84 YVD* 5^H((_"MV@#RS_ (9^\$?W=1_\"?\
MZU'_  S]X(_NZC_X$_\ UJ]3HH JZ;I\&E:7:Z?;;O(M8EACW')VJ,#)_"K5
M%% !1110 4444 %%%% !7S!^T=_R4+3_ /L%1_\ HV6OI^OF#]H[_DH6G_\
M8*C_ /1LM 'M/PB_Y)5H'_7!O_0VKMJXGX1?\DJT#_K@W_H;5VU 'R-\<[=H
M/BSJDC=)XX)%X[>4J_S4U]/^#IUN?!&@SIPLFG6[ 'MF-:\*_:1T5H=?TG6T
M4^7<VYMG(Z!D8L,^Y#_^.UZA\&-;CUGX8Z6 P,UD#:2J#G:4/R_^.E3^- '?
MUX+^TQ.HL_#D'\327#_0 1C^M>]5\P_M$ZW'?^-;/2XF##3K;]Y@]))#N(_[
MY"?G0!Z)^SO;M!\.)Y&Z3ZC+(O';9&O\U->,?&F%H?BUK@8'#F%U)&,@PI_^
MK\*^D?A9HKZ!\-=%LY5*S-!Y\@;J&D)?!^FX#\*\8_:-T5[7Q9IVL*I\F]M?
M*8X_Y:1GG_QUE_(T ?0OAZ9;CPUI4Z?<DLXG7Z% :TJX?X1:U%K?PRT9T8&2
MUA%G*N<E3'\HS]5"G\:[B@#Y]_:9D4S>&8OXE6Y8_0^5_@:['X 0-%\,(G/2
M:[F<<=LA?_937E/[06MQZE\0(["%PR:;;+$^/^>C$N?T*#Z@U[]\.-%;P_\
M#S1-.D0I,EL))4/57<EV!^A8C\* .IHHHH **** "BBB@#P#]IKIX7_[>_\
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MHHKRC[0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-/$NO12C2TF^TO)<*=U[)G=QGJN>2W0]/7'U'1THH **** "BBB@ HHHH \
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M.SN+^[CMK6)I9I#A545[?X<T5-!T:*S4AI/ORN/XG/7^@_"G:/X?TW0XBME
M%<C#2L<NWU/]!Q6I7)7Q'M-%L>WEN6?5??F[R?X!1117,>N%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^TUT\+_]O?\ [1KQ_P "?\E"\-?]A6U_]&K0!]OT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G7Q9\
M0_8=(CT>!\3WGS2X/*Q _P!2/T->@SSQ6UO)<3.$BB4N['HJ@9)KYJ\2ZW+X
M@U^ZU&3(61L1J?X4'"C\OUK?#PYI7[&-:=HV[F31117H'&%=[\+/$/\ 9?B
MZ;.^+:_P@R>%D'W?SY'XCTK@J<CM'(LB,5=3D$'!!J9Q4HM,J,N5W/JVBL/P
MCKR^(_#EM?9'G8\N<#M(.OY\'Z&MRO+::=F=Z=U=!1112&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4457O;ZUTZU:YO)TAA7JS?R'J?:
MA*^PFU%7>Q8HK@[SXH644A6ST^:X4?Q2.(\_3@TME\3[&:0+>6,UN"<;D<2
M?7@&MOJ]6U['!_:F#YN7G_/\]CNZ*@M+RWO[9+FUF26%QE74Y%3UCL=Z::N@
MHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.* /I>BL[0;F\O/#^G7.HPF&]FMHWGC*%"CE06&T\C!SP:T: "BBB@ HHHH
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M-"\/V&E6ZA8K6!8A@8R0.3]2<G\:T:BMIX[JUBN(F#1RH'0@]01D5*2 ,DX
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MWZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAU"C:2$7]1V ZU]$T4 ,BBC@A2&%%CBC4*B*,!0.  /2GT44 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!%<NT=K*ZG#*A(/OBO+_@EXPU[Q?8:U)KM_]K>VG1(CY*1[00<_
M<49Z=Z]/N_\ CRG_ .N;?RKQ3]F[_D%^(O\ KYB_]!:@#W&BBB@ HHHH ***
M* "LOQ+_ ,BKK'_7E-_Z :U*R_$O_(JZQ_UY3?\ H!H \E_9K_Y%K6_^OQ/_
M $"O;J^/O 'Q4U#X?V%W:6>G6MTMS*)6:9F!! Q@8KKO^&D]=_Z 6G?]]O\
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M>ZF>_D$DJLU?H;5%%%><?5!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'.AE
MMY8UQED*C/N*\\^$G@#5? 5GJL.J7%E,UW,DD9M79@  0<[E7UKT>B@ HHHH
M **** "BBB@ K+\2_P#(JZQ_UY3?^@&M2J&N6\MYX?U*V@3?--:RQQKD#+%"
M .?>@#R#]FO_ )%K6_\ K\3_ - KVZO*_@=X3USPGH>JV^N6#6<LURKQJ9$?
M<H7&?E)KU2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!2U72K76=/DL[M-T;<@CJI[$>]>%:G9_V?JEU9[]_D2M'NQC=@
MXSBOH*O'?'^EO8>));C;B&[_ 'B-[_Q#ZY_F*[<'/WG$\#/J"=.-5+5.S]#E
M:***] ^5"O2/A9.YBU* D^6IC<#T)W _R'Y5YO7K'PWTM[/19;R52K7;@J#W
M1>A_,FN?%-*D[GJY-&3Q<6NE[_<=I1117E'V@4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 44$X&3TKB-:^+G@S0YWMYM5%S.APT=H
MADQ_P(?+^M7"G.H[05Q-V.WHKSS3/C7X)U*58FOYK-V.!]J@*C/U&0/Q-=_!
M<0W4"3V\J30R#<DD;!E8>H(ZTZE&I3^-- FF24445F,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<5[;10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &C7C_@3_DH7AK_L*VO_ *-6O8/VFNGA?_M[_P#:->/^!/\ DH7AK_L*VO\
MZ-6@#[?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N"\5?#F?Q3K3ZA+K?DIL"1P_9=VQ1VSO&><G\:
M[VBJC-Q=T3**DK,\H_X4K_U,'_DG_P#;*/\ A2O_ %,'_DG_ /;*]7HK3V]3
MN3[&'8\H_P"%*_\ 4P?^2?\ ]LH_X4K_ -3!_P"2?_VRO5Z*/;U.X>QAV..\
M&^!YO"-U<N-7^U03H T/V?9\P/#9W'MD?C78T45G*3D[LN,5%604445(PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+R]MM/MGN;N9(84
MZLQ_SFI7=8XVD=@J*"6)Z "O$O%/B*;7]3=]S+:QDK#'V ]2/4UM1HNJ_(\_
M,,?'"4[VO)[([._^)>FI)MMM/DN@IX:1@@_#@FGV/Q.T^:0)>6<UL"0-ZL)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** / /VFNGA?_M[_P#:->/^!/\ DH7AK_L*VO\ Z-6O8/VF
MNGA?_M[_ /:->/\ @3_DH7AK_L*VO_HU: /M^BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN
M!T'X@+JWCJ]THNOV%_DLV ZLG4Y[[N2,^@'>JC%R3:Z$N25KG?4445)04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBOG_Q=XN\:^&?$MWIKZS*41MT3F)/F0\J?N^E9U*BIJ[,JU94E=H^@**^8
M_P#A9WC'_H-2?]^T_P */^%G>,?^@U)_W[3_  K'ZW#L<_UZGV9].45\Q_\
M"SO&/_09D_[]I_A7N_@4ZS)X6MKG7+IY[RX_>_,H78I^Z. .W//K6E.NJCLD
M:TL3&J[11TM%%%;'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_E6'7D--.S/!DG%V9U?P]\-'Q-XKMX)$S:0'SK@D<%1_#^)P/IFOIX *H4#
M P!7"_"KPS_8/A5+F=-MY?XEDR.57^%?RY^I-=W7IX>GR0UW9[&%I<D-=V%%
M%%;G2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRW^%'_"P/#O_ #]R?]^6_P *\:HH^IT_,/[>Q/9?<_\ ,]E_X6!X=_Y^Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!X!^TUT\+_ /;W_P"T:\?\"?\ )0O#7_85M?\ T:M>P?M-=/"__;W_
M .T:\?\  G_)0O#7_85M?_1JT ?;]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A^+=>3PYX<N;_ "/.
MQY<"GO(>GY<GZ UX#H6N7&B^(;?559G=)-T@)Y=3]X?B":ZGXJ>(?[4U\:;
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M/\B^Y&3_ ,(QH7_0)L_^_0H_X1C0O^@39_\ ?H5K44<\NX?5Z/\ (ON1D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5/*/CD$?6O/QE.SYT?4Y%BE*#H/=:HTZ***XCZ **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '@'[373PO_V]_P#M&O'_  )_
MR4+PU_V%;7_T:M>P?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JT ?;]%%%
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MC_SRTO\ \!V_^*KY^OE^*K5'.5M?,U4HI6/IZBOF'_A?WC'_ )Y:7_X#M_\
M%4?\+^\8_P#/+2__  ';_P"*K+^R<1Y?>/G1]/45\P_\+^\8_P#/+2__  ';
M_P"*H_X7]XQ_YY:7_P" [?\ Q5']DXCR^\.='T]17S#_ ,+^\8_\\M+_ / =
MO_BJ/^%_>,?^>6E_^ [?_%4?V3B/+[PYT?3U%?,/_"_O&/\ SRTO_P !V_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?4UK445P-MZL[$DM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMQ)SZ,2P_0UP8_%2P\%*%KM]2HQNSYY_X4QX_P#^@!_Y.0?_ !='_"F/'_\
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MJ_F'+B?,S/\ A;OC'_H(0_\ @-'_ (4?\+=\8_\ 00A_\!H_\*T_^%'>)O\
MG^TG_O[)_P#&Z/\ A1WB;_G^TG_O[)_\;HM7\PY<3YF9_P +=\8_]!"'_P !
MH_\ "C_A;OC'_H(0_P#@-'_A6G_PH[Q-_P _VD_]_9/_ (W1_P *.\3?\_VD
M_P#?V3_XW1:OYARXGS,S_A;OC'_H(0_^ T?^%'_"W?&/_00A_P# :/\ PK3_
M .%'>)O^?[2?^_LG_P ;H_X4=XF_Y_M)_P"_LG_QNBU?S#EQ/F9G_"W?&/\
MT$(?_ :/_"O1?A1XPUKQ5-JJZM<),+=8C'MB5,;BV>@]A7&_\*.\3?\ /]I/
M_?V3_P"-UWGPT\":IX-FU)]1GLY1=+&$^SNS8V[LYW*/45I25;G7->QM05?V
MBY[V/0J***[CT0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-!JI5=Y?@@HHHKE/:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY9I))W*JJ!'&> 2>6'%9G@KX&>'_  S)%>ZFW]KZ@AW*94Q#&?54YR?=B?7
MH ^:]1\+ZMI.A6&L7]JUO:W[,ML).'<* 2V.R\C![_2L>OH?]I?_ )!WAW_K
MK/\ R2OGB@#[_P"U%':B@ HHHH ***X_XC^.O^%?^'K?5O[.^W^;=K;>5Y_E
M8RCMNSM;^YC&.] '845\_P#_  TU_P!2C_Y4O_M5'_#37_4H_P#E2_\ M5 '
MT!17S_\ \--?]2C_ .5+_P"U4?\ #37_ %*/_E2_^U4 ?0%%?/\ _P --?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6TM8_/WS3V4D:+F&0#+$8&20/QKZHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *;+(D,3RRN$C12S,QP !U)I
MU>?_ !5\1?V;H2Z7 ^+F^X?!Y6(=?S/'YU4(N4DD3*7*KGE7BO77\1>(KJ_)
M/E%MD*G^&,=/\?J36+117J))*R.!N[N%>B_"?Q#]@UB31YWQ!>?-%D\+*!_4
M<?4"O.JD@FDMKB.>%RDL;!T8=00<@TIQYHM#C+E=SZKHK)\,ZW'XAT"UU%,!
MI%Q*H_A<<,/S_3%:U>6U9V9WIW5PHHHI#"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >$?M+_\@[P[_P!=9_Y)7SO7T1^TO_R#O#O_ %UG_DE?.] 'W_VHH[44 %%%
M% !1110 4444 > ?M-=/"_\ V]_^T:\?\"?\E"\-?]A6U_\ 1JU[!^TUT\+_
M /;W_P"T:\?\"?\ )0O#7_85M?\ T:M 'V_1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1XC^'%OXD
MUF34;G5+E"P55C"@A !T'ZG\:[>BJC)Q=T*45)69Y<WP8M2QVZU,!V!@!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#,UCP]HWB!(DU?3+6^6$DQBXC#[">N,_05E?\*W\%?]"OI7_@,O\ A744
M4 %%%% !1110 4444 %%%% '@'[373PO_P!O?_M&O'_ G_)0O#7_ &%;7_T:
MM>P?M-=/"_\ V]_^T:\?\"?\E"\-?]A6U_\ 1JT ?;]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 > ?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JU[!^TUT\+_P#;W_[1KQ_P
M)_R4+PU_V%;7_P!&K0!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445SWBGQQX>\&VZR:UJ"0NXS' H+RO]%'./<X'O0!T-%>*W'[27
MA])2+?1-2E3/WG9$)_#)K?\ #WQT\&Z[<);33SZ7.[;5^VH%0G_?4D#_ (%B
M@#TNBD5E=0RL&4C((.012T %%%% !1110 4444 > ?M-=/"__;W_ .T:\?\
M G_)0O#7_85M?_1JU[!^TUT\+_\ ;W_[1KQ_P)_R4+PU_P!A6U_]&K0!]OT4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?M-=/"__ &]_^T:\?\"?\E"\-?\ 85M?_1JT ?;]%%% !1110 4444 %%%%
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M>V=4OKI?)11U27^(X]N2/JOK5'4/B*?^%=V]];S*NK3G[.< 91UQO;'TP?\
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MJ-3D(/\ >12?S(J(^+O$!.?[5N/S%'U.?=#_ +?H?RO\/\SW*BO#?^$NU_\
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ML8H_L>K_ #+\0]HCZ_HKX\F^)_C:>3>_B2]!]$8(/R4 4^3XJ>.)8A&WB*Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"C6H ]_P#^&CO!_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=KY@HH
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MP44 ?3__  T=X/\ ^@;KG_?B'_X[1_PT=X/_ .@;KG_?B'_X[7S!10!]/_\
M#1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM?,%% 'T__P -'>#_ /H&
MZY_WXA_^.T?\-'>#_P#H&ZY_WXA_^.U\P44 ?3__  T=X/\ ^@;KG_?B'_X[
M1_PT=X/_ .@;KG_?B'_X[7S!10!]/_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\
MZ!NN?]^(?_CM?,%% 'T__P -'>#_ /H&ZY_WXA_^.U2U[Q[#XVM+6;3HKJ#3
MQDB.X55=FR1DA6(QZ<^M?-M>M^%75_#5D4Z!,'Z@D&NK"13J79XV>5)1PR2Z
MO4V****],^/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH <CO%(LD;%74Y5E."#77R_'K0=&\NRU;3]5
M>]1%\QX(HRC''4$N#^E<=7FGCQT;Q H7&5A4-]<D_P B*Y,9%.%SV\BJ26(<
M%LT>[_\ #1W@_P#Z!NN?]^(?_CM'_#1W@_\ Z!NN?]^(?_CM?,%%>:?7'T__
M ,-'>#_^@;KG_?B'_P".T?\ #1W@_P#Z!NN?]^(?_CM?,%% 'T__ ,-'>#_^
M@;KG_?B'_P".T?\ #1W@_P#Z!NN?]^(?_CM?,%% 'T__ ,-'>#_^@;KG_?B'
M_P".T?\ #1W@_P#Z!NN?]^(?_CM?,%% 'T__ ,-'>#_^@;KG_?B'_P".T?\
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M_AH[P?\ ] W7/^_$/_QVC_AH[P?_ - W7/\ OQ#_ /':^8** /I__AH[P?\
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MT=X/_P"@;KG_ 'XA_P#CM?,%% 'T_P#\-'>#_P#H&ZY_WXA_^.T?\-'>#_\
MH&ZY_P!^(?\ X[7S!10!]/\ _#1W@_\ Z!NN?]^(?_CM'_#1W@__ *!NN?\
M?B'_ ..U\P44 ?5.F_M >%-4U2TT^#3]:66ZF2!"\,04,S!1G$AXR:]6KX9\
M(?\ (ZZ#_P!A&W_]&+7W-0 4444 %%%% !1110 4444 %%%% !1110 4444
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MK?\ #J&GGZLX_P#9:]!5J?<XO9S['G-%>B'X.Z]VOM-_[[?_ .(I/^%.Z_\
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M.$K[QD?UIO\ PJV\_P"@E!_W[-'UFEW%_96,_D_%?YG T5WW_"K;S_H)0?\
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M,+9M!Y"@#[H X(^A /X41PKUY@A@I:\Q\E45]$6WPETF%]#9W$AT\'[1E/\
MCY.<C//&&)]>.*A;X/:0=*GM!,1+)>B=9]@W+'G_ %?Y=_7\JCZK,S^I5#Y]
MK3BT"_F\/3:XD1-E#,(6;ON(S^73GW%>]3_"K1I;W5IT"HE[;B**,)@0/U+#
MGN0#V[CO6[9>$;"T\&#PTP#V[0F-WV\LQY+X]<\U4<++J7'!2N^8^5:V_"WA
MF[\5:L;"TP&6)Y&8]!@<9^IP/QKVVV^$VDP)H>YP[Z>Y>=O+_P"/G/(!] &^
MO'%;GA/P79>$Y=1DMFWM=S%QQ]Q/X4Z\XR>:(865US;!#!2YES;'R_-#);SR
M0RJ5D1BK*1@@BHZ^D=0^&.E:CKFK:E*1_I\&Q8]G$4AZR#U.0#^?K4-O\*='
MAFT21]L@T^,K.I3BY8\@GGCDD]^P[4OJL[D_4JESYTK1T+2)]=UNTTRW'[RX
MD"Y_NCN?P&37N)^#VD'27L_./FF]^T"?8-PBS_J_R[^M;VB^!=-T3Q3?:W;!
M0;A D<07 B_O$?4@?2G'"RNKCC@IW7-L=!IMA!I>FV]C;+MA@C$:#V JU117
MH;'JI6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M9/VD/^1XTS_L&K_Z-DKEO@U_R5K0?]^7_P!$O74_M(?\CQIG_8-7_P!&R5RW
MP:_Y*UH/^_+_ .B7H ^Q**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OD/XX?\E;UC_=@_]$I7UY7G/BKX+>'/%_B*YUO4+W58KFX"!TMY8U0;5"C
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M]JTES:EBBSRQE#E2IR!&#T)[T >E4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFZ:V\KS_ #<X1&W9VK_?QC':NPH **** "BBB@ HHHH **** "BBB@ HHHH
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M(_%5CHG_  C7V?[5+Y7G?;]^W@\[?+&>GK7L] !1110 4444 %%%% !1110
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M110 4444 %>6?M ?\DS/_7[%_)J]3KRS]H#_ ))F?^OV+^34 ?,?]D3GP_\
MVRO-NMU]E?C[K;=R_F-WY5]9?!WQ!_PD'PWTYW?=<68-I-SDY3@9]RNT_C7C
MOP\\/_\ "2?!OQA9*FZ>.9;B# R=Z)NP/<@$?C6A^SEX@-MKNIZ!*Y"740N(
M@>@=.&'U((_[YH ^CZBNKF*RM)KJ=PD,,;22,?X5 R3^0J6O.?C=KYT3X;7<
M4;[9]0=;1,=<'EO_ !T$?C0!\R7SWGC#Q+K&I $L_GWLI8YV(,G'TY"CZBN_
M_9T_Y*+>?]@R3_T9%3/AUX>V?"WQMXBE3E[5K2!BO.!AGP?0DK_WS3_V=/\
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M8(HP OWF&Q1G)..?[M2_%+XJP^ H8K.SMTN]7N$+HCGY(EZ!GQR<]@/0\CN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%IC7OQ)2ZV92RMI)=V. QPH_'#']: /H+XD>'!XH\!ZIIRINN!$9K?'7S$Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP?<  #W%?1G@SP9I?@?0UTW35+$G?-.X&^9_4_T':@#HJ*** "BBB@ HHHH
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MJ^-_$'PS\3:3KMW86>AZQ?V\$A1+J+3Y"LH'<8!&/QK[)MP5MH@000@!!^E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img39825204_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2K>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *L*^$)1CA"24T$!       9AP!6@ #&R5'' %:  ,;)4<< @   J@ '
M)0  AR<C,S,S$V.!P"!0 ]36EC<F]S;V9T(%=O<F0@+2!):V5N82 @0G5S:6
MYE<W,@4V5C=&EO;B!3+3$@26UA9V5S($]N;'DN9&]C>#A"24T$)0      $'
M8(,-8NNY8=$_@-N'[%0.@X0DE-!#H      .4    0     0      "W!R:6
MYT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86
MUE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P
M!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96
MYU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F
M]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M  0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&
M)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M   P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M  0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M!";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <)
M    IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U
M!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M           %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G
M1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296
M-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F
M]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $)     0 ! 0D    !
M$X0DE-!"8       X             /X   #A"24T#\@      "@  ______
M__   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M  "0           0 X0DE-)Q        H  0         ".$))30/U
M!( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %
MH    &       ! #4    ! "T    &       !.$))30/X      !P  #___
M__________________________ ^@     __________________________
M___P/H     /____________________________\#Z     #___________
M__________________ ^@  #A"24T$"       $     $   )    "0
M X0DE-!!X       0     .$))300:      ,U    !@             #'@
M   TD          0                         !              -)
M #'@                     !                         !     !
M      ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M    !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M #'@    !29VAT;&]N9P   TD    &<VQI8V5S5FQ,<P    %/8FIC     0
M      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&
MQO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&
M]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M  !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M       $QE9G1L;VYG          !"=&]M;&]N9P   QX     4F=H=&QO;F
M<   -)     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37
M-G951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$
MES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9V
MYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&
MEG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;V
MQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&
M]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='
M1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))30
M0H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M0    ).$))300,     " G     0   *    "8   !X  !'0   " + !@  ?
M_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\
MX  @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /
M;6  $     TRU(4" @
M                     18W!R=    5     S9&5S8P   80   !L=W1P=
M   ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48E
MA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP
M"&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M    !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;G
MD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U
M)'0B!)14,V,3DV-BTR+C$
M                           %A96B        #S40 !     1;,6%E:(
M                    !865H@        ;Z(  #CU   #D%A96B
M!BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14
M,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=R
MYI96,N8V@
M          9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B
M!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2
M!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&
MEO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=V
MEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M            !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@
M%865H@      !,"58 4    %<?YVUE87,          0
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MR8_2G]NOY+_MS_;?___^T #$%D;V)E7T--  +_[@ .06
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!(0$Q P$1  (1 0,1 ?_$ !X  0 !! ,! 0
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MQG"4H[<RC*+<>9;KF2;:W75;I;KJMRC2>VM60K%>3F-DT*)C6TPXKSE_)6Z
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M^#@UTJG)MG9EY\L6NB_4,F3LR\F/,[I=K8^K3ME*<8+:,-^6*44DI79@&Q&
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M:/\ DJP^R, >^KT!ZQH_Y*L/LC 'OJ] >L:/^2K#[(P![ZO0'K&C_DJP^R,
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MAX ]&QWY R_94/X> /1L=^0,OV5#^'@#T;'?D#+]E0_AX ]&QWY R_94/X>
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M]@H#U PGY1>!0G.&V]8HB*2;J<J[2&*[(U35<)FDYV(9$,4>[.J8Q16 2E(
MF'IT*'4>@ZS6L19VDZEA[N+RL.^A22<G%S@TGM%-O9[=$OI/;_)IQ!+A7Y0N
M"^)(PC:]$XDTO475.R-4+(8^3"5D)6S<8UJ5?,G.4DDN]I'FY\DKL:K^3QY0
MV/3>UI&-C8ODRZ1EF-ODI^;BXJERC8)/S>K2U;DB-(MC(2ZK-)=G,)MC$<)K
M%0!UU$2YX?@K5X86-IVA9JE#*LQ[)QFZ[$IV56RK:WG&*4.5)N;E+UMH^P_4
M7^4O\G.1Q)K/&'RI<+SQLO1L35\:K,QZ\W#F\;&U'#CGPE&NB^Z4K>WG9"O'
MC758X;V<K3DW[(6[A!TBBY;*D60<))KHK)B!DU452@=-0APZE,0Y! Q3 (@(
M#U#PSZ6?B;^'OZ/ZUX'VP!@# & , 8 P!@# & , 8 P!@# & , 8 P"#O)[A
M)4N4%WC+9;Y=RW;0NH-D:TC(YJXE6*B$E?DDTR3ZKJ)D6"CI"-!,O:BW/>MW
M/CV@#J/4#!>K_)I06I;%KC8*6QWKNU:ZVD78+M\\&1+6W]>)2PJ3N$"L+R:D
M#'2(-TTWB=E29D?H"F<.]^R'.($B]2<:'U,W?<]Y$W#/7"#OB4FXCZBN95:
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M*V-U:R*I.%RC;!*,U&Q27,DD]M]CU%YV&(, 8 P!@# & , 8 P!@# & , 8
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ME>LSF%!VDDY5!)<AR"<1#-J>!+YP!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , C5H#[J.0_P"F>2^CT%D\7[E\9%\%[W\(DE<I!@#
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M?79[^'?T/@5U-^-=;CY--V-D4S<+:+ZYTW5RBVG&=<TI1>Z;6Z6ZV:Z--[W
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MDL1&8>O9F*610KSIG$RKIXX543 LN+4J+A0.IS#M3YP>C?B3OVB\E-#4+:-
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MN0HK F)@.)A3TB$4(H "0P& 0Z@)1 0'^@0$0'^SX/C\< _> , 8 P!@# &
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MI\RU7,U?0.*L"VF%F1IFMY"HRU*5:3MKH:I<9.*6/"MN*E*<MIOINWLC]U<
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MNJTA'+S#&PP[R*:E1.XD6T@V69($<ID5;F5<IJ&2(59)5-1,3& #D4(8O4#
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MNG_)G;JTO/-:VBW,QL\<E!D/#Q44P< Z04K8KJ) JQ4\V IP$$.X(IVC 81
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MFL'P(H(N:ZY;M3R2);80L@DJ\$J;1,.[\U<&*X'M]CH(AG(*CRFZ!UW%KCJ
M!U'W,'8=1Z>(@ V?PZCX]/BP7ZD_?O\ <T<C4.4W0>FXM;]>@]!'6#OH ]/
M1#ZJ Z@ ^/3KX_!@;_0E]OWMF$J%KCG.QV/LZ0L>[-:J5N2?0!X(!U<_[IPD
MA")I.3QZ9K8<&":3D!3<IB*AG"P&6^L[0@$\O^/T?A]Q//XF1KI2.7[RJS[6
MO[HUHA+KQ,BDR.IJYX?M+J,ETTDT^S:DQ36.J9,$EA,)4C]#B4P (#09(XX5
M_:U9U+4(G<=@CK#<VL'&(OW+"*5BSH*I,TB+MW@*OGYG;HBP'%1T"A 4$?\
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MY!_^O$]S'_Z;V+P7&-.R]G_P>\S5FS/## & , 8 P!@# & , 8 P!@# & ,
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M?]1'_?U\?Z< R1KNZ7RU+2:=RU9):[29D;F8K/[##S@29E1,"Q$RQ74S<6X
M41%;P/VNA>G0< A7R9Y?7_0V]@I<=$P$A5I;7$1,Q[^UJNH.K0L\1_:',D::
MLS9JY,1S+QL(A$5Z+* "YFG38H^"G0P>?/GP+0T=Y1^S;>W?6-*R''ZU4N0L
M9UFXS$LJ[\Q8O8F.-9+"U<&/'(I$%E5'4')M%C+%3>N)4&1/LR"@ !M6P!@#
M & , 8 P!@# '3_'40_[L _'=I_]@GZH?NP!W:?XLGZI?W8 [M/\63]4O[L
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MD1;(P)!LSD2$3?,CD76:.V;LJ1U$N_:/&R[=0R2ATSF3$Z9S$,41 R)@# &
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M=-W4C$R+!NN>FU\2(K.V:R"2IP+']1*0ZA3& ! 1 !Z#C9+N20.KK?2=*I]
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M(=_66CMA7GL;7(EF[A&3]057K2+<(-2*L6[I01.NDW.F10XB8P"(C@&0L 8
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M3$1$B:CE54R1!$>PD)"?]7!3*. , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
$!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img39825204_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T<4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0"^="0X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8              X0   5J          $
M 0             %:@   X0                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   X0     4F=H=&QO;F<   5J    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      2A     $   "@    :
M >   ,,    2:  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ : "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M/YC]+8K_ %2Q]73LFRMK7.94XAKVE[#I_A*V>Y[/WT#I55=_2,9E[*K6[00
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M>F75/#7.+V50#,_I'[/:[W./\Y^>J#\OHC2&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M083FJ[=*Z0N%PDWS%XLHW?U.VE;[TK3EO9X94A%R/V$(,+*1JA%RKM'H*,"
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MMLM&*E>-B?#]9V@JI#Y'2.F8/,0_/Y_B;AJ7S23']Z9/\(8!R8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & !'R^8X
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M)_A#!4Y, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M0WA/<T/5,NT;.6CZ<>3$I'LG%AD%%UFL-7&"JSV259N5?-NV BQP/CW'Q':
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MYA%+_MD\D?YK,,%/JOP?\XE\*/ZI+^K)_A#!4Y, 8 P!@# & , 8 P!@# &
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M:P=,;US; :&V%^?K>;BS5RVQ#J9<?[6JB6&(Z]\V\[+.+*4QX9H9=Z9DO]-
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M$#U^(M+=?Z'LFS&NT*IH-"I;AW)=]P6)76URM/MJH[M"+!%K!5"H2-29,TT
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M8" B'_CD2^]?5>&ON?W,V8?K & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P#C612<)*(KIIK(JD,11)4A5$U"& 0,0Y#@)3E, B!BF
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M0MX?"EQ)>))EI.:X,P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MM2<XI_1M+DLQR<>=T\>-],KX)2G3&R#MA%\I.5:DY17A^6D?:R^7A@# & ,
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MHLL<J:21#***'$"D(0A1,<YC#\@*4H"8PC\@ !$?D&4;23;?"2;;?LDO+;_
M^HQE.480BY3G)1C&*YE*4GQ&*2\MMM))>[*FH[QE.39/H,FAD'4^":]A+5FN
MQC$B_P T5Y@Z_LTU03"1^ETX59\)6B<P=B" G'W!DRL?)UD&AOW3YY45^C=9
MCHT\[]&U[F>!:M!GG<]OH+.X]/ES^5/G_K-*/DZTR?L<=2\;9-FZ):IM>>O4
M:(]QY'3V&I2>\*='4/6E=+!]+L>1"C]M+&4^>$ZHV2R/V);.0Y3E*<@@8I@
MQ3!]1@$/,! ?V@(#Y@.3KW]CDIIIM----IIKAIKPTT_*:?NC]8*# & , 8!Q
M+KHMDCKN%4T$4RB=154Y4TTR%#S,<YS"!2E*'S,8P@ !\Q$,I*48IRDU&*7+
ME)I))>[;?A+][*-J*<I-))<MMI))>[;?A)?>R"^V^T*CYSVL]"M9S=6X7<<_
MCXQAKAB68AJU*.6ZS5I)62RJ'3@X]HP>F3,Z#W2JB1B>A8J0#Z@U]K6^<-K)
MTK;D,G7-;MINKHCIE7Q%&)=*#A7?DY":IC759*+GVSEVOA3<.>5KG6^H.!&6
M5H^V:\K<FX'5977CZ/7'(HP[IQE&N[.SI..'CUU6->HIVNQ-<.!1+IK2/;%-
MZ+C[7%ZOV6XN]3L@V6S+O%58]I/L$'Y7,Y''L\BJ$-(DG6XKLDA3>.0>_%,=
MN5;T#Y:1TG1MW8>N59.+H^J6:E@Y'Q5W="='K>G-2R(V9MKA19'+CWPDXW6^
MM&SY(V>#E':^U>K&F;ZKU..C:S+.P\Z6;J-E]_IX^=BJ_ORL>&9?-XUWQ,'*
MNKB34GYCPHFP'KKMO4%OFTZ7<QF]+[&]9$5:/M6//6)!5P<Q$TRQDBY'Z(E"
M+G-_RP-WGQUTRBH" %\O/?.F;]T3-O6#G?$:%J?=V/ UBJ6)8Y-I15=LOV-G
MJ-_LUWQG)>T#KK2>H6@Y^3'3<]Y&WM8;4?T7KM7P%\Y-\+T+;'\-DJ3\1]"Z
M;E[I<$P$EDER%514(JF<H&(HF8#$.4P>8&*8/,IBB'S 0$0$/F&39--)IIIK
ME-/E-?>FO#1.DTTFFFFN4T^4U]Z:\-')E2HP!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# / _,!_Z#@&NUW#,ZHTOM=>$W0[Y@D):314M<%7V/(&\-TV^
MO5.T6<L)%25R>:\L3Y&+&Q6E8L4Q>/VL<E,S!Q08HF4_1P4^_P _[OS^?H6&
M>&9==;7?25K>:R)3THN#V99*M.-*;I/8>AFD7:80K5&:AY2E[+55L(3<:LH1
M"0=#Z$!4$$@(51,X8*EC6 , 8!0U^45_S"*7_;)Y(_S688*?5?@_YQ+X4?U2
M7]63_"&"IR8 P!@# *H]RI_[M_B(Z5W2@D#.C=0U];0]^732;)MD[RP.62HK
M]8 42'W#\4$FKE\L0YB-6ITRC^EZ<B.JO]%[ET;5>>,?5JY[>SFY6<*].>9I
M-K2^1?-'*Q$Y</FZM+GZ=>;%E_E/^S1O_8-DO7W!TEU*'4K;-;<W;/0,E?![
MEQ:_$^Z%'J2R:Z*^U.ZZ,Y>R9:V'U!_T#)<<AGG /PHDDL0Z:J9%4U"B10BA
M"G(<A@\C%.4P"!BB'R$! 0$/D.4:4DTTFFFFFDTT_=-/W3^J*-)III-/PTUR
MFON:?N0PV+Q/09F=<7[4$W.:#V>J853V?7:I&,3+*^KXGP[-4Q (29:J*_\
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MELW<&XY*[>^NREBR\_JYH$[<'2^WE_)F9:<<W-YCPIISJKYYX3C[R@@F^AM
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M7?1;7=3;!3JMJG&==D)+F,H3BW&46O*:;3/HY=+@P!@# & , 8 P!@# & ,
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MI.&VW]FN&ZZ9545T.>-VK(K)' #$4253I)B*)G*(&(<AC%,40$HB ^> <O\
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MI.6RR2Z"Z9%D5D5"*HJI*% R:B2I!,11,Y1 Q#D$2G*(&*(@(#@'+@# & ,
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M:JIK))"B4N"C%XDLTH-I,L9ZI[A<#8Z;MT&B"+9JBDV;-TR(H-T$R)(HHIE
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M6Y\S[4H#Y^I9?#ZUBG0JG.Q&PF^QK4Z%8]7?W]^]CHVAJRCY>PMG$@W42/\
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M^S3+YO8G>^-SL-@QS-R.UEF)(JNP<0PC&\51X!D:*AQ014%NG4%X@%*4
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MO.;*PIKKI/AOWE?GH/:MAVW &E*7>7VW:PZ=)V>B*U@KIQ!LX-2&E(>RQPO
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M622D=$WA*OMXWX&Y+A!S<0W*YVA.OFCI=J_8'3)'03PC1V=X]4<*@!<>
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M(]JV8L&S=DR9H)-6C1JBFW;-6R! 30;MT$2D21013*5-)),I2)D*!2E   ,
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M9".W?J4?G\_E@V)TTTT4R))$(DDD0J:::90(1,A  I"$(4 *4A2@!2E*  4
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MHWBXX57Y58Z5/[V&52^EX27*K'KO !1W&_'13^&!-? & 0L\0+C:"[QY=O\
MSG.7*Q4$]G+'RD'::ZX, QUE@'9)."^GHLP^TLM66D$44[!6WY3-):/%5 WH
M4^&H4"J7PK]>7V3['ZKD>YZ>>-[=UYJBEZ$8LZS14X#G.7Y*:K-W%8F=5N&R
M1XJP(W6RLGLA:(^4.20@G*)(4D<V9HF(#\_G^X%Y&B>?=/\ ,]$#6.C:1&:\
MH2<]8;*WJ\,H\&*9RUIE7$U-JL&[MRX*P;NI)TNX(Q9_ 8MOB"1LW2('IP#,
MN ?,EI>/A62KZ1=MFJ!!*F07+A!L"[A4?0W:(G<*))G=.E1*BV1]8'65,4A
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MRFOIXKJ.I]@:$4=JPA4%3+ F=N! +HB)D2(5-,A$TR% I"$*!"$*4  I2E*
M%*4H          !Y8!^L 8 P!@# & , \" & 2F #%$/(0$ $!#]P@/R$/\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'I+K/$U/2
M@R!PGZ0'U^Y31\C?/S#TF*81\OW_ %#Y_+ZAP#A]U)?98??D?P8 ]U)?98??
MD?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)
M?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P
M8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98
M??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]
MU)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D
M?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?
M98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8
M ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98?
M?D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U
M)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?
MP8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?98??D?P8 ]U)?9
M8??D?P8 ]U)?98??D/P8![Z1E#IE,JG\)00_23]0'](^8_+UE^1OEY#YA^_
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img39825204_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>:^9C X0DE-! 0      %X< 5H  QLE1QP"   "J  < E  "')R,S,S
M,38X' (% #U-:6-R;W-O9G0@5V]R9" M($EK96YA("!"=7-I;F5S<R!396-T
M:6]N(%,M,2!);6%G97,@3VYL>2YD;V-X.$))300E       0;%J4L4I>6(Q[
M:?&?<Q#;4SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #-0
M  8             !(,   2U          $
M 0             $M0  !(,                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P  !(,     4F=H=&QO;F<   2U    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $    !3A"24T$#      /:0    $   "@    F0
M >   1[@   /30 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ F0"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MUTP/HB6[6?RJMS&.]-W[B:KI&+3D4W436VCU"VH:MFW;O,L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_  !$( 7(!@@,!$0 "$0$#$0'_Q  >  $  @(# 0$!
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M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(D4?(3]%/V$$201
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M?4TI#]+>P''VF9YR8,HWH<QAEYHR5\ZRCA33<MM=J6V95/*LMLMV'>V/>@)
M#J' *6UEJW5AL>095^HEQ>QJFJLJ848V2HLXAFHRU=J7*ABU3'MNK56A+%*[
ME>+*S7^()- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1(H^0
MGZ*?L((D@B B B B B B B B B B B B B B B B B B B.Q?'V]OX0B#(C^
M,B/O\?<(D4^$R_4]C27<B[=NWL^,B[>SV'[/Y2& 0PW!!&Y&X.X\/KC_ !\/
MC$Q_6U-M>9B_IJ#0R,C=VM185]5J84&#9S,[/EQG&(MS%K[)MVOFR*YY:)3,
M::VY%><;2A]M;9J2<=U;65LB6-4S;#N(!S4;CEPY;@,5W ;8\2=QX@22IUKL
M5VK6T*=^VY(5CL=N7$@D [$C?9@.)\"90W2WT]W'3CB[;'VW)]IRN[:WTO1O
MZ>^S%)0Z*=;69^;<V6@GU#CKVBMK66?I#]C8N&XPVAF%$;8A,,,-W+;ELJQZ
M4I2E,9#54E;-VUJ\&"*A\%)L-MUMA+6777666LSG>4ZJ72[(N>YKFR66RQG5
M>;6CD"Y=0/9%?:IKJ4+7352B5JJ^$V;$$L0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$2*/D)^BG["")((@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(G"OB/^3[/:,'P^V/PD")1'36M;G$E4MQ:UK/3<B$:EJ4M79/
M(>H2DO$HS/LE*221&?L(B(O81#E'H39G]'FG,S,S'6>K]RQ+'8=7:V -SN2
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M$0$0$0$3A7Q'_(?V#!\OLK^,1*&Z:/V(JG^<W(W^(NJ')_0C^QWIO^F>K_\
M>_7):S/HY_DZ?ZI)?0ZS*L!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$BCY"?HI^P@B2"("("("("("("("("("("("("("("("("("(
M"(")PKXC_D/[!@^7V5_&(E#=-'[$53_.;D;_ !%U0Y/Z$?V.]-_TSU?_ +WZ
MY+69]'/\G3_5)+Z'695@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(D4?(3]%/V$$201 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MKO?!P]*WU3H'[UU%^<1\S_PW\R/#U!?C>(_R.N]\'#TK?5.@?O747YQ'S/\
MPW\R/#U!?C>(_P CKO?!P]*WU3H'[UU%^<1\S_PW\R/#U!?C>(_R.N]\'#TK
M?5.@?O747YQ'S/\ PW\R/#U!?C>(_P CKO?!P]*WU3H'[UU%^<1\S_PW\R/#
MU!?C>(_R.N]\'#TK?5.@?O747YQ'S/\ PW\R/#U!?C>(_P CKO?!P]*WU3H'
M[WU%^<1\S_PW\R87C-GSMLUZY$1CBN&>1VESBY7I"-6OTN53-0779C/@=+P,
M/%.23;:_UQ)MJ-7QD/,=-=2>D[J5NH5HJZ&QOTO=3:GTS?W5Z@?UB_3$Q7?)
MKXWCC5:,I0J-NZ\#N3N-I;*\>L5^-Q[E:V#YSP#<AL? >(V\=CMX^'ULT\/4
M%^-XC_(Z[WP]/P]*WU3H'[UU%^<2+YG_ (;^9'AZ@OQO$?Y'7>^#AZ5OJG0/
MWKJ+\XCYG_AOYD>'J"_&\1_D==[X.'I6^J= _>NHOSB/F?\ AOYD&CJ!/V>;
MQ'^1UWO@X>E;ZIT#[O.KJ$_@.1_[><?,_P##?S)AF Q'.O'V8C9>!8\5SHT:
MPO;%,F5'U2'E.7U[8WK[9I:=)!(8?LG&&C(NYM-H4K]6:C'FND>E_2;TAH6/
MH6+F]#Y=./E:IEK??1KR6,^J:IF:I:A6N\*%JMS'JK\V-:*6);<F6ZVBURY%
MPW"KL.!\%4*/</<![IF?AZ@OQO$?Y'7>^'I>'I6^J= _>NHOSB1?,_\ #?S(
M\/4%^-XC_(Z[WP</2M]4Z!^]=1?G$?,_\-_,CP]07XWB/\CKO?!P]*WU3H'[
MUU%^<1\S_P -_,F%\A[+G?CS&7VSFL<56$6AC-27H<9&K;??2[+CQ"2VXXZ;
M:3)4A*S-7L,DF7QF0\SUCU'Z3NCNFM5ZER:NALRC2J:KK,:A>H$MM%F31C (
M[WE5(-P;Q!W"D>_<2TUX]UBU[W*7) 8\-AL"?'P/P?6F9I+J!4DE>;Q&7<B/
ML;.N[EW+O[?UX>E"^E4@'N= ^(!^A=1>&XWV_7'^/@$B^9_=WOYDY\/4%^-X
MC_(Z[WPSP]*WU3H'[UU%^<1\S_PW\R/#U!?C>(_R.N]\'#TK?5.@?O747YQ'
MS/\ PW\R/#U!?C>(_P CKO?!P]*WU3H'[UU%^<1\S_PW\R/#U!?C>(_R.N]\
M'#TK?5.@?O747YQ'S/\ PW\R/#U!?C>(_P CKO?!P]*WU3H'[UU%^<1\S_PW
M\R/#U!?C>(_R.N]\'#TK?5.@?O747YQ'S/\ PW\R/#U!?C>(_P CKO?!P]*W
MU3H'[UU%^<1\S_PW\R=?*W7*>*0N=O<)5W>>:[JF7W&ME/M)M5%1[7)MAE;>
M##L'XK*/$[(73SK22TVGQ)ANEXO!2R.J.N>FD?+ZJZ6P-3T>LELC5>B\[,SL
MK!H&Q?)R^G]1Q,?+?'J7FUK:9F:CD*J@IB/X\9!519X56LK^Y+E50Q^ 6*VW
MVP/'SV]UPT=W4Z2I@7M'/C6E3:1FY<"?$<)V/)CNEW0XVHO;V/VDI*B2M"B4
MA:4K2I)="TS4\#6<#$U32\NG.T_.H3(Q,O'<64WTV#=71QX'WA@=F5@58*P(
M%=E9&*L"K [$'SG:B_-9C&UUM3@L?J-O?+=12Y*AM=%:J803CY0*>$].E$RV
M9I);QLL+2TDU)2I9I)2DD9J*;&Q[,O(HQ:0#;D75T5\CLO.UPB\C[AN1OMX[
M3Y^K:EC:-IFH:OFEUQ-,PLK/R2B\W%&)2]]O!=QR?A6P1=QR;8;^,_G4TWPX
M/*3EW//(\/X>'GBD.E6-7UI>3K<XB5&3*YST%V%%3(6@B6XVPSY;:E&A*UDD
MEGVC']%.%VD]9U3+-Q4&SLUTK5RV\0G,.W$'WL=S]8;3\":C^C/ZB;,R#I72
M&CUZ?W&&*N?EYEN6:@=D:]J&IJ[C+XLM:<5)XAF Y'H/T[WG?]ZKC#ZQI_S@
M)OU*=*_=/4/N,;^[E+_+-ZS_ 'I]-_?M2_OX_3O>=_WJN,/K&G_. ?J4Z5^Z
M>H?<8W]W'^6;UG^]/IO[]J7]_'Z=[SO^]5QA]8T_YP#]2G2OW3U#[C&_NX_R
MS>L_WI]-_?M2_OX_3O>=_P!ZKC#ZQI_S@'ZE.E?NGJ'W&-_=Q_EF]9_O3Z;^
M_:E_?Q^G>\[_ +U7&'UC3_G /U*=*_=/4/N,;^[C_+-ZS_>GTW]^U+^_C].]
MYW_>JXP^L:?\X!^I3I7[IZA]QC?W<?Y9O6?[T^F_OVI?W\W>Z&OA2++J5Y59
MX@Y'PE+E;V\K[*9E;G-3Y[T";+JHZYTFIGP+$WGF'G8#4J3&EM2U-F<1;+C!
M*>0I/E>J^@4T+3SJ6%F6Y--5B)D57HH=!8>*V(]84,H8JK*R>'('EX&=D]"_
MZ):[TC=3KTGK^AX>DYV9CY%^F9>GY%ST7VXJ=ZW$NHR SK8U"VVUVI:5/:9&
MK!(:>R8YK/UI 1(H^0GZ*?L((D@B B B B B B49RJPK7ZC \7N*4=)?2+34
M;".DS2FQS>43$4BF?-!DHXMK>6-2W-;]B7X3$F,YW;?/OS#KNH]0:WTET/86
M.F:O=J&N]15!BJYFB=.C$(TRW8[MCZAJVHZ:F37NJ78M-^/82EA1K5![:77@
M[.@6NL^\/9R]H? 556V/PD$>(EWLLM1VFV&&T,LLH2VTTVA*&VFT$24-MH21
M)0A"2)*4I(B2DB(B[$0Z:B)6B5UJJ5UJJ(B *J(H 554; *H   &P V$J^?G
M/T&T0$0$0$0$0$0$0$2A>"O\]S7_ $\;O_XE .3>BGZ+Z3?]J_5?]1I,LY/E
MC_YM7^-Y?0ZS*T!$!$!$!$!$!$!$H?J<_8(Y&_U3#_MJL'*?3A^Q5UC_ )CB
M?VI@2SA_KFKXV_H-+V1\A/T4_80ZHGSB_P 5?Q"5I(;1 1 1 1 1 1 1.#(C
M+L9$9?%[?X_C C<$?#X1**Q4=O#<J:W 0R)C.Z:I;Y'S<!/9+%;.58>J=E!A
M-D?A9AO6#U5<)801(1+M9QI2A*B(<OZ;J3ICKKJ#I3' JTC6]/KZRT7$4;58
M>4V8=/ZDQ<9=@M>,^79IVI]E/!,C4LM@ KJ!:M)MHKN/BZN:7;WL./*LGWD[
M!EW^!1+V'4)5E!]5/[6GGO\ HCW_ /=JQ'U="_\ C6D_Z1P__,5SQ?I'_P"H
M'6G^J^N?V=D3^&NMBHFV<*&XHTMRIL:,M2>WB2E]]#2E)[^SQ))9F7<C+N7Q
M#]:5CDU:G?VF12??[3!2?C\=Y_%/SWV\]CM_ZCW_ !;CXYZ77O0)'GZ+J)QG
M&T[4:74<5:[B#-8V#(*O2U:L\APREW%AHGFHR$1(M(T3DI4MHV(\>&RZ]+)2
M4=QSK'ZSM&)T_G9U>+C8VIY6OUZA;O8$QJ='#&MZB68E[2JH58,69E6L MX_
MJ'/] .-=J_I*T+IS(U?4]4Z3HZ!;0<5CB\M0OZL%+9RY[+2@2G#1[+$M0TK5
M34UMS,JL1J9S/Q9C,WN#X_X6L]/RQ-RM8Q%W6FJZPY]'.U39DBW+)QJR(Y,^
MYNNE*] 8LIZW%V$A"WFO TIHW/2:/JF7F8MFHZE53IN)DW?]&4W/PR3B\2:[
M,QG*UI=> ;$I3Q2OYXD[A>3=<=*:)HNLT]-])9NH]5:EI>&$ZES\.@9&F-JR
MLJY5&CIC4&^S!PK&]7?,O=Q?>2$6M5'/(>G3@.#N]UJ&>6X^MRN)XXXYU'*>
MSCPH'JW46%!FF&U-UU*FYC>0Q)MISS,1J;(8=88+S%^!:D]AKKNM_(_3?6-/
M;&RLO(S</3,-#8&I&9FW+56;C62PKK4M8ZC9BH&Q&XWM>CCT?IU+U+D8?4Z:
MII&BZ-H&K]4:RU>,:,^S2]'H-EE.$,M%079-Q2BNUT>M"7)&Z^%]P^EOB3G-
MS@#6<%JV6)R?*O*=IQ3L<YM+2NU%ID;.F@LW\BXJ;B%7U2+.#-S?I4M#$J&T
MXQ/8-DE+947;XS:_J>B7ZMB:Z^+EG#T"W7\3)Q*FQQ;518U%V+=4[6<77(-2
MU6(S<JG+, _@/>)Z,>DNNL7H?6N@EUK0\+J/K8]#ZQI>LY6/J=VGWKC#4$U/
M"RZJ<;OU/IR7VW4W("F0@KK)28OO^).F_7\4<J;W@B%R7067 ^ISE3JH6YO:
M6\C[G*W]M*HF-/6'75-<NAM$6,=!O5BO3(K<20VI*U.DLD[X6JZ[B9^@+K)P
M;L3J(7+75AI=5;IV15BC-6AK'>Q<BNR@.AL(4BX,%]E5+5.HNB_1QJG3/7>?
MT*G4>GZEZ-\W!ISVUK-Q<W'ZBTW+U)](;4*:J,>@X&35F!;10KV4G&*[_+7/
M:[+*<>='O(/%_,VYJ,ES[DV^+<05DU>Z'D/#VM-/VMP\FMR><37PN/Z^5(7:
MV1N/NM-SF5M5\*6LWD*2E8UU#.ZHT[)TNALG1+[-4U.O#IQZL++2XT &[+O+
MG+*JN-C*6=MF/-ZP%V)FW3_37HAZDT'K'6,?3?2!I572G3EVI7:AFZ[H-^$^
MJW[8NCZ<*J=#JL=\_/<!:Q=6W8JM/-3Q)ZGX,7]NYPO_ -_TO]T+\6>O/^JN
MI_Q,?X_US3_CSGS?T-O[,W1W\KJ?]CY\_LE'YHG];8")%'R$_13]A!$D$0$0
M$0$0$0$2F+']L%D_Z)-O_>W$#FN=^R[T[_L_ZK_M_I265_6EO\O5_0LESCI4
MK0$0$0$0$0$0$0$0$2A>"O\ /<U_T\;O_P")0#DWHI^B^DW_ &K]5_U&DRSD
M^6/_ )M7^-Y?0ZS*T!$!$!$!$!$!$!$H?J<_8(Y&_P!4P_[:K!RGTX?L5=8_
MYCB?VI@2SA_KFKXV_H-+V1\A/T4_80ZHGSB_Q5_$)6DAM$!$!$!$!$!$!$!$
MIBY(OT?,(?8NY\:;_N?[I]K[$&7]1^T<WU']ECI3_4GK3^UNC/RF64_6EW\O
M1_0OESCI$K2@^JG]K3SW_1'O_P"[-B/JZ%_\:TG_ $CA_P#F*YXOTC_]0.M?
M]5]<_L[(G\-M5(;B6L"4[W)J-/B2'3(O$9-LR6G%F2>Y>(_"D^Q?&9]B'ZTJ
M(5JF/DK(Q^'92#]GRG\4]]M_B.WQD$">NTCK\QV*V?5+O>-)L^9;<GZGAR;D
M:RYS[R:S1YS+52JK<4NA0ZH_0(UC!=D0DD9^>ZASSF#0XA"BY6G1>7E:;TYI
MFHU5-CX69U%;J7:O')*]2)?!LQV ):U+!79MN%1EV;<;[_L.WT_:%HW47I3Z
MFZ:NRGS^HL7T>5].5YNG-ZOF'I^FO&UW%U%"Y]7Q[\4Y..I\6L2T-64?9ETD
MY$Y2S&!Y&F;KI)W.[X^J-M4-2;G.1GK&AM<=/ENMR[7)-W$5\D7]#'L&TOU4
MMMWN3"6FI+9/,DXYZW3=.S,C!.F=248NH+A7CU7+8K8,VI%9*,B_'8;T9:5L
MR6_/*Y8LC;,ZSBG4O5>D:/U&>I?1/J^M]-+KF$7U32$-N)=HF7=97=F:7C9M
M;E,[2WR*UNQ6!1ZU1*G0<$8Y'PCU0SX_(^IL>H/3[C;YCDGBW3</ZJ]5.<OM
M51Y_1-$J+8U2;22DI14]BA$OU><ADGFW'R;5XS)*H]6Z;HLTIL71J,7 R:=0
MP=6Q@$[=%F;@6J]8OX#?:RM366V;8!?  $B_T1Z5L[&ZKNU#KW4M:U_2=7Z:
MUCH_5+VR#EZCAZ3K-+*]V$,A]G?&R.-XI[B!U-@!+%5-P5G4]P[P&73YDN%9
MFOY$S7&/+%KRQNM+I:&-DYNCE7-<SG'**AJ3FSW(S$/.*F-^DS7TF_.?2I!I
M:(S+YKZ#J>N9&KY6MU8V#ZWT_;T_AT8E[9/!;[&R+LJVSC4"1D"D5(O[2LJQ
M!&Y]7C^DSH_H'#Z&T;H>_6.H<;0.N?T\:WJ6IX-.DV93C$&F)IF%B]W(*@:?
M9D=RZUU'?=2GLD]O$-_R?TWX7A_F'"<%Z+?[6[YVT^=L+E[79:'FH6(RN=M9
M=^Q1MNM64YVZMG[%]B.]-9;9A'&CFX1)<,DKVQ=+U_+SM ;5ZL&C'Z=2^Q;<
M6][K-0R[,082.$:JL8]0I+V%6)<6/LOL^5/J#J_T;:/TSZ0<#HC-U_5=3](^
M;@-D5:KIE.GX_3^EXNJ-K-F*+J\FXYV0^25QELK45M4A9BI [E/[#E/(0>FS
MCKA/ OS7;&RT=KR-S'8/P'(+<S3I\=1DZ&&ZZHU3JZ@HS>D+D$1-.65@\;?^
M:,Q]E-.RK^I+]5S.'JN%@5X&CUJX9M\AAD:AEV*H'"Q[ F/6"2W90DA>?$>)
MS^JM'P_1?HW16A/>VHZIK65U%UIDO0::VNQ5.'H.EX[L2;\?&QFMR[V 5/6K
M1QY>.UL_!B?MV^%O^_:3^Z%^*'7O_575/XM'_F:IZ/\ 0V_LS='?RNI_V/GS
M^R8?F>?UM@(D4?(3]%/V$$201 1 1 1 1 1*8L?VP63_ *)-O_>W$#FN=^R[
MTY_L_P"J_P"W^E)97]:6_P O5_0LESCI4K0$0$0$0$0$0$0$0$2A>"O\]S7_
M $\;O_XE .3>BGZ+Z3?]J_5?]1I,LY/EC_YM7^-Y?0ZS*T!$!$!$!$!$!$!$
MH?J<_8(Y&_U3#_MJL'*?3A^Q5UC_ )CB?VI@2SA_KFKXV_H-+V1\A/T4_80Z
MHGSB_P 5?Q"5I(;1 1 1 1 1 1 1 1*8N?V?,'_1IR!_;V)'-]1_97Z3_P!2
M>M?[6Z+EE/UI=_+T?T+Y<XZ1*TK[EG%*Y(XOY"X_;EE <VF-T>8:G*2:T1'K
MNJE5[,A:2(S4VRX^EQQ)$:C0E1)(S["W@9/J>=AY97F,;)HO*^1856JY4'W$
MA2 ?<?<9\3J323KW3VN:(MHI;5])U#35N(W%39N);CK80/$A&L#,!XD [>,_
MD TGP<G69GKRRIBX-U%TB#*>8:MJ)RKLJFQ:0M26Y<&2U/)2F'TD3C:7FV7T
M),B>:;7W27Z0HZWZ8MIKL.JT5%U!-5HL2RL[ E7!3;<'P)!*D_.D^<_E%J'Z
M'KTOX&;D8:]%ZCG+1:]:9>#;AW8N2BL0MU#^LJQKL #*'5+%!V=%8$#I?TOW
MK._@]<@?5(/_ !XF_3GTQ^[&)]TW_+*?Z@WIA_>!KGVL/\[C]+]ZSOX/7('U
M2#_QX?ISZ8_=C$^Z;_EC]0;TP_O US[6'^=SI;[H>ZLLO7E:Z#@W:5%<<ZLK
M2F368#3)S[FQBU%5%)9SC_7I]G-B0HZ?].1(;1W+Q=Q+3U;TY>_;IU7&L?A9
M9Q7N,>%5;6VL=D.RI6C.Q.VRJ3*N9Z%/2KIU(R<[HG5\2@W8V.+;CAJAOS,B
MK$Q:@?6CN]^3=536/VUEBCWSN?TOWK-/V_>];\_X_1('_'B+].?3'[L8GW3_
M /++7Z@WIA/_ /0-<^UA_G<?I?G6;_!ZW_U2!_QX?ISZ8_=C$^Z;_EC]0;TP
M_O US[6'^=Q^E^]9W\'K?_5(/_'A^G/IC]V,3[IO^6/U!O3#^\#7/M8?YW/1
M3X-;H&Z@\1U!Y[E_E?&3./,UA8UR_#C7DB$5M>VUE52ZB-'BP(DJ2\S$CHFO
M2I$J5Y"34PTTTEXGE*1XKKCK'1LS1[M,T[)7-NRVJ#O6KBJFNNQ;"2[JH+DJ
MJJJ[^9)(VG?_ -#OZ"^NM$Z[PNK>JM(NT#3]$IS&HJR[:#E9V5E8MV(B5TTV
MV,E-:7O99;85!*HB*_(E?Z1QQ.?T%@(D4?(3]%/V$$201 1 1 1 1 1*8L?V
MP63_ *)-O_>W$#FN=^R[TY_L_P"J_P"W^E)97]:6_P O5_0LESCI4K0$0$0$
M0$0$0$0$0$2A>"O\]S7_ $\;O_XE .3>BGZ+Z3?]J_5?]1I,LY/EC_YM7^-Y
M?0ZS*T!$!$!$!$!$!$!$H?J<_8(Y&_U3#_MJL'*?3A^Q5UC_ )CB?VI@2SA_
MKFKXV_H-+V1\A/T4_80ZHGSB_P 5?Q"5I(;1 1 1 1 1 1 1 1*8N?V?,'_1
MIR!_;V)'-]1_97Z3_P!2>M?[6Z+EE/UI=_+T?T+Y<XZ1*T!$!$!$!$JKF7/9
MC3XI%5K] 69IBUW']F5H;D=KO:TNYSUO0UQ+E)6T?KB\A5]3X"3YKGIO@8-+
MRD**]IUU^/D]S&I[]GJ^964V)VKNQ+JK;/9\1VJG>S??8!23X3SW4^#I^HZ6
MF/J>:,#%75="R5R"U: Y6%K6!F8./O:"I];S**,7B!S;O<:R'*D6FGY)?_G[
MHHST,D$0$0$0$0$2*/D)^BG["")((@(@(@(@(G!F1$9F9$1$9F9_$1%[3,_X
MB("0/,[?'$U[LM5F"Y]R[YZ*C)EKBK:1W7CMH!--OKU>+6AA;AR/ AY:6W%)
M;49+43:S))DDS+D6=K.D#TL]/VG5-.%:=!]4TNYS<8*EK:]TLPJ=N[LMA5'8
M(3R(1R 0IVMJC^J6#@V_>J.W$[[<+/'R\OK^4V";<;>;0ZTM#C3B$K;<0I*T
M+0LB4E:%I,TJ2HC(R4DS(R/N1F0ZVK*ZAD8,K %64[JP(W!4CP((\002"/(R
MI)C:("("("("("(")%:T-EXG%I0GOV\2U$DNY_$7=1D7?^(89E4;LP4?"Q '
MVSL(E!\$O,JD<TI2ZV:E\[[LTI)Q)FHO1*'VI(C[F7L/VEW+V'^ <D]%-E9N
M])@#H2?2OU60 RDD=C2?$#?<CXI9R0=L?P_^FK/V-W\9?PZY*T!$!$!$!$!$
M!$!$H/J==:3P5R*V;C9.'4PS)!K22S+US6>TDF?B/^H<F].-B#T6=8*70,<'
M$V4L Q_Z4P/($[F6<,$Y-6P][?T&E[LNMNMI4VXAPO"DC-"DJ(C[$?8S29D1
M_P 0ZK4Z.BE&5AQ4'B0=CL/ [$['ZTK3]1)$!$!$!$!$!$!$&9$1F?L(B[F?
MX"((FO5UJLP7/&(>/149,L\<[UAYT[: 3;3Z[W%FAEQ?G^%MU9-N&EM9I6HF
MUF23))]N2:EK.D#TJ=+6'5-."5]&=9U6,<W&"UVMJ_1_&NP]W9'85V%48AB$
M?8'BVUM$?U6T<6W-U! XG<CA?XCP\O$>/EXCX9L"TZT^VV\RXAYEU"7&G6EI
M<;<;61*0M"TF:5H4DR-*DF9&1D9&9#K*.EBJZ,KHZAE=2&5E8 JRL-P00000
M=B"")4\O.?H-H@(@(@(E3<U4>5T6(;K-EH3S%*6PX\L"M"4RDU6]3O<Y:9ZM
M[OMNM_\ 35]$KJCMX26KT[PM*0X:5IOZ;;D4Y1?&I[]AQLU#7L3M5;B7UW6>
M!!^54N]N_B!P.XV\)YSJK$T[-TI*-5SCIV*-7T"]<D%!OF8NN:?DZ?C;NK+M
MF9U6/B'PY'O;*5;8BUT_)+_\_=%">CD@B B B B B11\A/T4_801)!$!$!$X
M4I*$FI1DE*2,S4HR(B(B[F9F?L(B(NY_Q!$U:W?6KTQ<<V3]/I>6*$[2*X;,
MN#1,V.G?BNI5X%M24YZ'9)9<;41DXA:B6V9&E9)41D'CY[';X?<)H;$!V+#?
M;?;Q/A]B8%^F.=()E[>39?M^,CQ&Z_J/_JZ'G,=VOZ;\#?DFEM[R%\'O><S1
MN37>3)C-"KS+*XQ#>"W::RST9/)<:G>8FB2<>O>/Q/SZU#?ER)*$^%2&'WVC
M_.6J?H:^BM4](576=@[6F.S9VI=,I4!AYVLBSFN4;0ZFK#M)-V7A(G"Z] 0R
MU6VU&^NJ,M!J#>WX!;-FY!1MM[O$CQ&_EL?+<>.Y[?PC'1\TVAIKDN2VVVE*
M&VT8;<I0A"2)*4(26<(DI2DB)*2(B(B(B(B(?HM$6M0B*%50 JJ-E4   *!X
M     >  V$H=VOZ;\#?DG=T?P@/25?SVJZ+RS!@OO+2AMV\H])00U+69DDCF
MV]1#B(]OQFMY))[EXC(C&WV/KQW:S^V'V=Q^$@";=U5M5WE?$MJ6Q@VU7/91
M)A6-;*8FP9<=PO$V]&E1EN,O-+(^Z5MK4DR^(PDD[ (@(@(F$[KDC!\94Z[_
M '^MHLE4(,TE,N["/"0ZXDC4;49MU9/2GO"1F3,9MUTR(S)'8C,DP6"^)('Q
MS5=_X1;I#8><9/E)QXVU&GS8N/VDJ.OM_I-2(] XRZG\"D+,C_"$T[M?TWX#
M^283O>N/HCY&RMKD=+R+.D5=HR;:U,XW>L2HKZ2,X\V'(;SR5L2XKO9UEPC[
M>)/A6E3:E)/S_5/3.E=7Z%G]/ZS4]N#GU<'-5C4WTVJ>5.1CW(0U5]%@6RM@
M=MUXN&1F5MZ\E:G5T;VE_P#M;Q!&Q!\/(C<&:W=-W-O1?P;87F@MN:)^KTLV
M9-8J9Z\1R"U'K*1QPB:-,5RA6A5O.:0A5C+,E&A/:-'6;9../<?]#WH)PO1E
MEZGJ^?JCZ[K>7?DTX.5QLIHP],=QQ/J[6/RU'*5$;,R&+! !CX[=ONV7VLK4
M4R JK["  L-B2S GS(4> W\!L/'Q/NVW"_3'.D+]\V7_ +D;G_\ G.D0_0$I
M=VOZ;\#?DEZ<7]2'"',KAQN..1L[HK%+9NKIVY*H-VAHB(U.*I[)N)8FA!&7
MF*3&42/](R#8_!-@ZMY,#];W_:\_LR[PFT!$!$!$I;E#J)X4X:-#7)'(F=S<
MUQLG6JIZ4J7<NM*,R2XBG@(E6)MK,E$A?HQ(7X5>%1^$^R:LRK\\P'QGQ/Q#
MS/V)0OZ8YTA?OFRR_P#1&Y/[,Z9!->[7]-^!OR357J9Z@^C#GJJA2*_F&9G-
MC5J98BW'W$\A+A3:M3Y+DUUK$9H$%(0@C5(A/$DW6'T^7W-EY9%P[TS>AG$]
M*6#C6XF:-(ZAP3751GOW7Q<C :T-?AYN/6Z"T*"U^-: ;*[E"<A58X%S$U!<
M8D$\D.YX['<-ML"#M]L>1^/QEQ<5=9W1#Q)CJ['Y[DVS=9BI\V?8S<9O'I]M
M9.)(I-C,=7GUGYCQI(D,H,FH[*6V&B)""'0NANB])Z"Z=P^GM)[ME6..YDY>
M2[696?F.!W\O(=F;VK&'L5J1736$JK4*OC!=EBYR[MY^0V/LCX/!0)9K/PB_
M2&^ZAHN4'FO&HD^;(QVUCL(,_B-U][/H::3^%:U)27[ICU\B[M?TWX#^2;28
M+DWC_E&H*]X]U]#KJKQ$A<NDL&)A,.&7?RI3*%^?$=[=C\J2TTYV,C\/;VA-
MPP8;@[B9T$S 1 1.%*)*5*49$22,S,S(B(B+N9F9^PB_C,(FH/)77KTF<3VL
MBBU_,F=*[ANFQ-J<\S9ZV=">2KPK:ELYF#:^CNMJ(R=:=4EQHR,G$I478_1X
M/274.HUB[%TRXTL-UMN:O&1AL#[)R'K#;CQ!'G[MYROJ/TV^B[I7)MP]7ZOT
MX9E#!+\3 7)U7(I<DKQMKTVC*-;*00Z/LR>;JH\96'Z:AT1'_P#JM9?^WG(G
M_P#6!>_2#U2?_P".3_ON#^<3RW^4YZ&?WT9/_A_J'_\ 632_4\[_  ;&GYBA
M\F.\K6<6E6IVRT.+:XWY#36W5ZAQM<>42TYM)Q84@_,>M8+:#1+?0@T&VA^0
MD_SIKGZ"_$UOT@X_6=FFI3ICNV;K'35=^ ,+4M45U>G(+C*7L8M[%[,_%1",
MBU5(:M;;E>\GZ*GT.K0:_P!-&26 XJYZ?ZA)52"#OOI9'@-@OQ>7OFYC/PI?
M0['::88Y2GM,LMH:::;XYY"0VVVVDD(;0A.7)*$(21)2E)$22(B(B(A^B4]'
MW4U2)77IE25UJJ(B9F J(J@!551D;*J@  #P &PE'_*<]#)\^J,G_P /]0__
M *R9+F_A+>BS46+59#YHKZV0\MMMIW29_4YB$M;IFE*?6%[2P(2?:1$HUOI2
MCQ)-9I(^XCOZ(ZGH0V-I=EBC<D478^0P ]_"FUV_!X^Z?2TS]$1Z'M5O&-1U
MCC8UC,B*VI8.IZ74S6$A0+\_#QZ?,>T2X"[@L0#O-VJ>ZJ-#60[FALZ^YJ+%
MA$F!9U<R//@38SA>)M^++BN.QWV5E[4N-.*2HO:1CR]E=E+M7:CU6(2KUV*4
M=6'F&5@""/>"-YV/%RL7.QZ<O"R*,O%R*UMHR<:U+Z+JW&ZV56ULR6(P((96
M((\C.S&DL0$2IN:J7)7^(;KMM?N9JB+8<>3BLVC:2M5Q5[W.66<KO$\Q(02;
MC01:VI67E^,T35$VMISPN(OZ;;DTY)?%J%UOJN:A0@GY59AWI>_@5.]5+66#
MQ\U\CY3SG56)IF;I5=.K9K8&(-7T"]<A2H+9F+KFGY.G8WMHXVS-0JQL4@+R
M(NV5E8AA:Z2[)(N_?^/_ ,__ "%">CD@B B B B B11\A/T4_801)!$!$!$\
MY.I#4;OG?FJKZ1.,=!-RE%&HV=9SILZE9MV==G)*DIAYBO>+OY<JT;>CK<)*
MDFXJ7'2[WBL36U9\/Q^'VMC^/P\/*0N2S=M3MY%F^M[P/'S\@?C^.;0<9=,7
M!G$M''H\EQSFTDVTA$JUMJV+=7=F\22)R586EDU(DO//+(UK2A3;"3/PLLM-
MI2VG$D5%4; #[/B?MS$.<.4>FOIY/%M<E9>,S-Y#N)U#CJG)<0WG(%W>6M96
M/7$^-%I</E;^T+T6LCO2W77(J&2:;6?F=R,AJC"R\8R M<<>[**A6(7'QWIK
MML9@.*JKY%*^T027\-]C%@6J@Y%G%:A?3C<B5W-]Z7655JOSS,R8]S>R#L$.
M^VXE1776'T2YN\>SVBJY-'/K\IG=MHG;3I]Y B5N+S.J1)<I;/>VKF *NP[<
MAN%*<>;U$BK>A(8=7-;82A2BFKJ:VRVM#631EU8-CFVM:1EWX^-E58ZWLPJ>
MUJLS&)17)5K!6VS@K(S:@%)[=G+(Q[LNJL4V-<V-1DY.'9<:54VJ@OQ+U5F0
M!U06)RK96-PY_DCIZTO-5KP)6XVO/=UG']=R@R](X]BL9B\Q-G,A5\:ZSFE5
M ]6W;!3I[,1_T)Q9LOI>;7V-I?8M5C5YKE"AT_)IQ,NJSV+JK<A<IJ>51'+@
M_J62%<;@FLCWB8:ZA;,*L,K_ "0Q;LO%LKV>JVG';'6XBQ=UYIZWC$KON5M5
MAN#+:T7#'$NLJI-+H>-\3:5LIM;;T9_-U22,EI-)J0ZU%;>:<(E'X7&G$.)/
ML:5$9$91R;BI]P^T)YZS**VZ!.7\C*SEI9S^ECES2,9>US-G*D3T\8:ZT,C@
M6-;)DK<<362%-J,S6X2G(R9;$GSI3,)]>?=Y?9D.QK8;':LG8@^0/CXCX!Y?
M /K>!W]54J)24J(R,E$2B,C[D9&7<C(R]AD9?$9?&,2><A$P'E/D.DXGX\U_
M(VB4HJC(TDNXDMH-).REL)),6"QXO8<B?+6Q#CD??N\^@NQ_$$PQXJ3X> )\
M?+PF@O3_ -.DGJ$<B=375*P>NO=>7K7C_C:P4Z>0PV3?43E,1U'C)B7-EQB;
ME)3(2XUY3C<B6B1.=6IG._NV'Q^\_D]WD?AD2IR(LL\3X$+^U7X@??[]SX^4
MW3W4+A3B;!:??:W)X^CQ6#SUEHM!.8QT&6FLHJ6([,G26X%;5R9DGT>,TM91
MXD9Y]TR\#3:UF23AOOKQZS;:2J HI(4L=['5% "@D[LP'E[Y9JH:YUJK0%V#
M$#P V52Q\3L!LJD^/P36D^K'HZ:XUF\M3LK?5.(B7F1SC$Z[Z;>2:6QN[?=/
M)CY:-EZ"SX]BWFH*U?6VTT_05]@PTMUDGW&_.;\5JVFVF['Q[%VORLNW!IH4
MAKCDT4OD6UO4N[UA:JW;FZJA*,H8LI J57T74Y&0C#U?&Q*<VV]E*TC&OO3'
MJ=+6 2PM;96."%G =&*\74GZY/5#TCJR+^HS^4D[*S9V<'CP^-\UPS;+Y9+;
M654J^A9V3QW<Y^FT55,?H4G=I?NXM9 ]5%Z:<PF5(4K#U6*V.%3NC)]9-;TL
MEM87#&^6UEB.4K]6\.ZK$6 LBA"SJ#N'JXW,Q%787'+K:CUV'UMS7BBNME#V
M>L6!DJ9%*$I9NP".5N?A;3<&<\8IO=87%U#=<W<7><M:K186#0:3.:;-V#E7
M?YS14DZ"4FLN*F<TMF5'6;B#(VW6'7F'6W59LJ*)1:'KMIRJ%R<:^IN=5]+.
M]?.MM@2%MJMJ<$!DMK=& 92)K5:EK7U\&KMQ;CCY%-J<+*;@E=H1U\1[55M5
MJ$$JU=B,"097_.G1=Q?RA!<O<?6Q.+N5*GO893?8R.FBF0[>.1N1$V;%;Z,S
M/@NO$29!J;*4TA2EL/$?B0Y%-VJ5O$#BWN(\/Q>X^^?1T><WZ?E/(:7(<EL(
MB<O\0:%W$\@,H2AI,^0QYOJV_;:2220BT88>)PT(2TY)BONLI2VZAM&2/LCX
M?L?\-_&*V)!#?/J2"-_/8^!^(S<$8DD!$U'ZPN<=#Q!@J>DX\BIL>6N4[^+A
M>.81I;<\BTL?U$FZ<9<[I6U5,K2MOS$*8]+>B^D]HY.F$CL8J !\\QV'_$_X
M^&=-P5T6<;<<1&]/R! C<K<OW':PU>[V;7KUYRUD$2Y+-/%LO/CPH+#AFTPY
MY)RWD(2MUTDDVRTA*PHW;VF\R3XG<CQ\_=YS+.<>3.F[IWB9"3R9F(<=S>Z-
MS)Y"LRO$UQO;R]OVJJ;=.P(5'B<O?6RU-UE?,EK=.&EE+;"^[A'V(]58/D)C
M+NUST9&2J!2?E&+VN_8S <56L7(6)(\"2/(S:P+72V0X5:DNHH+';<W9)<45
MJOSS-8:W V!\0 ?,2LM3U4='N,GXZIT.8MX=QN,1,Y&J:5KITY$GW4#%U]JJ
MFFWVIIZ_C^599"'$L$^3(^Z:+5NM$IMQ;9-.-K5(5VMR:B]8.'5B79-AL044
MIG+<^-SR"PI#.N/?NO/=#4X<*5(D8LK-6/:%?YKMRZ<>LU.+[7P6J7)XT%1:
M50WT\6X<;!8C5EE8$]5M.KWHXQKT%UK-EM\ZO'YSD+1[GCGBM.RP^!PNN>>9
MS>KW6BK("HU'4VWH\AY@TIES&HC#TZ5$CPT&^)%HL]8MQK N.U671@/9D,*J
M/7LE*WQ\06G=6MM6ZDJ5WJ NJY6+W%WP]U2TUW*#;W<?)S$JI0O=ZIAN]>5D
M&O8%4H>JU'4[6<ZK%5&*,!N8CC_C6T@MN(Q.*FP+"*VZA7W-TKT>5%DMI<;6
M7>$:5M.M+2I)]NRDJ(R^,1NCUN];J5=&9'4^:LI*LI^N"""/<9(C5V(EB%62
MQ5=&&Q#(P#*P/O!!!'UC-"NH+IH=X37,ZENEA@L1L\:R[<;/"57G)R>^R\4R
MDW,1RF0I4>--;BMK?2B(VVV^EMUQAMFP)MY>!MY?^_\ CX=]_K>,T=..[U^#
M#Q('DP]_A\.Q\#]8#R\MYN'^3*7F+C3'\E4!&BNUE.Q8IC+4E3L&41J8L*]X
MTF9&[!G,R(JS+L2C:\9%X5$9XDJGDH8>\?\ N/L'PEE!,P$3R\ZL=OR+SSSC
MGNB'AW23,="ET+>SZ@M[5+\%KGL(^MMIC-U;R/U4>RNFI#*UEW;6\4ZN;-U$
M0YY'[KI_%PM)TJ_JG4J$R66WU31L.P;UW9@!+7V*?!JZ=FV\Q[#_ +;A/SGZ
M3M8U_K7K+3_0WTGJ-ND4W8'R9Z]UW$.V7I^ANRI3IN+8#\JR<\.O+R=ENQQN
M*3>'VOX@Z1>GOA*@CT6+XRS'F(90B;>WE9$O]';ODDB=EV5Q:LR93KSZR-:V
MVE,QD&?@98:;)*"\_J74.L:K<UV7G7G<[K358U5%8]RUU(0JJON\"?A),Z9T
MIZ+NA.C<*O"T3IO34*H!=FY6-5FZAE/L ]N3F9*67.UA 9@K+7O\ZB@3 M1S
MKTI9+E^3P5.QLJTY(KVLO(MJO*<!;'8UE'&V:W49V3?:7,8BUSM)&GDP^X<B
MSLXK49EA]Z4MEII:R^?BY.9F-:M.5=\IRO4['LR'JK7(]7IRNV;+71-Q1?4Y
M(8@<P-]YZC)TC0\05F[1],!MQCEUI7IV+=:V.+KL<V"JJEK-C=1;6!QW)7P\
MQ,?J>J'HHN-_/XW9B4\*]K^0Y'$SMG<\-:2EQ+_)$>4<)6-A<@6F-BXJ;?.S
M/#%BP8UZXY+D.-LQB=<<0E6<6_.S*J;L?(R'7)KR;<=6OLKLOKQ'OKR&HJL=
M;+14V-D<NVK':FQ@"%)#(TC0L6R^J[2=,5L4XXR2NG8SICG*JHNH%]B4,E7.
MO*QVW=@%[U?(@L)8&NY2Z6<1S5QST]WU5CF^5^4HME.RF:AXB'/4J'60YTYR
M1;SHE4[!HVY<>LLU5A6<B,NR573BAH=]%>-+&R,W+?+KHR,AVP<7UO))OL5:
MZN5:?/,P#6 VULU:[NJ6([*%9261I&@XJ8KWZ3I:+FY7JF-_T=BLUEW![-N*
MTDJFU;CN, G(%>7($"VM5P3PQMJ:50:GBW!7-5,;6T_%E9>H(O"X@T*4T\S$
M:D1W/"HR2]'=;=0?M2LC(A)CZIJ6)8MV/GY=-J[$,F1:/([^(+;,-_<P(^MX
MREJG1O2>M8EF!JG3FBYN):K*]-VFXC#9U*L485!ZWV.P>MD<>YA/,UW/W7P;
MW-^'^YBYM;/I YQU,?(6.6MYC]A^A#NK922J[&LFS%N/(I9JD.*6EQTC7%;F
M(E$],C0GY'MQ=7UKI67ZQ56G4FDX[9*9-:A/DEAU_14M5 %-Z; +L!N64@A>
M07\\G R?T/O6.C?(W+RK_1-UGJE6DY&EY5MF1^E'7<L[8V3BW6LSKI^0RGN!
MF)XBT/SMKJ=_7BSMZNFKY-M;6$.MK(;1ORI\V2U&B,,EV+S'9#JT-(29F1$:
ME$1F9$7<S(<[1'L<(BL[L=E1068GX !XF?J:^^C&I?(R+JJ**EY677.M=2+X
M#D[N0JC<@;DC<D >)$^]*DK2E:3(TJ(E),OB,C+N1]_P=OW1K)0=QN/(^(E.
M\K1\-LW<UQ/I;YZ!<Z:ZI]92U=;^N6<U'&^AI->N0X7HTI$2J;G5T"+-ER4L
M-K]*3$8D)EOM$/H8+Y6-W\^BH/735;C6V/\ 0U]>HMQN/SRDV%'=D4;[<>14
MJ#/,=0UZ/JCZ?TYJ&8U.7G9>)JN'C4'?(N_2]J&%JQL([=@3%2_'QJ[K'X*W
M=%*N+'67&1=B(A\^>GG(1 1 1 1 1(H^0GZ*?L((D@B B B>=O3"J.UU>=:T
M>T\!:=W28Z5$-PC)Y>7.G-,,V36?B..E:HR5DV7@\TNY]O80S[A\9_X2)-N=
MGP[CX]B/#['^/@GHD,26>8/PAF'W>CWW1_J\G3\XR:7C_D[<VVQT/3_0QM#O
MLM76O'%S30)L6%,@648H\ZRDL5\A;D)_]9?<\)(425DPSVM5>YRZ5OH.J8JN
M!\K;(NS-)LJHN/B>%B46L!X>->_(;&1YRFW3:ZD5'L77-+RF4D]Q,>C%U5+;
MJAN!SK>^E?$$;6>4I^AZ3-YSSU!\^V6LVG47QQPGR3P'P+C+AFUI<90:#F"+
M!I]57:REVMA<9*TMZ2^ALR4-7:<G(SK[2KAS]4CQLDS/0E28^KC)KQK5OZH3
M4*=/4OZHU2:)H@KR4X,MSUC)QWQW1KFK+T.C+N&+0O9<V;I-V*V10V-T[9BM
MG,H&37D?I@UFSL%;%:E7%%U>358M0<);4X;8J!M/1<3:#,=?='JJ3)64/BC/
M]%D;C&KT*&%JHXMW Y3@S8.8*:M2E*L&J&.F6EE9J6<9'FFKVC--[W+U-;DN
M._J&;T]D(2 #>U-74GK;H![JK,NCF!L ;D WW)$5N*M-_3E>,A&-I^GZ]C,
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M3@YU^F5W&G;;4L>G1-"6[D]@=@HR,5L6SLFGD,8H?:YV/52.F3K<R_4MT_\
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MW8:=BD,02>)1F1N5MKIC^P/A21=NQ=OP=B[?@^P<ZGZGG(1 1 1 1 1 1 1
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M$9J+2RQ:D+N=E!4$D@!0S*NY)V  Y;D^X F2T4OD7545[=RUUK3<[#DQ  )
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MGF)<N>L\K[,BVM;/6\E<C/H;QQ\E*ULLJQ0C!B,?UQJ<FY+6N[JT5TGB!S%
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MK[7MR')W9GM8L2Q)E+%6T5]R\DWWD6W%O%P>"5U5L02":,>NG''$\0M2A?9
MES"K+,!$ZN\K3N:6WJ">*/ZTK)U=YYH\WR?38KL;S?+);?C\OS?'X/&CQ>'P
M^)/?Q%!DT^LX]^.6X"^FRKEMOQ[B%.6VXWVWWVW&\EHL[-U-O'EVK:[..^W+
M@X;COL=M]MM]CMY[31"-T.N+Q;'$]SO*JWXN>M,_IKB&O&/,;6=I*#)5>80B
M-J?NJ=APLY*=JH]@JN]0OV<>.IZG:NCA.^)'T<G*?(N;(4M1?2VJ6:?94W%L
M:S4WSK>[:>)[UN);J%UE#KV=WJQBX(IV>O6@I:PIQ9<GU/URNY.ZEBXCX[<*
M0QXU+<F)0EBNMJAFR+$ LNW3/.$^DTN(]K7[>;O).NL?N3F,:-N311ZQ&BY/
MNYY+T_*3JVK&6<2PNJ5B!GRIT(>8@P(+28\PT*4T>IO7CDHE9KKL-2XU8<$8
MM/&I\NI=D7DN9F44YSGV2+S>SBPW;I'V3O06M=S6;#86\[^WW:M.+D>//3\/
M)R<%')8V8[4K[ I ;$M=T<:'51&<LKDB@@X2IU?+FPH8Y<>N2]DBRY>S/(5'
M:Q;G4.[!$2?!IYG(4^? 5#H:V9,BPH5=82'%-'-55 ^9>P_BZZ-\A*W7V4&,
MMF$]=KI[1:\+@UK8%L6NRQK+RH=P%N)9V\A[@-TMU#&U-T8\G]8HO6]D1SX+
M2YYA-T:RE'6E'[*%'^CE/HK9Y+9T+*]X52B_B5419?<PW/)A%9PEN.'/:D[N
M*3R7T[15\:#\!(.O*M_5E*.:Q:JR.WEY64U:N,G4<K/-1/LJ,G(Z>O-.^WM!
M?D"%Y;#EZT3Q4U#GIBD8]>'7MR]4TW3-/Y#939\CL[4LWNGP/$V_)'M\/:X&
MD/R;GQ7(^3^D>%R/:SYY:PJ*-8PZ^(]"BY]E[L<'B?D[BWSB<*TCH-QR-R(S
M9D:F#\":%FO,U(DIDQ*[LS5ZDF_M9]FIVJ[>UVFU%.GAL1X<UJLT'F0.'<.4
M_P X:]WTQAZO9CMOR2C$T?%X ;!AI6HZCG<QXD*;USQ3M[7;%*M[8;BOS\.<
M&:?*\YZS8:.:F50T^2S4"B8AU*Z7/67(US2P*WD/:YZJD6]Y+KXDV@S6-J/(
ME64MQFU+3NLO&BP>4Y9]8#UYC%"MF3GW]A"RNV-I[]G.OJYA5WKR=7NR;T78
M,JT('9P$XP"@U^H5!PZ8^%2;V 91=ET-E8.%8ZEV'K.+I?RBQP C)D)VU0FY
M6W1%:6("(")KAN^GR-M;SEB\7?,PI')N-X]R;1JI6Y3U">!O-!>1[!J0<]E<
MQ4N3>)-M@BA^A.PTR$//K<\+<N-;ZNV,P7GZOU!@:ZPY<>Z,(Z6?53L#L+!I
MS*;2"5&0P[;!-GBSJ_7,6['![36Z/JNDBT#D4&IU9%9NVW4GLF\-VPPY\-BZ
M[@KI7RGTW<E9*IY-X[X\9GZICG"BLH5M<2^/85S5,6-OR'M]1$A1[T]S"/"-
M4L39+3:VES0:"!.9BILZ1EJ[)58[)@7!;=,IN 2C3\_0,SDS<&?Y&8^DXF1;
MW KAD-.D5V)BCC>+;76JQEN>VJ?)<&Z[-4,7R,;.Q7J4"WBEJ7&E!4QK7NV/
MDVCODM05%8R4XTH'W,XWZ>(V _0\<;O69DC#Z/E_0O/-4K<)RV/EF^M[V3"4
MXF<ZMA%2]9M(4\OTCUDN"U(6S$4:4M1FP<ZV"[+7H=&C!=_/L6Z58,CP&WM?
M(UQVMCQ.2Q%AXD/!=6;F1MQ7QU)=1=5W8,1IV=@&DD[$@',%BN1OM2%X#ENM
M=:_I.T6GLEU['(5! PB>6+WE^/7/X%RRV17^BIKZLL*M_6.ZUB&NF:DW\F7#
M4UG&K-N*U'J7)KD5HUKK\=\4XS[DIINJ:;18FRA:M23)4V6*=R]E)R6V"O6E
MH538.8#2U7;VLFR]1N+\G3,N]6\2;--R,"Y5J;;:M+5P$79E=JB[=M@GL'KK
MSHJ:N<C:97[OO12LK'"SSG(S"'#:^XOAF1Q'Y7D>NV_'ZQ3(.]4KS4^C*3ZO
M\+Y*],*U;=W;,MR@VRLW6,MD)\ -6P\7$-1\/:%(QN8;8<P_'BO'<QX!&%ZI
M_P#,]5P='POI2_R)UF[5NY[^/?-W8X^/;XBSD^_ ?OR)T6PMW-J)+&U;H6ZK
MBB/QB4>-F&7FW_1,=M\G'N%DBXC)039;$I95Y(5V17G$1,04KSXZS(=\C4L@
M <\^XWJ&)84V>O:9FCEY&P<M-2MMC6S*^X92@W@HH6JK%I+,R8^/5CMMLI=:
MTRT9EWY!&89;$;JP4H-PP)$R#(\)Z2-U'.[F]D-N9NEX^S4N2S JCJ<YI.97
MH4_*3=G45\BTN)T!RIP$")1.QI-A-(TV<<_2GWH9.)S7:@746 L5K\MEQ*W<
M,:*,FO&OU)ALBADR<G&PNT2 :VKS0 ?6;"V&J?CIU;,K]BC;(=0RBSU6R]=-
MK*%V -*Y>;9;X'F6PV5D%(2;C"O)X"("("("("("("(")%'R$_13]A!$D$0$
M0$2D>..5I^XY-Y[P<JJB08G#^MR.<KY[#SSDBX9TG'N>VCTF8TX1-L.1I%TY
M";0R9I6RPAQ79:U$6Q78*?I@3]IBO_":@[EA]*VWQ^RK?_EM+N&LV@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(E*4?*<ZVZ@.1.&W*N(U78KC3C7=QKE#SRILV5NK
MWD"HE0'V%%Y#;$!&-C/,.-GYCBIKR7"[-H&=O9!W\22-OB ._P"&:\O;*[>2
MAM_C)'_#ZTNL8FT!$I3:\IS\MS)PKQBQ51)4+E.-R._.M'GGD2JH\11UUM&3
M$907E/%.<G*:?-XR\M""4V1J,^VP7=6;Z7C^$[34MLRKM\]R^QL-Y=8UFT!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$IWJ%Y,F\,<%<O\MUM9%NK#C7CG7;:%4SGG
MH\.RDYNDF6K,&4_'(WV6)*XQ-..-$;B$+-2",R(;*.3*OTS ?;.TU=N*LWP
MF6?2SUVE/4V:VTM+L:V#.6T@S-+:Y<9I]3:3/VFE!N&E)G[3(B,_:,$;$CX#
MM,CQ /P@3LQB9@(@(@(@(@(@(@(D4?(3]%/V$$201 1 1-.NG_\ ;%=;O]*/
M%?\ @1@Q(_SE7\5OZQIHOSUG\<?U=<W%$<W@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(FG^,_;S<]?^'?I[_OISD-C\XO\9OQ)(Q]%;^37^D\W &LD@(FH'+_ .VT
MZ0?]7<__ -S: 2+]#L_['](R-OHE?_;_ *(FWXCDD!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$U0Z[OVEO55_0%RG_<ZV&]?T2O\ CK_2$CM^A/\ Q3-C<A_V3S'\
MWZ;^SHXU;S/QG\<W7R'Q#\4R(8F8"("("("("("(")%'R$_13]A!$D$0$0$3
M3KI__;%=;O\ 2CQ7_@1@Q(_SE7\5OZQIHOSUG\<?U=<W%$<W@(@(@(D'76V&
MG'GG$-,LMK===<4E#;;;:36MQQ:C)*$(21J4I1DE*2,S,B(S&"0H+,0J@$DD
M@  >9)/@ />3,@$D  DD@  ;DD^   \22?  ><^:!8U]K"BV59.AV-=.8;E0
MI\"4Q,A3(SR26U(BRHSCK$AAU!DMMUEQ;:TF2DJ,C[C9E9258%6'F&!!&X!&
MX/B-P0?B(,U!!&X((W(W!W&X)!'A[P00?@((GU]R_"7]9#$S.>Y?A")QW+\)
M?UA$=R_"7]81.>Y?A((@(@(@(@(FG^,_;S<]?^'?I[_OISD-C\XO\9OQ)(Q]
M%;^37^D\W &LD@(FH'+_ .VTZ0?]7<__ -S: 2+]#L_['](R-OHE?_;_ *(F
MWXCDD!$!$!$!$Z]FVJY%C,J6+&"_:5S45^PKF9<=R=!9G$Z<)Z9$0XJ1&:ED
MP]Z*X\VA#_E.>4:_ KL'B"1XA6X,1XA7XJ_ D> ;@RMQ/CQ96VV()'P(!\"R
M\U!\"R<BG(#WKR5EY#PY KON")]_<OPE_601'<OPE_6$1W+\)?UA$=R_"7]8
M1'<OPE_6$3D(@(@(@(FJ'7=^TMZJOZ N4_[G6PWK^B5_QU_I"1V_0G_BF;&Y
M#_LGF/YOTW]G1QJWF?C/XYNOD/B'XID0Q,P$0$0$0$0$0$0$2*/D)^BG["")
M((@(@(FF'",QBHZKNL?*62TQ+N^MN'N2:2(\MM#EMCIO&-3B_7,%LU^:_%B:
M;(W51-<2V2(\MEIM2C-]OO(WC76?@#J?CYD_B8'X?K2-3L]BGS)5Q]<%0OX"
MIW^Q-S^Y'\1]Q')("("(")B/(#3S^#VK$=IQ]][):-IEEE"G'GG7*B8AMIIM
M!*6MQQ9DE"$)-2E&24D9F1"AJJL^F:BB*69\+*554%F9FH< !1XDDG8 >)/@
M)<T\A<_!9F"JN9C%F) "@7(2Q)V  'B22  -YXC\?\>\R7V"S5,]I>?\%6\;
M?!N\=:7(46-M]5C837-D*5KS2J;"B16BN-17,5M4P_E[!,II^/):19T\DE0S
M;^UK=SU-U+G8K)=DT9FC>H JN0@K&G9+Y(JI(9+J[;%KKN!1PNW%2C-O/E:7
M2+&T'$O#5X^0W4(SR&:EO'4L 8ALN'&RKBEM]E)Y*6(8CDB$3J>1V^J+)<69
M"SRF[ZC)^IYLZ0H>SY(?>D:*YG9SF-K=\/H]8YB =8XQ@+\Z?3:R&O,4\2NK
M5UL%:ETW>N?>*QDU8R:[GZ52%&F8NN],^J9 8/8^/=K]F'J2'+)+7478(6W)
M5G9*@.XG:K)!K8]F0=,PLZQG.=?IG4Z9%;+Q5;*- NRM.8XZA5KNKS52NAU5
M++6)0E[&!%F\B<4\PY_7=6V=RG*W5"><XMZ=\;R[PBX6WUMLM7-%C$W!WK$6
MWD1Y,O;(<>RU J1@K.7<TD-=Q,\FCCG91_+^=9D-1IF=GUU4OF8/47JF'0]:
MNEFE#!TO->MJ-OFBJS(RLJ@Y+*UH1.TERM6QE^JA;L[3L6VRU<7-T>Z_.L6T
MHZYR9.116_> 4XUBTJEG9K-=3N%L>E@%G5<R\X<\XC-]759;_HTIW')/#7"N
MFZ=V,CC-K=LQ[M_C^LK-^C-RJ*HF0<U95FN:GSM!7S9$&5%:6B:;:VW4F+@J
MI]=.'6588O7M"6L[+Q/3]F;HA2PW,0EN$*TSZGV8^T;%*^VI:D<FT:?AY5RN
M'MZ&R"X2LACU BZY:5%2CG7F<;M.:L,J[JJ%2>TP7L=?#Z@:U?4!S54ZWGMW
M98+J]X@S?&V09L]2[B)?%=TSPS6;6,UA$17*K0YV:QH]9)LK=R),.KEP7I,.
M?7J@RS/. M*W]/UOVFKU'6^H,74FMV8U8)U'64Q%)8[8R55T8EN+<"C;,AYO
M4:UF^:+6JU=D>Q7Q.GM%R\'M[C?4$T[#NR? ?1[;+>[7D5.''M.IK5RS3YLK
MJNH*7R3BFF]#SPCJ@E]3.IJ>4\9:5&M=X&I>G)-_IX];91H4NN8X[9ST7#MY
M6XSM[2V1:NVU;ST25,=6].BLP8"(]."$*BE]#R7UB_) :['UIL&U@*U<HXLJ
MU@4TX>/C\:;=/]JP,C-;)<UN-N>;!8MRZCBKHE6*6--V!ZSB*3:0"IJMT_UF
MS4+KP;L?-Y)3L5I0^J?%V4YOSL^W?Y7Y?S/)-=)CM(IX-#Q:UQ^]524O*6](
MDS&]?I/62'&#2TE@V(OEJ(W?,7W\!1\J^T5[9%O-2+!8>(0*X9.V5\2S%"&Y
M#8(1Q/+<;*MPLY&U6JXN#7VP&YED*,+ WDJAU*E3R+ \AQV:Z1')H"([E^$(
MFF?&<^+?];/4[8U+J9D#*\3]/F!N9C)DN/&US4_E;73*(W4&I'K"OH-/G;"=
M&4:78[-U7J4GL^D;D;(I^%F('UO9&_VU(D8.]K[>Y%4_'NQV^T1-S!I)(")I
MISW/BYSJ9Z,]'<.IA4=AI.7>/FK-Y26XC>KUW'JK#-5<AY9I0T[=)S%K$KR4
M?>3/3'AMDIZ0TE4B>*6 >>RG[ /B?L;B1N=GJ)^%A]DKX#[,W+$<D@(@(@(@
M(GC%U Y;E.RZO]?$R<CE/*9S><E]&.:TVKX_*]II$S$QZ;F]>QA-Z6NC*3%K
M6EJJ8MW,COH56+F0EKD0Y3D-T;Z8$+&JX[4MU!KF196S%$M1.B,,XK.05;MM
MG4HJNI7E=7VU8N"LQJA85U64GY=7T_I]5;H S5V6];UB\*-F L&%;=8P()6@
MM8R]L$S'$93GK(0^:=14<A]2%I:<'=8O&N#X<J[F_P!/=U=OPI?VO&#VO@V]
M5(AK1R-1+9V&MCR-9>^N+.IB5+#<6[AIIW3*SB.NW2MEHJ>S5,S/PM9YJ@"8
M=>HZI@8KM6H1,.RO$Q\7*3(5*WML876O;6ZK*6>KHO40I:X+I^EXN?I:J[DM
MJ!P<;*N57W:S*1LAK*7Q7:Q%0/6J(Y)'Y['*<^R8.@Y#K>1^I*LU=KU_Q.*F
MJNGOM(BDK.GG3[JOS%^BHR;L"351:-J@ES+>#MRA+FT<AMNPK;J%&BMH1%I2
M5LG3E.3[29N+KYU4VDBQWQOTQYFG(]O);,7:S!T^E#4U-MM5HKY-WT(L9Y<6
M=06T%E;"713I8J X*]V-H*9CI7LU>5[63F/:EBV5H]9)13783W,?5<T<$=0L
M6!>7_.5WTT\8=16BSTJUM(FUY FIQ^\X H;K/,V]A%K[/1ZS)U/)<BTAP;F3
MZV31V,AJ!+G))MLFLX-J7)6V6E:W68/4.!00@46Y6'JVDW:<UBJ JY5F V=1
MC7%%&0E93D;/%]<I34<JO'-K*F3TSGV,7+\,>_#UFG5>%CG?L+D#3K<C'0L:
MF)MX*G@O4<01.:^?]GQ=6[S5]260P=S%ZU]!9MQ++;\;6CI5O-M-#XAA:&8B
M/7VE:<#+S7I68JGWXCDF#%)!-2J]N5'<K]MJ<&RP[',QNC] M0!EL(U=[\OU
MJT;%DNRE6I4M1Q8I# LA 0C<OW<C9.7JUO5>I4D%63GIB:=2U2@^R]6*]VY1
MUX-S)"LK$B5W2<E<]Z3!XRQZCM+U.Y-1]-"%\12^*\]N:^]U//U7KMO2V#VU
MC92B=7.V*ZFLPTNFH=A&8RMI&LK6Q<A2$N251[F:O'U^S3UJ;5WKT/(T_&WK
M]2[>5H>)E9BI781BG?6;,JG.2XAL3%2A4[8-CB+&'!\2K-=SH]>7K6/G9)+^
MN$8^KV4X0=ZAW^V-*6NS#LI_762;&M-C+5S]1,!F^KO0Y3AS1Z?ES(8:U5@L
M#(Y3P4OB6+H["1KT5D1[:,L:AK95+=:N?+4_'0TQ3R&:M\EJ9.4V24GOEC#J
MU3.[(&1@>MN<9*G:L+C@*O!+6#M8AL#M5:Z!C6RADW$BQ_6K=/Q=W:G*]7VL
MLOJ5['<V.:[;J5*)7<:#6+JD;@+@_%N) &X1?Q_'^[_**$OP$0$34'KXLHL3
MHZZA:YQYLI^NXTT6"SL,UD3]MJ]W$5D\S306B[N29UI=V\*'&CM)4ZXMW]27
M8C,MZOHB? &!)^  [F1VD=M_KJ0!\)/@-OK[^Z;2YV*[ H*2"^7A>AU-=%=3
MV,NSD>&RTX7M_ M"B_\ ]&I\23\),W'@ /@ G<C$S 1 1 1 1 1 1 1(H^0G
MZ*?L((D@B B B4#S%TY8CF*VSFME6FOP?)&.8FQ,IR?QO?N9G:T]?8K;=L*5
MR4;$VKO<]/>9:?F9[1U5O3NR&FI28;<MIJ0C97*^&P(/B58;@_\ $?&"#-&K
M5R"=PP\F4[,/L_!]8[B5Q][)RQ\1=;/4>1%\7_17 YGV_<[G^@[W,_XS]I_&
M-^:>^E/NK!^#GX37MM]5?[2_\HC[V3EC^&SU'_[)X'_Y/!SK^HI]U;_SQVV^
MJO\ :7\D[O-]//)E%H*6YL.KSGO40:NSA3YF;NZSAANHO8T60AYZJLW*GBNL
MM&X,Y"#CR5U]A"F)9<6<>4R[X7$X+H1L*D4_#RL)_"Y$R$8'<VN?K;+^'V?\
M?#-HY4J-!C2)LV0S$AQ&'9,J5(<0RQ'CL-J=??>=<-*&FFFD*<<<6HDH0E2E
M&1$9B%W6M'L=@J(K.[,0%55!+,2=@  "23X 2959V5$4LSL%55!+,S'954#Q
M))(  \2? 33K8=>_31FN(^3>9*G>1-SF>*:ZKM-1#R3;LNY.#>34P*6;7PI;
M</TVLN'_ #?5ERRXJGG)CR%1ISGDK[;NEB#$+UNJ9FH8VFHS*0$R<EZ5"7#;
ME4:Z[DOL1U#]GVD5BR!HNXGS8H=6?"PLK.L12"7IQ5<N:F'LV;V5F@%256T\
M;"@#$(G6YPE&G7\W6;/'Y7$,N<?1<AH9F@EN7.EM-_06U] J)F2521[.CL76
M:::FFB*>L)%ZVPZ[&996E##N[4NALJ93ZPN?E8:TUCN<UQ<##U![%="?E@IR
MQ8]''E74%L9O;(75;4=:[4/RAL&C,LM?Y7VN_J&5IZH0W@:S?CA%O#!6M9ZP
MOROFV69SK,Z6]==9?.YWFG%6EQL; J6@A,3WDKDWRGI+#>;EN/1VV*O3//1)
M3;&<MG85T^IAPFH*R21GE,>VUBM=9L(J-ZE.++94E7==Z6!*W"JKV[.T7-2
ME^/%ML-D4H-W<(.:UL&!#(]CBNL6J1RJ%EA"5M8%6QBH0MR&]AL<Z<1RJRON
M(NYH)%;;<AR^)JV6W*4;4WDB#93J>5CF%>#]5<LVE;.@KCGV(GXSB?'V21B(
M N*"BE_6\:_+Q@I^CXV-5??=:GN*)5C7NQ\^-;>! DUA%)R!80AQ+<:C)Y>'
M9NS&QEQJ[/@:ULS%"^>YN0>^4+D>O/IYLL!B-IO-G2<82]Q6:&[B9K2629%G
M746<TMKF)=];N5[#S-71KGU3J4V]D<*O)UQ,4Y)O)-(SL"E3@AA9IVG:A8=M
MDI34\.O,IIL=MD%I1V1*]P]K5MVU.VP,>-M]1\#5J.?IR$[$W6:?E68MME:C
M=C7R0.S;<:E=>X1.W@]<73Q8<O1>(&-<T4^PX@J>;JS6K;4WB9^(MSL'HTQN
M_5X8S'@JJYZZ>D3/1H":]39^EJD&;"9.Q8J:JUJ]DZ-=C49R7'@];Y%+7 @'
MS[:BI6\>9>Y%16(?C#WZC9IM=9[QU2K(NQ6J'-6&/D5XQ4D>(:RQWX>'$"IR
M[+NH;**SK#Z8[C*[#;0>9,6>8P,6LL-C;2I[E<S0U5S*1"IKJ:U/8C22HK:2
MM+=;=-,N54X_$<>6X25&6ME=E25V6(R)9DIAJ6&WS7:5%>,X\Z[W+KQK<*Q!
M! V\9NEB6,Z5L':NBW*;B>0.-0K-=>C#=;*:PK<WK+*I''?<@'%M=SEP]S%Q
M?I+O =3,GCJGR&ES$#2;_#?<\Y;5,^_:@+H,]*A[;+:"&3>J;T%*]7$BF5*L
M$RX"ZZ3X'E>/<4W(^,K4GEEY#8F,C [VY2N*WH"@@BVMF'<4[%!NS *-YH;:
MG6\I;[.-CG,O="-DQ56QS?R(*M25IMV==PQ1@I+#:?BCIFY76E*T];74?V41
M*+_HG@@O8?M+V'PZ1_UD1_A(8YH-P:$W!(^?M/\ ^<!&(!%S[$;CP7R/_9DO
MO9.6/X;/4?\ [)X'_P"3P<Z_J*?=6_\ /,]MOJK_ &E_)/S=Z6.1I[:X=QUH
M=34VLD)-N;$@+X<STN0PHC);3-U1\3PK>N4LC[>DUTN-*07<V7FU]EI=Q?VM
M58^/FWX&<C\$=MO?:Y^Y'X0-_P#'V)??$O#V X1R36+X[IEU53Z=-M["3-L+
M"ZO;^\LW3?L[_2:&XDS;F_O+%X_',M+6;*E.$EMDG$L,LM-QLQ8[D[^[XA[@
M/@ ]PFZHJ *HV'X2?A)\R3[R99PQ-H")7?*G%.$YIQ5IQ]R-1HOLS:KB2'8Y
M2IM=.A6%;*:GU5Q36]9(B6M+=U$]AB?56]5,B6%?,9:?C2&UI(QE6*D,/,?9
M^L?MCPF&4,"#Y?B^ @^XCW'W37ICI7Y$KF40:3K/ZFX-5'_40H=@[P]HY<9D
MNY-LN7=_Q1/N9Y-I[(2]8S94E22(W7G%]UGOS7?<U5GP]Q=?L^RX'X)'VV]U
MMFWU^)V^SQW^W/T^]DY8_AL]1_\ LG@?_D\,\Z_J*?=6_P#/';;ZJ_VE_).V
MH>G7D^GO*>VF]8//^AAUEG!GRZ"VJ^%$5=U&B26GWJJQ76\40+)$&>VVJ+*5
M G0YB6'5G&E,/$AU&"ZD$"I%W!&^[D_&-W(!'Q?',A&!!-CG8[[>SL?K'V??
M-JGGFHS#LB0ZAEAAI;SSSJTMMM--)-;CCCBS)*$(0DU+6HR2E)&:C[$9B%F5
M%9W941%+,S$*JJHW+,3L  !N23L!)54LP5069B%50-R23L  /$DGP 'F9K?1
M=873/IHEI/HN8L?80Z>TS%1-D-S7FT'+VMXG-9)V&;T=L[&NT5\HJFHMJ\I-
M7.FDMEB6I2%=IUHN<4%:G/K-XQJ5VV=LAJ3DK2RG9J[&QP;U2P*6J]M01(VL
MK0Y"LZ@XN/=E7^((3'QG[>1;R^=9:+/E=I0MV["$;9B <@V_4KP/QP]?,;OD
M[*9=[+WV9R^@1;6'HQU>BV=7*NLK3RN[9]I]_60I,NLCI\;DI+9H:)3BD(5"
MIYBID!87WY.+3Q!8V9.'CUY650BC=FMIQ[*[611N5.X!,W.RFQ6(4TT8^5;R
M8**\?*R'Q,>YRQ 6NS(K>I6)V#*W+8#>=#]]YTT)PS7)#O,.-BXQS6M8)=U-
ML'(*8NV>8=E,96?#E,M6-??2([*WH]7.B1Y<AM3*F6G"?8\>[5NAQU*$MF+<
M^,$^6'(&.MC7BGM\A8]0IM[E:$NK5NI7DI$T2Q+!D,K#CB"HY)8\!0M[U)2U
MO/B$2PW5%';92KA@W$[SX_OR^E\J"DTJ^9<8U4Z+43L33J?FOL3I>RKHB9TS
M*^J78Z+:/H&H2T2O5$F$Q-6PXV\VPIM:%*W7'NLOQ\=*V>[+JLNQD0AN]55=
M7CW/65)4BF^VNNWQWJ9MK..QVP;JA7?:SA:\:VJB]FW7M6WU/=2CA@"#=56[
MU; BP#V.1F2??/=/_P"B _Q:?*>13N6)<FM>I';'RB3;PX!VDRB]8N-IJ3OH
ME8E5A*HDSCMH\-MR0[#0VVI28T7N56WKL:J:[K;+-PJ]K'8IDVJ21W*L=U*7
MV)R2I@5=E((&SNJ/76W@]K4HJ[$L+,@ X];@;FM[PR]E'"M9R4(#R&^.UG61
MTP7&>TNJK>9,=*HLFNG3=34RY"#26CEKK\X[71G(R)5U'T<YMR%GY-*Q8,74
MIM<>M<D.I-!9:JQ4I<U6<;[?5ZAP<NUW:&1VC7MW%L[&U_%U4]G>TCM[M =#
M9=7S3E159?=[2\4IIL-5MI??@:Z[1VG96(6SY6=G(6=/(ZO^(?66=M(.OQ$O
MBRVXYY Y#M-^O5>CRJ6)QY>T5%>-N9==4N8N#62[=]G1V$F9 ?SLR*W$F0%G
M(6N/E:G[EU=@X$5:9;CE2KB_Y*Y+XN,0ZMQ2NUP@JN#,ECN4W3@6."ZFNJRO
M=]\C,HN4J4:HX>(<NWV6'-[516+T\59:P''+D%EA[7J4X,XZE28&SY+S%%/B
MTV?OUU\B8IZP>K-9,FP,P[#@Q&I$J?(T$NML&:>#":?FV!PI2HL=QN.ZM&O%
M^3H$<O7D#$= I+)D=E\@U%0">245O=9MN*JEYV%5()SS3A78645VTMD5N6 1
MZ%>JHVJQ(]@VW55(3L7L<(@9MP*_L*$^I-BJY-X8ZL.1<GB95>NI8A<6M<8V
M-!*LJNPG-64J:K8X#2W4.]9D+.LLZ]Z9%*&NO0TNOCR2D*=F9&IXBVD'N(MM
M;%F*O4XW1ZWK;A8C;'9E+ ['8^<C#+:6-=K#ML:W4#9D< $JZNH9& 93Q8 \
M65O(@SK/O9.6/X;/4?\ [)X'_P"3PUYU_44^ZM_YYGMM]5?[2_DC[V3EC^&S
MU'_[)X'_ .3P<Z_J*?=6_P#/';;ZJ_VE_).SS'2/F8VOS^^Y2Y)Y5Y]U60L$
M6V,<Y3O:A>:R%PTAQMF\HL-CZ'*8].@8;=6F+>V5/96L$U&JNE0UJ6:]2Y((
M550'SX@[D?7))/Q^0^MXG?(K&X+,SD'<<CX _"   "/AV)^O-LAI)("("("(
M"("("("(")%'R$_13]A!$D$0$0$0$0$0$0$3J-!6>NJ.XJ/\D/UI63Z_M/B%
M/@GZ;$>C=ID(W62EQ3\W_*(QO-$^UXFO,1X_$4.15WJ+J?9^6UNGMKS3VE('
M)>2EEW\P&!/PCSDE-G:NJM]KY78EGL-Q?V&#>RVQXMX>#;'8^.QGE'FN@?F=
M?#'4+P]H=U@LYG.2.+Z;C_CO+YB5N-5E<O<4<ZPGEJ&GMRY(T^4S]J;E;"+C
M2DN+?/9YB&](J):G9'@%ZW(9Z<9]FLS<?6M+U=#>_,*FF78>1ZG9EJHOR^_;
MC-\TY%7>J1E5>8Y\J:XX[N366[>)DZ;JVGV&A>+.=4JNH]93&9FIQ7QZ[6+5
M46=K)=N3A."3-&.C+EW0\U9'F;;W?&,:7 Y.X-Y T%!GGM+80$HXJXMY#P5C
M$IW[:DANNO3+'65EE5N3&XW@9BR_.6R^B.EW:BVG'R+[4%KK;G:[F+R"!U.L
M:#IFE(HV8@&F_#O9F!'*AT/SY=%Q;7;?BU4/VU>O3=&P=U+,C'2NI<K66L]I
M1L+L:Y*PNWLY ?P-8#GNI'11K5Y;EZC9OL:W-Y!ZVLGU0T\I+%BANLS.?T?'
M=Q)I):TUWFITCT7(6<=A<5+L#QSXY.3$MK?4C3'N%*])KQ)/3]NI-E<0!ZPN
M?E:_<!3Y?.UZMCI8;.(8T6* 1PWVRZCD#J,*0IUK#P,:@MO\J?$HTRIWNV\P
M[X5SJ4Y'Y:I(!Y3$FNC#GJLTN8RM3K^*E\*Y7K D=4\6;.9U2>2I[-[?WFGN
M<5)B,PGLTPJNNK^:NMN6YJSL8+<6+*AU[C;DIS3"=:$TP7ARVDZ7K.DT=K;C
M?7GX&J8N+D6\]BCTG4%2VE.2NM9M1P1V#G45LRWU)J611JN=H>??W =Z6TK(
MTA[J:^(V=+J])1Z[&V97L*,K#:Q<&QG0/U \34&DJ^/]?PQ=2N5.%K#AOD1S
M=UVLF1<TVQJ^1KRBT>*37PT+N&'*_D"1$NLS<)IXKME"8L&+)2/,8=@N'>TF
M[2'\*;<?2W-R[=X9F#H.GZ+=6 =P<:T:;5=CVD]W%>RZP56]SMK81C5JR:Q7
MN;J]0U2U:'^@G$S]:R=7I<@>*Y5)R#5?6H[656J5M:@K1YVMI\'AR18Y?.X@
MMQB6*2[Z*,_TF\EV2&+Y-M56&2=E6U/L,1';B)B74"9<OIB6U+?.TRE4Z7/)
ME*>>\E/TLO-6_.UC+K3B,W5=#US#6T"P+FZ%;:U.-F*"JV8>0MQ%S(W=]@*$
M(8LOSL;#:FO3%=^38F'KFF9/:)IYX>N/2]M^+8-WJR\?L**0P*#F6Y;HH;M-
MWT1<Y\VM[+1\I:'AZBV$[B;#\*9:DP<;5.9"1FLWRAF>1+O1:R9<5S-B]96O
MW/E74F?BUTFOH&7WVU6L\YCSS6E6155D+D!+6:_J#0=:RD=E=:JM%R+[EQZ&
M)!ONM.3:6R;4KW"4U]M55F:0T6MC>ILU79Q]%UW3,9TK*66WZQ@)@B^X;L*<
M>E::CZK4; 7-EO(MP4=AR)P++VOPAF%]2+G1>,XW&F2Y9YWI4U+J,WH]UQ7?
MVU-P0CUGX4Q';0GKFXL[6N22G%0,7G5R2\I#"2CTRP5'6;V"FO&R*<C3]R5M
MKUG5<'(T_/O3Q#.B:1CU<V]I4R;:6!#LP;.H5FRO2*%(#Y%.3B9P W6S1].R
M\/4<:EMU(4MJMEB(K-N^,^8A0H0T]4B+M["%>6H"("("("("("("("(")\-G
M$.?6V$$B9,YD*5%[26?28_\ E#*VO\HCFMOTAG]7^NL>8CS4>)OQI\7<HKJ^
M[3;5[/RVMZ_;7FGMJ5]I05++X^*\AN-QN)O6_"Q']KV'5_9;BWLL#[+;'BWA
MX-L=CL=CY3Q^JO@]N<RQ6[R#^]XWRM/%+B^UXHQV?<WFEP\39\5<D,\AUUY+
M8V#TK18#+WQ0(-%-X[Q]W;T%.VN39U;QOI:85>7*:LX&3Q:[,PM3PL]%R'Y*
MM.-A785^(<L 9&2,A;V>BW(K-F)VD16L5[-ZK4<SJ%/,58V?I^JX5SU*>;OJ
M-E=E>0,5F-%%F/P87"AU7+>Q['52E>V$<Z]/G4E6:NHY(T\OB>?R%S%UG=+F
MEHJ?-5.OTF&R#/&7'VQHW&=2Y8PJVUEUDB4AE2[YAN*Y$.4B4W%9?C,,O,-T
MHR-)QJ ]C4ZCU?J=EEQ%2M7J'2[8RT*Z<S38OJC5K9QL#.]9XMW&I73*JLOQ
M]8ON:M%MTKI;3JZZU[C+9@]5U93W%7*BU&&:+'J'$BNNU"XV%Q^WG/ISYQH9
M^,Y'MI7'<WFCFCKFX'VLBBS]'I;OB7&0>.\'IZ"@CV*I3$&^LTSF8).Z+5.P
M*M^/-G1#B15%61?2<83K1DZ+C4;NN/;U7J-]F05JY6ZCT_ETV8]+5]SLHB4T
MI0Y+O9>UECIQM[*YRJFOQ=;R+F5&NQ>F<"E*1W#VL#J3!O6ZU;.!N=K<BQ[:
MP55,=%K5UXM:;^P_1;R@OJ SW4CR7?<;JUDOERVY&V&0R#%ZYEJ>MC\,RN)\
MG7Y:7<0&9=O?)-Y-QH;VTA4RI!K]&BL&B$QYV<6RK#055]QU.#KE;V,$1_7=
M:SM$R6[:J3PQ*:-([6W,V66VM:5'<94QDTV9;/99VT<96AM6J\F0XNC4:RA:
MQF"LV3==JQ91Q-=552UAB5#-@-/\&_HJWE)^1-NLOH>,&^<-1SY63]!MN;)N
MBC:+06EIH8E"YQ? UU3Q2XFIO;5Q/W2O>D*LJ)HZZ?FW9,E^<5?&;M8-&*X7
MN8.DYNE8KE!>ER9F-E8?=O%Y)I'JN7<F553R.0Y[E=F,7]B7)K[V7?>I;MYN
M?@9^0O<>EZFPK<.\I2:=NZ3?AUOC/84]5'%&6]*D4_/F>@KFZMPN_P 9:V_#
M3^<?A\>,\>\;%8\M6>+KK;!Z>7?.:.FTLZS9Y%X=?L([L./G:/$7U_3X6QA(
MM:IN:9G%5,]Y>O'=A8^55GUY0L:WC=CTK@V8=E56:J][)L=K.:V9=3[4J<1@
MU=UCC"U%;,E5-:8]^)ET.HK+59%F1E59-;WX3.:JDK[3+:F-:G>ML&1NKTUK
M+/XNZ*N2(EUB;#FS9YK>5<'B;J&XSUE0VY;V4I55S/K\S<U%'&OK6NB3]7$S
ME#22*B?IM*F-?W,AQB7(8<4;JTQY*TW4ZA1N_P VZ/IFG&]42ACDX65F7OE=
MBLFFCV<BM:5I\GJ-K@,Y,WI:VJS!N4*AP]8R-12HV67A*+,"K$3'%U@%UQ:V
MMKG[A K2SL(S(BF49'^#-Y3?Q%#;:[D^CV/-V(Y3RFESENU>\@8RBO.->->/
M;/BS!8BXU.2D5VVSMLG/6UAH[.]I"F(:UUC8J3%L:^2X3EDYK]W'RNVK95U.
MJ/K'%VJKR=0UA<1,G*Q@G@J4UZ=AUT4VH4-7K%96ON*RUO4U->1C=QEQJ3@4
MZ..*N^-@:;DY.5CX^2#Q#&RS.RA:]3@J4Q+4)>DAO0;I,X$D=/G&MGG+0J<M
M+J]IH]_JO4%YN])4E>:)YGS41[OD:^O]/:NM0XD)J9:2G:Y%E,0_.145YOJ8
M+2^U6JP\:HL:<+':FLM553N;<K)S+F%=0(16OR;657MN< ^+[;*N]%++;F9%
M@5;<R]+K MEMNW:QL?$K#66D<W%.-6&*5U(-@H0\>;;/BM+,!$!$!$!$!$!$
M!$!$!$!$!$BCY"?HI^P@B2"("("("("("("("("("("("("("(")QX4^(U>$
MO$9=C5V+Q&1?$1G\?8OP!$Y"("("("("("("("("("("(")%2$*,C4E*C2?=
M)J21FDR^(R[D?8R[G[2]OM#_ !_P_%X1"D(49&I*5&D^Z34DC-)E\1EW(^QE
MW/VE[?:$201 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1(H^0GZ*?L((D@B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B11\A/T4_801)!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$BCY"?HI^P@B2"("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("(")%'R$_13]A!$D$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$2*/D
M)^BG["")((@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(D4?(3]%/V$$201 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1(H^0GZ*?L((GR/5E;(<4](KX3[JN
MWB=>B,.N*\)$E/B6MM2C[)(B+N9]B(B+V$$3\O4U/\U5OU&+[H(CU-3_ #56
M_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]
M1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&
M+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_ #56_48O
MN@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]1B^Z
M"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&+[H(
MCU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_ #56_48ON@B/
M4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]1B^Z"(]3
M4_S56_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&+[H(CU-3
M_-5;]1B^Z"(]34_S56_48ON@B/4U/\U5OU&+[H(CU-3_ #56_48ON@B/4U/\
MU5OU&+[H(CU-3_-5;]1B^Z"(]34_S56_48ON@B/4U/\ -5;]1B^Z"(]34_S5
M6_48ON@B/4U/\U5OU&+[H(CU-3_-5;]1B^Z"(]34_P U5OU&+[H(CU-3_-5;
I]1B^Z")V*4I0E*$))*4D24I21)2E*2[$E)%V(B(B(B(B(B(NQ!$__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img39825204_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_22.jpg
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MEK2UMK?3U-4U<Q@9(K,C,5%7="0S,C1"UB9!0V&7L;+_Q  > 0$  00# 0$
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M1 VK"Q<M?I?XEMB/-H;8!/Q6Q]13:'NQ)64N&BHAW:+HR>--@XS '(F3GO\
M=/[ZUZBEB,>LJ*1D0/R:X*>JX-P.\D$DW$B-IM,X0'*]-JK*2@8_EG+U 0]-
MEL6-QU0186(YWZ1M3@3JJ7;!OL^![5VUKV;R3D!K;<<UDP:(IAR;(1K,/N%F
M !P=O&]6" RAU@\VTY2:R[9HO8TA<QD0-B!HJ4C8T:*;\K78+BRJRA&4 M<$
ML4N3=[VZO8I4 DD $DRFIIJ;/Q$J.CM52HS!;$!!4L$"TP+@OR9P[6 4DJ !
MW*&\".)< +P!Y%2>[AT?@SG3!M_ \G$I>1#8TWX_$WY[4^Q=AI/82XD!*81N
M1$+R!90%((X!/%F0I:0 2B(QD@B->H0U^&2V8RY9*M06=5LUK$<N8) O8B\J
M73:="F+5;)PSCUBKM1-Z;/=;EE//D0";$@V$X<WW/'B0;UJCJG(SN5G%,=(:
M:X]/,/ +(V\(ZUT:[VJ^AS5?*6ZBD;)C(E'FX).]=R\&Q$R86281DU#B<5-A
M$B*H:BH&SLE\WJ=I%F?$'L<7'5'5-P>88$&TI.DTQ7"]2W"IT3ROU*7$*CK4
MV -ZC'( ,"%*D$7DOZ+XL\:^.VV9_MW6N$U9F-B.Y@3+B2T&;%4&1F?R(=+)
MD693-75^&W7JAZ0#\B2PN2[*D$=8K$"'@D*/Q50Q;T/5J.BHV-EMS#=MA8 C
M+ 6'<H/>3+M*C0HU'J4\@7+$@I>Q=@S$-P^(;D7LSD<S8=EKC^4"->_.?5&7
M?P=6K'S>D>V2.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1
MEW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49
M=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7
M?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW
M\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_
M!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P
M=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'
M2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!T
ML?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+
M'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q
M\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?
M-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S
M>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\W
MI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z
M1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D
M>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'
MMCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[
M8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V
M.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MC
MB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8X
MB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(
MO>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+
MWGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]
MY]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>
M?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WG
MU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]
M5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5
M;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6
M]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O
M9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D>4"->_.?5&7?P=+'S>D>V.(O>?5;V
M1Y0(U[\Y]49=_!TL?-Z1[8XB]Y]5O9'E C7OSGU1EW\'2Q\WI'MCB+WGU6]D
M>4"->_.?5&7?P=+'S>D>V.(O>?5;V3NE<2N*1,I9WJ[D)N&2;-V%*]&2,).8
M[/= D]4AW,TU"K!C.G>.'*:![K6A8HN*V$3D*NTMTLXT^DKLI-8U$(1'"+&$
MPI9\U;QDO,)K)#4T"JM0%2KACB^6=2DR7-UM@A( "DL06/E"B U.M4+LU(A@
M](TQE3P-*C72IA<.3G4 +$LJJIQ7^Z2T<R'C-R+<$>2$W8Z@P*K\O];<C]<(
MP$A-=?H*Z)>;0QA<?AYG83J\B6!$XW(Q$?>2G:R>KB4_-B#:0\2!#SC!94PS
MJ%2G^3!>PI-3:X5CGC<MCRN"";+D ".TKV2EJ-8FJPI@FO3K)B77\EGB%SYV
M*D"[X%B#8 ,.<V* #,P@(*&4=JO\Q D<,S?+VO9=[FP9HM<G:UKY9WLJYNE=
M92U\\[]?._\ JR_YWBDW)/>;S( 6 '< /0+2/=;^VC>7I89?D]J6I^M^#[*^
MKW^\MHSJ>[7YTWZ^UM'\'[I26*Q\[;,5G/=R>-35RX:YZMWEEFV750SRQ%P'
MJY9(J9)Y7QZ9[:_5O?&][=-K7Z.CIM:_L5]17HHVXRAAM#9-F (O4UE[$7Y_
MZG-+*OAQ]&E*K4I-NOOR6I5'IL1I=@6)1BI(OM\&Q(Y7 -O()IWQSWM&>2VG
M(CNJ'"CH2.3+*08CQDF2'HFVUX[)S45=]^I"R!1CCVSX&Y<-NP?+]9HJADKV
M2UU$4^A[;V17V%M/4[+U-2C5KZ;@YU*!<TFX]"EJ%Q-1*;\DJJ&N@ZP-KBQ.
MSO1UOWLSI+W.V1OKL;2Z_1;.VR=H#3Z;:::=-;2_L[:FMV56XRZ74:J@,Z^A
MJU*>%=[TG0MBY9%FZL5.[12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD
M12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*
M1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(D3ZW]
MM&\O2PR_)[4M9#6_!]E?5[_>6T9U+=K\Z;]?:VC^#]TI+%8^=MGSR#']6*?*
M+W[2K6YM/WNG]!?W1/ST:WX9J_UFO_%>>R'N3OF":)_N;1_.38-:S](GZ8;6
M^;0?=FCGL;X)_P 06XGTMZ/QEO!-%JZ5-BHI$4B*1%(BD12(I$4B*1%(BD12
M(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%
M(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$
M4B*1%(BD2)];^VC>7I89?D]J6LAK?@^ROJ]_O+:,ZENU^=-^OM;1_!^Z4EBL
M?.VSYY!C^K%/E%[]I5K<VG[W3^@O[HGYZ-;\,U?ZS7_BO/9#W)WS!-$_W-H_
MG)L&M9^D3],-K?-H/NS1SV-\$_X@MQ/I;T?C+>":+5TJ;%12(I$4B*1%(BD1
M2(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1
M%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I
M$4B*1%(BD3JD@G4/BI..!9%(Q0@O+G_@V,C'CK!-\:>679-,DV+6W66533=D
MAC-9QU+-D7A,:T56P<$&::UQ*52HKLB,RTQD[ <E',\SYP"0.T@$@<C+3UJ5
M-J:5*BHU5L::DV+FZBRCM/-E!/8"RB]V /.BR@XV,'&0[YJ3$EV+0F+),EL'
M+(@.?MTW3)ZT<)99)KMG395)=!9/++!5)3#/"]\<K7JAE*L58%64E64BQ!!L
M00>8(/(@]AE:LKJKJ0RLH96!N&5A<$$<B"""#Y1/W5Q*HI$4B1/K?VT;R]+#
M+\GM2UD-;\'V5]7O]Y;1G4MVOSIOU]K:/X/W2DL5CYVV?/(,?U8I\HO?M*M;
MFT_>Z?T%_=$_/1K?AFK_ %FO_%>>R'N3OF":)_N;1_.38-:S](GZ8;6^;0?=
MFCGL;X)_Q!;B?2WH_&6\$T6KI4V*BD12(I$4B*1%(BD12(I$4B*1%(BD12(I
M$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(B
MD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(E)^578/)7
MK4*..Y0Z5N1IT\QE#O9T,UD'4&0R7:XD5@BSJ::QVXR,E+RAM%SC%HSBS-XV
M9B"MKG$6#P@.(Y+0\J=8E>(@9%-,4:E9LJE.LF0%.M0*K@:BDER"6'5N 1A]
MIV-33HK\*J5=UJG4T=,N-*KIZF&5;3:H.W$%-P%IJ0$;K@$JUH];"V(37<$#
MC4F2 \7#HT/9(C3RLJ'IM6@9D@ABRE"[,<O)&MD\,>P/K#V*QA/JD56C;-SD
MCA!K,6K56:Y9JCDEDP-RQ)N@)"'O0$A?%!-IDM.JI0HJH4*M*F%"N:JV" #&
MH0IJ+W.54N.M87M.ZU;EZ*1%(D3ZW]M&\O2PR_)[4M9#6_!]E?5[_>6T9U+=
MK\Z;]?:VC^#]TI+%8^=MGSR#']6*?*+W[2K6YM/WNG]!?W1/ST:WX9J_UFO_
M !7GLA[D[Y@FB?[FT?SDV#6L_2)^F&UOFT'W9HY[&^"?\06XGTMZ/QEO!-%J
MZ5-BHI$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4
MB*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD1
M2(I$4B*1%(BD12(I$4B*1%(BD12)3?D&S*.);%8X-/3-R7D#:7RA@WP5X["H
M\'#!48$$?!VQ3:^IYL17S\(/$#+-B.3=$,UR\A7-%["VT7%C\AI2HIN[+3"H
M::$_ZVSLS&JP8K0KTU'(%238650JY%R<5KE8U::*]4NXJU%%]"E-$04490VH
MTM9CUF#A5!-WJ%W"BFHM#"F[EI#8DT>9*9NVT:!-W6:JH-PKDX1%M4ULE%XP
M*!QM93)3'*^:L?"APBF5[YBA;!CD@U2A5"#4J$=A=B/&'(L;<G9G'^=F;Y3$
MW)R-$$4J0-[BF@-RA-PHO<TU2F3?RTT5/DJJV [/5$N12(I$B?6_MHWEZ6&7
MY/:EK(:WX/LKZO?[RVC.I;M?G3?K[6T?P?NE)8K'SML^>08_JQ3Y1>_:5:W-
MI^]T_H+^Z)^>C6_#-7^LU_XKSV0]R=\P31/]S:/YR;!K6?I$_3#:WS:#[LT<
M]C?!/^(+<3Z6]'XRW@FBU=*FQ44B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD
M12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*
M1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$H?R#8K2#:@&
M+FQFPCL?1CDLDJ!$)Q\@&TFXATNKKL4.C8@M+-?2ENBQO=M(C92^.>)7,B2;
M-WCU0:R$M&64TA"4&=315R]-+-JZM D 569V5*J$GFB@^+8&PR+&877*:FI2
MDZUGIBG5J!ET-#5!"3044T:I0J +R=V_O%F +%54+;K6B+QOKF MR(AR ((0
MR,(O03QN#:.PSM((RP<"W32,LAL<:N&"N.;59L ', R"B620QDU98(H)X^M8
MUJI5@X-1R'!8A@6-F!<ES<<[L2Q\I)N9E-."*%$,A1A2I@HP0%"$%U(IA:8*
MGD0BJ@(LH L!W:K<O12(I$B?6_MHWEZ6&7Y/:EK(:WX/LKZO?[RVC.I;M?G3
M?K[6T?P?NE)8K'SML^>08_JQ3Y1>_:5:W-I^]T_H+^Z)^>C6_#-7^LU_XKSV
M0]R=\P31/]S:/YR;!K6?I$_3#:WS:#[LT<]C?!/^(+<3Z6]'XRW@FBU=*FQ4
M4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD
M12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*
M1%(BD12(I$4B*1%(BD12(I$IMRACD<E4AUX&+DW695[A9I'0;@%(C,50+.]E
MZI19G):L$.!6XP.47M;7+I5S=T76:3EVN!LDV'2%)YD-$[4TJLH 4$%F#(M0
MJ*-<E*896R(]]MR6](!KDI;$[2ITZM2@CL<F%J:%'>F'.HTV+U2CIBC$>YS<
MEBM8E.0J7GW2R+1OI[53=@6N>8M]<PINT-W8N1>19NA'!J2)'(8\7=/1V3M/
M#%?)B]=.GC3+.[=VY7<)J*YQ=02=17)7 FK4)6X;$ER2,@ #;O  /: !82=I
M !I-, _$ T]$!\2N0%-0&Q))6XYXDDCL))DF59DB*1%(D3ZW]M&\O2PR_)[4
MM9#6_!]E?5[_ 'EM&=2W:_.F_7VMH_@_=*2Q6/G;9\\@Q_5BGRB]^TJUN;3]
M[I_07]T3\]&M^&:O]9K_ ,5Y[(>Y.^8)HG^YM'\Y-@UK/TB?IAM;YM!]V:.>
MQO@G_$%N)]+>C\9;P31:NE38J*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(
MI$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(
MBD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B5(WI&%-D2L(D
M+A _9HB!(&F$P9B]ER/5TLB<I<J:_FT721D<47;DR#5<>S9G'\445P0S<^*$
MA434<LQ5KS],_!1LJAH&J5-,M12O3J(.+3?J5!B"&)45.[B)V93%ZVF=153&
MBNH6@'6J%U%335:50\&M3M4I$,05"N:1Y$\*IVJLL-KQ<.Y@$&<QT>*$Q]Q#
MXTN"%@G;<@#&AU0K)08P#/VB2#5Z*:,LD&X]VV110<M$T5D4DT\\<+1*V0JU
M0Y9G%1\F869FR.18$DAB;D@DV-Q>3Z!0T*)IJB(:5,HJ$,BJ4!548 !E L%8
M  BQ %YW&K<NQ2(I$B?6_MHWEZ6&7Y/:EK(:WX/LKZO?[RVC.I;M?G3?K[6T
M?P?NE)8K'SML^>08_JQ3Y1>_:5:W-I^]T_H+^Z)^>C6_#-7^LU_XKSV0]R=\
MP31/]S:/YR;!K6?I$_3#:WS:#[LT<]C?!/\ B"W$^EO1^,MX)FUL;D+O4?L*
M=L&.WMBLV+&92AFS:-I::1;M6K8V^1;MT$L'F."2*".&"22>%K8X88XXXVM:
MUK5XR[V=*G23I=Z=Y=+IM^]ZZ&GTV\&V:&GH4MN;0ITJ-"CM'4TZ5*DBUPJ4
MZ=-51$4!550  !-G%I4RJDHMRH/9YIKKP7ETIFVAVAR82$Q)C.4KD;7(H<(.
M2;_)LW4:600NZ=J*K721MGE9/"^?5PME?JVMTUO3X-NW=L[Q=&=#:6WMJZ_;
M&T&VWM:BVMVEJJVLU)I4GHBE3-:N[N4IAC@N5EN;#G(==0M0A0 +#D/FEQJ^
M^2S%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD1
M2(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1
M%(BD12(I$4B*1%(BD12(I$KC+82['3DIG$-\J:L*[7<I%2<4<"X.>>G# ,$
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M+,0(G(L19CL29PHI=$8&'7>+(V>EB*N.23$<V[5X[4M?!NBIE:]JC@$WL";
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MFS^U:O"K!LX3[3<,_4P[1%9?!3#KIYX*8=;&W6PRQSMTXY6O?6CI#!.]^UK
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M_5ZO\U7GB3X2_P >?2']::+[EV9-<NX/>YMR"^?$,^X2M?..EOX=L;]4U/\
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M3(?#\92_>7S6D*T>:I"%2=W%QUK,K-\;1:SM4J,S/G8E5.51U"@G%4:J6J8
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MVKM/93[E[3K/LS:&MV>]9=K:1%JMHM35TS550Z0E5J&F6"DDJ" 22+R\-*Y
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MT_\ FGF8KQ^F4GI=XM^;OIWYB!/L]>O?0Q\56X/V:V=_"F+J^^O](SS5O?\
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M_P#=F<ZKWM?IC]UI(G=1/Z]IWY(F7VV.UVOPR_SEN#^H[P?S&R91I/\ G/\
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MIJBK[GIZC6[(K;.2O4Q1JG!2I5%1\4+X V4M82&'8.&X9L&!\9;VO?OF2O\
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MKTNH;>G==EH:BA6957:V3+2JJY"WT %R%(%R!?M,E'67!'!?F+>,G_%-2-Y
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ME.UNF]K=%NGV.FMAVZ6-D$$?V;M#F"/&T_E'^\GF[3\!G?Y*E-SO=ND0CJQ
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MA020.R_+SD"6ZE6G2 -1T0$V!=@MS:]A?ML.9[AS/*=I"S&+R,D7$ 3H\N0
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M.B-51551961R22CA@5%A:Q(L5O>Q\;R$&P8VZ-2H]1@72I35 !4IE"KMD>9
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M1<#K?W\@>5R,;<HBC4J49ZA(RI# K24$/[[G87NE[4\&%R #F"3-(JCR9,A
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MK*2\0ERK9S&U]ID6*.O-AP0IDJ.66(%W+=N@/<U4PI5@4-1BR !20X6SY%;
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M2IA6/:5P&)/G(L3*-[7BX&8\AMT$ >G.;&]KQ]Q (U.$]4<HW6E]=0.9MM?
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MC'T;3Q-"$F#LP@X:-V#IVA13#EOR=\K'L[O+?R6/98\CR':1+E8T@GY:V!(
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M^'AQ <W#8DR-.8/"#,?A+Z^:*4H1; AI@^&$LY"#4(55@]U+,&R1;6J"H>0
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M\!@YE)@RR[Z0%524G'$(T!D'5'!SS&1&5@E5-2R'E48*X.--06!(/6)YD V
M[+$CF00+T5WPJKSI(6ID%ZSE48!AU%7D&87))+ @'L8$V[=W/_&!XZ4D%]<A
M(F,CM]L3M+$IK6<'=B:AEKIFH,'WD.G9-($D75M;I-&C.-AHTPLM'H,]CQ2#
MQEZ2 1T<2=\5\LQF6O@O)U"N+W-G [6N22>UKAC8D@<Z3'A' +;B/S1R]-NS
MG38\\+6 47"6*J2 #/P<M=GH:HVEHDZS):5UY)BL4W3'AFZN0TX-0[5T:#.W
M^H"!O6O>H]<8.E$XV0]%QZ2QH,3D0!9$/JF6E!SEYDQ=#W/-)<TJ"S, 4."
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MP.1ZO)%8(7.2]6Y!%AS>UB3C86/,<ZEF14*X@\0 U'IM4%(%7Z^*D&Y][OD
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MF,90)5>12-Q)^N$8&I84"N,#S,L+%-2'-$%LQ=K8@E44,[6=;6!(M8\R1<@
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MP+:CQW'=4\@-'Z57@DE0ET3Y$;_CF\R\NV>ZD,,6ADDA.(G<6_B,98!8\SV
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M+D];CK <28EU'#;HH/R!7:CJR6+4W:XPX=,H5'ER)1 01Y.L;\[CRQJ%-DJ
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4D12(I$4B*1%(BD12(I$4B*1/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img39825204_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img39825204_23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6\(:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E!R:6YT/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @(" Q,S,N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(Q,38P,30F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(# W+4IA;BTR,#(Q(#$V.C Y.C V)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(# W+4IA;BTR,#(Q(#$Y.C Y.C V)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.^* HB Q(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L;W<@
M,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!#86QI8G)I+4)O;&0F
M(WA!.R @(" @(" @("!#86QI8G)I)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!#35E+)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B
M965N(&9L86=G960@9F]R($-3.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I
M<R!L;W<@<F5S)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=);6<](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(Q+3 Q+3 W5#$V.C Y.C$T+3 W.C P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,2TP,2TP-U0Q-CHP.3HQ-"TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3 Q+3 W5#$V.C Y.C$S+3 W.C P
M/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O
M;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @(" @/')D
M9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW:61T:#XR
M-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG
M.FAE:6=H=#XQ.# \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @
M(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!
M9T5!<%%#;$%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!
M04%!0D%!<%%!04%!14$F(WA!.T%10VQ!04%!05%!0B\K-$%$:T9K8C)*;$%'
M5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O
M2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS
M8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!
M.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!=$%%04%W15(F(WA!.T%!25)!44U2
M068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#
M=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%
M04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9
M155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS
M4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R
M>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D
M;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!
M.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%
M0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2
M-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#
M:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD
M65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%
M:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N
M<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&6%EQ.'HX-S9D
M-3EU+U F(WA!.W-D>&]6>&,R*VYA9G Y=&1U9E9U;'1P2DER;61P649G:4)H
M;FQL44EP5FE#1F]F1$I$:WA.,C-P9FTS.#%*3F(P3S$Q2%1,4T=W=C<F(WA!
M.V$R=6(K65=7;VAK831*-7=+,&8Q:4]'4T551&5U5D9F1$=G=&QB+VE0.#!O
M9DU/;V%F1&%R9%%(53=H8E8W:E0W:%DT-T-/,4TX4$,F(WA!.S5J94]*+U9D
M1$5#4U-R+V$R6E9$45=Y;$5N-6HO;D9(<#%L3U!,,$TY>DY)>'59271.,5E'
M2TU#3VM496]Q56LK3G9J0F%-,#8W8G0F(WA!.T)&;%=4>F8K8VQS=#E#3E!7
M.6QT6F)T>$Q0<&PP9V1%=DEO25EO=E-K4E=":&Q-<7-/6'=Q4G566G-A0V)+
M2F)Z,2MB075R1T4V1D(F(WA!.TA'56TK=51Y5T]P34I8:G5P65971EE234EE
M55-*25!78FEE6#)G36%#,EAA6#5R+T%$675T9#!*3E-S:%DV9$I.06138414
M8G!K360F(WA!.S-:*W-)<$]B=3A::&TO9$Y)0T96<48O:%5Q>E%7>3E6>4Q*
M,DMP8C5L,4,Q,#=13#8O=3<R5%0W93)I85-3.&A%8E-2:&0V;W-Q4V\F(WA!
M.U=044%Q8U%P95@V;#4R.#=P*U8R:V%T<#)Q=UA7=5AM<&5J-C!1=%HK551#
M85-/,VPY2E1#2F5#;T@T055/4W)D:F5Y6&%8*V0K=G F(WA!.W%/;S9J95%*
M3G!&.%E(,&$Q=5I)-T]+,FAC6%!X5%A#>%-S5VPK<69#1W)5;F%M2&A2>$IR
M3BME3W-Z-F)C,T9L-6930GA"9%!A=F,F(WA!.S-,3U).85=K3C5)<W-+>$DQ
M0DAC0VQ(,TEP=#%!-%4X4T@P-S@V3F5T23<K9E5B2S(Q0S-L;FYA=VY3.&ET
M-&M%1G!B5'1!2&%*43 F(WA!.V8K:V-K:UII>E9P>#99,'1P+S5J+T]&9$<P
M3%%D5D=N47IJ5S=793=#3F1007%E9VMB*VY'>C(O2U(U4%5O;G=,52]01VQ-
M:W-V=GHF(WA!.S5A,FPQ0E P3$9X<U1+1#9T*W-4<4ER:U<Y3&A$0U1%-V<X
M,%)E8DU"=&IW<GA+.7HK6FYM2S8X:BMC.55T:%I7.2]O:WI286596D@F(WA!
M.V0Q:&)J=VQL:6UJ<41W67-H6E%(26]65VTW4VLW25A4+W=!,CED<V8P<EDS
M5VYR9C-/:D,V:W8W<3<Q0S-H6"]!16%D8F)H13979'(F(WA!.T=W85)G5C5+
M1W T;6EL<&)49GDO*V%D.7%-;79813%N82]5.4TP<416<D\R9VUL3C-+<C(O
M<D]O5U=/4&UV26-E659A8F)(;'-+5S(F(WA!.TPV9BMF3W!W:2MU3'5Y:'9O
M-6)M5G)+3DQP56I32T]',F(V=&)Y<F(Q=5IM86-N:59".3A00VII5%<O+T%$
M,VQT<G4T=$ED1G0U<%DF(WA!.V(R4WI$3G%C345)5TY78FY*8U-X<F)O>FAF
M:&HY470Q0F]A5F5&4$4Y6&AK.5-*2DMC96%H=4Y1859&8595:T@V36EY6%EQ
M-T9867$F(WA!.S=&6%EQ-T9867$K94Y5+S5Z1C!+=S%+-W-8.'0S5'1A5%-1
M331U27='36)L4U(X2&5M2V]B+V]D4%%0*W!:=78K:VE0+VUJ1EAF.$$F(WA!
M.U$V96=F.5-Z9&8X05-22"]!33!9<3<O;V1045 K<%IU=BMK:5 O;6I&6&8Y
M1' V0B]W0E-Z9&8Y2D5F+T%$4FER=CA!;V1045 K<%HF(WA!.W5V.$%P26HO
M04]A35966E K8WIV3&EW>'5V;#8U9#,U8S1H3V=+57!3<$M53F9B1E9,+V]D
M4%%0*W!:=78K:VE0+VUJ1EAF.41P-D(F(WA!.R]W0E-Z9&8Y2D5F+T%$4FER
M=CA!;V1045 K<%IU=CA!<$EJ+T%/84U69"\P3VYO2"]5<S-8+U-22"]Z4FEQ
M92M89CA!;DQ$>7)R5W F(WA!.S9F<'<P=6$S;C%#84\S5E=K-6-(;&-)=&%2
M,%!8>'E*2G9K<60O;3$O=T$U0F%:*UA/=3)U:UAE:GIA:$IC,G=U:$Q&2VM9
M04QS;D<F(WA!.VI+9C5-:W)"+W=$;V1045 K<%IU=BMK:5 O;6I&6&8Y1' V
M0B]W0E-Z9&8Y2D5F+T%$4FER=CA!;V1045 K<%IU=CA!<$EJ+T%/84TF(WA!
M.U9D+S!/;F](+U5S,U@O4U)(+WI2:7%$=68K8W902CEZ<59N<6,S;$\V92LP
M.5I5=$IV<E-J9TQG2TI2>$-H5'E#1#=14'1I=$IN1"\F(WA!.T%--6QE6#5)
M2G!F.%!4;S!10D5B6$U96C8O>2]",G=&5D0O;V1045 K<%IU=BMK:5 O;6I#
M<G8K:# Y02]W0W!:=78K:VE0+T%*;W@F(WA!.U,W+V]D4%%0*W!:=78K:VE0
M+VUJ1D1V*V@P.4$O=T-P6G5V*VMI4"]!2F]X5C,O439E9V8Y4WID9CE*168O
M3D=+=EI0>7<O34]Z."\F(WA!.RM622]-3G!A=EI2=DY*03%V27=D;&%),"LP
M04)U0T1I<DQ-5F1I<G-69&ER<U9D:7)S5F9M<#5S+W=#57 Q:B]!2FIR;B]K
M.#)+57 F(WA!.WA6=D9867$Q:7)E2W5R:7)S5F1I<G-69&ER269Y-B\U5"]Y
M,R]W0G1/,"\U4')I<C%V.$$U>DHO.&U&<%@O8DU4+VLO2FEH-$AI;#(F(WA!
M.TMU>%9R1E<X5F1I<G-69&ER<U9A>%9V1E@R>"]Z:5(O-4M29BLR:&,O<51&
M1#)J1EA9<3=&6%EQ-T9867$W1E@U<65B4"M5<#%J+VTF(WA!.T]U9BM4>EEP
M4VY&5SA69&ER<U9D:7)S5F1I<G-69&ER<U9:1BM84VXO2#-L>C(Q2S!0.$%Y
M6%A&6')8+T%$;50O=T-40S!R+T%,6FDF(WA!.V8X;C5C55!!.%5U>%8R2W5X
M5C)+=7A6,DMU>%8R2W5P:7%,,#-4<FDO=EER4T%6:VM93%AS050Q4'EY>D9I
M335C25EZ:TEI>2LR+RLF(WA!.V-9.4MM,'(X=%=S<%=$=$AQ1G=1-#)$0FQJ
M24](4&A/3UA#5T]024II=SEA>7!M-T9867$W1EA9<3=&6%EQ+TY4>EHO>6Q/
M<V8X>#$F(WA!.WHO>65B1DM667$W1E=W<DA906XU67%U34UO-F]W*V<T<71+
M3T]Q;C=S5F%P:7)G0V5G>%9E24IJ,&I9+U%C5E=L1T)O=TE)-F=I;4LF(WA!
M.V\O4W1&=F13;CE+,5%U459$,#=":E1K9EE:9&AW4WE'9S$U36=J>F5O*U1R
M9E(O3$AM2%$W2E=7-#%/-S%#,$1"<45G3DUG2C)O44(F(WA!.U$P.3@R95--
M34=->#5Y3&AX37-S-S520V0O.$%/6D@O04I-2%-V.$%T;4HO>69K>E1/93A$
M>%,W1EA9<39H.$U69%1&6%EQ,G%/>&\F(WA!.W%L:C1!5GA68S%V3V]Q,&)!
M94I"1TMR47!X5DAA2$-S;7)7:V)R>5(U541!.4M6>3="1S5G3E=5,45L-GAP
M;6MA5C5E<UI3<F-9-FTF(WA!.U-785%I=$%/;&%$3VIX-%E9;VUU5'%P-4I:
M1'4K:68K8V1D6&HQ6#AV,W5O:%-%6#EW:V9I46]48R]4;6<Q;554>45J:S=4
M0D%X:E(F(WA!.V5O6FET<G-69&ER<U9D:7)S5F1I<C@Q4$YN+TM5-G@O>DA8
M4"]*-7-5<%=I33="5D972F]!359:6'!8:W%A5T583GEJ*VMV>%-%8DLF(WA!
M.T(X-F(T;UIJ-54X;C9.8W1-,35&2UE9>79'4DYO<5 P1$)2>35%-'%M;FU$
M>6PU93!Z5V].3V1,93!U<&Q744ID6%-2<4EZ5&0Q-3@F(WA!.S%/+S)446YW
M>%9N4&PW>4(U2G8Y23%'85-A>G5',"M26359-UAO,%)P>6-/>&9F=R](1E8X
M4#5+9FMT8GI-2G)M+VQU,E0Q<E,R;' F(WA!.T=*1%-T4#=N8U8Y.%99-35W
M.'0O;')O2#%Y2G)M>FAE0D]A4E,X<$AF8T-I:4DX:E=T3VU+<UHP*R\X07EQ
M;3!Y,VMJ;6EK,4]2;5,F(WA!.V5W84MA26]+:TMY=DHK-V%O<'1Z<G8P>%9U
M+SAS84MI=U0V4D$S-E-U4S531S126&IJ:59U4$Y"24-N4&U#0GE*,C=D1&U.
M>$=C>4(F(WA!.SE-9G948517.35R;6U833!5:TUD-4MY=$=K:G%%;%-4:65!
M-4IW-4EZ.&518G0Y;6TK6F5$36-"-&\W9F,P-6-)>4-I:TAK-CEN=F8F(WA!
M.WI,,$,T;D9*6#%3,#5$9F(Y*W4R-4]3>3543UA%5V-)0TEO4%0O.$%N36XO
M04UM1G!8+V)-5"]K+TIL8DHT5F%78SDP+T-)5DDV;G,F(WA!.TU5<#=B959Q
M8U=M-4AW-TM4:6AM2&QF.',Y4#%/2C=I96)G:5!X36-90EEB5D9386I&535I
M+TPW>75B<%E);G4U>E5P=VI65S-'+S(F(WA!.V=T3594>3@O24<S;3!L-S=G
M.6]N<&E:5FQE3C5':4I!16Q%1W=Q4C-R-UEQ:V9L9CAG-TQ5:DY*8V%G<V%W
M36EP0TA":VQ:>E1I;T$F(WA!.T\Y861C5E17-B]*<E0Y3F4X:"MP6$IM<S!E
M4V-#845C5FI8;7A.5DA29#A642MN9FQX-68Q1%%O.59H85)R5U-5471*2%!&
M27EY32\F(WA!.W!Q<G%Q<U9Q,G=Q2UI#8WA%13EY:FUX6%4W3%1R0R]L<W9,
M,S%A-$M-43$X,%-Z5$U"<U8O9DPV64A)5DA&064Q5&Q/2T)M0DM86&\F(WA!
M.VQ+;W)/4RMU>51B=U$V>$%V<E=%,71'<U5C.&E%35EP-&QO9TI52&=Y0F0Y
M;7)7<3)X>65#4DE'=T0Q4DM(14M3=3DX*V%Z9%<X;'0F(WA!.U!(03A5:6Q'
M0E$Y1"]S<S)E5'1#8V]M2D$S8V%/;&E$93<V>2]W0V-3:E@X<%8O-V%&,2MP
M37=(2EIK;C5O865T+W(P33EJ3W1P;W$F(WA!.VU73S5J<$EB;4-'6#!,>59%
M*T=I,C!O268T:5-.>'9T:'!&<%!Q,S5S,V%H-61,='=)>F)V8WAX6'-"4FA(
M*VI,>3EH8FQ(8TYY.5(F(WA!.W)25%%Q<$-';C)V<VUK16\P9FY*;V-C-U=-
M=&QD5#9L2#9#;3-T1W,U+U5K;FU7,U950UA,1TTK;S0K0V)G,40P=U5N:51Z
M5&905VXF(WA!.V%L9%171G9B>GAA:F)X,V(S5G9-<V8W:')34EEI<W!34C$O
M948V<'=*<714=&I3,G@K>2]/6%-)+TQL;F8V;F$S2#9283)I;G9B5S$F(WA!
M.VI1.&5D<$1C=$MI=$Q8,%<K<TMQ1717<&]E*TY+0W%49FY2;TYV-F]U.4HQ
M4S)E3U-A1&A*2&)L;6YT<$EO-5E6-%1T.%,O5T5A=C(F(WA!.U-/:')T:E,R
M:')N.#5B83,Q<#1P9$YU;# R,6=L1W!P=VEA-71B;4LV4S-0<6Q:>D59=C-G
M4#=S<V1X5'9J4S(K2&9.;B]+539X+WHF(WA!.TA84"]!0V5B07ED-69G4U,T
M9#)P.$%&2RLK2W9O8E1B5%1T5S!U3T])4U%7-D9"-F)R>%HQ6&-E3S(R*TM%
M9R]-:E5.4#AP*U4U1C F(WA!.VTU;'0Y8C%7.6]%46AL4TM"5F1P2W1U<DUZ
M,$9-5F5$,TXQ8UA--WHS17)45%-'<GE/4WI%*S5/2U4S.'0K9&9-,VQP<'IO
M,39B6DPF(WA!.W!E1GA%5E-22%AB<6MI=71D=6\S>%9M,FYF;3,U;W5).50Q
M>E<W-E=7-VEI.412<&]O3&8Y,6-U<D9D:7%R>$90:3)*>%$X,'4W>38F(WA!
M.W4U,VYU6E=M;6M*6FYC,4I*3E0K2GA3;V=K67$Y>3AL-C,O:7IY6%EA8GE3
M2'I";S!O=$5U,T1"1W-74FU8;G=$2&MJ<4)8:G9M2UDF(WA!.WEH37EI3$(V
M9G!4,%0X95=,0WHP-BLO4W)*8S-*16LQ=3A,3E5-1BM&:5-%*WED-D-V=FM:
M5&YK,D%-4C%T04QY3'EZ0VMF-6PK6$,F(WA!.VUW9E5R46ME+W="65A->$0P
M;B]N36HO>5E7;&8Y<WA0*U0X;4MV3W9*0V%D0F57>C-Y;&]#03-W06LX>E%I
M;SA-5F5R-GHU6G5.5%,F(WA!.T(W4F]O-#1G>G%'<4]4379W13A19&=C5EES
M3F-N.&@R0S,Q.6)#-FYU,FU&;&%.+V-Y3W1&85-7;D4P5&QS0C%/2W-3="]Z
M<R]-93 F(WA!.W9,<35S3E13>DXP,THT;W)A,C1$86=#2SAB8V1V1$9+9"M8
M9GHY.'DR.6Y.<"MV;'14<W!G2TUH155Q;FU'22M(:7!5*T=+12LX<68F(WA!
M.VUP1&1A;G%N;4,T=#%S-V)35FEU64Q&2%943459:U)H:5!T;FHR>%9G9FUN
M.#-V3RMV6"MO>G9Q36QV8F%J>E-7,6HT<41%*S-":4$F(WA!.T-F:#)/2W-B
M,$Q8=%$P9E5B83ET2FY2;TI9-6I'1TE6:D=W8T)H,%!4=FM:>$5G465Q6'0P
M96LV9'%N;$]X,7)Y.6).1'%9=791;FXF(WA!.TI6;&QH;E(U66YO<DUI>4E)
M*TUQ.6TY<4A+<V,T:C!K*V],4V(R6&MR5%ED3VAV-4QF-G1F5W=,5WIS5RM+
M8TME1F5X5E@T;'-O>C4F(WA!.U!%<DA$8SEF24I!<FTK94YA=%)B,VA!6&E'
M1E-0971$;6-H.6MF.$%/2D@O04I+4F8K,FAC+W%41D10,2]+,WE!;VE#84Q$
M1S!D43 F(WA!.VE'4EI*47IH,E<T9%=$>F=S;W%*4W=W,E551FLS:T0X=C=+
M14Q084IB>%1K5W%E<F-Z2T=-.&-T<6M38W!/<E(S8VMA2U U=F@V3%(F(WA!
M.W-R4RLQ+TQ(>5)A,VDS:T=N<W,X8VE44FLS3GEY;S94:3989VI3;$9(<G%(
M24%O5#$V;D<Q<$AA8C56=$Q,6'1D,6=S2DHY8TU!;%4F(WA!.TIW-%(R.$EI
M0SAU4C5%;FM39'5W<'181S%P3%8O3%!Y,F(V95-70EAS2DY-='1(9W-L.5)#
M;'1A=5@K2UE0-FIL<5)I=7AO9S8T,G0F(WA!.TQ032\U6"M83F)S2C15:BMQ
M6&,P.&QY3'-.3$IX:W5*26YU1'<Y4E(K.$9U<2\U4%599W)32T@U82M3+U)N
M:$]N;#%U63-I=5AE-'4F(WA!.TAK;%=39&)H>DI),&AD;6%607A9;FPR<E1'
M,7 K9EAM>B]L2V19+S5J<FXO04I03F=:2T]I6'E7;#1$3"]D4T1I+W1V<V-6
M9EA(:T@F(WA!.U=T2VYT3%E06G=8560T231N6F\P3%)S9FAQ:$YE2D9C55!/
M9GHS<VUN.&LR,#!7;F-M,#8K6G)R56=O+V1X>F]%4TYM1RLW<&ER-2LF(WA!
M.WA3-T98<2ML9C@T*RME3'HX=4PW>F1,8U%7=6Y1,C<V:$194U!*-G-S8TM-
M-TYW0T91,T%F0E4W*S)+2&Q'2UA9<2MI4'E,.'4R,&8F(WA!.S5C>C9U.$MM
M.'9T5U=#1U5J-'93:6EB:V\Y=51$1D1*4'I4=B]+<393.&UN5W)X15)01D5:
M4T1)6&8X06%88S!P:7)W8GEV3D9**UHF(WA!.V9L=%DR-4-056).5U!B;#E9
M56Y&3#!N+T%*>DHO=T1*:&%6+S)Z12\U4'E9;UE8*U5D+UE.<3AD=F1+<E-#
M3FM4;4)3<$DT:V9Q>%8F(WA!.SE)5VMF;#(U,$=71TLR.4158F%0,49D5TI%
M<7%F:G%+-T56>%8T=BMF=6<V:3)G84YR84]R85IB>GHR6FI*4$Y*6#1Y.4]L
M1T=+=D0F(WA!.SA5=7A6;5@K05!03&51<%!-0C Q,#!',FU$=$]6-'5W8T5C
M*VQ74F%D5#!R:6AH=4M867$Y>B\U>"LP6%5H;V5R-C9T=S!D<CE:9W,F(WA!
M.S!G5FU(2BM%:FQI3VTR=WE%.%5*+U5!5G5N<$@U:'A*66%F8U!(<4%V6DDT
M;E=9:FQX0C9!2W@V-'=X4FHY24$Y>4Q,-6,X>G-494DF(WA!.T1U>%AM9FMX
M3E Q5GEA6#)"+WII4B\U2U)F.$%T;UA0-FMX47)*-5<O3E="63)%,F]Z=WIX
M<2MR5R\V4TAR354Q270V5G$W5%5H9'(F(WA!.T]M-G-G<'-7-5I+=WAP1&IY
M:BM:.7AD-F8Y9FEV8FE'0RMS8FUW.6$O:6MJ=$E)3E%L;61B>%!72#%M5EE4
M1CA95GIT44XT=&A&1FPF(WA!.S,U5S90-3(P*T\Y4&UI-74U6G!%9T%J=5A7
M5U Q5C4K<DI"2CEB=D=O.5)58TEL-F-51RM!<&IB4$U$2C)+=7A6,DMV>E4X
M,F8X<%0F(WA!.W)(+TUD8R\X;FUX4VQ72W,W+TQR.'<W:GDO9$='8S@W85%Q
M3GI3;%!F9GAX42MK;"MO*UHO265Q86E5*W0V4'%-6G1.5V=H,VQ6:'@F(WA!
M.UI*=W9I:DUR53EV9D98>7@U;#AG83-O*W%Z5VQV1$QQ3F]H2&]8<TU,.%I&
M24)"2VIK5D\Y0T1I<DMF>30O269Z9#5N,4M".5)G9E(F(WA!.W1'0E8U<GDW
M46=S=DEF06M22W53=U!Y>%8Y5C9S*W$R.6AQ6&Q30S!G3VMT<'-S5G1D;50P
M;&1N46]!1V)K0S0W<BMR1EAX5C5G+TPF(WA!.W9Z;F]L,TI$96%,94I'<%!#
M9C!*1VI:97A6=T-P*R]&2W0U8R]++WIV<G1W:3(K:S-%1F]D-4Y1=5EN9W1O
M,4(S3%-Y0E4K:71C5F4F(WA!.S8R97!A6"M82&QI,7-B<3EJ=7)M0TMK15%)
M54E:4GDY6&-M:&-B*S%C55!#=D]F;FTX,38V66HT270Q2&AX4%EE,DM53"M8
M6"]+9BLF(WA!.U<O.$%T<#)N+THY8U9E="\X-6LO*U1#,'(O=&U*+WEF:WA1
M.$AT-35)2E9L:F)I>3E#355V9%!Y>"].0DQQ*W-T4'95-4=A4DE7:S4F(WA!
M.VA30DEE0D1K.6I8-U=+2'%0-6<O;$,R=3)5;6QJ545J<TIL.5-054%!.%9V
M2VQ857I!3G-$.6=T6'9I<C5Q.'AF:SDK66UI6#AT<RLF(WA!.V@S;#=!:"]D
M6#EL0DQC5S!Q;F-.2$Q'<%4T<%)V:T@X<69.5W K87)',3%,4V)Q>'1U66MC
M,W-,,C9/14E01&Q+1DAX66]F669M,U@F(WA!.W W<GDS-6\P=3<P:6%+,6DP
M>3514S!00U5.17E-;RM%06).-#1Q+U V94=31U9O-49+3W!O5DEO4FEL=3-T
M<FDU;5=',VIA85IZ4DDF(WA!.S!"6FEF641&6#%F*UAC9&PU8R],8E,W1%5)
M+W%Q4DUB,C4Y46A';G5*4E=L1#!20CA03&9&1'EN.'@O>D=T-75&<&%R>5%%
M:V]'<'DF(WA!.T\Q0S%/9SA-5F534WEV3$DP:V@U3S5,350S2GA3*S%V*V-3
M4"]*4TPO=T)T0S4O56U+2'1'2W5X5C)+=7A6,DMU>%8R2W9Z53@R9C@F(WA!
M.W!4<D@O361C+W=$2C5S57!6:7)S5EI2-50O36YZ6#585C P=35P1$E'5U-'
M4W))47<T:U5Q359:5%IF;E)61D]O,DAQ>DQV>E%G9C F(WA!.WA1;3!(-2M1
M5WE..5=T6F]86493>7-!4T0R3RM+<DQ8."]P;VIB<S%S+TLR:SE73&I46FI3
M=&%K,2MY359:65 K8W-*;S13<U9S638F(WA!.S=M3DDQ<%=G2#=69D1&5TPK
M8F8K8VPO365S=TI"1D-!:V)C;$5T06])<G9X4VQ4=FER>7)8=DUE<F$W95!D
M-FI-6EI88FMF0W8P,7@F(WA!.U-L;4MS:"],<B]L4"],9B]!1S W5"]K*VU+
M=E<O=T1N36XO>5E7;&8Y<WA0*U0X;4M(9V5+5E<Q=3=I,6Y784)Y:VE';TDY
M<U9E:&4F(WA!.U90>G0X>39)6&IK26UG;$1,241Y645-<%AD4S%$,7A1.48P
M2"]N274Q=&)+3T4S<S!(1'!%1DE55CA!95=+;WI54'HT,$15;$IU3&TF(WA!
M.TMA-CE-4G!C>DI6,%%'<#0W9T)J6')41E523"ME5FIQ=6M$4W)V5U9I=&U2
M;UIV,VEH;E(Y<4TS9EDP>%9I33)H9FQ093!L=DPK,VPF(WA!.U X-C-#4G-2
M6&]A67%I3%A5=GER.'1X33)M9E97=4M':WAL17-T1#%O,V)B,GA6:#-N=C@S
M8C-7,VET-U)%:G1R6D9H:6]#1312:FDF(WA!.W!!2G%7<#-0,UEQ.#-D,F1I
M>D5S>D=P2C9K-'!A>%8Y<V8X04]*2"]!2DM29BLR:&,O<51&1#)J1EA9<3=&
M6%EQ-T9867$W1E@U<64F(WA!.V)0.$%L2V19+W=#638U+S503FEL05%M,E!W
M>DM62"LO13-0,TA&5VIB3V52:DEK5F1Y>2M(>4Y$:7%L5$9867$W1EA9<3=&
M6%EQ=6HF(WA!.VEK:UE*1W!::C!!1F-65C0W94)#-75P47!59D1';$=,2'<U
M0W%J1E4X+TPK4TYV4"]L=FA'14$Q3S W:VXK+UAX3TMV8W8X06Y*='0F(WA!
M.T-8.#%T3D]S.&911VE39E9X24=A23-"95E20U1J.%%8;#,X858R<FEH.#1Y
M=$=S>G!.0T9913$Y36Y9*S(W3%1&2W<R-%IV,TQI460F(WA!.V%F6F(W:C$K
M:D9616=G,$EO9D1&6%EQ-T985GA6,51I<G$T<3=&5C!C56MR0EDQ3$UE=WA6
M6$9T1$='*W-39TUV*S9K*TEN+T%'42LF(WA!.T5F9FER-U(O-7A-35HO2UI3
M:6Q6+U-&>E%%,5!235506G-69&ER<U9D:7)S5F1I<G-69DEM="\X-&EF;5)F
M-C%F,S!/<&%-<U8Q8WHF(WA!.U12<3@Y,$=#>5-&:'E!=&E+,%!J:6Q$<"]W
M031B+VU-67ES;7 V37)J9%=7939.9EEG,G=X47!J+VY$9CAZ=V%J5F1&0CA2
M4&0O.$$F(WA!.UI,:6Q56"]N1#<X,$%A='%E:'E6-C@U<F\O:CE6<FEQ-R]O
M5'(X=S-(>&%H;S!:.%5U3&]J-VUT9C0T;U=.+WIH<BM9=C=/<F%0.$$F(WA!
M.U1,9&8Y:RM+5F\O-7<Q+TUN=G$R:F8X04DV-B\W2G-65D4O-7<Q+TU)9F(Q
M8E-$-T-A-4@O67-C54QJ+T%--&4O;4]U,%8Y;V1F-7 F(WA!.TQI-UDO9#E6
M07A65"]W0VA09GI4,W!Q,FEQ1#%#>C-A:C=H831P86HO=T-C3G9Z2C5J,616
M,%E*,S1Z6%)0-#)W>%9-+TLO+T%$:5HF(WA!.RM996LK861+,5=B561)83%S
M3'E#-6M22C=L<$-K56=C:&$R>6IL465)>%9N2#4K+VM*-7<O35!Z5%IA=&]T
M-7 Y=F)7,6UT<S98:VLF(WA!.S9/6$5J=E5#3T=956\O:FEH-3-&+W=!-&8O
M;5%Y96YD86IO>F]".$5I5#-8<4Q4;TMM,3-(=&EQ1U X07IH="M:;U!W-G!O
M=$(P4'(F(WA!.S-94"]!1D,T<78X02MH4&9Z4W)6=%4P4B]W1%=N=7HK=3%X
M5F-0.$%N1&XX>%=R>C%(4FQ08FAC6%90=4YR+TA&5FHO05!/1W8U:R\F(WA!
M.W-A<F]X*V,Q,% X07-73TMR4#A!;U1B.'IF.$%Q-F%*+W=!:C=V.$$W2F-5
M=2\V13(O33<O<39A2B]Y4'4O.$%S;'A1<4HO>FAR*UDF(WA!.R]W0S-Q=6HO
M04-7838O:F)9<790+T](9C5J2U0V9"]O<D1X:W5,<VXW:&%G67%T4"]/2#,U
M<6)G871O<6<W14Q09$M$.'=,55EQ,6(F(WA!.R]W1$]',S5J97%V,6I63DA%
M6#=8<'I84EEJ,G)B05EQ*VEF>5@X:#9P-4@X;&I1=%-A,F%D3&U76E1A4$I*
M2'=K0S!Q,&E235<R,RLF(WA!.TA&5V0T<3=&6%EQ-T9867$W1EA9<2]/6'I4
M-6LX>$HU;C%D13%3-U96=F)K2V]N;$%!17)504%B1DYP6"]I9GI*+S%D8GHO
M<$EL+S4F(WA!.W%X5WDW+T4O;50O<38S;B]!16M3+W=$3E=+,EAF-&XX>68X
M058Q=E K:VE8+VUR1F)D+VEF>DHO,61B>B]P26PO=T-A<U9T,RM*+TTF(WA!
M.VXO5C%V4#A!<$EL+S5Q>%=Y:6(W>FHU:'5B9WI,9C-&=4-!4%1I;FQ#-T-N
M5&QG07!B2T@O=T%4*UI0*W)R968Y2D5V+TY71F)D+VDF(WA!.V9Z2B\Q9&)Z
M+W!);"]W0V%S5G-T9C1N.'EF.$%6,790*VMI6"]M<D9B2S503E!M4EA6=C!P
M9&YI46%'95=H<"]S<U9T;79K6#AW=DTF(WA!.T9Z-3(X=G=3>2]"2G%&<DA*
M4FXK24Y/;EAF2WAJ<G%T<RLO-7DY,6)68E!Z.7!C9&YE5#(P8F%A:%I)<$A1
M12MT2G51<$=7265%+S0F(WA!.VLX>&8Y6%,W+W=#4CAV.$%Z5FEL,RM*4$U8
M+U8P=2\K4CAV+T%$5FER=CA!16YM3"]Q-EAF+TDK6"]M<D989C1K.'AF.5A3
M-R]W0U(F(WA!.SAV.$%Z5FER=CA395EV.$%Q-EAF+TDK6"]M<D9662MB4$UV
M,6(V=BML3'(P*UA0*RMK-59P5#=6830P<6HO:51Z1B\Q9$QV+T%*2'DF(WA!
M.R]W1$Y72W4O>$HU:2]W0W)P9"\X:C5F*V%S5F0O:51Z1B\Q9$QV.$$U2'DO
M.#%9<3<O16YM3"]Q-EAF+T%#4&PO=T-A<U9D+VE8>D8F(WA!.R]W0EA3."\U
M2'DO.#%9<2MZ+SA!;D9854PV*R]+;$IR>31K=5I6=G)H0DI+>&1G<6A+0W)%
M-UEO97=9<3=&6%EQ-T9867$W1EA9<2\F(WA!.TY4>EHO=T%P5')(+T%$2%A0
M+THU<U5P5FER<U9D:7)S5F141D1Q67!44W=S=$UK<R]8=6YL4FA,=UEO4&=#
M;FHQ8FEA16IL:UI%,G(F(WA!.V5Q5VUH47=+,6AE4UA%>&5J27EC449O86UV
M>G=22E!-2VQ75%8R2W-H+TQR+VQ0+T%#,R]!3G1/,"\U4')I<C%V+VY-;B]Y
M65=L9CDF(WA!.W-X4"M4.&U+2&=E2UA9<3%I<G-68GA6,DMU>%8R2W5X5C)+
M=7A6.7-F.#1K9BM3:U@O=&]84#9K>%$Y;WA6,DMU>%8R2W5X5C)+=7@F(WA!
M.U8K86YM>B]L2V19+S5J<FXO:S@R2U5Q>%8R2W5X5DU.1S!3+S%A9#1B2D]B
M4G(V:W!/=U9/451K934S66)+0V9B27IM23@Q6E-0>3@F(WA!.W5:5RMP,F-%
M;'ID3#EU-F$T=#199'5V1TEI4U9H-$4P4"M334%-:GIP5FMF-5=E6F]P4#E/
M=$)%=G=L55-E0C-C13<X94QV5&)X>&PF(WA!.TML5F1B.&Q83G!P0FMU-V%B
M4UER8F\W>E)88T5J<V5R3D(X84TS,E%E3$-T2S!'*T%C43@Q3$,W,GEU3$\T
M83-N54Q);U9T;59G438F(WA!.V@Q25I345%664A9-4U',55-2W5X5FM0-61F
M.$%+9CA!;'8X03=A9' O=T%N,7A6-C,O>FU4+S5-3%-V*S)9;B]!0V9L>%$X
M1'A3-T8F(WA!.UA9<3)Q1FE!3GEE9T=+<#-$-5(Q3#9W:TXR.&1L>E1N>6M,
M>3AA+W-Y2F),4$EJ9C5,2T0T-5@T;3%G6"M03E528V589$-T0B]P9"\F(WA!
M.V9+83!$4C9F5D-F67E4=VXX36I+5U1P169%+W-+<5(P1%(U;S-E>C%69U5&
M948S851X369996@Y84<O=5)H134Y62])+W)P54)C-D0F(WA!.W%S1F=M;U!!
M5W-P1'A&=VA6,59Q:V-8-&MM3FI46EAO4TXX;4IG;75Q<&9K;&1I<G-69F)(
M+T]*2"]K<$8O-V%&>BMP355084U69&DF(WA!.W%L9%AD<EHR.&QZ9'I*8C(P
M4353>GES15)&2&1M66=!9E!&5EA&6%EQ-T9867$O3E1Z6B]Y;$]S9CAX,7HO
M>65B1DM667$W1E4Y,$0F(WA!.WEX8V%H2DA*24-)0S,R0EAM*S-B8G W-'$Y
M43!4>5908E=J2TEV<3%U-FYG26%T27-L86AN<G5W-FEH8G8W57EJ3D=7,&\X
M=V],2SDF(WA!.THX:D,Q.4,T:&U35V9I0S1"<3(T,TA!+T=+2'942416>$)Q
M44UF9GE4=V]R5W9,=FU.,%=45%9E3C0V*W!73G%V-$%B2'!H+TXT=C4F(WA!
M.W=2=W-A,4A1=DYL.5EV6F%J3$-,851J-C!%:4E:2$-S1S)!555)-B]%5C9D
M8UDV<U,R9T1)+UEK45E*-7 X<%=O;%I93%-3>%I/2U$F(WA!.WE->E-",5)1
M=GAI<D%6<%@T96Y43'-56D-0<4\V0U=%86IP;#%95$-/9&%":%9*0G5R1'A5
M-4Y52FER269Y-B\U5"]Y,R\R,#=4+VLF(WA!.RMM2W97+SA!;DUN+T%-;49P
M6"]B350O:R],:6@T2&EL,DMQ='1B4S-%>7A2:7).,'A6-E(U0CAH-G1,9'A8
M1FY'1&9+1TYT8U!49VHF(WA!.S V<4="*TQJ6&EA5C55<'9M4'%P5D-Z.4XW
M*S5)6DA*-5)H=&<W-GAQ85)J;"LY57-F=%8S<GEP;#A+;U9Y67-R<SE.,$I,
M54-/,SDF(WA!.U-*3WIJ;'5/.4=R:%<P=G5F3&-6*WIY,G0W-DI)<#9814Q1
M+TE5>%<P;6<X:%AO=DI%=5-L>'!J268P9V<U:C%):#A82#126&QY56,F(WA!
M.TXV8W%::39U5E(R*W9O;4QY<EAF3$YX6E-Y;4Y4=U4O1D=195,K4'I!>DI(
M2E5I=W$W1E@R>"]Z:5(O-4M29BLR:&,O<51&0W!.-5<F(WA!.R].35A'<S,X
M1G$Q=&-E6F%.8W1A-F=O=4QD;TQT5W0V:VE*5317;DM,.3-)+TQV5'!K<D1'
M:6\S6&MF.'@T=%8Q2S=S>&908V5H9C(F(WA!.V5J,WHV:5AA3T4S66MT>$E8
M=49D=61V>E9#,5-(-&QU3D%Y=')33$AL3#AY6F)/.35897$K;VUM,W8V36IA
M."MR370Y2DE046IB,#<F(WA!.S8X36=60S-"-5IM<#-/=WAS3%)A,51Y,RMA
M,7A09D,R;#%#0U=75S4K<UA386EO=#5O6DQY2G):8DM,,656<UER8TYY4$9#
M84568FPF(WA!.U1'=W1&-C-A,C!D=&)25SA:9&\T;$-+,'-J>7510E0T<$I#
M-W5F9&E4:U=3<FER<U9F;7 U<R\U4VY74"M9-C4O=T-4>EEP4W)&5U8F(WA!
M.V534$M-,G,S:4]W2&]H:%%(<#$S2DAH:6@W2%EA8G R;'E,1D-N<7IQ3FIX
M1DLP;U-C5E-/8GI$<G1X<DUT:F1O,7!:22\W:&M9;T@F(WA!.TA%;6Q6<#%0
M6$973E1E9&9--BM::S W,&MH9VMK0W!W6&DO<$AO,U!R,#-/07A#;W$O,5AZ
M9&%A9F141E9U<$-!1E9$>4UF=W1Z6G$F(WA!.V=&<6)D34A"2'5485,V8C5O
M.#@S.#AS,5A7,VE2,VQ!0FI5;%50158V+V%P<TUK14I&2#4P.'I2>BMP3&1.
M3W!.5$1/039'=BM38U8F(WA!.UI,<#=A6C5P=%I)65E3;#5%=G%Z,G)B3'9S
M5VA913<Q3TMS13%#=VQS<'948SAL66-K8V1#355P>"M86"]+9BM7+SA!=' R
M;B]*.4TF(WA!.U9E="\X-6LO*U1#,'(O=&U*+WEF:WA1.$1X4W%7,79*8UA%
M8T51<DI+=U92-VLP>%8W:C5$+TLY8E<R5U,X5E=U5TE9;6QE2VM$>#<F(WA!
M.S1O6GAQ1VMR66%C-U=R.$9+:$MJ66=K,$)&4&,T0TQ&1EAM,VQ45#=M-'8W
M<41Z3C9/<'@O5UAD67)M374W4V]704IN57!)83AJ4E<F(WA!.UER-UI24$(O
M35!$*T\U3G,P,7I59$UV3DMJ4T-/-71J2U1V1&-,1V5.2TAR0R]J;%%X-F=F
M>%)0=R]A;EIJ,G9E6DY..'5W5VLP5F@F(WA!.U!C1U@T0C9S>E-G8V%C;EE2
M:4%D.7$Y8V9!>E,K<68K;#(O5VUX,TLK=&5:3F)H<U=645EJ3G=K9F=05%1O
M3TY%4VE6-U9P;'505'@F(WA!.VE196-U.#@O;7A2.7)P3G1Q,FI7-U@X2T=E
M5F59;$-G3CE**VY-:$1X+WHW-4UU3D)U,6M#<CE7;7)X2V9:1DMF,7A3>$Q&
M6#)X+WHF(WA!.VE2+S5+4F8K,FAC+W%41D1).5(O3BLS3V]W-F1P3FI*8U@V
M86AB,G0S8F,W4V1N:6XY669U6'0W<#1K;#5W9$IN5VQD>&AP1G%.>BLF(WA!
M.V1E;'II>&TP=3%N*V\O5V])=%=V3&U.46M#4W=Y5%!&4EIF53ED5FIR.6QK
M.38P=S!T;W5B.#4Y16E94E!O*W$O5WI#3&]7;G R,W$F(WA!.T<R83-A-5=B
M+V5J:'A-56)M;DQK0TM&831+5S%+-2]/9E$T9TQH<E<X9VAG5C5,<3%K9VEA
M6C1V<5EV26YJ9&)K26=E33$K244Y:48F(WA!.S8T,'1O<6(X-&9,,79%2'5R
M2SAT:4QW,D4X37I78V,P57=-5WAH3GHV:V=P3W)(,&QE9S8P>'!B6D(U33%U
M-S%V>3=B-FQD<$=K.',F(WA!.VQW:DQ%0T5P1&-34DQ135=0,E5&9"MU2E-N
M94)8-7%E8E X06Q+9%DO=T-9-C4O-5!.:6Q!,DYO,3%D2D%P<'E0>$XQ;T(Q
M3TMV;VXF(WA!.SAV.$%33&4R9VEI8T)7=4-'9F%M>3E&+VAI:&Y:,"MY:'$V
M4FA&3WIB9E)I<D)F3DYR6EA%='IB=$]I4C%"-6-L2$4P-CEF9D954F\F(WA!
M.W9K5WE7>71';G5/9'1(14M58FM$5VQ.+T=M2W$R<V5556IU<F=1>$Y$04-P
M9VA)-4\S2V\U8VIX0V=%67%R:E-W,6YB45-Q0UEK3$TF(WA!.VQ+.&E25'0X
M.%992G(O:VU.,VM+,GAK:#5$:7@K0E)8<4LY<U993%IE86XP;EAX8C)-8V8Q
M2TMB,%<S*S)Q='@U0BMW>%9K+S5J-D@F(WA!.T$P53!Q>&=32&TO3F1X-FM1
M<G14<GI">%9H2#5D9CA!2V8X06QV.$$W861P+W=!;C%X4SEB+S5Z2B\X04IH
M858O=T)S>% X06LO2FDF(WA!.V@T2&EL;E@U4S91=#5R<'5P0BLW=$M30FHP
M<7!R5#E72T@P6F]S<TPR9DM08VMN:U!!-'%P-C=D46962F)A<71+=T@W=FM"
M=#0O4FDF(WA!.W)'+TQV;%9*-34W=3AK8C S8T=/,U=V655$13%X5FQ4851B
M=D1,8S--3$=+6E9I4C5V:$LX4U9(<$MF;FER1615<UET2S%'5U=W=4LF(WA!
M.U%K97%B6GAU,G@K0VQD-C!P.4]+=&DO,"LV:5=+-W141%=H-3 U4C$K,5%S
M0G1V,GA63C=#,VAA4#0K4$%B>"M(2'1V.'-667@U<7,F(WA!.TQB5W1/=F):
M5U9N9T99,D)$5BM'=D@V96U+=FY6,4M/>4A9<6%(-DU5=G1F+VY%:B]W06Q)
M=CA!,C!,;CE366]:,FXU52M227IY:G,F(WA!.TI9,D1P2D<V6&PT<E)T17IT
M2#940UE'24LP>FM"2T%%-&)24S90.$%+=GE&2$I%-F%504E19U=,,7)J,&HV
M4T=.1V5,,5!49'5$1F4F(WA!.U1+4U%D.&)7;#ER*U=F:W$Q4$M+=UEU23)H
M1'E83GI+-&EE03(S<#AP2E=B9TE72W%T84PK>E1',7!U-2],3'E28VAX4'!V
M4#%),6@F(WA!.V8Y+V-#<4IB:3!58E-$+V1!-"]J,3-X=&%D92]L;C5+=DPR
M93EU3E!9,TXQ2UHW;#!U3&U0,4A:;S)03E5K5E=8;&)X<T9)-&=R5VPF(WA!
M.V-B5VLY,'93<D13<D9,1W=I.4<Q:EHR4U!K>E5-:G1)*S=L:G5Z:SEC0U56
M:7(X,5!.;B]!0VQ/<V8X04UD8R\X;FUX4S,U6DMJ54<F(WA!.TIP+V1M;&9M
M359E-3)L-FQV<'1P3W)(6DAC;$YZ*S=O9&@Y3TM&83$X-&593E=H35=N,D4W
M3GE!0W5L4U)3<%DX4V%$-31Q<6%N;S$F(WA!.VY"2VPY<61O:5AL>79':DE(
M9'5G2VEG4$QE;4MS-#!30C=V5'=H:DUC3D%I:$YN,DA5-T5,5$96;FUC-FQB
M>3)T+TA,-CEM,&E7,30F(WA!.VI!1F]G-U96;#0P<GDK3$95;F<Q83%K8C9U
M:VMC;'<U65)X;S%A:%0S<C,R-EEQ=3E),T-35U5Q<6]9:#-7=31*,S9D<U9E
M1"]M5C4F(WA!.UET3$QZ8CE4,#DT9V)L;%E102]'2&Q*2DQD=7941E=76&5L
M>E=0;$-Y=&)T+U5N44AK-4YA:71/+W-C5F5E9FPV2V9M1#5C2&AQ9' F(WA!
M.R]W06XQ>%,Y6B\U>DHO.$%*:&%6+W="<WA0.$%K+TII:#1(:6PV<BM68GAW
M-E1Q3$MF:CE$;C<W1C8O=WA1>FY48G4Y,4,X:G-.1VPF(WA!.W)03E@Q2E$S
M=WAG0W!:9TU65%<K.'1A9F\Y;&9A;$AQ370S<59L1T1D0U)G,%HU141I>6="
M:#$R*TQ&538X;3)D.7%%<T0K<49J:V@F(WA!.RMS4V]Q-W)&<V5+,4I(3#1G
M359:12MI4F%T3F)713A,=TDP<6Q(5FY$>'-X-#AX56M6-S=J1E=&*UI02WE7
M5C%E>&%R3DDQ,6%-47,F(WA!.W%K0D-V2&M#86IU1&EQ5VI454U)=30U,F5'
M3TUT-F%G37)G1&-51F$K,DMP;S%X8DYP8U-X;&=S<4MO1D-J2TA3;W%'-E5'
M2W-8,#,F(WA!.U1%<SE596$R0DU.,T<S,7=&<6HQ239"0W9H.$Q(;&ER=U16
M1D,V:$]",#5K+V9V:6PY;F8X-&MF*U-K6"]T;UA0-FMX47%R-4\O32LF(WA!
M.T]-6$M8;7!T96E*2F948E5Y,&8Q;&15<E1G6G5(2#9H,5@W0C=J;FMR1$=L
M0TA1+WID83(Q2C4W6%5)<$=N=$IR0W=I,49M9UEO='<F(WA!.W,X8VLW-FPY
M85-*=6-:-4DT,T$O9%5"1T]Y3C)E95%R3'I.83-/<VI763=N,$I,9U-71GAE
M,TAR5$]R;#):9E13-'5963%J<494,#$F(WA!.VHU1'%G27=&:T=8645U>%8R
M2W5X5BMA;FUZ+VQ+9%DO-6IR;B]K.#)+54AP=#)B5SAJ;2]:0F]W+W=!:S=(
M1EAR96<V;DID86).6G(F(WA!.TYW=DDO:71&;TMK:TAK;TY/<$=+2&\O:UIR
M=3@X;'EX,DUV<&%K,'I,3S=5-44O0V$W.5!H,D=+<$@U:71R-DA69$=S>&1I
M-G5,3W,F(WA!.W0P:'!W:4)935-74%5T6'!81EAO4&MU6%<Y4S O55ET36II
M=4DT<$932EII<4U88FM75TYI53-P,D\R2V]V>E,P-#!M>3 R-2MQ<G$F(WA!
M.V,X;VPK<G=38S)9=T9D;DEQ3U-S,GEH<U9E9'@R5W5Z871Q:RMJ.%E,:3$T
M14M1;VM,4V)%<5A',G=/2W U9'HV;&(K5UIT4C%S>#(F(WA!.S$O15%T:D]+
M8VUA;$%J8V5V2VAX5C5H2G!I-G U;%16-5=356-!.&=*1$AK:$A(6C8X479I
M2UEQ<&5D.6175T(R9V5L=&)X='=Q2U8F(WA!.TY+3#DU>%9G6#5D;79N+WDU
M+S(P-U0O:RMU2UAR6"]/6E X035-3%-V*S)9;B]**U1&1'=,1DQ,=DEM=2]5
M8FMX3S,W;'9G;%=M-6DF(WA!.V9:<69,1D0P>GE6<D9J;UAM1#9Y2F96,&U:
M5VIL;%5%;&%I<3%&3U$S<&ER3"]/97%1,U=G,U9R;W1M,')8=U5Y,U)+;W9%
M34=**TDF(WA!.V=N<%1&53,O04-K5RMM.'IA6EEQ1V@K<E=23C1Z14501VEO
M<DE"=E=R34U66FQO5%@X6&Y456LQ1%5)949S=U,R4FMI43-$:TYX4DLF(WA!
M.T)4.$9..%9E5S9T-6AK,5HY66EN1'DS36DS045V2%DW37$Y0C1I;4MR=DIE
M<656-U!Y-T9B86I-24PV4&U,<%I224<S66M&84-N,F$F(WA!.V1-5EEB9CA!
M;3-5-3E3359P3#E9=&ML8U<V0U W4U9)5FE+5G%6>%97.'DK64I.3# U;VUK
M4DPR44YZ5F%%46]2=4\K-7A6-&)02S F(WA!.W-Z>70Y<'E74# T<&9A=B]!
M1&E2+W=#4VM8+W1O6% V:WA1.6]X5C)+=7A6,DMU>%8R2W5X5BMA;FUZ+T%*
M4VY74#A!;4]U9BM4>EDF(WA!.W!3;V=G,$EO8U94=E)0340R6D-432]%14=/
M4E1U=C Y9'-66FYP;FUI-FI5=D9C35%X<5A2>7!9+W=#5E1:=CEL:6AN,FAA
M='!M<%<F(WA!.S93>3A236\O95)-;T%$1'%W03).9DA&53DP1S<P=E1T6'-R
M;5<V4TLQ*W1X4RMP>5!W2W!(665W<&EQ05,Q:'9*-&)U<6HP;5IP6%(F(WA!
M.VE#-U9"0G%!2S<W;D955'%/<G@V5DA.<7)3=$I0440T;4Q3<TM"5E)72G)X
M2&AI<D%B-WID8UAS-6LQ3G!B>$]284LP:VM0<' W,'(F(WA!.S19<7AV5U!/
M.%-S66\K36%D4%%T;$-G52]M26]$.4]+<TXQ3%8W;2M)1$AJ14YW9THS4&EF
M2$9+6B]L,G),-2LX=#%&2S9L8456+S0F(WA!.WIR:7(S2"]N3&)Y,64S,VUQ
M1%=056IT-T-W,#)&2DIP:$I2-4I,:5%,1VA22$)B971#4G1I:#@V>5=%<6]8
M:F1*,$@R;6I.869-14(F(WA!.W9W>%-O4GE34D]S:4U66E1515EQ>5!4+T%$
M3VEQ1FM,=U-N-U5I13AA53EJ6$9$3R]+2&Y/0T9L:'4U:F-76%=-:SAI:F(Y
M:C(S>%8F(WA!.VXQ;C5Q,'E+-$8S6EAO=#=M2D<T>7%X:F)I=T9A155X5F9.
M-7@P5%=B4%-,8E186#8Y67A44E0S1#AA=DI+=TEC149J5V\W-'%U=%DF(WA!
M.SE/<W).66UK4G9456@R,F]4,5EN1E="*UDO33!S;#%01&%Y<DQ::V=C6D9(
M86XR9'$P<FER1S=R>E-.4$1-:S-O>71S4'$Y165N>E<F(WA!.VIF:FER1#E9
M,7%7+V8T4WEX-VQU4C-9;BMB1DM82D<W<T%O<51I<C=9+S5X3FI-9C542W!)
M2D=O6$YA1V\V2C-'2TAS,DMU>%8R2W4F(WA!.WA6,DMU>%8R2W9Z53@R9CAP
M5')(+TUD8R]W1$HU<U5O2S-V6&E91C!79$]H:FQ(254Y:C%8-DU685IB4U1K
M67DP6#AI3E)X-S%98V$F(WA!.V8X1&EQ-DM/+U-*-4EF5453+S-J>&LX4CAY
M=3)+='!Q9"MG*T=D,4DW9VM(-RMU2W):3E(Q0U%5:W5:5T$S;UA9:CEE2W!L
M6F5C4$TF(WA!.U9P15EO-S)6;VHK=S=S4G0Y3TMT6'9M-U@W=T%46%1M9W!8
M:U0O>$EN1E5'<F%T9'%A3DQ*2"LP86YH=#0O<S1Q;W1"1DAY16MT6$@F(WA!
M.S=-9$=(,'17;C-6>%9U935I6E930T51<796<3AN62M*86<O041&538O3'-K
M*V8X07DR4V%N.4HR;E@O:D]U2W9A4#A!;DQZ5TPK,C@F(WA!.S<R3F=S,&@P
M-C8P>4TS3FYZ26ED;&YK-'-6-F-L23)A;4M(>CE,8G9'9VYH9FY%869%<&]6
M2C=-3WAX4S)L-4<P4FIU259L+VQK5VDF(WA!.U-!+S9W0C5F-TQ&5DY)2357
M06IK0VMN65-56"]!26)P:7%O,7!Q1G9'2G=K:7A%:T-:83A#4G1S>3=9<7-.
M+V9L94IU6E-V47)Z86XF(WA!.S8X5F%T<GDW=%@U,CAZ=W8Q-4EX53=F3$95
M869-=75S<%9R,EEQ,S)G5T\O>GA645,U,5<V:S12>513=3-254Q%;C9":7)B
M-F)02%8F(WA!.W)Q4DE$6&1:1W$Y9CE15F(W.%9747DR54QK=$-B:VHW26,X
M1G(W:&%K+SA!0EEQ=$UL>F13:$9'-VYA2TY1:3$O=T)6840V8U9F86XF(WA!
M.R]/2TU0;R]L4W-F3EI#3E%U951)87)5:$112'941D0R5$9867$W1EA9<3=&
M6%EQ-T971WHO=T1+;E!8:SEF.$%W-S8O22MR>BMO."LF(WA!.V1F:356,W)8
M<EA&5VTO-54Q4F5F*TAA52M#=C%(<#=9<70O-4%T+S,W9CA!,#19<31F.$%+
M;#8W9C1C<B]W0D=/2W$P=B]+;W5).5@F(WA!.R]$+TAT>2MP52](1E9(+VM#
M,R]F="\X051J:7)V*U%,9CDK,R]W0D]'2W%S4"]+;BM1.40O1#-,='<K<%8O
M1$96<W8O04-P>C%'.6(F(WA!.R]$=G%F=&,O<5!,-F$T<7,O=T-13&8X069T
M+SE/3TMU2"]+;#8W9C1C<C=F56-65F)4+VQ54#%Q2#9N+T%)9BMT.#$K<BMJ
M.5,Y5#$F(WA!.TLO1'<T+T9Y<C!P:7%0.$%-4#A!>7(W-C1N*TDO=T)%+UA/
M03E0.$%34#%B,694<6%C9E<K3&I7=4MP8D@O>7!R;5!4+W=!3S@K,T@F(WA!
M.S9J6#A-5E=N+VQ3,60O.$%$9&8K:DA&6&8X9U<O=T,O8B\V8TU68U K5DPQ
M,B]W-5@R*V\T<7%N+VQ52$%6+W<O=T%+-U8K<%5R:7$F(WA!.S,O:T1L4#A!
M<&YA9CE'3TMR-&8K5E(X=C-0-D$U9C5(,4MV-%EQ-C0O=T-64CAJ.5DO44A,
M=C9N,4MV-#1Q;R\X9U<O-SEV+T%+8TTF(WA!.U9D+WE"8B]V,B\X07!W>%9E
M4#A!;%1N<&UN*TAF4W)V5#9J>'(K<D97439$+V@S-F@O=4$K<69O+VTS*SA(
M<&5J>B]A+W5V:#5E3TLF(WA!.W!J:7)S5F1I<G-69&ER<U9D:7(O05 O6CPO
M>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1-9G,](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]-86YI9F5S=$ET96TC(CX*(" @(" @(" @/'AM<$U-.DEN
M<W1A;F-E240^>&UP+FEI9#HU0CDY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P
M.#1"0CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M
M96YT240^>&UP+F1I9#HU0CDY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P.#1"
M0CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P
M.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S
M<SX*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP
M+FEI9#HU03DY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P.#1"0CPO<W12968Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP
M+F1I9#HU03DY,C,T1#-$-3%%0C$Q.#4T.40W.3<V03<P.#1"0CPO<W12968Z
M9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C4X
M.3DR,S1$,T0U,45",3$X-30Y1#<Y-S9!-S X-$)"/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Q+3 W
M5#$V.C X.C0Y+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU0CDY,C,T1#-$-3%%0C$Q
M.#4T.40W.3<V03<P.#1"0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TP,2TP-U0Q-CHP.3HQ-"TP-SHP
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ36%N:69E<W0^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI;FM&
M;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @
M(" @(" @(" @(" \<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H
M/D,Z7%5S97)S7')R,3$V,#$T7$1E<VMT;W!<:6UA9V5S+FIP9SPO<W12968Z
M9FEL95!A=&@^"B @(" @(" @(" @(" @(" @(#PO<W1-9G,Z<F5F97)E;F-E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DUA;FEF97-T/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA
M9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R
M871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U
M<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&
M;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R
M:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.
M4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A0
M86=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=$1I;3IW/C8Q,BXP,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS
M=$1I;3IH/C<Y,BXP,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I
M;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z
M36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @
M(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D-A;&EB<FDM0F]L9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-A;&EB<FD\+W-T1FYT.F9O
M;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y"
M;VQD/"]S=$9N=#IF;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G14>7!E/D]P96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-BXR,CPO
M<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F-A;&EB<FEB+G1T9CPO<W1&
M;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y#86QI8G)I/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^0V%L:6)R:3PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT.F9O;G1&86-E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E
M/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E
M<G-I;VY3=')I;F<^5F5R<VEO;B V+C(R/"]S=$9N=#IV97)S:6]N4W1R:6YG
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S
M=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M1FEL94YA;64^8V%L:6)R:2YT=&8\+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D)A9SX*
M(" @(" @(" @/"]X;7!44&<Z1F]N=',^"B @(" @(" @(#QX;7!44&<Z4&QA
M=&5.86UE<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^0WEA;CPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/DUA9V5N=&$\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y996QL
M;W<\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y";&%C:SPO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G
M.E!L871E3F%M97,^"B @(" @(" @(#QX;7!44&<Z4W=A=&-H1W)O=7!S/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C:"!'<F]U<#PO>&UP1SIG<F]U
M<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P5'EP93XP/"]X
M;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4W=A=&-H1W)O
M=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0
M<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z
M>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@!" %^ P$1  (1 0,1 ?_$ !\   $#! ,!
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MEQM25[&T.#JCBUCA5,O:0[#()((AP<(DQWLC>5S.S,+*; Y[32!:QX+2X @
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M'?/P R?3OG@B",?')V&P^/MZ')[CXYSP15P<Y[^GIVR?AZ;>OOZ]R(.^W?\
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MNIV&J4TGJ=D2@E APUN$O*4\$)PG/!)M/V/7YTS6USE9K%]V[I38D:^K$4S
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M]J65JLW8:M%DDGN8Z0@@0;%^$$6$NE7IOGGU1O:Y=-;3T6Y?[7NV7K/<O-C
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M;_E,N?\ '[_Z.,+;<AX!- WS[;^A]![C&-_AON/;@JGW\KCIJ5NSJ;&?\N3
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M+9:AJ6'Y#C;#24 ];BUNHZ&DX_SBX$8^7;(XH)$P2)$&+6D'/Q 3KKV7H):
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MAD>@/<YV&W;_ .KGV&W!55!V^).X'W;^_;'QWQMV!%S2I25=0/8I([_YN,9
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M*W(3MM^7-<]_7_P'3KL,=QWX(H!)V]^WH,G._K@^_P!V/;/!%49SDDY[Y/\
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M#8;=O?&YQCMMVQMN15 P<[D '_8-L]]_CVVQZD7J _0]_P"2CNW_ %OM7O\
ML!HW[[_CP12J."(X(C@B."(X(C@B."(X(C@B."(X(O$2Y^Q_AO<X/?'[YW7/
M/M_E,N;T]\[_ ._@H,A:+9<.2:7"=99?:7)8$EA"^IUCS%->8@C[2/,0DJ1D
MC9202.W8\%4H,*B6;<7V(%67;<[R5+3'KJ_,ILF0G 3&8J#(26"YDE!D)"
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MO:?W#KK:MQ.SM,Z=2.:^G7],J%?-.F1E,Q+79N::NKO)I[TU9BH86M*$+<*
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M9= -[$=T :7XF4[2IJ]Q\3/'DDI,Z03D.N8/8>8YL#DCLH#[\#U^7'=.T?\
MW'U51.D C+KF,]_-=R/E]O.?CD@'& 3C@,Q.6J=H_P#N/JNQR8^GI*7G%!0R
M<NN'.^V,*]0>XWSQIPB()@\?8^A^N60=H_\ N*ZOK\GOYK@SM]EYW'XES?\
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M,(I+7TV 8M3D)QDC\NZY;9]?J.G1'W]]_3X<  +!.NO50"<';/;;Y#X=^QV
MQ^&-C40.W[=\9^_;8;8^7MC@BJ/PW^&#W[8^.#D[[>^>"*A)&-MO7!.?7X;C
MX[;[Y]>"(QC!^X9R<$_?\,=_E\2*GJ>Y(![#&Q]1G._W^^![D50?8';;M@'[
MNPS]QW'IG@BY)4I)^SD9P< [DYSN!L<^F=CN.QXH)&1A%W)D.']=14GN-R,;
M' ^7N2!GMCN#H/.M_+TX(NI:NI:E?\XY ]1Z;X^7?  [>W&29)/'HHN/<^FV
M,9[YR<_S;'[]^(BIZYQ\1G/KZ?#[AL,Y ]2*AV/;/J,D;8QG<[_?_-L21<L]
MQ\ 3]_<; _/&^<^W!%QVQ@Y/N"1D >O]'?'OZ\$5?GL/?89(V'???&=]]NY'
M!%5)R2-]@H^OQQWV]-M]_8#@B]0'Z'O_ "4=V_ZW^KWP_P! -&_3T^7!%*HX
M(C@B."(X(C@B."(X(C@B."(X(C@B\1+G['^&[S@#OCF>UTQL"!_&9<W<>R?7
MX_$\%!D)S@2FA[#/SW/Q./?X8QOC@JJ>VX [#N<Y^)_8#D?/;@BKV'8?=M\_
ME]_RSP1<=CZY!]/CW&3W]@!WQZ;<$1M[=N_J<Y.P]1D[CT/P)X(NUM"5*(4>
MD)25$A)5G<#'KMDY/W>G:@3.D"<IU'Y17)JGA0*NKJ*<$H( )!W!2%=).V"/
M0GWQCC;6M,NQ AN<VCQG/\CR)=@AAP@A+8^SU8RVG*<G!!R,@D$=C^J<[CC4
M-/\ 9:-6C[^'11=(:95LGH/RZ" #\4G;?T]![;$26\ >,"1>-8](\(R5 )R^
MH_*O=*3)@RHLAIMN4MN3$?:C8RIY3;B"T@(2"XI*RD)/2#ONG<#C#P#3<T.:
M&ND&[9$Y#"3)B]HRX)!DC..%^NI3S]0=:[SMRZ++N:Y:#;\.H1FUW!$H,%Y/
MUR"W5*='IRV*VSY8=C.SHT4O(BO+\Y$=[!2VKH/'H*6P,J4:M*C6J-#GN!J%
MI$.%0N[I@& ;2+$#$"0MA@#0XD2=#D #J+W-].&N6-7/S:_EZAUVBJTNTYB(
MK<!Z )4:@)9E18JTA+28SP/4VZTL>:E\>8XI9PM1P%*FS[B?L^T-K_ZEM-3#
M<TR26<8;I&F7G%EESI@<+#J!].6B9C+D"0490 I/ZRPI7V]C@8] ,G&<D=O4
MY^@<Z8U(UF2=+_O_ )SXKY?8'&3G[Q^SX9_V;C**A(]\'MW^XG!]CGYX[\$5
M?CG^GU],8/P_G'!%N9^C[8_LO_)#L?\ *H_OD;D6C<V_IC&<[9'I\R*2[]-A
M(%J<A.^/[O:Y?^P:=_[>_P N"==>B@$#&Q&YQ@>GP].P.#C/^[@BIGM_22/C
M@_'YG?N <X)%7VQVWV'KZ#'8=M_NVSWX(J'(& =O3[O0G^G8@ G??@BKV/PW
MS@=MAW/Q^ SL/3@B/?< X./V[GW]^VV_QX(C&=A^.WOD' V.2/GO\>"+N:8=
M>R6T@@$9)4E.YWQN<'.,;=AGOG>Q/#S('U3KQ55QW4 $]!!.#TK0L]O4))V]
MSMCL1PPGD>0()]OLBZRVO_F>A/R/J?E[G&WKMV0>!]"B[$1WG-T(*@ K(3A0
M  )R2#]E. >DG (Q[C@&DB0"?"_L+CSY(NI2%('V@=P<;@;COV)P23G./7X#
M@01F$5,;GVP,';[P<[G/])XB*F??W([CT[*V'OMMV)'J,<$1W)^(P._;UW[>
M^/NWWX(J=^^"#G?VV 'N,]_Z/;@BJ"01GO@C;MV[GOZ_ =\#WX(O4"^A[?R4
M5V';?F^U>[?^@&C?!%*HX(C@B."(X(C@B."(X(C@B."(X(C@B\1/G[R.=WG!
M[_\ &=USS@ Y_C,N;?;MVSP4&0TL$T 8P-O7M\<>A.,>VV-]AMW*KEC[_P#O
M]_AZ=OV9X(C;W]??U[?U'OZ<$7'&2,D'!/OGOVQM@#![D]MO;@BJ$G(P"23C
M"0<]]O7<;#;'RV&Y%=:?3W)"W4 MI*65D)<4IL@A2,J2"G*RD$GH&2<D^@'&
MFM))$9"3) @<;D3' 7UB 2*!/5]?PGEV/RKUN31*;?NJ5TT?2.RJM%:E6U(K
M\*JUV^;QBJ("Y=FZ:T1AVY*M3% )\FOU44"U'W%EIBOK=;>0WZ;:=_TVUCLV
M[:%3?&UAQIN- BG0V=X'>;6VFI%%K@)FF'.JW P21.Q2J 26N@FQC3,1Y<[Z
M<E7LO0G2^YZI-IEBZ#<TFO$^GMJ=74IE7M'1VB*;#86'':!^:NH<UMM72H-L
MHO1F2\5-X+3BBCCF6_$>V,?_ -1NS=KS);AH5MO>UMC)-=^R40[,$!M0']0!
M%E06M_4V3)!XSY@R,I@B,[3;KM>U;/N:[W[)A<BE38F4NH)I=>?J=^ZO";;J
MRHH6NM.0Y,&!&>3T*(*J<A#F 4LEL@CUE;9=_P"R[,:NT?%C60PQ4?NC8J;
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M2]3*I'04Q*K3W%*+$V,25?96G9;945LN!3:MTDDJL!^/?Y?U_KZ<$6YGZ/L
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MT(4I12X."JU[K0I*BE600$^Q[X4D[$CL1G/[-^"*F3G[ON_'OOGL1[]^"+U
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M!)QE3A*4(&X45 >O!%-LY*N7R#IGIO:]J0X3;54KD6#)KRDM /-L*::6&T
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MS!C-.5G\JK=V7-2+#HD!ZQ[.I5NH=;N2M%V4]6J^E#@DMOEM24M)>4VA;:"
M&T%(! 2 -3Q&(<'20,K@38VCE)XJASFF6G"8X#7F0X9B3'/B$V/4[0O4C1JE
M*N^B1ZA-H-/N%ZBR9LE+K*%ELI*I2PVV<T]U/FHCN$@I2HY*CC&<+9!+0X:L
M<.Z8RD @VM!!'#+.FI4((<\EIMD!XS:8G@8CDF_TCE\Y2=5;QAWK6K09L?5F
ME5V-=*+GAU!(C5.OL243/,D+<*V)(?DH<6EASI<2%)[E1/&IS@!H(@M&4?\
M[2??4K#209#G&8S,B!X>$7.8RLGO7[H-"O"CLRGX-,J4I-+<B!IV&?[80N.I
M+,AJ6P0"I!\M>4$@])2.P($@AHP- ;$1.DF\DY:7\53-X,'CJ#U.<Y^21W0G
M0*DZ*RD5:<(;]Q35.TR*XX5>>PT_AQT-%_[?3D #904I.5$D#$)DDZF_JER9
M,S>9-SSX7Z,9O @V55$./R8JT?5%++R6&VR2XMP];P6I06"$X^S[9SG<#@,@
MEY^G+Q$QZ73)^</1>C:S::74@1X[]8MR!/D14I:2N7)98BR5S::\,$K 24^2
MWLI"B#]HXP23;(CC<:3.MOR!HH9^I-GO69>%9H+B5MMQI:S&2ZA32C%=4X64
M]*P,J:2GRG$D@H6DIVQP56 C[\X(^61^'X=S\MB+U /H>W\E%=G^M]J\?_\
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MD5QMU]ZJ,H0RR)/1A$:=@DNR%(3T];B>H>:@!>!G@KU]TW?F:Y;K<U*TDO\
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M2.RJ[?%PU6+#K?U9^0_(1*8?JU72\Z@HID"F(4'5,E]/0%I+;;(*EY2D')+
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M?4GI8=>5(824]L-/A;9 [$=)[G<\$2NV_P V&J=!;+#$Z&ZRII*%->2I@$(
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>ikna-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-16T15:36:06.4273+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ikenaoncology.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ikna="http://www.ikenaoncology.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ikna-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2" id="DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2">
        <link:definition>100020 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" id="StatementConsolidatedStatementOfCashFlows">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization" id="DisclosureNatureOfBusinessAndOrganization">
        <link:definition>100080 - Disclosure - Nature of Business and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100110 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100130 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS" id="Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS">
        <link:definition>100140 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with BMS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100150 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>100160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>100180 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100190 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreements" id="Role_DisclosureResearchLicenseAgreements">
        <link:definition>100200 - Disclosure - Research License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1" id="DisclosureLeaseObligation1">
        <link:definition>100210 - Disclosure - Lease Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100220 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100240 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100280 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables" id="DisclosureRedeemableConvertiblePreferredStockTables">
        <link:definition>100300 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100310 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100320 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables" id="DisclosureLeaseObligationTables">
        <link:definition>100330 - Disclosure - Lease Obligation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100340 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" id="DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Nature of Business and Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)1</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100400 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
        <link:definition>100410 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with BMS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" id="DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails">
        <link:definition>100460 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails">
        <link:definition>100490 - Disclosure - Stock-Based Compensation - Schedule of Total Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100500 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails" id="DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails">
        <link:definition>100510 - Disclosure - Stock-Based Compensation - Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Employee Benefit Plan (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Research License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" id="DisclosureLeaseObligationAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Lease Obligation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" id="DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails">
        <link:definition>100580 - Disclosure - Lease Obligation - Summary of components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" id="DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails">
        <link:definition>100590 - Disclosure - Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" id="DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails">
        <link:definition>100600 - Disclosure - Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" id="DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails">
        <link:definition>100610 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100630 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" name="AccruedExpensesAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_CollaborationAndStockPurchaseAgreementAbstract" name="CollaborationAndStockPurchaseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_Supplementalcashflowinformationleasesabstract" name="Supplementalcashflowinformationleasesabstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" name="AmountEligibleToReceiveInCaseOfExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_AreaOfLeasedProperty" name="AreaOfLeasedProperty" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" name="AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" name="ClinicalManufacturingAndScientificDevelopmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" name="ConcentrationOfCreditRiskNumberOfFinancialInstitutions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" name="Deferredtransactioncostsinaccountspayableandaccruedexpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_DepositsAndOtherAssetsNoncurrent" name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" name="IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LeaseRentFreePeriod" name="LeaseRentFreePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_LesseeOperatingLeaseMaturityMonthAndYear" name="LesseeOperatingLeaseMaturityMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LetterOfCreditToSecureLease" name="LetterOfCreditToSecureLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_LicenseMaintenanceFees" name="LicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_MilestonePaymentsEligibleToReceive" name="MilestonePaymentsEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_OfferingCostsRecognized" name="OfferingCostsRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_OperatingLeaseMonthlyBaseRent" name="OperatingLeaseMonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_OperatingLeaseTermExtendedExpirationPeriod" name="OperatingLeaseTermExtendedExpirationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="dtr-types:gYearListItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" name="OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_PercentageEscalationInAnnualBaseRent" name="PercentageEscalationInAnnualBaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" name="PercentageOfHoldersOfOutstandingSharesOfPreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_PotentialDevelopmentMilestonePayments" name="PotentialDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_PotentialSalesEventMilestonePayments" name="PotentialSalesEventMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" name="ProceedsFromPaymentForIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" name="ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" name="RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" name="RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_RoyaltiesTerms" name="RoyaltiesTerms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_StockOptionContractualTerm" name="StockOptionContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" name="TaxCreditCarryforwardExpirationBeginMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TemporaryEquityDividendDeclaredOrPaid" name="TemporaryEquityDividendDeclaredOrPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_TemporaryEquityNonCumulativeDividend" name="TemporaryEquityNonCumulativeDividend" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" name="TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" name="TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_UpfrontAmountAllocatedToEquityArrangements" name="UpfrontAmountAllocatedToEquityArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="ikna_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="ikna_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_AskAtLicenseMember" name="AskAtLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BeginToExpireInTwoThousandThirtySevenMember" name="BeginToExpireInTwoThousandThirtySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" name="BMSCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BMSCollaborationAgreementMember" name="BMSCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BostonMassachusettsMember" name="BostonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_BristolMyersSquibbMember" name="BristolMyersSquibbMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_ElectronicEquipmentAndSoftwareMember" name="ElectronicEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_IKFourOneTwoMember" name="IKFourOneTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_IKOneSevenFiveMember" name="IKOneSevenFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_NotSubjectToExpirationMember" name="NotSubjectToExpirationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" name="SeriesAOneRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" name="SeriesATwoRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_StockPurchaseAgreementWithBMSMember" name="StockPurchaseAgreementWithBMSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_UniversityOfTexasAtAustinMember" name="UniversityOfTexasAtAustinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_VertexPharmaceuticalsMember" name="VertexPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" name="BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LeasesPolicyPolicyTextBlock" name="LeasesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_RedeemableConvertiblePreferredStockTextBlock" name="RedeemableConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" name="ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>32
<FILENAME>ikna-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-16T15:36:09.0393+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="ikna-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="ikna-20211231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="ikna-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization" xlink:href="ikna-20211231.xsd#DisclosureNatureOfBusinessAndOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="ikna-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="ikna-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="ikna-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="ikna-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="ikna-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS" xlink:href="ikna-20211231.xsd#Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:href="ikna-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStock" xlink:href="ikna-20211231.xsd#DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:href="ikna-20211231.xsd#DisclosureEmployeeBenefitPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreements" xlink:href="ikna-20211231.xsd#Role_DisclosureResearchLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligation1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="ikna-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="ikna-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="ikna-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ikna-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="ikna-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ikna-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="ikna-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="ikna-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables" xlink:href="ikna-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="ikna-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:href="ikna-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ikna-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="ikna-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:href="ikna-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails" xlink:href="ikna-20211231.xsd#DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_DepositsAndOtherAssetsNoncurrent" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="ikna_DepositsAndOtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ikna_ResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_23"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" xlink:label="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RedeemableConvertiblePreferredStockTextBlock" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ikna_RedeemableConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LiquidityPolicyTextBlock" xlink:label="ikna_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeasesPolicyPolicyTextBlock" xlink:label="ikna_LeasesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_LiquidityPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_LeasesPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ikna_EmergingGrowthCompanyStatusPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OfferingCostsRecognized" xlink:label="ikna_OfferingCostsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RestrictedCash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_OfferingCostsRecognized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedResearchAndDevelopmentExpensesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesA1PreferredStockMember" xlink:label="ikna_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IKOneSevenFiveMember" xlink:label="ikna_IKOneSevenFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_StockPurchaseAgreementWithBMSMember" xlink:label="ikna_StockPurchaseAgreementWithBMSMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BristolMyersSquibbMember" xlink:label="ikna_BristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IKFourOneTwoMember" xlink:label="ikna_IKFourOneTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UpfrontPayment" xlink:label="ikna_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BMSCollaborationAgreementMember" xlink:label="ikna_BMSCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_MilestonePaymentsEligibleToReceive" xlink:label="ikna_MilestonePaymentsEligibleToReceive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesA1PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKOneSevenFiveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_StockPurchaseAgreementWithBMSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_BristolMyersSquibbMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKFourOneTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontPayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_MilestonePaymentsEligibleToReceive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontAmountAllocatedToEquityArrangements" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityDividendDeclaredOrPaid" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_StockOptionContractualTerm" xlink:label="ikna_StockOptionContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_StockOptionContractualTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_DeferredTaxAssetsLeaseLiability" xlink:label="ikna_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="ikna_DeferredTaxAssetsLeaseLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncomeTaxesTable" xlink:label="ikna_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncomeTaxesLineItems" xlink:label="ikna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_NotSubjectToExpirationMember" xlink:label="ikna_NotSubjectToExpirationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLossCarryforwardsExpirationYear" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_BeginToExpireInTwoThousandThirtySevenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ikna_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_NotSubjectToExpirationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_OperatingLossCarryforwardsExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesTable" xlink:to="ikna_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LicenseMaintenanceFees" xlink:label="ikna_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AskAtLicenseMember" xlink:label="ikna_AskAtLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PotentialDevelopmentMilestonePayments" xlink:label="ikna_PotentialDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RoyaltiesTerms" xlink:label="ikna_RoyaltiesTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PotentialSalesEventMilestonePayments" xlink:label="ikna_PotentialSalesEventMilestonePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_LicenseMaintenanceFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ikna_AskAtLicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialDevelopmentMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_RoyaltiesTerms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialSalesEventMilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BostonMassachusettsMember" xlink:label="ikna_BostonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_VertexPharmaceuticalsMember" xlink:label="ikna_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AreaOfLeasedProperty" xlink:label="ikna_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeaseCommencementDate" xlink:label="ikna_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeaseRentFreePeriod" xlink:label="ikna_LeaseRentFreePeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLeaseMonthlyBaseRent" xlink:label="ikna_OperatingLeaseMonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PercentageEscalationInAnnualBaseRent" xlink:label="ikna_PercentageEscalationInAnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LetterOfCreditToSecureLease" xlink:label="ikna_LetterOfCreditToSecureLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ikna_BostonMassachusettsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_VertexPharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_AreaOfLeasedProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LesseeOperatingLeaseMaturityMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseCommencementDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseRentFreePeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseMonthlyBaseRent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_PercentageEscalationInAnnualBaseRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LetterOfCreditToSecureLease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseTermExtendedExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_Supplementalcashflowinformationleasesabstract" xlink:label="ikna_Supplementalcashflowinformationleasesabstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ikna_Supplementalcashflowinformationleasesabstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OptionsToPurchaseCommonStockMember" xlink:label="ikna_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ikna_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>ikna-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-16T15:36:09.2489+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:href="ikna-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="ikna-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:href="ikna-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails" xlink:href="ikna-20211231.xsd#DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="ikna-20211231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ikna_ResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OfferingCostsRecognized" xlink:label="ikna_OfferingCostsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="ikna_OfferingCostsRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesA1PreferredStockMember" xlink:label="ikna_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IKOneSevenFiveMember" xlink:label="ikna_IKOneSevenFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_StockPurchaseAgreementWithBMSMember" xlink:label="ikna_StockPurchaseAgreementWithBMSMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BristolMyersSquibbMember" xlink:label="ikna_BristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IKFourOneTwoMember" xlink:label="ikna_IKFourOneTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UpfrontPayment" xlink:label="ikna_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BMSCollaborationAgreementMember" xlink:label="ikna_BMSCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_MilestonePaymentsEligibleToReceive" xlink:label="ikna_MilestonePaymentsEligibleToReceive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesA1PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKOneSevenFiveMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_StockPurchaseAgreementWithBMSMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_BristolMyersSquibbMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_IKFourOneTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_BMSCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_MilestonePaymentsEligibleToReceive" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ikna_UpfrontAmountAllocatedToEquityArrangements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityDividendDeclaredOrPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ikna_TemporaryEquityNonCumulativeDividend" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_StockOptionContractualTerm" xlink:label="ikna_StockOptionContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_StockOptionContractualTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncomeTaxesLineItems" xlink:label="ikna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncomeTaxesTable" xlink:label="ikna_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_NotSubjectToExpirationMember" xlink:label="ikna_NotSubjectToExpirationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLossCarryforwardsExpirationYear" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_BeginToExpireInTwoThousandThirtySevenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="ikna_NotSubjectToExpirationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ikna_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LicenseMaintenanceFees" xlink:label="ikna_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AskAtLicenseMember" xlink:label="ikna_AskAtLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PotentialDevelopmentMilestonePayments" xlink:label="ikna_PotentialDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RoyaltiesTerms" xlink:label="ikna_RoyaltiesTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PotentialSalesEventMilestonePayments" xlink:label="ikna_PotentialSalesEventMilestonePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_LicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ikna_AskAtLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialDevelopmentMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_RoyaltiesTerms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ikna_PotentialSalesEventMilestonePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_VertexPharmaceuticalsMember" xlink:label="ikna_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BostonMassachusettsMember" xlink:label="ikna_BostonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AreaOfLeasedProperty" xlink:label="ikna_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeaseCommencementDate" xlink:label="ikna_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeaseRentFreePeriod" xlink:label="ikna_LeaseRentFreePeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLeaseMonthlyBaseRent" xlink:label="ikna_OperatingLeaseMonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PercentageEscalationInAnnualBaseRent" xlink:label="ikna_PercentageEscalationInAnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LetterOfCreditToSecureLease" xlink:label="ikna_LetterOfCreditToSecureLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ikna_VertexPharmaceuticalsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ikna_BostonMassachusettsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_AreaOfLeasedProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LesseeOperatingLeaseMaturityMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LeaseRentFreePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseMonthlyBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_PercentageEscalationInAnnualBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_LetterOfCreditToSecureLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ikna_OperatingLeaseTermExtendedExpirationPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_AffiliatedEntityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ikna_UniversityOfTexasAtAustinMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OptionsToPurchaseCommonStockMember" xlink:label="ikna_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ikna_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ikna_ResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>34
<FILENAME>ikna-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-16T15:36:09.3968+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="ikna-20211231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows" xlink:href="ikna-20211231.xsd#StatementConsolidatedStatementOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ikna-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:href="ikna-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="ikna-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:href="ikna-20211231.xsd#DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:href="ikna-20211231.xsd#DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="ikna_DepositsAndOtherAssetsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_DepositsAndOtherAssetsNoncurrent" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="10" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" xlink:label="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="ikna_AccruedResearchAndDevelopmentExpensesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="ikna_DeferredTaxAssetsLeaseLiability" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_DeferredTaxAssetsLeaseLiability" xlink:label="ikna_DeferredTaxAssetsLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>ikna-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-16T15:36:08.5391+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:label="us-gaap_PreferredStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncomeTaxesLineItems" xlink:label="ikna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" xlink:label="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BostonMassachusettsMember" xlink:label="ikna_BostonMassachusettsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_DepositsAndOtherAssetsNoncurrent" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityNonCumulativeDividend" xlink:label="ikna_TemporaryEquityNonCumulativeDividend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesA1PreferredStockMember" xlink:label="ikna_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_NotSubjectToExpirationMember" xlink:label="ikna_NotSubjectToExpirationMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ResearchAndDevelopmentMember" xlink:label="ikna_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OptionsToPurchaseCommonStockMember" xlink:label="ikna_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BristolMyersSquibbMember" xlink:label="ikna_BristolMyersSquibbMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarliestTaxYearMember" xlink:label="us-gaap_EarliestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UniversityOfTexasAtAustinMember" xlink:label="ikna_UniversityOfTexasAtAustinMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LabEquipmentMember" xlink:label="ikna_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LetterOfCreditToSecureLease" xlink:label="ikna_LetterOfCreditToSecureLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncomeTaxesTable" xlink:label="ikna_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OfferingCostsRecognized" xlink:label="ikna_OfferingCostsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PotentialSalesEventMilestonePayments" xlink:label="ikna_PotentialSalesEventMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_DeferredTaxAssetsLeaseLiability" xlink:label="ikna_DeferredTaxAssetsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLossCarryforwardsExpirationYear" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LicenseMaintenanceFees" xlink:label="ikna_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLeaseMonthlyBaseRent" xlink:label="ikna_OperatingLeaseMonthlyBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RedeemableConvertiblePreferredStockTextBlock" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_StockPurchaseAgreementWithBMSMember" xlink:label="ikna_StockPurchaseAgreementWithBMSMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AreaOfLeasedProperty" xlink:label="ikna_AreaOfLeasedProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RoyaltiesTerms" xlink:label="ikna_RoyaltiesTerms"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeasesPolicyPolicyTextBlock" xlink:label="ikna_LeasesPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IKFourOneTwoMember" xlink:label="ikna_IKFourOneTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LiquidityPolicyTextBlock" xlink:label="ikna_LiquidityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_MilestonePaymentsEligibleToReceive" xlink:label="ikna_MilestonePaymentsEligibleToReceive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PercentageEscalationInAnnualBaseRent" xlink:label="ikna_PercentageEscalationInAnnualBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_PotentialDevelopmentMilestonePayments" xlink:label="ikna_PotentialDevelopmentMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_VertexPharmaceuticalsMember" xlink:label="ikna_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_Supplementalcashflowinformationleasesabstract" xlink:label="ikna_Supplementalcashflowinformationleasesabstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_IKOneSevenFiveMember" xlink:label="ikna_IKOneSevenFiveMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AskAtLicenseMember" xlink:label="ikna_AskAtLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_UpfrontPayment" xlink:label="ikna_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeaseRentFreePeriod" xlink:label="ikna_LeaseRentFreePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_StockOptionContractualTerm" xlink:label="ikna_StockOptionContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_BMSCollaborationAgreementMember" xlink:label="ikna_BMSCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_LeaseCommencementDate" xlink:label="ikna_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="ikna-20211231.xsd#ikna_ElectronicEquipmentAndSoftwareMember" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility range maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable convertible preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of equity instruments issued in connection with asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_CollaborationAndStockPurchaseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And Stock Purchase Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments to acquire property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 150,000,000 shares authorized, 35,975,034 issued and outstanding as of December 31, 2021; 230,000,000 shares authorized, 3,096,903 issued and outstanding as of December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront amount allocated to equity arrangements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Amount Allocated To Equity Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront amount allocated to equity arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UT Austin License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Leasing Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Cash Flow Information Relating to the Company's Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contributions to defined contribution savings plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Option exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized which were previously included in deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, ASU, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 15)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of issuance costs, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payment for Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from payment for issuance initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and principles of consolidation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Principles Of Consolidation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Affiliated Entity [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AffiliatedEntityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Affiliated to Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows (used in) provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares purchased by employees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Purchased By Employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased by employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BostonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston, Massachusetts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BostonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Boston Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BostonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston, Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits and Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits and Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DepositsAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deposits and other assets noncurrent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityNonCumulativeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of non-cumulative dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityNonCumulativeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Non-Cumulative Dividend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityNonCumulativeDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, non-cumulative dividend.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University license fees and certain-patent related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series a-1 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) provided by operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Not Subject to Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not Subject to Expiration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_NotSubjectToExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Not subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research And Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical, manufacturing and scientific development current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Manufacturing And Scientific Development Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical, manufacturing and scientific development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfers between level 2 to level 1 financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Remaining Lease Terms and Discount Rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Remaining Lease Term And Discount Rate [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of remaining lease term and discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets obtained in asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bristol-Myers Squibb.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bristol Myers Squibb [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BristolMyersSquibbMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earliest Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earliest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2021 and no shares authorized as of December 31, 2020; No shares issued and outstanding as of December 31, 2021 or December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UniversityOfTexasAtAustinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Texas at Austin.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UniversityOfTexasAtAustinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">University Of Texas At Austin [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UniversityOfTexasAtAustinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, plan effective date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Plan Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan effective date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LetterOfCreditToSecureLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter of credit to secure lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LetterOfCreditToSecureLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit To Secure Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LetterOfCreditToSecureLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit to secure lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Cancelled or forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred stock, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payment for Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from payment for issuance of preferred stock and preference stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BMS collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B M S Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-cash research and development expense for in-process research and development acquired in acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration allocated to technology recognized as research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities assumed in asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments for Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss and comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and of Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with private placement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets recognized upon adoption of new accounting standard codification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-use Assets Recognized Upon Adoption of New Accounting Standard Codification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets recognized upon adoption of ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OfferingCostsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs recognized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OfferingCostsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OfferingCostsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialSalesEventMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential sales event milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialSalesEventMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Sales Event Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialSalesEventMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestones payable contingent on sales in calendar year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration begin month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Begin Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards begin to expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock (Series A, A-1, A-2, and B), $0.001 par value. No shares authorized, issued and outstanding as of December 31, 2021; 169,396,576 shares, authorized, issued and outstanding as of December 31, 2020 (liquidation preference $0 as of December 31, 2021 and $202.2 million as of December 31, 2020)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from initial public offering, net of offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds received after deducting underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of components of Lease Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquired in-process R&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards, expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk number of financial institutions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk Number Of Financial Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of credit risk, number of financial institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Latest Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LatestTaxYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Latest Tax Year [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility range minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected option term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less amounts representing interest or imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A one redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A One Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves for uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities (operating cash flows)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount eligible to receive in case of exercise of options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Eligible To Receive In Case Of Exercise Of Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount eligible to receive in case of exercise of options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-allotment Option to Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease monthly base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Monthly Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued for purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, remaining performance obligation, expected timing of satisfaction, explanation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement with BMS.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement With B M S [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockPurchaseAgreementWithBMSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement with BMS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased property.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Leased Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AreaOfLeasedProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of leased property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value On Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RoyaltiesTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties terms.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RoyaltiesTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RoyaltiesTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeasesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeasesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeasesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance increased amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKFourOneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IK-four one two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKFourOneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I K Four One Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKFourOneTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IK-412</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax returns years open and subject to examination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash obtained in asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of holders of outstanding shares of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Holders Of Outstanding Shares Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of holders of outstanding shares of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseMaturityMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease maturity month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets Current Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred issuance costs capitalized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Begin to Expire in 2037</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Begin to Expire in Two Thousand Thirty Seven [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Begin to expire in two thousand thirty seven.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_MilestonePaymentsEligibleToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments eligible to receive.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_MilestonePaymentsEligibleToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Eligible To Receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_MilestonePaymentsEligibleToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageEscalationInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage escalation in annual base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageEscalationInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Escalation In Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PercentageEscalationInAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage escalation in annual base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties accrued on uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in number of shares reserved and available for issuance as percentage on common stock outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Number Of Shares Reserved And Available For Issuance As Percentage On Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares reserved and available for issuance as percentage on common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential development milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Development Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_PotentialDevelopmentMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments payable upon meeting certain development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex pharmaceuticals.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Pharmaceuticals Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease term extended expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Term Extended Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extended term period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets and lease liabilities recognized upon lease inception</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets And Lease Liabilities Recognized Upon Lease Inception</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets and lease liabilities recognized upon lease inception.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to exercise additional consideration if clinical trial not completed within research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Exercise Additional Consideration If Clinical Trial Not Completed Within Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to exercise additional consideration if clinical trial not completed within research term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable convertible preferred stock, liquidation preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement and Stock Purchase Agreement with BMS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to revenue arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Supplementalcashflowinformationleasesabstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SupplementalCashFlowInformationLeasesAbstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Supplementalcashflowinformationleasesabstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplementalcashflowinformationleases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State net operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized start-up costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one stock incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for issuance percentage of annual increase in number of common stock outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Issuance Percentage Of Annual Increase In Number Of Common Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for issuance percentage of annual increase in number of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKOneSevenFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IK-one seven five.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKOneSevenFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I K One Seven Five [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_IKOneSevenFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IK-175</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recognized on uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with private placement, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AskAtLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AskAt license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AskAtLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ask At License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AskAtLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AskAt License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront consideration payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average fair value of the stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity dividend declared or paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Dividend Declared or Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Dividend Declared or Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deposits and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deposit Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deposit Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-deductible expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease rent payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Two Redeemable Convertible Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Two Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation balance for unvested options expected to be recognized period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseRentFreePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease rent free period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseRentFreePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Rent Free Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseRentFreePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease rent free period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockOptionContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockOptionContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_StockOptionContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BMS collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B M S Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_BMSCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BMS Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in accounting principle, ASU, Adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development revenue under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash included in other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred transaction costs in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred transaction costs in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DeferredTransactionCostsInAccountsPayableAndAccruedExpenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc., Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends payable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and other liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Other Liabilities Current Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities and other liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax effected at statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' deficit:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued pursuant to acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc., Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares acquisitions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company issued and sold shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Electronic equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Electronic Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ikna_ElectronicEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Electronic Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized stock-based compensation balance for unvested options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value On Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfers between level 1 to level 2 financial assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options exercisable as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Total Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_CollaborationAndStockPurchaseAgreementAbstract" xlink:to="ikna_CollaborationAndStockPurchaseAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_UpfrontAmountAllocatedToEquityArrangements" xlink:to="ikna_UpfrontAmountAllocatedToEquityArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IncomeTaxesLineItems" xlink:to="ikna_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering" xlink:to="ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock" xlink:to="ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BostonMassachusettsMember" xlink:to="ikna_BostonMassachusettsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_DepositsAndOtherAssetsNoncurrent" xlink:to="ikna_DepositsAndOtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityNonCumulativeDividend" xlink:to="ikna_TemporaryEquityNonCumulativeDividend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesA1PreferredStockMember" xlink:to="ikna_SeriesA1PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_NotSubjectToExpirationMember" xlink:to="ikna_NotSubjectToExpirationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ResearchAndDevelopmentMember" xlink:to="ikna_ResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OptionsToPurchaseCommonStockMember" xlink:to="ikna_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent" xlink:to="ikna_ClinicalManufacturingAndScientificDevelopmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BristolMyersSquibbMember" xlink:to="ikna_BristolMyersSquibbMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_UniversityOfTexasAtAustinMember" xlink:to="ikna_UniversityOfTexasAtAustinMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LabEquipmentMember" xlink:to="ikna_LabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate" xlink:to="ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LetterOfCreditToSecureLease" xlink:to="ikna_LetterOfCreditToSecureLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IncomeTaxesTable" xlink:to="ikna_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock" xlink:to="ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification" xlink:to="ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OfferingCostsRecognized" xlink:to="ikna_OfferingCostsRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PotentialSalesEventMilestonePayments" xlink:to="ikna_PotentialSalesEventMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_DeferredTaxAssetsLeaseLiability" xlink:to="ikna_DeferredTaxAssetsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear" xlink:to="ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OperatingLossCarryforwardsExpirationYear" xlink:to="ikna_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions" xlink:to="ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember" xlink:to="ikna_SeriesAOneRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions" xlink:to="ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LicenseMaintenanceFees" xlink:to="ikna_LicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OperatingLeaseMonthlyBaseRent" xlink:to="ikna_OperatingLeaseMonthlyBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RedeemableConvertiblePreferredStockTextBlock" xlink:to="ikna_RedeemableConvertiblePreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_StockPurchaseAgreementWithBMSMember" xlink:to="ikna_StockPurchaseAgreementWithBMSMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AreaOfLeasedProperty" xlink:to="ikna_AreaOfLeasedProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RoyaltiesTerms" xlink:to="ikna_RoyaltiesTerms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="ikna_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LeasesPolicyPolicyTextBlock" xlink:to="ikna_LeasesPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IKFourOneTwoMember" xlink:to="ikna_IKFourOneTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock" xlink:to="ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LiquidityPolicyTextBlock" xlink:to="ikna_LiquidityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LesseeOperatingLeaseMaturityMonthAndYear" xlink:to="ikna_LesseeOperatingLeaseMaturityMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock" xlink:to="ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BeginToExpireInTwoThousandThirtySevenMember" xlink:to="ikna_BeginToExpireInTwoThousandThirtySevenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_MilestonePaymentsEligibleToReceive" xlink:to="ikna_MilestonePaymentsEligibleToReceive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PercentageEscalationInAnnualBaseRent" xlink:to="ikna_PercentageEscalationInAnnualBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding" xlink:to="ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_PotentialDevelopmentMilestonePayments" xlink:to="ikna_PotentialDevelopmentMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="ikna_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_VertexPharmaceuticalsMember" xlink:to="ikna_VertexPharmaceuticalsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OperatingLeaseTermExtendedExpirationPeriod" xlink:to="ikna_OperatingLeaseTermExtendedExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="ikna_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception" xlink:to="ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm" xlink:to="ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_Supplementalcashflowinformationleasesabstract" xlink:to="ikna_Supplementalcashflowinformationleasesabstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="ikna_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding" xlink:to="ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_IKOneSevenFiveMember" xlink:to="ikna_IKOneSevenFiveMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AskAtLicenseMember" xlink:to="ikna_AskAtLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_UpfrontPayment" xlink:to="ikna_UpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter" xlink:to="ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityDividendDeclaredOrPaid" xlink:to="ikna_TemporaryEquityDividendDeclaredOrPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:to="ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember" xlink:to="ikna_SeriesATwoRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LeaseRentFreePeriod" xlink:to="ikna_LeaseRentFreePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_StockOptionContractualTerm" xlink:to="ikna_StockOptionContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_BMSCollaborationAgreementMember" xlink:to="ikna_BMSCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_LeaseCommencementDate" xlink:to="ikna_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses" xlink:to="ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock" xlink:to="ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions" xlink:to="ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ikna_ElectronicEquipmentAndSoftwareMember" xlink:to="ikna_ElectronicEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901604184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IKENA ONCOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001835579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1697316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">645 Summer Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">273-8343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IKNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,108,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Portions of the registrant&#8217;s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903947400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 232,217<span></span>
</td>
<td class="nump">$ 162,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,299<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">236,516<span></span>
</td>
<td class="nump">165,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">6,538<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_DepositsAndOtherAssetsNoncurrent', window );">Deposits and Other assets</a></td>
<td class="nump">2,386<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">247,879<span></span>
</td>
<td class="nump">168,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,384<span></span>
</td>
<td class="nump">2,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">5,854<span></span>
</td>
<td class="nump">5,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">17,100<span></span>
</td>
<td class="nump">20,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">27,189<span></span>
</td>
<td class="nump">28,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">5,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">7,678<span></span>
</td>
<td class="nump">35,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">40,002<span></span>
</td>
<td class="nump">63,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock (Series A, A-1, A-2, and B), $0.001 par value. No shares authorized, issued and outstanding as of December 31, 2021; 169,396,576 shares, authorized, issued and outstanding as of December 31, 2020 (liquidation preference $0 as of December 31, 2021 and $202.2 million as of December 31, 2020)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">205,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2021 and no shares authorized as of December 31, 2020; No shares issued and outstanding as of December 31, 2021 or December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 150,000,000 shares authorized, 35,975,034 issued and outstanding as of December 31, 2021; 230,000,000 shares authorized, 3,096,903 issued and outstanding as of December 31, 2020</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">353,295<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(145,454)<span></span>
</td>
<td class="num">(111,339)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">207,877<span></span>
</td>
<td class="num">(101,048)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' equity</a></td>
<td class="nump">$ 247,879<span></span>
</td>
<td class="nump">$ 168,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deposits and other assets noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901589688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 202,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">35,975,034<span></span>
</td>
<td class="nump">3,096,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">35,975,034<span></span>
</td>
<td class="nump">3,096,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901466856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Research and development revenue under collaboration agreement</a></td>
<td class="nump">$ 30,985<span></span>
</td>
<td class="nump">$ 9,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">Research And Development Member<span></span>
</td>
<td class="text">Research And Development Member<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 47,108<span></span>
</td>
<td class="nump">$ 44,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,015<span></span>
</td>
<td class="nump">8,866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">65,123<span></span>
</td>
<td class="nump">53,713<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(34,138)<span></span>
</td>
<td class="num">(44,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (34,115)<span></span>
</td>
<td class="num">$ (44,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (16.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock outstanding, basic and diluted</a></td>
<td class="nump">27,983,359<span></span>
</td>
<td class="nump">2,765,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123410239&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900501672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,727,268<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,867<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,651,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="num">$ (61,463)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 5,617<span></span>
</td>
<td class="num">$ (67,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions', window );">Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc., Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc.</a></td>
<td class="nump">2,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc., Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock in connection with private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock in connection with private placement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,806,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (44,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 205,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,979<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,096,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="num">(101,048)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
<td class="num">(111,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Initial public offering, net of issuance costs</a></td>
<td class="nump">131,302<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">131,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,984,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (205,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,396,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">205,979<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">205,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,678,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">215,188<span></span>
</td>
<td class="nump">215,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 5,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (34,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,975,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 207,877<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 353,295<span></span>
</td>
<td class="num">$ (145,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901506488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901628200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (34,115)<span></span>
</td>
<td class="num">$ (44,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">1,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash research and development expense for in-process research and development acquired in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,452)<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLeasingReceivables', window );">Lease liability</a></td>
<td class="num">(740)<span></span>
</td>
<td class="num">(978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(30,985)<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits and other assets</a></td>
<td class="num">(1,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(60,252)<span></span>
</td>
<td class="num">(37,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash obtained in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments to acquire property and equipment</a></td>
<td class="num">(1,760)<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows (used in) provided by investing activities</a></td>
<td class="num">(1,760)<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of offering costs</a></td>
<td class="num">(146)<span></span>
</td>
<td class="nump">116,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of offering costs</a></td>
<td class="nump">131,302<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">131,738<span></span>
</td>
<td class="nump">116,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">69,726<span></span>
</td>
<td class="nump">81,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">163,363<span></span>
</td>
<td class="nump">82,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">233,089<span></span>
</td>
<td class="nump">163,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">232,217<span></span>
</td>
<td class="nump">162,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash included in other assets</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">233,089<span></span>
</td>
<td class="nump">163,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Assets obtained in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Liabilities assumed in asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Fair value of equity instruments issued in connection with asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses', window );">Deferred transaction costs in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification', window );">Right-of-use assets recognized upon adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception', window );">Right-of-use assets and lease liabilities recognized upon lease inception</a></td>
<td class="nump">$ 7,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred transaction costs in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from payment for issuance initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from payment for issuance of preferred stock and preference stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets and lease liabilities recognized upon lease inception.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets recognized upon adoption of new accounting standard codification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLeasingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLeasingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942987358216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business and Organization</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. NATURE OF BUSINESS AND ORGANIZATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment (TME), with approaches to targeting both cancer-driving targets and mechanisms of resistance to targeted therapies. Our focus on patient-driven development is platform and process agnostic, allowing us to research both known and novel targets , with a shared guiding principle of aiming to address the unmet need of a biomarker-defined patient population. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust pipeline of discovery-stage targeted oncology programs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 22, 2021, ahead of the initial public offering, the Company effected a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7fdb186e-815c-4baa-b15f-3f79588d331f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.154</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Company&#8217;s common stock. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of the Company&#8217;s convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 25, 2021, the Company&#8217;s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;). In the IPO, which closed on March 30, 2021, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,984,375</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, including full exercise of the underwriters&#8217; over-allotment option to purchase an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,171,875</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and received $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903664312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation and Principles of Consolidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#8220;Arrys&#8221;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#8220;Amplify&#8221;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and development revenue under a collaboration agreement, and intangible assets acquired in an asset acquisition and, for periods prior to the completion of the IPO, stock based compensation expense.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December 31, 2021, will be sufficient to enable us to advance our long-term strategic goals for at least the next 12 months from the filing of this annual report on Form 10-K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing, or terminating planned activities related to its product candidates.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segments: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and of Significant Suppliers: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, substantially all of the Company&#8217;s cash and cash equivalents were deposited at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> highly rated financial institutions. The Company maintains balances in operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers and clinical research organizations to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value of Financial Instruments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amounts reported for cash equivalents, accounts payable and accrued expenses approximate fair value because of their short maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cash equivalents are generally composed of commercial paper, corporate notes, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Cash: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company maintained restricted cash totaling approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, held in the form of a money market account as collateral for the Company&#8217;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Electronic equipment and software are depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the shorter of their useful life or lease term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Long-lived Assets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets consist of property and equipment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue Recognition: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to revenue recognition are recorded as deferred revenue. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts expected to be recognized as revenue within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had one collaborative agreement with Bristol-Myers Squibb (&#8220;BMS&#8221;), which the Company entered into in January 2019 (the &#8220;BMS Collaboration Agreement&#8221;). For a complete discussion of the accounting related to BMS Collaboration Agreement, see Note 7, Collaboration Agreement and Stock Purchase Agreement with BMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Expense: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials. Research and development expense for the year ended December 31, 2020, also includes the write-off of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) assets with no alternative future use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Asset Acquisitions:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#8217;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividend yield was assumed as the Company does not intend to pay dividends on its common stock.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6242453e-6005-48f3-94c4-c7e1e8f8f635;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting Standards Codification</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC) 842 Leases, which was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company's operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Comprehensive Loss: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Issuance Costs: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred issuance costs consist of legal, accounting and other third-party fees that are directly associated with in-process equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the proceeds generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 30, 2021, the Company completed its IPO. Accordingly, the Company recognized offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from the gross proceeds associated with the closing of the IPO through additional paid-in capital in the accompanying consolidated balance sheet. The Company incurred deferred offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2020 which were included in prepaid expenses and other current assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company Status: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942905181320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. FAIR VALUE MEASUREMENTS</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.878%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.452%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.527%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Cash Equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.878%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.452%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.527%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Cash Equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between Level 1 and Level 2 financial assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942905198168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.247%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.605%;"/>
        <td style="width:0.817%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.605%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical, manufacturing and scientific development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">850</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,538</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,299</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,478</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903826584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. PROPERTY AND EQUITPMENT, NET</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.832%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.538%;"/>
        <td style="width:1.285%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.257%;"/>
        <td style="width:1.285%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,776</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,071</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Electronic equipment and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,513</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,081</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,439</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense for the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903854984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.194%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.631%;"/>
        <td style="width:0.817%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.631%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,816</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,489</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,251</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">955</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">380</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,854</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903771080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement and Stock Purchase Agreement with BMS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_CollaborationAndStockPurchaseAgreementAbstract', window );"><strong>Collaboration And Stock Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreement and Stock Purchase Agreement with BMS</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. COLLABORATION AGREEMENT AND STOCK PURCHASE AGREEMENT WITH BMS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2019, the Company entered into the BMS Collaboration Agreement with Celgene Corporation, which was acquired by BMS in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the BMS Collaboration Agreement, the Company entered into a stock purchase agreement with BMS, which resulted in the issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,545,450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A-1 Preferred Stock (the &#8220;Stock Purchase Agreement&#8221;). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Company&#8217;s IPO, the series A-1 preferred stock converted into common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Structure</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the BMS Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the aryl hydrocarbon receptor (&#8220;AHR&#8221;), which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program ("the research term"). BMS has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, BMS is responsible for the worldwide development, manufacturing and commercialization of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BMS paid the Company a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in case of an exercise of its option with respect to IK-175, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to BMS to support the decision to exercise the option for an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Considerations of the Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The BMS Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the upfront from the BMS Collaboration Agreement was allocated to the equity arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the BMS Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on the distinct performance obligations identified above, the Company allocated the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for research and development services for IK-175; and </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for research and development services for IK-412. </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the BMS partnership, the Company made the strategic decision to pause IK-412 developm</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ent activities for the remainder of the BMS research term once the ongoing CMC work has been completed. As a result of the decision to pause, the Company recorded a change in estimate during the three months ended December 31, 2021 and recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of research and development revenue.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recognized revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, from the BMS Collaboration Agreement. The consolidated balance sheet as of December 31, 2021 includes deferred revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> related this agreement, of which </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were classified as current and non-current, respectively. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for IK-175 and IK-412.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_CollaborationAndStockPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_CollaborationAndStockPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903774440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_RedeemableConvertiblePreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. REDEEMABLE CONVERTIBLE PREFERRED STOCK</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the closing of the Company&#8217;s IPO on March 30, 2021, all issued and outstanding Redeemable Convertible Preferred Stock of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23,678,568</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock and are </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> longer issued.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, the authorized capital stock of the Company included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible preferred stock.</span></p><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, redeemable convertible preferred stock consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:29.828%;"/>
        <td style="width:1.649%;"/>
        <td style="width:0.685%;"/>
        <td style="width:14.491%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.649%;"/>
        <td style="width:0.685%;"/>
        <td style="width:14.491%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.649%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.859%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.649%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.88%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares<br/>Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares Issued<br/>and Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Liquidation<br/>Preference</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,727,268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,727,268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,035</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,727</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A-2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,863,094</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,863,094</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,806,214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,806,214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,188</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205,979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">202,227</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Preferred Stock had the following characteristics as of December 31, 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a)	Voting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Company&#8217;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and have other special voting rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of outstanding shares of Preferred Stock shall be entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b)	Dividends</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of Preferred Stock are entitled to an </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% non-cumulative dividend. Dividends are payable only when, as and if declared by the Board. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Through December 31, 2020 and the completion of the IPO, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared or paid by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c)     Liquidation Preference</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed liquidation events, holders of shares of Preferred Stock then outstanding shall be entitled to receive the greater of (i) an amount per share equal to the Preferred Stock original issue price, plus any dividends declared but unpaid thereon or (ii) the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d)	Conversion</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for one and are automatically converted upon a qualified initial public offering or upon written consent of at least </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain dividends and distributions, and mergers and reorganizations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The conversion ratio was changed to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.154</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for one upon the Company&#8217;s filing of its amendment to its Amended and Restated Certificate of Incorporation on March 22, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_RedeemableConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_RedeemableConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903782552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. COMMON STOCK</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">230,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock authorized, respectively, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,975,034</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,096,903</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were issued and outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Voting: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividends: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are distributed to the holders of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942905181320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">. STOCK BASED COMPENSATION</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2016, the Company&#8217;s board of directors and stockholders adopted the 2016 Stock Incentive Plan which was amended and restated in December 2020, (as so amended and restated, the &#8220;2016 Plan&#8221;) which permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code, and (2) options that do not so qualify.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">       </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021, the Company&#8217;s board of directors approved, and on March 20, 2021, the Company&#8217;s stockholders approved the 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;), which became effective on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 30, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The 2021 Plan replaced the 2016 Plan as the board of directors had determined it would not to make additional awards under the 2016 Plan following the closing of the initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to officers, employees, directors and consultants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the effective date of the 2021 Plan, no further awards will be made under the 2016 Plan. Any options or awards outstanding under the 2016 Plan remain outstanding and effective and are governed by their existing terms. The shares of the Company&#8217;s common stock subject to outstanding awards under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2021 Plan. No more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,263,664</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock may be granted subject to incentive stock options under the 2021 Plan. In addition, the 2021 Plan contains an &#8220;evergreen&#8221; provision, which allows for an annual increase in the number of shares of common stock available for issuance under the 2021 Plan on the first day of each fiscal year during the period beginning in fiscal year 2022. The annual increase in the number of shares shall be equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the 2021 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,250,479</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock remain available for future issuance under the 2021 Plan. The vesting periods for equity awards, which generally is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, are determined by the Board of Directors. The contractual term for stock option awards is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.301%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.591%;"/>
        <td style="width:0.817%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.591%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,750</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,007</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average fair value of the stock options granted during the year ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.53</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation balance for unvested options was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> which is expected to be recognized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.97</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes stock option activity under the Plan for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.128%;"/>
        <td style="width:1.188%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.935%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.188%;"/>
        <td style="width:1.37%;"/>
        <td style="width:9.496%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.188%;"/>
        <td style="width:0.707%;"/>
        <td style="width:10.074%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.188%;"/>
        <td style="width:1.37%;"/>
        <td style="width:9.517%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,650,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.01</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,463</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,435,687</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">215,188</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,522</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.21</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.27</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested or expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.27</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,841,894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.71</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intrinsic value of options exercised for the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each option award granted during the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is estimated on the date of grant using the Black-Scholes option pricing model and the weighted average assumptions noted in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.059%;"/>
        <td style="width:1.06%;"/>
        <td style="width:10.8%;"/>
        <td style="width:9.583%;"/>
        <td style="width:2.897%;"/>
        <td style="width:1.06%;"/>
        <td style="width:0.744%;"/>
        <td style="width:17.272%;"/>
        <td style="width:2.525%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.68</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.47</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility range</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.58</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 20, 2021, the Company&#8217;s stockholders approved the 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 30, 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">346,613</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been purchased by employees under the ESPP.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903786696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. EMPLOYEE BENEFIT PLAN</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a defined-contribution savings plan covering all eligible U.S. employees under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). During the years ended December 31, 2021 and 2020, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t make any employer contributions to the plan. Employees can designate the investment of their 401(k) accounts into several mutual funds. Administrative costs of the plan for each of the years ended December 31, 2021 and 2020, were immaterial.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903878968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. INCOME TAXES</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.517%;"/>
        <td style="width:1.473%;"/>
        <td style="width:0.803%;"/>
        <td style="width:12.008%;"/>
        <td style="width:4.458%;"/>
        <td style="width:1.473%;"/>
        <td style="width:0.803%;"/>
        <td style="width:12.008%;"/>
        <td style="width:4.458%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax effected at statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired in-process R&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s total deferred tax assets are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.779%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.924%;"/>
        <td style="width:1.285%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.924%;"/>
        <td style="width:1.285%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,233</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,445</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,593</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,385</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized start-up costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">629</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">327</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,461</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,204</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">648</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,434</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation Allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets and liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2021, the valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million primarily due to the increase in the Company's book loss reported in the period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of Federal and State operating loss carryforwards respectively. The Federal net operating losses are not subject to expiration and the state net operating losses begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million respectively, to offset future income taxes, which will begin to expire beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 2031</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company's ultimate parent.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company follows the provisions of ASC 740-10, Accounting for Uncertainty in Income Taxes, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2021, and 2020, the Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recorded tax reserves associated with any unrecognized tax benefits. The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December 31, 2021, and 2020, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reserves for uncertain tax positions. For the years ended December 31, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> estimated interest or penalties were recognized on uncertain tax positions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's Federal and Massachusetts income tax returns for the years ended December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> remain open and are subject to examination by the Internal Revenue Service and state taxing authorities.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903849256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research License Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. RESEARCH LICENSE AGREEMENTS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2015, the Company entered into an exclusive patent license agreement (the &#8220;UT Austin License&#8221;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#8220;University&#8221;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon meeting certain development milestones during the term of the UT Austin License. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2018, the Company acquired IPR&amp;D on an Arrys&#8217; immune-oncology candidate based on the intellectual property associated with Arrys&#8217; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, as well as certain sales event milestones ranging from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million contingent on sales in a calendar year, during the term of the AskAt License.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903815848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lease Obligation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. LEASE OBLIGATION</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2018, the Company entered into an operating lease with Vertex Pharmaceuticals Inc. (&#8220;Vertex&#8221;) to lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,170</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office, laboratory and vivarium space at 50 Northern Ave, Boston, Massachusetts, expiring in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 2020</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In July 2020, the Company extended the term of the lease through </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 21, 2020, the Company entered into an operating lease agreement for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,752</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company&#8217;s corporate headquarters. The commencement date of the lease was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 19, 2021</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the lease term is </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63 months</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The lease provides a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-month</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> free rent period, which commenced on the lease commencement date. The base rent at commencement is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand per month and escalates by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% annually for total lease payments during the term of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and an operating lease liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the commencement of the lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.231%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.201%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.201%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,693</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,011</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">479</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">706</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,717</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with our operating leases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information relating to the Company&#8217;s leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.235%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.2%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.2%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities (operating cash flows)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining lease terms and discount rates related to our leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.966%;"/>
        <td style="width:1.627%;"/>
        <td style="width:14.89%;"/>
        <td style="width:1.627%;"/>
        <td style="width:14.89%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Remaining lease term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount Rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future minimum lease payments for the Company&#8217;s operating lease as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, were as follows (in </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thousands</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.788%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.187%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fiscal Year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Operating<br/>Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,774</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,827</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,882</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,938</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">817</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,238</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less amounts representing interest or imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,251</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942905193368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. COMMITMENTS AND CONTINGENCIES</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December 31, 2021 or royalties on future sales of specified products that have not yet occurred as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903864904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. RELATED PARTY TRANSACTIONS</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company entered into several agreements with a director and an entity affiliated with a director:</span></p><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in Note 11 abov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e, the Company has entered into a license agreement with the University, which was affiliated with a director of the Company at the time of the license agreement. During the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Company recorded expenses in connection with University license fees and certain patent-related costs incurred on its behalf of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">233</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thousand, respectively. </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Certain entities affiliated with directors purchased shares in the IPO.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903672232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, restricted common stock, restricted stock units and stock options are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share were the same for all periods presented.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.636%;"/>
        <td style="width:1.165%;"/>
        <td style="width:0.951%;"/>
        <td style="width:16.472%;"/>
        <td style="width:0.951%;"/>
        <td style="width:1.165%;"/>
        <td style="width:0.951%;"/>
        <td style="width:17.892%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to Purchase Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,650,396</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172,046,972</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903975400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Basis of Presentation and Principles of Consolidation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#8220;Arrys&#8221;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#8220;Amplify&#8221;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and development revenue under a collaboration agreement, and intangible assets acquired in an asset acquisition and, for periods prior to the completion of the IPO, stock based compensation expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December 31, 2021, will be sufficient to enable us to advance our long-term strategic goals for at least the next 12 months from the filing of this annual report on Form 10-K.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#8217;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing, or terminating planned activities related to its product candidates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Segments: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#8220;CODM&#8221;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#8217;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable segment. All long-lived assets of the Company reside in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and of Significant Suppliers</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Concentration of Credit Risk and of Significant Suppliers: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, substantially all of the Company&#8217;s cash and cash equivalents were deposited at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> highly rated financial institutions. The Company maintains balances in operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is dependent on third-party manufacturers and clinical research organizations to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value of Financial Instruments: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amounts reported for cash equivalents, accounts payable and accrued expenses approximate fair value because of their short maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash and Cash Equivalents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cash equivalents are generally composed of commercial paper, corporate notes, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Restricted Cash: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company maintained restricted cash totaling approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, held in the form of a money market account as collateral for the Company&#8217;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Property and Equipment: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Electronic equipment and software are depreciated over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized over </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the shorter of their useful life or lease term.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Long-lived Assets: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets consist of property and equipment.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Income Taxes: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenue Recognition: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts received prior to revenue recognition are recorded as deferred revenue. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts expected to be recognized as revenue within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had one collaborative agreement with Bristol-Myers Squibb (&#8220;BMS&#8221;), which the Company entered into in January 2019 (the &#8220;BMS Collaboration Agreement&#8221;). For a complete discussion of the accounting related to BMS Collaboration Agreement, see Note 7, Collaboration Agreement and Stock Purchase Agreement with BMS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Research and Development Expense: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials. Research and development expense for the year ended December 31, 2020, also includes the write-off of acquired in-process research and development (&#8220;IPR&amp;D&#8221;) assets with no alternative future use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Asset Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Asset Acquisitions:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-based Compensation: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#8217;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividend yield was assumed as the Company does not intend to pay dividends on its common stock.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LeasesPolicyPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Leases: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6242453e-6005-48f3-94c4-c7e1e8f8f635;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounting Standards Codification</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC) 842 Leases, which was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company's operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.</span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Comprehensive Loss: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Issuance Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred Issuance Costs: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred issuance costs consist of legal, accounting and other third-party fees that are directly associated with in-process equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the proceeds generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 30, 2021, the Company completed its IPO. Accordingly, the Company recognized offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as a reduction from the gross proceeds associated with the closing of the IPO through additional paid-in capital in the accompanying consolidated balance sheet. The Company incurred deferred offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2020 which were included in prepaid expenses and other current assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company Status: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Accounting Pronouncements: </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and principles of consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LeasesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LeasesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903838808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value On Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information about the Company&#8217;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.878%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.452%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.527%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Cash Equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">232,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:35.878%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.441%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.452%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.51%;"/>
        <td style="width:1.37%;"/>
        <td style="width:12.527%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Quoted Prices in Active Markets<br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Observable Inputs<br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Significant Unobservable Inputs<br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Cash Equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903773880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.247%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.605%;"/>
        <td style="width:0.817%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.605%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical, manufacturing and scientific development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">850</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,538</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,299</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,478</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942905181880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.832%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.538%;"/>
        <td style="width:1.285%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.257%;"/>
        <td style="width:1.285%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,776</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,071</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Electronic equipment and software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">430</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,513</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,081</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: accumulated depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,074</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,439</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,393</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903798648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock', window );">Summary of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.194%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.631%;"/>
        <td style="width:0.817%;"/>
        <td style="width:1.513%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.631%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,809</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,816</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,489</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,251</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">530</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">955</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">380</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,854</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903809464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, redeemable convertible preferred stock consisted of the following:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:29.828%;"/>
        <td style="width:1.649%;"/>
        <td style="width:0.685%;"/>
        <td style="width:14.491%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.649%;"/>
        <td style="width:0.685%;"/>
        <td style="width:14.491%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.649%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.859%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.649%;"/>
        <td style="width:1.371%;"/>
        <td style="width:13.88%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares<br/>Authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares Issued<br/>and Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Liquidation<br/>Preference</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,000,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,727,268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,727,268</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,035</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,727</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series A-2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,863,094</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,863,094</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,500</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Series B</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,806,214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85,806,214</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,188</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205,979</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">202,227</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942985189096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.301%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.591%;"/>
        <td style="width:0.817%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1.942%;"/>
        <td style="width:13.591%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,750</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,007</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total share-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes stock option activity under the Plan for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:49.128%;"/>
        <td style="width:1.188%;"/>
        <td style="width:0.685%;"/>
        <td style="width:9.935%;"/>
        <td style="width:0.91%;"/>
        <td style="width:1.188%;"/>
        <td style="width:1.37%;"/>
        <td style="width:9.496%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.188%;"/>
        <td style="width:0.707%;"/>
        <td style="width:10.074%;"/>
        <td style="width:0.685%;"/>
        <td style="width:1.188%;"/>
        <td style="width:1.37%;"/>
        <td style="width:9.517%;"/>
        <td style="width:0.685%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,650,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.45</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.01</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,463</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,435,687</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.73</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">215,188</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled or forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,522</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.21</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.17</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.27</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,275</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested or expected to vest as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.27</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,841,894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.71</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each option award granted during the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is estimated on the date of grant using the Black-Scholes option pricing model and the weighted average assumptions noted in the following table:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.059%;"/>
        <td style="width:1.06%;"/>
        <td style="width:10.8%;"/>
        <td style="width:9.583%;"/>
        <td style="width:2.897%;"/>
        <td style="width:1.06%;"/>
        <td style="width:0.744%;"/>
        <td style="width:17.272%;"/>
        <td style="width:2.525%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.68</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.27</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.47</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility range</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.58</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73.15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942904732824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#8217;s loss before income taxes as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.517%;"/>
        <td style="width:1.473%;"/>
        <td style="width:0.803%;"/>
        <td style="width:12.008%;"/>
        <td style="width:4.458%;"/>
        <td style="width:1.473%;"/>
        <td style="width:0.803%;"/>
        <td style="width:12.008%;"/>
        <td style="width:4.458%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax effected at statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-deductible expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquired in-process R&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal research and development credits</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Total Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s total deferred tax assets are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:62.779%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.924%;"/>
        <td style="width:1.285%;"/>
        <td style="width:1.473%;"/>
        <td style="width:1.928%;"/>
        <td style="width:13.924%;"/>
        <td style="width:1.285%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,233</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,445</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State net operating loss carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,269</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,593</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">R&amp;D credit carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,385</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized start-up costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">629</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">327</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,234</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,026</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,461</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,204</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">648</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,786</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,434</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation Allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,034</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets and liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942904796184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of components of Lease Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.231%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.201%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.201%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,693</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,011</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">479</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">706</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,172</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,717</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Cash Flow Information Relating to the Company's Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information relating to the Company&#8217;s leases were as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.235%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.2%;"/>
        <td style="width:0.696%;"/>
        <td style="width:1.606%;"/>
        <td style="width:1.381%;"/>
        <td style="width:13.2%;"/>
        <td style="width:0.696%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for amounts included in the measurement of<br/>&#160;&#160;&#160;lease liabilities (operating cash flows)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,259</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Summary of Remaining Lease Terms and Discount Rates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining lease terms and discount rates related to our leases were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.966%;"/>
        <td style="width:1.627%;"/>
        <td style="width:14.89%;"/>
        <td style="width:1.627%;"/>
        <td style="width:14.89%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Remaining lease term</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount Rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments for Operating Lease</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future minimum lease payments for the Company&#8217;s operating lease as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, were as follows (in </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thousands</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.788%;"/>
        <td style="width:1.938%;"/>
        <td style="width:1.381%;"/>
        <td style="width:16.187%;"/>
        <td style="width:0.707%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fiscal Year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Operating<br/>Leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,774</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,827</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,882</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,938</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">817</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total minimum lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,238</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less amounts representing interest or imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,251</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903669752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.636%;"/>
        <td style="width:1.165%;"/>
        <td style="width:0.951%;"/>
        <td style="width:16.472%;"/>
        <td style="width:0.951%;"/>
        <td style="width:1.165%;"/>
        <td style="width:0.951%;"/>
        <td style="width:17.892%;"/>
        <td style="width:0.817%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,396,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to Purchase Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,650,396</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,822,373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172,046,972</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900347016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Organization - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-7.154 reverse stock split<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds received after deducting underwriting discounts and commissions | $</a></td>
<td class="nump">$ 131,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Company issued and sold shares of common stock</a></td>
<td class="nump">8,984,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment Option to Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Company issued and sold shares of common stock</a></td>
<td class="nump">1,171,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900249576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>FinancialInstitution</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions', window );">Concentration of credit risk, number of financial institutions | FinancialInstitution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, ASU, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, ASU, Adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember', window );">Electronic Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the shorter of their useful life or lease term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_OfferingCostsRecognized', window );">Offering costs recognized</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk number of financial institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OfferingCostsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OfferingCostsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903769400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)1 - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation', window );">Revenue, remaining performance obligation, expected timing of satisfaction, explanation</a></td>
<td class="text">Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of when remaining performance obligation is expected to be recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901661720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details) - Fair Value On Recurring Basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents</a></td>
<td class="nump">$ 232,017<span></span>
</td>
<td class="nump">$ 162,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents</a></td>
<td class="nump">232,017<span></span>
</td>
<td class="nump">162,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents</a></td>
<td class="nump">232,017<span></span>
</td>
<td class="nump">162,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total Cash Equivalents</a></td>
<td class="nump">$ 232,017<span></span>
</td>
<td class="nump">$ 162,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942985359880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfers between level 1 to level 2 financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfers between level 2 to level 1 financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900323528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ClinicalManufacturingAndScientificDevelopmentCurrent', window );">Clinical, manufacturing and scientific development</a></td>
<td class="nump">$ 2,820<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid Insurance</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="nump">$ 3,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ClinicalManufacturingAndScientificDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical, manufacturing and scientific development current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ClinicalManufacturingAndScientificDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900463400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 3,513<span></span>
</td>
<td class="nump">$ 2,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,074)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,776<span></span>
</td>
<td class="nump">1,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember', window );">Electronic Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ikna_ElectronicEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900664248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 544,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942901659112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses And Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation</a></td>
<td class="nump">$ 2,809<span></span>
</td>
<td class="nump">$ 1,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">2,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 5,854<span></span>
</td>
<td class="nump">$ 5,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and other liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942896481368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreement and Stock Purchase Agreement with BMS - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="nump">$ 20,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,678<span></span>
</td>
<td class="nump">7,678<span></span>
</td>
<td class="nump">35,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_StockPurchaseAgreementWithBMSMember', window );">Stock Purchase Agreement with BMS | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">14,545,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember', window );">BMS Collaboration Agreement and Stock Purchase Agreement | BMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_UpfrontPayment', window );">Upfront consideration payment</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm', window );">Option to exercise additional consideration if clinical trial not completed within research term</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_MilestonePaymentsEligibleToReceive', window );">Milestone payments eligible to receive</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember', window );">BMS Collaboration Agreement and Stock Purchase Agreement | BMS | IK-175</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions', window );">Amount eligible to receive in case of exercise of options</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember', window );">BMS Collaboration Agreement and Stock Purchase Agreement | BMS | IK-412</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions', window );">Amount eligible to receive in case of exercise of options</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_UpfrontAmountAllocatedToEquityArrangements', window );">Upfront amount allocated to equity arrangements</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to revenue arrangement</a></td>
<td class="nump">78,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized which were previously included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | IK-175</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to revenue arrangement</a></td>
<td class="nump">41,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementMember', window );">BMS Collaboration Agreement | IK-412</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to revenue arrangement</a></td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized which were previously included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount eligible to receive in case of exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_MilestonePaymentsEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_MilestonePaymentsEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to exercise additional consideration if clinical trial not completed within research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_UpfrontAmountAllocatedToEquityArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront amount allocated to equity arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_UpfrontAmountAllocatedToEquityArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_StockPurchaseAgreementWithBMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_StockPurchaseAgreementWithBMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ikna_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ikna_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ikna_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ikna_IKOneSevenFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ikna_IKOneSevenFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ikna_IKFourOneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ikna_IKFourOneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_BMSCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942896254680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of outstanding shares of Preferred Stock shall be entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends payable to common stockholders | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,727,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,396,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TemporaryEquityNonCumulativeDividend', window );">Percentage of non-cumulative dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TemporaryEquityDividendDeclaredOrPaid', window );">Temporary equity dividend declared or paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock', window );">Percentage of holders of outstanding shares of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">169,396,576<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="nump">23,678,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of holders of outstanding shares of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TemporaryEquityDividendDeclaredOrPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Dividend Declared or Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TemporaryEquityDividendDeclaredOrPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TemporaryEquityNonCumulativeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, non-cumulative dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TemporaryEquityNonCumulativeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942899500888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 205,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 202,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesAOneRedeemableConvertiblePreferredStockMember', window );">Series A-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,727,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,727,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,727,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesATwoRedeemableConvertiblePreferredStockMember', window );">Series A-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,806,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,806,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,806,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ikna_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesAOneRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ikna_SeriesAOneRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ikna_SeriesATwoRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ikna_SeriesATwoRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942905513992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">230,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">35,975,034<span></span>
</td>
<td class="nump">3,096,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">35,975,034<span></span>
</td>
<td class="nump">3,096,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942896150136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 30, 2021</div></th>
<th class="th"><div>Mar. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of the stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,435,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized stock-based compensation balance for unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Total unrecognized stock-based compensation balance for unvested options expected to be recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate', window );">Plan effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of stock granted</a></td>
<td class="nump">3,263,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding', window );">Available for issuance percentage of annual increase in number of common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_StockOptionContractualTerm', window );">Stock option contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate', window );">Plan effective date</a></td>
<td class="text">Mar. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding', window );">Increase in number of shares reserved and available for issuance as percentage on common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees', window );">Number of shares purchased by employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued for purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for issuance percentage of annual increase in number of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in number of shares reserved and available for issuance as percentage on common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares purchased by employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, plan effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_StockOptionContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_StockOptionContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900546040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Total Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 5,177<span></span>
</td>
<td class="nump">$ 1,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900452104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">2,650,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">3,435,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(215,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled or forfeited</a></td>
<td class="num">(48,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding</a></td>
<td class="nump">5,822,373<span></span>
</td>
<td class="nump">2,650,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested or expected to vest</a></td>
<td class="nump">5,822,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">1,841,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding</a></td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
<td class="nump">9.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
<td class="nump">2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Cancelled or forfeited</a></td>
<td class="nump">5.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding</a></td>
<td class="nump">7.17<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested or expected to vest</a></td>
<td class="nump">7.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested or expected to vest</a></td>
<td class="text">8 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Option exercisable</a></td>
<td class="text">6 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 33,275<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest</a></td>
<td class="nump">33,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable as of December 31, 2021</a></td>
<td class="nump">$ 16,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900235848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate minimum</a></td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate maximum</a></td>
<td class="nump">1.33%<span></span>
</td>
<td class="nump">0.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility range minimum</a></td>
<td class="nump">68.58%<span></span>
</td>
<td class="nump">73.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility range maximum</a></td>
<td class="nump">73.30%<span></span>
</td>
<td class="nump">74.89%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139943001298936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions to defined contribution savings plan</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942896173928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax effected at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Non-deductible expenses</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquired in-process R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal research and development credits</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.20%)<span></span>
</td>
<td class="num">(23.90%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900136824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Total Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 18,233<span></span>
</td>
<td class="nump">$ 5,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">5,269<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">6,385<span></span>
</td>
<td class="nump">4,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capitalized start-up costs</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">6,769<span></span>
</td>
<td class="nump">15,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">40,461<span></span>
</td>
<td class="nump">27,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(648)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(1,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(2,434)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">$ (38,027)<span></span>
</td>
<td class="num">$ (27,034)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900281976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased amount</a></td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Reserves for uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued on uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties recognized on uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Income tax returns years open and subject to examination</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Income tax returns years open and subject to examination</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear', window );">Tax credit carryforwards begin to expire</a></td>
<td class="text">2031-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Not Subject to Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 86,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development Tax Credit Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear', window );">Tax credit carryforwards begin to expire</a></td>
<td class="text">2031-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Begin to Expire in 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 83,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration begin month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ikna_NotSubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ikna_NotSubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=ikna_BeginToExpireInTwoThousandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=ikna_BeginToExpireInTwoThousandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942896385896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research License Agreements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Total consideration allocated to technology recognized as research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">UT Austin License | University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PotentialDevelopmentMilestonePayments', window );">Additional milestone payments payable upon meeting certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_RoyaltiesTerms', window );">Royalties terms</a></td>
<td class="text">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember', window );">AskAt License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PotentialDevelopmentMilestonePayments', window );">Additional milestone payments payable upon meeting certain development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_RoyaltiesTerms', window );">Royalties terms</a></td>
<td class="text"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Total consideration allocated to technology recognized as research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember', window );">AskAt License | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PotentialSalesEventMilestonePayments', window );">Milestones payable contingent on sales in calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember', window );">AskAt License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PotentialSalesEventMilestonePayments', window );">Milestones payable contingent on sales in calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PotentialDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential development milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PotentialDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PotentialSalesEventMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential sales event milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PotentialSalesEventMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_RoyaltiesTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_RoyaltiesTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ikna_AskAtLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942899846024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total lease rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
<td class="nump">$ 964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,538<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember', window );">Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AreaOfLeasedProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="nump">20,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Feb. 19,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LeaseRentFreePeriod', window );">Lease rent free period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_OperatingLeaseMonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_PercentageEscalationInAnnualBaseRent', window );">Percentage escalation in annual base rent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total lease rent payments</a></td>
<td class="nump">$ 9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LetterOfCreditToSecureLease', window );">Letter of credit to secure lease</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember', window );">Boston, Massachusetts | Vertex Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_AreaOfLeasedProperty', window );">Area of leased property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_LesseeOperatingLeaseMaturityMonthAndYear', window );">Lease maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2020-12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_OperatingLeaseTermExtendedExpirationPeriod', window );">Lease extended term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_AreaOfLeasedProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_AreaOfLeasedProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LeaseRentFreePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease rent free period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LeaseRentFreePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LesseeOperatingLeaseMaturityMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease maturity month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LesseeOperatingLeaseMaturityMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_LetterOfCreditToSecureLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit to secure lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_LetterOfCreditToSecureLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OperatingLeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OperatingLeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_OperatingLeaseTermExtendedExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease term extended expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_OperatingLeaseTermExtendedExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_PercentageEscalationInAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage escalation in annual base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_PercentageEscalationInAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ikna_BostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ikna_VertexPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ikna_VertexPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942904803848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation - Summary of components of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 1,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903877832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ikna_Supplementalcashflowinformationleasesabstract', window );"><strong>SupplementalCashFlowInformationLeasesAbstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities (operating cash flows)</a></td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ikna_Supplementalcashflowinformationleasesabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplementalcashflowinformationleases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ikna_Supplementalcashflowinformationleasesabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ikna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942903769400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Lessee, Operating Lease, Description [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount Rate</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900519592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">817<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">8,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amounts representing interest or imputed interest</a></td>
<td class="nump">1,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 6,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942985245352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">UT Austin License | University | Affiliated to Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">University license fees and certain-patent related costs</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ikna_UniversityOfTexasAtAustinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139942900543736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">5,822,373<span></span>
</td>
<td class="nump">172,046,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,396,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ikna_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share amount</a></td>
<td class="nump">5,822,373<span></span>
</td>
<td class="nump">2,650,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ikna_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ikna_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>ikna-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ikna="http://www.ikenaoncology.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ikna-20211231.xsd" xlink:type="simple"/>
    <context id="C_a4cf98b3-916a-4266-a09d-ad4151809aea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aaa01b2e-dd1f-4221-87af-21a855fd6176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_252420a7-5245-4f24-a1b3-549a5657e10c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-22</instant>
        </period>
    </context>
    <context id="C_1e48cebc-3625-4ce6-9967-9afa2709e2dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_12fe0903-8181-40c3-af42-92ad1bc22546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_eb6c9d92-b86d-45de-b6ed-45a7a20b5125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c2e15ff7-280d-4489-8017-9492ffa9ab32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:NotSubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_967cd9a5-9ca9-47d7-aeb3-bede932bd3d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_04f5fcbc-3f2a-4fe4-b203-67a710042614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ef57b772-1e45-4cbb-82ff-1cd3052d6512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bc07950d-ff60-4171-bee4-68de5e8006fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_85fb6b92-dfdb-4f1c-b04e-5cb23fd29f2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f814b099-b5e9-4532-849e-ed0d7f1514b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_b400e939-9adf-46fa-ab34-47a059eaa533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:VertexPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2da448fd-bf19-4ae7-a240-59e52b66aea8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_53dec454-cb02-4c8b-823d-02e9a70817b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="C_4f1aee2b-76d8-4d4e-b29d-300c4f6ff2c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_74803d30-fb65-4987-a08f-21d2e606fe63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b875a6d3-58ee-468a-91f5-65132ce52f74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fb2b28a5-0c8c-41e7-a631-b5a284180f8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_80c83882-abbc-4f18-9ffe-8a6f1fe9f705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c24f3ba8-ff6c-4e9e-a73d-2853c35d6b11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c95a6922-ca79-4e5a-9bb5-f9b65cbb34cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_4162d822-49e3-40a4-b0e7-b0f69534abbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:VertexPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_6e00cf6c-4267-4556-8c5c-74e987e32883">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7884ad66-cfc9-4e7d-b37b-a43da1f827a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2df7bdbe-e8b1-4c47-ba9d-7aa5fe65b63d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_73a95a4f-2717-441c-8d33-6cca61d172fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_66a7df3f-5f7f-4365-885c-11ae27335bd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-21</startDate>
            <endDate>2020-07-21</endDate>
        </period>
    </context>
    <context id="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9449ae95-9c4e-423a-a742-487a9fa3d5c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_77bf16f4-0053-4b65-a6e3-44bc05446deb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c9ea63bc-0e26-4e82-ae9c-c05ca061173e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_932834ea-9c54-4858-96f9-52377c047cc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_38798bf1-ddbf-4fcd-90e3-e5ba57c070a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_064ada85-12cf-4684-b1a0-b4034e155188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4e968a25-daad-4006-af2c-b4b4e11eefe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_1ea44336-4474-480c-bcd2-a098f4164455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_305a280c-d1de-4413-b7dc-476f60a09329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3dd7a94f-ebbb-475e-ab24-17fd8d19e2fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_95669789-5d67-45fb-83c2-2a62765d4576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-21</instant>
        </period>
    </context>
    <context id="C_c92572d4-da38-4f18-8896-9db108cd3d8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8f918b3-befa-4a88-93fc-46d5041b9f1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9d2ca6ed-69e8-4b73-9331-739f008d6068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4d387d5e-0476-4899-8453-c870bec1b749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7dc9500-a312-4bbb-8606-fbcf3215bf2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3ccefeed-c353-4dec-a464-be4c75fc07a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9265d692-1067-4446-93b5-77437f4ec759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_640f8a26-ca73-4101-8b04-267f50272b4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ead8d980-42b0-4dc9-aa5e-8601926b283e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_84ac8be9-5cfc-47f7-b50e-f6ab75a07026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_93401a31-e235-4435-b893-a060400d5a04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_de1f00a8-10d4-4a23-8b9b-2bef95a2e119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="C_28765881-e2d0-48c4-9202-c01a1e66bfc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8e5351be-0edc-42b6-8e62-f402a7a84729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3f3abad8-6574-4e7c-b859-64ad14c715ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_eae5cf94-03a9-47a6-b996-4d2859e9ca20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0c5c2a21-5b8b-4673-9f3c-9fd33b740459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cab5b9e5-69a0-4f7b-8c1a-81cbd3afcba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-31</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_d59e96ca-e70a-4673-a757-3997f4bdb74c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a3d09b30-c88f-47ac-8386-fd1150b5ef28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ikna:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_035aefe6-e027-41ce-80d2-5bcb01214d81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_99ed35bd-4774-4330-bc6b-2c695190c3de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb63a3a7-a4a7-4296-b5a8-5e3cd9e88878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-20</startDate>
            <endDate>2021-03-20</endDate>
        </period>
    </context>
    <context id="C_a363f018-7c61-490f-9200-7d87e22a642d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3cf264ba-3822-4bc8-8611-e5f6c96c4ced">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_c47f385d-2c66-422c-92c6-8542e19860cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a3d192b9-f1b8-48f5-80bc-54ccb8098dcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9b136456-ad76-446f-a0d8-ef8a597b5f71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f2ad82ad-ba0d-444e-bbea-c7c079ec8603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3af77da4-b3d1-4363-bc9c-05213b03b1ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_5e239a4a-5d8e-4aa5-91c9-b646ab6d2361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKFourOneTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_7dd562f4-b1c2-450b-8d06-e06ff831105e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_1751049c-5a01-4bb3-88da-acd002119349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-30</instant>
        </period>
    </context>
    <context id="C_bb21e98b-d1d5-4830-95ae-a8521474d69b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4ca75a5f-a6d6-4a47-bdba-3f6e337cfabb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_53a98858-94fb-4019-b8a9-8e6c8638bbb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_554ecddb-159f-4002-a088-c37b9e72c32d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ikna:BostonMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:VertexPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_9c6adf68-b45d-444a-96ff-b973670159ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c1b60113-9aac-46bb-90fa-37d525cc890a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f7dcb7f3-11ce-4fd1-9003-09bb1c7904e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_88f610e1-84c9-450b-8088-d8260b8a860e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="C_97c448a4-24df-47b4-8856-f4896b80ad75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7eb39d52-adcf-40e5-ae5d-09ebf80bd382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-31</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_fc3f0817-4c02-46a4-a64c-d9eba5dae732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_b652551b-9695-4fe5-8980-18380f280c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesATwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f5cf5caa-b798-49d2-bb71-6baf51e18554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f6feba73-11f7-4c3f-bf74-b2fc74138690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0bc3c318-3f9b-4004-b2d0-fd1298f6297d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_249d1b32-5370-4599-8e89-ab6c0f09b80f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ikna:IKOneSevenFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:BMSCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_a8900e3a-21a4-40ca-8258-8f61c746cc01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c083b51c-b8f6-4949-af7d-87bfd8ace549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesAOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f861265f-3133-42fb-a89c-dac532459910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_890c650a-b769-4a05-90cd-2d91b6fcb220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5c03768c-e908-427c-98a3-dac6ad6d0a7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_ad57f0bc-0185-4d7c-aeac-29addd35778c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_4f40c434-b11e-4ddd-b726-08e4052dba90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b8ca6c84-2e8a-4657-be34-b7027d2c0a54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ikna:UniversityOfTexasAtAustinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0d0023fe-0f0c-46e9-b39d-3d9294d1fdf8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">ikna:BeginToExpireInTwoThousandThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_58e59c96-9c20-4175-a767-95e0b0fd9b9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_de68a06b-52a5-428b-8fda-644108120c2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2a718982-72b2-4b6f-8b37-4cb567dba4b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_33e372af-72dd-4109-9ecf-cd6de6a18366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6838680a-d30e-45b3-9c96-ca296d3f4897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9ce46fba-908a-4541-9693-823709dea22f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-30</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="C_df1f510f-8f9a-4d97-92ef-ba74f342490f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_eba92ba2-7e7b-497e-aa6d-b51e12ffe499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_aea069f1-935a-4fb9-93fe-05cda26d80fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_45284bec-8438-4ce2-8397-a8f69b9c192b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ikna:AskAtLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_f03341b9-2f76-48f3-8446-954e602ed32f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_905f0da9-40cb-4e6b-881a-7396023d88fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ikna:ElectronicEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6b98e2af-28de-4a15-9b16-1d31248fde7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ikna:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6bda0fb6-7d7a-41ad-a5b7-dd54a0540cc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c485b7cf-0678-46d2-94de-86fa847eed87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ikna:SeriesA1PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ikna:StockPurchaseAgreementWithBMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_6b95089c-ecad-4ea3-b482-0bde43865eb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_de81f154-ee2b-4f17-b724-5dba00646bdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835579</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_Segment">
        <measure>ikna:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_FinancialInstitution">
        <measure>ikna:FinancialInstitution</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      id="F_bec7d1a7-68ee-411c-8334-470e5b31718b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      id="F_70301994-e88a-4217-9c45-d103d1876a85"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      id="F_d76f71c9-2042-4b06-8c63-f4b8806de07f">http://www.ikenaoncology.com/20211231#ResearchAndDevelopmentMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_88f610e1-84c9-450b-8088-d8260b8a860e"
      decimals="4"
      id="F_7fdb186e-815c-4baa-b15f-3f79588d331f"
      unitRef="U_pure">0.1397</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:AmendmentFlag
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_06ffd91e-b7c3-4c7f-8398-70d37a92ab69">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      id="F_2ce08d35-be16-47c1-8be1-42857608cb48"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_6242453e-6005-48f3-94c4-c7e1e8f8f635">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_fc0a9acd-1f51-4c1f-ba72-2d676951d1d7">0001835579</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      id="F_474b6704-871e-4bad-bd66-06110622c38a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_d31c53a8-537c-4399-a1e0-f3fda99cb66b">http://www.ikenaoncology.com/20211231#ResearchAndDevelopmentMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_7402aa32-4d60-4e85-9dcb-3a14cb833246">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_ec10c90d-19aa-4472-a625-bdff4b7533e2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_fd60d503-206d-4997-8a7a-dad7cecade5a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_8a48aaf5-ae7a-4272-acdf-7e2d4f2850d6">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_73fb70dd-2b27-4f03-8fc1-3bab59badcd0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_bea4cf2e-21d0-4f17-b327-2ca19864b0f7">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_75d1659a-b7ff-494f-add6-cbea096fcce3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_0860bb77-ddbb-4cfb-a1ac-c375bc0224dc">001-40287</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_f7972686-82d3-4a51-bff3-606775c3779f">IKENA ONCOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_65a7454b-41ab-43ac-9788-265b778e301c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_98a506ab-9ddf-4cf4-8642-9fa520edef03">81-1697316</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_055c112c-9863-4f23-8fab-aad2a3394472">645 Summer Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_8075a6fc-cc68-491a-bfc3-146355af89a7">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_f1bb89fe-f414-4544-b578-1c5acab49efc">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_4a7cfdfd-72f9-4326-a934-b923e5dcd31e">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_d66197ca-1ed7-4e88-bd86-ad3e6c4e1e8a">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_f6d5389e-0162-4f4c-ae5e-2fb78a07f441">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_d1889869-796d-4074-b719-3d9c57ec97cb">273-8343</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_58f735ce-bfca-414f-8e32-45fc25d661af">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_fea3eb77-d852-47a1-be1b-d6c3af3c8ea8">IKNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_eb868f23-5203-4a20-9895-25d97178f314">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_5580c5b2-72ac-47fd-ade0-81f0023ec428">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_38636d8b-9bbc-45de-ba5e-f5a5c1ae6cd6">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_6460eef5-bd3a-4f94-9b51-edd7ffda9ed5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_b901a2bc-3f8a-4de2-9c16-bdaa1e7b7337">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_23c1477b-4b53-4880-a3c8-7204af62e1df">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_3d2d1de9-1971-4fd5-81ad-b73e5af80683">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_16d8b808-e52b-43b8-aaa5-598cd4adfedb">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_6f24138c-23d7-4da4-ac6c-93228535ee08">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_e68ec91e-86f3-4064-ab61-54e8bfe47fc6">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_787594eb-fde1-4740-bb5e-feedbdaf29ff">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_eae5cf94-03a9-47a6-b996-4d2859e9ca20"
      decimals="-5"
      id="F_ba7f31df-e007-4b82-bab3-8ee5eea1cfe0"
      unitRef="U_USD">296700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_de81f154-ee2b-4f17-b724-5dba00646bdc"
      decimals="INF"
      id="F_e9a3559d-e102-4b59-a6a8-42cb67730773"
      unitRef="U_shares">36108995</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_e04406e5-2128-47a5-9b11-c3f6122eead0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Portions of the registrant&#x2019;s proxy statement for the 2022 annual meeting of stockholders to be filed pursuant to Regulation 14A within 120 days after the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference in Part III of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_d0f32461-9dcd-4a7d-afb7-34dd3ee7899c">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_db6039bd-6be1-4fc0-890a-a16660f69ca7">Boston, Massachusetts</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_d0511b34-8f48-45fa-b867-1848dabb6592">42</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_157da8d0-c119-4428-b5d1-7501a7117667"
      unitRef="U_USD">232217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_79c693ea-0fcc-44f1-a031-776cfa9c9a11"
      unitRef="U_USD">162491000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_8b3cdae0-6255-40b6-a780-e63a382066c9"
      unitRef="U_USD">4299000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_96bb49ea-e9f9-42ab-bed6-b6c1df531fa3"
      unitRef="U_USD">3478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_7fe08dc2-b240-4ee4-af50-05c4186dcc90"
      unitRef="U_USD">236516000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_b33cac60-3fff-424a-8f31-85ee3faf1032"
      unitRef="U_USD">165969000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_da9a2a30-72d2-4a22-b4f0-8d06b2d7c639"
      unitRef="U_USD">2439000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_c91bca9c-36cc-4a6c-ade9-481b9bedc88b"
      unitRef="U_USD">1393000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_f07c6470-f3f0-44be-9b32-6d5b93c84fd3"
      unitRef="U_USD">6538000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_7791982f-085c-4bc9-81b4-db9311871f5d"
      unitRef="U_USD">170000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ikna:DepositsAndOtherAssetsNoncurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_fd0958d4-30a3-4163-b40d-3a064c8c15c7"
      unitRef="U_USD">2386000</ikna:DepositsAndOtherAssetsNoncurrent>
    <ikna:DepositsAndOtherAssetsNoncurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_4ff21ceb-85df-4a40-ac4d-9105c8da713e"
      unitRef="U_USD">872000</ikna:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_e83d31fd-6930-4cd3-b8f9-4a80ffe56d03"
      unitRef="U_USD">247879000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_835257ff-ceaf-4a66-842c-d17455e7b7c0"
      unitRef="U_USD">168404000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_4555c935-8fcc-4cf3-b16e-b8b7e7fc0267"
      unitRef="U_USD">2384000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_6b84e193-4d69-4fb1-916b-6b9f58799f91"
      unitRef="U_USD">2122000</us-gaap:AccountsPayableCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_f23607d3-e0ad-40a6-ab12-174c705b7dfc"
      unitRef="U_USD">5854000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_805c9528-e1b4-48b1-9f1e-9968f1105ed2"
      unitRef="U_USD">5402000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_23b70e5a-92f2-4677-8c9e-da068754140e"
      unitRef="U_USD">1851000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_8f35d240-ce1b-412f-af32-5b30f8f09e27"
      unitRef="U_USD">186000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_a8e0db88-89e7-48ba-a1be-178315ededde"
      unitRef="U_USD">17100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_168605e1-1d22-470c-b1a6-05381873c940"
      unitRef="U_USD">20622000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_6af6b698-b9d5-4cfc-ab11-4f4b7acf50e3"
      unitRef="U_USD">27189000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_30d32e0b-49a3-4e65-bbb7-808dcf354190"
      unitRef="U_USD">28332000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_d4adeb3e-1233-4012-9c74-5cfb85b07985"
      unitRef="U_USD">5135000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_0473efe4-6bd9-48fa-9eca-edfddf4024e3"
      unitRef="U_USD">7678000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_b73d23ba-b42f-4157-8f68-a2fb6ce61787"
      unitRef="U_USD">35141000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_e4fc5822-71be-4504-b474-4a0394250fc1"
      unitRef="U_USD">40002000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_af968b44-4f04-46b7-9052-0c9a15771366"
      unitRef="U_USD">63473000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_090f4f11-0322-450a-ae95-323b4c1601f9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_0d6a4e05-dd96-4d58-8ef5-a50a56644a65"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_21ef3ec9-ce70-4978-880e-256ca1019977"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_f4514dd8-553b-46de-977d-d781bf2e845e"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_1fd6a053-6f5e-4be1-99b0-e9dbd89c663d"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_f2cb10a5-425f-4dcb-a028-9659078c1fbe"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_eb69895b-1614-48f8-acde-bc626763030a"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_7d2d4029-f4d5-4b4a-93b8-efaa97073158"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-6"
      id="F_aa3028d2-a061-40fe-9885-dd19ae27da55"
      unitRef="U_USD">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-5"
      id="F_21493f00-1e10-4a22-81a4-874463281f22"
      unitRef="U_USD">202200000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_7467ec34-05b8-463d-90d1-2f74b18fc230"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_f02e4c3f-6114-469f-a0e2-647f032839ff"
      unitRef="U_USD">205979000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_23f3422e-d897-4752-9fa9-bedecb7f19d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_0480a3d1-0fa5-4a7c-a187-d5a2787feec2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_c508ef2f-b198-40c9-adfd-fbea35631fb7"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_adc422c1-cadc-4ce8-8605-5ec3b7f58580"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_4ad13fcd-1825-4095-bdc3-d7aa75ad253b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_0982c15a-29f2-48d3-99cd-65902ebec87a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_e9616bff-d96d-4bfb-9dfd-7d4a6f8388dd"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_291ccfac-e31d-4618-aab4-db7f1d43e86d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_d58bcc8a-2c4a-4bea-803f-2d8eac834723"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_50c144b5-2fdb-42d8-9f27-3adc6df2ecda"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_7434956e-b862-4573-a813-652073a5d373"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_7c69c06d-6f2f-481a-a314-b40f3487c6c8"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_f20d0013-7ba0-4fa6-9d1e-3377350602c2"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_b9f3958f-42f2-44e2-bbaa-03fda99779c1"
      unitRef="U_shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_4dc1e385-a0ea-471f-a8ca-d39249238ddf"
      unitRef="U_shares">3096903</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_f0ed077a-a335-4005-9413-eaf965134cb6"
      unitRef="U_shares">3096903</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_0571eed2-e3ca-46ea-b4a3-712cac26f2fe"
      unitRef="U_USD">36000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_3deff738-46eb-42b2-b59c-4a8318ccc1ca"
      unitRef="U_USD">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_ac126601-9b74-4039-9930-6ea8bdee96d8"
      unitRef="U_USD">353295000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_6d19cbd6-63ef-4c77-bfe1-c5f6e297d6e2"
      unitRef="U_USD">10288000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_38232c8e-41e5-497d-b7bf-80bab96d013c"
      unitRef="U_USD">-145454000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_b84d1ac0-f2a7-4ffc-b9fe-0500ccf990c3"
      unitRef="U_USD">-111339000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_d3823ca0-dbbe-4fd3-b370-9eabb2f444b3"
      unitRef="U_USD">207877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_d5ef5e9c-58f5-4707-8646-beb8c21f3cbb"
      unitRef="U_USD">-101048000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_c01fbb75-f01b-4c4c-b149-7a1c9bc611b8"
      unitRef="U_USD">247879000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_138fd023-cf31-4787-8695-a2268a64569c"
      unitRef="U_USD">168404000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_8eebfe4a-3032-4645-9442-f65b8e40aef8"
      unitRef="U_USD">30985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_0db272f2-6068-4280-baf4-9e7f15793b97"
      unitRef="U_USD">9194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_a9c7fdc3-0f21-42f0-b956-b461ba15bb11"
      unitRef="U_USD">47108000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_643ad46b-4e67-453c-93af-a24f18ee6f39"
      unitRef="U_USD">44847000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_0dbd1eea-26da-4260-9c85-a941c25cbbff"
      unitRef="U_USD">18015000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_81631ecb-a751-4fa3-9336-353336c5573f"
      unitRef="U_USD">8866000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_b7cfd760-6e6d-4d86-9e30-27e980484640"
      unitRef="U_USD">65123000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_a63bb337-22d1-4eb3-9352-2696ebc21211"
      unitRef="U_USD">53713000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_0734c2cf-bb21-456d-848c-a6cb7520a5c2"
      unitRef="U_USD">-34138000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_dff6a63e-9c7b-457a-ad53-f5e8bac3c2ab"
      unitRef="U_USD">-44519000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_2bdeee6b-8494-4b08-afa1-0d053cbbadb5"
      unitRef="U_USD">23000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_a096cbbc-edcb-4611-b980-71ff9e2bc556"
      unitRef="U_USD">263000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_293f1952-bd2a-4ef9-848d-46b565e7e9db"
      unitRef="U_USD">-34115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_60773824-17ba-4cd7-a2c4-3eece7bd15f7"
      unitRef="U_USD">-44256000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_72af52a7-2f6a-48bc-8fd4-03b2a2812cf0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="2"
      id="F_5be22f80-7e06-42ed-8a30-ad6ab57f82ce"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-16.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="0"
      id="F_d424209e-7590-4b6c-9823-66de032f5f69"
      unitRef="U_shares">27983359</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="0"
      id="F_6e0f8c11-6a4d-4796-b2f3-c79dd9f28d75"
      unitRef="U_shares">2765494</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_9b136456-ad76-446f-a0d8-ef8a597b5f71"
      decimals="INF"
      id="F_d1d3fdd4-0352-4016-8e97-78e533dc6d9d"
      unitRef="U_shares">75727268</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_9b136456-ad76-446f-a0d8-ef8a597b5f71"
      decimals="-3"
      id="F_4cc0b675-2904-4e83-963a-16900875918e"
      unitRef="U_USD">78867000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_df1f510f-8f9a-4d97-92ef-ba74f342490f"
      decimals="INF"
      id="F_6dab9b40-e3a3-4e9b-a706-86cc8a2f9b30"
      unitRef="U_shares">2651333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_df1f510f-8f9a-4d97-92ef-ba74f342490f"
      decimals="-3"
      id="F_b98e4823-43c4-4f30-af5f-483bdc9454a7"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7dd562f4-b1c2-450b-8d06-e06ff831105e"
      decimals="-3"
      id="F_0f677be8-5881-4e74-b178-0b04a1a9bfe8"
      unitRef="U_USD">5617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4e968a25-daad-4006-af2c-b4b4e11eefe5"
      decimals="-3"
      id="F_4beb4286-99db-405c-8782-3d90e630a990"
      unitRef="U_USD">-67083000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b875a6d3-58ee-468a-91f5-65132ce52f74"
      decimals="-3"
      id="F_982de6db-1f5c-4a29-9a6a-9a759ac96edc"
      unitRef="U_USD">-61463000</us-gaap:StockholdersEquity>
    <ikna:TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883"
      decimals="INF"
      id="F_e08d461d-8ea3-4022-90ef-a59f549684d7"
      unitRef="U_shares">7863094</ikna:TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions>
    <ikna:TemporaryEquityStockIssuedDuringPeriodValueAcquisitions
      contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883"
      decimals="-3"
      id="F_17a56939-d975-4407-abdd-334e8f285362"
      unitRef="U_USD">10924000</ikna:TemporaryEquityStockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_c47f385d-2c66-422c-92c6-8542e19860cd"
      decimals="INF"
      id="F_8e881cd5-4025-46ff-b3af-e3cc09058835"
      unitRef="U_shares">426159</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee"
      decimals="-3"
      id="F_814965dd-9ca9-4419-b192-0b931a55948d"
      unitRef="U_USD">2804000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_3295a477-7602-4b8a-b238-52989641e759"
      unitRef="U_USD">2804000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <ikna:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883"
      decimals="INF"
      id="F_fab8831d-1583-4649-b8e9-ac5547d92ff4"
      unitRef="U_shares">85806214</ikna:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883"
      decimals="-3"
      id="F_fa2488d8-489d-4844-bc29-e59490b43cc9"
      unitRef="U_USD">116188000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c47f385d-2c66-422c-92c6-8542e19860cd"
      decimals="INF"
      id="F_4a95d869-ee29-430c-86d9-ad031175dd8a"
      unitRef="U_shares">19411</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee"
      decimals="-3"
      id="F_620b1c1e-8003-47d1-a6e0-9850898896ff"
      unitRef="U_USD">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_e225b86a-e541-4109-b6a8-93eccb2ae522"
      unitRef="U_USD">70000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1d9e7e4e-0a08-41ee-8589-f18ef8611cee"
      decimals="-3"
      id="F_31e89162-88c6-49cb-8520-be2880927be3"
      unitRef="U_USD">1797000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_c0759279-d5e9-45ab-b928-c33dd6a298f9"
      unitRef="U_USD">1797000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_ead8d980-42b0-4dc9-aa5e-8601926b283e"
      decimals="-3"
      id="F_b534e1d4-b2e1-4679-9483-cc14dfe78435"
      unitRef="U_USD">-44256000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_528decc9-c7a9-48ea-ba5b-3daaf9afb36b"
      unitRef="U_USD">-44256000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_73a95a4f-2717-441c-8d33-6cca61d172fc"
      decimals="INF"
      id="F_79b3c370-7673-433a-9453-fbeac5857aea"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_73a95a4f-2717-441c-8d33-6cca61d172fc"
      decimals="-3"
      id="F_bf7d1c3a-9000-48c9-b543-d094f8998fa4"
      unitRef="U_USD">205979000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_4ca75a5f-a6d6-4a47-bdba-3f6e337cfabb"
      decimals="INF"
      id="F_aa1a4a91-1ba8-4df3-8aa7-747cae2690b9"
      unitRef="U_shares">3096903</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4ca75a5f-a6d6-4a47-bdba-3f6e337cfabb"
      decimals="-3"
      id="F_e97f848f-d3fe-43e3-b021-3ab590dacd63"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aaa01b2e-dd1f-4221-87af-21a855fd6176"
      decimals="-3"
      id="F_5d3e916d-383e-49a0-a3f2-447cd7d4dc58"
      unitRef="U_USD">10288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4f1aee2b-76d8-4d4e-b29d-300c4f6ff2c6"
      decimals="-3"
      id="F_7b4b6383-3e1a-447b-8c5d-a28f8347aa37"
      unitRef="U_USD">-111339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_79d51210-2320-4823-bef5-a3632f99d366"
      unitRef="U_USD">-101048000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_2df7bdbe-e8b1-4c47-ba9d-7aa5fe65b63d"
      decimals="-5"
      id="F_0aef5f52-e048-44b5-a502-8a28cebe2021"
      unitRef="U_USD">2400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01"
      decimals="INF"
      id="F_dee328c6-e8d0-4e83-a39c-ea779b43e492"
      unitRef="U_shares">8984375</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01"
      decimals="-3"
      id="F_a2c27d7e-795a-4610-8d86-60c3791eddc9"
      unitRef="U_USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414"
      decimals="-3"
      id="F_5a331a7d-65af-4d63-b11d-66f1912803a6"
      unitRef="U_USD">131293000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_6a1c24aa-db07-4c77-9c1e-9ca3513a6503"
      unitRef="U_USD">131302000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc"
      decimals="INF"
      id="F_975a1fc3-ebb0-4070-9ef5-cdbeb92edba4"
      unitRef="U_shares">-169396576</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc"
      decimals="-3"
      id="F_9316c2c2-c114-467b-acef-618d2a37b398"
      unitRef="U_USD">-205979000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01"
      decimals="INF"
      id="F_c72c57bc-b0ae-4923-96e3-31468de2520a"
      unitRef="U_shares">23678568</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01"
      decimals="-3"
      id="F_1c09146a-7c69-4162-ad7b-cf0ef3669e0d"
      unitRef="U_USD">24000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414"
      decimals="-3"
      id="F_cc6c96b9-2893-4803-9f48-9df1bd55eefc"
      unitRef="U_USD">205955000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_3438d432-6307-4973-92ef-1092f868c519"
      unitRef="U_USD">205979000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a8900e3a-21a4-40ca-8258-8f61c746cc01"
      decimals="INF"
      id="F_df5a1d52-e188-4234-bc37-87cad2a84da1"
      unitRef="U_shares">215188</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414"
      decimals="-3"
      id="F_513af5b2-d171-448f-a086-303867f3b7e1"
      unitRef="U_USD">582000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_780271b3-7db1-4ba3-b00f-b7e762362bfb"
      unitRef="U_USD">582000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7c705f75-a3a4-4da4-b80d-26dcb66f9414"
      decimals="-3"
      id="F_cc3de1df-49ab-486e-b6bc-723e9cf61d81"
      unitRef="U_USD">5177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_84b085f8-0cd3-4bc0-9be7-e137d199e16d"
      unitRef="U_USD">5177000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_305a280c-d1de-4413-b7dc-476f60a09329"
      decimals="-3"
      id="F_70905a4a-035e-41e8-9972-79b27c0e4a9e"
      unitRef="U_USD">-34115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_67a97f3c-1179-41d2-8745-ca77af244edd"
      unitRef="U_USD">-34115000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_93401a31-e235-4435-b893-a060400d5a04"
      decimals="INF"
      id="F_215c9295-e93c-4b3f-a591-bf397a53b90c"
      unitRef="U_shares">35975034</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_93401a31-e235-4435-b893-a060400d5a04"
      decimals="-3"
      id="F_948b0432-e865-4b37-bc7a-26ff181c859e"
      unitRef="U_USD">36000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_04f5fcbc-3f2a-4fe4-b203-67a710042614"
      decimals="-3"
      id="F_b6207541-d20f-4279-b371-bfa5f6980a2e"
      unitRef="U_USD">353295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4f40c434-b11e-4ddd-b726-08e4052dba90"
      decimals="-3"
      id="F_23529365-09ba-4d4a-a9cd-e67e98fb39c9"
      unitRef="U_USD">-145454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_8bdc52a3-3168-49bf-a44d-d6e53614d20f"
      unitRef="U_USD">207877000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_7ddc5755-6bbf-40a0-a7bc-ce09e08815c4"
      unitRef="U_USD">-34115000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_ce082770-6e12-4589-a15e-fd11b0a45dde"
      unitRef="U_USD">-44256000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_1db1333e-bb1f-4e89-8887-c60f4c057345"
      unitRef="U_USD">544000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_d7969399-3315-4660-8747-1c2f8fdd748b"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_cd0bb34a-e5c6-4d0d-b7cc-19c919c0fd0c"
      unitRef="U_USD">5177000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_278a729b-a55b-411e-b68b-46e46a7d22a8"
      unitRef="U_USD">1797000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_b1754de4-39bf-4580-be04-bc0c4ccedefb"
      unitRef="U_USD">11140000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_ef6bde2d-de7a-4a4b-8517-b2625dd08dc9"
      unitRef="U_USD">1174000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_77bf18e3-38e0-4ac4-ae76-4f33314ca5c3"
      unitRef="U_USD">964000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_66e901d2-39d3-47cd-9b43-d3879a5c1043"
      unitRef="U_USD">1452000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_07a6c48b-0f6c-4179-8fb5-dc90feaf86b3"
      unitRef="U_USD">-297000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_05b93051-bbb8-44cf-aee5-8a52a9353574"
      unitRef="U_USD">361000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_29e0e612-9455-41fd-b1c2-41269d2a60e8"
      unitRef="U_USD">519000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_b72fb660-7eb0-4a8e-87ca-642be688531d"
      unitRef="U_USD">1298000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_58f94b97-bd68-41f2-9b76-5fc34618d4be"
      unitRef="U_USD">1585000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInLeasingReceivables
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_539936ed-6259-4f51-9251-29866ebb4101"
      unitRef="U_USD">740000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_bb1fe4a8-6ba9-4e1e-a2f8-7437791582dc"
      unitRef="U_USD">978000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_cc0421d2-0890-4632-9a4f-3b0004aee622"
      unitRef="U_USD">-30985000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_5ea35441-e58e-419c-9fdf-301b3e0d070b"
      unitRef="U_USD">-9194000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_fc8be0fe-32f8-4117-9b23-053bf7599a1f"
      unitRef="U_USD">1514000</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_1741f21f-e90c-43da-bd7a-f7e8b91373d0"
      unitRef="U_USD">-60252000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_ea542c5c-98ac-40a2-9348-e6d07b1a7310"
      unitRef="U_USD">-37826000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_6febdcea-f497-4121-858f-405519fdc77f"
      unitRef="U_USD">3688000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_21381e29-ec79-4ec3-b17c-104aeea1f5e1"
      unitRef="U_USD">1760000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_a47d553c-a793-4fdd-bcc2-ff8046d41080"
      unitRef="U_USD">766000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_351756cc-bbbf-4ad0-9514-92150e23129b"
      unitRef="U_USD">-1760000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_36265e63-fd62-41b5-8970-4acb8316868b"
      unitRef="U_USD">2922000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_5251b3e6-1a99-4d02-affa-ec68cc97a63f"
      unitRef="U_USD">-146000</ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock>
    <ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_7ab392a8-83c0-4740-8b82-7a49a2256b60"
      unitRef="U_USD">116171000</ikna:ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock>
    <ikna:ProceedsFromPaymentForIssuanceInitialPublicOffering
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_1a25f07a-a9bf-464a-87b3-7cd8a04293e9"
      unitRef="U_USD">131302000</ikna:ProceedsFromPaymentForIssuanceInitialPublicOffering>
    <ikna:ProceedsFromPaymentForIssuanceInitialPublicOffering
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_8c3ab120-678c-400c-b861-4d92152ab835"
      unitRef="U_USD">-57000</ikna:ProceedsFromPaymentForIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_3cc37e8f-d9a3-4bbf-8847-7ac3e7912302"
      unitRef="U_USD">582000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_a7393107-72ba-4693-9f53-99b90532990c"
      unitRef="U_USD">70000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_4d10dc34-3b5d-44d2-aa2f-4dd696704bd7"
      unitRef="U_USD">131738000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_fbb7c5c4-9ac5-4820-9b9c-64ab9ca8b971"
      unitRef="U_USD">116184000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_7d8bc51b-075e-4a96-b147-b04ecde774e2"
      unitRef="U_USD">69726000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_0c2999fe-516c-4b38-80f4-be5fc72c3985"
      unitRef="U_USD">81280000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_4ffa9e63-f33a-4b4a-b3b4-d37d80041334"
      unitRef="U_USD">163363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b875a6d3-58ee-468a-91f5-65132ce52f74"
      decimals="-3"
      id="F_08a9d709-45de-40c7-b7df-d359dc27d8b6"
      unitRef="U_USD">82083000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_d48b3a03-e704-4002-9078-097e57024fec"
      unitRef="U_USD">233089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_a20a8b7b-748f-4418-a8cd-fd7dc7089254"
      unitRef="U_USD">163363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_206cbc76-4f77-4d65-8eec-b47650353d63"
      unitRef="U_USD">232217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_9a00bf27-da44-412f-b161-45ec51d46fa9"
      unitRef="U_USD">162491000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_d89ab509-a649-45e2-b26c-78c8581c22cc"
      unitRef="U_USD">872000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_04aae3e3-557c-4be4-87fa-16e6fd363784"
      unitRef="U_USD">872000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_f539f489-1394-4775-9b75-b48bd737eac1"
      unitRef="U_USD">233089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_e61fa811-c313-4588-9bb8-595bd4f296bb"
      unitRef="U_USD">163363000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_e05b5aba-9aa2-4f82-b522-118a8a272312"
      unitRef="U_USD">34000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_61802129-1691-4e9f-9759-4f4763ceaee9"
      unitRef="U_USD">970000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_284ec3b8-3039-48dd-929b-b3ccc233d882"
      unitRef="U_USD">13892000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_96288169-1320-4996-95f8-3a4e2ff17274"
      unitRef="U_USD">13000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_77a3a714-8add-443c-b666-6047c767d3a2"
      unitRef="U_USD">367000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <ikna:Deferredtransactioncostsinaccountspayableandaccruedexpenses
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_7b536ce1-6274-42eb-8aa1-b6c14cb8efdc"
      unitRef="U_USD">591000</ikna:Deferredtransactioncostsinaccountspayableandaccruedexpenses>
    <ikna:RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_d3333fcb-4319-4bf5-ae48-980a9f430262"
      unitRef="U_USD">956000</ikna:RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification>
    <ikna:RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_94d45c4b-6230-47c4-a2e1-cc1d61c09104"
      unitRef="U_USD">7541000</ikna:RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception>
    <us-gaap:NatureOfOperations
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_598d58cf-ea7b-4118-87d2-ca54ff03986b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. NATURE OF BUSINESS AND ORGANIZATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We are a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With our robust biomarker and translational approach we aim to develop targeted treatments and define patient populations who are most likely to respond to treatment. Our current programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment (TME), with approaches to targeting both cancer-driving targets and mechanisms of resistance to targeted therapies. Our focus on patient-driven development is platform and process agnostic, allowing us to research both known and novel targets , with a shared guiding principle of aiming to address the unmet need of a biomarker-defined patient population. Since we commenced operations in 2016, we have advanced multiple product candidates into clinical development. In addition, we have a robust pipeline of discovery-stage targeted oncology programs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 22, 2021, ahead of the initial public offering, the Company effected a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one-for-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7fdb186e-815c-4baa-b15f-3f79588d331f;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.154&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the Company&#x2019;s common stock. All share and per share amounts in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Shares of common stock reserved for issuance upon the conversion of the Company&#x2019;s convertible preferred stock were proportionately reduced and the respective conversion prices were proportionately increased.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 25, 2021, the Company&#x2019;s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). In the IPO, which closed on March 30, 2021, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,984,375&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, including full exercise of the underwriters&#x2019; over-allotment option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,171,875&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in net proceeds after deducting underwriting discounts and commissions and offering expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_29f0b849-6181-43b8-becd-febb4314616e">one-for-7.154 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_c95a6922-ca79-4e5a-9bb5-f9b65cbb34cb"
      decimals="0"
      id="F_15739e67-eff2-4af0-9c1a-977b33f29e75"
      unitRef="U_shares">8984375</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_3f3abad8-6574-4e7c-b859-64ad14c715ec"
      decimals="0"
      id="F_d4e34638-fbdb-4d09-8772-cdd8d2101f65"
      unitRef="U_shares">1171875</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_53dec454-cb02-4c8b-823d-02e9a70817b1"
      decimals="2"
      id="F_03ec6e98-dd1f-486c-a2d2-495b9a996e4c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_2da448fd-bf19-4ae7-a240-59e52b66aea8"
      decimals="-2"
      id="F_b77e4dcd-87bf-4511-9ff9-bc3a2ba928cb"
      unitRef="U_USD">131300</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_ca6fdc7d-109d-4826-bf7a-801f66849adc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis of Presentation and Principles of Consolidation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#x201c;Amplify&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Use of Estimates: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and development revenue under a collaboration agreement, and intangible assets acquired in an asset acquisition and, for periods prior to the completion of the IPO, stock based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liquidity: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December 31, 2021, will be sufficient to enable us to advance our long-term strategic goals for at least the next 12 months from the filing of this annual report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing, or terminating planned activities related to its product candidates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Segments: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable segment. All long-lived assets of the Company reside in the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Concentration of Credit Risk and of Significant Suppliers: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, substantially all of the Company&#x2019;s cash and cash equivalents were deposited at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; highly rated financial institutions. The Company maintains balances in operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is dependent on third-party manufacturers and clinical research organizations to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value of Financial Instruments: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The amounts reported for cash equivalents, accounts payable and accrued expenses approximate fair value because of their short maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and Cash Equivalents: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our cash equivalents are generally composed of commercial paper, corporate notes, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted Cash: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company maintained restricted cash totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, held in the form of a money market account as collateral for the Company&#x2019;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and Equipment: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Electronic equipment and software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the shorter of their useful life or lease term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived Assets: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets consist of property and equipment.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Income Taxes: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenue Recognition: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts expected to be recognized as revenue within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had one collaborative agreement with Bristol-Myers Squibb (&#x201c;BMS&#x201d;), which the Company entered into in January 2019 (the &#x201c;BMS Collaboration Agreement&#x201d;). For a complete discussion of the accounting related to BMS Collaboration Agreement, see Note 7, Collaboration Agreement and Stock Purchase Agreement with BMS.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and Development Expense: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials. Research and development expense for the year ended December 31, 2020, also includes the write-off of acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) assets with no alternative future use.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset Acquisitions:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire IPR&amp;amp;D with no alternative future use is charged to research and development expense at the acquisition date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based Compensation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#x2019;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividend yield was assumed as the Company does not intend to pay dividends on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6242453e-6005-48f3-94c4-c7e1e8f8f635;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounting Standards Codification&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC) 842 Leases, which was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company's operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive Loss: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Issuance Costs: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred issuance costs consist of legal, accounting and other third-party fees that are directly associated with in-process equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the proceeds generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 30, 2021, the Company completed its IPO. Accordingly, the Company recognized offering costs of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a reduction from the gross proceeds associated with the closing of the IPO through additional paid-in capital in the accompanying consolidated balance sheet. The Company incurred deferred offering costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2020 which were included in prepaid expenses and other current assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Emerging Growth Company Status: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Recent Accounting Pronouncements: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_00d987d1-10da-4607-9dee-62fe38ebaf9b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis of Presentation and Principles of Consolidation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Arrys Therapeutics, Inc. (&#x201c;Arrys&#x201d;), Ikena Oncology Securities Corporation and Amplify Medicines, Inc, (&#x201c;Amplify&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/p&gt;</ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_eb66cb15-01d2-4cdd-854a-c3023784e6a5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Use of Estimates: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates and judgments are based on historical information and other market-specific or various relevant assumptions, including in certain circumstances, future projections, that management believes to be reasonable under the circumstances. Actual results could differ materially from estimates. Significant estimates and assumptions are used for, but not limited to the accruals for research and development expenses, research&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and development revenue under a collaboration agreement, and intangible assets acquired in an asset acquisition and, for periods prior to the completion of the IPO, stock based compensation expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <ikna:LiquidityPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_0a322403-2c71-4c0a-9879-8df1ad5dca4d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liquidity: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December 31, 2021, will be sufficient to enable us to advance our long-term strategic goals for at least the next 12 months from the filing of this annual report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company expects that it will seek additional funding through public or private financings, debt financing, collaboration agreements or government grants. The inability to obtain funding, as and when needed, could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its business strategies, which may include amending, delaying, limiting, reducing, or terminating planned activities related to its product candidates.&lt;/span&gt;&lt;/p&gt;</ikna:LiquidityPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_2144c307-11dd-4ed5-a3c5-c23f91fc76e1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Segments: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#x2019;s CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable segment. All long-lived assets of the Company reside in the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_bc61491c-d5ed-400f-877f-8200b25e653f"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_bf32a972-d405-4ede-8296-38d81a4f9776">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Concentration of Credit Risk and of Significant Suppliers: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, substantially all of the Company&#x2019;s cash and cash equivalents were deposited at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; highly rated financial institutions. The Company maintains balances in operating accounts above federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is dependent on third-party manufacturers and clinical research organizations to supply products and provide services for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <ikna:ConcentrationOfCreditRiskNumberOfFinancialInstitutions
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_08663525-f2c9-456e-a350-906fbe75c2ac"
      unitRef="U_FinancialInstitution">2</ikna:ConcentrationOfCreditRiskNumberOfFinancialInstitutions>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_220f2da8-a1d7-4006-a7a7-ae7a7ddb372c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value of Financial Instruments: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The amounts reported for cash equivalents, accounts payable and accrued expenses approximate fair value because of their short maturities. Fair value is estimated based on a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_8cdebe0e-6ecf-4ed1-a03a-d4cea6fa43e1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and Cash Equivalents: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all short-term, highly liquid investments with original maturities of 90 days or less at acquisition date to be cash equivalents. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our cash equivalents are generally composed of commercial paper, corporate notes, U.S. government-sponsored enterprise securities, U.S. treasury securities and money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_d6f46a72-ed6f-40f8-8b53-1bd0fe57986a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted Cash: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company maintained restricted cash totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, held in the form of a money market account as collateral for the Company&#x2019;s facility lease obligations. The balance is included within other non-current assets in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-5"
      id="F_e0682bc5-190c-428c-bcd3-c4ff7c6b4133"
      unitRef="U_USD">900000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-5"
      id="F_875f2e3b-44ee-41ab-a521-e92f6269e855"
      unitRef="U_USD">900000</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_4d678866-604d-44b8-9eeb-9094cd42b980">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and Equipment: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of each asset. Lab equipment is depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Electronic equipment and software are depreciated over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the shorter of their useful life or lease term.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to income in the statement of operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a4cf98b3-916a-4266-a09d-ad4151809aea"
      id="F_b3c65899-3a9b-48d6-8c44-c0eae8154976">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_905f0da9-40cb-4e6b-881a-7396023d88fb"
      id="F_d96bfaa0-d1ca-4268-9dee-1a58e96cf14c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_eb6c9d92-b86d-45de-b6ed-45a7a20b5125"
      id="F_31f99d28-7334-4136-a688-c3a7ea6a1266">the shorter of their useful life or lease term.</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_4a4e95d6-9100-4278-bdde-d084548d8b69">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived Assets: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets consist of property and equipment.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_de344f6c-edf8-4bef-9755-666624c4f42f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Income Taxes: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Recognition of deferred tax assets is limited to amounts for which, in the opinion of management, realization is considered more likely than not in future periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_fd3a92c8-1d94-4ec0-ab9a-1a1d36503e65">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenue Recognition: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has generated revenue from a collaboration agreement as well as service agreements with related parties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To determine revenue recognition, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determine those that are performance obligations, then assesses whether each promised good or service is distinct. When the Company offers options for additional goods or services, such as to receive a license for intellectual property or for additional goods or services, the Company evaluates whether such options contain material rights that should be treated as additional performance obligations. Once performance obligations are identified, the Company then recognizes as revenue the amount of the transaction price that the Company allocated to the respective performance obligation when (or as) each performance obligation is satisfied, either at a point in time or over time. If the performance obligation is satisfied over time, the Company recognizes revenue based on the use of an input method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts received prior to revenue recognition are recorded as deferred revenue. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts expected to be recognized as revenue within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had one collaborative agreement with Bristol-Myers Squibb (&#x201c;BMS&#x201d;), which the Company entered into in January 2019 (the &#x201c;BMS Collaboration Agreement&#x201d;). For a complete discussion of the accounting related to BMS Collaboration Agreement, see Note 7, Collaboration Agreement and Stock Purchase Agreement with BMS.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
      contextRef="C_9d2ca6ed-69e8-4b73-9331-739f008d6068"
      id="F_fbff147c-5877-4b4d-84a5-c4c3dd5de3a7">Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_a363f018-7c61-490f-9200-7d87e22a642d"
      id="F_4dc57546-d749-4e70-96f2-2c910b07bf39">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_c8868192-8973-4e71-ba2d-335e4f68d970">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and Development Expense: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, acquisition of technology, and external costs of outside vendors engaged to conduct preclinical development activities and trials. Research and development expense for the year ended December 31, 2020, also includes the write-off of acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) assets with no alternative future use.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_27dea584-cef0-4726-8439-536fbf7abb3e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset Acquisitions:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs, and the consideration is allocated to the items acquired based on a relative fair value methodology. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire IPR&amp;amp;D with no alternative future use is charged to research and development expense at the acquisition date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_db394961-2363-4be0-82f5-0a4eb3a15f36">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based Compensation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s stock-based compensation program grants awards that may include stock options, restricted stock awards, restricted stock units, and other stock-based awards. The fair values of stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The fair values of restricted stock awards and restricted stock units are based on the fair value of the Company&#x2019;s common stock on the date of grant. The estimated fair values of the awards are expensed over the requisite service period, which is generally the vesting period of the award. For service-based awards that are subject to graded vesting, the Company has elected to recognize compensation expense for these awards on a straight-line basis. The Company accounts for forfeitures as they occur. The Company classifies stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s expected stock price volatility assumption is based on volatilities of similar entities whose share or option prices are publicly available. The Company uses the simplified method to estimate the expected life assumption. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected life of the option. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividend yield was assumed as the Company does not intend to pay dividends on its common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_ac609f84-eabe-4a82-989c-41a7e6a59ec4"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ikna:LeasesPolicyPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_ef1c76e2-77c1-4594-a72c-9a0285dc03f9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Leases: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6242453e-6005-48f3-94c4-c7e1e8f8f635;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounting Standards Codification&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC) 842 Leases, which was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company determines if an arrangement is or contains a lease at inception. For leases with a term of 12 months or less, the Company does not recognize a right-of-use asset or lease liability. The Company's operating leases are recognized on its consolidated balance sheet as other long-term assets, other current liabilities, and other long-term liabilities. The Company does not have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. Operating lease right-of-use assets also include the effect of any lease prepaid or deferred lease payments and are reduced by lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has elected to utilize the practical expedient to not separate lease components from non-lease components.&lt;/span&gt;</ikna:LeasesPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      id="F_8d3acf18-1ecc-4467-b703-5b9e84013cbf">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      id="F_8695050c-4d05-4b9a-a6de-41c58710ea4c">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_4b6a2896-8ec3-45a0-96a3-eb9564f14b00">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive Loss: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss is comprised of the net loss and other comprehensive income or loss. Other comprehensive income or loss consists of unrealized gains or losses on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_8f2b75df-a72b-4b43-89cd-a225e224c186">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Issuance Costs: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred issuance costs consist of legal, accounting and other third-party fees that are directly associated with in-process equity financings and remain deferred issuance costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction to the proceeds generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 30, 2021, the Company completed its IPO. Accordingly, the Company recognized offering costs of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as a reduction from the gross proceeds associated with the closing of the IPO through additional paid-in capital in the accompanying consolidated balance sheet. The Company incurred deferred offering costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2020 which were included in prepaid expenses and other current assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <ikna:OfferingCostsRecognized
      contextRef="C_c95a6922-ca79-4e5a-9bb5-f9b65cbb34cb"
      decimals="-5"
      id="F_50b2dccf-526b-424f-a7fa-1a918c3c8cdb"
      unitRef="U_USD">2400000</ikna:OfferingCostsRecognized>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_c9ea63bc-0e26-4e82-ae9c-c05ca061173e"
      decimals="-5"
      id="F_e1acd174-e8b9-4fc6-96f0-b48be42848df"
      unitRef="U_USD">500000</us-gaap:DeferredOfferingCosts>
    <ikna:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_4fceffa6-ada1-4d98-a6b1-3255cbe29e2b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Emerging Growth Company Status: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such a time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company no longer is an emerging growth company or affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</ikna:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_1e8d9a60-8a89-47cc-af4e-93b604008f38">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Recent Accounting Pronouncements: &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements and disclosures. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_b7cf6c95-ae78-426f-8fca-f6f728db1607">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.878%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.452%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.527%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.878%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.452%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.527%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between Level 1 and Level 2 financial assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_99777e26-9e38-4049-94aa-12cb904a1b57">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents information about the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.878%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.452%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.527%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;232,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.878%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.441%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.452%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.51%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:12.527%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Quoted Prices in Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;162,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6b95089c-ecad-4ea3-b482-0bde43865eb7"
      decimals="-3"
      id="F_3d76479d-b1ef-467d-a278-8acf7f8e6f52"
      unitRef="U_USD">232017000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c1b60113-9aac-46bb-90fa-37d525cc890a"
      decimals="-3"
      id="F_7c4c75c7-01ee-463c-993c-a8376fe13c50"
      unitRef="U_USD">232017000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f6feba73-11f7-4c3f-bf74-b2fc74138690"
      decimals="-3"
      id="F_b33886c4-8224-48bf-8f9a-077e91633d20"
      unitRef="U_USD">232017000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_53a98858-94fb-4019-b8a9-8e6c8638bbb5"
      decimals="-3"
      id="F_5094eddc-4cb9-46e7-8851-30723aad6ac5"
      unitRef="U_USD">232017000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6838680a-d30e-45b3-9c96-ca296d3f4897"
      decimals="-3"
      id="F_c3c671f7-9c1c-4da6-a8c1-9b3aea342735"
      unitRef="U_USD">162290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6bda0fb6-7d7a-41ad-a5b7-dd54a0540cc5"
      decimals="-3"
      id="F_59475548-4c79-450f-bd1f-47b4218601b0"
      unitRef="U_USD">162290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_1e48cebc-3625-4ce6-9967-9afa2709e2dd"
      decimals="-3"
      id="F_7415ad57-595a-4d3c-ab63-469185856574"
      unitRef="U_USD">162290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a3d192b9-f1b8-48f5-80bc-54ccb8098dcf"
      decimals="-3"
      id="F_ea359384-99f9-4d85-ab08-e915ab86089a"
      unitRef="U_USD">162290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_4ca8791f-a5af-423a-b271-65cecd0dee26"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_2ca67394-75b3-4062-ae27-418ce6291240"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_347e86ca-8c5c-40d7-bf41-13360c5f8134"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_83003673-fdf0-465f-864b-83f0f62169e3"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_aee58fc6-6bf3-4783-bf15-5db407f14409">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.247%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.605%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.605%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Clinical, manufacturing and scientific development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_1a7f1e88-2ff8-40c0-9f6f-504450b92c2d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.247%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.605%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.605%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Clinical, manufacturing and scientific development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock>
    <ikna:ClinicalManufacturingAndScientificDevelopmentCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_b3eb3d5e-571f-45d3-8289-9312ac73a536"
      unitRef="U_USD">2820000</ikna:ClinicalManufacturingAndScientificDevelopmentCurrent>
    <ikna:ClinicalManufacturingAndScientificDevelopmentCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_6ed160e5-5d14-4803-aa6e-643218e39c85"
      unitRef="U_USD">1917000</ikna:ClinicalManufacturingAndScientificDevelopmentCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_89721938-8a2d-4d24-ae0a-e5f4fd989624"
      unitRef="U_USD">850000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_28633099-1cf8-48aa-a1ba-343ad1baf308"
      unitRef="U_USD">23000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_a30c3545-5cbe-4d1e-b237-bc070d425987"
      unitRef="U_USD">629000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_0da0e44d-7698-4ad2-a7f9-40d161977af7"
      unitRef="U_USD">1538000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_879d2abc-014f-4860-9c7d-58b62fcce897"
      unitRef="U_USD">4299000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_c3a3f346-cf9c-49e7-b14c-362c7af3f7da"
      unitRef="U_USD">3478000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_0e0490c8-132e-4851-981b-29cbe3ba64ae">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. PROPERTY AND EQUITPMENT, NET&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.832%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.538%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.257%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Electronic equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation expense for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_0878cc41-0b9c-4588-bc21-52aaaf5d79e4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.832%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.538%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.257%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Electronic equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_33e372af-72dd-4109-9ecf-cd6de6a18366"
      decimals="-3"
      id="F_fe2b62aa-b5ed-438a-8033-569c7f910521"
      unitRef="U_USD">1776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7884ad66-cfc9-4e7d-b37b-a43da1f827a0"
      decimals="-3"
      id="F_54808c68-0826-42d8-94ba-7135996b1a0e"
      unitRef="U_USD">1071000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f861265f-3133-42fb-a89c-dac532459910"
      decimals="-3"
      id="F_88d02de6-94c4-4124-b233-dbf3f6353ac0"
      unitRef="U_USD">923000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_12fe0903-8181-40c3-af42-92ad1bc22546"
      decimals="-3"
      id="F_19538da6-1dc0-4cad-b793-d42edc78f33c"
      unitRef="U_USD">939000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d387d5e-0476-4899-8453-c870bec1b749"
      decimals="-3"
      id="F_20d7f299-8906-4725-83d7-51e3dc603ff4"
      unitRef="U_USD">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1ea44336-4474-480c-bcd2-a098f4164455"
      decimals="-3"
      id="F_0ee0dbd3-a96c-40d9-af8b-dc4c54f25eb2"
      unitRef="U_USD">71000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f5cf5caa-b798-49d2-bb71-6baf51e18554"
      decimals="-3"
      id="F_f20f3c38-48dd-403b-9b3f-9f7135c173a4"
      unitRef="U_USD">384000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_9c370917-41a3-4ff0-a844-947d1c955e3c"
      unitRef="U_USD">3513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_7d72f2cc-7e80-49d5-ae70-6e9a908d0d5d"
      unitRef="U_USD">2081000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_bd77f8c8-ae37-4870-8032-ef55fba98070"
      unitRef="U_USD">1074000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_c69f3181-1eb3-4598-a613-23de71fc9c2f"
      unitRef="U_USD">688000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_1568da09-8d09-4bbb-b94d-23f4f91aacce"
      unitRef="U_USD">2439000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_18c6ecb2-257c-4f23-b073-d6e5f2897be3"
      unitRef="U_USD">1393000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-5"
      id="F_7d31b3c1-f4f4-4770-8eca-da5ed689f22f"
      unitRef="U_USD">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-5"
      id="F_eae23c5a-27d3-4185-b549-0cef7a03996d"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_afab7e61-5833-43dc-9928-e2e23b8c53f2"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="INF"
      id="F_09d98a7f-ac86-4b68-95b6-04676a37928f"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_ace347e5-606a-4362-822d-11a85b7fda97">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.194%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.631%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.631%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
    <ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_5b24084e-91d3-4f2f-bb09-5be671672c26">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.194%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.631%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.631%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_16694904-9fdf-42af-aa13-9a42b081f3fb"
      unitRef="U_USD">2809000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_f5594f51-a6f2-4574-a744-f131cb9684d9"
      unitRef="U_USD">1816000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ikna:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_4c46711a-f4b9-4d6e-8764-a2c037f1f205"
      unitRef="U_USD">2489000</ikna:AccruedResearchAndDevelopmentExpensesCurrent>
    <ikna:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_1ac774ea-cab5-4cf2-bdae-fb05cc7326f6"
      unitRef="U_USD">2251000</ikna:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_bbf418a6-20ef-4f20-915f-e3a02c157a3c"
      unitRef="U_USD">530000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_952c2414-3228-407b-b00b-0eafdab064ff"
      unitRef="U_USD">955000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_1f83f02a-5e8f-4823-81f9-a33eaae5721c"
      unitRef="U_USD">26000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_a8346905-cd5d-4ade-9842-ef1c1803d684"
      unitRef="U_USD">380000</us-gaap:OtherLiabilitiesCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_44493149-97d9-4e71-929b-0392370cc561"
      unitRef="U_USD">5854000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_8d93abb4-a569-4503-a046-6a16aa11107e"
      unitRef="U_USD">5402000</ikna:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_ae9cf183-6f10-4d7c-a0cd-b7f27378395e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. COLLABORATION AGREEMENT AND STOCK PURCHASE AGREEMENT WITH BMS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2019, the Company entered into the BMS Collaboration Agreement with Celgene Corporation, which was acquired by BMS in November 2019, whereby the Company will carry out initial research and development activities with the goal of identifying and developing drug candidates for certain cancer types. Concurrent with execution of the BMS Collaboration Agreement, the Company entered into a stock purchase agreement with BMS, which resulted in the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,545,450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series A-1 Preferred Stock (the &#x201c;Stock Purchase Agreement&#x201d;). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Company&#x2019;s IPO, the series A-1 preferred stock converted into common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Agreement Structure&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the BMS Collaboration Agreement, the Company will conduct exploratory and discovery activities, with the goal of identifying product candidates for certain targets, which are in the kynurenine pathway, which the Company is developing as IK-412, and the aryl hydrocarbon receptor (&#x201c;AHR&#x201d;), which the Company is developing as IK-175. The Company is obligated to advance research and development activities through the earlier of January 2024 or the completion of a Phase 1b clinical trial for each program ("the research term"). BMS has the option to receive a global-development, manufacture and commercialization license for the product candidate, which expires in January 2024. Subsequent to the delivery of a license, BMS is responsible for the worldwide development, manufacturing and commercialization of these product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;BMS paid the Company a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in aggregate upfront consideration related to the BMS Collaboration Agreement and Stock Purchase Agreement. The Company is eligible to receive $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, in case of an exercise of its option with respect to IK-175, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, in case of an exercise of its option with respect to IK-412. If the Company does not complete a Phase 1b clinical trial by the end of the research term, the Company may provide a data package to BMS to support the decision to exercise the option for an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Upon the exercise of the delivery of each license, the Company becomes eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in milestone payments as well as a tiered royalty on worldwide sales from the high single to low teen digits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting Considerations of the Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The BMS Collaboration Agreement and the Stock Purchase Agreement were executed concurrently and in contemplation of each other. The issuance of Series A-1 Preferred Stock was initially accounted for at fair value. The purchase price for the Series A-1 Preferred Stock was considered to be at a discount from fair value, and therefore $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the upfront from the BMS Collaboration Agreement was allocated to the equity arrangement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determined that the BMS Collaboration Agreement represented a contract with a customer and should be accounted for in accordance with ASC 606. The Company identified the two performance obligations, which are research and development services for IK-175 and IK-412. The options to receive worldwide development and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;commercialization licenses for the two targets and the option to receive manufacturing services in the future were determined to not provide any material rights to the customer and are therefore not considered to be performance obligations. The arrangement also contains certain di minimis items, including participation on joint oversight committees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company identified $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of total transaction price which represents the upfront consideration allocated to the revenue arrangement. Additional consideration to be paid to the Company upon exercise of a right to receive a license or potential milestone and royalty payments are excluded from the transaction price as they relate to amounts that can only be achieved subsequent to the exercise of an options and are outside of the initial contact term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on the distinct performance obligations identified above, the Company allocated the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million transaction price based on relative estimated standalone selling prices of each of its performance obligations as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;41.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for research and development services for IK-175; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for research and development services for IK-412. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determined the estimated standalone selling price for the research and development services based on internal estimates of the costs to perform the services, including expected internal expenses and expenses with third parties, adjusted to include a reasonable profit margin. Significant inputs used to determine the total expense of the research and development activities include the length of time required and the number and cost of various studies that will be performed to complete the applicable development plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is recognizing revenue related to each of its performance obligations as the research and development services are performed through January 2024. The Company recognizes revenue related to research and development services performed using an input method by calculating costs incurred at each period end relative to total costs expected to be incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, the Company re-assessed the IK-412 program, which experienced manufacturing delays as a key component required in the manufacturing of IK-412, is similarly essential to the manufacturing of COVID-19 vaccines and therapies. As such, the availability of the component was delayed as resources were allocated towards vaccine production. Considering these delays and the timeline of the BMS partnership, the Company made the strategic decision to pause IK-412 developm&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ent activities for the remainder of the BMS research term once the ongoing CMC work has been completed. As a result of the decision to pause, the Company recorded a change in estimate during the three months ended December 31, 2021 and recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of research and development revenue.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recognized revenue of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively, from the BMS Collaboration Agreement. The consolidated balance sheet as of December 31, 2021 includes deferred revenue of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; related this agreement, of which &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; were classified as current and non-current, respectively. This amount is expected to be recognized as performance obligations are satisfied through the completion of the research and development services for IK-175 and IK-412.&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c485b7cf-0678-46d2-94de-86fa847eed87"
      decimals="INF"
      id="F_79763eba-d343-475b-b8dd-de98ec5047e5"
      unitRef="U_shares">14545450</us-gaap:PreferredStockSharesIssued>
    <ikna:UpfrontPayment
      contextRef="C_cab5b9e5-69a0-4f7b-8c1a-81cbd3afcba2"
      decimals="-5"
      id="F_962370de-4321-4ffb-b2c3-131b662e4aef"
      unitRef="U_USD">95000000.0</ikna:UpfrontPayment>
    <ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions
      contextRef="C_249d1b32-5370-4599-8e89-ab6c0f09b80f"
      decimals="-5"
      id="F_2f06a812-a6c2-4cad-885b-f239c07a60e3"
      unitRef="U_USD">50000000.0</ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions>
    <ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions
      contextRef="C_5e239a4a-5d8e-4aa5-91c9-b646ab6d2361"
      decimals="-5"
      id="F_dce8f3b4-c08a-4926-9cd0-bffc8f02dee4"
      unitRef="U_USD">40000000.0</ikna:AmountEligibleToReceiveInCaseOfExerciseOfOptions>
    <ikna:OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm
      contextRef="C_cab5b9e5-69a0-4f7b-8c1a-81cbd3afcba2"
      decimals="-4"
      id="F_fde315c2-644b-4a64-adaa-1761191a6ab3"
      unitRef="U_USD">250000</ikna:OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm>
    <ikna:MilestonePaymentsEligibleToReceive
      contextRef="C_84ac8be9-5cfc-47f7-b50e-f6ab75a07026"
      decimals="-6"
      id="F_9fe2706a-b251-412a-b830-f6a9153f337d"
      unitRef="U_USD">450000000</ikna:MilestonePaymentsEligibleToReceive>
    <ikna:UpfrontAmountAllocatedToEquityArrangements
      contextRef="C_7eb39d52-adcf-40e5-ae5d-09ebf80bd382"
      decimals="-5"
      id="F_38b1fa04-82f7-4fe9-8441-15a8c48b64c2"
      unitRef="U_USD">1800000</ikna:UpfrontAmountAllocatedToEquityArrangements>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_9449ae95-9c4e-423a-a742-487a9fa3d5c8"
      decimals="-5"
      id="F_71c65691-5206-4366-8436-56d79bbd80dd"
      unitRef="U_USD">78700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_9449ae95-9c4e-423a-a742-487a9fa3d5c8"
      decimals="-5"
      id="F_33db7bf2-d4e3-4696-8e4f-ffabb90ef4ac"
      unitRef="U_USD">78700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_fc3f0817-4c02-46a4-a64c-d9eba5dae732"
      decimals="-5"
      id="F_6e351b11-4ef2-4683-b56d-9c6870a41cf5"
      unitRef="U_USD">41200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_3af77da4-b3d1-4363-bc9c-05213b03b1ac"
      decimals="-5"
      id="F_aca1cbde-fa98-4db6-90c8-0cd56a49d609"
      unitRef="U_USD">37500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c92572d4-da38-4f18-8896-9db108cd3d8f"
      decimals="-5"
      id="F_84f15625-a7ff-4413-9049-6b1815e9fc5e"
      unitRef="U_USD">16500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_035aefe6-e027-41ce-80d2-5bcb01214d81"
      decimals="-5"
      id="F_5e13ae0e-6243-4e72-86b1-2ff68ce0d456"
      unitRef="U_USD">31000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_c24f3ba8-ff6c-4e9e-a73d-2853c35d6b11"
      decimals="-5"
      id="F_fdc3938c-2e8d-48f9-bfdf-f13c2cf05ffc"
      unitRef="U_USD">9200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_640f8a26-ca73-4101-8b04-267f50272b4b"
      decimals="-5"
      id="F_622ced6e-ef5a-46d1-9b8a-41e12b2db556"
      unitRef="U_USD">24800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_640f8a26-ca73-4101-8b04-267f50272b4b"
      decimals="-5"
      id="F_69886587-03eb-4c84-b03e-415af776183f"
      unitRef="U_USD">17100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_640f8a26-ca73-4101-8b04-267f50272b4b"
      decimals="-5"
      id="F_01b8e3cf-691d-4e11-bd75-236aba151c54"
      unitRef="U_USD">7700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ikna:RedeemableConvertiblePreferredStockTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_f3a01ec3-57a2-4c11-a0d2-1c77be232fc9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. REDEEMABLE CONVERTIBLE PREFERRED STOCK&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the closing of the Company&#x2019;s IPO on March 30, 2021, all issued and outstanding Redeemable Convertible Preferred Stock of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23,678,568&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock and are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; longer issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, the authorized capital stock of the Company included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of redeemable convertible preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, redeemable convertible preferred stock consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.828%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:14.491%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:14.491%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.859%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.88%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares Issued&lt;br/&gt;and Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Liquidation&lt;br/&gt;Preference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,727,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,727,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,863,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,863,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,806,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,806,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;116,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;205,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;202,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Preferred Stock had the following characteristics as of December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(a)	Voting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Company&#x2019;s Amended and Restated Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and have other special voting rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The holders of outstanding shares of Preferred Stock shall be entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(b)	Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The holders of Preferred Stock are entitled to an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% non-cumulative dividend. Dividends are payable only when, as and if declared by the Board. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividends are payable to the common stockholders unless a dividend is also paid to Preferred Stockholders equal to at least the amount that would be received if the shares of Preferred Stock were converted into common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Through December 31, 2020 and the completion of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividends have been declared or paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(c)     Liquidation Preference&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or upon the event of certain other deemed liquidation events, holders of shares of Preferred Stock then outstanding shall be entitled to receive the greater of (i) an amount per share equal to the Preferred Stock original issue price, plus any dividends declared but unpaid thereon or (ii) the amount that would be received if the Preferred Stock was converted into common stock just prior to the liquidation event.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(d)	Conversion&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Each share of Preferred Stock shall be convertible into shares of common stock at the option of the stockholder, at any time, at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for one and are automatically converted upon a qualified initial public offering or upon written consent of at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the holders of the outstanding shares of Preferred Stock. The conversion ratio is initially set at one for one, but may be adjusted for certain issuances of additional shares of Common Stock, stock splits, stock combinations, certain dividends and distributions, and mergers and reorganizations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The conversion ratio was changed to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.154&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for one upon the Company&#x2019;s filing of its amendment to its Amended and Restated Certificate of Incorporation on March 22, 2021.&lt;/span&gt;&lt;/p&gt;</ikna:RedeemableConvertiblePreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_1751049c-5a01-4bb3-88da-acd002119349"
      decimals="INF"
      id="F_b41e8abd-dc26-4f91-9587-773eab474934"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_3cf264ba-3822-4bc8-8611-e5f6c96c4ced"
      decimals="INF"
      id="F_4c5f3b15-29b0-43ac-9ad1-b1e746885068"
      unitRef="U_shares">23678568</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_80c83882-abbc-4f18-9ffe-8a6f1fe9f705"
      decimals="INF"
      id="F_35987cf8-d1be-4e29-8f69-99671cdcad0d"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_73a95a4f-2717-441c-8d33-6cca61d172fc"
      decimals="INF"
      id="F_f390d491-4df3-4f47-b604-06c2bfeb669a"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_049510f1-d807-4ae1-ae18-db4b1d8feb9b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, redeemable convertible preferred stock consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.828%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:14.491%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:14.491%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.859%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.649%;"/&gt;
        &lt;td style="width:1.371%;"/&gt;
        &lt;td style="width:13.88%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares Issued&lt;br/&gt;and Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Liquidation&lt;br/&gt;Preference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,000,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,727,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,727,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;47,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series A-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,863,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,863,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Series B&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,806,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85,806,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;116,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;205,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;202,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb"
      decimals="INF"
      id="F_86424d1a-0d33-4aaf-b93a-bd0c1382fd93"
      unitRef="U_shares">28000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb"
      decimals="INF"
      id="F_f61ce486-793d-4f3d-9807-d309c1be90f1"
      unitRef="U_shares">28000000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb"
      decimals="INF"
      id="F_fb2501b6-2413-41c0-a714-04e42066a4a3"
      unitRef="U_shares">28000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb"
      decimals="-3"
      id="F_26884425-f4a3-4c86-a4ea-1bd7cebbf138"
      unitRef="U_USD">27832000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb"
      decimals="-3"
      id="F_9bd08948-9720-4f56-bab6-abaf22c01865"
      unitRef="U_USD">28000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549"
      decimals="INF"
      id="F_443def15-881f-4cc0-a6f9-70065b1854ee"
      unitRef="U_shares">47727268</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549"
      decimals="INF"
      id="F_5c95e15e-4431-49b9-adde-83e5407f31f0"
      unitRef="U_shares">47727268</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549"
      decimals="INF"
      id="F_827fe749-2587-4630-b795-abf27b1f1f2d"
      unitRef="U_shares">47727268</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549"
      decimals="-3"
      id="F_228ee6dc-1b86-4e56-96bf-f1d666e825b6"
      unitRef="U_USD">51035000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_c083b51c-b8f6-4949-af7d-87bfd8ace549"
      decimals="-3"
      id="F_86173832-c758-4a6f-a610-83decc33fc2a"
      unitRef="U_USD">47727000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_b652551b-9695-4fe5-8980-18380f280c59"
      decimals="INF"
      id="F_dce5ff83-8e00-4912-a541-1eab658d2eda"
      unitRef="U_shares">7863094</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_b652551b-9695-4fe5-8980-18380f280c59"
      decimals="INF"
      id="F_6db6bcb1-66ab-4f17-9b0d-4a7e97654f8c"
      unitRef="U_shares">7863094</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b652551b-9695-4fe5-8980-18380f280c59"
      decimals="INF"
      id="F_dac9f731-8cd3-46a7-ae59-cf5ebb7167a9"
      unitRef="U_shares">7863094</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_b652551b-9695-4fe5-8980-18380f280c59"
      decimals="-3"
      id="F_f7cae3d1-c074-4903-92da-22a5824eda93"
      unitRef="U_USD">10924000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_b652551b-9695-4fe5-8980-18380f280c59"
      decimals="-3"
      id="F_f612f2ba-e887-40ba-8ec5-816e2a731fda"
      unitRef="U_USD">6500000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb"
      decimals="INF"
      id="F_52a23cf1-b4ef-4960-85df-9b31b5acc61f"
      unitRef="U_shares">85806214</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb"
      decimals="INF"
      id="F_4961d228-1091-41d5-810a-27f86ade20ca"
      unitRef="U_shares">85806214</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb"
      decimals="INF"
      id="F_2bb8acde-fd47-49e5-baf5-02fd8c7fe573"
      unitRef="U_shares">85806214</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb"
      decimals="-3"
      id="F_81d3599b-e25a-49f4-a2e0-446a115635e9"
      unitRef="U_USD">116188000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_77bf16f4-0053-4b65-a6e3-44bc05446deb"
      decimals="-3"
      id="F_702f39fa-0175-4304-bbb8-d7d809d832d0"
      unitRef="U_USD">120000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_e667f5a4-a979-4bec-80ea-416068ec6332"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_209aec18-2edb-4285-b759-c4fb2e00311a"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_4fc9278f-7abf-4d20-ab4e-5677427e6309"
      unitRef="U_shares">169396576</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_50e72a7a-e82f-4589-a3bf-c4118f6ba1bb"
      unitRef="U_USD">205979000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_be754fc8-2169-4bdb-af92-4e5aaf60555e"
      unitRef="U_USD">202227000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:PreferredStockVotingRights
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_4cfe45c4-2855-4583-b9aa-e43d6e825add">The holders of outstanding shares of Preferred Stock shall be entitled to elect three directors of the Company. The investors have agreed that two of the directors are to be named by one investor and the other director is to be named by a separate investor.</us-gaap:PreferredStockVotingRights>
    <ikna:TemporaryEquityNonCumulativeDividend
      contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc"
      decimals="2"
      id="F_d29e7ab7-2b75-4c03-89f2-33edc397d807"
      unitRef="U_pure">0.08</ikna:TemporaryEquityNonCumulativeDividend>
    <us-gaap:DividendsCommonStock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_59739d17-7c8a-4ce3-bdaa-95ad71810f4c"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <ikna:TemporaryEquityDividendDeclaredOrPaid
      contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883"
      decimals="-3"
      id="F_35d81a36-b2c5-48e5-b3a7-e2494144fb55"
      unitRef="U_USD">0</ikna:TemporaryEquityDividendDeclaredOrPaid>
    <ikna:TemporaryEquityDividendDeclaredOrPaid
      contextRef="C_3dd7a94f-ebbb-475e-ab24-17fd8d19e2fa"
      decimals="-3"
      id="F_408e55b1-6ecd-4380-be4c-9b7279c4ba83"
      unitRef="U_USD">0</ikna:TemporaryEquityDividendDeclaredOrPaid>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_58e59c96-9c20-4175-a767-95e0b0fd9b9e"
      decimals="0"
      id="F_c3feb9f2-294e-4694-ae5c-0f171d752449"
      unitRef="U_pure">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <ikna:PercentageOfHoldersOfOutstandingSharesOfPreferredStock
      contextRef="C_72a6fba1-d2e1-431b-9bd5-18b148800ffc"
      decimals="2"
      id="F_12085029-8dc1-4aa2-8646-a79791a79c62"
      unitRef="U_pure">0.75</ikna:PercentageOfHoldersOfOutstandingSharesOfPreferredStock>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_252420a7-5245-4f24-a1b3-549a5657e10c"
      decimals="3"
      id="F_4ac07fee-b54e-447e-b06a-acca55e5fe0d"
      unitRef="U_pure">7.154</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_3868ee1b-e4db-4dfc-85bf-fb46b96dd9a7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. COMMON STOCK&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;150,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;230,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock authorized, respectively, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,975,034&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,096,903&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; were issued and outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Voting: &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividends: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The holders of shares of common stock are entitled to receive dividends, if and when declared by the Board of Directors. No dividends have been declared or paid by the Company since its inception&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Liquidation: &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;After payment to the holders of shares of Preferred Stock of their liquidation preferences, the remaining assets of the Company are distributed to the holders of common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="0"
      id="F_5246cf27-46e8-497d-af2e-8104728b23e5"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="0"
      id="F_e1a2a11e-1bbc-4595-9e26-8568beffecff"
      unitRef="U_shares">230000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="0"
      id="F_4e884684-168a-4dc4-acc0-b3d73cf6e3e3"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="0"
      id="F_e4fd1854-8a70-453a-9a6a-95bc38d4f20b"
      unitRef="U_shares">35975034</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="0"
      id="F_49f7eb85-2a91-47d4-b468-b621979703f0"
      unitRef="U_shares">3096903</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="0"
      id="F_8f94e9bd-b579-4030-817a-363493b1235f"
      unitRef="U_shares">3096903</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockVotingRights
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_dc5173b9-fb27-4f95-8959-c42ea4cb0a2a">The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. The holders of outstanding shares of common stock shall be entitled to elect two directors of the Company.</us-gaap:CommonStockVotingRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_b74c3860-4afb-4b6b-ba09-5fe77263c003">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;. STOCK BASED COMPENSATION&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2016, the Company&#x2019;s board of directors and stockholders adopted the 2016 Stock Incentive Plan which was amended and restated in December 2020, (as so amended and restated, the &#x201c;2016 Plan&#x201d;) which permits the granting of (1) options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code, and (2) options that do not so qualify.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;       &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 19, 2021, the Company&#x2019;s board of directors approved, and on March 20, 2021, the Company&#x2019;s stockholders approved the 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The 2021 Plan replaced the 2016 Plan as the board of directors had determined it would not to make additional awards under the 2016 Plan following the closing of the initial public offering. However, the 2016 Plan will continue to govern outstanding equity awards granted thereunder. The 2021 Plan allows the Company to make equity-based and cash-based incentive awards to officers, employees, directors and consultants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of the effective date of the 2021 Plan, no further awards will be made under the 2016 Plan. Any options or awards outstanding under the 2016 Plan remain outstanding and effective and are governed by their existing terms. The shares of the Company&#x2019;s common stock subject to outstanding awards under the 2016 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will be added back to the shares of common stock available for issuance under the 2021 Plan. No more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,263,664&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock may be granted subject to incentive stock options under the 2021 Plan. In addition, the 2021 Plan contains an &#x201c;evergreen&#x201d; provision, which allows for an annual increase in the number of shares of common stock available for issuance under the 2021 Plan on the first day of each fiscal year during the period beginning in fiscal year 2022. The annual increase in the number of shares shall be equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the 2021 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,250,479&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock remain available for future issuance under the 2021 Plan. The vesting periods for equity awards, which generally is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, are determined by the Board of Directors. The contractual term for stock option awards is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.301%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.591%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.591%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average fair value of the stock options granted during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.53&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, respectively. As of December 31, 2021, the total unrecognized stock-based compensation balance for unvested options was &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; which is expected to be recognized over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.97&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes stock option activity under the Plan for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.128%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.935%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:9.496%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:10.074%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:9.517%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,650,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,435,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;215,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested or expected to vest as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,841,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The intrinsic value of options exercised for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each option award granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; is estimated on the date of grant using the Black-Scholes option pricing model and the weighted average assumptions noted in the following table:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.059%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:10.8%;"/&gt;
        &lt;td style="width:9.583%;"/&gt;
        &lt;td style="width:2.897%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:0.744%;"/&gt;
        &lt;td style="width:17.272%;"/&gt;
        &lt;td style="width:2.525%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.68&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.47&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68.58&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 20, 2021, the Company&#x2019;s stockholders approved the 2021 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;346,613&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;An annual increase in the number of shares of common stock reserved and available for issuance under the ESPP shall be equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the number of shares of common stock outstanding on the immediately preceding December 31; and such lesser number of shares as determined by the Administrator as provided in the ESPP. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares have been purchased by employees under the ESPP.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate
      contextRef="C_cb63a3a7-a4a7-4296-b5a8-5e3cd9e88878"
      id="F_171e9dbc-d2a3-4a5c-a2a0-4a9e8c7bfc53">2021-03-30</ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_de1f00a8-10d4-4a23-8b9b-2bef95a2e119"
      decimals="INF"
      id="F_f216f317-14a9-4aee-a848-4f1accd46fe1"
      unitRef="U_shares">3263664</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ikna:AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding
      contextRef="C_9ce46fba-908a-4541-9693-823709dea22f"
      decimals="INF"
      id="F_5948fd60-af34-4646-96db-f88407d1df40"
      unitRef="U_pure">0.04</ikna:AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_2a718982-72b2-4b6f-8b37-4cb567dba4b5"
      decimals="INF"
      id="F_26c3db5d-78d9-4338-856f-c7824f3e7f6e"
      unitRef="U_shares">2250479</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_ef57b772-1e45-4cbb-82ff-1cd3052d6512"
      id="F_a7ee8022-c7de-4ef4-8762-0cb737fb6147">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ikna:StockOptionContractualTerm
      contextRef="C_ef57b772-1e45-4cbb-82ff-1cd3052d6512"
      id="F_d2fcc612-2b1a-45cf-9359-b336f8b56a16">P10Y</ikna:StockOptionContractualTerm>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_825b8156-76c5-48d6-8304-a8a2cdf081c2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total compensation expense recognized in the statements of operations associated with all the stock-based compensation awards granted by the Company is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.301%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.591%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:1.942%;"/&gt;
        &lt;td style="width:13.591%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bc07950d-ff60-4171-bee4-68de5e8006fc"
      decimals="-3"
      id="F_d5d3b3a3-6033-46fc-8f7c-cef6c539fe37"
      unitRef="U_USD">2427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3ccefeed-c353-4dec-a464-be4c75fc07a4"
      decimals="-3"
      id="F_2a0b99df-3927-4e7d-80d3-ad6920045643"
      unitRef="U_USD">790000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_de68a06b-52a5-428b-8fda-644108120c2e"
      decimals="-3"
      id="F_0e12ba9d-db91-46b1-8052-40cbb0bd15c9"
      unitRef="U_USD">2750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bb21e98b-d1d5-4830-95ae-a8521474d69b"
      decimals="-3"
      id="F_17c20a45-5e2f-4a25-8ffc-01304fff5bb3"
      unitRef="U_USD">1007000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_d8d69f5c-69f8-4b3d-9b56-47afe4acc693"
      unitRef="U_USD">5177000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_c737cb56-33ee-4ff9-a0a8-3898efc2312b"
      unitRef="U_USD">1797000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_a504273b-8eb4-4d62-9fbb-300b2cedd99a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="2"
      id="F_6528a562-fb63-45fd-ad4b-7e374647a9a1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-5"
      id="F_92a1eb94-4e0e-43c3-9f1e-e028b6f49d27"
      unitRef="U_USD">19100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_1a78a0a4-9641-4e92-b3b4-e1a2b392f3a4">P2Y11M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_c54a77e6-35ea-4a97-80ca-dd883c0382d9">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes stock option activity under the Plan for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.128%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:9.935%;"/&gt;
        &lt;td style="width:0.91%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:9.496%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
        &lt;td style="width:10.074%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
        &lt;td style="width:1.188%;"/&gt;
        &lt;td style="width:1.37%;"/&gt;
        &lt;td style="width:9.517%;"/&gt;
        &lt;td style="width:0.685%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,650,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,435,687&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;215,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled or forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested or expected to vest as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,841,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.71&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_bca76deb-2c57-457a-a278-ac53e9bcc18c"
      unitRef="U_shares">2650396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="2"
      id="F_b44ba32b-f8e8-4a21-8378-169fc65d6119"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      id="F_fed4ceee-9fa0-4174-998d-68eeb1e8aa9b">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_7b792740-dc66-482a-81ad-98af4b080401"
      unitRef="U_USD">5463000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_79755176-24a1-47d1-beaf-a838a14fa03c"
      unitRef="U_shares">3435687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_b42e4447-f0e6-4eef-90d8-6f192a8ce49d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_45ae54f9-d894-4a97-8ee5-d96a73e9e8ae"
      unitRef="U_shares">215188</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_ddbe7bdb-0f83-4489-81c9-7e29e10cad4f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_009e05d9-6570-42d5-a99e-aade31af5b0c"
      unitRef="U_shares">48522</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_98e1c7c1-9261-468c-a8b6-ac5ce127a6dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_79fa59fd-be60-4184-a2df-add665d7dcb3"
      unitRef="U_shares">5822373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="2"
      id="F_5cacc511-2066-404b-a105-cc57fe970c07"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_b0843db0-bc9a-4de7-9a32-aa857e94c48d">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_2bc7a596-0b10-4140-8a23-a5c07a883d38"
      unitRef="U_USD">33275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_e2999e95-007d-4272-be70-4d2dfe12c682"
      unitRef="U_shares">5822373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="2"
      id="F_5c17891c-8371-48f3-b4f9-b49093add791"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_93485350-0362-4e01-a928-578bf6a01123">P8Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_ba23f09d-8901-4603-ae5a-721c823cce69"
      unitRef="U_USD">33275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_6a42b71e-75cb-4f36-b7bd-856a80e75875"
      unitRef="U_shares">1841894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="2"
      id="F_2c423af1-bef7-46b6-abce-a4541605fa7b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_b116ea04-3a39-4ef5-9678-5de98475315a">P6Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_ae1c8fbf-8f3f-40aa-8ea6-4598fb3f828b"
      unitRef="U_USD">16928000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-5"
      id="F_4734b56c-cda0-476e-836d-11e6dffed957"
      unitRef="U_USD">1900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_980963b9-31d6-44f6-b9d9-326e954f5319"
      unitRef="U_USD">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_98e64089-1384-48a6-bcbe-f86606861f48">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each option award granted during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; is estimated on the date of grant using the Black-Scholes option pricing model and the weighted average assumptions noted in the following table:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.059%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:10.8%;"/&gt;
        &lt;td style="width:9.583%;"/&gt;
        &lt;td style="width:2.897%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:0.744%;"/&gt;
        &lt;td style="width:17.272%;"/&gt;
        &lt;td style="width:2.525%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.68&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.27&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.47&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected option term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;6.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility range&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68.58&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73.15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="4"
      id="F_7ba6f1b0-1662-4536-941d-549a5fa49822"
      unitRef="U_pure">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="4"
      id="F_53428fa0-adfd-4a1a-bf0e-1b9008f53fb1"
      unitRef="U_pure">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="4"
      id="F_6837400d-b0d3-4184-9d57-3ea82ae15ec9"
      unitRef="U_pure">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="4"
      id="F_fc01c010-e076-43da-94ad-baffea811644"
      unitRef="U_pure">0.0047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="2"
      id="F_6e215cda-cd04-447f-b80b-d370e4b90c72"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="2"
      id="F_b7c574d9-96ea-4c6f-ae86-2a0ef1481666"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_85fb6b92-dfdb-4f1c-b04e-5cb23fd29f2e"
      id="F_0b59ff96-46bf-448c-9e38-469a28249ed2">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_97c448a4-24df-47b4-8856-f4896b80ad75"
      id="F_7dde1cfb-2967-4d32-a45d-5833ce2ff9f2">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_74803d30-fb65-4987-a08f-21d2e606fe63"
      id="F_311ec8fd-f6a8-44db-886e-b9a1e6da83d3">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b7dc9500-a312-4bbb-8606-fbcf3215bf2f"
      id="F_aa7340c9-fc68-49f4-bee9-7931c3bdf603">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="4"
      id="F_a9cefa88-c836-4501-9e7d-17556bc3ffbf"
      unitRef="U_pure">0.6858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="4"
      id="F_c14c1e20-485a-4412-b1b1-1a42b5a7c3fc"
      unitRef="U_pure">0.7330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="4"
      id="F_fff1bc81-98d6-4860-8b0b-da55370828a5"
      unitRef="U_pure">0.7315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="4"
      id="F_4254c7c1-4982-4cf3-8241-7a0b87847d94"
      unitRef="U_pure">0.7489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate
      contextRef="C_967cd9a5-9ca9-47d7-aeb3-bede932bd3d4"
      id="F_3c8fdfa6-9041-4e2b-8d15-190efea725ee">2021-03-30</ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_8e5351be-0edc-42b6-8e62-f402a7a84729"
      decimals="INF"
      id="F_5e6ab1f3-efde-44be-b930-250b6b75835f"
      unitRef="U_shares">346613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <ikna:IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding
      contextRef="C_d8f918b3-befa-4a88-93fc-46d5041b9f1a"
      decimals="INF"
      id="F_fc5ab3ae-c262-4790-aba8-84dd56349d3c"
      unitRef="U_pure">0.01</ikna:IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding>
    <ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees
      contextRef="C_6b98e2af-28de-4a15-9b16-1d31248fde7e"
      decimals="INF"
      id="F_00662e61-48b2-472f-a192-58eb9ace1277"
      unitRef="U_shares">0</ikna:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_146e1515-2303-42ca-b300-7c5554ccd85f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. EMPLOYEE BENEFIT PLAN&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has a defined-contribution savings plan covering all eligible U.S. employees under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). During the years ended December 31, 2021 and 2020, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t make any employer contributions to the plan. Employees can designate the investment of their 401(k) accounts into several mutual funds. Administrative costs of the plan for each of the years ended December 31, 2021 and 2020, were immaterial.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_d673b94f-ae52-4479-8a14-cb7062784fa4"
      unitRef="U_USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="INF"
      id="F_854932d5-1084-4f75-8188-3f2fac2c7f93"
      unitRef="U_USD">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_2945daaa-a919-4726-8003-949ad2a1d9cc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.517%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:12.008%;"/&gt;
        &lt;td style="width:4.458%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:12.008%;"/&gt;
        &lt;td style="width:4.458%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax effected at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquired in-process R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s total deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.779%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.924%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.924%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Capitalized start-up costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation Allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets and liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; income tax expense due to operating losses incurred since inception. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on this, the Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. During 2021, the valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million primarily due to the increase in the Company's book loss reported in the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;86.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;83.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of Federal and State operating loss carryforwards respectively. The Federal net operating losses are not subject to expiration and the state net operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. These loss carryforwards are available to reduce future federal taxable income, if any. As of December 31, 2021, the Company also has federal and state research and development tax credit carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million respectively, to offset future income taxes, which will begin to expire beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. These loss carryforwards are subject to review and possible adjustment by the appropriate taxing authorities. The amount of loss carryforwards that may be utilized in any future period may be limited based upon changes in the ownership of the company's ultimate parent.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company follows the provisions of ASC 740-10, Accounting for Uncertainty in Income Taxes, which specifies how tax benefits for uncertain tax positions are to be recognized, measured, and recorded in financial statements;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;requires &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim period guidance, among other provisions. As of December 31, 2021, and 2020, the Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recorded tax reserves associated with any unrecognized tax benefits. The Company&#x2019;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its statements of income. As of December 31, 2021, and 2020, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reserves for uncertain tax positions. For the years ended December 31, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; estimated interest or penalties were recognized on uncertain tax positions.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's Federal and Massachusetts income tax returns for the years ended December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to December 31, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; remain open and are subject to examination by the Internal Revenue Service and state taxing authorities.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_91c18f39-52b9-4d76-82a2-b94462e5329d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective income tax rate differed from the amount computed by applying the federal statutory rate to the Company&#x2019;s loss before income taxes as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.517%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:12.008%;"/&gt;
        &lt;td style="width:4.458%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:0.803%;"/&gt;
        &lt;td style="width:12.008%;"/&gt;
        &lt;td style="width:4.458%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax effected at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-deductible expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquired in-process R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_d73da998-420f-4ffa-89af-74e62c64a85b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="INF"
      id="F_ba98942c-d9c2-49e0-a4dd-c2713c19b4e6"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="3"
      id="F_bf4699b1-1d29-416d-bddd-1273da8607c1"
      unitRef="U_pure">0.074</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="3"
      id="F_8461d96a-5656-49d9-973b-080b7efde5c6"
      unitRef="U_pure">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="3"
      id="F_ca55485d-d0a9-479a-859b-a967ba029dda"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="3"
      id="F_591e0207-49af-4fea-996d-4ea7f17519d0"
      unitRef="U_pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="3"
      id="F_ac0c2edc-59ca-47b5-9a1f-c8fe4ff82bc0"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="3"
      id="F_ea229e43-b13e-47d1-a8a0-8856cd029cbe"
      unitRef="U_pure">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="3"
      id="F_775761cb-99db-4abe-8481-97c50ab78797"
      unitRef="U_pure">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="3"
      id="F_997f33a5-fba9-44c6-b14e-c83ac0545a0b"
      unitRef="U_pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="3"
      id="F_6d57cd8d-1d76-4b4a-8412-5dd5b366988c"
      unitRef="U_pure">-0.322</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="3"
      id="F_ea9f0b04-edf4-4397-8ce4-2b03032f4cd3"
      unitRef="U_pure">-0.239</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_3ab025b0-5644-476a-acd8-3b4149876b95">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s total deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62.779%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.924%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
        &lt;td style="width:1.473%;"/&gt;
        &lt;td style="width:1.928%;"/&gt;
        &lt;td style="width:13.924%;"/&gt;
        &lt;td style="width:1.285%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State net operating loss carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;R&amp;amp;D credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Capitalized start-up costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liability:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation Allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets and liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_cca2863f-118b-4a8a-96be-bfbdefc67f22"
      unitRef="U_USD">18233000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_977dce96-4477-45e0-9c52-89739eda72f2"
      unitRef="U_USD">5445000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_36d16f30-45a7-4cac-b493-b49f72c54e64"
      unitRef="U_USD">5269000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_fb8f69e5-efe2-435f-b70f-23fefe40f4e9"
      unitRef="U_USD">1593000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_f54bd8a4-cc3d-4f8c-adb0-b010f3145092"
      unitRef="U_USD">6385000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_fe0a7a8e-905d-446b-bd69-623160135aa6"
      unitRef="U_USD">4023000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_736d3e86-3cac-4d1e-b206-60fcbf75c628"
      unitRef="U_USD">242000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_6127611b-8768-496c-acbf-d9633bb66fa7"
      unitRef="U_USD">264000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_40e80ef1-c6f6-4f5f-8997-3796ee8d4979"
      unitRef="U_USD">629000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_06e0fadd-a349-47d0-9999-59b30c227617"
      unitRef="U_USD">327000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_c7439aa1-ac33-48f7-875b-6c02d963eeb4"
      unitRef="U_USD">6769000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_0cf70fd2-6955-42d4-8448-e5c4eca8f5f8"
      unitRef="U_USD">15234000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_0818337a-ae92-42cf-b935-a1a2c43cd384"
      unitRef="U_USD">1026000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_493f825f-54eb-4bf2-a445-9c898feb7d5a"
      unitRef="U_USD">318000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ikna:DeferredTaxAssetsLeaseLiability
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_71a31753-fe9b-44b0-a288-aef9bcf5246e"
      unitRef="U_USD">1908000</ikna:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_c3231fdb-02d1-40f1-ab82-cae368289368"
      unitRef="U_USD">40461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_c8ccf511-de5e-4171-a634-e4b4ace84a05"
      unitRef="U_USD">27204000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_50ed4121-84fe-4050-9235-75b6ffe70b66"
      unitRef="U_USD">648000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_c8615f6a-cf6e-41ec-952d-e0a8d97ffb83"
      unitRef="U_USD">170000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_b369e550-b743-4eae-9b0a-ab0d019b8464"
      unitRef="U_USD">1786000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_e36396f0-33c8-451c-8605-c0f4488c0b1a"
      unitRef="U_USD">2434000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_ef980860-de33-4fc6-83af-52e68dde8011"
      unitRef="U_USD">170000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_2efc523b-537d-4f3a-bf53-acb2ac2e091e"
      unitRef="U_USD">38027000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="-3"
      id="F_dd74fa89-1605-4db6-a359-b5d84a74de43"
      unitRef="U_USD">27034000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_e0e6b850-ab06-44b0-873a-684a4551e25b"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-5"
      id="F_e97a4c0f-6d60-480f-aadf-acf61512b0cb"
      unitRef="U_USD">11000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_c2e15ff7-280d-4489-8017-9492ffa9ab32"
      decimals="-5"
      id="F_cf460918-1c35-477e-8cd1-4d4ec443a007"
      unitRef="U_USD">86800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9c6adf68-b45d-444a-96ff-b973670159ef"
      decimals="-5"
      id="F_21e15466-3c45-4060-8ae2-4f352e145000"
      unitRef="U_USD">83400000</us-gaap:OperatingLossCarryforwards>
    <ikna:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0d0023fe-0f0c-46e9-b39d-3d9294d1fdf8"
      id="F_2a8b031d-df86-41d0-95d9-43d15cae492f">2037</ikna:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0c5c2a21-5b8b-4673-9f3c-9fd33b740459"
      decimals="-5"
      id="F_937aa46a-3906-4efc-ab45-e58bdf10fb33"
      unitRef="U_USD">5000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_d59e96ca-e70a-4673-a757-3997f4bdb74c"
      decimals="-5"
      id="F_6f4eca15-697f-46d7-863f-2778a1d95cc9"
      unitRef="U_USD">1700000</us-gaap:TaxCreditCarryforwardAmount>
    <ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear
      contextRef="C_9265d692-1067-4446-93b5-77437f4ec759"
      id="F_215e7ccc-be76-48c2-a161-0f847af28d63">2031-12</ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear>
    <ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear
      contextRef="C_f7dcb7f3-11ce-4fd1-9003-09bb1c7904e9"
      id="F_37d12481-17aa-4f4d-9963-a3143e51f9d2">2031-12</ikna:TaxCreditCarryforwardExpirationBeginMonthAndYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_e23e7d2a-1d94-47cb-bfb3-0497e62159f3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_007b2d68-e52a-4773-ac1c-4857087c5408"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="INF"
      id="F_e610fbd0-2b16-4d04-a7da-fd563cf00e83"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="INF"
      id="F_a3680e2c-77f0-4a26-b89f-d862a48dd2d7"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="INF"
      id="F_8f37b006-708c-49eb-8cf4-8d02e6b23a4c"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="INF"
      id="F_a63f910f-e376-476a-a53e-8825dc1a8a73"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:OpenTaxYear
      contextRef="C_fb2b28a5-0c8c-41e7-a631-b5a284180f8d"
      id="F_c3eb15bc-d7ec-41c2-a814-9f6ff3a487f9">2018</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_0bc3c318-3f9b-4004-b2d0-fd1298f6297d"
      id="F_e2d2d5e9-8bf5-4537-8511-a78dd838a9fc">2021</us-gaap:OpenTaxYear>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_0cbd350c-66a9-45f8-b91c-fac5af0f4eb5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. RESEARCH LICENSE AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During 2015, the Company entered into an exclusive patent license agreement (the &#x201c;UT Austin License&#x201d;) to license certain technologies and intellectual property rights from the University of Texas at Austin (the &#x201c;University&#x201d;), an entity affiliated with a director of the Company at the time of the agreement. The UT Austin License shall remain in effect until the expiration or abandonment of the last to expire technologies and intellectual property rights. The Company shall pay License Maintenance fees annually of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand. Additionally, the Company shall make additional milestone payments to the University upon meeting certain development milestones in the aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon meeting certain development milestones during the term of the UT Austin License. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company will also be responsible for reimbursing the University for certain patent-related costs incurred on its behalf.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2018, the Company acquired IPR&amp;amp;D on an Arrys&#x2019; immune-oncology candidate based on the intellectual property associated with Arrys&#x2019; AskAt License as part of the acquisition of Arrys. Total consideration allocated to the technology was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and was recognized as research and development expense upon the acquisition. The AskAt License is intended to be used by the Company in its future development of therapeutic drug candidates for eventual clinical development and commercialization. The Company shall make additional milestone payments to AskAt upon meeting certain development milestones totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, as well as certain sales event milestones ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million contingent on sales in a calendar year, during the term of the AskAt License.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <ikna:LicenseMaintenanceFees
      contextRef="C_5c03768c-e908-427c-98a3-dac6ad6d0a7d"
      decimals="-3"
      id="F_dd8b5ec1-cf3b-45e2-b2cb-ad33d5b77a03"
      unitRef="U_USD">40000</ikna:LicenseMaintenanceFees>
    <ikna:PotentialDevelopmentMilestonePayments
      contextRef="C_38798bf1-ddbf-4fcd-90e3-e5ba57c070a3"
      decimals="-5"
      id="F_789c472e-2920-40f3-a27f-9449fdb53c17"
      unitRef="U_USD">4700000</ikna:PotentialDevelopmentMilestonePayments>
    <ikna:RoyaltiesTerms
      contextRef="C_064ada85-12cf-4684-b1a0-b4034e155188"
      id="F_b567880b-1fc6-4359-b8ab-7699787af5f8">The Company will pay the University royalties as defined in the UT Austin License on any commercialized product sales related to the licensed technology in a percentage in the low single digits.</ikna:RoyaltiesTerms>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_aea069f1-935a-4fb9-93fe-05cda26d80fe"
      decimals="-5"
      id="F_d182c70b-39a7-402f-b098-9d164388e715"
      unitRef="U_USD">28500000</us-gaap:ResearchAndDevelopmentInProcess>
    <ikna:PotentialDevelopmentMilestonePayments
      contextRef="C_f814b099-b5e9-4532-849e-ed0d7f1514b0"
      decimals="-6"
      id="F_5e2a2d71-5e68-40ec-aed9-3441ee474146"
      unitRef="U_USD">4000000</ikna:PotentialDevelopmentMilestonePayments>
    <ikna:PotentialSalesEventMilestonePayments
      contextRef="C_ad57f0bc-0185-4d7c-aeac-29addd35778c"
      decimals="-6"
      id="F_30a6f1f4-ff74-4ec7-9ab6-b27d69b6822c"
      unitRef="U_USD">50000000</ikna:PotentialSalesEventMilestonePayments>
    <ikna:PotentialSalesEventMilestonePayments
      contextRef="C_45284bec-8438-4ce2-8397-a8f69b9c192b"
      decimals="-6"
      id="F_ca0070c0-090c-401f-a624-4384ad7d86df"
      unitRef="U_USD">250000000</ikna:PotentialSalesEventMilestonePayments>
    <ikna:RoyaltiesTerms
      contextRef="C_eba92ba2-7e7b-497e-aa6d-b51e12ffe499"
      id="F_adbaf799-c874-4088-9d72-e2bfe4a09390"> The Company will pay the AskAt royalties a percentage in the low single digits as defined in the AskAt License on any commercialized product sales related to the licensed technology.</ikna:RoyaltiesTerms>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_10551298-8e0b-463a-bca5-d1ea74064d0f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. LEASE OBLIGATION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2018, the Company entered into an operating lease with Vertex Pharmaceuticals Inc. (&#x201c;Vertex&#x201d;) to lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,170&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of office, laboratory and vivarium space at 50 Northern Ave, Boston, Massachusetts, expiring in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In July 2020, the Company extended the term of the lease through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 21, 2020, the Company entered into an operating lease agreement for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,752&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet of office, lab and animal care facility space located in Boston, Massachusetts for the Company&#x2019;s corporate headquarters. The commencement date of the lease was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 19, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and the lease term is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The lease provides a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; free rent period, which commenced on the lease commencement date. The base rent at commencement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand per month and escalates by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% annually for total lease payments during the term of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's lease agreement requires the Company to maintain a cash letter of credit to secure their obligations under the lease of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. This balance is included in other assets on the accompanying consolidated balance sheets. The Company recognized a right of use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the commencement of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.231%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.201%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.201%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our variable lease cost primarily related to operating expenses, parking, taxes and insurance associated with our operating leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental cash flow information relating to the Company&#x2019;s leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.235%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.2%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.2%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of&lt;br/&gt;&#160;&#160;&#160;lease liabilities (operating cash flows)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The remaining lease terms and discount rates related to our leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.966%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:14.89%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:14.89%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The future minimum lease payments for the Company&#x2019;s operating lease as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, were as follows (in &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;thousands&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.788%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.187%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fiscal Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ikna:AreaOfLeasedProperty
      contextRef="C_554ecddb-159f-4002-a088-c37b9e72c32d"
      decimals="INF"
      id="F_c5ac2030-19d9-402a-8490-b3c38b3b3647"
      unitRef="U_sqft">13170</ikna:AreaOfLeasedProperty>
    <ikna:LesseeOperatingLeaseMaturityMonthAndYear
      contextRef="C_b400e939-9adf-46fa-ab34-47a059eaa533"
      id="F_2999d8cc-467b-4098-b443-6ac77c544dc9">2020-12</ikna:LesseeOperatingLeaseMaturityMonthAndYear>
    <ikna:OperatingLeaseTermExtendedExpirationPeriod
      contextRef="C_4162d822-49e3-40a4-b0e7-b0f69534abbf"
      id="F_a1f88253-c652-4527-a520-1fbf25e03747">2021-02</ikna:OperatingLeaseTermExtendedExpirationPeriod>
    <ikna:AreaOfLeasedProperty
      contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576"
      decimals="INF"
      id="F_4e50286d-4aea-4a8c-9407-86a79b950845"
      unitRef="U_sqft">20752</ikna:AreaOfLeasedProperty>
    <ikna:LeaseCommencementDate
      contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2"
      id="F_d9426996-8ce9-44df-aecd-d46dc66bcd48">2021-02-19</ikna:LeaseCommencementDate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576"
      id="F_ca014a1d-859f-41ff-abba-c4b6fb2bda8b">P63M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ikna:LeaseRentFreePeriod
      contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2"
      id="F_3ffaa1d7-2a18-4190-92c8-ba7d7694e24e">P3M</ikna:LeaseRentFreePeriod>
    <ikna:OperatingLeaseMonthlyBaseRent
      contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2"
      decimals="-3"
      id="F_2f3ae466-554c-4d74-b3b7-2156769e17a2"
      unitRef="U_USD">145000</ikna:OperatingLeaseMonthlyBaseRent>
    <ikna:PercentageEscalationInAnnualBaseRent
      contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2"
      decimals="2"
      id="F_588b99cf-50b8-4ada-8623-691a1d5c7969"
      unitRef="U_pure">0.03</ikna:PercentageEscalationInAnnualBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_66a7df3f-5f7f-4365-885c-11ae27335bd2"
      decimals="-5"
      id="F_2b9f4772-45ba-4158-b83a-31659d81fe6e"
      unitRef="U_USD">9300000</us-gaap:OperatingLeaseExpense>
    <ikna:LetterOfCreditToSecureLease
      contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576"
      decimals="-5"
      id="F_eb4885fa-9179-4e01-9b39-b5fad4bc56a1"
      unitRef="U_USD">900000</ikna:LetterOfCreditToSecureLease>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576"
      decimals="-5"
      id="F_36aec6f6-3806-4759-9d3e-a76a989a8224"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_95669789-5d67-45fb-83c2-2a62765d4576"
      decimals="-5"
      id="F_2d7ee38a-de37-4607-bec0-2e8c599c5f8a"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_9f4f96f4-e906-4380-9a56-021dd52b21f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of the lease costs which are included in the consolidated statements of operations and comprehensive loss were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.231%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.201%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.201%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_d66e17d4-05c3-4ed9-937f-7bc1869a6e4b"
      unitRef="U_USD">1693000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_8dbc7fdf-088e-4151-a5cc-3f9af7bb7723"
      unitRef="U_USD">1011000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_ab2d8eb5-b4ad-47f0-b66f-ccf49f0d3927"
      unitRef="U_USD">479000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_3f5c73b9-058c-4f0b-b944-07b953a05f0b"
      unitRef="U_USD">706000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_ad6794fe-d7d4-4322-a741-c41d7e0938dc"
      unitRef="U_USD">2172000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_d9356536-648c-4d41-9d7c-7e2289b4b230"
      unitRef="U_USD">1717000</us-gaap:LeaseCost>
    <ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_a756527a-ea8a-40f6-bbf6-10f4d1f0dc46">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Supplemental cash flow information relating to the Company&#x2019;s leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.235%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.2%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:1.606%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:13.2%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash paid for amounts included in the measurement of&lt;br/&gt;&#160;&#160;&#160;lease liabilities (operating cash flows)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,259&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="-3"
      id="F_7f4274f8-d946-421b-a66f-163ad294001f"
      unitRef="U_USD">1259000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="-3"
      id="F_ffdb23e1-d2d5-4209-9760-8794f038e581"
      unitRef="U_USD">1025000</us-gaap:OperatingLeasePayments>
    <ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_93513f03-5cc1-4e5b-aaa7-92e6c84deb7d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The remaining lease terms and discount rates related to our leases were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.966%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:14.89%;"/&gt;
        &lt;td style="width:1.627%;"/&gt;
        &lt;td style="width:14.89%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      id="F_94630ae6-0a1b-4fb2-974c-4063f1d62450">P4Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      id="F_ac740cc9-a617-4953-b07d-b8acf028184b">P0Y2M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="3"
      id="F_c8345306-bad0-4a6a-ac4a-f5aea8dd2ab2"
      unitRef="U_pure">0.077</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_f03341b9-2f76-48f3-8446-954e602ed32f"
      decimals="3"
      id="F_0a70fbf9-961a-48f6-baf2-91648088df17"
      unitRef="U_pure">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_12c8ea3f-5635-4c82-9213-7c12ad3ac94c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The future minimum lease payments for the Company&#x2019;s operating lease as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, were as follows (in &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;thousands&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.788%;"/&gt;
        &lt;td style="width:1.938%;"/&gt;
        &lt;td style="width:1.381%;"/&gt;
        &lt;td style="width:16.187%;"/&gt;
        &lt;td style="width:0.707%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fiscal Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Operating&lt;br/&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,827&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less amounts representing interest or imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_17d8773b-260e-4219-9b53-c41a3b9a1c51"
      unitRef="U_USD">1774000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_356d9c65-9f49-42ea-836f-4d34ea87f545"
      unitRef="U_USD">1827000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_461b332e-f6c7-49d7-bd0c-27875f690525"
      unitRef="U_USD">1882000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_c1fd7876-5a10-4628-9359-ae4b407ec826"
      unitRef="U_USD">1938000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_d6b470ec-dc7c-496c-904a-bf4ab6c340c7"
      unitRef="U_USD">817000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_3306b995-2cac-4867-b6fd-8c6fbbfcba0f"
      unitRef="U_USD">8238000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_bb7865c2-35b8-41be-adde-63b87e75c357"
      unitRef="U_USD">1251000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_28765881-e2d0-48c4-9202-c01a1e66bfc8"
      decimals="-3"
      id="F_d3216d94-de1d-4c52-80dc-dd45bb71a2a5"
      unitRef="U_USD">6987000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_fb4319e7-f4dd-430a-aac5-9408332a6faa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is also party to various agreements, principally relating to licensed technology, that require future payments relating to milestones not met as of December 31, 2021 or royalties on future sales of specified products that have not yet occurred as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_127702ce-2ae9-473b-80fa-6d1675c58292">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;16. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company entered into several agreements with a director and an entity affiliated with a director:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As discussed &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in Note 11 abov&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;e, the Company has entered into a license agreement with the University, which was affiliated with a director of the Company at the time of the license agreement. During the years ended &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the Company recorded expenses in connection with University license fees and certain patent-related costs incurred on its behalf of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;233&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;182&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; thousand, respectively. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Certain entities affiliated with directors purchased shares in the IPO.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_f2ad82ad-ba0d-444e-bbea-c7c079ec8603"
      decimals="-3"
      id="F_2633638b-d465-4033-baf7-828b77493d2c"
      unitRef="U_USD">233000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_b8ca6c84-2e8a-4657-be34-b7027d2c0a54"
      decimals="-3"
      id="F_f7dda7d0-dbaf-455d-acc8-49a4ae571c88"
      unitRef="U_USD">182000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_e3952032-902f-4b79-ad6c-b50b62b6d7c5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;17. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, convertible preferred stock, restricted common stock, restricted stock units and stock options are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.636%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:0.951%;"/&gt;
        &lt;td style="width:16.472%;"/&gt;
        &lt;td style="width:0.951%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:0.951%;"/&gt;
        &lt;td style="width:17.892%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,650,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;172,046,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      id="F_e30f1564-76a9-4220-95c4-8f1d93133f4d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because to do so would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.636%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:0.951%;"/&gt;
        &lt;td style="width:16.472%;"/&gt;
        &lt;td style="width:0.951%;"/&gt;
        &lt;td style="width:1.165%;"/&gt;
        &lt;td style="width:0.951%;"/&gt;
        &lt;td style="width:17.892%;"/&gt;
        &lt;td style="width:0.817%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,396,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,650,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,822,373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;172,046,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6e00cf6c-4267-4556-8c5c-74e987e32883"
      decimals="0"
      id="F_047643b9-29dd-4ceb-94ab-637898d406f9"
      unitRef="U_shares">169396576</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a3d09b30-c88f-47ac-8386-fd1150b5ef28"
      decimals="0"
      id="F_f8452cce-696e-46ef-b3c4-fc50ba4e0daf"
      unitRef="U_shares">5822373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_932834ea-9c54-4858-96f9-52377c047cc1"
      decimals="0"
      id="F_bd76e819-94ff-4ae4-bc6a-71324bec69fa"
      unitRef="U_shares">2650396</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_99ed35bd-4774-4330-bc6b-2c695190c3de"
      decimals="0"
      id="F_5aabbc8c-c6c6-4077-8c7a-94cda49bcdd0"
      unitRef="U_shares">5822373</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_890c650a-b769-4a05-90cd-2d91b6fcb220"
      decimals="0"
      id="F_1985ef32-b52e-41f2-a288-89806cf9e9f8"
      unitRef="U_shares">172046972</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MZC-Q5">OS <4!P  '!T  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RE
M65UOZS82?6Y_Q<![4;1 '$N4OW*;!'#LI/7>Q/'&:8MTL0^T1-O"E427I.+D
MW^]0LB7?0!X)[4LBR9K#0U(\9X:\W$GU56^$,/ 61XF^:FV,V7[N=+2_$3'7
MYW(K$OQE)57,#=ZJ=4=OE>!!%A1''>8X_4[,PZ1U?9D]FZOK2YF:*$S$7(%.
MXYBK]QL1R=U5RVT='CR%ZXVQ#SK7EUN^%@MA?MO.%=YU"I0@C$6B0YF $JNK
MULC]/.DR&Y"]\7LH=OKH&FQ7EE)^M3?3X*KE6$8B$KZQ$!S_O8JQB"*+A#S^
MVH.VBC9MX/'U ?TNZSQV9LFU&,OHCS PFZO6L 6!6/$T,D]R]ZO8=ZAG\7P9
MZ>PO[/)W>_T6^*DV,MX'(X,X3/+__&T_$$<!0^=$ -L'L \!;O=$@+</\)H&
M=/<!W6QD\JYDXS#AAE]?*KD#9=]&-'N1#686C=T/$SOO"Z/PUQ#CS/5$^BE.
MHP&>!'";F-"\PS3)OR<[+VWX;3&!'S_]!)\@3. AC")\K"\[!ANW$!U_W]!-
MWA [T9#+X$$F9J.QE4 $WP)TD'5!G1VHWS 2<2+\<_#<,V .<RL(C>GP!Z[.
MP76R<%81/J'#_YTFV+I3U?HWO?&*B? R/.\$WEB^"@7_'2VU4;@8_D= =@O(
M;@;9K9O;Y_>MJ)HQ.MQUVE\(%KV"18^$&2&%(*-Q%_%U%0TZ?L4C+0@>_8)'
MO]EHS(4*I?W8 \ E4SDP-4C[#^_[[[ZKF?Q!P6U (NX7WI-8AW;ZD>2,QY7,
M:)SIE]O9"!YGX\?[QU]>SF Z&Y\3](8%O6$3>F,</<4CU(= O,$7\5Y%D$9R
M',<=>KW>X(*@=5'0NFA":YKX4FVER@3K#!8&)Q6D@K%,D2_2ED'E4-+@DUN"
MH>N4\NHTX7@71@)F:;P4JE(Z:1 <M';78<,!1>E(\=TFE)[Y&TP#G-)P%?JY
MV!,$:<BAVW;[%P//[5,,6<F0-6$X"@(EM#X[7, ]O@>/2>5LUD#VNSU88&Z#
M&HN/T2TIHJ5FN][?)_J\DY5$:<A%&N+GZSJ4K+BE [BTAG\D.+9WN#:>Y2ZI
M)$?#W4A,2!**6>D*+BWK'YD5RW:NY&N8^-633&,^C"AJI5&XM+Y_I#;'7J/L
M_1EN3VI)#2)F&*Y#<2N-PJ45/IO $6;XIZG0 ,,>J2*E);BTDM]+'\=DOI$)
M*6PT"!MX[:'7]2A&I1NX-8I],/B[4%MN+X(KN,.'U=DJ#59C[*PT $9K]T=6
M^^SC)*\:N+L7BE7I :R1!XQ3I2RW)X'^:<)DG2W#$\1(1%N??M9;[HNK%A:@
M6JA7T;I^$1HHOJ4C,%J^#T2/IY9*X&K@VFV7M3UR@DL/8(T\P#H\YAS(9RU5
M9694@S.329O[/E;$F,F(( >D&)8FP!J9P"+F400WJ<:?=?44TSA&I50BSDKM
M9XVT?['!<A]U+-[RI'K$_EEEP$K%9XT4_P_DT_Z:H#?"0G"-TA; 5.NT6MMH
MS.H%,9/D>BAM@#4J&'Z7$>:X7.T_O^I)I9%FDB)4V@%K5"),$R-4OI=CUR8_
M*$PE,1+Q[PE*:1:,UO?GT&!&+E?@LA^7/^%T^ZG"#E3RI)'P^XTQ=UX8Z7\]
M@RT*TRN/4@&?G'/,VV&+JJ W7%$?JE>ZB4?+_[/B02;3[_%21E5L:P"F7V94
MDN25#N+1#G(8,;A]\S<\68N3)6L-T&RTF(S^0W$J7<*C9;WPVE&2I&@3N:U5
M<J*!:I3..]K4H46]W(+!JEZ'695%L*+!ZO3.*QW!:^0(MU@.K>WG] LBF TE
MQ36 =0-66H/7R!INWXY'+,^9*FG],X?P2H?P:(>8CN^>8)0&H<$2962,P)(@
MXW9J4ZL&KY99:05>(ROX5H865G$T/*8&>296,JHV2/?(O0S9GA"\7GM]UQE>
M7/0N.Z]5K$H_\!KYP3Q=1J&/@R1YU1<_V:/TCQBPB_[YX$3SI;Q[M"@?9NJD
M)M7L+*E$&_B!Q]N?X46FN$+N[^?4CFPIX%U:?P_$;/EDOY_*;5D:(B_"S^"!
M:\W]3:J%,9HB5VIZEY;B [F[4,4PG51RHQ&ZC")2"GFWF9#KH\T]S,66=HMT
M)3"AJ-X>J$&=VQI')MK:OMD(4,5VZP__&C)W\+.&K9)O[V#7MLAD>X6C85^U
M9P3 <U>)A<A*)431=K5M9!1@[@5&PE+ "A.Q +:ITJG=Q\6'3V*=1KE8N-T1
M[$*S"?&2.1#P=PU\A2G3*3ZKO-YYM_6.L.<F,!&^L-5V<?)Q!KC4(?PP3NHP
M3O;49LZ5@>ETFG<\U&"/S,#N[U?N#G>.CI.L0V3'<AI\NY^:GRP53XNCOU%V
MX-4I7\_/#1^X-1@-D5AAJ',^0*U1^5%<?F/D-CN<6DIC9)Q=;@3'\;0OX.\K
M*<WAQC90'(A>_Q]02P,$%     @ ZC-Q5-I:?2SM!0  &!<  !@   !X;"]W
M;W)K<VAE971S+W-H965T,BYX;6RM6&U/XS@0_BM6A72LE%+;>6>A4GDY[4I[
M@+;LW6>3NM3:).[&#B_WZV^<AJ0D3H"[^T!QVO'XF1?//).31UG\5!O.-7K*
MTER=3C9:;X]G,Y5L>,;4D=SR''Y9RR)C&AZ+^YG:%IRMJDU9.J,8![.,B7PR
M/ZF^NRGF)[+4J<CY38%4F66L>#[CJ7P\G9#)RQ??Q?U&FR]F\Y,MN^=+KG]L
M;PIXFC5:5B+CN1(R1P5?GTX6Y/B<AF9#)?&GX(]J;XV,*7=2_C0/7U>G$VP0
M\90GVJA@\.^!G_,T-9H QZ]:Z:0YTVS<7[]H_[TR'HRY8XJ?R_0OL=*;TTDT
M02N^9F6JO\O'+[PVR#?Z$IFJZA,]UK)X@I)2:9G5FP%!)O+=?_94.V)O _$&
M-M!Z WWO!K?>X%:&[I!59ETPS>8GA7Q$A9$&;691^:;:#=:(W(1QJ0OX5< ^
M/3^_OEI>?_MZL;B]O$!GBV^+J_-+M/QR>7F[1%/T8WF!#@\^H0,D<G2[D:5B
M^4J=S#2<;/;/DOJ4L]TI=."4"YX<(9<XB&)*+-O/W[\=O]X^ WL;HVEC-*WT
MN4-&ET7!<XV84ERKXQ&-;J/1K31Z0QJ9VB#P#4K,@O\JQ0-+X0BKKW:JPDJ5
MN68/<^I22L*3V<.^3_IB)*!>3!JQ5TB]!JDWBO2FX%LF5H@_02507%6HI=[P
M M)MWRTVY#O5_AXDC\9Q!W=?R/7"R([:;U#[HZAOI6;I.P#ZO;.I&_@DZ$#L
MBY' CX/8#C)H0 9ON!:J:Z&?*Y>:'-A"O=,.RKFV80WZ6#VWZ\R^$'%CUXXS
M;'"&HSBK6CV5ZVFI^,Z7-GAA[^3 =Z,.O+X0";$=7=2@BT;17?"M5$+O$O.Z
M2LSA>$>6>$?=:/>%HI#:0<8-R/@=^3B,*[;$-HS";G3[8B2(/.S9P1'<%G7\
MK@*7"G8G4J$%'ZUR9*];D%&[%TDB2RAK:,N>V5W*K:V V(+B=4RW21$Z$!;2
M5G9"WP)8E'RTO.TYQ0J?]H#YD=^#;Y'R\!#\MHV0\3YR#06$:9'?HY0#.6FP
M/EN1NOWTB7S216J3"@: MEV$C+>1"[[FX,X54+D'GI?V1.AW A(2C+L ^V(4
M!X.IT+8,\I&>\5;4+9TC)%'WPMK$(M<=PMIV#C+>.K[)_'ZJ>9&AK2PJ?BO7
MG108 M[O$#YQ_0% ;8L@XSVB&]^JBQE0+_ZL<5HA];M"&(3=UF&1<GWB#= ;
MTK8/,MX_=F%_RVO]GN!AO'=_:XQ]L0#(S$#_)6WW(./MXUQFF="&'>P*5")S
M<^EYG@!>='@E-4?$_V1%/JK93'W':LL2?CJ!L4[QXH%/YLA*N?^[HM?DN^U.
M%(_S#[[B,(Q"^S"&/P!E$F8-Q]0Y!U-/\A,=+GEAW+%PT&)*S =U*F^=?7+0
M 3["F$ ;*A P[9(?H2N)U(85IN27>B,+\3=?.4@H9=I!U05*K30L3'5ERN0R
MS!4\NX/6\#*:?$8DB!TW#AP_#&IUSK_7A]%A*H 'KEAUI7<&0I YP!^"4*D^
M@-41A7DO3:M9UZ[=FA^U[_=3MEMP+2(4^W$X0']IRPXH&:4=2Q.WC4Q7O%"_
MF6%:)$*/$0^Z-[&-]_6;)CFJ0_H) -,JP0[<8?/7SX11=^>6U!ER^N>]1/M8
M<B%9]-590SCJB@]<\?]!T>MPM3R&OC$/0X&#Q%7V6#E0W$9BY2#7=^+0=[#K
M??@"4W=<LX/A=L?8_>!-ML:ISZS<[NQADQFX9BWWHN/<:[%:"5-0H,V947XJ
M<I2PK8"V9T5IF<=]E\9^%ZF%K6$:#0SNM*5A=)R& 2,OLS)E&IQ=EP0KS#ZS
MFA+/]WK,VRI(B.L.E:^6A-%Q$K9C#NI5$3-C/$STAS5R>\FU3/(8IKWN"QV+
MW)1@@KTA'[=LC8ZSM1[G<8"WO:O)FO2W66RU,^R_N+)-M18YZU@[VWMM:=X9
M_\&*>Y$KX+UKV(B/0O!4L7L-NWO0<EN]R;R36LNL6FXX ]A& 'Y?2R!.]8-Y
M.=J\#)__ U!+ P04    " #J,W%4Y[<6=6,#   ]#0  &    'AL+W=O<FMS
M:&5E=',O<VAE970S+GAM;*U778_:.A#]*U;4AU;JW7R10"I 8F&K5NH'6K:]
M#U?WP20#L3:QJ>U [_WUM9UL($M(:+4\$#L^,W..,Y-QQ@?&'T4*(-'//*-B
M8J52[M[9MHA3R+&X83N@:F7#>(ZEFO*M+78<<&*,\LSV'">T<TRH-1V;>TL^
M';-"9H3"DB-1Y#GF_]U"Q@X3R[6>;MR3;2KU#7LZWN$MK$!^VRVYFMFUEX3D
M0 5A%''83*R9^V[N!MK (+X3.(B3,=)2UHP]ZLG'9&(YFA%D$$OM JO+'N:0
M9=J3XO&C<FK5,;7AZ?C)^WLC7HE98P%SEOU-$IE.K)&%$MC@(I/W[/ !*D&&
M8,PR8?[1H<2&D87B0DB65\:*04YH><4_JXTX,7 '%PR\RL"[UL"O#'PCM&1F
M9"VPQ-,Q9P?$-5IYTP.S-\9:J2%4/\:5Y&J5*#LYG7_]LOKZZ>-B]G"W0+>S
M3[,O\SNT^G!W][!"KY>8 Y4I2!+C[ WZ"WU;+=#K5V_0*T0H>DA9(3!-Q-B6
MBHGV9\=5U-LRJG<AZ@+B&^2[;Y'G>&Z+^?QZ<Z=I;BO]]29X]29XQI]_P=]*
M8@DJ-R5B&_2>4$QC@C.T9(*87/MGMA:2JXS[MR.87P?S3;#!A6#WD( JQ74&
M*&9T#UP2/59%N '.(4'JF<>/;]$.<[3'60%MVUN&&)D0NE+W4^?&<=16[D]W
ML0_5X#^H^0]>A+](5?8(A N9,D[^AZ1-1QDJ.&7X3,,YP@TC/PJ#8=BN(ZAU
M!"^I@PA1M&L(>C6<(WHTA+6&\"4UJ->XD*IB"=VV"0E[A9PC>H0,:R'#%Q&2
MD1\%2;"IRG(1:-Q:(66\88>8<X1ZG7C>L%W)J%8RZE2R_*TZ'EU5QWVH!M&H
M)AK]'M&K"C8ZSP"G_#WC? YTVOFZSK%5.7_$^')I5@Z[4KH3TB1ZTE/=/R+:
M4W^5UTZV79 FVV/S<[U.MG.6YZJ<KDG7RE-?OO;"FDR/G=/M;IU-IE?E:^6Q
MD;!!>\:V0#W_.;3)_-@SW>ZFV<J\(V_/NYX?1,/ \0?/2;<@G2B,'/\"Y6-[
M=+O[8ROEO@P^[W27>+<@6WG;)V=;_6'Q&?,MH0)EL%&6SLU0N>#E6;V<2+8S
MQ]TUD^KP;(:I^KX!K@%J?<.8?)KH$W3]Q33]!5!+ P04    " #J,W%4XS6J
M)1T$  !L#   &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*U776_J.!#]
M*Q:Z#[M2V\3YX..*(E'@[JU4"BK<>Q]6^V"2@41-8M9VH/OO=^RD*24AK5;[
M0F)GYLPYX[$]#(]</,L(0)&7-,GD;2=2:O_5LF000<KD#=]#AE^V7*1,X5#L
M++D7P$+CE":68]M=*V5QUAD-S=Q2C(8\5TF<P5(0F:<I$__<0<*/MQW:>9UX
MBG>1TA/6:+AG.UB!^K%?"AQ9%4H8IY#)F&=$P/:V,Z9?)]33#L;B9PQ'>?).
MM)0-Y\]Z<!_>=FS-"!((E(9@^#C !))$(R&/OTO03A53.YZ^OZ)_,^)1S(9)
MF/#D5QRJZ+;3[Y 0MBQ/U!,_?H=2D*_Q IY(\TN.I:W=(4$N%4]+9V20QEGQ
M9"]E(DX<7.>"@U,Z.)]U<$L'UP@MF!E94Z;8:"CXD0AMC6CZQ>3&>*.:.-/+
MN%("O\;HIT:3Q>-J\7 _':]G4[):XV,^>UROR.(;62QG3^/U/1J0\>.43!;S
MY=/L^^QQ=?]S1AX6JQ6Y)C]64_+;E]_)%Q)G9!WQ7+(LE$-+(34=P I*&G<%
M#><"#>J0.<]4),DL"R%\#V"AIDJ8\RKLSFE%G$)P0UQZ11S;H0V$)I]WMUOH
MN%6>78/G7L![@@-D.;0@>1629Y"\BT@2F @B@IG&@CW@3MSCOE*XJ4P(DF,&
M!<'"2-B&"U;LEIT T%9-2U/$ZYEX>ML?1JX]Z/M#ZW":K[K5@ Z\RNB=%K_2
MXG^@I:"\%3PE$RP @=L:=X"*R,34/H@KLA0\S'%:ZUV!.,0!D#]G+TJ?)9L$
MR$,LU5]-NCZ*7>9QC+C3DSS.(=V :"J9_Q'P7;JZ5;JZK46TV(->SVQ'X 7/
M<0FR!;17@?;^4STU9;17JP&O1^W^6:4T6'E]K]=<*OV*9K^5YA^0H?C$L&0A
MGH2XZCH9!V@B6F#Y)Q1HWZ;G)5VWZO>[W6:>@XKGH)7GFBMDR3]8J8+EH!:_
MZU/'/6-9M_+='G6;:5+[[>"W6XD^<"F+C5>2Y5GSP6W7XE^['G7/5[W)SO-\
M.KA ].2&HJU$%RK"\RS. CP.KD@&C9598IQ&KR6RR:9[*8_.&SVGE=XC]EJ)
MSJ6N3.2(W52DCZ8#F.E&LDYMA^B4UNJSR<[S'/]"B=*WRXBZG^.,*T]DQ 00
MII2(-[EB^DA57"M)\>+ 0SAXCGB"5XJ\T@U3'!0'19SDZORB+M45L0>GK.F-
MXYR+<^OBZ"5E;Y<C;;\=?YF^#<)K=L"BWD&A3A*^?:>(8$<K%0K!+?I965Z]
M>GJ#ONOZ@W-E399=WZO=EM9)WX97W<ZTLQ*)YIDJ.IUJMFJ9QZ91/)N_TZVT
MZ0??8(H^?,[$+LXD26"+D/9-#UF)HK4M!HKO37>XX0KO6_,:X=\!$-H OV\Y
M5Z\#':#Z@S'Z%U!+ P04    " #J,W%4G_Y?B@\&  #X&P  &    'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;,69?6^;.A2'OXH53;J;U#38YG5J*S6$:M'6
MEYMDN[I_4G :-, 9.,WV[:]-: C8.&WOJJE2 \DYA]\YV'Z.X6Q+B^_EBA &
M?F9I7IX/5HRM/XY&9;0B65B>TC7)^2]+6F0AXZ?%PZA<%R2,*Z<L'2'#L$=9
MF.2#B[/JN[OBXHQN6)KDY*X Y2;+PN+7F*1T>SZ @Z<O9LG#BHDO1A=GZ_"!
MS G[NKXK^-EH'R5.,I*7"<U!09;G@TOX\0ICX5!9?$O(MCPX!B*5>TJ_BY-I
M?#XPA"*2DHB)$"'_>"0^25,1B>OX40<=[*\I' ^/GZ)?5<GS9.[#DO@T_2>)
MV>I\X Y 3);A)F4SNOU$ZH0L$2^B:5G]!]O:UAB :%,RFM7.7$&6Y+O/\&==
MB ,'B'L<4.V GNN :P?<<4!.CX-9.YA=A[X<K-K!ZCA@K\?!KAWLJO:[8E65
MGH0LO#@KZ!84PII'$P?5[:J\>8&37(RL.2OXKPGW8Q?^[<W\]LMT<KD()F"^
MX!_7P<UB#F;!) BN+\=? L!-O@6SQ50<W\V"JV VJVQO_<_@\J8^^G3[91+,
MYG^!X.^OT\6_X/TDN)KZT\4', 1?YQ/P_MT'\ XD.5BLZ*8,\[@\&S&N7Z@8
M1;76\4XKZM&ZH"Q,%6Z^WLVG6<;'\)S1Z+O">Z+WOHSC1,R!, 5W81(/>0I^
MN$[42H(CL:)HDVW2D)$83,@RB1*F"'*E#S(C,>&KRWU*@$_S1U*P1!S?\1E)
MBH)'5B0ZXJ-B/S30?FB@ZD)FSX7&Y"')\R1_ .,P#?.(G(#Y*BQ("4+&Y4>G
M ,,3@ SHJ9+8Q;:JV&)Y>[QP+ <YR';/1H\*57BO"K],U;/4[&(ZAVI<UW;4
M4LR]%//M"N2;4H&0;4&,L5J4M1=E_?[ZC"VI/D,;FG:C9:=9-NM83&0+RX9.
MVRA07<TQW)[,[7WFMC;S:5ENJH3I$JSWLZ$4LT$L/!'-\QIGVX2M %OQTD0_
M-DE9S6_A=9FMTV3Y"UR3F,_-G)0G8)I'IZH!94LI0,-#ICH#9Y^!\V<R>!J8
MJDP<>:*Z-C:\GES<?2[NLW.)=BOPV]R*L2M/)-<P.^/RB%$K16^?HO<'4M3<
M*]^3LC"1#2U/G0<TFB; ^)T#;UTDCQQB8)V&$>%MIIIBACQ%H W=GO4?'G0L
M\$W%ZB9#?>G#"KN6:]@(]HP5V- 4ZG$:_"1%E)25[)U8NA8JU8V0 I]&9TCK
M;=HJ&[I"/5Y[5>J&91WS4 GT3 A[Q#1\A7K 5IW,4&P<8C'!^&ZJ#(489<5D
MGD+'<[HU.V+5%MHP%^JA>\.W@"DM.?CSG=*"K,3NZY%47ROU*B!HFLBR.ZRL
M[:Q^N[;FAI90C\L@CX^W+LA0:K?E*MH>]FS+Z<B_>I9I.X.&EE"/RW8&SU/N
M2%5'AN4Y7E?V4;NVYH:*4(_%UU?=AS+#.*9MS^CIFV##,:@'V6L**:-H" UH
MF&ZG9:P-=3VC(A8TD.MV9X+JDI!WS#TW!37X0T?PEW,H\PW>>G.?)A%?^CA3
M>$%.0,[G-5\(DR?B1+1DRME<7Z"5 H;80)UJ(!F*G:$W48="7L]=1@TWT1%N
MOBA+W7J/%)3T7!,[5H_&@RVG'I*['6U9=TC1P?Y6)CVCK:Y+N0E%\B*KF\>H
MX232<_)_"-7U'T@FZ?#(>HD:G"(]3G]O<<=(L8-5K*5^;==:2[OM>4\LJV]
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M2GYC#Q]IIU"DY\M9)<Q?\-#)!C.0-T*R73=8(=B5=?M+_G2&.!H XXD!J!N
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M6[7B=W$T$E!16D!/#G"A-"2GG.?9NRA,6D%6UHI<3'1IX$-0Q):V$)CTENR
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M1Y_,']YDH[@8$<VAM6&?"^ .!>>L8A+C6<M)$NU,V6TO#HG=%"GLP@#<9W,
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MP'H>L8>4_YQ.84@.<R:E%U$MJ!U_X?.$/DC1( 3;1E)V'W$1'UR?$"* JT"
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MXGV!8:]@921ZQ2<6\D00P"04R^6-!Y'.;P35*=]R/0_^7<52U1TN#6N/%^3
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M0;W>[= !U4R+QC"RK#MT+PWU>[W-:,"BL@YTGTIISH8-T([L^2]02P,$%
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M-,4?"P6:L+0 S^<&C7O\0@K:E]+G_P%02P,$%     @ ZC-Q5&OY?P1C!P
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MQ:D$G3^_%;F FU=*L"NC[X7UDM8WL(VP5N3LSIOLR^G(0Q91C+*&[V7DF[[
M=Y*R]T;[PK&ESD7^F,$((%NDZ0[I9?HJQW<B&[+I)&'I.)V\PF_::CX-_*8O
M\ N*%4;EPKJ?V?)K+?T#^V"\8/^Y6#EO$2__?47,42OF*(@Y^LL-_#K?Q9#=
M+M\ME^\O+G];LJN/'SXO;S]=T_KF=OGK\A:'[.[3QZM_LFO-,J-UDP9;Z0OF
M"\$R99S4&V;687MERHKKA[_]L$@G\[\[=GWSD>'Z>VZS@DW'T>P)XTHQZ5P-
MX%SG#&GN/!;$Z/LT)7F3XY-D>G*<S.;';"NL('QT'W>\8>DT.9XODMGQ@KF"
M6^%>@IB9L@1$%]@2&EQFVC!E]$;8!N:0700&"!]1KO"X"2%H1#QY[0MCY>\0
MG?%*>JX:?H]E,JDS52.0'V'OX-E.]ZRG>]7J'IB^@N7[&-"9DXX,U>!;&X6Z
M"O._??,"[S=W$67S<QV==\6M?2"O76PV5FRX%V_NA)6X<,'213(>C^FOO_R1
MI?-D,4UI$9ZV!+],V-$\F>,XA<]ZR]DD&4]GS9/N>LK Z'B:C$^.>JO).#E)
MCQ@LV[&^9(M9LA@?)^GDJ+^<3(Z3R6+!)FG ]N:3(<?U7=-? _!XEIS,3\(J
M3=)TSCX53R.SX/ECF[(,-D,= !CG9>88?][$;]D!/V2?C2>:CV@U"!@T#-"1
M YW03603<]<K._M!AAY+>VE#LT)H8Q\\CLL\-C$?F:/<-[G[&K\#T*\>V-9*
M8 E5@+ \H9*:*2EJ>MXP/DR8X,C[>(,.^HG>A?V^!7&"^K 2#&*D5U'KC#L?
M8.DZ6 UT]RBSCHFO-;S6V*4[W$*JZ FYBFD>)4B-^]M"9K&(O0RE$"HGY5W=
MZ<'MX^SBK<6LR(S-68X\"%[(!9R'=AO4[=NJKQAI034RB(C^'K+EMTQ4GEA7
MUMQ+*AE H?B616>0-(-_-I[3</-B@;O ]),WE?96P/X41U>$?BTS@@JZ:PWD
ME8GQD;!>)#SOG #:FXT(&-INT*-[9&_HP1GU"2I,BCL7P!3\?J>%JT0F>>!+
MQK(T!;EAR*\>SS\1/F&  T8K!,LE'.7-DTB/\B0\Z\)IP,=1V(A%@:3Q6[,C
MZ7A0.$  Y&E>1C\9W;$)FG;NVM&AK^Q3P4*B0J7P'?&0':P.V3M)$:!SMV^/
M?<T)2E]IKMF"_81FIG_)ZK)6G&970(CLACW&1%GQA] YC%;(]D(@#GATE%PC
ME.$W&X&2-I>&6W#X8%IVCYDT^=AOKCO@M5:"(J"E)%MPY0R(9<"]IU>;-;M,
MARN4V-4#7II:^^B@K:DI7T,F"N@:H+^>X7N30Z@,?=04%-;4F^)IP6Y=B_N5
M$K'61GF8>Q(:(CKCA&!:"130UI2(@J!Q8](V"@^R0_:;Q"B9QW(=(0N="9K"
MZ*JX;RHPU>=[HV  O L10T1.NU4=CP1(G,-)W!C*V9A'=;67!>&TKLR>I SV
MP=O9+HPQ9D"#GH1XTSVJ'2];'4ST?CH_3=K&BP$(TI#[6-H/Y"&%=N/XBLI'
M$4*_WPF>#(RH*5+S9NY$V9292%BE:A>,V#FJB_3:(U9C3$)G$3OI@83T[XZ[
M)]'&W6O!QOZ'=S7"1BT\ZO'$Q(B/_+"9C<-+[9)Z;+3 :]6PW[*"X,X[CT?@
MF%:FZL=S+X&3W?C@\5H=-\PV;80*'S4^^MV-TIB-#=H:6HU"7>F4#R'&&?D,
MC2A80WKJ 56]4C(#.^@1QI,F')\90-I",)^ASC58]\:8[VH:L?1GG5%#)Z3"
MU* "="<\">SIF(08*?D#V9?GY#PPI,-=ME"P<21ND,GS7))1Z>W@V;DD:5S@
M*B4IE7;3>KE"Y!(EGNTX]\HN#(WL]E:NZN82/2J%W9 9:(W@M1NNY>^1RPO:
MAN L.%Y[0O;-AY/94>O.MB+LCQ=KJ9HA$IB1%<!4DGO @1[\W]-'][Z8IO%]
M<?C<"_2H][4BJ$K?9"BYD)3QPT7[M/WL<Q&_=G37XS<C2$-I< BE-4C'P_EL
M$">0W<:;*GS[6!F/6 [+0G $&5W ^=I@'&HV)*#]&';^!U!+ P04    " #J
M,W%4SD6,U&\#   $"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R=
M54UOXS80_2L#77H1+-ER-IO4-F [6[1HLPDVV^VAZ($6QQ81BM22HVC=7]\A
M92M.6J? 'FSQ8]Z;-T/.<-99]^@K1()OM39^GE1$S766^;+"6OB1;=#PSM:Z
M6A!/W2[SC4,A(ZC6V23/WV6U4"99S.+:O5O,;$M:&;QWX-NZ%FZ_0FV[>3).
MC@N?U*ZBL) M9HW8X0/2[\V]XUDVL$A5H_'*&G"XG2?+\?5J&NRCP1>%G3\9
M0XAD8^UCF/PBYTD>!*'&D@*#X,\3KE'K0,0ROAXXD\%E )Z.C^P_Q=@YEHWP
MN+;Z#R6IFB?O$Y"X%:VF3[;[&0_Q7 2^TFH?_Z'K;8O+!,K6DZT/8%90*]-_
MQ;=#'DX [_,S@,D!,(FZ>T=1Y8T@L9@YVX$+ULP6!C'4B&9QRH1#>2#'NXIQ
MM%C;NN;D/) M'V<9,6-8S\H#>M6C)V?0XPG<6D.5AP]&HGQ)D+&40<_DJ&<U
M>9/Q!LL1%.,4)OED_ 9?,<171+[B#%\,K+):HO,_P(>OK:(]?+2$\.=RX\GQ
MK?CK#3?3P<TTNIE^9QK?1E^-8'UW>WOW$1X^WZU_A:4'NP5.!=8;=$,Z0!@9
M!CFD0!4".VV$V4,E)(PO\C3/XZ\W*Y[GOA(.(V79R_1!)HB6*NO4WRA3+B_?
M8"P0O4^#95>ILH+B(KVZO$CS8AI)BS2_>I=>Y05TZ!"4]RW*N,/E[HD'RNQ
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M?C7BL.)G&ETPX/VMY3(Y3(*#X>%?_ -02P,$%     @ ZC-Q5($!@M(9"0
MV!@  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULU5E;<]NX%7[WK\"H
M:<>>82A>=,TZGK$=[VZFD]@3I[O3Z?0!(B$)-4DP &A%_?7]#D!*E&,[;KHO
M?8C%"W NW_G.!<SI1ND[LQ;"LJ]E49FW@[6U]9OAT&1K47(3JEI4>+-4NN06
MMWHU-+46/'>;RF*81-%D6')9#<Y.W;,;?7:J&EO(2MQH9IJRY'I[(0JU>3N(
M!]V#3W*UMO1@>'9:\Y6X%?9O]8W&W7 G)9>EJ(Q4%=-B^79P'K^Y&-%ZM^ W
M*3:F=\W(DX52=W3S/G\[B,@@48C,D@2.GWMQ*8J"!,&,+ZW,P4XE;>Q?=])_
M=K[#EP4WXE(5O\O<KM\.9@.6BR5O"OM);7X5K3]CDI>IPKB_;./7CM(!RQIC
M5=ENA@6EK/PO_]KBT-LPBY[8D+0;$F>W5^2L?,<M/SO5:L,TK88TNG"NNMTP
M3E84E%NK\59BGSV[M2J[>WT!OW)VJ4K$VG""ZW1H(9W6#+-6TH67E#PA*4[8
M!U79M6%752[R0P%#F+6S+>ELNTB>E?A.9"%+XX E41(_(R_=^9HZ>>E3OJZY
M%J\7SM<;O@6U+#O7FE<KX:[_<;XP5H,G_WQ&V6BG;.24C?X 8)^7%++;S]>7
M?V47Y[=7[]CE]8>;JX^WYY_?7W]D[ROV@>ML#83B2<#L6CA=O-K^Y4^S))[^
M9-A"<9TSM62YU,@$I0WC5<X,F;=612[H0:YJ"SMI/TEBSGA(SP +DH;=%+QB
MF[6$I@W'>L"%$#M!6AC+:;.L& (FRH70%+ H8,=8:M2CJ[VM9&02_>14D@IW
M'_]TTJJJA2ZE-6[I"F&RLEJ1)\?Q"8/! !/O%*L;( "<6:;*$HGN7(,YUJO%
MBB\-+^1RRV"/W/GDEW5R&JS5[+:M%:,D(44>SUP$SO;CI*=VS2W+%:N4)1=;
M!2&[[@(2SSUM7QZ4NM;JGI A76H?V.?D'$:QE="&,8D?#^/Q ?)8U4<^:*%?
MB QA8V*Y%*YL[@U*6X-8R#YW>IQ<+>J"9WT6N<?<Q^\1C]<\1_VT%.2*^&-1
MP)LB=Y@B:"6_$V!F+@EQ7C"^@80N4(<ZEJI <R%VT/.L4*9E"MW*"A*POVX6
MA<SP="DT7H?L5[41]T('#X1M9%& 2L2V1I A*X"J*X:.!NY6.8D67QIIMYU)
MCIO><2V<?0^QX62?Z8=PYZ$7U58E"GW&S;J]W9.UU81-L%]F"'? 1%D7:BL$
M+@]S&\8;-"4894)V;CH@]L',D8+=TYV1 8!GRT:3%YT^A\5"P-)</(8\Q,.5
M+BG4;E\?J\<"I@7-"P?+R/"]A72'8MUB#R@66Q(A-1-?I7&%@(AC/-"&"KO9
M9^QADAR4!=,L_@4=#LF^]J?)Y5)=?*T!<< \6QU\VAFH"*Z-1/4QC=94<33E
M<,81NJ*@2PQ.2R&)']B")&FK5>?2CA#0XCU46JXD,5X:TY <5FM)?QM-]\YV
M[AA*O0J5IR>5:9I"=G%#^I B#L>QR1Y =0 +O^>RX(M"D+E[Q7T\6IJ$[".8
MJ^ Z@*E8&B23-)A,1O]-$$J^)>NZO.G%Y/GR_, 0=+^N/@2'[QPZ8!CE0U?K
M*-=76HBNUC&JEM*XS;[HM5E*"%#.5A5A"XLP[!JJ(TY'U;@.!S?_9RBIJ-*#
MI=0&W02@0);@L&0I30;=6\$URQO=538T1*D03P%^5/00-O670G+B,^*EQN/'
M,T50"Z,(C-B?NQA^U]5^!K6^R+(4N42"%%L C'G O=P-!BEP=^-' R\+80R>
M?:,&+:/7%]HT.<]Q*VD^LQ0?X\.7^\'C 3%\S>LI;5L6?H)D' 6CZ?PIE]K*
M=!C$96,;$/[YM"#8[X6O33Y0GDH'O:*CVDI40@/Z+81B5:-=  TLI*+RK?<7
M7?M\UU5ZK[!?!6B/T]A/G:ZR00WFH5:+WVN5Y=3I]K,IE3E<HXJ(3*TJ^>\]
MNFYLHRG9088SH>8^,[DQ*I-N MQ(ZY*HW4#SK^]C!SH>-,T'55"Z\/N&;MBQ
MTZX: \Z8DS='?R>6N^/%072/7!AHZ#SZ)(QP<PJQ+$?.%ZIVP_TKQ'Z43/$[
MG4='OWC\?9_9,XL*3Q),QQ&+@RB:'GUV$)G>N>%1N%ZQ<1!/278<3.=3A^[&
MG0=%_IJC[N!XRY8<M?V>%\VN]1Z6N Z07KZ[I!;?N.M91Z:3RVXB?\4F89RZ
M9Z]8&HY3HJ W/*"AN_9]M=@^F1R^@GI.-%6/ $\&<L$+EPU$N:8BZE./:[WQ
M1L7S,,:IM2AHO6<^ DRP9=:/YHL#LE&W9TD("!U1/4][TYW+2/_] .O- Z:3
MBY1J^_1LIT/]733?''W<5:'?N\CUKLY7:!TKL/SHNC\U/ IE! I-4&72^<0%
M8S1FLS"*'4M&D_3HES;0:3!*Q\%D-F7S<)H>77T5.I.$\C%+8A!J-F,G &,:
M'5UVTP2-$/MYXIB-9L$81Y43-@Z3^ 6FQ3 !S2](IRDE0AA/89I+BA2-?#H^
M^JV-HCX($L7V1R5>MX00WCT7P:=$Q<%LA'_SD<,M'8/44\(-9]MY,G-DP+$.
MZ6$PR.]221UJ@,G]B)N7)E <SG=4;?,HVA6?ATGD>'F0T*YO]VON4PG] H,H
M1]!(2E=5V\;:S>Q.*FM,)_("AZZ[U[<93H'4SKP!-##2@A*'5U_D;*\DL:XD
MH78W98L>3EW[:O\@Y5Y4>*6Y>[W$?.5.WG3.9YI,CL+)#",%6!2':8JKB.CA
M'D3A"%<@?LNT7%)#A[%;*7 .C&AQ_WWKG.MSU!D<FB<@2121./S.D C[F_U.
M7R?\&'VO"M2O@@J%^_3#)K-PW)HX!>M(+7[C<?MH%,[FN+QJ3UOMH?JF&[A=
MB;G^0X[KSZKH']NO;F]N?OC$3IN[0[$;TMP8A7F*:PO6U-Q-,+O#I>_JI%S5
MM=*VJ0BY_F>7IG8G$M"^*Y+$TW0T"29H22\_%M!A\H>G;CP3^KX]0G]W!'<8
M?#O[QO^OLR_Y\TQGQ\&^%;]&ZL-E3(('Y]!]M \Q"A_[$#KL?6TN<:9RW]0I
ME$UE_8?GW=/=9_MS_[5ZO]Q_\P=!5W1**\026Z-P.A[X$VQW8U7MOETOE+6J
M=)=KP6$B+<#[I4+9:F](P>X_,\[^ U!+ P04    " #J,W%4P;BV->\"  !)
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RE56UKVS 0_BN'!Z.%
MS6])M](F@:1-6:'M0M-NC+$/BGV)167)D^2D_?<[R2_+8 V#?8EUTMUSSW,Z
M748[I9],@6CAN132C(/"VNHLBDQ68,E,J"J4=+)6NF263+V)3*61Y3ZH%%$:
MQQ^BDG$93$9^;Z$G(U5;P24N-)BZ+)E^F:%0NW&0!-W&/=\4UFU$DU'%-KA$
M^U@M-%E1CY+S$J7A2H+&]3B8)F>SH?/W#E\X[LS>&IR2E5)/SKC.QT'L"*'
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MX\9CX#M^"=]./-$.Z16*K 3!6#]+\?17O(!XKY>[,&N2@RB,:EXCG;S$E&'
M2,*&3&I+_X!63Y(YWU'=EDZ&1BX)G5WM=RB7>E,F<^FG6E^EGM02/V+9NKST
M5@EC-[*HN2-I:A)O9CX8K("WRNTS:STH^1(E:K.^Z4-(U5].QJ.(89H@=\A3
M(KB?P1K&X5T75 K]W=&_CA$%5:X !]O@/8+292F46!'KDH2REN"7 IF37HI'
MX#,C$KU6A$S$<I -0,%5F&82;=* V$HJ4)BL!GM!4;+G;4NLE:3-2X]W;5\[
ML &7XMB^S<W0])R]%K-EEI*]20:"IM--]USRS-.K?RT]#TD5F@?@-EP%&?XY
MD$2\\SKJZU*FW'=:I!$PUQ!G.N%YIK!)&@VS3QL7Y@[78N=?I6H/8;E.I.^M
M6^DV/@]+U49@+WZ#@Q-YH3.9[*@[^3*J3@;'A'7!>Z%X1B7".$VG :F@ZT@V
MT%!#B:R5",7T='*JR2ZB=*#T:A.A/? 7 /.#VI_)@0'[6/7\';@2<\J3-T*O
MJ:,(@@&)K\FT10A"6H"V>-8I 0+JJ/K'@Q+UJ$0K>AGT8XIU9=J,/"^\QNT3
M%<F6MA) 5(338)- 55UB=/K_$WQ.%88])F)$*UEC);11O#-,-U6U^P[5:L*&
M[PIDYU$,)!M88RF(G0HR0WF_:3X_ AK2(0QHAZ8A@G IA.I,>FL(L.[@EX(7
M7XOQO$K11VY4))5&?M#L+FYK3JE:(7W+> SWD5F.(E:&J168-(+HG0-V)\W1
M/6ZRE'O[95/-+E2$3VRO<C-8OY=^:#;=$>PS>(4GL$<X9_>^X0CT.&6;8?F9
MPADOR.2GU60$?6LE.P.#/FKDXH%C. [@5%W[$Q4:ZHM]J]YY;U':,A&=<>=
M,S_T96S8^="8"[/VGU,I<9&,X9MC\[3Y8GL5/E2VV\/GWL_<8&RQ+!,K'!T-
MYK,^,^$3:KAQNO"?+9?:.9W[RXW@P)@V8'VEM:MO2$'S'?OR#U!+ P04
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M*<-!J+W@XSYU68_?:U#AVP=:W#G))O0/(4O!W+@=(G&9T?4BHP]R9D#?(T0
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M]FUYTSX*7UI+=PGMW!GX ^UVC#1+T>4PA5,=IP97##(R;<$FL<N"&K([5Y>
M&DDLLC&)@VCFQF=Y9!)F(*'4I"@P>U>(9_]6'PFQ!"U/:'-[\1LRTL\V$J V
M@.XN4"NXL*W ]H/VQ0ICI.>+C6S62*=EG4ZNR,*//UR'G? GZ/1O_.Y-W^\-
M^A>+*D^(Q;)044(]_T-EAIY_'89^=]"%T._WVM;P8B,-$XV5SB#TVU=]_V80
MPO>:1]!HV2FJO7N8V*I19*;LWO5L_?:9E"W_?7OY<'ID:L^)K\ =F;9; WIJ
MJ/(Q4@Z,S-T#8"L-/2?<9T+O-U1V ZWO)!UP-; .ZA?A^"]02P,$%     @
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M8:RE/C@S%]<J752#NABG%X=%@]@]LY1X>$G1EUAH]G44)E>$/(9C(O*>T);
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MT8%3T))!]1DEOND$6\"Z(GG;KU@I6UR.)4+C5N=A&7P=7_Z6WW*0>_AR[^^
M=[]VWI_2XI;J('EX#R:UAB,=Y&2FY B\E\NE9ORZXSMR:+,D!=N9BH$8G2B*
M0-$T']\=C[:3//IC8]@>;&\PY:,_H +\Z'M-F3]N-9524]@&N7;#9Y#LW_%#
M()Y:^KL*'=QLA/P^ARTX.(II@Y)ZE.?3/<H?%'#RX+?)!KR,FI1O:%G^TCR7
MQ6OV)- 6*!AW6V##)G8)MEBTTU^TQ\\0<3K+9\!%LKFW$.,7I@Y5OI#.6""N
MRE+<_@=HZ)OA=L/8\.T@)GT'3.^KY(>=,^D'98*LA]^#6'+'1PLH$XS*4/="
MO6JO<L7C2"*%^:E#*/W.Q+T<Z='?_4F_*71$@!YE/WL'7>0?]^-;JFTGOX 7
MG\8?$+R2G\U+K\NO#Q)460'Y-FI)0\_/?GAR(K%@^-"9+?^(WL)TG=GPGVM5
MDDW'"_3]TI@N?, $\6<57_X?4$L#!!0    ( .HS<53)S(U#) ,  'X'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;,U52V_;, R^]U<07C&L0%$[
M3E]+DP!)'U@/1;N^=AAVD&TZ%BI+KB0G[7[]*#EQO2[M=MS%IB3R(S^*I(8+
MI1],@6CAJ132C(+"VFH0AB8ML&1F1U4HZ217NF26EGH6FDHCR[Q1*<(XBO;#
MDG$9C(=^[TJ/AZJV@DN\TF#JLF3Z>8I"+49!+UAM7/-98=U&.!Y6;(8W:.^J
M*TVKL$7)>(G2<"5!8SX*)KW!=-?I>X5[C@O3D<$Q291Z<(OS;!1$+B 4F%J'
MP.@WQV,4P@%1&(]+S*!UZ0R[\@K]S',G+@DS>*S$-Y[98A0<!I!ASFIAK]7B
M"R[Y[#F\5 GCO[!H= ^B -+:6%4NC2F"DLOFSYZ6>>@8'+YE$"\-8A]WX\A'
M><(L&P^U6H!VVH3F!$_56U-P7+I+N;&:3CG9V?$9XQKNF:@1+I"96B-EW!KX
M=,L2@69K&%KRXG3#=(DX;1#C-Q![,5PH:0L#IS+#['> D,)K8XQ7,4[C=Q%/
M,-V!?F\;XBCNO8/7;SGW/5[_[YQ/N$F%<K0-?)\DQFHJDQ_O^-AM?>QZ'[MO
M^+AIBAQ4#F=<,IER)F!B#%)NEXG.@%GHQ'(IX1K36FLN9S!EAIMUR7_7K6OA
M@:E8BJ. >M2@GF,POBT0<B6H_QRR=1<+_M1=-)=-9_L62:AMP9+ZL2HK)I\_
M?CB,>P='!O*6 VLXE!T.N>,P]QP<"/7JBD7B6 "3&;G)>,HL>G2!<Q0N-6[1
ML2XX:J;3XAEJRP7_2?!648]9U%3Z2),C+3KZ5*5<$H:J#;DP6X.-B7&H5"]8
M)JA]S7RME26<*\U3=&QAXN< 7##]X(C<\)GD.<4F+5PF+F,^/^>RJE^=WDGU
M^GSCF)D"\+'F%)!+YV"#:A^?J4,=.N0UQ06;$/?C[:AWT)%\9N.CU7_C5EE*
MKH<[?8%;:[K9&K?2.N+4+-'_P;ZW'V_'GZ..],_L_S1=PQ[6]6O8F8DEZIF?
M_ 9254O;C,=VMWU<)LU,?5%O7B9*UHQ+0V6;DVFT<[ 7@&ZF?;.PJO(3-E&6
MYK47"WH@43L%.L\5W<)RX1RT3^[X%U!+ P04    " #J,W%4D(:2TIH"  ":
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6RE5%UOVC 4?>=76-$>
M6BEJ$@=:0( $M-/Z4 VUW?8P[<$D-\2J8V>V4]B_W[43,B:U:-)>XJ][SKD?
MN7>V5_K%E "6'"HAS3PHK:VG462R$BIFKE0-$E\*I2MF\:AWD:DUL-R#*A'1
M.+Z.*L9EL)CYNXU>S%1C!9>PT<0T5<7TKQ4(M9\'27"\>.2[TKJ+:#&KV0Z>
MP'ZI-QI/4<^2\PJDX4H2#<4\6";3U=#9>X.O'/;F9$]<)%NE7MSA/I\'L7,(
M!&36,3!<7F$-0C@B=.-GQQGTD@YXNC^R?_2Q8RQ;9F"MQ#>>VW(>C .20\$:
M81_5_A-T\8P<7Z:$\5^R;VU':4"RQEA5=6#TH.*R7=FAR\,)8!R_ Z =@'J_
M6R'OY2VS;#'3:D^TLT8VM_&A>C0ZQZ4KRI/5^,H19Q<;#37C.;D[8)D-&,)D
M3C[;$C19-UJ#M&1I#%A#+I[95H"YG$46=1TZRCJ-5:M!W]%(*'E0TI:&W,D<
M\K\)(G2X]YH>O5[1LXRWD%V1- D)C6ERAB_MLY!ZOO3?LG"2A#;XL$_&]^76
M6(W_TH\SLL->=NAEA_^;_+=R?I;:]?+4U"R#>8#-:D"_0M#KP:F>\GI9I\?:
M8F<*V\Y8P.>"H $IE,#^Y7)'+KC$&]48!)O+Z6!IG U6!*HM$F%5!JXJKC3Q
M8(U^\8R)$/]9V128MT8[$B=L,HZ*O. 9MM$KCH>Z<AY\(#0<TQC7))PD-X.C
MT_?2-)K)#,AX%!.:#MI$7=,)&H[2\>!96280-@SI9()K&@YOQN2M,D4G_5*!
MWOFIX()NI&U;I[_M!\^R[;<_YNW4>F!ZQZ4A @J$QE<WHX#H=A*T!ZMJWWU;
M9;&7_;;$X0G:&>![H90]'IQ /XX7OP%02P,$%     @ ZC-Q5-RP@"[1 @
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MXR!T .X?.%[ZSM$"_9=A^0]02P,$%     @ ZC-Q5.KSW_??!   C0L  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULG5;;;MM&$'W75PR$%(@!FN)%
M%"G#%B [;M('-T;B)"B*/JS($468Y*J[2\GJUW=F2=%R:@E&'VSN9>YSYF@O
MMU(]ZA6B@:>JK/75<&7,^F(TTND**Z%=N<::;I925<+05N4CO58H,JM4E:/
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M)UU#T-:@FS0P5S4,>P6FQ^"S+,Q&PX<BQ?0Y0)<XM<38GM@5.XFXP*0#42\
M%K+>";RH#31R>-%/ X6%T$DF=:40_IDOM5$DC7]/N(A;%[%S$;_BXHXZ)JTR
M!+F"#ZL5.L'!D>-;;I"\TY+"%%9*YC#/9548N)9Y61F:7.Y@7I;93A1K^(@I
M*I[!G>&F,E+M',!+Q3G-ZWZ#@"T?4?,QQ$=9/NDS/H9L><TI.>+$]YSL^JKA
MI5M>#LA(MVI#X<7NW6\CUAM>:J!,:U@BG1_'ODEM7,-*9G0JZ+'W-W)52P>H
M\)@O4=GB>[;X5@&A9_-7!T$VW'SOG/4Z(;QM_CR;L;V;82>FA7Z'N7F9/+C
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M- R":-2'. A9Y%WS4E "Q'_$E3I F?=527K6%#^+&;!!3)I,5,4S[<35Y))
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M]6SH[+W!#P%;VUDS%\E2ZR>WN<W'0>0$@80,'0.GWPO,0$I'1#*>&\Z@=>F
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M=T6J3#T\Z@WJRO??4B-ULU\6-&_!. .Z7VF-NXUST$[P] ]02P,$%     @
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MOV[D RW2['"]$AJ/ZMEE" RWH#' YVLA]./ G-?+;TRS_P%02P,$%     @
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M.X?;GX444FVU)-\/$70G"?9'3!#T6H*>D6!$./^I:(%O)"WH$+DZWC>0ZX]
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MM/-%U\&C.Y]Z2]$KLDX$[$B\*,%7$7*(D90$ Z>'SXT _X=.T,5JK!G@<S?
M/V@'[,48/K47I^MASZ=)$F77GCND<!H,.'ZN^GB\[#<CG1T$:G-)AD^G7[_-
MYEDRL/NY@N/Q$NZX(>,7M5^>)R2Z2-XV5@ZQX5B=RS@>K^/?*:]I,Y?><3,9
MTRIW5J'6RF5[GH19<%$ 6TJ''$F#7BGR+P8_.W7_2>6650IQV!C%X"8U?LK3
M('M::+%O9L$GH<UDV3SNS/ /T@J8[QLA]-O"CI?=OQ.+?P%02P,$%     @
MZC-Q5&2%?B9)!   T!$  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&UL
MK5AMC^(V$/XK%NJ'.ZFWB0T+[ J0%MA35[J[KI;>5575#R89(+TDIK8#;'4_
M_L9.B.$6#-NR'Y:\>)YY9CSSV$YO+>17M0#09).EN>HW%EHO;X- 10O(N+H2
M2\CQS4S(C&N\E?- +27PV!IE:<#"L!UD/,D;@YY]]B@'/5'H-,GA41)59!F7
MST-(Q;K?H(WM@Z=DOM#F03#H+?D<)J _+Q\EW@4U2IQDD*M$Y$3"K-^XH[<C
M=F,,[(@O":S5SC4QH4R%^&IN'N)^(S2,((5(&PB./RL809H:).3Q3P7:J'T:
MP]WK+?I[&SP&,^4*1B+]/8GUHM_H-D@,,UZD^DFL?X$JH&N#%XE4V?]D78YM
MAPT2%4J+K#)&!EF2E[]\4R5BQX"VCQBPRH#]:- Z8M"L#)HVT)*9#6O,-1_T
MI%@3:48CFKFPN;'6&$V2FVF<:(EO$[33@X<\$AF0W_@&%'E'[N(X,>GE*7G(
MRR(QR7XS!LV35+W%(9\G8_+FI[>]0*-[ Q)$E:MAZ8H=<449^2ARO5#D/H\A
MW@<(D'=-GFW)#YD7<0S1%6G2GPD+&3U :'2^>>BATZQSV;1XS7-R^><'?$L>
M-&3J+P]VJ\9N6>S6$>PO/"W*N> IMA[/(R!)'F'G*H@)ST21ZT-34J)V+*II
MZ=6 TM#^]8+5 3[7-9]K+Y\J5LTW!#:H*0H.>2\QKG>\'W';KMVVO6Z?0(%<
M87JQ-DF!29!8E[FEL13*EJXZ1*3M(5*62OM%HHY0[=14.R<RI$&"TH3G,<$,
M\50G2)Q'D2QPRG F7\&_<Y*_;\0>_V[-OWL>?\RTHR\A$O,\^??5$70]^2TC
M\(W8B^"FCN#&&\$]EVEB(L".)'\ EYX^I*$3S/#B74YWY)B>VU<2="%S19Z1
MN2)FX;:EI(KIW[@&$BVP\S@N"586#LJQWQ4+:=?'F3G.S OT@>MSL^RDE%Y>
M2ZD34^I7TXMFV>_JY=*TS]D)+O4K[GN(0>*Z_(T8$>0R6EBB8UCA7FR).ZMR
M!D82< DG(R[E,XKDFLM8^?P[Y:7MR\^($TOJ5TM#/2JI1[O4/4M;A;@K&->^
MI8TZY:-^Z3M*9@ISHW6F)I:)/+CDG8!F89.^H\R7,R=OU*]OKB(^"4TFKF+O
M#;L#!;N_R7**QRZO>,PI'O/+T*]+,%SS.4F%4OL)/Y3@"FYWVKOMKF?>F1,R
MYA>RB48ENW"#,2=Y[/*2QYSD,;\._8<&8P<VCQU?HIV6,;^6_9\&.P%]NL&8
MDSSFWVUNZV&X964;RVR\\<C0[/A\..%CG<O/NE,RYI>;5S?7RTU8M]GRS;E3
M*^97*Q^5<KK+\\WSBRU$1<T/?VQ"@IVS<09R;C\9H'M3].5)LWY:?Y:XLX?Q
M'YX/Z>VH_+C@8,IO'1^YQ/I0)(490H97':Q067X^*&^T6-H3^%1H/,_;RP5P
M%&\S -_/A-#;&^.@_H@S^ Y02P,$%     @ ZC-Q5'Y?+FIA!   MA   !D
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M,V5QF2*C9N)>H.<+I>QVX3:H_U4Q_1=02P,$%     @ ZC-Q5!$K :U!!
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M *!L JXOI32;P&[0_U.ROU!+ P04    " #J,W%4L+T8=8L"  "P!0  &0
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ZC-Q5!ORR6 8!0  +2H   \
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M-H:R63$Q,CV\[7AX4_/'?U!+ P04    " #J,W%4)V75I0P"  "$)0  &@
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M#?]VFKT!4$L! A0#%     @ ZC-Q5 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #J,W%4A4Q[D.T
M   K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"
M% ,4    " #J,W%4F5R<(Q &  "<)P  $P              @ '+ 0  >&PO
M=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .HS<50GK\P'% <  !P=   8
M              " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"
M% ,4    " #J,W%4VEI]+.T%   8%P  &               @(%6#P  >&PO
M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ZC-Q5.>W%G5C P
M/0T  !@              ("!>14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( .HS<53C-:HE'00  &P,   8              " @1(9
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #J,W%4G_Y?
MB@\&  #X&P  &               @(%E'0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ ZC-Q5!"O6 %+ @  GP0  !@
M ("!JB,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .HS
M<52);Z/"*0<  "@=   8              " @2LF  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #J,W%4Y0" X),&  "F#@  &
M        @(&*+0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( .HS<52%_6(TQ0(  /@%   9              "
M@=Q6  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ZC-Q
M5-\ /)ON"@  H!X  !D              ("!V%D  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #J,W%4:_E_!&,'   8$P  &0
M        @(']9   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( .HS<53.18S4;P,   0(   9              " @9=L  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ ZC-Q5($!@M(9"0  V!@
M !D              ("!/7   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #J,W%4P;BV->\"  !)!@  &0              @(&->0
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .HS<50GVT)^
MTP@  -,6   9              " @;-\  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ ZC-Q5!B))18;!0  T0P  !D
M ("!O84  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #J
M,W%44/3J[0@&  #\#0  &0              @($/BP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .HS<534070-F (  *H%   9
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M970R-BYX;6Q02P$"% ,4    " #J,W%4D(:2TIH"  ":!0  &0
M    @($"N0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M .HS<53<L( NT0(   \&   9              " @=.[  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ ZC-Q5-'6X%VG @  V@4  !D
M             ("!V[X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #J,W%4@T+A\]0"   E!@  &0              @(&YP0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( .HS<53J\]_WWP0
M (T+   9              " @<3$  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ ZC-Q5,N6KKAX!   $0H  !D              ("!
MVLD  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #J,W%4
MZS^X#R$$  "S"@  &0              @(&)S@  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( .HS<50M)9Y?#@,  $X&   9
M      " @>'2  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ ZC-Q5(=.W&]& P  B0D  !D              ("!)M8  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #J,W%4K]B::5T$  ">#P
M&0              @(&CV0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( .HS<53<D, 2] (  +P'   9              " @3?>  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ZC-Q5"R4[6;%
M @  Z@D  !D              ("!8N$  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #J,W%4)1607BP"  !-!0  &0
M@(%>Y   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .HS
M<51[3LJ9A@(  *0&   9              " @<'F  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ ZC-Q5'5K8X 6 P  9@L  !D
M         ("!?ND  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " #J,W%40O <:UX"  #-!0  &0              @('+[   >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( .HS<52F WI(H@(  %<'
M   9              " @6#O  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ ZC-Q5 MX$F42!0  LQ@  !D              ("!.?(
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #J,W%4<#]J
MZWP$  !O$@  &0              @(&"]P  >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( .HS<52SN)F1)00  .L3   9
M  " @37\  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MZC-Q5)T*?E(+ P  -0@  !D              ("!D0 ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #J,W%4ASJJ,+8$  #J$0  &0
M            @('3 P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( .HS<50(D$ KW (  +X(   9              " @< ( 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ZC-Q5$15*T)S!
MX1$  !D              ("!TPL! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #J,W%4L!CB3'(#  "A#   &0              @(%]
M$ $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .HS<50V
M#?191P(  #<%   9              " @284 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ ZC-Q5 UZ; <Z P  Y D  !D
M     ("!I!8! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .HS<52^9GE]?P(  %\&   9              "
M@84K 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ZC-Q
M5+"]&'6+ @  L 4  !D              ("!.RX! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " #J,W%4ZK N$#P"  "0!0  &0
M        @('], $ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( .HS<51;)$%JNP(  &T'   9              " @7 S 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ ZC-Q5.;.PRI_ @  S@4
M !D              ("!8C8! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " #J,W%4'$%-P1P#  "?"0  &0              @($8.0$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( .HS<52Q4082
M,@,  /03   -              "  6L\ 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ ZC-Q5)>*NQS     $P(   L              ( !R#\! %]R96QS
M+RYR96QS4$L! A0#%     @ ZC-Q5!ORR6 8!0  +2H   \
M ( !L4 ! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .HS<50G9=6E# (
M (0E   :              "  ?9% 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( .HS<53NU>T8Y@$  /4D   3              "
M 3I( 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  %%* 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>119</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Business and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization</Role>
      <ShortName>Nature of Business and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with BMS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS</Role>
      <ShortName>Collaboration Agreement and Stock Purchase Agreement with BMS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Research License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreements</Role>
      <ShortName>Research License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Lease Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1</Role>
      <ShortName>Lease Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Lease Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables</Role>
      <ShortName>Lease Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Nature of Business and Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)1</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)1</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with BMS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreement and Stock Purchase Agreement with BMS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Stock-Based Compensation - Schedule of Total Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Total Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Stock-Based Compensation - Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Employee Benefit Plan (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Total Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Research License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Lease Obligation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails</Role>
      <ShortName>Lease Obligation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Lease Obligation - Summary of components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails</Role>
      <ShortName>Lease Obligation - Summary of components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails</Role>
      <ShortName>Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails</Role>
      <ShortName>Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails</Role>
      <ShortName>Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ikna-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ikna-20211231.htm">ikna-20211231.htm</File>
    <File>ikna-20211231.xsd</File>
    <File>ikna-20211231_cal.xml</File>
    <File>ikna-20211231_def.xml</File>
    <File>ikna-20211231_lab.xml</File>
    <File>ikna-20211231_pre.xml</File>
    <File>ikna-ex23_1.htm</File>
    <File>ikna-ex31_1.htm</File>
    <File>ikna-ex31_2.htm</File>
    <File>ikna-ex32_1.htm</File>
    <File>ikna-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img39825204_0.jpg</File>
    <File>img39825204_1.jpg</File>
    <File>img39825204_10.jpg</File>
    <File>img39825204_11.jpg</File>
    <File>img39825204_12.jpg</File>
    <File>img39825204_13.jpg</File>
    <File>img39825204_14.jpg</File>
    <File>img39825204_15.jpg</File>
    <File>img39825204_16.jpg</File>
    <File>img39825204_17.jpg</File>
    <File>img39825204_18.jpg</File>
    <File>img39825204_19.jpg</File>
    <File>img39825204_2.jpg</File>
    <File>img39825204_20.jpg</File>
    <File>img39825204_21.jpg</File>
    <File>img39825204_22.jpg</File>
    <File>img39825204_23.jpg</File>
    <File>img39825204_3.jpg</File>
    <File>img39825204_4.jpg</File>
    <File>img39825204_5.jpg</File>
    <File>img39825204_6.jpg</File>
    <File>img39825204_7.jpg</File>
    <File>img39825204_8.jpg</File>
    <File>img39825204_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="470">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ikna-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 119,
   "dts": {
    "calculationLink": {
     "local": [
      "ikna-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ikna-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ikna-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ikna-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ikna-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ikna-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 486,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 11
   },
   "keyCustom": 53,
   "keyStandard": 355,
   "memberCustom": 21,
   "memberStandard": 24,
   "nsprefix": "ikna",
   "nsuri": "http://www.ikenaoncology.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with BMS",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS",
     "shortName": "Collaboration Agreement and Stock Purchase Agreement with BMS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Common Stock",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock-Based Compensation",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Employee Benefit Plan",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Income Taxes",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Research License Agreements",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreements",
     "shortName": "Research License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Lease Obligation",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1",
     "shortName": "Lease Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Commitments and Contingencies",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Related Party Transactions",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ikna:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Redeemable Convertible Preferred Stock (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables",
     "shortName": "Redeemable Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ikna:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Lease Obligation (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables",
     "shortName": "Lease Obligation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Nature of Business and Organization - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
     "shortName": "Nature of Business and Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_9d2ca6ed-69e8-4b73-9331-739f008d6068",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)1",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)1",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_9d2ca6ed-69e8-4b73-9331-739f008d6068",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_f6feba73-11f7-4c3f-bf74-b2fc74138690",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value On Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_f6feba73-11f7-4c3f-bf74-b2fc74138690",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:ClinicalManufacturingAndScientificDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
       "div",
       "ikna:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ikna:ClinicalManufacturingAndScientificDevelopmentCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
       "div",
       "ikna:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Collaboration Agreement and Stock Purchase Agreement with BMS - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
     "shortName": "Collaboration Agreement and Stock Purchase Agreement with BMS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_c485b7cf-0678-46d2-94de-86fa847eed87",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "us-gaap:TemporaryEquitySharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ikna:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "div",
       "ikna:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_0ee54f8e-33d8-4cf5-8ac7-6aacc1bc5abb",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Stock-Based Compensation - Schedule of Total Compensation Expense (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Total Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_9b136456-ad76-446f-a0d8-ef8a597b5f71",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_9b136456-ad76-446f-a0d8-ef8a597b5f71",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_f03341b9-2f76-48f3-8446-954e602ed32f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Stock-Based Compensation - Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Employee Benefit Plan (Additional Information) (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails",
     "shortName": "Employee Benefit Plan (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Schedule of Total Deferred Tax Assets (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Schedule of Total Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_890c650a-b769-4a05-90cd-2d91b6fcb220",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Research License Agreements - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_5c03768c-e908-427c-98a3-dac6ad6d0a7d",
      "decimals": "-3",
      "lang": null,
      "name": "ikna:LicenseMaintenanceFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Lease Obligation - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
     "shortName": "Lease Obligation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_95669789-5d67-45fb-83c2-2a62765d4576",
      "decimals": "INF",
      "lang": null,
      "name": "ikna:AreaOfLeasedProperty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_sqft",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Lease Obligation - Summary of components of Lease Costs (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails",
     "shortName": "Lease Obligation - Summary of components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails",
     "shortName": "Lease Obligation - Summary of Supplemental Cash Flow Information Relating to the Company's Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_2df7bdbe-e8b1-4c47-ba9d-7aa5fe65b63d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_2df7bdbe-e8b1-4c47-ba9d-7aa5fe65b63d",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails",
     "shortName": "Lease Obligation - Summary of Remaining Lease Terms and Discount Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ikna:ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails",
     "shortName": "Lease Obligation - Summary of Future Minimum Lease Payments for Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_28765881-e2d0-48c4-9202-c01a1e66bfc8",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_f2ad82ad-ba0d-444e-bbea-c7c079ec8603",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_f2ad82ad-ba0d-444e-bbea-c7c079ec8603",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Business and Organization",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization",
     "shortName": "Nature of Business and Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ikna-20211231.htm",
      "contextRef": "C_99ed35bd-4774-4330-bc6b-2c695190c3de",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 45,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "verboseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ikna_AccruedExpensesAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ikna_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities and other liabilities current.",
        "label": "Accrued Liabilities And Other Liabilities Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AmountEligibleToReceiveInCaseOfExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount eligible to receive in case of exercise of options.",
        "label": "Amount Eligible To Receive In Case Of Exercise Of Options",
        "terseLabel": "Amount eligible to receive in case of exercise of options"
       }
      }
     },
     "localname": "AmountEligibleToReceiveInCaseOfExerciseOfOptions",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_AreaOfLeasedProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased property.",
        "label": "Area Of Leased Property",
        "terseLabel": "Area of leased property"
       }
      }
     },
     "localname": "AreaOfLeasedProperty",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ikna_AskAtLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AskAt license.",
        "label": "Ask At License [Member]",
        "terseLabel": "AskAt License"
       }
      }
     },
     "localname": "AskAtLicenseMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for issuance percentage of annual increase in number of common stock outstanding.",
        "label": "Available For Issuance Percentage Of Annual Increase In Number Of Common Stock Outstanding",
        "terseLabel": "Available for issuance percentage of annual increase in number of common stock outstanding"
       }
      }
     },
     "localname": "AvailableForIssuancePercentageOfAnnualIncreaseInNumberOfCommonStockOutstanding",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_BMSCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement and stock purchase agreement.",
        "label": "B M S Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BMSCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMS collaboration agreement.",
        "label": "B M S Collaboration Agreement [Member]",
        "terseLabel": "BMS Collaboration Agreement"
       }
      }
     },
     "localname": "BMSCollaborationAgreementMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of presentation and principles of consolidation.",
        "label": "Basis Of Presentation And Principles Of Consolidation Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfPresentationAndPrinciplesOfConsolidationPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_BeginToExpireInTwoThousandThirtySevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Begin to expire in two thousand thirty seven.",
        "label": "Begin to Expire in Two Thousand Thirty Seven [Member]",
        "terseLabel": "Begin to Expire in 2037"
       }
      }
     },
     "localname": "BeginToExpireInTwoThousandThirtySevenMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BostonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston, Massachusetts.",
        "label": "Boston Massachusetts [Member]",
        "terseLabel": "Boston, Massachusetts"
       }
      }
     },
     "localname": "BostonMassachusettsMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb.",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "BMS"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_ClinicalManufacturingAndScientificDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical, manufacturing and scientific development current.",
        "label": "Clinical Manufacturing And Scientific Development Current",
        "terseLabel": "Clinical, manufacturing and scientific development"
       }
      }
     },
     "localname": "ClinicalManufacturingAndScientificDevelopmentCurrent",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_CollaborationAndStockPurchaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and stock purchase agreement.",
        "label": "Collaboration And Stock Purchase Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndStockPurchaseAgreementAbstract",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ikna_ConcentrationOfCreditRiskNumberOfFinancialInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk number of financial institutions.",
        "label": "Concentration Of Credit Risk Number Of Financial Institutions",
        "terseLabel": "Concentration of credit risk, number of financial institutions"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskNumberOfFinancialInstitutions",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ikna_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_Deferredtransactioncostsinaccountspayableandaccruedexpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred transaction costs in accounts payable and accrued expenses.",
        "label": "DeferredTransactionCostsInAccountsPayableAndAccruedExpenses",
        "terseLabel": "Deferred transaction costs in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "Deferredtransactioncostsinaccountspayableandaccruedexpenses",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposits and other assets noncurrent.",
        "label": "Deposits and Other Assets Noncurrent",
        "terseLabel": "Deposits and Other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_ElectronicEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electronic equipment and software.",
        "label": "Electronic Equipment And Software [Member]",
        "terseLabel": "Electronic Equipment and Software"
       }
      }
     },
     "localname": "ElectronicEquipmentAndSoftwareMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status Policy [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_IKFourOneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IK-four one two.",
        "label": "I K Four One Two [Member]",
        "terseLabel": "IK-412"
       }
      }
     },
     "localname": "IKFourOneTwoMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_IKOneSevenFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IK-one seven five.",
        "label": "I K One Seven Five [Member]",
        "terseLabel": "IK-175"
       }
      }
     },
     "localname": "IKOneSevenFiveMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ikna_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ikna_IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in number of shares reserved and available for issuance as percentage on common stock outstanding.",
        "label": "Increase In Number Of Shares Reserved And Available For Issuance As Percentage On Common Stock Outstanding",
        "terseLabel": "Increase in number of shares reserved and available for issuance as percentage on common stock outstanding"
       }
      }
     },
     "localname": "IncreaseInNumberOfSharesReservedAndAvailableForIssuanceAsPercentageOnCommonStockOutstanding",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ikna_LeaseRentFreePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease rent free period.",
        "label": "Lease Rent Free Period",
        "terseLabel": "Lease rent free period"
       }
      }
     },
     "localname": "LeaseRentFreePeriod",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ikna_LeasesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases policy.",
        "label": "Leases Policy [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesPolicyPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_LesseeOperatingLeaseLiabilityPaymentsDueThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due thereafter.",
        "label": "Lessee Operating Lease Liability Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueThereafter",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_LesseeOperatingLeaseMaturityMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease maturity month and year.",
        "label": "Lease maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMaturityMonthAndYear",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ikna_LetterOfCreditToSecureLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit to secure lease.",
        "label": "Letter Of Credit To Secure Lease",
        "terseLabel": "Letter of credit to secure lease"
       }
      }
     },
     "localname": "LetterOfCreditToSecureLease",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fees.",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity Policy [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_MilestonePaymentsEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments eligible to receive.",
        "label": "Milestone Payments Eligible To Receive",
        "terseLabel": "Milestone payments eligible to receive"
       }
      }
     },
     "localname": "MilestonePaymentsEligibleToReceive",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_NotSubjectToExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not subject to expiration.",
        "label": "Not Subject to Expiration [Member]",
        "terseLabel": "Not Subject to Expiration"
       }
      }
     },
     "localname": "NotSubjectToExpirationMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_OfferingCostsRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs recognized.",
        "label": "Offering Costs Recognized",
        "terseLabel": "Offering costs recognized"
       }
      }
     },
     "localname": "OfferingCostsRecognized",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_OperatingLeaseMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease monthly base rent.",
        "label": "Operating Lease Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyBaseRent",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_OperatingLeaseTermExtendedExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease term extended expiration period.",
        "label": "Operating Lease Term Extended Expiration Period",
        "terseLabel": "Lease extended term period"
       }
      }
     },
     "localname": "OperatingLeaseTermExtendedExpirationPeriod",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ikna_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards, expiration year.",
        "label": "Operating Loss Carryforwards, Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "ikna_OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to exercise additional consideration if clinical trial not completed within research term.",
        "label": "Option To Exercise Additional Consideration If Clinical Trial Not Completed Within Research Term",
        "terseLabel": "Option to exercise additional consideration if clinical trial not completed within research term"
       }
      }
     },
     "localname": "OptionToExerciseAdditionalConsiderationIfClinicalTrialNotCompletedWithinResearchTerm",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_PercentageEscalationInAnnualBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage escalation in annual base rent.",
        "label": "Percentage Escalation In Annual Base Rent",
        "terseLabel": "Percentage escalation in annual base rent"
       }
      }
     },
     "localname": "PercentageEscalationInAnnualBaseRent",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_PercentageOfHoldersOfOutstandingSharesOfPreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of holders of outstanding shares of preferred stock.",
        "label": "Percentage Of Holders Of Outstanding Shares Of Preferred Stock",
        "terseLabel": "Percentage of holders of outstanding shares of preferred stock"
       }
      }
     },
     "localname": "PercentageOfHoldersOfOutstandingSharesOfPreferredStock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_PotentialDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential development milestone payments.",
        "label": "Potential Development Milestone Payments",
        "terseLabel": "Additional milestone payments payable upon meeting certain development milestones"
       }
      }
     },
     "localname": "PotentialDevelopmentMilestonePayments",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_PotentialSalesEventMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential sales event milestone payments.",
        "label": "Potential Sales Event Milestone Payments",
        "terseLabel": "Milestones payable contingent on sales in calendar year"
       }
      }
     },
     "localname": "PotentialSalesEventMilestonePayments",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets current.",
        "label": "Prepaid Expenses And Other Current Assets Current Table [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsCurrentTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ProceedsFromPaymentForIssuanceInitialPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from payment for issuance initial public offering.",
        "label": "Proceeds From Payment for Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromPaymentForIssuanceInitialPublicOffering",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from payment for issuance of preferred stock and preference stock.",
        "label": "Proceeds From Payment for Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromPaymentForIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_RedeemableConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development [Member]",
        "label": "Research And Development [Member]",
        "terseLabel": "Research And Development Member"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets and lease liabilities recognized upon lease inception.",
        "label": "Right Of Use Assets And Lease Liabilities Recognized Upon Lease Inception",
        "terseLabel": "Right-of-use assets and lease liabilities recognized upon lease inception"
       }
      }
     },
     "localname": "RightOfUseAssetsAndLeaseLiabilitiesRecognizedUponLeaseInception",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets recognized upon adoption of new accounting standard codification.",
        "label": "Right-of-use Assets Recognized Upon Adoption of New Accounting Standard Codification",
        "terseLabel": "Right-of-use assets recognized upon adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetsRecognizedUponAdoptionOfNewAccountingStandardCodification",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_RoyaltiesTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties terms.",
        "label": "Royalties Terms",
        "terseLabel": "Royalties terms"
       }
      }
     },
     "localname": "RoyaltiesTerms",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ikna_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities and other liabilities current.",
        "label": "Schedule Of Accrued Liabilities And Other Liabilities Current Table [Text Block]",
        "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of remaining lease term and discount rate.",
        "label": "Schedule Of Remaining Lease Term And Discount Rate [Table Text Block]",
        "terseLabel": "Summary of Remaining Lease Terms and Discount Rates"
       }
      }
     },
     "localname": "ScheduleOfRemainingLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Cash Flow Information Relating to the Company's Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ikna_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series a-1 preferred stock.",
        "label": "Series A1 Preferred Stock [Member]",
        "terseLabel": "Series A-1",
        "verboseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_SeriesAOneRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A one redeemable convertible preferred stock.",
        "label": "Series A One Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1"
       }
      }
     },
     "localname": "SeriesAOneRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_SeriesATwoRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Two Redeemable Convertible Preferred Stock.",
        "label": "Series A Two Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2"
       }
      }
     },
     "localname": "SeriesATwoRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares purchased by employees.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Purchased By Employees",
        "terseLabel": "Number of shares purchased by employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesPurchasedByEmployees",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ikna_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, plan effective date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Plan Effective Date",
        "terseLabel": "Plan effective date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanEffectiveDate",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ikna_StockOptionContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option contractual term.",
        "label": "Stock Option Contractual Term",
        "terseLabel": "Stock option contractual term"
       }
      }
     },
     "localname": "StockOptionContractualTerm",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ikna_StockPurchaseAgreementWithBMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement with BMS.",
        "label": "Stock Purchase Agreement With B M S [Member]",
        "terseLabel": "Stock Purchase Agreement with BMS"
       }
      }
     },
     "localname": "StockPurchaseAgreementWithBMSMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_Supplementalcashflowinformationleasesabstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementalcashflowinformationleases.",
        "label": "SupplementalCashFlowInformationLeasesAbstract"
       }
      }
     },
     "localname": "Supplementalcashflowinformationleasesabstract",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ikna_TaxCreditCarryforwardExpirationBeginMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration begin month and year.",
        "label": "Tax Credit Carryforward Expiration Begin Month And Year",
        "terseLabel": "Tax credit carryforwards begin to expire"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationBeginMonthAndYear",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ikna_TemporaryEquityDividendDeclaredOrPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Dividend Declared or Paid",
        "label": "Temporary Equity Dividend Declared or Paid",
        "terseLabel": "Temporary equity dividend declared or paid"
       }
      }
     },
     "localname": "TemporaryEquityDividendDeclaredOrPaid",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_TemporaryEquityNonCumulativeDividend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, non-cumulative dividend.",
        "label": "Temporary Equity, Non-Cumulative Dividend",
        "terseLabel": "Percentage of non-cumulative dividend"
       }
      }
     },
     "localname": "TemporaryEquityNonCumulativeDividend",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ikna_TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares acquisitions.",
        "label": "Temporary Equity Stock Issued During Period Shares Acquisitions",
        "terseLabel": "Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc., Shares",
        "verboseLabel": "Number of shares issued pursuant to acquisition"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ikna_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of preferred stock in connection with private placement, Shares",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ikna_TemporaryEquityStockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value acquisitions",
        "label": "Temporary Equity Stock Issued During Period Value Acquisitions",
        "terseLabel": "Issuance of preferred stock in connection with the acquisition of Amplify Medicines, Inc."
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one employee stock purchase plan.",
        "label": "Two Thousand And Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one stock incentive plan.",
        "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "terseLabel": "2021 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_UniversityOfTexasAtAustinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Texas at Austin.",
        "label": "University Of Texas At Austin [Member]",
        "terseLabel": "University"
       }
      }
     },
     "localname": "UniversityOfTexasAtAustinMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ikna_UpfrontAmountAllocatedToEquityArrangements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront amount allocated to equity arrangements.",
        "label": "Upfront Amount Allocated To Equity Arrangements",
        "terseLabel": "Upfront amount allocated to equity arrangements"
       }
      }
     },
     "localname": "UpfrontAmountAllocatedToEquityArrangements",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront consideration payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ikna_VertexPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex pharmaceuticals.",
        "label": "Vertex Pharmaceuticals [Member]",
        "terseLabel": "Vertex Pharmaceuticals Inc."
       }
      }
     },
     "localname": "VertexPharmaceuticalsMember",
     "nsuri": "http://www.ikenaoncology.com/20211231",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r265",
      "r419",
      "r420",
      "r422",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated to Director"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r50",
      "r52",
      "r90",
      "r91",
      "r209",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r208",
      "r221",
      "r269",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r478",
      "r481",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r208",
      "r221",
      "r269",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r478",
      "r481",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r154",
      "r252",
      "r255",
      "r440",
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r154",
      "r252",
      "r255",
      "r440",
      "r477",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r208",
      "r221",
      "r257",
      "r269",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r478",
      "r481",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r208",
      "r221",
      "r257",
      "r269",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r478",
      "r481",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r90",
      "r91",
      "r209",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r252",
      "r256",
      "r480",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r252",
      "r256",
      "r480",
      "r494",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r97",
      "r98",
      "r99",
      "r100",
      "r159",
      "r160",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r196",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r334",
      "r335",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r416",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r41"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r184"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r53",
      "r54",
      "r55",
      "r470",
      "r489",
      "r493"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r26",
      "r302",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r299",
      "r300",
      "r301",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r271",
      "r272",
      "r305",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r272",
      "r291",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r345",
      "r346",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Fair value of equity instruments issued in connection with asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r87",
      "r137",
      "r146",
      "r152",
      "r161",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r353",
      "r357",
      "r383",
      "r425",
      "r427",
      "r458",
      "r468"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r49",
      "r87",
      "r161",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r353",
      "r357",
      "r383",
      "r425",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash obtained in asset acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r34",
      "r76"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r77",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r76",
      "r81"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Cash, cash equivalents and restricted cash, end of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r393"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r93",
      "r94",
      "r96",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r196",
      "r295",
      "r296",
      "r297",
      "r333",
      "r361",
      "r362",
      "r363",
      "r384",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r400",
      "r416",
      "r442",
      "r443",
      "r482",
      "r483",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in accounting principle, ASU, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r93",
      "r94",
      "r103",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r196",
      "r295",
      "r296",
      "r297",
      "r333",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r384",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r400",
      "r416",
      "r442",
      "r443",
      "r482",
      "r483",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in accounting principle, ASU, Adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r85",
      "r87",
      "r108",
      "r109",
      "r110",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r161",
      "r197",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r218",
      "r219",
      "r224",
      "r228",
      "r383",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreement and Stock Purchase Agreement with BMS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r43",
      "r194",
      "r461",
      "r474"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 15)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r195",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value, 150,000,000 shares authorized, 35,975,034 issued and outstanding as of December 31, 2021; 230,000,000 shares authorized, 3,096,903 issued and outstanding as of December 31, 2020",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r126",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and of Significant Suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r246",
      "r247",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r246",
      "r247",
      "r253"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Deferred revenue current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r246",
      "r247",
      "r253"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Deferred revenue non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized which were previously included in deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of convertible preferred stock into common stock, Shares",
        "verboseLabel": "Shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Issuance Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r20",
      "r21",
      "r322",
      "r459",
      "r467"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liability",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r48",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred issuance costs capitalized",
        "verboseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capitalized start-up costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets and liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r328",
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r324"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liability:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTotalDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions to defined contribution savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r74",
      "r182"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r242",
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "terseLabel": "Dividends payable to common stockholders",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarliestTaxYearMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earliest identified tax year.",
        "label": "Earliest Tax Year [Member]",
        "terseLabel": "Earliest Tax Year"
       }
      }
     },
     "localname": "EarliestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r88",
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax effected at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "negatedLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Acquired in-process R&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r315",
      "r338"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateDifferedFromAmountComputedByApplyingFederalStatutoryRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Total unrecognized stock-based compensation balance for unvested options expected to be recognized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized stock-based compensation balance for unvested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r59",
      "r60",
      "r61",
      "r93",
      "r94",
      "r95",
      "r98",
      "r105",
      "r107",
      "r119",
      "r168",
      "r235",
      "r242",
      "r299",
      "r300",
      "r301",
      "r334",
      "r335",
      "r370",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r484",
      "r485",
      "r486",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Transfers between level 1 to level 2 financial assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Transfers between level 2 to level 1 financial assets"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value On Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r374",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r373",
      "r374",
      "r376",
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r210",
      "r258",
      "r259",
      "r264",
      "r266",
      "r374",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r258",
      "r259",
      "r264",
      "r266",
      "r374",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r374",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r210",
      "r212",
      "r213",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value On Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r177",
      "r178",
      "r441",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r174",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO",
        "verboseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r74",
      "r181",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of property and equipment",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r179",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r187",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r316",
      "r320",
      "r327",
      "r336",
      "r339",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r106",
      "r107",
      "r136",
      "r314",
      "r337",
      "r340",
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r312",
      "r313",
      "r320",
      "r321",
      "r326",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r73",
      "r438"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.",
        "label": "Increase (Decrease) in Deposit Assets",
        "negatedLabel": "Deposits and other assets",
        "totalLabel": "Increase (Decrease) in Deposit Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInLeasingReceivables": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.",
        "label": "Increase (Decrease) in Leasing Receivables",
        "negatedLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeasingReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LatestTaxYearMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest identified tax year.",
        "label": "Latest Tax Year [Member]",
        "terseLabel": "Latest Tax Year"
       }
      }
     },
     "localname": "LatestTaxYearMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r412",
      "r414"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Summary of components of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments for Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less amounts representing interest or imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfRemainingLeaseTermsAndDiscountRatesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligation1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r87",
      "r147",
      "r161",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r354",
      "r357",
      "r358",
      "r383",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r31",
      "r87",
      "r161",
      "r383",
      "r427",
      "r460",
      "r472"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r87",
      "r161",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r354",
      "r357",
      "r358",
      "r383",
      "r425",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "UT Austin License"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r123",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business and Organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r56",
      "r57",
      "r61",
      "r62",
      "r75",
      "r87",
      "r97",
      "r101",
      "r102",
      "r103",
      "r104",
      "r106",
      "r107",
      "r111",
      "r137",
      "r145",
      "r148",
      "r151",
      "r153",
      "r161",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r372",
      "r383",
      "r462",
      "r475"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss and comprehensive loss",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Assets obtained in asset acquisition",
        "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "terseLabel": "Liabilities assumed in asset acquisition",
        "totalLabel": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed, Total"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Income tax returns years open and subject to examination"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r137",
      "r145",
      "r148",
      "r151",
      "r153"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r409",
      "r414"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash lease expense",
        "verboseLabel": "Total lease rent payments"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Fiscal Year",
        "verboseLabel": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfFutureMinimumLeasePaymentsForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r404",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities (operating cash flows)"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfSupplementalCashFlowInformationRelatingToTheCompanysLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r48",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r41",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ikna_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other Liabilities, Current, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment Option to Purchase"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Payments to acquire property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r273",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r24",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r24",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred Stock, $0.001 par value - 10,000,000 shares authorized as of December 31, 2021 and no shares authorized as of December 31, 2020; No shares issued and outstanding as of December 31, 2021 or December 31, 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r24",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r7",
      "r9",
      "r171",
      "r172"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds received after deducting underwriting discounts and commissions",
        "verboseLabel": "Proceeds from initial public offering, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r294"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r56",
      "r57",
      "r61",
      "r70",
      "r87",
      "r97",
      "r106",
      "r107",
      "r137",
      "r145",
      "r148",
      "r151",
      "r153",
      "r161",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r352",
      "r355",
      "r356",
      "r359",
      "r360",
      "r372",
      "r383",
      "r463"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r37",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r36",
      "r183"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r185",
      "r427",
      "r464",
      "r473"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "terseLabel": "Property and equipment:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r35",
      "r185",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r265",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "University license fees and certain-patent related costs"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r265",
      "r419",
      "r422",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r417",
      "r418",
      "r420",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r308",
      "r439",
      "r512"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Total consideration allocated to technology recognized as research and development expense",
        "verboseLabel": "Non-cash research and development expense for in-process research and development acquired in acquisition"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Research License Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development Tax Credit Carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r81",
      "r457",
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r11",
      "r19",
      "r76",
      "r81",
      "r495"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash included in other assets",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r27",
      "r242",
      "r302",
      "r427",
      "r471",
      "r488",
      "r493"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r93",
      "r94",
      "r95",
      "r98",
      "r105",
      "r107",
      "r168",
      "r299",
      "r300",
      "r301",
      "r334",
      "r335",
      "r370",
      "r484",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r134",
      "r135",
      "r144",
      "r149",
      "r150",
      "r154",
      "r155",
      "r157",
      "r251",
      "r252",
      "r440"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Research and development revenue under collaboration agreement",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price allocated to revenue arrangement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of when remaining performance obligation is expected to be recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, explanation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Company issued and sold shares of common stock"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Total Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Differed from Amount Computed by Applying Federal Statutory Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r37",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureResearchLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r273",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r276",
      "r282",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Estimated Date of Grant Using the Black-Scholes Option Pricing Model and The Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r44",
      "r85",
      "r120",
      "r121",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r224",
      "r228",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility range maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility range minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfTotalCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of stock granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted",
        "verboseLabel": "Number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-average fair value of the stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r278",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding",
        "periodStartLabel": "Number of Options, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued for purchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Cancelled or forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r288",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfEstimatedDateOfGrantUsingTheBlackscholesOptionPricingModelAndTheWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Option exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested or expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r82",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r85",
      "r87",
      "r108",
      "r109",
      "r110",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r161",
      "r197",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r218",
      "r219",
      "r224",
      "r228",
      "r235",
      "r383",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerShareDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r47",
      "r59",
      "r60",
      "r61",
      "r93",
      "r94",
      "r95",
      "r98",
      "r105",
      "r107",
      "r119",
      "r168",
      "r235",
      "r242",
      "r299",
      "r300",
      "r301",
      "r334",
      "r335",
      "r370",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r484",
      "r485",
      "r486",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r119",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r24",
      "r25",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc., Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r46",
      "r211",
      "r235",
      "r236",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r235",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering, net of issuance costs, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r235",
      "r242",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r47",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with the acquisition of Amplify Medicines, Inc."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r47",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r29",
      "r30",
      "r87",
      "r158",
      "r161",
      "r383",
      "r427"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r219",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndOrganizationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r197",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Redeemable convertible preferred stock (Series A, A-1, A-2, and B), $0.001 par value. No shares authorized, issued and outstanding as of December 31, 2021; 169,396,576 shares, authorized, issued and outstanding as of December 31, 2020 (liquidation preference $0 as of December 31, 2021 and $202.2 million as of December 31, 2020)",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Redeemable convertible preferred stock, liquidation preference",
        "terseLabel": "Aggregate Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r15",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Redeemable convertible preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Redeemable convertible preferred stock, shares authorized",
        "terseLabel": "Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Shares Issued",
        "verboseLabel": "Redeemable convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Shares Outstanding",
        "verboseLabel": "Redeemable convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockScheduleOfRedeemableConvertiblePreferredStockDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of preferred stock in connection with private placement"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r15",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationAdditionalInformationDetails",
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementAndStockPurchaseAgreementWithBMSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Reserves for uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued on uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest or penalties recognized on uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increased amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r410",
      "r414"
     ],
     "calculation": {
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/DisclosureLeaseObligationSummaryOfComponentsOfLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares of common stock outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.ikenaoncology.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r516": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r517": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r518": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r519": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r520": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r521": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r522": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r523": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r524": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r525": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0000950170-22-003998-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003998-xbrl.zip
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MN_G(FX5SN^48*34M9DLB!!!>UX:QPX#&H/" 1.O%PK<"OZ_'")RGDOB.EL6
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MFAL\B0@T8,>5%,B7YP+1\D(2^7%$/-L) FZZ >>]M6KNPP@BP1I(5_(,4Y"
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M_6CP&:#FT[12CYQ,I)[4(&(/I'T@[?T\:$W:AP2S%=I.+_[$^H8)=GBYDA=
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MUW]*A:_4@ 5?2D37/,//7\X,3/FAV4RS--JB<ZY[1 $]&"5EE1>S7:.%;=B
M^M_'P[@_P/@ XYN&\1&]DLBEID4!(%S"@2<QJ/)99602.%5>8JMAX&Q<*BZ'
MOTS:!FG8@@>#GRJIF>6U!)Q(4P-W,\FF$CFO&KL9"'LA:XY7 (^4J,(:\;2:
M%G+ E0%7M@)7LMR8%+F8<FQ<,H%?KP!O$*ZQ4[DLE#NDI*EN2E6_41F7,D/F
M(!%G9H8J! ?H$1?YN!E-O50.:#"@0=_10)'X0OXY35 ^$KIA)D ]IY.D@I]
M]+6O4[.,O&V=N6/ I/@(=+"90@I4J*YHDBHV@"R%(W-1?X&2-H;G :V K= T
MW36.8V0O*))-,_U(;A0T 4VK^>[U2&; M:1 6:S  =4H"\/FQA2G 8MH5#I
M7:YT,4-(.( =6!F@H\01)$IV&7*W,A\KM0_7T^"K "1.\XGR>L*URX+"MQ;H
M0/)OM6Y#QO"1:L#M ;?[C=NG@$ZJ<<LJ3B/*<CH%;!-).E50#1B#Z%#.$TQ+
M1)ZR*A+ CD7,1[QH*,:T5*B+T <7RI&A/#%E,UXE^2A#/0M-,/D<W4 F%8D
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M:N]EW8*Q'*R9 SAO#3@C"<>"@=HMRW4<$1;]PQNZ6$QJ3*8L1>J-50$QGF@
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M80OXF6X@2!,)I9S7RN:SZ&/&?!*U>#3O8]J7#JIJ;#8JN$K>)"7R$OA^J@(
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MTFYX45OT105^$4"7+_!N=2WENLHX*JVWV60MKMX10KL4:]18;77*CEXD9;)
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M*?OND)Z;:I4J<8;V4G'Q#*?OT*A)^ZT$ Q_Y1PMUL&U<T5D&L(>Z$=L@^:I
MK*>5* /C5Y:9?$ZV4F-LR+SB.1:&-[JH'@<CB%:+F';GU$&.I8-4%8"2L3=H
M4?>B%YS[!ZH>D:K@'F5L6U!%S,P1$&;@=B#"H#U-YJ"=\-;%;8Z><+^W"=5"
MVC4%%Z153_,9;CEB64KE-^X[.BP5:E754N/I(UL3I;'M;KMKWC3MREM::U_C
MP;8HFYYV!%H<P69:Q6:J@ A'PJBJ'3N22^IJ"X8=BC6(>"Y6M9V.E=( 5X?
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M,6@(_2K#?M'6&4]#G7%PF_G]+_GF]\NGW_E@T=$0+/KR&^L[4F"?5"ZB;'6
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M1W?;]%?C*4SC!'9UOS,PZC.H)/7EVI&W["KQ%UK1#&]-F:7!_,TC@U[@,5J
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M[WA-X\P,H.N=6N(;XIZPI.P!+\UR0GI1W5U6@G(5Z686# SCY=CW#'+H]5B
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M-^XS9E&._PE32WWA-38GV27P=>TN$=$? W(%F(*L1 *7Y$4OMNL;RH4!ICG
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MBQ'Z0A:[M#J)6>\^7;GN12>;TQ"NPA77VP$Y@%+"9@@T)N)_HVB:EM-F"8L
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MGAP>_\#:]B-$AM.WP:*VA[6KD\> :+;9$3)C618>K77+LHY=M1TC&#3>UQ&
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M'3JZ,??2C?G)[PMRO2]A4+W*5]8KZ?O14SII&EBR!P/CL%_0MUE!B:EM80[
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M&T 36HDWTK_$N0;C:]<T4LT5Z\*%Z?(PX0TZ,T]I867?6H>R=2YO@HV)#\&
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M4'*#ZKBUUB'> !0$$/Y.%*$.12>%A">S9N7@$2WGF$:[@+X./I"*/DR,CH2
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M,'WP.CJ%.S$P-\.4NM*5BV>G*A6 A59>Z1=GH+P,(]K>,*%)O0;_VWZCRA#
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MS]YF;9,5[2Z&;;_34#H=$+D$(?PW=SWV1=M!N4PH J3)MN9DE_M #,S_WFW
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MI3V9R!63>EH?-F]5KO5*L*.I-@D2I%=M+6R-&2%JX+!I>_CPN#/5V;M\,$A
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MD9P&?N \G5F4$3)[J11DF1?J*1NC@RF ARF:<908^DD&D6[D.JR9TFS-[4]
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MF[Z+/)M?>&X]J5=I/BF#+/CDNW32<'#!X4HQXLC]&UVTZM8Q?_7\YV*N5P5
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MCB%7C) 5 ,PBK8TE<U)@=?/T\SK%&JW;MKM.Q%SU"KW ^3/>6$TE\@>RWL^
M]S8F7]3A (NPX5TJXE[SDY<Q"*0N:IE]-WQ;>SF]Q^RVUI[GEX[]#]9KNPTA
MR4]C&[WR"_)[=!3_S,5'YM'_GC5B01<%%I#(@*<D!KIDA)^Z<6W;_$@W5T'
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M<+>^Y7X+KNJ9\YSV)=IFS0XQ<_0%>R5QLXV'P*,V++^H&2RU1X#=0GH?G%J
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MDV6$U>4U?VA8L/2%MD9 /;BP@S)A*K@@9 QK888L:/& %NO[YLURJ!>6@O+
MD5BY*7DJ7M+?'XJ+DBHC@GO7>I3-%.O\!JZXC/6X$&_GQ6I+F_&:;J(^P "&
MDKJO3I@]8.][^.E\+&.-\8>.#P :\U^Z:F^%135?![ZODL:L(ZG4 27Y"\GA
MB\1VH4],"PJ^7PQ[<B.$ERZ:/ZYOXR%ONX EH8_&ZV.,UQNMH^BN&G$J;M%P
M(]+2=,0-TJ?1=NW)/ 3,.*3G!<.E%NV..5>2<ZE2DWX^OM&//8[.* 9I^)Q1
M'C$.+,_M'?TD@AKI5"KD6*)8]XNGS#[V^//%@\.??@A(G)UO<B+1$=.42ODU
MN5$Z>"B*YE":CAZQ=8=O@GL@!:5&L\O\1(?0?BJ0ZR?F'U6XFR"D[&34D$(M
M;P[N?4!Q#'*W;9<:R.JU>L6JYEP/30Q.$.1D?;@IX*_4B%/L05;0)&.N@<^.
MUOGVET&?6C&],7, =;W!F9G20!0&F)7DJN.:M0FU'SJ$N9R.C7OXA5C0<\MP
MZE6\ 1-G(3"94F&-,*"^M&*F )ZSZ-Q_P"R0>U-F[@U"2<02,C,Z"W 'Y%Z.
MH^;@$VL#6CY::U@P>B9A<DU@@#1?EIR@8%A#D'_G@7YZ_[=$/X(M)3OSJ[V*
M&O>A7#>2X\GQ_",8V!BKR95#UE=C(1Z*(MEKB<O%L2YK4/LG+CW'>U79#DQ!
M]75=1E[&$PZ[-58K8@0Z]T9>N(3.&YS\0E_VTXLWWR::QR' >3#2J,2?Q<T"
MX^C%0QSB.+DED4D%Z;\ZAS4Z2HV/RI4&D.')5X;M0D&UE O.QW7M**L0;YMQ
MJ;E!S%UZ< 1552UA-;\L"C'9K2*[](K^LWB1J/4<YE32+V,40$ZMA>X=7,)=
M ^LT\K^PQTP_T%=.&(O;Y%<@4Z9#J*T'4[8$9_?@.P/(I77-B)LYT-HYE]+A
M!U96E1D2P_<:F5@E3BO@07[]V$+\4"Y0];1=]>6G181'>AUASOX2IW$*_1Q8
MJPHSI^UGSH-XVU/Z!4N/DKM>LDA84 0V1NW1!?-+:/2\?D5I/:Q+6O$Q[4;Q
M ^_JI>5THQ&8)>N:Z]@:V[^X8IK2Z,1<=_;HK3H5'4.&<Z<7PBAR5606+#2L
MPJIV-SIL"(^NX$?C24O.D:T%5R>OJ]\U6@G5&'KB+66N>\9Q*ZR@S\_,?&FX
ME]JW)VG;34,NB-#?,B]N&!'C*F7NZ?^[Z!>?_?FNTS;<Y<K:G2_9?GDLV?X?
M+*RCD,@A(1%I3&L:+7%\B(C(4;3C%R4>:.N:L\!YU2BZP2I^0V4B[/"!MNB1
M8A .WLL0EO09R^/V]353;XA4/-A)66Q0<LZ: P_1B8C,Q$GR(TJ."A1U+BCB
M"#H?5H[YU>_F'YG_YD@E]'UWGF3%1C?& M66 >NG!)1?)DK29P>N5?B)<9DV
M5TBTR64&V3X^P4]7P>\-?@NJ(1L'HNRS5E^R+@'RC,<.XU\U-?^,/^J*BC[E
MI![O7Y^]BG4-#9$="EL+*U]PBH<,&T;)WXAX"LU:*I!24\7YU%T(<-,0"=[M
M]ETK;5P_4@KWG_-\CMH8@=?]#I'.EC7)=02C>Z,,U[;Z^+%D@A2/#O:RZRJL
MO2'T6F7I#KQINK/.&@>AVZYWJ?&+0+N*\8AFZ&:^[>8OM%=<)1FTYRR]HHZ>
M^=)%K;&;M^?%(7CM[!F]T@ OJ/92+*_+1\'_1TFGL]AAT! G&RJS!=/L<RC,
M^O)-)_B"\H+K)%?=S7AR!UZB56$/4TU!@6)5.,S/AYQ]T/'\VMY@543&U<>(
M22YGI9$K,I+@(HK]5FD!%D)-G*@D>L3#>@:-QI'X^62I]@@FVTY+[[83[;XV
MO(N]XI3C_:>\ZTNT.ED^-'NOW%0AB\U*^CV@'[5P_.NS=/W@-QP#9FA:D'(3
MPZ%QA!:@D/)<24]!_IY&YZQNH$3TY:42 JNL!H$^J'BKI";XJG&5\APK,?BH
M:>V[@]ISLRE2>31-@EJ8&L/=\=Z =MU8 41,^(BQ*@I^%!;?X'=9]&-6;RWH
M*%!.#PT?OY[+6^QC+I G&LPT$$%#?/Y'38^(A4N%L<NFNT!-AHZE77#@BD";
M!5WVL5])VAYLB9?+;Y^@<0W_+^/DD!ZV'NNJ/UV\I+"R0YP?9Q(@G&%D?S"U
MZ.3FE\**N%'X6EM_VI/X"U6W'LMIU^T*EL7#Q_B.IXN_,NA++""CW%0KM0H;
M^A>G4,@R7$H*Y!9+5T297ZFV3H$3>#RMIF,9Y7H5Y H526W;BQNK"$)(#2G)
M6=GL\#I1.O$GM-6_K.%:I%AD;QP:(.>1QT^(_6EMX>,D=YDVUJY5"114<]/I
M5@+'1&^&5LPV(P7@N^7[21A*57MVZR3;XY/O6L=QP(+*OL:2X=SC'%WL)\^4
MI14AT-;+&7=XH+1MC^FC?U_B>+4#<U,L%/\M&9KPKMXFD_7\YYGZW"-G)I8!
M/?%:TXO-7C__;:8K2RMI*#DH[JU=,/\P[*U=W"4=2UC&63XF/^21_7[P#]I(
M55_>E,W#Q1FM>_8WV;/I^DTGI/]Q^ _H%O56X)=A?CP 7CCWVR2&Z!$CM@&P
M3.R>A[QX._XC+=5"&#?41"B?$?U)S-U/Z8=X;M'/8T<[/@$**+OMY/$GIB)<
MPH8ET0S'2X WRT^$-:OMIGC1[[O@*1V#[<F<O;*'R$\V\FL#D(A.\-6..<Z1
M//WV\5>G7RQHN38:.,GA1]%A4]VPDZ&'W>C08H>-SZPSZP#5(=0F["@=Z0J,
M,1Y45U#TCRI'<N8$.)*M!^:L/3\W[^RADCO?F!2)(^TR=C1#1/(F&-0M@V$T
M-\C-K1]67 H840] 9!&=L:F[;G2IL+H)C10W-0T(1<)=:_$AES'^;NZ6WK#(
MWJ%]<AS]N%&X (J^E;E_[/;%EZ !Y ?,0MP+ERG?P]/,6*FZ7UO+YJ$116LE
MPS''5)]^Q07>E:#9CV?'QRJXTAX689=?&!VHG_KSWXKTXAGEQYPV59(FC0Z$
M1/)C*Q,W)]M)>LMSWOSIXD<ZJ79M6'SN#XKGY[93V7\0U"$S")@"#1PTP<JS
M1[L;@@N61VLLBYU[%UREW?<9/_2#+ ODS@X[=QYJH'K@:@?S%7IY<;6WLU=.
M4(1;'U%1/H+"N.V#V'E"QJ@P(<.B-+E1G1Q<$6H1M[="GD?#-N/*]OB]X^:C
MBTT#5)0P058*=B0_)=TL-3+&];H.'$+4P[HP&B@N?(H>%>, "HD*;*G/V9?3
MQ3_FDY5Q ?,'!WT!:9T#S>UDVY)!'B^T;$IUN4<7H>J0FND.AR\BXRY9@VXX
M BD_SN ].Q"I[$4.D?]1U:N5Y%KZSIIJ?RZ4VDM=1!_@1#J\E"RGZ)@6NOII
MPU5W,\BY+SPQ*8Y+ A!MZ!/0XK9P"NMC".$MK\W ^)SEM"%9W-#O,AZ#K6W2
M9<,8KSHCE4B7MB0;+5L(4#,T&'8U)5UEK5ZPL#0G4UW3='?XNC>E*H%AK/SX
M%N.B78I]"H:5DRNQXZB4=>4D#2&SBMR$!V:0H4(BZ'3Q7"8!6S0+DM7SYMT"
M7$BWK!$C8(IBG"[!3II KKB3@QMER-&(5K$-"JD?C)6\;0(*EZ%QY#?6R<+]
M*IO0&X6I) O0(7UWH;-WODC]U;%(?2_1#W?[<,@R*6M.E8UJC\D+%K\U*9L9
M6Z)0P%6?D:$3&L^VA"\ -O%PQ0UIUV'JY2;P\BF'J>- ? A*/;M7M0X'!+)R
M [R(K$B+3#C_.E78!Y'Q)6O:10/'>=$3<-5@;.JM?DQ*-+IA'Y\&S5X!G9S,
M@T:#V&WK1J1%./*7EI;8^]/UPZTP@6(R"/1!<A!.:]*%IDC#IZGR+&P-!%BU
M J&:O0+U-MXS/QS31=V+JG%*TICCBR%SVH,^M^8'Q&)!32I4%C\ 3$U_6Y4,
M9\YK);P4<%LI=_1^X(6]MA6_'^]#KB+/>4K=F*8,/>HO/^9T><V<=+_2V?:I
MXV3^TB-M:[Z,HZ+_+@(N<F;(O]&N(\_M5Z-,^76>X]>A4)E;#8^^^/J;+[Y^
M:O_WY#ZLC8\[GBP+\N0ID!9*=1$8#=()R4),T5]WFF]9E=<"-R"G_]K2E^RJ
M,_(8# >C1+8LN,+GK5?6F^@$+N:*!U;$NI$D[:0FH-3,$N/0)4;$&;!D5@!S
MA8>8];3$MW20O[?&X")M?1 86<9$"QD QE@%#:FCZ1(:!3X/$-#\=!YAM#>6
M[AP4/.7/X8'9),<E#5P[0N#C1$Z^Q@":J&+!.16ZJS5X#*D:X=J4G#A2/H^I
M9T&^+A'F5 .!UL1?H4+?"EV3]CZE[DW4=<LEGW*UIL[FZ#7I >DZKOM#DG+2
MUIHT#SMN.N3F]X[.^;(Y-"3.*;?5S.IPY]OIX@R- 0->4:Y=P7/M4XYT(=\9
MUEG K?P4H$M8=_$HP\AX%J8/ZOMDOM^MF?(CRGZ\=EX#[<PGJ#XIH\?##Y1N
MT>7J.BP]I&Z$_X\EN1FEEI^N1I1V7./AS^8S%0L1BXN^*RM>E6P#AXS#W(U(
M/ M5^=!TPHCQ=@AZ-XWY*^9L 0F?U9Q;T]K)QN(%W>.XM=-XKLHUVMF\5^)"
M4ZR,+-=?ML2\%W[T7G[IJ?^'/\NN."\W?.H?L;D?<<*?P01_%RYZ'")/OI:N
MV4(BA&KQY5>TD9KF!"0M@<Q<MP^@GEBIS7_ZN1QR+T^?G8(:ZHK_404^T<AN
M_D-$9]FM9[N"O%FQ^/S+="VA2VXORTOQ'V*KN !V$N\2_\SG6_[QF!1T'[7
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M"]^+0G/I',FMT*XMA23'7I;T35G]0E5M$94OF?S&VR)Q8?F-#H-W!/XO,=E
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M4ZMXP(D9^>-!=4R\D']P)>8\<L"I*9C7B2)$]7X! 6%>N\UNYO>V3S#^XX3
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MDU0R&$2HNHBN%BQ1 HZBO*2"_@5_J<X+H G:4S:)DJ"]?Z,@(>28H.S"CTE
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M<?F*XL^D44R-&(I!6Z6\CG/ ZD,P#'BP06_L$PX3B0Y%O>$.G=L+5Z(^,8%
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M!XZ0>6@Y7@)MFJY&;*AIG%Z[E:MK9">$ 2'A+5J]]:'AF!O*T&$QN<0BP?I
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M@<_.E-#(+(E,#HW)P1*_=B-!=K6=*XF!A!%%O3QCPN]EW5Y@1\P+PC6C@Z/
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M$4YE^FV6'6'.5HP%">?.UBT5VK'E![+%]!PEI"RJ'M;%(I;T3>F& _ !>KI
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M _:783GBNJ0D.4H^PKL9:3A9YXR>G?8]-RW,AC@AE5%V':1]*=E@FT1#H&-
M#;ORINWD.9>^RL=[&.JNP+($<9Z!*BLUW.954KD](599Y;R2^1"L:%9=I<5(
MB<VLY?=GZM?QPH1XVQ;M(",)/?G]N&?VT<9=M4,E&?]MNQFQO7&5R?1BI+TF
M'7%[\H?F8VA$@SYV(67SMUZ'X@:>TI043D*9$+C@GL$;T3'$G1^JYACN-4G&
MQ3.Q[*5'O)<2DGJS1N=-< I8+'*L;B:!9-%C(4V+?'"3W-)FA!U83T+J)%4<
M/ DX5I1V'SN3V!V.#[3"*!\R,&OH<VD,/&%B347T)AA%-DU[%.9Z)X/^3H:
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ME [$%ENHFT[126 L ,-HTO9@R:77=Y":2NK&5Y!8A9\B%(E"G"<,,W[GPO%
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MH.1=EU?^U5]7W)[ WH.Y"+WS<Y*NN>,6*^K' Q.FH+4<U\S;Y@^/J@8(5.V
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M&'V9;+QN%"IBGLK=13! R'U /R.W (?MRF=-V/V2\-N6^_+*Y(1"3:6\+:&
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M_T%KL@=0='26Q8G;*&KS@^S!!:DUZU)U@ELB9@F_Y"$S6KU/)8*E@O[;"Q/
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MJ$5H WTTF$># 21^08BUL,!K<-DPR5.XY'W0V/+J8H@DO =4Y<0FN*.?4DI
MPXPD,9[$B#VAH*?7LFN!9W8/X2#)90.%-_1Y;&#J!C"HUWG [%V79@JN8[Y%
M%2\U' \ U:V98QMR"OTUR%CAC9]_ 8FSX=I_%MQOW@;^T6N_:X:@F; C!O^M
MBDU1<B(>DE&S]18<@BEZ+_X9_&ZX\I-P70%$F-)^PL"+18);;=Y<!U@^88.I
M28=UP0<&LN8FAJYVSY1F1OZ<L.*YF4> 0REG.7.D53O[#1YI$)L 1/ )38FS
M.483J3$^?T.Q,AI#'C ^3:R&&L_Y=<Q"LK!HF-*+E'&59;4N^ZI/;$PP'()_
MGYJ;I/=(!UY+[H6I\!-0_?WAY.(OB)@SMD=IPCEJB9J9U=0NHBTDR*G^GO/D
M:^?WU8T3D=N(BN/<%3MM4"Z">[>#HY=3<F_M"4WO,.'K2\]67HX*1H]ZGTO1
M6*7IS$FSV9;PH%8=Q- L9%]AO^2)$KW/[A@FU/1%^[.P]0^]@<4&G5^H.4%R
M9^J1]Z+25> [BN2YW)MK;^A1O:OMHE*'SJHEMV,+DCL]L8<:%<#0I26,!F<I
M'0[$VFXZ/D5D+8)J2!7F?NUQ^[9VF[%V/;4F5HV2&FVM;G;V3H42 %8-U6OP
M\M4 XKW4U7'=UELPT^W$A$YRM>NZW;S.4,T9@K4\X(Q!'-##M.:#-!2L@WP?
M&P[D<1 [#3V=>-Y% _,11]5)%^<1-R4^87T,,D*RF?#-\3JARYEU<KEZ1<HP
M]5'T%7,F[6V70$F)2.W9BARI4)/;I0Y1VF"2L/:MF:@$VT#*PY&/(V)R=#43
M1_$E[GK-9[UEH48@3_4=WWCNG?(KI:W?O_7;],;.540*4L*T$31)[_R.!ZB$
MTK#>QD8F3 /JD*4W((8RMY[NNF41'=JG-MQ]VQ@!0XV>"%:3ZO((!M**[< !
M,':-I9:MCU-^PXB:76= 79]*EY5W*@QR PME:VP%4W_/%(=*8F+B4 &A&]%!
MP]??$L!CB>\?97S_HWH?KZNIUCN#?GKG7A/FB-96U?PR-ECT"WX..-4#)["\
M=[:+%[*M$F9MVHZD1T[8MO.CTF]8D%2S>2(?'#=22/,@ME/(?D,=Y*C8:K)H
MS.I,I/OB*\:E66ROZ#E!(0W\AJ%0NRK"WOV.O#RD,,4CP4A6L<.7-&:>!5$W
M+_%.G!D#N6,>A0G$.P_DQ@.30>/)*'FY6#("Q:3EN&5A6 IY@Z\(PH9EOH1Y
MS0#50DA#]M1 7'+P%DS+4G/M%.=BR8_\%@,' K05"&<GY[2<)N']Z]E%9P22
M$_&WJB'WN;OE^2(A'M(SHT52KGLIZ5KY''Z]C:.S),ZI\ULX,?-X-&Z]T[])
M>(+AX*OK]C;:BI&2V7D[\I]QK"%'5&/DFG5X&%28*8',/"[O)G,R@Y<HW@!G
M.EAZ[=99VD)Q#]Z?F4E5\9(C.3ZRE\/QL=;<GR\U]U^AYK[P4\L1-HEDSF/K
M,!3% N8^.TTUIA_H)?HNL!+OC[0X'SY<H[P0E'+@3+IMNYIY;6^SRE-!24"E
MA42V<Q:2;@^]^.XD>WGKR"L-#[ZP+S^LG?$^M<M8"TQ0(I#.*:_N5:N2E:P:
M0][)PF(,IGX M$G$XJCYOHOX9'ITV-[F'MF=$MP2;2W#L$@A%%P/N8.XMV>E
M:[Z3OT5?;5VH:7$Y%(,=__(9G8$(36(+LP6P5$:&%&5%[5BJ8N%NG(</U&4G
MQFKS!SB0 =5HO6??L?J-]\X'OJ4=U-=^MP-V"!RH8L:TL-)NXLY.9) GNL?Q
M:THG+W3%:0=?A\$%L<\K \T>J.9"XUQR"WJ);7@@M>$) ^[7"2)7N*B3M/Z<
M'=2:GF;W>)^80\%D#2GLA0J9/@?18Z-G3,0" "+I!H-=S<1>^&)=U\&X@QRQ
MC&<R!*GDP(?X%-ASW8#(9H$PJX4MR.4GNQ04="3S?HR;A>Y%33L_D[RL"1'K
M@Y.D*G:B_G@&DY99O9H-P2;1H-P3+6BW9^T)6AW-U>7J^S$H0\@$^_>T:^NJ
MQ:(;F1G48W4H&.VWUA7%M<27ZX23#?K237"[#817R5D?C&_L8N"-F*(I7O@X
M.AT6EG#1"P@%A:TKMW"D+4G#QWE(?P^;0^E':;\ ==6(0NS;2 G-+QO_R@G4
M*4MH<M#>==C-4(<#<(_T$OIC#_U 6 9BV(.:]T1#7?YN&-W,1]D$(!R/TG+&
M5@6>L"+A&;V+T,7:P6@TAKF3&5L2;K@TU47Y!M'OW%9@/*"('^0[^X&L_(3+
M[2P]3TP?:0_[+IB?8'[]Y(4L8T81A=_;E6O@B ?]L!\-AC(1&.4/VP2EV)"\
MJ3WK*>;6#$]? #[8Y"!A0$E-4DERO*UNNT$3H!$Y#AG/N*P8&B7H5H?Q/'E=
M,-[('.>OLW:T*;"PAGBMEKN0_":&'YNRZ]K;FL@$Y^;*7! K[OXPDYW'0^O:
MF_:UR^0"">(W*09$LG-P4D$^CQ-YJC$4:,I8T43808S>DJ!B@0H33N7;LD-M
M% D[S5D994KWKH1NR]U87ZY>;C9M!TL*O$/[ILP"NS/,+#M">JASKO!7"5JC
MHJ(U;$:T!'.G<-+:SJ1LDS//C?AB2-A)ZLK+2?B(3T())$@GVEO,L>Y;+3VC
M@"1$-X2N8$+2B"U',5U@;6MFAB80ONWB3S0'HK!M'P\%*?KL"69:.!0CR3O[
M"@+JAA7!_4'.U1?S:Z/2)06KWMES,Z7_"=9<N )EMZ<'&;6= ;R@0CF9:W8M
MZ]&I7"1=V5;\\9',+)6VS)_ ]2!" .E49@R>M\9Z"40V9<!EP;C;8CF*WTB[
M0%+:+]1$OTT'71%W]BDZ1 7,2HPDW/:)F(]<'OC9)X_"?KS71'"(YE?*Z:%V
M &/&]=GD'ISM(*<.<UEPL"&YNPT^ZZ/I02&H#6Z<V.0L.=8'M>C>DF VX($4
M)!7"!U5_0!-)ON=,0T<J6Y9'1)FJ@N08  \656@SF.Q@T<6IZEUZ /ZL'#4<
MK9S+CD'*:M: >W-?%H%WV_4 9B&,?XAT8=HX'2+T[O34)GHJ-P0[.'LHXA1*
M"UD%3H(/-3!_23DB?4\$X#TQ.N[FCIY,O5.$0?JWO!WYF(1,(*P;'ZR4!]A5
M5M+:3X4TZ2MG_X3,?X(+\!<J9_3)PT@)#RY$"*.P'X1QMUTHB$'FBF-C8,:^
MBHYJ2S.&X0D"SR?%M'=Y/Y ^17MH%(T)%4$#QUC<[W-+V.+#-,#MM8TFAGMJ
MP+D#OBCC1*\G[#1,2%<9YV?F\W#CL4GL>1$#%!3L;EPP2#V QO+]D)6VN2)\
MWL0X4Y"J^"UO ;5(AIOX5A)L)KT%MTC2PR(O)]XU2\)#99&AJV6 NU$SJ+(!
MPHU9Q+T%/'WB9IH_^VNT?KN*B+BD-[I!L%@1Z$E[5??*O^%GF9OE#- 3FR32
MEY,'?5Y\$-3GT_ Y/T)0RXL%U++(E;WO507G[\M3-#/=?C9J+MZ.7R:FO7D:
MYNBC#X%C@@1DGSJ&*F\X1WO)/)?>2V5:+YM@8Y\D5 1.$6!.(;&1F 9@,WS\
M _C8;=5WXT&+HXET//<375>'/HQ99:$,IS:HV4V<6$D[$=0@DW=:XN^'M>+?
M">-$BPX Z>!LP7^-AK&N#8JRZKI<MYW@^G6]3S,T;PGE/@_&_0H;N,+M60<"
MEG(C>EUF@P8R:A,V%GX'^4^0TK?W?>EWDT$52+;&*NLU4.<UH R.?O*Q" DP
M_$0%6I<E7U%P)X3I@BO9$FXHU%I+ N%2D+:0Q@$.[YP;HK@77A6B%X@FM_76
M 8;>)[4J U8WE:EYX+DZUE&^!(GW*<HDWH.5X>6E +OWD;MBX=; -\#W*V+K
MXR?2K]FD?U?P.B:J O=O YF%\&UGWSI.$UX*0PD2!L?&0!9WRWPIA!V=V[<W
M#*G"TH $(6<U.$:0I2@N05"@:E7VN4%</M2 X6&;*W#JY/VRN8A;-B0[@8PB
M< +71XN>E*,<RLV"LH/3V']RNY+ M()=G1;G<2VUU*UE2Z]2O-5*MCJ7[]R:
M6<BBTX X=/+'5:5 GHCNKE]D6[#G+64/O/,+S<50!%0IR7;'^8F6L_%&S([:
M[U$6$X_\WN*IDP3I!C3_\(GN3L<90,R].G9.>O+G$$:^A9L_SWGY%!W]C\V,
M?%/UAU&:GS%+6Z+\Y-H-M\[I 1P?6=2Q.0\1,T*PY=3BFW[&1:=N(<M>U"IR
M7-FK?N,W$UA<P>U!N1FIK80+9+*Q$KPCPM+05E\(P1B)1RYB+<OR?\C+WP+@
M$2I%_2G^-*$<4M2%<10WA(EB[JG#>K+$N#/[#(''I79&F"-NB,K=NAN77;;L
MLH>\RS /10F#UD"7%+2L9XGM&+.Q%IU$)@MVXZ+0)\J[+KMAV0T/?3=H"C3*
M0J8( F5HM:>#V]H3";@K>?%+K>"LG,#]TB&W6)A0@KX5@!'ZG32O9!]F$>]Z
M0KOPB:H$&7K97>AAC#NEHNVVR%\M"_M1+&QLP0!O*%K9E&![W;2W%]?M;4Y/
MZ9>V0O5(IZ1B?/[DHQ>F;N73(V3MX#8FG0=N'(SGX4L />1M\;N_3%@:W@7Y
M$.N.9P 0);[2UZCKU4IODM])7"'AH@(6=7J!8_29 C&J9?0;=Q@J!BON8=GY
M2R6Y(\9S P*Y'JTEEN:CY/, Q0@9*0R9,;7<42D62A74)TG^RZU3WFAZGBCW
MI3&*0A^U]^>,^2N8)+G#RDS^=KA3M.BA527K (:,F][<Y+(9D*H\V1]<OBM1
M%0O4T=4.YIZR^8@I/]WM:!>C\!L0H499=6G93NO<D57!?$?7E=S-C!5[0*H>
M!HMOSL&0 Y<B,MB>8LY]!U#R>W@+<]6O)UG\^M@)OZ"\*GGV.SO#WTJ1@=E
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M]*848ZX^BZ1OME5YU;1]A9S<CH-L%.S2M):_2EWMW,5PC36>ALDM-M==BUL
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MJ5%J(^]U/G@H_C"C>:)!$HB!RG99T)T^0U_NP[# W"0/1>%D!1_"(18P+'=
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MZW\-56!U+<6B^@NBIQKJX=/!&%0JFUI8X7_]KY>:\@H7TSBE5?I0DY4-40I
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M5 RRW-/\H+'$27 Q33G\AZY8\!?D:4UOV<M[58N_:4JR][E3?1N"..]G256
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M5O>YR(\F]Y+6BHBTQ!WGXEBY$#>3+(1>Q5TTO<K#^R[.\L]3LC"QQS68I+8
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MO7<C0V9>G<?+N5<1P<JF*4,F>]?RB'A"N<<[MISI3/@2NN@-ARGPKMP@*&F
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M5)#9/L!%P,+NHC"6-3#>'[^\':,VW"ST4!>];(;P!WD93*7LD0VN*IB]BO?
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M=2B0FK=[Z19^;'R6[OK._.6+..I.<TN)NSS\>(8>VS?F(N^Y^R3*V.&&D,S
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MJ)<4@&H&F$*BO !)+9+C7P@)"C?4!L_XF7@"7UH2*E9,CQ(I4V\,>\?VLFM
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M"G4XV=._Z[>76U:WZM+=45_\L";/.+OB.UWW=7MR$'%#1[_EU^>8?'_P=3W
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MLXPJTQU.?G%?*J5+'SA^P5^P<<UC:&)0T'Z$%]T:P(_X$ %D),M?[AZ-*VZ
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M'VUCL^,D:@.4U1"Q$[?$RC&F!@GF*M@W&'TW&?\T8H5]:@ONB.BI&^";HFV
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M4DNG<6#4<-#TAH.[8#*ZC&*!_O+E&3$#^T_0K[YJ ,K&T%,\0KA;J])!@?8
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MW;0U%SG1\4C5HSG7X'5%!U?9N35K[NP%>LC8/79U]8*T=]K<TM+VK35KG0V
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M+GG ,NI?Q8TT_0J"[JW#C>JOD!JS#1VIMQ$S6HK50T;%$SDTZT!Y(86F"&0
M*?[R]W=VZ]TK0%P)AW37[3JL&,=!>JY5/&&EP\T;6$/KX!>5WR6Z[TJ$[P#'
MC7:[HO\/P"TCLE^5$'<KGPR"_8Z<#NM@[[V85!Y.8S GXPKZM/@DR<^U__"&
M%$?DLUJ.-4B,E5&,H:N&9%;)B(XX&W$V<U%C#F>K$V<K&=$19R/.9BYJ#.%L
MI^C$CZP3$;DG%E<RZB,61RS.7-08PN*NI(.'>%SIR.\1IZH*]*_K56W4NY5&
MJPZ0;HACM@X6 8QKPW^]O(-R>%8WR]:XYO<\F/*CS>AK$_P\T_>]*Q2]2@W]
MAA+J!6!>R@F, 7R$3]D!Y G:^P!MDV!++(0.-4&[=- V";;$0NA0$[1+!VV3
M8$LLA XU0?LUH+T]GU;JY<E#43UC(P=7OKN1G8.587S())_7BKKH2#K#Y%CY
MOPTBZQ=U(O+_+0P"R48>O*&#VB12W)'$.3R@FD,^/^TFKED6.60.HIKU2K_7
M)AHBQD1 +1E0S6$BQ.U+PNW[%;O?(A(BOD1 +1E0S>$AQ.Q+PNP;=J7;?\NJ
M+9-P0XR)@$I W55^.3'K9S/K9I?.OX%X^9F2E\N-0-5P,KA+F[52'C.%_TT1
M0+L6] 3MDD#;)-@2"Z%#3= N';1-@BVQ$#K4!.W20=LDV!(+H4--T*8\YETC
MR&SWUZH\9G(V&\.Z"*BF +6$DL <3M/J5NQZCTB@W"1 0"6@E@.HQ*Q?PJQ;
ME5Z+,@Y*3@($5 )J.8!*S/HEN6&51H?R>$M. 014 FHY@$J\^@6\FDJI3<3*
MVV;Q4K!C1VC^C0<\8KZ(=3!W[ 5>G&#R[_V&K<$I4FYBO';]MOJ$! .00.K$
M"SB:W:O4[0UUBM?$[N)X Y.0NF>T1J U@(T1$@Q  LF2%\B27J77Z9B'7!(E
M)$KV ;0D2DJ%!!(E+^LCUNJ;AUP2)21*]@&T)$I*A002)2_Q<-6;YJ&V?(+$
M'(2^<JSM>9%2ZI7S'-3=A@GSK7"A8P[%M(T1:!L!E?2)DH"?-(D7<*].NV(W
M-E0F7@>OY5,C2DE?!%22&8<+?I(9+TG7;%:Z-LF,PZ,O BK)C,,%/\F,EW@L
M[4K+KIN$5Y(9)#/*"E22&24!/\F,%\WB,0FGY9,7YF"2!D*4'(%?PCBVAE$X
MUH&N,-@PP$7),R;F;1!H7PVTI *\@.^\;[8J=G/#!GE[3 _F8.@#X69_>!6!
MEL2 B4SF?:M5:=MOGSQO$HI(#)0+-R7F501:$@,F,AF[7FGV-G0*$CF82 X$
M6@)M^4!+3/P%3+RZ:;KQ'M.".=BA0J32HNXR&?'(\@(G'&_8NH\2/,J784#@
MIP2/LJH"5'AT@+1%0"5Y<;C@)WGQ$GG1(8%Q>,1%0"6!<;C@)X'QDKR!1HMJ
MCO;$O;5AA@&)G/+Q/ (_B9S2BIP^52WMB\2ALJ628_"")Y8?QE2J9)H$VUH?
MTD:MT4:6YX;3@<]+ID>80R@_F8Q&TD=>6D&U\VE8R_!+J@FEVY-$(XE&$HTD
MVG.+P1KM70_E(HE&$HTD&DDTDF@DT5Z*61L>WGK[NK9]%&@E9IH$6A,8&6'!
M!"R0."E9A=T^RA)S,/IH(!+^90!E\7$5/']^-CCM-^=<C4TXU^:;[KS)IDTY
M0_)B7-.1E\!R'5CH-;_GP32M%<PO>Z?KL@B_&_"(VQ$P6AYS%CDCBP6NY0)Z
M_7 R!FC!#P+5%JR31Q:LRF? L44?3XO=19R+J\*A]5,3.*D%K_#%3_"8G_JU
M1OK%,(RL!%XT@]?$%H>GN=8I=_AX (]MVA6K46_8XC;X4*_@@B;<23Q8R:QB
M>3%\X;,$;DI"N J+54&PQ!S?K)<HNHSB.SY]O;%."BL]3E>JUW'^>]7NML4+
MX6/+;EB3*+R+V#BV ,P B <&R_S!G2F^U NL?[)@RJ(9+,_NUW9Z\K=USA7?
M/+2#+@]+=H "?0#@D+GP"QXP( 'U,V ^G$86CQ-O#.</SQL>GT3,;HQY=.\Y
M\!:X9\"M"8_@>(WAO,!#U2'+G2QX>H1S'A.QC#'S!$FI!SYV9D&+'=>L96=N
MA3:64YCL-X7P>9 1-1)T1>SM)!S#FF>PZ2J+8P[_<Y> IZ((#\=@1AX/'+@*
MGCH=,B>1@'.!!<QBN)[?>^$T]F>6Z\6.'\:20O&%-7A9$'L 6+B!J'0YE6:&
MD9ET:C=:<Z ;I0ES$W;'I6E194/8Q1'S'^!0?'QG_5)Z/78C"]RHD[4^_]\=
MCP+. WQ=\1*4_X*?PV4(B#P[GK H"7@4C[Q)D8^-F<O%%W$"O)K?>0[*"R]&
MK@V28,*F<<K<\KH40WW&2SQ8D%9#ELJ!5!E#Q@^RQ)%O"X.[$-F@$X['7H)J
MR<G7$PM,Z^_6")25 ><!_C;Q.?Q6LXYA=_BHJ9_HAR^L<IX_.VB,NW"?,V+!
MG9!^J>3+2:]D!*+)&@.81X_K<OC$NP!0 ]J@W:FU4W50J&V/JYRU\A_R72LY
MS(_#5--QE:J#:F^FZCCP, ^N=:48!N&LT(-XUHI+&52/W/%$&V/5L=S2J>H=
MU*E:[@/(D>]ICGS/YL:8DW>@Q)B7_&0(ADGX(,@+'896/!W#GN 1L3".5G)R
M/='^:"\T\;=1$K<$EG5\HAHL6J>4P%$H5N=0>N?QU8#^H_I'\6L5=*=PFAP-
MO1_<_?C@N<D(X"4 J&X0CJ))S(]B#FH4J ^JMB57^G(/JLC \[UD=J2O7E(
M(Q_>ZM6ZK>[/"*ME00FU@IK=>?J:YE.7]&NM=NN):^JU3J]]H,MIVD^]JE[K
MVUM8#>RJWWGB&I##G<83US1K#;MXS2.56%*POTY7PL4FH)H!K!7-ZKU^,&NY
M9V CEC0(?7=A\<_E1Z]=!5DZ5#SA0E@'RD_$\ &D^,O?W]FM=Z84$Y<#-Z^A
MLVU 1?]&Z^=LP?HQN[:X=,A^54+<K7PR"/9O91IM0&;OSS'&$TYC,'KB"I@Z
M#H=#/N$1GA=VQ^.W;#M"Y+-:CC5(C)51C*&SCF16R8B..!MQ-G-18PYG,[RW
M7.DP2YQM+X!,G*W<G.T4_?B1=2*2!XC%E8SZB,41BS,7-8:PN"OIX"$>5SKR
MH_:+Y4DZ.?4B[B1/)Y98@YE.4CO:C!:I[/I-I-EAS<PL<:DU09M8"+$0.M0$
M;8)VB:%-7(7..4&;%!-B(72H"=JO[Q)+G41Y**IG;.0?4\!"VM?/V36"S':9
MG?]>[3??,J_ )-HQL=_=7@+5G/.^85/;E\8QRR(XS$%4K])LOV4FITFH(;Y$
M0"TO4,WA(<3L2\+L6Y6^3<R^Y'RIA!102CB;!%7B_R4^_>8@JEEIM<@)07R)
M@$I )5YM-J_N$J,V$2UO.SN>XC6[B]?8W;>?KFPZ'>Y:#!%H300MR?D7<)IV
MI==J$37L#S40: FTY0,M\?"7V&H5N_/V<UY-0A!1PZZIH<30-@FV=)!W?9#-
M8>OO[4K3[A(Y&(N@#9MX[C%N2LRJ"+0D!4QD,N_M'M&"L=CY\,H!F71/%(K9
M72BF93<H&&J,("*@F@)4DNLOX"N-2K^W8>"%*, 4"B"@$E#+ 53BU2]*7.[T
M^T0!1 $'%E2APVL*4$MX>,UAW^^[]H:YE'M) .8@YBVGH)F.E5*R)0(J\7JS
M6,I[FQ1U$_'RVH$2JEPQ \_GOU?K=4I:,4T0$6A-!"U)^A<%4#K-#>.R1 TF
M4@.!ED!;/M 2#W]91[!6DZB!J.& @RQTD$T$;0D/LCEL_7VCTMRTT^,>DX,Y
M"*+*E3UB501:D@(F,IGW+?(#FXL=JES9=PQ?)B,>6:X7.R& =@8+9'=<3T2.
M*4IJC( BH)H"5)+W+^ WMEWIUC<L5B42,(4$"*@$U'( E9CUBTI:VNT.40!1
MP(%%6^CPF@+4$AY><]AWKV*WJ2E%R2F @$I +0=0B5>_)%&U024I)N*%*E(.
M LW'SG^G7NPE7AA8X=""?4RBT.%Q;$4\YBQR1A8+7,OE]]P/)V, HL7BF"<;
M1DCV.'BY:]%%H#41M*0;O( Y_?4O/QIUNT4$L4<$0: ET)8/M,3&7Q;ZMC<=
M;4SD0.2P%Z$5.L@F@K:$!]D<OOZ>&+OAWAVJ9-DC7D6@)3%@(I-Y;]=)!IB+
M'BIEV7<,7Z^*U$QX%(=!P'WQ"]:YC#AS+?YCPH.84Y&+.;)K(Z .X"<>9?ML
MUV&15ASZGFL5#QZ!?Z?@)_7B)=[#=J7=>\L<D2?QVFBW*_K_L .B+Y(9I0$J
MR8R2@)]DQ@MD1K_2:F[87H%$1HG)JX1$4THXDQ0I"?A+2!#F2)'.&Y<1D10Q
M@[P(J"0R#A?\)#)>(C+><I3:'LH+<S#YMO5/&P7*"(&/(? V3)B_NHKI94&P
M/8Y<[UJ\O0"T18;8J#7:R!#=<#KP><F4#'/HZ">3T4C*RDOF2W0K]J8MZ5X5
MO>736TK,- FT)C RT[%@#M<B>;2W\JA5Z>V@*SK)(Z.89@E)J,30)A%%(LHD
MQ!HNHAJ51N?M1S>1A#**9Q)H3>!CA 43L$#2Y 729,-@(4D20_'Y:,P0_F4
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MI0PGJB&J,9YJ5  !<VRE8@3DL=(!E@\*I6;\QD&/RM-A&7&%S%]^X#IPO"3
M0Z1&I&8\J;$QYFY+:T/DI6OSN9*E1(@DA(SP)$T]%K:,1\()_C@5$>$0X928
M<%)_EZB4B(1H&8)]HV0*G.28.U-QKB<L$?42DXGO.=*TJ:@@EI)(TOS1]_(
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M]8!'@+< DW>_OK<_:+0MP9=<A*F@>O=KUL;A)AUODIY"V(_Z;X$]J,."9P#
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MP.&20@.8]5&]B[.X)1+NO1()6Y[[]W>P\?$WN_,-)<$WN_[M^[=X.H;;9V]
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MLUX=.)U!M>%T^FV[7W>:+G]G!6P,:W2Y=W0\=;TDC!#KYR\[XZ\)[%;FB"L
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M>VXQS /CDGX8L,<QK':&##)O>%HJF<*2R12K2,QZCT\YD<_X8#%QX2EW^'C
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ML1M:>Y?DQ&-HK9YH*4%J1T=%#UQD "<</^;Y-OT)Q_.!2EPA1UC+) +8JI'
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M>;TO%1'G7?RQB]F99^;=S&]?F_Y^VW:M:Z?M\OV/%Z^^91)\_=G4/"-:_;5
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M&YP^EKVA@T$ZD8),&&.@:3O,#@#MDX6V'N*$6/"IB:(S.O)R>BAG/L>"J9P
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M$2DC+.*28*2#EDABSY0A,01_8QGX@(+V/W:ZBK?KV5U+W(<J2@..J(4C %0
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M#V=^?A9_F7?=U]<O=KF3Y+\^6\C(^(00L<WM7G=0Z>OIMS^ 57@J6@7P@U4
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M[DVW1M?8#SH.MRL]HVL+$*/=%R,*8C1&,;K[1G*@/-M0'I 48+;*FZ8>9L/
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M( SHR(#SJ*9#R4#3H02F0[_2:\[=TN8[[B="^\KK;#3_M6J[MD2%D*6LC,H
MVAJA':%6U,-"]RN%@@%1XX  : ':\4$[0AK?J9D7F:(+/EJ4N%'E\#N"M- )
M<2P$,2EXI6XL-;G+S$OQO7O%Y"YB>+&8G^U=&=YA#G.=2 UGP>Q,]>[E (%
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M_-):UT[[J9@2$J_.!HV.(<E:8ZJO=FCK&1V/O\?J"/U3/<UUOWAYAT<4D!5
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MFMV\'1,23?!!84Q(15EVIB8\N,NF"17T:]7NVLK"&J:I"<SPQK81Z^HBIL6
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M0=-ONRIAT44T(8M-M#HZVO@.QLM=CGA[*,1?]*+XUW\;3H;X3O3TQ<,>NGT
MRL=XZM^'*+/HR=QOW,<S$N[WOU?SX(E\F]I,@9UZEMR9O\44_R:QPA]^C98P
M_C'SPR,ET\P/,S\<]_&,A!^^AQ7&?CFS9?%&AYZ.T4_T*HQ6W>2&)'/#8R72
MS TS-QSW\8R0&_X^F]_*#VGFAT=(IE_PZ[:AGZ]Q[)*R/B&L!*B3B)9W.5$
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M:CV+]X/;;R/NI]7BO0HMWM^\??GNP_\76[N__-^_O_KP]K>7KS^<%*]??GC
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MJS#.(PV?TD%D+>K Q0"D]-10 <I02.POJ4924X^D#RF/!M=4;;D'?&7@?Z&
MH YC$"4H4%K7&'&M?(4=%E7%#J!%4<'&$0K)PPV/EQ_E@\@'D0_BR"7T>(3N
MO_R//TB)V4C/.,NA[QK%S[VE]DY?<7IN<;FSPU1VH8U.8&7 C@FP1RC9'Y7M
M+0VM2XEKQ+"BB'E?(B480Y+5%AM956X[#?%^TVL?WO8^J? ^,^\SHQ@3H\B
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MIE"'C//SOO3_4GUT*=4?*0]P?J:FG]55\_Q/Q;_>%P?&D6%^SQS]49+ N.7
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MP2<Z..>VA'NS>GFXO&YMKMFUM"^_;_VN59,*EA-A%!=N>3Z/K8% 7IE5\'3
MSXFJ)RFST(:,O%0.[@!M;:PHZ9TBP?\;J2C=TY-Y<GEWC\C.W>,CCU>SXF=G
MNCY1!&^Z:^$]J@&&W;2")XGUKF/ H#0_9'\"G=AKD6T+"'35I'STO[NKR.A
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M-J)_$*?NPX6G^4F5BYS'PCIRD?,11J=_RJD<HY.P]P+LW2=9Y",X^!%D1>C
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M V9[&4YUL7*WI/Y_@=+%T6H2&J#TM:@B3XL7;W[[[<WKXOV'-R_^5W;=?"T
MSW8FNN,HR$((<MQ,]&0C13FD]3]ZI1'T/FX\J1'C3B F:PM"@K@PWH;51&A"
MW59(E(B:5T)@Y(@M$1.&(0F'BTR)%7:<:V_$=<8UR-#XRN9LY>T]5*HR=,&]
MM1/N.)$MTL2CQR^'%5$8.X2U-HA5LD+2$0[2D0OMO'?&;\TFO$\9X$/A%Z%'
MBU\WN<-[P)P4\/NE,R'!;1HB<;XM7WCT6,F<$(P+AC /"6H6.!A8R:!_45M3
MX[FC;BM%8B]<[TY-L6['R!OHC'F+1<604#6LKJ(*2<5#RITV5%BP[,NM#AI[
MV='=VV'=OBT:>F14)R7]BAE>(R6\)\'8F?2UTZ)"1(61>+5E"&P=@30G6-:R
M+JG?ZJ>_%\:^+X2[83J/E\Q),,IT%1K6EF"4"5PK1#EEDFI,:/4P\FH/G(&>
ME)*?R)(>/07%M-"8.I%\8,,P0:J,&_<&;C: -F7NT_;UW\="3Y5ES[Z=O][@
MR+&FPC4%6O8Z&$4>]%4A8\M,XA0SN@1U=A^.G ']'V.QW$VZY;5*G> $CT6=
MP2/N-M(Z-NZ+%;$A\6(Z[>I\FZU:X$!"75B[X]E;Y<'-\Y0^%:*#LWDQJ.!(
M1: IEOC%LK^-U=U6\_=Y?G/%7ZZOVP_-]V4>N\G^V(FDRSOL@\8G(9\O8OOY
M,$]X6$04O6P=WIT6K^?W23$.M=/&Q8!3^!#SHS)R?N69#W*-QXZ>9SZV?5!7
M7:AQ>1.^;J6S^K;YPS _]++/K&Y.VDX%%RKU)5!-XY9;/1\"XO>Y$.NV$X,5
MW%CZL^< YI$'KXYXT^(Q[GDLO AOQ%=V*[BZ9H8*7B*FO XS[332JI2H\JZN
M":>F++=<7_>KS>QBDF]\8 !NUD2V\<Y-0S;#BWFS;*+E^Y-JG'V;F%)S4_PR
M+F@R WOP;'G77?PG'NDQG:;H8O'3V?N7/X> X]N7K]^??7CUYO67-<9OCUVW
MD%3#7GUW@^:]#H'<._;\U&*GK_H4GA+SD]UY0[I3_@8M0F;VFIUDYY=1O,(#
MPJ-:&?YJ%G)L@J+Y=@K;3Y[^D".G!LE&BR[9""RKWHF1_!8_P*7-?.?5:;%I
ME>9Y?&=X1_K"/O^Q?=EEZ%L$:D$JL%&SKD_4#_C'-CL_MBVY7 $0@"EL:LT3
M8$CQQ7!%2H.^"JZ@2;^K=%GW'#A/6/E[E^Q$1LA:&;$NY6#^0 :O#74U=@XF
M8YA=V;W@=)<^]SW]8%VKPB>LD]^[TUFB)2R3 ^XKZ.DR=+\*2!T]CVNBO/5!
MFQ38/J(E08)WD^ /FU0#EVU0S4E+-MH9(+HB!DOCS?,]]#^YP?V%:^RDU099
MHBCP]<H@153@\-()4VMOJBWMP&A.52BC5@S^841RI"LE4.6HL7";$+78R)Q?
MB_VA8G"V6/S_[+UK<]M(EB;\?7\%HK9KMCI"R<Y,Y-6>Z0B5+SU^M\IVV.[>
M[4\3>;4P19%J@K2M_?7O28"D2)&R*8D2 2HGNCP2!0*)D^?RG$N>DVIU$PSX
M]7(#&9Q^A8U*Y'FU(,-+T#SKX?#4(@T4QO3,F\O+D/JW=Y8_6YXJYSSU [/?
MS5=H(VE+M@5C<#&$1ZS8G>9CT^K[+8*6ZFL6S>R2Q5D<;$PZ&)3\N?DCK%;E
MF\0!"\6^_HRKQIM-=P. G7/+,FU:;FT]*3,H_G/\-7Q)Q[_6;_:U&@Z72"<M
MY#.(\F3]_&AH2N\62VIL69B?VVS6=YTV)JVO7G.&%V_8W@J 4STWJL[49_-?
MKXS;_$DII!ICY4#)G!3A_&(XO@S)^UY' ^G,SVP(:UUI=G<H"Y9MUQUKZ)KC
MT$N5[^=%W]-5MCI)$>XXFS1GI.<<TG"O#<!;/FR3E4%Q"LRW@#WCY?=6N7N;
MB+6QG?5$'+#:U0H7)]A::5F&*ZM)$;ZE+KA).$'4ZU8TKD)-6ZWI>OA]9O^[
MB;6/UQ]_LSYHT%SX=@%2<5*T"J:A7]MFLSE3_K4"@ G>Z22!RDFR]BX=!1H.
MTX]@5&*HIFW@%/3:')!NQ$_;DZ7PBFO'O=-]VA/?"<JFWYNUFT:II 1L.C=^
M==>V+>5RXT#CI0>9=&Q]?*U[SGH8^8NIADVWG]AT_)L_>)4><SYIXL/GX]1*
M\.PI]$Z+E(A8$HD(P!: +B$@HYA"+!+CG&<B!G(=Q/A (L: 6@CV#+Y#2Z2L
MMHC:$#4W-!"B-XJQ[XICWC8-9=_%>:7:8B-?CR=_2Z;DGF/ERA/PO4^$Z-VQ
MF=LHA?FYOH7I7=$1W_<(KPD&^-P+B'&R_K>&/T#E)9.Z!.D)+Z26G4N0?M4I
M=X'6YZ8^-LTYX7^C).VPIDE(LEZ-KG44OK=P%_,C1K&:U.#" EG@7DVJ-5;I
MN%61D'#A9Y,%/ (OO!JG]A&@L9I@/:QI]5*X,VV5]*Z+O\J/+EIB'+V*X9JI
MZ 5&)I:@+M+A8BV\15$IAJ4G/K*-ZB?M DM'C)'&J>B0,P+?T:!G:"FQ]L'0
MJS*AQD]:50QOYBRP>NKXM-F?-_/M>3-:J)65VH*;BJ6^<_+X1^JE;VIE>?3X
MAT*WBB[F4E6=GP=? 7@87J9\%[@WZ8\KY3W/V_A;:K.=^NK!9QN/,?6JFS.'
M$*<^M?"N 0\T;7Q76G+/I>Q*264(WU,(OU$%UFU!>0(- *EPI;?<(ZF\3HDL
ME0XB1.2DHBR604:Q,92(&DF45A1):FG*<D1 AJ5$S%DNI+>&6?Z=ZJX7YJ*:
MFF$+]3X$T!!?@@>%_GHV!1V\4.OWA'STA')\PKXS8[";+'>3)IY[F^LH*#84
M^X&GDW!+:F^>U'2+=%HLMA:Q66"USV$4)DW[B*I^L)"JD2$HP%3 9#X@%B)#
M2@J*L+.RE-$*PC:.AH;(I962(A+2L7QG+:"$&!%QOL2<>L$)W9LWTOSSCY9F
M[QN2D<T^.P @K]I.=I.9XG@V:2!LW<MXZDE;'[.!%+;5>\W[72RC">D[#9NO
MNCR+",D#\K:GT3E!*+C))$%:%Y$NN4:V+$54H!\-$??A[39=T #9YI5>7+WS
M)WCE7K)I*E_M+Y=N5&6MEA.LU&4U0]3N46V0R@:VUSGL,MUL*[,JRJTB7" I
MFNZ_7B!58H:,,M3YB!5Q&UVA[G1&WYT%/QM>JWM)!2]@]C=5\)6"KD^'P[%K
MKI['AC;4>5,V\^MELG6?FCG%^S[O_]20>M*DTS$ M*8I]H+,*7@,/[?#ESZ/
MTF')A5_65#PTN]54CU_,QU\E-Z\>NZHIGF@F%Z68R++3X#RAL_:,:]FC:['E
MJG$<V\Q67?S2/'T\J\';K/^\A[EQCU,8MZ>-W$7D%S9N43QXL1STV,QY7*QH
M_A)IL<]2L[W%),VTGG2P!#]O+D=#<SF>39_%ZEOPS[]6?GKV3#5$G5\/;S8T
M%W5XMABKLR!/$\UO;_W3U>#)Z;(;2XH6VFH(8/39XAXK%ZX.#6V?*MB@Q.3G
M1-F;IHNV%Y(!W^DJS>@NUY4#KG=Y+!XH(ONVO-5!H*N;,Q>%MDAU^Z[\0'7=
M9HCK%N'9:4"KVD68[S>?=7L[IGU42.Y2 +PIR[><K/LTMN,A2JTW"0UD37_]
MCY\ R>^?Z.N#C/& 8UAT48^'E;]YH'<_MN<1RHUWV>)_IJ3.JZ9T<C4@>?>Q
MU0^SSYOSJGNWX0\NC]EL9;/5_^UX9+-%L]GJH]E:JXO--JI?PK?_O>D081_K
MU&/6:4>HTW#6:?W3:3_ W?/HZFV -\7RA#(,5*<-L^VRHT#2G?=BMX#O_O5@
M=P+[J=2B.6333& (7\)P?)'"]G>7O[OLV2VMUZ&V[4$Z%63R=D\J_G20_=FJ
MP3NS8TW&YOJ6'579F^>^M*4ID<!EB9A(W>FC=,B%*!PO=0SE1@F2=5AJCCV*
M431#O@BR(3 DE \\*(Q%W)@,,L]?![\]>?VJ3:K>:2KL9L4;H_+&:K>L?;)R
MS^0]"O)V1[=FV_D4;2<UV&KM(RIU:@@:I$<*^Q(9+S3%F''!-J>I.["L(< ;
ME1SL+1@M9)A@S1AVR2-85L,.:#NEOKF7?=8]CZK:]Q]9N%V4*,<4;K.7?VO/
M"[1GW:\.<%5?0D>CX<<K.(<*ERY9+&_!P;<@0Z/#0B,<"+5&>^1M&@$A+ %H
MQ"EBV%F+K2?<;<P.]T$H@X5%G!J.&%46J>@-$HP1K C%CFX4U#]J6$'R?8*C
MQ\K9=(GQCTH;9<(>7,WG+3CX%F1+>UA+2Z2CV#".>* Q=2?B8#6C0YB4F,48
MN;4;00AK*0D:[*LG/AUW*S'2W*162)P2)ID7VA[0TI(3C/<9P,^6MK\QBVLA
MI%6R\N9F=XIEK![UXE>DZ]A^=4?U?&J.038=&;8=5YP?B<R!PHY"@'N0=UT-
MT@'E20WZ\2P=G.P7&.N..!TF772+K<R@[L!5&0H@6.0.P;\*,5MZI"T7B$D3
M S/.";V721R/".KX"9$=J<KXL2!D;)>M^#&1-UOQ;,6S%7]L*^YD*5,G0%26
M(2 6HT8F]9$NE58A.EH2NC%X78&A%AP;9*5(#:HQ1_")1]1K8D5TEE)\T-",
MU-F*]]C,K$9HX.?4T*;;?8(>AB3 P.&;&\[\G=_^ =IA/=X!M;MIN=>HVPWH
M"%^?AM<R^=DR"GEA/H=6NR"3YIT^,\.OYK)^_E/QEZ<H W]9%8*M4U1[391=
M.H-M$J7+;]P=24NM\=H;!(\,V&>0K"*::E)\,</9<AS-^I2%13>[E8$#S52!
M=G;?[JIEU:R31WWMC:[=3;G?ZM'=;FY7,\OQ3]O6>%1XVW#,J"PM4L$RQ+R@
M2$=K48FQI2YXK[792Q?/N[93;CO5ULTDE_K-J.VH_'_F<G3:BE'SQS3 [C6(
MTS^2-*T#]U$:/O0Q=9JLW\731EN;EZE;X*2=F;N$]7@5UM.?_BH&I.Q;#_ D
M7L?/MX)393AP:[2B1(Q'T*F>621#*9E@TFBS,93H+GYB/_FV'/#>\>T%V(@F
M6WJ2!N%>M'/0AI>#XH;I#^V H;;9[&RTTEGVQ@ZQU@R;3O>IL_=LE-K:IY%D
M<TN;U'VW*73\0JVI(<%JL"D!!S LK@1C1 (*F"H04*8]W3A82Y447"F" O48
M,>48TL >R&$"-Q/"1J>N"_6K^:C'CV'RI7)ANXR_'<]9I!'GNDGG7^\=_78\
M_6> E2QX;Z6W>GUC[$BLQ8[X]V-'>D#Z)LCP^1"6V?%5MB,KJKHIQ'#3=A*V
M76M1G48O/MQH8".5P0:X53 "#*\ILB5 L$ ,M:6FL4R'VNX/O!Z,UUN+]GH\
MF7^4KML^Z2)Y+)UUR^@@!6?K_HT.:*<>Y'%6W8H$W(9D^U8ICC,C91"HY,&D
M&>,2*>P,\EZITN%2 =#=[T2&[=IDU0J>)AA732^_.UYA.1_:GTYW?9'_(IU5
M*2G2LS)#N^V7/SL'GH5;U,7Z4)DY?5;&+\UG<$_N'NTYQ$MOX/-GQ2W4ZD]K
M^;#[32K9,B-E9X;J<BBS>],?=A_V0##^[K2'O<QV8 "6J=II+ )1NUR'!T+M
M,F9!#W2YRW5XL-.0A5V71P;E+J,B](!IL<>WW9UZ$N\TR@)80[(#+'!G^O&=
M1G)L7UYN,IZ;C/=_.W)#WDYO3T<:\KY=S&K^=SLI_O+7N0O0_4-HO=OOOK8=
MSX3.>N\(]=XBK8=:O3?/[K6_O/H6)JZJY[^]!P?XL;L;9868%6+/")T5XO$J
MQ _-,/IJ]+G]=64&=?M!FD1=_)+&K-5_SIJRIP*<-676E-W>GHYHRM//GR?A
MLYG.E>,;4(;5J*Y<^VM3$Y:58/]D,X^XZ59:?I<,YKO9M)Z:D4])6[.UYO >
MTZ;R.>\'A129O%TE;SY0?=B:6NN,%#ZDBAXN$>/2($.E0L;Q,FCK'%'N>E%0
MQ&7)B-6(1BD04[%$BC&!-&=!8!I\2>.^"^57M&^;1EBKGVT*P^O5PMDW;U__
MH/6LX/BDU*(;)Z^[Q/1'J&4R>9\T>;NCA/-4FR=I9!FSIJ061154:BA+D"K!
MR!*AHQ/<"T(V*F\/;&2O'45;I*F:!-7>3J$QGJUO-@^9O)F\'2;OL1O/&TZ+
MQ."9"R$@'4TSD90AK95'0H5@25#&Z+UTVFILA/VQS;*WMEG+3.)*#C%E#VG_
M3J&I 28_."Z15<[QJ)Q,WB=-WN[HG>RN/D5W55JIJ608>2>2ZTD-4L1XI)6)
MS&*%&=YHGG)@=W69&-_2)N7.W;69N+E+2E98!^NQF2>W=MUL_*UM2Y>'QW4.
M-67"=HFP&>@<&.AHR3D!O$*9(8A)3Y -)B*C2F4(BP:7&\GOPW<W_-MD7-?W
M3'^7)ZSD)T(=?"9<EQC^J'1+)FPF;+\(FZWAH;/4-##&)(HX@ L?0D0:>X5$
M))H:Y0+3_E&L87V?IJD/D:G6 [G/2$!6.UU2.YFPCW!2J(>ZO;<,G6F=E4=6
M'IFA,ZV[FWW(Q_4>VL=9^ 'WR$+DC%VNX'B2Y.VA$>B.XOGEZ.=P,&X"9U$C
MK](PCJ9=<@@<>2V,+(,.RH2]!(I2)^PW=3T+_F4SX*P-^#2QFGJUB_A2U]_W
M4"#A)T2I7/31+U-_CSY 1[P_/;=!F;S9Q!^Q#?7>!FF]13BJ$C&F-%+$:20#
MU8%@9SR+G4BV+&SK8^9;Z$#B;(2?@!;*Y+U=^/1I*?R>,W>F>%8G69UDYLX4
M[U-F)I\+>3A7Z$6:KSP<IMFIDQ2'BZ'*QT2ZJ*;N1-C=NP'G+3CX%O30FG1'
MCQU_B@=C'3#W&@DN,6+4<V2T#L@8'TIB(K>X$R=C7K=&9#:YBD_=,P?$U FG
M]-#5OG?HLMTE^>TV#'GLN1%=WYG>FKM,V%P%>)3F5ZM G'0$:2H(8D(Y9)05
MJ2NS"X1*(_SCF-\?98>VV-]'R _Q 26'MM!=$HBCTCV9L+FDOJOAVTSKCM.Z
M2Y3-RB,S=*9U/[(^U_)RJW3ES<WNE V:4R\I@OEM#KUAW0[,_'C$%LEU!1W%
M^O<@[WJPDPXH3\%./Y[98<B9HX[N1 \-TU&%B*2.ANL(6QM$ZL^N&#+41V2\
M%X)[Z9TMKX>(J)*"*T50H!Z^HQQ#&I0J<I@8$H2PT:FN#^[B)XK2DW*O#5D>
M5&+ZEZGIN1++Y'W2Y.V.XL[=TY^B8>;..,<)012G[NF8660(Y@@^E#%HB1V6
M'3/,CY"RD0.RSUZC1ZR_LGG(Y,WDS47VCSGLRV+%2F]3Q8 VB/D@D38E1<8H
M+H-FCJG]M?[,P[Z^OT-J0&4>]O5D5$XF[Y,F;W?T3G97GZ*[2JV3AFN!L"4I
MCLPP4H:6R'#P4XU2I2]5Q]S5!QCV598G5.9IU!TQ"/E49Y_LQC]"/6V/=(9O
M%\&EGZ?CX@M\NO\D?BX*ZU)Q4B9LKOHZ2E 4J-8Z:(XPEAXQ*BFR(1V$]-3'
M0*@3BG8!%+6J]W3D7\TU[Z=Q^J@/.?>L<+JD<#)AGRAANZ.)[Q%^R#:VAS:6
M.R*5)@ZI4I)V8KA-3:4MTUB7QGNI-Z:,=]/&]B]]?I2J+-N(3-A,V&P['RY-
MKDNF>,DQPJ6@B 5,D-%4(2Z5C<)@0NA&S?4ATN2W-EDW9<])SIYG[=,Y[9,)
M^T0)VQTMDYW5I^6L6D/+B+5'2N/4D >7R 1ND*3$*5HZ%X3NA[-Z^OGS)'P&
M#[0/6?2CU&)]S)_G>94/?O:]%> BM-$CD\X/YC/P79*J3-[^DC?CI\/B)V$8
MM9($)+FSB,52("LMP"DNC,)!<B5Y%_#3JROMNY?,.3E1#/[3+)<6/@$MD\G[
MI,G;'26<2_F?HI&ECM'21()LB!(QD1H&6Q>089R!T/)HI.V8D7V$U'DY*'-A
M?S8/F;R9O%TF[[$;SYM.GA,B@L$,E:;4B(7(D192(>Z#5DSRDG#3A93ZS3;K
MB'+G8B#)WG/G6>5T5>5D\CYI\G9'[V1W]2FZJR80IZ*-2,4R(H:-02H8@1C7
M\'$9%57[<U?W8_K7<^9D+TES(DXT5=E#[89%6$V=P\]ITV^FR<^W)@EY=)+0
MNY$$N#%)7C6:F3D[^NI+MRG1'7WWZ2P4U4)5%%^2KDB)_/%ZBC_XI!:**5R<
MO +X',CIBVVS16\0])7.PN117W"C)*$P(Y]^P+NO_A ;4WPU=?&G;6L\*LO*
M9,DL%PXY;\!*2A&0*H5'!$RDCS%XS3=:D!YB>NLBW+N<'?=I/#7#'0O3Q)J-
MY=^WL0-]HX'M**?"Y\.THTFPCI]CM<):E%:CDGA @"P*9+6'7ZD(FK/(2[)1
M7ZF *07'!EDI-&(&<P2?>$2])E9$9RG%G>+86Y52XKXQ[/1L/*N!6T^*2:A3
M\6GU)0PO!]M6_9C+6D4U &&V2,\N"&G[<2 5!,-*(U(J4)D*?!?K;$!1"8&%
M$B2RC=99=U*S[BSXV3"\B]MY\^-T[/Y8%  #![8\7=>S\_:S3PG%?H(U_#J$
M"W\J O#C1<)P$V#6NV*Z.=F>%JB+III<X;E@W-D<U!4F;43Q&?1(ZG_D9Y,T
MPRA#NT<4] JH7$]!>S;-J$8-\3W\DG:JV9=B5B\VY=<AK!N!7(V'<)OY%EZ
M9*<+SL<^#)NW3I=^G4?["].&^PMS)5C%:)S^4K4/B^/A</RU>402N&==TGQ=
M]MOV1)-=U/B")@N']V+IZC=;MEC1ZMPV,YN.%U->TGI@?Y_AY\WE:&@NQ[/I
MLUA]"_[YU\I/SYYIGH@ZO]ZE^H2+.CRKPX69 "\NR-,$]]I;_[2M4/]+55>V
M&E;3RV>+>]Q0KM\^E;,!YOKG1-F;8D7MA62 Q2Z7X8':X3(]X*K<X3HZ4%KN
M;W5X(!G;Y79R0"7=:7V<\HWK?G"*0MWZ$,5]3WXMA&>G$)UZ^ C=5=3\WN)L
MQT._L?C;RO(C'\3KQW;\(#ZX"Z5O,W!6/,3 V?4A6WC ,2RZJ,?#RM\\E:X?
MV_,0 .H.PO1/0*G%JP:DK@+ 1SZY]\-]WIREUKL-?W!YS&8KFZW^;\<CFZT'
MF9.>S=9#"],!FDEG&[4OX3O<R?]'(.P=4O59IV6=UNHTG'5:_W1:;KK1OYS.
MAZK^ \5):,IUPB2-K$AAVEQ[=[AJ[)W-5Z[\[6VUA[1&1&(Q(B+UT>2E0)H1
MCSC3AD?#M*(;XQ4>M3[IM:DF32W'2A8]Z8K7H"K>S#7%!U 4OU>CZGQVOE;Q
M<3%;.8R*Z&K-!_MNR0<>B)O+@+NI/W].DWZ.OCB)EXRJ:# R/@+_&6*0C3@@
M8C7&*O(RVHU.Y=UD5_-M?^Q*!N7-\T ZRJ[YG,ENUB:?O,I0ZFB9^ZALDU"E
M9!C#?F%?(D840]ISB<I@%#6!\. .6SA[("A%;QZ7T5';]"2@5'28P/\P"E@*
M@$7> /(WP+TF1N!80@1C_6#7?4(I/&"]8]<,I;H"I?*TW#Z%'!>-N0M??:F
M1KZXK,+0=S13=N0(.1.V-X3MH>H_*N0F B7< 5YS'C/$F(S(*FR1+R4.S (B
MD]V+V2Z4[<NYKDW(;5?(1K\/V?*4@[Y8W'M U:/<F=Z:@$S8;%N/TK9:Z;AD
M7B,M@D',B8A,4 )1@T,D3!$A1.>B(MFV9MMZLVW-U5#]V\QE:&)^(!H,P7GQ
M2S5JS[#_.:?R<BJOLRA [VY\UYMX8,MUC%JD?OD1_%KED ZE@E^UH8HR<&$W
M_%K%HQ564^2C3]-LB$,6LX X6-TR>JHCW5\#XN_9WN[U&=YE'\0 7U4X;V\S
MW,EUMW+ZPS3=G5E1>A^(BQ91+21BOJ1I=(-'7)6E"Q2X-&Z&6*0#GC4,4>:!
M?:5E2"DN4&1*"ZNP\6FP4F;%FUE1=:GC]=UUL.YF?FMWN<KP(L.+SL*+NP\X
M* D)3D6/HC" *A@ !J5$0%:GAL7>J-*7UY6Z9 K#QQ@!S."(:261P2HB2CP-
M HL81/E$E?I.&\$["#!N(:K[* 2Z@1N-D27#3J/H!'"CC@S9$#22NB2NM#X*
MO,&-5GJG.<;(E(0B9BUP,# A,*>+)27<1AHS-SX%C)&+:'(132=$:AFIJE/K
MRZ9S7RB^C(>@95+3M*)1,SEHW&DHF3-5/<Q4&>U"-$HAI\HTJ0,3I(/TB$C.
MA75EC#9VM@KD'TL%L?>"<Z$&/!_>ZR+'.L(<"30-B^$&_"^ L)98@DB:2,Z-
M!)YU?>'8?=:<RW+0NQ[CCUW)TT-KT]L:E"Y1-L.G[C#T41FC&".Q3@%H4FG,
MA1(8*9N*: WGI<2**L,[6^CS@/ )C!&Y>4AW1XW1DX!/C'+FI",I"DT1<[%$
MBC*"I,%62<6DU]T[L/<8\(D-5-]F"F7XU 'XM'7 X$98^![#]HC:0JI^#&:Y
MUBUOMU#@^<5P?!E"T4S!*=[/)NX,=$3Q?FA&]Y^ (0Y(R\/-@'DW*GXW0,>"
MXG8&S$DSX"1I9C.Z_+?_^8UBHI_7;?3U##8M3.K"7%Q,QE]".S6E&1SSO:TI
M?DF7M;=RSU]]?/^^_=D___-) :\%#[?!@8DH0HSM,*DTU.6A\F)E2M%&(\!0
M@7%C@5JD/.$(G/T0@Y&4A[ 1)1#2>6W N#D#9DYZB4RP);+!!UU2ZTO/%F:N
M^F-D[F[C$L%>+<CPLJFS7C5-:<K-.2SMS)O+E D+HX[S5\M<Y9RY[IVI/=R+
M#(HT%2IQ;P%P>%J9X?"R2&)0>;CRPB2K6%W -H\^%V$N#77QM9J>-5(ROK@8
M3Z8)CEPF,'FQ$)#91?H57MM\_CP)G^=#C!X(:QZ.>C=TVPK"6 (X,T0?$&,V
MU4J4&%&.K;"2JY)OA)A5X"4G<"4.WB%&K4 J"(HBP]1( S"5ZKTASN;3^@W
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MJ]'GT\G$C#Z'! /W4ZY%3J3:9\^O?-BJF_)YCV!0!AG]MVUY(SJR$1EDY+/
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MHSK\&D8A5EO:+EV%1=^\?;T6%T5U<"DVFG1G'48__74TOC$HVDT.*ZJ&"DW
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MP)BG8'91@UBDL.FP[:[2:KTYCO)7@*"IX#6I-"I5A9K/RY8,P_'7U)[F\S
MM/F<:BWZZ3AOT+TYG=A4&-<@3&W1?@KE34)U;F>3>B$S*_N2_KP0MA;.H@5A
MW;B>KC3T&;=E'S: .8HY/]0_!^?-*#DWZMJ!5M>&[XLW[S_\FSF_>/ZR%;[B
M=#*YK!?IC:(Z/Y\!G<8CUTJ6 \Q2I7,\ZPV8MF/OZW5/Z[<^K?\XG2XE/W4L
M,I,EV&^6-Z]W3)7[Z9L XL=3N+]++.[#Y"KSX585PHH>^ IW/7XHXXFB3H))
M*K61 &5H1!9KA;0G@I5*!4DV CTF&"PT0!E=\G1:S&KX*1V$Y\X;*KS"\<9
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MLX9HMOJ2^XC1&&]-E& (G4JJ":N$A25%@=H8F,&ZU!NMR8(UP ^&(AFD1>D
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M3XB\#\@ZW#84];]FIFE;&)J8S3C&*AWL'AH[!HX>3RZ;0,R7ZHN95+/SHEE
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MLXR"V8^V'YX?S#X]OO_XK![9]:K[F]LK#[5O.IJ]W>TSW K?EF#X$EC_-%C
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M?E!(3[F&Z@H%?44:GZ$W!-TU+E+:10H43E+]H0B>QO@?$\;?$D41JB@DZWE
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M;-#/U-5"%0ZGAL3<<*XK;\H'<0V%,1@:54PIF&:Z]I"JZ\ =RH\%:=O3FPS
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MXB4A:TFA<)SNZ(WG'H[V)W=C&-W4IH-?S-'\!9&VI%:-H9G.&0Q'_.0%713
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M+V>S-;M9Q"W"9,[F?%HF!BJC;LXFDG9A]$C">LY6]+%L$;:-'SI;3,@%_/.
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M8>*AOZ!,V)UI'-Z69A;LJT[8>("]C#DF1W&8/529?..\^XO5HNN=;E?VAS?
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M3E>)'VZ6>E5=-:K'OAW^8]M=PRV8\;,32F )V$D36"H\U?(,A$[@59,N'>W
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M1TZ#=,>2RX=;KE5#=1Z_^BXO]W[>XO0A7SME3#]&*1;79M\C C"\)7_E:08
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M]Q)TE>^"/;']OI&]:_49R?7W#'B2WPQ>:&_.5I])T[O'EK8L<<SVSELNN7_
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M0\YH/=<*>%+VTQ2PDSGTJ3* (HR#&?!$>-=TL0S\^1J,-P_V\1#GWU7HV@H
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MPI0P K77$(<<.5*@["#7JQ]A^(&L<' 9%5_L#E9AD,X)@K4H^:H:8+ JSYS
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M+>9QOA_K2]%[: +3B5)-D;XM5Z9WJ8LYZ[8H9&WB"6C^;:'DJDARKGM-HGR
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M(O_^!GT+"M40L=$']X5[JX J/UJ]V]0Y8M]9*(7 T>AL022!;+[9@XY<#G9
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MT?<M.,BHLLZ./30E:X&(EX[,HAP@6-SA?E0>*#X\G8*\.J7A_F'<@C0E7Z+
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M?EUJRSF@.3.CZ2"]KGGN$QP.!3>G)2C>1 N#:]_'WTFB[ 92DDZ0]01.L$5
M+ OIOB49OM,45O"G5:I\UG=.;ZAE63-BF=LL0@"RJROW]FW_:+1;5GG-N@I%
M$S\@M?)H :9N-4518.(4(A#VPT>=:YX_1,E'Z-I_A+>P=F'*K-SU6D8#!35\
M7J>K!,-YTBD7/SNA_T_+:&OM50F*6F2D^D)/*\73:9&@5XF<8SU!KSM5<JM"
ME3Y6,5!*L\E%1G"'T(2;3H.#4TKO2X;C0Y(7F-W#)%1O]60D5:Z,0J9<<A6*
MP]XOW']^P;[$L$ [SUQ]?P=G1)N>HV2+ZVB6^8JDP.@ 4(D'2F@FI=97,9+[
M]SK^YINHZ!Y5C-&DCWS-37!P?2@]<Y9^Z@0M[>,*@/#LZ"O9]-4NWI*VN8V#
M?"_T.F2U50(HC_:3?J!_=_%E/+[$O*U;YE\/6)4V?AEB:!,^Q4C?Z0I/0.*I
MY--X^H 4L*-5_D0SF'*[.)5NH]#CWLJE8Z9,*RC?NM"6:=>Q120(NKT8>P/J
MOJ]_+2=.EM>]-6_*NL?->$7D[B1F\;UH;N]=1O'E"L^/*C.V Z#'B=Z/Y1NC
MF%'1G6"G>^,<L.KEI= 2\B;^_\N[MM[(=>3\GE_AQPUP@LW,O@8+M.WQK+.^
MP>Z98).'0);8MG;54D<7>WI_?:I(2J(DDJ):DHO>!0[.S+2J*%$BBW7]2IUS
MO/IDFQCF^?$6SAN8%2ZPJYS]7\72\#C#)%>&.VO&6]T<7V$^ZN?23FK-H^KI
ME24)BJ4@/;7^5YY)?*0S.92OCZSIG;KR<S>V6X#9?GS7<PL()"S?]K-JQGJ]
MR0XKFY\+3:$VU .1MBIE,Q\2#QXAG3^D]\DFC=8)_70:NRB@9!>*__VA\;\+
M)0;-)VW$Y7>RQ>2_?KYWD@Q>1P.GLC)8#,J+ZW"7;ZHH+K-\4Y:L$#F25TEP
MJFUQ?7'U>"9'/%.&/,,Q5\JWZR-ZK55QTS4T!GI#+&IP#E6.*@.'+%"*D#[Y
MW$VE6,,0F9?56!_ZKGKYQBU\'Q.;6KXIL5PB4;(E4.3JI:2\KM7 P#[J;4C!
MT <Q5!IM]@O7:N-CW;*U5EU"$S$_R$ZU/!/^ J')\N-%%IV<X"%4I\[0O_$,
M#M@V^9F\P1G>X=-,3>MHH9EAXW"0#:MK16MN/*GIN=UH61\4CUUL(AW3EI6B
M0^.AF4T_-T6U_E>KIRSR\G\?&1R,X6M0L$W="IHO$98?@KP\W@5[=IDAG/7)
M;HQVL#,<[>Q_Q'@K?+15Y]--3>E-ZD/ EA5=%#W@V#);":#-\T8^8M0+58"J
M8"(J\IFFI$.[^$>8D-Q#'2CLCH$F[]&)$*]S;FU@[(A[C$XW0IHQ5K(Z9C]G
MIV1IY8<=HF9R87]^O$A@N<Z! 54K:X4V]PSG/8[ZD1B@LV=C@OT44SI??4IX
MFCSD&<8@[O,GEK_%X1RD-#F4<):(T5;S^2[UZ#V8I_[S?V!ZY6:/1^XZ^;)B
M;))\V;G36BA?=L5NEEA>>9>E3<J%B/LM  \A2F5C/AR'#?HLDTC4YU='K6.B
MOY,#K^@U7?BSJ)U3QZ>U.C;),*'(BO*T; [5*'C7IYVW#;CK0V(W-5"U\$,)
M%]5UJF#8+Q//:3W(TN$EG6'P<95[?<X9]]HQ8N2P]GCBP5YD2>/L[ %Z?7BB
MN.@F! *$1ZV73G_G%5SU'42Q]2>;8;]ARY2I?EP[QQ6GKO9VF3;Y#^SNN,K\
MM041'UO<O?R<%"5BVM=<69NX8^^R*0I&7W+0;"K9,E@62RQ3,@&W.6OO<]:]
M$4W5Q-HS[Z+3ACR7S_0&5HJV?4M86,*-XK#!#\<T@FQ7OL,A>%K+XUZ<L;U%
MVWU5'K;B+FM%$M>86QV/:>?4MEQ! *-Z]!5;4Z\VMTZ*E6Z"@3+!%1NAZ;HI
M"D?!W&)^79_(LX /_2GFD[13T72!K#TY*T8#]X<D.S(F_5_Z].@[]+P46)K$
MWR\_G?KITW=9^1=68L[S2QK_G44J*/M:B)+-<W5KQ7[C=7EPM3P[LO*L?:9_
MTM<YA""MTKP96=A".CS29Z%)\NSDJG[3JV/?-UF]2OYM 2^BRC%Q8Y:,;U&H
M,!%0CKBB7%]S2H9V1O>I,C-8>?%'?"G1R_8&4>N_;#/^YU=NT>_@(>?)Q7J4
MLV=6OC.6GB4X^MD7S"@0?_UZMFM0)$7QVZJ"7R0.S4H@0&$O\X_6RQQH,']!
M]8SBI,(2E2=<&3S..CL)0AWVK!WWM[43(M::5B=.:IL;0?N?FYD-L$::*-Z0
M]FLZ>7*]2)ZE;^*'3! [--WO%/5D#L)%EL#?>*8;K$ 591$_G?IO$9LH7P/T
MTJM,:]?>+#+=KNMV[IS7"3K+-H_?6?:2!X?7. R268)3'6CEQ+'%'EW]3NIH
M*Z,K/(_C=#[;P14PC^(Z+4$9*N*0JRJSXM&;EY><YYB=-8/6ZF3=^HJU-P9M
M!",.ERSD"M[9'[[\=O;UW[]^^6=X:QH+[D3DV#[\!S[<;_WWO^(KK9X+4 :"
M_*C$L&:(]DY@;G4IO=C3=S*7U"FL:%W$:5PRWJ\0OG8@&A8*2^,V^&N6\URI
MV7JLN(MLB]C>1S1&A%7';R7SLCY(M6T3SOI.@:LL'T+**'F2LK^'2,8Q%KH7
MYUP+6Z;%PYB+AGMBGH5B)A/;/@@?Z3.\16U"(&PMX:7I2,S5N_0UUGS;=KJ8
MNSP4QX0RZ@<5.BPZ(8.[177H6&>RR</.LP=Y6-\>_CKR!)+B]X@GP0[EOXFW
M*]FQ1^7* .<_LP2&P00;!+:X#7[%^VK??(N,XN[\^_V>[#5?[P_PQ*)#"O;5
MY>>'.#/^Q!*$C?A1,-T;<F(DGMS)7Y'_[R<KRJ:H[\NBJT0S/O6K$B:6:.*+
M3Z4+(FO?@0LC\>1:(*RL*-2P5*&;D9F:>!K]\E-19UJ5KUF.\0_=7$98B"?$
MQ852LGH!PC*.)*QK[3'/620>_AKKNF#/B%2[31KQHFK06G037VAHHA?$JV4$
M(L"-5.'426HN^[+#ZH9?-0B#=8/UB8DG83'4SH^MJ89FIVY:$]A]^5HB_1OE
MG/4[M61$#\[S2A0?*1RR$E#DH5]1JEMX)[ 3;GQ1)?YMS_(7>/??\^R]?)7Y
MP'TA8"&EUBMK-+O69K&)! LY_41ZB?L/.0/5-ZK3[*40J_N5B0UOF.,)(U'K
MA:>JN-WT^,U;$"=XH()=\!UXM8M@K7L1O\(:;W6;<7TD9\80HNZEN',339,'
M:.I>F&I0I7].6@F)OY$"G\BM=]V7Z-.0'Q&;*(+E7O!W>I_#NGB+TY#ISP@]
M+?%;5^KE=2]<N4R^/)3P;,?%FD9WP&ZXK!0#%3=U>H!^:2TW/J6*]N, _P"I
MQ#.EFB;=VTSBO2D3&ZAG[JS4)^( Q^Z187$O$]#,!UBPVL-MG(UZD:-U(D-K
M(C:D7:H#*G(A$G*MJ=;@MRS?%R(542]4C.3>:9H20@3K+^(WU&@<]<HA'_'4
M>ATA.OJ:@C".:9XAB+Q+S%G3.[1.&XE: S2I;-^*,MZCG/M1L%V5H.] ^XDG
M#4 \V1:85,$E;6!)N=PP[TYG9LI33@%2J0Z'A(N1(,%ZN*LD>[].=UF^5YOW
M8"8Q[,NB&V(=G(#+#$O\]?5X2Y,LGHE#T$\8-*^(5_,C2AQ\'WQ$63^1HS\C
M9_AK@ B"+9%0= SSGS$BN:CC+@VM*T/V;[?Y@2:P$T_T.TNQPR@\XB;:QVF,
M#X7JN7QTLXAS8J36<9?+O^L=V(\,549L'R3A+ZH@017,'%_]V,<@/SS5OMOZ
M$U*EH%XG+ ?1?.YZNEO(J4,_W0H@V)S*T2-S8Z+[M*E($G9Y7O^3UR=M3;'(
MQ0:G_MKQ2QKOXA /X+;V'"/]L9*0I/WP3IS4]J\-D.=18.FT=8QZ-\Z4$:B_
M9J-N2GWR 2%359?2^;%SQ;2\3QJ(.@**:H6R"Z5NH8V"ZDD)O;\7W"'& L2)
M[GM[U6N4-I(;5+J0B@IF^< H.G$<;_:6/F"E%D'CLPN]ILT8-%N*Z]R!WH:J
M+3YQ1'[/#2D)>DJ_\K) R-WG/- BUF6-3^Z0GV5B)==*^=%E3>KITU ?YKRE
MZ'6J@N3$:1@?$M;^](3>0DSL^W&(X)UOHNQ@<#O.&(Y:%,UM[WN5Y3L68^LX
MIP:_)P7V%WX&ZK5G4P,GZXWDD]GOX[(.1N*3PDIG:6B(V5K(Z3U3BM7Y,\,'
MXTCT!H^[B=JK:2A>\A9C^!&WU_BDS+S4(JO1;?3@"-]^A4D5L>@*N%"@5*4L
M<C)V!+%K4$O=A?JUV=H1W;%W?DF[V-TX*<V))C^0Z1,IC$24#_V09R%C48$K
M2!YJ<)#5K<"N4UAF02+:+=[+;HN#.9TP!O6!$12O/?C)KL\2SH7N#PJE]DB9
M,R"YYMSZ/<PY%4,JZIP*3?_X2U:$><SU,9L=X,CJIZSD1I?:"4 Y(]N388((
M=1N0/O$$Y&:3FCF>IST@I?Z:&F?(5$O#P;TY<W#*HXC'$.YW#]BH6Z*?@M1L
M;-B"+\PB2^*(7[/4_2TPW#] K$>KA*QR \*L[LUN!P^-)Y/((1X&]LQ4Q-_X
MCI6H"/ \9]#ASX\_"JS*NN;@C_C*0U#VC<+<G9M<USK$99#PU(&H]H_@,H*'
MKB3TYD,0ZUU:CKS4SE4M1*VA!,]([.,D6L@7YZGT4&+H)E3#PTK-U2V2-LKD
M=TK/"<D\Y+XB0\X<"#B]?\A,3RWI;"Y2RYISX2.?6E-7I/:2,7E7-:2>A.\:
M_\M(78^-GC2O=YGZP[JF&/2&6N(-?54KWHLZM:)C^G.?^?T.%"BN#&L3+&P,
MI$93!O(BO0V*(@A?*WB84E-78J>D?/Q+=LB*F-L?2A8MEI,-Q:43 V'*B_25
M'+_]"GDD%A6A?NJ+CH;0>GK$9]";3,HE:ENXRE.N^\,WOXI_<2O G+]IIJ8^
M0K5=CS2X:2;_LA.S1_E4L"DOJGV5<&7S,D8S-8T&&]J%B7!37\IF/ ]UM[1+
M, OZNUI+Y)?#M,;@,5FE%G)JQVD#JWJ?BS5RR\K7+!*>#L84L%701P;$-9G9
M=[K@^!Y%<I3<UAK"".-S:LHKVALJRUC8YX0AJ65NWQ:Q(Y%9R$EU?EZ2L/DR
M5L(P2DS\-4!?OM_5U:!:*=2E\,1D;/(XNS:AS6HTL'AE];AX)NP<?DJ[7B:_
MZ<!SYR8__ZR%MK9(J",K]01KI4.%;3!]-B,Q-4QD]->J*"4*$M;/I&&<L#M6
MMKATVTP7L&FV6!NPL7W2->Y#_>KFI;:9BY07&=BW0PCQY[I8;!WG7!J=LY3M
MXK(PHZD[G5P+W(<Z_K/;,5SKK/'A(J2U2/>MX$/+'=&KZ)G.[=L* 6%@DR V
M>E_@PN0?-W'*OO:-;2,A9;6;4(BNXB(,DK^P(#<X"DQTY)J4+/N4!><@ ;F2
M (SWSTG\$M0F'R8O;N,]+O_=$_Q:[(369,$?7VILKW1GDQ0=4E':C7=9^50]
M_Q7>[#:#-QP+>66P&VW$E)-X9 7LDQ"]GY?8@C+CP5[#)&S$E).0)4+;K(Z%
M*9X&PU3&60CC!A>H&;'\@"82AC!T,)HZ&FI-4^2ZV=3K#@6Y860I>5@R ]AQ
M1%)@;?@!<5AO@[3"@Z&228E/80P[''$;E VO\6B</(B'6>Z-'Z;&W;VLP +\
M56[?6?+&;D%%?=5CE9XX%G7\3]/Y^*OL?/REU_E8&Q&<P$\MH$2=;@$?@^/+
MF3US>DKR7*[X#;39AR0(F?Z4ME/Z$RV84A_OP.8'$F"C@_.=CU!2''VRX"L)
MK5MG\+^)(WGI"*B=9[%HMU*GLA:U#NGN%!@;B5R-P$+_-,*8;O*?<.8541SJ
M+0%'%NH)<75%05+53J%/1)WM#R1!\7J?8UQ!_D-!@^'BXGXG]4^!HJ\WJ$\:
MB/Q@,"?MGA^W<&\[X*(K-_7"'.!G@U5MG9J=@]PMI+.FI3=8U$OI/3ZC;*09
MDR#-RBRY/<(K?X)7_OQL2I@T$%*?9D&>@#%6PCF#'D2S$-<2>I!*A1NV[QA5
MKU'[T^%@+\HXY/Z+7%-09B4D%[0=2!!3FQ -F5?^U<8JU6<".S-1FW,J)K#9
MW>2'\:87VTJV?UVFLLVD#_\JRWD.=B$/86.FQ0(#DW8,26/N&"N/]SNP:8)B
M4VXJ++(T'!PC])13N0F>&^W)\/1#$FJM:B;"LF(#."(L?]4M8X+'\"*%&-0'
MJ;O)B+_NY1A(J0^5 3"[]A094'DBB55IF48B5X7E3]FNA&6EY/Q;(:1.'HQ>
MS>UDXSCT71EA(??D!R,]9[L4U+K+O.2I\Z-^ ).2L.+M/F6Y)N^F47L;^ZDD
M"P]-JI"PLL124>$RW6;\TS&^$X::B9F6WNS"EB#7*4A0S&PQV%P=&A^TJE.6
M3PW8C%4OV(:\R=W)\"=%R]F\O.3L!=;7-?9_24$6&^U1LH<A/^EG)D?=V#!^
MEAO=G\"<D^_?1D\M*4#XZC)F=-<] ;,<5,YI":C5E3 49:,LNF2'G(4B& =_
M3YA,6-[LL[R,_R[0OJ8T^UIJ[$\N\34 UVO(<LUM_ 5(Y?ARBBN5(\SA#PPN
M\E\&&V?N@-2KJ$D"6* AL .@X5)W\>6DYYUU1O +G9G()]6#N.WA$^A_M776
M/'T\:E=3'8JH*Z.M\8J:B#0.>OND["V0T'6W84R(Y,E,,O&XN6"*DYXX$+5W
M\^'>O!*;BSXXC4S5!M1%!DN=^&;/^/RN'<O<FCIW2(_U.;%T=/HH],>+)G!X
MG7(-2M][:82%^CLZI6XI2'.\&=:L/##-8/26FKX7T;=?)6Q@+#FXB?4"SY&5
M7&9;TNQO@Y(#@(UW3SMA&,]"-C9A9*+U^=LI)1*84+5]US:PF3@$M4A2D0,,
MIT9+0*UH-%:A6R*V>X/"Z>.1NT2!)"V%QOT8%W\301'\F]XC:B3W\I ?[5#N
MP.9!JJ,H]!9.K"OXK;/#K(348.#N+4VM79M.&<<;_:1N_FPM&#52TT^C=EKS
M!!>TCW+VBFI2+>50HH-XO]^!N!OQ>[L,05HEWD7D+=H.UC\.8 ]BETN>-P"+
M;*A$7F01;_R-) /OQF(C>XBM\:4OCHR$U ?_3#._-N:;B,(V*X-D_;BTRWT_
M^:M5/"@"]GME-XVX"2F8@^QAAYXW11P,)(>!CC28E958Z!XD"&I:?'M#7VP,
M?RNSE-6FR3!@Y<!$;;8Y]?;PKIF'C.^([+9A#XB'/(NJD+O16?X6APX>DGDC
M4N=&Y-DN+DV&:'O5EY/T 39VD/QW?(!C?E#19*:DQ=OO@7]UW1.#O3]"3XHV
MKFL^U"(7G;.7..7X%;#:T=<RF-O4 3[K0:WB7U1[<:"BX7^5,\R&8[! ><W^
M;? KWE?[1<_OB??^K*]XJ*:LKUL:;T9]%COZ/^?X3@FAK^016K1G:#%LD&8E
M],NUPX4?1O\X_LVFA)7T7)7<U9D]!"95:O(@]*I%DW3EW-QZ,C.URV>0'17H
M$Z+,;M6)0U#+:P60YN0:4X<<M+FCT\=X' /_\](&J%=##0TN91*<JF"AXD(>
MPQ+7,9"?HC*WQR50K"6E/F:"7\+E9>F#VA)02TZU^G,<'[)'2)N>S*N*ZH3"
MNBU:_80"RMN(Z#6)F_@;_0SR&!>X-25N0$3N*W@$,Q*725KJ^L'I:*BS.!Q"
MX: 7P%$ VBUZCN3JT1^2VMR/1>] B^M;6RI94:ANA*+U(VA]#ZZ,I)"K:LY
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M"TUS^BC4V\Z"I3.W_,,\"*E55/QM4]8@^GI5?TA"#X^C27R LT9)?;#VDIK
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M4O)MB8]4S=\.VG__0EI_^O'''S^0W^Z:II#6$ W[Z<-_W]T^D7F^1RN4(=3
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MVE7,,TO4R^1INQ,&*H4?Q?W,J8A81:V=/]@3B/9)0DY=XF$O-5L2VKJ),I"
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MQ^).[E'G^'6V01CTRY%<M1R'0?4<@VX^)2U(57"G>+FK20B%9KN(BX.-%/]
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M=&UL^3EHN#\Q'C3L'R?_#U!+ P04    " #J,W%4#F)"YZP%   A2@  #P
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MQ9^G+\Z>C(0T0BX5=!C?R5HX_/K<*/HYEB++RZ5,;T9R?AC'=*XM##>"@7X
MLB=YFN8KG<V%J98PO[5?C[G*5"E3 =MK"93/8E&4^:4VL&K&/U,V1R62!;8+
MT\ZCC^+=1Y5)\4N&TYNO1^)=%DW$0SYNT07]RA_BBY'P7Z_4YG=Y5?HO'XDX
MAREEN15%519YB<=2S)2(\F61*JMHD-K 1&9_P/:"7T?TU:<*YIMH&*3.A+9&
MP/[0I;)K,8.AE2J!"621PM:@._&]3NQ"O.:M1@W\IHR5%CZ\4:6%EB+X@"2
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MLP&+J^!)JBL4E;DQ1-=@3P2I(2/GJFA8#286SH FTGJVR^^N0V:]1;37G9R
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M_::LT)KD_R^$?XC\0^0?(O\0^8?(/T3^(?+_+R*_&[RFME KUPUJSD*F 7$
M"0$!$0$>"1$!$1D)"1D5"PUJ8Z#B8MY&Q\+')23 Q\7'(R*EN4=$<I\$#Y^"
MF>(^+1T#(P,A.0L'"ST[#3T#_4TC,$C(R*@HJ#AH:#CTQ/C$]/]Q@#0!6,@P
MC7""<# 4 "P6#!P6#*05( , & 28;^&[CP #"P>/@(B$C(**!BU0?AN A8&#
M@X6'0T" AX>^]8:^!^"Q$.[<8Q-%Q%8V1*)PP&'WC?J 3"E6W(RK,KA/Q6'D
MZ(>">A</GX#P/C4-+1T])Q<W#R\?O_A#"4DI:1E9535U#4VMQ]K&)J9FYA:6
M5D[.+JYN[AZ>_B\# E\%O0Z.CGD3&Q>?\#8Q+3TC\V-6=DYN26E9>45E577-
MYY;6MG901V?7T/#(Z-CXQ.34XM+RRNK:E_6-S8/#H^.3TZ]GYQ<WN&  .)CO
MX2]Q84%QP<+#P\$CW>""@76[*8 %CW"/#?&.J#*2H0,V!;LO,HY8U(?B9A1*
M#I5]7"/'0=2[5)R+]P]NH'U#]E\#YO??0O8;L-]Q30'H<##0SH/# H2!"\E@
MVE38_VMBSZM6?IOV#X(9'/%>CAJ/X6U6*6_EFK3/M@B$CBZZV,K""#SL@!$A
M?C9Y?+*AT(O0:9&?4R>5U99'PON@VQ'>-(Z*&>?!&P+*+/(O0YD1>L,9([;Y
M 5TH-EBD*@JXXG%P:QM).4OA&@SI8L%9I$59W1XNUB0KU%ZL'Q=Y0EOQ3; W
MVG0T-)4ZQ!G0_6Z)9IJQ6:0% [0_QER-FK: S0Z#:O'5O@'NY<HOJGY\6[VB
MWDM,PHH-=U5J.^V-V<_M/Q[BL.?T\3MNG:F6U@<X6RDKE:^6W,5T0(TU*(B'
M@S]&FLO%\%'TJBBO3-G!EK)GRI267$:+G3TR3@5Y,H*<)(-?[50T/([98=V&
MS[%C-< :,4NF?IW)QAAD N<@TD+NN12)F19,"_P4LS>GVI)#;(B_[FZ6='UJ
M+VX?XJAU5LI%H5J* VD-GS!(VSXMHHBC6SZBO/?IL5<2J7O;@P>ZFLR#:O':
MPSI*W S>MK8/GS@$2;-C\\Z>CT:4ZVQ+'2U-[903N;>0B6Y:E!(PX6+55J*+
M5@7=;I9FYJ5)O1A[1DHYO%NV[&4U)(__KH,^2"[P"/U9D1(/7'\6Y^. 7FUZ
ML@J=IZZ7#W54B?H. OH?76@\KUW2>]#R29PY[?#YI5M<\3W'9K52T@<(\(EW
M;"91U\I-W(N4JH;J[N5NWGUT=VEJ2,;8J!K&+YIW3SM2GJ2WSNGS='HL7+HQ
M ;R)!EZ$STKRUOS)(@_8SR)\9<35W[HX\\.LG/?BM=#F0F"<E\6*(R)[FZB
M^F;W/N@J6%OQVJ,- J2BCGS8Y;7&P5&6H/#[7U7=#O_6"^=$*L_,UC ;.TI^
M?XJ5L'RUF- %>P7+J+-2:0\[I1F<2YP\]- .^YZFVW@1[XJL"A^[XK%S9^<7
M*+9R:[N&D&;5]E>^C3*RF+ Q^@+L4@&"G6U29,'.IPW)?7;<1"'N=SS4TQF!
MYR]P.V@VSI2[=NS7)'MQWP@HIG/&==2\?#HN@N_GYV82R0$B]A\GP<Q\/'SB
MA:$F[;R5D=)-Z3HWN>[=O.U)J%O@C):VBJ,L;2B!HP3S+R(2\1S.&--Q@93L
M<%%^W-#:DEQ01N*=(3JWN0[1KJ@1VW8/8H?'KC[HA>2!\[UUE1X%0[CABHQK
M@O'R;%->ICHVGDSV\5/7I[&%^IW7F6O-Q+W$#GHE(%2$D)[(.+2J97(8'4E5
M3PK"X)D\\_VAW2EGL_IR92(1GC:LQU18/8=V3K,=S\Q'U-BNV$<6A\TK B\5
M(_H"YY"F;<#E1H]AS&AX7>=0* ?"SPO*#\(N=<[;V\>HS -G">7\@&3I,3'\
MY0 E#T$9_#8>Q8."T\S[N3H;Q:P6<98SCUQSV6SR,\(E1S'VDE +K5Y.45M?
M<=5R5V))>=N26N27DHL1S,V*T(-JN#E.MJV+]W>C.9E@IQ544ZAX#N+@&'6
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MB1:O35+@+5VRR_68$ZZD9P29A95W,X%HQ* \1N4%9K68<0(@CNJ%O==P/<\
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M!'@^HGGI"7ZX)-8AE'N%+MD\ L^;UVYWQP<C+OYL5@8"M*H03DRD%1/:X4
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M5>4?A>U[8%TP[/+-'WJ13"K/2/J9JTU0Q/#L*G<9[!"[EF" R5] M%OXE6<
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M)O-(RE/:(9#L0_O#)\D#@#]^WRFBG&X.UG8ONY\8C/2,WXK^7)NZY*1[D>J
MD=;XRVB"%*#S82=4/2EL3_G<\XR%:KWE-5XUETVNH[BCGR3.P;N<3V8DUBP4
M];3 =$H6=67JIS6S;U"B^U0A(SWK9J.;8U$;<CW/T'E,PJ/,:T]$SQ0+I ,]
MO0X?9"[XWCED^XYI.W+#7(X?"B>1BKH6%)ELD_H ]M$9>MT*YSDFB?:OEARM
MH=<41O5*Z*;,?<IA&GW0X#Z7#/8+J3H*'(;2_F'5- 7? WYJ;Z:1D\N^;>]%
MHU"\0-<(Z!@S.?K.3?AVWH?#()]$5<OTUD[BEYYJ:^GT>MAO*B7-T?FSWTG?
M[W2H7_%H\_55(^1B7IJ5%9RG>B7$&.(+/9H1!%,]S#XMB.5QN^95OD7^38WK
MZ(0.?P[;PV[.UYPS*EQ=GU;HCO&U-;$2JYQ5O[?:B:=O3J,+]FT_FU*]S'T7
M?"RP>?%R85M"8DL;O?'-N+I[M0E"^X;7..8Z)UPVN*WM0GS'J^?KME?<SEVN
MBV2Z@OC;NTM2K=F_#-%UD_A5K^E"$6/126^D>F8F=-2:\-!D$^QET3;ELD+2
MJ,U!M*EW9RCW7AWAC@J\76X/-4M7OJA,$55*X$JA8]3*4#8?;[VM>EKY>>>&
M'X_WL0+%G"<CZE+NDPIG6U*STBBF/\<0FKS@D.YNPEA*>8X5!SLR$_OJV PO
MSR+EFH7P>CS7T\$PBLU82")-YC(9P<NA6=?REB&3K<;\!6*HET5VQ6V7NDUV
M#).B6<+16=<KYP)/<T(JR  ,!^MZ1*U1C%^QHP]$!3,S8^CG%QWV\\<@AK%A
M3RR(33F,\KNYK]]OVAT,/_-,&"-]7_D.[3/>VN&9F4HTOS[-<']2R"5X5W>'
MT&3:=*+[%7(^*HKUNSU-HU:$I!]O5U"Z+DP=6-Q<M8F-UCN(9X@"%9%,SIIC
M#]F<;,IXLWV_C=SD!=!H* ZJ>%F\W6 M;.]LNA6OTK!,_E,-8I91VBR>^=OG
M5Q W4%M]W % DL]1F&[R.@3<L;%6_IW86Q"B"DJ3,37E>_2P,28Z7!+EKLQD
M2QK*_(Z4ME-]Q::'C:3/1X"AH5!UX]TC?"Q(L]TC1+\Y[B6B3G\ 6_E";GMX
M2*! A!1 ,J#Q[K]@6'B],&N[Q#E1'2 !QX^H?6!M39G.JS;^.[//1I(BD! K
M=7MPP6"UD$_"GMTZ-^P\D=*YN6-_U,A]RF;S_^U'\W\,UJJ.<K,0?$#8H@&_
MJ6G%\"-ADPF$WE2 %57_>B(>-:'##('T>7J2H]K_ :2I9E2.16$\ONET]2QV
M*^&B.4ME_]?&:JQAO$HVO'+?9EZ<(W*5O%MK^#6JUC4HO<>6]/*C3=+_'DG*
M?_/_!U!+ P04    " #J,W%47.\/BO5-  !?7@  $0   &EM9S,Y.#(U,C T
M7S$N:G!GQ'L%7%S-EN?%G00+#L&=! W>$((']\82'!H);H$F1$AP)[@[#<%=
M$AR"NQ/<70(T]/;W]KV9;W9G=]ZL?'/[=VYWWUM=MTZ=JG/^_U/5B!G$"O!0
M65Y)'D!!!0 4Y M S .R #8F)A8F!C86%A8.#C8N/BD!/AX>/B4QR0-26BIZ
M.EHJ&IK'S+QLCQFYF6AHV)]Q<#_E$Q04I&<3E13AE^ 5$.3_HQ(4'!P<?#Q\
M"@(""GX&&@;^__2!: >(L%%=4"714!@!5"(4-"(41"= CVPG!LK?#N#O!PHJ
M&CH&)A8V#BX>LD#-0P 5!0T-%1T- P,='7G7'WD?0"?"(&;@D\$DT7R-Q>A"
MRO\N.@N;Z7G%=S*MT6-F 7/7(!S<1^04E%0LK&SL')R"0L+/1$3%9%_(R2LH
M*BEKZ^CJZ1L8@BTLK:QM;.WLW=P]/+V\?7S??_CX*?CSEY"8V+CXA,2O2<G9
M.;EY^06%1<655=4UM77U#8T_.CJ[NGMZ^_K'QB<FIZ9G9N=^K:ZM;VQN;>_L
MGIR>G5]<7OV^OOE#+Q0 #>4?Q[^K%Q%2+U1T=#1TK#_T0D'U^J, $3H& Q\F
ML8PFUFL7$D;^=]BDSZ.S*K[C, EH'9.9NX[B/F(6_,5R\H=J?]/LGU,LZ/](
MLW]1[%_UF@/PT5"0QD,C D# U0U[=B#N?R3RKW*85[2F/'YNRK=OLZ-ZM6@$
M:&JDS(I;G!9/:&!DU X<7&M>SOJW<<+D ,-;A];E>'K'Q/G_Y4W42[7?\.(:
M4A3_)V@T1-<Z.XSUO8^G5#GBLS'EV+CZZ+(#A=D+'0L,5_$)5*4Q2#7_4B$:
M\ORQ'&\5&Z.T"]%R^6JTDSS A!X"*/_1#UBL(5B8@:(S;Y4$>/,VY^7#G6*:
M*2R^/*=YZ'\3X,$$>79F)@N!T,8D5JM\@@2_XO?#U^:5$.>>>SFU)P%Q=6))
M$'WZANPW9T#F1-&O[67-$+_.NOI/XB\"F<K>M-\=0G*N_-+!!G66\*:W]T>G
MM"7V=3=&<GPU=7YZ\8RKLIM\DNW=7/;?RLX'M1SMG#7W+3\1A7KG+W^^,T(K
M\9O:'A+=6ZJ,+RWUU'1SRQ Z&/LE1ZI#BZ+,E^Y+1\!"B9?@1":O/J*!3D7V
M_8PE,*-^0V'%Q03#U93:@N=GY=DG\^6DLMK_>"3\/Q8TP]B>RI>^YU>7,+%/
MJQAIN,G S^RL^I#+&?@[*YG98%":IK_:"2&H:@(!M \"]IJ&H+GIC'-"L]O]
MT3N8#P*0WD  K8, Y/_Z1H3@WZ^CQ+XS2)[*IE3]6+',=,)$V#&6PIW<<LQ7
M^+#;]P,%* ,\.O96XAL1<PZ/]*-S//K*N2 %UMJBPG>D*&-I?_E@_4.PI27E
MGGZGW,W.S0YDO)4P6Z"/I[<)O7U_6F2;B=TZ3'Z%M:$PNWJ_#2\&OQ:)5R@4
M!):KNNZ^(R>E=UL]B#,A! C=/X&^"=#Q3W]R&-F?EQU(4<%XKJF>'0*P_Q<+
M9W5Y^/-%4',$E%NGCH#3J'<DT^=Y3(@:&MV/"OD"LJFL?)/WE:QU:1E>QT1U
MC^]$2[ETP[C3;P+L")A\0XKR%_O\K>N>D,=5$EMH^7#,9!1NPJ8J8N)T$G[*
MR)'J IIRI'^=O$S6#<)AA391)8"D!0P5S$(DT6[U;*F$1''H]A-$VTL+P*2+
MN0=Y]XJ>PNQESLHG$M->4?/+!D)U<YC;]*G/-D'@'0Z-<K5FG\SO)4BK&V'_
MN9^XOK8=KR=2P5V[-QRL%L8S1=;7WB" =Z\":L9'#::S</OD_6F[TSX [,@(
MMH*B(D?V+2B$/1/U+Q1,56)5]&C0@@?G\G.N*#/\!15NX6G?4M>=D=J-2(D,
MYU-(>8)0 EOX_5Z1=J2L,6L>Y-> TLM'H^H^[FKH+B#**Y%[W8U-S> FT=SI
M%,B&9=H=[I<Q4T/)PYJ" 9JH4(AQ!4JKN3\ QW#4)_EUA+?85=A3N/#.X;,7
M\^.--GKE@Y*W)'%KG+'!7,[G*OW?'V>'<%5'98? /$ )PN5@($;E\]JNJW\Q
M9BMPG'DO]#)&32DW$R_#";1 GT;_M[-V=B"O?ST">!/@_M_?/-1"@(;+->0\
M&OW;>5*,'75K/O(*:TOA;V>=[4R\/=^"0GBX6F5)!('E>/SG[1G)R#P ,JJS
M?]@Y*_]K8B6DX:^):,/T:<[,1B%'6@VTE5R?J-A'\ZWH&(+F9/M0WBP/"\V;
M]H_,+"AG^#!9TVMP)1U?!9_O+?(Y.TTL# OP65M+T&0HGYY,M, ,GO,UER[.
MVP^H=<G-/A(,Y=KA96HP>X@WX 'BYU646H3DE2FK8+L_(;5# *^L(\1A?<SB
M53UK%W=<,-@WK@3^]WIV>R7^CZ9QD&TRZ?QH];)K@WD*9MF?9_EX!.V/45P.
M]:Q]1+)826Z@T:#Q1HU+#$0D?4.]&_ BL.3:&C]\_JQ]>$U?*-3.61 R8"O-
M/T"DB[[&MF=0E&D2KO=,/*!KH[0L)?CF0C7G^ C\7:9G2:2"I)PJ(;\:4J?O
M'R!7??(XC;NK)JQ*W8,H3FZ3\T##9>)":N*VQ6EW:G.)?O^+P0)M!8D8AT58
ME(*#GMUH.>B;PS[+V&I] OMG0[EV^8^G/L,N(R=@?KNZTCFZ*Q+)G$T?/ L0
MK\"PJ7UR?L;RG9,%Y:H5K3/4JR!OJF1R!QIMKFJ8U599G="O XD-W_@TZ=C
MM$Q7??#\QN") P_/)-@HB?"@0]Q",P'47[0[LBM@?TEB9(!C7NUZ&[;;=%K?
M_>"E]CE\&7(UW4G/NX!GX+8WV0M_P^FCV] <;J(<H9:V!#-2L8.TIA=&>^13
M50N3/R(Q2@GL)K?6;J)UQ5*>+//]L:PC-F]F3^7-N]P4/O5+^3M]Y07SE=#(
MQ"#S9/BW\=3LA:/61#W/VRA-.3(L&2VEP=H2G&'B<I!FSV_]%\&N:,:?\E@/
MS,<>^[SHH]=& %-EM0\NN,XS<?X*UR\_7WW8O>"6_K5,RH1DOTIQ3KZ%MEK-
M;8/2FS[Z/G[2E.S1,XQI5^QYURU*BAWCUJ1?@^1:WR+VN[BMSDZO9[MQZ.*W
M+%[MJCT-T_9MF?,7R]5QY]Z^D7BZRWAYIJ,R/_3YV9;S>&KZQ;@>;>+'\Q*N
M^L/'9Q(S0_K\EGH;CN]S=V2ZNGA\A>\O.Q=_A+"756!H-D42-&6"ALJUF<,4
M/ZH"EN=[<L*;XBD.<9J<GEB%</O0W0'R!S92_I\S"7"Y!&Y=Z:_/Z^_8[Q>#
M[_UY0<K >'85J.XU LA0B1R+/)B!;HVMG6<2B"%+>OYS)4,V-[D4J7Q2L%N:
M*L[)DECK&%:7^OHNHA" C.[:N/,%Y&/,P1>T[#7 'P, *828*&CY]2DLB=+]
M:-*EUL$M>FV>X(*A.6C\ESA[W*OVV@Q7@/GK5T#\&!(YULR L9E$^_.*G$C<
MB<4;</67\TPD8)Q7'@D?^\""5=1#MI7]ZX*Z-M1LH@PF?\AXVE]$/WY:SL1W
MJ9Q+JWAF.S8UD+]?OS1'52MF&OH:9E0*SHTU#KZV0'\Z)!XE4M;= ,(RF*$X
M="(664\0_V2P+A%53]&S9V+EG- ]X1.C).E0?A-B])%4T_0=@QRI!NI#['6=
M)W9XZ1HZYQH89ONWT,,G&PJ7_FWP,[-^F*8T&;3J  %L)=_K0&WF$<"P$+QX
MDA1%_U9J^=ZG_#\N:.CPRO0SB#/-0H>>'35-#B#5_&N$[,/-YL?"1?\@:R4E
M<9D8B2RISJF:PZ-OQ@=#1QP5D<949S[EI>K! >W);J$U#M?S6"9++;XNIM:O
M0^,QLV&09^5&1NI)FOK/7D5*O^],&"A0 J6;89B+1A:X0O,\=7N]H?IC:^EX
M7*K\!KEO.>+C+%,]V& >%SY>7/D+CB7;I5&*R$E[CO-O\/WS@%<<]JP.QO*M
MF0A 674&QS8[Y-5?U1__$%DO)ED;B:+P/NJGPX5DG^<6.^FH:B<HF6+L:)A0
MGXI%S^\8>:5(=;EL.LUNU!ZTN$2X&'^,_%!:(XY]R-C2;) :0Q1T$B3G,].@
M?QDBZ.$H5;M;PV%4U%1D3S(/$;.JEGOAA?]#)BPV3*_+K5:***C_GKJMUEAY
ME*:XE<^$S/G3Y7"RKF[9N7Y+?%1:XQ^![_F_Z:("@37=&O4CYN#3+H-TJ[JZ
M&!M\+2'N>7DU#*L!,?6R':W.7]DQ.(:*AU+&>D+Y,2JPZ<U/X2&<>"J]SN9V
MK\Q[:?+W7Q$3$DK*J8.[E97W7B.?\/*OA'6X5PC@E+ 1 90]@8>[^"H$.Q^Y
M]Y8Q3+$$/>/YW.Y J'[[O"DI8R!(23AQ+O> 5@U+>1,K#)>@),<X4 Q 0KI-
MB]?!E]'Q7J-7I[LAX0>9M[2X1^H3!^OUT\EJK@P.X?<+->X77>%J)I#.9./0
MUQ)<>,*K*U=PR9)JV%/BW(E)EL."K;+0>N6[YT@O??K\3RT#PL*H5H^XRP\\
M!OS%1LR7Y.)DV>"G"MTGOU^M[7)5Y[8/N?26.:C1ZBN93MV7"NXK.#K3YE5[
M'I?-K&D42Q:#V<L^Q.C]8:RO?R67(XB>8I]3$)'#^'J#8KRP]$0IM2O/4-V'
MU24M]\EO!,"YO1%N_675)<Z#LV-F6A0!8'<-OJ].ELKCIA3E4^K/.#LOH['H
MW-GWW(.8;?CCZNW*92]"DKN.YJR317A>Q>7\R$&/GK^X*"MK4,6WOU%=,UR<
M"0Y9M6!(%XC"H5NLORPK"VN]'UAJ>V:T#-W[IO(&"9/KHW*M<?G5,'@TF^,2
M9AZ@!CXRZH@AB?0-7%"$?KZWSLX.9#[+N.TY$_09OEN[3HX( 6*'H$?T/T>W
M0%>1F_9(5*R.;&<S5$ A%0$L@9(*MS-Q)+;N3^"#=.X9?_\^M2MW"$TSC#A0
M0W/)Z*_:7CGVI:M&^8;-Q)A0Q<T[G'QY2I]$*+ '=O]+J-J'C^BQ@:+,$X^\
MIFX^L$(,)7H[R!90T$#A8H=,DJG'1=]CA#4"<LCZ;=.9JL=*VZIJ*-;KDC%?
M!3R764^?[#,B+IP,LQX+5==?5L6,'YV0O*CVZK,^=4R76PB16??W]12R1O*'
M [(3K!!N@CBUU]4#$J5\][XHOZ=?JQ-\OH0/VL=6^I^;%0J]0G9^H8PAL>OZ
M5(O54 H+TU(@8W8(.QJ766/ZV-#L2GR.=>,7BG(/MNB7)P3[40J.=A@C->F[
M)MGFTC.9EJD9[0%"7EKCV1,'"3B6,4_+*KGDI5]U%&CJCLO6WCX?]N">'OJL
M&3!9TXZ^E2\V5>&B]&QDK01W+"[.TW.OSHWG"#FA&>[RR,Y'C.<[;^$Q3P^;
M:8[]!7I@Y- Y)$K7YMG,$JI^_[,AX3&,TTI>^.3*+7G2A'"4QQF6LQ2U1&Q"
M&DC"A.5,HY-(93Y,RI>WL=@6EV[PM*_.]?8DI,Q[698MN'C-\Z(2+%5T=":O
M5^ G<GQ0<Q&1?Y@2Y?,.X+<*W!IO(W/NY!T#?R]XT679&B<7/<&F!XJZLYN6
MHJM)_X%'FKZ)9]NH0!+&-^3J2JAF=[Q3Q5M!.S%.:1ZTW/^AR6J ),%ZC6ZB
MG'9:!0&T4Q<8+O&\5>:"PO&.V?<>^-A K6C#X?EV5KHJTB7?7HC%=D-III_[
M3KU,QG<L4H72WNT+J 0N&94]%<>/B(=I"B?K/<O"Z=9V'3M2=4+.4DH1,BRE
MYTIAX'5OD*_0\"XHS[W7-7.:*B9TF:A*H5_A [I7#P(P$YI]_ -%FA!I-.#_
MLZ#$BBO@1WPVB5?"%<]07N?U"&W*N8_^9<%QX<Z, +:%)LUB!&]C<-!?S#!M
M0R+&FDVYS[</-JKKDT9JC9^9JOIXWXR&K>$,QPO>L,WWQ9/:[8!;9AM#)FP)
M[/#J?N[FHAQ=R;E/#MG=\T3<WW!I6DA8RX9WAN%N[^5@B/0_2'@[,+:<31J$
M],#?,72;PN*7,%WF8%I$T>^E*58^]6FG>ES>C&HO[@3I+9.00G5%2I-*:]Q%
M5 J8%M#NV%'OR.(O_9WO XSNK\V.<_9OEN'PNKO3ME_25-5Z^K,7;=?7SK<;
MT!^157O0L]/EJWX$\!&P'S4TLYE"8J^-MJ-X!( K-0Q#XJ\!Z#+7/2E*B9R5
M?X81$C\G((!6?3C[K50= @#Q(("WY;\U,+^AGY<Z:AL83,(<YG^FU?,V?T
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M>*0J I"J*2B"]O(>W=>WG0J%S2T?Y<0<R2=91QY^TW))K^\MHNX<J8R_)1A
M?2JC.6B%;TK%"]LZ:=H_'^5=DK')@G1DG*+5W=3=?[!KA,5=B>6G""HU,$0E
MBF[S%]Q0%3VJ\K0@,K =X[8X/$1'N8&"7:JG:U!"0^.J/U\8W-QGK#TO4?.V
M_?6+4JU?G(N'9W+6'0_B)H\ ]*O&OQ/W)8G+I]8A '#EQ]:L\F]^J7,S6XQ\
M5^G5#N[47*QGPI1Y>ZUJ+N=D!29F^C!DD/3QC#PMG[PX!^/N.,@Y.Q+DXN%C
M$Y%GDO&0ZF=1%);(&1*_VO5%$Y<<2F.+%4>E1/E1+VE/\$ [5/V=^]Z&GX]F
MY,\U7%>WW_HJNH?[CN4YLR[$]?OJFN="6^HH??KSO]+R9O>/KGVS&ZJK^(5J
M"8IM]W/)^(\59,]XG*<%7'Y]R4X6+>6MV*A=5_*CV2I'-KO@?FSJP+M^_$4[
ME!09';BG2%U(LO1R3QY"DF")_*,LC0B H<8CT]OK'N1A=G,(/6?-.V&[67QV
MWX0 /EKO@$OLSI::+_7IVV*]47Q=U41[8%2UI1Y8-4\-%P(V53O)]L;'Z@/J
M%&Y!LV9+K5/006AOB10D[>,KVT[>NI(8:91NI9L:^CG?R=&NUJ3U]W"M](QT
M3FP) 1>),56HQWN.A1URM]2S^?.RW=]?IDO4#+Q%76LOC$NLZP):OBCW+034
M%7_W<;KQ_PKYLOXX8-\2_Z'O5<%.*_W;'I>BMC1&=APB45VT?(CIL'K-MTBK
M9AE)=:V _-*ID7:Q>/]6E@+> 2OGX:TKO.3^7D[1E9#-1R&6A.$35#$AY\FJ
MAOM*0T+Y69F]EI6+;I9J8)+)@(Q5+K4.PZH)@*B7V/2D#0L!E(/)4ORS9LUB
M]M.-V\[&I C][R##-S4.PO4VW@B ZXY>736DT2]Z9TI@?O?FPRD[T4\9V?3F
M6 WO1(T@'C&(1M<A#2J33 RF MN(GJRQ?4*5B>&\O6:E[*E34KR15&C]5F1_
MBB-L;N>XIF7P@P/SIL*95W7P1+K;]92]SO:O1<[H.)_R'%68<U.DJK^#ZN&Y
M]6&PLZ#O6W)]?;G$7A0+>F[;^J-=_T$+[B]W<63D#J[&2MQX=S-]UP&!IW9.
M;V6=B^4>I3F31DLKDL3W$$7^HMA)M=A)_N0#MJ,\!LUJMM,%M>"2A.V4Z=?U
MJAH$><\9&)+UD\!E:UB:5?'QJ'LM7\/ETRQHUT\RA%'I)3 H5_/<;><A15@C
M(8L[65PF\OQ<86(E#RX_V0+L/P*Q,LG0IP-4.]]<J\TC9[]G"2FX0Y6_Y6<B
M![,Y]ONBV\[+$A>V),Y\WU0=A^^D533(J"J\](M5AONE\A9=G#NYMI,XBK^_
MBR-U]:.$7/E!>F+E==0 IW9+]Q)^;PL5[Y#/!DJ3UC:\[?>B\&("J:W^R<F^
MNZG,U-N7[S,&WT!QFZ^2,SWQ\KC8)>BK"WOA10Q-'HQ!EZI""?.:+UZP$2UT
MUX>W?+XGN=&K%Z6DY6)5@<DKSHE6:VQW8 2,Y!(=)3O%.OL[;W&$]M;VGIK'
MJ&Z(K:.*N[<70U2^2#HX:,J187S\BW=5/E2R@@@D)LR16TPFH0AV5U1'"%M6
M!4;Q V%N>H4%GEQ,8=4QY!4ST28J?H*?C#[_JGV,N=\@ J!T&;]7G+#J.80=
MD$S);K:M/VT;:O3EP A#R07C55?7-[4D>X7UPC;C-%#0 NO18#:+UU^8+ZMZ
MK?QL<&/JEMQ?Q_<=*C )-3Q% "$)DVT[<S((()+'"L)1!8Z[3)@U.M%[C$2T
MSU.>'UI/SKM[>/_ZA)Y\^LKP19LK,WUW1YL$BN[*"Y;<I%I9XL3H%E*/LK#2
M_'93@WEFKR=4)#3O$S3AZ)<BK('\A^=I<@^;>&K&UC85+4Y3_3$501%<O.RK
M<WH+K]B6PLJF9 ];2BHJ6D+N9VU"F:J8WO1V%#)5D"66S'3XE-GMWD95NZXJ
MSD-0A:.'M^32VP\:XHF;+RN-NEW$HH4:SJ-]Z+_VPB'%%4T1]]W4A??[Q=1T
MZ3G'90$J7#!^CP0/NQ79#"GTZPEH=<9$@*[S\\; Y>6YN?[*>2=RHKCMIK,&
M_P;TM:6HP;D_]AK]G]J0W^SICWM-3=;Q;_6]PPZWVMN9E ,S]KX70TT^!;TW
MGO,@GCRK+Z>['1)O%^AA;,$7+2H&WALQ6R\5![Y!/ BV7A&#6GZ?ES0&I'A@
M?;D(G7V(S:O'0.)$<V!,)ZYG%EQ]IZ#P09;U'8D:E?RM08+$60Q6>699</]X
M36, .%W'O]2&#C)W>C2Z4Y?8BR1I."P]<.8?/SOH+UU2Y[XT+&YA+$;4[_4H
MOYU+KW)9I5X45[_%S2M%LJLV!98ZPB2LR/Y*HQ_)/9=4"*  S;W*O]3(1RGR
MF2A(R@V,2F ]W/DL^8,8>(@WZXO+Y4>-,%(;R=Y!X:RQSNY\AED=+:4F>+*O
MG7]:\Z#C [W[Z4H?\!-.;RM;ZTC1N;UIS K'BT'/U>XSS0@N'!Z85328MJR2
MOUR+FMF&;A+VZX#3A+=;TW7W2E] \(ST-BOE6ZF*"JWOO&K;../XFJ:;8!BO
MZ2_/XC9Z=\LMLO]6O)G^0Z&X;7RH3B@DRT&DD&WLZS!#J*R%[,::R3)IAL$A
MG*&4LA=C7T:6P911EC$82Y(Q)2EC'4M9LLQ8HK$S?N?WXGG^@?-\/L^+^_W]
MXGYQW=?WNA1-UT:TBUZ'7BO8:6C/]52)B>L6G-K-67!G<M7XUY.>,FBK%_U^
M0,+2VM07*LC#6PG#*BRF,XWNW*"G!I01\N4S\M [445P:OFJ>G]+4F>&)C.T
M2KA_^-1-\D^5HK7N..R]F#1.3P<O8@N9&*C<DYNUT:L[2"@A;V+-KO*\F7IS
M#3SK26M?(^,0:H0:EV/ DZ;--<-+$^CDT56\8L9:O1./!"K>8&@_-W&+5Q5A
MZ(90A67J%BQ8F%#>O?/3-^08B,UJ_9*DQ(AV;(+>=(F(R*"F(3T=PU+1ZU]J
M>#5G_UFU]@IMD#ZN@GOJ>@+/37X(VKJ8%;MNCM Y,ATKB58A3P4%!#=$3C3W
MK0MX3$P&*9XW_>B'D/AVGGO2?12;E41@-,G8ECBD#UI;CUSG1XI!Y>YDO+"D
MUHRUZ;WJ"288+]5S(P:GQTFIK7C00"G%8/A;%8-> T443Q6X0<?;0BTH/JN*
M)N\ X5)0E5,3^\95B<A5[7UXU8>=9=+,6Z9GL'W[B.KJ/S<;#XXIYTJWF[[[
M\&+Y CMK%?R!I&?0OY7]0:#"8A/74!L+D[*+8L;S+]J-+8^.B$^Q-@-1GMQK
MG^LF\V&\XI@)R,%@&N?!BD&*DI)GFLG:*M_,;TY %XM*+:WFT_P0N-6*/%B=
M\'X_?5WOHO0(ICNB];/I.W.EZD"ZGCS*%P1N#:^MI'H1.M2F3Q<:^MB_?EXJ
MUX)OE#1IXX;C:JR0<PIN>JDAX\S!5D9RNBZ-;*!>A^^/(OWJC=W_SN)1**L#
MQ_\OKNUMW3 J#HC<=NL8E%-V<G37GS3W0 W,.*_J!%DS<TD))5\L1LS,32O^
M$!.C,E<=9V3?P*YX9>$^5;QA>);5RVT890?[CF9ZJ"<$Z,[O(8KGJBE*/=,-
M=V"5E:60W28T68(S$KG\4&$^UV>;1?R[[U;DDG=90]5H^$$,. 8O#U8U5G]5
MJKS'LM.:+N3KK!R AX5B7C2];/Q$=?K*[R1C6#V?L\T?;+6]X+*EO51#ECJW
MW)KVWN1D[96_IE-D;Q;VOIH/<P[> M[2%%"9?*\#(YIQ^QL]Y+,LI5C2NYWP
MGR ,JZF^<&?[!RDV,3'Y*9]2D.3Y\Z9+7>@0<VTF;YSM$/)4VWE07N66I>]=
MY8YRF0+]*V/9B15T*VMO#1T!U!_EB*A3#9-*E(WZRX#X$)-%DC F#A']%Q"8
MTNL@.VOQ1.-HC*+'@9W/9D+M=ZLLGL)E@G*D=<=E4RYHRD2+G. LK+X5C/?L
MAB'"\6@N=VJ2O>.;FP>/,=.%]DW5MU];V5JJM>$0?MLI0V\OB<X =;ZWL+F.
M =NP71=;5P.CTDKW9;U<Q<A%+EE_<E'IJ1(\B+6<ZE#24^ 1+*[1RJNV7[?M
M9A1[B.J7R$1SS"KTR,T3?\MUQ+N?P>"AET/BYA:$V3KL7\> P-BRPC"(BWA.
M&NK,L_1KEYPE-_/9V<A1Y\:V5MUO6GOOKV25E]H+L9B'KW+R@RL]IRQC_&1Q
M=_)I??I<F>&^'%)']Z()7X?FY%J@HZQ)>F5%8$*R-!Z6<PFFS0!J^?S+!"\G
M,"5/15ISLE]"XW'\IOKMO8+: DJ^XIV+Y8$_'1L0Q38 1C3KM7VWT$96@78&
M_Z_6^*O0'S6$&6_.(/L:C:23&(60EQ(H"AKH:F)Y#S4+_)*5:0GM/^I%(>("
M'KA"I[KTO=ND7^@:-6MOA"&1M]YBU2"\%)6Y"$/42'/QN>"-BP4!C2DV@<IZ
M"J;\=,?4NR\ <[7\.GD%_7G#=T9Z>O<=&&<EN9 JU#$P[.7 G,N*ZDIZW.J%
M&_I7.BL+/)E,TF=6=LNC6O&I@-3/Y2JBJ&9^>P,:=/^;#YS.X.#1<'Y!U8T'
M"S(]/)9&V,!AXH-Z*,7U[,,X(>6\.*H/6VA"11/M8B[H!CEO&8SOU^P!?0Y-
MW<&M9-=^]^T@ZTXZ(K<.,*2]HUXDR7D=L?T$*_=8[/>U^.9]5O53?!6QI?G/
M$0H@(O]D7Z/4S47AGH&H/RH+;C7FP.&(H[)O7L;-7'<]SH%^/"X8W$@H)M9B
M.(B-"9[KES\I)?!_?*<=<R6\Y/91A,WY(OM&EY*@8N7([3!WX@>7$,B9G0HW
MCMM;AHH-]R)$?I[<&?GV)T<6Y!7YT9*9K4ZWYCIIX^; R0@MY3,7W,RI=J?Y
M,QZ&K5[OZ_1H,JFZL(T6%O;E>"#?,O4UAK8-;.%7+^Z0&B"[!],07V81+C8D
M3!^6/2+_#O%&$]];RUW5'1<0:F<2>1+7!:PWGGC(3/VK5LMQD*]X1D7I3&/2
M6N:";"2=NTO^YT#(:>$X>Y.@V0D-^/G+[F+Y D(<Y*(0P^48!1;Z&,#))MV^
M&JV[BT:O;QKH#2F7MX@,1"$;L!G:KT398OT6.^KF!L:_*0U7%<5"Q#H>MZ-R
M1*!WCP'\_JT%H(K\V4Q+>9\S>_D@?6;1+-Z0.%T:B0,%'(0;6#0G8G'#76+[
MZ5?%#9/)H[Y>!G#YOIB*T?)E1O3Y6T*9EN)6:;(/IDL? ;'YDOBMO@=>:^"C
M8'=RRMI-'Q_P\ZE-_J\;GK?\0)MDR4:E ]>PVO5?B'_TDOW]_X$+8="=P[3_
M^KZUF+@EZ3)K,EJ+LH_Y;BO9ZN%.\86[WVL"@>23&>(*4\/CPOGZ]F961XH-
M[ETA *SH3\#\:;NQ0Z:33I#1R"$2U<<K+P]JC_KG#\X<^]V8:EGNVIAR4$B(
MC$:*3J9EE"Q:X+691FF:)$S9C="?23-L>YG#1SI+_6>10I# +BXEGL>/&8J0
MQ/K%3S>IZHN!>\\Z"=ZD3?UC0$/3#OGO8T E!A0C5EXW_+=A5)1TKS\=VB/Q
M_+URWL?%E]2*H9_IQP"'C5.KA4GW:=;J;8FA!'DO_FN///O<W_]*]!*E7U(_
M5PW<LWMK^F(/*.2K#/.Y39*R\AKVVE9C:/Z<7Z"AB>V$G;AN";-,.?'.9U^J
MI"'>L/Z4ZV1CW_++#4-SPE6U!FZ[KZT[VBXKC\BG^=_)3K[VM<1J&9*($MW$
M"!P-9/W=:6L55F:1(.OD9^CTU*2",>U2A^IJIH78,TJF$.SUYA]K6\#"UVH"
M;AV5!0EMNE18M@#@(T.S33RS']G9Q&)UYI\E5$FM["1%U%IM\ME8^Y*O$TGI
M<DF7DF#(ZG. .)ZHI])V>2_RV#-T(^\JW-7[A+N=K\5JSA9EX8 3HV3T(8O5
M\F$Y&EL8],.M1M4O'=R8[EK1% IY/U_$VVY[V^D-=*Z;'OL8_RE5UMI-95YT
MWL_2./;9GDLT D%'@4T$\L)?O)R\*A[^MD=S-4<[(ZS((%[+O,FEG73Z46&\
M![TBD]9@L[X&H8[W5?*O"/,7.P/]Y;\U_!YUJ:VV/;>+.'?'V0UPXBT=6!;H
M&R5BEB1&6ZNSL]@7=T[7\_._X7\M6_;N<QP?D1[!;I*$G);U<& 0YC'M'0=%
MA;B#W;5CP(I@E^!1CB$EL"\>M!ROU!M_(DV396&"0JO.E@.P!CS+)U%)9Q\)
M@<^*],JBX3+)H$<"E&KNCSP:&*:#4FX:86P$*YA9U=CI%BNS5)9,7?G7_?&R
M L,G$8)CA&816@Y<$#6/;5O4B4Z&$^LTG_BUMIBB_[1M$6$CFN6FSJ+.?>;!
M7["@&F5M#]:46(L'&?/FV6&=;4UH6&)HLGY)*#K;$#W\)L-&4O73U)HX"*#'
M@U>U!+]/>REQX.2]:Q;^O*XW4$6W^X*(<3U(R=;+9( )'7)8R$49:$^G ]<4
M) 5O(?0.(.,?$%HE:I)'8:-&1_<4#O5QYJ<SFUIL->[N5?B#<TL_ZL\-$A7*
ML9Y=7RMVDE?KS.;,W[9BHRI)O+(;49J2'Y"V-OS,D6*17+]3=$]S@-N@ &>'
M+9<!3\L-U0!B[TIIS.;K['5E!)$K!UC])+%6TLRBF^]9\D4*W7IW'7H)"3--
MW(.<&(+A7,M2ZHNDI^CL',JU79A9# ;L6KF 6"'G73;":36RG>)61+X'NW]7
M0)?"-K,W']Q<%%UV5JC\*4^6TX;W!N(V%<?A$=!PS$<XLDZG.Q@#OZK!+K:U
M:KDA5!@<6B[: U6B*I0EW_A_:U?^'XW4\?A_ %!+ P04    " #J,W%41"V7
M,UN1  !ZM   $@   &EM9S,Y.#(U,C T7S$P+FIP9^R[=51<790G>@D6/! @
M0+ @P2$$]T""A6#!W:70X.[N#L'=+;B[NQ7N[NY6-7S]WKSW^GN]UG3W3,],
M3_>IVJO^.+?NNGO?LW][__;9!SH'70/>?!<1%P%@7@$ S,L'@"X"7X'7" B(
M"/"O$1$1D9!>(Z-BHZ&BH*#B8[W%P"8B("$F(B D)*5@I"(EHR<G)*3FH*'_
MQ,S*RDI"Q<7'^9F7D87U\U\W@4%"0D)%0<5#0\/[_('PP^=_\8"V YBO7YG#
M=L#"D &O,&%@,6&@W0#)RW/"P_S# /[O ?,*%@X> ?$U$C+*RP4U;X!7,+"P
MK^!@X>'AX%YFW5[F 3A,>*P/S(((;V5U$,FLL#][166^)A>JZ,#Y.7%&P:)K
M[8V$C/L.#Y^ \B,5-0TM*QL[!R<7]]=OPB*B8N+?Y>05%)64553U] T,C8Q!
M)C:V=O8.CD[./KY^_@&!0<'1,;%Q\0F_$Y.RLG-R\_(+"HLJJZIK:NOJ&QH[
MN[I[>OOZ!P8GI\#3,[-S\POK&YM;VSN[>_L'YQ>75]<WMW?W#W_I!0/ POS7
M\4_JA?FBURLX.%@XQ+_T@GGE\-<%F'#P'Y@1L 1E$76LWI)]]GJ-+1256=&!
M1,[R\PQ'UWH"&9>"=9WR_"_5_D&S?YYBWO\JS?X?Q?Y?O18 5%B8EY<'BPD(
M +</U%F>R/\I_\$DAPJ(1+HAVH,Q+F>I]]EP7;";:?O8H)/3+$%1F)G,N2,9
M$HVSB\A%BAJWN?]S]6Y*=;I:Z_7"G@1:?,6&V-,4?;^^A'(4;/^: V]8P]HX
M8O:$.I/_M=:;?4VFY,Y62C#9-,K\^T-)<8:95X.$=-E99Z\IWHA:U(PM'FKR
MGR-XV6UJ4"E4U4[I@0RJ)M+Z.1:T0Z,2(I\&1ZK7T+EM1P#G:9S=I+Z0:W.3
MU<Y&#[^MX-[;;MR=XY/\4(D;3AQ8YL7Q6F68-$[^!MPGAF+3&W[&YK.(("8=
M<!G6B.4QV^N,-XFZRQ4^&?=?$?JD>CUY@NF('[MK"=RVXJO4#LK)]#ZB?3S0
MYP+.]O'E9BLV\U7S!<)MU=2<+!C)9G2\*9@HHHT3B@HR]*-_* /H-E^(*'$T
M.Q]6Y:9*RX^V+ADLLL0SW7(L1(#"CBU]S)D2&1AA[/]S16RX(/>WYXLM'%_%
M)U. Z,T) \M"D2O_])->P\D@)DANNJ'TO1TSM=K@8Y$XF^0*ET^ZX3QA>\-)
MYVU#2 5YT-GCGC]7@"3F.-:U0RA5COL"-M5"R.U08%&%Q-H#MZW9HW.,,LJ*
M(6^D$:' >&$F%%AK)(%\K!%)R ]C!65U@I7AYAA<XRZ\'\QZF8^#@;72:Q22
M=Z[JXE<AL4T54ZQ.NDD7RSX].X.'OJB<5,94P=UG?:%7ENBNY/43-3QSI#/5
M]67TVU/SYRQ##=Z^<MX=E<U>7FG-!->I C_^3)J[C^3-+:JH;=7%F6/U)O))
M8</(C&2"WA'$.L<^*(36G6\:3"UF?T\7)2>_S,"@KPESQ7 ZVX$":A\GQT'6
MH%N6[[]J+QOI"FP6*3[==(P1SMQ$%2PXIF]2/*3%\#HXVR=F/T=+%*C9FO-&
M!RR4<)I1#W0<:EPOIY9EFE*6'E=SL%^@\LJ1VNKL":Y-F=D>$C&"5?=O[&_B
M#ZS)ZH+TOKA[PGS!-4T_7WV*&<." G.TAU! F,T69^SN%"*^&^1QA&,'!;*2
M/#%>>0SPGLT^>Y=Z7/V<%52' EX"6VF.II .Q;8'&M.,C%?!U/]QI $*$$&!
M =YSIF?OLK8K.:6_#!(.!5XLD@#I4-)ZH"D SJA>3(KF,4<[^V)1AK\L^O;%
MHOYM1SBF+Q:-;T0&J+."_\,(W7\NL?]<8O^YQ/[Y0EN6R]#-;7:AVD-15;2-
M]2GW]R,"J;MA3$LU@9(]@ZPZWOF[P.%>S'RMQ/8!WZ\(9YQ;3W=]Y*UNQ74U
M3A35?CN*XBK8C7\ GW#!/I(X@^_%A2X]Q:#21F=V^?WZ$PEA[ '#X#>HE3G:
M5XSMAC7FE/9?'FC;%H^@P.X)QN,=7<ITS8"E!7]?7C^._';>RCLK8M\;B%U?
M<-]$5U=B4VN0Q6"HFI&2L([Q"FGP"1/M^22=[X&R)\GJX;%JFV45%$BO%SA=
M*Z76HY[Q+D2B^V0%FJL0)JML]%=$S=%_8XW&8!N-K2"IJ%;/6EQ8@L71%/[1
M,?K+]RJ82/37AU.EBO4S:Q%=HBJ!3E%L]4F41.I_[I4.Q&'/,]"^T[%+JO)Q
M3X)-?DAN17E/J'90Y$0B;!1X)1M3E=?O%"S?!2\S7C5D-T(!H?JWEJ\^JR1^
MZ3SN/6[?,H?EVL2&&9=5*2Q1T]B?=<"MPEM8?N^QP+#U%1\E4I4=>>YTD3R7
M^7I10JQT<D?E8T,T3F1I;DYE"LG&G%>B?,JF0"I@,J$BNSI %<CKN:6:3)E"
M]W$22?>S]6?.(]#,"NF4)>//%7R#Y8^N^2Y.6%R.8_U'F5KA[C\=X<814K%E
MO\#_:\4&P@,%HITVM![A-3SV\LJ\_XX,,C!KTO=4:010X(]".218=8\N_6_
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M6:@>"D0X8IQAG)+<1.RKLD@256-)L_@&LS&>+.-\&?C8H)VOJ3FQE]#9IO3
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MY73@@XO5BB<WCX:'9'.CA*-A9'7B16I&E%X"X5.X/-UYS$5,^PAH5F#C]4:
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M2V>E.LACU:;?:'^X<(B=OY4Z;FF\[K'E,:L> GU$@J\FM;!70.;/QQF)UU;
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MD1D9:>-/,]>F!GD7";(%KT#A4@GW32+AC70^8:)!;!7<7/T0PE)S.-=-!GJ
MXKEA:7G7.A]'EQ)2OH;IS<Z%:5WH=_,/\JAS<AVZRM3\?0>,CEH_9VW'\%8<
M1;7 2O(ZAFPH=*>DWT:(GT/#WVWW<^[/[>X/B6+=(1^N[V27(M95A4BZ<9\8
MDC!4CQ8-DHQCX1EE]+$U99FPI]'=M5B5@#Z7SB3F[9/HFA9<Z#FM?-E6:&3'
M1MV<\62S:R.! KJF;_=7SX(<RU[P=A$2HY-W_Z=5GF-PT=\JA>27:<*Y47=Z
MG2.'>A44\*7K582XIUN]2[7*-0OGF_BS=-SDAS_ Y^?<\S< SX#]V\ZCDL#?
M\/M_C&/]MR2'@IHB$MB*6<AL:O8>)/GLL, -<-&[ 2>FB;/77D;&"00IUE$L
M9M63ZSMJ"4<8UT=T^-.N*Z-).PF6TZTA#\*=Z%+]'H&N*D1^B2[6BQK-!?/O
M;,:H](,\ A^O<!#]>6FX-<J:RH&'9-BMCB9K59HK@>[=)G?8X(KU4[0EAK59
MMDW"QBK&.1WI:T5F*&#-?'BP# 72Y920:3&2I)/<'IBH;S163L<G7VA6Y/V?
M'$/D_ZMU85Q!4E2NYL5I%PO9M]8Q153&LL)W*N,['S5U&(L(%OJX)' L$Y^W
M!!ZI2S>E#I-4F0[U.#L/3K]Q2RJ>*D>55O^@)SV.?IZE;NT7>'G04C0>T9HI
M72N"1,J81,/8$R>,!DB</><DW@QGE"RVCH((0-SY$F^QV@+S:N.GOOI+.$E-
M)O2/UW(-O*?87"CE=Q@@>I=^H+#4,K<7R"J)VSG;H]H<]26C4^\B0'^IP4Q)
M3I,FM^><P./MX4R4:1T*7X7/J(XI*'Z96(D+;W__;K8<5/>N#I.YI<)45!U
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MVB!YMT_\_F*C*7&[)3F0WCQF.$T/,HCN\=;K5'T$"@0T2YPC#XJQW;\3FC#
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M0^YK(F+Q9 %#;&&LZWDL7PFS>QFA/KB5J*9P!%\N17*HD\8F4"90! BYRQW
M]-(UEPN<]X\K=>.:;PP,@1C,.O&^E;$/OX^G#; :3('MQ^/J%09L\SK7FTT:
M P,,JIV=/ >B'GM!L#"AN]O(SE# )?RZ3IW$&PJL:T$!LQ>+OZY[\G!"]'B
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M:'_23QI"1_=&"JOO296_CLJ:"U>>;JK2B?!L#.95\"5#6'.S"O3,G3LL8]
M=]"Z_&A37V]F880"RB?-UX=]3">K2_9YEKZ4_*0CW/A#J!WH^]@A,T!"&Z:]
M^Y- ?-@\"1*T.?$RP[^:[HU3DAVV>L?TM7X0<_BX[]U;NW< FS%5796G0XV#
M[-G3I0X_<EETP"L/.L\+MO]+L33?)N^:/7N&7J/*37YDLZLI%<;M3]>_SVK!
M@C6T?JS5!M7G.ME[TSI^9E+KJZ"[ #)KU@J+DF($"O-FL"-$+8M@K>'DJ1_J
M/N^>'!X>LLR;'VYQ<5(RL>P#+V8!ER*AWH S:V_1I-S4._T_5??KG:B&L<)>
M49WQ+)%(>SU4OF_A4N=<\HU4VX;IU7F?5H_SNAFP17F9CF_Q#\8EHIF^.Y\=
MSS]/7SGOG/7IEYKQG=54G0_%0?=&WA"J#0O-R,D =JWTL-SR-"9;8E>(IN^E
MFIZ#M35^MJP ^VB4CH_;"WE:"*R'T5/DF#<-XK8VQ-#E7-M*V10CM5E3P4\^
M)M_5K%;KO+K9(!(VDSLF3NO<LNK@D&<F)=ZL+ZPV^HKG:B/REVHR'X^-<!$+
M$#U"VDH-*RVQAM*4$;O&JOM>:L4OZDK'5Y &+#]T(5-U8ZIC^K-EXW];)5;A
MTBZ?,UYRLE]DF#_S"V\?>W.^F*99<_X*"U]Q*I'[W=0MYY?4)E]GP9LM(P-M
M/KO@$=(LZ9BMK2G;['HLR'."OMY5H1O74G"Q QK =7#;;T6UL47&+\0L6D[;
M*6R*&QP:C0L[K2#.2CFZ^$[-*T:*#7L^U":IM7DV_3(IOVNW(.*AU;T2@63+
M?.UX385_?F3)SDIBQ\;@U8R%.B;K@5^H,.PA'D^]X'$>9[<BRSZA7U6P^Y)'
M)4SZ\-4M 691BT*3N K5C=+]M,$U ]VYNMVXILP,-9EMOBD__LQA);BNA^\(
M<7^M #3,A7F48"MVOE&/@]8LR:1P1^AAZ_'3#;";XW984+&7\1J9MQ^T.;D=
MK\PUK\NN'9QO)%,;II+?_^HM??L4C8CGDN!!['Q+ )W]D5;DM?#/BX=ZL[**
M?'DOA-G7SXF>W3U%:/V@+=OEM*C)X2\RW]GT(FLA+_-(GO9;3!%B/S3>2[H,
MU5HRGCRR$N%\L"AC:=5FT_8##3C)X<9./**E'IX0HU""TDQ.-DO/% &"TBT-
MW$M]0LBART\,^^G8CD,N" :_?4?S>81</!K0C/*^0&T?1EUSF!A^1$S?N(@H
M^=:(@LK:CCA_AXGA&[H@./8V-">J!]F?]+\XN]8Y*)DX[*5>]5(IN.2U"&&+
M;MK]M6"]]*>NT_<_9OC8#([)D]>*6 [/%0Q8#"2H*WN&3C^D=48$)&F/X5;'
MS17)V)5[JL-RAKJ^2'FQ#;)ARY ?*C"M$L1-+N_R"5F)69]OD(^A 7?SVX33
M@>1UTCW9)H4F26S?;1EV$@C&MJ>3 BH>"8 ^U7WRN6[Z*'[9GWN%$I@"3;W;
M:61BAI<R\7,3?J' NTKRC,QO*7:WW':J"2Z MW4BI"B/>/6<$O)BPG\K0"ZU
MF<^*5^ 2J$472\1A7J'ID=3OJX<0.+8KRJDNUXQ:-JQ^PG'!TBB,/.(5Y8U>
M0>:8A%M+'":7%01CW-*F*/\X VZ ,A%E;GTR#<I?BO\(5[N)7<=704D*W=0F
M$^T1)-[5B43L,#^ZN6.SO-?X)A52N^L<183D>IV.>C=D#*$WJTRMO7VI[IUL
M58(9IN]O(2:%1B.2J/K;S051OGIP+/$(.SL/[/F</C00/Q\V)(B,'$1HRSUX
MN"!=(4$L0WTFK9KN?;MA!"XO(N&"!NCI25-)SV(0FX][IV37Y>::S=U0=:KC
MCINB8B-8P^O']C@[ZGL.5LFHYEZJ;D\BL,O5[,XN3?*@'L^*D\,#W)N=]RPW
MEFD8>B@+W4I5ZFKL[A=5?R[3R "_CR&REK98KA9SR)']'Y]CFQ9C.9EGMIXE
M\"P/'K,E9<WSG8,W[9B/9P)68P?UWP@'"S\MK.Y" RO I"$LWF#)+A=NJ)5R
M8>FGYP@*34'%C4E8WRGVUF\FZH LA=^.[-.HMA\Z1&W0UM"?7"=<+?X6.:)>
MMH]/$DL)1'DHGM:C@59Q,G\H&GBP>]E*4V^MW<WYZK60-*S7&M<3AD<"^1@[
M0[8=1]9=3?'EA\W'"+-(C6BIYTC\U_D%,KD+SQQ)H1/6?^H8K[Z]&4]" QIZ
M?$W5M:JS;KGU,C)4&X?,.+ ACTE#PC.98 JOTX_B?2W?34\LYE _Q]JVB3ZB
M 9]^%%GFW;LXBCT!Q#Q'0P4C 3][XJYJ!.-@]&%A5(:J6G3WVKXSW-R/0Q+E
M"?:U3DW,.>&""TKC0[8O5/>=/.Z#!R*,4 \M"1'W]D#P5[%(,XR"J3M1OD(C
MJ <82$Z]LYTU)U7N<=_KWWF;14 -[&3Y5+;1=T9U,KR3^;#K,F);QQ[KMET$
M6VT^AS4Q8ECO';V& H6Y64H680;=<\4P:HNN04+EW :5I#58;A-?I6/.Q,L[
MLR NTI]J*3;,N2O><6<VX1\<6\A[VB&_+%V)GZPW +<M[WF"QOU^V[D5X29*
M)HHM7@?15>WHBSP,]7!=T_JL,\GR<H[IST8L.FOEJ/[:7Z]<#3\L>"E@<L8>
M!K0=W<\YWZ]CUIMYQ$5[Y7SY*ZA-YN"=>Y[/T'2<$S8UJOZDV8KH)<=<EE$$
MU@-[MJK,*L?T2UGUC#?:C6*?,&K0TT>-HT90 XW7;PZ:/*LB2]V-5G(\WL2N
M/JL>M_X ,9A>3V2\-;Y\$\,KVA'F6#H>TA%/0+K@D3+YBG2'[_+5"Q'6>(H*
M?7Q;O90>A\WWAMP]BT9QHI;>(6RYG&IC=-%^GTH>%M,I=QFPC]';8^/3'O?H
M?&%^K'@Z^YW8Z+ADU_=D8$&UUL.R7MU,KU"@;SW**^C\0$--JNOHMJO16PI6
M:OXZQUE9EWC*^Z(*3+<.+0)*:"OTX)\%?U07>!$WT>\_\9S:,\0WCZ_#%= K
MV @[C#QPJ7H?M# E'=&N4O^[^J55R1'UW331W\MJ/.^C:WX^HA>"J>@":?\_
M/#6@^/K&X<V$@EYHW"EX*\9SY(H +#1 /5U6:)>S@WHMA]);!(L+W*B,9^;(
MOQU7,5CR5K 8U-B80M#1-$K[;YA(&RAQ_B0+!P678*<I?[<W?.U^3VX0#7BY
M>W'KS!=N(X385T*;)>CE?E4,OAP%+ZGU8X;P5\T2I!XX7V[3E;]#F[C#W= P
MLE(/<A$@>\D@SA+&2::Y1J^Y;+CIX0UZ9$-TRM]%?9CSZS07<@MUS\W3"]S)
MH#@XR0O!<574K[N$M5R)R,2*["^URO2/M(*H?TZ.I4#@RLW>4077\Y_#EA5O
M<*GB>C>U>13.EI[SN7+_3+"1QW"R@BSR@?69H=@MVX&:B-LQEX5U_'!O/J6-
M5A.6J9BQ=U[=*W %$<-29"-.0$"JC;O!7H21P(6__<KK: D8=E(Z%[RM2WN^
M\=Q2P[9R/K+P<7]O :_#?AK_)!I87U>?<'2-A,U+VC!A^%3'UC:+82!"OQ-G
MVN:<SJ1]!&$]08HS1X$7::6M4JT&US5(:FM!A1D,X$$3ELJN'D>[AK;3DX?I
MF(_/=BW=J4VE^/'+J^O#Z7DIYO^AX)KJ!7T!L_FXV,%G<),F\*/R;; S@;Q@
M[U"O[@4-W<M.I="!\LJZ&I7#SH?B8-8-$=LU.HJWS9$:;>,U7K)KWZ4JV]MG
MLYB(J7RP8B>F0W@?%3X73E[;E.4EFT"UKO?%2E7 \D)XC(J69BW<'?>IUZQ-
MEX,DVO$CTHWY1>AEO)X3R]&R1!46*Z8_2?^)5<LYW_Q6$G8WCF?D;M%:Y,,L
M)>>.YQ+BT1UZ&RNG6X^<?H+"/43CLK7(^2Z^')ZDAW]2WM=9?? @=B9'ZZ6%
MUO3^#)TZMZ5>M8H,J3;1EC]I_],(RE\Q??G?BCA_,H0[7+:*PEI"KVR+)7A2
ML9WG$H//KF[EQF)8M*QP559F,^((6I(^,+OCT-?9LG$\_^T0B[CWI'A]/=7V
M[5/KH[-K$U'RGAZ/?NWCQZJ3#3*V3*V?.<@4S!TF"\-1-3D[4D(!69:6!SP#
MV2CLF52OA+>35XV!/4*Q]!4#Q[.2*["'$D47]-0MM=;3]+BC^Y#\&-3V(FCF
ML<+(NM*\U!#B&8?-2D<;Z*0.:E7714?]2?MUH-I4"NVGCJ%%TQLH<&/Y'1Y8
M9(& ^#,I+>%6#Y)'*RK8N6<JT*00LDL@5M.F9O"%>TCRB2W=K4,B@.I*CJ\'
M+44X/?1WIIWT'Y9/']:PU:<(M3_)-ENN!Q[0>WD5FFHILG=07R5..YDHSX$Z
MD0LBD>U:[EXSP27KDT>'Q23.C&ESOI7]:6)&EW)M$WL&/>S>=&:QB8>E5J5'
MH!"]Q/#%[!LQ*X9TLM\&%+ W!:5[3W"JXFG,GLTYO0C1>,;9X+8[VTN_7N-U
MRS1[9_[+[8&.Z06&TYZG*ANLSZ&6VLTEQ@ZK68(RK1HMKYF.XYJ#2!3'>#TF
M>X@RJSE[,0-=C/,-:OS8:XM\'C\N2)3ZXA3#BUN-&*8;W5FOF"ZCMST$6S8O
MP:]_@RI%-%V&5H(?U[R=%J;A1'#'@!5!:W?+(2A)W8"B M/"Q66^E>M-YY _
M.5.NM#5C_^.,H?[K4([[V]3.^*61G\.$0#%4;4=90Y8 *0  7X"<S!(9]FB[
M,*-L30S*S57][]]M_=]?6J^EU50ZOZTE:QZQHQ>4B9, 6CO2I&P09N_%_&+4
M"ODMP@&=G':P=,W$6XNAN",5^<'CVIO7^[IK7C^4Q]NM_@=XD,VNI8WV"XA$
M>2(&'!G7M%)A\WVRP;J@0NW]^W9SHGBH&33,R?0#SMY[IZ/@<T$HE]R%-=>,
M />B?!N"Y*/<WONQ&4>%LON]+W.@^C(.UT642>)MVA\ ^ETVEB$5N,+(A"T2
MS[81%1#=65>$!!71M8R$/3(]J1Y\5V8L2G/G[3D5R*>08J2@I4K?<KZE-?+C
M(A6VU$Z,/9CSK-B_%NY?F!&I4C7AR6&V].Z'\A>Y&6SO#PSN)FWM16S)&6Y0
M=EO5J</3U$-X;SE3!=:VC%D^/](BI:C:"0RGV"T6EA5^Y\T!&\W@B!1YGIW+
M(RID_<G&SH&3_&(CHJTY%H"D\QJBB G)X45!A[8Q4XU2:]>2/I&RC<DT*HVE
M;*/[S<_7K+%Q/TU89=B-F\.._OBVRI[62Q&]M065\_DE'[%0H0KDUR%SZA]6
M(%AZ0O+*%LKCQW#.T^+4&_VVLF8HC^WMW=J)F]P9A7&>@MG-,@[]&II?B$,K
M%I#B#F@-AV)QK_&P",-JI#^?/ ;![ATC=PWA*M54 M4QA^<M[,6;X!D;UN=(
M2]9G<*1@$2N&;!T8U1H.S5?%\R<NHP'GMM]]B V*G^-G:$#T756NJX/,F ]J
M>/R _0>8U@Z_=W=)94O7:8L?3,(<='#B:&F$!I2=) 09-(-U"\$=UE"E(_BI
M(2^X)<_L=! QH IF#114TN,_00/<N)_6F:?:]AIV>;03C* $&6.\RH'P-"5+
M$6] 6%4$#[IPR%&C(VU:/5-'4HZ\)9-S='$]?_-2I2X9_@%EFC/B8FW15/KR
MB9][WQHXU<VE.Y),-YQO /\E8OJW%"/5 Y*8,=@K^S!@UU6P",-L[WWLYT_J
ME"=4PT^Q !_E+5NP>ZRQ%YE;$D1OJ=@UW9ALSMVZ*^13%/F&4V'EX%WI?-L)
M=_'>,+[]PK%(4R?J1=-$S:!P<D-VTKW?LE].Y)WS/R@ K_I[7$6TR[N/I:ZE
MUZ5A/17@M/!-?\/N@%6V.%A@QX&ETDQ)V3F;DN!'7W#]Q 7.D<^MD7SLB+FS
M,HLBBZ1852VE8^X.]<+,\[H^Z(0&_&O^*SX4P_A9%Z-@6R,7*OI4V18?/J+Z
M]@(-4)84QO[2(K?@/+.7TK:6$;X0%HU#/5L9019_88 55"<G8C>6%A19<&%L
MYQ&&!EZC:HHL8>L=\849CCFQ#*?3VN#1%.^X*355:,ZQQ=/ [-8![A)'?.K!
MNS.*%7X1.S;I*->2AP!PRX<E,TG!RB(SO@\#T8SN9Q29S7LW6-0VQE4N2I8R
M:7R2I;S-W4X77'2F;L[[^5FLEBD_CH\GA[4=+6R'Z$5%N>.'HW:<1^>E,2'/
M98DB.XI9.E[!_X3(0I;_[O.=_@OG/?V"+Y\,(9\7[RB[W398UE%^\"J!9BZ5
M2GMS+RRM/EUH-OFO*TB<J\G7E$B.K)W;)R0>IB9DS5'DMY7'TM6=SWNI1G(<
MS]R^C<W^C_X*3U?FYK<.*+Y(1;0:?P4G%G*Y0F3#2"XV,*;IUU6YP:96MV ]
M&<VA$HTND7'@IQ<<3U?O$(ZGS[E-B'0-Z6R 5^1(+SR<"]PF5YI<0@.>^<\R
M>0L&UV*\,> \VF! +D/-X*W=\6=)PN\%8<:45GD)YS_)(D'=^(J?-#\W;1@#
M[ =HX(Q_29>M)1,-P*@XAI["@WO8H#%R=1KVBU(VW#QC/:+Z/BBG57YZWJG/
MGYY^T!9  _+3FH$WIP\M_&V<+!/NXO)\C?U6.WZQ=HH&O'_R*I(QS(+Y&<:5
M4=C7BGAN:5O\P8XZ8J@\*Y5,,32PF93%$5[M*!"V^%H%RY@)O*U3QA3Y^IAL
M>.)B21_'\(P#/X:PW)P6$RC*M+0[J&M&;XZ/B]>!->\1<XC!08CW<)Y9V;5;
M6V>T]Z>+2:%G(W+)O?)YET+O-\#N[\APUL-F&$5.=REB+2@<Y.P$^C1EKQX2
M^+AK67CRN@A".MQ;9D?T5A[V-%Q>W9%  _?10%<K74/3-$\+W_#X ,\RPMU
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MI[KF6Q6K>FG-A\P'6'&=2-!EO5V-^',*=>W41+WP719HLH:I)9O%A$JS65Z
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MK@!39:XPID\YR<8VA$F7DI#TW2[[#3=GX)FH>3#7I6]#% <;?2K+!>Q9:I,
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MOWB1YNTS2PU6:"'(XWI^\4I(PX <R\"Y=DF1X#I_C#9WA+\0*TX!$4"%!CH
M=#C PT--";NO'WE?)9<7V&<LYN  >1PHL)\XF3<VQEAM?>UBCLM,[LA%VJUT
M;7/-IT#M7T<DWM[NTVN+_#$&(S*T,(16*B1$.841YS%PR5-JJ+^?.N D/D+6
M=LU->SX@24EKZ>0D$B^])TG&AS>LLG&$3$8\I:'3DN6TE!>QC&+C^ZMJQ805
MK:,2W7T2S#OR;DIW"G2%@O014O?]=A'5,@!#>@$72OJ58"> /P4=4J[<J_"!
MM-G!+P"5"?H+,"?U\S+;?CX7.CIBJQ(?&Y0?I^#>-; EMPU5+N9L.%VO1+ZA
MVEQ7AX2]&53 19L-//RHGS:84YK;+:X2O@U8;]?1G]JI]XA8WU\"\XQP:5N9
MJUB)85"D>&LGF;3%L!^M1G%UQJEOYO3*:*ZN'_82,;'D+:DVS?)F* P3"!=^
MX8$)(TU#K#@83_^IF]Y"-7M)K:9P4;@OL9>AB>N87QY9&4-$:,F=&<HT\\G&
MTVO*WEM'IPROL+Z*U):&$!D0^>-J@/:4F8Q K2U--VG4NS65QGF[;'&A7(ZJ
MYOQH']T_)AJ8:YYV=-R2/ZZBC% 07Q^D5%_<B'F8*>T_PU[Z\97;0+^3UYF$
MM7<!O2SN78QI=ALVTTV:$FC-E[W<A#6U=<T.WOW\L6 <O@)OE/F K:3?<KX&
MB0V</8F(X\=)"3+F F=>)'=L?RTRMO>;HQ8YJ0W(ID57I[.@_23$($80%S9]
M(4E&T](7<]RI)JO(U0']%:Y'@-&8"*;8O"!>U<4A)VX[P$1FDLV)B-QAG'PM
MP>P=!UO('$[([12OXIY52SLXZJ.:WN+["R:3=,,:&N>\>!-C1IC"=+IL@J@;
M.+.PADB)$#SU,87&NJ\[\'I%+E"IWNQS9 !#[DZ#!4J6'JA^1*H!ELE75.IH
M6+%&[8'I(+&?-OMJ:AQ*L\ICH&J.B+XIQL(!\;LEJA@Z\Q$N%"FF# C6Y4T(
M=>R;TKA@Y*0_7U;_TBJI24 RCS+-WFG8EH,+3KX[DZTHG\RU$4=IDYN>\8[M
M!2<LIODIN\H!J-OT"ZXYK>A,')#;C_ ^0S#;A S>7L*?(7B\[?3G;_B?U\W9
M/(_XH9/%NGM=0:SQ) /?=*T$1=V@-@-8)@\^11B!^ +,//RSR"<7C;'/3)Q\
M48X,?P[)0FT V\'"SAC]#@2?#M6'W,6J(QU3TNQ<#^)^7U8P5YD[H<70'ZTE
MK19?$ -O<)Y'W5RU_^+)UGMQN9Z!=R-">O6#1HE;YL%1.(3J+HPPI7EM\XO&
M/L:(V>N30PZM Y7SR\?+-EX7T*+Y+J*8FA9Q'Y$+2U3$P_)^+^XEC]+_'-],
MWWN<[&GB?'Y([@X\N[NYSL70+H_'>P$&<BI>:<S'%^">K8Q!L?'YUYGG=?+W
MYKB)RX%*7!$B?*'/+4Z=0IN _,#HO'-4A:CD#SP(:DMO6!_K=_:R(NXD?M+@
M#U/QE6B 9\(+4!S_-/%8<CD0--W_O/NL>0\PEB8K!M8FHM5S4%C;R4NDLL2>
M$7SV)!,Q: #+0Y<C!'3U]8:%"N/$*P<Q3^)N"5BZK7-Y[,JE>Q_5+$_H32S9
M<_?4RMDY#:QRYXB>8SS"UV/6R+ #CFY0HVC2VL(T?&SAE%BAW,Q\H7CGUSUA
MOPC?,][)Y5Z6OP"88VR-29:ALK&/NQ%;!V'48??$O9,-).V*/=[I'\#JG619
MTTG,R1'-JB[0.<<<;X1WR%KRXE+%Q(=8TIKC1I?828_MM"F)XM\GQZ0'C!0V
M'+YA*?,IBN$T3<HU2QQ?O2D'N:NE*@I1U1B,3PR';N6!7=99'[>YY89=GQ9S
MWHW4-*7>R$^;CC;PXH.EJ&SG^MVI\;0[6;6:6/U6-XART4L-6 QBGSWKN9U5
MV,!]Z%L']3O%UT4&^@N_.Z@:0AFIC:.PX=1ND=>/BMIG'+_2SCCEI0YUCV+@
M.-(;C4KX]H^ 36&Q0MV/C )SW&Z(E2JFRSXEP29VD"&IJN!""?Q>>P&RN<Z?
M;98H_!]63/R&9RY].2;Y&OT)@]T.V5D_;K@^4PUT8QC;3GV0<BZQ%_!*['7Y
M#@^EKVB'R3E/DC0$'$R6W78MK4@U-4>?G\\;>+#&@D3DDN0/XG[& L;5$R"/
MRWJD]F4(#K)(HP\MON!>DIP^F*X<VXD-U>HSPJ(J3I.'<_&1'J;AXMQ^OCS8
MA'\>$=^WTNE8+P=5U]22-">MN8^%\[;K2/M*Y@O.(+$<77/4DD6BL62.;P+,
M-&FE#&"W%TCN(/9^Q5#)_AS.2J:A'I-=-W3X,6O816C5<QWLD/J*JS_I1*RO
ML=<_<.$5]J@JGRUR<6R#.B5U&M<27%?P?I8L-J2F^'J$<:!R4(>*!"L!^GG-
M631'_.F]]6P!KIYD6XE-"<H/C0/(YS^7$%Q777NYYXSU?$KEIF5VDCU%Z H^
M^^B3@@8T"$XSX7>R;6%*\FKY0++/\\]]OU0:0_6<4F4Y1 OQH %_:&7WZ.'Z
M,Z.)AK@;U>IH%+LCNN88.?X;$PXBM [2G1B*"L!34YLMHJ1$H8PNY:FP_HV!
M5Y-<A/D<U!<09<C8R+2K;LN/ZO%YQ?(Q5V:[LWTN.<(W+A:R5!EQK1D2P;A0
M\VJ&F^G;I>LRX)IZ'H,.=AL%=G3HQO5H1 36-^=^ 0Y.79O+=I!9&7ZB/#WD
M'<$!!*)'6^C>?R(2:$EOH_F39!$C47BX.@!/OF0+DGVP0^DBE:Z&A'E4!">&
M'N+SV=&NV.#W7R\ S@(DV/W[@CB]6%%"$$)+R<&^SZ&#0Z%)5UO'FS>A"AVD
M2?8M,&[K.K!OT2TT5I[RGQ@I]D Y=Z9%\==CMT'"=:^)O<=[[^X%Z"#OU"H/
MFA9X\@AZ0IP^[L6LEG63"/=+KS"W1!RDQ9:[X+&JB5/V)U8/:H_/?X+YYA3-
M6/'Q7]5.W'[0M_\NG?]MY*"2K]O&QC"OEH*:! T_<HA(2KKQ<TW[ U/@C<MR
M%\=HO@.(,PYE*M3**#=!?BV2-B;ZDT&\9BW.HI)_H;'=UN>G#'692$J88%I2
MS^,A^YT(OE:0@W+BD6/VI" MY^$\/[;(-U+NAVB@:(.E@KH+Q2#+ZF1^<7"K
M''^XTRA>@E.=9R_451<?\HR9:IN*@;@_+EK K-R(W5\GZK2,0>8W:[!NY/UN
MO'XF30<J]VN/ Y'DPIBAZ=F"Z"Q>H8G!2)F^8N&!OE.X]2B,;L6](>]=!\K6
MCCGY"M.))/EG,^M&_"C'9!5FAB6[%7^HO>3!_G8%5V>X132X8:X1E(#=3=4A
M_W,T11G 5R;)+O$#9^/S[X:?SV.?M9OLZ&IMY!J@?5VI?D?,B[6[:QUR3'9Z
M''D63E=^X"C:K_WL4%;O2ZMKC/;#AL8W1EX76M;%878W%X-FZDHD@$0OK'<^
M>E'FV[+1"J&-@_?3>/*ON2W) 8RM1B2R_@K/0*R)]6E1/%2_V/(2W!N>I7Z4
MU*A$8QW+ 5BL\T;7$Z-87*A!H]N@]Y,-*QAC-DX30\Y9BD19MP^B2W\DSK?,
M]\Y*;+*MK3P@"CPGCQAH AJ6L71*2=0MV</<3#-H,TOM7^#]2Y((0X#63*AT
MS P%H[BX94(%+FEBG.G2$'4M$3$#E6E:V\,3JJQIJU0!V! =IGK(>DP^G4]K
M;C%]7<3Z]O*Z#+VB%QL1 B&MZ9,/GYB-D8-V:H[3Q8>Q2UJY-)1L$L'^*FGY
M/.LID/[\_E(^/<MWZR_XHJD'E\6.]0X.)/D>M$WIJ_U;OG5#1HTV@CO+Y7(!
MJ+,7>OW-!>%2B<%WFMG1*I5"_87<+X!:7/>0!FF=$@]>'*$FOB-J=@$JU&(Z
M$'<A'WWO3@L6L _W$N4:U2+U#SE8+A^Q0[T&V>X]1"B%:V[$O\M_:HJW!F/J
M&H]=< ^2VK:N6^T3XI,^\2BG&3;J5A@O,QVG;XD.;(1 @<*(+)(XA6#2@28V
M*@)%]_J[,HHOZ$&?A)Y3PH(*Z>I*?^NNU/D:0#4VGT.4%5"H& 2)1!_2E^O:
M(IY'6<J\V'#+FA4()=Z(V?L! Q,>)H<]D0/[8V3U7KNE@I)"@O<YF\Q=N]=V
MO!JLCK4]Q_N=HX'NJ0C3. N%(IK3$6FVLVQV[B[1*((AFBF 97(2XQ0?QA&+
MF@L;.R@EF)E!"RZ$:*"3%RHXG4>Q6*\?+VL3_WH6VIRA"0W79Q36'FG4_1;Y
M@+&XTIK_E+<,M0[K!6!=!VKN+4,DL2>T>)_>B+T1(C)/):)V)TU\WV0IYMM)
M\PTA;+EB_&^[Q=;=9?VNI23R"5^T B;)X3<I,<5D54SL6VXX90>J1.W'AD)7
M\>_]QF'K5=%EY=[]>P3X?9"ZET0DDSDFW5-;8D] \ 5(52,/F@]Z!E_<:RHK
ML;#-44'.JM%8P[ '!RF6R,)Y=0VB/BS%_ISU?0&(ZV0XK%!H9PY%PG'5]!'_
MK+K,$@$1E7 7+_1VR\::X(#A,F.M2Z3-W@0=W,Z:!8GU5L0DZ_]NV-R'G\.;
M0;G87T1>Y?!HC7US;E 6#V.OQ%K1/'0@)24A10\'>&63IK/$H]M=2#OCM3DC
M)Z(R,&=W[^FG:"BJ<"@VJ-0$?'8T#<AP$==Y$"*EZ/I\I*,R17/!<0(Z2H/H
M0>]<Y*)XZI6S9:@K2>7![U%SEG\5I:),C"_&T^_O$>8O9(K^I5G7E&"Q%6?%
MD.,(>9W5WSXV\E/'J>OSPS2Y5I'X=.:H;IVXF>S^ZY]-4'>O';A[+3/H(SL&
M-FLCXQ_K@%."[+!H2%XPHUT+7USR=H9\=%NK=&NS%Y4LKF62"X+4?-GM?W\;
MJH"Y8+-8(ISMKZ4J*+BE H%J7P&4%K&AN4'24,2]8SAM$';G$L40M?PQVI!P
M,VHM>=O.MUTY:7U<55@"KS)?^U/19-FJF6\)?1N[W8F:*V_J'' ;Y)K#U7[=
M)2P*RP_[I9JZ*9RD3^4%<].>CJ:>21.&3U"K_Q&G;<*%-*C3>==)FX3NEP[1
M0OZF"0 =, VO ^F)$-Q,>BM9104W0%H#0_H,:'JG)JS,*SBXM+X2H31:RT \
M,5PHO4.V@J9T[\\>R6^IDFG7$FQB@CIB;:360.Q !^TY=A2Y59,W%5X8<TPV
M0*D]@POUSHA^R+G>.3*G7CYI\()<CZO^!=C(JVAA?5V41(280[)2Y%_V&6'8
M5[JO\6N&$P-R?4NVCGF:+:4F,'>8\\<U$W<A-?L23C9-J:8*4KR'!T1B[TH$
MC077ZQES$6GK(PR:G+)X>)E_D5B>DA ]ORGECS)/K9$AJVT*1:**%C#7<8!*
M$<]=U4YYC=![Y!3M<>?^)30.T&S$DVBS((^#Y,RM%JB0\'O(^1Z^>1=D,&\)
MK>9-</;!>([)@4YQ+KJ<SNF4&>AR1,1-E TI8454"B_J3D]N12HS_&B L#*[
M;TY/UT _8I$JR@(MQ@; V-.8^,?RI96] (Z182SSX-"[7RWK5J_+#RM'Y3I>
MZC9[AK\H$.+:C]>"Y,P@0AF9C73</R&G'M274Z3+GN.HX9MJ1_)A2D"/](KA
M#FH.8(9\_AHBUM"FG3JQT/$W.MB5;^Z4V5=TP^RR&81U2;Y<7\NCO$TXB"P!
M$3PZ%'L!4I1+BU_G-M<42E?@B*PE,&A6[9 10(4*?EVXXU+_1K."(/84GAO4
M)=FWS^-=\J["Y:<]&_O,*/IXH!8,I:D?\JXD , #NW!NY!QU4R<-*+H+<JTS
M?'11Z8)'QS$D- .PJ8L(#!2&6BN(O1;.-NYH%2DC7_88"?AG>>K+XX-E"6M@
M,>6H@^G.\/.MS/C36^+G(*-V7RW]<_DKL2([16$2HW=^KC&<7LP3L2;+$G3=
MF4;0(0X?;,,M YV[;BQ%L\ZF#2!QD<\^=''KFV]'Q/G[^&O&Q&X[[F<%GHJ/
MW#P-C"04GWOCKD X-Q(_OAPC6LKN!?>'Q+U)!XYW_V_!ZQ^SLM;GRJ !@^Z?
MUYC.3PSIC<700AN^YLS)HFQ/ET#.-)8>>)YF'Y]'7Z7$B->M<A*Y_Q7B:3?@
M3J?/C7IL\-F1QG]\9'$MT!51]&1KGR[WCNSBG$?JIU.9/:M,7Y[7-?S*09^)
M%5L+"P2M,#/WXFED9+121Q#CFGY#2_M#AV =T)? *QVPL+!S@@E&TKA8O3 J
MY,J+!3O%HI]%#!Q<%0MP7FJG3@X9L5AR[2>@#1LFU6V^ !5C&MG/G^+?I9ZC
MM#>"ZY;T.OV=1@EH[Y3+A1!$=X+=CPS@,)O<\GT(T>(DOZLX.'N$L%-&6R)0
M64IV2\0";M>,YWNSP_?K\PJ>GK2#W!]5=Z&KH'Y^8IDFW6B74&B.7K[O\@_!
M*^#>^T:#ZE6I=>ZB4H.P9X0+P?<F$3V0ISWOP_E@>D3^>T\E&[*\!VTHA3N
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M1-S[_/(%".4LMSJ3_3*[8HYM&)#_D&.9]MTU\ZB/9Z70$<+\ @P<,3R%I;T
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M^5_U>G_2G*YJFN*%R(\]MJU8\]U_?.@_6S#A5SE=,,KHG7P[91=S(O3'^AG
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M\-?)#>'C#TX')CYR43!*TMB;;'.M?,RXQI'TL<HE@@'2@=L(AQ0G)Q^NOCL
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MXY7V J)<JB#;C^AG]:#H//E:IDGYM^A:%(=:]7SU-9S_][U==:?UCVS80B_
MW%GTIZ/.:JODUY/G!-8-Z'6!@4GSFZHJ=:A>2C):6OXD^T:HC.'J#->S>2>R
M"G+Z0I UL;#9*%R_ZX9(@+Z_^C1K5S@27:'U _HVDOQ:G6;HRO0/VAPRHT<,
M04R4Z-\!QOC+H,/JKIS/^CN]H,753Z5O!:"CV>B>B#L O*XASOO5*H1+,Y):
MC=Y[POQ>J]G-Z"\JY"<$D.J5.P# W\B:3%Y*-^V9]W=_="7#!'(:K;^&/<O6
M!V'47:FH#$7I(-G1VQA: , OBAQ7<;4>$F"E#G1_]X!^^*L"/8*3J;VNR,@Z
M5L4E[]U7OE*8_Y?:W[Z= ZX3I.WTUN%6,"[C#5=PD"J_XJZL@G8<E>;4"(V>
M_T%.FJ+U'G>FS<=6!8NZS]&#CS4?TR5[ZQDTZP"/._LA<[K &VZI-C6H:GAO
MF$$J+T G^@*,.0H?*WBU.OOVX^9X,%MG-LPZXP[PS.P.("6SM/$*/#%T6UEF
M>F.^<0>P)/4+2S5SL%I''X<F%J96ZP9M84*.M'W3M"0=,ND5@-=G?F&B03.(
M@P-+R(P@YAV 3\*7P?!1_(6OKLQI,/8I'(=M_>-NUL9%\PEOI8^)KB2/F94O
M5S4S^+4[ ^7!:)G$L]S%.X!5@UB0\KFCA\S:_&]G53F2C1+!V3X2EPQ%,T7"
M.P N0I:?6AGTZ1W9T5LU[+[7M;>%$\K2[1L)1$H-M@LSG(:K[-G3<G/!V>^6
M%IUJT%9)R/Q\WD(2;XPP-U(8>-]-CB^JFRTS3/;_-O,MG0UBV91DFWG16+Q]
MDXS/\9?T35FOOY^FC+"DEV!&YGO/Z%-J\XH9P=S1YXW1MUO&6!+)J9#K"7C)
M5M+GI,EPK@2A(9:.'7D!),>[0NXU1OV5Z.\B4H%UU#Z>W P*W!E1%.H?F2+?
MW'M>V ]JV3_FX4QP*&79ZI9O-B-@-C7*VC'#JW1CVK6B39.5;RE:]+EN*V];
M7A3EA31(K?J6HX^],+IC'.=";Y\$""Z,F+A#3_NOK)8.[P"!+NHV4E2_<>.B
M0]\M$$(89!U57K69BMF2=,V>/[Y-AK[T6!A$_SC8>M]P*,/0UAXA.4[5[8!K
M,U""K]Y"]QF>JI8@M(^^F*+1/*>PN0.0/9G3V?YH\@EYKJELXHMO65=MVB@A
ML[V<!9;K<*D[GS=#6)@>I=M,*E_8[76-LMP!<+X;SB&$6@B[WC$47:C< ;Q6
MG:[O %%I"N,=C96-E>-<&3$Z,-$S;%I11.:01LCR)&N,CQ,G \\WM@_947%]
M>U1]ZJFC!LO4\)R39P!G7X)JF4N=Q(K*V(.Y-TL'<OC&.=@D,>,;.6I$5#%Q
M:Z[G;ULF0F0P3U]5*FQ1.8G>X-=(%5&8KJF@.\L&=47)43/)$":-_13R@AG?
M.\ A[EF_%QKOQ@:+5F!/RE+@W&*A6:K>>[T*6'Y/2=:/@ LIS7 7JQ9,-/&?
M_"=K-T)+KVH_-@\,C1T5Y6; 9X:^IC(ZWXCD(9HG0ZUDU=$#D.O']UA> J%)
M()9\._E__6Y!DY*9#$;90-C]PH;0O<!3PGO/N7D)90LLAZ(>OKP#'%S< 0S#
M>?X, -=N57!6/CME><IK)XPTJ)%MZ%@$-]G_I%SU(QVY U@07*$:@>?SDVI?
M&S@$?>_1LNZ>\M@Z8C0F_0(E8*AI*Z!ZSE<BU@MS74:H_<$'RHPA^0A"LV8^
M65AN>MEC2* >V<=@:SZR,+AT[QSLI?[ 8A'Y^@Y@_/O9_&\:G8"LK39XLAKZ
M<N%VVW(\>V$F1]@HWH4%8GKY\, '1'[=]T,+M07(5RW+>YKXO?HFLOY*N\#,
MAGZ^,@"R$(&3_+Q$%G.3PW>TV6O5D8[EZ'W)Q\),&T3,W#L E)=F?U.>*0W=
MZ.9>5VJD(#LZ.(6!_4-WX1=WE%,77-$W<\Z6G$]-(O;@6U!7U9L'POE%1WF)
M5+GKX"Q*LQB_RNR\^]$5M1XNH:J(RW,]/[Y5,IT]OP.<#&Z@;X&7&J@2ASN
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MCB\=;^GONI!1=613+^\I 2RNRX8^H^?@"]'E:/LI3BCKZJ;;VLHMQF[VI=;
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M[7])76-*!))B FL9H-OK*JJKAO<TO<Q2'ZQO]5;$#?I)(Y_*BPK.Z)ODH%/
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ME$ L<=3??]-+U1L2WV&-WQ$"D*RJVOOYPY+5^BK/A/I8IA9T'R>L(2%,,OH
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MM_1=!>DRK1<=P9M>ECEM060K28D\08I3C%87TS0*&RJOO0XRD=7]$"4%^5\
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MY93&4 _^^AO:4=\PG;BN2'T?_4;BH>9'F"F8S@2I5O8QV+/P86$K8^S5$Y#
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MJ&L79?70(?I <1N-_%_8;?]_<+$<#OT;4$L#!!0    ( .HS<52,I*UFH;T
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M ;"8,'"8,,^= +*7]T2 ^7L _GG P,+!(R B(;]ZC?(B4(4!@(6!@X.%AT-
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MP((X)&TT;)LVN=0"75[G7OJWPG%E)PL)7-'@JGK^C@WX1%?<'B-AR2G'[QE
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M/IV0)*+$.W[R"^Y#UZXYWA\C%L[YX@C[$N,]1)[6;6U?4>FI[?F'A *&K_B
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M\\ .U\H0>[/AQ@Z[1&I=ZW/4)+M2YH!UM<DG2A+;SA3\4Q0=+;E-,&[8K&6
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M*T#Q[:@*K(I9MQ)3F)4_(7HJ,P-I-I4417"0P]=6=G[A "/>F&T].?D63A_
M2M!%)OP%-JH\&NNK PAZ9PH%*2E0./&#V#SKU#S1U<'(=U\Q>:/JF*)9;K5H
M@1WSZ*E\8V-7L*DM?\C::<!\.OPQ5=Z*AR!,+#U/7'WT["G1;JY"$H@95OR[
M\M& AVVN07=EKVA47U/WF(*GJYHA]C_<\=Q?IPL1K61NF20,:'E53;;.//FO
MHK3NOZL8;8=L&__["K7U7<\OMODNP\XGTDF*WQ-9/W1T>VQA8@A&[:AAD3_W
MD%\5U#2_F=Z:M%O&D"P%H6. 9*BQ9*]D#LXZMX5X$1=X4WP%1/8+?36K4G7J
MQC%:Y@[30YQA#&(A,2A>"P\YI6HD(T*^JX%MIEEYD[@*#>Z0^R]7CH&P:Q)O
M5M+(HNQZ0-_S3T;N0=M=6,!\9X-Y/-R7X(?8&0*FP(??6/U9^JX+/Z.]KBT4
M=B_!>RNW %+?5#6<;YO='&]I<1AD+1'T1BO_B[:_P/Z'Y1OD/3*4XD;2ZU4:
M3V15RQCADIM>\L,1R9#XDNDJ6H:9C\8BG$P[=C-4$[F>D"Y=.9I&$V[1.#4Y
M8L,FZ[ME3_MC;)[BF+K2.6"6CFYQ]PQS8]TFTYAV#0Z)QZ_7QXQ9=]Y-58_9
M43GB(E// 'KDF= HH\T?[:?[4S]U<XUS]\*< C\TU4TJWKGW=[-\;6Q$L<E$
MM5VF2^AK&&V41 K@03.0FK#KC;BC-W0J9<D*RP_"0&;L*-G;1UZ+1$SVMOV1
MJ'C*W2PR66+7L,.\6+FOM:1],"=K;+5DE$ON\V&>KI0G/_.&@UOA\(V.:P4U
MH7'4U2"U08IF>'3@QC<!I%"7O=NL+MRWIIA6*\72)+@LI$"U.04A/6FF 0F6
M65W*?B/Z;8=7VX ?C$<5*QM3EV@F.H$98>::F" $J=LU(X=/M\*DLNMSU946
MH&G]\?2)(H5$YYJO2PTZ/HQ.=UZ:K):'!^L?ZU/X59,--</+4#C:2R=2&&9?
M5=MZS( .ER+SM,Q!/C'M:\,*1JXZ5 3, \$'"F2]:L^ =O(*O4P]7:9YCR\>
M1@.$^:BS5*SHEDCR\R^O![2Q('%\+"&RJ[6NV9P95+?=CQ;6Z'>0L$BR#_7F
M\4F4\]6>LCBZ.*24BIGCMPBRD=_)5NGO\N-'$J,GX"&\83R;5X!VQ>2BNJ2D
M>HALO&VDR?S,Q&%DW,O?84A^B0-=W(N9 H6D?N:P%KD7? >[88QGW7?8FKM[
MY]V<^]621=&'@TKFO+O7)LNK#;!.5>K"[#TXZ/'&#*]>ZJG4W2-/QMDZ7X&X
MQ-!W0)TQ\1NB,C&JXV7QG342=YS KGHEE^6:&J&N2=@+'HI.N3O\Y0@*0J=B
MN[)CXIE(?-,[^9/<M*YU6(1#O?(8?P=4(3BK)W]/R14#T59U@(FPZ8?)M6/B
M<HC(4RC9#=L9@V#I,>Z>^<W2SGUKZT7IYNJCJOHPZ::7OC/G7];<$,[ZZXLD
ML<-XOT32#Z4N_AVS>ISX:C"C=W.5L7U>('Y\YZ%YC1G):U__$$ZN!=+,O-["
MB\[V%SPF^[^$HJ,^/DGRB5T>XSUYTX *"I\!%(FI=]>!SP")B&*-"OROCP9;
M+ZL!I6?8I,C'CV6C%[MLETQ9U56AQT)W5P!'T?;?E60D.]^IFGDUU71[;%3J
M:88:I+;H]SZ*2+UF*<S"$P0Q?'-G8'=_69+45NX^BCFN?8:LNPMU>!BQ6K&D
MK!\2G598.LV'N-@/<2?.\/+M\,B FNO&+R"%\WJB.O=^'VQ 7==9HE[%P,_"
M-0GV58-3I1;,OPL;T0>D93>5:_.K8V%=Z-LNLMLN\O&C-/6:6PSSYLS?@BVM
MLGZ;!FAEPI-Q2#O8"$(O2"3V-<<LCJVX9ROG_<79(!P#,L,"*^XN*FM3J[82
M >PRYKID\CX<#(PII05S.R[ X5P771T=VMO7K.M!ZS^7BVTUR=X^<'@XHM6E
M[(WEDK^_CAG"$A !&':]3LHJ"=-C&>X.8#=K*XIKCXB%5Q$G*= :C8J.72/#
MU'(R5'@:FTA0M=IB]J@''FA=K)\4Z).=IL2OZ?2Q?/TT017!_]!N:4%(0\6_
MDO( O;*QWJK^:>]*@H;]Z>[%8(1]0?+T;2)Y+_K!T&>WD>2U9773X$2F[TW7
MYS??FX1:Y[JGK'3A)=ENYSUQ],A/OTA$Z>K%T5E7_KE9/MS[SRJ?[75,&/#G
M-![;_>N*[@5N0,G_;%X:&1?;>/7Y&: _]@S8H2S1$*%Z>A=#=GE(]N3)N*E;
MPYY[PO8NFP1,GV7F9!(@[?LY^Z98_!6D4!GBH&[SV?;QC8=@4N=UC2";/RN&
M?Y4'1F&WE@V%0332>:F:P2NSP/0%L_9>=\\U2>IP OQ-_V';I)!W^30G4Y$\
MU8F65U[]4#VC2I4#X6I]7Z^1=9!M9NC>657I,P#]&8#Z[71W:HG]U,/_@]Z$
MI6$H,$S& E87/X:Z[7%+Z&+8?1_674:U^<8QD\ >Q2="Y)M.AP/^L5GWNZ_7
M/1>E2E/".*N++B=Z>X+F"M9!!#BS*.CN6::GA1_U"<>.#I@/C'^+0TPI!^!5
M(WX2N)#2;TO:41\_ZJX=7#P#;J1$:6E"DFT=69JF$JG/NJPY(MT"E-!%;AZ!
MME-7[.8I,,VG]D=53O5KW"$1*!D9M)JW*FPMEZ6ZD3*_8W4"M9UL/;"EL6.M
M5]%50Z+#^3J> 2BZYJ8JD3*_AG5<T08Q:O(5#Q\9&$+4]0<LE,4F[6IY1K!N
M.-<UWKZJTM%=#&=0#$LRO&_Q!4VD=ES53W<%/@HZ'V56 CF9B]YB<P( ,'$V
M,A[M#4U6'8)B?ND^+)I]IEI*AAW83'LP:OPKUFKS.R"+G)*[+-Q[-E*<&DY+
M,6L75%,2;^+5 Y[I>H^?&^O:D]S'WM,G.DM*BJ &K:QN14&IE,0&%]-JB$%[
MO71=ME,"D@[9P2,OQ!G^I+J U0U:0S%A*C LZ#+MB.3##7$7/%;6P88HU('
M:V&Q;[;S-TZA59KC+_8^1#PLJ3P4^)*4;\#>._Q.Y%T??^[@K[P^[OGYNP/G
M'"\+8\C)V7%G0O)2/O7OQI@Q9CP:>8:O%OH=U&= T,F/!J@HA=8<BASWO>L
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MRUY?U3/ K_K*L0:/O8,WG#@64YPBU'F_<CUMY*Q8V=>"67-N. 4ZP,T+\NJ
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MN.T2[F(VG"OC[NYZT.LO09KGGM1);&LOVFG'\U'(^SV?SNL*MGY!.Z6'PMJ
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MQNE&ZG?3KRZK3C0QXPYZ$5,DRQ1 :&AYXNKP9V4Y!653Q=K:ZBGHHHUEZ/(
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MO8+/9C+*0>WH%#V:+=?^*W-#-B\,ISV&0QI@@59L9N'J1)R53;&ZWJ2[6.;
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MB#Y21'R5.8SU/%V%.3G._?NK0<7S>7[DN$-N>8L%0HKN'1LP:W<C;G?DOL3
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MY-/>E0@TRC\T< T%Y,PU#%^-+3EYE^3P$3N<@5?ZGGCZ'[@ / G7NM$/"W*
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MC<-':UVRQ9?C1XN(^WSTU>W$H/F\*UE*$'T<@NW$>%V*4/?5S$!!)UBMP+8
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M UFHEHU^_L]1R']2(GF:^Q]02P,$%     @ ZC-Q5/&ZA3I&C@  'Z4  !(
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M%N,'^Y_?(M\GZX9YAB!N7[N^.+ /B)2TK%;4$G?$3+5?6@Q+FO0Z"X%5+#X
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MMK(+*C4/QNPVP'B]E3&K#-1#A-S3EBN:P-'[-,O,&>\PIQ]5@9WC&S')K_"
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MC\2G4_7PKIMM)'R4._W=>K5W#2<^,QN_U)G3Z5K_]I, 2;7<R@;N<D-ERX/
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M\=)&_VJWO.V<5[TQ1=[VA2Q?+UD)92^NO7"]Q")WSEL'!_>+;K7PLC0SL,6
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M:&@;4@L"^GW:;WNE4?=7H)ZH@WV#VPW0<36<RS)4,)7_=8.2TX*J8@DQ,B(
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ME>9QF_&]GM75) \\0>^HPN(X):L([K2Q(WWTTP.AUTIF+OBD(AHTDDO?L/)
MA66+).&AM_K\#1>WJRTU#K$+]4X?#<1O='2C=,<.CR:BV!"H1J_)TZW\6X0D
MG2LO&GSH9P(+&M^99X>V7XC^%[8)^(9 _0OM)(/<K4/AN:6<A34%D7731X"
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MEB2WYF>B,+MW $FXOU5_R6@G[-EM^!!7B/4MLC,<?_3PDAQK3Z-M[FW1LHB
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M 'H*OSZJ&AI<A%TAK)M8KM)H32L'PM>?\%B^GZ7[M4BV65[.;F@]9_\F4IY
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M.,U _>+F#T^ +)3YX-Y(U,$G #"^)?)E$YB[$[G(3<)&EP5/MRBZSZ;B_1J
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M;SKPL:/<?XNQC%E^8>D;@G&66KKR[!OR_>D*DF9:,@D<C-EUXVPW+J6<#=U
MII%;2MJY+,6-U+80:!S/\;SLX0'\,3[-7\\UD\_=:R:.P!Z;LV33-J0<ZEF
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MX+\P:BM:#,'I"%W<ZC_M>4ETA$_J 7"BS,YZJV$XZR*?Q;Q:@S!E;/^F9R$
MM"M1EN:>'\=[YDS,AQF[W!?+7Q,YNEG-.D"Y&2>770_[@*I.PCY%GD&90/TK
M2%+Q#ZR@D'./V]1Q<XW$O?#F$YN@^8@'5V2[]=E6!'AS7O 0, KDUWC_JC,-
MJ1,5SKNG+&UE.W6KL2QNZ.SL6&AVA/.]N/,T("+"]P7O=>ECUF1%HKI"^1TH
M>;O&1!VTGBJK@+[01X13(4N2XW:AX$;Q6@FH<$7WN.AZ5>@EWSX_;P//R=6U
MF-I3E&_."NH78R1[7$S_'7,[I<9B9!JTU=16DM6EZK@I.IP;I)^$,1L:FY.V
MCB0TG3.['=4=Y7GKO4X-%1"VHQQ)AEC'_55+R8US3CT$1M%H/KDMD-YF&2V4
M\P0 Z\T4T+]S=P3&2<X:;N_(L!D]HU_JCK]#M&J<<J+$-+*-[9F/.AB)%-!Q
M'YK0>AWTGI+MNM,6G*$_C0TH*^*OVY.P%:,X8EF[5:]5\S@G2,1*+%WY>@L$
M'Q>.$[XM>@,.D2J(U.@;<T6(9ZJ-[=B.0[5_2.+WBAB\<W&%D]8&]]1YF&20
M1,YTZGX637S[_7"*VL.@LE=2\+4'LPP?*0,*>W':"?2"!X6A#=K"7Z Y.T Y
MKS'UC<#7?P+H JH5;WX5+=V+Y$,GH+;6RM*EM(^+J97(K9SDM"M6J>&+X%@Y
M1B/X@B->=2@!TUZNKH:'GJ$(XO1( 7\O*R??.V-^_&YG;C/6@ANWT^24!T&0
MKNYT82\#T;,YU2G66WY7'&>5FY'U?$O!.H-=;52RPF*N+9$W5&#/9G ,H<;Q
M2\<$M) BY:#V';],ZI\!L&3!$\!,IQ8:AQ*2W+T7*4\XE2&99W].].4)<)SR
M0?EKLLA4+'3X_D.''J7^^UW@#<U+9:Y^)#-B4-]964:+V-J[A^X;8#?,;SIX
M_0T\_FC0X3<TE=."P_L;B6T>)S43EI*R]=]Z<UOZF%XVY++4@?DRJK0+SO09
MTO!5>'LBV /WI[-(CIO/C>*&$RMF\G%?X*-4>2I5S';\5DP8?^QP7Q%-J]/:
M7I'0-W?>?*JIT#SB97C LXH]$G*C!3? 2->1#35S)K?-DUX2L:T&3+6*6:VE
MVUXO'''-FW9'IZW%^USS;33"Z!PE&PO^8N,.9M>4"@B76,8,4,7_J*:TJ^S_
M,[\<3 -6;JS-&-R6]4S2P\_A<5LT"!"?Z6Z09JC-JEPKQ]&[-3HS#4F1%97,
M?"'PZ5@R"_L2,;E(>S^!55=;BH1.E:_B^)U7IX0(278KQ1I:T_,"9WZ-'WA?
M8=YQ"(;X@$8;*S_I8PJ&E[P_.<Q80C?*CB8*GX3B'__KB@3_&-@GOW&!N#@[
MN3%5I-WJ?:X)L1IZBYK#S:;^$B'!#3SEU?SJP3#M4ZP15Y:?-0UA_HW-@9("
MH*'/_&?0O4RM*70EY1)WZ\N[2]C*JAF06\M)H$"Z,7)(L[(I54@5%Z/_04(>
MVX\'5@*>@JD4B)6[%1\<U;M8% ?AU'_JUMR@NGGYF2Q2\"#H8#+T&!P4:!=6
MVX[U!!#+8+>?/53IYI/(S-U7Q&F<.3XY-G8W;5BQ_6K.AFP@/7H\=Z2EKD=W
M>IUG#Y:EK.>**+4X[6'5=B2+=!;FXB4, FRWG(?VK-)QC[CZW%SNU8M/9>E-
MI".VELR.Y>ZE<"7N".8%)VV[0QCD*-+B:C[X];ULA'WH])=>?;$XH9OX0T"0
M7**-HNV'=P)"JE0F7(\*";#Q$.I.TXA74L3GQL>LD+>2Z@D7GO&7'@4*FG44
M)YR8Y04C>A*:K\5X;M(R1>E@BGOP[.EP1:S=,1^N0UX%,9QGBWS:L.]U_RN6
MP\198.6>W1#8M@2XRU8:>@@]-0QQRJ3R9BGV)E6_.#\8/ZHWECB_?HN'6H^&
M[8FV,PLDXE9?_A@K'J1?I?6QR_BD_NX)P%O"I652'Q<AIDJ8>T!$DXU><)DW
M#MK847D"E ? 1AP@Z=;B6O:9S<CZ<JE5;:VM0F>[,?(GLK53)Y>U@<A,+,/#
M#MKQ9?X'<(&=)T"9#:R$1?,)$)T1]P30C;K0@CQOL2C>9VR0"J)?>">/M:/W
M'BBS<B_SP;52LJO]_%7PX_._QB/4)Y\ FX;3;46/EGW!H$UD](>Q)T 607G>
M$Z"_J\1;Y7Z&HSWPQQUH#]7.A81:W-/ST^ ;;@#1O<'D4%9K2?)E29#??=+L
M%B$,SN$6]RB>^.A5?LY9YT$PM0\Y,"J^ *LS98R87QNZQ'ZZ+,<0=_O"_5E,
M^#,H,*H^SU:=.V?OU)*/L(?O"3 $G.\J3D.+%XP_O+>9W)L/LP4^ 91X=[O&
M(:MGSL;RZ!C%\6 6H;%+@\FVH,582J7J_@XE"=D/O@P85PPCRF)HOS)T/J^5
MZ=C?@C('8\!EM<W5U[ENC$;6C&8!'TEJ>9*/8"*OPS5D#1&_6/*<P+'VH45:
M"[VI%N[-<-DQUTUD#7\Y^BFYVMCK/:UKTPYJL0Y*OZFSDY2Y.N?8>3J,EPR_
M#7+J)"P36I\ 9-I1M^CP'_33P;  </M!+.BCMN(/VG5B>LNA>.'T%=W9C.(M
M)JYMBUH;&3I*QIBJ0Y6%\EL4V8/D'&C-+J8H19S/%3$Z-LFSE#ZV:C]NPFWD
M(.V;II-M4; (1_JX^V)7:.83P &]J,23O,M88 POQEAT2\$+I0<^7-U8)2>!
M"Q^++COJGU5[EJR/6DD)J)_\ M[0?LZIU3M)>(+69<-W'#$5D^;:SSFEE<9@
MI$8?>I#P!. '9^S*BCN9+KCE'(X:-8\,HN&L+\DBPG\EW*?WE,:!:Y,>&,--
M1.QIE</=!9BEB>^VDZGJLJC+[<VK4_O7/JM1VY0B$;_!&Q/L46Z-L=Y\N4ZW
M2A.U7$!Z,][/64<@P['2,B\'=IU8 !U DAFJ#F^J%R.J!FPP8\9B$+7A][:9
M\>H)&K"DK)!7BJ+-2H[C'G%J7B69-8RIB8?#C0A$*4Z5C!,<MFQ@*&+3)9D;
M67A S)%B\\+\RV%EP;Z*K:BK@A[,+LQ>WT"]9$Z]108]G>H+MCI$3VJ>OH//
M T9-_BX,1+X5.Q9XPC%Y04MD%B@X0L:VO+R%SN^S%X;WZ&.V2!ZJQU7KN88<
MBLN&F^5]5.20;VAT</#WM(%56II6*K7=(01)'P[+=E!4\+U(=1<S'ADPDZ"5
M-?ZCHD0QZ9&-I.588/OE/I6"''V==&73CU(,EL&WBD\ C!N[K5!(&37.I\Q+
M"YKZZR"Q>O@=+VF>=>JC1.<,?TEBT#:D0N4<;PN?9]6!\#)KGS.K61Q+^?_A
MKJJG>QE5N+=P6H$(XJ[Y??7G\ S@S583EF4%AH@E^3JS.F6[9N&]&[,W)%=*
MB8QQ;&"%>97OQUY_WI!AC$^/,"AG2DXS7;TU"#(G= C&UTO:N2B\2J<^Z"(8
MGM<]Y1%+VNQ#*\@BZ2V!YJ;$"DE\CZ=;^!9Q*Z#.F5^"F&>6;S$#9<7E#>7N
M.L;CK^J#7/:(FZY['KSEU]:81)+5[G!'CD&FAR>/+0G%AXD3%?K,%SA:WV8_
M'K$PF48N:]C:^D"KI&[>;(Y*ZV2\V!49PUH8P]19W(LJ$+,R,[5B"*&6U0B]
M*^6SI<SLM]> J&R)7D_5EF$#K[_2ACL+I*18)&#O)!S2"[(K9&I @*_&AAU.
MYB3!7S=CF0-IZ!A(8DZK!B871LC@][I=NSS/^O8Z<$W<'HX^B3,Y+UA4BR%:
M>(T]"TVG<74\H!.;ZY"L^"M=W^_O8)^>ZUGHW$KG3+U5>AU41C]JS4#RHF]'
M+T25LY69V$Z\><KL":!NC__U">!T+>S74?RCT20YWL-G,BUK\:Y>H0E'*P*\
MO;2.#]1M[#TDVN <EUN7H[V-97)9^=HDF^7";*+>!)38H7Q187P0I],SG=<;
M5?1L5SY&NA$5"#X![I=_Q>_.R:IL\19(GZ=3N.695D*8J*N9$W$[[Q?O,O<)
M732<=B@BIXV5SE+VPTI%G(WT)N^ZQR5,[\!Y@'=_-J+M^]<;^>C.OPA5*L^T
M7Y7?I3.F',=S!TZ)RO'ML;)D5 M.1E,QU%-:/[2M@&E".=_B<VH3,GS33F>7
M"^)1[9[%O'% ;Z1)V=[-$J&QYSNWKSZ'H25V^Y!/U4+$2#)=K4^S^^Q(YU6[
M,",[7B*,S33RUR^@+1_UR!P7YB6MHF2_JH?*$EEJ+AZ)8Z5GEX:&Q6M>2%V2
M!B8<4V78CI$7PMCAG,<33X 2_3QWJ.^E<,6"& [[5GCEE?%,*QXJJGHZMSN7
MMSP)6CHGSC\%?/;"V#H%_B8=?[@Q@NZ?13&MAZ\O?CLF9>/8R1<1;I6LQ706
M=0TY1CCK%2:XZ\07Z-X)TL/SA-KB/X!)A5,['L2%*4I/=;C.N6H9KZ-U'C/E
M8U6EXQR"7AE 56Q>1QP=1]DQQQ0$0FH*,M9B%^F8L5;+A$[D9P_TC&('<$Z8
M)>6ZK&R,N-'%]NDZ]]=DL!M^8>D6BF7^\D 7.=(:?->\N)$7$DZ>/?T$6!M-
M& ?UE$%NGP!)O_3OW]E:)1#$/P'".1A:Z>ER*]\OI%ID(PV%2"X/$#'SCKBO
M)HA@_)1:9W-0L9]7**/;<W4D8D)U9:>4N\G1?*-R14S[W;4AYV<4?9AN^]LG
M0/)>8CT!9V_Z.MVQLJ83="9G2)M')0V@0404OOEP#Z7:6',2,'2S]7?X,&"R
M.V%#J-!.['VAL_N/>Y#_XQZTL9K49$,4C0CFS-VK'H[S/Z>V7%%F,RW0M$%:
MSW<@Y()\$PRR JVEA6>0_8H\<WP">*-LG5!UWAD7'5R6;:QEI&U+,_<+MQJ$
M71*#]+<TH3Y[4PD=#ZIC+O4VXQ^OBRQY<*WI!8ME_DL*UK^(>^*O:D8'0&OE
MQ*GC@ ;NN&$^6'OS/\:<3>0S'>8H>U.S'??5*V](X]V?4497.Z8FNW6U;+?^
M>FVT,)SO.TCF/GE#'<_@3>E!!,Z\8_IO@@;5$CDMS*EJ*!Q]_4M1K^3@RFF8
M6S#<5RL3_K+]5NU ^,5MY GJ/&C.&/X(\?]X1_)\"?J-KK#-P2^EB+V[WA'?
M;NVZ% =R>BC#-1*]-G=:OU:C+$\K3QYQ5^_9";/28RQ>$*/_:;*)+"!2/YS/
M6Y5;IQ*M.X"6^9CM3?GI!=IGRS$G,O7T(YA_+D9\&1X.X$>9#WOVP,Y,W-0
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M>#U%6<A(,V3=DN;U6^23%C=UO8#7PGW*X*X]QY3'>R2Z\0&[!O1S7LFDSZ&
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M*$^M5Y=0.Y]Q#&\<T+1B(0>BJ'"@='U>](_2_Z3'_B]Q\A?M[U!+ P04
M" #J,W%4E>[V]O/7   Y> $ $@   &EM9S,Y.#(U,C T7S$U+FIP9^Q]!YP3
M5=?W+DL7D0[27)9.8-,GR0(+Z;TGDT*123)))G4RF52*" I2I2.@-$$4Z;U(
MDR*]-RF"2%N:M%5I\LTF(+" R(O?\[@^S(\-FWO/.;?][VES9_;^X?LG,ZK(
M1%)11F9FJ<Q$9B(CX_Z/:[YTXSB:1R8'PKF0(VB#<^U!/SD.H61J+H6<T:Y#
M'(7L7AC/ML$N)- ^Y^>5:W*R$4?['!-325&B?-B-2)(8K$^J#/:DU\YQY'3(
MK]@NGA?WHWX8A[+C?E\@G!=OGY,2GD?\7E1,SLE.D>#>]CG<HHILLU*3S0]B
M<#8SE][&3J%2LP$@E\I@ @"U=3:-0J61*<0_H V5D<<$\FBL[ =73GY%XK,=
MYG#FZ02B!\T1W]KG/!A7+!;+C=%S@YB+3.5P.$5B:+0V!$6;<"* 0_$V@7#C
MM)"'<@1PV(XA*(X$ ]E%WR%;,(*WS\FIF/W8E6[(8?^C'32"^5*M..QDV ?[
MX0 >)N:02OY#>)%\ASW/&<3\$)X/H:@/L4-%K9#18!A/M]F._(CB238<P7UP
M_A-]2/66Z\.?+'U8X4.*.IGG@P*N]CGQ-@[8"45\>$Z^0*^A4#C\=N0T43&1
MY*=EIOI4O/FB+CD>3=0K= R#40C!<O)%B _.5D%^.*\8TX,.YT)(L\9Q;EMC
M&,8"3Y,)A H#-T6@"-HA7[8!*4Y"H$<&!=K0*#1J-I6:QZ#G,9@I!J'>\ SR
M)^@IM#SJ'_3ZU*BS01@+$T-_Q$7+!5+U4I\O$L8Q" ]B3Q!1@5Q*+B5%(L8@
MU(W8L_$$^GBS"B0 9_/=$(:GJ%(?K5JU,KCA;!2#G3[$Y<:S[6[8[LU&PMG$
M3D5], [G9FM\,!2&L^% .$)L(3\4B! SD*(+9T-$R4-*1S8*8X2HH!T.AW,)
MR8^:*6K#&?3Y@C$DX")^(^";8B7:#1-8SD8"V3A!X@C:(T78SDLQ/>HY'_(A
M-@QY=FD;7M#G>%Y3]J OB+U<6TJ+O%@1ST=HJ4<MM/G_>:5:^$^CE<G*HP$O
M@5;:'_2OT?H:K2^I[)^AV-.T@F=4O*3))*S^'S;SF3['<YC$4K_KSQE=9,3O
M>M+<$GQY2L+?<$ X)(!P.+]H>[2A$/\ 0WI3T6DD"C./3FE'?HJVN)R@ W$F
M_I*41Y3%9/ QF"C]*S(>HWR6C"!F" 9]^6G?Z?$=S-<#V2U,2, 1C(5;/B;J
M 4,Q609WQ&\+0(@O_)(&O.@_%,+"L(%0">US=' X&,'L<,Y3# ]:*EJ]O!CB
MP-WY-":0ZM=C17_&Y(:+U$@^P'[$]*#HS[@>N% RC5#\B.\IO^II/L0/N>!\
M,L=#9G"Y6KW7*M.YN#RN2\A3<(5A+E= 9FFY8:/8'76(.4E(S(E)!<J(DLME
M:+T^%9=$X:8N'I>@+[J$:27/U18Q$Y>6RR.3&%R!5^2UT60^KMB09G"2;5PI
M4>G2"GE<HY#G,HIX+J^8I[7(^#&7F.=R*03<H)P?"Z9UB8#'50JXL:(?K8#+
MT BY;+6 IS2(>%J#,!ZSB>-ANR3.=O[Q$Q-*>#&[2L"E6(@6+&*W42?2!5-U
M*8%/$+_D#YE-#%3KXNJ(X7)C0EUZR%RICJM5ZHBA";F0M&B0$F[1Z+1"[J-+
M*^+&I&)B6B1\KI<8'E'GD@J*TSV80RZ?&"TQ+W8I7QM4$-5\H@$!UZ7E$V7$
MC!"" DIBL90Z'I<KDNJD<2TH% MI0L1N$1J5J-C-BYOB6D3#2YMF7.)6QJT(
MFZ]+N*)"GS:I,WA#\H2%KN&KC-J %U G56Z'T2HQ""@1J5065,KX;I?5+2.F
M+J2G@+@*E/.P!(.L$:8$4M4&BM5L$OD@$S7N,/LX)BO-C4)^/&PS,:,6NH[J
M"#@8L!EE.254DI.N%KHMD 21^N4((Z'R!$E\+U,/^E#8XK>F!(9L 1D-#C#E
M'E1N\J, @H9"D3 & =&@CIA?8OA2 4]+P$5K$?()0-B*YLPM%/#X0KW2*!09
M=2JWU&6-NZS"1$I@T":)B902'4.OXHM &6*/"I,R@4[@<D-Z8\*$6%@*/H^N
MT:M@F= 5=QB],5=JR#*/521&'%Z'R$AGA]3)6,*%I@122)JD6Z;WXDJ#D:G1
M^1P6$XC:S"(J;*;J?%:_(PB94,PFID9LM!<-/R60)/#)3"8?$['ZT8@]8 6<
MWI#:BT)0("3WAT)  L="I"@9(H F*$*$L AB C:78V2$XLZDB&1U^B0)5L@,
MJ*DI@28 %C,901;/8I48^09?G X:J P";@B%1C$G!:@)-SEP&'+**5X176AE
MB"$5A2D5,W!.4. PT:0QHT\9!BT&9H*=$N@"B'@7,T X"D?I8@\]0)7+D[B;
M;^++P0!DTM$9X:C"C_&T&@C%<*TK*-63%.R(1@-1](9DW*%V.0,)CBK&X'&4
M*8$^'8E$Y\EQ3@A7NU CP\9''3*2,1#P T(YY&8R(C:_7,4P*PTR*:A!V1%0
M!\0$8M3H\MHH]#C#A<O<H0#3""1#8$H@;E,Y8*N,J2!1PVZ(;_*Z/'XO*:PB
M1@B0@B:+TF.'I1J3F\6UT'!9G"ED>R&4"44<6E]49;&!QJB4915R=!+0JTH)
MC& *HXAI=?B9H :..KEZ3,'FFRTAENBY'R81/<J,D;28G.,-8WZ25\] O+!8
ME]8V6K]*XO'!(CP695-T,;9,9U-*B5%:$HC2ZQ<E)5(^IB TKY/FDK.4 J/-
M(@SYY6$]&X"-9*4_3/=%[8 "<U,<059*(*RG>X.>B"'I=_N8BKA#+N'$XYJP
M72KGQT,V8O:38B]5S,*9497=EPSB+)O9Z)31?2 #M5(84HU>(%2'.#JV!8VF
M75Z6/X:K4)+!']9"B)>*,WT^4DA+!Z,:D<V@D#-A-=V A Q*+\5BH9#$H9 *
M<4*>N,) E4A1!X*%00<2$KBI ;TLW4.2P<"P 43'&5J#RHK*/08I3RO$Q8*$
MA.:FBN5!">A4!KQD T:)0:B3!F*P5ZKWLN(ACL#LYF#.>(P2PJUTGQNFIP2J
M W13(!%/THPXIK;(+'JQ1\YF:-4R,8UNX(:@IQ;%;9,Q_1$%TRKC _&DV^+2
M!ADABX4>5$O3(8V#IC&+C&"Z\\4^0@E&1*J ^7I&1"9RNQ!C5*&0QD 1J#.&
MDV(7E\MBA%"3. @X0Z*(PI\2&(L$L0A=)D<@'M6G]3IT":W79@E%51CD97OX
M;A5$92 XY(L*XI: "!3'R724*B#[I69R2(+$01'C4>_3^I E KU>ME*GU>OE
M;J_-+19+)3(/302C<=")8$EYC!V#-$$G$R'94905H#A4+IP% Q%+T AK^08$
M2>I)/K[$ZD^; (N=QJ!*G!:K'/<JXP$V3C*JG$HU1E?[:9&@RA[7:03VI(Y'
M@^1N2,.RA'@ZM@@%608]1TT!R&$,CN,6S"264_V>E$"/!]%*N2XO(A7'V'J#
M"U39GYQ&'L4M$0I9485,;E6$&%*.+F(6\D$O*&*+N&:+A=#O?($#0KA0.D P
M\UTD.LD3EXB,U@=RDE$V#62'_2R*B@-1(QR*W*K!K&%;)"X F6%$AR?D<E8(
M9+I<+EBE5_I$/ M?HS0STS%-C$9-A,V!9%(B4(5 1I@=3N!RF=8KM.E(8:>+
M'*%Y&.08WP3+/1ZVBB='XF%E@AV!8:=,XDN8V"X_.P$$0CBN$9+2-H5L=F@Y
M)H;'A2 1 :22B/71$)D>H=/T:HX=T1II"8&>G(38;L 7,J8FUDMW4-B0"5$)
ME#P%0'&&=#X3PPX*^"F!48+!:/.@+H;>3[-8A)$X*">KY":,9'* )A9?3".%
M#*20C(LIXD*K&L#9,E* +[*@)%/ 3]=3V"'8Y%!%;50Z59,V]%+4@IG]X;#+
M$>0S(67";?* 7H^9I5 *#'RM2R0VD[EJ&YDKXX<5@#X1P9B$O0] ,JI0B'&5
M7D]<%0EY;2JQ79+N(8A[:0&]G),D.B%%[6Y#PH@1#H(;-_*#'#;?:'MR]VC5
MP;A.;S;Y?100P1,FLY<+";5ZBA1#0NJ4P#C(8#)C?@.(V]D<P.:DVRE^#XT:
ML'AI<2L+H6M1F4@F!;2ZA,YN8O+=))D!-[(<5C=BTGO840;'3FAWXC\'51U+
M"41$'BLF$$!ZG!LTJ158W)+PZ<E2D"3U&H& DP=!5E&0YE&@0K^?IJ&&&%$3
MSE)#4KJ**K7*)*A,".&D)!VE ):T;X,R72!-3BP%31[4@!ZU G1J_1 OJ>*B
M7JW4$(>M1HM3C'GL*H8E%(+<(5, L$%ZLS]H5H(HI..'O>PD)D;(*G]:VXCE
M81DED!0PW>QDS*"%34$S):F/V\U<'SM&#YM8(4HRK FI(C0652#@,&4Z'5D>
MIR5 (T+AL ,DDTI!X0*8R J'TG;9%W?P3:P(ANA0*XH:>&*3UVN-,!5"%E=
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M6<B-<$1BMA%'S3C+H>%X1&:)FQT3J2T<*8$H"=TKPX)TDMSG-(H,!ILIAL"
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M!?F4 -6F"S*(@(=)]WLB,$T<IRMAL1EVHV2IV >X[4D]P,+4$2@ID$DE"*Y
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M9 INR&F4Q,6("PE$B5ED^M-F-)H4A(1@Q.^!<!)BU@64["BJ4"7 H!_4BJ"
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M1+TXQ:8"HN0$:G*3]0% A)(8&$ /.C0A.LE#P4A)CAF-L8RH ?:K 3\1,9%
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M4)_W!ZX:MCVC\:;,4H?6_SA5^</%B@?VAI> E0VT[EN7<*]6J_#%M2&;>C.
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MV4G<$W35J^HME,>Y^H6OZ(0P!";MGJ[Q0BCD*HL4ZD.)D\DZ6U'(&DHN^4$
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M;%*Y*7J@>XX!O)4K,'&2AV[E7%2Y.&$ZWAXF=M6'<D=\/4W&;ZGCC#F:1$H
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M'3T&$(V4'5$XE7*D33\D7DZ/%']7L'/<BMZT+K/']E!%RS5X%:K+"WG/CJ)
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M*I?J .AZ>HXR_ 2MV3QN\EETVC9OPQE,E(K,5,=#]5/$U_=-2)R.=?BKBP]
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M_.>AJ^/S%_GRSKI!O$Z8</W5Z_@/ %'7!%/ZU']\S/]FR\5GN;G[RGNY^6^
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MQ;*>A</KZP]-()[7KNZW["N?Y>1J"H,./WSW&O:OO+)-/D2-S/=4JI44??<
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M@V#2(@XQ"AES1#M&//B'N_=?/I)9O."HEB0>T$@XMCRE,Z?CY!E[6GV9D##
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M+T/5@.3T,TLO+KROU_:'2A>M7:Q9;&!^-N'@_I8#(%I V-;&"]%BI;EDYGT
MDN"NT6MN:YD\+;H>:MHAOQS9.NH8%,[3E48@_V0?G8U>_+6IH/V]3Z^(N744
MHK#">T-%5TV>AM':S6#B["X#I!!_0T>92V>"&YC/W 'XZLQ[X/03^<#,N#KI
M@LH&#Z-U;:;8H!\<ON8_"(X1FC,%Q<#P:UV43+KI;&JW]A!(9,(@?A&47WG@
MB=9V,ID($>LMHD5LNPXUHCO=R'V2%/CU8AM>%G+=3)PZU1J^#*%Y"B[[@_\F
MSTU\)<-A<#2Y'-]4_G N23>/[W/<DO=M9RKE^1M8T?CT:04\'8)&H(IQ".(K
M>DN^N!LK%KQ:+"/X?&;!V+H18'V?6?_"?('2]%:Q"9I9_^*:,^KN"0@X.@1G
M<B0V!S;V+X 9G;V^4R,LV1 =7'E#E6D7&+ZIG[K=T3GGV(N%:-IDGY=FBU9W
MI'X %NJYR3AN!!I<F\74]WPEF[(YCIIB*F7NZMU[Z[>RFW[/N9=:'XI\\>@M
M!+M'-V1"FPP^-:H'RAQLHH@4:0D2K1-.^?&]J ,YD!3M7K N*$/48ZX%GYS!
MP*:W;B"VF>DXL'QY=\[=<A0M0JY#?"1>*U4OHA]^71'W%>4Q5"G71KPQ+XL$
M3E'*/WKWTAKMW07_O=(D',?=+G0"J[1LW-,UE9Z!W,Z7;G<5\8(;G9,MH90C
MXJL1>%_0PL%^XL)_?.YP&DK 7%\C?R51%MB]J/$-Z4]AI^"S\8]>ZP] .(BH
M.3??!+RP\0&P]\N?!]NSABL67+V@-+*MT9OL)*IU( \-/U<!ZQTX//P,?Q@4
M!??=A\7\^7WM!WO2)ABNJ3AA<P%R86)%,A#XT_0!8-DF,"<7(_4/8/#=B&4(
M\WA]L?'9?NCEU03U-N-.H*RO_2D_Z1 ?*EKGA]H5FWC(^O%J,0MF>O1])K[@
MCPE9[9E9,=/IZFY.U=[0_TWH4 IBD"B4$* #RD4$+(QEMNH==I4IV7MC>F#6
MSF RY2]7P6&H'\3+ S$ ],L:"L9Y(;4RT?P!K@%29GA6Y1AQJ>L1X>\_QR2)
M+,Y?1!GUS?6RR].=!8 <&(G*ZPR1-QSB_.NP$^G:P[\M$LJDZ#7Z!5J;>R9?
MF$OF7@0+^R_L0Y1+YE^$U[KS.@PFP:K8K3"),$ >CDKF@8)9LY%2^W,*XO5T
MUC+702*3(&L\C90?##PJ*DT4.C*S)<O9=#K;324K1>7PRZTW*EC5-+Q/ISK+
M]]T6@>+H_%R[P8)INZ\C&'?WQ&7$J'#0D/!Q<'7P<?"Y2D+$?X18GP?3#[/:
MJP=2ZNOW)H@C9F@1M1<(B)#%FEJJ1XSUP,2)_I@6!O.H=R62BNZ\UJK5 PE%
MI\EKD-A*%^.A@>[BR..M>[2AUV'?Z4,9 W,0&%8GN"?;G%LR">D[@F*F$;5O
M!7*1Y?*EA]-=]OO+?;G63@UIK1I;V"E2D44@"1"2  WJEGLV[FF[JZ1$YV)6
M?9^.TT,92;,V4PZYKE&QCO?&5&=ZQG^7T)?$;=#WI$_3BNP/GZ\<]N>J)W+
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M1-;++2)#1" _1GSF^G>_(Z]P[EGMLIM9MVXV&<4O!O,Y>K:OE+X$+IF5.WX
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M(XG=@]G%A0OG"\@R=-M&\AI\E9'@1AI7^"%I%9M(CY';,]3<QD=UTCS6BP]
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MPQFB@AWR]U3-M]]OGU^51[P_ !;OGY],VD? ?[U%ZNW(2>N88/'2!\ S0"0
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MBQU[F@=FW(C%LRI3L6K%03P&!S2R2'7)YCH  2-3*AD(CDZ!B:C\OQ[5_7M
M^Y5%N>979VH^C'6S?1FXU6I'?:_Y]SS(,Z;3"Z&9-BW0ME3-<77"$_&Y7D%S
M_6-4CL<RB2[K+V#&94SH".K/""=*A^I+_2S.4-^!3313:M7&:-1G.S5;6M??
M@?/M1JE"(-DZZ!=X2-[!"72H=7[\?3K37X#JK0#J?ZJXF]*2;5,+M90R[K^M
M'2YN:;1;M'TQYKR0;"DH?DH@JV8"O.L>L#R@AL&A\JQCFC$C@+/^BJ<Y]"*1
M/T?#8;K.NM2^?CX '%"HI[UUZ6Z]1-6"F8^BGU>#_Q(AYYM;!BA\/[]63@*E
M:QUNR$@EA7GTHE+9^(VJ!W26 TU+T8TLEB FOH^RA0AGJT<4/4UBMHL0?6N7
MP(+/I)4=$A)O#(?6 W"(OL= -?[R23@0.M7.U[3'(! 7ZN.[&H:H>ME78Q7!
M8)1:3MJ_XS?/9[@;C=S8 \0OX+#>;=FMZH]+N %?AK^ZB+B[_%K$ *N"R;=A
M0#OW6UK115(?H5-R%7':5[E'<)9^&4OG/$I0?Z82Q_0P $U;68CJDNZ_5!5^
MIQ)@;NVGJOO3FV"'H5?@+2MP@,V2\/- 89OKUAU\UXP:;5[EI0[S!>IRQ X*
M@7/&J8=0?P$[I[25VSVY:X>+%/!=.)1AT^1)^E[8"_YKIAJ%\G :0;U[-&M'
M*6C)W2@Y<$]#MH$M7Y[F15:7B/Z6 S!/\G1WMNQ<R*)V+]<V?17V*S7K/C>S
M&W8:*)!0498DJ  6 KGJ]F^  *N41[<42)[!FDLE*AFWA],OI!CO9:G.KR:0
M/0:B=2"X:YBJ/_07&:_3E?0P74"680[JI=.2^\AV>,$F1J$4B.DKGJP;R''M
MT5J)FW1B1++.[O%\Z6*(=1:O6O.?BRASF#>^IQH9I,K]V9$VH18'1'!Y>WU^
MJ+BV$V6HPBJ)&3F1!HXPX2FXV3;O[.&H.*6VECN&!46I+;^V?]3PGI^F;@5U
M.;9]THVWUX[9.PQSH-G*7V(RHV^G6?F94Q,20O-C+KORAC"+!KQ(*L8]AT47
M<''IE]\O%:2\80]>[!$+G1*-=@UG\JXA2#Z..,8IR883D!#;O2^^[PNA4WUK
M7[BBEV*H >R:>B>D[!L6[[$I@(816Z_^WYYN@H,Y[_]XAN)KG*3&4Z&\#3ZQ
M=.M3Z=?(<C0]0MOH#=:("UK,Y?B*9L'_04A=A9FM:NK1/T?J#:I>N3!SSYN9
MA*'&3'YS<8N\E]+N6Q7TJ>#*1M'LJM<RWXM54%%#"HZ0V \9(9DN66O+;NX.
M)>]\L)R4#,[72EFN54)#[MQ)LVGE>\>,EM,'66)V\8OG<I$IK+._[@QM:RF'
M="2FP!,^J 2JE<&DOOX^-6IHQCDR8IE8$9IB5.FZ@CYEP79CQ%?,*NH^EW*5
MI(I1JU1EBJ;#X$X:FO0-.K7A%=LABT?!MYQ"DW>LM&9*<D@AM<C/!_RIT;S%
M#[S?6$L5=UQ@I+KMOJ)F+MDJ;!L-_ ^NEAN=Y5VQ<T'T/Z4-I3G[?!CD>:<3
M%PUF?=;5WPFV,\;QY')BE9X*M=P%G\[QV, IWJHR!\/S *_A_9A?:=& ]O[X
MK( !-[2\&S64)3H3\,?-#/KJ_?J 1%BA+R.F"ZNG9#C-$RE'@4Z6J3@-F'X0
MFGH77^)5P;[^9B\SH&O(\E%)N;UL @1D.,^/KGS,G\,*>^OHH"BA78_%WH=H
M71<AUL@\1"D<,U.^B2-DQ#'>D&5*_' 5'(OD[GJ0PQ[OJ<JPZ?$C"LP?[W(+
MZ;MQH.V7_D[:&0<-$DGN^C1J94H(]I6:3S6,-T^KKH+]]D>BGW^G67DVQW#S
M!T/=S1@@G(B0XFL*4;I=N+[B.EA3!7U]4UTJDOP8D4SE>Q0AF3F<X@7^]42X
MA-"39CV,MDJT)@MK- 9%_@5PJFU/E#6/I(@30+4,T"1%P7F2".T)DJ#S0M1U
M SZ^UO%8?6>SSMYIF/BS+7NY DV0@: OX(G=WK2?[U<Y&JS+UA^$3/9"%?V6
MS^YL308_U//%C=LPD6;X_7DYC9&) \A]T9&4;.L<JNR[8C!PU1FMA,P,I63"
M4I3 _6VKWZN,-$.4Z+@$1?]2E-%Q9-;3WFHHQC*BID[4OV;ST$?OKBUQCJ0F
M3G 8_I&\Y['RK+U!^$Q?1^(7N%"6]*Q=V*GV+-7BJ P_5% *P.)2TLIMN,\@
M&QY4O)#/')O(-R=;OE'LWC0BYMS^5-:O;:WT[S-8=;]$7V1OFOO\/SM\X>O"
M?S ?*$..3=5Y("$Z7U JOQOTO)=H!@NX48U:):[E_5GG-L3+\PUY?,=X<A9/
M1!F!0;NUF:" @/D"?%G5=S3-SD]SW9G$L\3C'L8Y+^9>)26U:980361!P64Z
M5GYS;<D-N2*>_/(_>]1PH%GOT1(+>8\&P^:*!J=D4D'0#(M\P<C0)$9[W]-Y
M3(7IR,H5+;%*K0;" ^T!"M*!S@Q@Y(M+[L.>+2]'/;5C9[TFCTOYLQ'HQ::?
M483_\VZC,67+LWPQ^3')'[0TN[!>*?GQGPFPX%VN+!3%0;7!S%:(KBBSR1N#
MS(KDMO#\3;,-R%(1DSQ+UU[ (T#X1*Y03_DRX)S4PV$?.).B.KUOV7*<NLQ\
MFVBHMWEI([;F:P:8:#^D_/!.V";B>-LM9F&_Q?22.HI);WB&8DDRR_NLQJWG
MWBE4GM99;,8G6^=!Y#TB*23(MI#%S7IC*)*RP7D9! 2G%Y$_?Q@G#I;IGP(A
M)[/7-:^?PB2_RL=V6V[0,)GY@OKU'D^J-H<4FH) ?P&,,KMEH1_2N&J<G$?\
M>\3?>JP5=,(%C.4^/F=NH'(52 (JR%)-8[:&1U=ENKG%577:.KF*^=D7BG?5
M<Y4R<^5'\R#'S[XMD]5WET\T(UA%2RC[P2H-,'ATK>V7)IF-&8LRH;XN$^&2
M>ZOU8EBEEP2-Z92A0AW8]IKF5KG1RU[Q_26C&\(>X3$I+<HO"^6=@3,?6U/Y
MJ65666CA,#P3'37SRK?#[IJ&N"%(/<T^#D]^020]1?<?;BN@6878FD/GOX[.
M)#A&Y"4/< QH/8>.*XMC@ L#41EONY_JGJU-\.X?3\]J4UTE#/=C*.\0S"@Z
M K_Z^QP=\:U;Z:1()_#NL_US(_;:C\.I'T@%.JB)1939.C:)@3UZQJV).:>Y
MA90W[#E]\0L7LN(D:,Q,Z*<3$BBW4CGXDK_(<L]-TUB0-P1Y\BJ&RZAW=*OP
M*O)U!#+(]]CJG]R0]!U8Y5^ RN\\$YC WHTC,=MAT1J.J=Q!L2SQ'L''FHV:
M8_LCDO(%UTG/9V-!PMJ)?=/+?LU56SQH_C?U6\W-:0'[N_%+HM%-(2I&['X
M&SG82&.4QR-9Z'\O7\3^+OT+4$L#!!0    ( .HS<51@T7!>B'$  ):D   2
M    :6UG,SDX,C4R,#1?,38N:G!G['P'G!/5]^^N=!$4I->5)A!@,NE#69WT
M2<\DF1188-(GDSJ95+!0I?<.-J1*$UQ FO1>E-Z1WJ0)B&"!-[L!15P4W___
M?Y_WWN<W'W;8W'ON]YY[SKFGW,SLHR./3N>]II(C\KS\_)?R,_F9O+Q'9U13
M_30=[0@ X7@'W!UQ>CJX(B$@C4<!L ,;R.O\5CJ*NT@/7>#T^(APEV8W5ZUM
M5D"XNS2S\K5L;53B\1/*+.4Q975F5Y9T0>YF;Q6^W#G=,1V*ACPT7I .!</Q
MCNDNS4K!.S*_ES0#S0I*26BR2S.XI*/ IC442"*4IX#?@=O>Q0;! H&@ \CC
M"P1@NP(.&^0 ;.:?H#W(Z\@7=.0("QY?S0I?9NZ=*;>W(RJ5/YZ.^=2EV>-U
MI5*I#BENAPCE T (@DI@.)SV#$7[>"9,X^GVX7CS',@3'*DG[J*(*$U$P@4E
MGW%G)$%W:=;LY8*GKL?K"D5_GZA, 3YGD ()^?Y^H \@0C[@=\9*>&/&=910
M'IR.4.9()%B8$QP2#";B-%726B Q"0I:6XFP.Y**M^D,/#N@+"R/E/DIY+ Y
M8'LVIST(FMG<CFQ^1QZ7Q=RY[*= <I3/8&@99;IQ&G\."N]IE#_1/HL3<1/>
MS NA_$'Y#(;9GP@YPS@1C!?^2>JE2H6#])];GW0$B5(E1W$J[C%GHIXNS5!/
M/)*@7)YF?QGP>*82[75,$6[:7\CA"TK9>JKI[P;Y/83/3S-+Y/TQZG';WPWS
M1J@03A>J##+%'^,>-_[=."*$^SR% !0 >#!L-)$.%>J#Q;!/!IM@,0+#4D!H
MA.,6A3_I5D!97 &E$*DVH85AGI$,ZF 6&RZ]Q#!#7W+)X%;-TW GV%@RF+F,
ML!A@\6 I*2>='%405IAS [R $T:83I]1)H8M,K'/(A?[2(78:%=)4CZ%V.?3
M2.&(6I**J$L!I6)8*X53)3]&*<PSR&"17BK6FN5BHUF63CD5Z;A+F19Y?_])
MR93BE$LGA=EV9@:[PF]!Y6BDM*\4\$_$__('$#$+-?K@++-<."5#<TN&$10V
M:E%F:3(8+UV]$BY9G5$&_W$9Y7 *43!B44I@DED>T^=#I,_2/98A+&%6R\C%
MA4B,$0W3+6$FD,(^HX1I8R3" (6UC+*T*"-_.8(B:2,F4\@X,L)EEUFT485?
MG+:FC81!7 IHH95^;=I!B"1HQI>4!8U9U$S&U!D[UR#168QA4J#/ZOQNBT-I
MEK(3"***:%42O\_A5S&BBYG8&*W#U&(JPP,,LE) 4&]F.VQ6>1"W@FFW+0A9
M'1Q_% _1<:>5G[1S4= ==O,\MJC0JP197JY>YK?C2@()J0E>1A>(L"0DWX0%
MHQY[R%$*&'.&51Q/F*\.1-764%1 1&.Q1)S"!<D(RLB763XB%1L9<S':91+&
M()PE,O/+I&*)S*2UR.065.='?(ZTSR'+E )&G,J47*M$>2:=1(ZI"%=2EE5)
M4:G/CYLL&2MA%VHD8J[!I/.H9+ZTVT*F?*5+5@4<<@7A)MUR"U<4TV=3&5^T
M%)#-,F3]*A-):\T6O@$-NNU6+.JTR4&/#42#CI [@ENCE%,!)IR<?UI^*2!+
M&E19K4$^X0A%$ZZP0^ E8WHRBN/AF#H4BPDR-!5C)0&<,31IB47(2DQ,*H(A
M"R\FE-OL,9_.G5#0D"9$6DL!!::LRV4,IC4:I<2GLKL=*H0/RCTA@5*BQU6N
MH":3]'!U4$0>=-LT(1./-$-"!).(0AB11,3NF")H1$$%2V&,1(A20*?$$0YR
M8$-69^ YY"1H-;,L7H]78(\)XF%1A"4"V&D,=!CX*,0'H@05RW@S 6$6@&5/
M-\>";C,W9S9:C0GE9&T:(HC80T:]FY4FM3C@X:B#XA3.AQQL0HEI3.Q@ HD&
M^1*YE3 9-4D++:#24=K,<O+M.#<J%UJ#4(#/+06,.Q-6L8S6$#H'AS"##K%"
MC@I]\@B&!^3) (;[8A)=.DD&Q(0J[J=4@-J0-$!:7]9=QE)* <M<CUENPT@@
MJ.2&62%UXC&,""ZS&=)B3\!S2ODG8?T+\%+ IV=@P!-IC*,NZT;9@H21[08M
MX:C%9Y<BTE!,#.(<VFV*.S0Z*BUTJ_!20!?7YX;Y%J7;&Y &"*Z1"/%24I7,
M;?01H,)L=N(V<XC-LEFB5IKKA\0^J3,=#F14.H,Y8)3$ #%-IX48-\72*).2
M4D"1.N#RV"!9F)D.5)M0LPIW>6,BHU6,62(2.4N+J&(2VF.(N;Q.91K%K $_
ME]8;*%U2! LA,P CB%VO-W@R&&PL!31*I!:E2^90,49?:OG_^[=P*2"0DCAL
M+ @* VG""1!65U1H!&Q*KHY4*!W9K.JQ")-V2 +P>)ZP5Y1B&P!5W"%01I)"
M0@F9#%P=RH\(M<'<DLT>I\X<8 .F@-H)4@H'5^:."SR$WA45\R+I,,8#;8FT
M3@V[74&9U:H-&$U9F]N5L+L16B7T6C6H(V)/09# (E+K<CLE[9?Z[08+D<!B
M:98*37/E.A&B %0!M96K\]KQK-? #YG 8 *P^A*8!N6XG*F0B<N$35 30XP$
M*K%220&M)B6A4D"5(F-T<RQ\<>B?9(3I^0E$Z!%'H[ 0"5O0B(@2AD(9U!\R
ML*5RBXJ5DZ%; Z $'E)9\2SIL*#! .G(9 T"NP6-14F^"_!'TY0_PC7I$0S7
MT'QVV&]RP#PT;9&@RH!38'&I4RS2+HOY$:6E%) 7 S.VM$*=X&MX ;G-%12A
M!)4PL9 TYE/R25(!Q 5>H:!47]33^J+^T!<M<7C9JB@K!PAP0WZ KPL8C) <
M<!F!&,KBQPPZM4%KX!,>*P0GTW;<)XHD)$3&AZ:#Z;2=E+J4G"Q"@ZRHT)3B
M.5S:;%)(QH%20+Y-QU<!7+[+*X(1$@#3=!K@.]E<CY>T>4542$0"0E'"P$)5
M !7 @0PWFA !2 +XZS@O/^=@_S)6!),FKX#'28IH@3-IR&CT>D8"J037_3S9
M<%5>&:,VLA0P23#.X7F4R1+],E&>ICC\N,JN40M84:[,!UOY/$\T+7<+-!FS
M*X#3[CABM"05I8!^FTV@,IM-8$ %$WZO*1CGDH1**O*9 EDR[$SC20TO!L5U
MP@C/'4,3A,"NT[(3W+A8[4@:Q<J8S.6AY#$Q'B((NA10+G?[?:IX%(X@;)\R
MII58$VH6S"Q#[H6991!)'[."M"VE4,=A0$O"-BAL!KQFK\B4#7IQI8#'XL=]
M*:'>[="G2P%S_DXHCY@HEE]GX"A9HK+V:E+NS5*P,JQ2,TK0J.1 6B7** -Z
M+N,+ "7$>%,KS"L%M*%/G"CD=&$B,<$*ZWD43\H(L^03]3Q^$V40Y99<0LDE
MJ#CF+N/F\0(A#$AZ'8#('@)XP;#:PS: :2CK$/LY+E'F"27'8&3\8RE@P"]P
M RF8\4DB..-4>/P"#8OG!RP!*&OQ.--FD=# LF081ZKR(TF6RA RBAP<)G7E
M\H!80)A)*24"W9,M4PI(>>60OBSF_O[V!^LIJ4+%<%?B24L!7\2=PI*_83TD
M(QC%E+)>"LCP#\#*,OC_>];M-)^RV:)N+&Z'D)#&H*#,)DXIH"D3@N,1M]'F
M2 0TR724(V#KS0',&5?9/%G$;? G[$X)QY^(&JP).X\T>9PL#XK!#AJ0"?FR
MN(_02BP)44JE905-I8!1:52 AQ$0IJ,:@<,82G)"LBAFD@O85%+H=FD]3 H6
M C1@R*E!G2:VVI0.R?5BDROB$!O#E,!I0L0\6(M+%2@WE\XA')3/=Q-B4=K&
MTHLUF,K ]T-I@&)2!Y,W*Q4& )O<9B&!D)*K9"74B:@*T!H2!LB%V<4LAU(C
M !P@8A!&$[['_A ,JUF_FQ;+)?C#M)1&'R"0L5E^N2'&-C >-NYA/:L:IT@@
M 'AI4X+/BJ'N4D!=DA/.(AZMD-E20I$79#(;N]3O5CR))B!E,K/L7A?CT)+1
M[-]SG4M%,/?O(V(",BQ*L7A 2EQF,\AD4W\GDER.G5#'M2(@Q7'17%SC1E/I
M"!)5!A+1B$H3#B.4Q@1K%!F1!\-! ]OA$%.A#&52 Q'F/RED-410C$ZS RS8
M*T[F0@ L8=)'CU/K(FT^4QGIQ;_)+')!ZOGI15)NR,89P"?[@4>R'-)TV G
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MP";A" *85&;4*UP4$$K3;B<7#AOC"#<0P2VD)>9-E +J,0%E8C&U&^'7,XX
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MT=_CE-HY^^E!95K^_X; RI+)?UNP=;M^CU'1!!4L?8>22>X\00\3'NDX$Z?
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M6?6O3I@8J#"EQNU9SA]:4;?X$&$[K.)&95U7:5<=&C0_N7/&=-:XOF/F3OL
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M:SSX15  T>&[Y-H1ETZS+@'5AR3ULT0N^8JU4DX349NB86X<Y$3C_)30'@P
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M[I[G-B]*AOC7BD1A>$UL8 J"2<2@'!PG*35^"<3.B(FNN,J"8^CL@I4E)M@
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MD.B1E/G.9E9R=)+!TY?GU#B%]!, 9UWP-PYXZ!U&SYLZ"8$L&I;W'='94/M
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M0&FYP3""_N%_0Z.WY?\!4$L#!!0    ( .HS<53'\ 5ZL-4  !0  0 2
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MGD?\7)9,SLDN%PE[NN2PRS*R37)5-M>/(]GT7&I'&P""V1"4"]+H$ 1VR*8
M((4,$/^@CB MCP[E41C9/U\Y^=6)9V?<[LC3\ 0_FR-^ZY+S<[UBL5ANC)KK
MQYUDD,5BE<%0*!T)B8ZAA"\,QSOZ0BU3(+_@\)"0#4<#8=3ORR[[';;Z(^$N
M.3G5L]^Z4H;LME_M!"(X5F[%;B,C&.)%?.$0T88@^5?P,GR[+<_AQ[UP.!\.
M!##4!I=9(0?\H7#*9F?R;Q*_5PNC80S)_UT9RDO+QL*_3_TE T/+"IF'P3YG
MEYQX1SOB@"-8."??R0!\ -B9G))Y!Y'\1\CR(KUKO:Q$]M_:Z;]1+AP)P"B>
MDR] ,21; 7N1O'>4G!#508%R8;1-RSB[DSZ$X+X_2O$0+ R7"\C\-AC+UJ'O
MBH! 1P%B[4@!*& VP,P#@#PJK5R!K]6]1SP;8/TF3Z'D47^5UY97.MN X"&B
MYK]I47*A\GPQAD5"81P.^_'?"5&HN4 NM5Q$B,,!%VK+#B<";YN5H3XDF^N"
M\7"Y5/FC??OV.A>2'< 1!X8Z7>%LFPNQ>;+14#8Q3@,8$D9RLU48 H>0;,07
MBA #R O[(D0+E,N%LF$BY1=)>W8 P0DHOPT)A7()Y-_,E-EP^#','T-]3N(G
MPGG+50F[(<*3LU%?=I@0L?MMD3+/SBM7^JWD7!A#K3CZ_M2.'#]F?R=+KNVH
M$OK#1"/\61EL?LR/_[-"R,W2=Y(X&!&\?K/0\7_R*K?PO]B+03"/SOH'7DS[
M5?X_7OQ?]N+_!YRU?(KX&V?%<0H58%"8_[*_4H \P@5!QE_YZ]OR()!'_U7^
MO^JO($3X*_!7_LK&PS$_[OD_U%G?%US?]N/_:YSU'Q*6]Y"3E"SO/1G_D/41
MQ/57VO=>VOPG2D*QU_G7BDXRZG7^GC$2>GE<'"ES;)W?C^6GZ/+;[L[50MD?
M&U&?W1\+M>M,?E?A?5@(C_CDEXVRC@"E(PCH4F.30B4!=(+JO 62DGP'0^ZW
MHX[$GV#0W\9X2_)=#&(98(?#\+^$\K;L.S@Z5\1K]<$H%OJ')+3LOP",AQ =
M$0^ZY&B0D#^"VY"</RC\;*FL]_)BJ#WLRJ?0H?*"O97T5THNI"R,Y-,IORG]
MG/176C^O B0JOO WO3\L#?ZHAWIA)Y)/9KG)-#9;K?58)!HGF\-V\ME:-D?,
M9O/(##4[I!>ZHG8A*PD+63$Q3QZ1L]DTM0=3L$D N_SBL GYLHO/+A]_;'69
M,G&IV1PRB<;F>00>*T6"L86ZE(*#;&6+B4RGFL]AZ_D<IU[ <7J$'+59PHTY
MA1RG4\9C^Z7<F#\52W@<MIS'CI5]U#PV3<5G,Y4\CEPGX*AU_'C,*HR';*(X
MT_'K)\87<6(V!8\-F D+9J%+KQ%H_.5YY8"_$_Z''S*3J*C:R580U67'^)I4
ME=EB#5LMUQ!5X[/A\MJ+V&6U4_/9OUUJ 3LF%A+-(N*R/43UB#RGF/>NW,]M
MR.82M27:Q2;FJOTR(IM+&."QG6HND4:T" 'DDQ.=)=<0[2\0:\1QM8$OY%/X
MJ,W,U\L#0A<G;HRK414G-36'12YYW((RN9J$,\K'U$F-SA.4)LQ4%5>A5_L\
MD#*I<-GU%I&.!T3$8HE?+N&ZG!:7A&BZH!8PA!4&*0=/T,@J?CD@J-0!%I-1
M@,%&,&XW82RCA>(*P-YPR&JD1\U4#6CWV6F(*<!PB$"2@ZKDN\RP"!5[I2@M
MH7#[25P/76O  HC9:RD'#%I]$@KBHTO= :G1&X#00# 8">$P%/5KB/8EJB_F
M<=2$NZC-?"[A$-:R-G/Q>1PN7RO7\P5ZC<(E=EKB3@L_40[HMXIB KE(0],J
MN *#!+5%^4D)3\-SNF"M/F%$S0P9ET-5:16(A.^,V_6>F+.\RA*W12!$[1Z[
M0$]E!I7)6,(9* <$2*JD2Z+UA.4Z/5VEP>QFHR%@-0E Q 1J,(O7[H>- =PJ
M!"-6RM]5OQR0Q,,D1B-&1RW>0,3FLT .3U#I"<"P+RCU!H-0(HP'25$R3#@:
MK\PC^&4NQF.R62HC*01I;-00Z+::P*@"H:2XNDX%QQ-^9LC!=XJ\3HD%Y@-4
MH32D!1T)%YT586D4<0L">T.X69N0AT,AD\2(>CPVDI>E,]'T-BDN3GA$-F90
MRC:D.D47X.HT,EM,FU01XTD:%!H26JU#[;:X(SHM+M>IK3QV4!4WN%7>I$:E
MM)-M%"85HYH P&ZF4;2P4DO5T@T465 -BLH!*:0$5\4*T=3.@(!'-Y 5%*.
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M?"D[&!4+Z.PP"8 1I30(F[ (&=,C9HX%]G"M*HA!0BE>GX!J HC95N2TP$B
ME$SM<$9- GT"X)))44C'L9$P%8\54;GLLKA7Y8\ )H6+( E*-8M8D)G?L_>;
MVG'Q,F.0W)I( 5)! 4>B4@4\]AA3Z.. 6BG=XU%S]!Z",["\3A4<B!OL?I+'
MR '0N"(9T MPFY"*LF"*E CI"A*;+C:Q23+4'F3]O+-DA"0!+"P+&$(@*\!7
M^.PV1!X.T5"O!9%(T1#A27RG 4>#F%_@]+ "2HH?$O',VH#=)%7'PY ^C@@L
M7I;4Y/&34DLS;Y@79]CE!C.9;F>"B $'6::(#*("E$3(JHD:T(C.9F3Z/2Z6
MAH81TP ['DQ(^*"*[@N ,4!O#!/+(0O=%%')4WL.9*N)X+<8'K"9W6B(I4'H
M8:V$KJ7R-2C;HW0SO6:A'\)U8;>6$M0@9KL@HE+QA9C:*/1J(9V,'7."4B44
M1I/)4&I907<+0IR$F<P+J1TBR""U0BXX$4?,5H+OJ&0 T6H ZC'964:IPJPF
MBSTDKX&,\(4*Q$N.FX,A9EQM$A#TRN;%2*G@(+9K4 ]&.*-:*.5KI 0K]%J<
M1)S62@U4+DE*"T:8R0 "V05P A+1'2@H-"<\"9*7:8\PU6Y-0)S@Q24JI4:@
M)L5_7IIY*)RW_, K\CK(F"%*4G%('@?N((G)N" ,1?T.HU(D<PD@A\K%%/%<
M,3H".AP28OH.>0)DNEX&"5)D*48*V<A!ALVA(T5(>"P(.O2!:(($@D1'*2$%
MIHP1TCR600<0Z*"5)B4%2!Z5EL9@*@T.@E%1XU2]GH4";LB7ZF74*H,P$^2#
M^";0BAFC 1LGAIL<#(7<F= @O^[7_MTCJJ(Y4H &B3[BT)'5Y #)S6%9R6Q9
M%"!KZ3BD4D9C9)A&=IDD5C]%H_0[F$$;6:MS$%%:P7,$1!! #B(X) HZC"0-
MG4D,Q]2<DL!!*NZ.1!*X/TJ6!E2 BT-R10$%R\&R1(-1T 1%(1_.=+A9*E<T
M02/# 0I$4X 4"^9,?1=#)E/47;K\]N5[ZIOU/YPG^ <'4]Y_8.'?>3!%+O_K
M$R9>[WM/IX3"&L3QUYJALG,2Y%^.21#B+=\/Q(^&_PD0/XKXPBW?/?(BE^=I
M$)\=+:LU%X-#H?R?SR^7M^$?<_^@K<11)^J#,=[/1YK$O/Q(!+7G070^1&4!
M$!/B"D"0QV%#? J/R61P^6PNAP8P?L%_C_X?;+R51R3DV@EX/AMD\ZETD"V
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M\'7-5@R/QL8!1QD=[)3!V=8$UHYYJ]NRIY<]]>]TVS;+]&35R-6?EL1KIF^
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MV+#X9,&ENZO1+:V691=,;=W5V*/%G@E?97:H1;V56[)T2@FKR= B0*S>N7S
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M-&2OY]FW$G7("HY9QS!H&0Q5T$^0#-)L'_QI7$)91"'$**YR,7__H.R6*UD
M650A]X*FACGZS\F-G)\(=:/L;J7C>\OWL'0$VD\L.<$B%2:C&%17-T%SA):Y
MO^-6J$D3ZET9T #M!?C.'B6A/"R=/N:*[$:-9)/:Y&$W?OI5-+2,R0Q>)P0G
M=!CT3W%*R,B.W!$?09XIYW+C69][[[QL*J9<9FJ4F1,WZL?/_IAZNE&ETO\
MC1/G@P*MHC^5Q P<Q?9<R6W>( SNQW@,*PF-WZ6_)]:G:J<U7J:9<<XMLMA2
M9DN3D\R;SE3@FPA8S.[IEV(KD)H>45@%_&Z7,6^CP3Y6!0!2R3"FJ!BVV/XZ
MESROPAX:E@:BJE2(__P9D'<K]ER<W)F=G ?>W]WK%_8,]13(_0/82;6Q?1K+
M%+>HVBO]Z)Q:W $Y!E$CU4$[K'(3;C:;"^00+BFD\7^(>D$$<BRY('=7XL98
M "J)"EE0X#TN^,_K]4H)$$>HA)6E1/=*PTFKAG:RXX<W>'./L9XG]Y%0Y294
MN&)QOF8M)4W17>5#MI"[OV2EB(8J\,%1$/&1?<HX09=OG8V%3/7()W3G:@<4
MZF_>)LI'^6!^+A1=8?LPCIAXF?5\;EAZJ"B"V5K73-1VUS8 Z4L1MNZ4&B'"
MJCYX5"L)EX30==$HZ 5A<=?%%8'Z =3>+(-/[[BA-?#"RUIUY<!X2*!N8L6J
MR(:I2^G1U5:+4=I_28?/R5!FGS 0O/>_&LW\0U33X"_X<S!XE^*LX6)#_ YM
MAXZ=^,F5I(2APSA5Q[*J2<:9113$]5:U!ZT;6R<:V_#@M6$B0HE?</@HG.(3
MSLEKZ[>XUMW $32 <_C)GT0/.QMXL[*:OF A7H8B-?I)%J$,0&ZZU3;^($V.
M%/C8!29=\8_MV?(6#XJT2W9BY:>O<'---P#8B]:E%-R^T?!&/HE3#VW<6^F@
MU!R3HI,#7R7CS,3C,V.<*/ZZWW2)F;H?(P_^!QC+_^Q,5Q8RKVTC/$F6*'2*
MU#23=. RF*;^)3&.@U1"RP!9Y6^LSB\E. U7G\MU>7IT#5YOAYW8Z9IA1,'#
MD8.M3\+\TW;ONZWX31%SHX\\MW%%'PR]V1VEOX@'^%<3YH5Y:!!D^UXN5+^F
M _BK'S/L#:/ZJ60H?KW*\*3HG]Q*W\3!)85@XK(=M.=@FE;++?I^."9W>U1*
M&/3=4MG>CS%;>KL:IA'HRWTRY@?-1X1X3+ :_I7=N!A4*851=UO9P38-SH4-
M'^<XIY0R( AUC##APX)2EITCB B >@V;FA?HW0+AQ\1BZL$Z6*YL14Y;DG5H
MGF21H#;@%A<&V8-V0WZJAY\0GIZ#?\#%HI 63^^MRH:VUY:L9D;5!^:WK_0#
MV;E?F/BNWGCF^A@2<9@T?%EGF&Z9.RFA!%%$H+AX&KEJ9$HFW,6YY[!2&6GE
MC,DHS?(KM^_*23K\C).3^BB5T'QH.JRL?B_8K"),7[^!H?]9Z7,)GLK_2!/K
M/N(X<*LM;73<CIV:[/3.>T]P(YSXU*VS3T>(:[/+-RC5UDC&J0IQ!X3RN5)E
M5B2R"XGP1SF.Y-2:I-9'/*HM4$LQ-Q5C"4^^6\FU:)L+-Y_H+A#[Z'!Y4;0.
M1:T:+"UF"ZU=Z>6":'=34W":XQ1T&4X='/>BE[$V@7Y$1WR_.8\^M'B9[E?T
MD@NMX3"#4OY"Z28\O(PL(T]Y[F\!M/T#?.5J_=LTZ,WQ04^88D'ZS0>6^K3)
M-?8J/36'/@$69?HO'6W;7FTX3,@HUC_%00R[_P"&+:'%>39"?XU8>XF2'].0
M^FWT'3<EIC=?3"/__VSO_V-^?2Z"S.I7;Q%>NDMOAXS!OQ^S<:/@W*>$:MUR
M2>/)M$'D.G*\X V[0GA9>_?.L;HBI2=%K\!0?.ZNGV;C=9^SX0=G$UQKSA*Z
M-^&Y\!BTW?@;DT7N,5+-.2C,S\)G^@F76IMT$S!VT-ZV>%OS=1%*V53+9DK;
MF"<=;.L>0)V&Y_<#._'-O($BB3#F\'Q!=J,#3<]U"H:6^2G""(W"ZD_C4]R\
M-/; %(WE&=G1CR):3T<K,V'B)Y8IMA]CXJB?&7[*XC/8PT,; T)#*AU,4S3_
M&OG7*DI26]S/YQ"J:W#&?S-OMF5XR+_2U^$\<];T:OU]W>%6SNE^;;?WI!"0
MXQ^=F\AI4JD?4>+ARC%PG2\C+UH5C-.L%<75'UI EL=JYOF!XV>(YN3;C<3)
MQ:<A!KF8EMGPUV]DOCF_OU\>XLL]\*TZX^QA\P.V&86V6>?K_^X4C1W4HJ)]
MX[KEZ2I.$$5_+?K&G)8N%"R*KR"B$$C>QK61MM).W3'1.E#HB9+-+87Y65;+
MD>="B,:T_:4J(([L1@JM3,XR+V@Q8$>2>L+0#T=1*'O A\HI?^0K3 2EQ!\K
M(LS9?#K=O>D6O-#NYJ#1T2:9Q/'!IJ5>7/.PV5Y0,-Q<#/JMN-TA: OPGKT&
M6E\:[T*#OQM'/A7C]<V,=S !_9L;IF[O(]M=]K1-'*%(,FN<AA1];*6)2YJ?
M?"K61'R).)4@.J1"-B9DY'.6FQS;O%RZ1)-A6Y>"J)AGD_7J7)YW-_9I"PM"
M6I%N 3)F>*R:F^TS\:MR/).&3NSW1#*%J*N5PP"CS$[P]FY 9L3WEZC!Q19+
MAKV4'IF@UMT?(]34OXZ@9GN7>[-OAB*[W\'3*;N;"^^0C\BIMS?[, U5%.CE
M51"L8J9%#:J;NCZ:;9K=$91^&C34WXA@'UA?Z<$0'\!ZZY&=;D'TE!D5#87X
MRT&]K@YL>6DRCMMYQ476CK/2,1+U6T39(M:Q]0 */K[TL.FKKI6";A<K^WQ$
M&0%7 S"*I1Y-P%/UI#\H$,-;)?[B9U@8T<_H".>;%V,D:?55BIY0PM$LK /B
M1(44@GB'?Q2".#$6"$&B+) *O$X%VL_(/PI;Y#H*4/O!?X =CP[9UI;_/0]H
MRV\AJ-23K*G$UBJ MUAHO4HXYC;*JW6CTC*&N'&;!?SGZH6 <B^0%C)#DFRT
M5#,7=88+PJQ? \+.-9FQF6G?MQUW*YT-L3,88.5Y&NW,=Y#_*_64@WV+_?M2
MF,B1(!2ZKV\:51?XE!Z:*1+NZ1C^23+ELNDRZSR_R\OH^LZXD 6MR^S"-6G0
M7.=/=^]FH7?GRB%R9H7=F&$L)(WEIW=M'H35B\TE<U3H%@=+\@GP'VB%^P@P
MQ5H+,V<1OHKPTJ]@UD1&UYB$%]U];Q(E' U[W('2%]T65W'1LZ]0F*M]"CML
MJRFAP_.^KEBJYKWK1_NN">3B)1/H93-469R?JZ>>>P:K5?3Y;[NJKS87:#FE
M<;A1N]-2FSZ@K<A71'$J8+=0F=D""]R'K4,6*-@Y221OK3?0.OXDR;/:UY:6
M=S38NJ[>6M5OV-.WO5:V2,B"53[^U#'G44*? A4DQ!<8#>&AH>-3OUM"0QO[
MGK-LD2%J/-_=+-;H31=LWFTF;+=M9>,1G.7^Q/%DGN+SB%>_X^M&VNQ/"I+Q
MN1\#U'M2.&2 P]H:^:1EZA\9JH<ZA_I7 L/=V\#$=1J>O$\%%.W38A.'29>W
M<T"" 5#IW?#];H<+L1+G1$^54V>81Z4::7N0V%%_LPIUTO4YB'^=>\[QMGTU
M>7-R91S7ZYB=/AC?Y70+[W7Q>^7EG48?+;N,C1*!9M<W"/"G];F8XL!/+5_!
MX<5P\[=[+;R\+2ZK/F92K#D20E;BZZG*4>A\AN"U(H;\FITK.>U(MV6S%:3S
MUNIV06[=@ JGQ_3KH:+YFL =%C9*8R%+8DV27)J?H(-RHXR^&SK/HK^-Q"Z;
MM5PR="B_)N^$5_1QQ/L F_X%N)^>DO*)9?N#GM F2![Z0,= 6GI]7NOLFBGK
MGQ>BOD32:5"V 6_[L1?4';V>93%+46^5\5)&U;64#0Z8\U*KZ,NKC]50]X+U
M'T=X\T;>0%'K ^YEJHK.ONSCLI5[B70%H#XA?J2<V[*MTJKT4[73&HW<>E.8
MMLDE81DL5ZE[E<\'/"AN_9-CA6GURYHWWWQB8Z*O8\_WTVQ^[Q_2BW#'M<NM
MK0;!"2.PTS.:_2G/*Q8Y+[:_'U656CJ36"+F<O+VYTNVCRJI@D_3WCB<?FON
M3R9[,OLJ #HDS/6KC%"Z*[9=/33\!YB.QH7]]DG]-'KL:0EL4.* M^QN-T6S
ML-I5K!CFX2N14*0BWD=H/6N"\T!CGZ*(+_8(ZH39#*_*6"XI*<-RU"NP6S%*
M#U=:(1F [#)=2G-TMXC.?AP:(<HE*++J/P#*_E5OHN:EM_;Q=^#A*D*L[,V(
M9BTLS9G*X)H0&3=B8Z.5;AHQ=MFFGL44\('#M.>(#W;<>'%%A!/&6"L]IG0>
M3<"Y<EVG2W-FT->[#+^M[EOS]14C:G+?V"BJ>2I:[2FTDMOFK^]YJ#G3B/ P
MYB_'2^L^\AV0O!,:L/F6;'8G@\0&V[K:.AGUIRYJ)LE)+VK#EW@WS N0TX8/
M[U7I54X^9OO_ U2VS'VCR-!O+;%NNT@N8X^Z_%]BU* =&42I]]A=S'"':(&8
M\AC/C;<-@Y5GZ0HTQ[MKM%W)F%&82-FYO"<2N9UNJS@L4L==$+];SO@.HUJS
MJSS";E8L+X*0IX$I=:!3-1(V+5/M@5Q94 /O907%K @ Y8S.S>9G_+(\G3NQ
M9Z03E#^W7C^4/+'_Q>KVWC.MSPAH1N7M]::O+^N=0X$EM>,6':A+AM]$?-!G
M;S"</9UF+39D**J00WGP@D+98[9US>2"_!I03O(/0-!4*[[<9!,V>=0N0M]O
M06J7;#4MJL#6_J>'7==]WC/ 4VQBX XFLJ/YS4;]NF%I"C)UUVV-'\R#S_5F
M<VIJI#59;PTV[Z:W O86/I5YD3"#=Z^*[O22GZ2>KI^RE>T?*<3[\TRR*-RG
M0CXPC[:_X?F\L!SF/U2,.94I8?FNU$$TQXQ6:I#5L7'SQH5J74;^,_\\^Q5A
M/^D;.%*@A5O&%I'8!R.A]4@GF31N*N"UJ(I;&)]0P$N2I )(OL'\@A'BB$G5
M:AY'Q(9/(AYQY6/-C2/%AAS.A6\RF)#FFX]0+W(+ZQ'^$5Y9T5YJ1''T:'?E
M-//N$N-PI;R\6<"6I/ \GP[L%],QK1N#.IA]@<LJ<E[*$+?7UA*2R-.%O1Q.
M$6^0T-R-0Q>.A"5 3 N41U@H7=_MI&[[&HG02KS1XWO>%U,[P&(L ;+XXD0
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M@<P6WNC?9NB"&#N'LR_*/- [LOO]T ($QI5+9ZX3WAS_FAH./TZ]O?F/:6B
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MUO\HR\N7S=&Y,&#:.JGG?GSDWFI%VZV=R*"/I!70B*Q#4I-1\,3T3;'Y4,D
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MF(H:'96HERERC2F 9J;$"#ID&CV5&/SBNFW_U>[K+/N+4Q3C=6H3XUK;_C_
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M1H]AW6I=ZJP&S5>"5:@N9 3?FX *PK U.8>6]96PXX[@ICZ>FRK9WZ37F)5
MT 9#\U#</3^V03%9 Y44+_!G=K+4%$K6J^H,_4'']::%Q8$DIY)$ ZP1%M(>
M*EXS=8Q,3KR;A<7V%ZG (&1'O+SED;L/7'6UZ/K5%JNGJQ6][0K,9\*0I[F'
M=S@EU^1Z,S*5UZ"J\_;519BWGO%K3]ZY\7>DO>B@Z2!)-O]K2&1T!=:N9J.G
MQ69<P&@5),:/U=(4E'WPRRCJT8;PT1IN7U<W7N4U*SQCWS@1^)+YQM/8=2OO
M,6O^=E9M-1A3G(^_G &O&G6MP<!M^PI,T>TWLLQGT!W (V[FE?5Z3&RK#S[:
M">'")X^Y!O"*=]P"F4AA=ST0M%VS[N9F_^%*GI(<RWPJX8QA?DW;81+:G$@,
MIY[H6BZ615KFFFXV&X7(@QV>=HEA&3VO4YZ,/7$AW1/+C0]AM79Y$3<4#!(\
MIE<,Q04ZY*YW5HWJ2%Y3&;&<8Y=V+9MCVL+KJ@J> X\$AGK '_2DD[B]=P#L
M<-D3Y#^ AT9^_-/N7X<':FZ)&*<I?,H<'$<?CH,+1#^S.HK=OC7O$BV@P7I.
M^Y2K*M[\R!GS+%^:EXGXV!5WK>#Q4<FA*1;BAD\FE=4K&\R?S\QET\AQ/_VZ
M&LL-O>SBZN#7)!ODKH20^RQ^7K%3:FH?QP"+, 0M0QP" .5"RG1]* EKC4_2
M5@T?4>[#7BUDPFQN1$7(LAZ[(!QF4T3.Q.W;'1B(- 54Y$W?E2$/EXK(T#%^
M6AKHFF16QWCBB"*6:]:7X8T?61(;'1>&GQ(54BAC\Y@\5[E7-P'IQ&O2@![Q
M)FF**;[D)'?A-N! [+MJF"_.:M/&^PX?;5V8-_9".WRZ$:MEP^-1)O% VY1C
MZ7%M9KCO9ONV6=?+N+U%7''D-GZ$?-.PP$A64RQ1PM!7HJ3[F@FC!S\'B+)@
MJ>%P$*,Y94>H+V825"E^JJR<)Z,($$K7JI1;1,M! ?3,IC[,%CWV_'>"M/ D
MR!@T))">])2EZ;"CV*;G"!HUPC88*P*?'HM>'R64IV.R^FB&%KSJ(^K.'[CR
MYI2R3M$S:7'9:X-:J)XQ;)E@6E.;)H>S'??07+UEU&1-:(B<\2_0P$DQ+<OG
M%+P6^-)!TE[S)24-";JM5;'-[3([78+OA@2]\C^A.Z#7Y25_-U$A?P<RDF%M
M.IGDX*NKX7/&&J*O=Q819[&#7/'U7M(;O:IUG!J9EI3<XI0OAWK4.0K&L\I[
MV83][8B46:OY @;_GX/+MSNT;E?I2B;,8=L;,U$]=;CZV;2Z1TB.5DP.__S&
M[M+7KC:2Y09/KVHF(86F+%IW=^TK&6XX"UK-9QZ-CI%D)-',%OU5! LSJ7(6
MB8P?6 94M_81L-_SG4$5#U^ND!M?Q3=\%?2JP=MW,]W5@!ZSWIM\_J"W$YO.
M:2GL>,\IN0DF5Z34>G0I0=K\CLI!ZW,->[)IN+])\!BSJ)'1(O=M<H_DKD+;
MXS^(;E$L)N=R%Q0P&)?;9'RC<J)J7W[<F/4?T#^G-;IO/^RL@:R%,VMNCE M
MH(@_7I,'IAX\0M4E,6_&G;7\V79P:!,_=2DOSX$F-"O\*I?:K(M#6)UC.AQR
MFC]G6<0N5J)]@:M'8@);7#O[^SXX]VTV^%&S>KT:ZMJ,B\3AG:3O1[%O]!EZ
M[%)[=(W%LC@G<+-8-]FTI\T8;AM;X*0JVK%PNUUWZJ++"UKV1N84[(DYL.D4
MI[/C-YF/[GA7+X0RJ/->6Y1'ZV?1Q_PBY-E(?7UHD%VA]L0P)!R>^YVCMJM>
MV72,K&,+#X)BCX,)%.&86X (:E9^VC:^/\MF%D(ZCJ50YW%MG&B"NXN4_6NA
M5)-#'%0NO0623*G NOQUR:H4&B!;D*2)JJ+E5@J .P[X&;?N^7E6IPNQ"J;M
M]\3#>\W6-S X4";C:6T=8C+0M6NC,TTFB(SIFF9M^L]IU(;3E4>)"U<HPVZC
M3 G]MX3W4[GHA%"D[_@I^[C#N'"CPWK3>9_4:"YD4C90N]%J@"(/BCL:-J]0
M\5QOX ^MG7V;.F'GK?*WGB;+3],RNB [NA;?"%4*"QZAWR2?4T80.-A;H-?1
MN>'#!M$F2-;.7.D1015^-?\V6L-J)H3!]O&Q&M5/D>FH)YK [B&(\?=!XYYT
MN19T[FG<MF734@L/PZ_LQRA.!N DAIB-J]E%2D\E;U"L4.[/H732>LGO\J,>
MX-LA2D.PL.VNP/8*S)3DX^$_@.MW%!%^/:7O3C!))!WIY$+TK$3Z/M,_ .>A
M>8+(^;;S0=-EV5#6UO G!=33_8F:]B3E#U3BP5:7!0MOWC1C5E8CI/902M<:
MGC([9.0S0P)M4(GU%?3RWN,4C"/F*HYC)_"*X!%A2N]R%4@I+C6$I'4.A6K9
MJ3]PJ55[7>Y9+]\'MBSJGQ=%[E5D+U52:@]Y\HW.LLV_[BV=6V[R1MZG=@J?
ML/SR/GG0CXL2M@Z9K0DI/:(T.B]:V1X!D3\4J581B4L%;GG=7#MVO9#7[Z3Q
M /G1)Q(1NFSK'5.4"X57H##3;1I\[\;6R:M$O;H,3I^>Y'C[XI!WHILA=<EC
MW)$?O%8RS'GA5Q>O7R7H,>.610G>)0003UL*2SMC9_!\61(RX[OS(PPZH7,F
M_!PW>)?]%1)@W^6J>]'%C4><OLDJ6S;^:A?M6PG:+3?E#1]]K)Q#I:>3J[O^
M''&6V&:NW?*#L>E1 4U!#UR;2)2P1T%QA\Q#,+96$=F5__,RH:C) ,T2<]W>
MJUOESX?QK?SW: MZ$H+#O,)XF.I2Z&W;U(XB2(^^0F+N+T!T_&LC8>)VY3RP
M 3;6];>*F  S\S9WT"!Y_7;06R,BH9:+COUB&UIT21P!#32,Y!)"7A>[+&'L
M:\1V!XG@MHMJN->A9*(%&NT1)46?_,ZQY.[F8M3?/K:_SB]G@]:4ERM94>33
M )22@!A4B-N6^2T]=+XTB[+;D'$WMO'705#8PQ5RL7-5P'0Y'+?43_?O/F5[
M+MBL)\6B^[KZR&H5X;/X3$O1OR=,KF+LA<[0W/35V+_%8+.K;+1UZI<;%1)3
M3MA?#AERDN$7,&'!,+3< VY>/\3K?^<#.$I10L\)Z B#K5=)=6G<W&S)-L_S
M6S#_/%7TG+8:L0+556T<4-N\9V71F$N%[L@H-4_)Z/D13<5HG/CS4*(D"6N@
MY;-;0\(:L3Y&N6U 3(Y7)?D@5R^2G@*Z65/?95CPC'#T"G32;L:W*25O!F7S
M?M3H,8NM]B3.E(K]^#(;J:>9]3U3$@Z5&K(X2)[]%&YJ "+)=-S[_=+]U<P\
M?PWV7V,1U#=\2PV!D:%!@],PL;_0%E;"<-I-\<]BQ(M\-8=:CFRY7155S@._
M:_G&4@IK98]VW O,CM\I=YH$2ZJYRL_@_+G;^2H6/Y6=OBQ=\<,55Z%YXRPM
M-#J0"1X$+$5;BN00Z9MIGTA#?6_7^7B"WD6)Y<"US.R(GV]M,A8?Z\A%RM:,
M=J2*DW7749#BR,)9RCA0P#I[(/*^H^3,'1#&\,<M%G*F$-,FK*O_RY=[#_W7
ML!$:?D_#62_]K!/5+^?US(A+Y,/U[F8XUOKD )B N67Y3T E0J2F-4YQ/&/%
M0V<JF_><5G1GXG0,Q*U5RLCX=EL$UVI9Q $0C./0IJ^_(D9[W*.VW"8 E-&=
M&;YY]7#JBD<6<7<WX)D]4V+.N/H"6MKCKK.#7Q$0*6]_=+S8H('@A%W%'$R[
MG]_;VY2$*?F*A,7/.SW_V(Z*?_CMM__E8;&:(NE,*U:^2OP,N/<[L#-(+3*.
M>)?B5Y'8+3%C#[*0J^%^,^3=J%K\-,@B%=+R@^Q,'_H +DNNMKY\<5BW$M"R
MDD'F#AEHU[L_K6^0\/2L+?_5!7J[E19(O*W*,'7/!J)HNMC/!PUI%\O\K5D3
MY4_YUF]W)82VRY\?O+*=5 T"-5M/L-1(^+N3/&P?7#S=4^H+SM)]]9DCJRF.
M%_OC&_'<^<3!5@@.BJ\ ?RSG$%GL<-I,1[A./URZ:^FQJK>+\;!W'D?G!78T
MD^TF!T"XYL0'.!D(X/\ B><U2IQ&CRDC&IZVXK:TP"Q!9FI^>.:2=JBW@%3O
MB@ 8.\$-Q,E-6Y7;\+% SC5C6T'CH3QQV^O=(OGID+^8MX\8(&?(U+!AJ 0Z
MJA:P(CYW_ZH/&30LY_#0UW-3V-9X,_$C4I&6YD;PA";/K2:F=9^^['X_'_1!
M\E;G4%4'Z+M@@SVB_CYNS' W2_\D:T4H3->ZA>_AH=,NY]-#)*'YLC=?_5#J
MAF;?8&<&N0-AKM=ZYRQ)70G>:\_B<"@EJ2#,*+CWUUDRH_J@>=/)QF+:GNZ&
M>= 2F."TTK,:+UU#;_EQVJ?F0,' %M@P*0)'-IS36/!5=:Y6$*MOF"O0@=J@
M#P?Z/G57B.OA0&\S?H2ZL^K$_ [>]-6J&CMR][ECG=:*J#EBX$\4(YO%C7@>
MWYSXLO# 63G;1DOM9=99P]>O\ VG07.+$#%;:>I.A2N*%YF&G;W P8%A0&7E
MIT\ %+Q>3,86A.>H+Y&T]%)+F'GMPPNF6>:,=$MRR: B*5.6=)*ERSK2SU]^
ML =_&$"56@H+RF\"_[9+7Q<-?0+F*V9*5G1<3U@+O-;1H,Y8QQC-V96T5#S=
M=?#/6GD'OIXM%/K!"-+_S>E,V\C66_;TI*M\>7GJV7A;V[7LY9SCF2P\]Y7B
M/\P;E'$_MZS+MNBS03+-\\'5C]BX]B+J_7*8@AKLXH6 _W"YF=BAH[M_:&!5
MMP:'1H,>1FJO"Y*V1G9D\C,*5HG( / ZA'\(M\:5&/U_"QK]5O1Q!7SUT]1#
M;4GTR)!7,$W+)'EJ@L&1+&2%R@1G&8-YND%; .B<$/A'F+6/@]4B-*\-7RO]
MGI$F0N%2@!AA=J!Z\;&*7B$8L\4[6D:;?5<<D0@SV%7U]G'I(/"KDG+-N&7^
M,D^JZQ-[3/!ED7"^^0(]\20SA%OQ6JO<CXCN28$EZIC,QV? MJ4E\!)=Y#?)
MZ-_.K<^./J2/+7#P^I14"\OE['4 Z;6*YT;1.I_.[.:=V,[YNRN-:SZHO.9W
MBB^)&U'9RXC(_<25(OG,ADLC3\IGGW0'!W#3+K.(!V5!P;<1ON,/^#F8I=DG
M'$"VK/@/SCE&MK#6PH5\6[*J7Q,?3+< D*3/,3-$$ST0TAND1Q-U\!K$Q#ML
MF.J)A^L"X?CLZY#+I="8?1$?U!'I_O$? ,L8R[PJ%N,M1*NT"^.M;&;[9,^6
M>X$D11?O%G,'@.N#]P/:Y7BW'^9=#X//47\N6YD&MSTK( Z3R.NRO)7@/7HY
M7UJ.PS9=\WL#0:I7H[)TG5F3DB.MATL?H? ZOO2X+LI-H5IYC]?3(NJ/7J99
MFDK%T1J2KUN$ZE3CVF9ZR]<H^+XM4 ^J,UM"YBG:ON/&>^7,]O@]=_ ,VVU1
M9T%NHN'3DKNO_D@J$#_<L-GA'Z:AE8$(%8D8<)^HG84C*Q2W)='_&-YY@RZS
M&<;5=Z67.KW6D=3H(>C&G<](!?-48=_:H<0,(([AV_'CV.N*WW2"$%8Q2W$G
M&CB(SZ#9H= E]%A\Z0-F]S#Z:^J1X:P.5*][T)30]Q+,8SH_0EH!86O^.4$3
M4FRE]X)^,DDD<=C3.H),91;@I[J6Q]?%KJ3N#*7YC@*MMU UUQM-B77BPGY=
MUTZG542M;CMYXX[V.NQDJ[9!AK(QH>43ITF"1@#GERQRNT2/9LI8:Q[K8ZRW
MNU+X;-PXKR@ #7PQ,[]#V9SZL-X'(G9IC]FMDXPI3G%]\BT:F7&XO^6(QRX$
M?=$D_;M2^8.W[OE3X<]#'^2AN=AI+/-;9.^VDL?S9XS]I@ /ZANQD$>R_3&H
M4(#9$31O?;74C1OLL\FK9/ /8*<#9^#56.B/@RFQV<1H2]+F%7 K$F<IEWC)
MI/GC8,7HDP<TGVKNX"M:3&\>F@CRNV!H$^R,J-DDT;D=CH@5D9K<.$6F7O^=
MAQIWRVG5NE_)OK<:9C_Z;<5!+_/,("(_^-0T5OP=9.KV\2'%J JH\-->?8V'
M]3-1B^M@R!O(;QUL#K[L1J9LSG'E[#_E3G\F6 ^H_?6EZ!LH?,7=<"]I6&$B
MJ++[QVCS?I%=W6)H:/A2Y,5>>Y$&#Z:2-["U@IU08FX5TU.[3/LK464F1M9V
MQ+L*]>0%'/T\7KQQ%)M^;\MRI\'X#B.>6+%YN@^5.A9L(W+M7J;=_@ 4S3/T
MZ07T/JR2LJ57E/C:@EC4>-;P70\@[YA,N"HV>R53' I]D<LLP1#J"293M^2+
M-4+FZ3UI.Z( 8]3NNE+YZH4DF=7+'.,B1X,5?7F=/A_Q)&5%G9^(23R[<+ E
MEHI?A*@L1,$^+<+_'C>[/KF0+ZV4*OYZ$WMG%D,F9C91#5]8CUS;#7(K*<52
MT7R/PN*S_]&JT8^5D[@P.[7$*:#=AAC2,,5$:CQDUB^SZ2GA(OZ%U<>T9_5Y
M\0+3KG<CAOW*UIVA33>.9*QG]T.[@(3T^Q$1118UNV0KFO?J^F74OORN<HM6
M#7"MW_H,K#BL$/5:7+2>@%>+.9KZB4H+H8[^ *1X-VY.0*JE3FLKF\.08_H[
M5,C0^%P%\6CL-'/F>)^9C1/8S5+FG7GG\=>>E^+(2D\KM0./'8>Q<*=R&,L]
MW1 X/#,0:FC1BK+=LL84)U9Q&\95)6#7\ 2/;5!M7N$1:BI(S:M93V=3EFMJ
MFE/&OT%S?S5><U('),'ZS2OL/\D4!R0[M9V;:VB]EF<)1I,;X_XL#Q""*=X:
M)Z(H&@TH[?P#6/R(_KJCA\$-W=*YYHL+[V?6N-%:/QMOT?:JL!?[.+5H]%9,
M.NNF>> BC4"T"5Y"V<V7:W_Y3<S:5GU-.F@,;$W-1K1%JY+(7KT-)=XV/C8S
M8W B,3Y&IY!1<E0"$"6C-I(<"\!=]N=!R41Y+F 'W!A&XOR?PG--9(WL2=<;
M=8-J#=ZX[W2[B\];8HT;&7:6YR]T0^%/JI%='? GV,+'C:IZC,Z]H_T@9W=L
MOJX)+^L0@-<U;8!ITUJ68E#*F(<,^'/8<CY[4#X;/WU^$%3\5 H/'EUD0@IS
MC@-=!GTV-^2X&=%)0&;L;)%ZQ.'Y^-S2Q^SZ85,_4!SDFS[\ESDF\]G&%??I
M$3*<0GERV^?1DY54TMZ;M52S+')9'PS$DI.8C\1/_-@CRI7ZAU2%(SF1RX>$
MD80-24?/8N5?\0]0_@Q=W) 6Z+?CL94/=C5L$_>(G#3S_K--H"*(CYS=S*O8
MTR5UA.[^W7U=\D9T)4=ZFNF$%GO58DI5Q+5N.JKLZ_F00@:YU"\BPY]T_P"+
MSXG:YO2T]FO/I&V'$-PFAH&K/?@JXEA"<VU31YNA4$:@9;^,HU'8V @?O4DU
M<$1I.+XJ&";H4T6[!=+3G"U0U].<'@$*BTQ>[BPWO$?K:!<Y'4<9GF)P_$;D
M)W5C_@^0O_:_3U7G8UVWSKXED'#$,=K>B8IOX^W6A!8!Q! 3 +H58NKQ6@6F
M@( 2-Y+MU%TN7VUK;C,6C8SK% 52[-F2>:=@]"81E-T8/06!:/VPEMIT;'.P
M43@F$RDR9#%*#KKX<>+Y<U@8^-;Z\;S8Y>9[M/;/1)+$C=B&K8"Z5U9_,2LY
M-FB<"8)VFV=G' >Q)# *W'<;N:BNWLV&?I21.CES';G]!R!ZC&R[;'$'X[V]
M1_O5MLFF$LJYPWKX*_@/=SGY370+8UAB#LJ:707:!4=SU_![OL&]+97QSUX6
M\5.3_B)85\QV=+R;0+V)4.,WNJ30K_BCH<0UF9W,<QHY-U4\FIK"6JYOHL;?
MD!]_*OG\9\2A;/.K2>B/'ZROAOF68O\:.08[?6I *CW]I J+O[+U@3_CRK@-
MAQ\T\?\#;+Z,;Y%?=#FM7^#M6HM/- YO?/ON,^;R?7T=U<O)V'E*^4PW&=/4
M!"U:7&.6)A3&[3DM ,KO44O1#^A0(;T:GLF<Y-Q@R7;O&[.=^=Z^0-:?AR9_
MAA]P*<G(:K=%^&&-O]*8>05C?FD07(/G^R71(DVXL!4SM!'F8$1#DJS6$$OM
MKFSRT!9G2"(0_?I[)Z.=22-\!:ZK^P]P&22Q,:?/L;_O/GQ6 GL[4Q&6HTAU
M!C O;@$':P;66"/B&Z6CZS_Q?T;401WJ1?"=0T$VBV0Y7=%B3N;!LJ_9UL2W
MY-L'M6JM6$T:?VY:-^?U>AJ3BGE[L"WA"O>L,9!']IDI/_8E<,S,&%W6Q-/9
MH7D-C%KE<IC9I4ZZ.!W6&^Y9P^<75V$U9M2VRD% V9;^,L=V#>DJ?E"W>?HT
M0;XI2N8P(O,"?*B7UCA9ZZYPC&5IHTV\):'C_FG^K2_UG-]F,R)_OUAL?#F+
M=JZCIS^&IP+(5A@!K)';LC<F^+OR8>G%H1F,^, N=;=9FO#Z%G\"TAS>#LQB
M<TPII":LEHS>^4;?26)XG3<;C.OM8\^1>?@/H%^MVPJF*QK(BKNWOE!B[4:)
M^I1S(H-$/4:'WW2YY527A/P#?"&]X#HB&OFT3W7QE^'".(*K]7%O/#TB-=I<
MUBKBV_9"[.1DXB?P6^7/./;<BVC7=JW*74FOPQ'[%>L$"XZ\8+T7PBL>/P3<
M\VK;C*PA6WTBWC7Y7JJ<=])?O+>E9=+*)=D^8YV<.;/P,7HY?HR("'9U@0 ]
M\XG12EH>=19:Q?T#6/:_'@ND%?TR]#')37>46:J(HQ#W*XG(3#%Q))5T?\N>
MZUW:1&O+)3@[_T#U4] %#1G)&5--,/&L\T4_.OQC6CT0KDCPK9$DVLI'#O.J
MU(+D;9'7H7?"NFW U^\\R@+%<I.E("/B%'.2L::.2DUO[3&\>.-,,A5=I(.W
MH_9'O;//P0=Z#$67VA:GJU67P8/]=(&3^E9 ,!F:8V*J"IB_T%OTUR[;_<F@
MJ117 '>[Z6\WI1"TPQ])3T]WY_0*#F(O'4Y_A3T-MNT?T1>61;Y*IW2;=5-Q
M0\DA9GXWJG,R(TY^"HGK.UW1E-:/,J[Y+@>_I*RU3C:PSJC_ 3 LS92F8KX.
M?<EGYR@>!95'M$DNR/T1N'_<*%H<6V; >"Q]\(^J^VWM#DNS"Q?BU"U80PIJ
MVJJAGI!L(J/:'B6-'WNRVGKU(7\ML>YV7HHH!OJ?-/\!/*!.3XJ'#V]R>;[/
M45:I; G,TS+P6J0FHP:AC_3EN&@<L'VKB<P4M$IAP?N:$\%/-QZ7[O_"M1HE
M<%DF<;X^:._NN6(%1N8&-]@_3 Q9:(/<\%_MP =;-E;YGE-O69N P>RI?].?
MFY3X8#EVT_58I'9U_I,>W:V.KMGQ@%;'$=GTW3RLM]2T7:7#^,_4D_TH$Q9P
M12;,1 (8(5^[LO +C7?40IC+E9#R%@[3*['E1_[;;K374G[&OGY3<B%Z6BKK
M>'@YJH"C7-WAEV(<YFET"-<9DU.6<+ T*F'0Y_:3.&%UHC0_-"9TM )&'/2"
M84XT#\WANY)$3L"S:U7IAG57?3U"/@<1??SZZ[%YS-"ZND> L"H"E5PR[2N+
M-XF$=7=B694P/22$3K0ATB]-T(%,D4&OOW5,FT>ZIXCXM&]!TK$^A.XD[%<J
M#C+D8+'2*<;/;Y1JP^?60! ;!&$(^J6CB$[T6_9IRD"/']G@ H(G]4-Z]?%-
M/'0=Y=6'*"(HDP]C/FWK4#*3UU[Y^ZT1OQZC3E.P-^+0^/F7BUR1L%+YV.C
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M.;@@$YN\B'Y0)J93U-NQ?]37]1MA0%I2*TLD ! ]2$K!UX/Y3C^I$N,0@2&
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M]TPY'(GICRF@#0ER RBN>T;=^E*%@6@+M^9.S%8"FY9FGL'0.VJ;!Q+O_.V
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M9%7[T<GW\^1X])99J!@#8Z6E"?S?=2?@%-C@1[)0(/D1\VDX3P,QN0.)SR\
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MD8;I8>^+!<O4^;74'F%9Y]K">^G7HHE"-;O.)OB&A>^%_4&-LK_\07=2&WZ
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M8'T(@#H8KV,!Q]1#9SUQB@0@*YP ")1!L9/^P1I  )P T-3,+AW30@\$GQ"
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M[BG3$_XT_)ZU$L;Z>M?>?UO/^(*'7)G\<#[T^1=Z+37126:K5E<"@"YK%"8
M*NX$H*4"CKD%;Z]'(XY)AO#X7@+096JD85V)</7A_[Y  &8MO0WQ02L$ /Z
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M6R^@/55)W\A\Y8F$WC"\2P>XRYCV?L4VH+2ZE!ST](7,<Z/]IVW+$WLC!0B
MXT]IXI!5S'A:]>@SVAGE^$QS<^I \ W=N/@N)6.@'1DT!@A0U?!OF2$ T1E"
MZ-A*&22K[.>%E\X+!C6Z@4-. :J*U4J<\AN1ATXCBS3CVDZE>3JEBZH"KGP?
MZ^-?J.Z<#1+,?J^HCKR-M5%M&)%EIS8W%UKL,5$BC7/5)ENSOCCMO80"=4F<
MYE;0\'M[UK_BSAUM&^T!KP0#Z5V;Z#FRS$QP\3(RV3F0V=\ ??S:P;,FX;,
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M_Y D3+F.)VE'W#LN$D]JB7W==26YTE^'R_KQJP_\,+4NT+WTN<L -8!JIB<
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M[<_Y8#^R%<)</;/CK1K^Q?HYHU*.Z5D) %:ZCNC]1(@F4PZCAP^G@>/8)P@
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M;3_88%_O0R$@JK4YUSL5("<_MZHP_"ZPGT=PN*QQTJ]SI/FGUJ*%/ %HWB,
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M#T0)N=X?]$=O"F7X(;+#_$!'MT;ZAM"0XLJ< 6GI'PIHL5EV!S)*Y )$ -@
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M9XW@!0A!RB058V:(T,>99?I^ZS*_D)%+X_(><I,@J4,0(YL9\2<,T&<7819
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M4\K/Y?5TIS[Q*"]LF%B0YZ;5NA"!P!AL'"&0#8&GUU#$WT"%UNWR3\)F$SR
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MIMA&?.+X]ECH]6NA@6'JYG'89<BL^&XM\JE-IN7P\&7[<_GYZ7II<GB!LV<
M]](\#$6]:^E-QM [!MXM8.7YI(SZC1@'.=!#;ZOW.*G/JSZ7L+6IF /]]U_/
MFEE3MG_VM96"C3U?XIQ>K-FO]<;&"D$L:\[JD>UP2Q!>R*C_@. V^<F7!?Y'
M#DPL# [FL"/78$+@>>7#.K4%3"=:F[33.3,5<[YQS4C3)>S#MV<0!C\^)6$V
M;225F38,0M]%M"8KZ5)W(>1"7P["@5T."FB0:>\-<:O7NH+?+S_7'G*0]*&
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M;]&G"CV&[_2\20:&O,Z\S&W,-=)_..+('9D(?0$ <MT_3 UV_]36_L]&*[7
ML,.=9"7&3\^(#7]M95V@+KP/+$W[2@?LD[1ZI)4AR?8UD6R,X$1>.X'"3<,(
MDQR4.[$6>^'EC1$!;$XDR"&PQ4?+:NC_.-+\E_B%4!!<WL]V591.Y2"F.Y-@
M6L&+:X?)$,FMYS%7@W_$-"C ]>/# ?(<\1T[^-X(ENE= :H-K&D3D4-@X( T
M'4<;HM%=@ONW\\%Z$Q4AIK)X22SM_L%;,V53YZGDJW%\49# .KJC %,(] &:
MED$-;:REFJ'-K?7;=^S+MW?;D?6%N!>5:]I+X8D?![,ZN+)Q97.@TE?V%E_
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M0/)MY/X>8[:B=G1L>X=.9LNXEN:,.3D[$7D'Z[R((NY30Z:8.ZL6Z"W)GC#
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M.!^C<BWP$<MDI HX%C1OV!4DVZMQRXUG<?."ED-/+WK+SG#)H"IR??5Z1U,
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MHY4QF(XB<+#+"1-%85;%^BQ(0!,-!-+#* 7W+K1RL?1AR3XX8KGX=["S^E>
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MP,22J J5&>CZX4(GU<1^1FK!+Y_ZSW2(H4-#@LX0N?O->^U=U:,O,>H))[\
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MOW8[+BZ]..X+=E*SON#;/[:@2&1= $-M.9NPI-.,#OXJM*H^D$=\)4+[ANF
M\[!E 8694%%>:.V<JKS_$^;COLMQR?/Z:?GB1T?MQ'@U/]= #U&4?]$@Z5LY
M%I.W2),RG0<FD2.CM3RX BI^!1>D]@^MF+P'QD=0DNOMJ"/0[1NFP\D+FA)D
MJ>F>,^3H!?,!&:\'1<\.@0Q][$SX3<2_B\.TU'I!#"J(VC0JH@.KO#*TV'A,
M5A%+ ^*X N30BK%SC</O'(5-K5ZNZD0ER^Q\L1/1GIOQ.[][_Y''T$"=J/_
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M%BU$?0^=12U#2:>3Z(".CE6CUA$?Z[4C=$"DAS;YB7;+*M_*]$ ;T2[_IX8
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M )LJ\$-JJ]N@%9B5]@/D-W#Y8_ZR#%(8V=R2$^!Q+%"/%)\Y2@<PNC/8JT<
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MF1-S'=14X;7Q'!AKJ-!Q@6C@0#-Z+X3&*1./V%HI0DQ%(<A=YXC*K9)T8#P
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MORY9QD1]M0CN2)C"&TKDINE?T+Q+D2)%BA0I4J1(D2+EWP5X9^)O4$L#!!0
M   ( .HS<50+;AU4584  /[F   2    :6UG,SDX,C4R,#1?,3DN:G!G[+T%
M5-1OTS>^-*(B#5+2W;!+([F$@-0N*AU+[P++LI2!H-)=4M+=W8HH+=(@I312
M"D@H*OX7_.FMO[B?YWV>^[SG_9_#R#>NN6;F,]?,7/'U&-]>?9L%D&B U<$
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MQR,!B.K\]/Z$A#%28C]B1P+X*_W".Y83GOTW C_HEP42?P7:T8IY'@?3AN,
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MY5R&*;.K[6G5Z-TWA!BSF^_!VAWBG-U1*E[LM_'\]@)&0VNB<N+CDN^GN^?
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M)B:8E]?>HJ9@O#6FJ)+L2\$@8G=6$E%.I)&MY)M <F^CDM+0> 7V<%V@7E%
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MZLU2]8:2?>D/W+K]<])9>=[GWG>/"O%CCAB;J4J=UXF3'?U?0ZVN$]:;6$Z
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MC!F_42/EA'=&U=DB6E1J8",9)3VN+XU5+4K*W)Z=X)+<(*;G67!7)+%B_QM
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MHY-J>UXEU56VJ_7D#Z9:%-V[6TU$YG+AK*G+$;]8>#>U1I,Z:[V"J%7_HV\
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MK4SIDKNTYW<;9MXD*3FZNR,:IS=:!E]RE$M/GEXY&_=6A-K,3<<(0JJV[++
M]).:$GT<6[[("V.M:ZFQM;+U1I57"PF!C>,%+T65?!;'$TB5*5/LKL7PS.NI
M9QP9*NY)2AJPZ603-!@HZWFP?8[_Q\6Z__TU5A?FLCCA#5#FR5+\54?0J-/'
MS CNRA\A28ON;P21FSO/D#OX[YP[9;>;\7W";X#.(*4QK)[0..46JHLQ#A:K
MXJ^C&#894%$B&-$_4KS0Q #$P3\^U2X9:)[9KWK=^U)%'R:E39XOK2M\Z<U[
MYMK+=S&D!8?3/"SK."\E?MT(:O;=S,JW5%W,"(T5ZT;48%@-XE'Z,++$1U/S
MG,& +!DU\I/]B-W<"H(54$%4\^MKG:YP96:J;^?J)W,M]7N0^ZK&QEAG9\7Y
MT[A]OC/HKJ^_@..ZX57U 2;D1H@%)HSSDFEWL^<WXIB[# P/CV)6GCN5-E%M
M<LS>9>I+K9/^B@'MF( ;&TM2]Q0:,'T93"SDT*'-Q-)LXDXT+[V0D6ME=?01
MU2%DU^RKV;JPD%IN:>FHY[O/)=BNDMFSPGC,%*OZW]E@P-)..>J[M'.8<F,J
M22FZWD)+T=8WON[>#QXWPG!N//L&#L) 'E,S-1YDJ[[.)3?G:.LQMUDZJ<ML
MO=(N2%TL3^\ <0$TD8\_@BO)+:HS_]Q_37:P-E])W C#7S@F?8F#)O=>IO?)
M'UB\'R23.O]"YV&/ /LNH(0'=R3EI[L,2;I;:LR"P&R8N1\!E4D,S1B9^3@-
M-8Q(/\4Y!0IDZV2Z+HPQ&(*Q?*9<V!H^>5IT42=8DB#=<755:F'R.S/K]P%=
M5OW*%*O=;*5C@>$^UC@I7G([(N041P6*T(??E5978UIRG^).5_&W5XI/.9S%
M:5%]SJ>[NE;CMDC/"\RZ%;#A&Y=%T9[%\>]\28*-OM 0RJA$QD#]0(\W@WDA
MA; ."*L5@1LQJ7T&?L5"50T="7&7>A6/>,-L\U!( %('4UA6@J11PQ]$WKEM
M3%7G"Q(E'OI\!1TY&]+)O-B_Y%%K(G4>F3+Z1.P97@95TVL)?ED0>M$S][(&
M%SUUUC5>"6IYFMZX=RO'+\^Y@-U>PC7.^YA_43L;6M\XZM@P72VOI"6PXU"$
M>G*I13?*-8$T#YNA[=^CBV&GZ'\K1,X2)I[4VMO2*MX2+^9@QXA-_261Q#,Y
MGNZ^F#;O)]GE\7#[-#^MC-9+$<$Y<U]S\M33&D>P.Y-].3:KX\D^F9>M;I];
M*9,)_JZ>ZC&GFAM)PX+KI?;+R&4:Y"G6D5]_SUWKKNFP,=H2V+UHH,B;DUND
MDT&NKA64F>PNN3G)B$@ME9S*!ZB?<E*'580GO($??Q_U3P?TO[TB+!<(G_*A
M/5DF/0G!)8\^IX])_3"\_Q%)Y9Q@C *#=45 E6QA,QU+7&KG(M>@39YB3F)B
MPX!]@8V#I7),7ZQ6]A.W?I$,(F 052DLU71*NZ#*K/H1$/=;8K]M<A&M'A-/
MIVJ?MYH ]+[P6/VQ.C<)FFG&BA'-3B:]3R0QFS%E@C93RP3B/%ZB'BBJJ,F:
M#3.?+R30'9V>?8X?_[$-N= "/.=SE'GGPB,Y#0C=[@*05B0H04/]0+.M\!'_
M0!*^^'KT*B1&7R0,'GT#:+&_GJ>IN!-'-U@=:*=B"5WB7*MV8N' \)Y_[(2+
M4:Z'#56:H*5\^D9CI7"[Q1'3V>;3[>+<9VA_=[2QO//Y_?-OWW!S^G(W^7N3
M0@@J!%QTH>'"O+!2VJ(/YCE0O?5LVRFLYW>O3M]*55*WNGB1+]*]#1U:_AR9
M7\MJ: "C4&X69?QM9J/J88Q">@HZM\0LZ;Q+;$<+,5**_>;ZZ>.LUFGJP3 !
MU[CPB4R3NXN+#KYR.;O<N/W&E??E;^46G^KA$+M%7A@>\7Z]9NY7C*7C++ F
M5N5"J)^F@+LR$0.NN*TY<4,,G^95Q^)5(CYG_SM/D<E7:,;M1IW6L(F4]%7V
MLO5/@CJGBN/>3-HK/YW"(DT4WC<E13G+:ELLLALD0:&CJX\<$T<\9)[N//U?
M,!I_Y2L=O0&VYQM$^,I>>.H.?'_>O\Q@!I%<*!K=NK!<3IK#R0#BL1\?.IBF
MFVV<,>VP_#^Y()N&F>^@XPHX2Y"&!#"M'U."N+P3Z> K*M0 "; "!ES:=T.U
M$MR1$%1O<X/E8;?9IDJ7J[VNJR;O>Z$NBN.G[=ST"D<>1%O>M4S,L25;,&?/
MV>;'.EP%X6FV3MV=+(YP_IT7'9K9=DG/WC= "M&X/&Y<_E(?".A3<JAL8ZO0
MJP&^IL_13V*R^\&6-"+]Z0R249HHWG.2HUA='H<#8F7L:*5GQD8M9[U0SB&.
M?4CNM^I)^0IF*A;M(/.(20XSF9/_1(FRX#S/9;9F3B!B84HX:T1>5,(_B3@'
MC90HGB%;*"F:I/U?F$>-,:I%?<'.)#?S5#=>R#31]RPQT=]ZKW8QY0])_Y8O
MD/T&\!8>^'V4?;/=G7@_OG//*H_@W\KFOSS3WTV5@D,(3>3PPE7ONWSS>NH$
M^S5-.[M9FT^FLGSK2:<T,.F<($M#/">@09I7#.Z#1RF;FLJ6($SSTMQIEL/'
M^:56/M5>\IY4];)VI8DM>'W/[1,NP\T%9=>\9R;(W3;4?A[5&X"C8R? !NS@
MI>0>Z% <&<]'YT7TY"#)[J#MY.30KU W39$X3=LI+4S]:<>+P<!9657_IFXM
MY*ED]7[-K9 Q(>#G!K0LFU9A*$RG61-J1+J79)Q)2:6 ;]QD5XHD_ ()IN%%
MK(RC0KQN^^3%9*6?,/N6ZHH*)!7QC,FYE,XYP;!=VP6+#9%X_9UP/PWUM]*&
M2FQ:Q!P<+ 'G!>B;\T2V4^I7M(N[5V*1R%ZC<+C_UX"+BL1+9?1KG?D+A+&@
MXAL&0[;*RN.VT#:!*L5A_GQKO.JG"/$\/IJ9K<&RFF:>;RU1E1B4>OP6"1VX
M1W@RDN- S(@<EWDG*4]NJT=;3-RYXT&(;NF@$D<=LV/>M37M&$A_P\VV2'CZ
M%V)^T<D.78^(>W]R:&S95B(A8;YRG/K/JW*5'-;Z<;>]53ZE:>L^F[HE&U/.
M4E.(:V_'N'O;.1&'?,L6/O.<@Q*ND+D&2'M4-1'**MSZ62Q*PPP)8AXJJEA%
M,@>0=;@!>%EHAJ8F9Y>9F)EKGK5-V21OK8#OZUCRA+*MI97=D^V?W2%9:*F^
M\-*[=0)[[TG$)L.D\R/SDY%V\<V'OLP:.:S=>YF1F;:A'S@[Q5NVI--(2.49
M]6']VK$'D76B#>M\X+#; F'Q)R.-]4=>&R1UTD ^E,R4>NDDU2[[DC8[ER2J
MZ>.ZKI5<</#8^7!_GQ-ZV0F/S[N(V_F=WT]GL7QPU-3R,SJ5[;+0$V/L5GN)
MI#M='(0XC>+CPIF$T<G"2/ZYNB0%XP/W 1M*)Q(#M(DQ;X;:(ADV>0"T!%2
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MH4+)"AV48_FCQKFS;X#>?&,_%^#39X.)Y_VKYPPJ6)'UC/[3(Z.MI"FD.,
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M2CU9;ITD6.=,' =S_;+")#)-.76PHJ(Q3*(X?J_H #G<@%K*P#NZ@ %C*-J
MVU-H(E&)\A&R_1=\^+/_GE]$T/2K6)66PY7)VJ13LN! 9WM]\$FNI4FC6L!=
M-68K8^:,&X*=.Z1IT.F89.'Z*I<9U2P)MDN:Q-\CIWC=)A9^#1G<DV2H^D[(
M!?MQE"&JDDC).$BF,A?'V.=KN?K,U*S[*+ [%0D\B7/6=I**IQPX'1* 4 !
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MUH2H9AH>(^ 7'*QTT0-C#3A7)'@,UL &?G$7:_5O6(V#0RO?$0DVJ4BKX^#
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MS.33Z-;ZA0+YX,&(S^^XU3QN7;+EEJRX9PP#[U1U/TEG>[L8V$=6#+)7J-#
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M<W*(;B[Q^0$;[#B+59%A!SRD+0,\R2/%Q177P[<DQTXXJ%@/0(P03Y$$F/8
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MJ>J9!E Q.;9Y(<$]!/JB[K:E1EYCE:)<V5O-#0X'OY,JX@#."1NLTZP19Q:
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M#W7D9,W"_-!BT1^=<<F4U(,.V&L,L93+E::%EG8@=8[(0+EWW5UV@#@4\7U
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M\;(+LG!PLO]V H.,C(R&BD: CD[ _H;D#?L_?#S] &"]@.U&1(.#H0# 8L'
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MOAX>7H-0ON9F;^>:VU+HLU?!8DO[<>5JSYB9)E:8A2> T1/ =*E&X:I5S;#
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MCK-]:Y67%REU/Q@U\<P#)?"\HFM--CBC/_B\".$:TU_U-?<2X3@>M!;WO0X
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MY.%&Z?W#EZ]F([P943LC[=<5@J!TD[;.S')9DV6FLNZI0ZZ(7+H#Y5'IAN@
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M]VV4A(<8#:VRL,/^/-KC;E;6DWHDY4RR(_D#3SVKQ6,ZKW/T^Y[WK82M"JT
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M3$1_><P8RXCOQW$N >1?J\6<\>/VFX<_*$D9IB/"K"#%R^^&"'2> (C"1Y;
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M'I^@=/B7B^\K%KM)@*S+4E,,D1DX,!T6;5AG0<$&R1()ZYZB>>+G/V;QM'?
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M;*'!O2.-6PVYU":E05<Z  8Q\OUXV]?[:.J!0"J=.RFHD'6 I[P\!WHYC-Y
MXX"!ID$H\'G37L]S(_((_Z9XK3)_V6)FXY"#6)-UK$785,(.Z6PC5[OV=+O2
MHL M4F>Z5H[!HHPS(4B*\V; YH<AZ6?:M/D,C*K17CW"*=;UJNH9YOPTJ;"!
MEYO6<'RT&1MI($;;KWJX+5-*/:2FB,D2\X1\J)0>C%C^EFDWCG@IF5XDU5-R
MT>RH/(W?&6 GTJ1'/#;M=?1#(=9F6J?<4<4?.068V=>/%[2UZ=@GRX?8 G[
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MYU+$NT"6NG@?UFO.O*A:!;+3D+' _G)AW5\U;>CUK+L<JBV%FK#\B"_].H0
MYC.!NT<"@>L.X?$OGL28VC)S1#Y:.+O((O +O5Z\"KFEE<PN5*A:*!M__KFI
MW@J .B^Y[@OC$7@ T*/=VA?D*3)=K<1G#-LQ-]1E1C]QM/4R_&%SE[I X=Q'
MDG]%X<C$=-\+G$S'O$*\K1-U'0QC?L/Q)<]'SBL<L-O,!ML'<D[;PXN0!_?4
MZJ:_PG+_'"F(#ZI9G)./>20;_BUU:28%?ZKW)\7^%"):DPC9#M^Z)5_#0QXR
MG775V3I8K*F\P"<B-EFLQ,3E^#I%1,_1DQ&QIHP4N^&AMJ'YN/73T=[,'!Z4
MRRRAR'*>1?CY2ANU%+@:"K7R+C4 &?HG+.R"[<@U69F#H-M?L'0MRKK6N)PX
M*<<$;7WX1O2:!RRMQ>=4/3%D5KQGTCRVNR9V[G$2%&)Z=>O&C>S@E1-NO09O
M]2":74GJ4HE>+R[#"I=WO'R#_$J,](?QV=WF%__P"5$Z: R0822L^)':C/JM
MJ;!U4WX!I9/(W*>3>6-F@[I?TYE__L4%YZ%#1W1=2?),P&T-.:6!MA*\L,"P
MSQ_NKO:3,.M@LJNEPA-P-2H/'J5ZPWWR*GY9*>SW*;+,9O4W?0MGNK?$Y>#+
MML>?P4>?H\KL\H-=+#'B9IX7 QON73#F/72-U4C1)FK3FE(\AQHXUF?I40N^
MKKF>=&?Z:O1EG7C!;YF_EZ]$11.*K=6/!L,H0DYF9&(T?W(9KSK3_$8J<BL^
MY5_&R7?7QMBHJUA'2M'L9M!)<M69>4-8[OUF*3=FO<S$MVI<4^\,NU*N I]/
MNV[&L=0W"2<$/>MC>G*:':+*T5OW 'C1U&5R2=!P_SEU_886)-_GBUG;_)7-
M?]&H*JI7AI.*F7D/(XNP]#W*,F1-A#5":=*T(8GA(J[\'<;LREF,5T41>KW+
MX..-OO'>)4HUA 0_GOD!X!%-B2IWT CCNA?=&7[T"L(=\]HGE[9RP;*! 6L6
MG:I^LE3L8%OLX260<KK)D]U:9YGJZ$1XEOG!#$F&<<2KE/ ^OGL/58]?5O@\
M<$&K%*<CY4,CY3>!13[;_F/@$E<&U,\UV*.O]@UL[S];Y<M\4=?_NIPXT>K-
MWQ*Q_?_46\^9B0KCS#9W)2D\*P\HVJM]MB?D^_[TQ]@;2/O7_G(H2$0[^XV\
M6WA$3<+KA!Z:4%G,]]]7,-(R3V 2#'J-DX7Q8E$BAXF4C#\R5+UT4D:?%FF(
M0_%]4/JU*9$S0.;FFC-RV%J8OM!UIM=FI(UFFN=>G;NMOANG7'I<A2R9;I[E
M?^UI5)\R/UWUWR[;@?LV#+^]JWB5K2M#WRV,RHL+3'-R1!,;7-;!W+V=:>3$
M0Q5D6'W/KAB"G+0JJ+7!$H<.W864GS?)-$#F0?]E#^%_^@2"4&XG?QHAH6RT
M!I^EZ'1_S&1#371 SDK?8^)@<_S'38+;<*3\BOR(V?'A8F?C,=9.HVHQ,%^H
M_)> SC[PJ=""O9W5'UUF$$5@B<$LVMND-@64L/@V M"W]&FN-/V/"U]7?4ER
MTOR]["%GYS3*(UFK;FIJ."GSZC*-<J&=E:C55@%MIE@WV?Q!LHMK$#P8A?7H
M+>ZH1BR_,@S=IM(Z=KY1)^; ED+9UIDAWNSKRG/+DF+>6!%.PZ5UD.F@T /O
MG5Z)+HR6_;RP5&@3]>2F9/3^J=^)I*5D6/[?!&EXJFF7;RZTS#SQTYG^CWHZ
MH+14D/9,300!IA*\^H= RD*6LB3MYE>%5<>%J3M*[5J$X%!3!,SYL, 0EUG9
MGRYV UIZYOS1]<Y$#448:.4MD&%<9X_%S[W$ICJ<:9#OZ\#,6GS#5B?4TE;Z
M .@0,6 O:+*3<Y QI'N\C&,L6!B^.N_Q_1?#]AWG3I2H@] <[7RKW4DC/SIZ
M[&MZF=[=:]L=&'YF%:MM<$6W#RL>VH1?)YR];.1?;'8FW:VB$^(2C<]\ISRC
M&2-/VHZ!4R'K#P ZH0P3!<1&SP!5AL8#X%5?UE7%"TNKS[][?J3%JRK"=L=;
M?XDW&TO%G6HM-TS8W$O,P"']]E$U7']E5_[X&<.'%9D'D7EN;A=F"2HYC=\U
M9U';FL[N"?4:RP(:'P*556<N0!S2E^X3\O<C!\6W1.3+U@QD=8T=9=V4XKCK
M=+Y,S:WA85J1=:+L:R4(WWW)9'ASP"EY"JZFPJR%OJI,*?G9<0A4UV=UH.M]
MK[*F,PO+!7 IN*5+?NH0[OVD_#"/B*ZTGF:C6*4CXY*6G ;5.)ZBK2%KZ1*,
MDT\%_/[_@$],&)DZSO==7V =:B;"%3ELKY\7/>+'RDY^&<2PVL,3":4L]%!3
M!C*.Y:<@]A#:8A]^$N+N&D> <\"7HNE+N1"<9&?W&)% .EYZU(2 S3Q7< .^
M^MXSSW'9YW'J59A?+OH,6GV@T7Z?&HQ3KE[-J=K7W-@&@V"O%!F!W_S]8&H*
M_^!\Q_3'L3$(S$H"!N<79>\L&R1E'T'H \+9\]3_M<LH)&+V$[-W;\\O3%46
M(-IPJ-:^1#,M:#$E2,!$70$ ]"L3M+LL8'3Y"C9M=WY$#JM4;7LNO*[?S_R;
MJO8)V+*H5M#BE[[L9YX=PQ:^9;QGH"&U#E3^!H;QI$""WQXO-DGX>!;#VPAV
M[IDG$'TZE>%[BU1\G.;DS-E83IPZX8">EI.DP**=2NNK%'-^/4-_QK"SFV:7
M+BOFLZ+S&&P/O[<!>_1B*M'D32H)\0>]LKVO%5G64Y9R_%_.@G5$+9,I?EK9
MQ>F_SS!X*Z+>FC:-)44 I7?8^N-%4$D2J_ B%.NUPW?2TU/^7L[2''\^P6-\
MZU;6FO 9O<KH/?94J&G88Z*BYP$<"E"QO X_L _Y=UM7*X=+:Y:!0=F[\5&E
MB1Q_D47;]@PJ%,%)RY1 *#>WVR'?9FSEN9C"Z+IN>;-8[M+.0.YH8>>\$P1I
MCSU%JRK_P1VFE&]6JF>CM=AEY4J'T!_:6.!@N'"XFSB6QL[.T[,)LTF>'N";
M'TE^ALVV$><,#Q:+3.EK0_NM@M0^^JB>_2V9ZCX=]?S 8<ZVP,%!D2/&I9^4
M%'TE?EL2"< &D&<2!N8C%VSX>RPCN',?  QVN'?'5-N9JF]@-.R80O282H'2
MHF0Z&N5)GZU5*MGLN]*B&XYL#F$U0CJQ\T@YY@ RXM[ G"(JS--BZRQ\"9..
M)8895TX?><T)IHS39:!V]Z_*CGXZXKA,@[%:1!E$D';X[=*<65/+W&68G#-K
M1]#HF*/.XV[6%618+O_C!;,%88S]Z/IB=DS1T;>(\P= '9XM>ZS)X 0(WUSI
M<#+6QY9F:+7MF\N=G-@-B(+JB,F/CX]^,-<KB WSM+PD'/"DOT<3\3>8D?R>
M!]<..-B#\F9_]FZ)L&5JZ?[5;M\'1[E&]&O \+,];N-CK/N+T ZV3#6E3:CM
MRG3325)RCK40+YZW\H[Y*9ZIS@N[.N,6+UUW68#SO/S79OYLFYAB<(HXQ57T
MDS,Y176OH %&/WP=+!.B0T$',G3!=K>HD3"%>S+%Z5R#0^IFA*U3'O&H_<4.
M&0F )0U#FNR5"XA?!:&K7%T5P/E8,V?A.8?,?JS7O6!< 53BI""JF#O7- ?9
MY?+M.[3:CNTF*QYG%43'+^M(,H0?Q@*Y E$]\_VFM0.H$)YHI9VS$5T.LT)Q
M)SSN%C;PSQB.2$<*?3K->R91BN!(:\R/I,EO_<DUR'4X*!#;J?9[K\TCIL#Z
M47,&[;C%&/:W:T@#HA.+ BDIC7-QM:]=TX;I82M;7U<_<?[#-&/Q9T[RJY'\
MX(DS$L7U2)JIZBD[0;S2(5OE'YLI(S+TG2^WA)B?,W26JV,#\U>.B?:N>UHK
M? IDN>Y:Q1M.![MPF-\PBU]/W4BP=G9>7IY.SWVN;W6-W^P0B?-O9SLIK5%_
M3"#\?L+E6X,RWONO]@7@+;R$%F2QR$5)K23IF,LPWYEJ]<3SX)&3:J/W#=U!
MP81.-NM[E[AE\GGPR<_W"I$#V+Z?_5=2FJ3)7%IH5<==:B8$]A4.#V*?518-
MKESLS\!,Y4]F.L8%>@1H'9;I*E^$TFUO4G>>[8;O[601<JXQ!%= M; C"@R1
M<I>VO@F@P0U,.O H9JN7KG4)\=LB#.EVS,K\''_^"QC1!Q1AVKPOS#)9IZPC
MTB'-W$5<FR8SZ%S%<GID1GTBNSY@(/%PO#JTGXJJXQSF55BP-TW33*)2N"CO
M3.<DH#J>YK_W17Y2_9&-EVQPE0-Y:[9=0@]9\=\0]=A51*LO7WOFEBO'(X<J
M9]H%?31-L4C]6>;=@0PV'+CVM^HQMI[6Y]/  PQ'U]/O*0&&(Z01JY-<#NO5
MLHWPNIM7?!N;3/?'QHDLHI*9V%6.I;(V$7[.-'T"*VF-%3*[/<9_HYA-HVQP
MPZ=IT<1?1DA^3JKE-RQT@7TM0B!*U4SMFLE\N%QSC5PTKJ)(E&$1@T&;+,"J
M-:A L;P/!D_SF]?H-C7\&HLD,IN]%[3?FJ<=TH>4,Y.\XR!SL8_,^Q2>% [8
M.G< H V[KCJO/HRO!F_@O\K_.1@#Z5X_*15]  2>$Y'6J)2!JXP&GC")X'(,
M$MD5XY#7R0(LK3. "*B()40@X@F,D:LA@%#O.MY3*LIB$2IVDGA4[FH813)W
M3-T=^0!XC=^5S4&(\,UI]#*?D'4@518(H[.=6O3'1 E@R&N/N;180'0U?H6O
M0ECU5P@R%QO/F<ESI9_[R_0+J#^FKO&1]/F\K),T17._)!3^,DQ$UCX7D72L
M6-G:]JNUH5:1VTX_9?Y=6J^>:>AU>),L0"-9;F)K^M/4!EQN\GEH%]U&6@EI
MO 0GPT>T]ZJ*@[KWS1V0FMM\39'\)]X#H*4F\EYP0D/ZV;R!C!F8'%:F3$;,
MKK NXY_E\JB@9.;JLA'T[6JF^A7%V$M/%M]P"1M#[]!R6$[]U^[8P>SQF=R7
MU-C^+/])('K3MZ^HT&XO9:"24R-R)!IN/RXW+EW^'Z]&KF2+.5$Y_O5[+YMD
M:64Q'">UW,*%PA^M%Q4<DD'('O=IJ,RSS[/C1>>DUFC4J%/2RPI;YUIG<8L6
M[QFXT, *Y\J%/2T"H84X3# (>?+:$X=\Q$^7M4Z?KJ,T.O>R*@KMO$V@!:0I
MD?YW1!L^VJM'V&AA@*$JUOR>JEB<_RXZ):@3'+ :DR2LR/C',2.@89W^FU R
MID8PRI7D&[-*?'Y+Z:^3?8/6&/OGUA&A?3](J4=;/'Y(66D]:V"F0II(3N^:
M@1?E=8;#_ZF\#\;H_Z[^7S7#K8;VY8?VI?O&/_SQL?[[P,Q$ >,<75\)4^#8
ME>W]6D?F^I+768#IH]+<4#Z3= F3&1N3;3PP!AZ8*;[@FX^)'YONVTC24G48
M9/DW+W(W+V #_WZ7A3.NTIYKG=/Q'S_Z^+]MN_^/IO_?AS=TWGX<-]$Z&6O^
MZBP1\:?9E=UK)O(=>]+KK@I'$S7EI\JDO7O45.06$D\J,IMM5_5O.4L%IG<,
M5=.K:5V1]P/WB>-R;F-G_/A24L=,9AH?HK6_6ZA)]$@VQA 7U/QG*ZOV\8O1
MH\D[\,3BX\&^@8OSO(F:W0LQ>/!S3Q&W@]SIZK3$Z!2!5' ZVU>!K234T>!M
M[H::G\&5#Q\/QSA%_2CNCJ(#F4)8Z)ACQOW%,M-C:0G.:-6C[7'-PH.5',5_
M_J]B[O52AN[K_C&HE#/TR9DV)!1XY.47LVJ E/5,[FF:UIXHTXXM,] !UJ_X
M&=3+IRA2K=G<B&K&BP_JFV=8I>CP,%=9FDTF?,@)/Y8T8B\_[KK^V)R!ZR,G
M\4A"Y^8P0V=Z,395YL!OQ 9>D&!Q"=$RF1)H8\73UWEROO.CB _5P9;V-,8Z
M.K-4:6#9QU>>5M:U[K+5:O;V ?#4SY)S@>G/H!%GL<030>^>U^!IT?,4V;J0
M3^$8KY2XDWV_?%%C66]EW\8)!@O[M/CUK[)7Z$Q!A?-@]\5@[D#ZX/3';3\I
M\LJZMN<)1=Z(Q_,::[UGS5/Q(HRH-@4Y=(%\#@3!+L4LDMIY-4I>V$<XJ[>E
M\44UN_/(;J$)Q@[]I,2/'BF?"E9UMB>?];-(R[_3U%&-D$JW;("IY-2KY?T'
M*'3_C]@RMTRM42>S]&_8EF2<@+I:NA(H29&]>_S-(D]A!./C@>2QP;;Q6=\7
M]%LI4@:2HYI/M$/MBP.]DD><>4TG1O,C#1)]H5"Y"DM65C&6'P!*<>SM<!A;
M5X1N"S%;F/1X]Y)UU9D,9MHAW1I<A<XI$MG8MN0E^QTF&%13[G1,PL^@J4VJ
M-4$A^/ZC3)#ZHZ^S;OGSG,R5&?_(ZC]1$6AI2PRO5O[[N)FQ\0$0(_( V$_U
MXS@E"O9[!A7.0G,LJTWRF(=OB10L!.!\XMNXP"0_H'P.+QO,9<D%X"#JEX,,
M(-.I*YR&D+?CAT<4X+!H[2Z 49PT%1!K$L+=+++>HO2F9RHM^4H+ZXNV4BI_
M@&CD=(+'- \A5/1DNM@BESW@O.NIOG3?E6E'9T7Q",ZZAC6-:C9VT/I._J\4
MX::61EO7EX$<-1Z/?60$1]$IG(<\JU)?UX7L'6!'!P^ <9/-S^MHM>Q#:7J+
MBBC!&P;BW4:_,!<J.RZXG/6A5?#Z;\[GU$_6J_KRI<5=UR34C*=K?'"Z8A>4
M"T!4&6O>,=Q<]>MI5H[G)?-!AU?1S2JK2%L?(HU?-1/VK7,^$AN2>CKJTE%J
M*+J,W/#!D^VP@I,'0+2X/<MXQ?&KO,F!LX.U,R4%,FB^O'BDLS2]1&;WD,Z)
MQ3W<SXRK92M3!-Y0I=70?+O"E/&GOT<GH0_(-FY>U802#CX\%$AMT"05;!G]
M<7EPRXV*SJC?-=I#RW=3WN-.N\I\,IWB<?TVM3*Q\0925<D1=20-,R&QF;F7
M1$"@$J99-DF_C-1(390],:+%S'7PNQQO^B+QU7&* N/B$,THJ/,:R%!SZD"
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M9VA,5R,"^ORDM*-P<+X@PI5^M\H1OC%_F-A73FA;"4>Y7K8F4USK!!4C%;A
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M=0M[%PV<:A&M'<\PYGP\?"R]REY2]\QD]]>/<M-X(1PJUP(8ZI[E-LKE9>Y
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MM2;4CL;^^F)6W[WY&FY<8FZ==P@]CKZCK*=-&@Y*\4F62I:EW\!&<8)T4H$
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M^,8TU%UFJ?&9YR%])K$O50F^,5OF:D@;\:/X_HL$>W *O<,KNA^)M.X.+PN
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MN'[G4D]/R%0K=/REZ?*'(1='X;/BDPI?!=<V1&5DT7>,099>>BU7U<%@P+
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MX?T]!NF(PRGPH!VGQ6CDK[7CFQ=BEPX/+Z?T C"C6-H!<72M&]IW'TURY>I
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MG?#2_GZ1P6#D>7:X,'Q<%_M#Q8RM[C>;L^JUS^1+#O[B<KA"T3?9'==GYT\
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M8?98IN>0W+R&(SO=!T-B<]E/UYK6XVB,O'%+ZX4C_/SYH5Z'/S0M;TV?!41
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MO/%G1=I_@+SI?UD^]L]U9HZ<HSCU+Y>DC".U7)7GN>.7(HWWR=HS ^%/C*)
M0'(Z$>+_ZT9PS-SX1'W7WQ6\73 &4J10M]6\ -P^OU*N!;*=['O?!G+\E\/4
M_U:[*G1%I6"4.R^SJX8\+.[R;NL\<D:Y+QTQD;S_Y_AW.G*[<[R*+Q^6M_\
M(OG_%B'^Q8]_ E!+ P04    " #J,W%4BR("#CFW  #%#P$ $@   &EM9S,Y
M.#(U,C T7S(P+FIP9^R\!5A47=<W/G1*"(B A#1(#1W2#=(E+3!##C,P,Z0M
M E(BW=TMW2(JW=T@TBE(J$A\@+?>WO&\WU/O=_W_U\5BYIRSUUYK_=9>>^U]
M]IES.">C)^\!1"H*R@H %!14% \4#P#@9(/ZFJ8M# E#V,*<Z/BX> #",LIJ
MZ.B 4Z(&O$(R_EX$F%U#,0*@43$I7D,% %"S ==0-0'8<#@?'Q]04/@:*@9
M7,W."@Y#P*R1= 8P.(B.DT[9 0RUH*.3<4'80<$(!)T.V II!X/2Z7 "Z90=
M+6S "#H-*,2#"P2S<C]'8CI'(H(8A1>KF-T.O&NWG80@FM YKQ,]KULXJS_]
MHIR7\)S@=E"DA@O2R05Y6L0XXVDBD#J6,!CD7$(9B@2#H2Z./X[/]K(0^%F9
M\%Q7Q\[]3$+&#GFF\[M-,%S=PA&L*W];]R?8=P5-. QFK0-&NCAI6-I;G;+Q
M 9H . !V^F<-H /H ,  ), %X'2N@NOT4_J'&1D($OJ;1_B6+G80I!WTW.1I
M&>=<6E;-4/5[-XB=R:-R_J'%EW]IL8;36301IUSR\W8Y(:$_&G':2$OXSX*V
M#4+M]QHX5/;W A3Y>^&6)03QLZ!N@W3]69!WA,C]+)S&\7?3,E8.-K\%XKN#
M &U%&=G3'=KY,8B.#@1SL92"O0?\($4X]"\\&<A?Y63@(%T]*%*!01N"!/Q"
M,A 0W=_QM1$0Y#E?TQTB!7_]@XWK>IIT,+B<!=+B9U9HVF@B?F3%V?%O>]GS
M(("MD7]G7O=T@/P=7\<*\IVO";>2,OS))CH="DX&MN#3SCWM+SNHS8^($9Q5
M:)_Z) -#(F&.$!C4YC<5_!\U9R[\PK_T@Z]M9V/[:P7>CXI3WWZRSS(';>.[
M#V@-QP( 5 #JC_UY5C&?UQ'\W@+)1]^UT"^=%\]&^_?12/&S3'-N=>>\C/-#
M#^5<BX7H>YA_=/]W%+2]\V,E +>U]6D-Y'2+^9O2=TY*3.Q/#N_YUNAT^X,C
M<+[E_)US;O/+^?'I2#KY6T);/JO^[]>=QP+[>T3/_0*@2GW__E9'\S-.W\N4
M9T=H C^]/R>TIZ?SD_W/T/V5?N&=R9W)_T.!G_3[Q " ND#.$@SU#-82Y@(%
M(?XT+JV0P!]NGB7S+XD$^%/& 61^9N9W-[1_)MYY$S 1$#LK,$(?<NMLZ*#\
M 0?CO.[TX/+I%^N\H"SWBVTL&SC,Q>D/+$P8W,[&[N>L**]SIJ1QSCLM7[)P
M0<(4P5 PW ()!IU[[^'T8U+'_2Y\QCFK47:TH?M_T'XT%SCD#Z>&\^#_D:.&
ML/GCZ0/3 H+4M;#Y X_ "GRJ!W9'*B.4=-5N_9B@L'^P_R",8PN#>TI#[&Q^
M1(KP>^.5?K#/H@L"6UNXG,]0.*Y@./)OQ/5_L/\HCF=I(PN#P."_!)?XNX*,
MXL^*,S?48="S/0X2YG1Z&D* ?PT<+N0TD'_AXEN>3W5_X>/!SR:T/['/1Q#K
M=[VS=);< OS.)SX_1/D^\Z"3GI?..A3CO'PF#[C\]+> )9]^;4\/WP, ;\_X
MMH"K )23T9,- +XT"&8)-I=5 Z">; ((SDL T*,SO9,)P%, /C8V-@XV/@X.
M/C$>+AXQ&2$^/B'951(2,A*2J\3XY_3;[N\)Y1(>WB6"2T0$!$2D! 0$I&<;
M M+O*L3_C(&3UP!B[%/GD]%0Z &HQ"AHQ"@G4Z<-Q3UYAR)YZB4&RCG]%D8T
M  HJ.@8F%C8.+A[*GRM13F?_'Y5$ !1T%#14=%0,+$QL##1\OM-*8C3TZY>!
M&-):%B3TSH]Y,4E#4HIE&!C)M!LM^?CA3_IDL9A"=;9FMZT0 E=22[R8Y<)T
M0?)OTI""Y/UZ'\"?2I^^'7"9VU%@"4_W+HMX-SB_FU'>-+2PIV_MZA.96=$\
MO+@OI&A@X^8;E579,K+TF1B BGKJ+?JY3UB8& +G+EP'7D8_]<"9G@2#]W$(
MZ9D'C=I]6WR,EK/P)Z&R.F16"/YM)LPS!["8!=[TGSJ11@Z2UQ-$@C_\=.$?
M>\#RNPLGXP!\M'-,8H D8!=:L224.6I$4)A_^=KBE2?[ CU3:M'[WR2B,COR
M]A[&ZAD&Q\7T.TOT6!479M'7/HR_*Q^AY[9"8<?"/!5SN^L8O"]I?0)0;\F;
MTFN,%KP- =_*KNB@ML7P#D1 2BH[S"N'K.Z+?[N\XBK:23F]UJSL[+%'U3*
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MJ0V4\Y>%HM"AU*&A$/]X6>@[ ,W9FS]14=%^>6DP-@X6+AHF"CH&ZFF]&A$
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M63FXU!UN([=R0 _1KUXOD'?+'+X<YHK/$!Z;Z.5&\SK8S(\,LR!PUA(U[U!
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MD0.=7C-P& B,F_ \UH8UQ_G!D-)*5>PD(S@4"1GHM#*JB'H9<*4OC?>(T=^
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MTCG2ES)B\%#N2.0-8U+&% 5/0)E@L-L!AXVF S4+1]<\7_ECA2;7H=54K_3
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M[Z>_0NOJ;HCE5.0("0OO=QV$Q 9S.#HV^567!3IJ7#&#/ D:4A8VU.N%UEJ
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M!\=9WFEI;Y<]75"![[6U4;CV0&1@H_%?> "IS3RIJ,Y\M</G]B"+ 6?#G3U
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M</3JA($5[,Q& O3GK&B"M##N[D&GRS-O;*O(FN"NB"TA\JJ<!P!AG_VLM&;
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M,=VV9OP?WMN'IQ^.JZ%L;_+.OH;\=UQUY6SB2!3=)P9A@9GA<MHB8! OD?B
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MM+=-O._['>S=/G(N/;<7E>PEW=O.JIZ8:'\ $LP^IVK3-&9]DS@&YG6@I<N
MJB[?9M3MZK^3>@"T5!<JT7^UO.MP_XR_>S+,X&GHL0H1T'=,Q,@WY; Q,;8E
MQ( =[]?:_UP[,O3;,NPOA;;7+!O\QIIC/AEB-!L-I7,7$^^(SR!@+U/2$,F,
M/F%]&01XC> N.0JD_O[FS/>I06\F#YU%E47EO\XX[:_-.G;A)4:I1:!8MS:-
M"PR,C^9 IF,<ZZ2;<DA%9O\1VAA-#$HS24.1'NUXU)-(,MMLQMG)?0P;)!+#
M^3!/47Q(J3@=>>I4'V*R]LZVO_^ODM#R=:#">[K6$8[#H73[QUD?TA\ ;$&3
M20&'@N7PA$;WW!M+)][3F@'O8=PE.)!M+T P$ZAXWE!":#/=")?.8Z,=E+2Q
M3?.O !)XSGK1$-G,5!\] ,@GRY2I7+*_F5^/PU[2ITT_2?6ZW]$0<:I%1P<Y
M%>60ON1"&HN5:CR#I2G,Z5EC@3,J'_6J8_=:?E>)?A2SX*(24/5',*6QP9K"
M.[Q29+6O6V/$PU:-YA$G>+>WE<%+*; 8Q7'R5L3+L-/H*F5PGB).:>^@'*57
M=7+=^$-UGHJK'G9L95E(.;]HWI'NCFSS71:^03UCO*:0 L-K0G1-[*-B T,*
MC[&=CJD9FE[J"5U6T$CJ[;SQ5GY#%*;P"L)<':9";2TR].ED)IT378'7Y'%'
M^#%9H\JE'.G*8[W@F+078U1 UFAHL40Y*R*BO*CIG*+&O\>E-')$%XDP-;.=
M25;HTCN33N6<:(3.:[K#<$54G323CM'.B26U3''6(GM.X?%C:XAYMMH24$*M
M?'(5YM6OT>,39WAH@&G!^P1U$YGN : HQ^I\5%RRBM$[6Y+=7DN5\+W))H8&
MC[)VJZKCPV->5]<"6 9BHO2,%?'FC%W;:-IR"FS@5B7^ 3C+.K]$N7IT <Q.
M2O^Y4A8?<"=:GFE64N5XGM]FS5S<1D29V[@QC-WLX*A8)KC+\[=.@/?Q$IE9
M\6$2[%-TV!RS&YY9,TY68LNGM8(WCX6MFIZ_EL(J? 2@'$G/BBVPUQ(/!./0
M"!8,VS75;!C:1["6+NMK71X6:N4QG%HWZXR<QGJ3ZZ6WP2.+S/NSDQA39^?F
M7/?+0=[3_-F1'1J)U_RR3X[KUL>0:0\ 5J?(I^J1Q4<RZHX8N"%SMPI6('L.
M0ASZ4W>$Y86+RC=D>['&DZ+Z[P$Y:C;VZ42MH)SR66-1)Y,<@4+V5HF;(SRG
MO>3+$:,Z*&%2(F3JL.6#\< \19#J8%)#60DY5_(/I[>&15M&/L99@LK.8G@L
M[G,Y8G3S5[85.+7$:'R!F_7:-N2DCB,=,_+7)$6>!W'-=I^V+(;6VMXZFG4]
MGC@*1Z]74E8":7GL4OER_=&9ZFT6W(+'.R@!]F.!"4VY*:WO!QH[A%F!6#5#
ML@<9<-Z>RW,,*0_3>)SA^6E_[UJ<8[2:K0-UB"9&#XTXP]P5.]5S>3V\\]=7
MDR&!T7\*^EBSG5^*48 M_8.KB_98JECIHREXS_7RE^&E]27+N2&C[H=:6HLA
M#X .EC"ITXP)]6-*V+"+C>?R=-%LB>WA[SHE8HPR:[)<DFWM,]!PI%KHO?8
M##_Y;[IA [^H"]LDQ^3IW.F.D;;O^$"N<+4[1DY^0^ I&D2?+5ZX^ON[&2-M
MX:K^@/3'JI3(!*>,.@*-(4VOOE7+*!Q%KR%UGE%]!KQW#*+6/+*23A9%;9GI
M)>W4<P>Y,_*H,J1K5?-[A@%+W*X&% <0#,IC 4U::$-.#2$3:&S1?V&XE[1R
M*HHPVA5J<)SNR+>)&?O[7\N)@K:S'R>6(>[&?\L-PW<>!<VW'#T'U]G'>E=8
MGSO& 5GC*_4AM4%S;*(U1M "F^_>-B.Q+K;X*I:1"5J?YLF!3*T !M((N&(,
M9^OL!7'Y^<LOWF@QK\Y*0;DH$_ L?[[F>1^CQ@"14EE%V>.:?"-1![JTZTR.
M]XS>PW+](:U"1<7TV%\^_6]LEGG\^C)L2[>Y&G;@.O)RH&#E>P8D64J?@);K
M3<U8\K5I+H>.[IC5RAV6$:_>%I7 B\3N=Q0;:\*.G0AEW='JGTB8E192]Z_A
M G.3YPO%'J:G$\LG3)11.:0]DNP%RQGHW86VK1D)0[3O7&R46+!AU5Y)HWU&
M!F*0T$7F+Z^EHRM&KW+#4I\;').8K'C8.E"/:D[+ECI9+T,[JCXU1NM:U70$
M)3)RE/+<%Y4\=_XJD_F&%?PBZS']F[. 1Q]7 #@O&G.VU:?X,U\JL=5B--[.
MXHM/!AB67UND@Y1*<BS=0(R9!C;?SOS-EL:-"YQ?PMSNLF)+35[@7HB4U+0D
M4PYR8H3(+B[^KJECZ!L.P/$<B(_BJ/3Y?S4AN9 3@G$8V*+@VCP4!@7R$MAY
M[&R-=+Y6;OVT.8]::&D7MM86Q9VTE7@^_3XR>OVUJ)XP5P[WS:*PWU/YC!>Q
M_H)^%CP<.BMV_,9'QT<5MA6;XU%)5>[Q+&/+%A8P;VL>35V>:[8BSR76V*3\
MO9:]GF*]11T)/S_U=FR9J(T,\>(C>2KN,R+K(-D\%:/<C'U7.I*L!6K*@-]Y
MM&^W,RR(5P07C^3HV%PT0AL=;FJ6OB.2L.T<\B)I)SMH6?CD2E)GBM85] HE
M.\62B37%$'89I%)C6D=\4Y56!>95JFJG6=7%:_0KT*V],_\2Y<H/T]K:;F@-
MZ!JFNDYRIKF8PIY+S'+%@3*V-1X!PMC/W6]44^!(]R"=([(S&G@-?O4B!%B4
MGK_R5O*<%H)HVAG=+ZDW65<0L'GYC27U7)OV_9:U<*C%V\L(5N-5?Z&A >69
M*WLD<P&:T*!+6YY7J19^8Q'USOF=8<&.&)*3)M=CKSI?K3ER[:^9I;VWO&*Y
MJ6R)SZ7$: "3=7& Q!@H@W6P_=Q^B]Z<2I?T>87A$E7=H4MQ''Q<@HOUGP*,
M36/-*]HG59EF,>\NI?R&TAZ\/*'W.(C(9MG:K/XQKO-KH53ME?:ZTPU5-%ML
MN>E?P!<X^[U&U;?*LZMOSVT0 ^17 $"NZ:,WP[;^3^QL?49[PA,B4Z_<X-=A
M NL0BZ4S!,:#@>SX]GR:[(/@7)3C2:E?[&39],0@L*RU-"AZ[-R8,N]:R'1O
M4(A";O8Z@,UQDKS&X:-T3*3V M/S:B#CV@9C*63PK>LTRPEX5&O(0Q6IM0-5
M0H8H5"3+ ))&-X[P_B!8/O^@5F#^\A_KMQX!CB_ZK??T$5D+HRWE-.1![ &2
M06+V1D%L$</0JV.;9D'CT5J4CB,<SRT[4LG F"+I,._.62'; A:N*Q., W<!
M-?G+9,Q_O2[<<N\GA!!_20@^5/E1JD<X0^CU6*\*"8QW2=):C):\?.<F_ !(
M'_2G_F[* 9Y.R1&Q95T"_]76U->L@'&%95F7W3MG)Z#)_!:S<175SA'I$;/C
M3F4]'$I^<2JG7)&^/".! F3T2W[=EV&<!Q$Z;K?R@EX!2,7R"_K=^[>4&1:1
M_GAPU7Y<&MJ$!)\QQ@,K$B<";B()O*K$[PDVGYA)>S\_(QU?IZ7)QWX]O'9:
M8;VF4$?F*[SHNYZYF^8V_5*(,G()EW_,OHDK8F.!4[ [MK(FMK)XQ=Y?C<_%
M4<+Z\8Q)"-)QL*O4UK<!IC/MF'JAD5H 5O2J)<EC%I%6[-94Q3Y8>@$O*;%W
M@&Y01?C.B6:1(=DDAJ:W4M,PJN.KS,O:1<]G:!<ZGH?*/@!>_ZQRZ'WU"YFT
MT AQ0Q@!=487FC7Y-QPD9AM=C=DULTB 94&"LK::[HF_/5"9"IPT>-$V2D/"
M;IART56-:5'/\_ _XQYQU?;DW;^W&1D$5FSOK.=.5TH#G;2[>LC;\AU[S6])
M<JC7\SBL07FDHCRQKDUVWV8*R6II(H Q6]Z:[G[6@?UVD$9#D81*]<RQ")U=
M)'TNK=:DDC1!&<^K+V#%GJ+\Y/@8KSX9(CR\KV&BII6"$3I-%8%N/=W;\L"V
M2DGKC'KO[NE? WVAMRRZ< M+U0+FPN&]XK[=),4+H*%(?_$#P+*\PB-;C(*/
MS:]EK[WX?*G^P@I6^&G;W]RH*],7Z9.>A9?3[1X-SI+8+RURITGNB6 N7C'O
M6U@>3D=E=9H=M,:/-CW?@BDSLXIE9]X._*259B ORT<R>CNE?ZR#>*QDB5R\
M)!/^X/'"0\OC<\D$G'RIR=C8./\"D?'S'+&:B!#URLN]OC9^6A@I.'DJO#TU
MU**RO:^M"-:Q*$C33H2^OZ,>\GQ5>J$:&XMW(5\6!OO"PB ?Q*&[//J<*/W4
M?5&NKILPFSM+? '5V#\9X6#]3(S7).(!$#%MXDD*5.B=;1(SW5P0(3;3N]Z
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M)TH3^<Z2.#^W<%5[D25[DF1J%1&P@6748]*P=5-KW;_+6LFQ>A'].B5QT:;
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M/0*A7[I'O>W2D(K&3&ABN0G].P?EEF]>-*]X#S]!;<?@EQG:'J*AZ8CU$TB
M0V6]A<5;_!RR?9?E:0PJ/D>$GIR/EFND<A,S.X:MCF*5EB4] %M*]_A%@B)
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MZ82?BH0J.T+]2!-*@ =M"HDMC#YM;4'T]FG9(DQTQ2!%;05!NX1X@L73QX@
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M<QT3 ,!,!5S'O <XAT!P<W-S\?)?QSP+$ &9&R'@2+@)BEH#CC"F9J>6LX3
M#*BIQ6V1YC ($DFM"C%"F<-AU*KL7-1R4 -3")):"6;ER&$,-W(X06(X0;IL
MI1V4*Z^GZ>ULOA*+O#RH>M(F>-+VY;@=_<$XJ5VT1IC#4$JV*&M;%+IZ]IAV
M#XE2-83#K4YZR,%0$ C,%OK]^'@O884XKN.?\*J:.QSW$#=''?/\+A."4#2
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M3^B3VHI]VB:)>AU#_QJ/ANVV1\2@5H>)++.?9J4+<M@V1 <A'R839!_)&<
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MRN(:#LX=UCG!=TTSC@ C!PCMYEV!0\78N0!]B<S&?^.2[I?QPV4U2?K)M9U
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M+A^ N\6\9 Y-TF:. !+PA9;VT<8Y][Z=M3U&JO#IC:)?/#R3-ZS;?&>,SL9
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MA=+'G9,C5 GR)Y0]"<">2C+#(!4&V]E@!MOT>%J3!RRTJ1A@-6.K]-< P%>
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MAR*BI(TFB:Y@A$COX]]I*_,(!X_<)'!(Z\&;WXXZ8#!TIL6E>JI^M=,%@BU
M_0Z^Z;CFQU*J#S:6?YC7R9"C$^OCGW)T=2,-7P2WU"G;L.U5["VT_ Q[Y2()
MFQO2<?V3UJ@RS"0:6*%)L&E!ACI,F0?$^7VB&'8^OG0G<C%=YH>A:Q_@O -#
MY]<$\"QM.WF*^!;V#LN33J4M(;B.1.1LQ#S5'&N$'/S\FX?U]OZVD%[41>;$
MQ?Y+UIS357*E6ML]76<$_L&F!%?IC8Y-2ZKR)N20<(\]=[J<V+%;4^'J5SF!
M[D\;!8U.=+<WZ):VAW6?3C&;N3$9CO#:; 8M^^M;2QO#D=;47_2UH:)$ ;-
MS<^TP[M"O#F&U[@.PO67Q61MU(A?OSC8VD+P?<CUK.IE_--12?;5]7-7@&_L
MAASWVPER:HQW0_1>-0W*8?SXMB@QCC\J^.W=TM !)68-9E3-&"$P%O^P F;E
M@-B4!V$PQ82^< \MC:/!" GX1'W(Y[%O>;EQ$&897/4\B]I=\07',5D$_G=D
MG*XN6O&+>5[/OV@!4WN/)>\%S264-JU=TPQQZP]A1&!93>)L%M_ZP-&>0LCV
MQG'WF+I"=9T+-$)//26.8CH)#LHZ8+.FF#U_FW@;P;HDHD?,.C]I]&ZQN.:,
MFD**% ;!+K?C_OD9HU37KLE9OV1AS(K/TXVVXAC1P?D@3!+\A M.F:\J(]@+
MQ6&VUA9:7B5]H/",7'=8[#XMO])]<:^7_)X7KG&X/E61S :N3FK!4C4JT*X5
MUD^VZ \"88]]2S*.XBNRJS@OX'N>5.1HXC5=:]D5+MX#\!4\:&%F)VOQ_>JN
M7M\05!84RUNOH[,9'@3YY*4>Q HYCL</HV>61#?Q=.BD1+A@D:7VWE$2J0)X
MLU@SPT*2VE-9:X7>?]*9R%6K#R"6;L'^<VH&@XG88+(+.:I%UY$7'?9Y.L9K
M+J3*7RP8!L.E1G2O[3'7I@U+E9:PEDB3=A33.A4C*-YF*?_:U:D7DQP:P-*O
M.R67][8CG@>Q("(H.^QIR,/O0?@;'.OD:<^H:;7@HL>]=0_)/&&5]42)(LRS
MJ7;R50X%7[XOUX)(&OCJRK2+;Z4OBE7'\I+Q^V:ZY87P?D</QW0P<!#/TAG
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MX.(1.C(.I'5>ZGCEKR?M_O&W\1S^OVI^_G^!Z5VEU6*%3.10$KM)AXW!#."
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M*+U*EW[3I:H(A(Z4! @$!$))0H?0BR*]2 V]2"<0:B!TD-Y!(=30I H$$"6
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MF2_5049HW8ZDGAI^"QVC9%>>*<E: :-01K,RV&)XI'-R*O[[_EAI-AON)0P
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MP,<1ZAT?X$,_,3!WC#1:6)E2"&BX\\INYJ>>,=#N+$"[7Z"T%XA+7WU7W0:
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M6:I[?9DZWV\AC>8B(I6O!A.)3L[F;+GRSGPUTZ1@MMQD_1)-MOVU9%H34IZ
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MF;.[2MF6DP;&S.WK2TH@8$%H(NUJ5$Q.\[O];KLW3-J3R5P=MFN(ET83+<;
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MDTE+7B4(R06$\C'-8B4.Q9UQ+.Z"$+YLU.1 @+7;8Z9-@K.&Z>TO6 MHSS'
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MK/>& H*R4A1)D3]$F>L"Q R$P88],S!FV#YCE;L\ D"!D%::@C$*&PP4(,(
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M1BAT55)VHT,%AJ^R'P@R@G!!85:2(E;]CM!_VH"0M)5A8!+YGJ:P>KJ"[*Z
M )TV@D!!=C?5T-2 82D.'%6$6N44;# H<,**( A%?C^7S6?@_0165U6@Z C*
M=@-?$T8H&&8&]"LP$%:2"$8-"@O8BM#PZH6U[QDJ>JH"P;JJ8I61' &@H$DK
M23+4H'X%SEA1 H.I'Y;0UZTJ2( *O&<_\!&D*1C*2C $,N@2.MW=TTD1J_3_
M?QX4-(&OVN^]T8$"[64UNVNE"#R"EL6^LC=R0]?0R6X""J<'CDN[,0Q%$LR
ML$!1*XPB-+K1*@L$[JZ!X$1/6XRD$(2PDC#)H /F*YCNM,(X/7!H^MU-" 83
MZ$:+BMXJ.M:W(2,IW8U;81REJ0$700 J&!Q'?]BL.;QN5! T0$77AC C"!-
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MXY5G^3.OWFF7A/1(Z!_L6=L%3KWETJGUPL'YYUZ\]H5K;G*<?NWQ,W8:<VL
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M?C=TRR3A*C?RV.U&*15]=5G'7=0>@_=3<OK@ = *(W#@]E7+9PHZII7;<2@
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MI3<X]\65'E^=T56S!+UMLTJ9FK&EA/)XZ8T0.$H[I1#D"B:-T=*.U*K4+YT
M?>T(\EXO(:UJ%XF>P]8L&--0K1W'U6_'2(XLCPP/>\DS55[R(:Q$G(<L \.E
M,;$-%HT9T=GQ I?VQ(GT.04ARX"SR[/K<"QY_O=N3PJ[<I7#NTZ2VGW\IGY"
M:&Q_ABHL]O09_*Y8II2I.- L>"OIR:B]H3')PDPL6V8 !GBG)4S!KI=4$ A%
M[7C-'+Q=\N^*V@LM .,R3D!=8X7/)'_O4VB<+@*N4^K[KPC]?WB$'AU>%$(9
M?+L153MAW:U=";]Q::&U(#WR+Z8P?=66<DX(00GZ+_^^X8OW?P 05J@%"?4&
MC-]2PP(N9K2R].!0!&WSA/9A?J 1(H=1)6":HG)O)>6ZRUE*:TEJ;=]&-;'Z
MW@,=IC>RA<KL-ETG#US V]L(P'T 4%&2[BZVH$SRC29OQZ^G+X>L%J4OFTHD
M#5/\OU'[]W6QGZFN^ILU!";/UHPDPNXMT&"--A*?4=NXI)$ @I^ZC5<2?BZ'
M:GM M4/.<NY=B8T'P-#MD*!8,O <19,[OJ/M1Q8\$CTX'E<QV1E'Z!CE\9&$
MT0/1PJBAN??I_4"QG07H>)<UZ\@15@UO6"O&2ZS/D0$VU-0O#<TV4Q<;FM;O
M[#<G>1R5*&KO2 8;EPNH[^QJN:E+@EYB,KI8;@!?X<3P:O]4J>">#>0H24]I
M?B4U Q3$Q7S].+S*C#T1Y\G.GA!3C3L2 Z_JO<S\:DOK^(#VR>#U%PN>(=RE
MY5W8@2G.0B".P_82Y'@1/H]TG.I V-0OS8SMS]W$2!CGVHT7EU76I1>]UFS1
MXLJKS)N$]/':^)QWZ&3PV6/#PNN-'34<$T4I]0T\GPEW.4'?$)"V1K'L"&9%
M$.6PY"]:VC(TV&;-F=ES3N^:S%I,P6XX#?$1W/)BT@42(P^ I!:A]P5SHCD'
MQGBC*,FF<DX\FE*!YQ?<Q>ZEZ<?O-)(ES)Q]E(A*(V,B!-=5;H&<+/;,S6+5
MC&^%HRVFVD/K'=XD?GNR,HBG:M[BC@NREM 9KXGC4]TMS(A.4IU=\^/.%JS7
M;9,0A%@MCN)R[LT;=E752SA,+^[R>];/S@+Y(+8Z]?&EBMGMQM)*FD4\-T%%
MX[;)[WZ5?N9ZUMHV][EL.$VX5+#J%!<U+#)W*RI1_!DL2%2*4?D^1/VKVBN<
MV=H:$7/M E[.RB"\)1YIL:\[IR*<?HO,?AHU:6OVI[TS%HT9!VUB[,X-3J9P
M,=OL^OKAV=$"Q?-+?PJ="WN/YD$*"G$VG0L* ^6G#C)OM=@&8GA^-_'@F-&G
M?,Z?%H+=BF $%I:^ !;,$:^!APEP:SG*BY_5JU[W_3+$96E.+0H]@Q>EF<S,
M<T"FX-6#EPTJ!W;+,]#0\>.Z[4&XK3:AU=$W7R3KA.8\MT7H"XT@UJ^"*W08
M,OU/YJMH!H +2*R!\P< 6FGR<W_J51\XCO SF? DG^N[/#EK'IJ>-E)8C?%\
MGR+#8K/P,KLA(['6<T[@W'1[K>VL2L#8V#Z<IL#:0<(RQ6J;/VG80;?!T"0Y
M10E<^ RSR%_&4E&[-.@=UV$9-JGXQC=LND>N/@ &T_O7Y\SH'62@:?X#8%!/
MY>]1+&MZT[D O6>>:4?;0T/UUH7R%1T'HS]S#C1TD[]]/A#48T+LOD.$)4 V
MVZ:Z\-+YPNC$,8J!8B4#9,P"9@&'B;!G>ZI.#RZ.M#7(%8WKSHEFZ>:HU9[?
M&*0ORC;#;-WKDOC=;2@N/'0\\#I!$A*B.,@R72^BB8042QSLY'TG.[?]AF3T
M!,<#X.4-X?WY;CMT/'"#'1RXH57 C?[BJ/<WNNR;WM<;K>A<O]A.2'\J*TH2
M4=]-SD7>]60P5X=4OD3D2V1#;=T/!M3SPT5918$A4F'1'J6"=/)/1FYMI/4Z
M"SM[[AYU[I<QG+K9E:/E1<8.G ZBD\L*6K+GH>Y(ICS]"0>Q,?J:*3W^N7@\
MLM+6_-[+:OB!$^<M9)E^] 0_3^I(M?P&37JOV6QUKR/*]P"8(MD(/)'L>0#L
M6?BQM;^&$V@2&&FL5$0',W3_"E)!> KG]EE+TER7U>\Q;!3TSI8M=N(8SG9H
M)XT^A^S/LT^[C>W5&:HI%,]1BNF!I[<]W)/;4CX50-6TBB;'7=S+/\!)?'5L
M&C<KHP?EOB2]?$\7]:H_6 0')/R_YP[]_XJ5A;Y*^>M?CH$*;K3M-%.AYPTG
M>1-8<^AV5'*^2M&1POE'I,FF56/TT$2>:2?/X*+3XP= %*3]<MH817(DWPRE
M#HB[>#L\ZMXU6O!S610C "=:KPP8<\-<':A7?H?T654+:>_+D0\TL&[;F$TT
M:@E>VEP(NCYY?AL"\5LK:@^W=T(*2/46"R[_DCYW*Z2MO.0^I1A(EY@VE3PH
M/Z6INVN)T?/=7CM7L@J$3P>*F=CIA8[VU5\$%+28AGO:M\([I'87\J[%U/R+
M+::U=H!+EUB(N<"6W!R78]PK*T7:<L?P$Z]D1?CXLK!N6YR9J7<.E$*<XYY_
MVQ\T2SM\H+"CFK'4_CNP\(CZMY,[.NKL!7[W&[OJ*^J 5">KV3)37QL+4>BK
M@)3SMV=>*NBI7,G8Q#M%WXJK+_>9CGVS,K?+-KTIW4Y%Z"=[_L,Y7F>2T86F
M@=U[A']B3G+J OH<3.&>1%LZ1W;G?8=U(+&2G&G^K0$M4UAO>?.5Q;WS OXD
M*N[JED*K<#\P*_ +Z*P)O<5+>HUIBGK<?&T:] #HP^RY:7!$3Y>D"$B>!WB@
M:V91ZNA*6_SDC>7/6*8NQX-WB,8<_8/EC7K[VL*#P+1 FR2GT&RWN8*-MSDA
MA<25DOBF5,#$FR7$;93MT$V<3^#I_>DPT6'Z;6P'G+'NCI,94G'<B7ZTV X[
ME]R8)Y!,Z7,J0'\<&N&][MQIE]> MFI ^+>!:VK.DDC[P,V= 1W_G?N(](U%
M\C.OAM'^T=EHW?,KO3N=P".NOGN2-FD$\.A:[3RUI<1_RB.P4%YM50.T-;+R
MUU)6<_#%VV4YIDE4<\[[=O=AQ%9*^F'7W\HA]%XH=KHPFY"64 QY_P#P>@"\
MVB]]K'8T<.^T:+-U3GKQ:YDM]M9 8&-SY&XE#^VF=.>>1K(OQ8M.'$=QB"]X
M8?W>:C\2@AJ(.EV!ET=+[!X )-&]FJC)FP\^%5#Z34U?JSD3!R#EF'O+\2N<
MR\?^ 2Q>#??#EZB5&*,>[C9\L)2O3RJ4=E/7URK,!]:-QL*X>S(%_[[X (CD
MC'@ 6%$*'?>01ST LAX <X%G:F^)U\X'U91:#<^\$.V\&/[9<."VV6JY<\"P
M_=&*LK&I?V"AI5+38<3I:V;<XECG@#([]C )WE"G@$KRC9AFIQ532S1)@\J>
M7+FWKGL9R#8_:[Y&VX-TY@C(_I+[OF7^"Q,P/07-K?8 F)SF$MPGQT1,.-N<
M@_<K?3_,#!9RB<!F:_:JXU-)PC_/,^HVZQ[ILG@<>+CNL4Z/SNQY.+2B7QVI
M3BZKQJ*<?"ZGFQX =9<0SMP;J*L&/_^U37U]NXQ:N#S\0W PN#C%N/):B'WF
M0TD>=9+GX\$'  \(0V&1.4J.0:Y@<!=Q",*PSK6@*GY#E8WWEN3:4P0:Y(,W
MQ'!LR, %%K9(UNN=-?P+%.?!;?BP.RY/P8&Y%C4+R8T#T=%:P; &*[C%W-Q'
M TC^)!(AH"-=R*B;!]9G92BA(Y!O;>6O?"?"S8.?,G1/L&6=U3;DLU=]^\Q;
M3^-R=!GTY<=T[+AOLP^N3X;RY$ G-EVV/B29VL^EQK--L%WF"'@K4&5,<;29
M4Q@S.7&DFF*E.^ON80!Q3+6^($9H:>!%MJA;"=@@P(7:[#\?/5*W5SA(MGT-
M[E%X$N5&X^+#J^>?]/\-C/Z?.@)0AGHKT6UI L*Y?Q6FN^=->V?L\ "H;SYJ
M;/"507KOG0>69CL"P33^5&'78X3'VE_A6@M.XQ)1-W#3S?)1 C_&>_$;Z1N$
M#(KK=_K& @U*<)UT](?5 J/=%C7GG9A90&GIO8!(_3T&;4$6'=JK.O#GE/+X
M8?,URL'TYT7QQH)MR[0<;;ZA&/JPY7KNS*"5*T"BH?R">NY.K-9BX_!OFM/=
MP!^8 QZ(<37G*"VAJB2S$>C%)[=QWTR[1-71ANY24:TU.H>QUYVP<R#%;3?:
M>WS%ZJ18>K^R_][)5DW1?>GBW@S-['UH!BS>-TVU#GA-:1SW:^\? TS#FK<(
M)5:D=]1Y>UY.1K/3(>S1N7O.JA;2J@O_?,U3<I![Z5:5O^V-/_<VL^&A_6U[
MVKD%_>T]LW[.$Z=H=,&EF"UZKZI8% HT!4MY%)8N?KQO*I943$=7"AA/=W&?
MA?T)*&X-[)N9R&(VN]N[?0[-&CT2^='>_[>Z::2>'KPCO1<6Y$:V>!W"/S:5
MH@K.H ?)H\WA!V[J?@U<MP#1V[@PO<VL[IL^QP< 9ZU%%K/=7V<J%_AQG&4C
M:5DS[QCI("['OE=K"SE3ESD+AKJFD\"A!T **MFZV'UZP?/%#F?QBHV$@U48
MZ3;> 1J:A^*:B3]O$_.GW64R<8D;(56Y^? 7N,;8%$LO4P"_7Y:;/0"$5!7+
MC]3.E:>YMD<SX&T!L@&_OS84=[:OEC\ ?#RECF&G-!G+@8.!A3V+TH>UY6CZ
M#X$$T5!)K[_6<I-$'AXMW8@(%L,G;U[<@AUSQ%NG/6GOC;A/6CWA#,>I5VE+
M4-1M^U6<A3Q%8(#:6<">VM]K48EYK>TU-P[E%O3:>H&_EVZZ5MC?\.4Z;C\[
MKNG+YEJCI)7$7]%PWW%$8(_@O;^TZ56=)5]*6_$$X;"%#RE?(D)RXLQN9BFX
M:/G;#[TJRKT3:7C[I5-#^W/;35;_8W_>6\3O'N\' %\M0OSM<"7SMC#I'R;8
M/M[1G8:]VJWP;'L8RV_3NZ-[Q ,@_1]9 *SI:[RZG-&6=?V#</]B;UF:EM@P
M^-+.*A#GZ^[M'OJ-.!+^ -BB?@"L0^\//=9U"U:('P#+.NC+-(7MC) VN[GB
M!P".TM64@DF%MYB?BJ/:[JWI"=YTZN#]S0- &!WT6744I303*&G1'O@3RNLU
M=-[NVS;A, H7T*+_)V'D*.5V- P6.8LT1 U>;!\%;?7@#=Q,.Z)7-/_O(3KY
MQU9>'XM>4D>)A A.?7O6\&-PI$\]H&F5A>.$;CV35V6P!#PD3J!AKUZ35ASF
M8Q;VR932 F@(;C-MDR3.L/,4@OH(N<9NV\.-.4/K+[,'BDO+ZR[<=VT)WY>7
M@PU&5?CW2Y!/>?;+NED%GWSW<>'O !GR<3WZBWN-'#F//H@'3YM;=J_M%SB2
M#2G(GGSNV#V*UV"B#WK5,Z4D+//\1$,YRC)981YW+99E#50#/X-#4"-AH@K(
M\Z+F=/CJE#U<<J </)\.3^"?<Y Q5A%4$8RRL@TUTRS3^KP_M_DAS_ZI %V"
M2@42S%JE[N2!>=E@\^9&L;3%YY812:EI 26WRY6EZ.G/'2!0C96R75EBQS._
MW&4+4IY4$:\>F%*8F]D"06-)AHK!*%@;ZP1WR.7,0LS%_&UY\:)*!K2@&J9=
M=W[A41];%F.P"DY4*^4X3PC.?VD'>J0?Q2(!-BXNQHN<?>4"-!SQ.^T_48IG
M%"$E3\IAI: EUQ3W: S)B M8N<=S-O)U<FR.%'G_/'&4*FG_($QXPVYNT6X9
MC":^: MIUITZAU9?3B&F]F.X^OQ!=:76!,DI6GJ:L&0P2 "S0,# ?;"*0^_E
M,SH35/*>)E'D-X5&YM0&B\)7_;'N\G7)TU*5<GO'Q>EAMJ\ZS9?(_88[41SD
M$<HGP\TOB-5PWV2TQG=>;0$W8DD&T:1_T5.Z>_G*&UBSV+)_:;.O\?3LO&+8
M:$%M666M1IT /]NDZ$$.>*K*5GM;E 6,'!:HI0H*$V3J;-9^^G&(7B3>SK1&
MJ55Q_21 GEGB=X6ZO6GW_AI9WI=UXY='R_AK=,T-AFV&>;->#=^U]F^R'!$-
MHQ#DKAEBJ1EO)\YT8F;)K7(F724&_<V3I^C0V-A!KSD0AHD<C>@M4L/#OW0U
MB_WD8G#9;1(Y&4J?2^"(O<DY:S-[><0EP)28;/8\PX*I.K/G+:\=-F[P9=;F
MM9["ZXDVM8QEV%Z='C3<ZC[#PVFJW7#F]]&R*C!F?&G!>'F)L%ZJCE*F>#K.
M>?\"J8Z2+-K3*O8MUI+? F$-N*SS;CH-A>0?\JD_@[>\RQQ)7E^J6?X8$_E]
M@ZZEY):D^YFWN>KCQ",O1S[[%+-L;JI%HUME[JG>JS5D7SY:Z $ 4MM&@:E'
M=]Y^JG,WK/',@]:<3WH80 ]>X.P0AIJ4YF<*&ES4VD^N%W*&QOQ>V9'@P05P
MSXZ@<_COYC.2YAH^TI!296W05Q.L\@J._EKEH0_W,;] X'J6K9_ C@T;+!ON
M),&ZNQY\>X'E^5.^[W8*7&\$YGPE$EN+;6-,6MX)QCS*'>,JRVG*T#!5?NLY
MJ=%SU>R;I:RFVWMW@*VPBZ&-\:AZ$^L@ITOEM$7[2$'L*IJ4E7$H%F-7=K7W
M\1^)AN#TER2\CL/V)DUM2J@!SRSMYN1ZA<NFBX/)[<&E/^[S31(,!UFJG8NU
ML)$6A5IV!]NVHS&NY+@F%MLZ ]'428K(GK(3V#FOLLRT8+_95U\U9>-O@ S/
MX-&T^\3D1:.DJ;D7D_Z9EUL5=: FK#?BS]DQA!=Y(_D5IOTL$NL7DXVM2BX]
M8;5[\]" # __M,77YRW-$F13L^Y"J0<\MU^3*ROC;J4^-L.Z9,\)&HA@OL*4
MNZQ_ /9AQLF;BDZ:5]\<[!:^SP,][WH]C'5^&TLT@I5SJ_:+2$71Y:@?^KGB
M9+7[LK#A^>R6:%.HG]N^UE!M7VV[*5>TKP,"H6\\N'/DW'#KM(-R^IQ5BRXJ
MS2N;U$0YCA@+X-$D1.F5@S1*RZ0_%[_ZWG_:F FG^%&4"L#*I)G].J)H]BJ:
MLI0Q_GL<TQDCCW5>YUKWGSU^AS#%/\O,AY2K;0I?\[VTB*"@XWIO4W:#6</B
MW5LE!WO_Z+H<NP.'M)KD)H_<>273HC&()9BH>4*TK"[TP_>DQ@\]TJR"C? J
M[/TG=[]R9H4[,DA-*?P6]&TFA:N9O49)"L(4.J7\MA@0PQ:\CN/E&T:<?J]4
M9-QJ;#;\M-3$3[?[J*#6OA)[B_YYI44%8TY,OZ9M]Y*)W)LEJFMAHND]K\IX
MBC[$%NU.LJM0S] GO/H4 U*@ GWFTOEV1/==Q,U5?M^B68TA/*AOC@N60;<]
M*TN?4;%Z90G)*&RYF"_,GU80(*K1M_#@#O+90NZN@0ZDK \<0-4[C/Z0NLN
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MN,Q<ZY_[.WV'_M=U?9(N2@'7)G#J8Z.KO%DI@X/E5C9YBAQ_*;[[@>B[6%3
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M9X<XN9[,0)_;RJB2ZL6DF$C+O%!GA4<9ICA 'P#+">:HZT2G!\!W6 H2\0!
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M&/X7["J_Z^_EVZQ5R;[N,[:KB+FEQ/KDXPDWC\.^7]LI]O[(K8;EBD0Q+Y8
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M@001\5AR5)GA&U5F%L^I:S S[US97?U%B3_-^[!=.K_=%&ICHXK7-F\7$I4
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M50Q#RT:QW/Q85=%AH0!)_NF*1'-UC_'"I<73K>4,X:GST_4DN1IV@^;:H94
MX033K[_T*X^;#&Z:CO1[37XYWLI+LP/>N&,@M;2(D;S,.3NREUDCP7Y)EKMS
MW1^/*6\[M)9J_F5K^:Z;ORB@>\#"OYS]*Q!V-OV8=9OVAZW:=,=NEKS"AN+A
MAC&N@0\IT]J1-8G[#\8^$ QF,256$UNGNHV'JHCY_B8U3/^L%@"._;\UZU)P
M=B3RT4,8__A(2-S_L2NMHYTK :#WP8#"'W'33C3;96JF"C8*GRK)8C0:6M+V
M4W;5R5ENA: 3!MI_>W^9(_'?:#S[[O]$XZ)"ANL@O0IKTYM.ODMZG92SG/9
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M@F!<;V8*CM"5(&N3&\[1S7\^D8"$[APEW?C/D<N/RGN+YY0F%JLO"I=(_^-
M#*=;C@8_B-7J1PC;X,60HJRF,(S;3FV8I.;9K%%%("4KDHY'R]@1&ST.:$L
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MFNY0KCR6W%/#A/&^>]\ZH.14"XN4%CV;<9*^_,IN1,;UP8HHG&T@Y)SW8KU
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ML5A*5K^6\->+2M=D0<'RU7.S,UA?K0A\@8OO)?+%!)6"*P2]W&*"""LU95Y
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MV/20A9\-5W"?<AN)E%;"U?.,>#KD)>.VK>/SYRJJ@=M&9V>&[R8MAJ1.8-L
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M0T_=K#6H G+T*/B%XTG>CJCP8>67][S(\MU4ON\3"B_%<T^5B2>$9A>Z/ZZ
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M5(?$$Z8,L) B?BW\P/JQ_(=-J.\4]V>=S,+N!>A!IDPU1#Z+3J7CF;:+N$:
M:UFBW)1M&NN#1#V\[%@(!XMF.U\-L?*FS8)$K]HX2ZA?O7*U_ENA4J]IUTRA
M/H0J>'7-"+(]1Q6HY#XG8T+'@@HRUY2"5$5AF5\5&39:=ED"6AT! ("4CS:
MHR-"80 %7?67G-G.9@'NDU:'YHQ?,BG:6"S6X[VQ#3 *-:/T?P%4BX(A =QV
M#.UV1=Y@<^,[;4NX:=TLW-*9@,A104NU-[KZ@)"1JB$>\&[[BC0_P&WK8D_,
M/YH(:%F[(?); ;:45UD:T^J=:\]C-EIO0E^;Y%]2H7S%8)5#P*%+HV^L*L3.
MR?6G .*;U?\ 4C 4<E407LD%@8:]9^'AA4[P9RGSE'U:4([S53#?PYOA"I!$
M(*WA.YI5[:V^T:*^AETM)JE& )FA>_6>K(]GV-Z3KF=1KP+QOHNU+B;P5;JY
M0O/3;)F0;S=D/*2+1@8+!.[R=42-(!YK!]<W!3J>O+A\4/8N-%\3&[KR(EW?
MU(SH(&_"N(5B0*#R=_SN%N2^=BX?DI2.A>3J%-8.51-DWC%#:I1='*C2O3\*
M ;++C@!ZRWBE'/;MD$"'+7*:&TZ_;.]16?4C^T='CCARA4.4_SU'\P9VM'K/
M*WW%V7"<-8>>DC_\?>:.?B$)#W07+W"2=F.+VE:</@1L#6I. ST6X%I$".:A
MKZOAQTQ2+@B7Z 8)K6:_&O'\\VWK>I#1[-2"Q]X US<+Z\)D_5G_/Z4#YPS[
M]9VZNO*Q(1PF_7E3CGDQ(@5T4=V^N^>JZ6O,4DR5:3)*_Y@[_HP,G(@7S Q&
M^TX*:&5X:_8/P3O"<"0BL^=S"QY!7L:MT&,T0?F&[QA::I 2MFS234F9JUD$
MP1&J/ ='=K:5ZJ&W8O._)?=&Z>M___U !M5N&PB9":^[Q,Y386SN$E\35,Q"
M208S,,IDFBDS\Z#P-=QL:U.94AB4U=S"W06+.5>-TSHG4QQ&&O+.GM^6T9H5
M4WAGOJ48"&;OP28 4L$]!$#27O./+Q7V']G.>688<8>95??/%EX0  $)LR1+
MY@MDQPSH51-!9 %D*GTY9#"<US+T7\!S.@M%H^QIA\;Z5218^ =90T8/\;27
M8P8@[+\JWX]7C@F"*R^V;M@2\ONN8"A:60JRI/&&8(IV"XU(#!&22GQRI8>V
M;&99M_9&^9L'2LACQ*.KB7X0[C%Z:A;\<W4A_S(#;FJKX2'FX!+* W@QDPHH
M&TB]H@>>UA2A)NJ4"KAF-S>UZT&V=S6 @JQU"@Z0YM YN?<PRJP$5QIL9N5H
MG!(Q<,;8G5"ITGZ5/5B$P7"+PHZ J*P,B5O3O <&'_FO%USJ-,S=*DE6B.IS
MW,:L'*&57K?J%8% ,B7DJ1!L1"\S^RF[!8,VR/UJDH9-T?W#+J,-C?-MU.)<
MS\C2<_X\[SR^^<A\"3NYQ&=..!!@['?06LX07CS$O@0K\RK$[YG"CGC)M@5]
MYKS I5%]<#T#H$-!]JQA]X5Z:3?=VFK2E7J9,O.>-B\)I"S_JAZ3A.J(+#RK
M6.-.XQI"W'S<0P]6NG2")\=/%R8[HRC@C;^O-.'&*/Y*2=).8;0XPH1JU?;K
M,WJ:DT\U,:XF HX.5>O^/Q26\BZC@:Q>*%6>$ID0.TDZ;]J,#!A"3_SAPX+T
MI#D^V"SZF9!*:XDRM_M"Q H:3)\E[Z(AI8<\7W41]&/L<:!3!ADI (3$C'@O
MD%R:1FKQD S>NLS'C@D>$9:M$@XCQ!1 [C (C1=PUQ#4=$,+#TA<=]PW9VJ]
MXQID[3:Y$B\@B1"-'Z_F3J?=2.Z[J]RSQ!R=,A#*K-'V/5OE19Y\L#BQK# M
MS@?SD/=64]H+;HU 60 FHDP4[4REZ6*4+9!F3N]S:8&M'H?;_&_?Z7I:U\-I
M7-]TBQ (%S9>$F#Y2+D=T4%&HLBAHL\A&IM3$4_.WGWL#1"W2H[XQV;:A^H-
M/WO4@XB4LF&8J6<R)\R&@-E1P6P6LKG>+<FAZ+70DY95G1M9+%9,>1::,Q*,
MYSO_C!+Q2+J1/CX)6RKAON7.$_\EOFO!LVKS3,)@$,/@7E7ZT0!9I^<KX_GE
M6NGGR$&*8.4TK]5!7!<U/#!,8/1? '/#]_QE =.LA0Q=5Q]*P?PYJ?8*!:C=
M50EVQ')3A*D3 *QPU$8Y)F+F"B@1I)6Y.L6JL]6]A,7:]4.BI@<[F]HM$?!/
MEGAR/O2L6L/6SN?O1RNAJL\'9'(\VIRFZRFN'G*4]T0QKK)Z! 7RZ>LN)YIT
MQW*&VH=GW9E;N@KF;%CU&XKOWCDZN72S'(IF!\X?+@3$>)6E$"BWY-$R5-G-
ML8>-_70ZJ+7J5#08+.3SZ<+(%Y08/62KC_9?4<PUCU3^^1NLN^=26@5WT KY
M^NT=:"-H4;]VM=YLNOV=;-+]E,=[?.6Z$&OYQSYJZW[WR2D!/ %F7@3#5^!0
M_NB%[-?Y#3W SQJ; @^+.;%VNIX6&HGDUG?[G76KDM5O!=U9#%9?HCN%VUV1
ML"!\KOGYIE3@N(+7\"RS;/FG5 <*W4@:6[[RI9U.<6FG3P^/]E2Z)4,#WIUL
M7;]";5T\^R">3F'B3$<><.>T__F9W4#@[P*%<!8NAN/^MSLJ-6;AG^06U(-)
M-P#6<[!A=$!@CW# @#URD+VK8:7;KXVOP-7WI(?SV6/-Z/MNH/[R+K7CH#7Y
MO=NOLL&3G4?M#M_A"^$##M'3\K=#:O.W=SKU<ONF;VHX]1I5SHIJF"2T!R!V
MIMI2 #H60L_79H_$%GH$<\G%-@?/KUW$_D0M0@H@CI B?Q7'D[9#1@;_,I:6
M\A3P$B/&A./6^FYRQZTNZ[ X&'4P4$ =#]G]#V4I)OB\-*J1,,1J=>U!;Y_(
M[M@&KUS5$"%1;M^4>[LQ=6^D;46[/SM_>@##-8*4+-54MY +1"B;;3 ]Y\*?
MT*>=KRL:U7G-?W]L/!ABKI<Q30(%EH YE@A7"E'! 5GSMK.%2K'1,"D*$J\.
M U@KE!8*3>CNCE>%:U[(J]09K?,0EWR*&,.;#\B2"+8MDBS75_JN'4U&EMZ_
MR3FR\?2_DIN=UB4;QX=OO<RCSQ^JZ,V&%]SK)9KV&Z5O.?U>1NG/G)SP.UL*
M]TTE><!"B1K%R_:15YJSEQ)0K7F@7QZI80"/=;)K)Z#9%BI1H8 A*2/8V=FC
M6]4G0@9V18"]!'38>?8_1<R3E4_(_/'Z[8_X.5F 8UG_97EEQ3E<>,F:[!9M
MXAIOF5N6$^^!X3!$JG>?P0CTW."PQ +#&U8[B;BWEJ?):B7L5$Z+-"Q]VWR^
MD([VZH)TM8Z]/$%#_TYQT^P7<B/H$R]I./&'> Z,KSOC$,%9FGA,<P^/3%I
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MJE,</&#H5INUB\_"@8)HN<D!13>:@T,*HV/-W%8(6_EX!4@SD50/&("DVUD
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MVY\S9:PMF9ARS7/QCKM OA1D)1*0EG!6]@\ &+'<W5$WWCO\;2O- G.XO\F
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MYYR?5@".49SY(@>^-$H%F>5:_U4DN0R/*2TX!H5)/-IO)!0#64T24H;T$@Y
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M!/DQKJ\>_;5&69(_LNEGE$9^;?7YV5]K]ME'R09__K7=[QS7[]M]*.C/,%/
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M90/!WGI1EFBACXT\O0$GZ]'HI%]&.KV><S-U5ND<2/@I\6^L5=!7K\+IP,$
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MZ^N6-'%0M'M[HOG<PKU>M5JE1G%QROLSX-F>3="]-9YDUTXGQ'CC0]PWX*/
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MSVKL%BNB*S\JHYC5[&[]G(3\*O_X^4#C'R0A@=?I7721(X^/^.L@*T_G1I5
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MH=Y%YEH]QEYI!;901#"<,VF?E=%#\+?J\2-C)P%VTG3\C*-/H0>Q!PDZR6B
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MT>S,23$SH);+.QDXU<O&[)EU^RS/0X[O2Y38!;;BK8:JU$!J-NZ*E2M[9'\
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M;B-_+1(Q^Z_]W3;PB-T-78G[V/\![/\!W.[X=05*LIT]JKWA:H:MHSZ 1FG
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MDT^DNI XX9Q_ZYBNS\OZ<2BR/FUNC$ *1[8_!<<6;V9[AX:S9AQ#BJY+]F+
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MO#[*U3"C8]!>GAW]L(0RHY4QX57YXFE'BT(^(9*I5L"$I(*%4?#;ZM-7 .:
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MF6<KW^QB^Z/)Y="-/1.&:1E*/"3\EBK%I6$M-D1YZHO0*Q8;JS#*FZQ*ZSI
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MOT.S5WD&K%.GZ8*/F<J?#L)>.$;>%S2_4'1M_P74G+<G.-\KM_\%T/0^" _
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MG[B3N@ [/NI,!K20VM6Z5#Z&M7/PZ#^[+,U)Z9Y/?E#CP[KB/C_C21HNW>8
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MOS_>Z/G8=FR2=&>"T79H4FN X_DG]ZVV6U3=M]"8W.[BOBPZAE(2WL%8&MO
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MO.'U</7DX*QZ0E-ZTHR/15LXC:VUQ:_$?[I=%>XUUGLI_GA#BWM#EP-9";S
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ML^2?:<$%=-+02%I<M=88H1]5Y%/$&JI??)5%AN;O\3T#R#T&N!GIXT_^_EH
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M3=(TA5*5=W+'SB@]2H=PG1Y*CL<VFD:$TZ*W@]68U]]19@.V"J-,RW)<\]S
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M#I:?BM%3+TG5//#IBOCNMS/$3"O,'L^7MIDZ><!=VR[I*_4R)J:7Z9 :P7K
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MI+I-&"WG@]RQ.X&JI?2+5+!^,WG5ZN)99&%08*6C62(K,5Z@J *5.=K'(C"
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MFO04K?X*VH[927TH=P_4AE'&95!)'2W?*=2U= TZB1CZH55>LU-FV9P;#=5
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M0BHY::/41DS#W2V(P' '^Z%F#.K%J:73C2T)!.O?<VD:0('Z0!+-.^[4$:)
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M"5,;HPAOTK'PBAB\*R6N0[:G>O+"4CQ=C73#W^Y#J]J9RN0=I[6B>4-EDC.
M:II 57O&A!/L^ZC6VP,8864,>A9Y_&G@B<RBW>.0V#N#(!,;$X&B659R07+U
M5+TT4V*E>*9R;I#,XY?!+SZS/\G(:N*SL^U;<&OTMX%-I97I5-+A8 N@"KDQ
ML/+'$2.8N:H+I1>@:N#M]<J9:J1U=TGH!KJJPU<W2,H &,WH%DO4UDB(Y5+1
M(F=)<>J$OX7[Z6K6!5@%]05H>1-1(/5KIH,5.1)@A1FE92W9YUT'7GP*4-TZ
M[M<&FN/OZ'R,FOA-8]39>AIR]4R3$&QM)XV@1OV84@2BO-'80Q'UT<+@\)G(
M]S&=PLN6PD!?M=B:+6%$LT8T-8$G Z00BIE7)AGEN='II=X3A<=PH50OL@[4
M.O0J+MI[MA^.,3=0HQI-*NL]I,9 ;0W.KJ]>9!5%'K[\_M)73:RQ\G!:U+I:
M8]<EQ]?"]T>8Q#)S1"ZK-$Z*Q$7 3$X^DS?369*MT6VIV-T0:,+O/6,U3?<T
M+1&*C2LT)V$H\EO>3(='S4I1O"^R"&ZSQ7%!38JKUP*!62<RR0W@#@%H#I<T
M)^>2C8=L2PY=]25_F:WU,.*0Q[&>"&QI7%/S.Q^7G+A7IM0 _K-3J6JH[!X8
MSYJ]XN9553$>T.!E6Y:9^Z-TIWK+->K9E!BY<-^:YR]R%_62)0B-B7KG B_*
M9S2CE-B[P#KM<Q:YP+#^ACH#A*8.9 DG':,C\3W<7826CE4OL)B(>PMFU\RR
MI1J@9-L>89[AV/LXI1D&WL]GE.$HJ"%O. ?68%?^LQW4%#+=-)5.ITH\#.PL
MKQ_.DO_FG#J0R0JV0M\A;0HGPL"']LM(CAC$U2>]6*SB=PWPZ6M9*H'_2)@$
M$UK)JVGPP+NE"AXKOH.)5 80_ ,\%*1LW_15E"]PC-+8#;OFD\K_[#L72T(O
M5J-*1)O#C-8,$X )$'R_E$5E?Y3:(.(._8\Y4#9W92X>TU4/J><$FSXEET'3
M4H>.N*A9+L_3E0ZF2V-Q(4^Z']/0B&:EX N^6P@UO90SM@P4P29U91)*9/$6
MR%$5&$%Y^$D.572 3B@%=UUJ/#X"%IJTMHLQBT:?)R]7SZ+<TTF/.)[QRT\8
M5H@X4U,7YVR0""$0* Y5 1!!6',_N_;0[Z/\19_\\3_MG9TTJDUZJW;+Z-YO
ME#=E:IU?*UDCQP&'I@_U^:KA&+;&XZ RLT_U0FT[#-/?.W&#'50MA>3IR@3Q
MWT^*2S77D51=U*^V9R8L-S+N3CO+X::_EGXMF5QI&/#52K]D<9T- F2Z9I\B
M;,U4@VH>8ZIH:;UOGIL=_1 %EVO8&K*<\^E:D==)%*/JJ3XU "3 !KJ:+9B
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MX0);(DR1OKJRW7>QG+;$:?]+??CW^?\ 4$L#!!0    ( .HS<531J*;W*(T
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MO#PPTE_DPWE*OB7;L( BXOD] @4$X&G<RIS)T8@[JUESG="L5*U%,E4[Y84
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MQ7R+.9&;HPCV0I;:H.C*6:%.V6W^D(/J58/-FP%:E$N/S18^XPFBYJHJ18I
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M,Q>)?R5])X8 7BPC ) I @C/@1. \!# ;V'0XA0"6"G)RFXVM9?:L Q4?80
M)%<O&3+^>[N_@8+UH@IN1:O9 1JNN^_=A/ZU,N:?ABH+#9<H10#)8>-'BZ<'
M4FXBA_]#66*0HIB=BPO=W<;,1?O_O;KPGP3;LLF!#5]___] \.=/VM[31D&X
M,E 00%DY7(#ECEZ4]NXJYL\JK!IZ:(D(E5C]+L"Q3\1F6C,'M3-D(8#ASW]V
M!IS_;R4!B"S]+]6K5QY2U\?_$+([YJ^%VJT?#_]6FQO<02%1NBTN:&89%<SN
M&^DBOVIPIH;RQX/YSR8M 4[SX=>/(Y(L& L>=U$D>DNV:M^L>VK 3",=:R*^
MQ98:3+=::G&NU;K'8;[PLRI+TTI/'OY2Q.;2Y _V]TVIS7@Z=K!:9\;0>=%O
M8)/_,OJ#=UOA08"R&5X"7@ZY[8]$V4B';FF1'7R5A!"7G$[1_:[S2+P+5SU%
M7(61K\QN>$2H4V@Q ]OZ&K+V0A_V.9>"+P?<(MRR>0NDA$Q$5B!:.06]IYO1
MI=_ CNF9_H;.N[_./F^$OWVCD?/!Q:M"F#]"G//9EW>1O:(_S&*O=.DN,%6/
M XYLG]^GOQLC"XDT>Y/\5#7?3P<CV<Y2-+"AR<5.?<XI,-'-=VDS_4 %JTA+
M4[>^]/@T8MUE<M\9-FM:5E# V<EU2Z(W<WTM\\"G3'<%=!??K+M-"X\T< ZJ
MWB)QU#C?;ZV_=?C\\_FF,V;,K[$6%@30)S;Q'FDFMKI*\XC)]:E]_'Z6*&6\
MGA*?;4, )QRS"* % =P\!L/:CT!W$8((X! *_V3O!17X!5K800!?X-99^"%(
M>&/T[G\:"_FU!W;=X)SXG7^ZC3@C/A<7:#9-VGFG^4-A17BFEY&5\0.O?5)8
M%T608(($_%OM9$K:"M:W_C<CA-@:NY'NT2_$==7V- 3?YGU&VS<IF-:EM6P(
M+5K!\E2V?]/TR;#2D%V-.([JR-+KT<#C[5::_!8PV4][*/$BS&"P:"#W\UF=
M4T@]KX*.E?&R>&NC:V0&AIN\0 W83HC"LU39UO(RZ<F;BAZ*-%:6J^0*K\(#
M^XPFBM :,(.=G_:9GW%:VU)ME'I41W2<R'Q[=!;HR;8!X57<SN:;EDSY4:NF
M%-S$FD@2;=UWM\-I][_=)!2)4"23R@9<B^T,K++0U(RF2]WX>IBWYJD(\130
M+##I)HW#8L#EAH;?9_JHHU-QAJDZ3UW"O'\11:/,]HAO_ CNT+03U9[/'3.1
M]O5G&RPT5@8>K.&)5Z &%$7S;)\70TR()[FY[Y10;'1PFR59Z3PCS/E8'5BO
MHW_C28GRD^3#$\H7%Q;;T"Z\\D5RN+HGMQ0F>\AQZ5IWQQCJRL+K[(UY_:,,
M.T8-;%3STL5Y&A*"6-DKRA/S%+FP-UG&).S+&\8Y2S.8ZN('3OEJ/J_&:,Z"
M916[<5-4>O.\#+)C]8UEV#$T?P=_M;7[P%IF;NRL%JJ4&LQ4(OWH<":DI9W1
M18$<4\)WB =6DV3XTS[UL[>"Y'#CD#LY-@V&BF'!:P@V ]:*;1_LXAS>%$7!
MSOOH?;LSG[L2ED+D3 :S\DAT*:\([:KV8=/+6IB;<8^M1UN^PD43!QY9-(BA
M!TI4S^2OY_Q843[U^VQVE9-GHZ'"R$;TVH,@^<Z' 37G 7AL_),=N_OY$;[A
M6(G2K"_E&2^W(U&&RVS6OL[[V<(V:H@SG<'Z<W.Y/-6938RR#'(O%>35P+\O
M[TI>QBL[&5F3EW3-L98ZFNK8*_4ZK-35U%K+L ^[O==6>P$\C(P+O*48J[7V
M5YA9"]=EP_;I)F[N80EWXF2/IZC\EJ;[THZ=A'W^]2.GA?YC<)[2]_G6$#*R
MVM4BEJ_ND<>#6A53W&6>9/06#@N6T7$PMN>),[K"5B(7U*'>#S4O'(9WGZL,
M739#N4_EE63?&9J:M$ %TCO5Y8&P7Y'/YGHV9N/\W+<-:CCU)I]HZDK+$FEP
M_&<#Y'\A]MBK3 3 >*A]@P0..20-.P7%VUY^DZF"F2#25$=!H?R5^C8T-Y$=
M="SRE0Q\)#"Q6KR_1-ZI44Y3WN^6FC%5:PSM[045OL61#KF/KYT+6, ?1['
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M=2,T990]2A V".OG$93TDFG0T1"AHV+='_8;&INTE?^@HT<N]7O3Z%D?0R]
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M!+:6Q85SL3,0(H!V ZX"WXO&5!T^HL?UBNEHX:*8.'++YR47%-J)J7GYJ?:
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M[_QPLKHP5XS<N@-F8>N=8@N1LFSRCO-86.03&:#:9& 9S1H/>):S4U5Z*7C
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MU5/3(2N.*WCI'KTM=/7(R=SX[M68P\;CYKP!PL:?C:#N$B0$&1Y%'L#^0P1
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M4U#QSRLWPY$R&#$F3N91#/]=3!]K@@+X1;3;&#-UV[0MB8USR2ZQ"'^3BK]
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MSFU6J*%#N,4Q8V[[4G4B0VSY;56P9EDK_17])S!U4AN,T^(=(3RSB&LYKOB
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M/HE,W&4)(\UW-7>;%-)D&^E$"W_R:FW!*Z]I.R0^"+%]/IP,9,HI[0/9L&)
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M(FK\T[QL. &D%PPWNBJR3\0^(GO7%H#$(E_DFD)&=J'RMZR*%53*^!PY\=P
ME CW7EP/$>LOCJ!5QP 5U7$C1:I6J!U?6*#;"SS=>C68TD%1H4OUI@E-?6OS
MC .TM#__1$P@]@M]Y1!OK":!N"NUVFRM>P/!W+NCA-%J.[;MYXP_DLF)/2":
MFQ8B -4WT7A"3*TF8$YBL26-+ZJI4G4-4V>I_6=/9\1VAT <7U.I\4>KST\N
MS591"USUDP8*%^P#7J6^G5H'CZKA#V8G_LI5M%RX8Y7:_SQ5Y_LG@N1Z<PYU
MNQ.#0I:=@MAU]A;?29BK-*OJ2X;)"5,G#*'=ZD2Z;!<X3ZY,+R=>[V7%\K5\
M>SVO0[QFMC^/@4&T^V<KCG4.ZN1B[QJD)+X^G^N\+6]OP^=L1:-H]!DS\<]"
MI>/V1_9N5P*CBQ3M$J-6)'3*-M*8>OH*#!$V$AD)<XJY\LQAKV8C*AC!,^7!
MWA0*[!22)FQ*X2%1U.U?5<([$3.A^?GSRBN>L39V$H,'!\H$%34HD9\5#L>I
MV;(G^=C$E7N\-C6G<ALBW8?>R8CYH+)ZH63<X;N:?)8EP:;6=LSI<C[:5&D'
M]R1I02X$7NY)N#SQ;_5=M2'=!M<6,24Y^Z\(M<@4C'D4+2CU]H34#EI^*WI1
MYH"")7U)"2_X$]]+W]9UN[(P" 4]9^R/W52L_SJJ8&!\DNW8K_3E]*/(>5E1
M^2HUSM%^#V+$87S>F"=Y3Z6;17\IS&*'!Q_-G?]?QJ=_2]%#LJLX=VJOO?;
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MG>SMYT0GYWU08,$3'S/Q+])*U95)%'B1$JYFRAS0RK'FZ:[+00*NX']1*%V
MD',Z6.&!I6U:*F%B%#)'VY<M<K='Y&=5?[E]9QRN3\]#E4P?BC$992$>?'Q&
MT'IV%E O*L(6K^)F&J?1.$7<V[?ON;T!S;!PL%H%X#4*YWWI@8G$DSOX.J99
MGQR)<B>/]@?%8J[&C4_L64I6:LR9-E[6M5UX)/SCSFC:[N).E^HS'MC8<[;F
ML6.V3$P,;X3/]Y'\P'\D96UP>]:P7,+\Z/*)V&I':N5355Z+4GI]!:T).R+/
M??E]QO[VU_M.&'DH>1SP;;%@6?8CDJD] Q<H5PV$5TT=1+3Y#S[/JREB28W"
MSO ?987$%.V(M)!OI)J7E=Z#]S793H+D3KX_D?K1Q7T=*%294YTPB@"ONK,5
MGW/8:%7#9KC6IG+ / QI:.F,#&N<ZVC%@(]RO)-E=CS& ZMLN[9U%,5GM\^(
MF%X2.4ZU"Z&A7.K2A&N8-<YHR!*&_OMCX(^6PC-*83Y"Z_I+S!E_*!.L*I>U
MOC6A-V$ALHEM$ EW?0"(&YZ6@W#5V%/VFUHBY$<Z)/=2CK9<GY3J\-VG5TPN
MM??#5/L/;0OZMPD=&2*("(FMQ0%4.USUAOX)G)^N[L($]J*Y$7/5,(PENK:(
MX0QP5M/B=WBFI>&62N\I32)%>A=L-MS?6:6Y^9:=)&9 </@))!+2K"8390]H
MEY5AG'YAU.%T\C31?]'@ >!G.W#/:O_/ =(H=SP38KN%.TDZ.I<X!@H66')J
MFGD1E<N&9]IRJJ)DT[E8B1N&(&,<FZ/]QC@5JQ0S=LJF ]'PN(BUS'SZ*_M)
M8+FF7?J"!Y%LC!"%)^299+FCAAI"N?V\D48G_ZY]IOS:UJW:^[U[-,6"TLH^
M1W1^DT+)$TL+9M0-^L48,7I"XGHVH+\8B8YAL!=65FR9(NV7#DJXO*PD4&+-
M7_7K"9+S7N0N9@C42?22\6>J1D.B<C*!;DR"6\+8U6QH?G:7ES]3-JV/VB_R
M^;D*]*./OA=BLR.$?OJ"?I%F6_E6-+NZ-[4CU),K]] A;+LZ8976SLQ:HXYJ
MQW%J90'AB\T"X)]-TM_.[9WV<EKKF^PMRO/\YG/R%Y=U=]=6@F8@2">'MGOO
M;I9N#N_=JT<E@SDJ9M?/*1HK#@K5V_R>OB>EC,S"P;/;7P;5]?#8^Z;/;'G?
MU>$&:W7T"U$27_*/:[S?MYF?VW&73#J%P]N'-^"=L>+KZ2.+E6X?'?$/$B:D
M4(]V_$>4:8+W7W9MYT$GJR R[&XXZ/*CTC3ISA/R=9DN>B)8R -D)>R:_FF+
M,&-/W;Q74_G,T+P<_?P/UBP,,995,8]BOD,\F4(U+U8CA8T-PN!0U,!2&'^=
M+)<=FQX06U%1"5%I*GEJ(TP3G .#51,G31DNZ(=J-6AKZNO%2F,$"6>+T3B4
MHY5[\"6]6, N9C+#C/EJL<66FY-9E_DQ(%_F&B2Y6[#A[OO.=5?0(#HA?/X=
M_6L(@/0!@#7XM6,<@=#/+S\[FD?P?C\@Q(GN8W@Q#@$6Y,06,TX7F]LI>RP=
M>]U-1.9Z?[(3A'DY^O%/P_5.R:4PZ"4R#>+^43W5 =FZ+41P^VGV_D59G6(*
MFY<(/BHK@5Q5OLD(XJ]4RTO7>(:@5I-($X_E-?,*0P))<"MQ2P#E \ K\ZK]
MG>-[-R[]*:<Z%*=9&!#[[6W&:XM3NF0U;8_^FR\_9QVH21IAU:W<.Z&X2CO+
M3KC=+QQE$0"M7QGO4=%LTE*VBRJS>:M#S'-,Y"O5RDT7NABGYK#U)DG!=%FB
M-1\5&3+[M:/PMS9EI_XB4+D(3[;R.6">@PW'0!3[A/8DL69R JO^(^1/.B3A
MDFNX#P!'C!/^9HT1-%W,&MM)V5'/IC5="<[PRK=:<74SH>GI8ZP=9^51V%%7
MF8:/^K[][*4Q[$(G\P$@(;!TN0WJS"0*22/ I*L+%:0B4W_"MEEU_=1 .UMC
MQ';J-CFW*.75;/O:TR(0')IY@UGQ%G05OR5 C-N3,(5H+=Z+:L66/Q.KNI,W
M-Y[+4:20VR$C?3[81?OEY_1' \,A+!F&%V(*6CD\3P@K6:7V(W!T9TA_=AS=
M>45=C*M4_HP\'Z<'^F3N4K2Y*F+$%-L3$]]\S-E.L=@<?=_5H/GYY31.6F;6
M9LJ6YC.+R DZ67G&Y+>!I!F*D@;%Z.'Y<PI1Z.G E_*#A&%R2P48A$\C[C\J
MTLV>)=.IG.08U3!??HOZK)_:$HFO-NMXSA96N>GM;1>F_^LG>I2-=$3&%[8H
M"V,_F9=#E)7D?#&;%B\&-ROP[<NIXPIEO)WIJV'*<;%6>C\<,EK&B87G!!)Q
M#3 K."L87BXT,4X+2EAJ;GK2VX[-_R#][:);R6>';LO/)M#8U)!P8!G-,:PK
MX4 B1H B<_D,M6H5S29E:TJY"G*VR)B&_?$7DP8I[IB)[5?E*E@SL,CA-V3Y
MM$DV EUX=ZR5!)MXZW_#K?U/%3DK6?9A(GE-U=? /RSM?UO\JNG6NM#*UX37
M.!^0ZUJGU#0=R.&(2X^(5-]Q*XZ;,ZRMMR>7@_7LVQ 1]@9PQ?O?,^E!8);R
MX/_XFK2>"?NL$Q\'Q7[B ,7 1G!W8$P0?C9U@D9X7 WOH\7-VE&V=)HPT7@
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M^9,"!2WUQJ5_RQBF5_=K?,(W0CA/3'K5I[?);5SO&)W<>AI<**M#>L1)U8K
M]\^54EUB6LS0H2ZT)N>JD>I-',B^4VZJUE2@'2<6TDPMYW/B:M[))EPV\R(2
M@^K#T7N3P*3%("S_,W?%4*/<+DTF2*;:U-8L(^..K?MPTC);5#P8_MF>CB/%
M=6\\C&Y3(<X"G:U,0!=/K -OYN7>>ST6.N 1#5-EZ514S!@+680;"+==&W$J
M( <#ET/2%&]'6TTW,FZU)\C+(#LN6$'$%#*(PC$4+4)E([>@"CZA/[#.6#RZ
M<BZW?W/?4_-YFT[!L0JOF$P[!HU19ZSDZ[4+*'/OI\&IH AKVH.?M%UE[OZ
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MX0CM7G8,R,GZ8B&],5,A&++-.E,2O(C<1H#QDXG?J8];*>3=Z9C+!* #.D
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M*0W4CVUB1/#$+03@4R<9C@GTQ,?R E&S.S#LD5<$X'D*G@%&B^A80J$I>0D
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MHP+K$5>W[O3^^MWV@JM\V<AIA NMHH^]?:V42?'N4P?K=:J[(L=.J6.SP12
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M7#VH-0"<JF.7(BO,8MT01UZTB@7 Y?UZ< #^TK(L&-'1HG]4<?]'Y"XC](>
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MQ#66!FRPR>%/>>./VF ?*J-W]5%>E=\<9HK+C"8*:9C4(G5$:4>'C3:7F]2
M>=N\TRJE7N]79 V=&K42=W/%-'M71H7HUV"M\GW8[-<&#0&]9MFFE%A9BD?(
MCAQ=][M5:[.!\#Q7@?(S"3MD'E25EV?OLS:1E(H3C32XDFYJ4.ERMY <B=*;
M2N(^":GM[6L<M7/3-A\U>3$0.KQ@L-,FK&P1DDSZ?>?,!U%$M<[BZ[5OWXK3
M:E(0@NM#K3)RNB<'68(+)4ENO;S0LLU(U$OYQF0ZY^E[:SV:KMF7J2]IY"]"
MHWA>/^S\\K+5B5Z- #BQU5KMTVRWSTF)>.2]R+PFVI8RV(R>C[@9*\Y@I?S.
ME9M\R'=,)'YV\K[96.4B5O;A9#'@DF[SM([AM$>:&^FP%-UBF)J/1]MH)@%@
M,)93$UH)?K@[P?1&^3KB+EM(^ZI&0QR>6*#K$>D=CB>*1R2>-6GWZF;QN,/5
MPG3QW:;WS&*D5D='M,S%@@!7)MX8D4SLN\TSV] H@$;AVK[/F(D5;>FL\6!&
MP%:\R;3P:G9P8<$1H1F9-9G[U#I@BLY;C]JB@N[N:ZTG4B]!X.W!8/N &#^V
MMHHCH<7A7QV$=?\:B ;:4&*PFR!7:?H&6QM]8_E(*/G-K>S5)0TP;63![\/7
MLRK2X^^FH-OW!]LOD)[M9AF\F:#I]4HE!H+=TL+,&2+-=?0Y8[;V7/D?U"M]
M/E>-$'V]<_8@*7T!6I44>D"",ZI\?2OZ+NVWI[)/3=N')Q?-7O^!R\LN@A7,
MU)QN"A^0\QG4FQ;Q,O>WF-<Q;^^"T<_!"8"%+6IS#K7;@PB!?(V%8_=%<%MC
MDX;>8/@^FXP8NQPF"MV;0^YV9N]-#R_MB".B?)K3<,\/TMED,$W3P(LC_B)@
MMLE- !*>@SQ1R/V!'^KA1FNILF<X' 3[B[Q) FU)4&O3!26[=+ZI_,@*LHL6
MK+=>^O#3_APLK6MKD1/6&-T_$'YL@EFT[,;4K16N@)*D<S)!2]^_9.J&GM \
MQYLQXQD*BE(9;$;0M:=H-_RC0#P!4#VH$3.,C^V303 X7O2 Q^;9G?\.UDGV
MOP92^[XJ#Y6I_4W":7!2=Y<+D&\_D8@JGRSO=8&MGQ9[2H$3]."W"0"J&USB
MWV@35?\#F-;=<3,6S:K0E?[:)CD5OE'[M[ZDG63%OVGSG44N@2YO$4:'K-%L
M,N=GO=1??#3)X9XHJK612YP-59F"HKE;X3172(8-STTB IW0@Q.C6S#Y^&'*
MZ4+&X=RGLZQ+]JE=+LU%U,P#:H4B4Z9G&T1:_K_9+6O0#0RJG/1K_JE^H_C@
MG^#1AI1]RS\M/C/]RC]P+QW)!2:@U1M;#2?%=E^W>?)XK3DV->ZNGL^\7]5K
MV9RL]7_J('BI?X\=L%\!,CNH4_6.I6TM^ " => # #QKKC',83XN<I^PU>[0
M^3QCD&2HZ>[=PCOFW=W[@NFJ"*(O ,:FCSW-WKOFKI$LYWGPJ[]*8P%+1?+$
M9IN,,XP,4UD:JOJ/+?*6MGC\Z=(U5B?#K<D,R9;'[/9<=&6PJO;.7KL_8WM7
M[G+M9PHY\CF79W%$G[DKDGY&HF;%S_;]:T4"F.,NW?)<///MH\SDWWTGN/4O
M?%NX-O?>PSRY>VISV<2<&C;('0>J8I@V[>*9S^[Y0J?5[Y<Z2.Y;OE<[ZO;>
M_3?O<<SB23ZMP?4O%MA58-NZ/>.N%$>7Y^&5CFUOSZ\U>/G-9^+"+0U+XE]=
M.68PW\]B41?#5,4NLSL3%TU86"3"/Z5$WJO/VSIR>>23;:W/_'<K*^C8M75I
M,#[B<)%SZ+)7E_CTK7?'EZ,># P,!NP.H+Z(%=!/YJ?]WW79;/GW FB:F?YW
M5[FH>M"Q-&#JZ?+OH"H71$&%T^Y7Y+M>>5=WL7;IK3N^6_1GJB3,X;NYZOZ'
MUA_I_QK*[+\_ 2J21^+]9^"(;RN>_T:;Y]=/I2X-8%NG1?^P_1?FC< DK=3_
MP^F/\7\&!VOYWY^ [N%'YJ(H1->X]D9%M?NE99EK3&YG9TJ6;3XJ$>2^+&-1
M@PG((XM!/M)8P(SD,;*%&93ZFOIU[7>!7 >B/EW^#9H2!E&4"U^9\U:D,O,O
M:'T1B'*?-O\N,'&R@R@D80=7659@N@*-;_V_"0!02P,$%     @ ZC-Q5'R!
M/#V44@  O&$  !$   !I;6<S.3@R-3(P-%\U+FIP9[R[!5B4V_8P_E*"H&#0
MJ0+2*5T#*B @*=T(2$F#-(,BHH1(*RB#='?7*%*"TIT2TC'4,##U#7CN.9[[
MW'M_\7W___"\/#O67K777GNO_;X+.X[] 5Q255)1 O#P 0 /]P=@IX [ ,FY
M<\3GB$B(B8G/GR<AO4!Y\0(9V06Z*U<I*)GH69B9Z!D9K['Q<UR[P<O*R,@I
MSL4K*"0B(L+"(2DK(2S#?TM$^!0)WOGSYR^07:"]>)%6^#KC=>'_\0_[";A,
M@D>&7TJ =P/ OXQ'<!D/VP:PX/@DPCO[ 7_\\/ )"(G.$9.<)R7# 51? O#Q
M" CP"0F(B @)<;U!N'Z \#+1E>M""N>N:EL1WW"G%'X:^Y&$]7;Y9RJ= 1C;
MK8<>S\Z34M/0TM&SW^3@Y.(6$143EY"4NG-744GYGHKJ UT]?0-#(V-K&]M'
M=O8.CIY>WD]\?/W\0Y^'O0A_^2HB+CXA,2GY[;N4C,RL[)S<O/R"BLJJZIK:
MNOJ&UB]M[1V=75^[!X>&1T;'QB<FYQ<6EWXNKZRNK>_N[1\<PH\0QR>G<N$!
M!'C_^/U+N2[CY,(G)"0@)#Z5"P_?YQ3@,B'1=:%S5Q2TB:W<K]X0?DI">3OV
M8_GG\ZRW=&!4#ST&2*G91.;9=T]%.Y/LOR?8L_^59'\*]I=<D\ % CS<Y!%<
M!D# T0EG1@CI_XNG?;1$-&^)9<+=Y&5&5 ]/WWLY4(A_D)-C/8C:Z<GHD9N#
MP0/UBU5Y-G6^BX]X0]"?GW8$('7H!@W-(K?D9C>YM$4<D9J/(\JU)F5TC%IA
M%\LJ\$-I/W4RZHYH>NA_5J34H=56I 3^Q8/7Y^B?5FQ;P!9)53>D-W@C"AS
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M3$(LJ26<6U0>8B:Z#HHG7X,/U0]$\,A704W0H^\,Z9@]W)%+5#\"J&Z@V!%
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M/V &88&T4]KU&Y"MV(5C<,WWV#HD_F/D->DG.[*><Z)KYB98P&N,:<&9K,V
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MM_[_4WN"B=SH3[\\U!H(I];G?=4MKH,A-)M]Z)^9I_]R_ ;! 0>9O?'(N6P
M]#]OSC:QNT"NG[F?A3E:TS"R\%V!9@,J;!>VWLB?C*7Y'BW0P9X4VED199AV
M==^LG[Y'QNR.<S-.H>:AO*]+0\"JBS)6/YA '>*C/LFWFIOZ ^.JK.6\_'J'
MUN8@_L &[X3 9GK34ZBGC-,-EQ];K*RBXA,09(_6)^K)66E?2N4+JE=$"+;S
M:/$A9V*',,+>#GR8N)W'V]E/NM]W/E!-\RJB9E'92>@"1=V$JMP^T09T7;)4
M0;@2O_A9EN4SJ8C%0$G8CAHN_N*O3G4P5XIWJPD+IYYO@5. 58&MX&]88-98
M[NR_W0>.(ZBJS*D.M0@ACX+>=A]F(6]A 3\'F96)H\:3!X&_NNBCOY?$VHRE
MA'W3AW?+.S"^OW!09(%01_%@ 04D"+DZ>O#9A56HCUZ-;BDS[QJ&RN3W;)ST
M"Z6_@0Z<95&"5T&G693T(_\A%8B3@ =S%4R*!?J#^S G(J?IF18G%*=Y%DK5
MX/^8@P'TU>[VA=U]BYFM9(L":(>=%V-(DQ8M3M,XHYT5<AR^K4AY0S2/?T#G
MM6L^Y&YC@3?>?W :\_\WI]UG.:;0 Y8SYG1' NWF7U69W>8\[%'VJ8G5N\,8
MI[M8[<4R,0E&$VQB@9U6W*GCP:@(DJB_^@8O'QYUQ9N[W"32FM6 A]3#IUD3
M%R/;F\"MH ;N7AID)!8(C.@>\HX6=-"WJN:1;R4DI%-2F.3N@W<DXD24!B%1
M/&$Y?M'2R6[0:0ODDIZSO #<=J4;NLZ"4#Y25T:79X/[-?HP.#:?80&#P2GU
M1KWAXO."=8"JY+'Z>4&5Z1Y$(#'J.FXGX8;,?AVF,%X7/$-DP/1#5K5UKM5-
M6?:P2N<\"_<>X#^F\ANZ_-QO/7D0:?YY<!WTJ"N3#-V.$UY1!S,^"%WEP*D4
M',8R16^ )CP5&)97>:OR#\@LG/3NH)U872Q0(U)Z<OY4B_/*\(XD?\<GD".$
M]B-IX56RV#T!]!Y7"_4N?UC6I*-8PXM\9R>)X4>N?+WDY(*.>:,B13&(=V<C
MC6>)G[4>J4#?3TU.OQC.;<L1#7PM/7J@7[3ZI=0O!01+11A@0N'@HX',WV97
MM!#] >=D^^7Z,"@!A/;O%0.%4=O?Y_YW8QHMA3^!8 %YY%D6F_+O%7DZB[](
M%:OS/!@Z[,I*5FMYML;J7#(0OP=1M?@M?RWWF42Q7M(D[4=]R1L2K:''6D3Q
MCQ&,I:J:ITXQ-B=0X/O48.HOO\$"M\/LC>3I9EEI:J_I-ITN9;TNVBKYM*I_
M_S[)U@3AJE+=2",X211K6/%L4T\S3\>-HE^_F'(X9?S5@^>3'@9EVHJ4D:0\
MJ56[VFF+.B_4-'DGBXK/S[7-&GTA?\\,^7 +<R7R54HKF1-G]/>1O/JVH4WM
M-+'0U^H.FUD>:(_H4O#GH_*A <-DJ9DQ^'-_[\2('K^E5SE&[).Q!.-OR#6"
MN&!.5VMJS[USM[\>I_9 >D%]ZMYCZVF?[_PJQC_1CSYLK3BG+;=3A?/7^LGE
M>MIFCV=W3KC=C#-Z<K$3H4Q\,WO4.V>P:,MT*E3T6^25HC@BW8>W]L6S&>,:
M% Y3 DL,!OQ :RD'^DR]]=X.#H\KQ@L=:71HYY_>)#)IV9I]"\\703_R\S82
M:40JUC8:HI8F;AYX]0J3$TMFQNG7\:J+LS.WQ&P?BG'_XQNV,.N%('%#:+QF
MS7Y;=Y$&0K64D=GQ8H^(WO_IY-SCH=K:![Z3&E))H9N,DRZZ(+GD.L/IC&L8
M88C&]5",";F3)DFYBT)1+D=NN:4,-0T.-894+C/1<0GC;LC(&,8PWCV<W\DY
M[WG/[_V\?^S/_NQG/>OR[+77>IZU/NN[$YZO !0=MAG+?O$R_#A0AK#FR"\K
M09.A+BM 7OBWK"U,WD:?>6@J-TWXW7U;+[T':JRL+=3_(A\*&C_7I'ETP"C.
M<-/.'G%KQ\8!-$&!)79VH"RJE&B?922[8!:"D4\^&?WRPNG3VS6\M0^@U6 +
MB]2^M2)R;3U.P1R6"OB.@>M=.^R,, V6/9"YV]:M0T'7(0QE^VSPB$//%*02
M@K,);\#MDO>5%[MPX7-]K5.\Z@C!:J^;Y:\>&[L!KN^&"5&KY(406DE'R: ;
MUK5JH_YC^\F9IS1]5J''O3XIR>,M;Z8CT^Y$7[/TR>M#[+GIYX95V;KG1W!6
MG1NL+0&"T6+.D[7,UNN6']VY<NU*QHC)*]PN5VU!!9L79=):" #;=K%JZ:3I
M&N?!Q-6__0,?T3Y@S[BNU#6RRK,TCQ?ZK0"9/*+%\[OZ!NH_Y#86:UXOT/LO
MLT54]7G.NXMS&EX]@!U<N&9P@Y @+?&;*C=YE8)1:\A? UW^UZJ+2C&LX$W$
M\V@];\7WPP=O]YYY??>TE]8=Y=M@+%HQJJO7BJ_4Y3^=;B? ?&J3$%71&X!N
M'7S&009F7')6V@;=K.F=]JFG[XOR**W\>3;,HM1_@/&T."C]U I0=8V'AVJ-
M<H5(QSJO01/8.^7A#+L3GCZXP+97M41,.N<\[ET<&%<-+C5 6=.WX&/ZQ#4:
M-* >RCQDA^LGHD9&N#,YO S+A?!AG>5,Z(C:IQFKL-S729\TI;WF%6*)/_YZ
MQ>SK<<^I/@%<:V(0#]:T3CL!7;!)8S>M ,A:CJP_)YW3@"]Z8+CML&34\HCO
M,W>WUW.N_U^%'?9=][@6;KP:5TWY 30%P3-%3;D/,C1:=\:9GA_=!1JN=,5S
M>A\<?W2I  X:\E9]!R,STH40W_U&H=L 6T% V_"K>O0GO"/$V&K8"O"+^[?9
MU@O"+AKAKP8_LMJ&H6G!=6903^6YU',=#(]O4F[J5SYZM^-K!YP"?T>FRE"Q
MO8;NGH6C%@F'>D+^<T_.94/,$5?[&.6::R02&$<([5I#FJH!<!4LN^X9^H<6
MZ-<!O]4%;$/[DNT3C,TME'BFQR[UI*V5Q3'DHX>8I7=61XO%!KNR;ER!_>R7
MK+6)X4*4O^YN-7+PWQ^-7@^4WJ^1((8>GSR:4O7+-[=^C9<R2V)PI.FX\>LV
M94$E#2WEBF:-3+G?D(:S8I=_;A"4N*KN2S:DCY6$%L>?"<NCV$R44);B;;2D
M4>V>6=45W\J>J!1Z>B4U(LOM8O=#YO)-W4KR7F.+#L<1VX7.;DT4B@LS\&#H
MC][0L#)%R+O/7\991*-BTZQJ6T;BW4_(7CI'+9,KGL)^E:XY(=TPZW&J1FT4
MXE5R '6BB;DP*"Z>FOOLZ&V]KOSXI_I:]//1)@%NGU\.4)UHZ2^8*X#\^T$I
M1D.NFXN+IK$@H8(01*MT$T3$W9"T]O3P*T(E3AC3AFJID_ND6-R?8&>#(A\-
M36LZ?R/Y*5FJEWR])"$J?07UJ7B*HETP3#NM!X'D&IBU< MK;C_7V )SYNV>
MJ&N2N9SKOETR&[[\_;-7(JOJ?=_CW_\A$)2PS%H:FX5RIM@4MQ]3QA2UA4;@
M\]VS.>]QTU6C^CKF-Q4,M,640U4Z+[:7*O7J;*VDE';L'0H6&4-8,5CAS@.A
MAY5ZE=%.YR\\3FB1EIS$F-SG,]D$R#_@[4U]?)0$FYF5K,'OW:.JM+J3N0<F
MS;"+H6DY-9M1'5TS*'F4,!G(#_;4C69TF%";WY1[LV5U6!PI[]2NB+L;[TH$
M\!$,:I9U-X,E^K DA=J4^G9=I+,ZAM ?!3Y[#Y,SB1;^'_8)ARMY;IM()<0_
M%BJ>UWM,/BAE8IB?]<'WT XO/251Q]CP#__7G 2%%:!:7P?"[V.@O7T6VLD$
MK;1O3T< !B.PC]7C-<Z+W/L\5"4+$I1 7S0;@9>-&_]RXP#OKO> 6YNK$@T$
M\.Z2/,4N&3[2ZW+_IA;)Y/WZ/&J0\\<Y*/EU2N!K!^^\\LPO9VW7(ZO?VA?Z
M-<POZ%@\?YI#2\4C5Y@Z"KYTQ$X27'-$K@"UQEPQ3(.=QNM6O_+<W\9150C'
M"W9&*8,C8\#2B0QPH&47XUJKGUS'+;O7E]K,;#-I&?(S*SO_""N*60'J70:F
M%P42.$P>"_>G(A/!<7O6>@7(#M%? F-X:CXMOBR!O;LB\WT'[G/-N6YZ<NW]
M#C"<;W[3QQ2!SH_7UB<LG"-J@0&@"+A*2%\Z(<T5OUT.SEZL1/8*,%?PO2&^
M.*>@4XO#GL.GF=4AY\)IXN4%S5=1'P-_)!^+>T9.\'2?6 $&3C/FE_GUEA<]
M&<6J,%GW5(WZP!!#]GXPXOF3184N=AWMG54]"$U+ZQ*1,M#;IMZI'3L(GZ:
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M?O!NP2<U7^N#PRE)0\>]34%]0\CN(FU=M%F(Q$)$_JO 4H_9>YIEK/9?T4_
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M[J4V>5AR>&Z#F2!VWX/;W^P4QN$7V7HT4\O,;%19'3 SP16"H$AE&0*H00,
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MSEK>^&C/5L,U\;>,;ATV2ES8,R%)VM])8+WLKL*N5WMP1"_-ET&/0,SX_R8
M4$L#!!0    ( .HS<53 0 @F/SL   ED   1    :6UG,SDX,C4R,#1?-RYJ
M<&?MNP587%V2-WZQX"$0W(-+<'<(;L'=0M &&G="D"18@ 0('B A.#0$;9P$
MEQ#<&O?@[M)?9W9F=MYWYS\[LS/[_7>?+]5/P;GWGEMUJDZ=<^M7MQL^"5\
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MM/X<K(@[:?\OT"\EOY3\4O)+R2\EOY3\4O(_2\F_)[PVSH@LUP>1SL*G 5D
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M TA40JYB 4QC2-8E5$M>;0@0#QJJ2U28EGQ@->4I$'+69&M:;*F8K=%)T!]
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M*6HA U]@TX9:/%VB[&!":+J (MB1E._UP<6*- 5Z <Z9+]*R+L.K<)$UF:B
M K*EJA;?R*Y,$@SZU!H5:RZSQ&D^K.<54RQ*^()PV8[AO TV)\6:4Z\#?%E[
M551<'CF+,"BO45W*FJ)(F[[F2U.5M FQ26A[7Z?-8%+"FS.EQ%5 BR6#<)H)
MS,9#@:A!C2(V'20Y(-1->P%1PYL5 T.1A*[H*554V,3H<JR!"E@#/JUOE%HZ
M+_/I'),'LTT&RQ,D74F64E$VH*3",;CB3(7=;H,[ZDA'$JBWR##%4,)N*4J,
M7(IF]OX(^UU%G4DGQV.\Y+%!<)/;8)C'RQ!Y*>J0$KYZ03*%='9]+8HEBB8$
M8KP>L%Z$RU0@&4Q'BZ4TE&>R.2*1BN:$8DYQXN%PV.OS1'C)FZ::@8_6+J;,
M! MN-,\F''[)&0[3HEOU1CB,+:AY%0>A .4TH&F7W^O(Y1DSQ6:(6I'4&PVI
M:# .P!BH,2]*L&ACV%"XUY :6(N#A2QZ3]!;2L"DJ9YUTWR\J OHY0@&*[#/
MYL*XH+[*YZT:W+P!D!72[93/!W*)2*89IU3C1, "%R)5+6+/D#[*!>=3>C-A
MIG3.4-;%:=PKBPAQ$812>" (<3@ 9_4%O8_-FA)&RN\#+7[.G^&T5M&1IH&M
MV^ @76?+E4!-<8M2WA-*H7$M6L)L>6LDY#:K=7.F3.L5?:WDQ@706\KZ--^@
M]^J#$J52L*4BHX:,%=1X!!UL.BDPGTX1?)D#2,WA<VE2*A=B41'-)EE&LR\H
M$/+;V6REID0,56^C7Q2.8QB-AD3A0B'L%#*,,V+)$ 3--]</%1$-YC(NN[M:
ME+U4KJ!SUZ)%@@@&- ]G=<0S?")GR?H%9Z12SOKU7!E&LK%,M&0@*A$B[B B
M,@1 52UN9@I@H*%05BVF<)I27%JSK59[#.$ *Z/03@6MB5048P*F@#,55X $
M48^Z-/.E4)4J!0A>GU]7(FDKHB_$P*I0DPJ$;Q=LC"8S0(5M$J0G%'<H:8[
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M%/4*6#480D@<"@'%*@A!6;B4S\'-*"#FUG2%4(L8U[.^B)%7RPEM*M55.>"
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MK.Q-92@5PFG2R<5+UKB+48IP#4%,HJZ@ADF*LSI]MCSK:,(F8>7QA+/LK<D
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M@'#)-"UT'CSL,R*'$/%3(Z(9CAP"Q \H^!60R08<K%RY$T46!PN'@R<1OWA
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M?CW8./B]&+J#(QD=L__LX&'\;J-.)_,G!QF6'-K!M4_%]ET8[Y3 .,B%\4/
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M?A)0&-M!83*:.P4H.A,MZ\R@0!N6POCS70':$Q3H(5#\D(*?!!1( Q3PSS?
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MC?-Q.V:Z(4]@8QH?K\/&/L-*BZN]VX9Q&9:MC24/6\]K(@"89O5GR=XEINQ
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MO/JXL[7$E(TKRRMCG15OSB!'KH&-$P?(@Y<;S9WB;8%TSB]VXCD_*>,! 63
M6,"QX1K>E4! %MZ_;V#.!%ZOX!IAXWG$^-B"]W?&XF([T<@TV\#UZ#$A>T1E
MC]O7:I[EKS<SP>M1AU3QQ >**7H\&2+F"I,/^2U6/.Y&K\62J1^M*G776_E;
M6%GQYS)RL_<1]5,T4-H9,;''UJ#$(PA WU+AT.L11=$*OOR%-SF,Y#9$/0.#
MN,$3>6:NQX%?VEU&R:4#L$%G^,57Y%X4'/+!/,TE]E?;0$;8!_[.M6H_QM<F
MQR.+:7I[5]*V1E8O/HY7.^8IOLG55Q?APM2A5IC8D&E"+O0+/(9+6FM;L1IM
MG^7/L,8T<IPWL5IM&HX;> 'D:.\T?-UK5=W++FNQ_\Z!LK6PKEV@RH1#Z;H_
M_Z6O"(PM*DJ1A8*%G2XS\FLVX5 ! WU\Z:..^5^B IP5/^HN/-*C/GX)YPJA
M.!(>B78=43JA^ 'S>"T\O%[N_I@YY_.R./4PM#Y[%T2[Y)Y[,3_3>I%BS(MG
M&&BF5^9C8/&8ABJ\8>:G*70TFO7%=.M3^W"\O2_?IQB8ROG8UM,:73#86VO0
M6K@0@FM>8]0KIU*%O$H#]I;SD_[7]02EAJ;=.CD--=!BCF1*_9,?:E &R]N_
M2 ,J4GGZ]WCO8(YIHD2H )*!@M\OCL@.GQPYC#$H>M2:YKZJAP[N2^4F$<A@
MX_:8]Q;3OCFM_59_*#N3X9!1FPR'2X6B7>BEJH0LZHVH4NHMD _G>O1KGA%,
ME[ Q\W&((FKE+SSY[0==9;UQ@I$LS_IR>+P78=JZ.*DG>@20TGG#G=.-$DN_
MW_ 77EE /D]#A%R$T.LJP ,#R\55NJ#VG+L?_ V254F> -K+5O^8OC\?7ZH6
M1#>U[SR<E#XX"B\Z$B3(/?JNG>?<$]3L_W):]2,9N&#]>_0B<XESFU(B)5>F
M0G5ZR\M*:UK3XN5(V33/Q_EC@>. E=']1NK,!A<B>UU$6=0!,_7M[9+'17FB
MJDHM$SK&U\1AB G$B@UF"4+5=S-^"?)EE/JK&3A9)D:MI-S9)3M.)3?#[A:>
MM6QWF/#5LHIM&8.J]/"UOSGVQ-5<8;&(_,QI(#ER]=9?D_/AS:OY:P+5H9M7
M"W\E:DMAKNFUCT&CKM*BZB9W ESYU#A1/4Z0@ 3K8^:39<><]I6&SM83Z@$M
M[Q%KC]^_TCI\<A1]9 [M5<QXP$), \HV]2,_IHMOMNW1]2;"MP9-XAC;VS*/
MB7RL.7GQ&KH7%Q04,=M=]$%D_8E@+:-'=152J5=UI:V?M_8@GOB-T1(26+O>
M8E$?81RH^^2I4C?-_FX^<&+C^TH;O0YUT-K]KV%E-<(:5F@^:N :X(*UO"F]
MER2!2IK@Z$C[A1]R)Y\YUEHV32VGQGGG4>:^A)>#;$,@QR&QNO&M\DQ_XM=\
MO2Z,U->[W<E%(X<F8H(;W$NA>T<E<G)Y;QP(LW2!;=Y<K88"AU4_Z&6^*2\"
M((.M[VC;U6O<'S;K5B-Y8B!398C4/EL-9WB[A  A8Y P0),KTS-[RQW'. @+
M5\Y.T:O6+(R%H*ECEX$T$;$5-$K@\O:NDM$>\[[23L>(1KK"[4^_FW&PJJHS
M69C,2(+":+>SJ<WY1<+Y0G-1QZJ9:5,.4X> L.OLS6$@7T=G95O[.V_P"_"<
M0Y-<P/E_#'F\AI^ \WE-MZ4INU!E(Q)_O7-_+],D.!%[BY5%HQJZKDI7WX/T
M)S0>58-HTV ID2R<-$9<IJW\[L+6;8458SM^((?ZE D>2RYED0&':IQPQ@=;
M\87%2Q]R\G4^!"(P@O8FI;*_21I9_^0K1\M]OGTO83;KN5J]"JF,-,8Q\+-=
MOW>(C>%T"@VHB3]*6M$PX L@2CD@CQ/AJ1F],-<U3P63G$])=U DD&]N)Q-R
MIG#/]B[*G/Y.I@<MEVGW-W8_+*M:%EW10K_6:5<UFL+RR/"_TB]3/3!Z2DZ\
M[FUI/>^M4[K,O9BF7!5?25O"I& IV];*B!?*N1<JG99Q<09\FL;UHXV%TT#<
M1$WHO=YH9R,[UR]\"3]]/Z>I(13YR9--^_Y^[)K.::&J8T_V%X^2% &G4,+)
MOQW@]V0F5ZH);:>9R2T.0::Y<B.\'MT %Y3T8M9]&)*E[/.+!]VPW%H3UE F
M1OLM&[DK$YNO[6)K'[.#J \0\?EH>'6C%U06C45.Q6&JA7#_  Q&A+JEC&EG
MG9_:%P=]<)_=_SSZ.RUH7]6COHGUXA_ D28A:O"8\J[$.[>V7>>=8V7K'N.?
MJC[\CP2Z%(O%*:Z@,:T:7E&:[D1^:@TMOY4%J%%H3&"XV#+-8"4NC9&?@&G9
M2:'KDGCUB J^)MRXE& ^$)3GM-O*HPWJ=5#VLZ%]KO,M+^\DU6P!'6_8<2.P
M*V_"_46LS7S28=%0C*G#9+_ZPN<[SN>%<-L5F\<YR+3"%\RY.8]" ?_N=M9Z
MQZ,M!UA4B,SQ +5)K**B]3?5IK\R7SM<QO#XUL88BC4T;NW##V4RYVDV?<+J
MPGK6#=M4UB;(YY/6+T&-SU3X,/S!/544]",ILYR6AO0V#YHNY5Q$]'I=:B^!
M;4ERA],<U9\98"+YYPJM#6K9E6S[!VVWHM.E!P^^3#/FOFRP(5Y,(HHS-_+T
M1=C$X_ER]QS[!D?1>(<ZP0IA >QT6O+5;BMQ5'&4T%!.D@ E?'G>RT!5<[O(
MX8,HWR="UNIUBEZC$U$E;J/ORH;4,<[1CFUMHW,3G(4.@\P"PNF651DF]H>B
MC13"5GZ]E)HDE.]B-<2+NW4;;(C0\$;\BG@B6856/I?:"4#F3Z503O&E3D[(
MZ8(E%193J^F=%4YD3J?;"SW95OK"DA)$G+[/<)2QE@0O;JV#/N;@Z83$D4=8
M48@&O4'M,(80>XTF?@E!V$%&Q?1_1,=9+:X#E7B+OQ(+2^K,,$?X6#Q&C=/-
MS9C6.IE7:MS"*^2!K?J\V$N_6*HN$>,TW+#]"11MFD;R (U*752)9>AKM%Q0
MDA(XR8%2N:N52)A$J[M:U/5T"[@BQ0ZPHMUI-N/H,GL4OT1J=;658>-3S%,&
M4Y&;'J#0LPPJ'%WOOF!=^UPGN:9(MEQW5R>_+P]^=$^\88V9EY:M35;DM-02
M?"MCSZ!7WJ*WN'47#^I;.[V=*XPGQ[U 7-G3*A:(FSR:LIQTVYZBVALW#_@9
M;KAC3L'5())VFX>6@QJN@]&((R(%KY5ZXP@Z%72Y])N!Z)<_#8(V&7%#4MQ/
MLVLAARENE76J>0S(F?S/!"Z./2'NP=!L[1:;T>7XQ?-I8JJ-Q9ZVMC8%P)R=
M*:N0G +,%.V 5#A?U6[&E#E9UH:MD +3MK$>?($H>HF.I_<SS1+OSMD]S.0.
M_]R&B38]B<36"@G+2GJ'[N49F]Z#KL/\_;"EU8%AE7\>>6V9&O\0#+6<VRE6
MG&N;A)L@1&I!%ICK."_><P=M6[>!LUNG?*),MW, 14F6H&E]?7(5VAQGC:[M
ME#01UWUENU #" VS@VU2;(0;MUX2Q>*SI*\!:"[?W7R2<:;&M65VPQ\$=#?O
MA?R?SONFY >MF"__#;\]*<O@8%X@L9W,ZINL>V(/MG3WGCM$Z_U<;%GT+/QP
M/]+-$+RZX7S"1/6<XY0(&0LLU\ WVQ4D(Q<W  3_#\[>,;@2+NH2OK%MVV;'
MMFW;-CNVG8ZM&Z>#SHW-CME)Q[8]SS,UJ/J^P?O.C_-[GSJU-M:NM?>A_"Z,
MP6OM_[SU;/^[1"LBF$R/B0[?,)IJQ&;DX&=J1F18?;B8+P>NN%%Z4-3O!KJ
M:=1'DRY[_=\*JUSJ_69VP:6T G9>,'_]C;_GT)M?MSYRB1=J93,'HZV]'TA_
M>CFC$LL'I[DP#)Q.ZXST5N4XSB@WO((AJN4%=]0J4C/&2&=AJ_ 1>^5<C%)X
MKTA@YPU"HK!?<0XNO+VK.4[3(2E>X%R@.N_FM0L^ELZR<7D-_MWZ,ZO?V#/H
M-#W:^06 T_-U[6?!OM15=1OL')Y%9E!MQ$"R][2H0 -4 =5*U/)]I1O99^L4
MFS@815!9EA.=.)]^*)1LII6PD7-@!J?3-&=2P$B5/.#ZM1&X&%P^4KC5N@=V
MOA(8=VD:(R4T*';OH4GEGDNR,D:$G$?Z@S,' O^T1SKW%_;_BBE?D'6:D: N
M]=6TDUEF%_K9U-I;73! =ZA-^V;>12LQPNC6>G/$#RMF0*7V\\3"4"L[$0P)
MJ<!5HL[%U=RUS?.X?%E-!9;R>]WA/CH*:VDRO??1CA4,F(3ZBH9ZW04H9+$*
M%I(.I\GISG,C^49XX=R-BS"JN2AAJ/0\Q>9,%5]A>9#03F1L8CV;?^M?/F<*
MIU)*RK_U5)*6K.NW]02"V19H_I^,[J$/GA$ < , A,$X?,?_-W/I_\)(_27]
M"-NV*JTF:Z-.HU3I$''8SIRL9M4)$KH6G\85?0(W+Z;\I+L-001" _L2TT\E
MGC:>LN4[EI6-UQPD*!2'FQ^:UK^]@^(Z?9F4QG:8K<HK%F8[L$Z4X*KWW0)C
MYXW)D,QO'\+=X^+G%G#-L#:E'QC] 3TM+EV@V=DHD,,8C1E1PMVGT'])#*+'
MFFFFC&2Q5MIF-+64+TM"FD<EXCLKHUHL15U/7EP6@;05F X#=^ ]5R:G9#W7
M602+D(3RZ*B@"Y7AR^Q#DG1 +FZW03:92?MWD!N]^]:H^(=A([6-!KLG=GBF
MPBT-;29-KHAAG<[4(1N6EOM6D;*#@Q>1V3&V=0Z]S/K*GS3J=>U,ZBR>M%_F
M88PI0XUKLL/<BQKM%B'EH1DTCB(9KBXLCC\I64E#&&KB3[%T6&PPJN6A(0(I
M&<B:N&G\4>%3S'GGE%0V._?>%(/I FKUG%Y$3I2DU1-3^%YF4, 7N99=O6A:
M&-K;!QGE+?W%6WF?2XV#<CN'RY#5(C%#8]N+O\MJEGEJ$2&I98A)M2C E/UM
MM.K0^-V')2*.5 <+KSA3W#J5?J8.+P<C:"AG0:>)X+U8=NJX>%4KC\XOF ;J
M5@DBWO:,<+D99B<3SY&LS$2!ICZZA:.LP,^D0['>\S0>ZKH=MPM*[!Y3T:TY
M@)<<;IMI&S-7:5^FFK".[P\.BC\I7NU[J%6WPG(NS[!OT#:3QT_03 _%4>R5
M@TCM6Y,%I$+&_JZ*MEEM]!ILU_4$DZ0LJB^S6PJ>0\_5B&OLQ*;VJF53O.7*
MX_IQU,P78+@QL=E%;#P@L!@,M_S)_;V70]*/1??0<^7'BKT7R3?_;6OKQ<GC
M]HHNK0]-H^77G@O0S_=R+AQ/1T6GYD)K1Z'D1^.[5"U5YO\O7*EYF_*+DS/@
M<G(W<C%J7=U]M,3-,,?@-"X?0>*UDR6AJ>DJR*[>[EK5X].N(>@99XM5.E4+
M&H2FH2>4=Y3GT)\0R4_()WV ?<!F?D0[]?[;^&;!'3OO?W4.B<= #$5#<@OV
MU3I3+[ ;("^X4+/20,2T/QV*B(S^.O<H1.SZH@T)@LAW%,<A6G <%U()',K3
MT!2AN-Q?Y?<<3!?^!$8K;:/1G4V'S(ZDBW/GAEC1H!@<\O=SW]6G1.D>)S0>
M 7K(+>IH3C$61#M<?0#W6"F$AF>WB:69;5Q+N,PZ.H42:>N(CLX>L O-?QZ;
MVBHSO$?=WXUS?S@G^T]VT[879?XX36$,92&Z;"I\;7.5ZL\^L#$ KP\ < V
MN\\3)=.RT%U&,QW:6_#Q/\; OL'-X"0+-'>=IXK95$E0MX^!1\]U@Z&TV?PQ
MNQ;DAX,9@U/&FF$;S=/<0H=85DT834DTG+@W1$""ULI>"UX' 3&%"KNZZ1
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M5=?00.[7?]/_+4(&[K6#EIR9;;85=EB1P"RLC^I'A6/LB)"EW;:Y4 8ZV"1
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M5D3[W?5 XZ__(ZT-0X78/-'*DT :P8$SO1>:?:5B#"K4.UCW2^'^ EOY^YW
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MGZ->#7) 5F#CY<;P/]44SS-K;)AM/F*I-/T9IW"&$N:,DE*S$#ZTX3;O0CQ
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MT,/KI4SJY/&32RV"^_'5X6D6D>Y#%,I52+Q!(C;*W!M@=[2GJ!/K\IEZ_X<
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M5?>*8!32L[F * &#D+R32K]Q>-B[!XN5T)R3KA@,2UA21EST]QS-T4"1[.B
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M1KB:I3GR[TB<2O5%B^5*Y;J:##*U,J5BA3!T8[0""1%I%0H9:?-I2CD1(YK
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MR)P\A']7-7)IWA_#P/Y_%'.>04TXS+H/2.\=)(*4T (H'0%1NJ$JD% %Z2V
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M8*&2F5UK4%$?JOQ1T;QYQ,KM+*7%*'.LMR\;?_#9,T.JI8F >B&M=^J7&NO
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M /#5>>)A_>D _OG PL;!Q<,GN$%(1'Q5H/PF@(V%@X.-BX.'AXM[]2KTZG4
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M9&1*YCH.Q5J'%'5)=<3T5EN\!#4YG_;=F#,V8Y9BO!)260Q ..^# =;-!S$
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M0"4? \*NWGK'HC)C-];T^S6?FEWC@XN!E.RB5 Q0NMVXUC^/ON1%J5VFO,<
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M=N'\\L,3/].1]V56H?!GLW<Z'K-(A)$YYI$/URT?PQ!MO5GSJ $UIY@3=<<
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MZE"^?>9XI('*_( =[GR;K#[#0>:,+WVQLC6/%S#]\;!7*LL6J[:Z$S?D2T,
MQ"!K\ 5JE1"EDAM&B*U >'RY^8(@'OW+4:U[B=06Y;4J8\Z@!,4I9K\*9%2'
M4/?+<P$Q?Z28R>K=4:]MB7DDU2$IX%+4&<BQVT YW[=)K*.*VZ7Z3N^>_,+:
M0:'XL6E#>$&=;%;QY;3$K3N=3YK'&@^I+O)J43,8@-5?'P-4PBXY0NI&CLWD
MQ!J_,$"'<.]<*@M#PE.)&LNBSY67YEA4T3>XGK4F[VZ#-FB*WJ.TWS.&MF
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M@G4$>CU!N+><.HUS&.9YIO1'&=D_/H_FM2P+ &PPN''Y-D\6P 2-*XL>A$C
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M7  'H,RM(BB;91A1"#&N@W!1\X;U""QKY*9'_-7GS#\R_F#O__9!"%W2=>/
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M4!-Q7&GL]2 '2&#9.#"L_-9/U#S.XYVN?EE>N5^W^CF7M5M6#29!2AF.2[.
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M]@YY3Y!K,^,YJG:J=[5281"#G/.N2 ]8$ (MTNY#8<JJ4Z);:I_;$KQDOPC
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MQ5^-@L%(Q=_1(?_?K"_]QI!>DVO3:'!<\MWBY=IZS[E>LQ*,KE_\1JJE_ZL
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M\+0G&RMNNY@=H![:>\QHZ1POZTU8[">  ZYRO<<!&[J#. !I2H$#J.190#B
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M)5C?7\%<9?X^A0?X]7BD[-BZ@#8 34%0]["#YQ \-Q:0T^]+ 4V^78=4/3G
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M9/;4Z<D-=G;7SA9"CN.5%1P@M>L(L16XH?K@K9LI_]6RD]<'G(Z]POB5ZW"
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M_EGW/3,0#B#M!FTXX(!N1QQ@#X5D!\@08ND_0P;QWO5Y 3NCC!&YAP.RZG#
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M8\?^8Q-IUE-/W".6[ QSLLTM=*RKL_=UVR/K]+% =5TO+_M0%+6<N@QGSSN
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M11N@FNP7/%HNV3XQY:6S[7N]JMJ(4G?YS4._)FM'.&#BERJA0V@P:4<L5Q#
M8.JAXDQ)+T0VDWS!L8P% D=YEN9"R@<W@^^_VGU37ZW6%<EW+H_9L,F/D):D
M$77Q\^9$-0\XF=4/WWT0@$K<O<CD)G9ZCI 0QAU,]VN;(\%06.6:%W:ZB+^:
M'JW8IU)5WS6)86/0$,;[)L&Q.7D0$8:A#]1%V7@XK@14#\E7^Y_[W" ")2DL
M#1,_ [8]^1=I>,A=W>&OAL:_<*N)Z>XQ$U$I5S(&C\(N&8U9KWVWE<[5:%-
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MV42XJ$0%93H?ICIC5(EH2PR"U=*\E:DQO^HPL,/B."2\L<Z.:R*#I ]9%(.
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M2+5[H(];P0 A3SM-.$AL^J\,>C/&2B(\A?M=V]X $GB>UG+UNQ/^$E=_V;F
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MPX4.JQ'L1[D1E5VZ8U@/O/,E'@C2Q:2KC7@G7V-_:6:_=1V_SKS\,O;J!UD
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M B1ROSLV9$8"F,&A;9L&DVV'V.!?;9U_-U[4%-NY**+&J&[I/PSV(@YJ%/2
MF;>S@-__>6&H+-@X=4[K Z3CX8K#%:FK _Q.'!((S6L+%)<CMF-,HYU4(7Y@
M;B,* *Z,*U$E&KNTNN6SA^P[NM_66XKUK;7&2-/,^TY5?LIEH(9ERI#TSY]9
M4-HU?2G;6>Z)@BP3M";<@PHDZR\E1/+69Y^_PCH80=#$=TR<)[CK!O;/ZN@I
M.3_>L'W9;1")K@QLY(HH=&N%ODS)9(0V'"P>-C:SW_J)9[37AVUP#=K?'GJD
MP^EIF)! IKOFK=ZS@F#)H.7[1\(W]QKK$"@*2*!K&GP[ V*M_^D,_!]/IX"O
M2?FKJTF_Q;?[R9!OB[C;NO&E[PD60\O,Y4WGL=\VA*""A%\D']BL@^]YZ'4)
M(;A&+=*?3-*'/891KWJ+DF@\"U-@C 1(3N==1E+RTGE_!A6*A3;<&AV]U(=_
MIVG$X)83KK3D/G+CXABY)?YZC>BJE#9*]$$+LPK]C&94>_WKRI.G&C[?EA8@
MUO?*K[&M05<X$RBGPD$^_+DP1>E@^3&ZXU+H6E*#I_Z9N\0/Z"GP"D!ON1U9
MWZ)K$4T:ZH QKYO;*)EO'Z2'A4F9\.3=2T(IE/89IS=\6+0L94-AP!'MS\5O
MB[:C^W!6I\76+X/?RJF-S2^GW\*Y?O8QIO.C!I:;3 HJ4A,IUD_4L'_:*]D;
M]ZEL6)8[84P!,!BC,9B:29?.XEL_'TU_2W@0<^DV-6K026C/;,WYW5@6S RX
MEX)G-&W61@7(& @A%BU=Y:($:SXC&7()/1BX7.B>&V4B0*ODXX%B?3&87OO5
M4-7=YWD6Y)H1H2)HICKHF%2$LI[0L(I,N%/005?T)L5&X!DGP\OZ^J %E@&,
MASETJ'2O N6^Y_L[X6_,^(A=D\$<EQ>_7-* SWWTFL/M3H2B^$40G-=U[O,I
M)\F+C155K<=^TS9H/3%LP_BI9! NF>NRALU.YKM.+'>^.=&@PR*RX5+7D'.-
MFE.0\3%\N(:>RWV_6Z@*\N:LQWIGIQUB;I_&>C6#!/:L@8OMOX"]@<Y$+:_I
M/;"GVXC%[K2PBKR)= U#)%.@3B-41 JL-#A+IS5:LUQZ6+7R(!':XM#E1SDM
M8,,\8<_\FN^!VW%.G-\8!1-PV"(A-H+1H&+(7K!E1&-K-Z7G"U&:T&\=)ZE^
MPXX2<.)WS$@&I7;NA98:P2!'F:XW%@B"1:(?>7$E^[P,N -4E4%TW1H-$5<
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M;O/SM]>4)'2.& M=<\=5GB+AQ2BWL77@[%W0': R?S'_;VAD)OY-O\D%^:
M95*#MR>R=.BJ'SAE&3P!ATHS>A]WU&WGIW7$'2Q?.BJ@>8V4R+S1;UW#@W]
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M-^[VI% TAFH@Z\TE_E-M]GGC.>E^VB.<N>J#&PWI&S%PDO'8GA!9-EV_:YY
M/[=MJHE9NP$WJGFO^4,/E?#U55*+XN/#UF)"&_"A7/A28SDX8JNS\A%%*66K
M'P78(']NU5HLFY_F,??LX7<]O'-<:E!I>F8^*BF> 6^RF:H:VM-W9BB[-30L
M:VMQ@ OK!V!UFH=@D7:IX.=QW(MVM(:7D7QL=IXR0X#PQ+R4LV+TO]*VUXY-
M!G^(W?^A*'X#CRPVR@JR0F#+VD(1#I#B=9VFRKS.M&VN17F?]>*^Y@7#80^'
M91(-S@4=>3O!F&AUMCW72)V?<MJCF^ZX6()=K@(>78+]$""<_EHWD;<PM]40
M<+M6&'RA-)?\F;\87%+FKUCB_6O>L1,370]B=^ R17&T*7[S(LAB+.ME#85!
MSTWI-9+A#'6R/B]!3=?\:V%XEH+/!7=C077,VKW:^IK4\Z_9<&I/]%2#Y$K-
M%]&'\+(OXQ%,$YT=ZE6'0K^(N<D,0(,.(<HZ6E=9;M^[[[^5A@^CR\?'6AT8
MU<0&R6S23ZDL*^#:ZLBMOZ'94;V\ X 0S.SM=:\FK!"]XL2E- EW@'NI9:^1
MQN3[(0_PX35@7\&S0DGRV?]'%4X7 YOQZ([4@RY ?.J3UH3?28I_-&)_@["K
MG/&,P+L[HT6PC\ZN"[>QV]>\G]J,R;@P_JZ[,=5]?5'KOB)LL:DVGGG*9D5A
MY\*XE^((L&$>ZR_1A6F?PC56WJU;8G+VTY\*C=;+L@1_G ^5)^BEO^0YRVYM
MOM^MCD(UV9KS)4*TMD7M*$(MTT5[XYM35B=K#KV;G]R'.#;#8ZEBG"_Z7V;:
M5@,2:)H@,RICX[?\UTQU7$+6B)KLTSO \[?"FDJ21"OD_R>WBH]DU%@Z?BO\
M N8ADFW>T ]RIR5O1.36/(P\(9B;#3K%LL*SVY,'ZH]"Z;N/JVW<_4^+U.O-
MEE6TQYX/E6X=@:=D8R]JD_!NMPF@PW&5N>!XQ;$4G)<?U_1_A+[$$%69UHA1
MTKI5)JD5VAN=J.R?-]#^=6. L1X 5D(R+.1/;U]J1;7X3;X,KT_J$Y;=_Q3'
M\(V-O6K(M0[+KD=OU?96E/Q@;Z^P@/6W;K4-;6^N%=Y6[7@;M^XY_FGB9QW[
MMWW[_7+ME94UNP@1-9'VZ^31.B;&HL>_5)S"_Y0('/Z?W[>JDCA%5Q'OVSK;
M$34P7V9$M>4@% !J4PY![J@2]1-L90954,>1":A8<\ S#YZ3J>]"XCG@&/68
M#^,F['0)3+CUY!=J5)YW *&I+(0RW"MM5^#Q2$5\+-L+KGQ9IN=X^]K'D<&G
MH3[4YZL3FP86=B*J9T(%QE;F7SNW"!^(][SA5M+.QMM%/H5W$R>GW49V<,S/
M#>$0DZ6JF3C<SV 6?NI&9*,]FX>@)IM'?^I<__;&KUR$CT;(-DSGHMB1U?Y&
MULJ43I!6.\'EECFK"OYQE3D!+_WG^&6TV=09Z_U@&&J5JP=,89[#*B!TV;7P
MW3Q>C_[TCYW;&SVC$-;*<+OCF,[RS?Z(OD5D[:=-FLL1'N'J5E&"01^>KD3
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M"G-$\-58R)N3COL)4-;VS]Z;_\>"":M^5_[1^ZF8#Y_>"32,HND-#*.=J2M
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M5'3T)^);*%LV M0B@<7A(J\U:7#</C75E-*BTG6[/Q9[./4,WZ.^G1QP?=!
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MZ='%XICPUR'GAIX P$/ OB2AQM#?KD--%)(+3E<8,^(0"F%)]P['7MUQ43>
MGPPT48_:-*5X@]2D,J)&23@%^IA%NK7'SA]I:;*IHI$YV%7D7 Z=%NAH=%5-
MSJ:5 "MD;T_;<'?,I7ZL[87I4 F-25H3R','_3[66L)<.]>C:"?>JIA&3&YO
MU+1!4^X9P)KUN?R@HLZE7<7/K48B#^]XPVR='>4KQS!N_UHJC/$SHAEL%H/B
MWVVG'CM#''(4-N853YHMN[W.J-!EL[?YZC+B63^;D*T/83:KZ/A%+<6#>?MS
MFI/N *>#;\3/A8';.N]MI;%!E#(Y02UJI \"5M*I?C>@&MS6Q:JHF'VQBQ4+
MJ1_!6%X\1N1GJ:J*!:8PD@)P )EI-=G**DZ1K/3!]5 <LTOV)GG22TB)'&2+
M7F6?FXJMM[W5F+R&'WO&0.3;1H59.DQNLN8WI?OP']6.>\"_&0C#2')69DQ7
M_G70PN0U'N&BD6RQ2-; I\\E81:CL=?<C>\K 2\=V@Y<0K* 1U?5)[.']XU?
M97]LZGV0X%R&4WN!X2E<KFNIK6;+*BAVFK]*'L."ZU8*GT_1?H]_T'<Q(=N%
M8,ZY?,./\"IHID!\#GXW24T2Z<JY?!@87BT<1HW<S+;6.G9A)@G(F0BF9LL/
M*1*1I4\RB=!P?N'(,M#-TG')4%NL=L30)FO=4 CL,#N:M1F9N9V*G+\#U G7
MW0J>)Z' #?53NA_FYE0XU44"CL,'/FR&5]]O&957+LE2A3G+3>._ DF!E2H'
M=-Z/+#^'8H$C& T_Y'Q/8?*:1E%6DG1,\OQG'^7\@;\-C7\3.D';U_\N!Q9@
M=P?X:_/G^0G&7^>]_/WCW/_?XGVTJA]#M,9C\E<F)F\ .%F>T_GY%M$PWGC6
M_3']IS;I^=7&U!L-@AH35@Z%<I]FL_IKKU3M)??2895".BL:QP\S;\KZC1_3
M$@K?:MXD#ZM2DQZ=+3R?(,:+JH(^$?*!:PR[)BW>6IQM*:NF#[$.A0UPV'5-
MJIKM4B=9UY8O 3'O !;:(7(70C-MB[0E*QHTPY#S1M D$S/(S)(UO;HZ6)K0
M@HC0_D%F$7FECJQ.LK17:S>6?+CUA"^AVA-YS?+1](<KP(3;Z:EHGO!IO;3:
MQT*VIS1LW>M[6HK ;34>=A)Y5X//WJA60^U5B..M-VDMLBN0I^XIE;[QR#5;
M%L_;TRWAYD0[Q\G1^3GZI\^=*9=0WH?RQ4F&\K#LV>1AT$^EF9&3F_/>K*$4
M9= (0NPA]BH/W"FD@V0JIFO,XV/IST5\8!4Y_^H9Q0?0)Z L-&SJP6>6J?#7
M"]/BW.6,WQB:I(8#;]8\(=B3/[;&\_;1;7FC-]/510,:Y+/!0(EXM?'U&6PW
M)MQ&Y@O)WTV]=L^(-B:3*T3],]QTS 5^8$UG=2/3&JR[FP2:CW_56&T.J"OA
M5U7-K/"<BQ2X)F\Q-^-&JR7*JZJ_J\TW4SV&!IW3D(/*++1\]O7JT3 ]-%7*
MH#NN<5LBI C>FN.F[(N@E*.MJOV;*^F'ZG> ) MW=Z#^@:02W'D):Y$*]/;%
M(DX\RL.=31I[B(.[)C+1H_FCN99.=$#6IVV80YVXN54\78@KKMY7E\BYJ=30
M+NDGN(;RD'[D8XZ0<Z/)Z.@+8AN8UMNPV38ONI"'1*KV -5Q);TW\X-O_U9F
M36TRR>Y7\XM>\R\WIC_Q!P3R7.\?!Y15+'3<5C)%QSK<5@_A^K2<EJFD'2M(
M%YL6R#S!B9DTVK=QK?^D@)WYFG'[7#@/\XS]03I;$!>>YUB"[=0Z4:)%TB^A
M'G.=*/MBU#3+&)5(Y]VU+AM1 B319*OUDP):1EJ95=U GP<9:0VU$S\6&P:5
M91C_H::*^J DCF$A@4?CE6\,?T#ZB037?I>GE$& !GD60Y5YMRJHN)]M,=3S
MBWJ_0F9O?_Q5\;R>(U<W0>2E*U>=5/!!7T[ZBY]+*-JZ]<<:[>1L6ZOU KXM
M=X!H1Q^;H?K;Q9[D3#!UY4JB70?;)]7Q[!KM-2G%Z>X1*8SMCU55,7Q36-;F
MUJP=@Y>& 5@<"/2O0\0+8=*4QX/;:"1.3YQ<A?M-[<NX$A+.^7- A35P\Y5\
M':)SV8I)S3'T5&SR#\T+,$&<V]O\B")9*7E[FSY.:(=W(/.P!Z6;<.TQ<2I.
M)@1+.N/M3>@QM.*IQ]8YV0X$IV(9@\_HC?@O[5+AJ78.>5Q?;G VFESTZWR?
M\=?BR9.5C&F-]@4%KKT??U>B,?RGB_T_\+?QA\WC[Z"ANQO)=*-:F#XC>_-#
M=!LG^[ $29-R>'A6>$@)S[ZA'=LCMD8F"IS<+]$\H%[N_M54!%-%*)&XB:$G
M!GW<0=O(S=<K&OZ$#>([@&G6+:0?T2_@F&R;I]=I:A&__F/)!5?9W=?5SS=M
M=DM+V]$&.WP@PC#&:J/,C6S9=_B+T(WO0Z3M3?OORDHWZ=<WM\PY!<<\M8M,
MTSM]7^\ ^>TP5=U3Q.\NX7VN+T WG24E<=M=[T )+DGMIYW.[A,#U3'LMH(Q
MX;]D>;9T&4(RCFY[Q&0I-+VV'@TZ-W+?;U<JJ&E']F%L!;WTG_NVW+)%VZ25
MX-!UG7WG;C\ZTV/TJCE$_<]D<1]=J.QOONKY^\;A"!*:)%KGO067?_^S(TG3
M=5/"S[*=5E3?^_%Y#W7MD<N>!U,GMRA!Y43R(5D[^TVFN-YPX&K^[I%JNN(W
M59?\G[+SOHQ=4BY.G2^(QF4OH-Y?SES9,<R#4MK7MT]:RK+VK U:\+4OK?7Z
M*ZVG\([\7J7"-5(S=OK6Z3]3W&1I,%_CZ32ZZ3A8E&DT%6Q]NH^F'_^&B;%V
M']+Y=%N_<+^JWVF,IIUF:A&6]_3'?-K+/3,+V& 1U'I#<2:\:4W^,AZ!T>A<
M59BOO4OBX=X*P,$C20O,MW,07F\'VM+)TE%_S+<3.VJXSOUXP"=AOHL GEU<
M%DL1+K\5&IT;K&;%<0D\CQFNJ*Z4=RS[WN6#U?4(X3*A=I046%R_YWSV4(KN
M:KS 2"#UA&NHHI%I5[WNZ6PJ7<B!R[-SGAUU8B7S20XMB4LZ;:-+X:%-Y=\Q
MY^U]S F#8+*ARVI7YM<E^4KQWJ_-$L:_=_<3ZKQ251WAO*:Y'")?7WLO=B-
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MA+QO'G.]:22EX'C/BL?THQ8R01+G2V+<$GH$./]U!\#AQ,)#^PC B!_%.2?
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M+D"_+WH.J*8^)R+&1?T^ B7?S_1 Z[0 AQ2&AP?TJ8SD@=VSF0[I'9;2E/&
MS;P*YP$RS.JF<PS=RX!6NB\CI?/ZAFC!EAW>L^=H+@VP,AJU]?P(GZ2WXQ9I
MYT_T&R/\''F5M]BZ8REEL<-T0CMQ>!5=YXRZ.DCV;G3Q:3W70:?CZT1XWL@9
MYI.'K?UKI1H>,F#=4@FZ"#\7[48HO+1<=5?%O-%OL#@]-P+ =\ FV?94#2&R
MAB\D[;,JT#8).YVNOTFNOZ2+X94M8!O!IHN1PG 7&!+^S;4D4O+*R?]ZX2U+
M1=*/=KP.F']13&<D30JW$!F#;U%[X%2T\>T+&4ZE7]][^F=I[@"?VDDLKQM"
MRNHB[[7*N!4^OS3!;G0G= ;?/CKT23>(ZGBK2,Z.]</D CT]0IXV>JJ1J6AF
MF(#W^#05E3 '1PP#H4Q5;V[UYT\@UI0V7==<S!R)9E=CC+(ZG/]\'<8KF/LH
M486Y2W.RQBX;9;&)QINEIML+E(]]-9G(K97*+@RBYL)@=P"$XA\U1HH &0B\
M SR513*AGM\!LD)04O?")S3?Y?<=0)M[>8"K"9Q\0*QU_]I/AS6N:VSP!OG]
M6U- JT(PLEL,T"D>&*E(1@ /Q$=6WR1=953Y^3U,-^-8'#@(XXD#9UU"6*>1
M9L76-;Q=;'/S8#PGP4=W $\XZ'>1M>'S*3<;MX#K@X$G]2LM)%Y(0%FS8H:2
M2>H T=%8JPFB:G[9_W:HY69VJYF#H-<[*HFWO!OB9JT\&"<H!SR(G]@=;VI^
M0:M!+:W+NUW(QK=D"Z&;9%]KKG<\^<5;4 @AGFB5+;42[%WZ?=!#]''>M\X>
M3&B]_->'+-F2S,DD?+^I#_/8M]$[DPCXGPY+SN8=H(S<83-IH6/P H>M[P[P
M]^/@UOX0ZL;QT6:JH^GLBW60I+2^:=HY^GAXZFI-"GE8R;>G+<<.9V*B+#G)
M^W_Q0'@2(!>75^\ ]0+'4RN@,P]P"&IF%*OC;_Y[(R'/LS72EE6"R.:T^LL&
M#U+WL:QHI;C=GB:+^O>/7CJ^-%^,XI5]KV3C((O@*/'L,&_YTQ-[N=_-A="U
M_LMA'.&,8YF!XW?VE=[23]ZTDVA'DUHO3FY^3'A2==GERI?*%],U6GWTB.BE
MUT3?P&VJY*5H/.H+.QM2[LI\(OG<,U>GH7F:>51<P,Y-(.]MT=AM#CO)KY=2
M"=J8_>[S9_5+^R]I%_^HI7S@$%#-!=AV;]G^M&K;',0UV+<TVR#F,KPXVT?5
M,@T,0*JL.00O232< $,WXM_7-%L:UR48?'^EC_GZJ3!&7^8WR$OUPPW"3J#4
MGX?6?"-).KH*(^G[^O3=I[U+*H_%QH5U:ULJE_1,+BQ[OF4!R)^"+1Y]MP_Z
MNMH9QI!2>6RS1LNMU>]&!<>V>M^'DE&7QBW$>-'1-C$OUAF1(VS>^'R%2_@H
MU:<L"@U@)+%M%<VWW!IZ/)'!!IANF)1[*H>:MR,.80^6E4<Q8BTI=1-L9G.O
MU'FN\GO1!NS0WJ>E)U_YVP+\,+/WC.8-@1-N1LS]-W9E6I*:A_-"6;86Z,+#
M?)\-B6"![UMAA=VW])V"=N+N)PKDW_/,[@!>='BFK%1XQ118# _XF(6WV@,"
ML.WLUAL:0I\%,#SZ8U^71@< A &/I\X:?H(/;CW6M[_6:7> G]Q6'PT;)?LC
M?[PVB2JFQR-:+I &^#0$^_+E(Q1>A\B-TYV6KV\F-WGIPSTD9M;/ 1\ #X'=
MQYBOUQVP%G7SFR6+[8/U'F%3)4H%O'_R$JUSSMGI%X-O3HLH"WH/V,*!6.(R
MY+A5R.6YPT2:@BUND0GQET0TISB24P73^Q6.'H%S47+5LJJ?* E$W $JK A?
M[6*4>YE9AWE@/&*"Q2DYU3_GZQ^6&/*COU_!6D0P;]39.X1>V9*VP8B5&S"^
MVI*!IWG+\D?78UF,Z-Y/8MYL6UR/]CL()>GG=PW)Q^OT]MG\0*XI49"+$-[Z
M[8^X[:^I7\Q5!?9CQ'_^=GB_IU*1(K>9-3<6FC<>"=%B/%?^YI(70TWS&>Y'
MP\*+2Y\D4L*NME_#R$+]GR+?5)]$API$UWMZ^[+S_N[\$MHNMX'7QU/R#>U;
M>@EZ# '&+?Y+((__6!>(T'5U/[_OC^VSXF:%+**CWI>+.03"M.B7[T1Z,2#1
M!.+29#@0,02@O?O8")SC0[TE3;T#?/CUMVQ+DS7%A+XNK@A22<Z)W*'R\W*W
M&L>KS/QN+[MN>_ST&?(S;JR!E\"W8QH'#G9P#LDYU+@R[]P68PK9G,S&!YPT
M6ADI&NL>P'NH0"J(P-*CN>WFH*XV--^7$-<DIT(.,[0373P.TU>Z?)\LXSFT
M IYZN>CB)1+;Q,"IC-/$$(0.P#L!D!PMT_K*.Q7O41I]<G4_XZS(CSQ284!W
MX>E6>=J"SG#T+ 1Y)E*!M0X,.6QE*T=XO*X3RZT=RWF%H!]TX<]?QDBS_]A'
ML2Y,C ;/_V<[7/_EB,545%"K&;>=V[LP)G[].:/,#W!D$]B.R)F?M>7?G",@
M$#L%HTV<E1$060O1,D,+S%PNA+7S##_[^1>6OZ9-L [<4MV>3-F/>*%FU#J5
MP;!OXN0,UKS\T-S>D3RF@U3Y)DS6[$S"G!CTB\[OL<O5-#!,W,0-TA1 ,ZJ-
MWJVS>3N/%%7GM7*OX";,AJN]E\YE_?6NVEYJ]#$?O/R9N*AOOT[:U,ELWOJ!
M&5LA%'EA;M!6V\"+$>FRIRP%K\A4E![/99H/#R:W&EE"'P,W@XS\)[^&4F)*
MX^16EOMQ=5TV9S\NWI2Z TCH.R$>PQ/TWQ3FC-',4!=D4)P-+"5M[I@A[X5"
MZ'6<3<YX*Z.+1[W>3[O5_0;$R.H\#%E:-'Z.R\'^,%*\O^4W,K-KO(XM9;M,
MHWKBT'7'MT5; \MEL;VP3??O+;(:!K*J5>/L>6V3]JMU]1&^X[]7U?W];DN[
MD18P! 'OR$]'TU/\VY].\#>@H0[6G>S@4H,Y7.27C<1M""*P^UHHJ,P?6F;4
M8T<QW&.2%'/-&J6\:HB[#HJZ+BC=TD$X"T[8$0 M?2D6?-R5NY@7M!+V=/-1
M-;Z7S0D+4"VNR[R$ 6!AY<6]BGL'P!>77F?683]L'_F@/.3EB'-_U* =]>TB
M8@T7J=N#*<7AZ;?N?,X.;YQ5!SBZ1_C'Q>.:V(</%'@D^B44O9F_2.)Y1G>/
ME4_-4"J&XY4EL2AT%,P@A"^%+X9\' +]GWIZ_)0T&$FXS2[F MDTOG?/O"#+
MN?62A"]IDJ?-'XP:@1#H[X]\0R"^K+#@SX[]3+$"&W3(FMD7R=CP%5-_.DV#
MS,^^6F#1+H?50_GO:6;ER>I^VA$$W= Y8DT%X9*$-(VNV=Q>% 627!1_0W<Y
M5+S8(?=9^2'AD;;>S: W*5:!,/FPLH-I3MA9*33=RV4H,>Y/G4;M")8*#ST8
M-!@):G*H$XX8N .P/Y,T33ZG<T4Z&3J4(YW3+V6S=\,I+U(.CAQN5I6PMFQ>
M3'\1,N>#*%'5C$G2[4U8MC^</.:8*4-IAY)3$QH$;/A\DD>R;;;7595[ENK#
M<"W4)PO3^6))W7L)JB,(QJOV ]J,K-AR![HU+ZJ;9UARPCJW<1;&D51K$C8/
MNV2;8ZGR(E()[P"=J>CP\HX@2I-EQ-&P76I._2)]'"]?[3KR1FO<#2J+/T)K
M1?/=E[68UHKOQWG'Y^NIWNG).EP] 0E-;C,G9,B>3=TX"M_S8Y^-07BZ5)^1
MH&)X9LXZG*GM<=A>%&V:-\WHS_'H5\'I.5:ZK^PF:O?U5"*>XDG)7V<4PDK/
M573S[2+'%=Z0#-M(8IQ,MXEDW '>AA:*)YLP"3)/)M"#HFQR<T*(SXU9BMGX
M'2\Z'HD#[9@N*A-]J3_S'\AN8%?TC@_/_9SE*#M<"_B;]U;=_T%ASC=C\H/0
M2.&^U3_UIXHJ__G&F_]_4>'1[4^L3+@@Q;982ZM*TJDXVS]2[JK^WDPW2/1D
MHZ@BB@!%D@8Z)XY'(:-AN7_W>\5IF*8LV84,[A6(#&6!=<^NAX'7./)W ']9
MQ-A?KJ!>TJ12M[$!*.6>.T#RYO4=X+.1_ 3EZ=)FQ1N+R_#-E2#XOKZ?SQ7:
M9XP'!!B4JW60D&(G/N7\=S&)(MS]Z;D[LLKY3-',//VZER>E2J7("J\AD@GP
M3TR(5XOOU_H[ 'A('QSIJLO<-7-8H .7CW-7B\7SFD7$0W??]B7(LO9,)7'1
M&SJ\9GYU0K_7K&NHORC1\-TY='.;;09.8Z/P]X]T @  /N"PED47%<8;TQ/G
M4[5?@K<<P2=E]R0B*R_S<@,<"?S["X]O*J9&__TAF-X.1G)FT,2MCN\6G@5$
M$,]'6"PO->.P5.6S-^#*6.<+ZT"$4,;2Q&IB 7]OK&S%0MD?G]P!YBDO]TZ
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M(]:9/:TYTVC&H,V>LJ@@BNR8;%:?)V(:'NZQ RVDYB+L?0PIT/VH>6L[^.5
M?6&]#9C:[ODB;4A!Z^&HHJL[%]1R([I;*W7?'P3C[&CBA(NH/KP#))+> 5K>
M>1.*@$(%'D:O0 AM+)GJ)O+T[ NVP(MOL"JV>L%XT^>2Z#5U=(;6#_=4INR2
M;$U0& L-&Y*UKS+H"0])"A<B4B%Z$T?"=(^$T9GJ#EH%BI=6PEV> ->3-F]%
M40G+.KN:@D#8H1VET&55(G)$H*E@!SI7^[W^RS<L?'K'4@343[R 1W\J_Q*<
MG,<-'ARF'?BA664,8?*:ORD]A2#N *R9.B?$<;J,\,B6^5Y/JLD#</;AK<V<
M:R;VS.Z-6>.#+:=A?=\2OQ $].7OBB **55N*6HB725R,UJY+J5;I?R@P@$;
M(&/_:INAX)QMVDTQAG\PQ*H==XJKXHD(_6D@-=KE]UL )&_S9"N:S]X'^_,=
MP((-6;)8D6YA=@>@G1Y[(_>#->LI LK[<W6BO:S_PX>,LFUQ@E5L7Y["VTY.
M!G*)7[3;3>+^&M,JTM:+PS/_EH@I9_P?P%#S?Q0,Z6^#RL!=JF";.X"9$=C<
M! 7R'T8I([WL;A#SEXW[T+"+O;]),_1NF:#2.T"7*HW1#>O-#1\0=G7A<0I>
M'W%8[EUNZS-LU6JX/T\_>G9T.2(Z?B9=$U\2V"=9 A( C!3:O&FTN:R\PK]&
MZ,L]+0);G2J0-.$HHA%RA/_-C<2FE=U69!?Y:59U7WP5E%$>I\O*G)EAK3TJ
MYY.X.3@JB98N3D*L,X.L8U) 1#2U&^TYU3?[#Q'^AG+L.@\VGBAZ*8>CJ#R'
M)[0"]O85VZ<$\%_Q^?@P)J3*Q;X[%31A#[0R_J3$_?  +^(I?//?JQ)\F4=J
MPT8"Y.I@QT&%&42LLK?9.%]1%]K(WWBJ@DN?W]Z./QJ6N[1F0>]U %L1/&;,
MK0N.+%5VY:D6Z79ZMIU6:4X?<0=XA*J+%@Q9'XGPWFQ ,B0^1?ATD5;7^*5_
MZSV0?<>&''FFB4-=)!5,9\'J=QT&@)B8.13L7DR3QEZY3X^Q<Q?(SX4!5.+[
M.]'+O?IZEH.63])T"HH+!(?<ASEB<R6?K'$K>%F(LYG&414*BW^ %(Z]I'V:
MA?1I&EM+581MA8-)"Q]V4L[-T#>RBL0)F<WU!?]:.5K!<TF&(#)[EBG7[9YV
MB1(GIF W/M1KRF.EL@$/R/[2-QX;_,#WH ECK3TTYQ.W.-FJ& C3TQ J7>,@
M]'M@0.1E.7^$\^!+)&!8[GTN,T7Y]3W5:(P.GR9+R?RY:#[\<]RGI5@\/>8'
M1>S\4QDE8F=/#!3)_-A+:MF?5+A#?*OVD19@*XG\R8]V)R,4D5 ^.1GU4V$Z
ME,#\F/2]0GJ(GVU#.7.R?:&9X ?>2,WD.Z@_YAR\TAX>=4H#_H+^63J^A[#C
M+N^CJO5RR76%,3>J'3*E-U8<=H8:^%N_'-\&\ 4\EMC?26')>NS2YT\2TNM/
MT#&6A\T4*S0OA[A=&/A-O1+#]X/.PH:;QN:7) 92;+*L[B:3R*;9;BI>)SMX
M6*PHA<G".-CQ$1::TI(4EM>/W]!1]?=H1F*^/B=++66>^\J-X^<&,M<8$[&4
M"GI:":^]JJF?9$6L!$9[7S/]LU6L_XPU'HL*FP*FZ3FZQ[K(]TZY5:Y2,.;>
M'B2&]=,RCPYF&%V45QQ[ 8"9;R?"M+<CY/%"GPO)R&  N]6<;%S?L;X"X[[S
M(PFM\"Q5&%4O[UXRZQ4.D-2#G?]IO95)9D/[W+TAFELW\\J$: \T9W\'&)BK
M*WRE!C5U^EA#J0Y\?ID_2S/=MKXH]'81OY@LZ74$O6^8W_PUP7CK]ONINNBG
MRLU;JF.!"9'^VA,G=P!X"H?KEW<"/Q; S:*:<44:.%D 430]EXG\$[;V;>8I
M)^TA)ZY$T.\.H_TCEKE=QQ_!\9?1QZ/^)%DE.@%%#!D ]'+;77_*MDGW7P,;
M+\&1?<P[8E"K@AUW7=U /)_\8[;3Y5N'GTW;(O)+[^"6QKOOHSD$3)T%#8DZ
MFC_G?RMOZE4!%DNB,K?#AION-XTL&T=:(["[M G,8Y@M+3T4S=DP!J<JP"5)
MZY/XO>)O$79P3O"8*0D5*Z+#^;63/H?  >R]E)/0^;?U5 8B1/2]/*F5-*\J
M_F$_\[LK?1PTAL6\'Z$5B<B\^-*8Y-<1[+KZX)Q,ZQ/?[:O'6&O*X\V6'_8U
M$:3IUX_ZZ1>/ZW E>,>.($>K=0W*;>SC&"J(E*O]=5"W!$&/IKNW8;@X],&<
M"WN\EX^)/3=@A+G#UL]F )Y):(UZUG*C!"E:,%28^7V%>U Z)EOY(+MF_!BR
MEFACHV.([;0U2'P0+2$D)'5K,]NU>=+E?UU6?Q.1+X'SZ8DC&O.H>L[X2L05
MUY7F4%N9^\Z#B ;W(VOO,QYJF<E#&3*#V1_LANU[(@4RKX-5"T<CM"I0(]SO
ME@0G.4GT^A4E8N>I37]]!V:#@ASCNN.99HF)#,-7N*AW_-%.)N;G=I.TO/,'
MDIIB9TU>1WQY+Z,$@-/(ER3ZO&VG54G93%JQ47B*!;/T(Y+VO2E&6L,8ES1_
MLRF0'&B">/K6%OP3^JP-6:%U$>&WAJ>N$B:\,9F7O];/(4^T&SD2!A)%<5>U
M)%,F6_56#X'/[P#:-:%]VLC.D3N ;T3F>..A\KI1B)USO>!ETLC,%Z)LI%[F
M>#NX/%+H9\K_P]U[AC7U=?NB"U%15!"DMXB =) F("4@ @("TI&JTGOO)0HB
MO4N1%JFA!Y3>>^@@(+WWWDM(0G+Y__?>9[_O?LY][W,^W&>?<S[,+\F::\TY
MYIQCC-]H$UL>^"''Z$UP3L"31UB4"*CDXY$62XY:8)=F8HR\0P'&8<+>@P=J
M8F$:G&G;NW(D LKUZCS;Z\J%2.S-9IAU[)O&'M[63<L@N-%(\ ;)N:S4('0Z
M[LX^]PZ#  4<H<:,>)!6E,$E'Y7HY91V%H65J",>S\S09?C]P@$3*@G>C;0"
M:7R/=&(W7-5__N335B\FNL,4JV" 8-.I1"H2/["4I!K='TRZM5[)9632\WBA
M+#ZVI]N([\*F[Y3^AIVZ6Z(FNR6,"Q$YW];XY)Y'PL@]S^^3A_GAT&X=>-+[
M2[AZUFCFW)>\B:;?/AKC\$HK 1>^22)MH26=ZY-& [<P<<M_PU@9E.N/I",N
MV#-4B5\,]ONY[5#N?<GF!=:8.2SM'1^9[\5[4,%.9O(S^B3EC#7T"R47L;1L
MXZ")PN&;AW9):DZ"Z;ZY2P1C9T)_$#2R- @:CB<1M]3^2N!;2E=0GG]3$7?-
M@'[\WZ=(DD>[+9?<Z.DUL*&PWG;45*2*SB<;<?CP/'&]DUP1H3OJQB\;>579
M0Z_-+D-RAA^K8R7T(>AO+ZNFRZRT'77<LN6R])^<]]DG@G@L%CMZ QF!N7WY
MQ@I5;"B\B_1Z-OJ>XID%>L^/[9+VY;:K[E^^0TX?VO0U/4;6$5,8OM.S,C>O
M_$(A-F%_(7&T">SLV^BYIF744VL64<G6?Y]_C PLM4DB_KFNQ/D&4R:U=BVG
MK(*Y,8U!+NPN3G0!KS)D8YRI#0(OQP>JXN];W\_N]\<&E*2*?>0[]VP^^*SO
M9Y[F&B;I7NJFH-CSW,I3?]F\(&>6^47.3^/)^*_\=-T9U]!P$Z)XCM9/=K#[
M6%L=HW"_D)[.]?$I/'7_] N;T<+:!PSSH<U8T\.%/G"P?;$9\U4<) :TI$V-
M6*?""I&+LC)X,I3BT]]7O#"^S B6)=,1W?IO]WS_G]+^K_30DP(]BV]OZX0(
M=0L^8#]@H9T1^Q@!H64(W#*2\9(L6N:,]_!@?^^_OQ*DMID]4C=$:ZB_/5V9
M\W!67IRB^UV'+94#:R:BK-@_8?0NFFVSTB)!Y_Y1)4B\V;U*J6@;!\C0;49'
ML1J@[&#2SW]E.^B+A6:_DQL_UEW$ 9\O2JS9B]]@Q[,RE(/GTY?1>:;2N>+%
M9G4N<<YRSJICXSE.\H2VD3?@/XH2M2GUOLQK%7,S>3!E7:E:[[HVW]&?^:B_
M_JCGJO6" #GNQM'KD^YI0$['?S4]T:R1..JJ/Z<6'$O!=,!YF(V!$.Z>-M]_
M9X4VC?'+<L+8BQ!,:H\49@5=*SCO@6>WN$U<BO_2&OY'@2>U @N/]^12VPH2
MM[S6RX_J6[W?[-WW$'X16,#8A"!:NPFIZ)1&!<AZ)75&TQEY0@UKAVW-+2OT
MV=\XDXN@7X5YL8[=$-GK\N/\%-4[S_>9RL%]O2KM<-*/T[#OY];VH&)-?NL4
MZ-46A Y#6:#R)-&F[\9KO-+%2P54IJV_T&;BA?9%XN_9&56ZX=?U<;JS_&5G
M-QUE?<W/M?>??53#;G;*"^W_,LN3_.Z0/P\Q[YY)F6)Y_P6=O_AG./$1.0NA
MLZ._CV]RP?(*J[F?\#(D/./1X2 RY6+O(APQM5NV"CI/W8\>DORSPL"*7%OV
M<_!]8:7\9.PHA&CK]47,*0[X]-G(A3ZH'WH\9'EFS]'OK=#-WX-PS$9-Y.0F
M+@FEC4$7D(Q#C\CKV90%JQ^)C_8>]VYP[7=^CRY@+7'SIT/:+#N0RO$P_J1(
M9(WW\O;-+]^^NQ8\3&.>#CY7NLN5&<0*.IY;(06/471K[/^@24%K7B-A\3[T
M3BILY_N:!6+=)HFDPTGO;?0 #H@=/'+2YTS')BPV?_4GGQ$.$4*>%75N] 1R
M/Y1,?K.!O3EYGH_Q6MD#&0QSGW+CJR8.#E)_^6*K._;I#L"1\5T4PSFX$KD>
M:Q))/5=#F,V,)1^QP@'$ON\*\M!^I&LZU/V+LM"\8P$C<E]W)O*<]/ZUD (U
MD4ZZ 7+F0R4[\1A56GDN6ZW?782Q8R1J$WC=Y+E9EB^@(?#(Q 1K>YX;U(1?
M[P7=O*' 3)3C[Y9J=''HT>:R16.*&CB5$PO_<X_P6:MNW?48G9!X.WHCL#T6
M$VNRQN)+;[J\U$.P?DV[->5YHK7WE_Y2,!'!CF'4]T.-]L14/91-_<8^-:8"
M''!R3? _/D5H);(Y-R<ZF:KU5K#T?..=#S^J="1>+UG)9T+SD*KM*,D'7V,M
M[A'%W?D,06^N8BO+#4HNHFPS>Z?:6=K=S2\I,1#%#5[?=T5&9J^6YX@/VYYC
M&VVJ,D@=<B,=J#:C7]4W5Y0;3NCP=8C=ME<=]H!SC_-T8LO=G$MJ&63*RR/R
M%_T_:0G_;1TT&8N/NR:?60U:M.:8^5BZ-=YJ!EKBH?:CP,9/P;D6ZI;WSBAM
M=AK!Y#JK QTJD28./LT'.>MV0L]_+@Q6Y!>Y6E7W+\,WS9<H]H<! +B/-ZR3
MA]0>F:<GFK9<U$S4ZFL2M5?U/AF0;/-3/!:S<>OC6SU7FTTY2]5WK:CX.@^N
M);W)@"0?BHC[&5I,(O17=:$?__VEI?ZQ:;[(R_AY*8<=4[AJY]\X'@#TLSY)
M4]/]DQOE/PO(W1.H;7DK%B]%G-6  S21M5GONG^_DW;R[?5'+3V\NKMQ6I@(
MH1:<8NY<3W*Y@0.\A=^!9<(F)@<GRJ&5P2XCFX5ZVO /)5/W&E^LL7Y),_,N
M.'U\3#Q>.JZL[Z+<]A\^ZLRZ^JKR:IOPVI4 \FO<^1;\2&U;[PN-=JH3Q'7F
MP^=[Y6>(#_O>.D,IYXV%2(2&U1K+>XV0S ?'KYK'4!EG)2]\IZM-3?0:+!$I
M;\ZI_9F1ZNR$$*N#QXO?@KI!4=?'RUCAB">RU"EO^]D@<B@I#AYM"",XA6<D
MR3A+6GT#F0W(V?+:FNJ'>XBM,"8L?Z1^O2EKU2.[F5NPT?X\D]VY@&EKFW,(
M0W)$-*%^O0^<S^>GCV?O]PF&!9B=41]L2R;\!D?Z"C (V[A;@.?B/8Z+S504
MIA'Y, JXBW?8.C,R=$FDE;M8SM'IN),)PE(XXJMZF/6H"BO?@J7UV#BY$6TA
MV3K$L/%!UA%^9-'.'IEW='(UZ>UO7J1P%"X-[/X<T]VH>PQ"T8/-)-O.8_;=
M4:5%%EE;Q\;&;YX$\/7LJ[XG<#&2+L'H_]F'F8V81/4"_CJFQ(P,,%'\K>B.
M/\24R"Q5VNWG1],Y9;HSL-EXD.>9270+,:RV\*&N_DS^#!7WU3JU4-9J3N.9
MNY<(9CR#_IC;.%803-J@<S\3!U0TM*9]\WP;B#+U)]_,($(F.90.,4 +NA*K
MASIL81?.4.F,X)DT;,)&))G]L^YBB3O%,P-<>!MZD:4->_38;SZ*6H+6B*>T
MXA%YV4(.G2!%-2,0<>?"P_:;:K1^DB]#R'J8[=]UTZO0W8?F,B)+EK_CW7WP
M@[6N!0$JX2WJOS!Z<L]EUA)^'TS28,%&JR>(TL_'NHZN1--U3]$$=$F(AT"0
M\>I;^EZ\#5WOOC*(]?AM7NC=!4A5 #B!).M1VJ?@\=[ S4+BS0K$'XR"8SV/
M&QH6<=@-H_V\3<1A\+%IY%F&TY<P9.0!A6?IBE%-W,BX3KB2NLX=1WOPM,G5
M@C02*MV?P]?U++8P^H-JUB]GV\O[VORE3^TU(#R!-Q5_%I>OBVJNF4;LF4G^
MB+*I^RW)+/OA_3#R\ZH7$P[0$G=:[96@(L(G-L(!>LOLU.1=U#+$+P54!#;/
MY":YNDHI],00Y=-&&+.R-^'T'.LFD_T[UR)'5P="X2OK$FMA9F</RR3Y5891
M0&R](RQL=I-"$>K]U@J89LV6?)PZ#8[&W+C73(YL5QM*S9_/E\BZZL8!""?=
MXW?6PNI>\0<>X$[F[^#!ZFW+$AZ+Z]$X<'W'+C_2.BO@#6)*WQ );7;G/((4
M#)1&.GM7V)RQ8CBP4%BJG(6[MO,SODD=&<K@RN]-ZTD>@;-M+?X5QI8TI:G6
M/ Y<\VQ*MV9?;_O]VE-[<9+RBZ\DM$LK;RSKTGO3_+<L^>?U6][@=L$@P9FK
M\% ]QT$_N6&"8Z$-\FTH\>D6U^G3F@3%RM&#MY"ZVP1GA>$2::%*._[[XQ[8
M1I6?86R%DL/_VNY6L%V77A6=IYIOF/CP)9YS-FL<@6K7E]);O9PA.""H9"GZ
M<L<-!_@_ !U6-O#A  G[YH/6$HEO:)(]IMF]S5(F+$7U5_!&R<054A#2-GZ(
MP)S5X8#FV]%FDJU_/;'SJ,.(8Z1!P)ZY.?DR$EMZI\L0&S@Z>Z3+C]$]G'ZY
M1VLH%L2BT=NU,FE1Z5E54CBWH_=MXN)G4HKVT,^H%F\\/?4?JU=[).2<S(VC
MOWF:! P%<$"6U<,LR*B5TJ-+/#T:U2Y.A3S=2D.)DF]'&R_1+:A2@>@\_X25
M,1VE3)7Q\N JJ,MVJE*]SX[NOIVYPH\8,WHB:7(A3][V:PP>?7^NS\[W^'GJ
M,ZZ7D5W"NU(7FQ!BQ5,P4F^>"@=D5!M?+$XP;RKR]!AL1NI6NKN?ZI#@@'OZ
M[:"3\1TLA@:\9.-I@O6>@RP$:NS")N%6#!L.LD[_2*@BBNL#+Y:_,#.EW^-H
MGB$;B?]2:E;E%J_9W[S)6)9,D^(?4T"]B#N;PUY$!U?><[B'-!0?<%XQ$<\/
MYY2MP907NGRGC;J#+GYV][T.6 'YR*ETJA.R,D2R/:&7VO%#EK[%Q9X?\2&V
M?7_[Q7O\>MI?*0@DQ.8*CE;PC#L^]IJWD]2?8F0Y25-8#1(=ZB7I!DRHZ+]R
M;EH#EQ/&A\;A3<1R\X\/AT*8ZX9+2F_^G.I?DYJ? 7LQN'?SE2O=?ZXB96#J
M _Z,,3-9@3^0+=;M.DSOX@P!Q9/]N*$C0?4^X,[VG4WGVW-G"4VYL-E)0\2Z
MOD''<']JR&S$G0^QW8L9"2?5NW/Y \1AE27L6N*ANYWM? 2.EK,<GP?Y0O7%
MW4$A! 68-R,-+B4/>%4/_7# )/?:B?^"RWI(E8F)_ E@2LT8W+,S1-XWC1VL
M>S7OBMH(J;1!3YE9T7A6R=:+I[<&QDWUL(IOP%QVQ]X2##2Q'%:'-]V;E2Y&
M.KRK;QBF6.QA)E)-HGU4P?4[L#*0Y\\)0(<#7/>&ZI$R'67(YK9$FEV* _LD
MRXZ.5=*(8JVO\FJU*L345(NNI1HKZ6>-L+9(1>K5&9;9F':@56SV-3SJA6\^
M JIJH 6>P@'**8BEN%G%;FW4L7Y(0'Q,MJVG_8OUYUL9=U!O"2Q6P!3OD)QM
M%WI_EB^;M"G8\(.L<E@)?T [TDR#[CLZA1V!B)$N76!:YA?5H95>NPWB<>M4
M'Y0+V.\[/U&!LID;"U4S!*ZW=C9/$YVCM8_D@\59S&A_]6:92C^GL#)SH;E!
M!'!6+(5B!4;3T%4),)GLS?,79O5BTA8.] UVC+?"LH)N+N*E$2L"1^DVBX^V
M*'# M-&=B4HV(1M3\U<99MK?8B,+GMR<=*IQB7'&X^"W,5EL[I@YH);WRK'Y
MR9Q2DG7YN[^@8HC$EBX(3UI=TRGB*YVCPEGA9;U^56H;J&(O:*"D4)XBVXLL
M-OCCTOBBEWJS06!C[F.&+T1\GZ5 KW_+DN&IJOVIV&.8LQ=2?CG>==LQ0*D@
MD84[P"GQL05PM&O3XRM]E')@T$ #:C=\X:=^A?1!5$L:6$OA):CP??V0&'.+
M:O69*$/Z,OC>YCSW:';9!!=VPH8NRTQ5:)0(#UA[+4&%=3.1&SYM)K;:^I"C
M*VUA77,URQZ) .Q-_J0"9E$*B*>?)-VO,F 9.\O:)4XN @/B=:YPYI]\YNX"
MKQ28CQ4D=K92+L/_.;3+3^S?P#YYBZ\ \OOU@:=$:V!90-=K_9X/TC>4VNR/
M \XIJ:8.QNM1 %LQ,:UG*O;AP1WCG053M/&4>/.L5X;1W@B'WRZ=B;NW>\ZA
M:FCS$M]A4%3C.?BG7U'_%>+[NMT,$^M\RZ#[!LP;6(18+ERRNH//R:)Q@*S2
MNX5?S>%-,]ESGNIKS7XFJ:E&+]H&3J((#NLMF.-\^XDH*O[Y>2,!&ZM"3]HW
MA]'1IX'U>T_,7)XXR":8QA(* [<\42[UP4Q45 ":-"PSR^9?A+<U2]WR74&_
M0M;OI53"@KA3+[1U:^M7BHN;GQR#@VA%;P:NOS^NW,>R']UJ#O+ER[=)DG%U
MCZ6\&R>.$']BBA_9KVE!9\$:=DG[=A@.]R7Q6FE4FQW*MUZ^$VJ89=C'U/?T
M^>?(5BD.IY@5.D( I;0(P\1QW]L"8Z/CZK<7_0DA/4^&F^)QP.8E9]-_?Q[Z
M_VJ.^@"X@B'=!W)$V#&M-R!BR/.L2Y 9?[W74?EFKUI80WJ4_G^I,_0&*9%C
M_0+264*J7\^^%$'=ZO&2[-'-3RZC!?#BS3N# CKA-=>0@NR_L<@[;XBO O?8
MD(T%HY(;R[MO)XRH:UYF_+S@@WVG64.0KIOZ"M-A ?>!G7THQ06)HOS;J+OD
MJZ>K'I'MV>3OG>^(/$G_=#;-&3'J:[(Z376P$F>EL__"9)T!!ZR\J3VJ[%O5
MUT-0G3GKX@!%;?RJ0IWIQJ\IQ-.E:K34DY(6X$.2 :^KP<9"PU4%K\<:&#;W
MZ)%?5KFS*E=$L+='8P/?1KGD*ZJ5/^, WRB(FD'EU6!!4?Q59H'B$?32#-0-
MC=E!CI7IS1I433Z.T\"VQ>N-SS_Z8_],CSE(U8L6=3_EMZ83TE5T(RA2=?DY
M!@Z;+4&FG356:.=K/Y;S8DY;SRLM-2:0MS$1ZAS/BKVT-/C%,V;@$J>P921:
MB%Q6%<H:97K[:64PQK2ZAKZ9IJO$$O'N9UK!A\6L"L/8634C W']DJ]SYPOM
M?6\@')N"8)I[J?DE;GQDC)-L-=2$M=C#TPM0@@F=EJB8[2N^;ZM[Y;O^!)%?
M='Z2'/]Z$K@O %WG+"GV-!_Q%<CIJ-8+*FE@MAC,T))FE.A2%>K=Q@'4XMPP
M>R6YVC$SNH_SW$70"R@^PXK0,/I7ED:$A[L$8=@AM_%*< C/Q=,$V)35IK=X
MSM#C"RPY*+:46/L(%"*TUZX]P5NJ5M>Y[N4$1=Y8]$_@*:'":* K<<!G9-IQ
MEWK4X,9(RE ',:'EK:2W$]RD6CMD#NO=DH6U3$=PR3\XP));0E@^TS+)HV18
MR?&5PEE+#]-.V)%I50"XGC3:USPWWQ,C+DDEZEWO?P\SZ&4"G9(Q4<_'$[7/
MR=BHA:G)>FG$IZ7EUHO0UM<3LA75228YE5B?U[EE4:0L2X5W.6VKEM%!<YGA
M/U@\3'6J*VOJO\G:W?SUVIO94A?:HJ.5Y_OLR!U6F:3H8SET-/<L''3XZ,0_
MX33A*]0J;SJW,KWA;4<80/+#8&6"W+P^^XNQ5<8W1S[TFR-#X46M]@^5RN;,
M9TJZ?9"5@>@UPZ_?#Z/;]/QIE!3@!A#R_AQL^.?+L/W\DI67:=[T).WJ4=VP
M#[E6TP;^1E 3.^N:UH>O"J#=6@7,KS]ZF;[/__2+;Q/(G#-1'VS5=&->U&%9
MOK(>-WRFIV<HSU0?_4QNZE*^YJ+352-O@X7,+DN>9,7&D+-3+[1&7_IFV/.K
M+$F&-Z[<DS@ [+T\]%EE7PBO>IX'DNXNJ.-:1N5U\"C1]8.P>T0S$=)'9?B,
MRL'^L:'TBNA=D4O)']Y7+D:Y+BM%@A%^*=/O3)E$?-E @S4TY68F+OFS7A3E
MU,Q=CG>H&&J%C#4SR;-^\I"\U0X3<O#5+S(RY6K[R_KS#")9&;)_+.IA;BZA
M1!=O:)?TF=57:&^D"US[<!8BT')EDUU^.)A@$I#8)@]""/=#VD]S=D9@.<JB
M^K,G1=Q/<,!;IMVJGZ]AR/(@S!#Y[RE/4HMVHSDN$W3L \2)./%X?<RS9R_4
M#$XZ!_8R%>_T_#P<_^ME14S1*TGK8#@HID0X3/2C98ZLY>3[ NJ;?NRG.F+?
M<O:GM$7U%_#?]:_M\3 L@-ODSC"B!&=">B @W]&\F<6G4#X 0@K)=7?5#B=1
MXS3(T%0?=4V5X'A$7ZSO<I%V/' FY![&^73&P^S6_^SZU7_9 O:/I]OF8'7I
MC*'>O](@J &7.(S4[]^]G?2KV^ HD:]@]0>LS-7/BD*S%::=%=*UR(-@GNUR
M8Z8DW*U?U1U)W2955T;/2J:M9NNT"O[HY(T2LF4%2OT/>T^!\3;*/_G'_!SB
M+A.C0A_H!UW*H#&UI6R9 [6\N:4!/LH).>*LY&[")<LFIJ@ UO ."YO>GC\F
M$:KX/4"]V=T2EOB]T*KHQ_6[_OVV=><,MJ//(_:W4_.DJKVSV<RUP?6?&(*&
MFC],G/9^^Z;Q+3WND86.K.?IL6?26PC_04>2&A_VGNH<!]JW9D!R_*231O\R
M,>4TZ3U=LD-P,NV,TZH_%5S"@HJ Q]@&*>9WSIGH<YS1*.LR3W6D^0(E_NBE
MG1#;;?,JD[3H _;]YK[+4Z'-O)0Z%K&_7&EM81SL]B6+0ZGB:BNE%_AD>-PN
M_HQ'@Z%+U<_F5$;F($,-@$ T_#%QQWH^<J'+T;*.-O+Y_EVWNZE](7+;Z^)G
M'R73);KA;&6' P.7PCHC9?ST"*<^/HD!C@3+#TM[3J1KQM^#% <D7W,V[Z#&
M]HF[?(R%\653^X;F3[J<3A%GI?#V>?%AC/SC@&F+KYNG 8[DJ5L]!"=#E5[1
MF"?:M$XG%MN0KI\'&%Z)))1R1/$;"\?65JI]SI0HA\1EEMTE,>'YS8$QN.I\
MP>VDOE-;U).P$^A]C.HHN.RW$+HJ_.V7;[8O=TWQLQV?$<-'*B%+ED@-+"07
M![1XX #"?=>\]&)7CECK"S$:SC!(6 :E=DM-C=/V8_!XBC\G\OV-5TFO4'=>
M8"M\V,^)_\:$CI##:G'AJSX<@#X&(PLCL;Q(-Y5;53G8'5*(3O:4:IG/:P^Q
M!S;ZY<."YXW-2:8F06_Y!^<2Y%V,G'R.Q/1JDW& ^5;5^+"[,/,O:(L)2!$Q
M7FGEJU/B5\/<)$5KQPA95%4GH)900!&-(2O,'U.; 2BV :>/O^X_)U:$&S<?
MRD?K4(=W:+H>OJW3$QX>KD+&+^M;:+A9F'A0H=O$LT&96R@=R%(S^=;\T\^1
M18(Z?!%]=KQ$&=B5A4N=[Y(1?,?*0^B7^5T3*3RP6V?-/2[X]NK$I$3;?M&*
M:<\M@CJ;])QUT,VWWSAY[C(G33#N-Q7!9GTZR==4C[R1L6M(JV^02C'058R6
M![*Z.'U&D J1IY3FG[#IPPYY<R99+7,9NU.A$]G<&4U*<FQ%$0:9#I/! ;\(
M/V/9D>6I3[I^$V3-@,^L_;L,A_V<HT\8)K2$E!5GY$<MFAO\8E[6)T?!AHF=
M/>&4D% COO=2)*4^X4;0= MK2>8C4&A6%$(SO:D7OOZ0\6X< =WG ]7)F7="
M)B^24<_"$\[IET%4-AG<-;$D&??HENQ6;'G T^ .2#=Y\%6DJYR'//0B&JDC
M8V.ZGR7FV:2U$@440:<HJ08WL=_!2P8)OZS)6+I7L]?&#INJHSN:O,D6>&%G
M2"H4:ZC0P5T#3AFFRE)_3[K]R.86=(1.O27-'BRD(J3RGLQQ<^^F*E_9-@R#
MT@F??=='&BL(85R1D"YF5\G.>]WSP<6-C-]W\JL<_E&GJWJ)*AF<HE$;872/
M'RJ6'1+-U730C_H8=NFU[Z9 :3/DV3Y<3P-_7!L3_4RQ ^+#2E[])^F$ 3:^
M-'HBF6,3\C#F1"['[=:G3JGIIN3PVC-:66.-%]$[QKR7ZI A81S0I,R@"3T9
MP $'\:K;?9>!.THHBU'>965"+J^4\;3O6W5;!&?P)\B$%8IQ(8J171[RBDF^
MVNSWVA9GW=L$TLB4Q2J1[9)+[:[(G,K1N]3"CRXT3U$IS 4?EK<'-B/XJ 9U
M[7QV$P^Z!\)ZUS\D+W^44 4-IJ'LIN\G*X!V8VP:P^4C> ],/_I1?E;U8[@A
MJ>,&3O=T7H[@2(\?_8T#C#\/YIO;N;#)>AD;'XN"[B'C#MI0;88O==M>ZX?X
MO&Y$3 Q/Y P<)2D97+XP7#GK.M="N3ZM4;9X]3XW(!('M*UD^]!T&#[9JOMB
M7 0)\A$LI[+5)-<\O6-.F.)4M*]@#STKWSSQM;1=IK]#[%&'_6S]I9E:Z"L.
MT(#IPM#HF4L2 ^O-.% C?_2/@3=US#('_1N;0-%Z.WPK5GPY  WYW"C<&?U(
M*3W2@A(=LW$9K_D4&;O<4[?=*9\E0X,#=FL+^W+T>+7,4=5(S;X/UNF/53LL
M+D?.3[5_B\(R-+8\KKR_K1_=KB_]V'NB59="?6>!]K5[C.BJJP2G'%L<U;@@
ME=I(PI-7Z) B[&9)O00WN<R@,!^6H:VAOT\@-SC@V^ENDD;<9,1\81"+9<E!
M]=ED5U9=0B39!S6ITQL_,KKNCJW=J+[X]GXB4#5D2U3/T<JC<; WC4]+[C _
M=<_&G_41)/=[+JD4&06Z)<U?2-.RFK6H _P(2_Z'GN>H],U#_3['1?L;S%RO
MSUJ*V)=*[(XB>7:@NMU8MS,RIRC7L8)Z6/F&_*.H7'2ICN=6Y:"X9;Q' EC/
M<7BF8=&/$@? #;,\P<:^)LHQ%NC^[,N4=-\'R[<';1/\?[&>"D'>%<W"B\V=
MIWEQ !X.^.2X(F-T07!HC&T4L8SU2, !C(;;ON )JN.JG;,DS"T5*)&0>ZM-
M. L]UIT9LE+1V&BTIB^4)'_![$11%3LMI\ZOHJ(@8>V]\ ?#DF]YW/)3T#FG
MMAV1QDX?)<M,8]8@96_,UZB/X>Q!K']SA%]$'?N1"/+[VO/DI"745[W_;<CT
M;N99:P"XU>G=A;?V[Z8%9@\5V&'IF^<^P25"=UDIT+M684L8Y3NBG04L,Y":
MGCN%SF3XN^Q_MNO  8(UKC,N$'.6>L[O]\0<545:1%9R;667]FCH;$?V^,4J
MI*-WC-:2MU:I0G/9>SA1LT<<Y>1!JSA@VXXU_JJ[!ZNU[Z0WTQK]]$XVXN(A
M\9KZ[UY71# D!;:$ VX>O6X0*!F(K#/LQ@%^A#A 7&NSX0&\;WS A '.@0->
MVDQ8PDRRQ,'!QF2IZ.;N0Z54+SL>T^IT0B5:<C.)D/RBX0:C.CML5CWCG!-E
M'W.A(^TD:F6\7)UMA>KU'_DR. %UQN],895[W^%QHDOM0F:L7KD,Z<:;SF?U
M2\K$:!<=W36YY[$/3AXZ(3Y 75#FQ4I6-UN"(UVV;S_P\">-:Q5LM;)Z&/;Z
M,E:AQ^5J]P*;4(4OG!V>Q%)K-G5VRI-$I))@QA&G<N_HN&RS@7H)66>UC?BS
MZHXU+Y5=NJ(!U>9.FWH\*P"76*D9]>S+WWL)OD]Z^82JA/O'7R9U,D_L,IZ&
MFNSM'I8LPK#M<=H9*^Y2IG>,,79F$IU*:D/BVF7BHR*OATWC%95E#7<?L',*
M#+A!@B?&CW]M?3%H4;W33SYQLH@#,CA)?+E+Q9MT1WGPSC@_7YZ6#KT]4IYK
M3ZB4?&48Q8_8]O$G3Q:R>_5\R<\)ZG47E.![9<_8_M*W3+ET(T'CZZ:*04_-
MY:--,/':(Y:N,BTU%=FZYPK@/9(NR81-CDQ-CD]D]P$"0(<I%UFH%?NQN3U3
MY$2JU3A_G[-46^=MKPP[]4V&.W"=6U'9X<%"K%4[A6)E2$)/D>-18\GEW[+D
MDZ[_,M+$9?Y%5<9!JW<:Q7"/X& 8A4C,+^'!1F!U0D96I%XLM*@() !IXUT&
MH?"L(<B[K$@U''"G.02R>:L !RPR0Y>,W_PV!.OY14B6UD/_/Y^4'X>^1]7M
M^_:P?JV<-/%B_BW$'(EG;E[I2$:4D^9:7(>J^21]TY3AQT2(Y\K2W'RL&S<V
MX=X03)2K.Y";()^I#GU^L.V6&Z+N[DWR0KQP<Y$M.U?5RL(%XIQX'J,@/NA8
M0)/(>EP:B,=MQ^-@3S$_,J\?FBIF$GJOO*6GA6X\&/,$RX@#?E# KKE!W#6K
M)F[' ?C0!U(3$VA]]>_N"01/6':J9U'0OH6:4H5EV[U'68(\I4/?FY<HCXBO
M@$HPYF8\A@T'?#'N )_>&,,!AZ2JA_ \RP+4Z*[.GPF7=0>D+.9:I9#B5KWF
M.,S7&MR?0T2P4!^$W$I .=N:KR/)2:!^ND8+[ZL"LR/GIB*[N)+U.,V/^,:V
M,+92$\=_R(+#7X=3^/U: B/(C\C\?;:\OY6X/.7W[5X%-T<C-7^6<Q7%$>SW
MP#-=[5R4CH@RDE"R&,K$DN@,RL$1*3%=-^U6:HT @>[L=\.GS0^WACX434I[
M64]=S?:DYP0(LV^7!#BVW[0(-+("[^XM3MF;)8H-F,_1]W&I&<AIX8%=[2/2
MB-+B_!1^/%@(62"K:,:W&FF_669D$WDL:PJ'<L40;4F):K7>)+IG:A)1=@R>
MVKZ[Y\^R777!)Z[1F=<;)_\DP?2#H%0 \>/ +LXQC,2A3ZO__887HUX7_-/8
M2QXA]K'<JF$%7Z (85 F,GVG2\#(!_U"3SG?LZA#[ZQSIH=?JEQAW2Q%.Z$O
MB4O%);GQI!Y.]\DG*4S(9X"@/<D[X6N\9(D;T4#B6PO?6D<8E;;X#569D89L
M#63Y$8,Q)YIS*?>L5&#=KW!\V6^.+[(P^6 G+2IY8R;_!_&W8K<^!P;DN1 R
MLV3H WE.[I.RY^MLTCPR+_N)/FY8<K7$%4J[/:9!)2)VH5/G"U-8^<F&7#1X
MZFCMTI/6W22RIHNOBS/YZ'KO"#;367H\&["YL5U$0N&18^<Y:UJ8!$!YF=>\
MME]3M](1["X4SQMNZ@U&BQU4E:6P/^YAAJ<V.T>DW>HU!0BX$&G#!'PK13/A
MS=,6BE^MA.6M(+!VH(7V;?)LU O,( )J_$9GI/)$IY.J!".!EK:BZ9P;Y,Y+
M[$69K$%GLT3DMN)F7^E_7J!:@>9: O#OS9;OUBN123D&^KV'0Q3ICQ#,MEJQ
M7T9BI.D"B+U1YDWVR%;ZZ!"LZ*8>^_=S\HJ?=<==XQ$-Q8B;$1:F82[=&Y-A
M $KNWY$J<7*S!?B2S3OI*N!:?OPNUQFM/*'<W?@K^U(=!Y090%'/.5#N?T>;
MBQ.<FV\M0TO@V'&X/QSOZGN=)VS'!@=4%BWDXW]"3N  YG!#E#0.R%[)7H1B
MXNCO86?^LKRR_8N_\/'/KS6J. \3'/#A-0XXU:P$!6(XB2/^RG.BIY$*L&)*
MW\OQ]=\WRW@9+,)\__ U]70_@5[\?^TT[$MV_8-LIA_K7SG3;PD(T-=@R.;=
M 8:D,.FKIV%>191O$1-^Z,?V:PKUD_%B3I\V;C<Y(]NSYSTIEQG25]+)Q6OV
MS4@EAU_>"T+WSDA=FAIEN^M?I!=-P1M<<F=\Q>.[U(133<ZEG6@HUM++*)YS
MUMLX,!(;PD0W+?%[)9];5V=P'V5$'Y[(7ZZ^4U>*_A;#XG2\WQ9'SL02>C-"
MM+MW/!A!3S/4OG!'T/!)ZW.]:>-V4D<\6UF>=V4 EXJ"R&J<=7.+PX-9:^^O
M!2M['WS[B@I,E2P\6V;[7;A^V+7TB$EKX ")VYPF_V7B%7C_/',=/P/B5M5+
M9CW*$<@5B,5C['^#\)7_UX;7@1SJ_*DK9I7BDU##=/&+*)_XP\'!S,[HP-R\
MO$5LN!A=HDF<LN[8ND^D]KZ50..ZN^A93V'E RATY<B-3R@MYW2S_I9[$\G1
ME_,)OBU41)Z2!Z-)[. ;BRI5V'$I1]C]LLF49.NPW&LX<A-U(RPS:RY\CJ(7
M(F3J_OE^D(J_7?9C]#K\#S2SS=I)W?#E]5GX\?]_NC.L8/O9EKNRB[#(DJ:;
MR984)0>C"_[SWX)FC?CW)U*V]?ZLPQBMUCA!:C1I;,5!C956S[G'6'JZ?C\>
M4 ]_[R-$OD$C'U)Z.D5N.*UO__6Y:,OY:6FA Z65&AL[<UR<P!<9Q$98*EZ]
MK-,$@[!)K)TY 5I=$B*-%4IP6D[76WEL<.?;>:34E?=H&4-8?WYN\B<"=66+
M69MIPRK?OLE0^I@#<*Y7Q83 ;-76>IS&]J[J27YH2T]6BWM*<(2=T;2EW<?D
M^LRW&X1X3"5.;UHU?ST$J)G/\YF;*D-(3V#TCBY&\LO-Y(;(L+,]KJGQ5B)R
MRF@!@@/A4_JB(N*@!)W26/TJL[VM^BF8R6_[!INE&87[SM9.OX@O5XM73M[*
M[V@+X@ RRY2< #$).=:8M)NVV8]VJ6[8=&HHQ$1GR!K_&'BNS.]*+4<<K?+
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M,@W(JJW63]9[CB'.++#,AXEJQ*49IO#DBHP%?ODS*GJ29QA]:09%/LQ&/S_
M>N* E7:,32Z:&X$Y3,(B!4?O_UCLP@$7/7 ?-(2J.@ -O<P@0/T*Q%KY[6"B
M;-"2UWV@_6]M>8(QY=9;U/1R[W2)G92SKSYVE"PV@TY8KW3;7=.:B8]%A\JN
MMQDEIN <Y3O27\1L'SH;&[;)EBOYI$.1FRT'O2WB.$C#K^YLQY-B+<2D&_.$
M38L>@*G)>G+7BC4.9:FI:>O?Z:56++O)\&.<93R5XXWO-V[J59/J2GLUPQJZ
MME(BE;=_)*--@D%):EVM<GF1;OIIFZ/[T9ARAW[UR.>[.* /A/&$1+H^)G6\
MK2PNPRY"4@O>3SEM'J?3F+ZW#UGWLOGJV&C&VXZ)<K5*@IST$R,?YM)H_<:2
M@PXYMFZ5M(I0',=CEV#W[K4Y<K.R8FNAA]EH%[KSO^CQK<;A=EW?@?&JBXQ"
M+7CVNL-H>26:2T1DWNLCIZ:5]V<1](.A*Y3#8>&)#$M#GFBVJ=.?ZY5:[5JG
MZCV]Y"B2NRIV?W\<P4,!JX"Y8R9[V;(:LO]0<RD)*M-&?"5/%M28AV"NCP=<
M;\[F@R]?X3.";C6H#IU.[F=X5(!3V_R<+1PE$$R9M.3$KPZGK5R?6'66D:7?
M %\,X0"C-$'3 P%_K0EBPFW3J\G@)I3G86*6ZD(U WH(J0.I'#16\.O#1)G%
MK_7M\C;B@.^(2!J&8U'4QPS!\/=33U]*W 4M&7H>^F&]4B:)S1T.8=$$AANI
MR<#Y$%+-]EJ?%UY4[ST^PP$\$\O.6U865+UZ<G3.()<XL$#T2&YIF/$=0_E[
M=;-RNS]B?M!!K3=>/UX\@PN [AN89G!<;+G4!=$()G%3Y30D!(2QE3YR_A.$
M0;GN"=6^77./Z\O@)SXM 2$5*\$'G3C 5U-/,OAI,3-$N"=29*[:716FIA?<
M&@SB1K+.<T'TSAV3?7__5L_T-TK)11H,JJ2?L4':M JN>0HO>CE-_%V!20X!
M%H!TE>" -EI6#!9^A<8!.[]QP!U;Z FJ^>+@+Q<+QU?7NCX<<,-XG7.4 ]*F
MGX\#W(G1UQ(L$G28N V>"\0BP2O:J:V_3-8:9,Y>7C-][,.=Z$MT./92L#'1
M[>J@$9)L]#VVP+KZ14[(Z"[M[1L_'OMY"<E5"!D^L7OZ>ER.J)2?7I[ZM!AU
MY*3XLXC7X<BM-L?.[L8U"+EMAU@ND1-1?\8H1L:SKJZ .E'! 5^JU;"[H(M6
M'$ 31WQG3NG&ZU$$M=G-3(W876M5I$PI>&.?%[TZ,2R7X3Q2+=2HEK"5@ .6
MN,<@]017AY"NV&OLP?"5Y%2Q]I^F*8]A_ D9VK[F;<W81IVRP?KKG;M.F:=^
M_;TB#2S&^**3R1.F8<;4'V%JPBA:M'#XM2?#00=[A0/.MA"MP024F/-^\%4"
M;Y&%:G'S(0OV@[<%AXJ*,MEEEN=3SQSUTN";#%W?C25'5?K'.#K35\<I.<4?
M5+8P94BC_G@/C[@6".EGDU8GAO$?VPU*<+X1YQ@L-I%?WF2UL=;_SQ& #A.L
M(0OA6&311FLPG7& WQ(.V"UHOAX*#@ 77:\J#D"=[3=(_L=Z67B;22\/O+Y/
M<O>"'0=,9&-)Y^3199 % HSUPC].E_'0MF;YZ.Z%#%;0AVZGH>GL>O1FQD@E
M-]#^-95]04>%*5&U'@5ML:IKA>QS7VZ:HD_T((?!!I"A6>.+GD*:TD#)),(W
M(UPA""L.R:T] V2*5V$NJQZFT8W&L>FK,IF:$?L/'8<EI3SH&\NTU38D2*8;
M6]FAX[2D+U<]2J-SDSK5<>A"7G7':('XY,IE;GKP>K %Z?K.J15JLGZ_>_]7
M@@HM#) 0N<9O?2XYDP/LVP?VN=$K$7_")23[5%\F:KN?=WL7\W'@7Q+^DA4K
M_Y>UCVY!JO4@EA"+JT+BJDLCR%1#Z[J7UTRS@V'MBH2 -N>@/Y,OTR_DYWS]
M;>/I"0K*X8XRTU<L$5WWJN=ZTZ?\Z\L_CS:Z7#3?;) OT)/(Q0$=>WK[XV\<
MOGKFN-K2103R$<00+TF18,R1X38\2<*!XF+.%]X#<RV5=4JFSB9& E3OY0Q#
M[VC:KWBGT>QCJ9'RV(?-^%-6/TMY37& 0L,&N.D]_XO8XT\%L:TS&6?&K0N$
MXKR+J<U56X>J+O["-^L;8L2ZB@%&*3QYF4&!$Y(T.AT'*6H23YA,:H<' TA9
M!:]H9F_!<L,FO:?!;E 8TY!>B_#5;O3:B&PB\G3I2CJQCNOQ,"M4_"+406JO
M\S[S;=US.3*V)?>-M(P5:.#B4-C?=?61L.+VFZ])1584M-2D6H"[AP!]/GX9
M,G*E4;@U@[:1-Y]9KR%QEZMDU*9O_=G[Z+)K^?Q>@37Z6Y0*WBK8HOG>@N4\
MS9A0^.8\:,\BHO51WMU0_(\JM>V4(C>)R!AD"&N7H)^,*'^;?]W13/0SWY94
M'+PAI?M<^AC!"@ R NP]W1O1VC^(J:]^8!A=BC:U_1^759V8CWJ4#$<]-FCQ
MFE=QUKHC_G[%AP$0FL#P'^U!(\5YS4>,6J;'U.P:JN9OIGX+XK=KN=3GF,*W
MY*X6)9^9B+.!W+!].H$#JGSY2@V1SFOI<XE3PAP45%?CXR\##TQ-HU/Q@8^?
M))@Z&!Z/-@AD#Q5:)Y%<4Z"#\T618JN2K7+';6>R18N4(^(O5=7S8DA8D:]4
MD\*3@+EDJ<;P.EO=DXK;=REO'CJ_S<BKNR-Y(_>\G/PB#*-?8--#&J2[>C]"
MRG:/9W##@KNE]?+G';CVR&D]_2.EZE'7&<N]XKU14[7'2_(GS&EQJLQQJD\_
M\?R'U?1_8IZO4;WERS;<<+=XJ-#*PSMB= "OVJPNEOKZ '1/A[DDT._4_YNM
M/][_+G(:=->S<\_MWI= I;$Q6<&?#XO(PN-IXP.<XOK&\)J9,95G.C,EX%\X
MH$+R#\%D QR\)_G^WRY!R_OK#C1X:M,MI(S4D5]UR(^)BLT#TKO<&4\,8V-B
MGXF8/5X\BDVC(Y8VG, () 7B@$VF4L@"LAGY!W"&TDH^F?:,5V4 '?[IFW\W
M4P[5J/D,ZL/3?<*S'Y$:PKQ8\%2<;B(7\P@'Q,ED0F;^LEY;ZV&$#H.2@@\J
M./TH1$YWSN5K(Y2?;BG&Z/#6^^-1XXNLHM+V-E.>IB\-/'G J5B-EHB@;:BI
M_K4WVQG-I2 >YR6(MPZN<,#$UX/0A/(X("NW-/ ?XL/K'$B0QG)']FDI_K46
MY_6:W]X4K#=X.MXA8)/>1)P4T3P-A7EZO Y4'"G!#IG=/N#AWD5[\)GTD:HR
M9R@#;X^@05P8JR6?$HJC!KCP [(E?$%^_(3WQ,M$SQ03J:D'?+,=<,!=N:)S
M\%=6K*XU/$2?=TWI@I:KOIS&_RAJ7M+")(/OW.ZC_-*#&[SD \M!H]DOQO))
M2K]/A="^/,S9TZC B\'K\E.1XK'T%H(&5XAQ_^TV>%7."E @M&V!>X_B5$29
M4TZ(IX6Q"G/15T%,.."W^@1<&QR"X<WVK%91!AO\0AL6*C[5/#$2%[F)_^WQ
MJ<GE,(' H096@2+H%(H#Y'L,SRRNR0==FOMW\GW[9_()9?[WET7X%XT!O"(A
MY+I \H9D+!=QT!;8NYH6(%F+X806N/5M"3UP/]Y+CCNN6C C /QU"S^ZS)K7
M602F*" T3HHU(HH4W^H][]G,?X,-5[N,;'CN19896, ;+G/KD>(@]D U=:"B
M)HYR7ZT<"B]QIS'NL$DN9X#9_X)C3L/7'/HRKSCB85^$?#SGQ<9'>=_AN;)U
M24QNS, SR>/=?LRV)U4ESJ-(AKY;/8Z/=A0%);CTIBW52;QPH/QRD:^RTS/G
M.Z%:<^8GT/'"J!2HJ)=AQ &)JL?-J]Y8\@(CX*Y&;(S\EB%1THJRB?)TI/!T
M)J@5W"]U;E\I+&$@_%!VR^CYB?&J]QEY[Y:_Q B\*K?'1E352E05O8-Q,GSE
MS%Q>'%M7)\SX;174E7]A^=%*1R>7&:'VUM!H1K=]?4Z5CN]TC@E/%]$US_"@
M&BUS=&P,0CW +PC)5I[.&3FSHK]%KMVG]FOL(_^[V<X74?6TS'[RUI72Q:8Y
M<$K7:V&+_R]N1A+HF)<,5/B^N\NDGYJS-!7=0WVZ4E#TA478,ODC']GAX4;^
M;M1@V%&HK\^R*#,7[Q<34<*R/()U<+KU%I@4_B-60S.4Y^.F:>3+F@N$S.ER
MM:=BJ,%)9L8',QX=M_4)S*.Q_,)SG2I49)J']L]0QA@S7:VP-6M$:4K<WZ7J
M;_]]FWQZ_DZ=47SGV>[;*H&RM"KP'-TX921&$T5?]VXJ]GQJ0JQY(^5T:.PD
M.M<KSJJZNG14465#E)N1)3GC[&>0B,RT=ER$[Q O>70!30;B 9$5-YII/.L(
M$?PTYLFVXET1VA4WT'<J4*2#C* ."5>98EQ7.\=F2^#IDP:^"NJV-5-UORZ.
M\="2;4F*9HT36G-PPQ=H B+_5/)4P]/V)40G/V<BQ?S>L\YAFQW7$H8=V+J/
M&;GB@L[HOMU*AECW\]>97TV!1534V,8?0627$6K*98<_>N>=<Q.B?(_19HYB
ML]!XAL;XZF8Q#CA 7:OBUPSM[NUP'"#M0XRYJWH$Z^-I<[."5S2=R(7U04@M
M0R.VS\51*K!+&A//;!E-9FOW0:ENS1A2OT]GV7&&07M;=OU-QV?[F38PF?4Y
M12:CP%K628]2=P?:#M!#W>Z=[>-;X)C;M44S/95BB+H:4>X+'?$GYS>R.GWW
M!4+8U5)ABN+C.SZ\2-8WEE6EIV*TX/^'N:\,BS)JUWU-%!%4) 5& >D61'(L
M6D"ZNT.Z:Y24%A"0[F88Z0;I[E*Z.V;(8?+@M\^N[\2O<ZZ]?ZR9ZYIY8\6S
MGN>^5]R+2DMAA<LX]G?&*KH?_'!D1^^1L'08HJ*"I[\BU9^]O]^?1\)R1QL[
M'!']J#"9?$,IZF6&/1QZC-E-X/(;EDO0$^&)9Z9U%R,/.YEK?;+$MI%;4V.@
M"T%(UJ-'OCX@PN9T.L"*\]H#+CF]8PI8;<LLG'_3C@O,'Q:WE#JJFL_PU[UH
M0=&)L-OAM&#$#<@O*QO&II.S%GC 7-!^AK+T3PNS90R"1C VPW*29*K$<GEO
MP!)<I]M[(=1DDM>3EN[2>I@/3F</1BQ%0K-_ZOS)-@U[H/ZJUF=<Z #E%]PT
M:Q#V% _TM(2SHYOJL->3A]'J>6L'QM-W.=5G11RD:;[Q26INE?&PJN;^''4M
MIY84;E8;W%![GE_:,R6@9]+IE,3-1?21]/L7OL=^M+B"Y,+9FP-TQTQ*V#6J
M+F^[N$Q-2P2+/YF5X\F'-0X(W5*0M:&7QH#ZFJAL?"&7)C0A8[W[IZM9:8'%
MMD=ZZ*J>3H<S?1^[WLYEQ_L>$:GBK8)CV,?H3N'W"3&Z:;)3]#'NW$EL19C0
MO0\S/JPF);_V8W(I-%<E*.=]*=UA=$VC=.,H2R:3)]V=CWL4NYM3&T7:S7GM
M'UPR-7+BC@:'G=)!LBDN%L6Z'EL=-7^&LRM TE,IEX1]]<BT/*F8FZ1]VVYK
MES'Z7OR%4AK.IUW2_'-&4YI8[68P=.,;S@IBP)#@D8N;N-0Y$_;."#VN\4F1
MO+'0C@?>:0G2B4^:,]ORDJ"VM5H+B^F[_WB]!]-9O[$G/ TEP-Q4@]@N9\&5
M(2$8T@2_=@BUTYD]II<9H0!S@Y*D%E9<SU/F[15U%9VLF=ZS?Z!T$;THGI]'
M2)%Y8T<O.EB4CGM5Y^ ]WUPM;R?QO6AE;Y*3L^,7/L>DN8G<C-[ND"^J1=X:
M^]L2W'M%/6/Z,Y_R-6=9=+RE&6Z@"Z]A=IL/ _)V'U:,F)$K(HH/C)!1-AOD
MKL2?C/?=FHK=QK73V0527]2YJ\1L.R8[Z;P!S8=*M?#9E#7#]0:%L?&!7"/V
MWL(=C^></I9W4WJ[7G1YY:? I5[7=!@LZNO7[5Y[^ QS6W'/0"*D<[IS7#9U
M+J0LA*UCYE-'^;):43[21F>:%YN1IS?/BN/_NH\'6AK\JD^GDY:7[N]0OM06
M2+43EAX[<KPB=K89T[7L?W5MDE*DKF$&+_<^('E7O8>@;M,)+%ZAC(M+L>M^
MU;]W6F^X?.6932AP=>E &BD]NJ**/6=DN_&/:WG>X&H\UO" [R_H6G!^@^YV
MU*/O7KKK!4B#%:9Q+@[CB4<WV QU;W/2TV4%\+[:JGTWD><A#EW&RGUH3&!Q
M,^B,4C.KN7E(U^B%!W@/;99\5*!= ME:FGI2S[YG"*PZN!4>Q.QEC->K1IKH
MLL#  CU&<(>/CDV+?5;V!L>82#IBLD0;.A%L0$G0R/FG&2Q*" HA0=)?:$X:
M!A^J3D 7?A[+7WP^-S H8Y^PBGU?02PE%NGQ0W0WN;BEG,1]H&"@L+5BN5IA
M*V^'6BT_)$]GI^;AI=OT7C6!\WS<K@QCAK.Z>5WP@KL\OR.LY.>-,QA[BM:4
MVQTZG$/AR\^P*#!Q=?KP<%=:..^N3!^L.2]8C3X_S^5,G;-_5O/L7O1CR_/+
MVPA=E.0]OYRP@3K$1C*DISEW''3>^P9K$Q@E&%_3';'OS=('98<06U^\^F/$
M%K#XIO)RM095S8+YH#N4G$@G-&G:&TSYC*Z. Z(/ENVO0Q!#G3/X<(8DIB($
M.V'3M7"N+.87(S??C9I%(_VJ2^R7Y1C;ZAJ25;8SGX*',\3IGMS*';[]^>Z.
M'O-7_C3A_DOZ2BY"V-&#U,_>SEIM;R, X!Q&P+N:3*F%%E;:BEW2>7Z9W$&\
M4?+B#D-A%UN1.V%FK ) NR?]6?+.3>_IQ&"HK615K&[+0HZ+K-_AD;/*Y]5B
MRE"T</FZ_2>[C W#=%JHTKB6!UBV5H*O\Z3O2QP#(B.SZY/.K,YLV9P'?:CO
MP^MX@"U,7J&=N]43$$\W'-E0,T4PQ8,P38?B88%X0':G)"JW-53)9_86P1AU
ME0:8.7R?(C#,'7SX&9RF%M>MEUV!T5;<"5M)=_0//A/?:^W-4]"+*BY9TI<R
MLG@^F.%*<&/RG*Q/9A5]OD+_A6 T#K,GC-9JF61X."]+9'A(^)@8TE=&(_5@
M99(ZSYTKV5(Y^ZB([#S+L7">JL )TI"3'?U&S3*[Y:5SO(R0_$)E'ONC=_PU
MQZ4_&QF*>@UMFL9< R=++Z35+*)#J+I]]T:VRS"M?$7^*8[3W"[OEW.]$E-
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M)K $,=M!5YZS^^"!F6?J\62/V?Y.0%)>;TH6%;#2+ST]YG=MI*_),"%/,T]
M.$=IM39Y)U=+D)T]"+3J>LO61RGHD!W&]@^EY"V?=YG5:T\&E)+*3PHN0@HO
MRH3&UIRB\C1I'G3<U"B:?*&M,V\RXL_*.^%U(PS^@BB,,JFA:HG=^]S\9_%X
MI6@'U&66("37,_8002A9P/J$6!,5LZ,G^O)EPD'#$TVEUJ:_\+W+PG\%J91<
MI*T[O3/J5.)J>E4IOE1?_XZ53E"3QH8ICA=9)YMZ18;_NEZ"7;=U$? +&\ZC
M5 L(G(ZPJB[:N" _GAT<'0RB5;@C0.9EMA $/;Y5_\6TYZT'P[;7M!$\/]G
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MTY62$0M;-[;KH5X=*5VHQUR],[\J4A^4UV,=PTX=- ?-*.N,CNSETNT$KP7
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MCKD<<SGF<LSEF,OOYV(F:_:+O06BW=3X;*6\Q0'I]Q7-'TU'FEQ8F@'S@HQ
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M     &EK;F$M,C R,3$R,S$N:'1M4$L! A0#%     @ ZC-Q5&N<D3%Z%
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M,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ ZC-Q5*$%I'S,10  3#\% !4
M             ( !^AD% &EK;F$M,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0
M   ( .HS<51N (3.W0,  .09   /              "  ?E?!0!I:VYA+65X
M,C-?,2YH=&U02P$"% ,4    " #J,W%4V-I^)QX(   B/0  #P
M    @ $#9 4 :6MN82UE>#,Q7S$N:'1M4$L! A0#%     @ ZC-Q5-ZGN2PJ
M"   HSP   \              ( !3FP% &EK;F$M97@S,5\R+FAT;5!+ 0(4
M Q0    ( .HS<50.8D+GK 4  "%*   /              "  :5T!0!I:VYA
M+65X,S)?,2YH=&U02P$"% ,4    " #J,W%4&16.1W,:  !HTP  #@
M        @ %^>@4 :6MN82UE>#1?,RYH=&U02P$"% ,4    " #J,W%4G^_+
M(JR=  #=T@  $0              @ $=E04 :6UG,SDX,C4R,#1?,"YJ<&=0
M2P$"% ,4    " #J,W%47.\/BO5-  !?7@  $0              @ 'X,@8
M:6UG,SDX,C4R,#1?,2YJ<&=02P$"% ,4    " #J,W%41"V7,UN1  !ZM
M$@              @ $<@08 :6UG,SDX,C4R,#1?,3 N:G!G4$L! A0#%
M  @ ZC-Q5/I<@6[A>@  +(P  !(              ( !IQ(' &EM9S,Y.#(U
M,C T7S$Q+FIP9U!+ 0(4 Q0    ( .HS<50 R%GI"54  "IE   2
M      "  ;B-!P!I;6<S.3@R-3(P-%\Q,BYJ<&=02P$"% ,4    " #J,W%4
MC*2M9J&]  !ZW@  $@              @ 'QX@< :6UG,SDX,C4R,#1?,3,N
M:G!G4$L! A0#%     @ ZC-Q5/&ZA3I&C@  'Z4  !(              ( !
MPJ ( &EM9S,Y.#(U,C T7S$T+FIP9U!+ 0(4 Q0    ( .HS<525[O;V\]<
M #EX 0 2              "  3@O"0!I;6<S.3@R-3(P-%\Q-2YJ<&=02P$"
M% ,4    " #J,W%48-%P7HAQ  "6I   $@              @ %;!PH :6UG
M,SDX,C4R,#1?,38N:G!G4$L! A0#%     @ ZC-Q5,?P!7JPU0  %  ! !(
M             ( !$WD* &EM9S,Y.#(U,C T7S$W+FIP9U!+ 0(4 Q0    (
M .HS<5345MPP6A(! )/] 0 2              "  ?-."P!I;6<S.3@R-3(P
M-%\Q."YJ<&=02P$"% ,4    " #J,W%4"VX=5%6%  #^Y@  $@
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M,C4R,#1?,C(N:G!G4$L! A0#%     @ ZC-Q5!6(>YKV,0$ B&@! !(
M         ( !'X\0 &EM9S,Y.#(U,C T7S(S+FIP9U!+ 0(4 Q0    ( .HS
M<531J*;W*(T  )NH   1              "  47!$0!I;6<S.3@R-3(P-%\S
M+FIP9U!+ 0(4 Q0    ( .HS<51BRCC^4$8  "!5   1              "
M 9Q.$@!I;6<S.3@R-3(P-%\T+FIP9U!+ 0(4 Q0    ( .HS<51\@3P]E%(
M +QA   1              "  1N5$@!I;6<S.3@R-3(P-%\U+FIP9U!+ 0(4
M Q0    ( .HS<50LI3=Z&D<  (EQ   1              "  =[G$@!I;6<S
M.3@R-3(P-%\V+FIP9U!+ 0(4 Q0    ( .HS<53 0 @F/SL   ED   1
M          "  2<O$P!I;6<S.3@R-3(P-%\W+FIP9U!+ 0(4 Q0    ( .HS
M<52RUJTCE!\! .C& 0 1              "  95J$P!I;6<S.3@R-3(P-%\X
M+FIP9U!+ 0(4 Q0    ( .HS<53C(),DH(4"  X\!  1              "
L 5B*% !I;6<S.3@R-3(P-%\Y+FIP9U!+!08     (P C + (   G$!<    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
